-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 V+uYjBLaZKLf6CLkIc3m+qB4NQvtqusG6cLTqomigzD03Si5BgDOZ3g/ruiGHxJN
 JpLriU+iJJpxvpSIHBcQhg==

<SEC-DOCUMENT>0001213809-06-000013.txt : 20060329
<SEC-HEADER>0001213809-06-000013.hdr.sgml : 20060329
<ACCEPTANCE-DATETIME>20060329160102
ACCESSION NUMBER:		0001213809-06-000013
CONFORMED SUBMISSION TYPE:	10KSB
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20051231
FILED AS OF DATE:		20060329
DATE AS OF CHANGE:		20060329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10KSB
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		06718800

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10KSB
<SEQUENCE>1
<FILENAME>form10ksb_123105.htm
<DESCRIPTION>DYADIC INTERNATIONAL, INC. ANNUAL REPORT ON FORM 10-KSB 12.31.05
<TEXT>
<html>
  <head>
    <title>
      Dyadic International, Inc. Annual Report on Form 10-KSB 12.31.05
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARIZER HTML 3.0.2.0 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="left" noshade size="3" width="100%">
      </div>UNITED STATES</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>FORM
      10-KSB</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Mark
      one)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">{x}</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ANNUAL
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934</font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>For
      the fiscal year ended </u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>December
      31, 2005</u></font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">{
      }</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TRANSITION
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934</font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font size="2">&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      For the
      transition period from_______ to _______</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;
      Commission file number </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>333-102629</u></font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="dyadiclogo3.jpg" alt=""></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td valign="top" width="20%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="top" width="47%" style="border-bottom: #ffffff thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
                    International, Inc.</strong></font></div>
                </td>
                <td valign="top" width="24%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="20%">&#160;</td>
                <td colspan="2" valign="top" width="47%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Name
                    of small business issuer in its charter)</font></div>
                </td>
                <td valign="top" width="24%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="20%">&#160;</td>
                <td colspan="2" valign="top" width="47%">&#160;</td>
                <td valign="top" width="24%">&#160;</td>
              </tr>
              <tr>
                <td colspan="2" valign="top" width="48%" style="border-bottom: #ffffff thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Delaware</strong></font></div>
                </td>
                <td colspan="2" valign="top" width="19%" style="border-bottom: #ffffff thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>45-0486747</strong></font></div>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="2" valign="top" width="48%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                    or other jurisdiction of incorporation or organization)</font></div>
                </td>
                <td colspan="2" valign="top" width="19%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(I.R.S.
                    Employer Identification No.)</font></div>
                </td>
              </tr>
              <tr>
                <td colspan="2" valign="top" width="48%">&#160;</td>
                <td valign="top" width="19%">&#160;</td>
                <td valign="top" width="24%">&#160;</td>
              </tr>
              <tr>
                <td colspan="2" valign="top" width="48%" style="border-bottom: #ffffff thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>140
                    Intracoastal Pointe Drive, Suite 404 Jupiter,
                    Florida</strong></font></div>
                </td>
                <td colspan="2" valign="top" width="19%" style="border-bottom: #ffffff thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>33477</strong></font></div>
                </td>
              </tr>
              <tr>
                <td colspan="2" valign="top" width="48%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
                    of principal executive offices)</font></div>
                </td>
                <td colspan="2" valign="top" width="19%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Zip
                    Code) </font></div>
                </td>
              </tr>
              <tr>
                <td colspan="2" valign="top" width="48%">&#160;</td>
                <td colspan="2" valign="top" width="19%">&#160;</td>
              </tr>
              <tr>
                <td align="left" colspan="4" valign="top" width="67%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuer&#8217;s
                    telephone number </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(561)
                    743-8333</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
          registered under Section 12(b) of the Exchange Act: </font></div>
        <div>&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td valign="top" width="41%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title
                    of each class</font></div>
                </td>
                <td valign="top" width="41%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name
                    of each exchange on which registered</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="41%">&#160;</td>
                <td align="left" valign="top" width="41%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="41%" style="border-bottom: #ffffff thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Common
                    Stock, $.001 par value per share</strong></font></div>
                </td>
                <td valign="top" width="41%" style="border-bottom: #ffffff thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>American
                    Stock Exchange</strong></font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="41%">&#160;</td>
                <td align="left" valign="top" width="41%">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities
          registered under Section 12(g) of the Exchange Act: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>None</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
          whether the issuer is not required to file reports pursuant to Section
          13 or
          15(d) of the Exchange Act. { }</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
          whether the issuer (1) filed all reports required to be filed by Section
          13 or
          15(d) of the Exchange Act during the past 12 months (or for such shorter
          period
          that the registrant was required to file such reports), and (2) has been
          subject
          to such filing requirements for the past 90 days. Yes {X} No { }</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
          if
          there is no disclosure of delinquent filers in response to Item 405 of
          Regulation S-B contained in this form, and no disclosure will be contained,
          to
          the best of the registrant&#8217;s knowledge, in definitive proxy or information
          statements incorporated by reference in Part III of this Form 10-KSB or
          any
          amendment to this Form 10-KSB. { } </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
          by check mark whether the registrant is a shell company (as defined in
          Rule
          12b-2 of the Exchange Act).</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
          { }
          No { X}</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">State
          issuer&#8217;s revenues for its most recent fiscal year: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>$15,882,969</u></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">State
          the
          aggregate market value of the voting and non-voting common equity held
          by
          non-affiliates computed by reference to the price at which the common equity
          was
          sold, or the average bid and asked price of such common equity, as of a
          specified date within the past 60 days. (See definition of affiliate in
          Rule
          12b-2 of the Exchange Act.) As of March 24, 2006 the aggregate market value
          held
          by non-affiliates was approximately $39,583,000.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
          of
          March 24, 2006, there were 22,712,965 shares of registrant&#8217;s common stock
          outstanding, par value $.001 (including 274,796 shares held in escrow).
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            information called for by Part III, Items 9, 10, 11, 12 and 14 is incorporated
            by reference to the definitive proxy statement for the 2006 annual meeting
            of
            stockholders of the registrant to be filed with the Securities and Exchange
            Commission within 120 days of December 31, 2005.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Transitional
            Small Business Disclosure Format (Check One): Yes { }; No {X}
</font></div>
        </div><br>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left">&#160;</div>
          </div>
        </div><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <div align="left">
            <table border="0" cellpadding="0" cellspacing="0" width="80%">

                <tr>
                  <td valign="top" width="14%">&#160;</td>
                  <td valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="TOC">TAB</a>LE
                      OF CONTENTS</strong></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%" style="border-bottom: #ffffff thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
                      I</strong></font></div>
                  </td>
                  <td align="left" valign="top" width="60%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td valign="top" width="10%" style="border-bottom: #ffffff thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PAGE</strong></font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      1. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#item1">DESCRIPTION
                      OF BUSINESS</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#theco">The
                      Company</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#ourmar">Our
                      Markets</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#SP">Dyadic&#8217;s
                      Products and Services</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#strategy">Dyadic&#8217;s
                      Strategy</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#RD">Research
                      and Development</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#RDV">Research
                      and Development Capabilities of Consulting R&amp;D
                      Vendors</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#manufac">Manufacturing</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#SM">Sales
                      and Marketing</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#emp">Employees</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#investor">Investor
                      Information</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#competition">Competition</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#intell">Intellectual
                      Property</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#govreg">Governmental
                      Regulation</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#risk">Risk
                      Factors that May Affect Future
                      Results</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      2. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#property">DESCRIPTION
                      OF PROPERTY</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      3. </font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a href="#Item_3_Legal"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LEGAL
                      PROCEEDINGS</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></a></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      4. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#legal">SUBMISSION
                      OF MATTERS TO A VOTE OF SECURITY
                      HOLDERS</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%" style="border-bottom: #ffffff thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
                      II</strong></font></div>
                  </td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      5. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#marketequity">MARKET
                      FOR COMMON EQUITY AND RELATED STOCKHOLDER
                      MATTERS</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      6. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#Item6">MANAGEMENT&#8217;S
                      DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                      AND RESULTS OF OPERATIONS</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">40</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#general">General</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#results">Results
                      of Operations</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#liquidity">Liquidity
                      and Capital Resources</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#offbal">Off
                      Balance Sheet Arrangements</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#critical">Critical
                      Accounting Policies and
                      Estimates</a></font></div>
                  </td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      7. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#item7">FINANCIAL
                      STATEMENTS</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      8. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#item8">CHANGES
                      IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
                      AND FINANCIAL DISCLOSURES</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      8A. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#item8a">CONTROLS
                      AND PROCEDURES</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      8B. </font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#item8b">OTHER
                      INFORMATION</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%" style="border-bottom: #ffffff thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
                      III</strong></font></div>
                  </td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      9. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a href="#part111"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DIRECTORS
                      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXECUTIVE
                      OFFICERS PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION
                      16(a) OF
                      THE EXCHANGE ACT</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></a></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      10. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#part111">EXECUTIVE
                      COMPENSATION</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      11. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#part111">SECURITY
                      OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
                      MANAGEMENT</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      12. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#part111">CERTAIN
                      RELATIONSHIPS AND RELATED
                      TRANSACTIONS</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      13. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#exhibits">EXHIBITS</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">52</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM
                      14. </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td align="left" valign="top" width="60%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#part111">PRINCIPAL
                      ACCOUNTANT FEES AND SERVICES</a></font></div>
                  </td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="14%">&#160;</td>
                  <td align="left" valign="top" width="60%">&#160;</td>
                  <td valign="top" width="10%">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Forward
          Looking Statements</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
          Annual Report on Form 10-KSB</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">contains
          forward-looking statements within the meaning of Section 27A of the Securities
          Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that
          involve
          substantial risks and uncertainties. Forward-looking statements can be
          identified by the fact that they do not relate strictly to historical or
          current
          facts. They use words such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;anticipate&#8221;,
&#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;continue&#8221;, &#8220;project&#8221;, &#8220;plan&#8221;, &#8220;shall&#8221;, &#8220;should&#8221;, and
          other similar words. You should read statements that contain these words
          carefully because they discuss our future expectations, making projections
          of
          our future results of operations or our financial condition or state other
          "forward-looking" information. Forward-looking statements involve known
          and
          unknown risks and uncertainties that may cause the actual results, performance
          or achievements of the Company to be materially different from those that
          may be
          expressed or implied by such statements. Important factors that could cause
          the
          actual results, performance or achievement of the Company to differ materially
          from the Company&#8217;s forward-looking statements include (i) assumptions or
          cautionary factors discussed in connection with a particular forward-looking
          statement or elsewhere in this Form 10-KSB, including the section titled
          &#8220;Description of Business - Risk Factors That May Affect Future Results.&#8221;, or
          (ii) cautionary factors set forth in subsequent filings of the Company
          made from
          time to time with the Securities and Exchange Commission. All forward-looking
          statements attributable to the Company are expressly qualified in their
          entirety
          by these and other factors. Except as required by law or regulation, we
          do not
          undertake any obligation to publicly update forward-looking statements
          to
          reflect events or circumstances after the date on which the statement is
          made or
          to reflect the occurrence of unanticipated events.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
          I</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          term
&#8220;the Company&#8221;, &#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221; refers to Dyadic International,
          Inc. and its consolidated subsidiaries, unless the context otherwise
          indicates.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          obtained statistical data, market data and certain other industry data
          and
          forecasts used throughout this Annual Report on 10-KSB from market research,
          publicly available information and industry publications. Industry publications
          generally state that they obtain their information from sources that they
          believe to be reliable, but they do not guarantee the accuracy and completeness
          of the information. Similarly, while we believe that the statistical data,
          industry data and forecasts and market research are reliable, we have not
          independently verified the data, and we do not make any representation
          as to the
          accuracy of the information. We have not sought the consent of the sources
          to
          refer to their reports in this Annual Report. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="item1"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
          1. </u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>DESCRIPTION
          OF BUSINESS </u></em></strong></font></a></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><a name="theco"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>The
          Company</u></strong></font></a></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
          International, Inc. (the Company or Dyadic), based in Jupiter, Florida,
          with
          operations in the United States of America, Hong Kong and mainland China,
          Poland
          and The Netherlands, is a developer and distributor of specialty enzymes
          and
          related products for sale to the textile, food, animal feed, starch, pulp
          and
          paper and other industries. The Company is focused on functional proteomics
          through the discovery, development and manufacturing of novel products,
          including enzymes and proteins, derived from the genes of complex living
          organisms (including humans) found in the earth's biodiversity. Using its
          patented and other proprietary platform technologies for gene discovery
          and gene
          expression, Dyadic is developing additional biological products (e.g. proteins,
          enzymes, polypeptides and small molecules) for use by itself and for
          applications in large segments of the agricultural, energy, industrial,
          chemical
          and pharmaceutical industries. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Merger</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company was organized under the name CCP Worldwide, Inc., as a Delaware
          corporation on September 23, 2002. On October 29, 2004, we completed the
          merger
          of our newly created and wholly owned subsidiary, CCP Acquisition Corp.,
          a
          Florida corporation, with and into a Florida corporation formerly known
          as
          Dyadic International, Inc., which was the surviving corporation of the
          Merger
          and became our wholly owned subsidiary. Following the Merger, our new subsidiary
          changed its name to Dyadic International (USA), Inc. (&#8220;Dyadic-Florida&#8221;) from
          Dyadic International, Inc., and the Company&#8217;s name was changed to Dyadic
          International, Inc. from CCP Worldwide, Inc.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          connection with the Merger, we disposed of our then sole operating subsidiary,
          Custom Craft Packaging, Inc., which was engaged in the packaging business,
          in a
          sale of all of the shares of that subsidiary to its founder; all of the
          then
          officers and directors of the Company resigned from their positions and
          were
          replaced with Dyadic-Florida's officers and directors; and Dyadic-Florida
          became
          our sole operating subsidiary. For accounting purposes, the Merger was
          accounted
          for in a manner identical to a reverse acquisition of the Company by
          Dyadic-Florida, except that no goodwill or other intangible assets have
          been
          recorded. Accordingly, Dyadic-Florida was deemed to be </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
          accounting acquirer of the Company because the former stockholders of
          Dyadic-Florida became the owners of a majority of the Company&#8217;s issued and
          outstanding shares of common stock after the Merger, inclusive of shares
          of&#160; common stock issued in the initial closing of the private placement of
          the Company&#8217;s securities on the same date as the Merger. For reporting purposes,
          the transaction is equivalent to the issuance of stock by Dyadic-Florida
          for the
          net monetary assets of the Company, which after the transactions effected
          on
          October 29, 2004 were nil, accompanied by a recapitalization. <br></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>General</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><em>&#160;&#160;&#160;
</em><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;We
          are a
          biotechnology company engaged in the development, manufacture and sale
          of
          enzymes, other proteins, peptides and other biomolecules derived from genes,
          and
          the collaborative licensing of our enabling patented and other proprietary
          technologies. We use our patented and other proprietary technologies to
          develop
          and manufacture biological products, and intend to collaboratively license
          them
          for research, development and manufacturing of biological products, for
          two
          categories of applications: </font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">enzymes
                    and other biological products for a variety of industrial and
                    commercial
                    applications, which we refer to as our Enzyme Business; and
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">human
                    therapeutic proteins for use by pharmaceutical and biotechnology
                    companies
                    in pre-clinical and clinical drug development applications and
                    commercialization following drug approval, which we refer to
                    as our
                    BioSciences Business. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
          more
          and more industries come to appreciate the financial efficiency, environmental
          and other advantages of applying biological solutions such as enzymes to
          their
          manufacturing processes in lieu of chemicals and other legacy materials,
          we
          expect many new market opportunities to emerge for our proprietary technologies
          (e.g. cellulosic ethanol for the alternative fuel market).</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          have
          developed and use a number of proprietary fungal strains to produce enzymes
          and
          other biomaterials, but the one on which we have principally focused is
          a
          patented system for protein production, or protein expression, which we
          call the
          C1 Expression System. This System is based on our patented </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chrysosporium
          lucknowense</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          fungus,
          known as C1, as its host production organism. A host production organism
          is an
          organism which has been genetically altered to express genes to produce
          targeted
          protein products. We discovered the C1 microorganism in the mid-1990's
          and
          initially developed it, without the application of molecular biology, to
          produce
          neutral cellulases for our textile manufacturing customers. By 1998, we
          began to
          apply molecular genetics and other proprietary biotechnology tools to C1
          to
          create a technology, which we refer to as the C1 Host Technology. The C1
          Host
          Technology, once fully developed, is expected to be capable of performing:
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">two
                    screening functions for:</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 81pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                    discovery of genes and the proteins they express; and
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 81pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                    identification of improved protein variants resulting from modifications
                    to their genes; and </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">three
                    expression functions for: </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 81pt;">&#160;</td>
                  <td>&#160;</td>
                </tr>

            </table>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 81pt;">
                    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o&#160;&#160;</font></div>
                  </td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                        expression of proteins in commercial volumes for industrial
                        enzyme
                        applications; </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 81pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                      expression of human therapeutic proteins in small volumes for
                      pre-clinical
                      and clinical </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">testing
                      for drug development applications; and
</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 81pt;"><font size="2">o&#160;</font>&#160;</td>
                  <td>&#160;<font size="2">the expression of human therapeutic proteins
                    for
                    drugs in commercial volumes. </font></td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
            have
            been, over the last several years, principally focused on the expression
            capabilities of the C1 Host Technology. These efforts culminated in our
            first
            commercially successful application - our C1 Expression System. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Using
            the
            C1 Expression System, as well as other biological systems, our Enzyme
            Business
            develops and produces commercial quantities of enzymes for sale to textile,
            pulp
            and paper, food, animal feed, chemical, agricultural, and other industries.
            These industries, in turn, use our products to enhance their own products
            or to
            improve production efficiency. We currently sell more than 45 liquid
            and dry
            enzyme products to more than 200 industrial customers in approximately
            50
            countries. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
            believe, however, even larger market opportunities will exist for our
            C1
            Expression System when the technology is fully developed. For example,
            we have
            invested heavily over the past decade in R&amp;D for cellulases, xylanases and
            other hemicellulases for a wide variety of applications. Some of these
            enzymes,
            as well as others in the R&amp;D pipeline may be applicable to convert
            agricultural waste products (lignocellulosic substrates) into </font></div>
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4</strong></font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
                of
                Contents</a></em></font></div>
            </div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">fermentable
            sugars, which in turn can be used to produce ethanol and other chemicals
            that
            have historically been petroleum-derived. We have a stable of fungal
            strains
            from which we have identified and characterized a number of these activities.
            We
            believe that the combination of these R&amp;D efforts and our C1 Host Technology
            position us to address opportunities in the alternative fuel market,
            and intend
            to begin to make plans to enter this market.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
            also
            believe our C1 Expression System can be successfully harnessed to help
            solve the
            protein expression problem confronting the global drug industry - the
            difficulty, despite enormous historic investment, of cost-effectively
            and
            expeditiously harnessing existing genomic knowledge to develop new specialized
            biological products, or therapeutic proteins. For the past six years,
            we have
            been developing our C1 Expression System to serve the drug industry in
            the
            discovery, development and production of human therapeutic proteins,
            with our
            primary focus on enabling pharmaceutical and biotechnology companies
            to not only
            successfully carry on the development of drugs from their gene discoveries,
            but
            also to manufacture those drugs at economically viable costs. Within
            therapeutic
            proteins, the production of antibodies is an area of special focus for
            us in
            view of the large number of antibodies in pharmaceutical companies&#8217; research and
            development (&#8220;R&amp;D&#8221;) pipelines for which a reliable and cost-effective
            production process is required. </font></div>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">&#160;</div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
          this reprogramming of the C1 host is targeted at improving the production
          of
          biopharmaceuticals from human genes (which remains a significant focus
          of our
          commercialization strategy for the C1 Expression System), one side benefit
          of
          this core technology development program will be to further improve the
          capabilities of this unique fungus to make even larger quantities of proteins
          associated with genes from diverse living organisms, such as fungi other
          than
          C1, yeast, bacteria, algae and plants. This will help us generate revenues
          in
          the shorter term by cost-effective production of proteins and enzymes of
          commercial interest to potential business partners in sectors such as,
          agriculture, food and animal feed. We continue to mine the C1 genome and
          have
          identified a number of enzymes that have the potential to become new products
          for several industries, such as pulp and paper, energy, food and animal
          feed.
          Still in the development stage, we refer to these activities as our BioSciences
          Business. These activities have generated $150,000 in sales in 2005 and
          no sales
          in 2004. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          have
          also been developing the screening potential of our C1 Host Technology
          for gene
          discovery and the identification of protein variants resulting from
          modifications to their genes, which we refer to as our C1 Screening System.
          These efforts included our purchase of state-of-the-art robotics equipment
          and a
          since terminated collaborative partnership with a Netherlands-based scientific
          organization, TNO Quality of Life (f/k/a TNO Nutrition and Food Research
          Institute), and the establishment of a wholly-owned subsidiary, Dyadic
          Nederland
          BV, which has engaged in, and partially completed, the development of a
          fully-automated fungal high throughput screening system, or HTS system
          for which
          we are seeking new collaboration partners to help us complete. We believe
          that
          if our BioSciences Business' application of our C1 Expression System and
          our C1
          Screening System can each be perfected, we will be able to offer a potentially
          unique end-to-end solution for drug companies: a single host production
          organism
          usable throughout the discovery, pre-clinical and clinical testing and
          commercial production phases of drug development that would greatly increase
          drug development efficiency, economy and speed to market. By the same reasoning,
          we believe that the C1 Host Technology is expected to benefit the development
          of
          industrial or specialty enzyme products by allowing discovery, improvement,
          development and large-scale manufacturing in a single host organism, which
          should result in shorter inception-to-commercialization time and greater
          probability of success. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently,
          we own 3 issued U.S. patents, 24 issued International patents and 51 U.S.
          and
          International filed and pending patent applications which we believe provide
          broad protection for our C1 Expression System, our underlying C1 Host
          Technology, our C1 Screening System and their products and commercial
          applications. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>History
          of Dyadic</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          the
          first half of 2001, we raised capital of approximately $13,635,000, prior
          to
          expenses of approximately $200,000, largely to fund the development of
          our C1
          Screening System. At that time, we thought we were within one year of being
          able
          to find collaboration partners to help us complete its development, though
          we
          continued to develop our C1 Expression System. However, between 2001 and
          2003,
          even as our Enzyme Business began to grow rapidly, we experienced a major
          shift
          in market demand for our C1 Screening System. First, we found that large
          pharmaceutical companies, frustrated by lack of success with some of their
          investments in unproven screening technologies like our C1 Screening System,
          began requiring unprecedented levels of accumulated scientific data as
          a
          pre-condition to partnering with us. Second, we found that the interest
          of these
          large pharmaceutical companies had moved away from gene discovery and screening
          applications, to an interest in the expression of therapeutic proteins
          for
          pre-clinical testing, clinical trials and drug commercialization. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          adjusted our strategy accordingly, and between May 2003 and March 2004,
          we began
          to focus principally on our C1 Expression System, even as we continued
          to
          develop our C1 Screening System and related HTS hardware and assemble more
          scientific data to support our claims regarding that System's potential.
          During
          this interval of time, we also continued to grow our Enzyme Business, as
          we used
          our C1 Expression System and other proprietary technologies to successfully
          develop several industrial enzymes, while continuing to seek equity financing.
          </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Between
              April and July 31, 2004, we raised common equity capital of approximately
              $4,735,000, prior to expenses of approximately $118,000, through a
              private
              placement. Between October 1 and November 4, 2004, we raised additional
              common
              equity capital of approximately $25,400,000, prior to estimated expenses
              of
              approximately $2,700,000, in a private placement we conducted companion
              to the
              merger of our wholly-owned subsidiary into Dyadic-Florida, in which
              its
              shareholders received shares of our stock representing a majority of
              our
              outstanding shares. </font></div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
              2005, we focused our efforts on, among other things, expanding&#160;the
              introduction of&#160;our pulp and paper enzyme products to that industry. We
              have assembled a team of seasoned sales and marketing executives&#160;and
              technical salesmen with extensive pulp and paper industry experience
              and
              contacts in promoting and maintaining&#160;sales relationships involving
              substantial on-going sales and technical servicing. During 2005, we
              successfully
              recruited a Vice President of Sales &amp; Marketing - Enzymes,&#160;a Vice
              President - Pulp &amp; Paper, and 6 technical sales representatives whom&#160;we
              believe fit this description, as well as additional technical sales
              representatives for our Asian subsidiary. The addition of the sales
              and
              marketing personnel occurred throughout the third quarter, and accordingly,
              we
              do not expect to see sales results from these additions until mid-2006
              or later.
              In 2006, we intend to capture both an increasing number of new customer
              trials&#160;and convert existing and new customer trials into significant and
              sustained levels of pulp and paper product sales. We continue to
              estimate&#160;the addressable market for our existing enzyme products in the
              pulp and paper industry to be in excess of $1.0 billion. </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;
            We have also focused some of our efforts on other industries and expect
            to
            pursue these other industries, such as food and animal feed in a possible
            collaborative effort with a third party. To assist us in our endeavors
            in the
            animal feed market in Europe and elsewhere, we have hired a sales consultant
            with significant experience and expertise in this industry, who is expected
            to
            begin in April 2006. Historically, we have sold in this industry without
            a sales
            support staff dedicated to this market and it is our expectation that
            this
            addition will increase our sales in the animal feed market in the latter
            part of
            2006. There is no guarantee, however, that our sales will increase significantly
            or in the time frame that we anticipate. However, we continue to support
            our
            textile customers, directing the necessary resources to customer support
            and
            R&amp;D innovation to maintain our market share in this segment.
</font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          have
          invested heavily over the past decade in R&amp;D for cellulases, xylanases and
          other hemicellulases for a wide variety of applications. Some of these
          enzymes,
          as well as others in our R&amp;D pipeline may be applicable to convert
          agricultural waste products (lignocellulosic substrates) into fermentable
          sugars, which in turn can be used to produce ethanol and other chemicals
          that
          have historically been petroleum-derived. We believe we have a stable of
          fungal
          strains from which we have identified and characterized a number of these
          activities. Accordingly, we believe our C1 Host Technology, coupled with
          our
          R&amp;D efforts may provide a solid foundation to address energy problems more
          effectively and economically. Collectively, we believe we have resources
          with
          significant expertise in this area, including our Scientific Board members,
          our
          strategic collaborations with leading scientific organizations such as
          Moscow
          State University and the Russian Academy of Sciences as well as our employees,
          including the addition of a Chief Scientific Officer in March of
          2006.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          2006,
          we plan to shift some of our focus to energy market opportunities and the
          need
          for alternative fuels such as cellulosic ethanol. We believe that this
          may be a
          significant market opportunity for us as a technology provider; however,
          there
          is no guarantee that our efforts in this area will ultimately produce
          sales.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          derive
          almost all of our sales from the conduct of our Enzyme Business, and have
          thus
          far generated only nominal sales from our conduct of our BioSciences Business.
          We have an accumulated deficit at December 31, 2005 of approximately
          $34,008,000. Those losses resulted primarily from expenses associated with
          research and development activities and general and administrative expenses.
          To
          become profitable, we must continue to grow our Enzyme Business (see Sales
&amp;
Marketing Strategy below), and generate income from the conduct of our
          BioSciences Business, either directly or through potential future license
          agreements and collaborative partnerships with drug companies. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Our
          Future</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Despite
          our Enzyme Business' history of revenue generation and growth, the combination
          of its reliance upon the expansion of the capabilities of our C1 Expression
          System, our other proprietary technologies and the early-stage, developmental
          nature of our BioSciences Business require that we be characterized as
          an
          early-stage company. Our conduct of the BioSciences Business is subject
          to the
          risks customarily attending the operations of any early-stage company,
          including
          the development of new technologies and products, the assembly and development
          of production and R&amp;D capabilities, the construction of channels of
          distribution and the management of growth. We expect to continue to spend
          significant amounts to fund R&amp;D and enhance our core technologies. As a
          result, we expect to have significant future capital requirements and continue
          to incur significant losses as we develop the C1 </font><br></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expression
                System, complete development of the C1 Screening System, and build
                other
                required infrastructure to exploit our C1 Host Technology, our C1
                Expression
                System and our C1 Screening System in order to develop new products
                from the C1
                genome and other genes from foreign origins. </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic&#8217;s
                future plans are to leverage its patented, proprietary, and developing
                technologies and its stable of industrial enzyme-producing microorganisms
                to
                develop novel, improved, and cost-effective products for diverse
                and emerging
                industries. It is our intent to move aggressively into markets such
                as pulp and
                paper, cellulosic ethanol, animal feed, and pharmaceuticals while
                maintaining a
                strong market position in textile enzymes. We believe that when our
                technology
                and business development are fully mature, our differentiating advantages
                will
                be:</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </div>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                      ability to provide end to end solutions for product discovery
                      through
                      product manufacturing;</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                      ability to produce certain products that cannot be produced
                      or are
                      difficult to produce using other expression technologies;
                      and</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                      ability to produce those products at commercial volumes in
                      an economically
                      viable manner.</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
          intends to accomplish this by leveraging its C1 Host Technologies and its
          attendant genomic technologies and by building on its existing business,
          technical, and marketing infrastructures. Dyadic&#8217;s future growth is envisioned
          to come about by identifying new market opportunities and the technology
          to
          bring to those opportunities to market both for ourselves and in strategic
          business collaborations.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          expect
          to generate revenues from these efforts by: (i) selling products, whether
          developed internally or for collaborators, through our own distribution
          channels; (ii) expanding those distribution channels; (iii) collecting
          R&amp;D
          revenues from third parties; (iv) entering into collaborative joint ventures,
          profit sharing arrangements, or partnerships; (v) spinning off new commercial
          entities utilizing our technologies; (vi) technology access fees, milestone
          payments, and royalties; and (vii) grants from United States government
          or other
          agencies.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          BioSciences Business has not achieved, and may never achieve, significant
          sales
          or profitability. See "Liquidity and Capital Resources" in &#8220;Management&#8217;s
          Discussion and Analysis of Financial Condition and Results of Operations&#8221; for a
          discussion of our expected cash resources to fund our operations through
          the end
          of 2006. There can be no assurance that our efforts with regard to these
          objectives will be successful. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
          noted
          above, between October 1, 2004 and November 4, 2004, we raised additional
          common
          equity capital of approximately $22,700,000 net of issuance costs of
          approximately $2,700,000, in a private placement. We believe that we have
          sufficient working capital to fund our operations and meet our obligations
          through the end of 2006. If we are unable to fund these requirements, our
          business, results of operations and financial condition will be materially
          adversely affected. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="ourmar"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Our
          Markets</u></strong></font></a></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzymes
          </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Industrial
          manufacturers and the agricultural and food sectors have long used biological
          products, such as proteins, enzymes, peptides and other bio-molecules,
          to
          enhance the functionality or durability of their products and to improve
          production yields and efficiency. As examples: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                    textile industry uses enzymes to soften and fade denim, as well
                    as to
                    prevent pilling and improve smoothness, softness and color brightness
                    of
                    cotton and other cellulosic fabrics;
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pulp
                    and paper manufacturers use specialty enzymes as substitutes
                    for harsh
                    chemicals and other additives in bleaching and de-inking to improve
                    whiteness, brightness and fiber strength, to increase production
                    rates and
                    to decrease wastewater treatment burdens;
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 36pt;">&#160;</td>
                  <td>&#160;</td>
                </tr>

            </table>
          </div>
          <div>
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 36pt;">
                    <div><font style="FONT-FAMILY: Symbol" size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-FAMILY: Symbol" size="2">&#183;&#160;&#160;</font></div>
                  </td>
                  <td>&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">agricultural
                    companies use biological products to increase and enhance crop
                    traits and
                    yields and to encourage disease resistance;
</font></td>
                </tr>

            </table>
          </div>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;">&#160;</td>
                <td>&#160;</td>
              </tr>

          </table>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">animal
                    feed producers use biological products to improve the nutritional
                    value of
                    animal feeds and to improve production efficiency; and
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">other
                    industries, including energy, starch processing, cosmetics, detergents,
                    flavorings and bio-fuels, also use enzyme products for a wide
                    variety of
                    applications. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
It
          is our understanding that the current potential market for biological products
          in the industrial, chemical and agricultural sectors exceeds $100 billion.
          We
          are also aware of estimates of the size of the industrial enzyme market
          of
          between $2.0 and $3.6 billion. </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;
                  We believe, however, market opportunities for our proprietary technologies
                  will
                  continue to grow, and that we will be able to leverage our existing
                  and future
                  R&amp;D and our C1 Host Technology to these opportunities. For example,
                  we have,
                  for a number of years, engaged in extensive R&amp;D in various cellulase areas
                  that we believe can be applied to the ethanol-based alternative
                  fuel market,
                  where the production of ethanol from fermentable sugars derived
                  from corn
                  stover, wheat straw, sugar cane bagasse and other biomass may be
                  produced with
                  enzyme products we believe we can develop.</font></div>
                <div>&#160;</div>
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioSciences
                </em></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pharmaceutical
                  companies have also taken note of the emerging importance of cost-effective,
                  enabling production of therapeutic proteins in the drug R&amp;D process. Drug
                  development is an expensive, time-consuming and risky process.
                  Burrill &amp; Co.
                  and the Pharmaceutical Research and Manufacturing Association estimate
                  that
                  biopharmaceutical companies spent approximately $49.3 billion on
                  R&amp;D in
                  2005. Of the potentially hundreds of thousands of compounds screened
                  in a drug
                  discovery program, less than 1 in 1,000 will become new drug candidates
                  and only
                  about 20% of these will complete human clinical trials and receive
                  regulatory
                  approval. Only about 30% of drugs that are commercialized ever
                  recover their
                  development costs. Pharmaceutical and biotechnology companies have
                  realized that
                  to stay competitive and meet their goals for growth, they will
                  have to increase
                  significantly the number of new drugs introduced each year and
                  employ new,
                  sophisticated biotechnologies to increase the probability of success
                  in R&amp;D.
                  Because government agencies rigidly define and highly regulate
                  the pre-clinical
                  and clinical trial phases of the development of new drugs, drug
                  companies can
                  impose little control over the costs of these phases. As a result,
                  drug
                  companies are increasing their focus on the drug discovery stage
                  to enhance
                  productivity and reduce costs. </font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
                The biopharmaceuticals market has progressed significantly since
                1982 when the
                first biopharmaceutical product, recombinant human insulin, was launched.
                Now,
                over 120 biopharmaceuticals are marketed around the world, including
                nine
                "blockbuster" drugs, such as EPO and Factor VIII. From information
                published by
                pharmaceutical market consulting firms such as IMS Health, Inc.,
                Dyadic
                understands the total market for such drugs to be currently valued
                at
                approximately $41 billion or nearly 10% of the world pharmaceuticals
                market, and
                it has been growing at an annual growth rate of 21% over the past
                five years.
                With over one-third of all pipeline products in active development
                being
                biopharmaceuticals, the biopharmaceutical segment could continue
                to outperform
                the total pharmaceutical market and reach $100 billion in annual
                sales by the
                end of the decade. We believe that this growth is fueled by many
                factors,
                including the following: </font></div>
            </div>
          </div>
          <div>&#160;</div>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Most
                    biological processes in the human body are carried out by proteins.
                    Therefore, a significant amount of current R&amp;D activity is focused on
                    finding therapeutic proteins which could be cures for various
                    human
                    diseases. This has resulted in approximately 500 therapeutic
                    proteins, or
                    biopharmaceuticals, currently under active development.
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
                    the complete sequence of the human genome now available, many
                    new human
                    genes have been identified, and based on this knowledge companies
                    are
                    finding new promising drug targets.
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due
                    to the shorter path to drug development for biopharmaceuticals
                    as compared
                    to small molecules, pharmaceutical companies are now more focused
                    on
                    biopharmaceuticals than before. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
                    many large biopharmaceutical proteins and the manufacturing processes
                    for
                    producing them losing patent protection, drug companies are developing
                    modified versions of these molecules using alternative, more
                    efficient
                    production hosts. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It
              is our
              understanding that roughly one-third of the nearly 500 therapeutic
              proteins
              under active development could be targets for expression in a suitable
              host
              production organism. We also believe that number is likely to increase
              significantly as new biopharmaceuticals are added to the pipeline of
              drug
              companies every year. However, while many potential products are being
              developed, it is not clear how they will be produced, often due to
              the drug
              companies' inability to find a suitable host to produce the target
              protein
              recombinantly for animal and human testing and/or commercial launch
              at a viable
              cost. We believe that many pharmaceutical research programs at these
              companies
              have been put on hold or canceled due to these problems. </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
To
            solve this dilemma, a number of existing biotechnology companies have
            developed
            expertise in the discovery, optimization and/or expression of novel genes,
            proteins, enzymes and other biologically active molecules. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nevertheless,
            such companies have experienced extraordinary difficulties in producing
            sufficient quantities of proteins from genes for use in laboratory and
            clinical
            testing and, subsequently, in commercializing drug product leads through
            low
            cost, high volume production. Thus, despite the extraordinary investment
            in
            genomic research over the past decade and the attendant increased number
            of
            available therapeutic protein targets, the pharmaceutical </font></div>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">industry
            has not yet experienced a commensurate improvement in the speed of drug
            discovery and development, nor any significant decrease in its cost,
            due in
            significant part to the inability of current protein production methods
            to
            create sufficient quantities of biological products on demand. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Alternative
            Technologies</em></font></div>
          <div><br></div>
          <div>
            <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font size="3">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font>Proteins
              are made by "translating" or "expressing" genes. Genes are the basic
              units of
              heredity and are found in DNA, a fundamental molecule found in the
              cells of all
              living organisms. DNA consists of a code of instructions by which each
              gene
              encodes a specific protein. These proteins are the functional molecules
              that
              control the processes of living cells. The tremendously large number
              of
              different proteins and protein combinations accounts for the extraordinary
              biodiversity of living things in the world. Some of these proteins
              have
              properties or characteristics which offer great functional and commercial
              utility. For example, one class of protein - enzymes - can be used
              to catalyze
              reactions that are difficult to perform using traditional chemistry
              and/or
              employ much milder and less energy-intense conditions. Enzymes can
              be used in
              various industrial processes to replace harsh chemicals and save energy,
              in
              foods and feeds to improve their nutritional quality, and to generate
              fuels from
              renewable resources such as converting agricultural lignocellulosic
              waste
              matters into fermentable sugars, which can be further converted into
              ethanol.
              Other types of proteins can be used as therapeutic drugs to improve
              the health
              of patients afflicted with debilitating conditions, such as, for example,
              insulin for diabetics. It is this diversity of properties that cause
              proteins,
              enzymes and other biomaterials to have such great potential to impact
              our
              lives.</font></div>
          </div>
        </div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          Traditional methods of discovering proteins do not utilize a DNA-based
          approach,
          but are accomplished by screening biological extracts or culturing
          microorganisms for the activity of interest. Once a biological activity
          of
          interest is identified, purification is performed and the relevant protein
          is
          isolated. This process is followed by the difficult and time-consuming
          task of
          determining the biochemical properties of the molecule, which requires
          producing
          sufficientquantities of the molecule by generating and purifying a sample
          in the
          laboratory. Because relatively few proteins have been successfully produced
          in
          the laboratory, only a small fraction of the billions of different proteins
          and
          their corresponding genes have been classified, or characterized. Among
          the
          reasons for this modest number of characterized proteins are the generally
          small
          quantities produced in native organisms and tissues, the difficulty of
          isolating
          and purifying these small quantities, and the difficulty in obtaining organisms
          that produce large amounts of proteins of interest. In consequence, the
          universe
          of potentially useful biomaterials derived from the world's biodiversity
          remains
          largely untapped. </font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Despite
          the tremendous utility of proteins, there are limitations on their use.
          Proteins
          generally are functional only under specific conditions of temperature,
          pH, and
          salinity. Outside of those conditions, the proteins may not be functional
          or
          stable. In order to overcome these limitations, proteins are often sought
          from
          organisms that live in extreme environments - high temperature, acid or
          alkaline, and high salt environments, for example. Another way to obtain
          proteins with improved properties outside their normal operating conditions
          is
          to introduce variations in the laboratory. The genetic sequence corresponding
          to
          the protein can be studied and genetic variation may be introduced in an
          attempt
          to modify its functional properties through a process known as molecular
          evolution. The generation of improved variants has, to date, remained
          inefficient and laborious. Once genetic variants are created, the improved
          molecules must be selected from large numbers of variants to find those
          with the
          desired properties. This selection process requires the ability to quickly
          screen large numbers of genes to distinguish the improved versions.
</font></font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
          Through the application of recombinant DNA molecular methodology, scientists
          can
          now insert genes from one organism into another and direct the production
          of a
          desired bio-molecule encoded by the gene. Once a desired gene is found
          and
          optimized, commercial production requires the insertion of the gene into
          a
          production system, or host production organism, such as our patented C1
          fungal
          Expression System, that has been adapted to express the gene and produce
          proteins from that gene. However, genes encoding unique bio-molecules may
          not be
          able to be expressed and commercially produced in traditional systems.
          Not all
          genes are able to be processed efficiently in all organisms, including
          our C1
          System; therefore it is necessary to determine what expressions system
          should be
          used for commercial production as early as possible in the R&amp;D
          process.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
At
          an enormous cost, drug companies have attempted to use a number of different
          protein discovery and expression systems to assist with drug discovery,
          each of
          which, we believe, suffers from significant limitations. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Bacterial
          Expression
          Systems</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
          Bacterial expression systems cannot express many of the native genes from
          eukaryotic sources. Eukaryotes consist of larger cells from higher order
          organisms and contain linear DNA strands associated with proteins to form
          true
          chromosomes. Bacteria are unable to appropriately process introns, the
          portions
          of eukaryotic genetic sequences not involved in coding for protein. In
          addition,
          bacteria are unable to perform glycosylation - the process of attaching
          sugar
          molecules in the correct arrangement as required to translate many eukaryotic
          genes into functional, active proteins. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Yeast
          Expression
          Systems</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
          Yeast
          systems are not able to express many native eukaryotic genes as effectively
          as
          filamentous fungal systems due to hyperglycosylation and ineffective intron
          processing. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</em></font></div>
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9</strong></font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
                of
                Contents</a></em></font></div>
            </div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Filamentous
            Fungal
            Expression Systems</em><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
            Most
            fungi have the capability of expressing and secreting higher levels of
            protein
            per unit volume in fermentors than either bacteria or yeast, but yields
            are
            still low without significant development work on the host. In addition,
            these
            systems also have glycosylation issues similar to those in yeast, and
            their high
            viscosity can make commercial scale-up difficult. Moreover, most fungi
            are
            cultivated at acidic conditions, which can lead to instability of some
            human
            proteins, as these conditions are not the normal physiological conditions
            under
            which those proteins are stable. The biological properties of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">commercial
            fungal expression systems also typically result in dense mats of fibers
            and
            highly viscous cultures that are difficult to work with, especially in
            the small
            volumes required for high throughput screening. In industrial fermentations,
            the
            agitation necessary to adequately mix and aerate viscous cultures introduces
            large shear forces to the fermentation broth, making the production of
            shear-sensitive proteins difficult or impossible.</font></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Transgenic
            Plants and
            Animal Systems</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
            Transgenic plants and animals have long development time lines. While
            scale up
            is relatively easily achieved by raising larger herds or planting more
            acreage,
            the ability to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">produce
            product on demand is limited, especially in plants. Also, containment
            is an
            issue, especially for pharmaceuticals where there are strict regulations
            regarding consistency and efficacy. </font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Insect
          Cell
          Systems</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">:
          Insect
          cell systems have many of the advantages of mammalian cells - for example,
          the
          ability to glycosylate proteins in a similar fashion. However, insect cell
          cultures are more difficult to scale up and do not produce the high protein
          yields that fungal cultures do. Also, permanent cell lines are difficult
          to
          maintain. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Mammalian
          Cell
          Systems: </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mammalian
          cells such as Chinese hamster ovary (CHO), mouse fibroblast (NIH3T3) and
          hybridomas are among the cell lines most commonly used by the pharmaceutical
          companies at present for producing biopharmaceuticals, with CHO cells being
          the
          most common. The mammalian cell expression systems often produce human
          proteins
          with better glycosylation and other post-translational modifications than
          other
          cell lines, but they are expensive, difficult to use, less robust, and
          in some
          cases produce lower amounts of proteins than other systems. In addition,
          there
          are some human therapeutic proteins that mammalian cells cannot produce
          at
          useful levels because the action of the protein hinders the growth of the
          host
          cell itself. Mammalian cells are also vulnerable to prion and viral
          contamination. Generally lower protein yields in these cell lines and the
          high
          cost of fermentation media needed for their growth results in high associated
          production and capital costs for mammalian cell systems.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due
          to
          some of the shortcomings of these current technologies, drug companies
          have been
          plagued by substantial capital spending requirements due to the expensive
          nature
          of the fixed assets required to manufacture biological products, including
          very
          expensive fermentation and purification equipment, shortfalls in manufacturing
          capacity, high cost and low yield production, significant labor intensive
          and
          costly research, and significant delays in bringing drugs to market.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Dyadic&#8217;s
          Solution</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;We
          have developed a patented protein expression system - our C1 Expression
          System -
          which we are now successfully using in our Enzyme Business. However, we
          believe
          our C1 Expression System, in combination with our successful development
          of the
          C1 Screening System, will eventually permit drug companies to fill major
          gaps in
          the drug development process by having both an available gene discovery
          library
          and a single suitable host production organism usable throughout the discovery,
          pre-clinical and clinical testing and commercial production phases of drug
          development. By the same reasoning, the C1 Host Technology is expected
          to
          benefit the development of industrial or specialty enzyme products by allowing
          discovery, improvement, development and large-scale manufacturing in a
          single
          host organism, resulting in shorter inception to commercialization time
          and
          greater probability of success.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          patent protected C1 Expression System is based on </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chrysosporium
          lucknowense</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          or C1,
          a fungal host production organism with superior genetic and fermentation
          characteristics that we discovered, developed and patented for use in
          manufacturing of cellulase enzymes for applications in the textile and
          pulp and
          paper industries. We first encountered C1 during the course of a program
          to
          develop a cellulase enzyme for textile manufacturing applications. Out
          of that
          program, we developed C1 strains and processes which resulted in a several
          hundred fold increase in protein production, compared to those originally
          obtained with the culture isolated from nature. The characteristics of
          the C1
          organism, which we believe to be unique, and the competitive need for a
          proprietary fungal expression system motivated us to apply molecular genetic
          technology to the further development of C1. The morphology of the C1 culture
          allows the use of culture conditions that are not normally attainable with
          fungi
          and which lead to increased protein yields and more protein-friendly production
          processes. This ability to grow under non-acidic and low viscosity in culture
          conditions allows the production of acid-sensitive and shear-sensitive
          human
          proteins that may otherwise be unstable under typical fungal fermentation
          conditions. </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
              major
              hurdle in the development of expression technology for the production
              of
              heterologous proteins has been degradation of the expressed proteins
              by
              proteases normally produced by C1. As a result of our focused effort
              to
              identify, clone the genes for, and eliminate those proteases, we have
              generated
              strains with very low levels of protease as compared to the original
              host
              strains. Recent preliminary data, based on <em>in vitro</em> stability of
              several therapeutically relevant proteins in the presence of culture
              broth from
              those strains, suggests that the protease-reduced strains will be useful
              for the
              production of biopharmaceuticals. For example, when a particular full
              length
              antibody was incubated with culture filtrate from one of the recently
              developed
              strains, no evidence for degradation of that antibody was observed
              after 24
              hours of incubation; in the presence of culture broth from the precursor
              strains, the antibody was rapidly degraded. </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
            believe that our C1 Expression System is particularly advantageous in
            the rapid
            development of new biological products from genes and in the commercial-scale
            production of various biological products at economically </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">viable
            costs, using a single host organism. As the following table indicates,
            we
            believe our C1 Expression System overcomes many of the limitations of
            existing
            commercial expression methods by offering significant advantages in expressing
            certain classes of proteins. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Capabilities
          of Current Expression Systems </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table border="1" cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" height="12" valign="top" width="14%" style="border-bottom: black thin solid;">&#160;</td>
                <td height="12" valign="middle" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mammalian
                    Cells</font></div>
                </td>
                <td height="12" valign="middle" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bacterial
                    Systems</font></div>
                </td>
                <td height="12" valign="middle" width="15%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yeast
                    Cell</font></div>
                </td>
                <td height="12" valign="middle" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Insect
                    Cell</font></div>
                </td>
                <td height="12" valign="middle" width="15%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                    Fungi</font></div>
                </td>
                <td height="12" valign="middle" width="8%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C1</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="14%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intron
                    Processing </font></div>
                </td>
                <td valign="middle" width="12%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="11%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Limited</font></div>
                </td>
                <td valign="middle" width="10%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="8%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="14%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expression
                    of Eukaryotic Proteins </font></div>
                </td>
                <td valign="middle" width="12%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="11%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Very
                    Limited</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Limited</font></div>
                </td>
                <td valign="middle" width="10%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="8%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="14%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Compatibility
                    with HTS </font></div>
                </td>
                <td valign="middle" width="12%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font></div>
                </td>
                <td valign="middle" width="11%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Limited</font></div>
                </td>
                <td valign="middle" width="10%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font></div>
                </td>
                <td valign="middle" width="8%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="middle" width="14%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glycosylation</font></div>
                </td>
                <td valign="middle" width="12%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="11%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Hyperglycosylation</font></div>
                </td>
                <td valign="middle" width="10%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Hyperglycosylation</font></div>
                </td>
                <td valign="middle" width="8%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TBD*</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="14%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Output
                    Optimizable </font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
                    Large-Scale Manufacturing </font></div>
                </td>
                <td valign="middle" width="12%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Limited</font></div>
                </td>
                <td valign="middle" width="11%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="10%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font></div>
                </td>
                <td valign="middle" width="15%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
                <td valign="middle" width="8%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*
          To be
          determined. The analysis of selected proteins produced by C1 shows that
          in those
          proteins, the glycan (carbohydrate) structures contain fewer sugars than
          do
          glycans typically obtained in filamentous fungi and yeast.&#160; Filamentous
          fungi and yeast typically produce glycans containing seven or more mannoses,
          a
          specific type of sugar.&#160; The production of glycans with large numbers of
          mannoses is termed "hyperglycosylation".</font></div>&#160;

        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
          We believe that our C1 Expression System offers many differentiating advantages
          over commonly used protein expression systems, including: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Use
                    with Eukaryotic Genes; Flexibility: The C1 Expression System
                    is the
                    product of the C1 Host Technology out of which we believe we
                    will also be
                    able to develop the C1 Screening System. We believe the C1 Host
                    Technology
                    can spawn the C1 Screening System to discover proteins, enzymes
                    and
                    bio-molecules of commercial interest rapidly from eukaryotic
                    sources,
                    which some scientists estimate constitute up to 90% of the entire
                    gene
                    pool in nature, and with genes originating from prokaryotic sources.
                    We
                    believe that the use of a single host production organism usable
                    throughout the discovery, pre-clinical and clinical testing and
                    commercial
                    production phases of drug development would greatly increase
                    efficiency,
                    economy and speed to market. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Greater
                    and Faster Expression: Our C1 Expression System has the ability
                    to express
                    higher levels of total protein in a shorter amount of time than
                    other
                    eukaryotic host organisms commonly used for pharmaceutical protein
                    production. The reduction in the number of fermentation days
                    generally
                    results in lower production and capital costs associated with
                    the
                    production of protein products. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Favorable
                    Fermentation Characteristics: Our C1 Expression System operates
                    under
                    favorable fermentation conditions, including low viscosity and
                    wider
                    operating temperature and pH ranges, allowing optimal culturing
                    under
                    human physiological conditions, i.e. 37 degrees Celsius and neutral
                    pH.
                    Also, because the high levels of agitation that are necessary
                    to provide
                    oxygen to fungal and other microorganisms during high viscosity
                    fermentations may destroy shear-sensitive proteins, the ability
                    of the C1
                    Expression System to produce proteins under lower viscosity conditions
                    will increase the probability of successfully producing various
                    shear-sensitive human therapeutic proteins.
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Acidity:
                    The protein products of many genes, especially those of pharmaceutical
                    interest, may be sensitive to being cultured under acidic conditions.
                    Therefore, the ability of our C1 Expression System to produce
                    acid-sensitive proteins under human physiological conditions
                    will provide
                    a greater likelihood of commercializing those proteins.
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Favorable
                    Glycosylation: Our C1 Expression System appears to have favorable
                    glycosylation biochemistry compared to other fungi or yeast.
                    The latter
                    organisms tend to hyperglycosylate, generating proteins with
                    7-11 or more
                    mannosyl residues in their glycan structures. However, no such
                    hyperglycosylation has been observed in our C1 Expression System,
                    suggesting that C1-produced proteins are more amenable to in
                    vivo and in
                    vitro approaches to glycan remodeling than those from other expression
                    hosts. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="SP">Dyadic</a>&#8217;s
          Products and Services</u></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
          Business </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          Enzyme Business addresses major needs in diverse industrial enzyme markets,
          including textiles, animal feed, pulp and paper, starch, food, beverage
          and
          brewing and other markets. Though we experienced growth in our sales to
          the
          textiles market in the past, we recognized the mature market dynamics of
          that
          segment in 2004 and began to move to diversify our revenue base by focusing
          on
          other industries. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          May
          2005, we obtained a high quality DNA sequence of the 38,000,000 bases in
          the C1
          genome, which was performed for us by Agencourt Bioscience Corporation.
          The C1
          sequence is aiding in the development of our current business and is expected
          to
          do so in the future, based on the ability of the C1 organism to produce
          large
          volumes of low cost industrial enzymes for industrial, textile, pulp and
          paper,
          animal feed and food, and agricultural applications and to expand the commercial
          capabilities of this technology. We expect to further extend its market
          reach to
          develop new and better therapeutic proteins more affordably. The C1 genome
          sequence is permitting us to mine it to identify novel and improved protein
          products for a broad spectrum of industries, including energy, animal feed,
          food, and pulp and paper. In addition, this sequence information is expected
          to
          enable us and our collaborators to expand the variety of proteins and enzymes
          that can be brought to market. As an example, we expect to provide unique
          enzymes to companies in these industries to alleviate production process
          bottlenecks and high manufacturing costs they often face, as well as to
          enable
          manufacturing of many products in their R&amp;D pipelines for which no suitable
          production processes have yet been found. We also expect that this genome
          sequence information will allow Dyadic to improve the C1 Expression System
          by
          (i) readily identifying and isolating genes that interfere with high-level
          expression of proteins and knocking them out and (ii) allowing the
          identification and improvement of genes and proteins that have a positive
          impact
          on gene expression. During 2006, we intend to continue our focus on the
          development of our C1 Host Technology for expression of human antibodies
          and
          other therapeutic proteins in our fungal expression system.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          sequence has already proved useful by allowing Dyadic to search for genes
          within
          the raw sequence data. To date, a large number of potential commercial
          targets
          have been identified in the genomic sequence through homology searches,
          and a
          program to clone the most commercially relevant of these for expression
          is
          currently underway. However, we anticipate additional value when the genome
          is
          fully annotated.&#160; Annotation will result in gene mining, curation, search,
          and viewing tools to allow the extraction of useful information from the
          C1
          genome sequence.&#160; In addition to identifying further commercial targets,
          this annotated searchable genomic sequence will serve as a blueprint for
          the C1
          host strain and will facilitate further development of C1 based technology
          as a
          platform for discovery and production of&#160;a variety of proteins, including
          high-value therapeutics. The annotated genome will allow identification
          of key
          metabolic functions that influence expression of genes, and further will
          facilitate the use of advanced genetic technologies, e.g. microarrays,
          to
          monitor and eventually modify and modulate these functions for optimizing
          host
          strain development and expression optimization in those hosts. Based on
          the
          Company&#8217;s favorable results derived from the outsourcing of the C1 sequencing
          project, we are currently in late stage discussions for C1 sequence annotation
          with third parties and expect to arrive at such collaboration in the near
          future.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Textiles
          Industry </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Historically
          we have had a significant market position developing, manufacturing and
          marketing cellulase enzymes for a variety of textile production and fabric
          finishing applications, including softening, fading and treating of denim
          garments. We offer a wide range of cellulase enzyme products for applications
          such as: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">denim
                    finishing where cellulases are used to soften and fade the denim
                    fabric,
                    including Rocksoft ACE series and numerous other Rocksoft series;
                    and
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">biofinishing
                    of cotton and cellulosics using BioACE series, which is a biofinishing
                    process to prevent pilling and improve smoothness, softness and
                    color
                    brightness, and biopolishing. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
            example of a cellulosic fabric is Tencel &#8482;, a high performance cellulosic fiber
            made by Acordis. Its inherent strength, handle properties, tendency to
            fibrillate, as well as its environmentally positive manufacturing processes,
            makes Tencel &#8482; more desirable than other regenerated cellulosics. Our BioACE
            series, an acid cellulase derived from Trichoderma longibrachiatum, offers
            a
            cellulase that has been approved and recommended by Acordis for the treatment
            of
            100% Tencel &#8482; and its blends. Our textile enzymes are formulated in various
            forms, including granular, liquid, and powder. </font></div>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
We
          continue to seek improvements in the economics and performance of our
          cellulases. Our ongoing research projects for the over-expression of a
          number of
          advanced enzymes for the textile industry includes cellulase endoglucanases,
          currently in pre-commercial stages which provide denim finishing with a
          soft
          feel and stonewashed appearance or depilling at lower cost or more favorable
          processing conditions. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;In
          2003, using our C1 Expression System, we launched two new products, created
          by
          isolating genes and reintroducing them into our C1 host organism, to increase
          the productivity of the enzymes: the resulting superior product performance
          has
          both improved our profit margins and increased our sales. One or our products,
          NCE2X, replaced one of our standard neutral cellulase products by offering
          a
          better and cleaner look on denim. We have identified, cloned and expressed
          genes
          for several additional products that are in various stages of development
          for a
          variety of applications such as textiles, pulp and paper, food, animal
          feed and
          beverages. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          textiles market, which is characterized by low profit margins and intense
          competition, accounts for a majority of our current net sales. We have
          experienced a gradual decline in our share of that market, which we primarily
          attribute to (i) our previous lack of adequate resources to match the level
          of
          investment in this market being made by our competitors, and (ii) our
          application of a greater portion of our efforts on higher margin and larger
          market opportunities such as pulp &amp; paper and animal feed. To what degree
          our sales from this market will continue to decline in the future will
          depend
          not only that market&#8217;s dynamics, but also on the extent of pricing pressure
          created by our competitors, how successful we are in developing new
          products,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
          our
          ability to lower our production costs.&#160; In this connection, we are
          exploring several product leads for improving the performance of existing
          products and developing new products as well as working to reduce the production
          costs of these products. We intend to continue exercising discipline over
          the
          application of resources to the textile market relative to other markets
          we
          perceive to offer the Company greater opportunity.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Pulp
          and Paper Industry </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Enzymes
          offer significant processing and environmental benefits for the pulp and
          paper
          industry. We serve this market by developing, producing and selling enzymes
          for
          bleach boosting, de-inking, bio-refining and wastewater processes which
          provide
          significant increases in process efficiency and</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">improvements
          in the quality of pulp or paper products, including increased strength,
          brightness and whiteness. In addition, our products reduce the environmental
          impact of the paper manufacturing processes by reducing the use of harsh
          chemicals and the volume of solid waste in the discharged waste water.
          We
          estimate that approximately $1.0 billion of the $8.0 billion pulp and paper
          chemicals market, including bleach boosting, de-inking and bio-refining,
          is
          available to be penetrated by our enzyme products. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
          offers four commercial products, FibreZyme LBL for bleach boosting, FibreZyme
          LDI for de-inking, FibreZyme LBR for bio-refining and FibreZyme LWT for
          Wastewater Treatment. Currently, these products are being purchased by
          customers
          as well as being trialed by new customers in various geographical areas
          and on
          varying mill furnishes.&#160; Initial data from mill trials with both our new
          and existing customers has thus far supported our expectations for the
          improved
          effectiveness of the enzymes.&#160;&#160; Some of the benefits of our enzymes
          are being seen in plant trials with new customers and in the continuing
          operations of existing customers such as (i) improvement in the fiber properties
          (e.g. increased strength, higher brightness, better drainability), (ii)
          energy
          savings (e.g. steam and electricity), (iii) lower chemical consumption
          (e.g.
          bleaching chemicals), (iv) and lower waste water treatment demand.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          are
          presently in the preliminary stages of testing a new bio-refining product
          to
          further improve the strength properties of paper. We are also evaluating
          a new
          product for bleach boosting. It is our plan to continue to develop, evaluate,
          and introduce improved products in these areas along with evaluating new
          market
          opportunities on a selected basis.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Animal
          Feed Industry </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
          provides specialty enzymes for customers who process grains such as barley,
          wheat and rye to produce animal feed and other related products. Many feed
          ingredients currently used are not efficiently digested by poultry or livestock.
          However, by adding enzymes to feed, the digestibility can be improved.
          Our feed
          enzymes are used as additives that allow feed producers to supplement lower
          cost
          raw materials and also to improve the efficiency of existing formulations.
          The
          main benefits of supplementing feed with enzymes, as revealed by feed trials
          carried out to date, are faster growth of the animal, better feed utilization,
          or feed conversion ratio, more uniform production, better health status
          and
          reduced environmental waste. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Presently,
            we make and sell two animal feed enzyme products offered in different
            activity
            levels and formats: our Beta Glucanase BP CONC, a beta-glucanase, is
            used in
            conjunction with barley-based diets, and our Xylanase 2XP CONC, a xylanase,
            is
            used in conjunction with wheat based diets. Registration of these products
            in
            various countries is on going and is expected to help increase the distribution
            of our products.</font></div>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>13</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additionally,
          we intend to develop other animal feed enzymes for specific diets in which
          highly effective enzymes are currently neither commercially available nor
          provide an improved cost efficacy ratio:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Enzymes
                    to improve corn/soybean meal diets that are commonly used for
                    poultry and
                    swine in the U.S.; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phytase,
                    an animal feed enzyme additive that is designed to increase the
                    absorption
                    of organic phosphorous, lowering the environmental impact of
                    fecal matter,
                    and to increase the digestibility of carbohydrates as well as
                    the
                    promotion of weight gain in livestock.
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
          assist
          us in our endeavors in the animal feed market in Europe and elsewhere,
          we have
          hired a sales consultant with significant experience and expertise in this
          industry, who is expected to begin in April 2006. Historically, we have
          sold in
          this industry without a sales support staff dedicated to this market and
          it is
          our expectation that this addition will increase our sales in the animal
          feed
          market in the latter part of 2006. There is no guarantee, however, that
          our
          sales will increase significantly or in the time frame that we
          anticipate.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Food
          Industry </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          are
          presently marketing products to significant markets in the food industry.
          We
          produce and sell the product CeluStar XL to the wheat starch processing
          plants
          in Europe for the production of high fructose syrups and other starch based
          products. This product has a competitive advantage over other enzymes through
          its ability to drop viscosity during the first stages of the starch production
          process. We produce and sell GlucoStar 400L and ViscoStar 150L to the brewing
          and alcohol production market in Europe. We produce and sell BrewZyme Series
          and
          FoodCel Series products to the brewing and fruit juice production markets
          in
          Europe, North and South America and Asia. China has become a large and
          rapidly
          growing market for brewing enzymes as the disposable income of its population
          increases. Through one of our subsidiaries, two regional distributors and
          one
          national distributor, we expect to significantly increase our rate of
          penetration of this market. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioSciences
          Business </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          expect
          our BioSciences Business to generate revenue by using our C1 Expression
          System
          to enable its business partners to successfully make sufficient quantities
          of
          promising therapeutic proteins for preclinical and clinical testing, thereby
          improving prospects for a drug candidate's advancement from discovery through
          development, accelerating development time and reducing R&amp;D costs.
          Relationships with business partners will vary, ranging from pure contract
          research, to collaborations, to strategic business partnerships such as
          joint
          ventures and product co-development and co-marketing on a project by project
          basis. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When
          we
          license our technology to our customers, we anticipate that the revenues
          to be
          derived from projects will be comprised of: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">licensing
                    fees earned for deploying the C1 Expression System, or Technology
                    Access
                    Fees, </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">research
                    reimbursement fees for the performance of project research, or
                    Research
                    Fees, </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" bgcolor="white" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">payments
                    based on Dyadic&#8217;s and/or the customer's successful achievement of Dyadic&#8217;s
                    research or customer&#8217;s drug development milestones with the biological
                    product, starting with the successful initial expression of target
                    proteins with customer&#8217;s genes, all the way to approval of the protein
                    drug candidate by regulatory authorities, or Milestone Achievement
                    Success
                    Fees, and </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">royalties
                    on those biological products that have been successfully enabled
                    by our
                    proprietary technologies. </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          addition, although the mix of Technology Access Fees, Research Fees, Milestone
          Achievement Success Fees and royalties will vary from project to project,
          depending on whether the customer is a biotechnology company, which involves
          lower Technology Access Fees and Milestone Achievement Success Fees and
          higher
          royalties, or a pharmaceutical company, which provides the opposite types
          of
          fees and payments, we contemplate that in some cases our customer may take
          an
          equity interest in us, or that we may take a joint venture interest in
          the
          biological product. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          BioSciences Business will be focused on the C1 Expression System's performance
          of its role as an enabling technology for drug companies. Specifically,
          each
          project will involve a protein already characterized by the customer, or,
          in
          other words, one that has been discovered and is believed by the customer
          to
          have high commercial potential. The customer will deliver to us the gene
          encoding this protein. Using our C1 Expression System, we will attempt
          to
          express, or in other words produce, laboratory-testing quantities of the
          protein
          for the customer. </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>14</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          addition, the BioSciences Business will be utilized for the production
          of
          industrial enzymes for clients. We anticipate that sales will be derived
          from a
          combination of research fees, milestone payments, royalties, and manufacturing
          rights. We also anticipate development of enzymes to satisfy the expanding
          interest and emphasis on industrial biotechnology, especially in areas
          of fuels
          and chemicals from renewable resources such as agricultural biomass. We
          anticipate participating in and applying for grant applications to US government
          agencies to fund this work, with potential grant revenues being received
          in late
          2006 or in 2007.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          also
          have several other technologies under development, including our C1 Screening
          System, which we anticipate will some day incorporate a high throughput
          screening, or HTS technology, for discovery of new genes and/or screening
          for
          improved variants of previously or newly discovered genes. In 2005 we decided
          to
          shift resources from the continued development of the HTS technology, but
          have
          begun to seek new collaboration partners to restart efforts to complete
          its
          development. Should these technologies be successfully developed, they
          may serve
          as additional revenue streams for the BioSciences Business. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          order
          to advance our efforts with our Enzyme and BioSciences Businesses and with
          the
          resurgence of interest in the production of cellulosic ethanol, we hired
          Glenn
          E. Nedwin, Ph.D. in March 2006, to become (i) the Company&#8217;s Chief Scientific
          Officer, (ii) an Executive Vice President of the Company, (iii) the President
          of
          the BioSciences business of the Company&#8217;s wholly-owned subsidiary, Dyadic
          International (USA), Inc., and (iv) a member of our board of directors.
          During
          the past fourteen (14) years Mr. Nedwin has served as the President of
          Novozymes, Inc., a research and development subsidiary of Novozymes A/S,
          a
          leading industrial biotechnology company specializing in enzymes and
          microorganisms, where he has been responsible for all scientific, financial
          and
          administrative functions of that company, including product and technology
          licensing, enzyme research management and biotechnology strategy and research.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Alternative
          Fuels</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
          has
          been much publicity recently surrounding the alternative fuels market.
          We have,
          for a number of years, invested significant R&amp;D resources in the development
          of cellulases, xylanases, and other hemicellulases for a variety of
          applications, some of which we believe could be used in the ethanol production
          process. Further, we recently hired Dr. Glenn Nedwin to serve as Chief
          Scientific Officer and intend that one of his responsibilities be to evaluate
          and develop plans for our entry into this market. While we continue to
          remain
          focused on the execution of our strategies in other markets - and most
          particularly, the pulp and paper market - we intend to develop plans to
          enter
          the alternative fuel market and look for collaboration partners to assist
          us in
          this endeavor.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="strategy">Dyadi</a>c&#8217;s
          Strategy</u></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          are
          pursuing a four part business strategy to commercialize our C1 Host Technology,
          which includes the C1 Expression System and the C1 Screening System as
          well as
          the products developed using that Technology, which may be generally summarized
          as follows: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Grow
                    our market share and penetration for existing and new enzyme
                    products,
                    with an emphasis on increased sales of higher margin products;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Leverage
                    our C1 Expression System for commercial and industrial applications
                    by
                    developing new products for various industrial and commercial
                    markets and
                    by securing collaborator-funded R&amp;D from third parties, and enabling
                    us to earn milestone and royalty payments on target products
                    expressed
                    using the C1 Expression System; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Build
                    and grow our BioSciences Business by serving as a collaboration
                    partner
                    and service provider to large pharmaceutical companies for promising
                    therapeutic proteins; and </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exploit
                    the power and versatility of our C1 Host Technology as well as
                    our
                    manufacturing capabilities, by forming strategic partnerships,
                    such as
                    joint ventures and product co-development and co-marketing ventures
                    with
                    leading companies in various industries and various parts of
                    the world. In
                    addition, we also hope to eventually spin-off new businesses
                    emanating
                    from the application of our C1 Host Technology, when we believe
                    more value
                    can be created for our stockholders by doing so rather than keeping
                    them
                    within our Company. To this end, we intend to explore the opportunities
                    that may exist for the development of cellulosic ethanol and
                    other
                    possible applications of our technologies in the energy
                    industry.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>15</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
            Business Strategy </em></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
            C1
            Expression System already is functional for the production of many enzymes
            and
            proteins for the industrial markets. We have already developed and manufactured
            a number of enzymes in large quantities using our C1 Expression System
            in
            150,000 liter fermentors and sold those products commercially worldwide.
            Additionally, there are several enzymes in our R&amp;D pipeline emanating from
            the C1 organism and the C1 Expression System. We </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expect
            to
            commercialize an even wider variety of new enzymes and proteins for the
            industrial markets with better functional properties and improved cost
            performance through our efforts, alone, and in collaboration with leading
            companies in industry sectors, such as pulp and paper, agricultural products
            for
            animals and humans, chemicals, textiles, and personal care products.
            </font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Using
          our
          C1 Host Technology and capitalizing on our strong position in the textile
          market, our goal for our Enzyme Business is to become a top-tier provider
          of
          enzymes to broader markets, including pulp and paper, animal feed, starch,
          food
          and other markets. To accomplish this goal, we intend to: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diversify
                    sales away from the commoditized textile market to other less
                    competitive
                    fast-growing markets; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Register
                    existing products in large new markets for sales to identified
                    customers;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Discover
                    and develop new enzyme products for new applications in existing
                    and new
                    markets; </font></div>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Leverage
                    the DNA sequence of the C1 genome to facilitate the identification
                    of new
                    product leads from C1 genes and to provide better understanding
                    of the
                    biochemistry and physiology of C1. The latter will enable us
                    to develop
                    strategies to improve carbon flow toward proteins and other bio-molecules
                    of interest and to rationally construct better host strains for
                    both our
                    C1 Expression System and our C1 Screening System;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Continue
                    to expand and utilize the low-cost production capacity of our
                    contract
                    manufacturer; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Establish
                    additional manufacturing capacity; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Leverage
                    investment in R&amp;D to continue to improve yields and to drive revenue
                    and profits though the launch of innovative products;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Add
                    sales and technical staff to support significant marketing initiative
                    into
                    new industrial markets; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Add
                    corporate infrastructure and staff to support projected revenue
                    growth;
                    and </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Partner
                    with leading companies to develop and manufacture enzymes and
                    other
                    bio-products under an appropriate business arrangement, such
                    as joint
                    venture, co-development and co-marketing of products.
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          textiles market, which is characterized by low profit margins and intense
          competition, accounts for a majority of our current net sales. We have
          experienced a gradual decline in our share of that market, which we primarily
          attribute to (i) our previous lack of adequate resources to match the level
          of
          investment in this market being made by our competitors, and (ii) our
          application of a greater portion of our efforts on higher margin and larger
          market opportunities such as pulp &amp; paper and animal feed. To what degree
          our sales from this market will continue to decline in the future will
          depend
          not only that market&#8217;s dynamics, but also on the extent of pricing pressure
          created by our competitors, how successful we are in developing new products,
          and our ability to lower our production costs.&#160; In this connection, we are
          exploring several product leads for improving the performance of existing
          products and developing new products as well as working to reduce the production
          costs of these products. We intend to continue to exercise discipline over
          the
          application of resources to the textile market relative to other markets
          we
          perceive to offer the Company greater opportunity.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One
          of&#160;our top priorities during 2005 was to sharply expand&#160;the
          introduction of&#160;our pulp and paper enzyme products to that industry. While
          we believe these products offer an exceptional value proposition for this
          industry, we made a strategic decision to approach the penetration of this
          market with an acute sensitivity to the fact that our target customer
          decision-makers are responsible for physical plants costing, in many instances,
          several hundred million dollars or more, and are accustomed to dealing
          with
          highly technical sales teams with strong support competencies, following
          long-term trials of new products. Accordingly, we set about to recruit
          and
          assemble a team of </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>16</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">seasoned
          sales and marketing executives&#160;and technical salesmen with extensive pulp
&amp; paper industry experience and contacts in promoting and
          maintaining&#160;sales relationships involving substantial on-going sales and
          technical servicing. During 2005, we successfully recruited a Vice President
          of
          Sales &amp; Marketing - Enzymes,&#160;a Vice President - Pulp &amp; Paper, and 6
          technical sales representatives whom&#160;we believe fit this description as
          well as additional technical sales representatives in our Asian subsidiary.
          The
          addition of the sales and marketing personnel occurred throughout the third
          quarter, and accordingly, we do not expect to see sales results from these
          additions until mid-2006 or later. In 2006 we expect to continue to
          expand&#160;our pulp and paper sales and marketing infrastructure, as we work to
          capture both an increasing number of new customer trials&#160;and convert
          existing and new customer trials into significant and sustained levels
          of pulp
          and paper product sales. We continue to estimate&#160;the addressable market for
          our existing enzyme products in the pulp and paper industry and potential
          enzyme
          products for the pulp and paper industry currently in our research and
          development pipeline to be in excess of $1.0 billion. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          have
          also begun to focus efforts in other industries and expect to pursue these
          other
          industries, such as food, energy (cellulosic ethanol) and animal feed,
          which may
          be in a collaborative effort with a third party. However, we continue to
          support
          our textile customers, directing the necessary resources to customer support
          and
          R&amp;D innovation to maintain market share in this segment. Although we
          anticipate increased sales in industrial enzyme industries other than textiles,
          we have not generated sufficient sales activity on which to base projections
          about the sales levels for 2006 and beyond.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          are
          currently assessing various methods to register our existing Animal Feed
          products and new products under development for this industry, and anticipate
          growth in this market through sales in the European Union (largest market)
          and
          elsewhere over the next two to three years. We also expect to be able to
          focus
          some additional efforts in other markets such as starch and brewery now
          that we
          have hired additional people for registration of products and concentration
          of
          these market opportunities.&#160; </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
          assist
          us in our endeavors in the animal feed market in Europe and elsewhere,
          we have
          hired a sales consultant with significant experience and expertise in this
          industry who is expected to begin April 1, 2006. Historically, we have
          sold in
          this industry without a sales support staff dedicated to this market, and
          it is
          our expectation that this addition will increase our sales in the animal
          feed
          market in the latter part of 2006. There is no guarantee, however, that
          our
          sales will increase significantly or in the time frame that we
          anticipate.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioSciences
          Business Strategy </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
          we
          believe that our C1 Expression System has created great opportunity for
          our
          Enzyme Business, we believe a much greater opportunity exists to develop
          our C1
          Expression System for the production of higher value proteins, such as
          human
          therapeutic proteins. We have been developing and refining our molecular
          tools
          to deal with the more complex issues involved in the production of those
          proteins, such as glycosylation, protein degradation and high purity level
          requirement, which are critical for human therapeutic protein production.
          Once
          fully developed, we believe our C1 Host Technology can integrate our C1
          Expression System with our C1 Screening System to create a fully-integrated
          discovery and expression system that will help companies in diverse industries
          -
          including pharmaceuticals - to discover, develop and bring to market new
          and
          improved protein and enzyme products from a wider range of DNA sources
          and with
          better properties than has been possible with other systems. Since the
          same cell
          line, C1, will enable all R&amp;D steps involved in bringing a DNA product to
          market, we believe that the probability of success will be higher and the
          R&amp;D cycle time will be shorter. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          goal
          for our BioSciences Business is to become the leading provider of expression
          solutions to pharmaceutical and biotechnology companies. Initially, we
          have been
          concentrating on enabling the C1 Expression System to express pre-clinical
          and
          clinical quantities of therapeutic proteins for drug testing, and eventually,
          for commercial-scale production of therapeutic proteins and other bio-molecules.
          In particular, we expect that our C1 Expression System will facilitate
          the
          production of biopharmaceuticals that might otherwise be shelved, and will
          enable development of functionally improved drugs using molecular evolution
          techniques in conjunction with the C1 Screening Technology we are developing.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          believe that increased profitability can arise from the anticipated capabilities
          of the C1 Host Technology to use a single host organism for both discovery
          and
          commercial production, which should lead to: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">shortened
                    preclinical R&amp;D timelines; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                    development of therapeutic protein drugs with better properties;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">possible
                    enablement of shelved new drug candidates;
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">improved
                    prospects for an increase in probabilities for drug candidates
                    advancement
                    from discovery through development;
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>17</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
          <div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                <div>
                  <table cellpadding="0" cellspacing="0" id="list" width="100%">

                      <tr valign="top" style="line-height: 1.25;">
                        <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                        <td>
                          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reduced
                            production costs; and </font></div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                  <div>
                    <table cellpadding="0" cellspacing="0" id="list" width="100%">

                        <tr valign="top" style="line-height: 1.25;">
                          <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                          <td>
                            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reduced
                              capital expenditures. </font></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
                this
                end, we intend to: </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </div>
            <div>
              <table cellpadding="0" cellspacing="0" id="list" width="100%">

                  <tr valign="top" style="line-height: 1.25;">
                    <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                    <td>
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">establish
                        a flexible technology out-licensing program and enter into
                        strategic
                        partnerships and collaborations to facilitate adoption of
                        the C1
                        Expression System, the C1 Screening System and the C1 Host
                        Technology;
                        </font></div>
                    </td>
                  </tr>

              </table>
            </div>
            <div>&#160;</div>
          </div>
          <div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
              <div>
                <table cellpadding="0" cellspacing="0" id="list" width="100%">

                    <tr valign="top" style="line-height: 1.25;">
                      <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                      <td>
                        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">continue
                          and expand our R&amp;D efforts both:
</font></div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
            <div>&#160;</div>
          </div>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
                    partnership with leading academic and technology development
                    centers to
                    develop and improve our C1 host strain and expression processes
                    for large
                    scale manufacturing by us and by our collaboration partners,
                    and apply the
                    C1 Expression System for customer projects in exchange for technology
                    access fees, research fees, milestone achievement success fees
                    and
                    royalties; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">leverage
                    the DNA sequence of the C1 genome to obtain a better understanding
                    of the
                    biochemistry and physiology of C1, which we expect to enable
                    us to develop
                    strategies to improve the production of therapeutic proteins
                    and develop
                    better host strains for our C1 Expression System;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">leverage
                    expression competencies to develop capabilities to develop our
                    own
                    biopharmaceuticals in the future; </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">partner
                    with pharmaceutical companies and biotechnology companies to
                    develop
                    higher yield, more efficient production methods for many blockbuster
                    biopharmaceuticals for which the applicable patent protection
                    is expiring;
                    and </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">apply
                    BioSciences to the research and possible production of cellulosic
                    ethanol.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="RD">Rese</a>arch
          and Development </u></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          scientific staff has specialized knowledge in the areas of biotechnology
          R&amp;D, enzymology, quality control, textile chemistry, and pulp &amp; paper
          technology. Our laboratories are located in Jupiter, Florida; Greensboro,
          North
          Carolina; Zeist, The Netherlands and in Southern China. Our R&amp;D activities
          include the discovery, development, improvement, and characterization of
          new and
          existing enzyme products; and the development of our technologies in the
          areas
          of gene expression, fungal molecular genetics, bioinformatics, and fermentation
          process development for the production of proteins for a variety of industries,
          including cellulosic ethanol and pharmaceuticals. Enzyme discovery and
          development utilize a number of fungal organisms, including </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Trichoderma
          longibrachiatum </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
          the
          Acid Cellulase and Xylanase lines of products, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Aspergillus
          foetidus </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
          the
          Glucoamylase products, and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chrysosporium
          lucknowense</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          C1 for
          Cellulase, Xylanase, other Hemicellulase enzymes and a variety of other
          potential enzymes identified from the completed C1 genome sequence. We
          anticipate finding additional enzymes and pathways from the annotation
          of the C1
          genome which may lead to significant product opportunities. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          C1
          Host Technology also forms the basis for our C1 Screening System, which
          incorporates a High Throughput Screening (HTS) platform that we have been
          developing, and are now searching for a collaborative partner to help us
          complete. We believe that this C1 Screening System has advantages over
          other
          screening systems in its use of the C1 filamentous fungal host, thereby
          permitting the efficient expression and screening of eukaryotic genes,
          and the
          secretion and glycosylation of their protein products, which other screening
          systems developed in yeast and bacteria are unable to efficiently perform.
          The
          most promising use of the C1 Screening System may be in conjunction with
          molecular evolution technologies, which offer a means of generating improved
          variants of proteins. For example, enzymes with higher temperature optimum
          or
          stability, higher activity, altered specificity, or altered pH optima may
          be
          obtained. In the pharmaceutical area, antibodies with improved binding
          capability, or protein therapeutics with reduced immunogenicity or improved
          efficacy, may be produced. In addition to its use in conjunction with molecular
          evolution, we expect that our C1 Screening System will, in the longer term,
          also
          be useful for discovery of novel activities in a variety of eukaryotic
          organisms: it may screen for proteins in libraries of expressed genes and
          will
          be especially useful for genes and proteins that have not been previously
          well-characterized and for which the only discovery tool is demonstration
          of the
          protein's function. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
          R&amp;D expenses for 2005 and 2004 were $4,898,876 and $3,621,451, respectively.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>18</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="RDV">Rese</a>arch
            and Development Capabilities of Consulting R&amp;D
            Vendors</u></strong></font></div>
          <div><br></div>
          <div>
            <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
              For over a decade, we have supplemented our internal R&amp;D capabilities with
              focused strategic industry collaborations with leading scientific organizations
              such as Moscow State University, the Russian Academy of Sciences, TNO
              Quality of
              Life (The Netherlands) and Bio-Technical Resources (USA), as well as
              outsourced
              R&amp;D and manufacturing relationships via our exclusive agreements and
              collaborations with Polfa Tarchomin in Europe,which provides low-cost
              manufacturing capacity, and Martek BioSciences in the U.S. When combined
              with
              our internal staff of 14 scientists, we currently have approximately
              50
              scientists working in laboratories across the globe on a variety of
              R&amp;D
              programs for us. The following is a summary description of our main
              scientific
              collaborators: </font></div>
          </div>
        </div>
        <div>&#160;</div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Bio-Technical
          Resources, Manitowoc, Wisconsin </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bio-Technical
          Resources, a division of Arkion Life Sciences LLC, or BTR, is a contract
          research organization with expertise in areas of strain and process development
          for fermentation of microbial products. We have worked with </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BTR
          since
          1995 on a variety of development programs for the production of several
          commercial enzyme products, most notably our C1 host organism, for the
          commercial scale production of neutral cellulase enzymes. BTR also has
          worked on
          the development and commercialization of products utilizing our C1 Expression
          System. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          July
          2004, Dyadic-Florida entered into a development agreement with BTR under
          which
          Dyadic-Florida agreed to pay for 80% of $1.25 million worth of R&amp;D services,
          out of a total of $1.8 million, it was contracting to purchase over a two
          year
          period from BTR by issuing shares of Dyadic-Florida common stock, representing
          300,300 shares valued at $3.33 per share. The Dyadic-Florida shares were
          issued
          and are being held in escrow. The Company must utilize, and BTR is obligated
          to
          furnish, a minimum of 1.1 full-time equivalent BTR scientists per month.
          BTR's
          rights to the shares of common stock vest and may be withdrawn from the
          escrow
          pro rata to the dollar value of BTR's actual performance of R&amp;D services, as
          such services are billed by BTR on a regular monthly basis over a period
          of
          approximately two years. In December 2004, the agreement was amended to
          extend
          the term through December 31, 2006. In addition, the development agreement
          provides for the imposition of cash penalties on BTR should it fail to
          perform
          its obligations. In December 2005, the Company issued 7,523 shares of common
          stock pursuant to the agreement and the $250,000 cash prepayment has been
          utilized in full. The number of shares held in escrow as of December 31,
          2005 is
          292,777.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>TNO
          Quality of Life, Zeist, The Netherlands </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TNO
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Quality
          of Life</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          or TNO,
          is a contract research organization sponsored by the Dutch government and
          is one
          of the Institutes comprising the Netherlands Organization for Applied Scientific
          Research. We have worked with and continue to work with TNO since 1998
          on the
          development of technologies for gene expression and gene discovery. The
          TNO
          scientists working with us are widely recognized as leaders in the area
          of
          fungal genetics and molecular biology. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          January 2003, Dyadic-Florida formed a wholly owned Dutch subsidiary (&#8220;Dyadic
          NL&#8221;) and entered into a cooperation and license agreement with TNO to cooperate
          on an exclusive basis in the development, use and marketing of a high throughput
          screening system utilizing fungal organisms. Under this agreement,
          Dyadic-Florida and TNO each had granted Dyadic NL a worldwide license to
          exploit
          certain patents and technologies, for which Dyadic NL was to make royalty
          and
          revenue sharing payments to Dyadic-Florida and TNO on revenue generated
          from its
          business operations. TNO was also granted an option to acquire shares of
          Dyadic-Florida's common stock beginning on the two-year anniversary of
          the
          formation of Dyadic NL, or earlier in certain circumstances. Incident to
          the
          consummation of the merger, the Company assumed Dyadic-Florida's obligations
          to
          TNO in respect of this option. The number of shares which TNO was entitled
          to
          purchase was based upon a formula fixed by the terms of the agreement.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          December 2005, we entered into a termination and license agreement with
          TNO (the
&#8220;Termination Agreement&#8221;), effective as of November 23, 2005. Pursuant to the
          provisions of the Termination Agreement, the Company issued 161,560 fully
          paid
          and non-assessable shares of $.001 par value Common Stock to TNO in
          consideration for: (i) the termination of the cooperation agreement; (ii)
          the
          conversion of TNO&#8217;s technology license into a paid-up, exclusive, worldwide
          license to use that TNO technology in the field of Fungal HTS systems;
          (iii)
          TNO&#8217;s conferral upon Dyadic NL of the benefit of certain other proprietary
          covenants of TNO, including a right of first offer on non-fungal HTS systems
          developed by TNO during the three-year period following the Effective Date;
          (iv)
          TNO&#8217;s agreement to perform research services for Dyadic NL in connection with
          its efforts to complete the development of a Fungal HTS System on a favored
          pricing basis as a &#8220;Preferred Supplier&#8221;; (v) the cancellation of TNO&#8217;s rights to
          receive stock options, royalties, profits, or gains, if any, realized from
          a
          successful commercialization of the fungal HTS; and (vi) the satisfaction
          of all
          indebtedness of Dyadic NL to TNO, including a trade payable for research
          services rendered by TNO to Dyadic NL in the approximate amount of $377,000.
          The
          term of the Termination Agreement is until the first to occur of (i) the
          mutual
          written agreement of the parties or (ii) the expiration of the later of
          18 years
          following the effective date or (ii) the date of the expiration of the
          last to
          expire of the patents licensed by TNO to Dyadic NL. The Termination Agreement
          is
          fully assignable by any of the parties, and contains the same arbitration
          provisions as were in the cooperation agreement. The stock was valued based
          on
          the fair market value of the Company&#8217;s </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>19</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font size="2">common
              stock on the date of closing. A credit of approximately $76,000
              resulting from this transaction is included in research and development
              expense
              in the accompanying consolidated statements of operations for the year
              ended
              December 31, 2005. </font></font></div>
            <div>&#160;</div>
            <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
              Dyadic and TNO continue to remain focused on their joint research and
              development program to develop the ability to express antibodies and
              other high
              value therapeutic proteins using Dyadic&#8217;s C1 Expression System. Though we have
              reduced our efforts to complete the HTS System, we have begun to seek
              collaborative partners to assist us with the completion of that
              technology.</font></div>
            <div>&#160;</div>
          </div>
          <div><em><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Moscow
            State University, Moscow, Russia</font></em></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        had our longest research collaboration with groups at Moscow State University
        led by Dr. Arkady Sinitsyn in the Division of Chemical Enzymology in the
        Chemical Department. Dr. Sinitsyn is recognized as an expert in industrial
        enzymology and in 1992 initiated the development of our first enzyme product,
        an
        acid cellulase, which was commercialized in 1994. Dr. Sinitsyn's group also
        isolated and initially characterized the C1 fungal strain. Dr. Sinitsyn,
        in
        collaboration with the Russian Academy of Sciences, has been instrumental
        in the
        discovery of new enzyme products for us and in the detailed characterization
        and
        analysis of existing enzyme products. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="manufac">Man</a>ufacturing</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        do not
        own enzyme manufacturing facilities, but instead have employed two contract
        manufacturers who have produced all of our products for us. We have phased-out
        one of those contract manufacturers (Martek BioSciences), whose contract
        has
        expired and now continue to use it only on a limited basis. Our key contract
        manufacturer is Polfa Tarchomin, SA, or Polfa, located in Warsaw, Poland,
        which
        has been producing commercial enzymes for us continuously, and without
        interruption, since 2001 under a 10-year contract, which is cancellable under
        certain circumstances, with several 10-year renewal options exercisable in
        our
        discretion. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Polfa
        contract manufacturing agreement provides for a tolling fee based upon the
        actual utilization of the fermentation time, and also requires Dyadic-Florida
        to
        pay a fixed monthly fee to compensate Polfa for its capital investment in
        the
        initial modernization of the plant and equipment, which ends after seven
        years.
        Under the Polfa agreement, Polfa has committed fermentation capacity
        substantially in excess of the Company&#8217;s current needs, and is obligated to make
        additional capacity available upon the Company&#8217;s request and Polfa's completion
        of necessary modernization of that requested additional capacity in accordance
        with its contractual commitments to make those expenditures. We believe that
        the
        capacity of Polfa's facility should exceed the requirements for our current
        business plan, though increased fermentation capacity utilization is dependent
        upon Polfa's modernizing capital improvements, at its expense, to meet the
        growing process requirements for our production. We intend to stage the capacity
        expansion of Polfa's facility to cover our production requirements based
        on
        sales projections derived from our Enzyme Business' sales plans, though
        utilization of this additional capacity will ultimately depend upon product
        demand. Nonetheless, we are always evaluating the alternative of having
        manufacturing conducted in a new facility. In 2004, Dyadic-Florida negotiated
        for an additional 50 cubic meters of fermentation capacity and associated
        recovery capacity with the majority of the capital necessary for this expansion
        to be provided by Polfa. Dyadic has committed to direct payment for certain
        removable equipment for this expansion of approximately $133,000. This expansion
        has been completed and will be fully operational in 2006. Additional
        fermentation capacity is, however, expected to be required to meet our
        requirements for later years. Should Polfa not be able to obtain the funding
        necessary to provide the needed capital to honor its obligation to the Company
        under the Manufacturing Agreement, this will negatively affect the Company's
        ability to meet its production requirements and therefore impact&#160;the
        Company's&#160;financial position, results of operations and cash flows. In such
        an event, the Company would have to locate additional capacity with another
        contract manufacturing facility. The Company believes it has these resources
        available if needed, to support any additional production needs.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When
        combined with our internal staff of four manufacturing personnel, we currently
        employ, or retain as independent contractors, more than 60 persons to
        manufacture over 45 different liquid and dry enzyme products, including
        employees of our Polish subsidiary, whose main responsibility is oversight
        of
        Polfa's production, warehousing and shipping of our products. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="SM"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Sales
        and Marketing </u></strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
        Business </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        Enzyme Business has an established customer base in approximately 50 countries,
        including the United States. We sell our enzyme and other biomaterial products
        directly, through our own sales force, and indirectly through approximately
        210
        distributors, including one of our subsidiaries. We have deployed our sales
        force to effectively target the main markets and customers for our products,
        including locations in Europe, North America, South and Central America,
        and
        North and South Asia. We employ distributors to sell our textile, food and
        animal feed enzymes, and sell starch and pulp and paper enzymes both directly
        and through resellers. To meet the projected </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>20</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">revenue
        growth over the next five years, we have begun to expand our manufacturing,
        sales and technical service support staff to approach a larger number of
        customers in existing and new markets. To this end, we have recruited a Vice
        President of Sales &amp; Marketing - Enzymes,&#160;a Vice President - Pulp &amp;
Paper, and six technical sales representatives during 2005, as well as
        additional technical sales representatives in our Asian subsidiary.
        Additionally, to assist us in our endeavors in the animal feed market in
        Europe
        and elsewhere, we have hired a sales consultant with significant experience
        and
        expertise in this industry who is expected to begin April 1, 2006. Historically,
        we have sold in this industry without a sales support staff dedicated to
        this
        market, and it is our expectation that this addition will increase our sales
        in
        the animal feed market in the latter part of 2006. There is no guarantee,
        however, that our sales will increase significantly or in the time frame
        that we
        anticipate.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        1998,
        Dyadic-Florida purchased 70% of the outstanding shares of its existing Asian
        subsidiary. The Asian subsidiary serves as one of our primary distributors
        to
        foreign textile, pulp and paper, chemical and enzyme businesses. At the time
        of
        the original purchase, Dyadic-Florida could only vote 25% of the outstanding
        shares of the Asian subsidiary. By subsequent agreements, Dyadic-Florida
        increased its ownership interest in the Asian subsidiary from 70% to 82.5%
        of
        the outstanding shares and its voting rights from 25% to 62.5% of the
        outstanding shares. Under the original purchase agreement, Dyadic-Florida
        has an
        option to purchase additional voting rights with respect to 20% of the total
        outstanding shares of the Asian subsidiary, by paying $20,000 for each 1%
        of
        such voting rights. Dyadic-Florida is obligated to purchase the entire voting
        interest for an aggregate price of $405,000 if the Asian subsidiary's cumulative
        profits since October 19, 1998, as defined, aggregate to $900,000. As of
        December 31, 2005, the Asian subsidiary had approximately $556,000 of cumulative
        profits, as defined. In addition to this right to acquire 82.5% voting control
        over the Asian subsidiary, Dyadic-Florida also has a call option to purchase
        an
        additional 12.5% of the Asian subsidiary's outstanding shares which is
        exercisable over a 20 year term that began on October 21, 1998, but only
        after
        Dyadic-Florida has purchased the entire voting interest for $405,000. The
        exercise price of the call option will be based on the results of operation
        of
        the Asian subsidiary for the 12 months preceding the date of the exercise
        of the
        call option. The call option can be exercised no later than October 2018.
        The
        Asian subsidiary became a consolidated subsidiary of Dyadic-Florida effective
        July 1, 2002. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioSciences
        Business </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Given
        the
        potentially differentiating advantages of our C1 Expression System over other
        expression systems, our marketing strategy is to focus on those
        biopharmaceutical, agricultural and chemical companies that are looking for
        alternative expression systems for the production of sufficient quantities
        of
        proteins for animal/human or field tests, cellulosic ethanol research or
        large-scale manufacturing at an economically viable cost. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        BioSciences Business currently employs business development professionals
        trained in marketing high-technology service offerings, such as the BioSciences
        Business' expression projects, as well as licensing, joint venturing and
        other
        forms of business collaboration. These professionals will be responsible
        for the
        BioSciences Business market launch. In addition to soliciting business from
        our
        headquarters and European subsidiary offices, these business development
        professionals will promote the C1 Expression System's enabling capabilities
        through presentations and presence at scientific and business conferences
        targeted at the pharmaceutical, biotechnology, chemical, agricultural and
        other
        industrial sectors, supplemented with the presentations of research papers
        and
        seminars at those conferences. Further, we intend to conduct large-scale
        promotional activities aimed at target industries, with an emphasis on
        individual visits to target companies to expose them to the unique capabilities
        of the C1 Expression System and the C1 Screening System. As the business
        volume
        expands, we intend to expand our staff of business development professionals
        for
        both our U.S. headquarters and our European subsidiary, Dyadic Nederland
        BV in
        the Netherlands. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        order
        to advance our efforts with our BioSciences Business, we hired Glenn E. Nedwin,
        Ph.D. in March 2006, to become (i) the Company&#8217;s Chief Scientific Officer, (ii)
        an Executive Vice President of the Company and (iii) the President of the
        BioSciences business of the Company&#8217;s wholly-owned subsidiary, Dyadic
        International (USA), Inc. During the past fourteen (14) years Mr. Nedwin
        has
        served as the President of Novozymes, Inc., a leading industrial biotechnology
        company specializing in enzymes and microorganisms, where he has been
        responsible for all scientific, financial and administrative functions of
        that
        company, including product and technology licensing, enzyme research management
        and biotechnology strategy and research. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="emp">Emp</a>loyees
</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        of
        December 31, 2005, we and our consolidated subsidiaries had approximately
        122
        full-time employees. None of our employees are represented by labor unions
        or
        covered by collective bargaining agreements. We have not experienced any
        work
        stoppages and consider our employee relations to be good. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="investor">Inves</a>tor
        Information</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
        can
        learn more about the Company by visiting our website at www.Dyadic-Group.com.
        Information on the website is neither incorporated into, nor a part of this
        report. We encourage you to read this and other reports </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>21</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">filed
            by
            the Company with the Securities and Exchange Commission. Dyadic will
            provide you
            with a copy of any or all of these reports (except exhibits) at no charge.
            You
            may read and copy any reports, statements or other information that we
            file at
            the SEC&#8217;s public reference facilities at 450 Fifth Street, N.W., Washington,
            D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information
            regarding the public reference facilities. The SEC maintains a web site,
            http://www.sec.gov., that contains reports, proxy statements and information
            statements and other information regarding registrants that file electronically
            with the SEC, including the Company. The Company&#8217;s SEC filings are also
            available to the public from commercial document retrieval
            services.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="competition">Com</a>petition</u></strong></font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
          Business </em></font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
        to Novozymes, the worldwide market for industrial enzymes is $2.0 billion,
        while
        another of our competitors, Diversa Corporation, has sized the combined
        industrial and specialty enzymes market at approximately $3.6 billion. Our
        Enzyme Business faces several major competitors in its industry, both on
        a
        global and regional basis. Principal global competitors are Novozymes (Danish:
        all markets), Danisco (Danish: all markets), DSM (Dutch: food and animal
        feed),
        AB Enzymes (British: all markets), and BASF (German: animal feed). Together,
        these four companies control more than 70% of the industrial enzyme market,
        with
        Novozymes being the largest enzyme maker having 2005 revenues estimated at
        $1.0
        billion. Additional competitors are entering the industrial enzyme business,
        such as Diversa, and others can be expected to enter the market in the future.
        Other smaller regional producers, located primarily in Japan, India and China,
        are also participants in this industry and, from time to time, can directly
        compete with us in those regions. Each of the major competitors, particularly
        Novozymes and Danisco, currently enjoys competitive advantages associated
        with
        their much larger size: developed technologies, more resources, strong
        distribution systems and dominant market positions. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioSciences
        Business </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
        are
        many companies, such as DSM, Invitrogen, Danisco, Novozymes, Lonza Biologics,
        Glycofi , Rhein Biotech, Protein Sciences Corporation, Biolex, Paradigm
        Genetics, Crucell and Exelexis, with proprietary protein expression systems
        that
        compete with our C1 Expression System. Most of them are developmental stage
        companies, although DSM, Invitrogen, Danisco, Novozymes and Lonza Biologics
        are
        medium to large size, well-established companies with substantial financial
        resources. Nonetheless, because we believe our C1 Expression System will
        overcome many of the limitations of the expression systems being used by
        our
        competitors, we believe our C1 Expression System will provide the drug
        development industry with a superior, low-cost production alternative for
        human
        therapeutic and other proteins. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When
        completed, our C1 Screening System will face competition from a large number
        of
        technologies in use and under development for the discovery of new genes.
        In
        addition to many development stage companies, such as Direvo and Nautilus
        Biotechnology, competitors of our C1 Screening System include many well-known
        companies, such as Celera, Novozymes, Exelexis, Diversa, and Maxygen. There
        are
        also many well-known companies, such as Diversa, Maxygen, Codexis, as well
        as
        lesser-known companies such as Direvo and Nautilus Biotechnology, which are
        very
        active in the field of directed evolution and, therefore, have an interest
        in
        fungi-based screening systems or other eukaryotic hosts capable of functioning
        in a high-throughput mode with eukaryotic genes. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="intell">Intellectua</a>l
        Property</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        own 3
        issued U.S. patents, 24 issued International patents and 51 U.S. and
        International filed and pending patent applications which we believe provide
        broad protection for our C1 Expression System, our underlying C1 Host
        Technology, our C1 Screening System and their products and commercial
        applications. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Over
        the
        years in which we have been in business, we have also developed trade secrets
        and know-how involving our industrial enzyme products. Our employment and
        other
        agreements with our employees contain provisions that protect and require
        confidential treatment for our trade secrets and developed inventions, for
        both
        our Enzyme and our BioSciences Business. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="govreg">Governm</a>ent
        Regulation</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Regulation
        by the governmental authorities in the United States and other countries
        is a
        significant factor in the development, production and marketing of our products.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Products
          Not Considered Pharmaceuticals</em></font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>22</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div>&#160;</div>
          <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Biologically
            derived products are regulated in the United States by varying federal
            agencies&#160;based on the application or use of the product.&#160; A product
            may fall under the jurisdiction of one or many federal agencies at the
            same
            time, depending on the proposed use of the product.&#160; The federal Food and
            Drug Administration ("FDA") operates under the authority granted by the
            Federal
            Food Drug and Cosmetic Act ("FD&amp;C Act") regulating not only pharmaceutical
            products, but also foods, food supplements, food additives, food processing
            aids, animal feed and feed additives, among others.&#160; Another agency, the
            United States Department of Agriculture ("USDA"), has shared jurisdiction
            on
            issues related to food safety, animal feed, biotechnology and crop and
            livestock
            directives.&#160; In addition, the federal Environmental Protection Agency
            ("EPA")&#160;is the agency with jurisdiction over enzyme-based biological
            products with industrial applications. </font></div>
        </div>
      </div>
      <div><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;International
        regulations governing enzyme-based products derived from microorganisms have
        undergone significant change in the recent past.&#160; The regulations in
        Europe, for example, continue to evolve as&#160;quickly as&#160;the EU
        itself.&#160; There are EU Directives and EU Legislation which are meant to
        represent cohesive regulatory policies on genetically modified organisms,
        animal
        feed enzymes, enzymes used as a processing aid in the production of pulp
        and
        paper, among others, however there are instances when individual national
        laws&#160;seem to contradict EU Directives presenting regulatory hurdles in the
        registration and sale of Dyadic's products.&#160;&#160;Depending on the use of
        the product and existing legislation,&#160;the product&#160;may require little
        regulatory oversight, or a lengthy and expensive registration process.&#160;
There are other regions of the world with decidedly less rigorous regulatory
        review processes; generally accepting the US regulatory status of a
        product.&#160; We believe that these areas present Dyadic with many
        opportunities for immediate growth.</font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><em><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Human
        Therapeutic Products</font></em></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        FDA
        in the United States and similar health authorities in foreign countries
        subject
        human therapeutic products to rigorous preclinical and clinical testing and
        other approval procedures. Various federal statutes and regulations also
        govern
        or influence the testing, manufacturing, quality control, safety, labeling,
        storage, record-keeping and marketing of human therapeutic products. The
        process
        of obtaining these approvals and the subsequent compliance with appropriate
        federal and foreign statutes and regulations require the expenditure of
        substantial resources. Any failure by us or our collaborators or licensees
        to
        obtain, or any delay in obtaining, regulatory approval could adversely affect
        the marketing and revenue generating potential of our products. We have neither
        applied for nor received regulatory approval to market any human therapeutic
        products. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        steps
        required before a pharmaceutical agent may be marketed in the United States
        include: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">preclinical
                  laboratory, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>in
                  vivo</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  and formulation studies; </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  submission to the FDA of an investigational new drug, or IND, application
                  that must become effective before human clinical trials may commence;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">adequate
                  and well controlled human clinical trials to establish safety and
                  efficiency of the proposed drug in its intended indication;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  submission of a new drug application, or NDA, to the FDA; and
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  FDA approval of the NDA. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
        clinically test, produce and market products for diagnostic or therapeutic
        use,
        a company must comply with mandatory procedures and safety standards established
        by the FDA and comparable agencies in foreign countries. Before beginning
        human
        clinical testing of a potential new drug, a company must file an IND and
        receive
        clearance from the FDA. The IND is a summary of the preclinical studies which
        were carried out to characterize the drug, including toxicity and safety
        studies, as well as an in-depth discussion of the human clinical studies
        which
        are being proposed. Approval of a local institutional review board, or IRB,
        and
        informed consent of trial subjects is also required. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Human
        clinical trials are typically conducted in three sequential phases which
        may
        overlap. Phase I involves the initial introduction of the drug into human
        subjects or patients where the product is tested for safety, dosage, tolerance,
        absorption, metabolism, distribution and excretion. Phase II involves studies
        in
        a limited patient population to: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">identify
                  possible adverse effects and safety risks;
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>23</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">determine
                      the efficiency of the product for specific, targeted indications;
                      and
                      </font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">adequately
                    determine dosage tolerance and optimal dosage.
</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When
        Phase II evaluation demonstrates that the product may be effective and has
        an
        acceptable safety profile, Phase III trials are undertaken to further evaluate
        dosage and clinical efficacy and to further test for safety in an expanded
        patient population at multiple clinical study sites. A pivotal Phase III
        trial
        is an adequate and well-controlled study which provides the primary basis
        for
        determining whether there is substantial evidence to support the claims of
        effectiveness for new drugs and forms the basis for an NDA. The regulatory
        authority or the sponsor may suspend clinical trials at any point in this
        process if either entity concludes that clinical subjects are being exposed
        to
        an unacceptable health risk, that the trials are not being conducted in
        compliance with applicable regulatory requirements, or for other reasons.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        results of product development, preclinical studies and clinical studies
        are
        submitted to the FDA as part of an NDA for approval of the marketing and
        commercial shipment of the product. The FDA may deny approval of an NDA if
        applicable regulatory criteria are not satisfied, or may require additional
        data. Even if such data is submitted, the FDA may ultimately decide that
        the NDA
        does not satisfy its criteria for approval. Once issued, a product approval
        may
        be withdrawn if compliance with regulatory standards is not maintained or
        if
        problems occur after the product reaches the market. In addition, the FDA
        may
        require testing and surveillance programs to monitor the effect of approved
        products which have been commercialized, and it has the power to prevent
        or
        limit further marketing of a product based upon the results of these
        post-marketing programs. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Satisfaction
        of these FDA requirements, or similar requirements by foreign regulatory
        agencies, typically takes several years, and the time needed to satisfy them
        may
        vary substantially, based upon the type, complexity and novelty of the drug
        product. The effect of government regulation may be to delay or to prevent
        marketing of potential products for a considerable period of time and to
        impose
        costly procedures upon our or our partner's activities. There can be no
        assurance that the FDA or any other regulatory agency will grant approval
        for
        any products being developed by us or our partner on a timely basis, or at
        all.
        Success in preclinical or early stage clinical trials does not assure success
        in
        later stage clinical trials. Data obtained from preclinical and clinical
        activities are susceptible to varying interpretations which could delay,
        limit
        or prevent regulatory approval. If regulatory approval of a product is granted,
        such approval may impose limitations on the indicated uses for which a product
        may be marketed. Further, even if regulatory approval is obtained, later
        discovery of previously unknown problems with a product may result in
        restrictions on the product, including withdrawal of the product from the
        market. Delay in obtaining or failure to obtain regulatory approvals would
        have
        a material adverse affect on our business. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Before
        our or our collaboration partners' human therapeutic protein products, if
        any,
        can be marketed outside of the United States, they are subject to regulatory
        approval similar to that required in the United States, although the
        requirements governing the conduct of clinical trials, product licensing,
        pricing and reimbursement vary widely from country to country. No action
        can be
        taken to market any product in a country until an appropriate application
        has
        been approved by the regulatory authorities in that country. The current
        approval process varies from country to country, and the time spent in gaining
        approval varies from that required for FDA approval. In certain countries,
        the
        sales price of a product must also be approved. The pricing review period
        often
        begins after market approval is granted. No assurance can be given that,
        even if
        a product is approved by a regulatory authority, satisfactory prices will
        be
        approved for our or our collaboration partners' products.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
        is
        no assurance that the FDA will successfully review our or our collaboration
        partners' INDs or NDAs when filed, or that foreign regulatory authorities
        will
        approve any similar applications that we submit to them. Further, the FDA
        and
        foreign authorities may at any time take legal or regulatory action against
        a
        product or us if it concludes that a product has not complied with applicable
        laws and regulations or that earlier evaluations of a product's safety or
        effectiveness may not have been adequate or appropriate. Such action may
        include, but is not limited to, restrictions on manufacture and shipment
        of
        products, seizure of products, injunctions and civil and criminal penalties.
        The
        FDA's policies may change and additional government regulations may be
        promulgated which could prevent or delay regulatory approval of our or our
        collaboration partners' potential products. Moreover, increased attention
        to the
        containment of health care costs in the United States and in foreign markets
        could result in new government regulations which could have a material adverse
        effect on our business or our joint ventures or its customers. We cannot
        predict
        the likelihood of adverse governmental regulation which might arise from
        future
        legislative or administrative action, either in the United States or abroad.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u><a name="risk">Risk
        Factors </a>that May Affect Future
        Results</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You
        should carefully consider the following material risks, together with the
        other
        matters described in this Annual Report on Form 10-KSB in evaluating our
        business and prospects. If any of the following risks actually occur, our
        business, results of operations and financial condition could be materially
        adversely affected. In such circumstances, the trading price of our common
        stock
        could decline, and in some cases, such declines could be significant. The
        risks
        described below are not the only ones we face. Additional risks and
        uncertainties, including those that are not yet identified or that we currently
        believe are immaterial, may also adversely affect our business, </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>24</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">financial
          condition or results of operations. Certain statements contained in this
          Annual
          Report on Form 10-KSB (including certain of the following risk factors)
          constitute forward-looking statements. Please refer to the section entitled
          &#8220;Forward Looking Statements&#8221; appearing on page 3 of this Annual Report on Form
          10-KSB for important limitations on these forward-looking statements.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
          General to Our Businesses</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
          should be viewed as an early-stage company.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
            The combination of our Enzyme Business&#8217;s reliance upon the expansion of the
            capabilities of our C1 Expression System and the early-stage, developmental
            nature of our BioSciences Business require that we be characterized as
            an
            early-stage company. Our conduct of the BioSciences Business is subject
            to the
            risks customarily attending the operations of any early-stage company,
            including
            the development of new technologies and products, the assembly and development
            of production and R&amp;D capabilities, the construction of channels of
            distribution and the management of growth, as discussed in the following
            Risk
            Factors. </font></div>
        </div>
      </div>
      <div><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        have a history of net losses, and may not achieve or maintain
        profitability.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        an accumulated deficit of approximately $34,008,000 at December&#160;31, 2005.
        Because we accelerated our R&amp;D activities and expanded both our sales and
        marketing and technical support staffs, we have experienced increased levels
        of
        net losses and negative cash flow. Whether we achieve profitability, and
        the
        size of our net losses prior to that time, will depend, in large part, on
        the
        rate of growth, if any, of our Enzyme Business, whether our BioSciences Business
        is able to generate contract sales or other sales and on the level of our
        expenses. To date, we have derived almost 100% of our sales from the operations
        of our Enzyme Business. We do not anticipate material sales from the operation
        of the BioSciences Business sooner than 2007 or later. Our Enzyme Business
        may
        not be able to penetrate new markets or enjoy the improved profit margins
        we
        anticipate, which could materially adversely impact that Business&#8217;s growth
        potential and profitability. Sales from our BioSciences Business are uncertain
        because our ability to secure future collaboration agreements will depend
        upon
        the ability of the BioSciences Business to perfect our C1 Host Technology
        to
        address the needs of the pharmaceutical and biotech industries. We expect
        to
        spend significant amounts to fund R&amp;D and enhance our core technologies. As
        a result, we expect that our operating expenses will increase significantly
        in
        the near term and, consequently, that we will need to generate significant
        additional sales to achieve profitability. Even if we do achieve profitability,
        we may not be able to sustain or increase profitability on a quarterly or
        annual
        basis.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        could fail to manage our growth, which would impair our
        business.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        business plan contemplates that we will grow at a rapid rate, both in terms
        of
        sales and personnel. It is difficult to manage growth, and our future success
        depends on our ability to efficiently and effectively implement:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">research
                  and product development programs which overcome scientific challenges
                  and
                  develop new products and processes;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales,
                  marketing, technical service and customer support
                  programs;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expansion
                  of our manufacturing operations to appropriate capacity levels
                  consistent
                  with our projected and actual rates of
                  growth;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">operational
                  and financial control systems; </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">recruiting
                  and training programs; and</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">currency
                  risk management strategies.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        ability to offer products and services successfully and to implement our
        business plan in a rapidly evolving global market requires effective planning,
        reporting and management processes. We expect that we will need to continue
        to
        improve our financial and managerial controls, reporting systems and procedures
        and to expand and train our workforce worldwide. We also need to continue
        to
        manufacture our products efficiently and to control or adjust the expenses
        related to R&amp;D, marketing, sales and general and administrative activities
        in response to changes in sales. If we are not successful in efficiently
        manufacturing our products or managing such expenses, there could be an adverse
        impact on our results of operations, our financial condition and the continued
        viability of our business.</font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>25</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
            Specific to Our Enzyme Business</em></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
            market share growth depends on costly new product introductions and market
            acceptance</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
            The future success of our Enzyme Business will depend greatly on our
            ability to
            continuously and timely develop and introduce new products that address
            evolving
            market requirements and are attractive to customers. We are relying on
            our C1
            Expression System and our other proprietary technologies to expand our
            Enzyme
            Business product line and improve our gross margins on those products.
            If we
            fail to introduce new and innovative products, we could fail to obtain
            an
            adequate return on our R&amp;D investments and could lose market share to our
            competitors, which might be difficult or impossible to regain. Any inability,
            for technological or other reasons, to develop successfully and introduce
            new
            products could reduce our growth rate or otherwise damage our
            business.</font></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160;
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Further,
            in
            the past we have experienced, and we are likely in the future to experience,
            delays in the development and introduction of products. For example,
            our efforts
            to complete the development of a high throughput system using our C1
            organism
            have taken considerably longer, cost more and have proven to be much
            more
            difficult than we had anticipated, forcing us to sharply scale back our
            continued development efforts and seek a new collaborative partner. We
            may not
            be able to keep pace with the rapid rate of change in our markets or
            to develop
            new products or processes that will meet the requirements of the marketplace
            or
            achieve market acceptance. Some of the factors affecting market acceptance
            of
            our products include:</font></div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">availability,
                  quality, performance and price as compared to competitive
                  products;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  functionality of new and existing
                  products;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  timing of introduction of our products as compared to competitive
                  products;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">scientists&#8217;
                  and customers&#8217; opinions of our products&#8217; utility and our ability to
                  incorporate their feedback into our future products;
                  and</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">citation
                  of the products in published
                  research.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        expenses or losses associated with unsuccessful product development activities
        or lack of market acceptance of our new products could seriously harm our
        business, financial condition and results of operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
        dependence on contract manufacturers could harm our
        business.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        Enzyme Business currently relies on contract manufacturers for all of its
        manufacturing. If we require additional manufacturing capacity and are unable
        to
        obtain it in sufficient quantity, we may not be able to increase our sales,
        or
        may be required to make very substantial capital investments to build that
        capacity.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        manufacturing capabilities, and any current or future arrangements with third
        parties for these activities, may not be adequate for the successful
        commercialization of our industrial enzyme products. In the operation of
        the
        Enzyme Business, all of our industrial enzymes have over the past decade,
        and
        are expected over the foreseeable future to be, produced at the manufacturing
        facilities of contract manufacturers. As a result, we are dependent upon
        the
        performance and plant capacity of third-party manufacturers. Though we formerly
        used two contract manufacturers, we let our agreement with one of those contract
        manufacturers expire and now only use it on a highly limited basis. Our Enzyme
        Business, therefore, faces risks of difficulties with, and interruptions
        in,
        performance by these third parties of their manufacturing responsibilities,
        the
        occurrence of which could adversely impact the launch and/or sales of our
        products in the future. For example, our principal contract manufacturer,
        Polfa
        Tarchomin, S.A., which has been producing a number of our products since
        2001
        without interruption has concluded an agreement to provide an additional
        50
        cubic meters of fermentation capacity and associated recovery capacity with
        the
        majority of the capital necessary for this expansion to be provided by them.
        This expansion has been completed and will be fully operational in 2006.
        Dyadic
        has committed to direct payment for certain removable equipment for this
        expansion of approximately $133,000. Additional fermentation capacity is,
        however, expected to be required to meet our requirements for later years.
        If
        that funding were to be unavailable, or if that contract manufacturer is
        otherwise unable to construct the needed modernization and expansion of
        production capacity, as it is contractually obligated to, our ability to
        meet
        our production requirements and growth plans would likely be very negatively
        affected. We could be forced to: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">furnish
                  or secure for that contract manufacturer the capital necessary
                  to enable
                  it to expand production capacity to meet our future production
                  needs;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>26</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">find
                      manufacturing capacity from another contract manufacturer,
                      which might be
                      at higher cost to us; or</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
              <table cellpadding="0" cellspacing="0" id="list" width="100%">

                  <tr valign="top" style="line-height: 1.25;">
                    <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                    <td>
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">build
                        our own manufacturing facilities, necessitating significant
                        capital
                        expenditures not currently included in our capital spending
                        plans.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
            the
            expiration of our contract manufacturing agreement with our second, and
            only
            other, contract manufacturer, we are currently utilizing their services
            on an as
            needed basis. The majority of our production requirements will be satisfied
            by
            the single manufacturing facility operated by our Polish contract manufacturer,
            leaving us even more vulnerable to a failure of performance by it.
</font></div><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Regulations
          may limit or impair our ability to sell genetically engineered products
          in the
          future. </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
          develops enzyme products using both non-genetically engineered
          microorganisms,&#160;as well as those that have undergone some degree
          of&#160;genetic modification.&#160;&#160;Products derived from GMOs are subject
          to regulation by&#160;federal, state, local and foreign government
          agencies.&#160;These agencies administering existing or future applicable
          regulation or legislation may not allow&#160;Dyadic to produce and
          market&#160;its products derived from GMOs in a timely manner or under
          technically or commercially feasible conditions.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
            addition, regulatory action or private litigation could result in expenses,
            delays or other impediments to&#160;Dyadic's product development programs or the
            commercialization of resulting products.&#160; The FDA currently applies the
            same regulatory standards to products made through genetic engineering
            as those
            applied to products developed through traditional methodologies.&#160;Depending
            on&#160;a product's application and regardless of its GMO status, it may be
            subject to lengthy FDA reviews and unfavorable FDA determinations if
            there are
            safety concerns or if the FDA changes its current regulatory&#160;policy.&#160;
The European Union, or the EU, has regulations regarding the development,
            production and marketing of products from GMOs&#160;which are
            generally&#160;more restrictive than present US regulations.&#160; For example,
            among other requirements, EU animal feed registration requires
            in-vivo&#160;efficacy testing, as well as toxicological testing of all enzyme
            products, including products from non-GMO microorganisms.&#160; The regulatory
            agencies administering these and future regulations may hinder Dyadic's
            ability
            to produce and bring to&#160;market some of its enzyme products in a timely
            manner or under technically or commercially feasible
            conditions.</font></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Alternative
        technologies may diminish the need for producing some enzymes the way we
        do.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Many
        of
        our enzyme products are produced in fermenters. Some of the product segments
        we
        hope to serve may not find it efficient to use the fermenter processes we
        employ. For example, bio-ethanol and other bio-fuels production represents
        a
        considerable market opportunity for enzymes. However, research being conducted
        within the auspices of major seed producers, U.S. federal government and
        corn
        growers association may supplant the need for enzymes produced in fermenters,
        which is the enzyme production process we currently use.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
        of Cellulosic Ethanol may not be feasible. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
        cellulosic ethanol should reduce the United States' dependence on imported
        oil,
        increase its energy security and reduce its trade deficit, commercialization
        of
        cellulosic ethanol in the United States or elsewhere may not be feasible
        for a
        variety of reasons.&#160; Among others, there has been to date a lack of
        significant private and government funding for research and development in
        conversion and processing technologies, as well as for the development of
        biorefineries. Furthermore, there has been to date very little, if any, well
        directed public policies emphasizing investment and providing incentives
        for the
        commercialization and transition to cellulosic ethanol. The current United
        States Presidential administration has recently been publicizing the benefits
        of
        cellulosic ethanol, though it remains to be seen whether or not such publicity
        will engender significant government funding and economic incentives to mitigate
        some of the foregoing barriers to commercialization of cellulosic ethanol.&#160;
As such, we are still evaluating the extent to which we are going to pursue
        this
        opportunity through specific capital investment, collaborators and
        otherwise.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
        Specific to Our BioSciences Business</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        may fail to commercialize our C1 Expression System for the expression of
        therapeutic proteins. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although
        our Enzyme Business has developed and sold industrial enzyme products and
        has
        used our C1 Expression System to develop such products, our BioSciences Business
        has not yet completed commercialization of our C1 Expression System for the
        expression of therapeutic proteins. If our BioSciences Business fails to
        do
        this, we may be forced to terminate the BioSciences Business&#8217;s operations and
        liquidate it.</font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>27</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font>&#160;&#160;&#160;&#160;&#160;
              Our BioSciences Business must be evaluated as having the same risks
              as those
              inherent in early-stage biotechnology companies because the application
              of our
              C1 Expression System to the expression of pre-clinical and clinical
              quantities
              of therapeutic proteins is still in development. We may not be able
              to
              successfully harness the C1 Expression System to achieve those objectives.
              Further, we may not be able to expand the capabilities of the C1 Expression
              System to produce commercial volumes of therapeutic proteins at reasonable
              costs. Also, we may not ever be able to successfully complete development
              of our
              fungal high throughput system. And, even if the BioSciences Business
              is able to
              achieve any of those accomplishments, we may not be able to successfully
              develop
              the C1 Screening System to serve the functions of gene discovery or
              the
              development of new and/or improved protein drugs. Successful development
              of the
              C1 Host Technology for these purposes will require significant development
              and
              investment, including testing, to prove its efficacy and cost-effectiveness.
              To
              date, drug companies have developed and commercialized only a small
              number of
              gene-based products in comparison to the total number of drug molecules
              available in the marketplace. In this regard, we are heavily dependent
              upon our
              use of third-party research organizations to assist us in the development
              of the
              C1 Host Technology. In general, our experience has been that each step
              in the
              process has taken longer and cost more to accomplish then we had originally
              projected, and we anticipate that this is likely to remain the case
              with respect
              to our BioSciences Business&#8217; continuing development
              efforts.</font></div>
          </div>
        </div>
        <div>&#160;</div>
        <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialization
          of our C1 Expression System for therapeutic proteins depends on collaborations.
          </strong></font></div>
        <div>&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commercialization
          of our C1 Expression System by our BioSciences Business depends on
          collaborations with other parties. If we are not able to find collaborators
          in
          the future, the BioSciences Business may not be able to develop the C1
          Expression System or therapeutic protein products. Further, our business
          model
          relies on a revenue stream derived from collaboration projects to be conducted
          with our customers to express laboratory-testing quantities of therapeutic
          proteins. A large portion of the anticipated financial reward depends on
          those
          therapeutic proteins progressing through drug development and into commercially
          successful drugs. Apart from risks relating to whether our BioSciences
          Business
          can capture such customers, or capture them on satisfactory terms, we will
          have
          no control over post-collaboration project drug development and
          commercialization. Further, conflicts could arise between us and our customers
          or among them and third parties that could discourage or impede the activities
          of our BioSciences Business.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
          we
          do not currently possess the financial resources necessary to develop and
          commercialize potential drug products that may result from our C1 Expression
          System, or the resources to complete any approval processes which may be
          required for these products, we must enter into collaborative arrangements
          to
          develop and commercialize drug products. It is expected that these arrangements
          will be for fixed terms and will expire after a fixed period of time. If
          they
          are not renewed or if we do not enter into new collaborative agreements,
          our
          sales will be reduced and our products may not be commercialized.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          have
          limited or no control over the resources that any collaborator may devote
          to our
          programs.</font></strong></div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        limited or no control over the resources that any collaborator may devote
        to our
        products. Any of our future collaborators may not perform their obligations
        as
        expected. These collaborators may breach or terminate their agreement with
        us or
        otherwise fail to conduct their collaborative activities successfully and
        in a
        timely manner. Further, our collaborators may elect not to develop products
        arising out of our collaborative arrangements or devote sufficient resources
        to
        the development, manufacture, market or sale of these products. If any of
        these
        events occur, we may not be able to develop our technologies or commercialize
        our products.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Potential
        therapeutic products developed by us or with our customers or collaborators
        are
        subject to a lengthy and uncertain regulatory process. If these therapeutic
        protein products are not approved, we or our customers or collaborators will
        not
        be able to commercialize them, and we may not receive the milestone and royalty
        payments which are based upon the successful advancement of these products
        through the drug development and approval process.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        FDA
        must approve any therapeutic product before it can be marketed in the United
        States. Before our collaborators can file a new drug application or biologic
        license application with the FDA, the product candidate must undergo extensive
        testing, including animal and human clinical trials, which can take many
        years
        and require substantial expenditures. Data obtained from such testing are
        susceptible to varying interpretations which could delay, limit or prevent
        regulatory approval. In addition, changes in regulatory policy for product
        approval during the period of product development and regulatory agency review
        of each submitted new application or product license application may cause
        delays or rejections.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because
        these products involve the application of new technologies and may be based
        upon
        new therapeutic approaches, they may be subject to substantial review by
        government regulatory authorities and, government regulatory authorities
        may
        grant regulatory approvals more slowly for these products than for products
        using more conventional technologies. While we anticipate that most of our
        collaborators will have experience submitting an application to the FDA or
        any
        other regulatory authority, we have no such experience, and neither we nor
        any
        collaborator has yet submitted an application with the FDA or any other
        regulatory authority for any product candidate generated through the use
        of our
        C1 Expression System, nor has the FDA nor any other regulatory authority
        approved any therapeutic product candidate developed using our C1 Expression
        System for commercialization in the </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>28</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">United
        States or elsewhere. Our collaborators may not be able to conduct clinical
        testing or obtain the necessary approvals from the FDA or other regulatory
        authorities for our products. The regulatory agencies of foreign governments
        must also approve our therapeutic products before the products can be sold
        in
        those other countries.&#160; </font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        Even after investing significant time and expenditures, our collaborators
        may
        not obtain regulatory approval for their products. Even if they receive
        regulatory approval, this approval may entail limitations on the indicated
        uses
        for which we can market a product. Further, once regulatory approval is
        obtained, a marketed product and its manufacturer are subject to continual
        review, and discovery of previously unknown problems with a product or
        manufacturer may result in restrictions on the product, manufacturer and
        manufacturing facility, including withdrawal of the product from the market.
        In
        certain countries, regulatory agencies also set or approve prices.
</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Health
        care reform may limit our profitability or that of our
        customers.</strong></font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        Our C1 Host Technology is being developed to assist our customers or
        collaborators in the development of future therapeutic products, including
        pharmaceutical products. The ability of our collaborators to commercialize
        pharmaceutical products developed with our C1 Host Technology may depend
        in part
        on the extent to which reimbursement for the cost of those products will
        be
        available from government health administration authorities, private health
        insurers and other organizations. Third-party payers are increasingly
        challenging prices of medical products and services. Significant uncertainty
        exists as to the reimbursement status of newly approved health care products,
        and there can be no assurance that adequate third party coverage will be
        available for any product to enable us to maintain price levels sufficient
        to
        realize an appropriate return on our investment in research and product
        development. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Adverse
        events in the field of therapeutic products may adversely affect us or our
        collaborators.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently,
        we are not engaged in developing therapeutic products for our own account,
        but
        instead intend to collaborate with drug companies to express therapeutic
        products requested by them for the ultimate purpose of their development,
        testing and introduction as new drugs. We may, however, engage in these
        activities in the future for our own account. If we or our collaborators
        develop
        therapeutic products, these products may encounter substantial delays in
        development and approval due to the government regulation and approval process.
        Adverse events reported in gene therapy clinical trials may lead to more
        government scrutiny of proposed clinical trials of therapeutic products,
        stricter labeling requirements for these products and delays in the approval
        of
        other types of products for commercial sale.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        C1
        Expression System has been tested for use in pulp and paper production, which
        requires FDA approval as generally regarded as safe, or GRAS, and has generated
        promising safety and toxicity data for one enzyme. A risk nonetheless exists
        that the C1 Expression System will produce therapeutic products and enzymes
        that
        have safety and toxicity issues associated with them.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        believe our determination of the genome sequence of our C1 host organism
        could
        help to mitigate our risk that there are unexpected safety and toxicity issues
        associated with our C1 Expression System and facilitate our ability to find
        and
        express new genes of bio-therapeutic and other commercial value. However,
        there
        can be no assurance that annotation of the C1 will be fully or adequately
        completed, and until it is successfully completed, we are at a distinct
        competitive disadvantage to some of our competitors, whose host organisms
        have
        been more thoroughly researched and whose genomes have been fully annotated.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
        Applicable to Our Enzyme Business and Our BioSciences Business</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Reductions
        in R&amp;D budgets may affect the sales of both of our
        Businesses.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        customers include researchers at customers of our Enzyme Business and potential
        drug company customers of our BioSciences Business. Fluctuations in the R&amp;D
        budgets of these researchers and their organizations could have a significant
        effect on the demand for our products. Research and development budgets
        fluctuate due to changes in available resources, mergers of drug companies,
        spending priorities and institutional budgetary policies. Our Businesses
        could
        be seriously damaged by any significant decrease in life sciences R&amp;D
        expenditures by these existing and potential customers, academic institutions,
        government laboratories or private foundations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Conflicts
        with our collaborators could harm our business.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
        important part of our strategy involves conducting proprietary research
        programs. We may pursue opportunities in fields that could conflict with
        those
        of our collaborators. Moreover, disagreements with our collaborators could
        develop over rights to our intellectual property. Any conflict with our
        collaborators could reduce our ability to obtain future collaboration agreements
        and negatively impact our relationship with existing collaborators, which
        could
        reduce our sales.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>29</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
              Certain of our collaborators could also become competitors in the future.
              Our
              collaborators could develop competing products, preclude us from entering
              into
              collaborations with their competitors, fail to obtain timely<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font>regulatory approvals,
              terminate their
              agreements with us prematurely or fail to devote sufficient resources
              to the
              development and commercialization of products. Any of these developments
              could
              harm our product development efforts.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
              will
              either commercialize products resulting from our proprietary programs
              directly
              or through licensing to other companies. We have limited experience
              in
              manufacturing and marketing products for the pharmaceutical and biotechnology
              industries. In order for us to commercialize these products directly,
              we would
              need to develop, or obtain through outsourcing arrangements, the capability
              to
              market and sell these products. We do not have these capabilities,
              and we may
              not be able to develop or otherwise obtain the requisite marketing
              and sales
              capabilities. If we are unable to successfully commercialize products
              resulting
              from our proprietary research efforts, we will continue to incur losses.
              </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          </div>
          <div>Pu<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>blic
            views on ethical and social issues may limit use of our technologies
            and reduce
            our sales.</strong></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><strong>&#160;&#160;&#160;
</strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Our
            success
            will depend in part upon our ability to develop products discovered through
            our
            C1 Host Technology. Governmental authorities could, for social or other
            purposes, limit the use of genetic processes or prohibit the practice
            of our C1
            Host Technology. Ethical and other concerns about our C1 Host Technology,
            particularly the use of genes from nature for commercial purposes, and
            products
            resulting there from, could adversely affect their market acceptance.
            </font></div>
          <div>&#160;</div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>If
          the public does not accept genetically engineered products, our product
          demand
          could decline.</strong></font></div>
        <div><br></div>
        <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          commercial success of our potential products will depend in part on public
          acceptance of the use of genetically engineered products including drugs,
          plants
          and plant products. Claims that genetically engineered products are unsafe
          for
          consumption or pose a danger to the environment may influence public attitudes.
          Our genetically engineered products may not gain public acceptance in the
          various industrial, pharmaceutical or biotechnology industries. Negative
          public
          reaction to genetically modified organisms and products could result in
          greater
          government regulation of genetic research and resultant products, including
          stricter labeling laws or regulations, and could cause a decrease in the
          demand
          for our products.</font></div>
        <div>
          <div>&#160;</div>
          <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            subject of genetically modified organisms has received negative publicity
            in
            Europe and other countries, which has aroused public debate. The adverse
            publicity in Europe could lead to greater regulation and trade restrictions
            on
            imports of genetically altered products. If similar adverse public reaction
            occurs in the United States, genetic research and resultant products
            could be
            subject to greater domestic regulation and a decrease in the demand for
            our
            products could result.</font></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
            scientific collaborations may change, which could limit our access to
            their
            expertise.</strong></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        rely
        upon the services of a number of research organizations, scientific advisors
        and
        collaborators at academic and other institutions. These scientists are not
        our
        employees and may have other commitments that would limit their availability
        to
        us. Although our scientific advisors generally agree not to perform services
        on
        competing technologies, if a conflict of interest between their services
        for us
        and their services for another entity were to occur, we might lose their
        services. Although our scientific advisors and collaborators sign agreements
        not
        to disclose our <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">confidential
        information, it is possible that certain of our valuable proprietary knowledge
        may become publicly known through them. </font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Terrorists
        could damage our facilities, interfere with our R&amp;D activities and cause
        ecological harm. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Activists
        and terrorists have shown a willingness to injure people and damage physical
        facilities, equipment and biological materials to publicize or further their
        ideological causes. Biotechnology companies could be a specific target of
        certain groups. Our operations and research activities could be adversely
        impacted depending upon the nature and extent of such acts. Such damage could
        include disability or death of our personnel, damage to physical facilities
        that
        we contract with to perform R&amp;D activities or to manufacture our products,
        destruction of animals and biological materials, disruption of our
        communications and data management software used for R&amp;D or destruction of
        R&amp;D records. Any such damage could delay our R&amp;D projects or the
        manufacture of our products and decrease our ability to conduct future R&amp;D
        and to develop future products. Damage caused by activist or terrorist incidents
        could also cause the release of hazardous materials, including chemicals
        and
        biological materials, which could create liabilities for us or damage our
        reputation in the community. Clean up of any such releases could also be
        time
        consuming and costly. Any significant interruptions in our ability to conduct
        our business operations or R&amp;D activities could reduce our revenue and
        increase our expenses.</font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>30</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
              could suffer claims from our use of hazardous, radioactive or biological
              materials.</strong></font></div>
            <div>&#160;</div>
            <div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
                R&amp;D processes involve the controlled use of hazardous materials, including
                chemicals, radioactive and biological materials. Our operations also
                produce
                hazardous waste products. We cannot eliminate the risk of accidental
                contamination or discharge and any resultant injury from these materials.
                Federal, state and local laws and regulations govern the use, manufacture,
                storage, handling and disposal of these materials. We could be subject
                to
                criminal liability or claims for damages in the event of an improper
                or
                unauthorized release of, or exposure of individuals to, hazardous
                materials. In
                addition, claimants may sue us for injury or contamination that results
                from our
                use or the use by third parties of these materials, and our liability
                may exceed
                our total assets. Compliance with these laws and regulations may
                be expensive,
                and current or future laws and regulations may impair our research,
                development,
                or production efforts, or otherwise be time-consuming and costly.
                We believe
                that our current operations comply in all material respects with
                applicable laws
                and regulations.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
                addition, our collaborators may work with these types of hazardous
                materials in
                connection with our collaborations. To our knowledge, the work is
                performed in
                accordance with these laws and regulations. In the event of a lawsuit
                or
                investigation, we could be held responsible for any injury caused
                to persons or
                property by exposure to, or release of, these hazardous materials.
                Further,
                under certain circumstances, we may agree to indemnify our collaborators
                against
                damages and other liabilities arising out of development activities
                or products
                produced in connection with these collaborations.</font></div>
            </div>
          </div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Other
            Business Risks That We Face</em></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        must continually offer new products and technologies.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        industrial enzymes and biotechnology industries are characterized by rapid
        technological change, and the area of gene research is a rapidly evolving
        field.
        Our future success will depend on our ability to maintain a competitive position
        with respect to technological advances. Rapid technological development by
        others may result in our products and technologies becoming
        obsolete.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
        products that we develop through our C1 Host Technology will compete in highly
        competitive markets. Many of the organizations competing with us in the markets
        for such products have greater capital resources, R&amp;D and marketing staffs
        and facilities and capabilities, and greater experience in obtaining regulatory
        approvals, manufacturing products and marketing. Accordingly, our competitors
        may be able to develop technologies and products more easily which would
        render
        our technologies and products and those of our collaborators obsolete and
        noncompetitive. If a competitor develops superior technology or cost-effective
        alternatives to our products or processes, our business, operating results
        and
        financial condition could be seriously harmed. In addition, demand for our
        products may weaken due to reduction in R&amp;D budgets or loss of distributors,
        any of which might have an adverse effect on our financial
        condition.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        markets for our Enzyme Business&#8217;s products are, in many cases, very competitive
        and price sensitive. Our Enzyme Business currently competes with five much
        larger competitors, each with dominant market positions in segments in which
        we
        compete and who, as a group, hold approximately 70% market share in the present
        industrial enzymes marketplace. Each of these competitors has substantially
        greater financial, operational, sales and marketing resources than we do
        and
        very significant experience in R&amp;D. Further, these competitors may possess
        other complementary technologies, such as proprietary directed molecular
        evolution technology, which may be more effective at implementing their
        technologies to develop commercial products than our complementary technologies
        implement our C1 Host Technology. Also, some of these competitors have entered
        into collaborations with leading companies within our Enzyme Business&#8217;s target
        markets to produce enzymes for commercial purposes.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Well-known,
        and better financed, biotechnology companies offer competing technologies
        for
        the same products and services as our BioSciences Business plans to offer
        using
        our C1 Host Technology. Customers may prefer existing competing technologies
        over our C1 Host Technology. Our BioSciences Business also faces, and will
        continue to face, intense competition from organizations such as large
        biotechnology companies, as well as academic and research institutions and
        government agencies that are pursuing competing technologies to enable
        production of therapeutic and other proteins and bio-molecules of commercial
        interest at economically viable costs. These organizations may develop
        technologies that are superior alternatives to our C1 Host Technology. We
        anticipate that our BioSciences Business will face increased competition
        as new
        companies enter our markets and as development of biological products
        evolves.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>31</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
              may need additional capital in the future. </strong></font></div>
            <div><br></div>
            <div>
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
                Our future capital requirements will be substantial, particularly
                if we require
                significant additional capital to develop manufacturing capacity
                for our Enzyme
                Business, if completion of the development of our C1 Expression System
                for our
                BioSciences Business takes longer or requires greater resources than
                we had
                expected, if we continue to develop the C1 Expression System to expand
                its
                production capabilities to manufacture commercial volumes of therapeutic
                proteins, if we pursue the development of enzymes for cellulosic
                ethanol, if we
                continue to develop a C1 Screening System, or if our BioSciences
                Business
                develops a number of therapeutic products. Although we believe that
                we have
                sufficient cash on hand to fund our operations and meet our obligations
                through
                December 31, 2006, our need for additional capital will depend on
                many factors,
                including the financial success of our Enzyme Business, whether our
                Polish
                contract manufacturer modernizes and expands its manufacturing facility
                as it is
                required to by its contract with us, whether we are successful in
                obtaining
                payments from BioSciences Business customers under collaborative
                agreements, the
                progress and scope of our collaborative and independent R&amp;D projects
                performed by our customers and collaboration partners, the effect
                of any
                acquisitions of other businesses that we may make in the future,
                and the filing,
                prosecution and enforcement of patent claims.</font></div>
            </div>
          </div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
If
            our capital resources are insufficient to meet our capital requirements
            through
            December 31, 2006, we will have to raise additional funds to continue
            the
            development of our technologies and complete the commercialization of
            products,
            if any, resulting from our technologies. If future raises of funds do
            occur,
            they may cause dilution to our existing shareholders. We may not be able
            to
            raise additional funds on terms that are acceptable to us or on any terms
            whatsoever, or we may be unable to raise sufficient additional capital.
            If we
            fail to raise sufficient funds, and our Enzyme Business is unable to
            generate
            sufficient levels of profitability, we will have to curtail or cease,
            or dispose
            of, one or more of our operations. </font></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><strong><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
            will need to expand our existing marketing and sales
            resources.</font></strong></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
          While we have recently expanded our marketing and sales functions, our
          Enzyme
          Business will need to continue to expand them to achieve our contemplated
          annual
          rates of growth and for our BioSciences Business to successfully market
          the C1
          Expression System and our contemplated C1 Screening System. Currently,
          we rely
          primarily on our direct sales force for the United States market and contract
          with professional sales agents and distributors for the international market,
          including two controlled foreign subsidiaries. Direct salespeople are our
          employees and are paid a salary plus commissions on sales they make within
          their
          assigned territories. Contracted sales agents are paid a base rate of
          compensation plus commissions on sales they make within their assigned
          territories. Distributors purchase products from us and then resell our
          products
          and services to third parties. Our officers and employees develop and implement
          our marketing strategy, although we do periodically engage non-employee
          consultants, acting as independent contractors, to assist us in these
          efforts.</font></div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        Market forces, such as increasing competition, increasing cost pressures
        on our
        customers and general economic conditions, may require us to devote more
        resources to our sales and marketing efforts than we currently contemplate,
        such
        as changing the composition of our sales and marketing staff and changing
        our
        marketing methods. These changes may result in additional expenses. In addition,
        we will incur additional salary expenses because we intend to increase our
        direct sales force. We also may hire direct sales representatives to replace
        independent sales representatives or distributors that we use. Similarly,
        if we
        increase our reliance on marketing consultants to assist us, we will incur
        greater costs. If we decide to increase our advertising, we will also incur
        higher sales and marketing costs. Our incurrence of increased costs will
        make it
        more difficult for us to operate profitably, and we may not have sufficient
        funds to support all of these costs.</font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
If
        we expand our sales force and increase our marketing activities, we can offer
        no
        assurances that those efforts will result in more sales or higher revenue.
        Also,
        the increased costs we incur by expanding our sales and marketing resources
        may
        not result in greater sales or in higher revenue. Further, even if we increase
        our spending on sales and marketing, we may not be able to maintain our current
        level of sales and revenue. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Loss
        of key personnel could hurt our business. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        are
        highly dependent on the principal members of our management and scientific
        staff, the loss of whose services might adversely impact the achievement
        of our
        objectives. In addition, recruiting and retaining qualified scientific personnel
        to perform future R&amp;D work will be critical to our success. We currently do
        not have sufficient executive management personnel to fully execute our business
        plan. Although we believe we will be successful in attracting and retaining
        qualified management and scientific personnel, such as the addition of our
        Chief
        Scientific Officer, Glenn Nedwin in March 2006, competition for experienced
        scientists from numerous companies and academic and other research institutions
        may limit our ability to do so on acceptable terms. Failure to attract and
        retain scientific personnel would prevent us from pursuing collaborations
        or
        developing our products or core technologies.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        planned activities will require additional expertise in specific industries
        and
        areas applicable to the products developed through our technologies. These
        activities will require the addition of new personnel, including management,
        and
        the development of additional expertise by existing management personnel.
        The
        inability to acquire these services or to develop this expertise could impair
        the growth, if any, of our business. </font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>32</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div id="GLHDR" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
            <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font size="3">&#160;&#160;&#160;
</font>We
              began to increase and upgrade our accounting
              staff with the hiring of our Chief Financial Officer, Wayne Moor and
              our&#160;Director of Financial Reporting Lisa De La Pointe in the first quarter
              of 2005.&#160;Our directors and senior officers require that we maintain
              directors and officers insurance at levels comparable to those of similar
              sized
              public companies. We have purchased such directors&#8217; and officers&#8217; liability
              insurance. Our efforts to recruit additional directors could be impeded
              if the
              amount of insurance coverage is viewed to be insufficient. Further,
              if we are
              unable to provide adequate compensation or are unable to maintain sufficient
              directors and officers insurance coverage, we may not be able to attract
              or
              retain key personnel. </font></div>
            <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
            <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
              Personnel changes may disrupt our operations. Hiring and training new
              personnel
              will entail costs and may divert our resources and attention from
              revenue-generating efforts. From time to time, we also engage consultants
              to
              assist us in our business and operations. These consultants serve as
              independent
              contractors, and we, therefore, do not have as much control over their
              activities as we do over the activities of our employees. Our consultants
              may be
              affiliated with or employed by other parties, and some may have consulting
              or
              other advisory arrangements with other entities that may conflict or
              compete
              with their obligations to us. Inventions or processes discovered by
              these
              persons will not necessarily become our property. </font></div>
          </div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Inability
            to protect our technologies could harm our ability to compete.
</strong></font></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
            Our success will depend in part on our ability to obtain patents and
            maintain
            adequate protection of our other intellectual property for our technologies
            and
            products in the United States and other countries. If we do not adequately
            protect our intellectual property, competitors may be able to practice
            our
            technologies and erode our competitive advantage. The laws of some foreign
            countries do not protect proprietary rights to the same extent as the
            laws of
            the United States, and many companies have encountered significant problems
            in
            protecting their proprietary rights in these foreign countries. These
            problems
            can be caused by, for example, a lack of rules and methods for defending
            intellectual property rights.</font></div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
We
        hold three issued U.S. patents and 24 international patents, including claims
        that cover the C1 Expression System and various other aspects of the C1 Host
        Technology, and three international patent applications which expand that
        coverage and include the C1 Screening System. We also have 51 pending patent
        applications which we expect, if issued, will also cover various aspects
        of the
        C1 Host Technology in addition to the C1 Expression System. The patent positions
        of biotechnology companies, including our patent position, are generally
        uncertain and involve complex legal and factual questions. We will be able
        to
        protect our proprietary rights from unauthorized use by third parties only
        to
        the extent that our proprietary technologies are covered by valid and
        enforceable patents or are effectively maintained as trade secrets. We intend
        to
        apply for patents covering both our technologies and products as we deem
        appropriate. However, existing and future patent applications may be challenged
        and may not result in issued patents. Our existing patents and any future
        patents we obtain may not be sufficiently broad to prevent others from
        practicing our technologies or from developing competing products. Furthermore,
        others may independently develop similar or alternative technologies or design
        around our patented technologies. In addition, others may challenge or
        invalidate our patents, or our patents may fail to provide us with any
        competitive advantages.</font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        Not all of our proprietary technology is eligible for patent protection.
        Accordingly, as to significant portions of our various proprietary technologies,
        we rely upon trade secret protection for our confidential and proprietary
        information. We have taken security measures to protect our proprietary
        information. These measures may not provide adequate protection for our trade
        secrets or other proprietary information. We seek to protect our proprietary
        information by entering into confidentiality agreements with employees,
        collaborators and consultants. Nevertheless, employees, collaborators or
        consultants may still disclose our proprietary information, and we may not
        be
        able to meaningfully protect our trade secrets. In addition, others may
        independently develop substantially equivalent proprietary information or
        techniques or otherwise gain access to our trade secrets. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Intellectual
        property litigation could harm our business. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        commercial success depends in part on neither infringing patents and proprietary
        rights of third parties, nor breaching any licenses that we have entered
        into
        with regard to our technologies and products. Others have filed, and in the
        future are likely to file, patent applications covering genes or gene fragments
        that we may wish to utilize with our C1 Host Technology, our C1 Expression
        System, our C1 Screening System or products or systems that are similar to
        products developed with the use of our C1 Host Technology. If these patent
        applications result in issued patents and we wish to use the claimed technology,
        we would need to obtain a license from the third party. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Third
        parties may assert that we are employing their proprietary technology without
        authorization. In addition, third parties may obtain patents in the future
        and
        claim that use of our technologies infringes these patents. We could incur
        substantial costs and diversion of management and technical personnel in
        defending ourselves against any of these claims or enforcing our patents
        or
        other intellectual property rights against others. Furthermore, parties
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>33</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">making
              claims against us may be able to obtain injunctive or other equitable
              relief
              which could effectively block our ability to further develop, commercialize
              and
              sell products, and could result in the award of substantial damages
              against us.
              If a claim of infringement against us is successful, we may be required
              to pay
              damages and obtain one or more licenses from third parties. We may
              not be able
              to obtain these licenses at a reasonable cost, if at all. In that event,
              we
              could encounter delays in product commercialization while we attempt
              to develop
              alternative methods or products. Defense of any lawsuit or failure
              to obtain any
              of these licenses could prevent us from commercializing available
              products.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
              the taxonomic classification of our C1 host organism was determined
              using
              classical morphological methods. More modern taxonomic classification
              methods
              indicate that our C1 host organism will be reclassified as a different
              genus and
              species. We anticipate that with the genomic sequence and after the
              expected
              completion of the annotation of the C1 genome, we will be better positioned
              to
              determine the genus and species of the C1 Host organism. Some of the
              possible
              species that the C1 host could be reclassified as could be the subject
              of patent
              rights owned by others. We believe, based on our evaluation of the
              relevant
              field of science and our discussions with our consulting professionals,
              that any
              such patent rights would be invalid, and were litigation over the issue
              to
              ensue, we believe we should prevail. If we did not prevail, to settle
              any such
              litigation or pre-litigation claims, we could be required to enter
              into a
              cross-licensing arrangement, pay royalties or be forced to stop
              commercialization of some of our activities. </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
              do not
              fully monitor the public disclosures of other companies operating in
              our
              industry regarding their technological development efforts. If we did
              evaluate
              the public disclosures of these companies in connection with their
              technological
              development efforts and determined that they violated our intellectual
              property
              or other rights, we would anticipate taking appropriate action, which
              could
              include litigation. However, any action we take could result in substantial
              costs and diversion of management and technical personnel. Furthermore,
              the
              outcome of any action we take to protect our rights may not be resolved
              in our
              favor or may not be resolved for a lengthy period of time. </font></div>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          </div><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          may be
          sued for product liability. </font></strong></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font size="3">&#160;&#160;&#160;
</font>We
            may be held liable if any product we
            develop, or any product which is made with the use or incorporation of,
            any of
            our technologies, causes injury or is found otherwise unsuitable during
            product
            testing, manufacturing, marketing or sale. These risks are inherent in
            the
            development of chemical, agricultural and pharmaceutical products. While
            we
            maintain product liability insurance, it may not fully cover our potential
            liabilities. Inabilityto obtain sufficient insurance coverage at an acceptable
            cost or otherwise to protect against potential product liability claims
            could
            prevent or inhibit the commercialization of products developed by us
            or our
            collaborators. If we are sued for any injury caused by our products,
            our
            liability could exceed our total assets.</font></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>International
        unrest or foreign currency fluctuations could adversely affect our
        results.</strong></font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        International sales accounted for approximately 86% and 91% of our net sales
        in
        2004 and 2005, respectively. Our key international markets are the European
        Union, Hong Kong, the Peoples Republic of China and India. Our international
        sales are made through international distributors and their wholly owned
        subsidiaries, including our Asian subsidiary, and direct to end-user plants
        with
        payments to us, in many cases, denominated in currencies other than U.S.
        dollars. In the conduct of our business, in a number of instances, we are
        required to pay our obligations in currencies other than U.S. dollars.
        Accordingly, we are exposed to changes in currency exchange rates with respect
        to our international sales and payment obligations. We experienced currency
        losses in 2004 of $213,471 and currency gains in 2005 of $16,785. </font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fluctuations
        in currency exchange rates have in the past and may in the future negatively
        affect our ability to price competitively against products denominated in
        local
        currencies. Also, changes in foreign currency exchange rates may have an
        adverse
        effect on our financial position and results of operations as expressed in
        U.S.
        dollars. Our management monitors foreign currency exposures and may, in the
        ordinary course of business, enter into foreign currency forward contracts
        or
        options contracts related to specific foreign currency transactions or
        anticipated cash flows. We do not hedge, and have no current plans to hedge
        in
        the future, the translation of financial statements of consolidated subsidiaries
        whose local books and records are maintained in foreign currency. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        imposition of duties or other trade barriers, trade embargoes, acts of
        terrorism, wars and other events outside our control may adversely affect
        international commerce and impinge on our ability to manufacture, transport
        or
        sell our products in international markets.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Business
        interruptions could keep us from developing our products and increasing our
        sales. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Natural
        or man-made disasters, such as fires, earthquakes, hurricanes, power losses,
        telecommunications failures, terrorist attacks, military operations and other
        events beyond our control may interrupt our operations. We do not have a
        detailed disaster recovery plan. In addition, we may not carry sufficient
        business interruption insurance to compensate us for losses that may occur
        and
        any losses or damages we incur could have a material adverse effect on our
        cash
        flows and success as an overall business.</font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>34</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
              are dependent on several key customers.</strong></font></div>
            <div><br></div>
            <div>
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
In
                2005, there were two customers that accounted for approximately 10%
                each of net
                sales. In 2004, there were no customers that accounted for greater
                than 10% of
                net sales. There were three customers in 2005 whose trade receivable
                balances
                equaled or exceeded 5% of total receivables, representing approximately
                16%, 7%,
                and 6%, respectively, of total accounts receivable. The loss of business
                from
                one or a combination of the Company&#8217;s significant customers could adversely
                affect its business, results of operations and financial condition.
                See Note 3
                of Notes to Consolidated Financial Statements included elsewhere
                in this Annual
                Report.</font></div>
              <div>&#160;</div>
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Risks
                Related to Our Common Stock</em></font></div>
            </div>
          </div>
          <div><br></div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Securities
            of Biotechnology companies are often volatile. </strong></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            trading prices of biotechnology company stocks in general tend to experience
            extreme price fluctuations. The valuations of many biotechnology companies
            without consistent product sales and earnings are extraordinarily high
            based on
            conventional valuation standards such as price to earnings and price
            to sales
            ratios. These trading prices and valuations may not be sustained. Any
            negative
            change in the public&#8217;s perception of the prospects of biotechnology companies
            could depress our stock price regardless of our results of operations.
            Other
            broad market and industry factors may decrease the trading price of our
            common
            stock, regardless of our </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">performance.
            Market fluctuations, as well as general political and economic conditions
            such
            as war, recession or interest rate or currency rate fluctuations, also
            may
            decrease the trading price of our common stock. In addition, our stock
            price
            could be subject to wide fluctuations in response to factors including,
            but not
            limited to, the following: </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                      of new technological innovations or new products by us or our
                      competitors;
                      </font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">changes
                  in the market valuations of other biotechnology companies; </font></div>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                  in domestic and international governmental policy or regulations;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">announcements
                  by us or our competitors of significant acquisitions, strategic
                  partnerships, joint ventures or capital commitments;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">developments
                  in patent or other proprietary rights held by us or by others;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">loss
                  or expiration of our intellectual property rights;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">lawsuits
                  initiated by or against us;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">period-to-period
                  fluctuations in our operating results;
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">future
                  royalties from product sales, if any, by our strategic partners;
                  and
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">sales
                  of our common stock or other securities in the open market.
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        the
        past, stockholders have often instituted securities class action litigation
        after periods of volatility in the market price of a company&#8217;s securities. If a
        stockholder files a securities class action suit against us, we would incur
        substantial legal fees and our management&#8217;s attention and resources would be
        diverted from operating our business to respond to the litigation.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
        operating results and the market price of stock could be volatile.
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        quarterly operating results have fluctuated in the past and are likely to
        do so
        in the future. These fluctuations could cause our stock price to fluctuate
        significantly or decline. Some of the factors which could cause our operating
        results to fluctuate include: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expiration
                  of research contracts with collaborators, which may not be renewed
                  or
                  replaced; </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                  success rate of our discovery efforts leading to milestones and
                  royalties;
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>35</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                      timing and willingness of collaborators to commercialize our
                      products
                      which would result in royalties;
</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div>&#160;</div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">general
                      and industry specific economic conditions, which may affect
                      our
                      collaborators&#8217; R&amp;D
                      expenditures;</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                      adoption and acceptance of our industrial enzymes and other
                      products by
                      customers of our Enzyme Business;</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                      adoption and acceptance of our C1 Host Technology, C1 Expression
                      System
                      and C1 Screening System by biotechnology and pharmaceutical
                      companies
                      being marketed to by our BioSciences
                      Business;</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div>&#160;</div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                      introduction by our competitors of new industrial enzyme products
                      or lower
                      prices of existing products to our Enzyme Business&#8217;s
                      customers;</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
                      introduction by our competitors of new expression technologies
                      competitive
                      with our C1 Expression System; and</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">disruption
                      in our manufacturing capacity or our failure to bring on additional
                      manufacturing capacity required to meet our projected
                      growth.</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
A
          large portion of our expenses are relatively fixed, including expenses
          for
          facilities, equipment and personnel. Accordingly, if sales decline or do
          not
          grow as anticipated due to expiration of research contracts or government
          research grants, if any, failure to obtain new contracts or other factors,
          we
          may not be able to correspondingly reduce our operating expenses. Failure
          to
          achieve anticipated levels of sales could, therefore, significantly harm
          our
          operating results for a particular fiscal period. </font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due
        to
        the possibility of fluctuations in our revenues and expenses, we believe
        that
        quarter-to-quarter comparisons of our operating results are not a good
        indication of our future performance. Our operating results in some quarters
        may
        not meet the expectations of stock market analysts and investors. In that
        case,
        our stock price would probably decline. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        may not be able to maintain our American Stock Exchange listing
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        common stock has been listed on the American Stock Exchange since May 27,
        2005.&#160; There is no assurance that we will be able to satisfy the American
        Stock Exchange&#8217;s continued listing standards, which include, among others,
        minimum stockholders&#8217; equity, market capitalization, pre-tax income and per
        share sales price.&#160; If our common stock is de-listed from the American
        Stock Exchange, we would be forced to list our common stock on the OTC Bulletin
        Board or some other quotation medium, depending on our ability to meet the
        specific requirements of those quotation systems.&#160; Selling our common stock
        would be more difficult because smaller quantities of shares would likely
        be
        bought and sold and transactions could be delayed. These factors could result
        in
        lower prices and larger spreads in the bid and ask prices for shares of our
        common stock. If this happens, we will have greater difficulty accessing
        the
        capital markets to raise any additional necessary capital.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
        do not expect to pay dividends in the future. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        never paid cash dividends on our stock and do not anticipate paying cash
        dividends on our stock in the foreseeable future. The payment of dividends
        on
        our shares, if ever, will depend on our earnings, financial condition and
        other
        business and economic factors affecting us at such time as the board of
        directors may consider relevant. If we do not pay dividends, our stock may
        be
        less valuable because a return on investment will only occur if and to the
        extent that our stock price appreciates, and if the price of our stock does
        not
        appreciate, then there will be no return on investment. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Our
        anti-takeover defense provisions may deter potential acquirers and depress
        our
        stock price.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain
        provisions of our certificate of incorporation, bylaws and Delaware law,
        as well
        as certain agreements we have with our executives, could be used by our
        incumbent management to make it substantially more difficult for a third
        party
        to acquire control of us. These provisions include the following:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                  may issue preferred stock with rights senior to those of our common
                  stock;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                  have a classified Board of
                  Directors;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">action
                  by written consent by stockholders is not
                  permitted;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><sup>36</sup></strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div>
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our
                      Board of Directors has the exclusive right to fill vacancies
                      and set the
                      number of directors;</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        </div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -13.5pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
              <table cellpadding="0" cellspacing="0" id="list" width="100%">

                  <tr valign="top" style="line-height: 1.25;">
                    <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                    <td>
                      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cumulative
                        voting by our stockholders is not allowed;
                        and</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div>
              <table cellpadding="0" cellspacing="0" id="list" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

                  <tr valign="top" style="line-height: 1.25;">
                    <td align="right" style="width: 54pt;"><font style="FONT-FAMILY: Symbol" size="2">&#183;&#160;&#160;</font></td>
                    <td>
                      <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">we
                        require advance notice for nomination of directors by our
                        stockholders and
                        for stockholder proposals</font>.</div>
                    </td>
                  </tr>

              </table>
            </div>
            <div>&#160;</div>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><br>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                These provisions may discourage certain types of transactions involving
                an
                actual or potential change in control. These provisions may also
                limit our
                stockholders&#8217; ability to approve transactions that they may deem to be in their
                best interests and discourage transactions in which our stockholders
                might
                otherwise receive a premium for their shares over the then current
                market
                price.</font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
                have controlling stockholders. </strong></font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
                Our officers, directors and principal stockholders together control
                approximately 55.9% of our outstanding common stock. Our founder
                and chief
                executive officer, Mark Emalfarb, through a trust of which he is
                the trustee and
                beneficiary, the Mark&#160;A. Emalfarb Trust, owns approximately 25% of our
                outstanding common stock. Further, the Francisco Trust, whose beneficiaries
                are
                the spouse and descendants of Mark Emalfarb, owns approximately 20%
                of our
                outstanding common stock, while friends and relatives of Mr. Emalfarb,
                who are
                not officers, directors, or principal stockholders, own approximately
                an
                additional 5% of our outstanding common stock. As a result, these
                stockholders,
                if they act together, will be able to exert a significant degree
                of influence
                over our management and affairs and over matters requiring stockholder
                approval,
                including the election of directors and approval of significant corporate
                transactions. In addition, this concentration of ownership may delay
                or prevent
                a change in control of us and might affect the market price of our
                shares, even
                when a change may be in the best interests of all stockholders. Moreover,
                the
                interests of this concentration of ownership may not always coincide
                with our
                interests or the interests of other stockholders, and, accordingly,
                they could
                cause us to enter into transactions or agreements which we would
                not otherwise
                consider.</font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
                are indebted to our largest stockholders.</strong></font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
As
                of December 31, 2005, we owed the Mark&#160;A. Emalfarb Trust and the Francisco
                Trust an aggregate indebtedness of approximately $3.6 million and
                accrued
                interest of approximately $73,000, under three separate promissory
                notes. In
                connection with the transactions completed in late October 2004,
                the
                Mark&#160;A. Emalfarb Trust cancelled $1,225,000 of the indebtedness represented
                by a promissory note in exchange for the issuance of shares of common
                stock and
                warrants, and we extended the maturity date of the remaining indebtedness
                to the
                Mark A. Emalfarb Trust and the Francisco Trust. All of our assets
                are mortgaged
                or pledged to secure the bridge loan owed to the Mark&#160;A. Emalfarb Trust. If
                we were unable to generate sufficient cash flow or otherwise obtain
                funds
                necessary to pay this indebtedness when due, we would be in default,
                and this
                debt holder would have the right to foreclose on its liens and security
                interests that secure the defaulted debt. Further, not only is this
                indebtedness
                evidenced by a promissory note that is transferable by its holder,
                but we could
                decide to refinance this indebtedness through similar secured borrowings
                from
                banks or other commercial lenders. Any transferee or new lender,
                no longer
                constrained by the stockholder interests of the Mark&#160;A. Emalfarb Trust, may
                not have the same attitude about any failure on our part to meet
                our binding
                repayment obligations as the Mark&#160;A. Emalfarb Trust might.</font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>We
                are exposed to potential risks resulting from new requirements that
                we evaluate
                financial reporting controls under Section 404 of the Sarbanes-Oxley
                Act of
                2002. </strong></font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
We
                are evaluating our internal controls in order to allow management
                to report on,
                and our independent registered public accounting firm to attest to,
                our internal
                controls over financial reporting, as required by Section 404 of
                the
                Sarbanes-Oxley Act of 2002. We may encounter unexpected delays in
                implementing
                the requirements relating to internal controls over financial reporting,
                therefore, we cannot be certain about the timing of completion of
                our
                evaluation, testing and remediation actions or the impact that these
                activities
                will have on our operations since there is no precedent available
                by which to
                measure the adequacy of our compliance. We also expect to incur additional
                expenses and diversion of management&#8217;s time as a result of performing the system
                and process evaluation, testing and remediation required in order
                to comply with
                the management certification and independent registered public accounting
                firm
                attestation requirements. If we are not able to timely comply with
                the
                requirements set forth in Section 404, we might be subject to sanctions
                or
                investigation by regulatory authorities. Any such action could adversely
                affect
                our business and financial results. The requirement to comply with
                Section 404
                of the Sarbanes-Oxley Act of 2002 will become effective no earlier
                than for our
                fiscal year ending December 31, 2006. </font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
In
                addition, in our system of internal controls we may rely on the internal
                controls of third parties. In our evaluation of our internal controls,
                we will
                consider the implication of our reliance on the internal controls
                of third
                parties. Until we have completed our evaluation, we are unable to
                determine the
                extent of our reliance on those controls, the extent and nature of
                the testing
                of those controls, and remediation actions necessary where that reliance
                cannot
                be adequately evaluated and tested. </font></div>
            </div>
          </div>
        </div>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div id="FTR" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>37</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="property">ITEM</a>
          2</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>.
          DESCRIPTION OF PROPERTY. </u></em></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            Company&#8217;s corporate headquarters are located at 140 Intracoastal Pointe Drive,
            Suite 404, Jupiter, Florida, in approximately 5,700 square feet of space
            occupied under a lease with a monthly rental rate of $8,700 that expires
            on
            December 31, 2007. The lease includes the rental of additional space
            beginning
            in April 2006 for a total of 8,500 square feet at a monthly rate of
            $15,200.</font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;<a name="Item_3_Legal">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In
        May 2005, the Company purchased an undeveloped 1.13 acre parcel of land (the
        &#8220;Site&#8221;) pursuant to a real estate purchase contract with F&amp;C Holdings, LLC
        (&#8220;Holdings&#8221;) dated July 31, 2004 (the &#8220;Commercial Land Purchase And Sale
        Agreement&#8221;) (see Notes 9 and 12 to our consolidated financial statements). The
        Company formed Dyadic Real Estate Holdings, Inc., a Florida corporation and
        wholly-owned subsidiary in May 2005, to which it has assigned the Commercial
        Land Purchase and Sale Agreement and the Site. The Site, which is in a planned
        community known as "Abacoa" is located in the Town of Jupiter, Florida (the
        &#8220;Town&#8221;). The Company has obtained final approval from the Town of Jupiter to
        construct an approximately 40,000 square foot commercial office biotech research
        and development building.</a></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Commercial Land Purchase and Sale Agreement obligates Dyadic to commence
        development of the Site within two (2) years following the closing date.
        During
        this two-year period, Dyadic is prohibited from re-transferring the Site
        to any
        other person other than (i) in connection with a sale of Dyadic, (ii) to
        an
        affiliate or (iii) with the approval of Dyadic's Board of Directors (a majority
        of its independent directors), to the Francisco Trust, the Mark A. Emalfarb
        Trust and/or any entity that is controlled, directly or indirectly, by Mark
        A.
        Emalfarb and/or his family members. It is not the Company&#8217;s intention to use its
        own funds to develop this property, therefore the Company is considering
        such
        options as a joint venture or other arrangement to accomplish the development
        of
        the Site. There can be no assurance, however, that any joint venture or other
        arrangements will occur within the prescribed timeframe. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        after
        two years from the closing (in May 2007), Dyadic has not commenced development
        of the Site, then Holdings shall, in exchange for a reconveyance Deed, pay
        the
        "Reconveyance Purchase Price" equal to the greater of the following: (i)
        $1.0
        million or (ii) the "Market Value" of the shares of the Company's common
        stock,
        as defined, determined as of the date of the reconveyance notice from Holdings.
        The Reconveyance Purchase Price can be paid in all cash, or return of all
        the
        shares of the Company's common stock to the Company so long as the Market
        Value
        of the shares of the Company's common stock is greater than or equal to $1.0
        million, or by combination of shares of the Company's common stock and cash,
        as
        determined in the sole and absolute discretion of Holdings. The Company is
        currently assessing its alternatives for development of the Site, and continues
        to expect to commence development by December 31, 2006.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="legal">ITEM
        3</a>. </u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>LEGAL
        PROCEEDINGS. </u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company is not a party to any material legal proceedings.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="submission">ITEM</a>
        4. </u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>SUBMISSION
        OF MATTERS TO A VOTE OF SECURITY HOLDERS. </u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not
        applicable.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="PART_II"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PART
        I</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>I</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="marketequity"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
        5. </u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>MARKET
        FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>&#160;</u></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        of
        March 24, 2006, there were 22,712,965 shares of Dyadic common stock outstanding
        (including 274,796 shares held in escrow), with approximately 176 stockholders
        of record. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
        bid or
        ask information or public trades were reported with respect to the Company&#8217;s
        common stock prior to the Merger consummated on October 29, 2004. As a result,
        the range of high and low bid information for shares of the Company&#8217;s common
        stock for each full quarterly period for 2004 is not available. The Company&#8217;s
        common stock was traded on the OTC Bulletin Board System (OTCBB) for the
        period
        October 29, 2004 through May 26, 2005. Since May 27, 2005, the Company&#8217;s common
        stock has been trading on the American Stock Exchange under the symbol DIL.
        These quotations reflect inter-dealer prices, without retail mark-up, mark-down
        or commissions, and may not represent actual transactions. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        following table sets forth the high and low bids for Dyadic common stock
        for the
        quarterly periods for the years ended December 31, 2005 and 2004 as reported
        by
        the OTCBB for the period October 29, 2004 through May 26, 2005 and as reported
        by the American Stock Exchange from May 27, 2005: </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>38</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="85%">

                <tr>
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Quarter
                    Ended</strong></font></td>
                  <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005
                      Sales Price</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004
                      Sales Price</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>High</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Low</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>High</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Low</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">March
                      31</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6.50</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.75</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">n/a</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">n/a</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">June
                      30</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.05</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.25</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">n/a</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">n/a</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">September
                      30</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.80</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.87</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">n/a</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">n/a</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December
                      31, 2005 and (October 29 to December 31, 2004)</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.23</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.50</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7.35</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.95</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Dividend
          Policy </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
          While there are no restrictions on the payment of dividends, Dyadic has
          not
          declared or paid any cash dividends on shares of Dyadic common stock in
          the last
          two fiscal years, and we presently have no intention of paying any cash
          dividend
          in the foreseeable future. The Company&#8217;s current policy is to retain earnings,
          if any, to finance the expansion of it business. The future payment of
          dividends
          will depend on the results of operations, financial condition, capital
          expenditure plans and other factors that we deem relevant and will be at
          the
          sole discretion of the Board of Directors. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Equity
        Compensation Plan Information </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        following table provides information regarding the status of the Company&#8217;s
        existing equity compensation plans at December 31, 2005. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="23%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Plan
                  Category</font></div>
              </td>
              <td valign="top" width="21%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number
                  of securities to be issued upon exercise of outstanding options,
                  warrants
                  and rights</font></div>
              </td>
              <td valign="top" width="19%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Weighted-average
                  exercise price of outstanding options, warrants and rights</font></div>
              </td>
              <td valign="top" width="18%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number
                  of securities remaining available for future issuance</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="top" width="23%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
                  compensation plans approved by security holders (1) (3)</font></div>
              </td>
              <td valign="middle" width="21%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,597,639</font></div>
              </td>
              <td valign="middle" width="19%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$3.62</font></div>
              </td>
              <td valign="middle" width="18%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3,536,184
                  (2)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="top" width="23%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
                  compensation plans not approved by security holders</font></div>
              </td>
              <td valign="middle" width="21%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td valign="middle" width="19%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td valign="middle" width="18%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="23%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total</font></div>
              </td>
              <td valign="bottom" width="21%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,597,639</font></div>
              </td>
              <td valign="bottom" width="19%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$3.62</font></div>
              </td>
              <td valign="bottom" width="18%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3,536,184
                  (2)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 27pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consists
                  of Dyadic International, Inc. 2001 Equity Compensation Plan, which
                  the
                  Company assumed in connection with the Merger consummated on October
                  29,
                  2004. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 27pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Excludes
                  18,624 shares that were awarded to Dyadic-Florida employees under
                  the
                  Dyadic International, Inc. 2001 </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity
        Compensation Plan in 2004. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 27pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Excludes
                  65,000 options to purchase common stock granted to nonemployees
                  prior to
                  the Equity Compensation </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Plan's
        adoption.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>39</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="Item6"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
        6.</u></em></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>MANAGEMENT&#8217;S
        DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
        OPERATIONS</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="general"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>General</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Merger
        </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company was organized, under the name CCP Worldwide, Inc., as a Delaware
        corporation on September 23, 2002. On October 29, 2004, we completed the
        Merger
        of our newly created and wholly owned subsidiary, CCP Acquisition Corp.,
        a
        Florida corporation, with and into a Florida corporation formerly known as
        Dyadic International, Inc., which was the surviving corporation of the Merger
        and became our wholly owned subsidiary. We refer to this transaction as the
        Merger. Following the Merger, our new subsidiary changed its name to Dyadic
        International (USA), Inc. (&#8220;Dyadic-Florida&#8221;) from Dyadic International, Inc.,
        and the Company&#8217;s name was changed to Dyadic International, Inc. from CCP
        Worldwide, Inc. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
        references to &#8220;Dyadic,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company,&#8221; mean Dyadic-Florida
        prior to the Merger, and Dyadic, as successor to the business of Dyadic-Florida,
        after giving effect to the Merger. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        connection with the Merger, Dyadic disposed of its packaging business in
        a sale
        of all of the shares of the Dyadic subsidiary engaged in those operations
        to its
        founder, all of the officers and directors of Dyadic resigned from their
        positions and were replaced with Dyadic-Florida's officers and directors,
        and
        Dyadic succeeded to the business of Dyadic-Florida. For accounting purposes,
        the
        Merger was accounted for in a manner identical to a reverse acquisition of
        the
        Company by Dyadic-Florida, except that no goodwill or other intangible assets
        have been recorded. Accordingly, Dyadic-Florida was deemed to be the accounting
        acquirer of the Company because the former stockholders of Dyadic-Florida
        owned
        a majority of the issued and outstanding shares of common stock of the Company
        after the Merger, including those shares issued in the initial closing of
        the
        private placement that occurred on that date. For reporting purposes, the
        transaction is equivalent to the issuance of stock by Dyadic-Florida for
        the net
        monetary assets of the Company, which after the transactions effected on
        October
        29, 2004 were nil, accompanied by a recapitalization. Therefore, all financial
        information included in this 10-KSB for periods prior to the Merger is that
        of
        Dyadic-Florida as if Dyadic-Florida had been the reporting entity. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>The
        Business </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        are a
        biotechnology company engaged in the development, manufacture and sale of
        proteins, enzymes, peptides and other bio-molecules, and the collaborative
        licensing of our proprietary technologies. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        developed a C1 Host Technology for both the production, or expression, of
        proteins and the discovery and screening of genes and gene variants. We have
        developed the technology to the point that we are now successfully using
        the C1
        Expression System derived from the C1 Host Technology, among other technologies,
        to produce and sell enzymes to the agricultural, industrial, chemical and
        other
        industries. We refer to this market as the Enzyme Business market. With the
        C1
        Expression System, our Enzyme Business has been able to develop new, and
        higher
        profit-margined products and we believe our increased penetration of these
        markets will be greatly assisted by both the C1 Expression System and the
        C1
        Host Technology. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additionally,
        the C1 Host Technology and the C1 Expression System have also enabled us
        to
        begin to focus on the production of therapeutic protein drugs for humans.
        Our
        goal for this market, which we refer to as the BioSciences Business market,
        is
        to become the leading provider of expression solutions to pharmaceutical
        companies and biotechnology companies. Initially, we are concentrating on
        completing development of our C1 Expression System to express pre-clinical
        and
        clinical quantities of proteins for drug testing, and eventually, for
        commercial-scale production of therapeutic proteins and other bio-molecules.
        We
        are also working to develop our C1 Screening System for the discovery of
        genes
        and the performance of gene modification for improvement of properties of
        the
        expressed proteins, which, when completed, would enable us to combine the
        C1
        Expression System and the C1 Screening System to offer an integrated screening
        and expression system to the drug development industry. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
        has
        been much publicity recently surrounding the alternative fuels market. We
        have,
        for a number of years, invested significant R&amp;D resources in the development
        of cellulases, xylanases, and other hemicellulases for a variety of
        applications, some of which we believe could be efficiently and economically
        used in the ethanol production process. Further, we recently hired Dr. Glenn
        Nedwin to serve as Chief Scientific Officer and intend that one of his
        responsibilities be to evaluate and develop plans for our entry into this
        market. While we continue to remain focused on the execution of our strategies
        in other markets - and most particularly, the pulp and paper market - we
        intend
        to develop plans to enter the alternative fuel market and look for collaboration
        partners to assist us in this endeavor.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>40</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
        date
        we have derived almost 100% of our sales from the Enzyme Business market.
        In
        2005, our BioSciences Business generated sales of only $150,000 and no sales
        in
        2004. We do not anticipate material sales from the operation of our BioSciences
        Business sooner than 2006. Sales from our BioSciences Business are uncertain
        because, among other things, our ability to secure collaboration agreements
        with
        drug development companies will depend upon our ability to perfect either
        the C1
        Expression System or the C1 Screening System to address the needs of that
        industry. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Enzyme
        Business Focus</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          2005
          and 2004, the textiles industry comprised 72% and 80% of our Enzyme Business
          net
          sales, respectively. The textiles market, which is characterized by low
          profit
          margins and intense competition, accounts for a majority of our current
          net
          sales. We have experienced a gradual decline in our share of that market,
          which
          we primarily attribute to (i) our previous lack of adequate resources to
          match
          the level of investment in this market being made by our competitors, and
          (ii)
          our application of a greater portion of our efforts on higher margin and
          larger
          market opportunities, such as the pulp &amp; paper and animal feed markets. To
          what degree our sales from the textiles market will continue to decline
          in the
          future will depend not only that market&#8217;s dynamics, but also on the extent of
          pricing pressure created by our competitors in that market, our success
          in
          developing and marketing new products, and our ability to lower our production
          costs.&#160; In this connection, we are exploring several product leads for
          improving the performance of existing products and the development of new
          products as well as </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">opportunities
          to reduce</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          the
          production cost of these products. We intend to exercise discipline over
          the
          application of our resources to the textiles market relative to other markets
          we
          perceive to offer the Company greater opportunity.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One
            market in which we have begun to enjoy some success in executing our
            strategy to
            expand our sales of higher profit margin products has been in the pulp
            and paper
            industry. We increased our pulp and paper sales by 75% over 2004, which
            represents an increase from 6% to 12% of our Enzyme Business</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">net
            sales. Our expectations for 2006 and beyond are optimistic for this market.
            One
            of&#160;our top priorities during 2005 was to sharply expand&#160;the
            introduction of&#160;our pulp and paper enzyme products to that industry. While
            we believe these products offer an exceptional value </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">proposition
            for this industry, we made a strategic decision to approach the penetration
            of
            this market with an acute sensitivity to the fact that our target customer
            decision-makers are responsible for physical plants costing, in many
            instances,
            several hundred million dollars or more, and are accustomed to dealing
            with
            highly technical sales teams with strong support competencies, following
            long-term trials of new products. Accordingly, we set about to recruit
            and
            assemble a team of seasoned sales and marketing executives&#160;and technical
            salesmen with extensive pulp &amp; paper industry experience and contacts in
            promoting and maintaining&#160;sales relationships involving substantial
            on-going sales and technical servicing. During 2005, we successfully
            recruited a
            Vice President of Sales &amp; Marketing - Enzymes,&#160;a Vice President - Pulp
&amp; Paper, and 6 technical sales representatives whom&#160;we believe fit this
            description as well as additional technical sales representatives in
            our Asian
            subsidiary. The addition of the sales and marketing personnel occurred
            throughout the third quarter, and accordingly, we do not expect to see
            sales
            results from these additions until mid-2006 or later. During 2006, we
            will
            continue to expand&#160;our pulp and paper sales and marketing infrastructure,
            as we work to capture both an increasing number of new customer trials&#160;and
            convert existing and new customer trials into significant and sustained
            levels
            of pulp and paper product sales. We continue to estimate&#160;the addressable
            market for our existing enzyme products in the pulp and paper industry
            and
            potential enzyme products for the pulp and paper industry currently in
            our
            research and development pipeline to be in excess of $1.0 billion. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
            have
            worked with </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">several
            </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">existing
            pulp and paper customers who have allowed us to generate product trial
            data
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
            our
            use in selling </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">to</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            other
            global companies </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bleach
            </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">boosting,
            Bio-refining and De-inking</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            products. As we had expected, the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            sales
            cycle </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for
            capturing a new customer trial is a</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            long
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">one
            (often 6 months to 18 months, or longer), </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">though
            we
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">have
            </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">nonetheless</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            been
            able to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">commence</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            mill
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">trials</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            with
            several key potential customers</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            over the
            past six months</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Animal
            Feed </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">market
            </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">has
            represented approximately 7% and 6% of our </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Enzymes
            Business </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">net
            sales
            in 2005 and 2004, respectively. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
            our
            successful equity capital-raising activities in 2004, we</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            now have
            the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">resources
            necessary to begin funding the registration of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            our
            existing products and new products under development for these
            operations</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            in the
            European Union (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
            </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">largest
            market)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
            and
            expect material growth in this geographical market</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            and
            elsewhere over the next two to three years. We also expect to be able
            to focus
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">additional</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            product
            development and sales</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            efforts
            in other markets</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            such as
            energy, starch and brewery </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">markets,
            as a consequence of recruitment of additional personnel charged with
            direct
            responsibility for overseeing the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">registration
            of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our
            </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">products
            and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">greater
            focused attention on</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            these
            market opportunities. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
        assist
        us in our endeavors in the animal feed market in Europe and elsewhere, we
        have
        hired a sales consultant with significant experience and expertise in this
        industry who is expected to begin April 1, 2006. Historically, we have sold
        in
        this industry without a sales support staff dedicated to this market, and
        it is
        our expectation that this addition will increase our sales in the animal
        feed
        market in the latter part of 2006. There is no guarantee, however, that our
        sales will increase significantly or in the time frame that we
        anticipate.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>41</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>BioSciences
        Business Focus </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
        we
        believe that our C1 Expression System has created great opportunity for our
        Enzyme Business, we believe a much greater opportunity exists to develop
        our C1
        Expression System for the production of higher value proteins, such as human
        therapeutic proteins. We have been developing and refining our molecular
        tools
        to deal with the more complex issues involved in the production of those
        proteins, such as glycosylation, protein degradation and high purity level
        requirement, which are critical for human therapeutic protein production.
        Once
        fully developed, we believe our C1 Host Technology can integrate our C1
        Expression System with our C1 Screening System now also under development,
        to
        create a fully-integrated discovery and expression system that will help
        companies in diverse industries - including pharmaceuticals - to discover,
        develop and bring to market new and improved protein and enzyme products
        from a
        wider range of DNA sources and with better properties than has been possible
        with other systems. Since the same cell line, C1, will enable all R&amp;D steps
        involved in bringing a DNA product to market, we believe that the probability
        of
        success will be higher and the R&amp;D cycle time will be shorter. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        goal
        for our BioSciences Business is to become the leading provider of expression
        solutions to pharmaceutical and biotechnology companies. Initially, we will
        concentrate on enabling the C1 Expression System to express pre-clinical
        and
        clinical quantities of therapeutic proteins for drug testing, and eventually,
        for commercial-scale production of therapeutic proteins and other bio-molecules.
        In particular, we expect that our C1 Expression System will facilitate the
        production of biopharmaceuticals that might otherwise be shelved, and will
        enable development of functionally improved drugs using molecular evolution
        techniques in conjunction with the C1 Screening Technology we are developing.
        BioSciences Business generated sales for 2005 of $150,000 while none were
        generated in 2004.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Future
        Expectations </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
          With the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">significant
          increase</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          in our
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">capital
          funding,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          we
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">completed
          a genomic</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          sequencing project performed by Agencourt Bioscience</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          to
          sequence the DNA of our C1 host organism in March of 2005. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
          the
          completion of this project, we</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          have
          begun to identify a large variety of novel commercially useful genes that
          were
          previously unavailable to us</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          which
          should greatly assist our ability to</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          accelerate our product development efforts and</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          further</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          improve
          the efficiencies of our C1 Host Technology for making proteins and enzymes
          for
          diverse markets, including pharmaceuticals, textiles, pulp and paper, animal
          feed, and food. We are in the late stages of negotiating an agreement for
          a
          comprehensive annotation of the genome, which will provide tools for identifying
          and classifying genes, their corresponding proteins, and metabolic pathways
          in a
          searchable and user-friendly format. These tools will allow Dyadic to identify
          additional commercial enzyme product leads and to identify genes whose
          modification will lead to improvements in the C1 Expression and Screening
          Systems.</font><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With
          petroleum prices near $60 a barrel, there has been an increased interest
          in
          biofuels from both the public and politicians. Reflecting this sentiment,
          President Bush proposed in his State of the Union Address on January 31,
          2006
          the Advanced Energy Initiative, which could amount to a 22% increase in
          the
          Department of Energy's funding for clean energy research. The proposal
          calls for
          the 2007 Federal Budget to include $150 million for research into new methods
          for making ethanol, not just from corn kernels (which is the current method),
          but also from wood chips, corn stover, wheat straw, switchgrass and other
          sources of lignocellulosic biomass. The President set a goal to make this
          cellulosic biomass based ethanol cost-competitive and commercially viable
          within
          six years. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Making
        ethanol from lignocellulosic biomass requires cellulase and hemicellulase
        enzymes, a market segment in which Dyadic has been a producer since the early
        1990's. Filamentous fungi are widely known to be the most prolific producers
        of
        such enzymes in their natural state to breakdown various agricultural
        lignocellulosic waste matters into fermentable sugars, which can be further
        converted into ethanol. Dyadic's existing portfolio of enzymes from C1 and
        other
        proprietary fungi, as well as a large number of cellulase and hemicellulase
        enzymes in the C1 genome could play a significant role in realizing the
        President's goal of launching cellulosic ethanol within six years. We also
        expect to bring to bear the power of our integrated C1 gene discovery and
        expression technology - a unique and powerful proprietary tool set we believe
        none of our competitors have - in order to find and develop novel and highly
        efficient enzymes for producing ethanol from lignocellulosic biomass. If
        we are
        successful in this endeavor, we believe Dyadic could play a significant role
        in
        the industry's goal to extract 80 billion gallons of ethanol from one billion
        tons of lignocellulosic biomass produced in the US. That is estimated to
        be
        enough to cover approximately one third of the transportation fuel needs
        in the
        US, a significant improvement over the maximum of 3% of energy needs that
        can be
        met with the current technology to convert starch in corn kernels to ethanol.
        Dyadic could benefit by supplying enzymes to meet the needs of the cellulosic
        ethanol producers and/or becoming a business partners in the production of
        ethanol itself.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
          on
          the foregoing and other R&amp;D initiatives we expect to continue </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
          2006,
          we expect </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">to
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">incur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          significant </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">costs
          funding our R&amp;D initiatives, including costs related to enhancements
          to</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          our core
          technologies.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
          a
          result, we expect to continue to incur losses as we </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">further
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">develop
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">our</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          C1
          Expression and Screening Systems, and build other required infrastructure
          to
          exploit our C1 Host Technology, our C1 Expression System and our C1 Screening
          System. See "Liquidity and Capital Resources" below for a discussion of
          our
          expected cash resources to fund our operations for the next 24 months.
          There can
          be no assurance that our efforts with regard to these objectives will be
          successful. </font><br></div>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>42</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="results"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Results
        of Operations - Year Ended December 31, 2005 Compared to Year Ended December
        31,
        2004</em></strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        following table sets forth (amounts in thousands) the Company&#8217;s operating
        information for the years ended December 31, 2005 and 2004:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="90%">

            <tr>
              <td align="left" valign="bottom" width="57%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="8" valign="bottom" width="40%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(in
                  thousands)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="57%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Increase
                  (Decrease)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                sales</font></td>
              <td width="2%">&#160;</td>
              <td align="left" valign="bottom" width="1%">&#160;<font size="2">$</font></td>
              <td align="right" valign="bottom" width="11%"><font size="2">15,883</font>&#160;</td>
              <td align="left" valign="bottom" width="2%">&#160;</td>
              <td align="left" valign="bottom" width="1%">&#160;<font size="2">$&#160;</font></td>
              <td align="right" valign="bottom" width="11%"><font size="2">16,741</font>&#160;</td>
              <td align="left" valign="bottom" width="2%">&#160;</td>
              <td align="left" valign="bottom" width="1%">&#160;<font size="2">$&#160;</font></td>
              <td align="right" valign="bottom" width="11%"><font size="2">(858</font>&#160;</td>
              <td align="left" valign="bottom" width="1%"><font size="2">)</font></td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
                  of goods sold</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,857</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,833</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gross
                  profit</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,026</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,908</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(882</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating
                  expenses:</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                  and development</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,899</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,621</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,278</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sales
                  and marketing</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,809</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,857</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">952</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General
                  and administrative</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,321</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,757</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,564</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign
                  currency exchange (gain) loss, net</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(17</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">214</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(231</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">13,012</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,449</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,563</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                  from operations</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,986</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5,541</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(4,445</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  income (expense):</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
                  expense</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(711</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(598</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(113</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment
                  income</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">249</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">69</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">180</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Minority
                  interest </font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(17</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  income, net</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">17</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(15</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  other income (expense)</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(465</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(529</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">64</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                  before income taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,451</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,070</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,381</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provision
                  for income taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">64</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">54</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="57%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss</font></div>
              </td>
              <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,515</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,080</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,435</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Net
        Sales </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, we generated net sales of approximately
        $15,883,000 as compared to net sales of approximately $16,741,000 for the
        year
        ended December 31, 2004, a decrease of $858,000. In 2005, the BioSciences
        Business generated $150,000 in sales, and none in 2004. Net sales from the
        Enzyme Business decreased by approximately $1,008,000. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        decline in net sales reflects both the continued margin pressure in the textile
        industry and aggressive pricing by competitors which has created a strong
        downward pressure on pricing as well as the continued, although decreasing
        concentration of the Company&#8217;s sales to the textiles market (72% and 80% for the
        years ended December 31, 2005 and 2004, respectively). The Company is
        endeavoring to transition its revenue base from the lower margin textile
        enzymes
        to higher margin areas such as enzymes for the pulp and paper, food and animal
        feed industries, and has begun to achieve growth in these other enzyme
        industries, increasing net sales in these industries by 25% for the year
        ended
        December 31, 2005 over net sales for the year ended December 31, 2004 (or
        27% of
        net sales versus 20%). </font><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>43</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
        what
        degree our net sales from the textiles market will continue to decline in
        the
        future will depend not only on that market&#8217;s dynamics, but also on the extent to
        which pricing pressure created by our competitors continues, on our success
        in
        developing new products and our ability to lower our production costs.&#160; We
        believe our sales will resume growth when new products being developed from
        our
        C1 Host Technology and other technologies for new markets (e.g. pulp &amp;
paper, food and animal feed) begin to achieve penetration and other new products
        are introduced both to existing and other new markets. We have made and continue
        to make substantial investments both in personnel and other initiatives since
        November 2004 to expand our sales, marketing and product development efforts
        and
        in advancing our C1 Host technology and other technologies. We continue to
        support our textile customers, directing the necessary resources to customer
        support and R&amp;D innovation to maintain market share in this segment.
        However, we intend to exercise discipline over the application of resources
        to
        the textiles market (which is characterized by low profit margins and intense
        competition) relative to other higher profit and larger market opportunities
        we
        identify. Nonetheless, the markets for a number of our new products are
        generally characterized by longer sales cycles for reasons relating to various
        factors, such as required governmental registration processes (e.g. food
        and
        animal feed enzymes in Europe) and required product trials at customers&#8217;
facilities of multi-month durations or longer (e.g. pulp &amp; paper), and we
        can, therefore, offer no guidance as to when, or if, these new products will
        penetrate those markets. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        following table reflects the Company&#8217;s net sales by industry for the years ended
        December 31, 2005 and 2004 (in thousands): </font>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="85%">

              <tr>
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #000000 thin solid;"><strong>&#160;</strong></td>
                <td colspan="2" valign="bottom" width="4%" style="border-bottom: black thin solid;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><strong>&#160;<font size="2">%</font></strong></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #000000 thin solid;"><strong>&#160;</strong></td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                </td>
                <td colspan="2" valign="bottom" width="5%" style="border-bottom: black thin solid;">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><strong>&#160;<font size="2">%</font></strong></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #000000 thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Increase/(Decrease)&#160;&#160;
                    </strong></font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%">&#160;</td>
                <td width="2%">&#160;</td>
                <td align="left" valign="bottom" width="1%">&#160;</td>
                <td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(in
                  thousands)</font>&#160;</td>
                <td align="left" valign="bottom" width="1%">&#160;</td>
                <td align="right" valign="bottom" width="4%">&#160;</td>
                <td align="left" valign="bottom" width="2%">&#160;</td>
                <td align="left" valign="bottom" width="1%">&#160;</td>
                <td align="right" valign="bottom" width="9%"><font size="2">(in
                  thousands)</font>&#160;</td>
                <td align="left" valign="bottom" width="1%">&#160;</td>
                <td align="right" valign="bottom" width="4%">&#160;</td>
                <td align="left" valign="bottom" width="2%">&#160;</td>
                <td align="left" valign="bottom" width="1%">&#160;</td>
                <td align="right" valign="bottom" width="10%">&#160;</td>
                <td align="left" valign="bottom" width="1%">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Textile*</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11,454</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">72</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13,320</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">80</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="10%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1,866</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#ffffff">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Animal
                    Feed*</font></div>
                </td>
                <td width="2%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,037&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,017&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="10%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pulp
                    &amp; Paper*</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,869
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,069&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="10%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">800&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Others
                    (5 industries)*</font></div>
                </td>
                <td width="2%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,373&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,335&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
                <td align="right" valign="bottom" width="10%" style="border-bottom: #ffffff;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bioscience</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #000000 thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #000000 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">150&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #000000 thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #000000 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #000000 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #000000 thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #000000 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;--
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #000000 thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="4%" style="border-bottom: #000000 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">0</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #000000 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #000000 thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="10%" style="border-bottom: #000000 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">150&#160;</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #000000 thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td align="left" height="7" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">
                </td>
                <td height="7" width="2%" style="border-bottom: #ffffff thin solid;">
                </td>
                <td align="left" height="7" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" height="7" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15,883</font></div>
                </td>
                <td align="left" height="7" valign="bottom" width="1%" style="border-bottom: #000000 double;">&#160;</td>
                <td align="right" height="7" valign="bottom" width="4%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">100</font></div>
                </td>
                <td align="left" height="7" valign="bottom" width="2%" style="border-bottom: #000000 double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" height="7" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" height="7" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16,741</font></div>
                </td>
                <td align="left" height="7" valign="bottom" width="1%" style="border-bottom: #000000 double;">
                </td>
                <td align="right" height="7" valign="bottom" width="4%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">100</font></div>
                </td>
                <td align="left" height="7" valign="bottom" width="2%" style="border-bottom: #000000 double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" height="7" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" height="7" valign="bottom" width="10%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(858</font></div>
                </td>
                <td align="left" height="7" valign="bottom" width="1%" style="border-bottom: #000000 double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*Industrial
          Enzyme Industries</font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Cost
        of Goods Sold </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, cost of goods sold was approximately $12,857,000,
        or 80.9% of net sales, as compared to approximately $12,833,000, or 76.7%
        of net
        sales, for the year ended December 31, 2004, an increase of approximately
        $24,000. This increase in cost of goods sold as a percentage of net sales
        was
        the result of an several factors, which include: an increase in the inventory
        reserve of approximately $154,000, additional overhead and labor costs of
        approximately $129,000 related to the move to a new factory by our Hong Kong
        facility, unabsorbed overhead related to factory modernization costs for
        our
        contract manufacturer in Poland of approximately $196,000, and freight costs
        of
        approximately $111,000 for additional stock movement to other warehouse
        locations. The effect of changes in foreign currency rates and the resultant
        effect on the cost of inventory and certain contract manufacturing costs
        denominated in Euros can and may also significantly impact the ultimate cost
        incurred by the Company in the future. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Gross
        Profit </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
          the
          year ended December 31, 2005, gross profit was approximately $3,026,000,
          or
          19.1% of net sales, as compared to approximately $3,908,000, or 23.3% of
          net
          sales, for the year ended December 31, 2004, representing a decrease of
          approximately $882,000. The 22.6% decrease in gross profit and gross profit
          percentage is primarily due to the combination of decreased net sales and
          additional costs incurred, which are described in Net Sales and Cost of
          Goods
          Sold, respectively. It is the Company&#8217;s goal to develop products, or sell
          existing products, for markets in which gross profit percentages can be
          improved. We </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">believe
          we are making significant progress in our efforts to create a line of higher
          profit-margined products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          by
          developing better products using our technologies and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">by
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">applying
          existing products to new markets. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nonetheless</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          there
          can be no assurance that our efforts will successfully lead to improved
          gross
          profit percentages in the future. </font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Research
        and Development </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, research and development expenses, or R&amp;D,
        were approximately $4,899,000, or 30.8% of net sales, as compared to
        approximately $3,621,000, or 21.6% of net sales for the year ended December
        31,
        2004, representing an increase of approximately $1,278,000. R&amp;D activity was
        constrained in 2004 by our lack of adequate capital resources. With our success
        in raising additional capital in 2004, we have substantially </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>44</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">increased
        our spending for R&amp;D personnel and projects in 2005, both on the further
        development of our core technologies, and on new product and technology
        development, in an effort to ultimately increase sales and profit margins
        and to
        also create additional business opportunities. To assist in this development,
        we
        added several key members to our Scientific Advisory Board; we hired a project
        manager, outside contract labor and scientific consultants, which resulted
        in
        additional expense for the 2005 period of approximately $516,000 for labor
        and
        R&amp;D supplies. The balance of the increase of approximately $762,000 is
        attributable to several R&amp;D projects which we undertook with three of our
        independent third party R&amp;D partners.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        February 2005, we initiated a genomic sequencing project with Agencourt
        Bioscience to sequence our C1 host organism. The C1 sequencing project was
        completed ahead of schedule, in March 2005. We were able to identify several
        novel commercially useful genes and, upon completion of a comprehensive
        annotation of the genome, we expect to be able to identify a large variety
        of
        novel commercially useful genes that were previously unavailable to us, which
        should greatly assist our ability to accelerate our product development efforts
        and further improve the efficiencies of our C1 Host Technology for making
        proteins and enzymes for diverse markets, including pharmaceuticals, textiles,
        pulp and paper, animal feed, and food. &#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        December 2005, the Company issued 161,560 shares of common stock to TNO Quality
        of Life (formerly known as TNO Nutrition and Food Research Institute)(&#8220;TNO&#8221;), in
        consideration for, among other things the termination of the Cooperation
        Agreement entered into August 12, 2003 between the Company, its subsidiary,
        Dyadic NL and TNO to cooperate on an exclusive basis in the development,
        use and
        marketing of High Throughput Screening Systems utilizing fungal organisms
        and
        the satisfaction of all indebtedness of Dyadic NL to TNO, including a trade
        payable for research services rendered by TNO to Dyadic NL in the approximate
        amount of $377,000. The stock was valued based on the fair market value of
        the
        Company&#8217;s common stock on the date of closing. A credit of approximately $76,000
        resulting from this transaction is included in research and development expense
        in the accompanying consolidated statements of operations for the year ended
        December 31, 2005. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        December 31, 2005, 7,523 shares of common stock were earned and are outstanding
        for services rendered under a development agreement entered into in July
        2004,
        with a third party to assist the Company in various research and development
        projects for a total of approximately $1.8 million over the 26-month period
        ending September 30, 2006. The agreement was extended to December 31, 2006
        in
        December 2004. Under the development agreement, the Company is required to
        utilize, and the third party has committed to provide a minimum of 1.1 full-time
        equivalent BTR scientists per month. The consideration for these services
        includes 300,300 shares of the Company's common stock, valued at $1.0 million,
        and $250,000 of cash which was paid upon execution of the development agreement.
        Both the value of the stock earned which is equal to the value of the services
        provided and the $250,000 of cash are included in research and development
        expense, in the accompanying consolidated statements of operations for the
        year
        ended December 31, 2005. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Sales
        and Marketing </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, sales and marketing expenses were approximately
        $2,809,000, or 17.7% of net sales, compared to approximately $1,857,000,
        or
        11.1% for the year ended December 31, 2004, representing an increase of
        approximately $952,000. This increase is attributable to several factors,
        including an increase in salaries and wages (including recruitment fees)
        of
        approximately $498,000 due to the addition of nine sales employees including
        a
        Vice President - Pulp and Paper, additional contract labor as well as additional
        technical sales representatives in our Asian subsidiary. This has resulted
        in
        increased commission, travel and entertainment costs of approximately $254,000
        due to these additions to the sales force. These additions are a part of
        the
        substantial investments both in personnel and other initiatives we have made
        since November 2004 to expand our sales, marketing and product development
        efforts. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>General
        and Administrative </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, general and administrative expenses were
        approximately $5,321,000, or 33.5% of net sales, compared to approximately
        $3,757,000, or 22.4% of net sales for the year ended December 31, 2004,
        representing an increase of approximately $1,564,000. This increase is
        attributable to several factors, including an increase in salaries and wages
        (including recruitment fees) of approximately $937,000 due to the addition
        of
        three employees in the U.S., including a Chief Financial Officer, and nine
        employees in Hong Kong. These additions are a part of the substantial
        investments both in personnel and other initiatives we have made since November
        2004 to staff the Company with the personnel necessary to operate as a public
        company. To this end, we have formed a Board of Directors, four out of five
        of
        whom are independent, and each of whom has led a distinguished career, offering
        relevant expertise to help guide the Company. Increased professional fees
        of
        approximately $816,000 related to accounting, legal and other service related
        expenses to assist the Company in its transition to a public company as well
        as
        maintain that status, are also factors that contributed to the increase in
        general and administrative expenses.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>45</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Foreign
        Currency Exchange Gains (Losses), Net </em></font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
          the
          year ended December 31, 2005, the Company incurred net foreign currency
          exchange
          gains of approximately $17,000 as compared to incurred net foreign currency
          exchange losses of approximately $214,000 for the year ended December 31,
          2004,
          representing a decrease of approximately $231,000. This change is the result
          of
          a shift in the proportion of sales transactions to expenditure transactions
          that
          are denominated in a foreign currency coupled with the timing of the settlement
          of the transactions. A large portion of our business is transacted with
          foreign
          customers and vendors in foreign currency denominations. Accordingly,
          fluctuations in foreign currency exchange rates, primarily relating to
          the Euro,
          can greatly impact the amount of foreign currency gains (losses) we recognize
          in
          future periods relating to these transactions. We do not, and have no current
          plans to, engage in foreign currency exchange hedging transactions.</font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Other
        Income (Expense) </em></font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<em>Interest
        Expense</em></font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        For the year ended December 31, 2005, interest expense was approximately
        $711,000 as compared to approximately $598,000 for the year ended December
        31,
        2004, representing an increase of approximately $113,000. This increase was
        due
        primarily to the increase in the amortization of beneficial conversion features
        of approximately $216,000, as described below. Partially offsetting this
        $216,000 increase is a decrease in interest expense of approximately $92,000,
        which relates to a $1,225,000 note payable to the Mark A. Emalfarb Trust
        that
        was cancelled in exchange for 367,868 Investment Units in November 2004.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        connection with the Merger and a series of related transactions, the Bridge
        Loan
        maturity date and the Bridge Loan warrants were modified in November 2004
        and,
        as a result, we will recognize approximately an additional $350,000 in interest
        expense through the new maturity date, January 1, 2007. Also in November
        2004, a
        $1,225,000 note payable to the Mark A. Emalfarb Trust was cancelled in exchange
        for 367,868 Investment Units and the conversion prices on the convertible
        notes
        due to the Emalfarb Trust and the Francisco Trust were modified to fix the
        conversion price at $3.33 per share, which resulted in a beneficial conversion
        feature of approximately $554,000 to be amortized to interest expense through
        the maturity date of January 1, 2007. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Investment
        Income </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, interest income was approximately $249,000
        as
        compared to approximately $69,000 for the year ended December 31, 2004,
        representing an increase of approximately $180,000. Interest income increased
        beginning in the fourth quarter of 2004 due to the net proceeds from the
        private
        placement offering completed in early November 2004, which were placed in
        short-term investments. At December 31, 2005, all remaining proceeds were
        invested in money market funds. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Provision
        for Income Taxes </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        no provision for U.S. income taxes as we have incurred operating losses in
        all
        periods presented and provide full valuation allowances against the resulting
        tax benefits. For the year ended December 31, 2005, we had a foreign income
        tax
        provision of approximately $64,000 compared to approximately $10,000 for
        the
        year ended December 31, 2004. Our Asian subsidiary operates in Hong Kong.
        We
        also have operations in Poland and The Netherlands. Our Asian subsidiary
        and, to
        a lesser extent, our Polish subsidiary generate profits that are taxable
        in
        their local jurisdictions. The increase from 2004 to 2005 resulted primarily
        from net operating loss carry forwards utilized by our Asian subsidiary during
        2004 that lowered its effective tax rate during that year. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Net
        Loss </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, the Company&#8217;s net loss was approximately
        $10,515,000, compared to a net loss of approximately $6,080,000 for the year
        ended December 31, 2004. This increase in net loss was due primarily to
        increases in operating expenses and decreased sales, as discussed above.
        We
        believe that we will continue to incur net losses in the near term future
        primarily because of our planned levels of research and development and
        additional general and administrative expenditures that will be necessary
        to
        accommodate the expected growth in the Enzyme and BioSciences Businesses.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><a name="liquidity"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Liquidity
        and Capital Resources</em></strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Capital
        Raising Activities </em></font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>46</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
        inception, the Company has financed operations primarily with proceeds from
        the
        sales of the products from its Enzyme Business, external borrowings, borrowings
        from its stockholders and sales of preferred and common equity
        securities.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
In
        November 2004, in accordance with Subscription Agreements and a Private Offering
        Memorandum (the October Offering) dated October 2004, the Company sold 7,629,204
        Investment Units, realizing gross proceeds of approximately $25,405,000.
        An
        Investment Unit consists of one share of the Company's common stock and one
        five-year callable warrant to purchase one share of the Company's common
        stock
        at $5.50 per share for every two Investment Units purchased. Accordingly,
        3,814,602 warrants to purchase the Company's common stock were issued to
        participants in the October Offering. Concurrently, the Company issued 711,050
        warrants to purchase the Company's common stock at $5.50 per share to
        participants in the Offering completed in July 2004, as well as 247,730 warrants
        to purchase the Company's common stock at $5.50 per share and 495,460 warrants
        to purchase the Company's common stock at $3.33 per share, both to placement
        agents in the October Offering. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
        Ancillary to the Merger and October Offering, in November 2004, an additional
        367,868 Investment Units were sold to Mark A. Emalfarb through the Mark A.
        Emalfarb Trust in exchange for the cancellation of the Company's note payable
        to
        the Mark A. Emalfarb Trust with a balance of $1,225,000. Incident to the
        Company&#8217;s completion of the Merger and the equity issuance transactions
        described above, a warrant to purchase 1.5 million shares of the Company's
        common stock issued in connection with the May 2003 $3.0 million revolving
        note
        payable to the Mark A. Emalfarb Trust (see Note 7 to our consolidated financial
        statements) was modified to reduce the exercise price from $4.50 to $3.33
        per
        share. Additionally, the maturity date of this Bridge Loan was extended to
        January 1, 2007. As a result, approximately $343,000, representing the
        incremental fair value of the modified warrant as compared to the fair value
        of
        the original warrant immediately before the modification (determined using
        the
        Black-Scholes option pricing model, using the following assumptions: risk-free
        interest rate of 3.91%, dividend yield of 0%, expected volatility of 50%
        and an
        expected remaining life of 8.6 years, the remaining term of the warrant)
        will be
        amortized to interest expense through the new maturity date. The estimated
        fair
        value of the original warrant had been fully amortized to interest expense
        during the year ended December 31, 2004. </font></div>
      <div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;
As
          another incident to the Company&#8217;s completion of the Merger and the equity
          transactions described above, the conversion prices with respect to the
          October
          29, 2004 principal and accrued interest balances on the Emalfarb Trust
          Note and
          the Francisco Trust Note (see Note 7 to our consolidated financial statements)
          were fixed at $3.33 per share, and the due dates were extended to January
          1,
          2007. As a result of the modification of the conversion price, a beneficial
          conversion feature totaling approximately $554,000 will be amortized to
          interest
          expense through the new maturity date. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Cash
        Flow </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>From
        Operating Activities </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        reflected in our consolidated financial statements, we have incurred losses
        from
        operations during each of the last two years, resulting in net cash used
        in
        operating activities of approximately $7,815,000 and $5,917,000 in 2005 and
        2004, respectively. The increase in net cash used in operating activities
        was
        primarily due to the increase in net loss in 2005 of approximately $4,435,000
        which was partially offset by improved working capital management.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>From
        Investing Activities</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, our net cash used in investing activities was
        approximately $448,000 as compared to approximately $101,000 for the year
        ended
        December 31, 2004. This increase of approximately $347,000 relates to purchases
        of property and equipment. There are no immediate plans for large increases
        in
        capital assets expenditures; however, management is continually assessing
        such
        requirements concurrent with our growth. The Company made a purchase of $861,861
        of land (the &#8220;Site&#8221;), which was obtained through the issuance of 300,300 shares
        of common stock (see Note 9 to Consolidated Financial Statements in Item
        1). The
        Commercial Land Purchase and Sale Agreement obligates Dyadic to commence
        development of the Site within two (2) years following the closing date.
        During
        this two-year period, Dyadic is prohibited from re-transferring the Site
        to any
        other person other than (i) in connection with a sale of Dyadic, (ii) to
        an
        affiliate or (iii) with the approval of Dyadic's Board of Directors (a majority
        of its independent directors), to the Francisco Trust, the Mark A. Emalfarb
        Trust and/or any entity that is controlled, directly or indirectly, by Mark
        A.
        Emalfarb and/or his family members. It is not the Company&#8217;s intention to use its
        own funds to develop this property, therefore the Company is considering
        such
        options as a joint venture or other arrangement to accomplish the development
        of
        the Site. There can be no assurance, however, that any joint venture or other
        arrangements will occur within the prescribed timeframe. The Company is
        evaluating the advantages and disadvantages of Site development relative
        to
        their impact on Dyadic&#8217;s future office and R&amp;D needs and cash resources, and
        is also considering other alternatives to optimize the asset value of the
        Site
        at this time. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>From
        Financing Activities </em></font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>47</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        the
        year ended December 31, 2005, our net cash used in financing activities was
        approximately $98,000, for issuance costs related to the October 2004 private
        offering. During the year ended December 31, 2004, net cash provided by
        financing activities was approximately $24,879,000. This amount is primarily
        due
        to cash received from two private placements in 2004 resulting in net proceeds
        of approximately $27,393,000 which was partially offset by a $1,500,000 payment
        for the redemption of outstanding shares of our Series A convertible preferred
        stock and approximately $1,013,000 for repayment of notes payable.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Changes
        in Cash Positions </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        experienced net decreases in cash and cash equivalents of approximately
        $8,361,000 in 2005 as compared to an increase of $18,861,000 in 2004 due
        to the
        consumption during 2005 of the cash received from our 2004 capital raising
        activities primarily to support our operating activities. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Financial
        Condition and Liquidity at December 31, 2005 </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        2004
        and 2005 net losses, when combined with losses incurred through December
        31,
        2003, resulted in an accumulated deficit of approximately $34,008,000. As
        of
        December 31, 2005, stockholders' equity was approximately $15,272,000, a
        decrease of approximately $9,197,000 over December 31, 2004. The decrease
        is
        primarily due to the net loss of approximately $10,515,000.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        had a
        total of approximately $12,150,000 in cash and cash equivalents and restricted
        cash of approximately $35,000 as of December 31, 2005. Our outstanding
        indebtedness was approximately $4,214,000 as of December 31, 2005, and consisted
        of notes payable to certain stockholders, notes payable for Letter of Credit
        advances, and the Bridge Loan including related accrued interest payable.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        are
        committed to make annual minimum payments under our operating leases aggregating
        approximately $368,500 for 2006, approximately $263,000 in 2007, approximately
        $72,000 in 2008, approximately $72,000 in 2009, and approximately $251,000
        thereafter. We also are committed to make annual minimum payments under our
        Polish contract manufacturing agreement of approximately $318,000 in 2006,
        approximately $310,000 in 2007 and approximately $101,000 in 2008. We have
        also
        entered into various agreements with independent third parties to conduct
        R&amp;D activities on our behalf. One such agreement, entered into in July 2004,
        is with a third party to assist the Company in various research and development
        projects, for a total of $1.8 million in services, over the 26-month period
        ending September 30, 2006, which has been extended to December 31, 2006.
        Under
        the Development Agreement, the Company is required to utilize, and the third
        party has committed to provide research and development assistance valued
        at
        approximately $1.25 million. The consideration for these services includes
        300,300 shares of the Company's common stock, valued at $1.0 million, and
        cash,
        $250,000 of which was paid upon execution of the Development Agreement. Pursuant
        to the Development Agreement, the 300,300 shares of common stock were placed
        in
        escrow and will be issued to the third party as earned during the contractual
        period, at which time they will be deemed to be outstanding. The Development
        Agreement imposes cash penalties upon the third party in the event of
        nonperformance under the Development Agreement, beyond the forfeiture of
        any
        shares of common stock placed in escrow. At December 31, 2005, 7,523 shares
        of
        common stock were earned and are outstanding for services rendered under
        this
        agreement and the $250,000 cash prepayment was expensed in full both of which
        are included in research and development expense, in the accompanying
        consolidated statements of operations for the year ended December 31, 2005.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
        Commercial Land Purchase and Sale Agreement obligates us to commence development
        of the land that we acquired within two (2) years of the closing (in May
        2007);
        however, it is not the Company&#8217;s intention to use its own funds to develop this
        property, therefore the Company is considering such options as a joint venture
        or other arrangement to accomplish the development of the Site. The Company
        is
        evaluating the advantages and disadvantages of Site development relative
        to
        their impact on Dyadic&#8217;s future office and R&amp;D needs and cash resources, and
        is also considering other alternatives to optimize the asset value of the
        Site
        at this time. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        employment agreements with several officers and key employees of the Company,
        the material terms of which are described in Note 12 to our consolidated
        financial statements included in this report. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Funding
        of Future Operations </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        believe that our operating losses will continue in 2006. In addition, our
        cash
        needs to fund our future operating loses will be substantial. We believe
        that we
        will have sufficient capital to fund our operations and meet our obligations
        through year end 2006 based on current sales volumes. Dyadic has established
        a
        number of flexible partnerships in the areas of manufacturing and research
        and
        development, enabling us to adjust spending in those areas as necessary,
        to
        achieve the objectives of our business plan, and manage both our resources
        and
        cash utilization rate. There can be no assurance, however, that we will achieve
        decreased cash outflows as a result of these factors, or achieve them in
        the
        timeframe outlined. We have yet to determine how much of our R&amp;D efforts
        will be focused on the development of new enzymes for use in producing
        cellulosic ethanol, nor how these activities may be financed. It is possible
        that we will seek additional financing within this timeframe. We may raise
        additional funds through public or private financings, collaborative
        relationships, licensing or selling of certain technologies or other
        arrangements. </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>48</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional
          funding, if sought, may not be available at all, or may not be available
          on
          terms favorable to us. Further, any additional equity financing may be
          dilutive
          to stockholders, and debt financing, if available, may involve restrictive
          covenants. Our failure to raise capital when needed may harm our business,
          operating results and financial condition. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em><strong><a name="offbal">Off-Balance
</a>Sheet
          Arrangements</strong></em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
          do not
          have any off-balance sheet arrangements</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br><em><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="critical">Critical
          Accounting </a>Policies and
          Estimates</font></strong></em></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        preparation of consolidated financial statements requires us to make estimates
        and judgments that affect the reported amounts of assets, liabilities, revenues
        and expenses, and related disclosure of contingent assets and liabilities.
        On an
        on-going basis, we evaluate our estimates. We base our estimates on current
        information, historical experience and on various other assumptions that
        are
        believed to be reasonable under the circumstances, the results of which form
        the
        basis for making judgments about the carrying values of assets and liabilities
        that are not readily apparent from other sources. Actual results may differ
        from
        the estimates used by us under different assumptions or conditions. We believe
        the following concentrations and critical accounting policies relate to our
        more
        significant judgments and estimates used in the preparation of our consolidated
        financial statements: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 46.6pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Foreign
        Operations </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        significant operations and sales generated in foreign countries. Sales derived
        from foreign customers accounted for approximately 91% and 86% of our total
        revenues in 2005 and 2004, respectively. Our Asian subsidiary is located
        in Hong
        Kong, and we have two other subsidiaries, one located in Poland and one located
        in The Netherlands. Estimates relating to our inventory valuation, receivable
        allowances, possible impairments to goodwill (which relates to our Asian
        subsidiary), and long-lived assets could be significantly impacted by
        international events. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Stock-Based
        Compensation </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        issued warrants and options to non-employees for services and in connection
        with
        obtaining debt in the past several years. We have recognized significant
        expense
        relating to the issuance of these equity instruments. In 2004, approximately
        $897,000 was recorded related to the modification of warrants issued in
        connection with debt, which is being amortized through the debt maturity
        date of
        January 1, 2007. Of this amount, approximately $371,000 was recognized as
        interest expense in the accompanying consolidated statement of operations
        for
        the year ended December 31, 2005. Amortization of stock compensation expense
        of
        approximately $77,000 was also recognized in 2005 related to stock options
        issued to consultants, the original cost of which is being amortized over
        the
        respective service periods. Stock issued for consulting services during 2005
        resulted in approximately $92,000 of compensation expense, as well.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        estimated the fair value of those securities using the Black-Scholes
        option-pricing model, or in the case of stock grants, the closing price of
        the
        stock on the date of grant, and expensed the estimated fair value over the
        service period or through the debt maturity date. The Black-Scholes model
        uses
        critical assumptions that significantly affect the estimated fair value of
        those
        awards, such as an estimated volatility factor of our common stock, the
        estimated lives of the awards (which is equal to the maximum contractual
        term
        for awards to non-employees) and presumed discount rates. Additionally, as
        further discussed below, we are required to recognize compensation expense
        on
        options issued to employees beginning in 2006, and we expect that we will
        use
        similar estimation methods. Changes in the volatility of our common stock
        and
        other estimation factors used in the Black-Scholes model can significantly
        impact the estimated value and resultant compensation cost on similar equity
        instruments issued in the future. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Long-Lived
        Assets </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        review
        our long-lived assets, including fixed assets that are held and used for
        our
        operations, for impairments whenever events or changes in circumstances indicate
        that the carrying amount of the asset may not be recoverable, as required
        by
        Statement of Financial Accounting Standards</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No.
        144,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
        for the Impairment or Disposal of Long-Lived Assets </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SFAS
        144). If such an event or change in circumstances is present, we will estimate
        the undiscounted future cash flows, less the future outflows necessary to
        obtain
        these inflows, expected to result from the use of the asset and its eventual
        disposition. If the sum of the undiscounted future cash flows is less than
        the
        carrying amount of the related assets, we will recognize an impairment loss
        to
        the extent the carrying value exceeds the fair value. Our judgments related
        to
        the expected useful lives of long-lived assets and our ability to realize
        undiscounted cash flows in excess of the carrying amounts of the assets are
        affected by factors such as the ongoing maintenance and improvements of the
        assets, changes in domestic and foreign economic conditions and changes
</font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>49</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
        operating performance. While we have not to date been required to recognize
        an
        impairment on long-lived assets, as we make future assessments of the ongoing
        expected cash flows and carrying amounts of our long-lived assets, these
        factors
        could cause us to realize material impairment charges. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Evaluation
        of Potential Goodwill Impairment </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        accordance with SFAS No. 142, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Goodwill
        and Other Intangible Assets </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SFAS
        142), we were required to perform an annual impairment review of the goodwill
        which is associated with our Asian subsidiary. This test involved the use
        of
        estimates to determine the estimated fair value of our Asian subsidiary and
        the
        comparison of that estimated fair value to the carrying value of the reporting
        unit. There are significant assumptions used in this impairment test, such
        as
        estimated cash flows, discount rates of return and terminal values. Several
        factors can change these assumptions, such as economic conditions or instability
        in foreign governments, among other things. Our estimates of the fair value
        indicated that it exceeded the carrying value of the reporting unit.
        Accordingly, no goodwill impairment charge was recorded. If the estimate
        of the
        fair value of the reporting unit is less than the carrying value at any future
        measurement dates, we may be required to record a goodwill impairment charge.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Income
        Taxes </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        recorded deferred tax assets relating to net operating loss carry forwards
        for
        United States federal tax purposes, inventories, depreciation and amortization,
        and accounts receivable allowance, among other items. We record a valuation
        allowance equal to 100% of the carrying value of our net deferred tax assets
        to
        reduce our deferred tax assets to the amount that is more likely than not
        to be
        realized. While we have considered future taxable income and ongoing tax
        planning strategies in assessing the need for the valuation allowance, in
        the
        event we were to determine that we would be able to realize our deferred
        tax
        assets in the future in excess of their net recorded amounts, a resulting
        reduction of the valuation allowance would increase our income in the period
        such determination was made. As of December 31, 2005, we had approximately
        $11,602,151 in gross deferred tax assets, which were fully offset by a valuation
        allowance. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        net operating loss carryforwards of approximately $26.4 million for United
        States federal income tax purposes that will begin to expire in 2020. The
        amounts of and benefits from net operating losses carried forward may be
        impaired or limited in certain circumstances. Events which may cause limitations
        in the amount of net operating losses that we may utilize in any one year
        include, but are not limited to, a cumulative ownership change of more than
        50%
        over a three-year period. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Allowance
        for Doubtful Accounts </em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        maintain an allowance for doubtful accounts for estimated losses resulting
        from
        the inability of our customers to make required payments. Our accounting
        for
        doubtful accounts contains uncertainty because management must use judgment
        to
        assess the collectibility of these accounts. When preparing these estimates,
        management considers a number of factors, including the aging of a customer's
        account, past transactions with customers, creditworthiness of specific
        customers, historical trends and other information. We review our accounts
        receivable reserve policy periodically, based on current risks, trends and
        changes in industry conditions. The allowance for doubtful accounts was
        approximately $531,000 at December 31, 2005. Although we believe this allowance
        is sufficient, if the financial condition of our customers were to unexpectedly
        deteriorate, resulting in an impairment of their ability to make payments,
        additional allowances may be required that could materially impact our
        consolidated financial statements. Concentrations of credit risk can impact
        this
        risk considerably. In 2005, there were two customers that accounted for 10%
        each
        of net sales, while in 2004 there were no customers that accounted for greater
        than 10% of net sales. There were three customers in 2005 whose trade receivable
        balances equaled or exceeded 5% of total receivables, representing approximately
        16%, 7%, and 6%, respectively, of total accounts receivable. The loss of
        business from one or a combination of the Company&#8217;s significant customers could
        adversely affect its operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Inventory
          Valuation </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory,
          representing approximately 23% of our consolidated assets at December 31,
          2005,
          primarily consists of finished goods including industrial enzymes used
          in the
          industrial, chemical and agricultural markets and is stated at the lower
          of cost
          or market using the average cost method. Finished goods include raw materials
          and manufacturing costs, substantially all of which are incurred pursuant
          to
          agreements with independent manufacturers. As part of the valuation process,
          excess, slow-moving and damaged inventories are reduced to their estimated
          net
          realizable value. Our accounting for excess, slow-moving and damaged inventory
          contains uncertainty because management must use judgment to estimate when
          the
          inventory will be sold and the quantities and prices at which the inventory
          will
          be sold in the normal course of business. We review our inventory reserve
          policy
          periodically, based on current risks, trends and changes in industry conditions.
          We also maintain a provision for estimated inventory shrinkage and conduct
          periodic physical inventories to calculate actual shrinkage and inventory
          on
          hand. When preparing these estimates, management considers historical results,
          inventory levels and current operating trends. We have established valuation
          reserves associated with excess, slow-moving and damaged inventory and
          </font></div>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>50</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">estimated
        shrinkage reserves of approximately $696,000 at December 31, 2005. These
        estimates can be affected by a number of factors, including general economic
        conditions and other factors affecting demand for our inventory. In the event
        our estimates differ from actual results, the allowance for excess, slow-moving
        and damaged inventories may be adjusted and could materially impact our
        consolidated financial statements. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Revenue
        Recognition</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenue
        is recognized when earned. The Company's revenue recognition policies are
        in
        compliance with the provisions issued in SAB No. 104, Revenue Recognition
        in
        Financial Statements. Revenue from product sales to customers, distributors
        and
        resellers is recorded when products that do not require further services
        or
        installation by the Company are shipped, when there are no uncertainties
        surrounding customer acceptance and for which collectibility is reasonably
        assured. The Company provides for sales returns based on a historical analysis
        of returns. The estimate is updated for current return activity and the
        provision is adjusted accordingly. Should actual returns exceed management&#8217;s
        estimates, the provision may require further adjustment and accordingly,
        net
        sales may decrease.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><a name="item7" href="#indextoFS"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
        7. FINANCIAL STATEMENTS</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>&#160;</u></em></strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        audited consolidated financial statements and related footnotes of Dyadic
        International, Inc. can be found beginning with the Index to Consolidated
        Financial Statements following Part III of this Annual Report on page
        F-1.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><u><em><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="item8">ITEM
        8. </a>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
        ACCOUNTING AND FINANCIAL DISCLOSURE</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>S</strong></font></em></u></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="item8a"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>ITEM
        8A. CONTROLS AND PROCEDURES</u></em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>&#160;</u></em></strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        required by Rule 13a-15 under the Securities Exchange Act of 1934, as of
        the end
        of the period covered by this Annual Report, the Company carried out an
        evaluation under the supervision and with the participation of the Company&#8217;s
        management, including the Company&#8217;s Chief Executive Officer and Chief Financial
        Officer, of the effectiveness of the design and operation of the Company&#8217;s
        disclosure controls and procedures.&#160; Based upon that evaluation, the Chief
        Executive Officer and Chief Financial Officer concluded that the Company&#8217;s
        disclosure controls and procedures were effective as of December 31,
        2005.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
        were no changes in the Company's internal control over financial reporting
        identified in connection with the evaluation required by paragraph (d) of
        Exchange Act Rules 13a-15 and 15d-15 that occurred during the fiscal quarter
        ended December 31, 2005 that have materially affected, or are reasonably
        likely
        to materially affect, the Company's internal control over financial
        reporting.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -54pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="item8b">ITEM
        8B</a>. OTHER INFORMATION.</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><a name="part111">PART
        III</a></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        information called for by Part III, Items 9, 10, 11, 12 and 14 is incorporated
        herein by reference to our definitive Proxy Statement for our Annual Meeting
        of
        Stockholders of the Company to be filed with the Securities and Exchange
        Commission within 120 days of December 31, 2005.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>51</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u><a name="exhibits">ITEM
        13</a>. EXHIBITS </u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>A)&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Index
                  to Exhibits</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table cellpadding="0" cellspacing="0" width="90%">

            <tr>
              <td align="left" valign="bottom" width="7%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibits</font></div>
              </td>
              <td align="left" valign="bottom" width="63%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Description
                  of Documents</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Agreement
                  of Merger and Plan of Reorganization dated as of September 28,
                  2004 by and
                  among Dyadic International (USA), Inc. (f/k/a Dyadic International,
                  Inc.),
                  Dyadic International, Inc. (f/k/a CCP Worldwide, Inc.) and CCP
                  Acquisition
                  Corp. ( 1)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Split-Off
                  Agreement dated September 28, 2004, by and among Dyadic International
                  (USA), Inc. (f/k/a Dyadic International, Inc.), Dyadic International,
                  Inc.
                  (f/k/a CCP Worldwide, Inc.) and Custom Craft Packaging, Inc.
                  (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.1
                  </font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
                  and Restated Certificate of Incorporation of Dyadic International,
                  Inc.
                  dated November 1, 2004 (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amended
                  and Restated Bylaws of Dyadic International, Inc. dated November
                  1, 2004
                  (2) </font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                  of Common Stock Certificate (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                  of $5.50 Common Stock Purchase Warrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.3</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                  of $3.33 Common Stock Purchase Warrants issued to Placement Agents
                  (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                  of Bridge Loan Warrants</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.5</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                  of Stock Option representing aggregate right to purchase 65,000
                  shares of
                  Common Stock (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cooperation
                  and License Agreement dated August 12, 2003 between Dyadic International
                  (USA), Inc. (f/k/a Dyadic International, Inc.) and TNO Nutrition
                  and Food
                  Research Institute (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.1.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Termination
                  and License Agreement dated December 19, 2005, effective November
                  23, 2005
                  between Dyadic International, Inc., Dyadic International (USA),
                  Inc.,
                  Dyadic Netherland, B.V., and TNO Quality of Life (formerly known
                  as TNO
                  Nutrition and Food Research Institute) (7)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Development
                  Agreement dated July 30, 2004 between Dyadic International (USA),
                  Inc.
                  (f/k/a Dyadic International, Inc.) and Bio-Technical Resources
                  Division of
                  Arkion Life Sciences LLC (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.3</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commercial
                  Land Purchase and Sale Agreement dated July 31, 2004 between Dyadic
                  International (USA), Inc. (f/k/a Dyadic International, Inc.) and
                  F&amp;C
                  Holdings, LLC (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.4</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investors'
                  Rights Agreement dated March 24, 2004 among the Mark A. Emalfarb
                  Trust,
                  the Francisco Trust, Dyadic International (USA), Inc. (f/k/a Dyadic
                  International, Inc.) and other shareholders, as amended and assumed
                  by
                  Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.5</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                  Agreement dated April 1, 2001 between Mark A. Emalfarb and Dyadic
                  International (USA), Inc. (f/k/a Dyadic International, Inc.), as
                  assumed
                  by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.5.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">First
                  Amendment to Employment Agreement dated March 16, 2006 between
                  Mark A.
                  Emalfarb and Dyadic International, Inc. (9)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                  Agreement dated March 30, 2005 between Ratnesh (Ray) Chandra and
                  Dyadic
                  International, Inc. (4)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                  Agreement dated January 31, 2005 between Wayne Moor and Dyadic
                  International, Inc. (6)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.3</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                  Agreement dated March 30, 2005 between Alexander (Sasha) Bondar
                  and Dyadic
                  International, Inc. (4)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.4</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                  Agreement dated March 30, 2005 between Kent Sproat and Dyadic
                  International, Inc. (4)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.6.5</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment
                  Agreement dated March 16, 2006 between Glenn Nedwin and Dyadic
                  International, Inc. (9)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                  Information, Inventions Assignment and Non-Compete Agreement dated
                  May 21,
                  2001 between Mark Emalfarb and Dyadic International (USA), Inc.
                  (f/k/a
                  Dyadic International, Inc.), as assumed by Registrant
                  (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                  Information, Inventions Assignment and Non-Compete Agreement dated
                  May 21,
                  2001 between Ray Chandra and Dyadic International (USA), Inc. (f/k/a
                  Dyadic International, Inc.), as assumed by Registrant
                  (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.3</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                  Information, Inventions Assignment and Non-Compete Agreement dated
                  May 21,
                  2001 between Kent Sproat and Dyadic International (USA), Inc. (f/k/a
                  Dyadic International, Inc.), as assumed by Registrant
                  (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.4</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                  Information, Inventions Assignment and Non-Compete Agreement dated
                  September 4, 2001 between Richard Burlingame, Ph.D. and Dyadic
                  International (USA), Inc. (f/k/a Dyadic International, Inc.), as
                  assumed
                  by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.7.5</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidential
                  Information, Inventions Assignment and Non-Compete Agreement dated
                  May 21,
                  2001 between Alexander (Sasha) Bondar and Dyadic International
                  (USA), Inc.
                  (f/k/a Dyadic International, Inc.), as assumed by Registrant
                  (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                  Agreement dated August 19, 2001 between Mark A. Emalfarb and Dyadic
                  International (USA), Inc. (f/k/a Dyadic International, Inc.), as
                  assumed
                  by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                  Agreement dated August 19, 2001 between Stephen J. Warner and Dyadic
                  International (USA), Inc. (f/k/a Dyadic International, Inc.), as
                  assumed
                  by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.3</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                  Agreement dated January 11, 2005 between Dyadic International,
                  Inc. and
                  Richard Berman (3)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.4</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                  Agreement dated March 29, 2005 between Dyadic International, Inc.
                  and
                  Robert Shapiro (4)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.8.5</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                  Agreement dated April 26, 2005 between Dyadic International, Inc.
                  and
                  Harry Rosengart (8)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
                  International, Inc. 2001 Equity Compensation Plan, as amended and
                  assumed
                  by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Standard
                  form of Director Stock Option Grant Agreement under Dyadic International,
                  Inc. 2001 Equity Compensation Plan (3)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Second
                  Amendment to Dyadic International, Inc. 2001 Equity Compensation
                  Plan
                  dated as of January 12, 2005 (3)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9.3</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                  Employee Option Agreement under the Dyadic International, Inc.
                  2001 Equity
                  Compensation Plan, as amended (4)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.9.4</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Performance-Vested
                  Stock Option Agreement under the Dyadic International, Inc. 2001
                  Equity
                  Compensation Plan, as amended granted to Glenn Nedwin
                  (9)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.10</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subordinated
                  Promissory Note dated May 30, 2001 made by Dyadic International
                  (USA),
                  Inc. (f/k/a Dyadic International, Inc.), as amended, payable to
                  the order
                  of the Mark A. Emalfarb Trust in the original principal amount
                  of
                  $750,766, as assumed by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.11</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subordinated
                  Promissory Note dated May 30, 2001 made by Dyadic International
                  (USA),
                  Inc. (f/k/a Dyadic International, Inc.), as amended, payable to
                  the order
                  of the Francisco Trust in the original principal amount of $664,838,
                  as
                  assumed by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.12</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revolving
                  Note dated May 29, 2003 made by Dyadic International (USA), Inc.
                  (f/k/a
                  Dyadic International, Inc.), as amended, payable to the order of
                  the Mark
                  A. Emalfarb Trust in the original principal amount of $3,000,000,
                  as
                  assumed by Registrant (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.13</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Security
                  Agreement dated May 29, 2003, between the Mark A. Emalfarb Trust
                  and
                  Dyadic International (USA), Inc. (f/k/a Dyadic International, Inc.),
                  as
                  amended (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.14</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inducement
                  and Amending Agreement dated August 19, 2004 among the Mark A.
                  Emalfarb
                  Trust, the Francisco Trust and Dyadic International (USA), Inc.
                  (f/k/a
                  Dyadic International, Inc.) (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.15</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contract
                  Manufacturing Agreement dated October 27, 1999 between Polfa Tarchomin,
                  SA
                  and Dyadic International (USA), Inc. (f/k/a Dyadic International,
                  Inc.),
                  as amended by Amendments dated May 8, 2000 and February 10, 2004
                  and
                  letters dated February 11, 2004 (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.16</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                  and Escrow Agreement dated September 28, 2004 among Vitel Ventures,
                  Mark
                  Tompkins, Registrant and Dyadic International (USA), Inc. (f/k/a
                  Dyadic
                  International, Inc.) (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.17</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
                  of Subscription Agreement from investors in private placement offering
                  completed in early November 2004 (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.18</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Agreement
                  dated October 21, 1998 among Geneva Investment Holdings Limited,
                  a wholly
                  owned subsidiary of Dyadic International (USA), Inc. (f/k/a Dyadic
                  International, Inc.), Robert B. Smeaton and Raymond Chih Chung
                  Kwong, as
                  amended by Agreements dated January 17, 2000 and July 8, 2002
                  (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.19</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lock-Up
                  Agreements from each of the Mark A. Emalfarb Trust and Mark A.
                  Emalfarb;
                  the Francisco Trust; Mark Tompkins and IVC Group; Ratnesh Chandra;
                  Richard
                  Burlingame; Rufus Gardner; Kent Sproat; Thomas Bailey; and Alexander
                  Bondar (2)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.20</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification
                  Agreement dated as of September 28, 2004 among Dyadic International
                  (USA),
                  Inc. (f/k/a Dyadic International, Inc.), Dyadic International,
                  Inc. (f/k/a
                  CCP Worldwide, Inc.), Tom Shute, Roy Provencher and David R. Allison
                  (5)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.21</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
                  International, Inc. Statement of Director Compensation Policy
                  (3)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Code
                  of Ethics (10)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subsidiaries
                  of the Registrant (11)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consent
                  of Independent Registered Public Accounting Firm (11)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                  of Chief Executive Officer pursuant to Section&#160;302 of the
                  Sarbanes-Oxley Act of 2002 (11)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                  of Chief Financial Officer pursuant to Section&#160;302 of the
                  Sarbanes-Oxley Act of 2002 (11)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32.1</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                  of Chief Executive Officer required by 18 U.S.C. Section 1350 (as
                  adopted
                  pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002)
                  (11)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="middle" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32.2</font></div>
              </td>
              <td align="left" valign="top" width="63%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certification
                  of Chief Financial Officer required by 18 U.S.C. Section 1350 (as
                  adopted
                  pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002)
                  (11)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed September 30, 2004 with
                  the Securities and Exchange
                  Commission.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed November 4, 2004, as
                  amended with the Securities and Exchange
                  Commission.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed January 14, 2005 with the
                  Securities and Exchange Commission.
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(4)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed April 1, 2005 with the
                  Securities and Exchange Commission.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(5)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 10-QSB Quarterly Report for the nine
                  months ended September 30, 2004. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(6)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed February 1, 2005 with the
                  Securities and Exchange Commission.
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(7)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed December 21, 2005 with the
                  Securities and Exchange Commission.
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(8)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed April 28, 2005 with the
                  Securities and Exchange Commission.
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(9)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 8-K, filed March 21, 2006 with the
                  Securities and Exchange Commission.
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(10)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporated
                  by reference from the Company&#8217;s Form 10-KSB, filed April 15, 2005 with the
                  Securities and Exchange Commission.
</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="line-height: 1.25;">
              <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(11)&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed
                  herewith. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
        management contract or compensation plan or arrangement required to be filed
        as
        an exhibit to this report pursuant to Item 13 is listed in exhibits 10.5,
        10.5.1, 10.6.1, 10.6.2, 10.6.3, 10.6.4, 10.6.5, 10.9, 10.9.1, 10.9.2, 10.9.3,
        10.9.4 and 10.21.</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>52</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused
        this report to be signed on its behalf by the undersigned, thereunto duly
        authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 216pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;
        Dyadic International, Inc.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
        March 29, 2006</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 207pt">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:
        /s/
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Mark
        A. Emalfarb</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;</font>&#160;Mark
        A. Emalfarb</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
        Executive Officer</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>POWER
        OF ATTORNEY</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
        person whose signature appears below hereby constitutes and appoints Mark
        A.
        Emalfarb and Wayne Moor and each of them, his attorneys-in-fact, each with
        the
        power of substitution, for him and in his name, place and stead, in any and
        all
        capacities, to sign any and all amendments to this report on Form 10-KSB,
        and to
        file the same, with all exhibits thereto and all documents in connection
        therewith, with the Securities and Exchange Commission, granting unto said
        attorneys-in-fact and agents, and each of them full power and authority to
        do
        and perform each and every act and all intents and purposes as he might or
        could
        do in person, hereby ratifying and confirming all that such attorneys-in-fact
        and agents or any of them or his or their substitute or substitutes, may
        lawfully do or cause to be done by virtue hereof. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        accordance with the Exchange Act, this report has been signed below by the
        following persons on behalf of the registrant and in the capacities and on
        the
        date indicated.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
        March 29, 2006</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
        /s/
        Mark A. Emalfarb</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
        A.
        Emalfarb</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Principal
        Executive Officer, Chairman of the Board of Directors</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
        President</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
        /s/
        Glenn E. Nedwin</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Glenn
        E.
        Nedwin </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Principal
        Scientific Officer, Executive Vice President and Director</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
        /s/
        Wayne Moor</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wayne
        Moor </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Principal
        Financial and Accounting Officer</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
        /s/
        Stephen J. Warner</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stephen
        J. Warner </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
        Richard Berman</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Richard
        Berman</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 18pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
        /s/
        Robert Shapiro</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Robert
        Shapiro</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/
        Harry Rosengart</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Harry
        Rosengart </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director</font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>53</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><a name="indextoFS"><strong>INDEX
        TO CONSOLIDATED FINANCIAL
        STATEMENTS</strong></a></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="90%">

              <tr>
                <td align="left" valign="top" width="68%">&#160;</td>
                <td valign="top" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Page</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">&#160;</td>
                <td valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
                    of Independent Registered Public Accounting Firm</font></div>
                </td>
                <td valign="top" width="9%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#auditorreport">F-2</a></font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">&#160;</td>
                <td align="left" valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consolidated
                    Financial Statements: </font></div>
                </td>
                <td align="left" valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
                <td align="left" valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Consolidated
                    Balance Sheet - December 31, 2005</font></div>
                </td>
                <td valign="top" width="9%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#BS">F-3</a></font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">&#160;</td>
                <td align="left" valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Consolidated
                    Statements of Operations - Years ended December 31, 2005 and
                    2004
                    </font></div>
                </td>
                <td valign="top" width="9%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#stmtofoperation">F-4</a></font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">&#160;</td>
                <td align="left" valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Consolidated
                    Statements of Changes in Stockholders&#8217; Equity (Deficit) - Years ended
                    December </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31,
                    2005 and 2004</font></div>
                </td>
                <td valign="top" width="9%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#SHequity">F-5</a></font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">&#160;</td>
                <td align="left" valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Consolidated
                    Statements of Cash Flows - Years ended December 31, 2005 and
                    2004</font></div>
                </td>
                <td valign="top" width="9%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#cashflow">F-6</a></font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">&#160;</td>
                <td align="left" valign="top" width="9%">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="top" width="68%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes
                    to Consolidated Financial Statements</font></div>
                </td>
                <td valign="top" width="9%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a href="#FN">F-7</a></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div style="WIDTH: 100%" align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            </div>
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>F-1</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
            <div style="WIDTH: 100%" align="left">
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><a name="auditorreport">Repor</a>t
        of Independent Registered Public Accounting Firm
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Board
        of Directors and Shareholders </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
        International, Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        have
        audited the accompanying consolidated balance sheet of Dyadic International,
        Inc. and subsidiaries (the Company) as of December 31, 2005, and the related
        consolidated statements of operations, stockholders&#8217; equity (deficit) and cash
        flows for each of the two years in the period ended December 31, 2005. These
        financial statements are the responsibility of the Company&#8217;s management. Our
        responsibility is to express an opinion on these financial statements based
        on
        our audits.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
        conducted our audits in accordance with the standards of the Public Company
        Oversight Board (United States). Those standards require that we plan and
        perform the audit to obtain reasonable assurance about whether the financial
        statements are free of material misstatement. We were not engaged to perform
        an
        audit of the Company&#8217;s internal control over financial reporting. Our audit
        included consideration of internal control over financial reporting as a
        basis
        for designing audit procedures that are appropriate in the circumstances,
        but
        not for the purpose of expressing an opinion on the effectiveness of the
        Company&#8217;s internal control over financial reporting. Accordingly, we express no
        such opinion. An audit also includes examining, on a test basis, evidence
        supporting the amounts and disclosures in the financial statements, assessing
        the accounting principles used and significant estimates made by management,
        and
        evaluating the overall financial statement presentation. We believe that
        our
        audits provide a reasonable basis for our opinion.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        our
        opinion, the financial statements referred to above present fairly, in all
        material respects, the consolidated financial position of Dyadic International,
        Inc. and subsidiaries at December 31, 2005, and the consolidated results
        of
        their operations and their cash flows for each of the two years in the period
        ended December 31, 2005, in conformity with United States generally accepted
        accounting principles.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 360pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certified
        Public Accountants</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">West
        Palm
        Beach, Florida</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">March
        27,
        2006</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>F-2</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><a name="BS">Dyad</a>ic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Consolidated
        Balance Sheet</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>December
        31, 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="85%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Assets</strong></font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current
                  assets:</font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                  and cash equivalents</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,149,848</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Restricted
                  cash</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">34,658</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                  receivable, net of allowance for uncollectible accounts of
                  $530,738</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,869,167</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,413,558</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prepaid
                  expenses and other current assets</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">804,628</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  current assets</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">21,271,859</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fixed
                  assets, net</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,732,929</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible
                  assets, net</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">148,175</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Goodwill</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">467,821</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  assets</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">132,280</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  assets</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">23,753,064</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Liabilities
                  and stockholders&#8217; equity </strong></font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current
                  liabilities:</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                  payable</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,601,455</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  expenses</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,400,937</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                  interest payable to stockholders</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">142,629</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Short
                  term notes payable</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">267,590</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes
                  payable to stockholders of subsidiary</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">171,986</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  Income taxes payable</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">54,106</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  current liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,638,703</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Long-term
                  liabilities:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes
                  payable to stockholders, including accrued interest </font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,631,677</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">106,685</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  Minority interest</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">103,891</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  long-term liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,842,253</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  liabilities</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">8,480,956</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stockholders&#8217;
                  equity:</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Preferred
                  stock, $.0001 par value:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Authorized
                  shares - 5,000,000; none issued and outstanding</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                  stock, $.001 par value,</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Authorized
                  shares - 100,000,000; issued and outstanding - 22,420,188</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,420</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional
                  paid-in capital</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">49,719,905</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes
                  receivable from exercise of stock options</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(462,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accumulated
                  deficit</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(34,007,717</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  stockholders&#8217; equity </font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,272,108</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  liabilities and stockholders&#8217; equity</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">23,753,064</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
        accompanying notes.</em></font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-3</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><a name="stmtofoperation">Dyadic</a>
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Consolidated
        Statements of Operations</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="85%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="5" valign="bottom" width="26%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  sales</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,882,969</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,740,847</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
                  of goods sold</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,856,607</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,832,890</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gross
                  profit</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,026,362</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,907,957</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating
                  Expenses:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                  and development</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,898,876</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,621,451</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sales
                  and marketing</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,808,937</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,856,710</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General
                  and administrative</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,321,229</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,756,965</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign
                  currency exchange (gains) losses, net</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(16,785</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">213,471</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  operating expenses</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">13,012,257</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,448,597</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                  from operations</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,985,895</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5,540,640</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  income (expense):</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest
                  expense</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(710,537</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(597,906</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  Investment income</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">249,280</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">69,011</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;&#160;
</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  Minority interest</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(4,725</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(16,987</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  Other (expense) income, net</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,535</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,654</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  other expense</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(464,447</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(529,228</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                  before income taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,450,342</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,069,868</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provision
                  for income taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">64,228</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,714</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,079,582</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  (loss) income applicable to holders of common stock</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,397,720</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  (loss) income per common share:</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                  </font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0.31</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.37</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Weighted
                  average shares and equivalent shares used in </font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">calculating
                  net income (loss) per share:</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,132,158</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">14,387,533</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,132,158</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,324,085</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
        accompanying notes.</em></font><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div style="WIDTH: 100%" align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            </div>
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>F-4</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
            <div style="WIDTH: 100%" align="left">
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        <strong>International, Inc.</strong></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><a name="SHequity">Consolida</a>ted
        Statements of Changes in Stockholders&#8217; Equity
        (Deficit)</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

            <tr>
              <td align="left" valign="bottom" width="32%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td width="2%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td align="left" colspan="5" valign="bottom" width="21%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
                  <strong>Common Stock </strong></font></div>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Shares&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  &#160;&#160;&#160;&#160; &#160;Amount</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td align="left" colspan="2" valign="bottom" width="10%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;&#160;
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Additional
                  Paid-in Capital</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Note
                        Receivable</strong></font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>From
                        Exercise </strong></font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Of
                        Stock Options</strong></font></div>
                    </div>
                  </div>
                </div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td align="left" colspan="2" valign="bottom" width="10%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;<strong>&#160;
                Accumulated </strong></font>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Deficit</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </td>
              <td align="left" colspan="2" valign="bottom" width="10%" style="border-bottom: medium none;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<strong>&#160;&#160;
                Total </strong></font>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Stockholders&#8217;</strong></font></div>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Equity
                  (Deficit)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;"><strong>&#160;</strong></td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                  at December 31, 2003</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,460,806</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,461</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7,557,209</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(250,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(17,046,228</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,726,558</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dividends
                  accrued on preferred stock</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(350,684</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(350,684</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accretion
                  of preferred stock issuance costs</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(16,653</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(16,653</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                  of deferred compensation on&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">nonemployee
                  stock options</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">318,485</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">318,485</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock and warrants in a private placement, net of expenses
                  of
                  $118,260</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,422,099</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,422</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,615,908</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,617,330</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock and warrants in a private placement, net of expenses
                  of
                  $2,727,513</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7,629,204</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">7,629</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,670,107</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,677,736</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Excess
                  carrying value of Series A Preferred Stock over cash&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">redemption
                  amount </font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,844,639</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,844,639</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock for employee bonuses</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">18,624</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">19</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">61,999</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">62,018</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock to investment bankers</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,204</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(32</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock from note conversion</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">367,868</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">368</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,224,632</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,225,000</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional
                  borrowing costs incurred from Bridge Loan&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">warrant
                  </font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                  modification </font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">342,898</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">342,898</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beneficial
                  conversion feature from modification of&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">convertible
                  debt </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">554,387</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">554,387</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercise
                  of employee stock options granted by principal&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stockholder</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">212,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(212,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss </font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,079,582</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,079,582</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                  at December 31, 2004</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">21,930,805
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">21,931</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">48,402,732</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(462,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(23,493,147</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,469,016</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                  of deferred compensation on&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">nonemployee
                  stock options</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">76,673</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">76,673</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock for consulting services</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,523</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">91,524</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">91,551</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock for termination agreement</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">161,560</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">162</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">287,415</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">287,577</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
                  of common stock for land purchase</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">300,300</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">300</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">861,561</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">861,861</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="32%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  loss</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="32%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                  at December 31, 2005</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,420,188</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,420</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">49,719,905</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(462,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(34,007,717</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,272,108</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
          accompanying notes.</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div style="WIDTH: 100%" align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              </div>
              <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>F-5</strong></font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">&#160;</div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><a name="cashflow">Dyadic
          In</a>ternational, Inc.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Consolidated
          Statements of Cash Flows</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <div>
            <table cellpadding="0" cellspacing="0" id="ftable" width="100%">

                <tr>
                  <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
                  <td width="2%" style="border-bottom: medium none;">&#160;</td>
                  <td colspan="5" valign="bottom" width="25%" style="border-bottom: medium none;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                      Ended December 31</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Operating
                      activities</strong></font></div>
                  </td>
                  <td width="2%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" colspan="2" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                      loss</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.9pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,079,582</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adjustments
                      to reconcile net loss to net cash used in operating
                      activities:</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
                      and amortization of fixed assets</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">534,594</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">496,556</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                      of intangible and other assets</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">68,136</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">90,132</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amortization
                      of costs related to modification of notes payable to
                      stockholder</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">371,136</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">155,013</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Minority
                      interest</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,725</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,987</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provision
                      for doubtful accounts</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">140,922</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">433,431</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
                      issued for consulting services</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">91,551</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Compensation
                      expense on non-employee stock options</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">76,673</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">318,485</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loss
                      on asset disposal</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,448</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Changes
                      in operating assets and liabilities:</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                      receivable</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">67,993</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">176,853</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,228,475</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2,090,823</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prepaid
                      expenses and other current assets</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">21,521</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(545,036</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                      assets</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">47,334</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,481</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
                      payable</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(363,635</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">471,172</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                      expenses</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">67,921</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">487,474</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                      interest payable to stockholders</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">34,925</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">56,148</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred
                      revenue</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(75,000</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">29,244</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Short
                      term notes payable</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">267,590</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Income
                      taxes payable</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">41,297</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,763</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                      liabilities</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">70,872</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">35,813</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                      adjustments</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,699,478</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">162,693</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                      cash used in operating activities</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(7,815,092</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5,916,889</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investing
                      activities</strong></font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Purchases
                      of property and equipment</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(413,288</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(101,379</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Restricted
                      cash on deposit</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(34,658</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                      cash used in investing activities</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(447,946</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(101,379</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Financing
                      activities</strong></font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proceeds
                      from sale of common stock, net of issuance costs</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,392,830</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Payment
                      of issuance costs related to private placement</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(97,764</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Proceeds
                      from (repayment of) notes payable to stockholders</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(103,625</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Repayment
                      of other notes payable</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(909,849</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Payment
                      for redemption of Redeemable Series A convertible preferred
                      stock</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,500,000</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                      cash (used in) provided by financing activities</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(97,764</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">24,879,356</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                      (decrease) increase in cash and cash equivalents</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(8,360,802</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">18,861,088</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                      and cash equivalents at beginning of year</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">20,510,650</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,649,562</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                      and cash equivalents at end of year</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">12,149,848</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">20,510,650</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%">&#160;</td>
                  <td width="2%">&#160;</td>
                  <td align="left" valign="bottom" width="1%">&#160;</td>
                  <td align="right" valign="bottom" width="11%">&#160;</td>
                  <td align="left" valign="bottom" width="2%">&#160;</td>
                  <td align="left" valign="bottom" width="1%">&#160;</td>
                  <td align="right" valign="bottom" width="11%">&#160;</td>
                  <td align="left" valign="bottom" width="1%">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Supplemental
                      cash flow information:</strong></font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                      paid for interest </font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">298,214</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">293,353</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cash
                      paid for income taxes</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">30,710</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">59,919</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%">&#160;</td>
                  <td width="2%">&#160;</td>
                  <td align="left" valign="bottom" width="1%">&#160;</td>
                  <td align="right" valign="bottom" width="11%">&#160;</td>
                  <td align="left" valign="bottom" width="2%">&#160;</td>
                  <td align="left" valign="bottom" width="1%">&#160;</td>
                  <td align="right" valign="bottom" width="11%">&#160;</td>
                  <td align="left" valign="bottom" width="1%">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Noncash
                      activities:</strong></font></div>
                  </td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fair
                      value of beneficial conversion feature </font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">554,387</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fair
                      value of warrant modification related to bridge loan</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">342,898</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fair
                      value of common stock issued for land purchase</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">861,861</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                      stock issued for offering costs</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">107,239</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                      stock issued for settlement of liability and termination of
                      agreement</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">287,577</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>See
          accompanying notes.</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-6</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong><a name="FN">Dyadic
</a>International,
            Inc. </strong></font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><a name="Notes_to_Cons_Financial_Stmts"><strong>Notes
          to Consolidated Financial
          Statements</strong></a></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>December
          31, 2005</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1.
          Organization and Operations</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>General</em></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
          International, Inc. (the Company or Dyadic), based in Jupiter, Florida,
          with
          operations in the United States of America, Hong Kong and mainland China,
          Poland
          and The Netherlands, is a developer and distributor of specialty enzymes
          and
          related products for sale to the textile, food, animal feed, starch, pulp
          and
          paper and other industries. The Company is focused on functional proteomics
          through the discovery, development and manufacturing of novel products,
          including enzymes and proteins, derived from the genes of complex living
          organisms (including humans) found in the earth's biodiversity. Using its
          proprietary platform technologies for gene discovery and gene expression,
          Dyadic
          is developing additional biological products (e.g., proteins, enzymes,
          polypeptides and small molecules) for use by itself and for applications
          in
          large segments of the agricultural, energy, industrial, chemical and
          pharmaceutical industries. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company expects to incur losses over the next several years as it continues
          to
          develop its technologies and establish the commercial laboratories and
          other
          required infrastructure to exploit these technologies. However, there can
          be no
          assurance that the Company's efforts with regard to these matters will
          be
          successful. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Organizational
          History</em></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          April
          2001, the Company formed Dyadic International Sp. z o.o., a Polish corporation,
          for the purpose of managing and coordinating the Company's contract
          manufacturing of industrial enzymes in Poland, and to assist in the marketing
          and distribution of those products. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          January 2004, the Company formed Dyadic Nederland B.V. (&#8220;Dyadic NL&#8221;), a Dutch
          corporation, for the development, use and marketing of High Throughput
          Screening
          (HTS) Systems utilizing fungal organisms. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Merger,
          Private Placement of Common Stock and Other Related
          Transactions</em></strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          October and November 2004, the Company entered into and executed several
          contemporaneous and related transactions (collectively, the Transactions)
          as
          described below. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Merger
          </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
          <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective
            October 29, 2004, the Company entered into an Agreement of Merger and
            Plan of
            Reorganization (the Merger) with CCP Worldwide, Inc., a public reporting
            company, and its wholly-owned subsidiary, CCP Acquisition Corp. As a
            result of
            the Merger, CCP Acquisition Corp. was merged with and into the Company,
            with the
            Company being the surviving corporation. The Company changed its name
            to Dyadic
            International (USA) (&#8220;Dyadic-Florida&#8221;), Inc. In turn, CCP Worldwide, Inc.
            changed its name to Dyadic International, Inc., and stockholders of the
            Company
            received, in exchange for Company shares, shares of CCP Worldwide, Inc.
            on a
            one-for-one basis. </font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div align="left"><br></div>
          <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            Company recorded the Merger as the issuance of stock for the net monetary
            assets
            of CCP Worldwide, Inc. (which were nil), accompanied by a recapitalization.
            This
            accounting is identical to that resulting from a reverse acquisition,
            except
            that no goodwill or other intangible assets were recorded. Thus the 10,807,668
            new shares that were issued the stockholders of the Company are retroactively
            reflected as being outstanding for all periods presented in the accompanying
            consolidated financial statements. Additionally, because CCP Worldwide,
            Inc.'s
            net assets were nil, the 1,653,138 shares of common stock, representing
            the
            aggregate number of shares held by stockholders of CCP Worldwide, Inc.
            immediately prior to the Merger, have been retroactively reflected as
            outstanding for all periods presented in the accompanying consolidated
            financial
            statements. Finally, the accompanying consolidated financial statements
            retroactively reflect the authorized capital stock of CCP Worldwide,
            Inc. and
            the resultant change from no par to $0.001 par value on the Company's
            common
            stock. <br></font></div>
          <div align="left">&#160;</div>
          <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrently,
            the Company's officers and directors became the officers and directors
            of the
            merged, reorganized entity. The Company's pre Merger obligations to contingently
            issue common shares in accordance with a real estate acquisition agreement,
            employee stock options, nonemployee stock options and warrants and convertible
            debt instruments were also assumed. </font></div>
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-7</strong></font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
                of
                Contents</a></em></font></div>
            </div>
          </div>
          <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
            part
            of the Transactions, and immediately prior to the Merger, CCP Worldwide,
            Inc.
            disposed of its only operating subsidiary as part of a Split-off Agreement
            between CCP Worldwide, Inc., its wholly owned subsidiary, the Company
            and a
            former member of the board of directors of CCP Worldwide, Inc. </font></div>
          <div align="left">&#160;</div>
          <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
            a
            result of the Merger and the Split-off Agreement, the only business operations
            of the newly formed Dyadic International, Inc., formerly CCP Worldwide,
            Inc.,
            are the operations of the Company. </font></div>
          <div align="left">&#160;</div>
          <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Private
            Placement </em></font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          November 2004, in accordance with Subscription Agreements and a Private
          Offering
          Memorandum (the October Offering) dated October 2004, the Company sold
          7,629,204
          Investment Units, realizing gross proceeds of $25,405,249. An Investment
          Unit
          consists of one share of the Company's common stock and one five-year callable
          warrant to purchase one share of the Company's common stock at $5.50 per
          share
          for every two Investment Units purchased. Accordingly, 3,814,602 warrants
          to
          purchase the Company's common stock were issued to participants in the
          October
          Offering. Concurrently, the Company issued 711,050 warrants to purchase
          the
          Company's common stock at $5.50 per share to participants in the Offering
          completed in July 2004 as described below, as well as 247,730 warrants
          to
          purchase the Company's common stock at $5.50 per share and 495,460 warrants
          to
          purchase the Company's common stock at $3.33 per share, both to placement
          agents
          in the October Offering. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          July
          2004, the Company completed a private offering (pursuant to a Term Sheet
          dated
          April 1, 2004) of its common and preferred equity securities, and raised
          gross
          proceeds of $4.7 million. The equity securities were offered as an </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment
          Unit, with each unit consisting of two shares of common stock and one share
          of
          Series B Preferred Stock, at a price of $10 per unit. The Company used
          $1.5
          million of the proceeds from this offering to redeem all outstanding shares
          of
          Series A Preferred. Holders of the Series B Preferred Stock were entitled
          to
          receive noncumulative dividends at the rate of 8% per annum when and as
          declared
          by the Company's Board of Directors, have certain preferences in liquidation,
          and have voting rights identical to those of the holders of the Company's
          common
          stock. All of the outstanding shares of Series B Preferred Stock automatically
          converted into an equal number of shares of common stock upon closing of
          the
          private offering. After giving effect to the automatic conversion of the
          Series
          B Preferred Stock, a total of 1,422,099 shares of common stock were issued
          in
          connection with the offering. As the Company completed an additional private
          offering of its common shares pursuant to the Confidential Offering Memorandum
          described above, the Company granted the purchasers of these Investment
          Units
          warrants to acquire a total of 711,050 shares of the Company's common stock
          at
          $5.50 per share. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company incurred $2,727,573 of costs related to the October Offering and
          the
          Merger, including the subsequent registration of the Company's shares issued
          in
          the Merger and the October Offering. These costs are included as a reduction
          of
          additional paid-in capital. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Other
          Transactions </em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cancellation
          of Indebtedness </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ancillary
          to the Merger and October Offering, in November 2004, an additional 367,868
          Investment Units were sold to Mark A. Emalfarb through the Mark A. Emalfarb
          Trust in exchange for the cancellation of the Company's note payable to
          the Mark
          A. Emalfarb Trust (see Note 7) with a principal balance of $1,225,000.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Modification
          of Bridge Loan Warrant </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
          part
          of the Transactions, the warrant to purchase 1.5 million shares of the
          Company's
          common stock issued in connection with the May 2003 $3.0 million revolving
          note
          payable to the Mark A. Emalfarb Trust (see Note 7) was modified to reduce
          the
          exercise price from $4.50 to $3.33 per share. Additionally, the bridge
          loan
          maturity date was extended to January 1, 2007. As a result, approximately
          $343,000, representing the incremental fair value of the modified warrant
          as
          compared to the fair value of the original warrant immediately before the
          modification (determined using the Black-Scholes option pricing model,
          using the
          following assumptions: risk-free interest rate of 3.91%, dividend yield
          of 0%,
          expected volatility of 50% and an expected remaining life of 8.6 years,
          the
          remaining term of the warrant) will be amortized to interest expense through
          the
          new maturity date. The estimated fair value of the original warrant had
          been
          fully amortized to interest expense during the year ended December 31,
          2003.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Modification
          of Convertible Notes </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Also
          as
          part of the Transactions, the conversion prices with respect to the October
          29,
          2004 principal and accrued interest balances on the Emalfarb Trust Note
          and the
          Francisco Trust Note (see Note 7) were fixed at $3.33 per share, </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-8</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
          the
          due dates were extended to January 1, 2007. As a result of the modification
          of
          the conversion price, a beneficial conversion feature totaling approximately
          $554,000 was recorded in October 2004 and is reflected as a reduction of
          notes
          payable to stockholders in the accompanying consolidated balance sheet
          for the
          year ended December 31, 2004. It will be amortized to interest expense
          through
          the new maturity date.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Increase
          in Shares Reserved for Equity Plan </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          September 2004, by written consent, the Company's Board of Directors and
          stockholders approved an increase in the authorized number of shares of
          common
          stock under the Equity Plan from 1,302,989 to 5,152,447. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Historical
          Results of Operations </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company has incurred losses from operations during the last several years,
          which
          have resulted in an accumulated deficit of approximately $34 million as
          of
          December 31, 2005. The Company attributes these operating results to, among
          other things, negative trends in the textile enzymes sector,&#160;expansion of
          its operations, establishment of new affiliates, and increased research
          and
          development spending. In order to advance its science and to develop new
          products, the Company has continued to incur discretionary research and
          development expenditures in 2005. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company believes that there will be sufficient capital to fund its operations
          and meet its obligations through year end 2006, based on current sales
          volumes.
          The Company has established a number of flexible partnerships in the areas
          of
          manufacturing and research and development, enabling it to adjust spending
          in
          those areas as necessary, to achieve the objectives of its business plan,
          and
          manage both its resources and cash utilization rate. The Company has
          historically funded losses from operations with proceeds from external
          borrowings, borrowings from its stockholders, and sales of preferred and
          common
          equity securities. Additional funds may be needed and raised through public
          or
          private financings, collaborative relationships, licensing or selling of
          certain
          technologies or other arrangements. Additional funding, if sought, may
          not be
          available at all, or may not be available on terms favorable to the Company.
          Further, any additional equity financing may be dilutive to stockholders,
          and
          debt financing, if available, may involve restrictive covenants. Failure
          to
          raise capital when needed may harm the Company&#8217;s business and operating results.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2.
          Summary of Significant Accounting Policies</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Principles
          of Consolidation</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          accompanying consolidated financial statements include the accounts of
          the
          Company and its majority owned subsidiaries. All significant intercompany
          transactions and balances have been eliminated in consolidation. As described
          in
          Note 8, Dyadic has an 82.5% ownership interest in the outstanding shares
          of an
          affiliate that, until June 30, 2002, was accounted for under the equity
          method
          because the Company's ownership interest did not constitute a majority
          of the
          outstanding voting shares of the affiliate. In July 2002, the Company acquired
          additional voting rights such that, as of that date, it also owned a majority
          of
          the outstanding voting shares of the affiliate. Therefore, the investment
          in the
          affiliate was accounted for under the equity method through June 30, 2002,
          and
          as a consolidated subsidiary (with an allocation to minority interest)
          after
          that date. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Cash
          and Cash Equivalents</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company considers as cash equivalents all interest-bearing deposits or
          investments with original maturities of three months or less when purchased.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Restricted
          Cash</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Restricted
          cash of $34,658 consists of funds held by our general fiscal representative
          in
          Poland as a security deposit for potential Value Added Tax
          liabilities.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounts
          Receivable</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts
          receivable are recorded at their net realizable value on the date revenue
          is
          recognized. The Company provides allowances for doubtful accounts for estimated
          losses resulting from the inability of its customers to repay their obligation.
          If the financial condition of the Company's customers were to deteriorate,
          resulting in an impairment of their ability to repay, additional allowances
          may
          be required. The Company provides for potential uncollectible accounts
          receivable based on specific customer identification and historical collection
          experience adjusted for existing market conditions. If market conditions
          decline, actual collection experience may not meet expectations and may
          </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-9</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">result
          in
          decreased cash flows and increased bad debt expense. The policy for determining
          past due status is based on the contractual payment terms of each customer,
          which are generally net 30, 60 or 90 days. Once collection efforts by the
          Company and its collection agency are exhausted, the determination for
          charging
          off uncollectible receivables is made. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Inventory</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory
          consists of raw materials and finished goods, including industrial enzymes
          used
          in the industrial, chemical and agricultural markets, and is stated at
          the lower
          of cost or market using the average cost method. Finished goods include
          raw
          materials and manufacturing costs, substantially all of which are incurred
          pursuant to agreements with independent manufacturers. Provisions have
          been made
          to reduce excess or obsolete inventory to net realizable value.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
          December 31, 2005, inventories consisted of the following:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="73%">

              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="70%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Finished
                    goods</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,125,150</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="70%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Raw
                    materials</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,288,408</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="70%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,413,558</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Fixed
          Assets</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fixed
          assets are recorded at cost and depreciated and amortized using the
          straight-line method over their estimated useful lives, which range from
          three
          to ten years. Leasehold improvements are amortized over the lesser of their
          useful lives or the lease terms. Upon sale or retirement, the cost and
          related
          accumulated depreciation and amortization are eliminated from their respective
          accounts, and the resulting gain or loss is included in results of operations.
          Repairs and maintenance charges, which do not increase the useful lives
          of the
          assets, are charged to operations as incurred.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Intangible
          Assets</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible
          assets include patent and technology acquisition costs which are being
          amortized
          using the straight-line method over the twelve-year terms of the patents.
          No
          additional costs related to the patents and technology were incurred and
          capitalized in 2005 or 2004. The original value of intangible assets of
          $541,358
          is presented net of accumulated amortization of $393,183 as of December
          31,
          2005, and amortization expense was $52,128 for each of the years ended
          December
          31, 2005 and 2004. Amortization expense will be approximately the same
          as in
          2006 and 2007 and will be approximately $44,000 in 2008, when these intangible
          assets will become fully amortized. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Goodwill</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To
          apply
          the provisions of Statement of Financial Accounting Standards (SFAS) No.142,
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Goodwill
          and Other Intangible Assets </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SFAS
          142)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          the
          Company is required to identify its reporting units. Based on an analysis
          of
          economic characteristics and how the Company operates its business, the
          Company
          has designated its geographic locations as its reporting units: the United
          States (which includes the Company's subsidiary in Poland), The Netherlands,
          Hong Kong and mainland China. All goodwill is associated with the Hong
          Kong
          reporting unit. In accordance with the provisions of SFAS 142, the Company
          was
          required to perform an annual impairment review of goodwill. This test
          involved
          the use of estimates to determine the fair value of the Company's Asian
          reporting unit and the comparison of fair value to the carrying value of
          the
          reporting unit. The impairment reviews resulted in no goodwill impairment
          charge. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Long-Lived
          Assets</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company reviews its long-lived assets, including fixed assets that are
          held and
          used in its operations, for impairment whenever events or changes in
          circumstances indicate that the carrying amount of the asset may not be
          recoverable, as required by SFAS 144. If such an event or change in
          circumstances is present, the Company will estimate the undiscounted future
          cash
          flows, less the future outflows necessary to obtain those inflows, expected
          to
          result from the use of the asset and its eventual disposition. If the sum
          of the
          undiscounted future cash flows is less than the carrying amount of the
          related
          assets, the Company will recognize an impairment loss to the extent the
          carrying
          value exceeds the fair value. The Company records impairment losses resulting
          from abandonment in loss from operations. Assets to be disposed of are
          reclassified as assets held for sale at the lower of their carrying amount
          or
          fair value less costs to sell. Write-downs to fair value less costs to
          sell are
          reported above the loss from operations line as general and administrative
          expense. </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-10</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
              Company does not believe that the there were any events or changes
              in
              circumstances that indicate that the carrying amounts of its long-lived
              assets
              may not be recoverable as of December 31, 2005.</font></div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Advertising
            Costs</em></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Advertising
              costs are expensed as incurred. During the years ended December 31,
              2005 and
              2004, advertising costs incurred by the Company totaled approximately
              $13,000
              and $11,000, respectively, and are included in sales and marketing
              expenses in
              the accompanying consolidated statements of operations.</font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Research
          and Development</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
          and development costs related to both present and future products are charged
          to
          operations when incurred. Revenue received for research and development
          is
          recognized as the Company meets its obligations under the related agreement.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
          and development costs incurred by type of project during the years ended
          December 31, 2005 and 2004 were as follows:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Internal
                    development</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,193,103</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,677,210</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Collaborations</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,705,774</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,944,241</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,898,877</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,621,451</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
          and development costs based upon type of cost incurred during the years
          ended
          December 31, 2005 and 2004 were as follows:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Personnel
                    related</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,074,383</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">736,851</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Laboratory
                    and supplies</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">204,901</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">78,138</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outside
                    services</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,705,774</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,944,241</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equipment
                    and depreciation</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">674,906</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">646.253</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facilities,
                    overhead and other</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">238,913</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">215,968</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">&#160;</td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,898,877</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,621,451</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company recognized $150,000 in research and development revenue for the
          year
          ended December 31, 2005, which is included in net sales in the accompanying
          consolidated statement of operations. No research and development revenue
          was
          recognized during the year ended December 31, 2004.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Income
          Taxes</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company accounts for income taxes using the liability method. Under this
          method,
          deferred tax assets and liabilities are determined based on the difference
          between the financial statement and tax bases of assets and liabilities,
          using
          enacted tax rates in effect for the year in which the differences are expected
          to reverse. A deferred tax valuation allowance is established if, in
          management's opinion, it is more likely than not that all or a portion
          of the
          Company's deferred tax assets will not be realized. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Net
          (Loss) Income Per Share</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
          net
          (loss) income per share has been computed using the weighted-average number
          of
          shares of common stock outstanding during the period. In arriving at net
          (loss)
          income applicable to common stockholders, accrued preferred stock dividends
          and
          accretion of preferred stock issuance costs are deducted for each period
          presented in which such cumulative preferred stock was outstanding. For
          the year
          ended December 31, 2004, the excess of the Series A Preferred carrying
          value at
          the time of redemption, over the $1,500,000 cash paid for redemption is
          added to
          net loss in computing net income applicable to holders of common stock,
          in
          accordance with the Emerging Issues </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-11</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Task
          Force (EITF) Topic D-42: <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>The
          Effect on the Calculation of Earnings per Share for the Redemption or Induced
          Conversion of Preferred Stock</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
          For the
          year ended December 31, 2004, the Company has used the if-converted method
          to
          calculate the dilutive effect of common stock issuable pursuant to conversion
          features for purposes of diluted income per share. </font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          following table reflects the calculation of basic and diluted net (loss)
          income
          per share for the periods presented: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="90%">

              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td colspan="5" valign="bottom" width="26%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                    Ended December 31</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="right" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="right" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    loss </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,079,582</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Plus:
                    Excess carrying value of Series A Preferred stock over cash r</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">demption</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,844,639
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Less:
                    Accrued dividends on preferred stock </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(350,684</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accretion
                    of preferred stock issuance costs </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(16,653</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    (loss) income applicable to holders of common stock for basic
                    c</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">lculation</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,397,720
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Plus:
                    Accrued dividends on preferred stock </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">350,684</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                    Accretion of issuance costs </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,653</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                    Interest on subordinated convertible notes payable </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,822</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Less:
                    Excess carrying value of Series A Preferred over cash redemption
                    </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">amount
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,844,639</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    loss applicable to holders of common stock for diluted calculation
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,063,760</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">&#160;</td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Weighted
                    average common shares used in computing net (loss) income p</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">r
                    share:</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,132,158
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">14,387,533
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Plus:
                    Common shares obtainable upon conversion of Series A </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Preferred
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,611,637</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                    Co<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mmon
                    shares obtainable upon conversion of subordinated</font>onvertible notes
                    payable </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">324,915</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,132,158
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,324,085
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">&#160;</td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    (loss) income per common share: </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0.31</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.37</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          following potentially dilutive securities were not included in the calculation
          of diluted net loss per share as they were anti-dilutive for the respective
          periods presented: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="90%">

              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                    Ended December 31</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="right" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="right" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Instruments
                    to purchase common stock:</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
                    options outstanding pursuant to the 2001 Equity Compensation
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Plan
                    (see Note 11) </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,597,639
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">750,000
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                    stock options </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">65,000
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">65,000
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Warrants
                    outstanding (see Note 9) </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,952,776
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,952,776
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common
                    stock issuable pursuant to conversion features:</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subordinated
                    convertible notes payable</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">473,835</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">473,835</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                    shares of common stock considered anti-dilutive </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,089,250</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">8,241,611</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
          are
          a total of 300,300 contingently issuable shares under an agreement to conduct
          research and development activities on behalf of the Company pursuant to
          the
          arrangement discussed in Note 12, of which 292,777 and 300,300 are also
          excluded
          from the calculation of diluted net income (loss) per share for the years
          ended
          December 31, 2005 and 2004, respectively. Such shares of common stock are
          unearned, nonvested, restricted shares that will be considered outstanding
          once
          earned under the agreement. As of December 31, 2005, 7,523 shares have
          been
          earned and are outstanding. None were earned or outstanding at December
          31,
          2004.</font><br></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-12</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Revenue
              Recognition</em></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
              Company recognizes revenues in accordance with Staff Accounting Bulletin
              (SAB)
              No 104, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenue
              Recognition in Financial Statements </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SAB
              104). SAB 104 sets forth four basic criteria that must be met before
              SEC
              registrants can recognize revenue. These criteria are: persuasive evidence
              of an
              arrangement must exist; delivery had to have taken place or services
              had to have
              been rendered; the seller's price to the buyer should be fixed or determinable;
              and collectibility of the receivable should be reasonably assured.
              Sales not
              meeting any of the aforementioned criteria are deferred. Sales are
              comprised of
              gross revenues less provisions for expected customer returns, if any.
              Reserves
              for estimated returns and inventory credits are established by the
              Company, if
              necessary, concurrently with the recognition of revenue. The amounts
              of reserves
              are established based upon consideration of a variety of factors, including
              estimates based on historical returns. </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts
              billed to customers in sales transactions related to shipping and handling,
              represent revenues earned for the goods provided and are included in
              net sales.
              Costs of shipping and handling are included in cost of products
              sold.</font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Foreign
          Currency Translation</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          financial statements of the Company's foreign subsidiaries have been translated
          into United States dollars in accordance with SFAS No. 52, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Foreign
          Currency Translation</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
          Assets
          and liabilities of the Company's foreign subsidiaries are translated at
          year-end
          exchange rates, and revenues and expenses are translated at average rates
          prevailing during the period. Certain accounts receivable from customers
          are
          collected and certain accounts payable to vendors are payable in currencies
          other than the functional currencies of the Company and its subsidiaries.
          These
          amounts are adjusted to reflect year-end exchange rates. Net translation
          adjustments and realized exchange gains and losses are included as a component
          of foreign currency exchange gains (losses), net, in the accompanying
          consolidated statements of operations. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Stock
          Option Plans</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company accounts for its stock-based compensation plans under Accounting
          Principles Board Opinion No.&#160;25, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
          for Stock Issued to Employees</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          (APB 25)
          and FASB Interpretation No. 44, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
          for Certain Transactions involving Stock Compensation </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(FIN
          44),
          including related amendments and interpretations, and provides pro forma
          disclosures of the compensation expense determined under the fair value
          provisions of SFAS 123. Under APB 25, since the exercise prices of the
          Company&#8217;s
          employee stock options equal the market price of the underlying stock on
          the
          date of grant, no compensation expense is recognized. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock
          options and warrants issued to consultants and other non-employees as
          compensation for services provided to the Company are accounted for based
          on the
          fair</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">value
          of
          the services provided or the estimated fair market value of the option
          or
          warrant, whichever is more reliably measurable in accordance with SFAS
          123 and
          EITF 96-18, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
          for Equity Investments That are Issued to Other Than Employees for Acquiring
          or
          in Conjunction with Selling Goods or Services,</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          including related amendments and interpretations. The related expense is
          recognized over the period the services are provided.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pro
          forma
          information regarding net (loss) income and net (loss) income per common
          share
          as if the Company had accounted for its employee stock options under the
          fair
          value method of SFAS&#160;123 is presented below. For purposes of pro forma
          disclosure, the estimated fair value of the options is amortized to expense
          over
          the options&#8217; vesting period. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          December 2005, the Board of Directors of the Company approved the acceleration
          of vesting for the unvested portion of all outstanding employee incentive
          stock
          options awarded from May 2001 to present under the Equity Plan, as amended.
          The
          purpose of the accelerated vesting was to provide a non-cash benefit to
          the
          Company&#8217;s employees and to eliminate future compensation expense the Company
          would otherwise recognize in its statements of operations with respect
          to these
          accelerated options upon the adoption of Financial Accounting Standards
          Board
          Statement of Financial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting
          Standards No. 123 (Revised 2004), Share-Based Payment (&#8220;SFAS 123R&#8221;). SFAS 123R
          is effective for the first fiscal year that begins after December 15, 2005,
          and
          will require that compensation expense associated with stock options be
          recognized in the statements of operations, rather than as footnote disclosure
          in the Company&#8217;s consolidated financial statements. The estimated future
          compensation expense associated with these accelerated options that would
          have
          been recognized in the Company&#8217;s statements of operations upon implementation of
          SFAS 123R is approximately $1.3 million. All option grants made on and
          after
          January 1, 2006 will be accounted for in accordance with SFAS 123R.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While
          the
          Company typically issues options that vest equally over four years, as
          a result
          of this vesting acceleration, stock options to purchase approximately 1.2
          million shares of the Company&#8217;s common stock, of which approximately 600,000 are
          held by the Company&#8217;s executive officers and directors, became immediately
          exercisable. The estimated future compensation expense associated with
          these
          accelerated options that would have been recognized in the Company&#8217;s income
          statement upon implementation of SFAS 123R is approximately $1.3 million.
          </font><br></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-13</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company&#8217;s pro forma information is as follows:</font><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="89%">

              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                    Ended December 31</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    (loss) income applicable to holders of common stock, as reported
                    for basic
                    calculation</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,397,720</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Add:
                    Stock-based employee compensation cost (intrinsic value
                    method)</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deduct:
                    Fair value method stock option expense</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,599,134</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(143,886</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pro
                    forma net income (loss) applicable to holders of common stock,
                    </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">basic
                    calculation </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(12,113,704</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,253,834</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">&#160;</td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    loss applicable to holders of common stock, as reported for diluted
                    calculation</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,514,570</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,063,760</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Add:
                    Stock-based employee compensation cost (intrinsic value
                    method)</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deduct:
                    Fair value method stock option expense</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,599,134</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(143,886</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pro
                    forma net loss applicable to holders of common stock, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">diluted
                    calculation </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(12,113,704</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,207,646</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                  </div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    income (loss) per common share, as reported:</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0.31</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.48</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.37</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pro
                    forma net loss per common share:</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.55</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0.30</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diluted
                    </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.55</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(0.38</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Weighted
                    average fair value per option granted during the period</font><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: Times New Roman, serif"><sup>1</sup></font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.36</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.57</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assumptions:</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;
                    Average risk free interest rate</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.00</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.36</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;
                    Average volatility factor</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">.50</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">.50</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;
                    Expected dividend yield</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">0</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;
                    Expected life (in years)</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.00</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.00</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: Times New Roman, serif"><sup>1</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
          Black-Scholes option-pricing model was used to develop the fair values
          of the
          options granted.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Credit
          Risk</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Financial
          instruments which potentially subject the Company to concentrations of
          credit
          risk include cash and cash equivalents and accounts receivable (see Note
          3). The
          Company invests its excess cash in money market funds. The money market
          funds
          represent an interest in low risk U.S. Government obligations. The Company's
          investments are not insured or guaranteed by the U.S. Government, the Federal
          Deposit Insurance Corporation or any other government agency. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Use
          of Estimates</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          preparation of financial statements in conformity with accounting principles
          generally accepted in the United States requires management to make estimates
          and assumptions that affect the amounts reported in the consolidated financial
          statements. Actual results could differ from those estimates.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reporting
          Comprehensive Loss</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Comprehensive
          loss is defined as the change in equity of a business enterprise during
          a period
          from transactions and other events and circumstances, except for those
          resulting
          from investments by owners and distributions to owners. The presentation
          of
          comprehensive loss required by SFAS No. 130, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reporting
          Comprehensive Income</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          is not
          required in the accompanying consolidated financial statements as the Company
          has no material components of accumulated other comprehensive loss.
</font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-14</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Fair
          Value of Financial Instruments</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company uses various methods and assumptions to estimate the fair value
          of each
          class of financial instrument. Due to their short-term nature and measurement,
          the carrying value of cash and cash equivalents, accounts receivable, accounts
          payable and notes payable approximate fair value. The Company's other financial
          instruments are not significant.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Recent
          Accounting Pronouncements</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          May
          2005,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          the
          Financial Accounting Standards Board (FASB) </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">issued
          </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Statement
          of Financial Accounting Standards (SFAS)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          No. 154,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
          Changes and Error Corrections-a replacement of APB Opinion No. 20 and FASB
          Statement No. 3</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          (SFAS
          154). &#160;This Statement replaces APB Opinion No. 20, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
          Changes</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          and
          SFAS No. 3, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Reporting
          Accounting Changes in Interim Financial Statements</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          and
          changes the requirements for the accounting for and reporting of a change
          in
          accounting principle and error corrections. &#160;This Statement applies to all
          voluntary changes in accounting principle. &#160;It also applies to changes
          required by an accounting pronouncement in the unusual instance that the
          pronouncement does not include specific transition provisions. &#160;When a
          pronouncement includes specific transition provisions, those provisions
          should
          be followed. &#160;SFAS 154 is effective for accounting changes and corrections
          of errors made in fiscal years beginning after December 15, 2005. &#160;Earlier
          application is permitted for accounting changes and corrections of errors
          made
          occurring in fiscal years beginning after September 1, 2005. &#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company does not anticipate that the adoption of the new standard will
          have an
          effect on the Company&#8217;s consolidated financial position, results of operations
          or cash flows.&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          March
          2005, the FASB issued Interpretation No. 47,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Accounting
          for Conditional Asset Retirement Obligations</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          (FIN
          47). The document is an interpretation of FASB Statement 143, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Asset
          Retirement Obligations</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
          which
          was issued in June 2001. The FASB issued the Interpretation to address
          diverse
          accounting practices that have developed with regard to the timing of liability
          recognition for legal obligations associated with the retirement of a tangible
          long-lived asset in which the timing and (or) method of settlement are
          conditional on a future event that may or may not be within the control
          of the
          entity. According to the Interpretation, uncertainty about the timing and
          (or)
          method of settlement of a conditional asset retirement obligation should
          be
          factored into the measurement of the liability when sufficient information
          exists. FIN 47 also clarifies when an entity would have sufficient information
          to reasonably estimate the fair value of an asset retirement obligation.
          FIN 47
          is effective no later than the end of fiscal years ending after December
          15,
          2005. Retrospective application of interim financial information is permitted,
          but is not required. Early adoption of this Interpretation is encouraged.
          The
          adoption of the new standard did not have an effect on the Company&#8217;s
          consolidated financial position, results of operations or cash
          flows.&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          December&#160;2004, the FASB issued SFAS No.&#160;123 (revised 2004),
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Share-Based
          Payment</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          (SFAS
          123R), which replaces SFAS 123 and supersedes APB 25. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          March
          2005, the SEC issued Staff Accounting Bulletin No. 107 (SAB 107), which
          expresses views of the SEC staff regarding the interaction between SFAS
          123R and
          certain SEC rules and regulations, and provides the staff's views regarding
          the
          valuation of share-based payment arrangements for public companies. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SFAS&#160;123R
          requires all share-based payments to employees, including grants of employee
          stock options, to be recognized in the financial statements based on their
          fair
          values, beginning with the first interim or annual period after December
          15,
          2005. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company adopted SFAS 123R effective January 1, 2006. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          grant-date fair value of employee share options and similar instruments
          is to be
          estimated using an option-pricing model adjusted for any unique characteristics
          of a particular instrument. If an equity award is modified after the grant
          date,
          incremental compensation costs are recognized in an amount equal to the
          excess
          of the fair value of the modified award over the fair value of the original
          award immediately before the modification. Two transition alternatives
          are
          allowed for the public entities: the modified-prospective-transition method
          or
          the modified-retrospective transition method. The Company will adopt SFAS
          123R
          using the modified-prospective-transition method. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
          permitted by SFAS 123, the Company accounted for share-based payments to
          employees using APB 25&#8217;s intrinsic value method through December 31, 2005 and,
          as such, generally recognized no compensation cost for employee stock options.
          Accordingly, the adoption of SFAS 123(R)&#8217;s fair value method may have a
          significant impact on the Company&#8217;s results </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
          operations depending on the levels of share-based payments granted in the
          future, although it will have no impact on the Company&#8217;s overall financial
          position or cash flows. Upon adoption of SFAS 123(R), no compensation expense
          will be recognized, as all of the Company&#8217;s employee stock options are fully
          vested as of December 31, 2005.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          December 15, 2005, the Board of Directors of the Company approved the
          acceleration of vesting for the unvested portion of all outstanding employee
          incentive stock options awarded from May 2001 to present under the Equity
          Plan,
          as amended. While the Company typically issues options that vest equally
          over
          four years, as a result of this vesting acceleration, stock options to
          purchase
          approximately 1.2 million shares of the Company&#8217;s common stock, of which
          approximately 600,000 are held by the Company&#8217;s executive officers and
          directors, became immediately exercisable. The exercise prices of the affected
          stock options range from $1.90 to $5.93 and the closing price of the Company&#8217;s
          common stock on December 15, 2005, was $1.75.</font><br></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-15</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          purpose of the accelerated vesting was to provide a non-cash benefit to
          the
          Company&#8217;s employees and to eliminate future compensation expense the Company
          would otherwise recognize in its statements of operations with respect
          to these
          accelerated options upon the adoption of SFAS 123R. The estimated future
          compensation expense associated with these accelerated options that would
          have
          been recognized in the Company&#8217;s statements of operations upon implementation of
          SFAS 123R is approximately $1.3 million. All option grants made on and
          after
          January 1, 2006 will be accounted for in accordance with SFAS 123R.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          December 2004, the FASB issued SFAS No. 153, Exchanges of Nonmonetary Assets
          -
          an amendment of APB Opinion No. 29 (SFAS 153). This Statement amends APB
          29 to
          eliminate the exception for nonmonetary exchanges of similar productive
          assets
          and replaces it with a general exception for exchanges of nonmonetary assets
          that do not have commercial substance. A nonmonetary exchange has commercial
          substance if the future cash flows of the entity are expected to change
          significantly as a result of the exchange. SFAS 153 is effective for nonmonetary
          asset exchanges occurring in fiscal periods beginning after June 15, 2005.
          The
          Company adopted this Statement effective July 1, 2005. The adoption of
          SFAS 153
          did not have a significant impact on our consolidated results of operations,
          financial position or cash flows</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          November 2004, the FASB issued SFAS No. 151, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Inventory
          Costs: an Amendment to ARB No. 43 </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SFAS
          151). This statement clarifies the types of costs that should be expensed
          rather
          than capitalized as inventory. This statement also clarifies the circumstances
          under which fixed overhead costs, such as abnormal amounts of idle facility
          expense, freight, handling costs and wasted material, associated with operating
          facilities involved in inventory processing should be expensed or capitalized.
          The provisions of this statement are effective for fiscal years beginning
          after
          June 15, 2005, although earlier adoption is permitted. The Company chose
          to
          early adopt the standard in 2005 and has recorded an adjustment for freight
          costs of approximately $68,000, which is included in cost of goods sold
          in the
          accompanying consolidated statement of operations for the year ended December
          31, 2005.&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3.
          Concentrations </strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company's credit risks consist primarily of uncollateralized accounts receivable
          from customers in the textile and other industries. The Company performs
          periodic credit evaluations of its customers' financial condition and provides
          allowances for doubtful accounts as required. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          2005,
          there were two customers that accounted for approximately 10% each of net
          sales.
          In 2004 there were no customers that accounted for greater than 10% of
          net
          sales. There were three customers in 2005 whose trade receivable balances
          equaled or exceeded 5% of total receivables, representing approximately
          16%, 7%,
          and 6%, respectively, of total accounts receivable. The loss of business
          from
          one or a combination of the Company&#8217;s significant customers could adversely
          affect its operations.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company conducts operations in Hong Kong, mainland China, Poland and The
          Netherlands through its foreign subsidiaries. The net assets (liabilities)
          of
          the Company as of December 31, 2005 that have foreign currency exchange
          exposure
          and the related foreign currencies are as follows: approximately $277,
          000 -
          Chinese Yuan, $317,000 - Hong Kong Dollar and $(3,906,000) - Euro, respectively.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company generates a large portion of its sales from customers that are
          located
          outside the United States. Sales from external customers attributed to
          foreign
          countries, defined as the location of the corporate office of those customers,
          totaled $14,459,260 and $14,475,823 for the years ended December 31, 2005
          and
          2004, respectively. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4.
          Fixed Assets</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
          December 31, 2005, fixed assets consisted of the following:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: black thin solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Estimated
                    Useful Life</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amount</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lab
                    and manufacturing equipment</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3-10</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,007,017</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furniture
                    and fixtures</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3-7</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">417,348</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Leasehold
                    improvements</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">163,871</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Land</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">Indefinite</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">935,245</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vehicles</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4-5</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">148,407</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,671,888</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Less
                    accumulated depreciation and amortization</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,938,959</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">&#160;</td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,732,929</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">&#160;</div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-16</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
          and amortization expense of fixed assets for the years ended December 31,
          2005
          and 2004 is approximately $535,000 and $497,000, respectively, of which
          approximately $85,000 and $56,000 is included in cost of goods sold and
          approximately $450,000 and $441,000 is included in selling and administrative
          costs, respectively, in the accompanying consolidated statements of
          operations.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>5.
          Accrued Expenses</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
          December 31, 2005, accrued expenses consisted of the following:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

              <tr>
                <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">&#160;</td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                    wages and benefits</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">516,096</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                    expenses relating to vendors and others</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">515,793</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fixed
                    assets</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">135,888</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                    and development</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">131,591</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                    taxes payable</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">101,569</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">&#160;</td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,400,937</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6.
          Short Term Notes Payable</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
          December 31, 2005, the Company had approximately $267,590 of short term
          notes
          payable, related to bank cash advances from customer Letters of Credit
          (&#8220;LOC&#8217;s&#8221;). The LOC&#8217;s were settled in January and February of 2006. The Company
          incurred charges of approximately $2,900 related to these advances and
          will
          incur interest expense at rates of between 6% and 6.25% per annum.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>7.
          Long-Term Liabilities</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Long-term
          liabilities consist of the following at December 31, 2005: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
          <div align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="85%">

                <tr>
                  <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes
                      payable to stockholders: </font></div>
                  </td>
                  <td width="2%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">&#160;</td>
                  <td width="2%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Loan
                      payable with a rate of 8% as of December 31, 2005 to Mark A.
                      Emalfarb
                      Trust </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Bridge
                      Loan), secured by all assets of the Company, in the original
                      principal
                      </font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;
                      amount of $3,000,000, less $815,000 pay down, principal and
                      accrued
                      interest due </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">January
                      1, 2007. Accrued interest of $239,941 included in principal
                      balance. Net
                      </font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;
                      of unamortized beneficial conversion feature of $115,272. </font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,309,669</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unsecured
                      convertible note payable to Mark A. Emalfarb Trust (Emalfarb
                      Trust Note)
                      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
                      a rate of 6%, in the original principal amount of $750,766,
                      dated May
                      2001, </font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;
                      principal and accrued interest due January 1, 2007. Conversion
                      price of
                      $3.33. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                      interest of $86,058 included in principal balance. Net of unamortized
                      </font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;
                      beneficial conversion feature of $135,684.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">701,140</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
                  <td width="2%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unsecured
                      convertible note payable to Francisco Trust u/a/d February
                      28, 1996 (the
                      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Francisco
                      Trust) (Francisco Trust Note) with a rate of 6%, in the original
                      principal
                      </font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;
                      amount of $664,839, dated May 2001, principal and accrued interest
                      due
                      January </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,
                      2007. Conversion price of $3.33. Accrued interest of $76,209
                      included in
                      </font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;
                      principal balance. Net of unamortized beneficial conversion
                      feature of
                      $120,180.</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">620,868
                      </font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">&#160;</td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,631,677</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subordinated
                      notes payable to the minority stockholders of a subsidiary,
                      interest at a
                      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">weighted
                      average rate of 6.0% as of December 31, 2005, no fixed prepayment
                      </font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;
                      terms, classified as current. </font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px">
                    </div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">171,986</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          May
          29, 2003, the Company obtained a $3.0 million revolving note from a group
          of
          stockholders, including the Chief Executive Officer, who contributed $2,185,000,
          and a group of other Dyadic-Florida stockholders who </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-17</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">contributed
          $815,000, bearing interest at 8% per annum, with all unpaid principal and
          interest originally due on January 2, 2004, and extended to January 1,
          2005 on
          February 13, 2004. Approximately $903,000 of the proceeds from the October
          2004
          Offering were used to pay off the $815,000 of principal and approximately
          $88,000 of accrued interest for the portion of the bridge loan contributed
          by
          the group of other Dyadic-Florida stockholders. The loan is collateralized
          by a
          security interest in all of the Company's assets. </font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>The
          Mark A. Emalfarb Trust and other Dyadic-Florida stockholders, collectively,
          were
          also granted warrants to purchase up to 1.5 million shares of the Company's
          common stock at the lesser of $4.50 per share or the Series A Preferred
          conversion price, expiring ten years from the date of grant (the Bridge
          Loan
          Warrant). In November 2004, the exercise price of the Bridge Loan Warrant
          was
          reduced to $3.33 and the maturity date was extended to January 1, 2007
          in
          connection with the Merger. As a result, approximately $343,000, representing
          the incremental fair value of the modified warrant as compared to the fair
          value
          of the original warrant immediately before the modification, will be amortized
          to interest expense through the new maturity date. The remaining unamortized
          portion of $115,272 is reflected as a reduction of notes payable to stockholders
          in the accompanying consolidated balance sheet as of December 31, 2005.
          Approximately $115,000 and $19,000 was amortized to interest expense during
          the
          years ended December 31, 2005 and 2004, respectively. Interest expense
          on the
          Bridge Loan excluding the amortization of the beneficial conversion feature,
          was
          approximately $194,000 and $234,000 for the years ended December 31, 2005
          and
          2004, respectively. </font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          connection with the Merger, the conversion prices of the convertible notes
          payable to the Mark A. Emalfarb Trust and the Francisco Trust were fixed
          at
          $3.33 and the maturity dates were extended to January 1, 2007. As a result
          of
          the modification of the conversion price, a beneficial conversion feature
          totaling approximately $554,000 was recorded in October 2004 and will be
          amortized to interest expense through the new maturity date. The remaining
          unamortized portion of $255,864 is reflected as a reduction of notes payable
          to
          stockholders in the accompanying consolidated balance sheet as of December
          31,
          2005. Approximately $256,000 and $43,000 was amortized to interest expense
          during the years ended December 31, 2005 and 2004, respectively. </font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
          expense on the convertible notes payable was approximately $95,000 and
          $71,000
          for the years ended December 31, 2005 and 2004, respectively. The notes
          payable
          and accrued interest due on the convertible notes payable are convertible
          in
          whole or part into shares of the Company's common stock at any time, at
          a
          conversion price of $3.33. </font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
          A.
          Emalfarb Trust and Francisco Trust are major stockholders of the Company
          and are
          trusts benefiting the Company's President and Chief Executive Officer,
          and the
          wife and children of Mark A. Emalfarb, respectively. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
          expense on the subordinated notes payable to the minority stockholders
          of a
          subsidiary was approximately $10,300 and $10,600 for the years ended December
          31, 2005 and 2004, respectively, and accrued interest of approximately
          $70,000
          is included in accrued interest payable to stockholders as of December
          31, 2005.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>8.
          Investment in Affiliate</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company owns 82.5% of a foreign textile, chemical and enzyme business.
          The
          Company can only vote 62.5% of the total outstanding shares of the subsidiary
          until it pays for additional voting rights. The Company has an option to
          purchase the remaining voting rights for a total of $405,000. This option
          can be
          exercised in $20,000 increments for each 1% of the additional voting rights.
          This option must be exercised once the affiliate reaches $900,000 in cumulative
          profit, as defined. Through December 31, 2005, the cumulative profit was
          approximately $556,000, and accordingly, the cumulative profit target has
          not
          yet been attained. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
          of
          the two other shareholders (the &#8220;minority interest&#8221;) of the subsidiary has
          agreed not to sell or otherwise transfer ownership in their remaining shares
          of
          the affiliate until October 2018. Until that time, the Company has a call
          option
          over any shares (presently 12.5% of the total outstanding shares) of the
          affiliate owned by the Sellers, exercisable after the above described $405,000
          of remaining consideration has been paid, to purchase any shares of the
          affiliate owned by the Sellers. The exercise price is based on the results
          of
          operations of the affiliate for the 12 months preceding the exercise date.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through
          December 31, 2005, neither the Company nor the minority interest have exercised
          any of the above described options. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>9.
          Stockholders&#8217; Equity (Deficit)</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Issuances
          of Common Stock</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          February 2005, the Company signed an agreement with an investor relations
          consulting firm for a one year term. In addition to monthly cash compensation
          and expense reimbursement, the Company issued 10,000 shares of common
</font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-18</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">stock
          as
          compensation for services to be rendered, which were valued at $39,000
          based on
          the fair market value of the Company&#8217;s common stock on the date of grant. An
          additional 10,000 shares of common stock were issued on May 25, 2005 in
          accordance with the agreement. The stock was valued at $27,500 based on
          the fair
          market value of the Company&#8217;s common stock on the date of grant. The common
          stock has not been registered under the Securities Act and may not be offered
          or
          sold absent registration under the Securities Act or an applicable exemption
          from such registration requirements. The stock certificate evidencing such
          securities bears a restricted legend.&#160;The agreement was terminated on
          August 25, 2005. The $39,000 and $27,500 are included in selling, general
          and
          administrative expenses for the year ended December 31, 2005. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          May
          2005, the Company issued 300,300 shares of common stock pursuant to a real
          estate purchase contract with F&amp;C Holdings, LLC (&#8220;Holdings&#8221;) dated July 31,
          2004 (the &#8220;Commercial Land Purchase And Sale Agreement&#8221;), in exchange for an
          undeveloped 1.13 acre parcel of land (the &#8220;Site&#8221;). The Company recorded the land
          at $861,861, based on the fair market value of the Company&#8217;s common stock on the
          date of closing. Additional costs incurred of $73,384 also included in
          the value
          of the land for a total value of $935,245. The Company formed Dyadic Real
          Estate
          Holdings, Inc., a Florida corporation and wholly owned subsidiary in May
          2005,
          to which it has assigned the Commercial Land Purchase and Sale Agreement
          and the
          Site.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Site,
          which is in a planned community known as "Abacoa" is located in the Town
          of
          Jupiter, Florida (the &#8220;Town&#8221;). The Company has obtained final approval from the
          Town of Jupiter to construct an approximately 40,000 square foot commercial
          office biotech research and development building.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Commercial Land Purchase and Sale Agreement obligates Dyadic to commence
          development of the Site within two (2) years following the closing date.
          During
          this two-year period, Dyadic is prohibited from re-transferring the Site
          to any
          other person other than (i) in connection with a sale of Dyadic, (ii) to
          an
          affiliate or (iii) with the approval of Dyadic's Board of Directors (a
          majority
          of its independent directors), to the Francisco Trust, the Mark A. Emalfarb
          Trust and/or any entity that is controlled, directly or indirectly, by
          Mark A.
          Emalfarb and/or his family members. It is not the Company&#8217;s intention to use its
          own funds to develop this property, therefore the Company is considering
          such
          options as a joint venture or other arrangement to accomplish the development
          of
          the Site. There can be no assurance, however, that any joint venture or
          other
          arrangements will occur within the prescribed timeframe. The Company is
          evaluating the advantages and disadvantages of Site development relative
          to
          their impact on Dyadic&#8217;s future office and research and development (&#8220;R&amp;D&#8221;)
          needs and cash resources, and is also considering other alternatives to
          optimize
          the asset value of the Site at this time. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
          after
          two years from the closing (in May 2007), Dyadic has not commenced development
          of the Site, then Holdings shall, in exchange for a reconveyance Deed,
          pay the
          "Reconveyance Purchase Price" equal to the greater of the following: (i)
          $1.0
          million or (ii) the "Market Value" of the shares of the Company's common
          stock,
          as defined, determined as of the date of the reconveyance notice from Holdings.
          The Reconveyance Purchase Price can be paid in all cash, or return of all
          the
          shares of the Company's common stock to the Company so long as the Market
          Value
          of the shares of the Company's common stock is greater than or equal to
          $1.0
          million, or by combination of shares of the Company's common stock and
          cash, as
          determined in the sole and absolute discretion of Holdings.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          December 2005, the Company issued 161,560 shares of common stock to TNO
          Quality
          of Life (formerly known as TNO Nutrition and Food Research Institute)(&#8220;TNO&#8221;), in
          consideration for: (i) the termination of the Cooperation Agreement entered
          into
          August 12, 2003 between the Company, its subsidiary, Dyadic NL and TNO;
          (ii) the
          conversion of TNO&#8217;s technology license into a paid-up, exclusive, worldwide
          license to use that TNO technology in the field of Fungal HTS systems;
          (iii)
          TNO&#8217;s conferral upon Dyadic NL of the benefit of certain other proprietary
          covenants of TNO, including a right of first offer on non-fungal HTS systems
          developed by TNO during the three-year period following the Effective Date;
          (iv)
          TNO&#8217;s agreement to perform research services for Dyadic NL in connection with
          its efforts to complete the development of a Fungal HTS System on a favored
          pricing basis as a &#8220;Preferred Supplier&#8221;; (v) the cancellation of TNO&#8217;s rights to
          receive stock options, royalties, profits, or gains, if any, realized from
          a
          successful commercialization of the fungal HTS; and (vi) the satisfaction
          of all
          indebtedness of Dyadic NL to TNO, including a trade payable for research
          services rendered by TNO to Dyadic NL in the approximate amount of $377,000.
          The
          term of the Termination Agreement is until the first to occur of (i) the
          mutual
          written agreement of the parties or (ii) the expiration of the later of
          18 years
          following the Effective Date or (ii) the date of the expiration of the
          last to
          expire of the patents licensed by TNO to Dyadic NL. The Termination Agreement
          is
          fully assignable by any of the parties, and contains the same arbitration
          provisions as were in the Cooperation Agreement. The stock was valued based
          on
          the fair market value of the Company&#8217;s common stock on the date of closing. A
          credit of approximately $76,000 resulting from this transaction is included
          in
          research and development expense in the accompanying consolidated statements
          of
          operations for the year ended December 31, 2005. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          December 2005, the Company issued 7,523 shares of common stock pursuant
          to a
          Development Agreement with a third party for services rendered to the Company
          for research and development projects. The term of the Development Agreement
          is
          a 26-month period ending September 30, 2006. In December 2004, the termination
          date was extended to December 31, 2006. The Company placed 300,300 shares
          of
          common stock in escrow which will be </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-19</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">issued
          to
          the third party as earned during the contractual period, at which time
          they will
          be deemed to be outstanding. Per the Development Agreement, the price used
          to
          calculate the number of shares issued was set at $3.33 per share, the value
          of
          the shares in the April 2004 Private Placement Memorandum. The fair value
          of the
          services rendered is then divided by the share price of $3.33 to determine
          the
          number of shares earned. The number of shares held in escrow as of December
          31,
          2005 is 292,777.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
          December 31, 2005 and 2004, 6,952,776 shares of common stock have been
          reserved
          for issuance under outstanding warrants. All of the warrants are fully
          vested
          and have expiration dates ranging from October 29, 2009 to May 29, 2013.
          Information concerning the Company&#8217;s warrant activity is as
          follows:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
          <div align="left">
            <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

                <tr>
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                      Average Exercise</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                      Average Exercise</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                </tr>
                <tr>
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                  <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Price</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Warrants</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                  <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Price</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding,
                      at the beginning of year</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>6,952,776</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>4.88</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,500,000</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.33</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                </tr>
                <tr bgcolor="white">
                  <td align="left" valign="bottom" width="43%" style="border-bottom: white solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Granted</font></div>
                  </td>
                  <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>--</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>--</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5,452,776</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">5.30</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
                </tr>
                <tr bgcolor="#e2eef6">
                  <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6 solid;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding,
                      at the end of year</font></div>
                  </td>
                  <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>6,952,776</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>4.88</strong></font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,952,776</font></div>
                  </td>
                  <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                  </td>
                  <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.88</font></div>
                  </td>
                  <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
          warrants granted in 2004 were in conjunction with the private offerings,
          except
          for 183,934 warrants related to the cancellation of indebtedness of the
          note
          payable to the Mark A. Emalfarb Trust.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>10.
          Redeemable Series A Convertible Preferred Stock</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          May
          25, 2001, pursuant to a Convertible Preferred Stock Purchase Agreement,
          the
          Company sold 2,222,222 shares of newly authorized and designated Redeemable
          Series A Convertible Preferred Stock (the Series A Preferred) to several
          unrelated investors for approximately $10,000,000. Holders of these shares
          maintained certain preferences in liquidation and had voting and other
          rights
          with respect to the composition of the Company's Board of Directors. An
          additional 888,888 shares of Series A Preferred were reserved for issuance
          as
          dividends. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          addition, holders of Series A Preferred were entitled to receive annual
          dividends at the rate of $0.36 per share (8%). No dividends were to be
          paid
          until the earlier of (i) two years, (ii) a Liquidation Event, as defined,
          (iii)
          the consummation of an underwritten Public Offering, as defined, (iv) the
          conversion into common stock of all of the Series A Preferred of the holder
          or
          (v) the date on which the preferred shares were acquired by the Company.
          Upon
          the consummation of a Qualified Public Offering, as defined, if prior to
          any of
          the events in items (i) through (v), all dividends accrued were to be
          extinguished. Dividends on the Series A Preferred may have been paid in
          cash or
          with Series A Preferred shares, at the Company's option. In addition, upon
          the
          consummation of a Qualified Public Offering, Series A Preferred shares
          would
          automatically convert into common stock on a one-for-one basis, subject
          to
          adjustment as defined in the Convertible Preferred Stock Purchase Agreement.
          In
          certain circumstance, holders also had the option to require the Company
          to
          redeem for cash any outstanding shares of Series A Preferred beginning
          in May
          2006. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Issuance
          costs were being accreted up to the Series A Preferred liquidation value,
          which
          was equal to the Original Purchase Price plus all accrued and unpaid dividends,
          and were being charged to accumulated deficit over a 60-month period. At
          the end
          of the 60-month period, if the Company had not completed a Qualified Public
          Offering or Merger, as defined, then each holder of Series A Preferred
          could
          exercise a Put Option, requiring the Company to purchase all Series A Preferred
          shares outstanding. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          October 24, 2003, the Company and the holders of the Series A Preferred
          entered
          into a Conditional Consent and Waiver to Placement of Securities of Dyadic
          International, Inc. (the Consent and Waiver) to induce the Company to continue
          its efforts to conclude a private placement which raises at least $2.0
          million
          for the Company, and to induce prospective investors in the Company to
          engage in
          negotiations with the Company pertaining to a private&#160; </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-20</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">placement.
            The Consent and Waiver was subject to certain conditions which included
            the
            receipt by the Company of proceeds from the sale of Series B Preferred
            of at
            least $2.0 million under terms substantially similar to the holdersof
            Series B
            preferred as the rights, privileges and preferences of the holders of
            Series A
            Preferred. The Consent and Waiver would have resulted in acceptance by
            Series A
            investors of common stock for dividends accrued to date; termination
            of the
            continuing accrual of dividends; subordination of Series A Preferred
            Stock to
            Series B Preferred Stock (and any accrued but unpaid Series B Preferred
            Stock
            dividends) in the event of a liquidation, dissolution or winding up of
            the
            Company; elimination of one of two seats on the Company's Board of Directors;
            and a one-time wavier of anti-dilution rights by Series A Preferred investors.
            </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
            February 2004, the holders of the Series A Preferred offered to sell
            at least
            80% of the outstanding shares of Series A Preferred to the Company, and
            in March
            2004, the Company and the holders of the Series A Preferred entered into
            a
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Redemption
            Agreement that resulted in the Company redeeming all of the outstanding
            shares
            of Series A Preferred, including accrued and unpaid dividends thereon,
            for a
            cash payment of $1.5 million in June 2004. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Changes
            in the Series A Preferred for the years ended December 31, 2005 and 2004
            are as
            follows: </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Series
                    A Preferred Stock, No Par Value</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                    of shares</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Amount</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                    at December 31, 2003 </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2,222,222
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$</font></td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,977,302
                    </font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accretion
                    of issuance costs </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,653</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                    dividends</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">350,684</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Redemption
                    - June 2004: </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Reversal
                    of unaccreted issuance costs </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">75,039</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Reversal
                    of accumulated dividends </font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2,419,678</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Share
                    redemption </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2,222,222</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(10,000,000</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                    at December 31, 2004 </font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Balance
                    at December 31, 2005 </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>11.
          Stock Options</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective
          May 2001, the Company adopted the Dyadic International, Inc. 2001 Equity
          Compensation Plan (the Equity Plan) under which 1,302,989 shares of common
          stock
          were reserved for issuance. In September 2004, by written consent, the
          Company's
          Board of Directors and stockholders approved an increase in the authorized
          number of shares of common stock under the Equity Plan from 1,302,989 to
          5,152,447. All employees, as well as members of the Company's Board of
          Directors
          and Key Advisors, as defined, are eligible to participate in the Equity
          Plan.
          Under the Equity Plan, the Company may issue incentive stock options and
          nonqualified stock options to purchase shares of common stock, or the Company
          may issue shares of common stock. Such shares, if issued, may be subject
          to
          restrictions, as disclosed in the Equity Plan. In addition to stock options
          and
          stock grants, the Equity Plan allows for the issuance of Performance Units
          to an
          employee or Key Advisor. Each Performance Unit represents the right to
          receive
          an amount, in cash or in the Company's common stock, as determined by a
          committee of the Company's Board of Directors (the Committee), based on
          the
          value of the Performance Unit, if established performance goals are met.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          January 2005, a second amendment to the Equity Plan was approved removing
          the
          grant limitation of 100,000 options, shares or Performance Units issued
          per
          individual per calendar year or Performance Period, respectively, as defined.
          The Committee determines the term and exercisability of options; however,
          the
          term is not to exceed 10 years. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          December 15, 2005, the Board of Directors of the Company approved the
          acceleration of vesting for the unvested portion of all outstanding employee
          incentive stock options awarded from May 2001 to present under the Equity
          Plan,
          as amended. While the Company typically issues options that vest equally
          over
          four years, as a result of this vesting acceleration, stock options to
          purchase
          approximately 1.2 million shares of the Company&#8217;s common stock, of which
          approximately 600,000 are held by the Company&#8217;s executive officers and
          directors, became immediately exercisable. The exercise prices of the affected
          stock options range from $1.90 to $5.93 and the closing price of the Company&#8217;s
          common stock on December 15, 2005, was $1.75.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          purpose of the accelerated vesting was to provide a non-cash benefit to
          the
          Company&#8217;s employees and to eliminate future compensation expense the Company
          would otherwise recognize in its statements of operations with </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-21</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">respect
          to these accelerated options upon the adoption of Financial Accounting
          Standards
          Board Statement of Financial Accounting Standards No. 123 (Revised 2004),
          Share-Based Payment (&#8220;SFAS 123R&#8221;). SFAS 123R is effective for the first fiscal
          year that begins after December 15, 2005, and will require that compensation
          expense associated with stock options be recognized in the statements of
          operations, rather than as footnote disclosure in the Company&#8217;s consolidated
          financial statements. The estimated future compensation expense associated
          with
          these accelerated options that would have been recognized in the Company&#8217;s
          statements of operations upon implementation of SFAS 123R is approximately
          $1.3
          million. All option grants made on and after January 1, 2006 will be accounted
          for in accordance with SFAS 123R.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
          summary
          of activity relating to grants under the Equity Plan and grants of 65,000
          options to nonemployees prior to the Equity Plan's adoption follows:
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="90%">

              <tr>
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                    Average Exercise Price</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                    Average Exercise Price</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding,
                    beginning of year</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>815,000</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>4.12</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">550,000</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.27</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Granted</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>980,889</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>3.26</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">341,500</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.58</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercised</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>--</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>--</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(75,000</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.83</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Forfeited</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(133,250</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>4.12</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,500</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.50</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Outstanding,
                    end of year</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>1,662,639</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>3.61</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">815,000</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.12</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exercisable,
                    end of year</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>1,494,089</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>3.66</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">494,050</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.30</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Options
                    available for future grant, end of year (1)</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>3,536,184</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4,383,823</font></div>
                </td>
                <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Available
                    options reduced by 18,624 shares of common stock issued to employees
                    in
                    2004 in lieu of cash bonus.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Summarized
          information with respect to options outstanding at December 31, 2005 is
          as
          follows:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

              <tr>
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="8" valign="bottom" width="32%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options
                    Outstanding</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="5" valign="bottom" width="21%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Options
                    Exercisable</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="43%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Range
                    of Exercise Price</strong></font></div>
                </td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                    Outstanding</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Remaining
                    Average Contractual Life (In Years)</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                    Average Exercise Price</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Number
                    Exercisable</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Weighted
                    Average Exercise Price</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$1.90
                    - $2.90</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">365,000</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.58</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.47</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">281,250</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">2.46</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.03
                    - 3.80</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">763,639</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.98</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.38</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">717,339</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.38</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.50
                    - 5.93</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">534,000</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1.94</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.72</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">495,500</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">4.73</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Totals</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,662,639</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.46</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.61</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,494,089</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3.66</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
          2001, options granted to employees prior to the Equity Plan's adoption
          were
          cancelled and replaced by options to purchase shares of the Company's common
          stock from the Francisco Trust (see Note 7). Authoritative accounting literature
          requires that such options be treated as though they were options granted
          by the
          Company. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accordingly,
          such options are reflected in the above tables and concurrent with the
          cancellation and reissuance of such options by the Francisco Trust, a new
          measurement date has been established in which to compute compensation
          expense
          relating only to those options replaced, measured as the difference between
          the
          fair market value of the options granted by the Francisco Trust and the
          exercise
          price of those options. A summary of such transactions follows: </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
                    a 1996 employment agreement with an officer of the Company, 200,000
                    options to purchase shares of the Company's Common Stock were
                    granted. In
                    May 2001, such options were cancelled and replaced by options
                    granted by
                    the Francisco Trust at the same exercise price, but below the
                    then current
                    fair market value. The options were fully vested and the transaction
                    resulted in $320,000 of compensation expense, which was included
                    in the
                    December 31, 2001 consolidated statement of operations. In December
                    2002,
                    the officer exercised this stock option and paid the exercise
                    price of
                    $400,000 to the Francisco Trust in the form of&#160;
                    </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-22</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
          <div>
            <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="left" style="width: 9pt;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                    </font></td>
                  <td align="left">
                    <div><font size="2">a&#160;$50,000 cash payment and a $350,000 non-recourse
                      note, bearing interest at 6% per annum, calculated and payable
                      on December
                      31 of each year, principal of $100,000 payable before December
                      31, 2003,
                      and principal of $250,000 payable before December 31, 2004,
                      pre-payable as
                      to all or any portion of the balance at any time prior to the
                      due date.
                      The issuance of the note extended the original option term.
                      During the
                      year ended December 31, 2003, the $100,000 scheduled principal
                      payment,
                      including accrued interest, was made. The principal balance
                      is secured
                      only by the shares of common stock sold to the officer, and
                      accrued
                      interest is secured by all the officer's personal assets. The
                      remeasurement of compensation cost at the time of the exercise
                      of this
                      stock option resulted in no additional compensation
                      expense.</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div>&#160;</div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
            November 2004, the agreement was amended to extend the due date of the
            $250,000
            principal payment to June 30, 2005 and to require all unpaid accrued
            interest to
            be paid in full at that time. A payment of $40,000 was made to the Francisco
            Trust, per the terms of the amendment; $15,000 for payment of accrued
            interest
            through December 31, 2004 and $25,000 in consideration for the amendment.
            </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
            June
            2005, the agreement was amended a second time to extend the due date
            of the
            $250,000 principal payment from June 30, 2005 to December 22, 2005 and
            to
            increase the interest rate from 6% per annum to 7% per annum, effective
            July 1,
            2005. The principal and accrued interest were not paid by the due date,
            and
            accordingly, the Francisco Trust exercised its right to assign the shares
            of
            common stock back from the former officer to the Francisco Trust. The
            transfer
            of the shares occurred in February 2006.</font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
            <table cellpadding="0" cellspacing="0" id="list" width="100%">

                <tr valign="top" style="line-height: 1.25;">
                  <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                  <td>
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
                      1999, the Company granted an option to an employee to purchase
                      50,000
                      shares of the Company's common stock, with exercise prices
                      between $2.00
                      and $3.00 per share, dependent upon whether certain production
                      levels were
                      attained. Options to purchase this stock were to vest on the
                      later of
                      December 31, 2002, or on the date that a production goal was
                      met. This
                      option was to be exercised within one year from the latter
                      of this vesting
                      date or the date the Company completed an underwritten pubic
                      offering.
                      Excess, if any, of fair market value over the exercise price
                      on the
                      vesting date would be recorded as compensation expense. In
                      May 2001, these
                      stock options were cancelled and replaced by stock options
                      granted by the
                      Francisco Trust. The options granted in 2001 carried the same
                      provisions
                      as the options granted in 1999. In 2001, the Company determined
                      that the
                      conditions required for use of a $2.00 per share exercise price
                      were met,
                      and the Company recognized $80,000 of compensation expense
                      at that time.
                      On November 3, 2004, the option to purchase shares from the
                      Francisco
                      Trust was exercised in its entirety by executing and delivering
                      to the
                      Francisco Trust an exercise agreement under which the exercise
                      price,
                      together with interest at a rate of 2.37% per annum, was to
                      be paid on the
                      first to occur of October 31, 2005 or 60 days following the
                      date of
                      termination of employment with the
                      Company.</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          October 31, 2005, the agreement was amended to extend the due date of the
          principal payment to October 31, 2006 or 60 days following the date of
          termination of employment with the Company and to require all unpaid accrued
          interest to be paid in full at that time. The interest rate was increased
          from
          2.37% per annum to 4% per annum, beginning November 1, 2005.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
                    May 2000, the Company entered into a two-year employment agreement
                    with
                    its Senior Vice President, Marketing - Biotechnology Systems,
                    granting
                    options to purchase 25,000 shares of the Company's common stock
                    for 110%
                    of the initial public offering price in the event of an initial
                    public
                    offering. In May 2001, these stock options were cancelled and
                    replaced by
                    stock options granted by the</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
          <table cellpadding="0" cellspacing="0" id="list" width="100%">

              <tr valign="top" style="line-height: 1.25;">
                <td align="right" style="width: 72pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Francisco
                    Trust at a fixed exercise price of $4.50 per share, which was
                    not below
                    the estimated fair market value of the options on the date of
                    grant.
                    Accordingly, no compensation expense has been recorded relating
                    to this
                    grant. On November 3, 2004, the option to purchase shares from
                    the
                    Francisco Trust was exercised in its entirety by executing and
                    delivering
                    to the Francisco Trust an exercise agreement under which the
                    exercise
                    price, together with interest at a rate of 2.37% per annum, was
                    to be paid
                    on the first to occur of October 31, 2005 or 60 days following
                    the date of
                    termination of employment with the Company.
</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
          October 31, 2005, the agreement was amended to extend the due date of the
          principal payment to October 31, 2006 or 60 days following the date of
          termination of employment with the Company and to require all unpaid accrued
          interest to be paid in full at that time. The interest rate was increased
          from
          2.37% per annum to 4% per annum, beginning November 1, 2005.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          2005
          and 2004, the Company issued options to other nonemployee consultants and
          advisors for services. In accordance with SFAS No. 123, such options are
          recorded at fair value, using the Black-Scholes option pricing model with
          the
          following assumptions: risk free interest rate of 3.15% to 3.82 % in 2004,
          and
          4.05 % in 2005, dividend yield of 0%, expected volatility of 50% and an
          expected
          life of five years (the maximum contractual term). Compensation cost related
          to
          these options is reflected in the accompanying consolidated financial statements
          as follows: </font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-23</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
              <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

                  <tr>
                    <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                    </td>
                    <td width="2%" style="border-bottom: #ffffff thin solid;"><strong>&#160;</strong></td>
                    <td colspan="5" valign="bottom" width="26%" style="border-bottom: black thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                        Ended December 31,</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;"><strong>&#160;</strong></td>
                  </tr>
                  <tr>
                    <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;"><strong>&#160;</strong></td>
                    <td width="2%" style="border-bottom: #ffffff thin solid;"><strong>&#160;</strong></td>
                    <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;"><strong>&#160;</strong></td>
                    <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;"><strong>&#160;</strong></td>
                  </tr>
                  <tr bgcolor="#e2eef6">
                    <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>General
                        and administrative</strong></font></div>
                    </td>
                    <td width="2%" style="border-bottom: #e2eef6;"><strong>&#160;</strong></td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                    </td>
                    <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>57,566</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;"><strong>&#160;</strong></td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                    </td>
                    <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>284,651</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;"><strong>&#160;</strong></td>
                  </tr>
                  <tr bgcolor="white">
                    <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Research
                        and development</strong></font></div>
                    </td>
                    <td width="2%" style="border-bottom: white;"><strong>&#160;</strong></td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><strong>&#160;</strong></td>
                    <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>19,107</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="2%" style="border-bottom: white;"><strong>&#160;</strong></td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><strong>&#160;</strong></td>
                    <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>33,834</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: white;"><strong>&#160;</strong></td>
                  </tr>
                  <tr bgcolor="#e2eef6">
                    <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;"><strong>&#160;</strong></td>
                    <td width="2%" style="border-bottom: #e2eef6 thin solid;"><strong>&#160;</strong></td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                    </td>
                    <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>76,673</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 solid;"><strong>&#160;</strong></td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                    </td>
                    <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>318,485</strong></font></div>
                    </td>
                    <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;"><strong>&#160;</strong></td>
                  </tr>

              </table>
            </div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>12.
              Commitments and Contingencies</strong></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Employment
              Agreements</strong></font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
              2001,
              the Company entered into an employment agreement with Mark A. Emalfarb,
              the
              Company's President and Chief Executive Officer. The agreement commenced
              on
              April 1, 2001, and terminated on March 30, 2004, but renewed for an
              additional
              two years because neither party gave written notice 60 days prior to
              March 30,
              2003. In March 2006, the agreement was amended (the &#8220;First Amendment&#8221;) to extend
              the term of Mr. Emalfarb&#8217;s employment by one year, from March 30, 2006 to March
              30, 2007, and to add an automatic renewal provision for succeeding
              one year
              terms unless either party gives the other a notice of non-renewal not
              less than
              90 days prior to the expiration of the then term. The First Amendment
              makes no
              other changes to Mr. Emalfarb&#8217;s employment agreement. The agreement provides for
              an annual base salary of $300,000 and the payment of an annual bonus
              (based on
              goals and objectives to be agreed upon by the Board and Mr. Emalfarb)
              for each
              fiscal year or portion of a fiscal year, including but not limited
              to research
              and other business milestones, sales, profitability or cash flow goals.
              The
              Company agrees to cause the Committee to grant Mr. Emalfarb options
              to the same
              extent as the Committee grants to other senior executives of the Company
              and on
              the same terms and conditions. </font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If,
              during the employment period, the Company terminates Mr. Emalfarb's
              employment,
              other than for cause or disability or by reason of Mr. Emalfarb's death
              or by
              reason of the failure of the Company to renew the employment </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">agreement,
              or if Mr. Emalfarb terminates employment for good reason, the Company
              shall
              provide Mr. Emalfarb with annual base salary and all benefits received
              by Mr.
              Emalfarb as of the date of termination for a period of one year from
              the date of
              termination. </font></div>
          </div>
        </div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          March
          2005, the Company entered into employment agreements with two of its executive
          officers, and in connection therewith, promoted them to new offices: Mr.
          Kent M.
          Sproat, formerly Vice President, Manufacturing, was promoted to Executive
          Vice
          President, Enzyme Business and Mr. Ratnesh (Ray) Chandra, formerly Vice
          President, Marketing - BioSciences, was promoted to Senior Vice President,
          Marketing - Biotechnology Systems. Mr. Sproat was also promoted to the
          office of
          Executive Vice President of the Company&#8217;s operating subsidiary, Dyadic
          International (USA), Inc., a Florida corporation (&#8220;Dyadic-Florida&#8221;). The annual
          base compensation of Mr. Sproat and Mr. Chandra is $190,000 and $170,250,
          respectively. Mr. Sproat&#8217;s and Mr. Chandra&#8217;s employment agreements include
          provisions that might entitle them to extended severance benefits following
          the
          occurrence of a &#8220;Change of Control,&#8221; as defined, of either the Company or its
          BioSciences Business, in the case of Mr. Chandra, and following the occurrence
          of a &#8220;Change of Control&#8221; of either the Company or its Enzymes Business, in the
          case of Mr. Sproat. Under both agreements, upon a termination of the executive&#8217;s
          employment by the Company or its successor-in-interest other than &#8220;for Cause,&#8221;
or a termination of his employment by the executive which is a &#8220;Constructive
          Termination of Employment Without Cause,&#8221; as defined, within 12 months following
          the occurrence of a Change of Control, he will become entitled to a severance
          benefit of monthly installments in the amount of 1/12th of his then annual
          base
          compensation for 18 months.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          addition, the Company entered into five other employment agreements with
          officers and key employees during 2005. The initial term of employment
          under all
          seven employment agreements ends on December 31, 2007, with automatic one-year
          renewals unless either party furnishes the other a notice of non-renewal
          not
          less than 90 days prior to the expiration of the then term. Each of them
          is
          eligible to earn a bonus each year of up to 40% of his annual base compensation
          based upon a bonus plan to be adopted and maintained by the Compensation
          Committee of the Board of Directors of the Company (the &#8220;Compensation
          Committee&#8221;) for such year. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
          employment agreement is terminable on account of the executive&#8217;s death or
          disability, or by the Company without cause or &#8220;for Cause. If the executive&#8217;s
          employment is terminated by the Company other than &#8220;for Cause,&#8221; upon the
          condition that he furnish the Company with a full general release, he is
          entitled to receive a severance benefit of monthly installments in the
          amount of
          1/12th of his then annual base compensation for a period of 6 months for
          a
          combined potential severance benefit of up to approximately $593,000.
</font></div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-24</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Employee
            Benefit Plan</strong></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            Company has a 401(k) defined contribution plan in which all employees
            are
            eligible to participate. Participants may elect to defer up to 80% of
            compensation up to a maximum amount determined annually pursuant to Internal
            Revenue Service regulations. The Company elected not to provide for matching
            employer contributions for the years ended December 31, 2005 and 2004.
            </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Manufacturing
            Agreements</strong></font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company entered into an agreement, which is cancellable under certain
          circumstances&#160;(the Manufacturing Agreement) in October 1999, under which a
          foreign manufacturer conducts contract production of certain products for
          the
          Company at its facilities. The Company provides the foreign manufacturer
          with
          all technical and technology information, instructions and procedures available
          to the Company and necessary for the production, packing and testing of
          the
          product. The</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          Manufacturing Agreement requires the payment of monthly charges based on
          capacity usage, ultrafiltration costs, disposal costs, raw material costs
          and
          reimbursement of plant modification costs. In July 2001, the Company agreed
          to
          pay a total of approximately $1.6 million in plant modification costs in
          monthly
          installments of $25,197, plus LIBOR (2.4% at December 31, 2005), over a
          seven-year period. Payments are denominated in Euros. Remaining minimum
          payments
          under the Manufacturing Agreement, including interest at the December 31,
          2005
          LIBOR rate, are as follows: </font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="60%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Year
                  ending December 31, </font></div>
              </td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2006</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">318,466</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2007</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">309,875</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2008</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">101,382</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">&#160;</td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">729,723</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Manufacturing Agreement is being accounted for as a service agreement.
        Accordingly, annual payments are reflected as a component of cost of goods
        sold
        in the annual period in which each payment is due. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company made a request of its product manufacturer to expand production capacity
        in order to produce higher volumes of existing and new products. The Company
        concluded an agreement in December 2004 with the manufacturer to provide
        an
        additional 50 cubic meters of fermentation capacity and associated recovery
        capacity with the majority of the capital necessary for this expansion to
        be
        provided by the manufacturer. This expansion has been completed and will
        be
        fully operational in 2006. Dyadic has committed to direct payment for certain
        removable equipment for this expansion of approximately $133,000. Should
        the
        Company require additional capacity in the future, and the current contract
        manufacturer cannot obtain the funding necessary to provide the needed capital
        to honor its obligation to the Company under the Manufacturing Agreement,
        this
        will negatively affect the Company's ability to meet its production requirements
        and therefore impact its financial position, results of operations and cash
        flows. In such an event, the Company would have to locate additional capacity
        with another contract manufacturing facility. The Company believes it has
        these
        resources available if needed, to support any additional production
        needs.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Agreement
        to Conduct Research and Development Activities on Behalf of the
        Company</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company has entered into several agreements with independent third parties
        to
        conduct research and development activities on behalf of the Company. Except
        as
        described below, none of these agreements are for minimum periods in excess
        of
        one year, and are generally cancelable by the Company with advance written
        notice. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        July
        30, 2004, the Company entered into a Development Agreement with a third party
        to
        assist the Company in various research and development projects over the
        26-month period ending September 30, 2006. In December 2004, the termination
        date was extended to December 31, 2006. Under the Development Agreement,
        the
        Company is required to utilize, and the third party has committed to provide,
        research and development assistance valued at approximately $1.25 million.
        The
        consideration for these services includes 300,300 shares of the Company's
        common
        stock, valued at $1.0 million, and cash, $250,000 of which was paid upon
        execution of the Development Agreement. Pursuant to the Development Agreement,
        the 300,300 shares of common stock were placed in escrow and will be issued
        to
        the third party as earned during the contractual period, at which time they
        will
        be outstanding. The Development Agreement imposes cash penalties upon the
        third
        party in the event of nonperformance under the Development Agreement, beyond
        the
        forfeiture of any shares of common stock placed in escrow. At December 31,
        2005,
        7,523 shares of common stock were earned and are outstanding for services
        rendered under this agreement (see Note 9) and the $250,000 cash prepayment
        was
        expensed in full both of which are included in research and development expense,
        in the accompanying consolidated statements of operations for the year ended
        December 31, 2005. </font><br></div>
      <div id="PGBRK" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-25</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Litigation,
          Claims and Assessments</strong></font></div>
      </div>
      <div>
        <div>
          <div>&#160;</div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
            the
            opinion of management, there are no known pending legal proceedings that
            would
            have a material effect on the Company's financial position, results of
            operations or cash flows. </font></div>
          <div>&#160;</div>
          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Leases
            </strong></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company&#8217;s corporate headquarters are located in Jupiter, Florida, in
          approximately 5,700 square feet of space occupied under a lease with a
          monthly
          rental rate of approximately $8,700 that expires on December 31, 2007.
          The lease
          has an escalation clause, an option to extend the lease for two years,
          and
          includes the rental of additional space beginning in April 2006 for a total
          of
          8,500 square feet at a monthly rate of $15,200. The Company leases a lab
          facility in Jupiter, Florida, with a monthly rental rate of $1,500 that
          expires
          on June 30, 2006. The Company also leases a 3,150 square foot lab facility
          and a
          storage building in Greensboro, North Carolina, with a monthly rental rate
          of
          $1,955 which expires on December 31, 2006.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Asian
          subsidiary leases its office premises and staff accommodations under nine
          operating lease arrangements for </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">terms
          ranging from two to ten years.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company's Asian subsidiary leases a facility in Hong Kong from a minority
          stockholder of the subsidiary. Rent expense under this arrangement was
          approximately $25,000 and $23,000 for the years ended December 31, 2005
          and
          2004, respectively. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dyadic
          Nederland B.V. leases office and lab space with a monthly rental rate of
          approximately $4,000, which expires on December 31, 2006 and can be renewed
          for
          one year periods through December 31, 2007.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Future
          minimum lease commitments due for facilities and equipment leases under
          noncancellable operating leases at December 31, 2005 are as follows:
</font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="60%">

            <tr>
              <td align="left" valign="bottom" width="85%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Operating
                  Leases</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2006</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: 3.75pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: 3.75pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">368,500</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2007</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">263,058</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2008</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">71,867</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2009
                  </font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">71,867</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2010
                  and thereafter</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">251,420</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  minimum lease payments</font></div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">1,026,712</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rent
        expense under all operating leases for the years ended December 31, 2005
        and
        2004 totaled approximately $316,000 and $252,000, respectively, of which
        approximately $81,000 and $56,000 is included in cost of goods sold and
        approximately $235,000 and $196,000 is included in general and administrative
        costs, respectively, in the accompanying consolidated statements of
        operations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Protection
        of Proprietary Technologies</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's success is dependent in part on its ability to obtain patents and
        maintain adequate protection of other intellectual property for the Company's
        technologies and products in the United States and other countries. If the
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Company
        does not adequately protect its intellectual property, competitors may be
        able
        to practice its technologies and erode its competitive advantage. The laws
        of
        some foreign countries do not protect proprietary rights to the same extent
        as
        the laws of the United States, and many companies have encountered significant
        problems in protecting their proprietary rights in these foreign countries.
        These problems can be caused by, for example, a lack of rules and methods
        for
        defending intellectual property rights. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company holds three issued United States patents and twenty-four issued
        international patents, including claims that cover the C1 Expression Technology
        (a host organism that performs protein expression and related services for
        laboratory research, clinical trials and commercial production) and 3 PCT
        Publications. The Company has 51 United States and international patent
        applications filed. The patent positions of biopharmaceutical and biotechnology
        companies, including the Company's patent position are generally uncertain
        and
        involve complex legal and factual questions. The Company will be able to
        protect
        its proprietary rights from unauthorized use by third parties only to the
        extent
        that its proprietary technologies are covered by valid and enforceable patents
        or are effectively maintained as trade secrets. The Company intends to apply
        for
        patents covering both its technologies and products as it deems appropriate.
        However, existing and future patent applications may be challenged and may
        not
        result in issued patents. The Company's existing patents and any future patents
        it obtains may not be sufficiently broad to prevent </font></div>
      <div id="PGBRK" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-26</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">others
              from practicing the Company's technologies or from developing competing
              products. Furthermore, others may independently develop similar or
              alternative
              technologies or design around the Company's patented technologies.
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
              addition, others may challenge or invalidate the Company's patents,
              or its
              patents may fail to provide the Company with any competitive advantages.
              </font></div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            Company relies upon trade secret protection for its confidential and
            proprietary
            information. The Company has taken security measures to protect its proprietary
            information. These measures may not provide adequate protection for the
            Company's trade secrets or other proprietary information. The Company
            seeks to
            protect its proprietary information by entering into confidentiality
            agreements
            with employees, collaborators and consultants. Nevertheless, employees,
            collaborators or consultants may still disclose the Company's proprietary
            information, and the Company may not be able to meaningfully protect
            its trade
            secrets. In addition, others may independently develop substantially
            equivalent
            proprietary information or techniques or otherwise gain access to the
            Company's
            trade secrets. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            inability of the Company to adequately protect its proprietary technologies
            could have a material adverse impact on the Company's business, operating
            results and financial condition. </font></div>
        </div>
        <div>&#160;</div>
        <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Litigation,
          Other Proceedings or Third Party Claims of Intellectual Property
          Infringement</strong></font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's commercial success is dependent in part on neither infringing patents
        and proprietary rights of third parties, nor breaching any licenses that
        the
        Company has entered into with regard to its technologies and products. Others
        have filed, and in the future are likely to file, patent applications covering
        genes or gene fragments that the Company may wish to utilize with the Company's
        C1 Host Technology,&#160;its C1 Expression System, its C1 Screening
        System&#160;or products or&#160;systems&#160;that are similar to products
        or&#160;systems&#160; developed with the use of the Company's C1 Host
        Technology. If these patent applications result in issued patents and the
        Company wishes to use the claimed technology, the Company would need to obtain
        a
        license from the third party. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Third
        parties may assert that the Company is employing their proprietary technology
        without authorization. In addition, third parties may obtain patents in the
        future and claim that the Company's technologies infringes these patents.
        The
        Company could incur substantial costs and diversion of management and technical
        personnel in defending itself against any of these claims or enforcing its
        patents or other intellectual property rights against others. Furthermore,
        parties making claims against the Company may be able to obtain injunctive
        or
        other equitable relief which could effectively block the Company's ability
        to
        further develop, commercialize and sell products, and could result in the
        award
        of substantial damages against the Company. If a claim of infringement against
        the Company is successful, the Company may be required to pay damages and
        obtain
        one or more licenses from third parties. The Company may not be able to obtain
        these licenses at a reasonable cost, if at all. In that event, the Company
        could
        encounter delays in product commercialization while it attempts to develop
        alternative methods or products. Defense of any lawsuit or failure to obtain
        any
        of these licenses could prevent the Company from commercializing available
        products. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further,
        the taxonomic classification of the Company's C host organism was originally
        determined using classical morphological methods. More modern taxonomic
        classification methods indicate that the Company's C1 host organism will
        be
        reclassified as a different genus and species. The Company anticipates that
        with
        the genomic sequence and after the completion of the expected annotation
        of the
        C1 genome, it will be in a better position to determine the genus and species
        of
        the C1 Host organism. Some of the possible species that the C1 host could
        be
        reclassified as could be the subject of patent rights owned by others. The
        Company believes, based on its evaluation of the relevant field of science
        and
        discussions with our consulting professionals that any such patent rights
        would
        be invalid, and were litigation over the issue to ensue, the Company believes
        it
        should prevail. If the Company did not prevail to settle any such litigation
        or
        pre-litigation claims, the Company could be required to enter into a
        cross-licensing arrangement, pay royalties or be forced to stop
        commercialization of some of its activities. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company does not fully monitor the public disclosures of other companies
        operating in its industry regarding their technological development efforts.
        If
        the Company did evaluate the public disclosures of these companies in connection
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
        their technological development efforts and determined that they violated
        the
        Company's intellectual property or other rights, the Company would anticipate
        taking appropriate action, which could include litigation. However, any action
        the Company takes could result in substantial costs and diversion of management
        and technical personnel. Furthermore, the outcome of any action taken by
        the
        Company to protect its rights may not be resolved in the Company's favor
        or may
        not be resolved for a lengthy period of time. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Real
        Estate Purchase Contract</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        May
        2005, the Company purchased an undeveloped 1.13 acre parcel of land (the
&#8220;Site&#8221;)
        pursuant to a real estate purchase contract with F&amp;C Holdings, LLC
        (&#8220;Holdings&#8221;) dated July 31, 2004 (the &#8220;Commercial Land Purchase And Sale
        Agreement&#8221;) (see Note 9). The Company formed Dyadic Real Estate Holdings, Inc.,
        a Florida corporation and wholly owned subsidiary in May 2005, to which it
        has
        assigned the Commercial Land Purchase and Sale Agreement and the Site. The
        Site,
        which is in a planned community known as "Abacoa" is located in the Town
        of
        Jupiter, Florida (the &#8220;Town&#8221;). The Company has obtained final approval from the
        Town of Jupiter to construct approximately</font><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>F-27</strong></font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
              of
              Contents</a></em></font></div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;a
              40,000 square foot commercial office biotech research and development
              building.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
            Commercial Land Purchase and Sale Agreement obligates Dyadic to commence
            development of the Site within two (2) years following the closing date.
            During
            this two-year period, Dyadic is prohibited from re-transferring the Site
            to any
            other person other than (i) in connection with a sale of Dyadic, (ii)
            to an
            affiliate or (iii) with the approval of Dyadic's Board of Directors (a
            majority
            of its independent directors), to the Francisco Trust, the Mark A. Emalfarb
            Trust and/or any entity that is controlled, directly or indirectly, by
            Mark A.
            Emalfarb and/or his family members. It is not the Company&#8217;s intention to use its
            own funds to develop this property, therefore the Company is considering
            such
            options as a joint venture or other arrangement to accomplish the development
            of
            the Site. There can be no assurance, however, that any joint venture
            or other
            arrangements will occur within the prescribed timeframe. </font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
            after
            two years from the closing (in May 2007), Dyadic has not commenced development
            of the Site, then Holdings shall, in exchange for a reconveyance Deed,
            pay the
            "Reconveyance Purchase Price" equal to the greater of the following:
            (i) $1.0
            million or (ii) the "Market Value" of the shares of the Company's common
            stock,
            as defined, determined as of the date of the reconveyance notice from
            Holdings.
            The Reconveyance Purchase Price can be paid in all cash, or return of
            all the
            shares of the Company's common stock to the Company so long as the Market
            Value
            of the shares of the Company's common stock is greater than or equal
            to $1.0
            million, or by combination of shares of the Company's common stock and
            cash, as
            determined in the sole and absolute discretion of Holdings. The Company
            is
            currently assessing its alternatives for development of the Site, and
            continues
            to expect to commence development by December 31, 2006.</font></div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>13.
          Segment Data Information</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Operating
          segments are defined as components of an enterprise engaging in business
          activities about which separate financial information is available that
          is
          evaluated regularly by the chief operating decision maker or group in deciding
          how to allocate resources and in assessing performance. Utilizing these
          criteria, the Company has identified its reportable segments based on the
          geographical markets they serve, which is consistent with how the Company
          operates and reports internally. </font></div>
        <div>&#160;</div>
        <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company has three reportable segments: U.S. operations, Asian operations
          and
          Netherlands operations. The U.S. reportable segment includes a subsidiary
          in
          Poland that is considered auxiliary and integral to the U.S. operations.
          The
          accounting policies for the segments are the same as those described in
          the
          summary of significant accounting policies. The Company accounts for
          intersegment sales as if the sales were to third parties, that is, at current
          market prices. The U. S. operating segment is a developer, manufacturer
          and
          distributor of enzyme products, proteins, peptides and other bio-molecules
          derived from genes, and a collaborative licensor of enabling proprietary
          technology for the development and manufacturing of biological products
          and use
          in research and development. The Asian operating segment is engaged in
          the
          manufacturing and distribution of chemical and enzyme products to the textile
          and pulp and paper industries. The Netherlands operating segment is also
          a
          developer of enzyme products, proteins, peptides and other bio-molecules
          derived
          from genes and to date has invested solely in research and development
          activities. In 2005, one customer in the US operating segment and one customer
          in the Asian operating segment accounted for approximately 10% each of
          net
          sales. In 2004 there were no customers that accounted for greater than
          10% of
          net sales.</font></div>
        <div>&#160;</div>
        <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          following table summarizes the Company's segment and geographical information:
          </font></div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="90%">

            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="14" valign="bottom" width="54%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31, 2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>U.S.
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Asian
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Netherlands
                  Operating Segment</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Eliminations</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Totals</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                  Sales:</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">External
                  customers</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,697,517</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,185,452</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,882,969</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intersegment</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">883,054</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(883,054</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  net sales</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,580,571</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,185,452</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(883,054</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">15,882,969</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">&#160;</td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Loss)
                  Income from operations</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,167,942</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">141,866</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,037,308</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">77,489</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(9,985,895</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment
                  income</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">291,407</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">742</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">20</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(42,889</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">249,280</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
                  expense (a)</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(511,793</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(65,603</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(176,030</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">42,889</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(710,537</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
                  and amortization</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">154,177</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">61,917</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">386,636</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">602,730</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Capital
                  expenditures</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">216,187</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">169,549</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">27,552</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">413,288</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                  assets at December 31, 2005</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">22,886,076</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,406,963</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">73,768</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(2,613,743</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">23,753,064</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="43%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="9%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>

        </table>
      </div>
      <div id="PGBRK" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-28</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="90%">

              <tr>
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="14" valign="bottom" width="54%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                    Ended December 31, 2004</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr>
                <td align="left" valign="bottom" width="43%" style="border-bottom: #ffffff solid;">&#160;</td>
                <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>U.S.
                    Operating Segment</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Asian
                    Operating Segment</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Netherlands
                    Operating Segment</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Eliminations</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
                <td colspan="2" valign="bottom" width="10%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Totals</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    Sales:</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">External
                    customers</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">10,531,556</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,209,291</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
                </td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,740,847</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intersegment</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">790,096</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(790,096</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                    net sales</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">11,321,652</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">6,209,291</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(790,096</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,740,847</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">&#160;</td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Loss)
                    Income from operations</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(4,695,798</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">146,245</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(961,463</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(29,624</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5,540,640</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment
                    income</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">112,892</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">228</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">63</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(44,172</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">69,011</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Interest
                    expense (a)</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(578,287</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(63,786</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">44,172</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(597,906</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation
                    and amortization</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">171,502</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">43,064</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">372,122</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">586,688</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="43%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Capital
                    expenditures</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">16,750</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">84,629</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">101,379</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="43%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                    assets at December 31, 2004</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">31,068,608</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">3,074,829</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">380,573</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,801,584</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="9%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">32,722,426</font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)
          Interest expense relating to the purchase by the U.S. operating segment
          of
          manufacturing equipment is allocated to the Netherlands operating segment.
          </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>14.
          Income Taxes</strong></font></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
        provision for United States income taxes has been recognized for the years
        ended
        December 31, 2005 and 2004 as the Company has incurred operating losses and
        has
        established a full valuation allowance. The Company's operations in Poland,
        Hong
        Kong and The Netherlands are subject to income taxes in these jurisdictions.
        The
        provisions for income taxes consist of the following: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: medium none;">&#160;</td>
              <td width="2%" style="border-bottom: medium none;">&#160;</td>
              <td colspan="5" valign="bottom" width="26%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Year
                  Ended December 31</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2004</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current:</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S.</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>--</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>64,228</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,714</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred:</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U.S.</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">--</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">&#160;</td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>64,228</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">9,714</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        United States and foreign components of loss from continuing operations before
        income taxes are as follows for the years ended December 31:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2004</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">United
                  States</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(9,318,730</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB2" style="MARGIN-LEFT: 0px; COLOR: black; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; LETTER-SPACING: -0.45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5,071,475</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Hong
                  Kong</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>81,706</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">99,932</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                  foreign</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(1,213,318</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(1,098,325</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">&#160;</td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(10,450,342</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">$</font></div>
              </td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(6,069,868</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        primary difference between the Company's income tax benefit computed at the
        U.S.
        statutory rate of 34% and the effective tax rates for the years ended December
        31, 2005 and 2004 is the change in the valuation allowance in the respective
        periods that results from the Company not recording a deferred income tax
        benefit for its net operating losses. </font></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-29</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><em><a href="#TOC">Table
            of
            Contents</a></em></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          significant components of the Company&#8217;s net deferred tax assets and liabilities
          consisted of the following at December 31, 2005:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
          <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="70%">

              <tr>
                <td align="left" valign="bottom" width="85%" style="border-bottom: medium none;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current
                    tax assets and liabilities:</font></div>
                </td>
                <td width="2%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" colspan="2" valign="bottom" width="12%" style="border-bottom: medium none;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: medium none;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accrued
                    expenses </font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>259,217</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inventory
                    reserves</font></div>
                </td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>240,188</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
                    items, net</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>7,375</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
                    Depreciation and amortization</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>133,999</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">&#160;</td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>640,779</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white;">&#160;</td>
                <td width="2%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: white;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Non-current
                    tax assets and liabilities:</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    operating loss and tax credit carryforwards</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>10,961,372</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
                    non-current</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>10,961,372</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              </tr>
              <tr bgcolor="white">
                <td align="left" valign="bottom" width="85%" style="border-bottom: white solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Valuation
                    allowance</font></div>
                </td>
                <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(11,602,151</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: white thin solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
                </td>
              </tr>
              <tr bgcolor="#e2eef6">
                <td align="left" valign="bottom" width="85%" style="border-bottom: #e2eef6 solid;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Net
                    deferred tax assets</font></div>
                </td>
                <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>$</strong></font></div>
                </td>
                <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font id="TAB1" style="MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>-</strong></font></div>
                </td>
                <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 solid;">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SFAS
        109
        requires a valuation allowance to reduce the deferred tax assets reported
        if,
        based on the weight of the evidence, it is more likely than not that some
        portion or all of the deferred tax assets will not be realized. After
        consideration of all the evidence, both positive and negative, management
        has
        determined that a full valuation allowance of $11,602,151 against its net
        deferred taxes is necessary as of December 31, 2005. The change in valuation
        allowance for the years ended December 31, 2005 and 2004 is $4,279,185and
        $2,562,724, respectively.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        December 31, 2005, the Company had approximately $26,428,000 of U.S. net
        operating loss carryforwards remaining, which will expire beginning in 2020.
        As
        a result of certain ownership changes, the Company may be subject to an annual
        limitation on the utilization of its U.S. net operating loss carryforwards
        pursuant to Section 382 of the Internal Revenue Code. A study to determine
        the
        effects of this change, if any, has not been undertaken.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
        reconciliation of the Company&#8217;s income taxes to amounts calculated at the
        federal statutory rate is as follows for the years ended December
        31:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table border="0" cellpadding="0" cellspacing="0" id="ftable" width="60%">

            <tr>
              <td align="left" valign="bottom" width="71%" style="border-bottom: #ffffff solid;">&#160;</td>
              <td width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2005</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #ffffff thin solid;">&#160;</td>
              <td colspan="2" valign="bottom" width="12%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>2004</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #ffffff thin solid;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Federal
                  statutory taxes</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(34.00</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)%</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(34.00</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)%</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">State
                  income taxes, net of federal tax benefit</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(3.63</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(3.63</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nondeductible
                  items</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>.22</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: #e2eef6;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">.68</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6;">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Change
                  in valuation allowance</font></div>
              </td>
              <td width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>40.50</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: white;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">42.36</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white;">&#160;</td>
            </tr>
            <tr bgcolor="#e2eef6">
              <td align="left" valign="bottom" width="71%" style="border-bottom: #e2eef6 solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research
                  and development credits</font></div>
              </td>
              <td width="2%" style="border-bottom: #e2eef6 thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>(3.09</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman"><strong>)</strong></font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black thin solid;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">(5.41</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: #e2eef6 thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">)</font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td align="left" valign="bottom" width="71%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td width="2%" style="border-bottom: white thin solid;">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">-&#160;</td>
              <td align="left" valign="bottom" width="2%" style="border-bottom: white solid;">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>%</strong></font></td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: black double;">&#160;</td>
              <td align="right" valign="bottom" width="11%" style="border-bottom: black double;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">-
                  </font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="border-bottom: white solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; MARGIN-RIGHT: 0px; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>15.
        Subsequent Events</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        March
        2006, the Company hired Glenn E. Nedwin, Ph.D. to become (i) the Company&#8217;s Chief
        Scientific Officer, (ii) an Executive Vice President of the Company and (iii)
        the President of the BioSciences business of the Company&#8217;s wholly-owned
        subsidiary, Dyadic International (USA), Inc. Dr. Nedwin will have responsibility
        for all scientific and R&amp;D related activities of the Company and each of its
        subsidiaries and will also be responsible for strategic business development
        of
        corporate partnering, strategic alliance and material collaborative research.
        Dr. Nedwin&#8217;s annual base salary is $300,000, and he is eligible to earn a bonus
        each year of up to 25% of his then annual base salary based upon a bonus
        plan
        adopted and maintained by the Compensation Committee of the Board of Directors
        of the Company for such year. Dr. Nedwin has been elected to the Board as
        a
        Class III director for a term which expires at the 2007 annual stockholders&#8217;
meeting. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>F-30</strong></font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">&#160;</div>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">&#160;</div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">&#160;</div>
        <div id="HDR">&#160;</div>
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>exhibit21.htm
<DESCRIPTION>EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<html>
  <head>
    <title>
      Exhibit 21 Subsidiaries of the Registrant
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARIZER HTML 3.0.2.0 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      21</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIST
      OF
      SUBSIDIARIES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subsidiaries
      of Dyadic International, Inc., a Delaware corporation:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;1.
      Dyadic
      International (USA), Inc., a Florida corporation (100% owned)
      ("Dyadic-Florida")</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;2.
      Geneva
      International Holdings Limited, a British Virgin Islands corporation (100%
      owned
      by Dyadic-Florida) ("Dyadic-Geneva")</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;3.
      Puridet (Asia)
      Limited, a Hong Kong corporation (82.5% economic interest and 62.5% voting
      interest owned by Dyadic-Geneva)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;4.
      Dongguan Puridet
      Softener Company Limited, a Peoples Republic of China corporation (100% owned
      by
      Puridet (Asia) Limited)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;5.
      Dyadic
      International, Spo ka z orgraniczon odpwiedzialno ci, a Polish corporation
      (100%
      owned by Dyadic-Florida)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;6.
      Dyadic Nederland
      BV, a Netherlands corporation (100% owned by Dyadic-Florida)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;7.
      Dyadic Real Estate
      Holdings, Inc., a Florida corporation (100% owned by
      Dyadic-Florida)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>exhibit23.htm
<DESCRIPTION>EXHIBIT 23 AUDITOR'S CONSENT
<TEXT>
<html>
  <head>
    <title>
      Exhibit 23 Auditor's Consent
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARIZER HTML 3.0.2.0 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      23</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Consent
      of Independent Registered Public Accounting Firm</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      consent to the incorporation by reference in the Registration Statement (Form
      S-8 No. 333-122339) pertaining to Dyadic International, Inc.'s 2001 Equity
      Compensation Plan of our report dated March 27, 2006 with respect to the
      consolidated financial statements of Dyadic International, Inc. included in
      the
      Annual Report (Form 10-KSB) for the year ended December 31, 2005.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<f
ont id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;/s/
      Ernst &amp; Young
      LLP</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<f
ont id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Certified
      Public
      Accountants</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">West
      Palm
      Beach, Florida</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">March
      27,
      2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title>
      Exhibit 31.1
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARIZER HTML 3.0.2.0 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
        31.1</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Certification
        Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I,
        Mark
        A. Emalfarb, Chief Executive Officer, certify that: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;
        I have reviewed this&#160;Annual Report on Form&#160;10-KSB of Dyadic
        International, Inc. (the "Company"); </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;
        <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
        on
        my knowledge, this&#160;Annual Report does not contain any untrue statement of a
        material fact or </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">omit
        to
        state a material fact necessary to make the statements made, in light of
        the
        circumstances&#160;&#160;&#160;&#160;&#160; </font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        under&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">which&#160;such
        statements were made, not misleading with respect to the period covered by
        this
        Annual </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report;
        </font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;
        Based on my knowledge, the financial statements, and other financial information
        included in this </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Annual
        Report, fairly present in all material respects the financial condition,
        results
        of operations and&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cash
        flows&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of&#160;the Company as of, and
        for, the periods presented in this Annual Report; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.
        </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 22.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
        The Company's other certifying officer and I are responsible for establishing
        and maintaining disclosure </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">controls
        and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e))
        for the Company and have: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;Designed
        such disclosure controls and procedures, or caused such disclosure controls
        and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures
        to be designed under our supervision, to ensure that material information
        relating to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Company,&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        including its consolidated subsidiaries, is made known to us by others within
        those </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">entities,
        particularly during the period in which this Annual Report is being prepared;
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        b)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's
        disclosure controls and procedures and presented in </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">this
        Annual Report our conclusions about the effectiveness of the disclosure controls
        and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures,
        as&#160;&#160; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        of the end of the period covered by this Annual Report based on such
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">evaluation;
        and </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c)&#160;&#160;&#160;&#160;
        Disclosed in this Annual Report any change in the Company&#8217;s internal control
        over financial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting
        that occurred during the Company&#8217;s most recent fiscal quarter that has
        materially </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">affected
        or is </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reasonably
        likely to materially affect the Company&#8217;s internal control over financial
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting;
        and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        5.&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's other certifying officer and I have disclosed, based on our most
        recent evaluation of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">internal
        control over financial reporting, to the Company's auditors and the audit
        committee of Company's </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Board&#160;&#160;&#160;&#160;&#160;&#160;
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        of&#160;Directors: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a)&#160;&#160;&#160;
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
        significant deficiencies and material weaknesses in the design or operation
        of
        internal control </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">over
        financial reporting which are reasonably likely to adversely affect the
        Company's ability to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">record,
        process, </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        summarize and report financial information; and </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        b)&#160;&#160; Any fraud, whether or not material, that involves management or
        other employees who have a </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">significant
        role in the Company's internal controls over financial reporting. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;March
        29, 2006</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;
</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/&#160;&#160;
        Mark A. Emalfarb</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;
        &#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; &#160;&#160; Mark A.
        Emalfarb</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;
</font>Chief
        Executive
        Officer</font></div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title>
      Exhibit 31.2
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARIZER HTML 3.0.2.0 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
        31.2</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Dyadic
        International, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Certification
        Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002
</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I,
        Wayne
        Moor, Chief Financial Officer, certify that: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;
        I have reviewed this&#160;Annual Report on Form&#160;10-KSB of Dyadic
        International, Inc. (the "Company"); </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;
        <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
        on
        my knowledge, this&#160;Annual Report does not contain any untrue statement of a
        material fact or </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">omit
        to
        state a material fact necessary to make the statements made, in light of
        the
        circumstances&#160;&#160;&#160;&#160;&#160; </font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        under&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">which&#160;such
        statements were made, not misleading with respect to the period covered by
        this
        Annual </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report;
        </font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;
        Based on my knowledge, the financial statements, and other financial information
        included in this </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Annual
        Report, fairly present in all material respects the financial condition,
        results
        of operations and&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cash
        flows&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of&#160;the Company as of, and
        for, the periods presented in this Annual Report; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.
        </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 22.5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;
        The Company's other certifying officer and I are responsible for establishing
        and maintaining disclosure </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">controls
        and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e))
        for the Company and have: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;Designed
        such disclosure controls and procedures, or caused such disclosure controls
        and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures
        to be designed under our supervision, to ensure that material information
        relating to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Company,&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        including its consolidated subsidiaries, is made known to us by others within
        those </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">entities,
        particularly during the period in which this Annual Report is being prepared;
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        b)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's
        disclosure controls and procedures and presented in </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">this
        Annual Report our conclusions about the effectiveness of the disclosure controls
        and </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">procedures,
        as&#160;&#160; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        of the end of the period covered by this Annual Report based on such
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">evaluation;
        and </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c)&#160;&#160;&#160;&#160;
        Disclosed in this Annual Report any change in the Company&#8217;s internal control
        over financial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting
        that occurred during the Company&#8217;s most recent fiscal quarter that has
        materially </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">affected
        or is </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reasonably
        likely to materially affect the Company&#8217;s internal control over financial
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">reporting;
        and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        5.&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company's other certifying officer and I have disclosed, based on our most
        recent evaluation of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">internal
        control over financial reporting, to the Company's auditors and the audit
        committee of Company's </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Board&#160;&#160;&#160;&#160;&#160;&#160;
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        of&#160;Directors: </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a)&#160;&#160;&#160;
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
        significant deficiencies and material weaknesses in the design or operation
        of
        internal control </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">over
        financial reporting which are reasonably likely to adversely affect the
        Company's ability to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">record,
        process, </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        summarize and report financial information; and </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        b)&#160;&#160; Any fraud, whether or not material, that involves management or
        other employees who have a </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">significant
        role in the Company's internal controls over financial reporting. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;March
        29, 2006</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;
</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>/s/&#160;&#160;
        Wayne Moor</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;
        &#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; &#160;&#160; Wayne
        Moor</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;
</font>Chief
        Financial
        Officer</font></div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title>
      Exhibit 32.1
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARIZER HTML 3.0.2.0 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      32.1</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="Certifications"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      OF CHIEF
      EXECUTIVE OFFICER</font></strong></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I,
      Mark
      A. Emalfarb, Chief Executive Officer of Dyadic International, Inc. (the
&#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      18 U.S.C. Section 1350, that:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Annual Report on Form 10-KSB of the Company for the period ended
                December
                31, 2005 (the &#8220;Report&#8221;) fully complies with the requirements of Section
                13(a) or 15(d) of the Securities Exchange Act of 1934,
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                information contained in the Report fairly presents, in all material
                respects, the financial condition and results of operation of the
                Company.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN
      WITNESS WHEREOF, the undersigned has executed this certification as of the
      29</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day of
      March 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;/s/
      Mark A.
      Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:
      Mark A. Emalfarb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:
      Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      certification accompanies the Annual Report pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by
      the
      Sarbanes-Oxley Act of 2002, be deemed filed by Dyadic International, Inc. for
      purposes of Section 18 of the Securities Exchange Act of 1934, as
      amended.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      signed
      original of this written statement required by Section 906 has been provided
      to
      Dyadic International, Inc. and will be retained by Dyadic International, Inc.
      and furnished to the Securities and Exchange Commission or its staff upon
      request.</font></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit32_2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title>
      Exhibit 32.2
</title>
<!-- Licensed to: Dyadic International, Inc.-->
<!-- Document Created using EDGARIZER HTML 3.0.2.0 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      32.2</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="Certifications"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      OF CHIEF
      FINANCIAL OFFICER</font></strong></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I,
      Wayne
      Moor, Chief Financial Officer of Dyadic International, Inc. (the &#8220;Company&#8221;),
      certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
      Section 1350, that:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Annual Report on Form 10-KSB of the Company for the period ended
                December
                31, 2005 (the &#8220;Report&#8221;) fully complies with the requirements of Section
                13(a) or 15(d) of the Securities Exchange Act of 1934,
                and</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 54pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                information contained in the Report fairly presents, in all material
                respects, the financial condition and results of operation of the
                Company.
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN
      WITNESS WHEREOF, the undersigned has executed this certification as of the
      29</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      day of
      March 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;/s/
      Wayne
      Moor</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:
      Wayne Moor</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:
      Chief Financial Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      certification accompanies the Annual Report pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by
      the
      Sarbanes-Oxley Act of 2002, be deemed filed by Dyadic International, Inc. for
      purposes of Section 18 of the Securities Exchange Act of 1934, as
      amended.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      signed
      original of this written statement required by Section 906 has been provided
      to
      Dyadic International, Inc. and will be retained by Dyadic International, Inc.
      and furnished to the Securities and Exchange Commission or its staff upon
      request.</font></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>dyadiclogo3.jpg
<DESCRIPTION>DYADIC LOGO
<TEXT>
begin 644 dyadiclogo3.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"C`,(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**S-1\1:'
MI%PMOJ>LZ=93,N]8[FZ2-BN2,@,0<9!Y]C5^">&ZMX[BWE26&50\<D;!E=2,
M@@C@@CO5.,DKM`24445(!7D7Q3^*>N>!_$]MIFF6NG2PRV:W#-<QNS;B[K@;
M7`QA1V]:]=KYJ_:%_P"1^L?^P7'_`.C9:]'*Z4*N(49JZLR)NRT#_AH7Q9_T
M#M%_[\R__'*T]&_:)U%+C;KFB6LT+,HWV+-&T:Y^8[7+!SC&!E>G7GCTKP?X
M/\,77@G0+BX\.:1+-+IUN\DDEC$S.QC4DDE<DD]ZY;XH_"71)]`O=<T.W@TR
M]LHGN)8X@5AFC1<D;!PC`+D%0`3G/7<.Z-;+YU/92IVZ7)M)*]SU;2]4LM:T
MRWU'3KE+FSN%WQRIT(_F"#D$'D$$'D5X]\0OBMXO\$^+9]*6RTB6U95GM99(
M9-SQ-G&<2]00R]L[<X`(K-_9WU^X&H:IX=9=ULT7VZ,Y`V."J-VR=P9._&SI
MR:[OXP>"7\7^%1/9C.I:9OG@4*S&5-OSQJ!_$VU2.#RH'&2:YH4:6%QGLJRO
M%]_/9_HQW<HW1V'A_7;+Q-H-IK&G,YM;I2R>8NUE()5E(]001QD<<$CFCQ!K
MMEX9T&[UC46<6MJH9_+7<S$D*J@>I)`YP.>2!S7AG[/_`(K^R:M=>%[AOW5[
MFXM>.DJK\XX'\2+G)(`\OCEJ/V@/%?VO5K7PO;M^ZLL7%UQUE9?D'(_A1LY!
M(/F<\K1_9K^N^P^SO\OZT]1\_NW-KX>_%;Q?XV\6P:4UEI$5JJM/=2QPR;DB
M7&<9EZDE5[XW9P0#7ME>>?!_P2_A#PJ9[P8U+4]D\ZE64Q)M^2-@?XEW,3P.
M6(YP#7>7U[;Z;I]S?7<GEVUM$TTKX)VHH))P.3P#TKFQTJ4J[C05DM-.HXWM
MJ>1?$OXP:IX1\6G1]&@TZX2&!&N/M,,A9)6RVT$,H(V%#QGJ>>P[?X<>+G\:
M^#H=4N/(6]662&YC@1E1'!R`-Q.?D*'J>OX#YCM[?5OB'XLU&Y99YKV>*XO9
M!#$\NW9&S*@&20I(2->3C<HYX![S]G_Q(]EXFNO#\T^+:_B,L,;;C^_09.W'
M"Y3<22.=BC/`!];%Y?3AA;07OQ2;_7^O(B,WS'T;7A_Q`^,GB'PIXWU'1;&S
MTN2VMO+V-/%(7.Z-7.2'`ZL>U>X5\F?&;_DK&M_]L/\`T1'7#E%&G6KN-175
MOU151M+0WO\`AH7Q9_T#M%_[\R__`!RM[PW^T*\EW#;^)-*@CBDEP]Y9LP$2
M$<$QG<6P>I#=#P"1@^L_\(1X3_Z%?1?_``7Q?_$UY%\8/A9I6E:--XGT)$LD
M@8?:[0$['WN`&C'\)!8#;PN.F,8;II5<OQ$E2=/EOL_,EJ2UN>[P3PW5O'<6
M\J2PRJ'CDC8,KJ1D$$<$$=Z\3^('QD\0^%/&^HZ+8V>ER6UMY>QIXI"YW1JY
MR0X'5CVJ_P#L^:_<7_AG4-%F7,>F2JT+Y'W)2Q*X`[,K'))^_CC`KRWXS?\`
M)6-;_P"V'_HB.IP."A'&3HU5=)?Y6_!CE+W;H^LZ\X^(_P`6;+P2XTZRA2_U
MAE):(OA+<$?*9,<DDX.P8)'.5RN>\U748=(TB]U.X5VALX)+B18P"Q5%+$#)
M`S@>M?*_P[\/?\+$^(K_`-L2>;$?,O[[#>6TWS#(&T<9=USC'&<$'%<N7X:G
M44JU;X8_B.;:T1)/\:O'LMQ)(FLI"CL66*.TA*H"?NC<I.!TY)/J37?^`_CM
M]MN[?2_%<<$#/\BZE&=B;L`#S%Z+D[B7!`&1\H&2/98=*TZWTPZ9!86L5@59
M#:I"JQ%6SN&P#&#DY&.<FO`/B9\([U?%ML_A'27EM=15W:"+B.WE7EN2`L:$
M$%06Z[@,#`KMI5\%BFZ4J:AV>G_`_4EJ4=;G8SP:K<:[C3)=434$EU.6Y6,W
M"QRR+<;K5'8,(DD,(PK2AUV>6&1E*"NX\*S+<2Z[/;AQ92:COM@R,@`,$)DP
MI`VGSO-W#`(??GYLU3T+PNE_X9TD^,M'TN^UN&U6&:6:%;AL`G:"[Y);!RV#
MC<6(X-=3!!#:V\=O;Q)%#$H2..-0JHH&``!P`!VKS,16BUR+II^/]6\BTB2B
MBBN,H*^:OVA?^1^L?^P7'_Z-EKZ5KYJ_:%_Y'ZQ_[!<?_HV6O5R;_>EZ,BI\
M)[OX(_Y$'PY_V"[;_P!%+6]6#X(_Y$'PY_V"[;_T4M:>JZC#I&D7NIW"NT-G
M!)<2+&`6*HI8@9(&<#UKSZJ;JR2[E+8^5_@S_P`E8T3_`+;_`/HB2OK.OECX
M':=->_$ZTN(V0)8P37$@8G)4H8\#CKF1>N.`:^IZ]3/&GB5Z+\V13V/E3XF^
M';CP#\15OM,7R+::47]@ZQC;$X;)0#:%^5QPHSA2F>M'PR\.W'C[XBM?:FOG
MVT,IO[]VC&V5RV0A&TK\SGE3C*A\=*]._:&@A;P3IUPT2&9-15$D*C<JM'(6
M`/4`E5R.^T>E'[/,$*^"=1N%B03/J+(\@4;F58XRH)ZD`LV!VW'UKL^N2_L_
MVOVOAO\`U_5R>7W['KM>:_''Q!_8_P`/Y+**7;<ZG*MNH6;8XC'S.0.K+@!"
M.G[SGT/I5?,_Q\UUM1\<1:2K/Y.EP*I5E4#S9`'9@1R05\L<]U.!W/E971]K
MB8WV6OW?\$N;LCI?V=M"46^K^(9%0NS"QA(9MR@`/)D=,',6#R?E/3OYQK,;
M_#GXMSFT7$>FWZSQ10S,,P-AQ&7//,;!6SGJ>O>_X9^,GB'PIX>M=%L;/2Y+
M:VW[&GBD+G<Y<Y(<#JQ[5SOC+QEJ/CC5XM3U.&UBFB@%NJVRLJ[0S-D[F)SE
MCW]*^@I4*_UJI.HO<EIO]W]>9DVN56/LF">&ZMX[BWE26&50\<D;!E=2,@@C
M@@CO7RA\9O\`DK&M_P#;#_T1'7NGP9UUM<^&]DLK.TVGLUB[,JJ"$P4QCJ!&
MR#)YR#UZGPOXS?\`)6-;_P"V'_HB.O-RFDZ6,G3?1/\`-%S=XIGUG6#XW_Y$
M'Q'_`-@NY_\`135O5RWQ)U&'2_AOX@N)U=D>S>W`0`G=+^[4\D<9<9]L]:\:
M@FZL4NZ-'L>)_L]?\C]??]@N3_T;%6#\9O\`DK&M_P#;#_T1'74_L[:=-+XG
MU?4U9/)M[,6[J2=Q:1PRD<8QB)L\]Q^'+?&;_DK&M_\`;#_T1'7U--IYG/\`
MP_Y&+^`][^,$\UO\*M<>"5XG*Q(61BI*M,BL..Q!(([@D5P'[-__`#,W_;K_
M`.UJ]'^*FG3:I\,=>MX&172`7!+D@;8G61AP#SA#CWQTKRW]G/488M7UW3&5
M_.N((KA&`&T+&S*P/.<YE7''8_CY6'URRJEO?_(M_&CZ"HHKEO%'Q"\/^#]3
ML+'6+EXGO%=]\:;Q"J]"ZCY@&.0"%.2#TP:\FG3G4ERP5V:-V.IHJII>J66M
M:9;ZCIURES9W"[XY4Z$?S!!R"#R""#R*MU+33LP"BBBD`5\U?M"_\C]8_P#8
M+C_]&RU]*UR?B?P9X.\1:E'=^(;6&6[2$1(SW;Q'8"Q`PK@=2W-=N`Q,,-6]
MI/;R)E%R5D>2Z'\?O[&T#3M+_P"$9\[[%:Q6_F_;]N_8H7./+.,XSC)K!\=_
M&34_&6DOI$.G0:?I\NPS+O\`-DD*MN`W$`!<A3@#.5ZX)%>O?\*M^&'_`$#[
M7_P92_\`QRM;0/"?@3PQ=F[TBTT^"Y/29[CS73@CY6=B5R&(.,9[UW+&Y?"7
MM(4WS;Z]_O?Y"]G4>C.=^"W@.X\+Z)/JFJVODZIJ&-L;@;X8!R%/&59CRRY[
M)D`@BO4JJ?VII_\`S_VO_?Y?\:/[4T__`)_[7_O\O^->37KRKU'4GNRU!I6L
M>8_M"_\`(@V/_84C_P#14M'[/7_(@WW_`&%)/_145=QXATWPOXKT^.QUI[6Z
MMHY1,J?:BF'`(!RK`]&/YT>'M-\+^%-/DL=%>UM;:24S,GVHOER`"<LQ/11^
M5=7UNG]3^K];W\A>SES7L;5]>V^FZ?<WUW)Y=M;1--*^"=J*"2<#D\`]*^4_
M`FE7'Q`^*B7%S%`8WNGU.^38&CV!]S+M8\JS,J8YP&R<X-?3NJ-HNL:9<:=?
M7D+VMPNR5$NS&67N-RL#@]",\C(/!K)\.>&?!7A.XGN-$ALK6:90CR&Z,C;0
M<X!=B0,XR!C.!GH*>#QD,/2J)?'+1=D$J<FUH7O^$(\)_P#0KZ+_`."^+_XF
ML+QI\-]&U7P=J=GHVAZ7::DT6ZWE@LXD<NI#!0W&W=MVYSQN_"NP_M33_P#G
M_M?^_P`O^-']J:?_`,_]K_W^7_&N6&)J0DI*6WF/D?8^>?V?M=6P\6WNCRLB
MIJ4`:/*L6:6++!01P!L:0G/]T<]CSOQF_P"2L:W_`-L/_1$=>^67@?P!INMI
MK%C;VMK?1RF5)(+^1`K'J`H?:%Y(VXQ@XQCBC6?`_@#Q#JT^J:I;VMQ>S[?,
ME^WR)NVJ%'"N`.`!TKUXYGAXXMXA)V:L]M]//LB/93Y;'G__``TA_P!2I_Y4
M?_M5</XY^)>L_$9[;2X]/2WLQ.KP6D`,LLDI&T9;&6.2V`H'WL')`->T_P#"
MK?AA_P!`^U_\&4O_`,<K=\/>'_!GA3S#HL&GVLDF=TOG;Y"#C*[V);;\H.W.
M,C.*F.-R^B^>C3?,MK_\.P]G4>C*'PL\%-X+\))!>1(NJW;>=>%2K;3T5-P'
M(4=LD;F?!P:\$^,W_)6-;_[8?^B(Z^J/[4T__G_M?^_R_P"-<GK/@?P!XAU:
M?5-4M[6XO9]OF2_;Y$W;5"CA7`'``Z5SX/,(TL1*O6UNNGJARIR:LD=G/!#=
M6\EO<1)+#*I22.10RNI&""#P01VKY0UW2-;^$?Q`AO+5,1Q2O)I]Q*!(D\1R
MI5C@?-M;:P&",Y&,J:^J/[4T_P#Y_P"U_P"_R_XUFZ[9^&?$VF-IVL-97=J6
M#[&G"E6'0A@05/49!'!(Z$UE@<:L/)J2O&6Z'*FV><0_M$Z&VF&2?1-12_VL
M1`C(T6[G:/,)!P>,G9QD\''/D6K:EJWQ1^(".D6VYOY4@MX-SNEO&.!S@D*!
MEF(&/O-@=*]AG^"7@"6XDD36;V%'8LL4=[$50$_=&Y"<#IR2?4FNT\+^&_!W
M@^W":0+*.8KMDNI)E>:3A<Y<G(!*@[1A<\@"N^&-P.&3GAXOF??H3[.;W-W1
M=(M-`T2STFQ3;;6D0C3(`+8ZLV``6)R2<<DDU?JJFI6+NJ)>V[,QP%$JDD_G
M5JO#<G)W9=K!1112`*^=OC+_`,C\_P#UZQ_UKZ)KA?%GPPL/%FM?VG/J%S!(
M8EC*1JI'&>>?K433:T/1RS$4\/7YZFUCYOHKW/\`X45I7_08O?\`OA:/^%%:
M5_T&+W_OA:SY)'T/]LX3N_N9X917N?\`PHK2O^@Q>_\`?"T?\**TK_H,7O\`
MWPM')(/[9PG=_<SPRBO<_P#A16E?]!B]_P"^%H_X45I7_08O?^^%HY)!_;.$
M[O[F>&45[G_PHK2O^@Q>_P#?"UXIJ%NMIJ5U;(Q989GC!/4@$BI<6MSJPV.H
MXEM4GL5Z*[KX<^!;3QK_`&E]JO)K?[)Y6WRE!W;]^<Y_W:[G_A16E?\`08O?
M^^%IJ+>IE7S/#T*CIS>J\CPRBO<_^%%:5_T&+W_OA:X/XB^![7P7-IZ6MY-<
M"Z60MYJ@;=NWIC_>H<6MQT,SP]>:IP>K\CB**N:39KJ.L6-B[E%N;B.$L!R`
MS`9_6O9_^%%:5_T&+W_OA:2BWL:8G'4<,TJCW/#**]S_`.%%:5_T&+W_`+X6
MC_A16E?]!B]_[X6JY)'+_;.$[O[F>&45[G_PHK2O^@Q>_P#?"T?\**TK_H,7
MO_?"T<D@_MG"=W]S/#**]S_X45I7_08O?^^%H_X45I7_`$&+W_OA:.20?VSA
M.[^YGBVF_P#(5L_^NZ?^A"OL"O+;;X(:3;W<,_\`:UZWENK[=J#.#G'2O4JN
M$6MSQ<VQE+$N'LGM?]`HHHK0\<****`"BBB@`HHHH`****`"OD/6_P#D/:C_
M`-?4O_H1KZ\KY#UO_D/:C_U]2_\`H1K*IT/H,@^.?HCU?X"_\S!_V[?^U:]E
MKQKX"_\`,P?]NW_M6O9:N'PG#F_^^3^7Y(*\6^/'_'SH7^Y/_-*]IKQ;X\?\
M?.A?[D_\TI5-AY1_OD/G^3/,_#'_`"-FC?\`7]!_Z&*^M:^2O#'_`"-FC?\`
M7]!_Z&*^M:FGU.W/_P")#T84445J?/A1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%?(>M_\A[4?^OJ7_P!"-?7E?(>M_P#(>U'_`*^I?_0C653H
M?09!\<_1'J_P%_YF#_MV_P#:M>RUXU\!?^9@_P"W;_VK7LM7#X3AS?\`WR?R
M_)!7BWQX_P"/G0O]R?\`FE>TUXM\>/\`CYT+_<G_`)I2J;#RC_?(?/\`)GF?
MAC_D;-&_Z_H/_0Q7UK7R5X8_Y&S1O^OZ#_T,5]:U-/J=N?\`\2'HPHHHK4^?
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*^0];_P"0]J/_`%]2
M_P#H1KZ\KY#UO_D/:C_U]2_^A&LJG0^@R#XY^B/5_@+_`,S!_P!NW_M6O9:\
M:^`O_,P?]NW_`+5KV6KA\)PYO_OD_E^2"O%OCQ_Q\Z%_N3_S2O::\6^/'_'S
MH7^Y/_-*538>4?[Y#Y_DSS/PQ_R-FC?]?T'_`*&*^M:^2O#'_(V:-_U_0?\`
MH8KZUJ:?4[<__B0]&%%%%:GSX4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!7R'K?_(>U'_KZE_]"-?7E?(>M_\`(>U'_KZE_P#0C653H?09!\<_
M1'J_P%_YF#_MV_\`:M>RUXU\!?\`F8/^W;_VK7LM7#X3AS?_`'R?R_)!7BWQ
MX_X^="_W)_YI7M->+?'C_CYT+_<G_FE*IL/*/]\A\_R9YGX8_P"1LT;_`*_H
M/_0Q7UK7R5X8_P"1LT;_`*_H/_0Q7UK4T^IVY_\`Q(>C"BBBM3Y\****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KEY_ASX2N;B6XFT6%I97+N=[C
M))R>`U=110:4ZM2GK"37H[&3HGAG1_#HG&DV*6OG[?,VLQW;<XZD],G\ZUJ*
M*"9SE-\TG=A63K7AC1O$7D_VM81W1ASY98L"N<9Z$>@K6HH"$Y0?-%V9S%K\
M//"=E=PW5OHT*30N)(VWN=K`Y!P3CK73T446*J5:E1WG)OU=PHHHH,PHHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
5HHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>10KSB
<SEQUENCE>9
<FILENAME>form10ksb_123105final.pdf
<DESCRIPTION>DYADIC FORM 10-KSB 12.31.05
<TEXT>
<PDF>
begin 644 form10ksb_123105final.pdf
M)5!$1BTQ+C(-)>+CS],-"C$W.2`P(&]B:CP\+TA;-C4V(#8R,UTO3&EN96%R
M:7IE9"`Q+T4@,C<Y-C,O3"`T,S8Q,#@O3B`X."]/(#$X,B]4(#0S,C0X,#X^
M#65N9&]B:@T@("`@("`@("`@("`@("`@#0IX<F5F#0HQ-SD@,3@-"C`P,#`P
M,#`P,38@,#`P,#`@;@T*,#`P,#`P,3(W.2`P,#`P,"!N#0HP,#`P,#`P-C4V
M(#`P,#`P(&X-"C`P,#`P,#$T,#(@,#`P,#`@;@T*,#`P,#`P,3<S-2`P,#`P
M,"!N#0HP,#`P,#`Q.#(V(#`P,#`P(&X-"C`P,#`P,#$Y,38@,#`P,#`@;@T*
M,#`P,#`P,C4R,B`P,#`P,"!N#0HP,#`P,#`S,3`Y(#`P,#`P(&X-"C`P,#`P
M,#,W,CD@,#`P,#`@;@T*,#`P,#`P-#,X.2`P,#`P,"!N#0HP,#`P,#`T.38V
M(#`P,#`P(&X-"C`P,#`P,#4U.3$@,#`P,#`@;@T*,#`P,#`P-C`W,"`P,#`P
M,"!N#0HP,#`P,#`V-#`Q(#`P,#`P(&X-"C`P,#`P,#8T.3`@,#`P,#`@;@T*
M,#`P,#`P-C4X-B`P,#`P,"!N#0HP,#`P,#`V-C<X(#`P,#`P(&X-"G1R86EL
M97(-"CP\+U-I>F4@,3DW+U!R978@-#,R-#8X+U)O;W0@,3@P(#`@4B]);F9O
M(#$W."`P(%(O241;/#9E-S4V.38V-S`W83=A-S,V,C9C-F$V.3<V-F4W-#<U
M/CPP,69E,S5B.60U-C,T9#0Y83@Y865D8CDY-V8T-64U,#Y=/CX-"G-T87)T
M>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HQ.#$@,"!O8FH\/"],96YG=&@@
M-30Q+T9I;'1E<B]&;&%T941E8V]D92]/(#DS."]3(#@X,SX^<W1R96%M#0IX
MVF)@8&!B8&#F9F!A8&#+8>!G0`!^!F:@*`L#QP4&XL&A56Q+(A2N7K1/ECP:
MUO5)E$W_0[PDNV&MTJ$CS[KL1.YHU?AUW'*,3_K*\H]SLEB7RA4O@4F,GH]L
M7>(ZYHN(J-T)3JB^J,_4RCJE:[-XG/F-3,;@(E>FW,/U74[".S37!&ED%IQT
M=&V^U<#`5</9('%36.B<>L#93N8R@3\*!YP,9AYL:#WH.D=DDZ2/V8W$BL:-
MRY@SVKUF[A=<9G(CR&'1P<BE1=U+^\6VW<[%CQ@8&#>=%=IS4>>V[*:#E_;(
M:A_4W8-@"=T&L39!B-LZ0*XN2.(22`+(W7,1K`1(@%E00OLL@B6C?1&H^.Q&
ML'E`.T!Z90]!N&>U@<0=;:"236>E=2#:8'JAAD+U0IRA#;,<XK0]2#JT40V`
M$@P=#1T=0((E@L&UP:V#):)!R0+(8NM@R&A@\&!@:5#K`'*5/1C,&E0S&(0;
M&#H8)!I4.Q@E&E0R@(H%04I8(I@Z&D0Z&#L:&$%&270`N0P6C!8-K!T,'B`Q
M!JAY'(P:#68=#&$@(J.!,0-$1`#-Z^C@Z&B(`!G``3(`:`<'B.@`:6-N8.Y@
ML`"Q-$!B&2#S,AH$0;(6'6Q0'6(=+!D0%@?<%(Z.(9'Z4+(8`S3+13+P,[Y@
MX&#@4`BP<V@Y*-OX@L6`38)]`E#J`</+-(CR]0QL[=Y`FA&(E0$"#`#*?5GG
M#0IE;F1S=')E86T-96YD;V)J#3$X,"`P(&]B:CP\+U!A9V5S(#$W-B`P(%(O
M3W5T;&EN97,@,3<U(#`@4B]4>7!E+T-A=&%L;V<O4&%G94UO9&4O57-E3F]N
M92]/<&5N06-T:6]N6S$X,B`P(%(O1FET72]-971A9&%T82`Q-S<@,"!2/CX-
M96YD;V)J#3$X,B`P(&]B:CP\+T-O;G1E;G1S6S$X-2`P(%(@,3@V(#`@4B`Q
M.#<@,"!2(#$X."`P(%(@,3@Y(#`@4B`Q.3`@,"!2(#$Y,2`P(%(@,3DR(#`@
M4ETO5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X
M6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\
M/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q
M.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+UA/8FIE8W0\
M/"])86)C,3$@,3DV(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B])
M;6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$X,R`P(&]B:CP\+U1Y<&4O1F]N
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MF,>"J/%M?'E,VY2MH`DDKG8?^E+*7@#1U18DT'X]'G>;%FF+5E%EQ1EYDC-G
MSHQG=)5G#WG&F?$(G%:R'$.]V]8_\DPDCP!I0)AT(D$HYKUTX'CT<+2PO<ZS
M2]@D+*N1@-`Y>L'V-L_N\NSF-4'1.CK@3&L5`S"M4,67\E+^Z_<:R>^5);]S
M1CT/*&'HT!L.3L3'\HA*G&Y>]LW#WHF=4XI#4J.09V^GJ\_K)$&(/R2Q$NA>
M'J5=E((CA*B01X9>2PB/E(.P)IJ_\VRPJ&:AG$`;BE"VKR!\R[,R8G]Z.0,+
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M]V.":_\T)HJJ6A0?H"D_UDV`134I&XBC(\3Y0,AU`P))^R\D.M13"!<E',V6
M;JX4XT!NX94^=_<9KPY*]>Z^A`Y_!1@`S.IH6PT*96YD<W1R96%M#65N9&]B
M:@TQ.#8@,"!O8FH\/"],96YG=&@@-3$W+T9I;'1E<B]&;&%T941E8V]D93X^
M<W1R96%M#0I(B;1438_:,!"]6_)_F".52CK^RB1'RH;=[0':X-7VP(6%T*8B
MI`U4J_;7UTY(H%JQ*VU31;;L.)GWWHSG,03_5%\X$_5*@$8#D19@"\X&"ZGQ
M#=AOG"66LT^<_>!,PC`RL4&(A!N$4D"5<78/.\[>NZ_>398/*P*AP&XX>PH@
MHQ`BJ6N`F`(M10SV-V=##"12!/;1`4_*"@Y?,]CD^]5R"[^R9079;IVMX2\Z
M3?3TVD=_]-0^N"D*`R=!"C<["%TOFNV6LWDO&K24G08,,`X-V%4M06F_]A*N
MLE56/&05*/$6)*)YD;F+>L[<2.J?N<`8*.JR'XI(M-D7),.&^D*0`C>9U]8^
MO(3N\M:B_Y?+)9R$3IX*XLAT\M#H8V5L.IK.;^WM;`II\G&66KB;7B4IS)-Q
M_=)%GZ4@S`(-KMTD8#8!>Y/X#^Y2]V,RA^3S^&8TO4Y@-+;^6,1*OTI,>#E;
MA/J4+>@[NF]T"O^U%N$SC>XZ@30UM9"!0J*Z%C58.WH')=V!.D/1H6P[4\=^
M[>L/K;L<JN5NGQ_R<@??LRHOU["IRF(A%%T:<"CAN?/>S3)V]]G]>FQ7(F^0
M1[-T;)IN/4MG.V!<%D6^WWMIFWR;P>YG[45]\].N.5I^&#0N.%!*O>QUQML:
M(1U=FD[;_ER:Y"EY,M"(C1D,AN?TX(\``P"J5V^4#0IE;F1S=')E86T-96YD
M;V)J#3$X-R`P(&]B:CP\+TQE;F=T:"`U-3`O1FEL=&5R+T9L871E1&5C;V1E
M/CYS=')E86T-"DB)M)1=;],P%(;O+>4_G,LBT6([<9QP!V@@<3$)%FD@]28?
M;I/1.IWMJ(Q?S[&79E\J:-.J*):3^)SSOD^.32CXZ_N7B##81X3#UX@DDB\$
M2"IQW/I',3UN(G(1D6N_<)Z)7%#(&-Z2<@9&1>02=$0^%A%Y][FL:@DLAF(5
MD=LJ9NVK^!F#1*8@,;3``A03%W5$9HSRE.=OH+B*R!DF^7:(?*POO:]/,/E"
M?2FP](@^P;))WPP>2'I&]F/N&8=X,D_SG`7_<[J(,XHQ:'1VH>K!=*Y3%E.O
M.^N440T,NE$&\)OK>HUIEE30"@<&_0I<J^#L=]V6>JW@0^W>OUCW,2H)%<#S
MD<J2)_0$8)C,7PG,^I7!_*.=XR29A.?I(H]Y!L4?5'O>:W4*2`D?(;&8IW>0
M_-Q#^M2J^A?L6X763?#?63O@M+.@>X?UKH?.<W,]K+J-PA>[WC@+N\'8H=3.
M?YAHQM`;8,(S;8XQ7<"2R=@/XA1^L?%&OS2[\YM*\1^_7C,+FKW-!LK-9O)Z
M'T*EQ@75S?-\0X/=J-?A_:ZTSJO=]MJU-M3&!"N\[5"WISA%LNR`):/R@"5)
M#GO%MF@4*>R4Z7KTV98N"+W=.,;_YWUIGW9#D#MB\L;?0JF;X(<'#BT&54II
M7%A=(2T?&&(PVL,8$VZ51LS>_T0'#X^FO+$+^(G[UW?,#]\QIT`C64`S]^<(
M$P<V3&1CRYSWCSH6_@HP`"BAL5<-"F5N9'-T<F5A;0UE;F1O8FH-,3@X(#`@
M;V)J/#PO3&5N9W1H(#4Y,"]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*
M2(FT5,N.VC`4W4?*/]SEM`+&=FR<;*?3D=CU@=3-;$+B@#O!9AQ3.OWZ7L<!
M"BJ5D*BB2#>V<WP>UTX^SM/D<YJ\I@F#<2X*02"G^$K"*#B5)M_`I,D#KKI_
M*A?5%.@4YDV:$`B/6Z8)[2L*E(&@,%^GR1V\@_GW-+D>.[N,G?$>FTPHR23,
MJS09DTDF0KW#+3^L5/4"N@&_4DZ![L!8J'57M;;;XH!MH%:M-J];93PTNE6N
M`VV01K>QIE/@+<R\6@,G(BS^HI;;MO3:&OAZ:S4\G^[E%&S""4';?J&&\<TW
M*LB?OG%V\"UGT;8'J*SQI3:J#F[X%1K76+<>06GJ,PMWNFUAH?Y'N%0.))F4
MQ9ZD8*$.+`\<1R$F3!AI=#[$%&JGEKKSKC3^ULP8-OM`C?>L[IX98S??A9&C
M`406XI`2%T-,';P8NVM5O52CD%.M&FVTUS\4;)S]^0;6X7`(+K9LYTOL9>ST
MT..5=1OK<*"&Q1M2:_"`F$H%G$^E\S";S:*5F/T30IP&'-(A3((,O=0+.RIH
MWO<&T()'*=,,,O1`8*-5J.9^AL(IA4<;D4+643D>`$$DK'OX4+5#5?15/]V7
MJ^,F<9I*#EEV_<W$\G@U/3-.3O4=6(E"'E@-!$_)Q`7GO(9YCD+_2DP"NG<A
M>8YF':*GC,?H0RE$3/[QK:QU!3/CE3-]N&4[PL]J<D%%3MA>Q5[0*?6XX$S%
M?I[A[7>MO?V_%_V-T?$\[Z.CQ=71\2+[!S2Z'["#^Y>P+YX[F2&X".#P6X`!
M`$)0C6H-"F5N9'-T<F5A;0UE;F1O8FH-,3@Y(#`@;V)J/#PO3&5N9W1H(#4P
M-R]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*2(FL5$UOG#`0O5OR?YCC
MME*(!W\`UZBIE$ND-DB]]$((FW7$0FI81<VO[]C`5KM=4'=;<7F`Y\V;9_LQ
M$2%*#7G)V96(I/'XC;/5=Z'%?;&MH%U#MRWJ&AYWG6VJK@/;=;O*@6W`]AV4
MF\+UE:/U^`'R%\YN<\Z^</:#,YTEH-(48J$!,W`59]^@X>R&5EQ_+AY+`V@@
M7W,FP#_NF3,,""'49A+RK1<3*W%,CC$HDP$FZFQN7TIE\]2I"=P*\7QN7[M$
M'@8C\HM-F25'WSZL5Q)!:0';P29"]8ABCX;?`6XX6W_<^TG?%'I/3\A*`.7<
MS!G-K),@*S-1DM!H^3M)_%35Q5OAJAF9J8@GF9/B0W7#@B.ATW^9X-E*=2KW
M2D4T'/N5TL=[]$\M_!Y-9L21$@(',Z[^9Q<C\,]!A$I-HI*S^RR<.$-[,O59
MP:D[*.7\F3$+`R@J34?]*.A"3!&D/9XBZ*$O>LH@!VV_H<QYV3G;/=FRMVWC
MD\DV9>M>6U<,'VB9>RX:^Q[>3T52\((D+WDQN[/Q;\TD5&323*)1TSQ[T7?1
MU^@A@MOM:]W^)-5W3U73V[4M!YGW;71*FC<3U6#F!8%&-;.9$Z8F;C3F;.ZA
M=H$\''@BOSC09LD/`TUF>@PTC^H1)5-DC/`@T.1(_Y>W"WX),``K[G/B#0IE
M;F1S=')E86T-96YD;V)J#3$Y,"`P(&]B:CP\+TQE;F=T:"`U-34O1FEL=&5R
M+T9L871E1&5C;V1E/CYS=')E86T-"DB)K%5+C],P$+Y;\G^88T&[Q<\X/O):
M:3D@$)&0T%ZRJ=L:I4EQ4G;%KV><-&V`M%)1E<O4C>=[^/.$<&#X<$A24$Q`
MMJ'DELV9-AJRHJNY%5@_43+CBL%]U8:\J/.FS4OX5/NJ=?`N^)_N!K[L//Y0
M3,&'W1;+<`-W91W\(G\!V7=*WF>4?*:$0WS"BI(4`:75@)A*\JXLA]+$LG^A
M*]>4+%]2\N/XOS38QT!PE'R%BI(WV/[57?Y8&.`2LB4EK-,6D0:5VMJ#3#;O
M)<ZD5,;\01%1."(;](3;:9#D-`C'#3*5>Q!FC1JL1"#56_G`-'N]6`37-%`O
M81M\5?@M6NJ>7;%KT4]<7OK"-?@F_YM<9P&R.VG!&78Z30_LXDESDPST5"I&
M]+[Y+;RM%RX2@"E[M.WML=,$DE/VX-9$=?BS!Z'8I#CLW8F[L'>W]USS"*X$
M&,LN-D[8N-?LCU6*WK;9?=/L7+@BCL3K-N#TR4$E0EP5P8Z4",GDD("$:=DG
MH('6E6Z[KBL'U6[SZ,)D!LXQ.',/E31C!E:D`P.M8CUD4">\BY]1\IKHN&=`
MMV*N&..0_4+(VZN"J)'$_:A)I;Q8R)FX:W&,Y&SJ?`2.]3A6+QYA">;=#".,
M:V,/,X+%.IY/YMLR3BEP>;&&HLR;YI^KS,Q_4U`XIT84N#U$1"9V'Y&/^>;(
MP#T7Z[Q:X4(%3VN/*\&M?(/?(;>8LD;9GE<W8N"W``,`JKMXG0T*96YD<W1R
M96%M#65N9&]B:@TQ.3$@,"!O8FH\/"],96YG=&@@-#`Y+T9I;'1E<B]&;&%T
M941E8V]D93X^<W1R96%M#0I(B9R224_$,`R%[Y'R'WS@`(@E=A(G.0*".Z(2
M%RZE*@S+S$!9?SYMIL,FQD&C7BSY\\M[=M4YS+0ZK+3:/ZDO&P9DJ*ZT,C!\
MW;56F"L$)"#OH)IJM7E!SFQ!=:O5<3]YJM6C5LX$()?`)@^8H&NU^K=VGETI
MCL/KF<^<-=!C@YV^NA\K&JI%.Y<3K:ZVLZ^QG6V%/VP%0+O"5N)^-&17NV8/
MB3Q4S5B'OG[KW1[-I]/Y#,Z>Y\W=#FSL&8/P4'?P6M^_M/#0=O`TJ;MV1:!H
M:!EHF>UGC@7P*]*ROTXF;^E'J,]$8YZ#:=O=-/68"([?FTD]NVY_7WO8*N):
MQ\ZC7/B1UM1>S*X2[U_>M1$A)`.4A;\4AM4.?7241(!<D!6L)Q(!Y_ME2X!W
M(8@`>Y2!X(WL(7H;12"5GD#C"XM`9"IH$!>VC98=%P[&SLB$+Q+,3CX)!N8"
M$3G)*\44K+P/,D-7)#"B_`I11/GV9&,A+;GH"AH^!ODNQ#$4LH1$5B9BXD+:
ME%AV:DU,\BL6$WW+`A\"#`"8&UXS#0IE;F1S=')E86T-96YD;V)J#3$Y,B`P
M(&]B:CP\+TQE;F=T:"`R-C$O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-
M"DB)A)2Y;40Q#$1S`>I!\0(&>!\%N`!G;L#K?/L/+.?V$#_\#^20,]2B\_N]
MOO=Z/O9B.6\J;7*RZ<AY?>WU!Z%=A@DG#DP$^4`D$V.BF'T@6AH3W8EG,6I7
M3'#70$@%UF':@F<Q:QF4>GMA(CH3$T4ZS-*4N,LU7[%SSC1XZ^8Z='$OO#$/
MOG\AD61XIU[4@XYFP4D.NA'"!.MP<R$Z3!OW+`<=9H;=C[MV[$N$]5`C?4AR
ME$\ZVA/72/+"OB0'XRXI84,-C2%!:4D#X1$#$5'X=<A,&916#DG.3L4[+<KA
MI2O.X1I*:DA0:1-66O>EP]=07O9_UC_V>O_<:Z_S(\``MYI(_PT*96YD<W1R
M96%M#65N9&]B:@TQ.3,@,"!O8FH\/"]4>7!E+T9O;G0O16YC;V1I;F<O5VEN
M06YS:45N8V]D:6YG+T)A<V5&;VYT+TAE;'9E=&EC82]3=6)T>7!E+U1Y<&4Q
M/CX-96YD;V)J#3$Y-"`P(&]B:CP\+U1Y<&4O1F]N="]%;F-O9&EN9R]7:6Y!
M;G-I16YC;V1I;F<O0F%S949O;G0O5&EM97,M0F]L9$ET86QI8R]3=6)T>7!E
M+U1Y<&4Q/CX-96YD;V)J#3$Y-2`P(&]B:CP\+U1Y<&4O1F]N="]%;F-O9&EN
M9R]7:6Y!;G-I16YC;V1I;F<O0F%S949O;G0O5&EM97,M271A;&EC+U-U8G1Y
M<&4O5'EP93$^/@UE;F1O8FH-,3DV(#`@;V)J/#PO3&5N9W1H(#(Q,3(U+T9I
M;'1E<B]&;&%T941E8V]D92]7:61T:"`Q.30O2&5I9VAT(#$V,R]":71S4&5R
M0V]M<&]N96YT(#@O0V]L;W)3<&%C92]$979I8V521T(O5'EP92]83V)J96-T
M+U-U8G1Y<&4O26UA9V4^/G-T<F5A;0T*>)SMO0>4'<=Y)EH=;YR$#)`8`(-,
MTK*T]EKO[=&&I_?LM65+LJQ(46(F(8(@"8@$08`@B)R!&6`&@PD88##(!),I
MR]KC/<>6_>RU+8FT2%,6)4IB0)IT<^I<[___ZK[W#C"@+(^UQ'GGUJG3T[=O
MW^KJO[[Z<]5P7BNU4E6\H%:*2]6^IHKKM5(KUQ3O`X!T5:V56KE.\:X'I%JI
ME7]U\7[%6BNU<FVIH:A6_MU+#46U\F\I[CCV5PU"M?(K%$".Q;E!1[MFB-7*
MOZD`<@S#2G!>-*VLZQG%4M8T2^([TS0+A9Q@5O`5(*U8RM205BO7%+MH)#P.
M4"D"G#QN(F!<.Y?+T;<HYDRK4"RE3#LM[JFAJ%:N*2Z!IY3)CKH>0,BU+$M\
M42P:I5+),(J>+_**B=3[!"3[P^UQK=R0Q?4\QS_U^,AP&HZV5:U.^[I3H31<
M0U&MC%O2J8+K(%)R&<\"EN/XU2AB%5C*9K-"@P+=J2;1:N7JXA$H'&X2CS$+
M>,PF_>AK*<^S*;K!XZZ+.G:A6-.N:^6:XB&$1JZ@R"H!FS&Q%E)XS"802/DT
ML2:7CXYDKOK=&#?2&-EGX0E]X7EEP>B*GU7=;`<WVV,:%0X'K_HV`X^>CV>Z
M[GI8Q2?7\QL9Z_6J]G%5NN>.35$H%W?,12^X]SI>,KP<O%U5._0;]P,<:[9/
MG'+C8TJE#V-==*[02WV'C'_5\@1-_$:L"I6JZG4<?N.&VMVQ7XW3DZK^5&5Z
M>*Y`42;)P8Z?-?GW(O+O*.PWY\S\75U:.FW2QX<O<\_FQ3S>6"PYJ"_9_HB;
MW+6QDO0C>HI7*YJ7.4_93@F!X/!"$6_(FP676SCP+EB`'`0HGG.XF+3<0<YS
MQ7S!!R#<4$IR^+F#G)#:!&L1]+%<(5OQ:=E>R?2@0[QDP04#WB!;A)F0S^<$
M&W5SF3RTX`6#5DCGQ;O3#?E<8=#C8#78IH4==VSNN#`$>:J6WQ.:4-""@(KK
M6(YMEB&4R=LV,'`;'P;MI)(YO&H;2!*@2\ZIS)<R^/$/("$U-'@!6BZF*W/%
M=F@J>/#4@H=D,7%X/*25@S=8)?O]DO,SS@<])Q$,>*;HI/,Y)+*'%(4Y/UHT
M1N"KP4OX5H4"CAHT#"V8KB>&W/%A8`>HPUH$FM#WHZ/#:*%SRT&#*^_PO(?G
M2%^;VDGG"S!TJ>P(O(CG9=$"2UWA0#H7P08TB,=^U\BC1#,*0%S4KHT2;VCX
MCX[%'2(7-#(\DBC/'I/N\H'D88<%BN!=.$^,C"3@A]B4A=WR40MD$92W\81>
MRJ4.TL]M?N4]>@QBVTXE:#2A`7N(\\NN-PH?BUD.=N3@90>>6*)&X)C(>P4/
M&K$2R<L"0JY9]"QLR@$,%_`Q\-&VB@)(<!O<#)1)93G8HT`_B[P7PT.7N%=`
MPGH^BF!488R(\MA]LV3@N-/0P$O!)W@7$]NQQ<@Z^:R;RR+\+#X.BCR!HH0-
MSX-9D@-[F*@!`^3Z#%]P;WB8Z6'+4`N`-Q@"Q#S@).&Z.:0:LIR4PW/PPV*1
M%TI9PX5WAYH1R@F\E$DC9!C859H0U2@JNYJ+/HN#:4ODSN7AF3Q7X@7#'Z\K
MP]R`H;1Y.DM=PBF,G4168%J"+24&DT633Y[Y,</DC/V1PK[6$+N7L?\HZ`-5
MEFZ%?B;3OM(]FDD$K-FB:OO#'DRWDC5DVFDD->"GB&\T,@(SEQ<L)`BPIER!
M%_)X`OV$1T/WLCEN0I]+.)7A5\E1&EP@RM#[P#1@\J9SOX"C&%_D;SFB3XDG
M$L`A><G$UP1ZIC,%`*TE9H^3QV$M8L43^`B/,AVX(9,N.&2$PD.M/$\/`X?B
M7HD;/NLS?""Y97$,(Y@7HF3H"O`D1%VI!.U@"T!(F/7"##'AW1R\L3!4J$C2
M,8+8MJPD(O8]@!R^!=`YD^.I%!(**C1;-``5.([0&-+*Y(D<+WG8K3RQ/L'Y
M"^9(T4R6BCB:!)!,(O-3N`7(`N`?OHBX0/J7P#+"^3(&15Z9-UJC0^\"D'+Y
ME$<MYXM\<(1@4^`AY1[&OKID03MCCT.-J$]I\L/Q^/VY'+!^)"#P<*M$A"$<
MZ-'?@+F9SG"=W6>F\75"X=].I/`%FQK^BTUC!!U(9)-.H#DXR.>@6D)#\*<2
MEF(ZFTDF^(PIGPM)=S#VI?KX7?'ZKT0:OQ1NO",2?S@2?2(261N)/AF+/1RK
MNS\4N9.QS\Z<\:3$[A@>Q`D.KP"S[\*581@^F`$P,P"6A1*PN`S0$LA>7_=_
MUD6^%-<?;*I;(;%[);8<GI+/(L"@JX4\$*QH&$E\,0%]V\&/O`A?V<1>0!!(
M[`]5=H_*'IX<6=N@+F\,?:DI]G''$NPT0Z(-P&,0A."Y.1);#MP@L?\4U;X<
M#]_56/=51?FTKGPAK/T^T'-XN.@#ABR48)BN54ILD!LM,Y>K["[&/J6JGZFK
MOV?:M$?K8P]"C<<>`K)$8BO#L2?"T;7AZ!HM_!B\7>.TN_,6SYJ\!#S004XE
M.*30S>AY^8)Q!5U_H,%>X2TWW:FSSS/V%8W=U5!WS\Q9GR<(V5XUB@*%:FCT
MDD=-C"21^#`$C'V!L96:M+LIWL/8%L;:&J(G&=NI28"H+;+TE*XO!SX`C&YX
M!(^@5\!L8FRQX6(+DZ+0Y[O#ZA_#161H'M?5WX+!%2@"'F:X/NLC"AN><&57
MZ8KBU6"6Q?2OR.P1A3T=CVQ@[!M,7<'454QZEK'=C+52W4D]W!"-[&%L]92F
M@X3Y^^)-]P'C`D*E<EG''TJ@$4S'#/`;Z`:PLICV@,36U(5W*6P'8\].;=QO
MYOFE]Y$YXDABL*:820Z16F/C"2_"1914-MX&@GO:I$V,/:&SO8W:09FMB:L/
M@:*"V@&2,T&:V"@QP`RA*&^"4'3YQ0N\,;9,9VLDMCH>?206`0`_TC)[R]`0
MDLAWLCF^1*OH/545M<0\CTCWA]FZ6&AU-+Q:8NO@]24&5`+B;"?Z[`](M#_>
MT"-K<.4)65\5G_PP8_\7$"51Y'E@PH8_;W/9-#VR:%H%9%-9'I/OB++'Z]0M
M,76[PIYB[#,HAI"8;L5PH%/3A1G`DUD8610-=?5WAO05FK*Q(=;'V"$:HWVR
MND\-=82C?:K:SUA[4\.+C.V-Q^&K+\*4!35N)$_@F?*[T"N0#E'Y`>!%Z2&N
MJ1\%<98K`L"6.B:2:"@!C,C-HR^@;!18O(RB0.):C@D\&61-3+^?L353ZXZ'
MY#9=W\O4S4S=SF2`2B]CQZE"/[M5Y0AC'0VQTXP=4.4#BK*-L8?4\#V#0RC0
M+XV,."C24&):;A&T:-"E031'M?MF3>HF@G?$0^<8VR2S;]@%9#]#HYFB44JE
MA8-4*,Q%^`@7X2O4QPI<8="WI^K#0),V(-3-DPY'E8>!_SL(0C=`T;!@2AYI
ME\E\'IX+?'Y:_0Z5'8A*78P]!DC6V%YH:G0$%0:<:(Y5S!1\[>XJ%`E%FN.T
MC:E/Q-2VB+Y+4:#"BW3*K`-J0)R!@#[P<:^L]3<UO0#OV#"YC84?8>$_R9)Z
M"59/-IL7=IGGD!^FD`,4P7C5J8\TR/OC<G>(=8>DPXJTPD;$Y7USV/,-3$=P
M,9!?8.?D8:S_0%$?9>R;]5%X],'Z.#RT$X@LJ8!G&)=]V$\%+AY6E!-P9<;-
MNR?/6O[619[UD!W%XI^$5TLF>52]<^A]E*<SIO_?H%_`HV-A4K#IB89C5VQ3
MH1"C4'0KFB'Q*[@)A./T24\I@%C]+/0'J[27R4!P8(E`?T#.$8GU2*PKI!R%
MBPKKEQB<M*EJ3[P.2/>TS!X`$3^<(KV69)"#]CP0+Y5S!===%E&/A:3SBM0O
MLP.3X_".GP.BXC"1+>6Z&=.^#!5..%V$K[)(J\_!S0H[J$E'PFIW5`<2+0-[
M$%B$XX@!SY-A6*&Y0]KI2`9^"_)WF\I.-T5?"2%MM];K9V2V;^;,51<N`\/B
MY'-P7=L9U\9&1NJ@[J$QD.!`"B!(FR0_S]AS,#1P14+*`+:!%#U$J_;ZAK/1
M"-S0%8]^.QP&L;)6B3^NQ;\&8A$,C7Q.V-I@SZ0%]P-+$I2K,++93@EQ>%1G
M9W7U6>0X?N:&$"45",%[`?-7HU]IG+Q>U;;6U1VCZ=G=4/=R)`2SNU77CFHZ
M=*PU$CFE:8"?SG`,NO<,B!@U]F"XZ6LPMR\-\GES;\]E>'WL3VZ>>F]<_R/0
M%2V3QZ/_(9/B<V9_LD"J8J&4QT=7NT:$W>%5V1?<+=JHEX"NKDK?4'"F=RO2
M247M8W(KDW<Q>8\L0=VE8-VILITRVU$7!ESM"\E'%'9$QA?O"VM'HBJ\R)>%
MCH3FO(U##*IXHO0.J$Y@5$:B#Q+7A=]V:DH'\(2XMAJ>BSP!=(-$EF`P2C4/
M'^$B,A-X+VVUQMHTZ2A-M$V-#=NAJ60*`9I(BP%WR_CQC2^8%P8"`*1#8_B%
M>NTO8)1CX>/$/?HT[,/70<F'%T_DKI!,]RJ"PU>07#)K\![0G"/:,S+U'.C#
MV"O`?&`B*-)VE;4J<`)"1-XNJ\]`!=CH>D](!0X`\_%X.`2#N(DICS;%[AM^
M'W6\4@FQ:Q2$'\9$MT")URG/Z.RXBC\Y(S'X[=/`H&CB6\(N<U"VH]H`6M9(
MBLNA.V0-N-`&/030W=90?R8>!IP\U=C0JJKK<<+&H2=/RLHF&#[&H.Y2M0.Z
M#D+MB4C=4TSZ,LSKX2$^:]K=R6%NYGT#'F8NB->YLS\%O-KQ&;/M"2>4*$X@
MQ:JM5'0O%%&[-;FF+0-J*#BSCI"$?;:I:1=CR^/1U8S=$PT_!+I?+/0@"!>-
M/=(4WZJRS6'E4$,8P-\^K>$[80E`M2X2^V*)3$5@;NC5@;?F:9/G8%(54)U;
M)>-`[%6U0S)RO'4-=7<#\*`3J,AY.1))&3AQA!/$XG`#W`:_TB48CC9%`57D
M*S`?06L5)!4O*XQ!>*E2P4=1B:8M*'(A]E((Q_U8+`)C!/.]GQ28U6!8D265
M\\I.5W<,D#SRB@A32Y'74,_;F02,]R6`AZJL"VG+(\IC(?4Q.`F%[@E%OJ1'
MO@+X;*@'[7&OQ([%U5<D-J!*/6%MM\X>G1S_&MH45=Y1TX0NY`$?8;8&4"0S
M>$>@YUE)VN8895L5U,N1HCMB4!@>N9#^=4E^4M-@=+9$H@">S?7U,/T?#$>^
M-IS$N0,T&,[CB1K^K,16*&QW3(%W/S8E_AW00QC;$8UL`%E?R*"VH+)/3IO\
M^YIZVZ2FCS74?V1*TR<&A=<1C0^[:&:YB-(&IGZ%2KZ!YI(*03:2Q37]/F`X
MQ*)ATNV?/FW_+]Y&1R(PNIPP[0W4<M$:S?&0=+N,NLJJJ-P>E<\`>X=?R6Q;
M7=TCR2Q*;9S".6%UP5@8EU/#0*]9-X'>^'08I\^!F'ZT(0;C\@`()M"C"@9T
MQAX>N0`53N`C\)E"#F#P`-P6TT[`Z(<UH-C#,^8L`_WP8A*X%+V'T!D<G$V<
M'*26Z252=L;@<N1S&DJ9TQH[KRFGA70.AX&G[;AI!G#%VZF?=L'*H2U79M$5
M%*%[#5$$/$UY'&$OM3$9B`-ZW6$P&82Q;Y)Y;I(3P$`M$&S2K]>'GFX*`TWV
MUVN@V;9K[%"=LEUB=PI=#NS]?,X(GI*#^1*65NOL&"D)()X&)'D3.H1(J'E\
MQ..704,W:5Y<O,RG3]^F('LYJ"M=J`5IFV&:`T,3%E;6!E2"@@R3%R$'PR>!
MXLIVSZJ#J71X2NS/553A-D]I>.C*!9X81KH5"[[L2*=Y*HD]!$E'[-D:25ZH
M,@\K_*<RZ9#D\-XY?[J%[E3DK9)T&.$JPVRZ'^`*X(%F,QD\R:7QO8H9E._P
MCL4<;XRND-D3478HJAQ5Y/VROK6A"=[HLP"8*ZF,0RX%("\)=.O=P5S!Y.$H
ML*.=I/AMB86ZX\!FE17"I3PRFA8]A1.;'+!A>07<`+<QM.RZ0."&HX\")=\9
M-,GI;)2<@ATP6,<6CGH@)+P4LJEH_3)@7U'Y.\1@=S5..L&D_63YPBS>$`NO
MS1OXX@Y)_\KDJD*1P":($TU9"8R:2;O)W!A@\FXP;6"&NB95BWQZY-^#H<QE
M^>!%/K4.3+GU&NN\N>$[H%+J8+ZISS1$[X<Y/IK`)Z13!6*B>4!1A#VNLVX)
M14`GD[HE9;U7)&F*XFS4XQ=-4`W(<QN//22SC0K.]*Z0!M-PG1IY)&OB&`&7
M*^1-8JW`8#,``#(?<.`8^^]A^5&-;837GQPY&Y4.*NP^@+1-:@.\9')41`1P
MR`!4&)E%OQ;,,]`TH-F`&57'F"JJ-1`\7X6BS8H$3'N_I&R8VO083#'AU2'O
M6\'(9\1X)4<MX2U/C?+ZZ,.-44#%4Y*^E<D;0M$]3'H0=!(DOHT9F`;YHM/9
MA$T<+Q3Y`MP<T;K"D6ZT\M"H>1Q'Q$,_!NCG6,D-"Q?A*P5O.!`-]T11JW\F
M%/HZSB]`6O$2D*=DI5`/-SS3\`*&:R0SEY-9C[&/U]>O5W%J`Q,[HNK[\.=U
M@)]G9L\^'E&/A)6MJOJI5$[XBL:1:&0EN`)%NO(H3'])VL'D?<@NE$V&/8XG
MARHB"K2:;(I'Y!6S&F%6[M*0R>R**+L:8NLQ0.#Q5#[I"V)N`>^(2*M":/0!
MKX,IW"&I:]&MBI,)G><>J#"9BZD\.FPU^1%0A.KTDSJV"31_)`/*#`$`E2P*
MX>4+5T@WR%EV,9FT<'Z5^*3Z!X#CQ;76F`Q\>,ND,,B%C^,#O)QEH?<8<)A,
MNR73**%3&$<MFQ^B=GA`7E_WI*D:6([DU[)QT(1$NUN5MBHX'?;+,FAHGX$O
M'#\L57(]=`-B?,)S1X=Q+N4+Y&;/<%F^/Q19Q^354FP'\GSV^.3I7S+0$+2R
MN1$8I/00:)&.L)I363ZEX4E=!E5\+]D1G;,F'X]'OPZVF)@('L47X"-<A*_@
M!AUOVQN6=TZI7X].8PS0`%6&1]/OD=K"+=\/8Y-OP:`X%Y\Y[3&%;8G*IP"$
MC?7'F+1A.`NP?!"D,&,;Z\*@@3R[:-ZV=`IUPGRQP,=`P@T4;.PS<("PO%)E
M>\"R8!*@J!=XA8%1%&`/%N9ZN7Y8#5B186:*1@[>MF`@4V+LKA#;,[7^7%/=
M@(0<>),FW6O@*Y22J;P`+TQ)X$4A=E`&&Q#:EP_*ZN,>3"50W;R"80YY.,M1
M8B;1(;.^(=1%"O.>2/C9*3,>NS0*<*');@I;KH!!S-S%4G[$+*'7&52LW"CH
M/_?+[*D0FIG;Z_0.A3T05OYST0;M*97*N&CM5M3IP(I'RS?AQTQYX%U$Q[6%
M+USE?+!1WR'M6K\/3#`5^>H!0%%3PWUH:U-,+96Y:%KHSW&M@H<^=-N!V>_R
M=(F#^@'LE(4>#$_>#N8)L-F&^IYPY+Z+EX3IA%$D,^.)"9XO9I"%%CAZ-27@
M8*!C`Z_8&U6_:9)G-9<WH<()?(2+Z'O!&P[1S?>C*0%3!KT[8'XF"J4A$>;P
M_)B"!<.7+YA`C?=^@8X%F/[U^KE94UY!*XE],V%P?=(WE,B:6.P`F0\@F[YI
M!NZ"<2/F0E<"52<LK=+!$&,[9$*1+*\SD>8Y/PFPHB0(328/K`-&-EW`R%$L
M!')D`_D#09_IBH?7YM")@1:T2Y,4!B#"5E>AZ("LKDJ-<(KV"I\\<J$?O<EC
MX7O0.Z0?UK'ST.S]H`"!M#&YK^X6TGD3H^`4%7),\0*HMAFHC-75/:;K3];7
M[]2T-3,G/99+D31W!T64O%`$`I9`N!>!'Q6%CQU#QLG11!E%#C)F4>T@K\V/
MNB**#+#10`?;IZ)?Z)`L;02%__(@%X$FW]X$])$&.S@(SP72VL)%^,X(#T^!
M.?Y$W?3GR1!N#RD;`"K4C91K)H$:5LXR@:`\AX-2XDU-#T7B8"CMT;3NL-+>
MH(*Z\F5R(5)$T08,?!DNPE=P`TZZ>.ODQF7P:F21@3Y\N6A=0+77P&EB%$W'
M+ADFC@L@:N@*GS-]^>3P(?+A=),A#)/W&R!36>2/F;Z*',X=,^(O3D9U_6['
M$OZ0ZKP7M^QU1*^7/\I@T>]66*O,^A1I?1''+F-[!=M%W1SFNT/C9L"+.J-%
M?L5`XO'+"=XX!63'1CW24=\`9D@_*"<P#Z_DWLD578SO.VBP1-G:*A1UR-I*
M<LOG/"M5R*=!DT<SO,@;HBOCVG;R_V\$,WG6]$>'1@FU)DJBLM<+11N=I%()
M8"M9PQ`)$&K3;RM-GWSK,L]8J$BC=]KC0\E!#!/#O;E+7GE&(.M+EJR?6\Y%
M7@XL5J%(>`"JV1$\$U"D*\M5UJJRHQ([+$N;0`,!\0@SKH1"$BPH(Y\ME%5T
MX$598-V@(KK8/2;_=U"*F'Z2L9-@3-6'#B6'R,$!L]4C>](5WH]$P1R!(0/!
M!)(%5"--@3FUM4'MCRG/P.-@DN8H5@L?ZS50B;?"#:1!K8*?.)BX8E$0!WV,
MK@O]L9V2&'$WF00M%!D:L)<06P&LIBGRY\!S0BJ89NN`@V7(SI'U;T9#H)3V
M:*Q?80?KM?4VQ?H%&_$CYIX?)$(2><2+T!('C70_>8=Z-6F=Z?`R,7W-7#@4
MD:H`[LM@E^3(OI-#=RCZTY("HF1W6'JI(7[@YYAIXEID$00H6D,H:F,2Z47:
M2GA9QTH8A5%."1B)48P^@\4*RA6`.23MBH4`G)]$E[@E7#BN\'JA)\KU_5$<
M8]V82Y`QAT%"#AMVTD%U.4NN(7AZ4;CM>2Z5_X4(/L)O@7?12B+,\,',!%!H
M\NY5$NW:.!I\40(4J<M`]"MHZ1^6I"VAT%V82N%+2/3-^/Q=5.HV6?%<6)1,
MV4A6*IBK73H[$%8>,I#.1I5.9E&<*X>:`*C9VH,:6H*[0C(\$:"[3PK?GG'1
M.0(GI$(<#4M'4#65MX3T^TTGH%4Y3D&O(<@%GT;2PS9:^3PSRD/HLC@1"K_,
M6&M=Y`!HI&`(8V#4YHUUT,]6@'H(/3-[&NJW@?8!!@:J%5;6P*RG'/(FXDEH
MSE=9^A)KDQ%+G9K\./7'JFC6@2/.$[W$R5<R2;R!4::KJR2,M1U5V0F=;0]'
M/F7XF384Q#.%=@TH0H>)0!'H7:62B!.[J#E3(FM4VZ*BF=FJ*JVR_$2)4A2X
M8,%EZ[NBW=ECDDF"V*[G^4D=Y9A/8'$%+^)?L@/G>:40_8/D0*?B,L)(FH=2
M)JP^4$816/H"1;:?$P!H*HQ!D?],6SAX@7N`$&3H-^L#4L"T!2.=-#M;V/N!
M"9,AA)-;&V@KKXRI^Z/*,9V=4I3#H?JU/[W,H>KU:S49&CD%7\$-<%NI)-*N
M[,K<#RPIBX3_:#ICHSUE71CBNO2-IAC@^8`</JTH(-?61/6OYLDR&DEB3"2B
M`@/LFM+X$HWLLJFS5J2+HEW$N6N-.&":%ORL0&1\`&QM%>E1!PA%';J\BE`4
MQ-R%\]SS_Q(3PS0HA_@\O&E(?41F^P&Z*NM'%(70R2\2R1!%%J#H41U1U(.1
M.+F#Z2LQU0=!ZF;S&>2Q-@\IH!YOE=#5<%!6VB7Y28"I)5#D6E>CJ"*@#3\7
MQ'/+4!\#MG'KF%+1^7YU%-US-8JJ?^B/I45.%7S':U#T**'('1]%+DY41;F=
ML:?!*I30+;Q3"6UNG+X+JAS>#!_A(AF,3\-M)9./DRD1Q+DMS)Y$5U'6<F".
MSYH"/]]2/^D<L)IX?'\XO#R3\\T$8`[)%)\RZ5G2=;=.GGPX7O\T8Y\#2QG$
M-2CG9$2DD<4Z8%J:UZ"H769@W72.CR+?XA(H<BCARPU0]#!(JP]$T<JK4`16
MJD<1/I%I#&TQ=GM=Y*`D`4TZ9.!7`D4V/=TKC<6`&W3)+E/I:I]S-52\JN,'
MEG\?%(WQJ-C$L*TJ%`T$*.JX&D7^_2)FBM,"6LR#U1!>K["]==%N\D/N8FPS
M53C9!Q<U^"JR#FXSO+$HJ@P<7LD;OF,G64#[FK'E3;'C&.:0`$(;5>TKB!#3
M$YH+=%6/?%5BFT,J//1I-;2>L:\-)GS933W,H'$$W#*+/1<H`J-I+(J$1'.K
M4&3Y[,@N0QL)8!)M?PF*3(&B#AF)W\>D3C`!TEDA?3`WMV0X(PF^=`%8]\^0
M6_BP+'=6H0@>G0WBME6U&E=E_#CCH>A?77YE%.GW5:$(=(H<Y_98%%DB,>P#
M4<2K4.0*NU5XJT3.G*;=!1*'L?6JW!X.]<OR4:AP`A_A(GRE:5\W2(LE"+E5
M65Z^K#=,5V12C60QJS82_D)$WB(4C/H8Z.>/2^RS?NB?4A<,EZOAW]<U,'-Z
MZNM`-=HR?7K[I,F/@/J-J238;*Z820B:&^0^!4T.4$21W$,R<L@N[6H4V144
M.<*7""I8#J,Q9).&M.55$FUG6+\=3=PQ*%JE8[8)14"D+D"1B6%$=*ID<FG4
M^A(P.^Z54:-#PU.6NQ!%%((4_FT_!;W:QJS&SSAN#![\N?;XZT,1H=WUJL29
M0<D\1<R%`Q2!C?9+4,0#"\C/509M!!XQMQET['6,;:)D*N`/O72R"2["5W`#
M*BU^@GH91442CD7!BWQ+DV.(7Y7OBZI[T5>)\?%=]9%GS0+&X\!6\2AT"\SA
M\B@/A[=B!$$]IZNG,&(;6@,CDBGQ#"T60%Z$,32>+R`,\JY`42=YF;H(1:L#
M;;^,HB"+PT<1"DGRAP@4?2-`T<#X*,((2)>,D9KC2`1"$4A8,(TM!UW2E)IX
M_]2&4Q1KZZV@R/<-#M'1N!I%UX)GC-I3_85]+<C^?5!4&@]%%?%4_-51Y*^L
M(7/8S121>X"Y6E^W+1XY2O3I8NCV/`H?X2)\A<M%B@)"1D7@DT]5S+Y\$8PT
M?BF9P'AWGD]KVA;&P`IH[.<9:]/9"K"C7?3PHS@&X9@S,=BMA]>0W`2DG04L
MU=?MNT*.ETS!7_Z3'AD40P$F.:'H<4+1X0]$$:T,\@W8?P6*W'%1-("JD?9X
MD7*?*.'3S>5L0%%#>!VIBW!/WU@4@>5[97P47:,P!UDTY95<Y7K5%;<:.O]6
M%&T#X_H:%!D5B]+/>[D*1==JUT$6836*?*'M%BU4&Y(9'@D]0>;2WFCT+%1*
MJ]@/%^$K]&59ME=&4<4S/TI/1]T><U$PVYLK\MTR>G3WAV5T6\5#A^*A>RS#
MM[Z%LZ-$/V/L"Y'X`1`?JO2*KCS'V%/1QJ^!?8?Q#K"O/=LJYL@)@LM?`$5D
MZ7<)D,O5*/*N09$KJ)V[#HKZKX\B:/EX&464N9HBASQFU0**5/985#UR'10-
M!1+-'H.B2G'I[45>.HY:%?,IH\@:T\(XMO^_,XH<C+06751LLZ`-`(HT;5,T
M"L-QH#YR/(PJQ#V8&.Q8UT,1QWBK;5$`'JP/D%_QNCZ1+D@GZS!SPT8C$&X+
MU-<QO$BL4(/VTP;F@0!)9?9H'!,`#JKL2%T8AF,Y9JJ;I)W@5CQ%L0AI%*2D
MS9782O16Z6#*M49CN[7877F'9TL\)9;">;9=PN4HXZ)(45:+M5I5*"J65REB
M'AI.+M2++H\Z)BK\7PMKH)SW*:RO/@SSY3.%DI]\<`V*3@H4%5#R8V#.\6S7
M%1+MOFF-9RDI]XB,"2J/D4.8DUTYZCM+J_7J`"2CJ4&1`D1KUF"V)2EV8Y=*
MI4"N(3`*Q?08S>K7@J+T6%XD]D<RQ#B29;06M)&0<E27@>WOGERW)F]>9:-5
M))KH8[&`JP.!=:<R?-+4C=B"?(BA#;(6/L+%(KGHX;9`AI;7L18I2]\JNST!
ML="'B`KVW0X5^6$71@/5U27*I31I!8/K8F>&LWRXB"YWI>$!INX2(1M:AG![
MEO*9X8G)T93PRCG(9:TB>AU7RW@G6N(?C"(*K&,/\]:HL-%^\3,^;?)ZC&ZP
M;A7)^_B<YA5@R)>L:R7:&%YD6`7A2\GES42*-\_8SMAV6>K#[&7I\)2INRY>
MP=X2%Z)UCF-<CK[D$FR\9*4RI9&BDZ;X!6#)2*93HNLFYBN[M$K4IMVN@K72
MOV84^0*"6G,\].2#W1I&)\^^:*@?PU[2P9#\4+IP%8J$!13D@XG5?`Y_YWW4
M(;3HG8P]J^E'-/THGD3OA(OO4(JI*58W^@$&\386`9A0D4ZB,0XPEOY$DW9-
MBC\/_%"18<+NFWYSQ\_>I=64)N4\9S!5&W"5-?E/+W*M<3D%-#N:&L^%H^W1
MQ@VA^CN'$IA.@',:(W:N91>K4-0K4(2JD?+X=7F12QEH9(.F\SETD61Y//PD
M8]OB8=#D]T=44.S_'Y'N^P$H*B&=P`+-N>0A!QLM)#TLLWV1,-RS.QZ'VYZ`
M=QG!L(]%P<IJU=@M"]EL8123;MQBULRB2\TPAI(9DU33*Y?2N2P^)IW.<L['
MBK9?LT1#LICE9D<3N*P!I/STZ0=(^02^O7W.C-,HC[PJWW4%189`$:YPHF[`
M'>]=YEK\"TU3V^GG'7`"'^&B+0(*J'@Y51*\[$?UK3,#%U#SIJ95NM1*`WU8
M47L4_1AC3T^>_I2F?XFQWZO3/]\4_^S-,^X'41N./1EN6HE9(O(./3)`EA>N
MC8HV/EJ@T*$@H9'/48Z)!7J7AAFSO90(BB@"9?L#4"2FV&#B,C25*XGXUPI,
M<F,=LZ:^4!<&EO)[*-&`AYM6X'44EGY@HVG8?CJ;,JT\R37T.JKLOH98!WH=
MI6Y:TO5-0)$#4CB=0Z-RC!/&#28:.O02V:0@W(7+!5.LD''YI0L8]7'(]6T:
M7J%0JJ+PKUDO(DL?U#V\5+1YD`Z4PFPZF-H=JMQ!:U@VWCQC;0IYD>%4NF`3
M[_77L8H^6+2@&%J7(Y]5E!VTF*(?3N!CB;8(L(PR<`1E\A7]7*QS\=",$<Y&
M7>Z(A4Y2VM(>)@^0&K,Y''HV(C\Y)?J,CIE%3\24P[0<:;6"NM`A60<!<2(:
M>G[RM!,`,)#"&+=-!]HX\J$RBOH"%'5>'T4H<R]='.449'1H]/,I/FOJGACF
M&&"&I\+6U==_`1A1R;[*=]U1\1=ICQO$LRV[D$@/64XI6Q1+7U>#F:;JW=.F
MG=7T]07*O^75'D67!XM]#.'-&TWBVBZ0%[BZ62Q,-C&9&7#G)S02\&AM*?<\
MY]>)HD(919EDJ8)Y%[GQ6V]EX_%/39_>&HD=Q7>4]LZ<W'OY?7R-9''H&A05
MJU&43F82&0S+,^6S,.(1_06HZ+Y6$$7)M)-*9?S>>D*M2E&R7#EZ[D\YQOZ@
MOFY;2.D4ZQUB32>8TB]%,$$Z'NT-LUT-ZOX(.ZBSHV%<87%:!\FKM&KQ-LK\
M.4:U0PYO5")?-&R?`68220*##<.M26MIM4L91:N,JVVT"HIPHAE6KF0`80>'
M^:3X_;AD3P*]:,N<FUZ<,64?#*A)A,T4\F/C:$?**"H:/$.+UX2#%MC:\!5^
MT\Q.2=D;;SA*LOBAAH8O9LG1[C-E'Q)V8$'[6JM)(J%8XO7UGPFIGQNY@BE>
MR4'\R=`E?(ULFA)N[++C\=>.(@$`V^#YK(N;DS@X'1H;_QAYD=S>6-\7CX)4
M6@,X+V+HJEB%(HN+M"Y"D9$TJ0.8G@W*;-.D%3JF<.#R23B!CR-IX7I!%!G)
M4H"B49'Y5EY79V,TG]?5+:.UNC!2'9.GG2)?T$$FTS(ZU)$VJF!?`\]AWV+H
M1SH9C0"6]LBXW&9U0_U973NOX9+D]4KX:Y@N:E84C"H4'?OE*/+\K#!;:,Z>
ML*V^.+EN1SPB&#6,_L,E@_9GP'N098U%$45`2**)EG/%1,G*@*I5PNR^;Y(_
M=L?T&6>;FG9%(I]SR*(JI8*5]+X3Q@A0Y*:R=H&X*_0JJM_!V%W3&[?6:<MC
MRB?@QO2H#S],'_#WO/I@%(G,D"HKR1>@*)("%.U44*_HD=C.B/H-JR`6GT+-
M@N%2%B68?Y)'80U4@OEJTKX3]?4=L@(4WBJQC3.F[L1N8TY%JAPFH`[X$1/1
M`1?W:QA-%A(P3+)V/PF:LU3;X"/(D60!'CJ*MY%V3:L7$X(7>91I;%+&>,'!
M10&,K9O4<)*"E<_*T5TLMHUA*OC>D`[-K@U)S^IHBW5$E6,D679KD1U,7:''
MU]'';C3AM38]M`KL>S_=`JS(?,DC7A%F:U64:$?+*#)%_D[%)O(==R:IQ1[9
MK29E4BGL`06'?FLL`I;CEKHX:L4%BWQ33D%XVP2*)%0LNXD7K88^D,_!PO1^
MGK4IPR0>75,7WP]-Z4J/B%,#\8$=58DS(<ORP1IARH\R,-=1DS]?'WHLC`L*
MML7DM9/B?\18LT>F1Y`7+=C1>"@*BC#Q/%KPY4=%/7_N`$L$P(259:JT6<$7
MZ9=8>Z.^QDYA>YBD6'B7F`"BR/+SC*SA_"@H^`5T/G]&DIZ640\YK(?:]2C8
M(W\@/($%.R44O"`9"1=,&'2DE\W9'"VLO,O5R`.DY;Y$]1!\S+M"6Q41(N#\
M"8>GT&-&&GZ1,CU@C(&EJ75?D[2-BM9%ZOV^:!34UP?4R!UJ]"MJ^!X]='](
MOR^BW0_S(J0]&`K=,V7*"L:^&HDNBT571C1@1\\V1LX`/'3M*&8<Q9;;2+FT
M+W8]#)C'0?=FO938=@Q#:>JC*"J$+CUF!-$%D<Q>$!&TD12?//DA8'=QO4?!
MK)(=H=`:QCX%L,F@=NUFS*1-O"XLK5(I?PG7F(#RK*XKT*XF13/IX=Y+0]#T
MI<N\(?Y`3-\1EHX`GC5\V4<9^_T\Y7^CIIK+![(L4S`'8<3!(BO0+C3)%*^O
M`\7U<>P#ZPE+VR8U?*FN[K?`:+7]Q8`\6W""9,FQ?B>O6BFQ*:NJZ(>MA7`A
MW($5;.6!%]VG*D\KF'Y_%%"DLH>M)&8I4L>&'?MRL9`31`.[(ED"N8U+GK+(
ML1^;W`BC<":D/P<3)-KP"/;<PXT"O"K66K:G"$4B7RY8QP0HBMY+O.@<U3;X
M&*!(./:+%-PL8L:%C6^'&P%9?#"%&P'H]2O12RGW-=1#!YZMCSP#_%GLX8-'
MVA0(J^E?]'?X,7!+.B/#;YESC"*_[3`T41ET[(=HI5MF\$K*1Y'!Z]CC,=:M
M5Z/(Y15+P2YK;G;1&+$I/PUZ#.RHKNYIE5:L1Y3#$GLFK*,XRY.!ELR-VGB7
MBWX2Z7%"T6Y<8R)W,76]2:GX(\D+M/%1*@V6NLM'AC'K$I3/*#M=KY]I;#@@
MZ\O2#A^BQ#J.2RK2CH?+B`R>RMLYD4"82'%-OQTDZ;R;0&$XH)'_7)$^)78K
MRANXU<Q(TBVKGQ^`(H>2/ZM4%(,RE[@P]T"BZ:&OJNHW)74'P\5$.^LBRVW:
M4")=$+MP8*Z418M&<.$SYOIB!3FKRX?(MNJNB_5%(R#W/P]D&?5]6D;%TTA]
M(<V,(IU"J-$$1B,H>H?,ME$`!>HV^%AR`E<^O9`3^#!<V_'L+'$G])0E<>7C
MG5.FX-I/C1U34;M^H)2GW9IH@2V>6%0IIFM1HE&:5ER"=I=+\!#[NL)6QOWL
ME$-A=3TH]JE"S@M4(]<"7K0JPKHT=I1T["Y)6UG"=$CTAXI$/5%MFM2XG8N#
MLAZ((Z$L.TAYE;MF3VE7V%UFD:>$5PI7GJ8]7R\"2[\5UYC@JO8.25F7HOTY
M'0],<TR*3A9',D6<"'7A%1%E1SVRS39<[X:\],LPES$BXX=W<6Z:F`3-$P61
MEB\<5H]'I(ZXALMJ-+8Q'OLT$`'7<+D^36@++^N7H$@L1G:KY3C>YHEL3)";
MX2\K^F.2MH56@.YD;-F%"S1G12Z0V(C,Q"TF+ES$V31UQ@.JOCP>VZTB88]-
MJH?N/1K2EN>R*&Z@V13:.`9M<!:DE`3+E_R(&*U>0:T,6'KD=D7:J+`.E74H
MN'8`PQ]^AVU_JS1@F+A'%N(.MRE+9H9'TUP/_\E-LPZ2ZML59L>CRK:&R'VV
MZ4^9ZNQ0(?J3Z11&IC@J`WDPM]-\[K2O1]4'<;6C=G1RT\L@@-3(?X,A&!X5
MXV+@JD-I90CCL,+KV`N\`O2QD@`,)B72VEBJ[[Y'6UM(GZFO7QG6-VE2^Y2&
M/Z.5W1M#[!$[AZ_@^ELXV/D";F85K"0ZH+"=M*R^4Y8WY+)^<F*J`.(L!:C(
MDA<"KDOLX>E-B/G)]?WDRMBAAQ^!AQ9,?GG$3X@JX>(.U#=&$UR1'IO6V!7!
MK4[VQC&;?0\HK@#(DECC`UI!EN:R[6?[?@"*O,"`+;O%J)(=06OUM?#MLKZ*
M:=MP89UT(!S>/64J6#H@UN_1U!63ZM=+[)LJ6S>U85]C;!?%.X"UKFILP'B'
MJK1&M`V@637?M!PF.%@HZ20Q.IAXE#=898>*1U?\6^B=MG@T?(?&-JAHC!^$
M$_AHTAHKSPGV;#2XE1,IW]#F1<X',<@%XDR^ASQ4/9,B?SDYBCX?8*&6(6#C
M>*[?B"?66Z$#E'8"+V9\S@B]S7*5?4&+;!?+BS1UKQ;ZZE""HBJHW:&&3>O1
MN@+MMP]S[)6G)/5A67E$5AY3Y96:).HWITW:`B(^AJVMCN$B:U#I6T-R1TQ:
MU3)SA0/3G[1-VW0N77Q'<&F@6)2MC=#B7]J^X)@L;?&7E)(&0;R%-N6@[)=9
M-SW"V'WH&$$I>3BJ#M#:X0=C]7<52,<`9>"=053*9?5V35X3U=!5I;#C,YI>
MPK5X<;!DOYPO4+ODS'=P02)N]4CS2]CRU['1G*I]!GP-Q;>S*)6%@Y$KZT\P
M=3=%LGIH2X0-X4BWKN-B\`@NNMD?QB#@?@PQL(Z(UA7%?2HVD7V]+JPO8^QW
MP31S:/1I)8+K%?.^\EEV9979H./GNCLD66*A.W6V24<4=>AL8TR_&^:U%_BN
M_6T;_7]&D;/-=S'-WN7O_9Q/CFV&+DV+_YV,)OS&277+D,D4"V-F4^7%4<@.
M#KV'PID8C9GGQ02?-NE.F!%J%'V>FG8X&EL#O!=4%@PX83H)IHBK_FX/7>2.
MZ$<=6#XDR0<EN0V4255JPXU-$`/[:2NS@3!9K&&]2U$/QF,`K3]$B]/TE0_+
M1`>LXY(-B"N5UH=8KX)9<,`Q3LML)Z!H=,1/P,-E!$XB8^=2!F+[G??XC!DK
M(SI,Y/6ZV+-%.A/1#^%JZ]`W0_'E3/^J&KT[4@=VZ^.@V&.2>?1_3([^*4RW
MQH;64/B)/`6OG7*"DX?[D:)D1@%J?P"*@A-A1P@%.R^BF0:I6$KH7MPX!9?V
M`)5.J.%C3#ZLX1I2I$P\WA\.(:Y4=7L8H])[:/>)SH;XJ;!^6%'7R>IG#-+6
MK@RZ_KZVGNL4B[X54^9%O&(4<]KJ%-<YPF34[]?9#AW7CX`2NRVJ/V"0>]\5
M[@ARDA=+CN/D;9-VNP+-\S*?/1U,U[U1-.O.AMA95<(DTI$,B(E17"GF>+1X
MG[:LM&DA/^GXN,+,S#M$I\0(CFQRA$NAM2'<"`BW:)#8YH8&W.`(Y$()!:E8
MI]^!JHC42:&N$\S/ACJ$?`G79;31=D9PI7=*P[=H#NZ>@9XKW`*.L2^:Y."B
M*+J;SEYQO#0O;PEK@,Z\D?8,Z2'_YWF)[36)G>)*SY)1M`MH*Y,C'[OD[P?U
MY8CR3$SIC+!3*IHD1T/J>1J7UI#>%@[!Z&QNBIW34"7KH]X>U)6MM&O69PNT
M!^RERR,"(*E,NBKOZ(-B^L$]><(/Z!4I4MLJ*-+T>P$,,+-$&`+I@`LH8$*=
MC<:^11Z5';*V79(W2M(60OX^6MCU-&,K]=A=8*ZF"OB")&%AHE<ENE2%>`+'
MD>^?M\6>/!C,O5=CFP*)M@D^EFB7/S*Z:3D.K@7&_/]DYEU<=$)J4H@M4VB%
M3DAZ@?8P_"+IY)FL\Q.*7`N)4'VD_0"\+#W:LDDC!2#A]DWA)V@&M4^?_+*.
M33T((Y4L4$==1)'*#DBXZE#,LC-D2Y[V7<UR!UU'"&F8VM$^N?Z<8-%*Z.%H
MTSV@1)FX53$^MXBQ?B!^)FO0TB>QO%U:+U8ETQ9)`T#A-(G<8!,AGBT6"G9)
M[#V;*M(Z)8,WQA\)H6JQ(<I.`"N6V2L1[17&3FGR.0PDX59(T)GC==K9N-(C
MLPTA]9&&QKNS)5K7CQY1U`]PZTPT67#;T""F_P$HL@)_5";8_Q!Y4<GV]2)9
M^7Q=##3Y9W2E305)*N^@O=2`8B\R=/F^*#P`\0A,R;6:M!N]7M*CD1@&W_.4
M_27L,=I86W@5[*J=TKE7D6PN64N@H=.F-RZ^%&.?!ATL%MT=C^PF9>S3<+%(
M?L42>A;%>D<P8$<HR0J53-I[![3BK2$-&,B.<'R='/W#-/R*@TYVT:;-`!U_
M6UV;GBAD%%Q/T3%'Y@RMA'*XK"]O:`)2P^PX%)-[8_*F;(HT9_$M^P:HOO7H
MEM\9#Y^2<"^U;U-]CDC40SH5:BD*3C?@2]L5>0WNHVBAEIMSQ)ZQANB#J&1&
M64(-IBCDMF@#J#=/A>K;U5#@CPH&,=A7`>8[+L$LDJ`%J2>Q+TR*KM%Q%Q'H
MVV&-#=2%7R`F<*H!E^,="+/.J+H[JJ]1Y+M"H<\"_'"I@MCTRS,I3\P/Y8M_
MA?;!<;0JCN2O=*,Y[HJ]O@>'^-2IGX]'OQX)?2,6`2P]J$;O52++%&V](N]5
M63O(?57=J&FKP7J=?3.H(O<VSWHZ3UO@&N38*:%SSB(O:8EV4S-I8V3'KNC1
M@EUZM$&%E;=S%LU$8#%@62R\=9D>_KJDW@=5C=RQZ)9E<)&46XXW.YFA_,4\
M3^)VZX51C_9E8NSC4R<]K&J/,?G14.-C3/J#/-DF%T<N.+B&N$`;J99KB:[`
M0T']3-,Q%]SCP"MD,+[PU?K8^K"R5D.+Z=[Y<RDC$1D^;Y[UH,+NTY3[96D9
M;0VZ%=BF(AW$;1ZUC:JV5M57J_H:35U+OHZ5==%5I0(JKN]<Q$044R3M5BH0
M"FE50A390SD^\Z:5"*3072QT.U/ODB.?)G]43B11"!M$["H!XYG.8M@(V%0B
M@2KEI/B7`*X2>S`461?2M@(.%7:@,80QS<DQ4#)AR+ZHL$_CMG46)C^`Q9T%
M'FL`/\^[Q(+&UC&)$U6ZD##UKU(R?8BALD%`&AW%IX!:"KH,;JPG,F)=FC86
M'5W*MG1X(HMW#E^A+9H-?Z-R<J47R8WF;XE,21^^+ZM<RXBJ7$'5CE\:P07)
MP'\*N*TZOSSL;_<]]H<85/*"'1[2"91$8)4,97!%;<+"Q4X%VF/*\_A5SPVJ
M.[96&C<H8#`T0B$P$^.5%,6XDC-^"D(O,4K[MXAMXG(8C@<Q5"2:Y(DYXHF#
M%_.T<\X[OT!R6+@;"=K.13/K!"X[\?JF;W?:H^8@(G\(791Y6OX\7.0%?[YG
M_*A3E6(9[$^+R;RX]:*#.THYM`]YJ.Z_,O:)VVYY1F'WJFQ9G?Y(3+UG:M,=
M%/1$+X0K7"LBD&V;@?3`/=@]UQB'"XVK%CECL.2;+[B^IIA.6\*I`C,(8QSX
M+;#]0>+`93$$4,K@QI^E(BYDAQ%,^GO$XZ[`7A%H`+2$$^"-H.V[Y!\<6UV_
M!LD,0`3+PDB00_+/MQ"(VNDL99<%?<[EQ.:"=B8QC%KQ%=QX"$Q"@_S_>5([
MTR6R0TV>NDR3G]0^A^#BT#9K_GGUT?6/N2+*$%L$/Q(4,L9_>3#*O?=I]UI<
M&&*:9LEPC&!=/$T6E+94B_[_-7`QW."1X2GHG(/>0#<I;%UF2<+_2>[>$;%]
MET$R.VMC1A%*,B_#W01ZERQ?40C^1P`&CW*92S3+7;/HKX$OF,3V7=RUS"3'
M6FX8Q8.9K5C'(T.TZE](!3_B9MA&SBQF<"L8=`99'XPBWV'B5I)S*U\C10!%
M9B&3%#M.8^X<.F0&B7J5S"M<')$:]CTM9?YG@2*8"N+UPL=(CW%=T5H@RL8N
M\BUP.^U5L(V=L8U2UBIERTYUGP'!;87@64;@?+1M8Q3#LJE4B1HH&@[^2Y'4
ME2S.YX*?,L:KLR:JQ&K0\\JW)=HISDAS+^_Z:CU(P1&3TOVYOY(_F%'9X1*-
MG47>AZ*?\2+6QQ5-\8)FNH"N8<?@A5$.6JL=N"RLX+D40_'XH&4GS)S(*_?_
MH48V]0O47;T<NN>K=0*'7'`>6+[HO4\,OH]$]H,O.<,<R:1'$5=&X&0#6XR<
M;$8V2SN^V2A%_8E)F!'CY0^-6][#J!H_8U#D56KUUXF14=SQ!GJ+_U,C1XIW
MHICX&7=&8?R0,5F.O^^10[S>Q0EDC*:1R%<&,=7)3O#T>PAZ_`<)M+^A2?YN
MBTP0W,HPC[O4V+03KNF6HR(8'Q8[D^;SN!+5S2$:H<()?"SD<'Z;I,$%W+=T
MY0IP(VXE<5\GT\9N($KSJ=2/$?.E801`FMZC4%'W*T??5*8Q%R<XQUU_FINT
M-0XZ!7+(2DK42)Z.6<KV(%W?AX%)WE+@I+BO7`GWGG*IXA`7\=]$V;05ID6[
M80J%L?SNI:!+N'G/9329TR(["?@/6*`7N3<($P+GBV54Z&G2X@,`G)NG6L1T
M`&#'-A]^]QV.$S]#UVGS,BO8K0K=T[:52F`_2SGTUSN6E4YZQ1SN'V$;8M:[
MI9*1S^'N0!^,(EH_(B+L/LNJ>.0H.@7CXN:LY+O<'<61,NS*;A,("0O!X.3L
MU`4B<I'>B#;&R.4HV&GY>K91S8%IDZT*BFCIB_@VF\"9#P#&[36!VD7"88IJ
M%C]:=+V01D2!O>13/F>^_P8O7>;6*/T_#]<<)K;/![W2V]RE77>S8FV62P_-
M<2>#KX/''%Y!Q5;\5Q@#/\)UF"]."E\!(0&W7>;YU[GUKF_1#E)K%HS=((KP
M8L9O4-"G1`\R*5;GT'PQ1K$Z&7?T$NT78Z.FC_^7)8'=LW/T](`X0,G\3T$Y
M\N&:@_;?X_8@3DRK2/_%1U2Q05(106+GO/P(/<MP,\3BR)1U$X9HUAE-T(L8
M;G)$$-P:2M'C7-0`\(>Y`&SB7WU@N,[(YBM+5J^/(H<BJ@'OM3@/-E1'%01F
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MVVM=>U\[W/%:9S=^A`K4Z.Q^L_?@J^T'?WC@Y3?;O_WJ_LYW3_3_4VOKC[KZ
MX(;O'QK`VMG__4Z_<:@_/'+T'P]U?^]0[U_M/OC6P$MO''GN^X=._?7N8S\Y
M]C_^YZ:>GY_\SAL]9_YF=_M;QT__X%#/ZSW]WSMX[*UC+_[=WK[7#IU\H^?4
M:]W'_O[`@7_H//R]OH'O'CKRMYW]_]A[ZF\ZCOUE>]_/7OE+_NX@MRN;T5R+
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MT=:^@7)+!IJ_8@%D:,;X>=O`LY-OW1]:W*<O/:8M/B:UG&0+3]TP=8`M/*I`
MG7]<FG^2M9QE\\^QEG-XTG*&S3U%%4[.LN;SK/E%/+:<8HL'V-*3;#'\_`R;
M#S><E.8>EYN/JLU]6G.?.A=JOSQ_0)I/-RP^0W?"6Q^7%O;+4/%9]"T^I?PL
M:&1`PN-9-O<<:X8GGF'-)^D*U#-XL>4\U7-X/_06VX$V;RQZ2O./:@MZE!9X
MS9/RXGXV?T!>TLL6_?,]ZW"K;-1\+/__:;JVCR)7\")>3E4-4$2X`K&;*?ZB
MK7]+TRT'M84#ZL+3\H(3;!Z\.SSBAJK'9<!V"Z$%Q@C'\2SAISR(IY@8W+F$
ML87GV.+GV>(7V<*7V/R7V-P7V=SG6;,8>G';>3;_13;_9;90U)?HX_-L_GFL
M+<^SEA=9R\NLY16J+]/'\SZB\$%G@J</!-`J=^`\'0EXV&<"TH=/P'*%^7A,
MG=\GSQN06D[#E&'S!N1%/6R!0)'G_\,(RP_+"MW)J[B+KD$1A2K3Q??V'P46
MUZ7,/R,O.(_O/@?:[R>LW@A'@9]3`7+.^6,TSCB*H3R#`PTH6GB>+7P>(=0"
M*'J)V!34Y[$"HN822.:_PA:^@D>`$T+EI:"6\?.M<5#4<M6C!ZZ&\9A.(I#D
M&XB><!Q0YAUG<Y!6\H(!-G=`7@`H>N/>=6`OT_^Y,VAO)-?Q4R-\%/E.A7(N
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M<9M@)M0R2@0XA\=5\T"!HJ`%@27H*G88ZKD;B9X('C;[+)MY'GLX]P1K'E#F
M=TES$46%'/$BB_ZGJULB*\RN^*<#%-GCHJAW;_V"HU(SH0C&:^8Y)JA]0U1X
M:X#0RVS62_Z(W'R&W1Q\6U&-D%%4QAKJW%X-:X^.%3X>51%.-/H^5Q%*`MZO
M@>)]\_%KD";:%`WVJO-%!2`1.Q)RMB7@,SZ*L$K8P[.$HA?9K.?Q_,,G8[F>
M(10]1RAZ#NC&FD%-\E&$"TF*M(8%_\-W*0@"5%!4#BNX52AR<!'F^_M[=S0N
MZ%::S\ES7X"6V<PSE3'Z\(]G`UYTGH8&1AG&.AAQWT"C06P1@XYZE"2,,D2.
M`!(<`0G$0UH(12CR`$(`B5ZM!;_5FON52IN!68<_"3@;HHZDY/P`/RUE5?^,
MCSJT!*&=XPKV\PSU^3S"_@:BYQGDD[//L)N@>Z>5N4?DYEY]?H?2\D_W"Q09
MP4*-RG_3'H.B2M@_0!'\'4V^=^CX,XWS^R;?UBW-.A&:<PQXD=0"$O,YMN`&
M.8)F`K,&7GD`ACO4<B3<`L=^O>64NA#TPY>TI2>`(&SN<6!9\8_`\2_T6T^S
M22^P>>>5!7VL&>R1YQH^TL%FGE#`"%UX1H*Z^+2\^(2RN%];?$Q?>$Q?`*V=
M5%K.R/1$JM`R_+8?<!*Y%9#S'%MXELWY4[;H908VR`)XW'-L_FDV&Q2GEZ1%
MYZ0%`*%C.O:M%VH$^PF]A3[[Q/RP:5@^0G_ZV:P^-NMT9$$KF](=67"X;O%^
M;?[?W[V:$H3++J-*.@2_%D6.[T$R*1[/,[FWNT\\TC!G6WW+WO#LWFFW'H[/
M/RPU][`Y-T[M9LV=4O-!M7F_WKPKC'6OCA][I#E=;,9Y"<PQL*$6#K";7@K=
M<I+-!.WN6VP68`D&%R"TC\WLKEMR.+:D79[?R>8?9O.[&9[`QS9E?JLZ#VJ;
M.N>0/.<P/>X('>'\6'QIIS*WDS7#E7-LP;?9TK]@2U]@LYY#)7S!GZFWO(#V
MW:*7U"5][*9.=E.;VKPGU+PSTKPC@B?0VW8%>][]81-P+#'G##3<VAEKZ6VZ
M9;?>W-JT=%MLP;;(PG]X>`-FJ'"*VSIC(K.!0D0F6QE%GF!6KHM!Y]+/SKRT
MLN4WUTQ;O*YI[N:92YZ,SMHY:<F>IEMNG+JW$8_;IBS9-&W)ANE8MTY=M+=I
MT9F;?J>=S3C-6EY`G\^BXX2HYUCSM]F<OV#S_U1?TL:FGIC].UOKYF]J6KQ]
MYD>V3KEMQZ3;=C5AW3GIMFV3;]L\];9-5.$$/L)U>!8];@D08?>T6[<V+MP9
M7]!9M_0@F_X\6_07[)974(2!AC;_6^B2`AU@P7/R(NC&P+2/09>@8]"]IV<N
MV3A]R>:IT,B'3[VKZBZ@9,/"-?JL]?&6)Z+-3TY>_$ATSMKZ)=]];#/]BZH`
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M[8:S/$7[`F>+F.]HTKJR&Z26*,LU:6%\/$<YQ]#)T3R_G$ML[NR9^M$>"3U[
MP(5.H!X+@SOO.3;G%`@R;?:.FV_C%T8QXER@G9%%YFR>$F;S!C+PHN%?%SG1
M68MG#:QP?S&/_Y,RG\$]3/_Z'W<W?V2W=-,Q-@=DV8OZTM-LS@DV^T5UR5EU
M<8_2TC7MH_SY[T*7L&.9(FUH:V"W$]3YTH=-P^IJ`#&+/$4=&\S@^6B1OY_%
M?[*$B0X4W7>KM"*W'(T=!T4E?R,84L1+A*5DQDTE/5MX#)P;I.(.#Z:#*[$M
M6A"."_U+^'_^1G+#K?V[)]UZ0$:_V7E]"1A-Z/U`CM%R)KQD?WS!DS,6\03E
MTIAB"PY*S<*,?LO/CO6P^O\LSZ;%/2)KR,5_<H=)5DX._T7-#UY[:L:B?;'Y
MIT.+7U`6`T2/L]G];/9+L=\X%5K2JLS=T;24_^-/H4OX+ZUP]QGZ?Y8F;;-A
MX"M\Z&0L5Y?2^BCAQT47HT4[D0&H4L4"9EBZ9CG,X8Y!D4&V6Q"BI44U0:*6
MS8,M"VB)F-C9`TGJW#"5_FL3K8/R,I@"B#FG"*1,X>>M?>OJ%^[5YQW5%H"]
M=EJ:?P)9Q,WD56LY%%_T1--\S.3.93S7($^:(*-'_QS!HMP@D]+I*8U4.$,P
M2]ZA-#L$`??R/#'$_^GU50W-T.!S8.*QV7ULYH`R[RAK/AE:!(QHCSYO=6P>
M_]Z/<1F`A8OXBYC*@]NR^&U^Z#0<2\^289$PPO\@XF.&'$,)VCN[5)T64J47
MF6)'*S>0=Z0Z&?[_&J1[,&<65\N2Q]*K&'0W0J5L1)')E:6D=OJ/:R";C)\<
MZ'NJON5`>,$1I:6/S1Y@<T_(\V&@7T!-J:4GLF1-W3R>S-,V3Q4W6K`\S15)
M8&;@H77*QFSE6R)2=H3_^*>/AV>!#O:BLAATH7[6_$+]1X[+\%`TY0XUW/)D
M0PO_WH]$9D6)4EH+05:C4SU/;X1*$"C0/\[)4Q9>SC2%MISD?(2Z[8V7IC;F
M/XMY?BBMG/)<`5[9/^#=2-7W2P3_V50@G^,N%6\?[-O4N."0-O>,BESH.)MS
M4@%[?Q[Y`Q<,R(LVQQ>AEH*2R_&J<>)3H+RY096'/V#@GL`J9L/F^6NO;ZN'
M!M&/=!;EYKS3\D*,C+#9I[4%8,YOFK*8__WKN&B2_O.US^%=@<:JY-(;HWI5
MJ>C5<\<LP[Y<//[_CT*;S"#3H'U2\+WH-7$%,J!H2T-+M]+\G#+O)*'H-"7,
MP/B>1L?@HNW11;@:TJOZ]Q.>+^L]'K3#W7*J@W^A'+W&[<8*&!3XX>N[8XO.
MHLMN`6E?\\](B]%;SF:?5ULZY9NW3EZ(*#(-L>(8"^6I$JCH7_K6RH=::BBJ
ME8F7&HIJ9>*EAJ):F7BIH:A6)EYJ**J5B9<:BFIEXJ6&HEJ9>*FAJ%8F7FHH
MJI6)EQJ*:F7BI8:B6IEXJ:&H5B9>:BBJE8F7&HIJ9>*EAJ):F7BIH:A6)EYJ
M**J5B9<:BFIEXJ6&HEJ9>*FAJ%8F7FHHJI6)EQJ*:F7BI8:B6IEXJ:&H5B9>
M:BBJE8F7&HIJ9>*EAJ):F7BIH:A6)EYJ**J5B9<:BFIEXJ6&HEJ9>*FAJ%8F
M7FHHJI6)EQJ*:F7BI8:B6IEXJ:&H5B9>:BBJE8F7&HIJ9>*EAJ):F7BIH:A6
M)EYJ**J5B9<:BFIEXJ6&HEJ9>*FAJ%8F7FHHJI6)EQJ*:F7BI8:B6IEXJ:&H
M5B9>:BBJE8F7&HIJ9>*EAJ):F7BIH:A6)EYJ**J5B9<:BFIEXJ6&HEJ9>*FA
MJ%8F7FHHJI6)EQJ*:F7BI8:B6IEXJ:&H5B9>:BBJE8F7"HH<%PYBV/$\;_V\
MK7]3PZ(.;?XI==$)MF``1IG=.L`6]TF+>K4E/?HM&^J6\K3%+4N,I`"1@$L%
M10&Z*M^6\00H,DO<,=S7WMS4L+17NZ5/7]J/^%G\'+OU#%MXG,T]I2T^J,S9
M-&4I_U]O\`+`E1J$'MK82:>&HANCP%@;""0:"#$Z!N=YSA/N8.<+&R9_;`L#
MS/R'/G;;GX4^\3S[V`#[R%[IEGU3_X]-DW[KL>D?A=MXP>590^#%#JI3QHR`
MI><_JWP#7G`<X"=\),=??7O=W/^T+G;;!FU)=_QW3K/?[&4W?2?RB5/J1X]&
M/K:)S7MFZD?YW_V$IVQ>`."Y"'('^VK74'1C%*]Z6+TJ%*4X_[N?GK]K[=E/
MKWCY]Y:_^/&[OOM?EO_/W[KGK_[S0\]]XIZS?[C\^&>6G[Q[#;^0YSD/!]<3
M@,1J^HQH'!29P3V.^!8^)TW^3OJ%AS8^]^7'3_S>`R_^MP=>^X,G_NJW[_R;
M_[KLW&]]Z=PG[S[_^17?>6P+'[5YQN9%0!&P31OY&+<=K*[WX5&O5BK%NZ8*
M[04DU6"29TQ>\!!768"6RY.<#W%^A?/+%D_2=<"$[1F&80<(L:L9D>-K2D*H
M5=]3*I60D0C0CCI\A)H=A&.)CQ@\"RP.8.,"<NS1%#(?UPU`2=6C*Y[+:S#Z
MT$LU>`)N)#A&PBP,YM,E&.Z@#N73./5'BGS8X$F+%SG/E`1H!)\QKV5$52CB
M_)K;X&+!Y#D":M;C0R4^7`!LV-PU2<["ASS503,#YR6Z[I11)$1;#44W0@E&
MP0EX!0"FP'WV`Q6@(TY&@.5PGTT1VE"068Y=,(V2:X_1B'B5.*L2:EZ5=F1X
M#K;DV,5\P5?)+/S:QL=9`)L17KQD989Y"3J0P8L()P$DKPRD&B^Z,8H7,`P[
MX!)"Z"3-0I[;.<_*.:99I1@#9DS7@3J:3=MC->H*A/AX@O*:QU57P"&T#+CT
M""1DU",[RG$30)9P"@5B30:AR"X#J:9:WP#%JP+/.)Q$\`>3V!/(K[S+4P4'
MV90'%[*>95:QE&M;'@]$E5(T2HA&1`4GA&"S*.9`5T^!F'-XUD)A!T:9[94%
MXE7P<\9KN5;^-Y<RBJZ&4)DWY6V$$"BZ:0N%G(G?C+JE`O&K3*E@>:[_D['Z
MU76'>^R=AH.B,&V7A`Q%%`E]&^U$`Q\-?<B5T"=0U;)30]$-5L9A%]?RD;+M
M%NA.]K]"BS8"M7P<\_^:^\O-5H#BCH'E!["U6KE1BE=U#$[+4[ZL+%4,>5Z%
MAVLX3K667@B`9%_;KCT&2]Y8]<RL$K57ZUTU5-UHY?IJL!WH1&63K725+\@>
M1VYYUT>1_]MQ?QA@R:CZ59F/_5+KKU8^Y'(]^76-!TDH*=>ULJJ\B]>3:+\$
M@<X8U]/X*K170]&-6,9PH+)I=FUUJM25<>N_4KOFXR&AN@K#T+K^HVN"[`8K
MY>$>H_K:54-Y[8#^*L/W*P^U-_:YU1UPQC"?&I1NG.*-:XF[@="IGOO7%V6_
M1/L=CTU]0"/C_/PJ%N2-^;Y6/O12S8O&M_2O,=;*)^.:46-0=*V\NZ:UZ]EB
M3G47JNS'ZY@"M?(AE^L.AS?./;^T?M!O?L76:J56:J56:N5_<_G_``S`_F<-
M"F5N9'-T<F5A;0UE;F1O8FH-,2`P(&]B:CP\+T-O;G1E;G1S(#(@,"!2+U1Y
M<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@
M-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N
M=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@
M4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O
M5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TR(#`@;V)J
M/#PO3&5N9W1H(#$W-34O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<
MO5E+;]M&$+X+T'_80PYN(:O[?J2G.$T*M^@K-E`7R(6F5A8;B71(RH[ZZSNS
MHDBY27:+0`P,R21W/._Y9H:^N)E.WD\G=*Z=(A1_PI6=*[G_RC?3"0LGC'!-
MF`Y/.-':SIWCEEA*B:2<U'XZ^9.4@9>1"ADI:_$7J>^FD]5TLOP66>'/T0,Z
MEU*`@+D42L`OX3A_>NZDPG,G#)Y;J\6G&7)R;J6C@EA&B344N*).R_]'\[X[
MM*X_Y&PPZN)Z.OGN=7:;@PL$N88_",X*3`_N89PPJ@RY!@<Y/A?4P/4_T\D9
MH]^0Z[^GDU?`Y(^3B.+RB2A)*=N+.C^Y)#M(HG/*!!#FT\DYG7.-UX\@].>K
M"U+5)"MW)-OX<@&?EK05:5=%0UY7]8:,X`&AOIH+A#L2I>;4&AY$@1.84*IW
MPIR\99"D\*7(ERJA/QL',RAQ]L7LH[G+:1=FQ@0_A%EHO$8++\M%D6>M)[<[
MDJ]\_HYLLOH=>5SY=N5KB+8'F7=%T]89Q!]"GY%FY==KDE>;>TR.MU31K"$+
MORQ*OR!%2=YLUQYDWY[:'&G<8,^XV2&M.'8=U<SVKF-XC:[CI%H&![WZD*^R
M\LZ3%WD+[F#S4^>)IF909Z0\`?P,?C6`S;JO!'O(D[]\<U0(OU;[FQN\&T$=
MIW7G>BYY[WJ)K2EH<]5BRA9-L_7UJ<4;V8N70?+96\[YR:78(R.9=J8W4D&#
M#D8VP/'!EUOP_!*0N&@;LJF:%I[FB,7+HLFS-=GYK'Y^\I3@;M#O2=M[QM3,
M6CYSVCV1N6?QYD=D\8CR?X(O!],&L!'P#7R$,OWM>CJY.DEI"#4H.DIE..X.
MJ<BQ,+HH&;P>4A%A(+N[`ZC$.X10WY*';+WU!Y!XJ-JBO(-^NB!E59Y:44%E
MK^FXT"BH/?;)`(Q2=\7960H-8E.5Q+_?%NV.0,]88(\9P78)L^W7L5TZ=V0[
MDRBH,YZ9SOILN2S6!61!$UKDMO7![MHO?>W+W.]G*$_NZP)NLA9:;9&OPJ,Q
MLA<^!XP9(`:FO+VR3V/T"'V\J=:+&0Y^(:,??)U!7[LM%B%QL^8=6+/7'-*Z
MV8+B3UC,@`1/8$BX]WFQ+(!\@17Q6,#<6.X-SP##-(7GNV8>QH<K[_?S0]$6
MP`K^?@1/6,B2KL%Q18<.IZG^3^#&G&%@"!LT&357&3.])#"3:M=/,`JO/SO!
MS'&$(2]"''_):@@QES/"*?@I@G(CUK<R]"OY3$'O/\H31H\F(:7<1P6.!9/=
MW]?5AV(##]8[\DRXF;)B1BD]^11HK.ZU&Z756>BEW<!+N>I70L6[;>A3.3'#
MI*BAP/&+\YEA.!LH6!*RV@?Z87TX>2N2KM=YQ%$-WV$<N<8R,U22[&>U#@>;
MMH(=JMJV30N("7UP!H!7=T7R;(ZYBY!7E/EZB\>$&SDS3A\<%NH(`&B,\$IV
ML,&H_21SYIN\KA[#TG+R[19%\KU(B(L\^=L"Y`]C3V>2L/UVR]VA&5^O$,UA
M>H;RQ-8"`_,:6A*.TX!5OV=U2RXO+V?DLO6;AK@9[$'P83/DC0V/25QY(5A5
M?5_5V>=Z^:%Y/6!;KS[L(`N`-KPQ67:M-.!G5I9;&-E'<(2Q_=L<)?NW.3`5
M=HU^XWT8RK!K8X:NH,W[NCG@_]&*#R;=>E@NT$_8M</YE<^W-1@("8INZ=O%
M2TAZV,+0M5V'9WS?V9'S#["H;&Y]300+8*%.#XE"]J:/`HE&]>\`(,/Z!#.Z
M@\1K\%D3QA:(Z]4&THM<;)NB]$U#?H`%;5TU6P#&UR$#0^6_#"]9?BL]%MUS
M\F2O_OZP6-]\_+H)E.'4@KF.$A'L&!0.[TPYT4:'8_[IXW-A>/2<22:C!+``
MJ;@$"3@9(Y`2\B-&H*2.$V@IXSH8:5F4P*9$.)7P`[ZSB[-@3*6<S95U<0K8
M;44B8$D*A>_KHQ1:TP2%T3+N46:U3?C#&1'7E%.CXU(XU$0\])R;A+5<&)O@
M`>D3CPL$CB5LT5;'2Y$;QQ+66D<3FCHK$@5/K8[;(IA-^$-PQTV<0CB5D`*+
M<X)"4QFO.6%H`EL@M(F:$]:QA"W.NKA/)74\0<$LB^LA.11,G$)8'==42D?C
M&2252X"MU"[1,J3%KAFE<-3$(P?!3\16B11F*ZEXW&-*L03"P`9GXSX%5$\@
MG;(T45'*X:`0[6"4)VI.,Y&P5G.HNC@%$*0ZJ7#QN&C8;Q(\M$QDLC8RI8=5
M+,'#*1&/"X!#HJD;IER"1_CG9Y1"@,\2PX>F"0J%_WN+4FAM$IH:G<AD`_`1
M]RGLG`FDLU#8B4F*F40&66YE7%,+2!>O!N`0F91@-'YU,YU,)_\"PF_WFPT*
M96YD<W1R96%M#65N9&]B:@TS(#`@;V)J/#PO0V]N=&5N=',@-"`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
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M^W\`*?BW]P,:,$9-!P-&.37_44U(^[YF'.YK*N&^4H)V$R35=XIQA"N%4:4D
M,E2!I_N>SY@A,24JJ5%%[8\6#?N6[8>884IE[Y..^P9$:N!!&,-S%=8-(&>+
MTY-_7BQ_N[/P+>[W7PW0NG?-70/NNU\)0W^O%O\Y/:G-JS]8XIA11YTQW4W=
M=$H/44?`%5:6O)8#(@V(B_^:KA;#L[?MB<B]GNB`4T,$>OH.#1#5YOI/T^M5
M74TOJM%TLJ@GB_E?&>":.`:D.!I'_^XA(!M)@%%J(Y^?[;S!U<9=F?G=^-ON
M\M/^!,-O,+\$'XD+O*H#*IIK%E'A5#I4;H:S134^P"\,S/,;6(]L$KBT#[C+
MAN-P_^!4)J!T[\HLDD*HP%E@,K)C`;0/_!7+<-_,\;%8"DP;,/&`2NF%^69X
M6?]5F`!XH4MU4DN65DF@70QNBKC%QQ`OU($D;1@8<Y@0U$T[)<?<D=9B0*DQ
M]%Z.B<!>CL>+^KK"@ZJ@VT-#4B1V6SJB@Z2;$;U[P;*=)N:F.`\5?CG%W.F/
M9@,I@`6O\U(KA]5Y/1_-QC>+\70")O'L=CZ>U/.V273D9I=`^D]8P_YM&1MP
M8-S\!1.&2&P:-9LW(L2L"!T[S<*8\<@[&5`DI5,QVH4\1<7Z17E&OPSME'X=
M!%^8`5`W`#3`Q'@JBSN+/97$8[_XM*I&CY^_+!^^Y?$6$@"F'F_"<&RV\::H
M6&536`!6Y:Z%SGD6.K7<YV#VJ[V!&2L6819P#3!/G[?5]7+[^VKWU!=FS#W,
ME,9F&^9R[R")A<%*60^B"&9U<+7T,*O,4IR"6?D5#ZR'L"B_._^V_+"^ZPFJ
M,O;:@8I8;$907\,=03QRY^;?`$!(EB_S7ILO]=9\Z3W4B,)1.#G%7CB?JIOM
MXX?GN]U3M7SX4,U7VZ_KNU5>4`WM?=XI%66\'Y0FVLSXRV4)Y!@H%ZI`4DY!
MCB4M5@&I,BI@:!>K@$*O4P$I6RI@F^WI*N3.JH#GKD`%&K[46_.E]U`C&C4J
MP%!4@?ENN]RM/N9702_UD5U!RM@])$#$;$L#NP>DWE`NE?J4:(+H&B^P5.JY
MSDB]H5TL]0*']568Z?3SQS#RF^G9ZFFUW-Y]L@;L?/5UM7G\\GGUL.NK%%QY
M&X9);+866V"^%/,4,`"<\7E*,6<H@[FA78PY(\'2:-:XCHRI-.;5:/EE^=MZ
ML]ZM5T_5X[WQ+Q^>GC>[]</':O:W\^K'U<.'QVU?/TA1[:;&K%>QV9X:,\;2
MJ4GA!_AB43PU!&>FQKQ=/#6$!G.&D9N:=]?+A^?[Y=WN>6N`[@LN0<&7%['9
M!M=P60IN"@$*4499#"XB:7"!=C&XB`5;PV%K[VT-@FN0^_ERLW*>DO/HCX`;
M80^WY+'9@AOX+H4[A0G`;4Q_(=Q2T0S<AG8IW%+Q8&8(ITZ6Z\]?-H_?5CU\
M4`>L5,0#2UALMH&%L'49L,G1`SJ\.+0F12:T!K2+@14B;OV;-9/*L&:.'[ZN
MGG:/VVK\</^X_;S<K1\?^N(M:!!D$9MMO'EQV"X)"H#&BD,MD)-)X\W*0RV2
MN1T%Q+80)DZ2(;9B3,0QV+(07[$+GFNVL67%\94D```0*8ZO2)*)KP#M8FQ)
MB*\@)7&490K73I9WJ\UF95:_Y09VLU]6VUW?@)8D(=(B66RV`2?%D98D*H`:
M*HZT2)2)M`#M8L"1;JQR-!X$U-H"?OGX=;5]`'?/`#Y;?7S>'&4_4(@9V"70
M-=N0H^*=?1(7@YM0Q3M[H3([>Z!="KG088^*-1'1[V!P;?WM]=/OU87Q\(SS
M7.T^+7?&__A6#>_OC=A7%\_&\5N9F0!/N^^R*93?Q#(;.G?-UC3`>`JG(8D5
M8"EH4:["OIK9:@+M5+HBE9&"3%TR(P7$$^F$)"8IQF%@+(U)(B,EF.J1D2*=
M&:E<MXF,5.BV=$2)C%0DW9F1`L*E&2G!<<A($=6DY@5CG0FIF]GTIIXM?NF9
MD#)\!^,F8K.M52PI08<34JQAO9604EW(DW)9HKB'+-&7LF3!):^8&+_,P^@P
ME7%F$.QM7-'$Y?`*)F14U^?CR67?)*$@P:ERAH^TG*H^;!\.UZG(]DLEZ.+(
MO-'B2.(WYDB2AJ/.`")0+I4_VEO^4+G\H3ZVC'7;LDRW*5N&,K:LE'0SH@.V
M#+U"9;"?$#X08%<\5AAI[QK/;\^NQ_.YMV77P\6BGLVKQ;0:5C].%[8(:5Z/
M;F?CQ2_5^^G5N;G;5ZF0-W3<7KAFV]"A<D'#?06-J^*8-5<91P)HEY:V)(D#
M.D"\T+DZ3+M=W<4%]]5=<+7Q5S*43?G+5G47_&;AE$=7=W%)7LZ9J^@:=Z(K
MTM'I)+HR$;JU$(GBL'"2-HR3%8>%.<^$A8%V,28IXG9@K#B:FZ0-`R.BU-SS
M7NX&[S3WN6X3YCYT6SJBA+F/I#O-/1`N-?><-H5G9C<>S;WQ-1U6U\/9]_6B
MNIC.JM'T^MI8_?J'6[#MP\EY-:NOAHOZO)HOIJ/OG;$/*T)/F^^R,&#SI8[-
MELV'T17:_#BXK,UGRL5<:9>1RD@;[E.Z)SJE+==M0O&9=MU2$5+CG4)7VH/\
MO_>`<=/%F],VTA)I=^H,4`:=R4]XA\[X&0<]@=RY2Y<-)\/+^KJ>+/I*/@[)
M&UOQYIHMA[V41T)YY/&HP@G*VWRIM^9+M[1%B\:]Y"$95IV/YZ-;YU^"B3&P
M7OTR'\_!K[P83X:3T=CLV$;3R?G8[J=[C$KOC\K;F;<;E7W7%_^846%.51P5
M\:-RMG)^>[6PXX#M_Q"X[VLEC2S[$``1L=FRDL"]T=EC[9>UDKC#2G:KHRS.
ME#"9R90`[=)()Y,R?H6!P6>$$5RN'E;;Y:9GZ)+)L'VV01;7;",LB[,DR<$#
M.+PX2\)X)DL"M(MQY2%+0A`A,8+,"8D5&Q`=AIJ,Z1<#-D3L^\:*&0]9$IM<
M=<TVX+PX2Y)$!5"CQ5D21C-9$J!=##@-61*,<"P5H!Q[.W*U_N-Y_6&]^V;+
M!4;++VN7+GEZ?-[VJ;#TT--6A:5KMJ&GQ=F2)#Z`'R[.EC"<R98`[6+H2:R#
MU$V5!F6A2F-Z?U^=+3?+A[M5-?^T6NVJX7:[?/BX@IQ5;^2Q3Y!0AF*SC3PN
M3I`DX3'P45T<UZ`Z$]<`VL7(HU"+A^1>71@)=6&C[7JWOC-R/KR[>WQ^L'5?
M-X^;]=W:E\W43[OUY^6NM_Q3'0+J&L=F:Q9@.(6SD(0*H)3%U7E49:KS@';I
M7C])W`Y,%L<_DK1A8)R7[O6I0#UV7[)S]Y7K-K'7#]V6CBBQUX^D._<M0+AT
MKT\%#6Z21*+Q4F5POAO_>KXP^_KK%Q^2'O90#==^.;?U^J[9UBG.2_?QD?%]
M#Y7C+MQ]O8G9^!\M2:R/)*EN2<ITFY(DWVUFEUW:`R9-%V]/NT'M@+3Z$IW\
M='1(*Z-A/@37S4Z1A<],1N^'D\MZ7HW=1M'L&X>7L]I);?73>/&^&HY&T]O)
M8@@_3"=])9FAD(70L=G:*;YJ5+Y^1_.!Y+09%?8NM6=Y/+FT@VHT$K;%5]/Y
MK=E&]AT(\45US&YV7;.MDJX.Z5AEL2K)>JLDPL7&'8D8:"&PQ8XEAW1?)8?=
M.IGI]Y!4`RXHO7TH)MT,Z8"^(%QNW7V%E68#)16)N6XH9W?Z,ITL9M.KN14L
MF_(^/T::8HF5+>JF+TNL@/E2`Q]XSTH3"<FYXP.UQ.>X(+-I._0&'HM]83KK
MKD(@(7%7$!V*'8N!5$(VEHS[GJ>+]_7,V+&+Z>S:QH5ZS@E1X3,_6__MFJTY
M(3XE6!`6BESGYT04N[0DE1FSV+TBI9<D;M$I3^D=IMU.F!(F?,(4KC;^*IXS
MX2];"5/XK3!A:@O>8<[00"OACL,P)H`1O7\:1G?RE+PB44ARB4)2GBA,TH8Q
MH^+4#>F5*-2=RTNNVX3+1S*)PF+2S8BZEQ<@7!KB)B&7QHSA"B?=G(]G]6@Q
MG<WS87AOL4*ZC^"FV7*N2GDDQBW<XU&JQF5$"OGYK'^N1[>+\8]0I7(Q'D'A
MBED(KZ>VA`661;]&5C?FA^ED_J]\=@&S_6%Q6WSUAL.R[X8`/1\HIII]&^8X
MK.S7-U=CXRC6SN^=FTF!W`@6OR*.EN8/AK2#666J^F?G-AO?N&^BBF#O$#.E
M8_.HP1T26`;G/N%#*<`NCLP;+8XT?6N.6,-19ZT;4"Y,M)"N='3GBHI5\4DR
M6$=A,3H03T0B\!GPWDDRJ-.HY?H]:'E4[/>042LE#2=')#.Y6)4?)8-#WHX-
M=*-8[I.0MKT`%:LG\V.\,QR3=G;_A5\F[;`J/$B&-9SG9<F'H@I"(ECVDJ7N
M8XER_:9D2?:J/"CM`9.FBS>G#9DEF917'\$KB1[@D.CD`RIX4VFNM8^)Q,K+
MZ4\3LX2]']_80^'JV6(XGE1G]:0VRQZ$$]Q]6//Z2G-(D'*[XF'YHK[X50/S
M0<_7E51@'@Y1L"45KMG6.!>$+(EX1.SS&D>+P]DX!"'3&M?]V46NWY3&94*$
MI:0!\F2$$-/R>#9N(H1,DV9?3?VV.HB]K5*#:@NC#O-6W=IB-C0V?71,*09F
MT1OBL=F6,5H<Z,:]HVK&^2N6,=)+QCH^Q^C1;TK&2$;&"DD#Y"0I8_@5,N9/
M1H#%6R)WV)QQ"]Z/S\:]<R,XG(J`;:81OSP5`3@L%1G2)3*D`U]=+C&HE\1T
M?T"1Z38E,"@M,(64[5ED*7G1KQ`71`-2S&:"P]<3V">S;V;CR6A\8U;@)CE1
M7=2ULTOS>O:CV9;V%BP4;!%6L=D^TZU<KE!?4R1%\;$;F=IU61Z12I%VAP(4
MGXN18AKR__8XXV.#=\Q^LN/K(%SYR;NV$@-M=/"H9'/W.PRG!*0>(`@^-4T\
M0!$7R0<8"'+J`8YX^@&!6)H'B:1./J!R76B<P0$.,TZ3P!C+#-C$.*KI)R@V
MLI)\@F6?X%BE9P0+,ZOI)R2A:42Q(HE3N.T3FM(TIP11GNZ%8#B-//D$H9G1
M$DI5A@9C.#TOA#.<&8M@@J6?D!QE1JLXRG"J&4WW0A$3Z;%0S#)X4,()3S]!
M.<_TPKC./,$%2^L<%2)C6ZAD&9VC"BHADT]HB."E+1@GF2>,6J;Y8(2)C)VD
M3*0Y969E2TL0XSQC;$T?,C,6*7"F%R5D>N:8YIFYY31GLXW*D31BG,F,A>&<
MJS2F7(B,I>-29#2**T$SG&J5T3F!=&:T9E9HF@]!("*9?()JG9X784Q0AH9`
M&4D6$N7X4/`I3_()C4EZ7B3"F45=8ALM33U!2$:")"4L\P0C*/,$)QDW3`HB
M,IQ*DI%D:5;D-*92DXRE4XAFM$%AFI$@1:``.OD$91FG4C&:\)2,9UO_?'IR
M>O(_$*?!5PT*96YD<W1R96%M#65N9&]B:@TU(#`@;V)J/#PO0V]N=&5N=',@
M-B`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA
M0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C
M97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C
M-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3
M971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J
M#38@,"!O8FH\/"],96YG=&@@-#<U,2]&:6QT97(O1FQA=&5$96-O9&4^/G-T
M<F5A;0T*>)R]/=N2VS:6[UW5_X":E_%NR5KB1H(U3W9B[WHR2;SN3F6V:E[8
M%"1Q3)$R+U:4K]]S`!"D;#4YXY`J)]V2"!'G?@?[]=_O[S[=WP7K,)8DP'_F
ME5I+87^DA_L[:JY0PD)"0_,)(TRMXY@IH@*X$@A&*GU_]RLIS+TB(?%&4BG\
M1:K=_=W^_F[[GW@K_#?X(%@+P6&#M>"2PR\>,W9Y/182K\<\PNM*A?SZ#1EY
MJ;B`FR@:$!4%<%>$:?NOK?G4713^(J,]4J\?[^_^ZVWRE$:$<O((7S#$,C?M
MR$,94((J\@@$BD,@#Q7D\??[NY?!FDK`ZO%T?_?B;5F=DFI#_E:6'[-B1QZ:
MI-$'733U?Y#'?][?O8&-_O=?!\=PY#HX84#BV$+S@GSKS9_#%6^NJ+EYL`Z4
MC,AC:C#E'%\CIH_[K":OBJ)-<O)!'\NJ(65!`/\#D&EN>!B(8@=0S-8B"*BA
M_8N7L^_$6;^36,<TBNU./SR\GGTO&0ZQXD$4V;W^P<3\))3Q@*<T5*+CJ:#X
M&GF:ED639$5-ME:,YX:!B_A&;$1K,Y#@.*)>@D.P,`;;W.EH[764G+)FGQ6D
MV6MRT$F!5\LM>=!IDX%PL^@5OL6K\%%;94VF00?2!C^E,>>SZR'8G#@4'<\H
M#WLL\#5BD12;'D#ZY@J`;WY+]TFQTP-(Q0H6)0W)BL]E_EF3NGT"*A1-!LI<
M9?7'FN!MVR+5%0H$WF9-WBXC%&$0>R27%8H0KO3D9#R0'3EER-6S0I$F!7G2
MB_!61!TP+/:\%>AX#3#9!@#(MIG>D*>S8>LV`1X:UL&[,]F4I"@;V#<':`'F
M*DN;'%:6!*QS4\);8&A9$9"%"FYEO@Z<?,3OMK4FI[+:U,#]=$^2>G8,9=2C
M:+$#R\;X_-LHOPTZ8Z:LNWIQ2,[S"VMP!24Q_S:AW^;",ZSF=_7T)DP*:<\D
M!<&E`M]G,#IE>3[[9CR\"9<$NQF7A+H)ER`EZ(U20*G3)/W;$5S,[+NI:TC-
MSZ98W(I-T57S,#N;HH%Y`-]AW=@+\-.ZF-T]1^(F%B\2-[-X:/!XL#2/T-ZY
M7<`G">FVPB`KS8[@KN<7BBMHS<^GT.^R,)O43=BDAFP*0FGSA!=/.L_TY]EY
M1%EX"R91SF[%)<K53;1)B"&?%(^=8ZJ;[+"`,E%U#:WY&16+6S&*!=?LP^R,
M8D$X8!2+E'-.6%K(BG9V1C%,])=GE*F>W(A1H;P)HR(Z=%#,U8->'*ORGPO$
M>CRXB4)Q>C.%XNPF"L794*&HY$ZACGE2+%*?NP&3I+P9DT)Z$R:%T85[4FZO
M>I_,G]WR^%ID-#^78G4K+HE`W()+@@8#+G$%$:;C4MGFLR=.0D2W8),8.,"E
MV31P@F"*HD$+0<:#<G39['5%ZNR0Y4EE:XQK\G]E2RRA8=-D,RRPFGKF$ED>
M7K2PQI+UL$;11;L#2ZF^%IHFE=ZV>7XF3SI-L$9J"ZU9G;9U3<JV(MNV:2M-
M;$TDP<)[O2*'Q)2-G??$S[#4/EA>Z;K-&_OI45>)6U/9-5F1%"E6WQ<@@T+>
MV'`LB.F`9=2389.9_@%`8]CB./BGA=I`5$4>J&4K_A1P[-$/:.`;F2P,HHN*
M_Y](5@"^!\.8Q9H=7-(;H8Y.MD>=QAYS$;%G6QU=/^AC49X*UP.RKY_I"EG=
M/23G1007>Z\6?![U+>A8.5OC]9,D:8-]:*=C*P(*9G@)H*)0)^D>LWF+HVN0
M?5<>CDEA>B5/FF`.68'^Y:CJVZVVW9*J/,#:TFSBT'PRB@\;U7J#M\X.Q]SU
M9TP;90DRA,R3(>C[F-AO-&3H^;<F[P[8B4]<JZ>L'(-28W>_A5Y7R&4)-"29
M(]0B/3(EI*_.(,;H1QTP\[<-_&[".VPV^R[1$"<SP^$X*F+7]UNL`8\%_6[S
MA2TO?*%'DT:A[[4*3'"?-T!IWFXT^4<@@PQ^4)+4=7LX>F\),HROD^KL)=SY
M9E!"\.7@S`K7#<=F/DG(,:F:+&TQ%%F(JA$.2MV$JA&_4`BN7!FLH^02^L=4
MMUU$>UEE5'UA?9`[.J_U"4('34Q8E=6+#011Z2%;>""(Q@,:T"#@_=Q,UZ?_
MX>'URHDN<@$M8>V$L,F:'"1S_N1,>*B6S)B"8(`\"WS`+]$U(^K?ZSJMLJ,-
M'[?D=5MG!3C'^6<).+T1P['"TNTT_V2=Y&HH3A'KQ8DQY]`_0*Q%WCKK]HC^
M^T>(/%Z!UTT;\M:F$Q^LZU[/;F$4O2)8\[>1,`7HV;EPNT]1/PD6R;B?90R=
M_H+E,@['>IPK+J;6#3H/\"=@UW!82G]J3828Y:#P7\64AP1<F`V*LH/&F,G\
M-@[IB^$LC*C]@!9\_Y#5M4E`7N6+)(-1++I!F8"Y=.C%0GY1<K_=PBH;^8VP
MUZKZ))<^&VDD35-E3VV3/.660P/^)96/\B&Z_02ALAW"LK6"#/P<)#^5;LYN
M+`NBZK[NX61FC6S5QP8'JRH0%UAOLH0\.2W"URCR-H7V=1E&A1?Q2N\@"D+1
M7I&3[F;'VF*#Z=Q'1.%,RJ<\VR76<Y7DV,+;%$C0'C=8%EA(3@2XV`[^905%
M@(GM*<4H[Z-2I9Z/2H$4E=[F:'XA+3)))$2B696V!QR;3%&/MY`-&2$RE`+Z
M+<'DT!??8M8G](*Y4L9IGZ76PO11&<1@QAP!Q`,T<$V9VK%`S/FV(`?]:,+&
MH?EMWF5DAIY#ZFY<'G*:KV,9^QGZ0'*'Q?M7'Q[)NP5&VD,5>ML7A+WCC;N=
M'X$JP,;#_+RC_>Y+=LEIZ+?!7E$_MR^";FY_8.>6J.M]C>4"37/NMUDZ=HCC
M6_"-!7+`MR!R6WU_3C99.OMF@M^"2TS$M^(2D_(F7`KIA0F)7/)]FG^H(0IO
MPB+%;L8BI6["(O`GO2)%6"4P>[7??/SJ^7F&F]@Z3GMEG3\9Y1?^(E#2D0MB
MA=FWXC?Q@)#3#3""#5R&4[;5_`T6<1,)&`0N"TA`R(?T"OH*CXBD2QT@9M25
M"8*M0R+O"@B2"I,E)/D*WJ9KD_]D>%BF+.HRSS8FBL1,.=MD2069[@HBS!PK
M0POU"<+0-XN$#^UXS/M6K_ZML2G:*:NQ0`FH`)3SEU"08;QKV3`1]22-(T?2
M7R'D?L(>FK:-\*QNS%$=(%N"O>3JHV[,&T-7UV]S^24`WM9-=>ZO0UJFTZ0&
MZK=8!6_V5=GN]F7;V!+L5X<TYR_'1D)YG!>N@$O6[_3%^<Q%Q(KZ'H88U.J"
MKOYIJCR.896N=5*E^U6?.">?DRPW)89!=]DJ2\=&N];.`ZQ!F:Y\3':ZT)5I
MM=G^?'\"S(J1*TLL@+^,?:T2YXX\_M155H9H&5K48&K3KC%L0'2SU*[36L$[
M),B*/+67I]AV;5)!#JJ[%B5DITEZMAH`"4NN&VU*RZ[8=M&N?[##)OEYD?JA
M')R;#7LB8)C6Y=W`X9/N477(7U'N,?7%=U_(DJE%]32#/?8);(#T@COIHR[P
MC"`(QF==V2*5JT$DRU"B/SZ)YS:[;@!._?KQG[ZV=.C*2I7&8AH`ZN2_[BIN
MGLO7F/KK`-D:39JE*;J806?:"YRI;NC*W7HA=?"G;F@L?3=,!HIWOA*-;.W;
M7Q>V=_W-$#WW$`"$B%F(OOW0N!K'F/8#7WWO*S2O$>-WCV]^)/0+U.R=/OPW
MWNF$8/P57K&U)#((X2=&3-2_R^_O'F:!-NRAQ?PL9-[S4M6IZO=O'K[[\.[]
MX[N??R(_OR6O?WEX]].;AX=)Z,,+Z!D7WPC^^`,F1.1K8^!X(E\;$TSV%:IK
MU9MG"2ZBP(*LI'_W[T$\(GX0.'80?WMH.B+;.-NX3-P+,9K@OE`6J'ZZ**)N
M/&HDV,5FT;!?`/F278W](W!LB1M&^&M[S.#;*_(V+RN(B5>V!328_W,/&_BE
MR#!>-D\+,0[NU4'CX>T5^9^RV)$?RF5Z^UAXOU(KI!'MK?D!PHL<7WRWSPH`
MZ'UIWN'_*(P_:0Q*\2.(\,'@)60##C!'%,V:35;;/@M..FY)?=0XYMB<B2Y^
M/Q]<`\R>7]_@].2F31LS_D+JI&_,8.R>H?];@@@!Z].?G@@A[R*\LMRL`,SL
M`(9\JS6\`:_NPKS\:!`X)AV^%S&Z>6S"0&610-LR-5$ZQDMMD5JY0LP;71ZR
MM.["=^O'LSHMP;,O$]9PY6-;SF2?,X4N2W&<-&T$*PI%B]VMMG(/QB@`MMQS
M;3@",>2NP2W#(=D-"/5GP-W/BV%<:^3=!GB_D3S[;.Y=[8#@]:&V?5E_VR6(
M$/;C#;P/\,-N2&G?`MJU:0QOR[;HFH`$HK-F_^>:/&7E!I"JZJPYK\DO-8*)
MB3#V40H4ZEXJ@!!'D(D&.\M'D'@,=4"TTWU1YN4.N\$H]TB3GO'FZ^8CUY`T
M[;LEZ"#IU_FS",)+:P@"[*0"\4PV=G`8!!C(@#BD22\/AG=ZO5L/),#)!:A.
MF9^/^MAD&R<E-:A73@YEKM,VUQW!*_.8BJ<SDE3GVRY>)LGQV&='2U"#^W9R
M,)BYC/R3.0H"Z<8.YWQV%V.ER:["83/0$?06F+;MSC[HS_"S=*\/ADY&-_8)
MA+NI;FV*,+0;"_A3/!WU!_QI/$HR%OO0&`_VFX+8CX"^_N;*VW.8R'ZS1<(.
M%OW1FX^$'<SW<`.J?"[)5,"^BO#(*:F=*?Q=;VRGW@A9D1Q@T7?OR:]EE6].
MH$,V,%EA9I60[\&=GC!O3,L*\@Z;<\%_#Z!O^O`$-V%\A0="V9K\7)"?TZ8T
M'\;F0[&(><&N4S?RVB=.7';#Z"?MD_R->_X2BDYWB*+0)\AQTTHGG4D][4NL
MAY2G8EAH!%U#NKQ*/[59;0\U?`=$0,IT0=B0*BX@L_48B#7Z14N0@/F`DP]+
ME)%_^E;/+70-$%:=NTG\>J3V"DB8OC]*BTF(V^JS=:,7_+?VR6JDP1@/N(`<
M(7DOB+D$ZD$_R=]/IW#53:?T_,.3%WE>GKHY2@OOJA."`:>)'9JR96>C$<]4
MJ(T?^N7AE0W.?0`_^Q"2BCV>2S[M*)8#<B[<*\:)^VZSA9_-Q2._DVVN.L2<
M0LX_A2^N<&O^9\^HX#H!37PS_VZ71%2T?ZB8?\B?";Z=GBR@ZC3VIU68'$1.
MTN645PT8FJ,%!U.P/-G!M>#)#@9?Z]$/L"GBQ^6%/]IA3!7:ZLY^C3?6#+NN
M^/JYXQY\.%X'_"*!#Y4^V_1T$:8"8<7BJZ,;0_-_,BG1L329LPT)X')!:L@7
MNGH*SNP-XP"(I)%T5;)MR/LD_9CL8,G7+E,7NV3GASL740GN>R@QZS52=D<H
MCAUPY,F-SV/&`,&(*8$`NI@9==5N2!BTRS:29N@.08PR4SHQ<>)?AE\RI"JW
MVRS%1JXMRU3:CC9_,;H,-\]V19>C+T$,UN>9?0>!QT'LY],R2)5+&[U9:$_:
M-$$@9TX!,B,<"\U&@8QV`"Y\K$3&0U)PQOJHR#],V+J^/]?/\.XOYNTRE!"0
MPMV&$B*^$`H^J,'Y$Q%=5#X(69_5?'-V=Q')#7Q-(([[IKZ(G6--TA1TST!S
M;"NT5?5J&'.CL7%KM*UB&"4_)&#VX+5YUB<6`4P>4FFL*6&#K,]DOE#5I_-"
MO`\AJ.R073CJ@_"H)VN@U*"Y2N4%[U=$VWEZ8_>*<ID#Q]Y##<XK\JX4N"O+
M#3ZNTIS:=W7>!GQXAOW]I*XUF%_3L'S28&]!2<MJHS=KR$;Q%<@%MJ<74E<\
M;GF;"7HY()/I^W9DXO1265'>-UH?;(CS!YZ@^VP="`_L7BW5F'HF%R2*`\+-
M3?MOF\?*0TJ*SV+#Z^SZ=1I$ZMGKG\P2(<T"&OU[?3X1<"*[(I";N.-?@3\*
MW$L:4#FZ@`7!\^";!7$4C"X0`9U8$,?C,(3X`/ZQ!='4%BH(Q>B"&$1PBE",
MC:^@E,?C*QCE?'P%GUPA,`H<72&IG%@1XO,L1E=$C$_00S$U`6G,Z?@N+,!'
M9X^N`'),B!_C?.(>G(?C?&$"QQ='5TA!QQ6)A2*<P#82<@)29<ZUC"J;.>,T
MLH('8H(>G(HH&E_!9#"Q"Y=B8H7`,SFC*V0X85IX*"9TCD<BG,!%"3%.4QZ+
M:'P%&-IP'`X!:CF.BV""CD,J./X%D]$50DS96BG'O=%+$<IH8I<(!UY&5R@Q
MP5O)IDRVY&-^T:X()RR,%'C6:W2%E!.63H;AA$;)"/]`S>@*I29T3L9J`EO0
M!34.!\`IQKD?@GD8YTO(XWCB'C*8D.0P#*;@B()PXAXJ4.-\"6,ZX=/!Z8N)
ML(#2"0F*&!X"&UW!J9Q8(;#_-KI",C8!:<@F)#F*\&_7C*Y0;,+213&;T`85
M\`D)4A#DC$,*8$S$E(KSD4@)XM8W?[^_N[_[?\2;V$H-"F5N9'-T<F5A;0UE
M;F1O8FH--R`P(&]B:CP\+T-O;G1E;G1S(#@@,"!2+U1Y<&4O4&%G92]087)E
M;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O
M<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q
M.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@
M,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O
M26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TX(#`@;V)J/#PO3&5N9W1H(#,X
M.#4O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<M5Q;<^.V%7[WC/\#
MGMIMQU9QY25YRJ:;]J73:>-.\I`7FH(L)A2IY<5:[:_O.2``TEX)W)7%R>Q:
M%D$`Y_:=[QQ@\_[7VYN/MS=T%:6*4/S/?$I62@Y_Y;O;&V:>,,(CPB+S#2<L
M7:4I3TA"X0E5C#3Z]N874IFY8JEP(I4D^(,T3[<WV]N;S5]Q*OQO\@5=22E@
M@9442L`/D7+^\GDJ%3Y/18S/DR02IR?DY#[ADC&2,$J2F(IA3YNO&_/1/:3^
M(9\(]?[A]N9O/V6/.:A`D`=XP2C+3.K4PT`K5"3D88?;9HF$@3D\7JE(Q>3A
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MP:Y?OFG7*2KS=E$579&5)"_K%I>SAMTWQ7/6Z67T0*73`TVE#=A(4NN"^S++
M]4Y7W<).QB(Z[F5!)V.1G,K,(QJ[J!.I&&1N2:OS'B*K0*,-EFDQ`-=HA*R=
M&'I%?JH;V,&^;@R@[?MF7[>ZO3-CNB:KVBSO"IBD:(D&L'O.2E1F5P_V!NMG
M56Z<9`'CIDGLY!0L,7**E6()MW(:#WP\+H2E#%3K=K`LE#)(:*.LC,6#33GD
M3/4222&9&,57NB,0A+K+FB-8M-5=^\K![\AA6^3;26A/K`FVW&QTWD'D@FG_
MG7?U(PSBZ1WAZ%L'W<`217FWB%%CZE,&'R+E'I"+JF00%=,K2E#`YL"V&2R0
M9_NBR\KB<X:;7UU_5VGLM_7NXMFC@,S*3HX`>O7YHW'^RS:?A@TFA,\T:3I`
MVS\TI/&LO+8H*O*K+6,')I:U`WO3YL-V2(!?6"P2%"'BLQ7$_;EZ7/#8+QJO
M+,EXL>*U%X0DZA8$S&<L=02<2XOYN.HOD,0`H(!7%G6G\VU5E_73D>26?.OJ
M*7L:.<E:/^NRWB,'N`/*6?4;P,`>WP=NU$(Z0^#4U>?C#M->#:\T0%A@XJ*"
MW_=ZWQ5KR*.&29F'"V!B`K3=AUCL,)$Y,@=R[NH2<GH)&X$"`FC9FFR:>D>>
M(`YAE[@YE#6ORS)[K!O`26!N99'KRO&PNF]`RNRQ-&D>B$#5.7[H1`::-B04
MKU0@$"L"ZL9:!B?P[RVA@X@['<1)8A.@3&.K@_F=(BFQQC9R36T-&L1!.7!3
M>'W=YYW56@'BH/+JE[HKCU9[IFK9F;P+%%AG3;Y=)"LF4'%;Z67JDR+F1Q1^
MXL.O1+/6/2F?(0L'D`RL]@3\82#^V7X/HIE,VGYW=9"5P,&=+(M`>,+5@A#.
M2<SBM\\?P+>84F]HRD;Z(RW]^:$%8F?1R7PHJG7?=L9Z@'`:715,"*2H0#9O
M.@Q%!20<ZRY@=45>Z"H'^J>KYZ*I*_09>#*&3[9^SN"KI]$;CNA$$P]:P+VC
MQ',(P823&BH6*W5;E_U`3-L>26OK$-E6&D7SRN?!RW,-O+=%F"\+W9N:%D(5
M)9BB=:F?LOP(;P,-!A5!6!PTT9_VP'YQRB-0Z0-\:/X`1KV$X%$TEJ>CX,K5
M:O4>2Z^^&HHU$!:*52C,3.P:Q#T'=K]11?7J:45R798]UMLYT=TV@P&^2LA*
M$+H:DL&FUZ65$UYEJP5<.^*I3]W49S$9V]0->62;/?N$;+,/II:,5/WN<6BC
M307>])#*2P+>GT$R1NT,X*:]=XQVQAPYVOBQ[X9V4X5_;"ET6*0#$3&?MX1B
MHVM'%KN-S"`21.@^*R&Q;.H<A%YC19V-&;4]MIU--)9]."2'L`!>,GX-S@NI
MJ#5?>\'`Z\NA_&/D@Q]`?C:SKLC#%E8;?L%U%U"#2ET"$RGUCAYSX3A,U@[5
MYMMY1(@F0\$\V0E-_$Z42FS(_;AMCFW=0MP5_8Z4??Y'51\PU5^=/J=3M7"1
M)GXSU'F'\?$>/!8W42'P_<CN\$<!%?VV;KN)%X`3/$%=W((]?SC[S+A5M8B%
M8]\:3]D8WLI1<[^#P2FW(,2CUI7AJ!W",OB^021M^)9UXX'"3F,;0O])HW.\
MBH.!BJZ+-J^?ATD&=P?(;^I1_('U+R%_-'1<4[%*T;2F_MH5ZVLO)=BXU*)M
M)XR5R'61:4*]>PHI;?L4RA'ZY]8R9=/;!2..`%Y`274HNFUMX7;"+1'+;=&2
M-99=`"N9V+G2/0![:1-8AKG<9;U.?^H*J,Q>YOPE;"I]]U@ICQ621=:G`:D[
M(%T-^-[[(P%M)(8_/`*IJ"P3`X6,<EI?;\\45B\+UJZN2^/YX,18@#3:]&?'
M/'^<`'RC-]C'JQ?1`O>]QXC*2?5A$=.VC&&;_T34>?#[P\1RZGO(5]@5WO0O
MW.7.-)$-]1H@X!'SUAYJ4E.#[W6#9V5@Z>N7)2@DO0*Q#\PO6;1<X0#S\R0Y
MW?ZYNBS*KW5Y!1>@B3QVF&.:S<[;#'N<\D1,'N!(S[9]#0C1D19\"3'C")4X
M=F=.T"I[X#&RI,''BM*>AVQ"O@QD%&HH8.2+<"2N'-I0PPM<,<`\VI3@_EDW
M-*\0"#=%`YO$$S?=Y`/Z0H&$E0_$U@NXO7IR@#K;[7?A-`2&GVB&)F,>XLPB
MD%'&:6I[]0Y&'/GM+./_S*.M0.[D"H;8ROH_T[([Q^4-.3Q`RL2?OO1QI?M0
M16`?$_3UP11)Y'T/$R+3LD`\)">;A=N)<Y&/?59U/DR6"("Q^<$GU7!*;9'@
MRCKD`:8UB]7_P`4@V/MR:.SMLST>46_J>HU-O&('6]]HS"^N`0!?/S4%A!,P
M!_.;S\9C-\7%^_C-G2&/?0.HXQN>EGHN<G0]]D3D!`<IM3B('+G:FN/5H0."
M!8+?4&W(0+&#+TQ]Z0N!L0=D^'+>-PW46@@<Z#2FI81M`B(5*8N/?3&4X>OF
M:(OJ<0F8?QR.IEM"";X_0J-H]`CSV=QCL-9!GNBX&)H)6V#UIP)+?A!-X:V$
MOK)VO38BX-&^7#"YX_R^=3*%/T653XF/NBP@?N^@\#M@$KPC\'<%61&/\5T#
MZV4WZ5"`P?6G`C*((]:G$`4XIAYRYH2;`E-[Q=Z&JP)+N,#80.',][Y%(JP+
MZ$_9;H\`<+#$H*B>=8M)<JNSYP+VZ#G"'CG"6N?9&D>1__[I[T;RL<*X(Y^.
M95:98F,$!8,:+ZN0#+0'DSQG2-V/K_OF"QQ!XR&QAX-H1(/8HL'/V/L=R$NK
MQ_.JU\F@=04PRKXO]N`U%=91>"?-B?`X`&M>@QZ;[@54D@-H<`(!V&4LBZ>J
MGG09V_X1.W*=;K&1N(0F)HT&>X>JJ%Y7/LBX%:3J.*5$F!7&J<R]0@Z%=)28
MY_ST<\XX#3UG-#[__D<S!*^ZR80(>4)&$#]P>8XD=(`4H/-)Y(Y6H_BU.M^P
M"%X!M8O<LQ7GMM=.OC`9'DO`&C&PD9.+S)S84F\NYJX`2AZIERG]1:?V]5F5
M#;E)M$UP']^<D)1I')ZJCS$2OB0_WU]9Z#AU18QT?7US1'G!*N?2#M`#M\J7
M/!3=0O!+?2]6_&M][\)%P/?<(O.^!VM<:@9?-["4VPMB,L("T[3>^UUFT+`!
MQMAW@%WN8-\X')*\QR/9;[-FE^5F@'6W4Q<+BN&L"9+G%450Z!M?566]99%T
MJB@J[24>OHI$;/M\.:0)+[W_9=WT3]/[$]<VGH@]Z8GDR'J4W=0TTE^A@+T*
M!F8LR_J`]9+9JV&%S\CXS^+"^Z+^V=!C,*<#AR_3^5<(=I8M"N4E.QFW,E$8
M4E`%?G/<2MN7F8_;2Q<!-W&+S,8MKH$:.KE(V/0R]85@,AZ""QNW>&FAS1NM
M*[3LIJ_LI44(VN\NV,<Y2W$V;N2TI5"#](P69VZ.2F6O@M7G+DLA^\`5HN3;
M56C>5:Y^%#3U2@1$<?7C=CPM,3EU.&EQ=X4\%,(O1]<N^YZ<2F)?L].S[11,
M($X7)Y4LV.5*%M'7*!E6N%C)PI_?"\I'6LY&'4.=4'7%9G+N8:OR\00+B4U6
M`<\!'0/3-EZ-U[=V]=J_.+GJ8`P5,,6,/&>1B?-18Z=,(5)Y*3*)-/Y*9+IT
M$4`FM\@L,N$:%R*32/U5/#56HP`QPED<<&G:77X)3Y?LYBP^<>6W<]I>L32A
M`S[Q;1U^>"+LE<.3'0WT,IP<O>R;)S?O!B<G0L47Q[RP]P3#,8\K7!KSPM]$
MI`F/1E[BR-*KXX7ATLJ`I1#KDU+EN2Y[U\Z<%#2VSS:E-U^6)Z@E+HR6OI5:
M&2VY.WAA+<$*J*5O7@'?'6\L<G==$__MWQD5!;@X**W=X?V5J;Y.\.RW[%AQ
M[G<<)MIO6R7RJ]QC2].6AA+*$W>8>IIJ7W,7D4@FUN$TENXVK;]VUNEVR$*@
MZ5F6_V9/X:Y!P$7DXRDVGU_S_/-9;VX'YUF>\CLXC:)4!%'T?)B!L<?>![?W
MX^MSF#>S3!"L[3+GP9J*R\'ZK9.?M[V<*HB-MA<I.XNE,T4[>NL9G/VRC$.U
M#RW"DWD@#E`:D%FZ%H^UK'S=@.1QJ'UXGT91\#G#?W\=&L#3<`/S7J1*!`?(
M-$F#`]3<$C$%Y`P-2$)=4J,&F@3;K/>,TC2L2<:PP@F.X+,CH$J:L8?$6`N.
M4'@[/S@B8DE8'2SF<F:GP#IF5DEY%#8\IWQ&6FZ.8(,CN)CQ<"X$#\O")?+(
MX`@E65A:'DDVL]-8R)E5$A'/R)**&7T(*K&W$QK!9!1>17"\AQ0<(90*1QSD
M]AED$4K,Q)R())^1)<93Z>"(1(J9$:D('['<`\[&85G`]G%XIQ+R5MB#8)\S
M4"NE3,*R2##+S"J12L*6D[&<L:VBLXC-J0AK3&'`A$<(F89UJJ2:03JEU$Q$
MJ4C)F9W&\4S,J229DS9-9'@?$4W2L/4CEM*P72*>RIDY1#KCR9%,Y_8143XS
M1TQ%V"Y10F=2>I32-#Q'3-F,!\4,<F%X!,?CP.`(@,LP.L22Q3,[56S&DV/(
MR&&=QC&?0;HXX3/1`'X\XT$)!6`/CV#XO\@)CN`\P)2`E'[X]?;F]N;_;D3>
M8@T*96YD<W1R96%M#65N9&]B:@TY(#`@;V)J/#PO0V]N=&5N=',@,3`@,"!2
M+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP
M(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO
M1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T
M(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]0
M1$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ,"`P
M(&]B:CP\+TQE;F=T:"`T-3`S+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M
M#0IXG+U<6Y/;MA5^WYG]#WCHM&Y'WI``>.M;W3B3S#3N--XV>>@+1$(28XJ4
M>=F-\NM[S@%`4'LA,ZGHR22110C$N7_G`K_[Z?;F\^U-<!=G$0OP'_J4WD72
M_"<_WMZ$]"1D/&9A3-]PEB1W6<93E@8!RS+!6GU[\R.K::M$1KA/E*;X/];N
M;V\.MS>[O^!.^,_DB^!.2@'[WTD1"?B?R#B_?)[)")]G(L'G:1J+ES?D[&T:
MBCA@:0C_)@'LBF?:_;8UG]W#:'S(0T_4N_O;FZ^^4=L<."#8/?R`>$6;.NZ$
MG(6!2-G]$8\=9F'"[O/;F[=((GY^O+UYL]/M4=>]VE::=<->M=V&/1[*_,#*
MFO5#6[-<U6RKV=#I@O4-.[5-,>2:Z?Z@ZJ9BJBY8TQ]TR_*#/I:YJCH&CWIV
M4`^:'<JN;UK\MCK#+KIF)]VW3:6'XY_9_<^W-^^!CG]=A=HXSCRY&;^301"R
M^U^!QK=7?Q5(?L)9SN'5EK-1''##V4*WY8,N[MB/VO!"L6N?@P0,/[("%BEW
MQQ!99D[1&=$V.[8;ZKVJ6->WJJP[MFN;HY7THSU@68`FE+L2!(U2S0^J57D/
M9/R*W[!Z.&Y!S+`5B+L#>O*^?"C[4G=$XU97I89=2/BP@N7-<5O6JB^;VO_H
MAS]^O0X;`NFD$:31J.>Q98/>[9JV[XRV#BW[>\B^;;J>W>O\`%K<[,_LU'0E
MG77H4,]54;2ZZUAS.L$OAYH():,`TE0%;$'2@-[=H"MV5.TGW6]H_[+N=4VV
MLM5[_$$#CS]I=JI435L#EX&/*W`A2Q-B`E`>A%PZ+G"1Q(8-/=BC/>O=[WU_
M_)I1@-N-S?O?_)?+X.I&!_O#KYTS$R-Y,HHM>3^B9+IF5$4KZ?>_G%"4*-N/
MYZ[71^?3NB'/X<%N0.\$VE[#'XR7.^CJQ+JF(GW6Z/1Z#:+4?B?X"@P+MFIJ
M,"6PFWI/2]<0JQ"CIXE&LF-2>21[7S5;L.RB'?:@?,4`)GY>X1QR/,BZWC6$
M(.Y)#A,^>C7)N76NQ.JBW.W*?*CZ\X85NCN5/82ENFF/#9BPBSS`D0?=]1CD
M-NB&<C#[:Y]8RO0+\49&4W4(PS@<>4.?K:_3Z)HU*#7Z(U!:7:!K&SJOYJBN
M^A?@$7[8`]<@=*^BN^@OS&%CZ?$'3ZP@/]7-8Z6+O4:K*\!HJ^;$:OW(NI/.
M2U51[-F6Z*(115CXT0-*:5I4@E:=]-##V:V)0BSZQCQA)P4.OBM_86=M8(T-
M<P1#[*N0>NLE5B`^Q2ALB$]];)918,'7<\<$3.AT:[W.I4';T%.47=X\Z)9T
MGFA`U29!6][8>'L8CJI^D47`BK(_$-VGMH1P<&:[)@>;68,%2+>-RV'JXW)D
M.`!'U34@%)3#"53SJ'(ZJS+`$@3?^P@-@.*D:@S#P*:ZZ5E3@T)?./%<M4!-
M8UDUX0\P!-EI<0\\+5M4>\]/V':S"@.05,.`4'H=2)RU;H?>!"V""?6P`U@U
MM*@`3:?MF0%0:8@SS=$"Z8>20!VZ,L1>(,SR-4G;Z#71"P6Q:ML4A&80$#'5
M:H4/K,6MP@0Y9B$<4C,'4A/\3%D(J1]`-`1?0,M#"1[`8$96J1:\@P>?T_/7
M3Y5F5)$U'*^CPH1@`#F<7_\U\?B:-U>7A(RRJ2B\)"#E-8(`=P3.$G("M+ZI
M_?PWB%9`=)[8>.2IN/IK)@J817>I%-Q$9\A%KOXND;U`DKSZ:V3D29H"#A#3
M]2-9'$TM.$@BKS=!:J'WJ3P!Z`9D059L\LI5$MY4C/EN)+P_#01W&EP9[T@I
M[`I@#V*Z.\/*.#@04VI3G]9&P5.H-_7Q\!$#(GKW5G\>RA:+$-?.]F0`&AB&
MJZ9[2>9R^E#&7M2AH_YO%03)87]@E-:V&@C?M^IX)%!G@@?@N@/F^?"\QSC2
M8R4#_GB$M0\N9;N,CX`Y+H.*Q0P&3R%FZ,@;&AU?0<.3)!GQO<Q\L$RDT_`C
M57`4@-M]74(*!"'1(C@X/\(Z"(-'W1K\;`HP6/;I]?Y,YFDY\PQ^HO<`8`VH
MJ"L+!,JUWI6]X25P,&\0EW@\-HT/:_`A'K-].;5TZ5R.$3>`V:K";!X`U&YH
MJ11IY&M0=*Y.:EM6IG[C2!GJ\O.@J29FRCU4H0%Z:H,W6O9Y0*#A?N0`%5-=
MUP!?48\(1!M](`59@P5R3/724#ROWA9@^BW`Q*HD96[:/8"?[@BX#U`Q..".
M*"QM@18KMB#W#29$'63#6U/=4QL`H'ME/"86J1!4WB.7B+-4"@$F(:6H0T`$
ML&GPQ;#NT+18T()_CVR[1N6!)=QED5$H#1_>K.';132^:EW?#C#!TQ1F2>PS
MHR"=\>T7JHBY??WK^6A4U-L\52#!LGNJU\-J4&3X=CMT&*`[2(S;'F1)`NS@
M'0U\M/H"JK!OJ:8".<@&G$5C:L%KR#3(?"#WQ;Q06/I!DX]PZIVV-?2<BFP#
MV3FX>.V\&!4OC/(^JV)/T@;'*=^;(-<_<H?*M3GNA-4'5V8@=[D"\7'&Q_I6
MZHD7+B'JP,9:DB1E_Y2<.I,^#6"09*N0[K4;AG:Y/T^$=<&YCST:<?D\(^YZ
MM==4%6GU#LVW>5;7Q[=A.%F#`8E+BX/4:[^(I(5Q[\KF8U[J&I`,>V<5%[W2
MDP.2()UG*M@?PBC8!$%`FJTJXZ-X`%@%^5(W%U_*ZZ,B)"R*5@5%L6\[A;[M
M)`DKV1JXZ3:90OAEJ8O<==["MU1P&97?PH87NB*H_Q=U$E-3Q(V<H>7JB6M:
M15]\FRL*/-E!8!L\#PH"&40NV+@#[X7D45`^-L5XQ,[JN"W]C)W.J0E8C0=.
M?!SY9,"1TS[72BKKO!H*;?I)IP&29M51HPT,J]?79D&2B)$'ZX8FA)^>VT$:
MF;3C3;.[^IO2]`O1A`HT-@A%8J'4&]"%:[^)9^.;5D808D)2&&4^B`3.%4"8
M9VVS;2"+Z1AF@KY4C+D#^%;";-BCU9@K5Y7:-JWI:CJ,<"A/!N@J]D$CB@1\
M6%R]N@:H[@NQ+0K3"=\"GOG8PT,;?+<*NX`=AA_R;Q97FTQJP^X__)/]:X#4
MJC^CN?^CW*W2]8O2,0V4W-=,,VY/B3GH[JM/7RDZT(<!4`+Y813O-P@%?G"U
MO._J#C*9H=<FOW/^6]-L0-D=7(%<@3\$)3A?O>P8BY&:E=MC<7+!M\1WG(2P
M5M$\UBC=80LY;JFPC_+U614@Y0^Z,.K-WOW'A0;PZ8"O]H"45L'`41*,?E:,
MY1TAA&V/E/7&(KT6XW1E>B`5EC$V+[4X%*,VR/6=6C(>=66O!CM[IH0N^%#7
M3+K$8.B;([DL.])R**D&U&(MZ#3T$X334>2F7N&W]Q_M'R<52HC\J@5(I/4G
M7+Z&A*,Q@^>^AB52-Y&!R<;$\V+YSF5G;@QAZ$:I/Q^T*0UR>PDN_XFITZF:
MP+-7QR$F4S%KL$",B:[P+4"1AE:>3X$636=H!>+90AS2+:;!J.\@+%?JH0(O
M\*?9(6Q3'LF"A=C2CJZ+JWN75(S$K.S'P(=YMDE7\NB;J[\H2[\025$PU03.
M0^ZKV>.4%NAAUU0#*2Q:*77`QY[>7PULV8/LJ:B[AJZ&KBC!(QG[$TYJCF,I
MQA;;P#Z-.AH'U`S]TSX]F-O5_227XUE7]L@\G7`E%#[W"ET5,J_*>FS9CW_H
MM1DN,7V8L38U;51@QM2YUOQ%+"/?MH9\@['N$D_GBJ1M*3PV0U6P?:M57^'(
M!;@F9=OP%^?3.'F$_A;$:UKS)B_N3MH,D-DA._;N;))N=<0D4W4-.CKR9<_F
M)5_(OE?@@$PC+TL/?M/,:GC9T<`0NEQ3$S,]@!?`AJM-8?V@==,#@(E-I<V7
MT+;`FJIJ'E$9)E9A:_1F,.OI*`L5X:^>;\;Q2/[:.70P830/N.T%=V`8JR0+
M,AZ[^DGH,1,/+9#TDR4HA;)^XDF=+W.PMSN0'9A:"A73;(T?D\83&N_U1^C$
M2,3*L54F$W:M&5NC]$N1%$\U((@#GTI$W'JVYRW!OK1E<W)WNJ615M,JH\36
M#E9=OTJ:).%XW-\_Y#)3@Y5N@F:E&JST77FJ)8S3J1;'_'UH6_!DU9D</22<
M3+"RZP9PJ?^^^W@'$!_A:K=A$,7M]]_5=J*\J3%(F@4DG2@T/\+/EZMV965'
M]4^`G*BB2[^;XOY5AOID.!:><%AW[%!+"PC&Y,K%..JV8T>Y;51ARL3Y"/)>
M2TLV]&2H,2L_(W7/`^3FM6*M*W*4JS0O1.8[](D?:HS"\`(E=D^QSU0NJS0?
M1/+_#N!G\X3[EGPT&3T.W##CMS1T3=[#%%56,#[!Q7C)08J1^SQ,[2&^,[VN
M7=EVV.FK=G@<#M[7-+M4B=6]7)W*WG0^0"IM\TN))07`?'\(Q286$7:1$+F7
M#;4%$!+5%JP^60\[F\6$6>`;FD.P-;8UE"^(?7W+B\!-!%QBM%=[&7^S&!N#
M`/'%C-+TE&7K5E/1%P(_#H/@_#1-QFC"\S;WWI5U\1M*%RMP@*=C.A+X.VTB
M=KU#5RUA)9C@A"$;2R32Z+K)Q73N_#5/=`=^YQ$[LAO@0?^(3374)S)O^"`V
M9G+$]H[>&_R[!N$)'\N%?AQ$2&Z%[RH_>/%(T<6C?=L\@LJ?RL(&(U3DE@I%
MV`0XJI\1NA_*':$\D[0`.XY(V<0W/]>?;]"Z:,==8Y0=E,F,ZJY!>!1YO^/G
M8$+7Z7AM"GC#=NU@1I\*S$,JE7^:0!O3V>BPZ6_FQ<IV<EV$^L1#35E*/2DJ
MCA-0V("NRD_Z.9?68(&_R)GP*>:P+'`QTXC>#/[A49``#=+&2V>05Z&F&R^6
MY\-QJ(@SDU9'H7J%BJS6J%I@(X!_D1N:V`C@DPN:D]%)GCHO41>F8X)3,L9S
M(<-()P:(SQ\QL2^>ZOA*7IW[_G:2^1J+=.(=1WK&FY3&V%[3?`A\!3N"YH*9
M/ZJS:8:_T,CW:CT%)QMJA==^D,C.CTSNOZW!`]_/Q%1]5'%WO<^0_NR2`SFJ
M%;05,NGQ2"NWIY-H?!/=W<Q&?067'SZILMG"VF92:L,BC$&;KF)ZF>NM,/\+
MN-<=^?H7%0#FA;%OXZ43E^_&X_"N9_$S.'<[@3$.N()C:UK,AC#BT24B&[*_
M!S/`:$U??D^=49P"LL4X&S#-&"W@OCHO3]1/P%+O,URPQA5F?[DUF4RX"-?O
M=0[>08T%$/-B1M1JX_"Q&0:.HWC$[A?-`W2=/B*P.^*,[]-X@+?2!KH'O=8X
M6#BYTRCB2489.>57Y1&'>_:*9&M\L:'L3YWO_]RQKTV)BZ9\R7T]&)0_`ET:
MC+K@'(&D"7)S,&ICV4Q_]<&7T0%_6S*=Z,!X76[:KZ.17O"!H*NZQSM\%[B$
M1#:Y&.>TX^E@(7RTDY%4^ZM&I2(F-M0:I=F1_HR(7X%9U/L52D)2CL0_<2=8
MM8\!X289Y'ZTJ_\Y_84;G$D>9O2<O_Q<H"N?><Y#/OO[,`!O]]KSS[0$D"@N
M@'3D.=W)#$X!=S1>$K6#5M%3\M-H[G!OTR29?4Y_\<?<`IX%?':!R,3K].,"
MN?2**)N7P%M0F?D=TF!>1F\S;-+-\@&<?3"_(EQ<`3%O7AHAY.<+*V20S;,S
MC$*Q(-,XS!9."L!AX2TI-F'G-8<O4,L#+N?W@'<D\W+AG"?SM'"!47!VA13Q
M/+4\$O'"26.\FSJ[(A%\@994+/$#;$G.6UL@P_FWB!#OB<ZNX'A';':%B,)Y
MV0K`'O,F)R*(T/,K8OQ;E&97)")=6)'BWZ^SX)_X/"UX/W#^I!+"UX*3XV+!
MTTI@V3PM4LJ94$(KHDC,2T[&<D&V,EMRV!&XH'F.@78L>)B(`S7S*X1<\'21
MC!8L*HIDMG#2.%FPN2A)EJA-DVSA'%DJYZ4?!VDT+Y<X3+.%/7BVH,FQR);.
M(;-D80\@9EXN<1(L1/0X#>3"'EFPH$'PDF!A11C$"RMXD,Y[AT1@DVIVA0P7
M-#F!B#S/TR0.%SQ=DH0+UI"D?$&#D@RBPP).$GS>&M*0SR`E@)SO?[J]N;WY
M'S^25^L-"F5N9'-T<F5A;0UE;F1O8FH-,3$@,"!O8FH\/"]#;VYT96YT<R`Q
M,B`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA
M0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C
M97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C
M-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3
M971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J
M#3$R(#`@;V)J/#PO3&5N9W1H(#0P-C`O1FEL=&5R+T9L871E1&5C;V1E/CYS
M=')E86T-"GB<O5M;<]RV%7[7C/X#'CIIVI&W(,'K],F.G4D[DR:-U38/>:&X
MV%TF7(+F1;+\Z_L=7`BN+).=5NQXK,L2!'!NW_G.`?3FY^NK#]=7?)?D,>/T
M3_^4[>+(?"G/UU>!?A*P,&%!HC\)6<"S79Z'&<LX9WD2LDY>7_V+-7JN-(II
MHCC+Z!OKCM=7I^NKPQ]I*OHW^X#OHDA@@5TD8H%O(@_#R^=Y%-/S7*3T/,L2
M\?R$(7N5<9&D+`LXRU*.66E/A_]LS`?W,)X>AH$7ZLWM]=6?OBWN2JA`L%N\
MH)6E)W7J2?"%BXS=0D&O^(XG4<1N2_USD$,5MP_75U^_D<.#E`U[W795S8IF
MS_XZUH],!#<LY#RZ80^2=475RSTKU?FL&B8_C-7PR,JBK8:B9NK`BK;MU,?J
M7`P2K_XNNDE%?,,YOV&85'5L4$Q^;&73R_Z9X4&0F<%_8+>_7E^]@V1_?Q'Y
M`_(*O$3R0WRM"B-^F"2Y$7\X=6H\GEA!6[W'CEA;%Z4\RV;8,:>;'\I!W<D.
M4Y)^_J;NY9E^C3Y74;'?5T.E&NCE/]56&-]$D'X[#?#(:2!.)@T(GE@'\";J
M![VI_9*QPIO4;;9JGM,:*:-4S7XL!^,R;=%`(;3`<)+L++LC5(>)U=BQAY.J
MZ\>7ECH-(B]V'NZ@7CC!)\CZZN67RN8:#I/,A-C7ZJ&!^!O8,\]2NUB0Y<*9
M,Q+T,YFS'^_Z:E\5W2,,!*6_?2SV5?GB&Q%BVLFV&@Y$^B69X\@&\;>UZJI]
MH5WRX525)U8-/>M/12?A8'O9]5BSE-4]3*(_[9T#]H,J?\/#%I_!>:OF")\^
M%[]B/@2M':3&H1\0^?34O+[[KRV;?,F1`$Y.S*]??/:$4J*=_)<PXB]M))H_
MYLY&*2::_#*S-GH[=J0_`&:L`?.@RI$0DQ0L#P?5P6*JN6$%0//(%+`"H'3"
M*_T-X9%1/^V=4`2>W2F"&$(6=:"/:9YVK%L-T6W1XG79?'H\`YK,T-Y`4#%L
M$I6(!RM]/F%LE`2!$;X"'O9#][AC_Y+L5-Q+5O0]DDA-*8,-LCB3K_6RZ!7!
M1E_4<%$2Y%QTOTGMEO*C+,<!+MR3M/1LD.6IJ4HD%3T>X,L>JN&$D0/0&R.?
MZL/M8A,%D._9$.5>`X+;+$,II:MD4TJ](62(H2";(&)AG[,RH:<EAG'QWUK;
MJ**3=4&V[D]52^_<J_I>1R/`#I$Y5)19FY<6*Q;1)->V(!=3]'L-\C"?\G0>
M)4:#1Z4EGEQC9G[9W5<EGN[8191M8.8LSZ=-9A,2BRRQCH[`[L>RE'U_&)'9
M"78[\!_MYO^L8/P?@9[5GG@"'/Z]%N8K]OWDY2^]94%E@]WSMB84<3:M1&1;
MI!/9#O/8@B![IR&IO]$Q_%0C+^Y5//P_"1_S9.X::>)S=&IY"?N1P.@K]B-!
MT8WVX.0IA/E$7&BDV\2#LW#:IH@]4,6Q]>"3.I-UX,EWLJXD8/10#92*>K:7
M?=E5+2$1).B1QNJ:OL]8_YI$2'0ZY;WNJZ)AGJSMV"WRFIN(@H/RG(_V+321
MQ!-D)]YB(K&`XW,/+(;$U$B`;%F.78=PMG43J)'>*-33[=F'L>@&9]VB+%5'
M2;M^U`E_KUBC!EU;E`/EXE[*24G]6",9')`):+K>:Z)G(^"]9N=J_^+<'6[J
M=+`QAX6RHVP"SFAR.Y$`G[2R@=@)@V\@S\ENQ_[2$(8G6G'(AY+P7E$1.8P=
M'!/T"#K&D[(#9R`3-:,N2>$WC7Q@H%:#.A.#ZI`:)\:`K'LO.[)!U4\)]YGQ
MIG+80@LB\#0I\CR)6WSLJV-3'1`^0$/:6X]]@0O`WVH$8JUI^Q-28]F=\23-
MKXA;5,THYS6M(XYP*SA;7X!Y66XU1>2DE*>T<0L]!*YB#$)/ED7N0@^LB';[
M)?X&P>[(+[!G2K6DE=\%.\[NJKI&S/SWU<D"OT]34S^DN]2XKRXDW/^77A!5
MGEL0^3/R\!3SU`+U?'E/J^M>3:5%#Y=V-9PO,6QM895967SUL-2.74_.HV'H
MZ=@;HC<GPOR#4GN#<PT\K-["2])D*JDB7_7RT#K)04)&TX11?5^12Y>JKHL[
MU>ED8V4V14%A(;H%0E.R452!P.'9J#FX5E&SE\6]ZO0'.EB,9'H=&RQX\F[L
M5&M8/")2/D!!4N.4-L`6:HBFVHI[7ISD%C,@EJ:7)I4@^"F7$(!HN>>(\J0&
MT;\.52^-O%4_!=@--:88/C!>(?<FXHX50:[ME!(\[]AW4*'J*-_;+*>5T*MZ
MDXR=AHGG+J'/V&$V@XV9'%H%E**==OJQ;<DE@*J'`^C,'CNWXND7K95).^`\
M^,``(RE!UU^F?M9#)ZKR`-!QF4B:IHI>Z]*)MM`&=X23ISZ9")'-PL.[+>T%
MR76@E($8(%PP)KPE!R99&\6.(##P%`F'/JD'I!QP&2VR%^M2W)E[H=I1G5L)
M60>\L2O.TKS_0(H84*2UT/?+XS.TD>03K\U]Z1'%+DR^<_(\7&9(YQ(DX2`_
M@FO)B0X`[O:(KE*G11*KD91OJ+>(+(HW\)OF)8X^N,G(@7[ZZBVTT:A[ZSEJ
M*NWU6ENH()T(;9#/"&T8S`FM:>%-,=_+HVGV;Y`S$S&1OC@/I@VY_;BD58&5
M]12&)^!O17YTKYM?(``%$'HORV*O-TPJ);I2HNX8:_@?#/3QL2X:^E$KW>2K
MDSQ7?HQ^I8#C8I+[`@!H.IM%V]84_D2RM_'(Z>@EB$)?:?'(4M[W-CV;3"MM
M93ROJ[0T4WXBZ=NJ15'6$'E[)`YDA:#<1WYH^6UQ!"0C"XP=D.<!.IRQN5]X
MS&M$K3(*4GU5FC82DJ;L\3381!?3$4&0![X]%@43<F/[!]F1*VII^O%84/S9
M=C:<=>P:%``-2:W9#5$5+11T!XQI5#WS@%*[`%%Y#3_:S4ZS7(599(.Z;NA4
M+<?SB_L^^%OR?SF`2?)TKMPTF!A"HG\FY>Z1]>_E7A<'&]@V]J<3833KB<6A
M6=ZU$1P[*"C]DHWA^X>Q.5*O`-Y7-;8`-B9WHW5K""E&&K99`KP*4)*N^J19
MCZ_[;-T,L+Y'8J9:Z/63"MQM9"/XC=.)KHK$Y^/<G0!\$[#O%/#LEEHDJE9'
M[*I48TM-<,W57)`[KDXQ#A>_)^`JB%15>V#9V.RGC&++.8"'[(YZ,/1ZQINJ
MT_274M<]G5MJO@=X4&?C_YL`7AP[HLJST%=U46R#_!NP<[>C"X,X6_ND^CQW
MO2"K2&+ZQ*NL1WTR1=I[7U;&6TKV1A6@^V=]4@T<,8==A'%'/)S5"=1BV4(7
M(GFF&XB@L%TVDJ^6A3E3\[M6W1&$\9/=EZNUOE=]J1[8^X%.FO_10(%=3^=S
MN@V.-/G3V.MVVFM*E&>=W;0F2)/S=$)D]MS6ZE%2HO&JVT+^P+>"P]RW@D.>
MN(L'E^V^@GUSJN1A;L(?#OBJRT_JD$,5CK-N0%4BWQ;53-)1E=QN=]Z0:L$X
M-'4\58?AHLK6E;?NNYB`M(Q+:58X-AJ7)JLU1-`U-ZF!9XVI60\CM7F<X6<Y
MVN:XK4`\\LW0/`UF[>O@$L1]`>08R$68?B;PHY9PU'Y8F.ZPACX';-V?YY7&
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MR-C9$.AB#R-7.E?J)IJ=6_?,[L`A3&OX4&D.I_%P"P7,6G]1[FLG=VGKC(K[
MHHP_=DB0SWBUKG?HI.7SL];WA@X0BM7J@2J?FYDR!F(:6MHOQ<_<Z[90@6_[
MI2*=E4R60OBXE96N>4RKPK1AW+6^5@W27`\XC/KH!-4BF9-*1*GOJ_7V/L*\
M<4H-(NC`W#;0CK3OQJ.[S+;%]9\$\.H$?OGK/Z3-4&QW_8?FY],]"<$I>C_]
M+VOE"VO%TUIT<#F_:A1;=/P!SOFM-O<&Z2A,_#&W#\PHM,7>6]FWU2"?"\7?
MVPI<\],.8$2A:X.-2*"./83Q<+JQX7:^JYK"$42ZTM:!A134OQY;91J-^FI4
M/SLRWL"V83QQP]!?($TM%)5%6]Q5M0%3"PTH]=Y]I(-OO;/WC_T@SZ8&,>T)
M`&A+C2CJ)$Z<:,X-@=HO?R\TRK))EFV[$E%^H;6<>R_-0DND^J$X(G_,LA)0
M"N8FE%K(ZYL86$SD5_CN%-*M-7%'EY@[W\H&[7W2AR#+;6,T.MUS^]O6:&$4
MS32!2LWW++-,S(QF$\'CCA'2S+(B>>ZS-J,^\WCWJSUAI&%=U?_6V\:Y83)T
M-M%L58Z&@>/TH1#^="`3D:]&52M=0X!H8/.XC4&#.)ZVL_&UBSB_$)S[0]0\
M"Y\QZ+PG0!J9,T9[L^(SM'*-98/9]EKGXV>$$Z]O85;N:J.0^R9#-'4^6W]+
MUAW)S.':Y9D&;'>Z3$NA37=]M!?LB0A7=^,TA;[#7S10FA/+I"Q=;OA#](L3
MIE9N<X$IR'S?-\\_;ZI?W"8YJ[$Q=X`/HU6%;@HV)YU0E8YDPKB9@7?L-57M
MIM+15-]+:`YZ9RM8@NG^T,-BIJ>86R@@F:Y(!,)WV?(@FLK$R0KP;*J(9QNV
M=9QND#E?U?;]YLD1")U?)"%G:<Z9T)OTN]%_\A2R.*0#63P/GW\>!4FT]%P$
MX>+[(4^#I><!!QWYTO,/9D@8ZQ%!^HR>TX5<#M@(A"O'[-V7Y*F"4*<N[>]5
M'B[*_PH<(5\<$.91O#A`K"T1Y0LZH@$)%\LSI%PL2YGQ6"RK@4?ILA[XZHB`
MQXN^\BJ`MZR,$)AD>42$PGMY1!SD*SM-PG!EE30,ELT>9.&:M+#[BNOP,%LV
M"Z(W798E!&_@RR.$2)>E#2.1K.PT%GQEE42(%5E2L::/3.2+:$+!%BZO(GB4
MK(P(8KX<;P*F7;8M9%V).!&!IB^/B*F9M#@B$?G*B#1,5_:1";$B2R[$\DZ!
MM,FR!T6!R%9`#BQ^699(1-G**A']/<;BB#A:L6V4K>%UE.?YLL9B'J\@3!S0
MWR(OC@CC%:2+X2#+GAQ'])<$BR/B="7FXB1=DS8%'5H>D67QLO7C/(O7<AQ2
MT/*((%_QY"3,5_:!@,I6YH#YE^V2)'PEH2<ICU?FR/B*!R4YJ--*TN?)RHB`
MY\OH@#0GEG>:`BZ7/3E%1E[6:1H'*TB7)N%*-*1IN.)!:2:"E9W"@9:C(>/A
M`E$"HWSW\_75]=6_`==,/BH-"F5N9'-T<F5A;0UE;F1O8FH-,3,@,"!O8FH\
M/"]#;VYT96YT<R`Q-"`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O
M=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@
M-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@
M,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU
M(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)
M73X^/CX-96YD;V)J#3$T(#`@;V)J/#PO3&5N9W1H(#0Q,CDO1FEL=&5R+T9L
M871E1&5C;V1E/CYS=')E86T-"GB<M5M;<^.V%7[WC/\#II/I;#NV"P+@+7G*
MM4VG::99=YJ'O%`4)#&A2"TO\BJ_OM\!P(O7$NG(TN[L6A8AX-S/=\Z!OOKY
M]N;#[0U_"&*?<?IK7D4/OK+_I=O;&\\\\9@(F!>8=P23_"&.1<0BCB=<<5;I
MVYO_L<+L%2J?-O*CB'ZP:GU[L[F]6?V5MJ*_HS?X@U(2!SPHZ4O\D+$0SY_'
MRJ?GL0SI>10%\OB&@MV'L>(@WN,L"CEV)9I6KUOSP3V4<?]0>`-37SW>WOSM
MNV210@22/>(#1EAFTTX\`4E"1NQQ2V3S6.%E>GMS#Z;\*&2/3[<W[[[]N*MT
M76=EP=X?ZD9O[UA:;G>Y;C1;ZKW.R]U6%PTK5ZS9:/:UQ]ZGE=9%5JS[#R3%
MDBW:+%^R$FLJ$/FAS2J]9%FQJI*ZJ=JT:2O-FI+IC[N\S+!=6]%>_RCKAOV%
M/?YZ>_,M&/K/1=CV!-C&ARS;GO2#GNTX4);M1YUNBC(OUX>[CI87DC!\N8>?
M,@W66%DMP2R8<G)BA7YBNZI<@MV:K:IRVXELK8MRJ^U^1D)X0[LE5^&>JT[I
MH>B5[IO7Q/VJK'2V)@ZR=5;4#V<3$9RVO#BR-+S[12A^:29I_R#L>;0*?O?-
M(5EFZ:7/BJ/^+&7/^44(<7&U<3%B27`N.[4IGUZ3VF`QK7&D79X4-4NL2^6P
MOBI9:Y;!ZG9)`V_5RSLRQ%V5Z2:I#M9#G962#3>=]6>P0GI&'ZV;9)%K<O2L
M6+;PVBS)F2Y^/VSUI9D-Y<!L+!X4Y_#6W\'A_>5/"L9B]65L56C=E&1Q!?^+
M?=X%'S_P>CUR>DUZW&9I59;5.BFR>EL_BR`E?MZQ;`OZ]J1%4DZ*('EI*D4<
M]F1>5P,2.X\$$OEJ,&P56('HU4JG3;;7H_!95FR)=ZK:QDV]U=6:]-49IT;8
M^KYA66U"=%:0W9,HMQ`<2]9K$\LAS<-5-"QEGU6E-V15WS$$<D!)4OVFR;':
M=,,2^&:;[PPONV2G*^19G>=M7M99RG2S2>"0I.]L"[=;Z4[YNTU2;9-4MTV6
M)GG-GC89G'2;X`3\(X$D\-RJQ`M['MMAQX:R&%)4HS\VM/X:(J#@[XP\C@8C
MCUV.L9$#2OJ?9@N=9[!PI,.D`0>Z,#KKH]#!(8@Z0U:LG\$.BG&K-H<6MPF%
M/INMEQD,IL+S+&F,");[!/)8(YH]97F.\SZ_=$8#-.M9?G>-?!G%P=OSY:G]
MH:](^-?+Q[0_C_KD-2`N%82^M0>;G*VC+DW02U*#-+-Z`\.`'R\.72XS?@[/
MZ1#BX[%\E32T$_1NX17V?I'6L*/!I;0?.00^I3]F=7.EN!_&/>CT93BXA'18
MN[/P.TLI.;1U<NNY-KJ-$3.\YSJ81@K>4WM%4".%&@LECH8X$42?8)IU53XU
M&XKGNMAG!,-10,!*4H.<%V7;D#JS)7G]ZD"R(KCM8EZYVY55TQ8(?$[UUU!O
MJ'H<$?7J]7E72A'8'\4TT+ZH#-HJ8=\E\MAS*OL,P18H"DS"0VRK=;[OC+R@
MR`Y`MX9M]]$Q+?,<XL#[$%']<`5D'<H.+WE4>G<:D\(E-P1TE'%(V,0"53)$
M(T[9ZZ+50^$#AI'7P3!Y]N?L%^[S#/]Y#"SF))<NU]]12C!ED8O\IG)L=%4D
M%/@A%Y+-P'=9D0=MJK)=;TPZN(:N18]8/-E#<1F&PLJ@?"J0A0B'+%J3;%,D
M\$+G]1>64<LIQ`1%&ALP!C#Y"?L18I.P$#[STY^_>2'5K"+X4)$!N<_M[4DD
M+QM`C,_T-K*_2O*G;-B5UU(-Y77D$.ZO)>A@(-U$,5.,K%#UUP`S)E]755*L
M-65X/(1RB2784;W)=HXORU:-<L6`G'*U,OZ.:``@F-K2I+&.!''FV>]FU1A5
M]"+:6\F.7/,*$@FB'@Z%HS`G(A?GD.S(>P'LP/$6F*QN$.'`^,%)@3R^*@])
M;G5+OUKB+?5K2*SK*OP7$00^\KZ!W]5L#<!;%;9)4[G^`J!0D1)$OD)X"%3<
MZU[$@^Y#%QY^A!*^RLKW.+\`S^RK+G)M@(&+$I@NW1`:7':Y[P#-[HEH^_X=
MJ[-UD:V0'L%2G4!4QD2,"24+Z+HY/+#W6K,__2O[T&9+_&YV^CK984%^%>VB
M8'6A/Q!]Z`_-:^+Y)UW#]L#MGRAJ7[P#P7L"@CY9RXN?$HS9]!R;[WY(BL2Z
MZL7E&@PG7K.S$O)GC(TZ*\'06?DFJ]/6=O_(EKY$[CG45%RNV'=9D10FY'Q=
M(IHWW1HHO<T;L^3'G78)^=+4^V%P1/GJXL=$@Y&?7]Z<WMT?JT#&?=CPI1?T
M/4F4LLM!#1`KQ7,+-1#NT@2%PC5\V_,[PH0:;"-2SK>KSK<)[JQ:UQ,N>XWW
M4(3PGZ;'*R8X#Q[8(T*Q!MT%"E)$/I;4=8LPGKI"V'#G$-)3!@A8Z752+2U>
M)/A4+GZU;9&^K+T&_Z9Z-_Q+[MG,]:YN3;I"Y7U^;W@BA9BNF&V?\"%9B@Y<
M?6GR!%0.#$/Y8*&;)ZT+]F/:E`LD"N^.!*R,$_X;*[;TIK)O`DP"BR9931]?
M6F^%YQ)N@$W18`+9(G69`II*=D@L'[,M4BFPYF="W(6<WW'.KR)JU540'@^'
M84P0.\8+;08M&>S$F`EU_NIC5'9$WE&Z29`;LSUA\%V>I"94'^FZ:.1?_%*W
M*V36C-#"4UG]1JBID\8)\[Z&'$1?843A4"BKR/4*#"[0VKI(N<BS]9RK?;\B
M#JE;U!:FC=TQ8SW)3:0ZP(E=AUJ\&L+XB&LB8=4'_FO(P.LJ#*[X,*$RKTD&
M:9]K.M\G[5-3'A:0+$UGE%Z9UJE>7GZ&`QI5S-^2$<))`:C0UA#W%`547T0(
MY8^`Y`^VA_KL>+O;3W^GW9Z(E'_BE7CPL2,2"L.6D>I_RV]OWE],'+Y\8PLM
MGI:([&H('KJB\]VWMHUZ%>UZ%^@X3D1YD^9=8@6\Z+P\%JY(_'X8,VV3HETE
MIN=56=\C#T_659;"-Y$T<^N09;ED->R]K&H;SG)J?+<4[!>9*?I2+!T:"WWK
MO4(^R0J\X]K2*$GUKLF6U^L6R:C'.SR*AYD'O38=!%.H@>IK2-Z=?=W)3J!&
M3'IJJ`41PUS5NRUS#0V2O&GX7VP<^J&F?I':W$P)F88]T+(M[MQ=@ZP:ID'&
M(LIN+M:]3\'QD.E\:1=HE]E2E(=?4J<WH7L,]><7]YTP'$1\^5D`V4X@KCH+
MD*Y7?ZW]O3"\[O[BK8%X[@*%C8SA0^AW-9?BW;]+'ZC\_D#JJ81BZ*G$K@89
M'T__1I-/@!S$S*;O,P+KD7^E;44#,K8K&S,GR[MF,]591V*EF1;B<\/L_XZE
M&[TUB\B[G@7C+@;KCZG6RZM@Q"CN2X0!(HH@=N#@,P\0'?$B1Q`P:)>P7Y+7
MJ+*>Z"5BB*X;@YCK[O)2G?VNN]<O[CCTHX157V]\)AZXX?TS^1`,AUU\^*=Z
M;C^))M1II<H\!`Z39M/AT^:N&56OH3+/Q?'GOB>"J>>*1Y.?EQQ(9.*YH*MV
M$\]-H7/J^0>S)`('*D+0."(V2/2TWT0L<H%&/,BH[XX$X:<:>L,A=.W0'7+O
M$9"QYL=>6`&-<$D52AP_9#IC1V&/E920(ZSD&E2/!(=<>D0BI#0(\&)J()-8
M`8O*O+6ERZKL,Z?IIU!_^-"73MV3`7(A;GQQ!C>GS)D,MF/G978D5?CAV?H.
M^&OU?>8AI&]WR+R^<<:Y^@Z&;I@2HZ:3.*5O*`U175=T[6.(VB;>ITE!??5%
M!XR`AJF95FES4<)$[?$F5/FNW:!`#Y<>GP].$/;.X/@D8@IDS_)QFT`4.=<F
ME'RM39QY"-F$.V3>)B@<GFD3JFM$>IX<=8=D-&D3=K0X0.5F/"3;(RI0^4AM
MHH+IM#0W)4P/89^91LF6II#5BT'1*U@Y&0""L.?EJ+(EHAKT(-4?5[9\M;+/
M/03*EJ]5-IU!$CIZR$R)UBM;<-]63MZ#5%XTODM@+V\YJ'*@.K?N"EBR@+I<
M`=S9RCA9TGWM(J/KV#5[TGE./XV9T`@90#"S4W=SL\#54?6V1!BP;3#:S(SI
M[)7#O'PY5W\CQZ*_("2&"T*^UW5]%U6VWE@2@,'2LFG<G,5&JM%MN56"M2F"
MU!D$GC):*41/X5&C!?0\UVB%0W?S1GON(3#:[I!9HZ4SSE2AZ._R",DM*"?`
MXKFV[?,+CI\T=6"\K-YIBDJ(7YT5)W0]<@&@WK0$U`FZ;)*JWO2U1STR`=O/
MW]MPAMA%`V-GT<L7=Y3?P&GH>SVKTRV4-QWBC^3)HP'U^5&'^K+B-W>!Z,)Z
M'&XR27_X?@`7[ML177QXVF2-MN%AY)VV-4XS%T0E7:R;C>GN9$5:Z:1^UIVI
M3/GENC=+[18\)76CGZB;S;!!TIB["XNV0OPZ[M1SK)Z$':A=.EZ/.[4R_B;X
M'\UP3/@37V\@DI4E^8]N31^=VIJ(%J>)G@H2R"U0=]=S#R(ANBC1_;G@86HX
M[!5A[\Q#*.QU'$V&O9DS9O0A3UW[I8?B?#W+&1.:V7JB+]MM;1Q\&+;S;KCT
MK)E#MW"3PMRD@G,>ZPV-O=MT6ETC-ZW*'5PXR5R+=M2,-55I6K;FFRFH0LUG
M46IDU*I*]4LW-[V$L[W1FQ$E/U]+4UM3@R,6YU8N7OQ:!SGW$#A(=\@L+J`S
MSJQ<O+B?YRHQW!CE?MC-<_MO-71E2S5M;2X!$0PNVJ;JQOC[)&]-"V^TX]1T
M8!@)?'%TSO,*MD_FEBCJ^3Z:6ZB&.Q,P>G[T6L,X\Q`R#'?(O&'@C#.!AA=T
M0V[A.<QO.AYJ/`,;OM%#UQG2O#6=;+I73-_.1+RH4M.VHALI>$)?4*VWND$%
M<`=,`12QMF/]59[L2^IFN<O_+T=K;V#&#V7/S2PF//^0<"0R+QBPF?([D+UJ
M=4[71:G531[DNM?/OCB5L"?J#EY8EVJX\SLJW]PP=Y_0EPT/[K)*#H^V]]//
M(>+DY"?R>RJ.NIP*3:OYJ"M/7$907#*_Z\>Y@<]S9S/SW*DV]WWLSC[UW(NC
MR3[ZO8@#,;E`<6^RDW_O\W!ZAX!/SPKN0XZ"9&I!Q*&"23',+?`XCR<'!O<>
M_LRL$&0%DRND%TW+`HE*SE#JBV#FE$#X,UH/Q1RWD8CF+$>*::T(+KUI7@1<
M=MI^!<KX&0.5BD]3*I2<\1+ARW"&ET#.R`,%'0'CJ161"F9.B7T^O4)R^G;J
MY`IDM&G=2B%G'$Y*Y4WS(I6,IV4J?25F5@32FZ$CE.$,+Y$,9BB-*8Y.1S`E
M9F*<IR;&A6:%\,7,*9+N3$^NP)^9%>%<N%8QE],24W$P$V%\KJ)IF2+KST0Z
M'R%HVI)]&,@TI3Z$/NUSOA_-<.L'D9JA(XSB:>W[$7T)=G)%'*NY'!?/6'+@
MQ3-T!)*+F3W4S%C\/O#Y3#X/0.K,'J$W8T%!Y*F9%;''IU>$W),SL,#SPFE*
M0^'-6'*(C#PMTQ"A<-KW0U_,>$,8B!D+"D.I9BA%I)OVAC`6$S@)</';GV]O
M;F_^#Y'U_!D-"F5N9'-T<F5A;0UE;F1O8FH-,34@,"!O8FH\/"]#;VYT96YT
M<R`Q-B`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE
M9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O
M=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&
M86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R
M;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD
M;V)J#3$V(#`@;V)J/#PO3&5N9W1H(#0P,3@O1FEL=&5R+T9L871E1&5C;V1E
M/CYS=')E86T-"GB<O5O;<N,V$GUWE?\!E4IELUNR`H#W?=O)))5YR&43UR8/
M>:%(2.(.+QI>[#A?OZ<!\");)F<]9FHJL4>$"'2C^_0Y#<R;WZZO/EQ?\:T?
M>8S3'_U;N/5<\[^DN+X2^HE@TF?"UY](%GK;*)(A"SEG4>BQ6EU?_<I*_:K`
M]>@]7AC2#U8?KJ^.UU?[?]";Z,_D`[YU70?OW[J.Y^"'$TEY_CQR/7H>.0$]
M#T/?N?Q"R6Z"T/&Q=L%9&'"\E=:T_[@Q'_J'WO!0BM&H-[?75U]]&^\2>,!A
MM_B"]I5^:>\=(9G@3LANX9]@&WCL-KF^^O)WZ?+^O[^SV_]>7WV#=_W[56:$
MFX<9^58(1^HY;^#&P/79[?VC^=FOBNU4GJD[M6''ZAX_ZPTKXOJ]:EEU.E5U
MVY59FZF&[:N:55W-3G5UJC/5QO4#:U5R+*N\.M"`^RS/65*5;59VBK45.]35
M_8;%9<K:8]RR>V6&[!2+=[D>D=-\\4'I%[^V+[3W\27K"R<,!E]$D?6%^B-K
ML-Z#7N6^:[M:L9^_>*O_2FOZ6K#OJJ9EM[VA#[3L]J@:=>Z>+?L6_E%_Q,4I
MARMAZS$FGY+78E9VQ4[!?7OVH.*ZV3!5'F!VRK(2WVE5V61W:AT'<+=W@"_"
MW@&NH-_)`60L%G$7UUG5-2Q1>=[E,:R+:Q4WP\;9&&%)7.K].YWP]]3Z@BD,
M@W=>/9B%-QH0R:W+.7;S3ZSZYO6GBLY\)=PQ5GI7[>"6E,5YJ^HR;FG#]IW*
M;;)@RX\*P4/N0(:D7=)F54D[;IW#]G55K+'%$<6U7K7DW!MV&*"H5[U7=:'*
M5F=<TQT0?2Q5-5:?FA4E55VRIJUTXL,&['?3UC$25X^F'<?VQX>XH:"@M(")
M-=ME58&/8/T#!80Q&>^\S]HCHOO/AV+P0T,!M(;A`>^WRY7.N%_26M['[+T)
MVQ2_Y]5I^]*5^#,K\<Q*OGPQI$?SECI.O\5A9*O(FZSZ)<E4F0!Y7]NY/KY%
M"&F=&XC1N?0[.?>G8UP7<:*Z-DMB@OWB%)=4!0CVD"0-D"%^KTI65JVB--`X
M4:CZ0&B;%02=,19/CQ(@[&N;X`$J>AO6A0X/23?QEA^Z8P[:(K/?JX0`@W`?
MB4@>.,<(2JGXI)U)3UJ5E0W!\@I9$P;14!$IINW&AL(NEO8IK;N#+H-8"^(+
MQ>TM?6(SB."$90W``+7K9&K7AK59H5Y[N8X;#>M==Q.):DX\(^08\J%K\1_4
MINF*GBS46?/^8730FZZNB=Q\P;ZNMI;S*/8H2WX&;8CKY*B?K[&WOK06\)'K
M.)[=V>_CLMO'"3@.V?"OIJF2+-81J,"!BKA5IMP#VD_/97=SHLU'^:^K/_17
M\@?VN1MM'7PKSW4TE\QR"BI'6_:C2?T3@AK,,,[QA34L!_&U""F\@?.Z@37]
MV)5IK=+&Y!J(#C:@,=`#).KH+TU2*U4:2A:;#$BS)J&ZJ+?Y4,?%!H2UT:2H
MQ+08*#8<8L>R6KQ+L5+=FR^CY*19"@\UIFJ6,#S>55V[BOFRI_S<YV,IE"(P
M]DO^.X>'#-(TJJ?JQ%6QZ\>N@$$)<$GO=EMCF\RJ:Y4H(CJU.H`5MA5<H??^
M+LZQLZ-)SO!^LMW21C!(F@.8CSC+LS_A6Z+[]%+R*BTE6X7UAV(@_=Y(#,`F
M/>.-*8Y1[4'Z/DI4LAUIT(ZL_U&!`SDV%FE+08.;-C:#5)MI;DBO*!14E#'S
M4)%/20V0*FJ/&_K\P6S$"BX((G?(!W^2#Y'E1MH(+#LK$^+YH(;9H<SV,+YL
ML:N4L:-FZ6.:2E+;$ST5`\=(S6A+%4*I>J"1X(V`#U)5"8+_W(WDONFD-,T:
MQ@?!L/_1`(0NCVPV((!W,?`J:Q_(O*9+",,IGX%<@'*5Q!U6=Z`H+7640*N5
M":V^S@Y9"@>E:I^59I./V>&(3VR*]`K@U6NA!U+6&[8RH?'=B0NY'XRUQ.OC
M9P`+\L`Y<C`4CT8U/>=;8W]]/@2W&&,;$NY)>D^C=V.!><AD4@7$1+'7B(4V
M5[I[44.K]?ADX&'$36/:%L43-:)639>W3]Y*L&<CG.KL:B@7N+TH<&0PI+@7
M1=8-^RJ!H$<Y'AC=6,^`5@>=_ZH\:A;>T]$[R@F#_)3F/3RNH)D"Z7RB9EIP
M#_?_VKY;/R%0AX?3MEOTM.VF6V^WV)<G7*OIFV^(-$,[`$V`T7-\1F1A<T2$
M>2#9S1;OL[JY1-[LUFYTW2UV68E7V)*_@MO]<)07;CCJ1LNAH6LZH,6&W<.\
M/.[*Y*C2+?N!&H4ZZ83DEYQ"264<0RV8FBB;-OJ^JO-T0_F6=RFE6TFP_-DN
MKY+WNZYI5?U9G_R`>1#OAGWSTX]K\6\_&/AWR$=M1>UL;?VW8-]@`/]Y]^[=
MEGU+W9>L!"4H#`L_=9"&S9%JY@-[M(DV*+0$R77#$MM=-(-1[[[_A7T'3D+$
MXEV9;#?L[4.<0DW"40IQH?DN.:RMVO%U1$?6<(/G#9DP-*0<WW.-%_2:+4^L
MJ'F40#LI'=?@E1UM\%.)(4:!40/2XQJ?BBFK-:'`+F>3Z4)G)JMVX/F:A6DI
MU[*5$F'HPDLN1A+J"5M!X[+LL!.&#;(Z-ET2*8Q)??TYQ<CI/?%)W3C>LE^I
MOZ8?5^7KZVW?&=:]LM[V@XF'A"/'I@D/W+X3D=4I.06BD9VRD\HIMX>F(NDT
MW54YZTOL%.WJ4P39K$5&_/&$00:3?DI_PO`4D!MUL-*C0\!.#TP@I4ZJ)D28
MY.IE)#`UFCCXYX+S(3G(*2:PFAA:E9!$-][*=$4^YH]]<X]/]%8TZ*TD3M5V
M<M9D91-D0I\`^(VZZ0;\4)L>V%Z#93,%=UWFJCS7J?O/5V<E+M#*"]U/IR4S
MM$?G_XKO=[UHW?=S;SW:!E[O.(-P#4?^X#E]$^Z=;CW2T=Q8V4QH(*#`"[06
M6P$:)5"I7]NZT"B#<.(%$8P)Y4KY"!FU3C?%T`,*7&PC:S]=@DJ#/ZB_;5P?
M5-NL10<<,<AQ=Q0JHQQ7?YR(Y/;P!4Z3F>.J(YV\3AOE]0$2JRDTDN@CAC,X
ML0T+A$>>O2?6\'Q_`RR`9.$S1',-'_#QK"H2$Q]8B(S3=#Q.'6J=[:=-Q*72
M\HVXP)9]UQ_7WQ^S7!G0'-JL8YTDBTQ5M)NOB##K-"HK1$%./9QC=3]I2.U6
M\8$,>\$J(AY-&%$XM&5T:PE*8`\K6&J*XB!?!R_\#=O:]V\P8)^ANCT.&WQN
MWV=*J0[Q/BFF4@C1H,_H2W!-T\XPVJA5YF+`&H[P_3&[!\K@.GTLE.E76-'8
M.K5"27-5=I=I(TF8/ZVH)@;."4/='SK8)G;#=.FE=L:CIJ8FQJ>NI:;!L0(V
MK(,'TNTEHG3D$`>>V^N#A#H2Q`3&`&@T[X/=Q3K-""E?H6K.F2SD7]N,Z">D
MLRQO/,L*GNU%5*RI<AU&P(44>%(4\>;LYLIP56:V,3Y@C#X;K-NLH6Z82>*^
M_80$/[59D?UI=*^-]S5NOT2#$'4G&DST=R,FE8<:A5@<!)DJ%4AG7SXW]C)#
M<W[W@9K9B3[,LH6UJ'*5=+GZA/A\=CO]Z,P2=]1*^G>RY`>J!%@<G4_95L>C
MC=';H>\+T-:T=5S5($YTB6L-QP>#M)-R[`*%7M^BS?:HQ=3)4%K(&:BFX&HZ
M>I(1/_G0`9[-W3/LSL!G]*T5O4L:N#L38'F\JVI[0G76DE;#_2[RRZY1'SK=
M:R!=<78\M1+8"U\,S6IWK'I!KW)U:;/%FJ$6ZSZ-)K(,.D?C_$:?,;"[*N^*
MZ>VB+;L]=M365LTILR</YUN;E7>PWQS8E^2TJ@`U'"K">9O!R+15?.`.=#:<
M*'W/$T/%T\N(6]3]--:K-;PMG0!0?!=GN;DY^)3G]B36Z/Q')?#,)'-.3D=D
M4!O:E''-^OXH]::%JY_+R\]]@0H^\]P3<O;[+@>KGWGN\)#//9=T?6_FN>#!
M\\\_F"4B+:&IO$N;B7U^'HSP'=]@D41"^WTU\X/'<?,)DX`)])/<B*U&$`H3
M]B0V(1AICL"5ER>9UYJ>/P@3WUHBMH$(+4A]7YE^NL7Z_JZ'02R*,D,4=U7Z
M8,ZZX[JF2Y%T(+Y[&`"+LE35"EBEJ*!.A`B+BZHSAU2V!6KNGO;G,-G3FUV?
M:+`WJ!"ZD$T&RVT@0SDY,2(#2LVI;<?EJ:*$WM#UQ<I'K-UB<7^+U#@&]5Z9
MX[);(A74>C5'9O:2Q5F'E^3K*QL[7)H3=!EL9-GA<-'IB6D;HKR7FH=CB_HY
M.?VT[G_$\I_M1$$C]NO_\LF+"4%0/I!9COO_IZ]KKP8LI^]+)T'Z]I,LIB_-
M01ZZ.,G\!KO#I3O);5]!;KG#+;G3G7)SAFOON9C:GPS7$4V8ZJJHP/[NQPJS
M,4J*>@3#H#.5E*4DL_<9J55]622VB:/Y\RO;.;FQQR=7N'VK%]]CZ9!+!_7H
M$+K/8;("`5YD^CQ:\PU;+"_&[-)*GXM9)W*&I5Z.6<E?'+,N_]B8?>$D%+-V
MDN68Q1POW4MWT&6N/2&D?Q9C>=#;L>/1'*NZ!="<8HKBRA[@3[IW^XM(19TM
M'06U:2<U!1V>#.)D\Y@9G4<,Y<`KVRL'W>)/[J;;R"TJ"M.QZERP1]^UV^GJ
M>3E:%];V;+1B8?WB+D:K`XKWPFC5,?I1T?K221"M_22+T4ISO'#WG'"0<>&D
M<^O):`*Q&BES`I3+EP\,9^@I?G%V"76D5!3.HPK$R`+R1P,6,H#B7;])RYXG
M-VY>V>A@O#TX-N>D;WU,>6+SD%975*DN`PQ2BAH)D\M"0]9!HVH).O[+$=07
M"GTU:-U)E_MX^<K-1QCU7*S[8K3J8JP+;N20""Z\.)B)==1:P7L2;3M;X6.U
M%<UJG9O(G7\N(BO6GAL@HV!6C=U@F?-O\+@SJ]=N?`Z(GAL0T*G]W(!P:4#$
MO5G-=R,X#Q9&",$7?`EA.^\*X5"K:7:$*^7"+!Y=/)X=X<LE:P/I+KPCE.'\
MIB!R@GE;)")C5DG?2.',:_4;>,.?7RFUN1=F<1UGWA;I.0O^D+X#Y3H[`N"Q
M,$OH^@LC(H_/9YO#/3F_MXYP%O+-D=2JGAWAD)";'>%2^9H=X=&I[NP(WW$6
M;`GH#&-V1$C7:F9'1$XXGY4NAS'S(X0;SL\"MN,LX*3C+NRMZR^A-11`-.\Q
M-_06$`;BT9WWJ<>]!:3SA+>049ZDGL/L""=8R#G/#1:L];R0+ZS##[V%\A2$
MWOR^>&'$%]X110N1[/-H81V^B.;[DC>^C!:JO>_RA7+N8W,7WD%+G1\1T,W#
MV1$A]Q=&1#R:1X>``\CF1PBQ$,G4:I[W:>"(!:0#K"]D0X!@GX^@P'?XPDJ!
M=//9$(1RAB:!#'[SV_75]=7_`%3F2W,-"F5N9'-T<F5A;0UE;F1O8FH-,3<@
M,"!O8FH\/"]#;VYT96YT<R`Q."`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@
M,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@
M,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O
M1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B
M8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O
M26UA9V5)73X^/CX-96YD;V)J#3$X(#`@;V)J/#PO3&5N9W1H(#0S.34O1FEL
M=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<O5S);N1(DKT+T#\0=>BI&834
MI'/O.55-94_7I5<!TP/,A4%Z1'"22R07J2*_OI^9+V0HE60A*R@DM`6=3K?G
MMCPS-^:/_[R_^W1_YSY&:>BX](]_2Q[#0'W+Z_L[CZ]XCH@<+^)/A.,'CVDJ
M$B=Q<<7U(Z>3]W?_XS0\5QR$-%&8)/3#Z8[W=Z?[N\-_T%3T;_:!^Q@$/A[P
M&/BACQ]^*L3U]30(Z7KJQW0]22+_[0F%\Q#'?N(ZB8>OV,6LM*;#KQOSR5R,
M[47A34+]^'1_]_L_9OL<$/C.$VY@L'A2`X\G"(G$>:IIV5X:!,Y3?G_W`-E"
M+/KIY?[N^[(IQG[H+LXIZYVF'9R+'!SYRUEVI6QR63B9D[=U+9M^[+)!.F5]
M[MIGB0\&IVR<X22=_BPQKCTX13<>G:+L<PS`C%E3.(5\EE5[IN$[3-_APXO3
ME\>F/)1YACD*F7<RZR5-5@Z]\^_.T__?WWV`='^['0:X26.00!$,!D$4*`SR
MML?JBI$7,5_<.>L&9VA9RK+)]F55#A>2-!^[CA``%H/$3?A9C/E0MHU3R^'4
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M(7)95;S\K*J<JGR&N)#^F#5E7T-B+!T>KNG+7@E)_@Z`X3<`.'3*JGL"\.54
MYB='9OA&:#GPCQ@)M,@#YN0SC#]X=)Y.$CYM"PQPI\8@BBT$(M56<)[O/$F/
M+6$)L",&'OBF4S:0T$/75CP*M^70!.66-$:,&TOB#!TY_*(=^^KB5%EWE$XS
MUGO9L=<O#P<Y]X8]ZX=QC1M@D*2^Q2`*9B!$QI_7^Y)<`6U<EN?0!NSM`2I/
MLLI?8`AM5V`$@A1\<`&7T?7:LVOAAQ.^]T:%7MJN@D/^1UNS8@R\N5;:4_;,
M?R%F*L_>.?DIZ[(<#@E:5>:;1+4DCC0(KA][!@3?310&2EE;VAKG2'%HK@FT
M/QS5N[S$G^/`@>W1^2.6+G_)ZG,E=XA$L)TJZUDGMMK-(/*L)*EX##B`?,;Z
M'V[_I'".6>Q/$81_)]!@TI\OM;S]?H5>_$YBAL*;B>FE8K(/L&`M)LB-LY?.
MV(.W$4_)X+`OGR6>E&EWQQZ"?`A9=PFOP3QH"S4.4[,E:9Q8-0YBK<<P*AAN
MC;6R6789`I!2XOPDZY*I*]3Y]Z2YT-OVXM0C%+\NJT)VK.AP>#TV5G;'R\UU
MRI\$V%A[D=!,4'GI9/%`*C!4?@!-E^38%4CPWA^T0L]W'&;\G'4EO+FCV7^Y
M3;Q.`C'Q[FG!03@%*QUUH%N=/%=9+N%-N_ZD-A?$6,62GCRLVL(=+?_0$L.F
M*P>D'GR[SDO(-Y<=HA.$TGH"SDW>;<?C,9)B-Z<RAU%B_D/7UGAX(U^R?;5)
MR$Y$:&"()VOT8\U:0,':L0,02!2@N4C#L('/%$N@\-FQ8^M#\D7DY=BT%);'
MJB5B]I+U`_&[`8&&]A+"P=TS_R)1^O$(+'>:MV@-.(P=(.K,,U@=<!^2E@R,
M^='Y"U_=`@77)J))DDR<U=6<=;B<Y3S47.ML1BX)VW:6"%8Y9YJOMQWT-*N&
M$T^!V"\IYF>'0U7F).5+B4N%Y!2.*?#,3'8&^1V3!!L!-T`A3J=4U)]00"YJ
M;+@?*];P#JXWVTNB#X_.STBV"0%\NV(K,]:A.%TVSIC)SL8S4OV6=Q9\!PHC
MR>090"8O++YB"6?<BA05VJ;014!PH)Z;8!$'EL$(P5A\#_J%-&2#G"T.@]^8
MF:X(XYO<Q(TB8>.8%VGU_C6IXA>IX],LW)FZ`C-N56(A+;;64K1<OF$NAU">
M46)S\RCDNE;0C>.=&\P@]1)OYC$,S4=V2I[A#`B0D^V<_:@H"S%^&'#9GW`9
M>5N?=U(V!-:LX,)9`!=<MM%MX5I:,[&:R-613[ET6A*B7-?:=-0F*<3#GK61
M4UQ'D!C@G)N<=G8FQEOCR%64!5GQH93%SCGC2530XO(4KFE*1=A11#P1[ZOD
M,Q6\MD#"M<D:.(Q!(HFN\E5><M]6\$P%I9RT2D4.Z,JAK:KV16TF+7?BI"Q`
M6<M;K]N/IX5OJ^@^N/H$$93%UC5P19A\%E&A9OZ;]1_9`TAL-3Y1J:HDC3",
MZ2H3Y5S5)OZ;1+0HL<E&,$LV7$/R%/OHY*>QA'+J0B>M>RJ+7E=%YRNF'==\
MC=D0U15(FR_\%W@A!6J3I5?9OL7`MD,F^Z-4H1":S27!Z@)J]#)YRRV`B&;T
M/)JY*PT$1]H]/!&%6U+MPUAA60H067PI!:7@&``Q:RI='3J5G!F,0&4JSM6^
M7H-19#AO.R!_)KH#U+C0I\+^%B"$EO*'[N2S/9-AL_Q<5=#.Z:I8\IFL_X>Z
MU5I-!P,DH'**<`0UU=N&6>WIZE;GB^*74AU"64$X4[0Y[%O@X$^</YUHGJ=U
M0=>I)[^O'%G?CQ*L[<K'*=?.OO%+$U"5J-?"[:QCG\T".=O]D"F?,3V8::,&
M8Q,@/$O[@\DHW%2[-E5,S&I5HINS_ZO`]W/#-5HX$3J44@B-#3-AKLA9UHJM
MAMG#LJZ);H&?S]AL3O9L1>_?^NOR7R?K;"OGX$Z\/[(*$?'O%@=:/'*W\UEN
M</J#183);SV=B6B:K\\?A;_^7.1]SDIB+,J>E83>%)^\0)OB3W"-Y:#\Q53G
M-C71N4JRVA&_Q%=5UIQ'LO]MM*.%YCTZ]NQE<CY\5#)57]FKCPW5I^S!P92,
M;J%]86"9=!1.5BB,]E%$D?69PNS8P;S.?]KIN@MR4:X,_V4<^K+0U>_VJLBT
M,R<(2NPZNW`BLK^6&;)R58)MN>U(>"28E,7D5%57CFR&ZB9<)?3MX8D_U:/<
MZ(VSD_8P4*1NQ^-I4&[CE<^D3)6<*B42T!JDVL]EUS8UUQUNG@[ABEG\QHF7
M%\]@<M/0G_BH:\KDI_)XNM:8+"\+VN2L^D@Z(Y7^\#@HT7"%CJJR;+&]WG0N
MY$[[*PSYT(4=4(Q&%4->H*NDA1P7)Q7F6I&N+!57?%I;@2XR(HDBU3X;>CHS
MXE)5I^B$C2,K%5RUN]`\;P/Y@]10<>$E$^M(S+[-"?*3ID=433-Q]153U(T/
M)D73Y;A^&(M2YXYF`BL=6_]>3H(SO\*-5*.LSWR(`!(']K)5LT<06Q8>^7-7
MI\\39C[IJGC6D:6#:YNT\V/3OC14=M2I2-8Y\KFM1KIW0J_+#".WZL)8D`\X
M43T1\A9@(3O-+1@/:=M!",,M,(@F$AZ+*>29I)OU@.K_NJ)PM8U<-H4#5,TK
MA?+N5KKI#+D>>W;RO<0G@^%6\\-AYG!V3BI.ETQ+*7RPB3%#E3WRPFU@"`P'
M%^[\&,RT/DW[KTL.2A3:4*,%-FWEFHSN_X$D^#3_6)G2TI=2JR2+-I\.@)OC
M6/:G:R"9<_(1S<W;?(1K1?_V+I\E7'4E/WZ,5;'BBN_=/""%]H&DS[.C`_&5
MTBHV4UDS;]KY7)G:%S:FD[HY`-9'G1^3=:OZ*A76D'CW;)_<$D)N#[Z`ND&@
M+'IG%2%HI@Q.G:)D.JYL9->^/3P0KCL_0M&^K8"JYH-QVJ8AC7M:C)DAW[GU
MPH2;VI5MRTT$KDP8S,B\2ZTP5QU`JC?'5@QIUVSYU&#!33Q<7J1N(3XB.0]@
MH)_)Z\W:(V986G^PQ>[:XQ!ACD-(MI28*A^0<1,B*>&L"*1D8-V;K[._](BW
M7%V!NQVNU$%KK#WTXN.=<T8)-$#Y+X]H^Q%B?]#=8;CG'WHZ)K[4*,IEG"TP
M"$VB(H)XZO!*8YVL945V'E33@FY>FU#034=,MRR5TPE_-F@5^%/[(N%Z=]J.
M64V(ZXQ-"0ZTA7E0IZT1:^/6#UC!!*`7S0I/H?_*0*[R-#XM!J1[:5#=)B#[
M@4V_W'16Y_9T`\-U6]+KVNCL+$RI-V+GGR$`U;Z.MFUQ)HMI+R@<R[@JKH/1
M'3:;HX:"O!I9"\@28`!*W?]S$PB$35%2=S+RP)Z"4X4!Z1&,FL]Q&DDB4*,:
MD0E=]0=](HV6UD![C8C3G]JQ*NRI.>59;SLRV+#,.JI-],ZYQ23[J8[^]]_]
M9+"[^4ELC+S$8+!)"[*OSU*V.N<5^KCCW<B/L.<K0GBSI,XDM5^PGQ\HKX!G
M0W9*A2S=W$ZM^70L"J4WY7^=DREW2H<EV5)7YZO&_DGYC#72+%371[AA=K\%
M^/:(Q8VGQD\_-`[D^@6$G>K5A3!\!K5S7NC\I2H1`'9\^D1DG0/$O.=_5H/:
MI`@K@G33%GGABULKZ,(#24'U`Q'<?#>.57#;Y%G).PN7>.\G7!*\LW">%]LG
M4D(Q?X_`F_F6']7YVEN$\)O?K?@JP0=EF=;D1=-)2>!'F@;_P9E6](83@@T3
MJS'LL*;WC317UH=NLPQ.CA\16ENN@:D>O&\W^:_)%+G(6^QA8!C.CB`2S6H_
MZ&7(WKR)P)WH5%3H].L+O%PJIY)WYNKY]=DA-?-3#9-JKTAF*;7MZ7T/:I/L
M^Q;AWS;!66Y,%1EJK1VZ\?;E2(CMI8DM1\[J+W&L=S)'FEZW?5L3[&93F<2-
MC:%QW-USINJB5'Q0]810>=&>/+3=8,[!9QOZNKBIWFXKF^>V>E:,4E/_+21/
M;)(JW(GHIHFV*^)E]E61G\'&"D5M=\[^;1A,%_2QNB">7RI5S[@YVP`Q,TO?
M^)1!Q#.0X'RF:D9L*K7S%U.XB#$,".>J<^1(!1N;RI@7?:AZG5,/&!3_J%Y1
MW&)SIP/%))PH?&0H?&;+ADRLS%M74OFB5QIJVG9M57JG6KJF%'83$N(%O[4;
M<IF$>/I-K7<C(>:![T%"WE>XQ'L_X4!"WE<X(B'>]%9?F$ROM+E)/)&0_Y49
M@N([$)#P:CVS-JY`1(9_J,48PD&.FB*+<=57S$-3CB^,GM)OY!^Y;DW#GX>R
MXC<G*67;XAUH^]J@\$/+JD+/Q&)=\S-"T;O0U!Q^0>"YCCE9HX^PU.)U*#9^
M&M[Y&_W5RGN__ONZD]1_-V_RKJ+!F;R7:/`E[RH:N9*;RK8805WSK%=%+-+5
MR(WY77N?)YWNYO\=0N"9:<K7Q=O78R_TEJY'GKMX?^B&R=+UP(W"I>N^Y_I+
MUX4;+5[WW/CKS_^DEJC_,X+X#=CCI9<"?"<TU3"M4NEK^`.QM+B'U(\7KV-S
M%M%_\-U@>8;`#1;WYR%THVAQ0.2"9BX-B-<&)"M[_)"ZR?(`S_6\135Z\#PO
M7,%2"&]YG9XO_)6G!%006!P1BA5AO4A$*W/$]/+XXHA$I"NRI'ZP:!@/PO63
M96F%YR?+*Q7"]U:>XOO!LBPB\%?P$"&_@+,T(J)74A='Q$&\,B*AMY471Z2A
MO[RWONNOF!OP2I=E@1+&RY@"TF6G^.`'(EE91^@'*[)$?K"R4D2M90WR$S]=
MMDJ@$2[+0AYL^2F!%RX'J8=`!"M[2V]&K#PE=MUEQ*!A*QXF2.B_^5D<D88K
MG@X1=<6B0L3LY96&(EZQN=!/5J0-@\1;64>81,N['T9)O+PO89QZ*W,DZ8HF
MAVFZLH[(3=/E.2)N<ED<`>-?>0K(SLH<H;>B05%$=&]Q1.PF*R.2%=+V$*5>
ML+S2V/56-#E&1%[&-!;>BJ>+?;%B#7$@5C0H#GVQLE)XNF5KB&.QP))`]3[\
M\_[N_NY?FYPWWPT*96YD<W1R96%M#65N9&]B:@TQ.2`P(&]B:CP\+T-O;G1E
M;G1S(#(P(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O
M365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E
M<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2
M+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO
M4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE
M;F1O8FH-,C`@,"!O8FH\/"],96YG=&@@-#,W,"]&:6QT97(O1FQA=&5$96-O
M9&4^/G-T<F5A;0T*>)R]7$N3&S>2OG=$_P<<O1O=W$*AGG,;:^RU#Q[OACO"
M<Y@+6`1)C.M!U:-;]*_?S`10`%M2<4/#8BBDEEA@(3.1CR\?T/?_>'SX^/@0
M;;(R91'^HK\5FS0Q?U3-XP.G)YS%&>,9?1*SDF_*,BY8$46LS$O6J\>'WUE+
MK\J3%-^3%@7^8/WA\>'X^+#_3WP3_@H^B#9)(N#]FT2D`GZ(,HXOGY=)BL]+
MD>/SHLC$EU\8L^<\$PF0S2-6Y!&\%6G:___6?'0/Q?PPYIZI[U\>'_[K1[FM
M2L8%>X$OD*SHI4XZ/&8\$@5[`?GDFSQE+]7CPW?_C)/(_?X/]O*OQX<?X%W_
M>Y,=0<SSCF6\$5&>LY<_[:8WWZRX-WL%OR-[17)O]CC/_9;1)A89ITV?P1@*
M_/N;)>!'7<M&M6,W#>S'J3W(FOWPZ=2K8=!=RWX[#Z-JAF^B+OLZ=4*4(76\
M$#-Q:2P,<7]AOW3#R/9`DV9'^:K8>%2LDB>YU;4>SZS;,V4I;0],MCLVJ*I7
M(_[KJ`]'U;-:O:IZP)6GOAN5;MFM.<G@#_R294247LQ1E!I.3D#)U.J1O7;U
MU"@&9.Q53T+O!^!*MDSI$>G=RFI4O9:LZ]E9R6%\8MMI9&>MZMW`9*_8,.JZ
M9G7WQM[@*QT\'/2AU7M=R79D.^2W.^&KV5O7_\'@"%%J1Y#DAOV\$OM1,I]C
MZ0]2E/8@Y6ZG1U"F)R1E`!:,3C%9#YTYV$-]KKKA7$M<QO0P3&H`OAI0S9Z-
M'7RO&TAL5B9XUO`NW=,YLU<]P-=1)4`(K)%_@)IT3:/Z2H,V#Y6LU:WYSM/"
M,P[N`PZ;&_?Q?/.MLCB4L?4=TVF-LRR+W!UE-A]D'%L]WND]Z-E4@RK]TO6J
M>U7]$VN\D:)^XF/]*D>U8W)DLM([7<%IM$8%AB?V=M35D0ZJ5G*'IZO;80QL
M>NC`1(Y3`RNLT<*WY&"5Q[]J%?[S:%9E[BTYR0NKRL!AVXUD4VW7-Z!>I^,9
M/&7='<`"ZY"\J=V!11MVC0([=JPARVVM-NP%7K7U+X`UX"Y&K<AKW9S%U/,(
MC$4`L@)W99D,;&=O`L(:D@9`YC3-TQ`+ZS.4#T$7[F(\GU!,]1DV'$#5T"GL
M5`O";>1((MOKK0*OBBX"G0.L)/<`T0U5<X*OH<<=Z0QFA48U)'^)3O6)J>&D
MD'_XLC8.=`T)B,Q)((V]M?'<BF``[:IMR!C@[1\GW8-5[3OK]<9CWTV'XPE#
M`(0]U4+<(Q^OV]TTC#V=GPDSTMH><B(/VOR;M:H"$<O^C-S+'6P`9@LL-_H3
MB4^J'CY8A75>.ES"(V]F661QR6<GIMNQ[W83T,L@)!S`>HX*0@/(`C^B"*$N
MF&5;L#4X20@&"`?P\8G>0`_1R^`+;LX:/'&\K1L4,H!W7HI<!'$W1V4B!0*[
M`%_T&C@>K_"@16L<;!1;DB*1FX/]3C>G#BP9G=VW[IA]/2DJ"K/C*K`=WY^E
M]\VYW(;W2+GNRQQD7'=C#A*N^S*'^9;;D=*M+$BW,I]NO?2R'0[@K"OV/S5`
M=A.I_MIJQ!*K95M10!M/TM1'FZ1PV59`V<E3)HFRP>#TN@-?&N88HP:L5NM6
M#1OV^U'7RJ!M!NA4KP+0BF3.&3GJCV%#(&Q%+GJ%.<0K1C'(%#3\D-51`\$[
MM@7((#6EBA1"((JJ'I(J<(3$+CYH`-7"-WHE#\I&2XM+(<3<FAL,^@$[A+(=
M%$.G1IFCB7HN=F$ZMU,-G@N(MX8$"7#V>[BRAM3%G.#FW*,UD9:63-*7#?LK
M0+0GQ,"CU"TIB$8M,AG=!9V(8DY'"0BZ4M.(D&X`J*QZ2O+Q$`@A]QIX[M5A
M,IDAHJ"#['=X5+#)H,%:VNI,>JHPL,GJO/EF_K\69'*L6%H!?'?SMV.(X7S5
M$):7R7U#F-OP'B'LOLP5_'[,00B[+W,8PMR.F)24A7=(9>%#V,^0;H%=?E#U
M:A$KCD5("@C:DP)OM1'+$E(A(2Y+I#@%'I)*">3!=Z_@G,"A4W;8R`;"F0:?
MA-^Z?8A*RPOU7S$#2,LR$%&483)@HV$J+.`@-ZL^R>94?Q[/?-%ME1POS^=2
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MMPN,CVM.D%&B0T/7#!(!-T>Y`+EI!/9;W;U+#)ZH*LM`4&LPG15S%2T)4[#,
MP@QSCEOERH@!KZ9X?PDIV!<JU]T>\I0Y$EVV-@QO6S6B5ESVP?#`.VH+KL%V
M[BIU:1&;^/3="5B[]5;@,]Q6Z^*AH@AXXED:]*\*6U8>L<)AA`NZV'0[:IN:
MS)*ZL$;:7K%-]Q4^/%,`AJ/%DNHK8*F+6`P*_\1J.'0&ICNY!B5@#&IE57(`
M?7>G7P.N6>=`T[G`4R39%UI7X%_:,>R%7S!M=94:"!<-6Y>,^ZX<?BA/9)T7
MKQH_0]>5;$,,M@[2ROP8099Y`XYS:\!P.ONI=J,`6U5)]+,$AN=N@.T/$#`$
M3[U3U)=7[-!W;V">=L613!^U0X^#JO<;]M[=DX?$/M7K5+<@I2W@45"04^_L
M>0W^_?1!Y*</J/QN>BF]Z4N.LM$M:?N&_;="ZK`08_3Q'2@V3:_APL?;GKL!
MT15*`IMM8<NE43LM6:O4SK:I3(O>RM#TZU:)6YD?0$AYX,*Y[5O3H1XP#@]=
MI:DW'32#D+%*GO1(8AJ`1*3]G5=WYG%SL!T5+"V2?Q-M+XLGS5PF%OO*;TH1
M'J7SMXETE`S<*OIP[/H18AS$O,%^ALHP]3T5?55U;*EAC1YRUT^'(*Y3_KU5
M&.]J>9@,$ABF[3!BC15%;$4]@"^E2MZM.8;\(DWG-GY:!"Z!SV5B:J:BZD+F
M9?A'OF<'S\!0("US\MCK3SC/,`QJ##JQE(6UTQ[<"*Z];.*C=@V8O5;U1&Q"
M,GL.-KBPG#4\`XI!S-`Y]064V/7Y3U,_!T"&3%%-_\F<_EZB/]-MP"*57>5)
M5GH\/P5^`*G'@21R'H%E/5V,)M5R"V8%2:L5`)D=?-VT\I7LJ^/3:H+@,[`5
MP5A'[(#MY0A5+<_$^18Y1J91Q0=SW/T?:OS&E'LY)4[RN24.H<O@L;^=Y4Y7
MM]X,4@FW6>)2N#B^^2YIP)*!?4;J6>JZ_`/[K:LGU)2;>U7XFMO]VTOV2Z>5
MQ+=.@Q<V3-)Y0YR8*&9;3J,D\7GP^]^_*^.-;<,./1@[0?1K;0"DB/]9NG)S
M<2$2<>2OFP*(/!04?)T'";HKB793SS[PSV=<;U\*YN6=^,:16<\WCT4PU&5M
MS<ZAO1DPWX*W'J8*QW\`&E/*CGX.U`&E\T/[Y[FY?4T8S29V.4I41'-<%HD[
MG.^1#B`J*/^^(9JHL87[U9/#*(L(9&OAK4FI<;7G\:)K;:,ZO.LW-S@UO^H-
MQVO78#WR64KIR^$BLIU>(*\=)X+D6`#6XWM@!>%GC[0U\E\01P_RY&"Z61CR
M![:-;"/R`@=`115(\K`1*U^EKBDK.4`&`%GL4'4$3&J][;$B12U_AMI0KZ(!
M-!]M_%A6!%C41H1)TU2DR;3"@:W^`%(8&E!4DU.9V;?.9.>>CR<L*MW<K939
M3/>ZA@RO#B3$N>^;``U642I(QPAD$H!R_QC5,+HI^&!^,Q#AZ4AU"-!]TI<U
MSC;W<^"1=T$`L^SXL%?1#?O>U`<'"9ZF5W+HT`J?G%W^A.?_XO*,,XX1('2N
M1@.[MZ"\>VW/_M*P@^%',!,[<#`"\C9.S2%SM(TU1)#FLX-+?05U'I0`^^[>
M"%)ZC=4-$/6J#/8.N2%<C:,J-U=H2(P=I2M'9(B!7B8\#Y3"F3SU["Z3#-L1
M)!]$GL"9_Y.M(MA%E*@H3"HJ=2(E7V%,!T\UF7MY61"VN+O?X0U._VDB$,U%
MX?D=0+='4V#9AC/N)C"M,1`IXG^W=[=<31"1\%8^JWA"52@4QJ\0=PW*-!B3
M;/:+@`N,>BNQ5]!]X]#20OHATB*@5$3^@E&:%K97\^'8GX=N.'6]GAI63]4?
M@(MPEOSV2#`-Q18')8EYL.()W=4'#BFP&[K_:@PD>+."FL?%G"7GL3]9D<W1
M&9")1O`![A>+OZC@%W6,ZBA[<X,)HE%EB\)O/C[CL%J0C<#7YWP$:VZ3N>1S
MZ0S`6K`"-]6@*M:+FPK=&A+(YEY0&@Y)SN[[=*KGCH%%7Z/Z-.+@(W$SU2?+
MUHG\DHE%-!V)5:0>3E2U%1;B41AH%CO#)374`+(.5'.2>.Z'7C;HT*S`X,/W
M<EA-#.F<2U`):1:##>2.Y<N#"H6S8;].%F=3HX^8(3#OCQ^8!^%(N@_3[AQH
M58--58RG5SL;#3`;0*.8VIVY!5'C$QS5-$JSAAC$W%$1B0_FI6LLN!0ZK'@1
M7K?%07/I![S+`1(3!/;=%B<VX"%9,!VY&?\`5]C55)?>]UUCBX^FN_C>I'SN
MXH/BG-NM(03N+VEFWBDDSHFZY(Q0&=YR_(B3GJY9@.(`5T&7$+`Q0!I+VGT"
MLQ@QX[#>[O,Z1-.YBV0393^H7V?XM%8@->F]T.AAHBWCKB&&R%_Q])X!4'GB
MQGEZ:J.]0Z,?N.T1=_WI:&CT!^@.GT"AZ3=-QO[=D^`VV7QG"1MJYNH93C>/
MJ%&4$I%.V7MXZU11>>';+&&GW%T/-&KH;_49X]R];RXA=32[93^_.>:,LIG4
MM=%M%`@EQEZ.O\ID@^8>]+S=858?I&+.U:%RX(1T,)37=V_VYF#[[771K\(W
M4=Q)-%ERH2^)'X%+TKDC;2Z'NO:!O\6[CCOG<QN,EX'Z)DY]OV!T@65>WAY#
MTF\_7I3/-*Y[.''.`VD([N_ZIAG_[/(87:Q?X[8<U@ONP[``E?,,Q\$5!G=Q
MQ+/[;CS'SC6<S9C$FQZ4B7/F^JXU57LK=:WKLJB\OJ,I?!C.Z._D9BY@^*S!
M[UI5])^(9`G.5D,B1T3XW>@_/(E9B;`'G\=??EY@_V'A><Z3Q>]G49DL/4_Q
M1NC"\X2+<NFYB,K%YS'GB_OS*"^^^ORC76)6\/P+YY@OE_<X=WF@;1SQZ/T1
M+=/_7*:+\GT&J+(HP&<1<;&X((E$M+@@C>)%&3YGUQ:`$2QS643)%3'@):FE
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M`QY>H;0HK]%1ENGR.P#(Y,OGDL71,I9YSL#XK[PCB:YH4)9&Q945&<Z)+*[(
MHWS9.V0%YU<H+?D53<X!F2S+-`=XM&S[><RO6$,NKB#89S2Y*Y2F6$587)'%
M"R`)@-P/_WA\>'SX/U'_:L@-"F5N9'-T<F5A;0UE;F1O8FH-,C$@,"!O8FH\
M/"]#;VYT96YT<R`R,B`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O
M=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@
M-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@
M,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU
M(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)
M73X^/CX-96YD;V)J#3(R(#`@;V)J/#PO3&5N9W1H(#4U,S@O1FEL=&5R+T9L
M871E1&5C;V1E/CYS=')E86T-"GB<M5UMD^,V<OX^5?,?6/=IXYI1\$H2OD_V
MQFLG=1<GMY/<I<I?.!(UXED29TEJQ]I?GVZ\DM2((C4<N[Q+B&B@^T&C\0`D
MVS_^X_;FR^T-6<1*1@3_U5?I0@KSQW)W>T/U'1JQ.**Q_H7!Q4(IED8I@3L$
M*E;Y[<W?H[UN*Q$2&Y)IBG]%U=/MS>;V9OT=-H7_MGX@"R$X=+`07'+XBRO&
MNO>5D'A?\03OIVG,7V^01?>)Y#$H3TF4)@1:19W6X^I\<3>EO\EH,.K'A]N;
M?_V4/2X!`AX]@(`&2S?JX(D1"9Y&#SM4F]%41`_+VYM[L"VE,GIXN;WY\+#)
MHUWVS[**-H=JM<VC8A\U\-LJ_YIOR^==OF^B<AWE?SQ7>5T7)=S-EYM]N2V?
MCM$:Q+#R<U6N#LL&[T+=3=[D%58H#S7>:O)B7T>;K(X>\WP/+3]5V2ISM5'^
M7Z*'?][>_`0F_?<LAE-P!Q0RAE,5>[MEK(S=UJ!\%31\/)KKK,[K:%]6NVR[
M/5K;H![<_D@7T0]UE($V]6&K@2D/%<"P/&!+^1H`::*FC(H5X%:LCW?1<EON
M<VWD4[Z'=J'&793MH?*VV!7[K,&;9?U.&!#A,4@#!HH;#+RU=]%+#@/TU2A9
M@5*KJ&ZJ#%%Y*9I-]#6OCM&V?(FVZ!8U&NZ$(QC79;E[SBH0`M/1U+(JGL"V
M;026-:ZE1?2W?(GN!,`;VZ%-\(/L+GK,$#[PAZM`4.=!2%+>1@%FMD;A0S%_
M5X"W2A,WUR`JF)Z^%DU5SCVV,*=;?7'T=#>O\1K'%E#/'HMMT1QQL&H8M@K&
M`P:GRI[S0U,LM7/#2.1?,STF=A+8Z8^3(]\O<Q1>@JL?JCQZA#J;:%V5.^NR
M=F#OHOKP])3730V_9XV+"-H[YK8\@0#I3%=L(0@!>[^!O??S]R3;($.(UN,)
M7JZCP3M,5Y40VQM1T@\IEXD9T3`AMUN(I!&$G/5A>R8&/Q;E\R:#$+:T@PW3
M[Q/4S/_(=L_;'";\!D)Q%L&TA=N';091[`#M;O/]$PPRN$3Q6*Z.T4N&+K$\
M/.J8H&.!<X=UL6TP5+P+%+#T6N!A]0W.;8.W]D&,JW;]J'1@`7^VJU8(7W<0
MR*/\*\9C<&;$ZF3Y`8_MF%L^UGGU%9K(UK".14Q`%#M4.N99)$#TSR<3Y3U0
MX+$+WZD*,,34PG!N;FJMEJ`SF.MQP)\[=D(@*%8:,P0D7RVN-B$^SS\4-29\
M^(T),C=$T'ZJE(-(DD!O*+?TYN\`#:PVX!9FI'&Y_DBCGP*=^7RLFWP7%75K
M+@`JV0KC8O:4(XFQ8ZT1ZS.C??Z"LPWH#DXS-PUK,Q9FS7\'UTA3INT&8PE)
M?;!@POD&4@RK-JS.N[Q:%MEV?D42K\G[1F,*<=_U!&,=)S+0&<YL@`3\^W'P
M:U85.(*OC1"X0[XL]^7.+H9SZRP2UM*941ITUM/Y1=.#['&+0P2KYQV$]&+_
M!%$9_X)?-7LJJZ=L7]0[S3QQ.-?E%I@85GP/O\)USJQ!,?/SB3,9&WT;K6ZQ
M7P%FC26.;H*=G5LED`]P0I@)NVQ_=$$;.6"C@VEM=AA%W:!5P5W;NXY=#IQC
MI4EZN5[GU7O9+\)VJ15/5&QI55T\[8LU&`^3WX<('2"<KFA!7C40=('[9S7N
M)1Q;UB1X[B"+2K/TC4$V.0\*4%D0I3[:)(F'A7%I8?F8/1NV61AS/QZJ"N/C
MB2]<'PP'[$\4?;]%!MK7FT;C%")1SGI)<$^%UG\7/93(R%:X\86-#:ZE#WJY
MS;;'NJ@-`]_FRZ:]W>QN+*-Z4[Y8`JWC-A)L5]>LWD_;(_A=]!N19)E5C^7F
MN$+^!66*RSS$-&`"N!G;:^][#R"DCV:MR1$G-IBM\Q<@3+`9R"IM">SU2ZLU
ME(_/-LZ6CZA?KM<G()$9KJ08H]>'_5.A]\9'V#HT"QS-Z-/Y"JTF+9:^,XO!
M.P4)R:6'@:BP$!&[]N)N"U:?*MJ5%9ZN[/>EWF1#8'_.EQ@^4'7-7C58QM*'
M$Q+OK-&T&VC)4Q[M#[O'W)!1URY2%_0[`/1/&VBV0K&R/FYU;/W38NX)ER3<
M(_!A]NDLB(PDE6$^O\<`"N6B/"7$$VL>"SN`V.];_HM&TTZ]EMEU<55@`0^.
M,KT0MM877$'UPECNP=L/K6.K]AI9FQ![]RZ0I>XXC;"$N5.4Y?:P`E6_?X^H
M+N(9HOI`^YRK=VV?Q6]=E8?;IV*&K=70JBK/-(]]TYCANDLBKML-#>@C<'/\
M*G0%]GH%V!C&0_=3R@;E$P)A:.!^3%(R=%]2F@[=%R09O,^)&NR?$9D,W:=#
M[9.%8A*?6"C*$WS&(!(:_>UG')X7'-O_N+U)"5W(*(DE_(E/1+@O;6]O/@\T
MH:4IZPAC*=8-.N'^$Q,OV>O7%&/"QLN:CL9UJUT2_$!8(^&*8V6\BJ6Y4N$2
M$(V%OA3N:C.`J&[="NW<Y6FK*O2::E5:S8:)8ZMUU12N_JGH%W\;/1VV[=/F
M)XA*<F:"GL.1!"!;-GE+F6A=MJ`D8[%T4CMW>=JL[U=7.(.EJ];3U.K_JO"7
M<)^2-(*Y/6V!PQZE66]4LJ`"MX'?-"N@TM';OV:[7;8M@-9^S+?;>@3D3'K(
M.Z9[0'`#Y2\]SDR.AMQ)[=SE:;/4]<LE.0NYJ];3-$B<"G\)]RD^<YT(.9/<
M0PZD0DA_.L*4M*=W/V:P9:KP),#N'D=@SF&/8C'OV.X1$8J'2^:`UF+C,'=2
M.W=YVJR/`+K"&<Q=M;ZF7N)4^$NXC^X^%7.N9-O-)574NWFLA`']__3>"EU\
M!-I"^>C<L=IC@97]9>(@UF+CT'92.W=YVFSJ^M45SJ#MJO4U]2'Z5/A+N`\2
M4\&6FD,%UIP&!T]2Z^#_OJ_SY6BP9:H<V!VC/10)]R$@8<HAK,7&@>VD=N[R
MI%F\-/WJ"F?`=M7ZFGJ)4^$OX?XUKAVSI(4V1?;E'Z"Y)VB_XN//Z!.>(HQ`
M&Q\U6K3;5@<L@,Z$2Q^QM=@XM)W4SEV>-NO#@JYP!FU7K:\I=1*GPE_"_5A-
M!CN1:8@C;,%2K(GG_A_I!6"[)!98$9))P2PA%+YTD4L:PNLE=8F-IK^]?DVQ
M)6[)&;/D+)G*)B(<!W=DR+TK)OK:3/RF@AW[?U7ETAX:3P(."%`7.#(%.=4U
M7DW"KM>U+?:Q(P8\I&)3P4L#>OJ\F1KX8%VZM/QW,0+&TE%43L`(.%#7R&D8
M];JVQ2Y&FCLQRYTF8H1K2<O#(-H9B/ZSW.>3,`*&T564C<<(.$M7ED["J->U
M+78QTER'V05A(D:",(^1$HN$X2$^QJB_X'.G?#4))^`&764G1"I@&UW9:;&J
MU[4M=G'2+(49EC(1)HD+QAS3#5;TKIYJ/$3P0U>V'U.&(>IU;8M=B#2WN-*5
M\%QX%HQ@'>XHRNEXC$"!KFP_I@QCU.O:%KL8:4;`#".8"%$BY3P0N;58M"F!
M+HVD!%X22[$BTRA!D$Y[XH82P"^:$G`QG1)0]_",<,[]4T1]C92@]7"@7)\<
MJ+^M;WR%VO:="/\VK-37NN_#[UEU+)MBB93$/)^\AI"$82-3QDUUH5>31J[7
MM2F>C!PQ\`$A8?$5A,2^0CH'(?&*R@D8.0;BC9R&4:]K4^QAA(3$8$0F8\3P
M,-]BI.2"J21Q!PM$N?.S_\67B*]9?1TW\-JS\<`Y6N)EZ23@>EV;8@\X9"D:
M.#$=.,U2''`SL92@[(3@Z6B)EYT6/GM=FV(/)V0IB!.PE*DP:98RQQQTW,#K
MJ<9#Y&B)E^T'FE$LQ8F;8@\B9"G7NI)F*7-@Y+B!4Y33\1@Y6N)E^X%F%$MQ
MXJ;8PPA9"F($,V4J1)JES`&1I0?:>QQ+,:5Q+"5(ZE+"1N+3[]<46^*6*4#(
MO?+@(DX2#X^2<3BR=,?#'_%;CZ:PWQ;H5U-^>?A\#5MHP4>FX*>Z$*A)"/:Z
MML4^@L1`>-7Q1>PQ!`CM,23LS*^@"D%+.0$@RPV"A=,`ZG5MBUV`-%70`%UQ
M=H%3M^5D5\]!NQ8'1=EXC"P-"+)T$D:]KFVQBY%F!8C1E6<7#J.96$%+V0G!
MRM*`(#LM7/6ZML4N3IH5).RZLPLVPURS"W%04HW'QW*`(-N/)F,H@1>WQ2X^
MFA)<Z4>QI#,`9%=AKR6GXP&R!"#(]J/)&#[@Q6VQ"Y#F`PF[]M1BEECD%F+W
M9HOPI9%\P$OJDA0C\>GW:XHM<<L'I+B:#TCW[C/13WD0G9_;+YA>L_`'G,@4
MH%375C4)JE[7MMB'BABLKGQNX<":X9@@*"HG8.06>V_D-(QZ7=MB%R.]]FN,
MKGMN$1SJS<\M6HJR\1BYQ=[+TDD8];JVQ2Y&>NU'C*Z(V1SB6,"(VN_^/OQR
M\F;W-20@:#TA0KE5W\M.BU&]KFVQ"Y@F`0#8E0\P9IEW;O7U>JKQ$+F%W\OV
M@\LH'N#$;;$+D>8!5_I43.)W\"FW&CNM.1T/F","7K8?:4;Q`B=NBUW`-"^0
MXBI>(%3;IRBS<>KAQW_[[AI>('F;%^C22%[@)76)3#PG"-)I3]SR`F+.">34
M[P%`5(1/PACS;S@(_#K$O&QS:)X/3?3K<P-[EF_ZL\'7GFF\00,6#G)D^#R:
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M;_.R_6`RBL8Y<5LDI\<[1!_O3(5('^^,@0B7!A9QB6]1X:=KKW1#R4`_+!+"
MO-S!%MQE?OJ-Q<FLO:2^EWNZ8,RRG.B$$:3"=$+3,[T,0`:R0OA9EUA:!;R.
M.5;U/W5NGOJTWAGY&=.<_#GZM,W_L`^&OM>?,Y_+M-+*5^2R04#57S#=Q4/(
M+E<>]-V73;'<M/-,S&TO<Q2(8N(_8R^EB7U3]R4W&9>R;:T_\M=,MBE=&ABG
M_.=EE>?Z@W-CYJ+[#?"K!N+7_/5S]K(_UPCV,[>UE/AM8.I&5TIJ1W=5U$O]
ML7%(/9#OOQTQ=P=^=_]8G.0R>XL^+(F]0L-T^DV]I*1E-DECY9Q:IO;]IUVY
MS9>'K4E>T4I`4NR;'-RW\<F2=%:?/'A^71ZJI<Z#HKVT+G=Y5"\+_(@;\Z&!
M:+%[+4?6&T>1*Y\?BZ>I-8<(Z[++<@_]-@?H]_",/J3(;P0BN)UJJ%QE4OW-
MJA=3:4LQFL:OY.AY+DM$-=IGF*S"9$+4T<1D2K*)`_7G[QIJ<,,^UHN3K^O1
MJ$.=O_;:W%MQ3EP&+A;'/LL235WP[:;J:6=OL%E[0"\3,#95>7C:8$C3V37M
M-#O>8:JN.946"?%:O]^4$DD;&TIBGP6#*V;GU');['7")1QC7VARD^5'_Q@F
M6@NZYXU.P#GW2(;C+]$ZKJ!2^%QJJ^KPU,GN]5(>MJOHJ<HSS"U7["$Z8\++
M?+TN<(HO8?1,`JFC-J=^SDT*S%U6_9XWIZE^QIAP[H-?*8(-IUDW\(/SE".O
M>/4,X`)YX8R,)"]7=Y+Z3BYR%]T'0#3U-`/193Y#&`D9%(ER7]W\C$,)BQN.
MUJ>LQLO`3[Z/?CV7I0-SU^K\>?:M%QACFW8CVA1/^%%9R(O:E(WQ9YV=H\`D
MB_6FK'2WN_)@DL;-;#9Q;_=2R<Q,I`L1"XLR+$&Y2<=3Z@_@6LM7)\-8W<LP
M@N=GW222WJPP74VF(YT54\]>FW/.Y*F9WU3,1N7.J\(G?D(_FC0IB"J<NB:]
MXRH[UC:CK4EVBDE[=;*N;?EB.(Y36X<C6.-Q['0RMBBKZQ)"DT][>9ICLP?&
M*[F]1MAZ-LN.I-[85^<[C>G5NQ7\Q'O<A+^^E]3W<G'&ZTZNC.LL?&&K1&I]
MG^)^5??W*?M:5GH%_M3VC(_@UN;;<EB-EO7`U"^?=3[D.CKL5^`R:]]>Q]-@
M%5@5.I7=7>2SXNB$R7.;RWU&9\;B8"YWZ02!5]08H@RQ0I6-!:@/V*.O,6$H
MWG_^!7CM_DFGIG(Y!4L\K\=)H!.+XB_&\,UAE^':?*Q#)L6.U8M\`91@=GMI
M*\VQ#+S=[E9R6)QA;#Y"["T.9HNRAUB%J8Z??UE$/\">[0ZXXC)#>H@S&,-U
M*UAG3S8%H<T#"\#L<_PB$W-30Y2'J8VY8Z/RCR/$$?P%<Y!93F.BZ=P&$[\_
M2]SNS%J[*Y95&8+UR@R/MBB,>]LM,:\4YG>MFZH\PBJ49]6<V@I\`Y>,W+U=
MWTO"VZ!PZ6#AL?/Z.M^#[<77?L*\5@+LYMQIQ.L[[+>,($W]WLQEAZ.+).;"
M)UW7J>I\'D`SO\R*%,8QS"US_.#9IUV''MO9O0]+]%E,X.Q2X:%GN-RGLP\\
M9IYQ5K[?P">R@V62V,=38;3G'K@XI%M.?;I\&7,[_TP(;*50'\CJ.4:5<TL_
MX['7Y=6E7Y%KF3ZU9UV7%_YK^TA]'Q>7?>SB.A9(67B7@;I5(67,3K$?EL7*
MGT'V69I-G7@T)PZP@],Y&35!-$DWD=EU6:\[!;K3\?0QCX(+-G@FJ'.^FD3<
M*SN=YS67AFV-S?4,BWY(]8SF+EL10W/R*@?^GI\$PK.9",UJIT,3-CB?`1($
MG`47H\75?<@62HS:_\\#OH_@LT.?+!(#S&;6X0O?7LI6LDDW-?J!WE&.S!P\
MX-)0_)YOBTU9KKJGD\4W3>HZF6)?C4075#^;BE,E3O=7PQ`W"?"FO]RN_P<6
MUATXL9\*?J#=W"%XVC"8`?">$LX&*S#"AUO@>$HP5$'@L>E0!7FI0DSD8!["
M^X0DPQ52L'.P@J)B&`=*J!K6$N8.&^X$*M#!A(;WE+,+IH*>XD(;DJ7#(T)C
MEERP)<&Y-5@CY</)(^^IXO&PIHS@<?=@#<KYL"V`^04\&.>8MV"HAA#L0B\2
M,ZD.UH@E&4S&>0^8L^&Q92F_,-F8XLFP+9QP.8PII_BX8[`&8\F%20__#-O"
M!6<7-)4\'O8@N)\.STH.N_8+MJ0BO="+`D4N1;`+8RNX$L.]"*'4,&)"R@L1
M1L1"#&,J8%MQ08]47IA10DDRK*DDR84Y)VERP5H(4F18#\E3.3SZ$HP9'A>`
ME%QH(U87/%DFZI(>J1I.E'LOE1I.=7L?PQ9GN)>8$7FA#4XN>%`L\'N!P1H0
MQB[4B(D:C@YQ0OD%35-ZP9-CI1-@#2[Z]$*D2RB[,!L2QBYX4`*!;EA3"$%L
M>#9`X!_@2,#3?OK'[<WMS?\#DL6-2@T*96YD<W1R96%M#65N9&]B:@TR,R`P
M(&]B:CP\+T-O;G1E;G1S(#(T(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P
M(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P
M(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&
M86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C
M.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R])
M;6%G94E=/CX^/@UE;F1O8FH-,C0@,"!O8FH\/"],96YG=&@@-#,W-B]&:6QT
M97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU6UMSXS:R?G>5_P.>3F6W;!U<
M>-WS-#.9W62K]EP25^T^Y`6B((D9DM#P8D7Y]:<;-U*VA\S:9J8RYD@@@.[^
MNOOK!OSQ7[<W7V]OZ";)8T+QCWG*-G%D_RKJVQMFOF&$)X0EYA-.6+3)<YZ1
MC,(W-$Y(JVYO_DD:,U<:Q3A1G&7X@[2'VYOC[<W^SS@5_IE\0#=1)&"!321B
M`3]$SOGU]WD4X_>Y2/'[+$O$RQ-R<I_"5(QDC)(LI3`K[FG_Q\9\]5_2\"5G
MHU`?'VYO_O.O<EL8%3S`"T999E*O'L9)GJ3D`?3SW2\\HG\B#[_>WGR&-__O
M?>9/QOG)JR9/"1,SFX^IF3R/-EG*,O+P.RST_47NRN)J-?OR3W_#E\^X\M_A
MB6]BDD<I_`TS1%GX5W5[\_.[;##*PP8C\E`8'7.^N+$HGVXLYN^_,8"MW]@]
MW5"6V.W!,Q<";`D[^:XC_]OJW5#T'9'-CORLVL>R4-WB[F,QW3W+7KO].51E
MX_Y?":L%GQ#TC3Z1S\,6OZPQ4K`HS;WN$_.,NO_<_'ZI%?DX=&6CNFX-$;-<
MO-WMOR5B@F\E3D2:0_AS(HJ$<BOB_PPM>2JFW.U:^*DZ4LM?=4L:I78=*1NR
M*Q]5VREXW`U=WY:R(LJ^6\OVB^J[._BJJ(9=V1Q(KW[KRTK!9[(I:QBZAVGN
MR&FH3@;))WE2[1WI>MD6Q[M7ZW;&O%F<>_/&++A6Q+B3?:\U;&BK0"AY4&93
MVU:=<?/XK/NC:KUD&_)PU,/A2,Z*J-]@YZ5J"K4CAU:?^R,J1X,F.PD"DUX3
M>#4HP$V!8_#CD^SZ.YRF584^-.7O,`M^OH8"(NX5D+$@?\0=O&O9#ZVW'=E=
M&EF714?T'O8C>]*I0ZT:LV].:63UHPZR00%K_:CPIX5$N;\8^5O093,HLI6`
MDNV%['6!H#H0W3AU>N@HT.A[NU-*TR#R^\<C=";^ULGG/)7&P5.CU%B+(5$2
MUE@_-N0?\H*6B`UZ]+:7X*X[(LFQ!%Q^'615]A?R_7]_`,M]'1">UI2*B.R.
M4HK_&\MT'HJ?&#FH1M<*9CR6!8!;=@2PO==M#3/##S)T:,<5L)D"P[/B<D8M
M..DF]M#\`/LJ`%$]^5CJKC#.1C[I]J1;V9>Z07<T^P^BEA"W2A-XG'`[P&*E
M3P;"H`>$9S&T+?YS&R(=0!I>1(<N>O1#`+0FG?9S[`?TD%6"4YHR[YLTCIS\
M49+&5@%HIQVZ#6Y#;DMC6V=.$%NWX(=E5^..3X8?*%+)%J+8HZZ&6ADOKO29
M%+KKG\?KSMAV_/C.!ZOG\7D2O%=1`\INU<"SV,<HRA,7HW$G-D[CDSRT93%4
M8!38DCR=JK(P<+"6!%V`)<T3:*G0=:W:`H4NY,FJL%0NO('1>U4<&UWIPV5#
M_JD<!G"./<`.0Q5H1"$^^A#!6R7!26#(&HH0:4A6-/7^$'&'!X=FR,5G%XC[
M'O:(&P4[#7U9(`YZ58(N:@U17>[!Q#NYK2[!5ZRO7[D,F+@N^Q[=9C")JP;'
M`)'QL=R!KV!D;R#65]97:ECD<24D<.H5D`0N1J/<100GG4-[;Q$L(6%KN2,=
MVJX=:C3NF&&F;$0UJCU<GG"1$5C7J-\0B+;`@DK$UIV%RZBU!L.C@=TJ:J!B
MS-D^+N0L<^7`DVBE&K"P0ML9QH(Q3E>5W&*8U&WWQ"4>):C%QI$`%OS.!P63
M]@M(\%N%B@6Z8X!@T;\A'W`TS"?K$T:*\RJ<)<D\8>4\SYS\3&2IE7]T4T0B
M0)0,30F6&670Z/D@<AGRW(2QV@&RJM1C*7OET82VA,<"<\)6]WT%<"F^6.68
M[%K+9MC+`@(/@@F#*FI+K9(9DR30UBSUF5&(R&E`[R$L$=@,F`#2]5E5%?X<
MP7"]5[`U?'`9_<;JI&S)3__Q/3F5)U5A+C3N9$E``QEP*'LSUW/]P-"C!.YW
M@7BX56H5'TABSUMIYD,A1[Y@6?O0[$S(EE6G0]Q&Z!I'?1;E)OYZ+E%9%29&
MVYTP<<X&-9]:/_]VPNH'A_]\Z7I5(P'ZA<:TA+]0%GBONH3HZ*N%-=0@XA`1
M4^%30L93'PIT)4WH!I&]]Y8-I(6]@@1P+J$N0?"^]\XX'[>6\TU$D;YAP^?^
M_5=*)DJ@.7)SHX0D8DX)%>9%!(&WV=/8]J71Q1=3CQ[!E'KHS:?&GM:@!@YN
M@+>JHQ73G.=YY!IV9IX*LSP?Z]08GU%&:UZ3G;QDQM;&#R4YZ0X2%3S"3L'M
MD33B&Q.E;,CW-AA`]9"8P(TPL8RIT"`PUFR8/$R]YEGG"P0:W.,'))1K*($&
M/IRGDV(5GU$)#X&NF5!U;?'C`#$.--276[TKG;)LP?DB0W+E^GYH#O(*/9WQ
M^,W[UXY)$'"5XC%./(WF-+#H*(E=S$0"&`+B$;*%K#".F:R`=&[HU'ZH,-`%
M;QCC8Z>P0V.T;I&(D<452*T\CQ/O9"^!;&I\P.3D*I)FJ+=@B'5\)XX";<YX
M-L(F]K01+`ZPP")@K`=ZW%?O$IE)8M[O01=.,I-&0`%!NOYH&!$YZMK"T.K%
M-KBP#`=='EII2K*BTHU-*/5*[A*+P);AO]#7@VFMW*.TD*M:!6%26C>V?.B)
M"T':=+4QC(;TJMJSA+KA!WW&YIB)&.A<17E"TN29,6CR4580.LY'-5&:*2P`
M3C"5;!K=PRN[#;8W5]%#:.'2+![UX,G2![N!D/M!8"@?T<8F1$*U`UB_0^&E
MY?K6J-:DCZ5M!O9:5YXW`G-`0:$V;*7E1:!3YSY3IK%O=7W=8UE#^BA/`D/@
M`?Q<./![[%KM3VJ::7F'$OJ2][F/N.HG&-(IR)##9RYB5-RI%M-2A\49@.,$
MB:<W>'/:.*[D$:9K;W4AQF:^R',7`X'^R]*F=+-/H,C8$D!`>_&?9#S8K&W#
MC*T"*]<)>!>:VHBU*[L"@FA[\1G:$V:]1[7+EZJN:66ZABH2'FHH9M/!=VLP
M09&$I=8E@H#>428P[\@/*'58MY%HDNT[V_<8D>O<<%(#/&%[8*`O4-+5"FH?
M70&P@1\4MKWDN/6^LD"_9A\F*]J0X9&TAE&C4`U$?'1V&KN(_Q34Z&X0F'"#
M<@?1O[`J4$B$`J!-ET1M#AL(A46K9=O*"_H\-OB;LL<6"_8''D%/@TDE-?"K
MO84Z/`Z56PE32E`6>L4:"N"!)J?Q2')X[%ID^M27=?D[^I2),<[AITYMA)G8
MSKYAK6_RO@9!\&4`S\=I!_:3:2E<WENJ&&B*%^M;1]/OL4PBIMJ+Q4B4S+,]
M9][+1]V:P&ZS9`>J:TNDAR&9K6%5QD;FFH[4U?-^J-@ZX.J%ZV7T5VU__!!B
MZJ^JL$=J$NK>D<B`10T^NQZ/]S!.#\;N%J'3PP,YI0E0-D/.:[$7V/:^F!C[
M3BOH0.2A"1ZSB6LSWP1OT0X$S^0&8.)CBR_@%E@VY&5W7O&Z\F7^J%S$:3`3
M"_!)S;,MS]QAYX^VT_;ZSMC,8;D0[W!'9J:*$J$%3=-H))/>17XH.XB(D"TP
M$)Z5+1^.$KE_5QX:DT@@R+C#`EN6ZQ"`#-&\[LV9*&I&FZZBJBH(J)VZ.J2Y
MX@_NE&85#(Y]9S[>$\A\<)WP&I/GY+;%!`G\N3L:42:',5-VTYEVI9%]+W=>
MZ!ZJS]YY-.3@LB8'V6*$[DQC3^_W"B4_8W^WE<W!9+&G^EE#"WSL/B=QXM40
MIQF[4H,SS?0`RGBF[/ZR!NYYDJQX-PSF9WR]^<&O6)RMZK<L\CF$TC0$)YZ+
MV%>!_M3"L"&')/#/P@,92IP'S`35NX,*3S7]_EQL!S4(]N[KY&E8!\BXH&EJ
MR?C[GUYCJ!A5SJ(H.$K$8M>S=+<2W&4"9)]76B^WYFK-SMP2^5#H%K+SAOQH
MCB>`/R-7@R2BFD,/M?@10H8]BX#I>D-95W!]QD,2%I,<S%WPQWXI(.1B3HA+
M`$U5V2[7>`2#)\6J>2Q;W6`L,VDB-&>O(W\X3,&4\$6MAKXXRH)@:Z(O1B]T
MZ[Q_@Q/YZ\0\*1V;Y%FXS(2'WCO5E9;"0L'FKQRU"LN>UM2`:^"&>F9$\S'X
MB,2?4(RP!X3C=;N/I?[PZ3/V24I;-A(HVG:3]'9%NQ\@/!TU?%1+4NGF`-"3
MQ;&4_5#?V439A8B&+[N3@<[V-2%%V0[O2D=4>2!,^=B`$FGJH@!><:MK])S=
MQ-%#-\C0`-]M893^0K'&7<<3!#BRV^V:CB`BZI=Y?S\0D9AH?$)0A$A\W'4W
M5L`'FIT#G&>-GE9BE811V53OIN&-%%,/QC#U%7T[`/N"8>TZ5Z#&UNU(.:,X
M=0V-JOPZE/Y^AC[O\%[&U2Y,T$[2A*2@%&&6']<Q-_QA`(S(S`#^C0&4`^N?
M&9"S=':"C/%T[ON4B6CN>P@4?.[[&-/1S/<1BV;7%W@^,/,]7YB?T1GYOUH5
M97A]AX"BGT,`T/%-#*0XN[#<%BA+EGB_3-*G<'O+*MFXRCW;<)_1R3-,9Y%=
M!(K:%U>9@3.\"HN$%@MWT1!O]V6NBO]KZ*_\K;H4NKM4IG3XB_'1%R\>0/2&
MJMX</9A:<^S0'*8SD&VIBZ.J2U-WF]LOK;T>9!,@'G.6Y(6FW%OEY:%UPZAU
M8+Z)1>X2WT7)KK=-6-@GWE;SMQ;Q\IT]?3Y>@-*-P@"?<KG:D21[7&MZ,L\@
M\8;=QQ$=MS_?NG[3*E=*HGF>.R4E0)JMDAC>Y;0W]FKL0H$:L/U6[@8UN:J#
M&I+/K]J\U7XT'!KC30M[XSC-(Q8.3`;DJWA5.YP$FLM!4.D^,1RB,)`.O35G
M0#M_S/X2MN]@FL-!=;V]>0&<Y=.S7/P&\5*(B4&^U0R<QFRJ1:`8KHGKKN0^
MIUQOLUB>C8?=\>2.1":N[DC:#&]O@=;N4EAO[C0_EH_:7FK!Y[[5EB!*/,;&
M(0YGK:J!<5;.-+XO;NBH=E=C@SE=M_P5@G[S&G\T2OJ<0V'&@H0+=0VDU7\O
M$<`[W%T76,XVKUT$"F"_R'RR@8H)UT@C_O(B\RT/'H733G/7P;4\:!;Y^\+8
M51O[<V>LJL<RP4)DZ&R:L$TZU]C;*7?[QTQ@VB-31OB3+K[@>#+6,.;%9JA5
MBQS2(B0,>V>QA3\%!.H9.&-FGNV)-V[HOUXL=_[`RM_ND;&P](N09$!:7PE)
MYGX#;!F2KUT$(.D7680DKO%*V[!\O*[H(,DVE/FK&$!21CAB.U?WO>LF3TID
M8G]?Z$F-;"^FEN9.P70:?V?77`<VIY3D5%:5;S/[FYU=K0&5^!L?S^N8-\J<
MAM]B29-T[!<G3FAT@?";)H6N(->#0QV.O=V,N<E?ZI.NK$#/X^@?V-ZW0"L`
MM'Y_+X)6V+J`I?_FK]-22H1OD[O;!8P_K<SX;%%QGV>S1=<]R_/9JN:>Y_EL
M67,OE@9$>9[,#D@HFQ^04HC"<P,RFLW6CO<Y]E%G]4#QMR%F1S"6B/D1G"U(
MR@0&B-D1$9\O<^]9S/F"+`E/9TOA>X`Z6Y`V$VQAISF/YE?AE*<+X&)\01^<
M"Q'/CQ`B65@EBNC"B#B*Y_V()U$R;UN>\@5?XYG@"[+D@L[K5%`QW^:X%VRA
MT7(O`&+SL@C!T_F=BDC0>02)&%N!LR,2D2W(DN(OT<Z.R*)LWG(B%PNVC7B6
MS:\2P23S&HNB>"'"1%"QS^LT2J*%.!=!O36/Y"C#8Z+Y<)PL^%Q,TP5I8Y;.
M-\/N8Y[F\]:/14;G[1*#,`MSQ-D"DN,D6]I'FO.%.;)<S-LEAA0WOTIBNA*S
M(SA=0%`B\/<H9D=$=+X)>9_$-)J/#DE"TX6=IG0!R0DDY(6<G[.%2)<"I9W?
M1\KX`H)2CK?69D=`I)OWAC1B,Q0)2-CG?]W>W-[\/T:H<GT-"F5N9'-T<F5A
M;0UE;F1O8FH-,C4@,"!O8FH\/"]#;VYT96YT<R`R-B`P(%(O5'EP92]086=E
M+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR
M72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B
M8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X
M(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM
M86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3(V(#`@;V)J/#PO3&5N
M9W1H(#0Q-30O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<O5M;K]NX
M$7X_P/D/?"B*MO!Q15+7OC5IM@W0R[8]P`9%7VB9MK61):\N/G%^?6>&%]&G
MB5RDUF*1C6-1)&<X\\TW,_2;#X\//ST^1.NT2%B$_]&G?)W$YG_E\?&!TQ/.
M1,IX2M\(EN;KHA`YRR-X$D6"=?KQX0?6T%Q9G.!$29[C7ZS;/SX<'A]VO\&I
M\+_@BV@=QQ(66,<RD?"7+(2X?E[$"3XO9(;/\SR57YY0L*=,B@0VSR.69Q',
MBGO:_6]C?G(/8_]0\$FH-\^/#[_]3FU*4(%DS_`"*8LF=>KA`C0A<_8,"LK6
M6<*>R\>'7_U;Q)'[\VOV_./CPSN8Z^]W61'>]"M&:Y[R@M9\`FUR_/SR:GW\
MPW[0K&R;H6I&S8:6]5I_9-7QU+5G?=3-T+.J8<-!,PVCVF-5]DPU6W;2W:[M
MCJHI-6MWK!T[5NJZ'FO5ZW[-_@;_;IM]6S5[$*'7JBL/#.;\49<P([Q)4\(2
MW;UUD"7II(1"K.,HXNSY,TC^=.^EZ(#A):ONQ!XQJCO"SZAN_>D$\O=5VZ":
M%&O&XT9W]'E[1NUMF6X^7XYZTLJ@/PU5K4'OV[$?N@M\*.MQ"R.\AN&=;;NO
MQU(UJ.\5*\>N@\.J<3#H6=];U#3.)EF7U6H*[AVH-4H`8YQ:19H:M9;M\:B[
MLE(UZP>U!]V\'"HPL46..(J]1V7<[T4"R-%>T%6JK69;W51'MJN:JC^@W;]4
MPP%.O&]W`]MI79/?]$/;Z!?5'^#@U>D$CF%<J(/73U5=XXMJ8'7[`E92MOV`
MCXYMI]E.G=M.;<`P8,$2;0J&@D]NJP&L"WSN6V5/O^9)X$1>^%_=7;5IQ(HT
M<YJ5TI^R+))DPJKW#1-1)%=L)($1:-YR]FYRJW]>^D$?5^Q%LUJ-38F:'5Y:
M!FI&36U'0!QPD$ZK`9YLP$/ZME8#3K;7C39PUNFJ&6@P?@]>>`1'`C2TRRU@
M5D42.=GS:`*.6!K1#^;H]PJL"82#K0`*@`S@^X@15K#J7`T7!!,":(,COZ-_
M@';&FH3L1\#J"JS(OG,%W0?5LTT+=FH1?TL2P\==-;"CZO958Q2TA`:D=!K(
MQ.3C4MK3=P*;/?6JIL#2D+/87=K#_>O;=^+#"C9PJA4B:MOXH`3HT&Q5MP5S
M&(<.X&+"4/<^VD2[VX&2T/?81@\#^!X*7=9:-?"Y;MN/,.DB2D#WLV903.$Z
MX=8."%36&*0/Z@PQ`?X]5+M*;\&D:Y!S2QNU40;^94P:0TFO(;J"P&IK$`(^
M>HF'`V",ZC#&L+,"ZQA[AZ.@MRV\6;<GC/XTDZ(QVEC:`CH@P:TAQ($K9!9@
M`2?KJE0$<V#.`/-@M39*PNF?QOID.(D"TU[!EEO0#CC.$40&X#4JVI`Z]OK_
M`,H9),M3X42(<)Q%LE1:$9ZGN-ZC7WW4P\J&K`KB^@'"0`E65WTV$`7P_R4G
M!$C238]\[7C2`YTJ"%J6[=A85J5@_(]M9U&!6)EA!F#_@_.A)8X0S\W(+WCF
MY<^%E=_9+Q@J2*F)]RBV[]1VA$/:ZA("'UDC^>P!39-030VOM/6"?@LGVU7`
M==0P=-5F'(BX_CM*H@K^QRTXZ#.9-2#"1T.W]$\CA`!$1A@``11?6D(5PA-P
M(8I`%9:`']4`<B!&U^AGN+>J.>M^('\CLETY&P&K15`ZPN8)I?`\[=FW7;\B
MHR"Y)\$#9S&,<T^1#S32=NY+'*=W8"]@-?#-H=H?8,`2NN">'4?II(LT];I`
MXR8Q:O@(F[!RMR?<[MB`C>O)Y\G3?VG\G%X*G'S-GENP$3"8K0:1]10TV*YK
MCU=:?0&B=97T!`:X@!:RPA-(S$N<0>1&!V@)NW$8P>1I7\`#@=VSI@4M-&#D
M@1/<>V\"MN,V%[OT5(B[+Q.'.A`\\@`19TELM-"S[:51F%ZN&'@T4W7?HFT2
ML?DTH&N`X8+K$T&C:(<:"VC=?SG'`4`4+`>I\FZL$3D05I8XW\S16"'2>)(M
MC1V1<2$5]W[%2^^^&UC3;0?2-!GAY\^62M]_L2R0G2=\BMW<G2MZ*<'2IJHQ
M*H&SF=PF8'"(2ICJ]&LJ2+RW$`@.VNC2!#E[>!`^ZI9XFF,WCM0"4]N:$&B8
M+(Y9XJA3Q]I%/(F;1`[<B9M?ET;TIZH?C-%:]H4Z^8I!(,J]`$.EO]ON(V4C
M+6P3GEXS?Z<SR_X#/DMLD:C"(K0]BSUMYY%/AV7&+6V'[7IHU9\P2:?$;5OU
M974BE,6R#\GR*E9=1>:P$F)AN].8MYT)L2%G\=&B)U8`*VGW$-D\S?`6`$$U
MET7T(-()T::R0(J?40\N[DZA[+*^=XH.UIA%9AO?[N'%K)AI[LBY*(07,Q7.
MP;]W[/M[BLKO7='JWJ+B5M+B_Q1UGL2GB2?Q&2SG$]+$GN@[6Z@SYM57^P8R
ML5)!:`HJ,I2.->>J:QLD=`!1&TC)@,E/!;[KA,77^<AO>]VA#8<4\!*`Q6H)
M2TZE)^]%G$_Y5YS[`I<MC%`%2YLJ55BVW`#\`D7;M"U!W0IV?.]]RDCZC2Y;
M@(2@Z5<"/411X6T!["YW,?TC";JIVKNOG_YLDJ99</@B2J<`GKM"5*>QHFG/
M_D7U@WXQZ80Q>5]Y=570T"U<!:<W56EZ81$#YB[EBHI)!AFGK@B_@PUAUGE!
M*>Z]@3SS&UB<<A51("P<6,"DN6.;7^C=0.9;VYH`@0]6`PE[IAJ::3+@04]U
M-T`EW>R'`YAY!SGBT.#YD1T<J@$+3<`U@*VY"M.*2-T2YQOQ2>0)F-.<AP`%
MX@8\Z1J#02FJ'%REU,@.#&W<P;=C9]F9M6<`7)K'5H+9V!./.ZBN/[#RH"%)
M@>R$]("/SVT]'FE$W];5(I0KR5WR%*72)Q@PJ04C<DMWUDBT#IA,6W=EY*\4
M7#2@\Q%K(*;^=P*9/]$7D&;^@J\C0#/`=D/&<*I?Y,%WKZ+6I`A7H)DLR(:#
M)33A.P92)M[XDQP_HR:6C$!9X9=?%I9S&<C)>3(A6IHD8?@QA<W[1R">_%RB
M\O1*UC0H#<@\N8Y`*RR5JK.J:NJ"`<_?(.UO]-"%-0##2X)LZ-Y,-"XRO^=O
M;XO-\-PDSA;EN8ET22QP&V]<(BFLPO]P4=NJ-#07^9TIK+A^ZQ0ROJLVG?X7
M*OO/;_[\91X8#/G#>QIR?[\$[_<B+6NM">1"?J5LG?,XII6>,&,HKHEAJ)Q_
M&.7<WU&SN/B91,\2Z5="4LP+XZD3/UP"[?G4(0R*2S*H+05J_N&9U/S#Q%&?
M,05'!K!F;]T%B=6K:@G5E4R9_31V$#E[`R4EY&3M$1T@*,F8<4,'?F!&8>UF
M`<'CPG<%Q91TR]QR\FEO0?]NK]M]ITX'#,HHE#(4I:41%VHC8'EY-W9X04'[
M8AM0-VS!J$&90CF-(A%[<X6!^L,(`BBLZ3;:BM:T#^PC#X=Q$78?9[X]F$QM
M8NYZ"#O588\;BRRV58Q-IG*P_4*7=/L&-R0#6%4\$W]]U3M?^UM1_VR/VCWT
M";QKG=C,=[*<7NN&<IP:TQZKO"54,;49TVS*U$5AZ0^=%QY38+W4-R0Y;%F.
MKE$`A;,*"DN4TVNNY3)UU8*\PDVXJS8FAX#9J%&#H_5ZO_YB#K&$/GS;,4JF
MQ$`*5X.SG:TI>UFY]OZV4U5CB](HWBKLH\%Y=_L+ZQ66D0.I`%C4T;A`#3:$
MS8CKM\WK]O*.)<BH]GX\GJC*Z:<RD9)T[HAT,-&9YEE"85-S,LHFA26^U8Z=
M.-I^D#N`05L<A>@-6=/VF^N8,Z1$%KY5F//)M"7/?0<9_0T[/_ZBFZF'Z[HZ
MPEEVE^`*PZ"-02ORAB6*-(7P6UZX2`.Q(%!.5DP4.1&O*+)OAP`Y!J"G&KGU
M6U*6<\;09[$F@!D=98@+=<ADYKM_6,=S^R^X]5/J]NFSJD<5')L3Y@O,<LW>
M#Y@.4!<)0)>%70=JZ%+%=.4FU2MW@8+F#,*!YP'&GGIM8^<26DA\HI.+20M2
M2*>%UET;#'2!FOAB5QS@1&$U%I`(R8CJJ_[;''.^`0!HZKN;A=]U&KD"X>]-
M#_X[O&BS9/5?1M&B69'('=D4/+#13.1769&M<T*$!)(!<7ZX7%7"IPCZ<FA]
MS7./T68*JAO5U?J"5UHTUF'P_N&%S/9DK?/UY273[5K`).E"K2W]1R(`%NZ`
MI:;<>LJF_X+M--H8&&>GMQ75&:?[QR,&?801O,#@"J_X8%L!-ML\_=2.-9H)
M**RN\.Y+6WY<LS]!X#GC#2X8@37%H,F`>*;QTANBV!)ZB">..<7%F+L*H]E\
M99O8)0#.9L(0<]V==!)20Z.)WI9'S]I=NZOQ=A>-ML?=D7S(86M#KX+;OYU"
M[\>K8:[F2%BYS-4E(:=;;,$E-N?I820)2NHA@<3&]U@K>R,9;[T=P?*O&/0D
M)[V`>C"09U2W0I5U8`<NQ:(1EE*7JNLJ8OD4XK8$[$LH@ON.F,RGWFX4V>OG
MBNYC]\B-]EW[@OF1216,XWJ627L?![":S\I6R.V7$*S`U.D",Q'QE;GD#=B.
M*@RZ_'XNP(H:%@*.,XSNTC):SR(59UX$/#&?0#^S8'A=72>N>/]"&X`RS_)%
M09^G_G<&<9!`1,[OOW=TDZZ@'-5'[7N@=,D\!.I7A4=3/R.<!.RCS^#:REW:
MILM_YASIMLC0_X[8S!L-B?@?W4\[V)OOV=N__?7M(E9.Y2M33.>^JY"X6TMT
M$UK=_2=*L5]V6=H<YX%\(@KX5N+XEO\!#566":XKO%73_#@VYH:-J7]0M+[[
MI;@\_YDT(8KPJ'DJPL*!32`VE*M#,!_LK5(TQ0^7VABA^."L4+%/]LMYG1EF
M8V9=PG*%OW$G@QL+N6N(D2!K]@^]A[C4^0M&KRI_0?&,KE!WR*HK(M;FEVN4
M,O2VGH11J`44KD_7/\78XA)X"SFX7.OITMU_DR-B+_RKW@.J1<+D+"L@FZ9I
MI_?IIY&H-UB<!HBO#(#)T]D!X$FS,Q0<>/3,\QR(YMSS3(A\[GG*\]GGB8AF
MUX_IUN+7G\L;\PL^+S_%RZ\]_\FH(*$!//O"V6<SB`8)4.%R,?MK4BY?V\#\
M\3T5,9]]S@N9S`X0MP;((IX]X*>X2.<')$4Q>X1/663-_&L#\BB?WV3!^?P2
M/,)KRK,C.+\A*`=;N3&'Y-F-\P![G1>%0[(V:[%/`/GI#6DSD=S8:7[#+\!R
ML%4Q:SJ`'?.K"("?8GZ$D/S&*A(O[,V.B+&F-CLBB?G\V8I4S"/ID\A$>D.6
M'&]PS#N;F$$3\K:(KGS/C>!"S,LBX>#F=RJE2.8M2,8@[_R(1,XC^Y-,\3?]
MLR.R6,R?'/[.9GX$)/5R?I48N-D-"`/6,>^5<2SEO$[C1-Z`N3B-;WA4G,GY
M:/H4Y^D-GP,XOB%M$J7%_#X2GL7SIY^(+)X_ET1FQ8TYXOR&)2=)?FL?*;"N
M^1%9/L]@GI*\X#=6*8IX?HXT*FY84,J+XL8(@;^4GATABWP>'=($4Z/9$6ET
MPY)3B,?S.@4+NX%T:1'=#/K\A@5E'%0V/T+@KQ-G1T`J_'5;!XKU[L/CP^/#
M?P#RG`,R#0IE;F1S=')E86T-96YD;V)J#3(W(#`@;V)J/#PO0V]N=&5N=',@
M,C@@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I
M84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R
M8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B
M8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C
M4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B
M:@TR."`P(&]B:CP\+TQE;F=T:"`S.#,V+T9I;'1E<B]&;&%T941E8V]D93X^
M<W1R96%M#0IXG+U;67/DMA%^5Y7^`Y[B34H:DP!X.4^[]CIQE7-YY:PKE1<.
M!S,#FT-P>6@\_O7IQD5*&I'RK)BRO2N1(("OT<?7W?"[GZZO/EU?!:LXBTB`
M_^B?TE7$S1_%X?HJU&]"0F,2QOH))1%;91E-21K`FR!,2".NKSZ22L^5\`@G
MBM(4_R+-[OIJ?WVU_1-.A?^,'@0KSADLL.(L8O`7RRA]^#[C$;[/6(+OTS1F
MYR>DY#:A%"9)PX"D20"SXIZV+QOSR;WD_B4-!U#O[JZOOOPV7Q<@`D;NX`,M
M+#VI$T^,DF`IN3O@MN''B-P5UU>W`"J.$W)WO+YZ\W:SD9U455Z6IQMR%$16
MG:@VI%-D(^Y%J6JBNKUH2%[)0UZ2K1`;(JK?3@?1DJUJ2%N+0FYE0392="U\
M3HY[6>S)7N[VY8F([584G;P7_J.\$:3HFT94';ROA-33_Y'<_7Q]]1Y0_>M5
ML(<4L,-'!GO`$NJPTQ1_1NR%.AQ$4TC$3O+[7);YNA2D`E1UH^[E1@!J(@_X
M"Z`N5-LA'EGDQ8DT.8CMJTNW'4]M.S#;?O-?RH,%%LAB_OGS3^A<FC&G<G$6
M.K%S%D1&['>*Y&TK09B]UA?5-Z`<&Y'?JT8_`(5XH&Z'O/E%=/CF?=^H&E^"
M#I:M.(+F"*VU^QPT;"\;&)V3-B]!SPI5M7W9Y55'CJ!CI)6["A45'RR@;6D2
M.]2,9=[0,IA4HQ:_UJ*1HBKL]O'73K;"`)8(?-.W78-6N%<$'N"0HA/:%M=B
M!^/@W[=U(TM"@R!>D;^"#%4#B)SM:BFTJMP\F52+0/6=ET[;U[5JEI%$E#FS
MRP:/$W%K=6V7;[?@7#:P<8M.;]6>,@I'=HA?ZX66`9H:`LH[,S2W3@M0E25@
M+!J1@R3Q`X-N4HGP39EW'7B=.@<1J*V5YQ*R0-36_69T$$9FA7&'&HQ@*T5V
M?=Z`<@K0Z+TZ@O-M;@SF`==#O".-!@<&7LN"Z^1!D&V3PY_Z^R-*HI.%K$'@
MJXM09M,HT;0U2AI[U4_P1\3XK5(;\IU3Q`4<6I)&BSJT)/8Q-`V]1G,.;$,#
M_"AT4*L;T9J@9G1-5CN,(YN^@+@(6CYV0&:$5]0MBLC9ZHI\%/9#XRM:`:>.
MP^QLY&M1]A^ZO"$_?6_,1X#/$/DBUIQ$+HC2!'B*!1^Q9##G!L(];*T0X-41
M<PD(VY&[1IHPVCX:+M@<$@304GB@4)=/35^W&J[A&W;>-2CZQHMQ1>[0_IT<
M]CE\`8[^4(.T-<E80@",>^7FW`N`1I9!Y9M[P)OOP/^`R=K=.[+3[1O5`TX)
M`LG7LI3=25,KD`NYERU0"GRRZ1L4G-8$V4!@;'&^%J6$SP81._%9:9_7E"5D
M`'S:NO0H\"&=A58'_E+VA=(*R8/@>[V3?R,X_2B,`J^EZT8<$2F.R,M"[54Y
MAO4XT)_']PXF^0](EWS`@&IT!GT,6,4BV"&AL-8?>0_.0VJ]F]W$V-`?(P4E
MAXCV<R\+\13MR%!NR-\A)._U-Q\@6._)6^"GX##TD[>MS%?DZ[VL<JWX:P&*
M#V*!6-;LC'@60!^G;$`_D+F0QP9^D]=R`RYOURB-UQXAFKP3@2?^K9;,1K:U
M:C73ADB&$$#-T3YJ5?>E"?4NQ&F#-Q:D*CU0Q\)^W<J-S%'P$"*/"E#M=`ZS
MB`1B3^QXP@<)6%X'<+I&KOL.R:MV7[#1*C<Y%1F]U0S-\)E'T0#$]X##0&JA
ML=:B$EV3.X<Y8DF7<Y6),!KS^#/#Z#1+B*GCA93'/HPF^F>4Y#NI/A2:(;?D
M70^A!#S<(CB#;%&ZH,F=P1EF/F+RE')/%ZP:X&&?10WZL8/#UXK0`!.L>O`H
M)]+K^(I??1V2][\BX6A1.3Z<VDX<\"M1&<,"<UJ[R9#DPEQZU@7L(THBG_AD
ML8>KJPV:(/0%QJIM7VIF]`O$LQZ3:,#<D4\],M-.FF`'SO$@6QL*P;.('E@K
M/NV$K$RY`3`7I:PPZ='6YG_I1(N,ZT9_*D!8)F^W)`RK%)V9(8?HV^\6D43D
M>>(@!YI8E@B6OI$;.-$O,($!SE"(`XI@"Z#13Q1('TZ>,=CJ"PZY(3F(L$1U
M0#BC-X;JHQP@\^T+?/O#'[[1E0IPG3\(XT[;O:Q;DP0O@9I[@L@&@LBSU*K[
M4SW46<Q]CJDN)#P[W+460MUC:4A5X//`.)!-(^^Y0;TM5%GF:V6<8:L?M>@:
MP>\73S5=XP6]VV/,^5E)$!384`?3MTO%R8@ZEL@83SU+3+D]?4=9"_7:BR>!
M7SRC8'?(SWZ#%6]??2$^0DG9*!:FB3WKL6IJZWQUM&%*_T]PPS0>X0UYF@V9
MGRME#8D>>.$<'<W/Z-?!^_@?\U:VKQ^N69;ZS;U9(DA&P;)%0M`9)]F$#UZ#
MQ3:E^+@7%1*F$DAS97E1)XI]I4JUTSD4/BD@808&V;0W#XL<KE;DHV=KBFC@
M.QN)M5SC;\P968>T%CJ3;"0FG&K[U:M+-0%L#O8B9\;C9-'",6?!HO/3A>LX
M=*CC)"D;U7&LSGU7^<HBA-P2"Z80B%&+#O)7Y"=W@P*^U:2&?"LP!?G!ABK[
MZ]]D"60$\X"WQ5Z"`FI_^*$?/C$A6YU@$2E&`7&)R$2'`DZ0^,C$D]"`'EL"
M&HG]\09,!?*/C?5MQ[W0=0T4AC,Z+%OF9"W5R"[1@O)*U["Q"22K>U7>`\)2
M'>&#\_);*B33H7`3\L%Y)ZE%_L)CPCH5[-V?U@W1)++>Y\TA+S1%!?KY"+CM
M'YF,5]4UUGG`*YUJ0W2W;O(Z/^&J,.D2`O!5FS#F0]V2<BN`HV%;XE"7WF?*
MBK28DQ>8?3_PL<#=P>\B?\\K(C[U6+C"9B&0*OU9;R3C*L[#Z(<,[,$WNE(B
M42.T$)>0@:_>T,A6[QP76R2)#M-7\)%3#=V8#=G6P,""T):C_O%<2NEBW%;!
M@6*$,](_ETA"@E*+!G*E`R8IKCS3*$@LL>!:F2Q3IVF#06-JM51B%?*AMQ;S
MH;>6,M_(!>.36"[Z8-O1IB<F<F.+VKG9YHGV2(:L85H)CKX1^09<%Q@TY!U`
M$'X#\:Q/#WP=JO:-;E9J-WA4S0;5O;)68^IQP%A<'B<6\6BAKZ"$FDBXP\^L
M0>O>&>ZD1'?V!`2Z=]LHA;@V=+])#9(`[I276&X;C=<2V\!L]^;CWO@S+$V`
M#A1J8U)U4Y%'8:[(C^,2Q1(B"%UQ)<AB'\T8CVV>]429-3/40+#E=ZAUD!-F
MU(UMFHT.U96;;XC--U5S>FT8/,H\CF5S&`[>8I`8#8,A_F>N[&8+)X]*,;9?
MHRW$]6^<7KR^XTQHXO?YB!IK\\<>3)(%A.EIA^_UA1L8P!B-]0#ZS`"*99BI
M`2%ETS,$(;#3B0%9F-&I]RD%]CSQ/@FSR?<Q#2;7C\(XFWK/9^9GX;0`:)!.
M?A\&$Q+^9$249)``D?'=+*\<H#?/:W%*LM0H!UVQU-36(,#&R6,]_(Q%(NX7
MN0U7U/5VR1-=AR",:R2<GE]D.G[KLI@-9=&H6NK:">]=XU"YBT?@J)OJRU:=
MU@)"[T'HK@+VC73DT;>IP).KJL3Z,*:V6"55?8G-=MTS.P(!<&3KQ]6'U9\O
M@?2<Y<8H\O2Y0@2^I!&>!QCP[S]T'KWTT"]<!`_=+C)_Z+`&2NCL(C.'SCT1
MMPT!"%E);(MF_]R?.F#;-\BLGMZRLRGIO>/G+01D[!V9FS.^;Z2ONZQ;U=2N
M7:2:'<Q60**B6OBO44C0=1[F>LVBNI>-JC`!.4.^/Q,R\UU3.H3IS!7.0+>Q
MQJM3(63^!WT?YT8K[&-8&[G#$&6[Y_!)D3=KM3]ML/ZKVXI';`O;]B+V$)23
MP5$`T^G(+C>7IY#(0`@K?GD:P5Z`]OG@%7JX9TV`\^A2O\=Y^D(3N'01,`&W
MR*P)X!H7^CT>>7U(!H7@G-E;%*;.IUL!F!N+O*FL+]N(NE0GI[/G\A5-XYZK
MS5P`X[F#CGCF<9P_:.!7EQYT&+[TH"]<!`_:+C)_T+#&I0<=^@25CJZ*9.Z^
MA&OKP,3RL.Z;UG;!A+U/K&WX8?;I$KBA(P3C'M7<+@#Q[#%3YE$\)J/^XC8R
M)M!=.(AH?&7[R>/?I02ZI_(B);AT$5`"M\B$$@PP08RX%(KQ`<ZGSW^/CC!_
M5Y;:-):M,%4QG3);$K-7O\#*OSGE&UF<.>%+MX"%,;<'[N1,Z6NN`#%AA)(%
MYN807:5!Y/KB&.R^?)1:?:'[EK9?3O)171+LX-7E$$5L83E$43*60VC5FJXB
M%G(G!^\2U%!M?,4]Q+#HLBCC[(%.0[IJ4;(D21Q*71P;-TA?<P/PJ;]U[:ZI
M07B-N5W^X&K=]A[`H\*KK8C>Z*N&NAK@1XW44582BT2N>N*N)>'ULVZXI:&_
M7.(8,^Y!+G6,Z4B,8,)#'Y^Y:_RMKGZUV!\R=W*/^=.NS6>>I+\S3NGP?Q)P
MSYV!'^<UIH9P%(\J-5K'_$43K/\U8H>7ZA0F@WT':8#T/8SY_L?-V=;,"]`]
MFRW&L8=WED&Q(+B40;&`O31X7K@(!D^[R"R#PC4N9%!LN$T_NG00A:YO-?0-
M=0T?;T\_->76%:8A<=25Z0?7L,PU,5T@QE(M?%,W4G38@?0E?5U.OP#9LV</
M.N.@G3W[Q-27SLZ;3!P][L=)S'2YWH3\<0TQ#J>*5[<98Y/OP[D!-&.3!<9;
MED73`WB63>\Q#J8KB+=)D$YO,@W#&3&$TT7&VS`(9W#"$FQF#CI3JKP-&;:Y
M)D=PF&1Z1$1GSCR,:32STP0)R^2(E(8S6#(Z(P\:4&`)DR-"%DRO`I&"SXQ@
MV"^<',%UQC0U(H*`.STB!I<[/2*A?%JF-*7)S(@,SF[:V@*,WI,C0LP")D=0
MO#HQ.8+19-HD@3=,=R9N6<22F55B3J=/CB5TYFSA9-GT*CQ,IULDM["+&?_"
MF28&4R,XF_%R/.(S%@698CJSTR2>L3F>QG-HLSB=WD<4)'SZ]*,PX=/G$M%D
MNBUS&[%T1I,CGL[M(TKCF3GB-)T^ERB!X#`](LWXS!Q9-J-!<9!E,R/"+)H9
M0;&1,SF"8X=R<D04S&AR'`=T6J9Q$LQXNC@-YF)^%LYH4!*$V?1.$_!TT]:0
M0(!Y7M>!0+W_Z?KJ^NI_8G.XQ`T*96YD<W1R96%M#65N9&]B:@TR.2`P(&]B
M:CP\+T-O;G1E;G1S(#,P(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O
M4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q
M,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C
M-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q
M.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G
M94E=/CX^/@UE;F1O8FH-,S`@,"!O8FH\/"],96YG=&@@,SDT.2]&:6QT97(O
M1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]6UESX\81?E>5_L,\I38IB<9<.)(G
MKW?M.!4[CB7'?O`+"`Y)>$&`QB$N]]>G>RZ`$@6L)<*U55J)&,QT?_U-7S-\
M^\OUU>_75\$B3"0)\)_^+5Y(87YDN^LKJI]0PD)"0_T)(U&X2!(6DS@(2)((
M4JOKJY])J:>*A,1Y9!SC?Z3>7%]MKZ_6?\.9\-_@@V`A!(?Y%X)+#O_QA+'3
MYXF0^#SA$3Z/XY"?GY"1VX@R'I*8!B2.`I@595I_WIC?W4/F'S+:*_7V_OKJ
MBZ_3908(<'(/+VBL]*0.G1!^!#PF]SL4FU(:D?OL^NH6E(I@R?O#]=6;;TN2
MKE9YFU?E#6FWBKS-J[LL5V6F&O*V:_)2-0TYY$5!EHIT;5[DG]2*K*M:C][7
MU:K+\&U2K4E>KKJFK?.T(*K\=-S!%#@P*V"^MEF0GQ5)RS;/\GW:*G@_;4F3
M%JJ?_Z_D_K?KJ_>@VW\O@@!E@`"\9!'@$7,(B"`0!H&5JO,'5*FN=B0E6;5;
MYF7J5*I5H](ZVY*U4LT-V>4@;EN5H'D*^H%6-Z2NCFG1YO@X+5=DEY;=.LW:
MKL[+#:GSS=:I7C354/^5>E!%M<=9<"6'6%O-`P/J:V"($NIA$,!N#4,#*C?K
MH[:J^K@'35#\O&P50-!JS=1NOTV;O"$`S<#4R[QJ5;8MJZ+:'&^(:O8J@\^+
M(PPB::W2!M5;=ZIH]#395NWR#-`PD->J5(=T62C$NNIJ)%[3`>(SH)#$D0-!
MX@ZP(-"0&A!`U'13YUE7@/F,:KNT><+<?5K;WPU&6JUTOR^.^#=2?E/#</T1
M:(I<TG;]Z8YLJ@=5E]KFZ09V66XLONY@AG8+V!ZJ^L,-;(AV'@"BP`(0A*'P
M[H"&=C/LP92@)ZAN-*B!HV4',BZ59K/*E-XLH'.!2+`@"`GH"W_#K]'BTB*#
M"TLX]_MW0-R`&XG=QMJF#XHT("[:K0(6@X-RK$20`6#X:+#G;D#HK.@TS8%V
MY"M*[K):J1(_N#LVK=J!';8Y,/%P8GWMK)IJ!SLX/<YB)(AI1F,6\,1K'#HC
M@=Q5O:]J%"8E6_`P0)VZZC;;?0<>U2EQ@X;YY_T=&>Y.).<J;S*DX1'W)6P^
M`D14>F]^`4_]^WILO@,7CQ9_2&&S@[_#=_9`B[SJ&MCB,&0&!.(D\0A$O<W#
MV```,L/23@T03BNP(-]J%DJTUPI\T`J>P-YJMOFZ'3@7[770S645&!78O7KL
MBO'A8^"6`*WFV%)MNE+/J]0'#=\<`,3,`<"D]`#$B65]5A5%ND0*8)Q"?U2J
M6GL2]-;P)U%K,%^K/X*0MB\4D"6'OP>J+LC=MNH*=#P0Y4ZW"P1C<,(`5[/N
MT)7;U]1*9PE'B')'`*`&/,!GS@%`*-VN#\-^#\C8YBTN:8'-;GT4@7"DTEWC
M<Y-SF<SBQ;*&([(*(^N;7YD(+CY_V,]_<:#!O<;,)XC)("1*V2>(58VN$XB4
MKAY2@%.[2\<O':GP@_<Z?]&A\!SRQL&8X6@=X&E78P14)G.T>08$DJ=YY1S\
MHB8K!%V#(/$$`P/:5"!31=$559-G1$&F"AOC!OW*-D=_\TVARI*\7Y#OU>J0
M0^;\PW;Q;H'"?Z>310R+-XC84F48*'X-9)###ZJ5^PKV8UH>+ZV5#!*OE@GM
M0$C&+KX,/''+)-&"1>B@/VGT:"PL:QKRU397:Z)IT.9K0/$_:_BIZAL#AD$C
M!1`_J@S*"G`D_X/'<Y@Z2GSF*\*^!$KP=Y3U!R`>Q(K>]5O[.$E[PST9.23Z
MTA5+I[-<6B$!*:S3:$8K"TBU!L"!93UP82R<D0];B$.7)S+X(;=VPK!4,PQ[
M<WOQE41PHB64\LX!LM@F&]6AA!W?=$LP?9[60(MWQW0%A/X6?9:I%"$*(5=^
MNOL2N7(S"XLC7[IPRGL6PZ:W?CI;F`)4L_;!["^R4[LE.&_@)/KH9976*_QC
M!6XL:ZL:`N([4ZAJKYN"!U[#P!8R0#T/%7J>(]3`#?FN=@X/,J'&A/\5QO\G
M>^/[ZJ'2U>P-L7+-`DD8>$CB/D<(,%PB)+YV1U2&*5YOS!-AR9=?W*&HA4IM
M\7N^QM4)%6QM8BO=_),M`UT)K]L`>5975;U)R[S9-?-00OC***2B9ZYSP@<H
M@B!B*6VM)9H4$-E#+9ICM8UI4HJ5C'?14!WD)01X5%A7M*M=#M*WF&6"?X8:
M-3.EK/9P:>MP&%92-G#K]P>(01FL8%TL2N8`@@T*)C[(E@T.QBQ]*V>7EE![
MFQH<Q#RUK597P2_XR+WRPK0Q&94ZC'V1$_7FDXQ:]_IE8?T+8/\U=D]FR/Y"
MR7QLC'KD@L0ZOWM#(<>?'?9E]MT2S)FW1]T.*%NH#B"5@_K3M(S0&:0#T4WC
M9Y?6'U2K&RE819E"-"5EY]R3=C'(I`=(`]'AYIL228E=B!__\FX.VH3<UQA2
M#+M!WGW8BM$FI8^J1),AI@UZN8_'`DC5N!Z@Z3_H/I<?9#7&.EJUVO$,VT,W
MIJ,`G_J6PU(5.:P(NPQK-.R^-H#+'#A07P(PT2=(L92NWV"Z@B8-'N;F\&NF
MJZJO(69L,;D[J)X5)E=^!U'#Y,LV=NC2V5:.SV6)&D4L"G1;#%P-MEP!'.R0
MS8%`X'O$D>P]*0^YIX+QFWF1M[8\!C740UITN@O3!QBR!R888^LRJ6QK;(3"
M:-W>\_M@FX,//O1-"%.[[U(`:%UEVM25Q=UDR*84PCEG`$#&/@D:Y$")T]\Z
MQ=SL!<-NH\D,Y@#:.7'FS?ZH3(:*,R8&W47K!$PLKR`O,DU?V,MU<31')?NN
MV.OG^W3O`;DX'@)>^'/P$$P.\8BP,^".";@MEI"R;E]6CSB/.P)SXK,AP,&#
M>,U!X-"EQXPF_2E/F-CCC:*J/IC#J&<[9VG30+(#7M;X>]BLH*5*'ZKZQ6WM
MD::1%-$KFT;1."#<),<)7[!$Q(8RNG(Y6<R\^^,W^.X!%_X7_,860`06P4\L
M,ON_BNNKNXO(!XFKDP\[G(9G;[))R00_D2R>0;+$2_9<=7U6L&0HF)P!,CF$
MC%(6]O4X\TV7.YN\3LHK3X"DP4N1'.-XT$/Y\L[EV`ZBP>O;KB.YL4A\>26C
MO@=/$]&?/-48!>JFP\0WU:6S=BE],\B7$Z8/OU.UJ1B5.W/Z)\:6^\%!@\G_
M3$6E3&T-P]Y_W$,2TJ#/,F=3IL+:SM(Q$U'HJX)`#@IKJ_F9HS),Y@Z0Z[IV
M@$T2F_[@@"`D&Y/-/=47SQ,@J<*#G%J?'3?=#B*&OFR08CI5%-6A^?O%>80!
MPJD["TN%#&<\'(#Y`S;K_)S36>=GT6OCX/C\F$[..C]_;GZ]>"2QCQH0KB?N
M9]!7A6"`X!`+<0![9@!GB1P=P)@<GX&R@(T."!BXZI$!"5:%(\]C%HP^CR""
MCCV'^C,<>RXGYA=T'`$>)*/O@_KC$`=1_.SSWZT($8$DBXLS_`%JC73SB4ZM
M\08;5-RA2SG"Z#%57[$(5+1ND5MJTBV=RC]Q=QCT8(U(L/.+3,1+GOAV;&!2
M<+J(9&1KR&_JZJ"#GBT$FBU&3UT^@=-O;4*.*;KZ"'FXCJCP$`_8;0//Q11[
M/28M']U(RO"N$;:.])TRW2W8V$IU`RG]A;5EKG,F`FKMY@3\QTO6>M;'4.D7
M>QJAD-XB1%K(<[YK@GL\YI_)O9<N`MQSBTQR#]=`A,XN,FX-'OM6'HT2R[TP
M<OV+?^M[01N?=#W-IDQIZ/(SVW[R[?^3BUQ+?QL".8K\],D.SH(-ODH7D?WK
M9VK>5^H;NI9=$-K<-%B$,9/N>HC7Q+5I=*<;[VQDYKRGKX.K^H*R<2:\<./=
MBE<M$@\0H-)R%P^@(UL+X84Z<`78.;;W??)Z97HXKDFKRG19(!2=:5VD=3FX
MWZG;__IFY]'?];RT$:7K.K*@/](3L:OGL/\'K@M\I2>8,L0=9-/GJX.S'FA*
MU.<\$(?PZ&0]ZX$8)M$OBWZ<LL_T0"]=!#V07632`^$:+XP'G/K&F0R\,2'S
ML(VSMUU>K#2K-BX0GKUJO33WJG3X:_1]Y#/]*CV/'I;IL/B0VQLZ!?*%0%"L
M=VFFNA;OV=ICNMP>05Q6;9;X8^E$]F=8[HH`R+;+'5/K=*]%0HE;E9<0)Y_Q
MC%,"/<=43(6=1&>92J,`200I[Q^G*I/Q9U+UQ:L`5]TJDUS%11"C\ZM,6*T_
M.6>!L,Y3AMRN!^ZDJ/+6%/+5P?(-0BA>$B]R<WIUOG\Q[`.89&]X&SY+]ZD[
M0[E!J@,A=_C`'3!DOB.[S?=G3LU?J[<_,>?X)0ZCMPB$/2C6U\Y!\-^JO&Q!
MWQ+$ML?Y[EP[JRXI$H,@YF2:C)8O7R5B`\T9C[S%J0LUPZ--?4?_HFKRF/T)
M:N*N[-6$:2)G8.&^ZV&2(22<-ZXN)=R-C]Y30KWP.)&S3'`?7YJ:_@X#3>PM
M-;:0DML,%K>%OUIVJ.IBI:\[]]_=.;A[\-7>GDVBAJ:5!HGJ):45(*H3=SYS
M"GX"BA34I_7NSE.U-O?7E_T=4X67.[2%_37O0?+^V&]=VH:!KX!#6X7`?HO=
M?:33KJ<JAX?\NPJ*83Q.5N`D2VR%8C7;VJ]:H<R0EF8?ME6QPN,JK$$J[3@K
M`IY3?]MA"^]]4&IOH^U.4QN/:U%A<U/GZ3V65VJLS]KL?NN_3T*]1[VO_$G:
MS>G1H<(84RMMH6J_K^JV*\W9NNX08S]8]P'\=>ZSMR^&]W,'-R_V56,N.9T4
M;I?6/7(U)Q-]QB<2]\T4R[63:_7N*@5$N,W1>9;CD_/%SY'LV1PHCKUH9W.@
MQ#3+:/0'3\;P>Y6NYC*IWALJ'W<\(?$;Z:3=XE=;QIX#G^CH`):(\0$\B<9%
MD%AKC0T(@W!<2/`_XTO$0?Q\P]#`,*$F#2@=GX)2*D>[JK>PAIA`F]-DM/-[
M2P43X[J"%'Q"TI"&$ZM$$RWJ6QJS*3P23&I'J1/HLF)L!.5\8@1D3Z.]Y%O&
M>3)!8<&"T7[S+9-,3N@2,C:.*21]<F)$3,6$'`D+)G9;P()Q2:'VYN,,XE,G
M&+><\_$3BELNN)Q818KQ4X1;'K()V_($(!L=(8(X'$=,P*8<WY6"<3:.J>!\
MPLD)(29VE)`\FI`T#"?VG(C"*6WC,)J0(XG8N/5E$+%QNT@:11-SL'B"R1**
ME(DY1"PGYI!Q.!%\PCB96"5*V,0<<3+!()DDT?B(,$CXQ`@H0\:]0\CQ.^6C
M(X"$XTP.(1J/8QJ&P82G@WI@8C>$,9U@4)C0>%S2**#)^&Z(*!TYYX3TZ/TO
MUU?75_\'N-KEK`T*96YD<W1R96%M#65N9&]B:@TS,2`P(&]B:CP\+T-O;G1E
M;G1S(#,R(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O
M365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E
M<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2
M+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO
M4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE
M;F1O8FH-,S(@,"!O8FH\/"],96YG=&@@,SDY-R]&:6QT97(O1FQA=&5$96-O
M9&4^/G-T<F5A;0T*>)RU&]MRV\;U73/ZAWW*N!U)Q>YB%T#[Y#CNM#.=IDW<
M21[R`H)+$C8(T+B(9KZ^Y^P%@"1RH4#$>&S)P'+/_7[X_:^W-U]O;X('F0@2
MX!_]6_P@0O-/MK^]H?H-)4P2*O431J+@(4E83.(`W@3P3ZUN;WXAI;XK"@5>
M).(8?Y!Z>WNSN[W9_!FOPC^C!\%#&'(`\!!RP>$'3QA[^CX)!;Y/>(3OXUCR
M\Q<R<A\%+&0DI@&)HP!N19PVKSOSU;WD_4M&!Z*^_W1[\Y>_IZLL(9233_`!
MS2Q]J6,/9<`)'I-/>T2;42'(I^SVYCYX$$D`OQ]O;]Y]+'\_[17YOFOR4C4-
M^;FMTU9M3^1/Y-/GVYN/`.:_KT=&R\.###7(O/N-A<%<`)>HE5KNU%)+&7?$
M\EA88G_L:O*!DH_?#C70FE<E^?G4M&I/TJ)6Z?I$\H9LNC)KX55:D$U5DW:G
MR*&NUIU^2*H-V:?EB2C-MH:DY1I?MRHOF_Y\7JZ[IJUSN&*?UE]4VSR07Q39
MI8]J-EL],D[BT!(=Q,E`M8!7FFI'W%H]JJ(ZJ+7&&LCH-FG6=C4^(&6W7ZD:
MZ7.DY24ITGJKR-<N+=N\S>$9:LF65)?8"!^A(KA#ZROR%J[;J'JORK:J#:>:
MJE@OP@$9.0Z(A/4<8#0R'&AW5=.+L2%9M=^K.@/Y%"=RK.IB?<S7ZH&\7Z]S
M(_KB=(>2K!5)X6\#C*M!F"/.(`M^^NX'<L@/J@#+(0KXF;;(G4U=[;4:`(NJ
M>IN6>;/7U-MG2]`O@EX#9.SH#R6:FS;RYY+2^GAU1,+@"29TD`1Z3(V)^G90
M64O::B2$_'=@<TF`R25!0=3D,:USU9Y0&TMU_*/&!I>T.[)2K=;`P9R78#SG
MSM\D`[FAX%;Q`-N#JK7I(/+Y'AX\@KUE5=,2>`-$@-YD"BBIJVZ[TWJE-O"X
M;>[`*U6ENC.?+.$S19&N*G#/*$=-8P%VC2H'O#R`GAG5M`PY@=IF:'EWI.FR
M'4D;<NB*PR)<0*=ON,`'\PN#V+I=+;<4R`5:MG6>=05X'1!(;Y`H2\!_GQ:&
M3[L.N`*(9SNUSS-X"M:HOK5YH1K##KBKT3+-T#[=/0]+!*TXD8O&K#A*^I`5
MB2%FQ=PP[W]CE_L/U)M/*MN555%!D$9>9.DA;]&*]#GCFD#^%?SO4#7:H:%:
MH*U8)EI#N=-'MY6-=/B?Y]D`Q$,PU94"!5LD=,626>+#@/?$2\&=Y@#XP[7A
M\J2'FS``C#G#[P#L_MJ`0CXBD%(^^,,HE#8RY>"CT"EHOS>*OLCVNDKQJ75K
M=R#%K.BTP6M+'IN5-AX(MVH-YMZF=;:[`Z%6)M17&,J&5.131=(,74:1-SO0
M"Q`R*L$=.2XC8\B]G8^422]C_3NR("];A=&Q^NLBYLO$V\W7<W\47R&E]=TO
MZ*+WBSA9]G[!EKV?+BO?,%I6OF&XK'QY'"T:OGCD$CZH[H;B0W);?'P:PD[3
MQYWC+H>,!/Q.MDMKJ$%4#3G@FJQ.I*B.Z`XW>8N'MYCHF?0'?`2D\.BU5*MC
MVIUV8EWIT@<X_[FJ<Y,U8BS+NKJ&V@,RR)8T*8"?GQYXO!LV"5SXQG+#A6]F
MZ7=U'R:^D-1"KH?5UK9.UQTX[+7*=/5@*XIFA^D,X-_NTO89MXZ8YX"7KW,H
M6M(6,MY5URJ,$[\%(LCA'ZKO@$S_,:^Z!HJW[`O>!3$$*C@X"B4`',A,<%F"
M%;Q/`QE+1JRPCGZ?MME.YR$%5J*(6UX^JJ;%$M&D*+G3$<@Y,,[M`7E4"RU/
M*WN=TJ)2:+H'PM,#!+0L=64Z,EFE6`(<()NV#T?I-:9*NWR+D7$)7M`^JPN&
MH,>E['F!RJW)T$6V"\^D.B"Z76GJ[2>9^W<FVNL/C0*^#NA'5)BU`I*5T214
M>%>*#EP]Y@7DS!64\V6G=6>D@$MP(>BS'QZ/4EM7E2LHS[`!8?!:JP,F`F4%
M7"A!R4=&<&W<&*#CD`LU8N`?&;LZF'#,`T:#WD&$D0@-%QJR/I4IE#F@U6#1
M4/0U%>HF<@?\)IH&*"Z8?J83/ZSCD6.95N[U6>/8@1,%S0%+;S9=@9X#W<H"
M\F5QG]I),?0=6$1=:N>:3H@[EO*N5#,6K,UVE1?HM4$9P?FKVCJQON.&I7+S
M@-&+_-.Z"%#@4F4F"%CBP+T6X/T!BFO6V"MTC6Q"A*F^\<P2K)!]GS6D0Y\U
M<,Y/]Q%'!3^F^M_RIC5"M74P\N0"P]`+'!58"?ZLZB_X'EA6*WBKGG<I-<],
M'%'-N#[^11&;;B_!`M$W7ZD8?%XD71>N>N)ZU#=L_P!ZZ[S)\H-V0Q7(3A/S
MS)D_"5TO*UEX7\#91WWODVI'ATV`H]S+S<9"^*![)O/[W#Y&\'`P>3JTXP)K
M%BXP#;[^]'#MU`]2,T8-&N^N3B.VVI.H-_U1TYF[EN./*,T-FBW:,U3QZ,(P
M/\.PMNZTJ;(@$.28:J%BZG,`IP^&#%:`GS/-O7;<>W?7/2U_;<T\F(K6D;3M
M.V&@]SM4E@5$3>,^_4V,`]0]6"MH4+Z5*G+UJ)Y9HM5#['I^R]3!-B@?TZ+3
M9_J^C6ERYDU/BG9X.BM*L<F#HYH\PRB>Z^XN4`Z64U>I3;0@H*JV[LU(7[4$
M%^30!F6.#6'$AV3')!_M#DE.,TQ<&TCH@<A'Z_MU,I!B:Q@EIW4&\Z(6TOBF
MK?;`+$?DU;LT+.H)6+H?1,>LBMG@&T32\^J+PFE)K?/U0P5,6H'JHB(<=J<&
MNZ'D4*2E'F/H\(%](3.4@FJIQ>`"T74)(8=]>B]L(L/`P476N[NXN^O*-8Z4
M]I#2H=JML6T-%`$!^ZJV[6PD#\HW(]JU2433`GV"5A+,RS$!Q$:GIMBDLZU*
M][:[;QN<3:==J$U_H+K*ER*>N7P^8*)W=RP2MDN[`2JK(Q)0`%[71B!.>@26
MU5#PY`.E%,?E?4[G\E4(7%!3X+RE<?.9(;]X#R5YC1W*PGBJ!@PX755=:W*5
MK.Z@L-<*T#1JCXJ=:JGB3=>.@$(.8GL6`K7+PIV`*`D(U]<.G]=#?#@@.(_T
M`7;A0,A`+KX#G(7^&QA-I/<`90'W'@@@V_0=2%C@?0\^R(M!A`'.\UY.W"^H
MGP5AD'@_SP,_CUD0,3^#HOCB^Z^&!<#B,"8T.J->H'F7O3GNFAB7R*"HE:Z,
ME-%S37X#$-QZL4#NZ0-C-KLB+ZP%)TFH*U!QG@4R,80*7/42A$.[@O4]^A\@
M?:Z;?'.RGC@]IJ=AT(VCW`I'Y]C$>Y:9]PEY@?.DOG_WB-&^>5'7OX$*P5A/
MAM])O@F('/-*1VU;Z?41?%N;0&`KD+_-$=7%K!Z<H(/_,JU'>Y5RKC)',GFE
M,L\%`LKL@$PJ,\*8J<Q1-"P!Q7P81]ND_"=(F1LLOU[6W_W*"T8U5T%BZF7S
MCXKD:P45[";'&;Y-3,]+>`K_2Q(.DX&`\Q(.$F0^GR-ASEXKX9E`4,(6R+2$
M`09RZ"R0"0GW!38-PR%'H:'S5DVF.PFC?LIHD>3IW@$^'W4;M!+TFH$7C'3A
MO*0GZ+B<G_">D)>2?L/%^%%7^I^;^KSEZG"X^IQRRE`KFHS_N'+BEN?KE',N
M$%!.!V12.1$&,N@L$+]RRJ$S(GABB^%81':EX5^Z3MJ:GMT/_WX/.?+73MF6
MH%T1VZH2%R[`WT!)C.U1'-_H?HAU/T-G;)1_NU8GAF5SB5T[@GOLBH';BKHR
MQ4,31";24IS0R`9$*`C!2T)EJE<7+)6KO-+;/7I32;=RL+HU6RUPY`-](#@Z
M+%*-KYX/J#+%BJ%K3+UHS-HU0:Q[-@M6N!:TPO8)CA/;ZIC6+QN>;R2Y+^.9
MY'W'0V][V+TOLZ4VK%\`P5=$@<:TQV$RVYD/1(P(I1%UA/(DLOLK^ZI068?!
M44_S0%:J:9W2F<:3WK+,P+.V-2JIU<`=;C*A\-PNWPK8='FSU$T+SNQ/OE&0
M0U>##_T8J7]'`G_.:J5*5%R#R=D0,`7_XGQ>LAZ!\_XT".>F<S*(7NM/9P)!
M?VJ!3/M3@#$SG9-!WWI)PM%*:6AM[<.3F<+!3$?7I(,J!#=+];RY.EX1)[#X
M'JEIVYL-)!I1SF@\C)02VW$S2Z2CJ4]Z@&@Q6H``QN!VQ7C5NSZOOQ-(^EHL
M#LFS^BN`BIGZ*^QBR;3^S@4"^NN`3.HOPIBIOR(:AN!RV([5J8A>SH;0N-*K
M>&F_?SX2F=[OM9(]*[PIU"X)CP<#;N>%QX/9PK-[T:\0WDP@*#P+9%IX`&.N
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M.`=D0KZL;RJ)?I8/EF'3S/^D=5OJ4O3L%V]&)>FS;]<]^?J2KQ:<BSM^T<\A
M/YF/S@<B1QQB(NX=']>_VZK7]-5TQ:]'_;B,<`"_!1:Q<E\J2>LZ+;<*8^7+
M6>T;91BXW@N+AS&MX&Y,Z_8I/U?@6@G8'`KH#L1X131H0GL\%A,'A>QQ1"R/
MAMPDCFP;U.JCSDGT%X6N227'@=;25'(`,%`Y7K`.$[=5-@1.O29YZ9M@K\#B
MHO?D@V*=]9ZQ&7&>]<J1QWE"`IZXVL"L#+ZC\OF@VC._A+?W"?/.5^]IXA_`
MWK/$/^&]#P/J'<'>BXD9[+VD@1]$!)6]]T!,)\A,*//?0`,J_)RDE`H_'92Q
M0/A/<";\I%)PHA.8"AI-0)$LF*`E8E/\B)GT3OY!<T`U_*H3<#YQ@O+8N\!P
MSQA/)A24,^K=$;AG(1-^6IA@W,]3)IF<.!&!9/PG8A9,&1L+_)CR`#>=O2<H
M$WZ#Y(Q3/RV<<SD!!4H;O^2X8!.RY3$PQ'\BB:6?8V$03G@7P)/Y>1HR/N7C
M>#AA46'(HPE,A9RPN5#**6HC.>'O(;PSO_3#).)^N8##CB9<.HTG-!F$/X&'
MX+&8N`.(\<M%B#B9@"(3/G%'E$QH$`"))TXDV'KVQK@@B?S>`5>E_)A*,'Z_
M)DL(QGZ>2A%,>#HI@PEKD!&=T"`9TW@"4_!T?FN(`LHNZSHD/Q]_O;VYO?D_
M3I7&4PT*96YD<W1R96%M#65N9&]B:@TS,R`P(&]B:CP\+T-O;G1E;G1S(#,T
M(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O365D:6%"
M;WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E<V]U<F-E
M<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2+T9A8F,W
M(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO4')O8U-E
M=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE;F1O8FH-
M,S0@,"!O8FH\/"],96YG=&@@-#`T-B]&:6QT97(O1FQA=&5$96-O9&4^/G-T
M<F5A;0T*>)R]7%MSX[85?O>,_P,>.IFT8[LD`-[:ITVSG?:A;=IU+P]]H2A(
M8DJ16EZL.+^^W\&-M%<F,XZ8V9E8-D$`Y_:=[QQ`^>8_MS>?;V^"ASB+6$#_
M]*?T(9+F/\7Q]B;43T+&8Q;&^B^<Q=%#EO&4I0&>!$'$6G5[\V]6Z[D2&=%$
M49K2#];N;V\.MS>[W]!4]&_RA^!!2H$%'J2(!'Z(C/.7SS,9T?-,)/0\36-Q
M>4+.[N.,2\[2,&!I$F!6VM/NIXWY[!X*_Y"'HU#?/-[>_/:/^::`"@1[Q`M:
M67I2IYZ00Q,B98]'VG:8A@E[+.ACPL.0/9YO;[[N5-XUM=JR+J]4Q_)ZRXYY
M^S_5E_6>J1]4,?3ED^K^RV5`SWI5'.JRR"LS_JAJ=B[[`T;VJNXPDIV&ZL2^
M8J?\I%I6UMNAZ]MG/,>OI:H+I9<HFKK/B[[#`'9JFV.CEZ,GOV:/W]_>?(1P
M?[^>"O"24P&W&A!A:A1PS$OLI:RQ`1+2J*%55=Z73=T=RA-M\JFIGFB'W;#I
M^KSN2RB@J:^]5S'=;,8?9!#@\X_8Y/WUEXI?Z`6?M6+NH9G4^<:^T3)[QY@8
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M/`"0[3P,\='C]TN9`,I#FJ@58*\HAK9%1/>'MAGVAV;H]5M03KL*?&=)X"R<
M@`B0&L('_#$R6O@\Y&WO3)L71=-NL>'J68/1MF%UT^OL4V";#8!+>15U0X4,
MM$/Z(0&Z41$=&P#Q%3N6VVO+$XG,"[1N=$12^)6TV]CH")'\I<U]`.V8-2U#
MLE/M`_MSS?1?H+A18Y2JRWI0]'D-ZX)C6>O&D4O.018G9H?8!^Q*L4C^J[D%
MV=FPBTN.6M:[-@?E&(I^:-6="5%V;MK_:6'R$_V9;1IP%H1"61<M"!"]6`_'
M#>9$#-3JS`K0EN:(W_L6N=[3'RCC2;6K)*],Q#[:A3-5P$7F%%%VGB1=V"%$
M(?<N]W6Y`Q``V6E@AT'@-HC6"B"&41#OE1)!O[90EE'F`_NW>F%QA46/\`Y2
M0&^P`H'3Y9M*K:($2M4VUM/0>D,89XGC:F1FMH/+DCMXG2B=X9PH&NYHLZ\D
M]614_ZD!8=4\[O7+-/O<VQK^ZA[L!LNLH0.B8H;$9$'D,UHL;$8CR0G<\[8X
MZ/UMR;3-Z4CI_%2>D+!J;;N-HAVJ'XB.D>%_!7]BF[*J`'$/[]YY_!:C3#*_
M]:^O/GN,MU([.?GBU>>7X_Q7-RIM/HY<=,=!:*-;B,@R;43=(0?+0""3W?9#
M30;<-0ARIG;P2./40*W1$TN+?2-4GX:VH[#5R>SUV#MBY@?"PUW3;._@]JK=
M/[/_!E%0@,,,5=.5Q1K^G$I?@`;TT<1TR"V+4?TAKYL*^PA-"J\!.!7;*85-
MG@\E]GS,GZTSYP"GJLHW3:N)C=6-*4%S2T%.X`-@-G]JSHB+5M.`*:)UP^E$
M[U`8]2A;2R"9PU(H:5NB9EFI,&"I"#W&RY&J\]B"/,%.K2A>0<XHR+%)_*8S
MEX-[MW_2U3^^^A9:J9LG7:S2,%?-VHS(ND/>*H.'X*Z=VA-*/+`/57\@\D;*
MH7*V*$\`>9<.?3=@#16$GJ]GL1C1+;:4I*R]SX[8//%XX];D,\YZG3:Q#A_B
M>GMR[)Q*SF[8(166!(N6*<"P3V7_C-+=>A:A).0E\/^>S$[<#]YE*:UYRV;.
M%7219(E'^M`3?"%=_4V92!,RLO5&/3?U]N':P!=RZ?>Q"FPGR<^=?`96D]C5
M!IP'WIMD*J3'5?+_,67G78?HHO!^RMNR`;P>`4#-5L=8J_8@%.H5N?A@`.F/
M`*21)#@6YO\PU%N\.$W%AD>4ZWB.'%DS]T`BN1`NB@Q9L571&.'[MCD#*QT@
M6)2PI9QU>,N>/@YM<U*(LW_6!"Z4**J\W8,1VM<\9",\U!EAB:3SI`QYJA&;
MK#\WI%;,CJKK&82E>S_MF%,&CSVD^"Z6C,)X]`%*JV.>1"[1!-:GV`[(RB;E
M]!<IUPC<^10*5NW8UZ959P6TKILSP5+OP0C)B/I>XZPGU9RP*OG%&EH(,I];
M1MHH,]?G-,[=YJ[2?^'*2)`%?'9\:CB$=8]&9YRAAB`H$8A^K1'+<<*]3V<>
M#:5PA?YC0]$+&=C@&QH*49<_-:UWV@E[<+O'$^/*+WWU[K6AK/=#%=08H`I*
MTXII2;6"V>(H\OTK*GY<_XH+7P!/&^?ZU[[LQISNZY+SH6'XW;@Y]6<TD\2P
M#Z>VK%AXIW,)B!%4V+34++)-$JV$KJFV%^8L>]W@<<IQY&,-1?ASBD`+;Q41
MA=;\"+G=#@"[Q<ZM>!,(,T!7]J0!@]ZD!4N+*"KU6-_I.J,*\FQ'O_`"^BY[
M$3VI\IX2!'%,"A.CT36T,;;F@Q'41)39(O!1PRU$JANV'_(6WJG@T@='>K7,
MHUPOY9VX-%)BTSKA4.H#GMK\J#R2C:GC?<PCFY4R2AT9Y,F8QF*9V/3]3=E\
M*K3S=^R;`6F;*ME/!%,*I<OUJ1"+8OGS:\P9C(ND8WPA#\9H'_G*@<J12=O9
MV_$/(?OX`S5U._+?3\_@*4=$+O`*-J5XV-//"50_^S:)Z?][!=Y-Y\_9D5*:
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M]+K?,4:F=?T_-2`\CW2\TU0-0*_07>N>E-.KM^-#NX9]^@D0H;0SV8?43M`!
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M<U]EI#P=6V[<RF_*?1.H8`6?2LH,IA<(D:E1SNAXY0ZX>F=B6-6ZEX!J2K=C
M\>+I9?+5YM1Y7>O$G;?I9JTI75[S/9NN-_FFK"C=K:&',/1Z",:D'`7C51E[
MD<=(N5&.7.F+0-@@"5L\%Y4M&]RH[M"T^C!Y!78NLG!5=JZOSUA8'WO34KI$
M_3?DTWUCF04EUXOU2=F9TKMHCL9U*I4;?$,HZ1B!<J=9H:D&TWFF(YP7&&C@
MH&SZ,?^OX`LB&HN2;#QPU)<M2&R?H.B&0$EGIM/&@8[;2?^(.&MMHD+#&!1P
MD:'TC5,"%*.NCL"`62?7RE@?I1,-!JD<>Q?ZL]8@5.'MZ7_Y/%!UK5'0=-P\
M1UW#R#(8&PK9I*%@`]Z5`MJWM^T`RRG=_S:=%6!3W0_&\C0"/G%4;0%?N/[-
MQ,!O=NT[D'*B%B[BL9&>QC9+=S#4E[73EP6D5I))'HC7ZV-3^`OI)`9'&W6"
M=3R]A;8L#-IRU."!;H65NCJ]FUP<6L.#N?`-PFS<5LRY.SR=:Y7H_+3+"\JH
M5/E\61+#;J\9J)[RB+S7&]N>J?&JDYRB['YGB<W(`J;G/YAR#2T$OIJ.Y,BG
MN<M1NZ$NS'D#75!Q](T"NF.#/O@:NPGJR:8>>W_PL^D;$)I_;Z<9>PPO"LE)
M07HV1VQC_^+ZJ3\1F9?[^F>44"I/XU6)A3[@MZP[G1QM^`.J%_1O/(6']79P
M5TL#J?3/6W)!=V=QTI[=TMTV,W),*)<:",B[`]UU9.0,<-D#/6_:/3)\=US#
M8WGD*T"9IJ/'QO%XRJWOX[VLF\<,,XE3U^<!RQRJK696$.AWJ_B$>.NZ$=TT
M3^@+)4F&5*4G'F?0WP#!@%B(1`_@;PR(>)K-#I!<SL\@PBR>':#/Q.<&A%R&
MLP,"'LP.R'@XNX4T3(.YY\G"_'$XKP/4*[/ORV!>R2)(^-QS'B3IO()FGG\V
M4\`#82<DTB\]$(_>C!R\PVWCF(-*FANA<,8X>>WL/V,1ZD>Z5>[#!^[*8/9%
M1(5!JE>),WEYF3D0T.^ZQD,@Y*0)FKCC/5TWUAKTE*?(5&12>4DU=_?[=VWJ
MS?N*0>PW]652T3$NWFLXE(\_T7#O780,YU99-ARM\E[#A4GJNZN3[]2DTSMK
MKVC/I7:[82"7FT"7#;NTZ;<,*_&>V_1EPXKXW885V4\U[#L7T8:UJ_P$PV*5
M=QM6^LN(]'U'UZ`4TEZV]KTXPVV=<2WWU2U"72>"EFS++2C(6W9<V..;`0J2
M[_9XT8XH7=]K1GM/>=F,[UQ#6]$NLFQ%+/)N(XY??TJCL645N<OBTP9N1Y69
M*?#'KSXH^Q7,S<@=?0=@M"S+MT]Y71@GT.QS)&ON\M@$!"X[PH*8;[+_./9B
M7O2#U*3PB_,F,Z<3`5%#JSU327T=)J^97C++H.ZS>7YR'V;S!.A>!.$L0[F7
M"Q3E/@J#^27B().S`Y*0STN1FENB,VH(HUF>=!\&(+SS(T+DE_D1G$?SDH:"
MR_F-`E"2A54B'BS($O,%=80)53>S(U*>+:R2"3$_`NP^G?=.4+MLWK*<TS?!
M9T<('LW+PB47\SI%"1@OC(CI*XZS(U`K+,B2\F!AIQG=79P/1Q[-QZ-`W34O
MB^`B7EA%R'#><G0BM3`B@;CS(](TGM>8`'S-1Z4,Z%NULR-"L0!Q*&07(DJB
M6)[?J93Q0LS)*%Z05F+`PCX2ND\P.R)-Q+Q=9)8D\W-$0;K@R1'!P_P(GD8+
M<X@TF;=+)--L894H$PMSQ-E2>DJR=&%$FLF%$5F6S*-#C`2SD`5YL.#)L:!V
M]^P(A,-\[,=DW/D1<;C@07$2I@L[1>C/1T.<T?^'X*T1H#8?_W-[<WOS?W:V
MZ0(-"F5N9'-T<F5A;0UE;F1O8FH-,S4@,"!O8FH\/"]#;VYT96YT<R`S-B`P
M(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X
M6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\
M/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q
M.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;
M+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3,V
M(#`@;V)J/#PO3&5N9W1H(#,X-#`O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E
M86T-"GB<M5M+C^,V$KXWT/^!AR`[N["]$DF]DE,RF6220Q:;:2#!(A=:IFTF
MLNC1HWL\OWZK^)#D;EMJ>&P,,.VV*++>]545^_L_[N\^WM\%BSB+2(#_S*=T
M$7'[7[Z[OPO-DY#0F(2Q^8:2*%AD&4U)&L"3@`:DDO=WOY/2[)7P"#>*TA1_
MD&IS?[>]OUO_"[?"?X,O@@7G#`Y8<!8Q^,$R2H^?9SS"YQE+\'F:QNSTAI3,
MXY2RA*1A0-(D@%V1IO7KUGST#VGWD(8]4]\_W-_]^T>QS(T('N`%(RRSJ1=/
M2$$284H>0$!O_J0\^"=Y^.O^[AV\^M^K'!`')$O#+]^?C>P?<[-_L*!!`JSD
M]W?S8!&9ST]P[(,FS5;51):K&7F21)4-?"2-_H;<@EO.;R=-'H"=9\&-#P"C
MOMD!8'!)2F^Z/[CR%^Z?G+<WV#^*8V]O$6/&WM[\)FMY=)1]\[>?\,TG//87
M^$07$;S-X']XG:7=;\7]W8>K4,>RCKJ,+U(&[S]\-NX0H-#1&T25;XD`^_]!
M/LI"[W>R;"8I9]F0\C!*+B1]7'$1CV\:*"*:.<4%6<9]H&`Q*A%%\Y^V(G6N
M0"!JK7)2-V*])EM1DWHO<R4*]5FNR-^E?BKD:H-Q!.**)**2L$2OR5+I1N;;
M4A=Z<R"_??W##$+.Y\/._#XC'UO8H3F07)=-I8L9:>2G1A62Y%NY4W53P1K4
MR[XM]A<'IC&S#:GC/@SCI.,^R9QA?$WV8B\KTO.P("B10BQU)1I=*5DCLZ30
MN6A`$L#_+^U>-;*:D1\+>+X2WY*?*BG+&M[0,_*KKIHM>2N`6U7"L_])8'-&
M'D!HOTH0754`O[5A&O;ZH%O\KB1OM[#:GGT#,7"`"DX,-.NR!8.,;<4`>B,B
M;]2C:I!A5>9%NY)&TRM5Y_I1HJ)6O?/,B-KM*_C>_H+<Y%M1P1ZR4I]%HW2)
MUE'*)_-,?@(AJ')C;4,2>'75YDW]K7EJCNGWOHD`DM0+(`(LX03`P\3R#Z3J
M=F`%5@C'EKZ1I01&]I6L:V!O1M9MN1$%`5.7>5N(RJQH5%[/T"M4N=;53MC?
MD<NUK)`[*QL00`[['+$-Z\V)MV`_#CO]IP/]4\>_TX?3&OS62%76AB)!'@5X
M`?@P/%'EJ@6G!?',G)&@4G-9%&VA:P@?8.$")&A]&@QB)W+9@@Q$42_(.ZO\
MSJ+,JJ$$8"7&&SCS%C+@'C&%`1^8`*8.E$'9[I80"8!+IUA=;42IZMT1KQ<1
MEITGC`(B[RFC")H=98GY;+!<I?*M7H']"(A#Y48MP=&V2C3M[NJ"8F`>`TG%
M:9<R.,^<I+RA?I>K%7EKE"]J:;3YQP'"&_X"P4_6SIB,J\^N+KHX&9)*.=0C
M7G3F,Y+Z'62Q:J.`1+1F\$ZPWYL8%WJ2BR\H)B>R!+'(4&0_%6VNQ>Y@!-:+
M!D5W=<L*^(`L%J2=9451ZBSK[;8ZU+K>0QX#6P+:,-%#*I-7-RL(0#TQ0<1[
M)$(C1PQY&YJ(TUG4K#.G&=&8)LE[``UY9W`VF=A<>A2F[.);J#D,O)H!=7HM
M!PBQ3!B%N`DX"F*')TVM++`"Y+"N],[80*YW^T(BF`"&(6=HB(FU_-C*,I<+
M\CLZ$D1,M0>\0=80<3'LB-5*87@>;&U"K&BV3^)0]YN+LM0NQ]R`?Y8QSS\6
M^UX`-`B[/(I$]'P];2%TD9TXD$(*+#])K38E(DU@TCL`T7NPP*8M#?I87)UP
M0,$LBCO%<=HG0*R:/`H&JM_KNB$//9Z%M*71)G>UX6LI:F6SHK;K/^2(_%!!
M'PYU(W<SQS#D"UWM$4&BHLA[M=D"`JQTN]GNVV;PVI]!%+Q_^``_PIOHBV5=
M6.K]GX<>_NX+T2![P)UHL$VP%8_`)A#G\S(0:<,3@F`(#F"I6$PA[18=Y+IP
M8%G!JWM1-27B:4VV$B`]1%MO[L:TE[)0L+$]SS0HCJ1X"Q%0VC5*:.^S,7>-
M$JLX4_&(U2-8I=A@XGI$*&#"2-U15YNE!AFJI@;>).D-?JT*@2!&8Z:Q`&*K
M$?GC)G)Y()"(=JHQ*!A?D6MP`BR[!ICR\CPP(8,@ZK)DTF6G*/1NV[,(_,CV
M;U$=-(0@`VA==D*2:PGK&D_GICCDNH8`[6$C+%&5!X^#Y&9=XIPPG9W9TNH`
M6+NYE10,\K7Y)QV`X"AP('AIJQ=A3+TMQ1+*5+#C3E&%T2&ZR\*4<SL,%L`F
MU+'(T+$Y/(\,)@8N3?T,M?!?;6G1]I."8K&O(.2C+MI;!6^:A!W_05\+<^:R
MU[#ZZ;2VAK(%O'PG1=E50>CKP)BK`%<F\X+CU,/:84%^A/`@/PET_EF7M`R_
M6PB'IN;>[7&O%L2M]XW:`02!=^I&+!4V#2Y$C!-"B'C7#L'JUQN!LP%'FJN%
ML3E1@$T`CZ8;@H:`7V+@<]_OWUO:A5>P7C8"L.]J07ZV!>1Q&63JR9E)\4N]
M4EXDG2R7+N'G8M^)0=\$RV!WW=>$`SB6)E%7$QI'1K\5>T.^(Q;X;G-TV-VN
M+358A!$+DMFQ89Q&Y$"\$XL-!TXL'LV@>_E(.NX8M^"?!GUCK#<$YPR=)YKN
M.81HF3<V:YU)_4!Q4<Q\UP#+-&/BU6YF403(`-A<MX7)FWT-C%T2^%0<]U^.
M\>P@)-]"$$$'ZDR7VF5(EGE0Y^O@;T!91I\VBAM&NEX!T%Q@86HZ9DBSS6I@
M"R:+F*".(D)!2-=;A(@ZD$F_KMO4"-Q@$D"U%I?<0`!A&G>%28\-`X^1*OFH
M(*L#L4]0>ES[?$#4_OR,0BT1V.[UF_G5#TH&C(*FT[ZP=U!HT,$#M9F>%:C%
M)@(T:EV"#'K+;;0NB,(,OM-EW51#(.!5^`\#AHQ+7X[KSW7/(_!;S]*;J^^.
MAA'?MC<?<@O/LV21A93YL468I4E?EF!O%N,/5.6V]J`!P#G4#GS@8).0/K_B
MLS1+9RF`.WSP%9O%-)Q!B38#FM#9$)P7A^NK`(7D!@RWFFR%P;G]C>LF44"2
M#"H\LW&_@YDYPX($ZSU<0,\LB&G&1Q=$-!K?P=2_8PL8#=+1!93R>'1!2(/Q
M!0&EHS1D81J-/4\G#DC"<2'$03;Z?A2,2YD'23+VW/2O1I[3B><A3L;//?_H
MEC!&@(LP.6&C8+[G(VN,[]I000%!V0H+[#5.GOO#EQP#.N[/F8<+2EW<)B_<
M.@1[,^?$(/63!XUE1/NR+Y98%'8X.4ZYPT<>`PXF!U`-^HG.1?2<BP$4$&E'
MS\LXC\8-XKQ0<5F6O5)OEQZ":O.G3&L-3[E<:4$WYF%!W^X-?(?5*PV*"]5@
M*Q'3"D!QJ,!.M-U>0\Y9G<5Q3\YIG4$2@\T9OT!G-'JMSBX\Q.C,G?(*G<$I
M**23QTSH+.L'!SRS*L,!E>])2*R&"U5OH2!8%_*3,DV)OD&IV^::%-&,=A2-
MH]$O.R4>\IUVX85'B>.[4#D`'JRN(,!L*K&S8^02P"E>9=+$X$VY@8K(M1SK
MK=K;ZF'0D=180VBR%CF6TMA0%RLLUT\T6+Y8D?UH@$:#"3M[WAE_U[?[?-/X
M7,_(-]Y>=J:_O8C^LT`Z#COZ3SIK&J>7!MC4=9VFG?720]!9_2G3SHJG7!I@
MTZ2KE..^9<)1?+:`TF6CRE:Z.P][_*$]A%\#=F]JLM3-]N4=O-=0=DY["'`]
M92>UET#I!X*-3F'O*>TQ_DKM77J(T9X[95I[>`K*Z.0Q4]IC7?6;43N\@A!'
M(S?5QIYU'TIL`PJ'5F;\EHL5CAZM1_;A=WAY(3?1R<0;][6]Y&-;8KYMA#,!
M$[S4Z6[_%S,9=A.?-.`^GX2A"T.#68.[@N**RD)4&TGJ7$!^V8FRA9`)L`!Y
M7V*3QM"Z/!@NCN)K)S,W)=KOB\/92'=];H-^N-/?G.!)F/5C][RM&[V3IE7U
M%U3"IE4E/^5;40+'9C`_&/CEYEK.6F(+'(@WPR[WZTX5D(YU">Z=;W&*9=1>
MM_TK1@25/H@"VWBG8_04N^>\/`'_\^R>]G(:7^KE2<Q>Z^47'H)>[D]YA9?3
M^&*32.+NJEOFNIDX\,B<`Q2@MTIL[-VV'W[]KIN\DQ>S:W!DV\P'[+64#4*/
MMER!J3?"]NC=&TNEN]N,[N+3`8S>XK,U;.B'*5=GE?L:C?*@:V'3@+FA]J!Q
MK0$[F8%6>Q2@/(J2YEL?JES_;G`C;#`#Z)NS@]M;7CZ#Z&;#RM599MT,BR6#
M^YR^56V#[(O`<\85)P@Y6]Q`/>4).>F*<9I="I?BC+[2%2\]!%W1GS+MBGC*
MI7`)W_/MYG[@R%F6/?/%05;"VP*R`8=T-ND-K)N'/?L>-:Z?2G3"9_<-_2AF
MW6)]>]H"IK@[&XR#H./NM`6PBZO;.'IM=7OI(<8"HM=6MWC*I451'/75K;M^
MC5=18G]?RMT6,5CKV9P4#4&4RB75XVOF_;.!);C1[4')8@7)6E?#.Q:#<+:3
MS5:O7MX"_&)>>5\`)H,*T-^UPW`(R.I`EH7._UX"*@%J3YCM\<P%`15\CZ$;
M+X195AII6<&_[_FT5PC3SO?=IG@Z^V<]+.MX.FGC479Q41@'KRT*+SW$V'CP
MVJ(03[DXRO7CTXSW%XRX[Y1:2/R]TA_0%'-KM*C:#EX:S*`A_ADM'R7>EU>K
M%Y?0?[;P!Z/P])^.8[8I?W+?D3_)X1`?$P_-K2^\"=/GPYMH="@RSY+1B<6<
M!N'H2&'.@GATIC`'U#1^1`3`<71!'-+1L<@\"</Q'=(P&AU<S+.0CW.!?]49
MC*\(*1]G%-A@XW2&#)+X^`J.-PE&5T1T0AIA3./1.=8\3&@V<4K*V,2*C(U,
M@ZQML6Q<L71J)#>GE$;CO%!&V;A,*:?QQ(HH')\=SFE,@PE>DHD)YIRFE$UX
M8X97J\;=D87CO+"01>.G,*ATQC7'&)W0+8O!Y\970+$]+C&6\HG8PC(V/I&%
MZ,,F(AP/^81'<<J2<4HYBR=\CO-X@EL>Q<D$'7%"Q[7/DX2.ZX6G23*Q1Y9.
M6#($[`DZHC`=GV3/(YK&$VF!I>/3['G$<7PTNB+*)BP(8/+X3'P>)1#(QE>D
M63P>'>(`KY.,Y[A@PI(AP(3C,HW!^<=]'Z#FA#?$43AA07$<IA.4)F$VD=%3
MO(ES;@4`EW=_W-_=W_T?\M9RN0T*96YD<W1R96%M#65N9&]B:@TS-R`P(&]B
M:CP\+T-O;G1E;G1S(#,X(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O
M4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q
M,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C
M-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q
M.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G
M94E=/CX^/@UE;F1O8FH-,S@@,"!O8FH\/"],96YG=&@@-#@Q.2]&:6QT97(O
M1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]7%N3VS:6?N^J_@]X<.UXI]1:XL;+
MY,FQG=V9RF0R[LYD:BLO%`5)W%"DS$O+RJ_?<P`"H/I"37F$5,JQ+(($SNT[
M5^K;?][>?+Z]B99Q)DF$_^E/Z5(*\[]B?WM#]15*6$QHK+]AA"?++&,I22.X
M$G%.6G5[\S.I];,2(?%!,DWQ+])N;V]VMS>;/^*C\+_)%]%2"`X;+`67'/[B
M&6/GUS,A\7K&$[R>IC%_^8&,W,4)HPE):432)(*GXIDV_]J:S_9BY"XRZHGZ
M]N'VYK^^RU=%0B@G#W"#9I9^J&4/9<B)E#SL\=A,`E,>BMN;MY]4I_Z3//S?
M[<U'>,K?[:V?_AMO/>*^?X%/;"GQ=@E_P?T\]?^L;F_NKW)`GOD#9LF21B#-
MA]]N;^ZB)942OH?#O,W;8D?R>DT^J$=5-8>]JGOR/C_DJ[(J^U)UI-F0]TW=
M#55?UEORZ3\^D'^H>MVTW44B>?:$2/ZU5,87Q!#140PT2ID6`Q#)0?2&R%^8
MB+[F#_FN:4GSJ%J2D[4J\K5:D*,BN_Q1D6XX'"J%[%)KT@PM*>%36^>59E$Q
MY>"Q['=DTQ1#!TN[OLU[M2T+N&$]P+].I&BJ*E\U\'T)C#;+*Y6OD=]G3+X.
MN[)46&YQ,'G+K10_([>ZH@2JR@T<L6FW>5W^-AZL&U!7.O+7IBN:([GO@1#R
M4UT"@[JR/RU(OU/DT]!U95Z3=\BN_0G5YQX?6*AN01Y^^!OY^Y`#7_2%[\N-
M(K]$,GJ`&W]0<'M;@2YV\!752OEMV5R;`4D<.0YD;"FT[H!5O+T+P>HX<:QF
MF6-U%H_6]Z"*75T6J#2J`R4")FE^_'3_#GFP0&X?557AW\W0FR5KK6'(GGU>
M#YN\Z(<65:55E1'4KCQTY+',M5JJ+T4U="`CDF];I16VTS>_I'4_-M4F#Z)S
M,AH9$<G4,R+"SYH1B$/-OJS!*LC'H6T.:G'<E:!OA[9Y+-?`EZHY7OM@C$?N
M9&%U@7$QX0'E$U5(#`>*INN?"!1!I-"&A?+Z:][VZE<T"6M/R"LTN9^6]TOR
M\T[5(-/]JJQ!0[0TSU"IZ_/-!HTNA'31]QG*6)IXVJ(1?ZD@(ZAT?:<AM!C:
M%OY=G0R8Y@<0\Y=R#X`"7P&?_')R;-I?D1M`[*BO38NHFA=MTW6:`=NJ62G2
MU`#3CSE<-.B"5@*/W;;YO@/X;<G0+0DB30@.H&\=]3OV'HB/D+H!6VN.F@HX
M.`#I?I\#\(-:%VUY0`/$`Z.\]CG0.4%@;Z7@<?_TU4>/7SFZB"#ZR\S9M9O\
MJ@VR6=ZD23;RAE,Q!DE?"^PS.T%P9W>Z@BW/;20G)#'N;%G&L7@5UA=@OW79
M-\>F6)"?2W"@=0>2OK8\&1S,'N[MU9^.PI39OZDL,X8$KCD5S(A0+E-&1Q&&
M"`-2OU50Y(=XU&X$X)!$/N#BC,^H"T2<Y6/9C=#P#C`0/NF`R<'_]]^_7T"(
M1KY]^+0PP`):!>%ET<,1.Z5#^VD$9[R"^G)0+4"K0D3-6Y7K$!_#TG]#'^?,
MGTGK'$046^H%M=B(O@U@&@CJ`!!]$H*(O5$M?LXM0NY+`/U5"9R".]9#T0.B
M_SP&Y.@GK.>[-AD"U<71$<7,T<%%--(!4B!@TH4B-(.<^JDWFI)VYI5"L#RR
M:2FEDZ,F<O3'Z#-'!HZ,[>!T+;`5`HB]:@ODL*I_.^W=.M#(/48H==/G*_#1
MZ*O>4[+#[XR.=?N%I@<?/GE,!WK]=+=:#;W>#4+;H<J[("XYR:B3EP=ISFS(
M:>@#!4+!Y577@!IU5HL:$UE-A69B9DN7-2F@QG*(##UD?+^AEQ^Y\_'+`0Q1
MV_#]J>O5?AD"DI.$!H7D1)ILZ0[Q*Z:6DS3A(R?_7)._#*`3+(K$@GPX0>9:
M7%V@$"?;@P1.VX"==B>@.,U2C]C9F+=]5T$,NLX)9O\MJ`M$V8VN$4S4Q69;
M!I%0R89ZK5IBTIHP7)+)[\4EF=(SQ8`X<N022Z/DG$N:%6L"+#KD)XT1:?1+
M)"0:SQNZ!%P-8?X\<2*,O0A%;,ZV+ZM*N\2FQ4S)9`N=:A]+[7TAV<8O<SAT
M#T!E#IJ2\2[PMB!60`OK;]'FD3SPW3N$L[%FU!\;<@(_3,#CELV:;-IFKS5A
M=0)_W0UX6[<#']P%2LS@=A=Y&#_P-I#B16ZOP'HGID3%TGLW*N-SM4.P!@EW
M?5/\NH!=$(LQK0*F\RA:P!_+_,>\&D!!\YZ\X6#E*"YSR>2+@5@&GOEWXAF/
M)DRC2>825!';Z,4R;>3($6!-JRBR!1P??$E6"EFW4Q7B71!MC;C'$U<D8F*,
M6C!9;HY&).^;_2&O3V0_0/QA_*XR91(T+XB%FU55;O/>P,YF:"$^V6%0O2_K
M<C_LT=[HDL*5JKIZL(C0.)(25K`BE6XGK'TG'N?2S,9Z)01QZO-0@I*C-])A
MJJ^NH*J#E?0['0?]H2-MN=W!]\"U`!*.T]B5P"(V*10Q'YAZ0)P:,'E473\6
M/4^@BMJKKMO\6!M4Q3N-@F`\1MJ\1^PV01R64%ICY/A80R=6V3"/4"TXI'V.
M<?LS+Q""`W'FQ,6\N'2$JK.AL<QN#V$L#]P.:#)X#92>SBQ:M1V0*BT[B+U6
M>8=:;_S.Z&[0@9T5UJP_@J`78K8/JE#[%=Q@XC9DU21H@8.$(%\R5RF<%,13
M8=M1L/G:&*WZTL-G?2P(LE#";3-L=_[8G"[PZ+$F)E^ORUZ[YF=QNZ/)E9)M
MFE+N#TU7VCB^R+L=L*[.*]/W"H)Q,7?9<#1IOL0QGV21NV9`D(4<."\K'5@8
M+86O'+)AT?Z9&*4AWZ+C".#)0C+^FEU!S-(-.7!GM!;/+C2V$!R@-CF-J'#N
MF\4V,L-#O&$R6D3@H(U,P'?G)WTF3-%62M46\[4K0A`W;J$>-"<PH3746F\U
M0H.I=3S5((D.@V5LD23)\MH)6@P8;4G^RHK<?'D5(W%;7\E<%"X$'3'UA9[;
M@ORO`O1?D"=]MQ#9J8S#9J=2"-OAYHR;#K>F^=JL3C.W%Z)7(GU=!3\CJY^P
M^?HY<#PY`A#K\$-&T8@?NB`(Y/]K!<'N`"C2M,:WH.%]&'I8LT4_4CL00,=2
M:_>(2_Y<=WW9#[T*XB`D<VG;)/&666:[9/M#6W8ZWWJBNW^;$H8(_^YPJ$H@
M[=YW4SZ-7'BY:F@J/)@A0*``<(C7S!74)U?;2VUU*`3YU(?I7KR"IZ-XIXX-
MY8&5XZ9JMN7HU;8*!*5\V0E)TM^ML>4`4CT9H-0$/>^Q:6('$W0<P55"S-"J
MHMG6&FH!/7$L0;6N\QB``R+SO43!?;DXMO,J*D?*-T.]A?`-:>O+PG2T]TVE
M"AT5K4IDRBE(N4TD/"B@"1G[+,A7;YE(A"^WY?6`#41P7CQ8Q2U-W%D"5]P@
M5[$[H=W[8JW@Y]DI!D&HB.2X@Z`>@/:(S6X#6MVPZLIUB6S!$8JKYUK2LV,L
MI?S"&+_Z-A`(3C2`1IDON(IH1$$C</+#]]>O240O$"E"E#Y>5"T]^'/]\@>?
MJ!<3S'=LISVH)[7<HFD@ZC;>!"]7D(W583H5@KN<,$X\Y+%LC.">E)(1N^&(
M]H!F\*&>#/J87+!\UL)8`+2K,8<&KZ<K8;K(N8.<W^97AZ$'SP`;UKHZJ=L6
MD\Y&"/*9RPFI3PGC4=='H+<])LAY?M)E]'Z'`8[E3"@09''JSA=X0B@YYP2?
MS#':Z,<5U$&$J`4J!]S;Y>#BVUS/(3I@0(ALVFJ-3MRIKDZJ#U4#B66AVA[[
MO0?0'SL0%D*TD<MV9>QD*R(KW&G\8KJ'T^X(TH%U"#CW/O]5D;8Y06Y^TH=M
M0:TQ3,,\#_5R3!#UXE#UVM31$[I>>\:YLS#H944`!+`,P8BHU85/71?#BD$`
MP?+4#S[[.HZ,V"C8%2!1C1U]!Z(X>P4G17GJ9JM564"NQDQ`(>P6GX>RG=8`
MP\A2B-21$+A$*Z?,HE+X#!T[8%-I_J$[K\RLU+:L-0J/^49_O/H83)R)WXD1
M<99.&9%*QP@91R,C=*\LK\U$,09R8;IB/*$^UDPFP6;B*U"Z*&PK@PZ.='8-
MAX2\$D<K'8P695L,^Z[',K*NRA6`N[ZFAL->./)GGX??[56[5>UYO2[O8)F#
M\:N//(G8D1Y6UHF,IDS&H$['DE[10TC5]>RI?P=`B#&&FE1-42H(126"9G=0
MA4FE,9XP2/1*+=&X)@MBF#KWU=C6MGU?O`#1%WP[''29'M4(,E*R*;_X(DL(
MXEVWFT:^L2(XE];1MOO.JIZ+FH+DQYPF0?-C[-N.BB5\`9W:!LKSBOA1/8WM
MD1ME_3RV?R'0QE0RA,PD<,E2$C"=Q,+_E&&I']/(4FG'#STWWED.7%UP(GN!
MWJMGEC&X%;L-8!S7KL5FEM=OZ,6QG+)W4GYGMF*G-AM`&/W^A3;`'YI'HYP!
M4$!O.A[%-_FYL(DDXZ;?L20_/NGZZ-98I]%Q!(D7M>+%]A*-Z0)\N&[#G"`0
M+\W(0-W45V<W\S0&CE98/.$FFW36);.E=O#6$.'FJVH:K[Y9XJ$.>1CYQJY(
MEO+)(+$M8Y@6]WL31-[K(-+[.CUQOK8E#7!,?]+@5NJ:B^VR6HF/2G!6!+%*
M\(VYS]\(3]:O@)G[8+NK2R.-'.W"@0>[_C9BPF*64A<;QM*^IM/YFOLI9$V(
M"5<32GQ!5+!L5+[1DZ&U79\-;O?`8>*4S"B;#(0(.Q`R'!:^L+5XN::!1:U^
ME_>F,.:E,Q;`-B7V@$$QOS.5I/]YN!_+6IW59*/*(107XB]+8DC%Y=D9)R?S
MCNY50SVLN%$MSEWKX-376,)D68R[8I;T8"4B"U8HFY6JU:;4\;=-I1KLZ*$_
M.N#H?*Y?CWU4=8ZU'8,N"Y`L:(1^/38W\TJZ(U2V.(L.[K;%A#F`^\&8S5(5
MN`+$Z(1_\""/`!8`-L^TV99Z3:*!QK`V[Q$&RCD8E>Z`8Y\*A`I.XMI[H7;3
MWZ/P)OB$J(A*9T8LMN_+GXWSNK?ZD,,?7:#W(>_5""V/H9"%1ZD[:T!DX6=R
MIERRB2%;8/%ITV14R0T<N$DV+.]ZT#$12:T*_V82UBHA7&[:8/.'-',%J#A.
M?)IL9X]PO*!2O7HV1*;;)!,'8E[G,*-XF_Q1CU``8!6H#*;]@G7.Z[^')#T-
M(9N0H.UV&VQ#,U^U9$R.:>./K4)W@@,6@YZT:*^.@I*_0.WUNY$RFRA&Q"8Y
M<F)SY&^"])1E$DUW3B<S1=S.%#WZ,!NKBU7E`O0`J))0Z@X4$%420!1/-Y>)
M0Y6$,V9A)>@D,DU]#7@Z9S2"6JL*A5!N*O&F+-@MQ@Z4;E9!A`*12Z<KPEL(
M7.!3"2!1G_!5@]S,)NH.#+[N7>#;C9`?O_P"F8Y2';9\H[-G5+='GV)UL+C#
M7P88;PG!D=C53^ED-#=QD\E5A3]9HE:]6IO6SJ0P/N:9YZ%9W^80J1_RD\Z1
M$?Z?.X46YWU;'[*X]MWH(W2]T@\QDWS?#`:/0[!`N.$S,6E%1W1LN[WA28)C
MJ:9`K*>2YZHE.#@'A\417IV'8'P*]#5%,>BZ\GGZO1_T0/JQ+?M>3=)MN\4A
M;\U<<OLT_U9?#F5[IDTA>,/=9%HTZ4WKT5;D#>"2J9;#%WK&_$EXY.M@:SVS
M\(P*\_7F%8JJW#!/7U&>)Z9]/6:#+VI1L-]\H-1-JB636,+]I,EK*F'J9'G7
ME=M:6\8*6]JG)W)>N'%$!)<1!/9@`.VJ[$?>3*IVN7UGIWZ]<//UY?X9+F3N
MC8Y$^."0V;X+\MZ`*/9&QA>M3(MD[&IN\K(=!U+\.QJ3,N/50]HDM8<.&3BG
M$]9D]F<OKC]AS3-J]WDR7:[#W00BC"2+B/G!-G^[_BTU]((\9GH!>V5!PJF8
M71#CX,K<`LF`IKD%@K%T=@''HMS<`I#?_`**+Y'-+8A8).<69!=V2.D\%R"P
MFKT_IO-LEE&6S%T7`,ISU_F%ZPRCH%D&):]?_VR.:`B@R0L*//,K=9#.$VE+
M5R;^?4NSIYHL9J5SEV6SW+MCD9AEWQV/DOD=],S2W`().C2[((ZR^2<DV,.<
M6Y!2-D]%1M-H=@&<D<W3":9"YX\)"^2%73C@ROP*"*\N["(OF.P=(L^%70"\
M+JQ(N9S5^SN:\7G+!MVBZ:QMWS'*^#PM`&!TGJ>,X^\1SJX0=!ZC[IC$R8C9
M%3'F1;,K$BP'S:Y(\<?.9E=D+)NGA4<XN3"[@N(PT>P*4/4+*V227=@EQM_N
MF5V1B$O0DD(",;\BX_(2^O`+%B5T;6YV!9,7;$[P^`*U0L3RPCDD_L31[(HX
MB>;E(I)$7GA&FES09)&E%\XAHY3//P/,Y8+?D2Q-+NS"L_G(XDZ*[((&29G)
M"ROBC%Y8D61B'AUDBA,A\QXLNJ#)L9X[F%T!<#EO^S&/+EA##-'.O`;%DL87
M3AK39-X:XF0N9H*PY.,_;V]N;_X?^"3Y1@T*96YD<W1R96%M#65N9&]B:@TS
M.2`P(&]B:CP\+T-O;G1E;G1S(#0P(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W
M-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;
M,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@
M4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&
M86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E
M0R]);6%G94E=/CX^/@UE;F1O8FH--#`@,"!O8FH\/"],96YG=&@@-#$S."]&
M:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]6]MRW$:2?6<$_Z$>-L+:
MB68/4(7"Y5&V-+L[$;9WAW1H'N8%C:YFEX4&6KB0:G_]G*P+`%(D,&L3$PI)
MS48!J+R=/)F5_/[OUU=?KJ^";9Q)%M`?\RG=RLC^4YRNKT)S)60\9F%LON%,
MA-LLXRE+`UP)1,8:=7WUB57F64DDZ4$R3>D_UMQ?7QVOKPY_HD?1G\D7P3:*
M!%ZPC804^$]DG#^]GD62KF<BH>MI&HN7'\C931R'*?8=!BQ-`CR5]G3XU]9\
M\1>3X2(/1Z&^O[N^^O-?\ET!%0AVAQN,LLQ#O7I"3II(V=V)MAV&0<CNBNNK
M&PB5<';W>'WUKJA/I[IB;5<7GQD^=$?%]GFG6'U@15FWNKK?LO>L:-1>=_1E
M?CXW]5=]PIKRPOXCB3<!%-ZHMB\[+&:'IC[A*;IE79-7;5YT&H_%C[HJRGZO
M]OA`RU7>%$>65WNV5P^JK,\G577L/]G=K]=7'R';_[V=!G"3TT"495X#49BD
M5@7JZUE5K:)]D?1Y`9V<\^I"TA1UU=:E)HWLH23\1]ML21'U634Y"=>R0]V8
M6R\0BJF*A/R@"G7:J09NN6$\".3V=\L6S\D66-G>_8-'P0K*R^"9]/QDFTBC
M.?,B__>M7X@@]2^$L60J!F/QP/GK]/7TEWVXY'M=&$>Z^^EG,AC<L%>LJ_'N
M4PZC'NJB;V$2Z]VZ8;_6&J[VJ@_"O^^;_$1/<%];O]CI4G<7^AH>@[M;W-GI
M7;W7JEW#<;,X<:K@(I2#*E+Z3*J@?=?86<..^O[('O*2Q,;/^5GU'70"03JE
MX9\]A;'3U%MO5`3QL-/(NPCG;_X:W#8J)(R@'Z^0(`NM0EKV0\@^6ML0Z-Q>
M6L3KEMT=ZQX*>E3LF#\HO'??%^0//8+U@-A%/,.H%/6EZHP*V7_?W;K;-ZN8
M5@;>M!$?O3RCSR2)W^I.W?<5;:Y5ZC-V6);YKB;4P;5SWG25:LS><PC<=K`S
M>]3=T4C@Q"$]`*RZ8]ZQ3A7'JB[K^\MV!2S*1/`'H2B;UQE=M#KCZ0CC"7TF
MG?U8MT7]R&X)I-DO%534M(C7#;,7-NQO/;24KR!YFHGU0#BFNV+O]]GH+#)R
M@G]RSG+,K4^7=76OV@G`3?P&WF`\Y+ZI^S,`K&.OJ(V5B)#=A7UHD/Z;S_G^
MPFYUI;OV4OE$^4$_Z-;YUPHQDLK,28V[![%Y*ES:_N&H3KK(2_:Q^NUR,F[M
M=S9<^J`H2@C5MT:24806^RGJ^TK_!CES@G)"==5T]`Q=[?NV:S2>H,:'$][B
M8@B6R>@YVI`">M\:TD?<2R_Y@'4BC!(K_31A$1F!W0^Z@=7-AA5A/U"NVY!@
M>:'WK%!EV9=YJS;L\:CA%8^0FMB?:@H(:O1@I8N>ZNJ[UGH+R\NVAN+JTLAM
MM4%:*,$#U]``E][KA8P'#62)2W_%,6_`+E5CMF[,'K)#7]W#:C`>,O]3.38D
MW@NA0'=::*C8^R+?J].%-'I;:%45JMT@KEH`L2*WP'-[4CE>X5QMKQ$^B)G+
M6E$0#/1=9O'(AV*7*2KU^,SDEH[VK?=7LTO5Y9HB>J(TJP):E%=Y>4$"(1'4
M5R028@O/'KH*?4W2]`\"9S*KO"2Q[#CC6Q$DB)S?*$_DU9-7V3O_]E]TYR.]
M]J_XQ+>2)3'J38;;A1Q^*J^O;M]D=R(>=G=#,6Z94W^`<?H&^E_<HHBG6\S$
M[]SB@H'DBN4%,ELB!K8?)V-J$X$<4MN^9E4-C'NLO$N>\FK4$\,GXN6:(G77
M=R9(%3*A28D*'*B^$#P\UJ8T(.>?/(#HT^.QMHNMJQ.TE:7'U!4B.@D]BQ5Q
M.B!['*:NPGD6QEOF\_L90*3V;[ZC+!BVA#B)3$5)<7+S]F^*)L+S0(QPE@0.
MSFI8L*Z4I:QUJUXSVC\"&?R(U`Y6_+VN/5;CVY#2VY,;";Z1VG7CDE8%MC.M
M$M<P<1`,/9=X3-Y)'%LI>^HVD*#(G(3!K-0G34EUEP.&M^QG>-YG=7E9>.(N
M_UN7AYS=$;NK3QJI[?;]AL%=S/<;,,#"Y&B@_Z>\:7.07UR!\#[W#RG-.AO%
MT0IJB%//V(,LB`8U1/39]YXL^W"A/:0N9Y^Z;\O+QEB-4G5MPAO)J^G/E+PV
M#'5MH:B]$K*^VD,W.0O?OBL!,;PHZT9(E"83I84B&*M^SAT\F!Z3=PQO3[A$
MD5=$\?)=J9PN"K!9ZG^L8=G85R1!&HS<C'H!UK*Z*?I3V^6601F>U8*Q-C#U
MVQLH1.KP.UH9PD`B1MG#0"837AI-#-0H$#,(6Y]MAU!])4=OC75@$DHMQ!P;
M4Z"_/;>*(CGL\]T:S"V.XE6)0<RS(0K&XD]DOOB[`ZFU(/@"1A*<Y?>-4KZ=
M]Z#W#EMR('Y9&MZ@%,$M4+(_U[[SV_6P6=^!4#AZ;/*0PN+&T'[S7:=/RH*2
MJ8C6"*^0#_E#C#W[6+A&5Z.^],AG[4HM/=09?@<KAQ/RY"AK0*<W7E;I"]V_
ME'6C]V0W=LY1A*/,_0JCG6#V(](GF=$U[U354@_#N@49&V4?8/&L;;GVH%K3
M"?`UD2M>\22`9?7,X&=DR\[8>`7SRFRH;",QLMX@=@A"UC65O8=W5>U1SAV0
M^0R*5N:@`3SA%X/SW1`+@]-OW!='5^/KCNC`$R^&8L"<NPMK^QT!M2OD-?5!
M"FIN.TVL(7_B:]H@=O*_^\&>N;PYE(CA;2LVI^-D(E.89.F8MK/4]Z:+OFG(
M_2JE]JW%#RJY=Z6^MXVD&A#V&2BTWVNR$%QSL%'^@/+=IG8/5BLI3$;_%HU1
M>(\JFS9T)?<D@EIT7WKJ9)*NC$-_US[K:U>*?#5O5NE`R7@X.)1B>G#H8/@%
MY,@[OVFJ-EZPI*[,`6.S)VIDB9&!*9?%*/_8@+7GC-XI;#%D3BKQ3)0!MB[<
MJ5(#$%Q[?Z5HC88:/9+1Y-3%E6R#:%"`-Y(KR@$N(.WEWD"*:]*YW&7%(Y0F
M+N1C8T<G500^A+\;DIH.;D#R&V52]<L(-DW8>I6C.,F'DZ=X/$2/N!"^&TN&
M(0E,?'HU>`<Q)\D^$9V(D%CY-]2`)_.[(^B-L;=2UI;W3?U(=V*]`>07->>Z
M!89%?E*F/%HI:85#31N+B0JDBU8ZI.KR>WM\-I@&@N65/R3XQCM,XD95\$R2
MIY):DD8S"GD)RH-EOZK"LFIH5S^06]#,`3WCH^T0K2!^E`UE62PGXKLSF.^=
MXW[G=PG_;0<'_H91PDM?`H='78)^EIV?KK!N97W*J0??@>CNM^RGNE)0-5Y&
M!1;21H._Y6-^624`HO$(RHQ3>);&'10J.GW.3>/8,.D27*6RYY00^)@_T)6G
M#!V01P+9-D7.J)'M'6/+_J>BJC[:K,1P92@'D=:EN#+,)LH+TI$;B$3*IQ2W
M4O>U.U4RM4HU=1(9`"5WN@`^=-0!6\/(PXE;F(R=!Q$['X<A7\9?4PJU;5W8
MO=/!FCD1F?BU.V<YY;]"5)LK'$X84!S3N!VET>T$.8`2.^7+.',H:8#D]U?-
M<RH8C]WBB:D\SKMADZ>TFN9$@%:(310HIL(@(7SW!3!6/QCJ-M#ZEX3\=K(J
M%()&JVA\X<G*H7>WAOC#F5N0B+%Q*60X=.S,C,3>]>0`5S#-H:?*89B'LH=C
M"-]XR]Z/#ORR[V@Z8*L?J3>T,6FP<"K=#51A/V1%@OAOLN`::@A&9II-)F\R
M%[!T`MKX(NS64AQ;<-%1Q8YFA4I3EM8[XP.FA="#N0'V1E>GBM8ZM5E`=0&=
MT+F0P-5C7;DJUE4)+AHF]-^U^E:B?B(;"#"/Y-B%\<-8/SX!]/=C]6F<V[@'
M,,VD`3A(?CA0D$QV#RXPF:HR)B9I7V,"Y',TWZ1@=D5$"J^F_M-:TB<#\4TG
MQ#=*'!X.0M`>#KH"HZ=^PKENM>U.VZ'(Y\.")$61MT=V*.O'UJ2ZMC=C:(QJ
M>Z.]T;Z/QKG,^0]49!O[KW`'8.P:6I`#]4W340O2CRKEE9U!>Z4/-Z;TNXE4
MKFYIZ12$\`Q/:"G>6T0XPF-2[^J#"PS#C=O^?*X;*@@O4R5,'&8-#42>^0KI
M#NS>F2)^C2DJP?_H%-5\8U4$`X^-PK&F#:3K4WPZ*IJ2..U`9^VIBT%=<^Q2
MF<D*A#%Y](&^?FIK^'A;5Y4J#2%U-1T"WY["F@.J1AE`S&D<>"R:O._4#;+!
MB8)[!3/R-'ZQZ^8E1PU=D8:L%*[T'H[=F*E3`()[#1@SQ6JI@4TV$^X!Y\\&
M)C9NX-G,4MAC:-7Z8V4D"PT$H-:;WFLD`W]J>5KIP(;'GMKQB=6S,/4-Y18U
M1JL=&%-?RLR!W1^[:>$VQAGVBX(#F<],EI(*VJ,^G^D')^*J@R,\RE8='.&"
M#Z,9?"SXP08<]M^:*H_D_C%O/JON7YG8,$,E>(2=V`BY''Y\RY$-[OKI:XUA
MAI/F=3*X4CQD15>"^X)XE:GW1*Z*D:$<>KD1GW2\_,#ESV.G81#SZ&8(@8\[
MBFUB<GW;U2>@!G4P3)'[A.!305?W`#XSNC*"!67_7RHS#F"&,FVGKU4TE$(3
MR_;%*QU-("D,C&\<OS>_`F-K0)/K=[HF(<R`Y#"N8FL@.J_OCHUI>]!V:6['
MMD1`V@IW;@;L=XN'M4]UPR'`7M,(YJZW66'4CQL/66DZ)^0#Z<NB9*0[F3N;
M&2!;J\EH#E*9G3.B74W$-;\L8&BOI<!=WMR[[IY!^I,!#\<)G;M\T]MKWWX$
M/0:EF4@:3KP\DN[@;=2X89V&NV++'_L&9':5J?@P&*AF.#GT3;SS_03J=V3O
MH2-=Y!MV6_>=_>V-'Q3QAW*\1%_:U?3)+GS?ZMQ8S&;C)_YE1^Q=A'7J:Z=+
MB'BHZ[T;D(1C4@4+"[M)E<U:$9@-;=8L'?TOEM[_:)<`&?^+*^>^/-L/.8C+
M,$>S0Z`.$>D*)QMH-!5>EHHJU[M)L]FU5=4SF2BA!"DX8X)]"2/,N&OSVVZ4
M$01R`BW@KRQ(!4)I;D%"HRYS"V(.!<PMD#P.9Q=$E+OG%@@NYQ=PGLSO(>0B
MG5T0++PBX_-J2,-H]OXDG-=S'(I@[KH,:2SU]>O1PG5!TPHSUSGB>EY!R>L*
M_&*W8!>$R?^/TT5!P*2O?-RP+0^>N[J8U>Y-&(2S#G##@XC/+A#!O`)OHB">
MWX,,XODGQ#14,;<@";)Y*=(%+[K)PFQ>3"@JG=\E'"&<?TG(0SDO")QM01<(
M^F`V(F^`&]'"6V*>+JQ(`!WS*U*QY%I9*,6";R$AS*\(:3QM=@7GP<(*0>>Z
MLRNB!1"ZX3*,%G9JIIUG5R14=LVN2+E<D"43P6(XRGG+":#^PHHHB1?>(M-@
M7F,BCA:0!20HGM>I2`5?V$<F%B(J"D0XO],HE`LQ%_%X0=I(Q'QA'U&<S%L_
MDG$R;Q<\@B\\(TD6/#E*DZ5]9,D\K0!@I^&\76281O-OD3Q-%IXAL@4/DE'&
M%U9(:O#.KHCIES!G5R297-AIFBUXLLRR>9IT`P];0#IXV$(TQ")8\"`$)9_?
M:0RD6\C&<9"\[NM@'1__?GUU??5/#1:,Q`T*96YD<W1R96%M#65N9&]B:@TT
M,2`P(&]B:CP\+T-O;G1E;G1S(#0R(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W
M-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;
M,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@
M4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&
M86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E
M0R]);6%G94E=/CX^/@UE;F1O8FH--#(@,"!O8FH\/"],96YG=&@@-#,U-2]&
M:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]7-N2X[81?9^J^0<\N.)-
M2J,`X/UQUUX[3I4OR:YCI\HO%`5)M"E"R\MHY:]/=X,`.#,:TMD,8U>M=X8@
MB3[H/GVEW_Q\>_/A]H:OXRQB'/^EOZ7K*#1_%,?;&T%7!),Q$S']1C*1K+-,
MIBSE<(5'`6O4[<U/K*9G)6&$#XK2%/_#FOWMS>'V9O<7?!3^._H%7X=A`"]8
MAP$\A*^#3,J'U[,PPNM9D.#U-(V#ZP^4["Z.!+PY%9RE"8>GXIYV?VS-!WLQ
M<!>E\$*]>7][\]>O\DT!$`3L/=Q`8-%#+3P"4.%!RMX?<=LBRP1[7]S>W(%L
M,7M_OKUYU:A[5?>*[1M][@Y,WZN&=0?%:O6Q8[OR7K&+RIMVQ<Z*'7+X<:/V
M?<TZS=3'4UYOF>X;=LSK?I<77=^4]7[%VKQ2+<.+G2H.=5GD%6M5<U\6BK7]
MZ:2;CK5=OMOA8_+3J=%Y<6`YJ_)F#Z__,WO_Z^W-6Q#O'R\'`MPT@(":,8`0
MQ$EJ8*C[XP9>K7>LZ-M.'U73LK(&&<NV`YE(F%J=0=+F-]6U:_9>`TQERU2]
M]=@TJFCZLE-;$.9?*.T/C6K+K:H[?/([@N5/[%MZ!C[UI26-P\2+FLEUR#G\
M_7>0[^[%7P46X%X%4/(@"2VL,HLR`RM[6_]^.:IV]8L,^1-,7GI/"=#$_TG\
M),O\JUXMH[(\M"H;!;&S6Q$+@^T/?74";?HA/ZEF10K:EA_'%D?JUJ@3X`UH
MYQT8<\NV9*-,<A[!32VH;E7A?_/MMNQ*7<.-<X\`NT"C?]V6>0WVO('3+//F
MLEX"A2Q-+`BQ].0E`X/!:[?KZK(B-FE;L%C6NUV"?:K\7AMS1F++Z_((HNT4
M6*FQ9KSRMF_T21&*JFK5^:`:Y>WZ4#9DTP:/0M=M7W4Y:/"Y!,YLRWU=[@"P
M!50:(4BXA2`0F:.NS&(`/*R:4M7%L'W\L2M;900N4?`M<%IS8>>#9DA9L*)`
MD@*\@,UAV>M34U9,K%`MXC7[&T"H&]0`1-6"T.IJ>^69@(#N.P>.Y?<E@$#B
M)B`X"3\`$8G(`&%<RE9M8>>#>+17<\K&1,H.$2#%(!1RU!Y8EG=FK34#D`OL
MHJR+1N4`)=Y@Y)O4(KQ2Y5T'GN24-T3Z!M$ET$!.&#Q:)CT:^'=$XSVJ,`I;
M:[;O\P:T4X%*'_09/#X0!LGLY7HH[TBEJPO3C16N*X^*[9H<_J3[SXA$5Q;E
M"1!??ZJ4\7,^AK-,&"E?H0-Y<1\&=P&/D[>`V)%GQEL`C"(=4/RF9A`UI2OV
MY24'O7KQ<PREW\*B#DM`P&??!!XZC%*K,A'/$B/L5Q58_39GI[XI#J`&6Y;P
M7SB$IJ#'>/I@YV!C]18=2'O(P2G@E;)K?9STU"F`'C[Y+46#&"+"`VJ%#UG`
M0%(\0V,@$AYD#20)!KI`W0?>.^)^MK#]IMST'3H*X(V=;A28`+C"CUU9@=F<
MT-DB@9R,NRT.ZD@NDBB7@ARVZ=NR5FVK(#Q\W7E[L>@U)7`MW&+A74JIDL`+
MOW`4!!QDWX0Q8)*9.,5ITA+'&D=6B6,7<4("90ZUT#UX*5T#:]WK3C$9S2MP
M=T5#U^S-A7Y4'WH,5?-]H]01_M8N=6I1&CG9ECVU*,U&*(HH3GQ2:+V'/4#K
M$;9DYOI<0V)T*$_P>W!RJEW$SZ>A2UA3QU)A.&1J@R=Z0BF[1A\M7X$%IW(]
M=_0F'FA14?"W8)X'^(F>,Z@-/">>?<Z:_0@QILF:ET`C\)EKG'H_'P]X/*$5
MKZM+J:KDL=O6LJHJ\38'@`P#[[221T[K@$D,Q/PG$]'I$1X^M7EXU!2]PPEB
M((AWR`?>KM,=W'%%;Y8X9.%SO<3G>CP9JC3/L-2*;2[@D2ZXN<\D7W'.T74Q
MA?44885I>_CI@>3KA10C!$:VHBRK&"&H_PBT-/!$$8OX$8<!<6VJ<F^3`J<8
M""F8"21W%AY':XCB`N><9#:=Y<CWUIA%-M1+X'3S/9@O[A6#DX*BA\]"2-;Q
M;,OK:O`YY*3]L:\H/X?;]`YI#8(1N/W[HM-8V1+9:HADP4ZV:@>1RG8U>AG@
M\EG&284@>B&_^*4J%%7%E@`BM4DMCYV^!S(9W'A@<M%H=9WK#_G6U`T_0OC6
M*7#VGT513!!1!>\Q%F.AUPQB>I?FV1R1[((*",6''A7"^8]!,R#I[QI=+8)%
M;/-:*7U>&R8VP7<UV:?FOU!6DH5N4PMG)5DZ%E]('XHD5A>L&>=5JPW+,ZQ,
M7&7Z>DSVXI'KOF(V5]C]?"B!+I<XYC#V*N_+%R(>CIDJ,ZHIRC;?5,I4XG.P
M`BK`0R;2'$W.O0&#!3]7.].6PIHV)#`F]LUW6(-8B.03+\O")`_N;X1:EHRR
MN#1]ZOY]WCK#[)90%RG,)#)S;BD:Q:^1<(49>]`CCL<=C]6:ZC$;2"I)'FV"
M7A"@KSHB9PUIJ"E>/:/=)"A>@"T=@;P.@$\#C$ZZCK_?(NT/-R\!@W#I-\CN
M0YK(E2T'")X*;XH&8S0*$&WC8=MB40LHGG@Q'UD"%^DS%8>-*K!JE5/U5E?E
MEJ*!T8)EBA#8N1S4=XCK7BV4/G+WKH6SQ]"]"`ME]**A[2/D(\I6NQV$UNB(
M_]X#*QFG+C_=ZIXK%&*:8#?UZ<V8YYZ.QYA$_V,9,IM6DRAU.4[LC"6AOR.@
M;TK]KJ`:?\O>#&6F1>0<>L5+E5MCWX8-$Q_J"#&4';X&73%4=](=$CBV(-BV
M!#UJZ$?3C-W>YW67[TWY!NMX7PCV]B-VJ5IDBW>7ME-'XT$U/(R*_?9B2Q<A
M)#2-:]N*;3N@4[6_8+8`(<425##JYW'I90\'O[#31=\:IM=`BYM2GR`B.>:%
MZCLL-6*T#MX"'$#?#(5'5X4L]/&4UR4`0B$"!#*LTOHW%`S=0%X!5=8F)'X*
MA?,4$"UO^\(ZE04@B'PW3_*1,^>V@]/O=B7J><<^]-A8Z$ISQK"S3I6UV:KI
MO?SUT!\Q#FK8KE05CAJT&.@7JJKZ2K=EP13Z!@C9L7F90V2`:VG$X,4I,0B<
M:`N3;Y",0.19('P_,!CTJ`6%4`]',ACJ1,T4^#Y]-'T]=E]2F+G$*;N&91`+
M4Z)]5>BV>WG>QY=%?%'&PK.U#>C$1W/"#HY\#RQRE9V+OD'*`J35\53I2^OZ
M`Y")WJM*G[!$1QFJ,4?(;QB0$.:HV&[SU'2`W/3%)0ND$VWA09$@'H.8^4I-
M%-L@GB8.=*7W%S<GI)'R07HPZ2545+CF:3:JM\4\L42$`TDML>*UT_U\3*-P
MA+]"F-,^F*>H0(BZI7&H7S4D'PP<FS5&G)HBMP1L=B1^<ZI1Z*K*-]J$]A3*
MMHO8:.A:@2)._5Q%8!WQ0[6TR0C62B%\+I$XK-.XJOQ#2[S*^[HX/*FX8/Q=
ME*3;3G`JNZ-+/JA\"^3?=#B"A5"9T0R@KR5@\#W"E/O:`\4F1@]&^0&X)M52
M1:I5?\28"37XU1$;40C5M2CE<QPA`R:F&E-^RC=E9;Q>=VATOS\P/WL#R"^"
M@6\%47G2Y:NAK4ENATW@A$G'6G+0.!U`QS-2W9JB-%2$#MTLS<&9/NCC2`:"
M&V_SOIMZ)<0QAC*,FT`XN`@"H8^^?5":61T`V]8X`8FC+14U5D`PZAV8H&E\
M/F#++MR@5K'1X1;DJW/\H1O"NQ%::_95WZ"8-&N#A8J:ZM2P!,.Q96(6;(-;
MN9=N$F=CA+D<\F`3IRQQG+YC%HWZ`B)*'+>!29H:88[IJ3&XO#P."DO*ZW0.
M;9Y.&R.H(VAR6U*8#M?AUFV/;:6RQ8H[%I/-O:-XG`9EM>DV'$V]6;&^+C_T
MZJ'!+X'$J$,B?<H1!@^Z2E>3)YK>-1??%8U2-1*4N4;]`;SF3/]>5_U1#1/!
M[2,U'LT)FPFML;\;L^<"``29'Q\4GMMD&EYS<^C2-AJGH&&O/Z[?K9\Z([SB
M'-+32CS[3FU54^'*-_^R0U/?*31N_&6[2`@<),FB(7`0^UY-Z!,.&45N1DHW
MU`'7)C4OS,"<V@&@MLVJGXF3S7PAS5=^7:FZ9F_7".*YK%?LA\/ZRS6B^"WQ
M*8[2K<S0(MB78K_PB)?PAUBJA!F$;N`P#HQC>/4%6?;EY:-D][8A8_I%2OGB
M;TG&,D5BU(4(AL"O95\<2K5C[[R7_YXB'_!.!+A!'+3_[4=5]%12>#KJ3LQA
MD"*S,7?ZPWJR>*P:CAR6*TX',OY_GNSPMH5/ULDD1.HFHX+8<AVVMB"[>'$!
MQ0C/A;N%P((C*>-1Q"[M]RPXHK2]QLS?U$,-C/P^*N2/[UZC0J[@4K%F7YKD
MC$*ZG/I$$)2!WZ.E(B35I4]AV+>-I2CJ.M$LX]9FB\M]W8`P\\P?L3OA5`CG
MS[_3]]I\<4%2K?"K&O!AI@/F8N@'X?<0K$#J?5(%7"U_-ZN'L4;C]R`\;[1N
M]A#4M%@\I0%Y<(^$P`9A>IP;8O=F`0ADYMM*43BJ(-OBEZ6M%=M!R%VC1"1!
MOH40O*0R+W+6#C)3%[)3T72`884S;U5/D`T%4?\IDP%LE-L/HY\NYC_F=;ZG
M'(%N6@*`Q,T_)GYRSWX4\O!D75$;]V+W^(DQ2#*]JZ%QD,;@5^1``&^/IP>O
M,G?^\VN\\XRO_3O\3:XCN#N"/^'V('0_5;<W[UYD=T'D=H>?4'!C.*\J?5&J
MG=T?[<7M+TX_<7_3$9P4R[9=)+<9$0^Y<_HRX_8SFH?S/G[ZYJQ<U'N];XJ)
MR]-I'`')QJZOJI<O?\=.EJ6[G`]0R_Q@2I"&@T.EX6Y3W%68Q7\WS+)3[&M_
M3;V8)3X/2VUJ)Z4O8*9V?M=]LP6'M0'&PIHB9IU$>'B8]ZHQE[#B.#1I-Y"\
MYB5E>G[>><U^&CX`JG7'_,=&<.;@,\ZZ^0UH1I].U(ZCIA1Z`4P'$(<E)(]=
M3I>%+JF->#RD]Q9Z>'`U5&4H9V![K;>+D!^0BE%)8"\JK/Y.6=']'Z`7HC\A
MDX'^,O?3B]$?*/)H?W'J/W+A;L2J`Y7XIL9J-`$VN^N0CW<-UOZ)VYYFK<PU
M#43D/W"*HT'%_ZU[F@N!^*:IV5&#G8&6]]V#Y&-S,<49U&G4Q[,"XNJHCGD^
MG]=+34AE=O,+#TBE@4>)IV+\E8OMJ#>Z/ZTAMEF/3]@.%%DX\#,Q55*I=9$!
M1U]>'7]V%-F)_D(W)^QY4.>KTRN@&IQ]L]_0F0E-A=\5$AL!_<!9`N&P"^@`
M&'<#(>[P_9XK&9OUC\IJQM>&.(C+F?D?!/@=T[?[L("'04@+Y/4%V,.*)Q>D
M03C]A$3"L4TMB`/.)Q=$`4`YM2"4V?2"`)+^R052)LGD`C'W"BZG<<CP`X^)
MZZF8!CH1<39U/180+$]<CV:NAR*9/(5`1)/7I1#3"/+D>?D_F%<8`.$Y_R7K
M@W[;9-'0PBLIGMC"I/1W@O-)#;D3638IWUW`@TF`[D(NIY\`?EU,+HAY-"U%
M(OBDDMT!;TZ+F8EP>I,`U,1!T@K\9WH%33]/K@AFU/T.C)[/O"62X<R*6$X;
MW9U(9LCI3J1"3!H^:(Z(IF4!2:89[@ZL*YY9(7DTO0\9"#$M"^#%9W8:B7!:
M@60,J$ZO2#`'G%R1RGCF+1DHR(PYSA#J71#@9P>3*\)DFA3O@BB8IM6[()9R
M&E/81CJSCS28L:@@D^D<^T0S-H==PYEGR"B=WD<8X+3-Y(H0IV0F5T1Q.O.,
M.)G19#BXN7VD23SSC`P>,D/8*9]^2P3QT<PS9#JC05&0IC,KPC2<61&ER30[
M1'$V'2/=14DVH\D1Y.33F$99-L-T,<]FK"&6?$:#(*),IW<:`]--6T,<X?^>
MZKD5$%.\_?GVYO;F/ZLT4&8-"F5N9'-T<F5A;0UE;F1O8FH--#,@,"!O8FH\
M/"]#;VYT96YT<R`T-"`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O
M=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@
M-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@
M,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU
M(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)
M73X^/CX-96YD;V)J#30T(#`@;V)J/#PO3&5N9W1H(#,X.#,O1FEL=&5R+T9L
M871E1&5C;V1E/CYS=')E86T-"GB<O5M;<]LV%G[WC/\#'OK0W9%5$B!XZ5OB
MI-EV-FFW3B?=F;Y0%"2QH4B%%RO*K]_O`.#%L0-E7;.3:2V)('AN^,YW#L#G
MOU]>?+B\\)9A(IE'__2G>"D#\[]L?WGAZRL^XR'S0_T+9P%?)@F/6>SABH</
MM;J\>,=*/5<42)I(QC']8?7V\F)W>;'Y)TU%_R8_>,L@$'C`,A!2X(](.+][
M/0DD74]$1-?C.!0/3\C951AX"6>Q[[$X\C`KR;3YNC$?^HOQ<)'[HU+/WUY>
M?/=#NLI@`L'>X@9M+#UI;QZ?PQ(B9F_W)+:7!`%[FUU>7$$I&23L[?'RXMM-
M7J@U6YU8NU/LNMH?TO+$CGF[TS_<J*RK\S97#4O+-7OY,=NEY58/W.=-DU?E
MDKTXI>L\PSU%P0YU=9NO%3M5G9DD95EU.+%JPVC>JF8I1N$;)F\4M#E4==NP
M/SSIJ8^9.K3L'^SMGY<7+Z'=?Y[.!KC)V,#G43C8(*+/9`/U<9>O\K:!&#Y+
M6U96#'K66[5D_X4B^_2$9Z9K;0*M#NEB95^PIDU;M5<E](!^%32K65YNJGJ?
MMC`05,641\7(TC2[MNO+ZZ=6-/2#45/CZ&__X)P__7/BJ44]/_`'B^K/9-&&
M';I5@:BHU4;5JLR@?IKEA0VEE@72F\?57J`%@S0>YX-DG$<VWG_(-PC+F[96
MJEVP-\MWRP5[ES:[O-RV5;E@+Y;72\8]K(\E^Z50*:(THYBU7B/9_:<67(3Q
M*'G"EX'G0?)/D/;JR1\5\3N/$EX4F4<!-Y_\88GWM^F5!'<>Q:/`/FJ&I18@
MZ?Q->@5\8D):;4DTQ'02!2:F/2$\!L!AFZZ^!S^UVJ;U&N&M0]BQ+)?L+0;,
ML"B3..KA-Z!L9,3'I-*(3\MJG^9EB_\`#L#*%6OR5BW8KFT/WW_WW?%X7#8J
M6VZK6ZQ6C:=998</,(S4\_$T!6-"ZZDA/KMT'ZA'2\UAA,CK?1C),0]S:7V(
MA^=-6Z<DGM90IPM5J*RMJS(G#)KFY9?7"\B>%=W@69N[C1?MER>/1@!5K\B,
M*2:(1GM=Z:`?DC:7O<$:#<>P$@P`C];(K453L?0VS8MT!=NUU33B-W6U1]3L
M]ZK.\K28Q<7@BSW-".5(,T(;Y^LJZRC^,'%;Y^H64C2JOLTSK+W'BA,ZQ!%&
M'+@H>!RT1VYUZ>$$@&(I8T(H`D`$WIU'F3M_?45W'NFQ/^$37TK<C=L8;A?A
M\*VXO+AY$NE$-$H7+KG/I9'NH-J<EOI9$44T%3&*'BFBVT%Q$OY%!R5.!\7$
M>2SNTD<3CV'04Z&7Y:?37K'G79.7JFD>O22^I&*(NV3R%U5T,5'<%?`>526-
MZWFH)?;/LJRRN:]B;ZK;BA1N%AH7CE5=K(]4K.S3^KUJ=0+-RW4'%":`4-HZ
M#<L;]@U?>FR%^B8GAGC<:2)?F@2"6J;J:D(6'5Q5C>E?Y+>J;M(Y,":F4+8*
M\VA46%J?7E<U\J'.9TB?:8-$^@GU'2D,$5=P]'JJ)"7"YJ`($=O3H+(U"))0
M>J"TFB-!*J2?;P1J9VN')?L9:G\>0F`3N+]1T!^S[],_8=,YK.#U1:WOA:,5
M0M31V@H3;T!;AM*N5_JT8"LXCB'=IVQ;5"MK!$J_58DOJ[3)085^J9%=\P-^
ML(.F4U*R&:))%Z\OTC)O=M_KZM983Q>3"`6ZD%5W!LU@D"CQQVPIQVP9A,)8
MY+Y@-Z^-4%V;0:9-59GZ%C+NH>Y&J;49^.RY];+1]#FU`QY4E>Y^_NSF!SWL
ME0*K*K__?#JPDVJK:.$L;`M@TZ\>C%2/QR"7;:*!/4O)QR43^7VPE*!84*:"
M6T&]2A9Y?WB!M&V*^YA@U5X8.C8&PDKU7*R@YD'3CN/?`REVZ2U=YYXGH<.M
M*CO<@U%Z=:UIM7WC+V>IBB,Y$/`P'@FX\*P%AB7];+W6^?&!>`=O476OWWV3
MK"P"+%C393L&X+$@N!C)=H-*NH25F/H(R"&=@<IZ7CVI19V\U-_F,$,P4O!H
M,(,05)[H5EC7=K4"L&E@;Q"W!?X.R``D7'>9(H`OJDS[[%##>74.:(34/Z6(
MX07[L5SGJ5;Z>I>7I']/30]IW>8$*J7&(ZB9C[A$=RP,2T5$&/:*OPMMLSF,
MP4>R&HR9,XYM3*SS&CZ"9B80E`GVS@I>Z>8=&098^3*%Q^UB,9!_)QL:M3NL
M"<PVKA:RD$5'*-G5*$?I<:K\LSHUPPP(HEFT]\)>^WA,(('D/5RN;^&E=$MR
M-DV%_$CN[LNOO&9[BG*]S&N=8K]G:RSIHCI05*ML5U9%M<V):VA8J54#G,N4
M;A>BGMNR-55[^:HSI>FI06EJ;+*N]@@;5`EV/<R@?1CWQ)!'B:WC#E6CES[\
M.4,M$H9_E0>ZJ6XH>QZ(E#>47E'0EU[/\^HFRZGAT<S'=TD.P6?ENZ$_T+_(
MGT!8:`DO:G]"FYH68GD:\^H$EF]>$T;=Y@C#K2H7XQJ<\.-_5^6GE,%H%,09
M?GA5G+)JD[,%^Q7A7](EBO(%>!(^X(?!NC.$JTR&+0Q?#DKSV),/<%X26GV$
M8&F=KO/MGKU2)8"$E+BN`=]%87<R%(;EC4WBP'9@N6I3`/'!JH0LA67;3->G
M;3U-`)'8R[6/Z8:Q<Q@@'O<OO)'!Q'VW_4:+MV2O*W`.`\1['006DZCI0,T&
M`K1I3(#T[ZINN_N:H-!6^RPN3*"I==[M*5_-H7EHFZS1,@A\4\5?$8T)8Z.Z
MAF"-P/`DG/O4,H`N#3+,VNA-1F6AGPB3L4\:6%W!%=-5`?*MUA/&K,.PZ5:X
M6+;$R#:4/G2/:\@Z2_BQ)-I=:(JV4EG:(8,?P=M4D2-('HAC$U1F6V\.SP8#
M)_5'3BIBSY9P%=@CE+1`9ME%D>_S5B_TIO_I@55J>#@4U/N:]ZKSK]:ZW\R<
MB8Y*T=-17XY[:'!WS\#J;CM=P2-5M#NK37<`):]JXJ/'IQ:0(QA[">>-?(ZU
M/-J"^P/`!8D8ZGD`F^'?FB\!N%1=IIH=4MMFUR%*R$]U>E"@5-FDPV_A?`9>
M$XID$/S;.=B$]+U9V00,/*Q!;]*PYK;%_FZG2KUV"N0[5"=VN=QDM5(EK;'I
M:J'6STC;X21=RZ2&)+.RVZ],MVS*CJF8("`B;W7E&@.F\4Z>G6GM!=&#_#_H
M&TAKRGY`((T\I3HR9$6"T1\1>[9&IHRGL6DJ\KT4.U;#*/DKK>B;%!%:H)*R
M)$H;X[2X4W';KB*,/8?RLJ?_GDCDR*>2?C_N<_^:C28+Q7-D68[HZZ6:&6R\
MY([^<3+J']L>ZONR.I8/.?$:^;-.[S#ED4?>Z7>\3C^>$#)Z,\X2<MT"F,V"
M$:+X[[$@!=#0=?=Y//+1*.9G##C8R-H'G+Q:&_/AZE&3\X8125'U'"<$>L'G
M/HL03TTTH7)!3UL_L]#_`Q/'74YCZWEP<=A>\*48<=$3MD6F(3'-=.*UC;I-
MKHHU`9;I&(%T08/"]#5T3XNRL`*6TWY^>DM@CUN1OZE!BCDV7;G-GWP'68:#
M+C,?T*`\.EB-QV+8VP>=MU7Y*B4NV@RPVA/5X;B8ZMZC\JR(N.Q`=:A1>M![
MV##K'%X>MT_"9.P'^TG<-T)+S;-(UIPV2G;Y=O?T<HA!D+D1*YJHS.G!O8MX
M7UNUNYHJX4/7LCT@R5#LB5ML_G]JDB<0(KUHLU!($<>S'@(0D=\7Z$E`^$\>
M_!'+NZ"3*UWZ=8<!1!B;G?8P&;X]V6&`R)M**;@(QS:";?<6U,=",=6>SLH;
M>5-Y?1X\4N`S;I/^K,Q?B*'5$$DQ[@A%-H._`_0@00F6-TT'[/IM>;-DA[2E
MTU,+AOK`_DZ>UH68V2$Q`W3Z@@+Z)OI\=Y0Y<4R_'U2I-^?-?;397.29+>]-
MFCO.DN6$/_0>Q,A?@$`VR_7M@;X!L*JK=&T*25-_4F7RI=Z!*9-T-5.<2#L,
M^A?5KV\G2?Q+E119Q6PPV&IWEH:J\(:-,#[!_Z'19,XY#T>EIGZ997>`Q_/6
MN3SLZURN>5G?7@ALM/]\:[<@3RHU)P:&Z-.,904GT:_C)F=_19/ZR<Y/G2)<
M&@6WVF5`1.^I-9)Q.*@T;^:4R=1X7B+D&"R6V^RJ(TP#QJ<WMRFN[V\.SQ#"
M/!@*>-VNZ`%,6K'ZY6..J:C]H:A.ND(?&T/I%HO/G`<=6OEFH%)-?\#48$"C
M(4EW_RT*V$,C'SJ07AJ[`4Z8]FM;J[0=^A<TJ8F*.8S`AWT\?8S;&D$?QM-'
M)">!.`8IO$6B0J.%%M&<AQD/\V@+X>M#>V:/7/YN#N$G0U66Z$--%,NOJ/U2
M?N5A0C].+'_PAF]/QA]"?Y"0CM=$8SWG1\+V:LG=OZIM5Z1?=;PP]*="^\%C
MI7;#JA_-NQGIRZ%83+RQR.T/Z([VZ%\OVAJ?FMTHE+>[RKY;9$O)W\J<ZL<;
M.J@]/:2=55U))V;U8;R4-?FVS#?(2+3&4(SJ<WMZ@DDK;C'M%\_QIHD8:ZA)
M!S'J.X@DO=G!U[AH^GDC*LUPUM+W_RK5/_=NC7__K9%9]O/E\"RJJ,>]$2GZ
MO9%?>G;TIFK9-:`,\%LC='[9I?4^S?0>`'+S'<DT8%*3,T)6$UJD\=GZS3T,
M\(,XT@/X%P9X@4A<`_Q$),X9_)B*/M>`B%X\=`T(1>([!TBJ'UP#`CHQX!H@
MZ)42UP!^[A$^/V,'CP?.&1+NMG3,.7==C^!MU_7PS'7)N=,-`?><UU%E.$W(
M?>&VH!=]6;X/1D1C()0S_U=&`V-DPUZSH73??O86!TWNE/Z*WB9U7?>3R.G_
M*_W^DFL`Q'0ZZ$IZGC,"KD)/2N>`R/?<6L9>XA8R\;C[$7B"=*OAP]-G;,E]
MW[E>KQ!+P9FG!+3/[APAN7!&])4?\L#M5,1\Z(SJ*Q]9X8PN";T:Y@P=S_?/
MC/"I*G*.X)X\$Z#"DVY)D?P2=_QPZ7M.%+OBH1^>T26"-NX1,55I[L7FG_&M
MX*$;KZZ$B'RWQ40@W)A\A:P1N6TJ0NY./5<BXF=6E$!N."-I$IQ%'WE&VP`+
MQBU'P&7D]CXJUMCMER`(^9DY9'@FD@-0U#-S1)%W9HXXXFZ_!`!T]U,D4II[
M#NG'9R((-A=G1@ABX<X10<S=Z"!E')Z1-(S/1+*,Z&R!<T0<GT$ZF21G5D/H
M)6<B*`11<4L:`NG<JP&4T\%&0!A>_GYY<7GQ/W`)!%,-"F5N9'-T<F5A;0UE
M;F1O8FH--#4@,"!O8FH\/"]#;VYT96YT<R`T-B`P(%(O5'EP92]086=E+U!A
M<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#
M<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P
M(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y
M-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E
M0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#30V(#`@;V)J/#PO3&5N9W1H
M(#,W-S@O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<M5M;<^.V%7[W
MC/\#)@]MVI%5`B!!LGGRQKO3G>EDTF;3Y"$O%`E)R/*BY<6.\NM[#BZD;,N@
MHYB3V:PD@L#!=V[?.<"^^_GZZLOU5;`6:40"_$]_2M91:/Z75]=75#^AA`E"
MA?Z%D5BLTY0E)`D"DJ8A:>7UU4^DUE/%883S1$F"?Y%V=WVUO[[:_AUGPO].
M?@C68<AA_G7((PY_\92QQ\_3,,+G*8_Q>9((?GY"1FX$#P2(30.2Q`',BC)M
M7S?FBWL8C0\9G3;U[M/UU3\^9)M<(_`)7M!8Z4D=.@+^%_"(?`)\OOZ%A<'?
MR*=?KZ_>PZO_^4,+<-\"--$+!&N:4O(IO[ZZ`>PB7/8!EGVGFK+9J3PKRR,I
M9*ON94$.;5,,>=^1K)6PXFXHLQY^5C7I]Y+\6"O\]D,//W9D<R3W67M4]8YL
M)4R0E23;R3I7LL,M;;(.QC;FS>QP*&&I7L'WIB5#)TFSU4_LBFM\A;PU#)0!
M#`$=80CC"0?\C#C<.A%(E1W)%N`@0PW;T=+].K2J*U1N!-_"=B3*7V7U\=FF
M2=;K=[JLDJ17E5P!K`=9%XB0Q0&6.C2(RTL(?((?%D`A34('0ARS$02>6A#<
M7CXT34&RNB!W[;`CMT6E:M7UK5'<+T$4?/7A[O8K^$!)<X`WT`XFM+*AWS>M
MZH]DUV8UF@K8"#[X<#J]GAK7^+;I*MFKG-P"^';ROWR+W\P*2^`@8HL#"Q`2
MBT/,N,'!FCQJK&YZT!KXQF&?M566RZ%'9QE=9$4V0T^RLFO(%K8%W_$OT@U@
MZK*2=>]^R8I"]>!=[CM,D,NNPS4RA>]EM:I@XJV4!GO]88G-1\&X^2`:-R^X
M,)L_$32K&C1:T%W;&<.\K?4W8^W'U9EX<"</6=OCSM&R;W>MRH>R'R"0:-W^
M^(.UG!799QWI`%5X][&#U41UW0!SM=($GMZ`NP@:G#N7X'$ZHA$PBT:7;65_
M?*0=4+EJ>IGO:PR=1ZVL'#Q:?R@1N;[)/Y-"M3+70!KH/M;6!IK:X.:\[7U]
MK]JF1LC@V_<MSJV!N-4@&]S>?V]@PZE4I]]?`@W,508-G9@,&GS,%D;MY$'U
M^R<ZNP>CD/7OQTJ^M5@,7G-RI0Q4@Y'\=Q#FYNU7"D\1$&(*#?HS(F#RV6;,
MFE.NU*"HNA@@4BI,"%.RZ]87*^LE[A"!ZSI9OU["%!+T!I@\7L?&$#1#<7_>
M>D'@?VY!M+V$3;:'GQ^>+(]_/D)J:6N-+Z#M0C:`379HC35&UH4L,DE':1>V
MR)2?XI).`2JF\:E!CE;H*-RV;2I2*8A+3;N#X-55'03<>VGR]`X93*=VM=J"
MB4*HSO=9O9..X4'@POB]A%4)9C<3B!,EL]2&VT/6G5"@4Z6":.\'B+(2\R?$
MFM^R"C+LBN1-#8EZD)@DY'U3PA8SS3R_#"K_#(G;?,-MO?^1J+Z3Y79<`;(2
M4EQX<#=&:QW&X9=_RYWJS.KD8:_RO1ZZ!"9AY!0<!6+4,(5:0V-22=00;*^5
MAU9VJ)F\V<L.A'4(-2T0E`;"#1)0D!?"M.PMJ:^:`K2,)-P9PF.N87P$?K0?
MD)0"`P$<GG`49QU+0,#&(B6F4Y7"0TO(K'E;^GT82I-L#QFPS\<T!6A%\R#O
M#16UZE5UUV<U[`3T*&N,T>I>%0,`,(:/,GO09M))62'4:%5MAMGMB7%8#2`D
M2^!`IRHE2J8J)7W$2U';^Z$M2ME-'KN;&#I"TV6E+BWNCKB+OW9CA%B[^'GW
MM"IY7HSHF>1O,#,.*R>'6#F7L@/Q*]9-"T`2IV/-(L*I9F&".DS`T4')I>K[
M\I%#8!:`&+?O5UBL92!_O>OW1[LIV+SSH`DY:_!/XX/AO#@2(Y'%Z*%IR\)D
M_4+FJI`%.!NH!&BKVC5M,W2+P!&/I0NEDX7$(7]F(JV\5_+![4EVW^BPT.J@
MD.6Y/&BM:@;_PRENX"S]H+>9/:Y*?Y)D(TL%W@5OF3*WTP!EHU]8>S.PZ/IX
M"0R$JV"".(BG)!+8E-@<#DW;#U"68#C$;*&J2A8*:@DH29N'?K^^2*K4+Q5S
ME00+I]06IHZ__&L`/+110=3"*A*IOG;)M^:&*$S`%VTKB62BR2=FR&R=@,G[
MP]WM^8Z1#D^J4F76DKW,2K`4US)0)J*!RB20$XC"`X1A_+$;-K]""(:PAR#V
M)R".S`<3I',\L,:\5+4FZ`L8H!`C)4M..%G$$ULF847HUH<M:T?#'VWQ?`"A
M[TWMD,L":F,H$/Z7M0I%=U6A]D('URD1TKT&0W$QKJEZ6PY0E4F-M%ULA;XW
M;+,<"F_]=0D0(D?E:#B9`$^I!>$+)%AL`NE4VI0KXDKI,L,H@E)!H=Q"2;E"
MPMFTQ9NS9\%'*1?FZ2(^P8,Q.G484^<3GZ4\.#NHLO:SU%8!4?9EFUYK%FP#
MN&X\;OI,U39L=W*TI$52C>#1M*&I491$X63ENM,Y;#I(PH:7`BE7R+5,!M#R
M'5H=><=&*?:VK(._:.0NJ^/\.E<72O>0``-<#NA<KW35US5#FZ/_W"Z3:\34
M/A?II%5.+?W89JI$P39'@CFS)2`/P%""D8-M@WWK'X&9`]V04D<IHT1#2FIL
MNI?`G"#JC<I=G6;C,5A`,"RQC8BL1F(*WVXQ(B)"DSDACDN@,'7/$SZ"$$X<
M[%YB"6;XA1;DT/32Z`C-%C"9;!IHA*Y$:ZE<."RQ/L%$73>MKCYU#7L.!<#/
M[%9C]]QU%MA\-';-.0],M/]ZVLT"R3L2X:+)6Q]ZV,@=3HY-63AE[ZZ7A]$-
M"^!]Z+)("!^WP;$A:(Y,-LX,7SHH4G5>#H7\YR*(L?C/(^:9/TR#9>?G8M'Y
M><*6G3]\@U-,W_Q!LJA'L'2,;[&8"%T8V`#WJ1GY'$1>)%DK&]#D23Z?N"B&
M,J@W=G7385!JVD<Q"@KM%;@2)DL,8M70V<QY'.NFPO9T1H*X5&1G\5A>Z\3N
M=AZGI^<?F*A!IK;H".P]VY2JVY^<ZP'3UY07-]3"4SF=AIYC\VORSH23#534
MM:8S)I`_X\RF!AU320WE[!(81/%83\83D^6QC8=%.^R>*6RK<)LU^?C=G64O
M.FO!'B1@@`Q(MV`M/H;)X5B%C;5NJ,!DCE.[92I7NGXHE&Y58<OQ`5L0>=:V
MNH$WZ#;@$@B$P9@1I@-1KL^+$8$<HCX4$[)5OQM.9B`Q(5W3T>8WE2/;-[TG
M:S-Z)ROL)3[(LM0]16R_O?GA`40'MX-E>7[X""L6B*E7F7#K,84\8$M(=?G0
M=;9CB9`],?''>LZT-RS4561C9X+R,#W1;C)V5_5U!"#1CF9IQRL;%!2[IT"^
MQW,6W53:-!`,-(7]^-]W*ZUU*$2;MI(8!NK.'O^:DS!;O'?:]K%Z=;3B[=F3
M`&KCMGOYL9@G$[&%&RMT:JSP9+*N(!"G7:0I4"+`YIY.?SS8_`0*P#3DB%@K
M@<Z9`@VU`0RN&^T.F1NV$LKLL";?XQ/R$=[2YRCFE%EA&TV;0?^H";_020"=
M6BMI>-(!=_D(`P_*TEA_&FT+3/$`I0?>N,`VOZT=72,;C\PAI]@JPW4BBJ;3
M[8>^*:6.V6#)FZYI#^:0OI*0ZAK(==4*_1FPW@QC@UW^EK<2OUUNQ#X8IN:*
MH%/%Y6*,U=2)JEPX`8V#XZI*,V\+"&30@ZVL8:M/"#C:-$_!96+@N%P+.DFD
M+\QA`(EHI`>P%P;04,3>`0'V!CT#:(KIUC<@07_P#8A#FGH'"+SAX1L0\=0O
M0\BCQ#N`SRW!^`P.E`G_#`'S0YVR*/`]3U@D?,_CF><"C,'W/&+<^QRTY,60
MT\@+`*.!5SX:Q"_/_\6(B)<GP`'C,WX)+ONB8\([D:U$V)HGPMV+$/'3$/`G
M%@$%CZO<T#5C-DN39W&&PBA<18#5GEW&%V/P73J>H^BT9H),I#\;7C#1TK&?
M=7S>3)Z5PW-PPI@XD8/'4[`3C%HY(*;=J_OF+;>/K>%I69K$SW?O&I65"YTV
MQ'YSD1Y>HA0\34=!GA,6=)=(VQT/_[BMAC%]I:U>N@C:JEMEWE9Q%<3H[#(S
MMAK&(X=EEA<A+0AL0K1]Z$H9R@WTP!6FR&2QZ,!K>6KGSONQDC0U#%+8[^Y6
MC^XFZ]--7>5M)!1]DDC=:\7RSC;"GI#Y-]]M9%@@&&1`X_%."(]<26IY'](W
M$+#"\Y_S=CDGQ4MV"2E_E.*L7>*EX4OMDL:OM,M+%]%V:5>9MTM<Y6)-T9&O
MNMX!6R?<=<:S`H@WGGY@,-%%L#T.*X&>/6UZ&)WB/2;78W&EM":<VRW>[\'[
ME],M#7.-W))BO-V$W%C6Q9FKPW]ZI\%(29G5&MZD,2YSWOCFEGNQSA+3<N>-
M#RJE"Q,X%_RUQG?A(FA\;I57&!^>IE^8P+D8;X[IBW5CL70V*.J:W@6^TWBG
M@^!W=[>KD[CYS=F&XVL$?DFIF"><P.>5"D7(I4IEXK5*O7`1K52[RBN4"JM<
MK-3I+ES$IM(O<O\X8>RXGO1J\+?OL,MXB3`OIH`X&H4YJS!*+_9"2E_KA9<N
M@@ISJ\PK#%>Y5&&4CN?D?+JT%S&7JU6!G9<MWM`$1]3=<7.(:VE%=]HT;57W
M^06*.2?CBQ03].AD/*O'U!3_9^>-?6U7T(RS57M'G/&GS87$6U'?I*&WV+NA
M:>BM]FY8FGC+W1M(0GX1HH!Y"^H;$<3,.R`.A%_(.$W]2Z0!]^^"!L$,$&`>
MB;>POJ&,LIE5.!4S(T(6>!L8-Q"U_'V8&UB#<_^(V%?$ZQ%)$/DAI6F0S(U(
M8[\<#**(?R^,!<PO*>.!\)L/"P-_:^N&193[]\($3696B2$\^4<D=$:W7-_!
M]8Y@(O$CQCGS=]EN>$A#/Z8<RO09.02;\2@>X[^G\(Y(PAF?XVDXL]LPB`*_
M'"&-_`VUFY!%D5\O(<<;.MX1H9BQ9*CVYN00PM_=O`ECD?KU$B8QFUDEC2/_
M'%$0SUA0!.%A9@2+Q<P('J?^Z!"%"9^1-$IF+#D2>'#H'1$G,Y$N2M(9;XC2
M=,:"!"08OZ2"X3^*](](/:UGH`/O?[Z^NK[Z/PD=7D8-"F5N9'-T<F5A;0UE
M;F1O8FH--#<@,"!O8FH\/"]#;VYT96YT<R`T."`P(%(O5'EP92]086=E+U!A
M<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#
M<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P
M(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y
M-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E
M0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#30X(#`@;V)J/#PO3&5N9W1H
M(#0R,3(O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<M5M;;]S&DGX7
MH/_0;\DN1K.\7W">'#@^\%DD9S?V(CG`>:'(GAG&''+"BQ3EU^]7U3?.2.($
MC@C#LLQIDEVWK[ZJZOGNE]N;WVYOO&V2Q\*C/_Q;MHTC]:,\WM[X_(DO@D3X
M"5\)1)AN\SS(1.;A$R\,12]O;WX6+3\KC6)Z4)QE](_H][<WA]N;W7_2H^C/
M[(*WC:(0+]A&81SBGS`/@O//\RBFS_,PI<^S+`E??F`@[I+`2SV1^?B;>G@J
M[6GWY];\9CY,[(>![X3Z[O/MS7]]*.Y+5L%GW,#*XH<:]?@!-.%GXC,4].V_
M@\C[#_'YU]N;[W'K_[[)"W!GGOE__?GAPO.3B)_O;7W^M;R]N8-MXBP7GQ_Q
MVI\/LA7_<R@&*3Y^%/*A:*9BK+M65/+8M</8%Z,<Q'@H1OR0XM1WU52.XE@\
MB7LIY&XGR[%^D*)H*X&GX%]1E*4\C<5](\50[.3X1'?MZD9N[(L^BK&OBP;+
M>RG>6FJ8+8]2(W626J&#+%)"3VTE^['X`M''3NRF'J+U1G@IJFXH]DJDLJG;
MNBP:DA3_ED]\=783M#.*7=<;4>N65"!_/V&=K,0)RI3M*$[=:6J48J')X]2,
M]0GZL8\?QJEZ6D43H6<T$06Y406"4MM_J"'!5KP3I_JA&[&3"Q.)6MFTDK^Q
M;DC\1]DT;[W5(`_M7O-@&WD>XN(/;/#N[=^4SK62QK%UD"C1#E)V[=AW30,+
M*LL\'NKR0'[\4%<<#Q0*];'H$0;%`!V1"U1RE/T1%FWWN$$J_\`/24H<IOMA
M+-J1=+J&G>E#EBCPG4!IG"F!).V[+26Y[C"=3EVOXKELBOHXB&[G0KF5@Q*G
ME8^BZJ?]P$;'E:,2W`D,Q_CQ_;NM^(RKO=R3AW?02#&-AZZO$0T=*T`,)T`)
M?B?46$'V+$\LQD6YP[@XU3X^#2<Y#V8#/B,D`#IU-2(4@3L>(!=L7)(&:JBD
M5K@`HT$6^$393)5!0Q>ZT_VOT)S"LGM)QD?X=X-DG("*IG:&B`=9-.-!]/7P
M9;.*+M+<Z")&?K709^+=(OD,@-MNU!N'C`3OV#K447;'4U,7Y#6/T(0H3OAO
MR5+,C-T#&.I>'J&E84,&)\?H6'&]+`88?OO5<BXDYBS.5\V;6108/6:>RYL1
M7LUZ5"X_`,@Y>DQ>K.2#;+H3:6.#B_(,X&LYG"<5>Q%&@!L=ZW%47D,&^O#^
MG4!"/14(5;Q!Q9H*NQ,!$>['95JYAAL%L1;?8TWHM`$:R-(#^+[(D3R&Y>F.
M1]F7A&S#H6;AS=:T7A1$D$0$`4"BIS,AM&P(N9=]K`282/BK]=8!J738U;)B
MCUL+5KS,I4X72EZ@845[/G)C55-FARQ5,19;\3U`E(09)N0,NJ3Q7]EW8ZU+
M^R8F<$1B;4@M)4#:<2U22=7!/9S$X!?P-ZN.N3-LQ3\I4E?00YK[%E)\ZPN1
M#Z[->JB'82*Q"AL%UK::)A)\5'WQR%JYA)69G2E!5D5?#:0PDOI8`)KQ%U$!
M46N.,_@&9:RRG"#\;E0YUKYZ#?E32Z'3F?QA$!L_*,J#)@4J,+;B8VO=XMS>
MQFF(-YKX&:;^0=9-PSJ!(/N^H%3;"3#P>M0Y5.5GCA;6+I%+)?.@V<FA>*`$
M!-];0PFQ9=1Q[G*LE^>&,1D,J/]@9X!<]<@E`9NG>R1#=82)#XP/O6AJ!(0E
MT@Y22$1K3Y`-2#J!0/!S9I"+_P[TX&%\<_A'16KD79>+)JA.S)N@3L\+7;62
M8Q<78&M\X^TS:IIF=B/?KI&OTS!=-5^G@67T@0O2,(LU2'UB_"Q*+L&L]U!4
M/B,P`_RR*?JS#\3]$Z&MK/?M&=/=@U0C@R/&GTZ4T@'C5%<"[N'F/1#P21;]
MH,*!65=]7`>C/4?_T\3Q_UQC5"MEI:B%2238S9$1Z8&*F%EUTCQM+J,.PJ%X
M9^"6OQ,7)G%:8%!#'%]E>JH4SM.]0ZP]EO8M\X(59$\R2_^S6;4?I;[!Y[VI
MO74^@AHJV12J/G&8=`9!IVZ4JEJS,,OIECCR@#S=,TDY(0]W%>N`+*N;`_61
M^#]6#F/SI"J*:@)T*8UV2%QKJ"')K0M$\Q)0PPC1<KR9^&0K^V_`.JG<0XJB
M^O\SEZDEB-@],2P03R0ESD>6CE"L<,WW9.G]>1R@2D82$T"H=D8!=OH>JT55
M::RA@#AXT0\2);^FYO!KQ/(TB'-]".K,L!$;7=(S%E")V(!;?9I*516V9ZP>
M*Q#?#3.7O7Q68%KVQNHDCF^?`L7AI>JV-7016OZ>NK9?&!H\N-CI5KPGFMK=
M:[*UZ[OCF:!G98MS'%VY#%3>UA0/<'["$[(PF)OL\8R10\^0E+*;FDI%WT8S
M`"C11.`:FO`MBT\C5\B%IC,R]V)+I3_NQ`O7SYD)*"J[.K$=9OIGK%=#`$NH
M%:#!M&XK:)$*O6F0"E24:HHU26SB61(?XG;;!XP,QV!@5`@HJZWXH&C91DA=
MS+RD#ZC`N,Q&>W15#R6A_9.JBN5#W4T#`F1JO[3=8^L(O&HIG#64%;FCZ%A!
M`7%F67SH)TX!H67Q`V*A/#.5WMP&6Z+6#_?U="GCJF\C`<?,O`9XSRD&TB@=
M<5[IQ:ZH&\("1(JZ_I)FH1Z.DS7TD!@B'WBA(_+<0R,]<!51"*I)N?];5+`F
M/+G0V5SEK_MIJ*E1N$IO)X[6Y8KQK/OK.Q6$H8:$[R11/993)XFR0W5VW_6*
M1>B4,7PC#M.Q8%?IBY.<QKHD;Q@E9PF5[C;<U6@!=CJYFA##<T?B$<:-_@^E
M'JY^&FG@PC7CTUK3D=CVBOW$F_<(,],OY8XFN>A+46_X,?>ID"`U3ZY4"_69
M)-3O[*;]0==O,TZM:"'%!;>B5>^1]'&1G59IE$:N:1R'_JRKH0M:$]9-74H0
MOG9/_;RZ-#4[2H'C_83`8%;+'/H1U@32,0X@S;4CKD%'^M>M^+$3NO[0KF`G
M4,HGYC2)YTCV*?A9KS(UB&RW&,9WGI![VA-H\D-FA^0\_%'=.9:!*GMN-MAV
MQ/V3-O&S00`Q!78.ZIL;=5")4$Y]+^=LT73?H5"ZZ5*7:Z@@L:PQB6?!8/B!
M?OM%"4<#!3;27B.[E6"^\_/PH$S/35U',^`*-(CD9CN]IM:ACRJMD0,[G#QG
M'<=I6(4?1%%LR7,^FXB9_@["L".?-=96]C,107E>/KIJ"*43%N]KI%+5HC,>
M/F,.FCRIN+#EA@Z-/0VB6'^.@9Q1KS54$&1.!:Z&#DUFG#MZ\>*\:Z.K:X0Y
M76?S#:HJFJE.34BN)Q>30K9O?NP`/-@(NTJS)_+>X-#$0@(/74>:RSO3C(QS
M.YQ10]?7*UDVBJ['=A/U;;0/_PG#?/SQ/9>//[Y_1V4-O)-.-ZA9!+_$=(I6
M<-+0-:,]-\Y/O>AY-3,#7Y96^Q^G&9/#9XBNYYJ/9A2EYU#'62U@QU)J'LPR
MSE]#)%X/51DE*<&MH@37C$[C64<^UL.Y1NY5<3Y7ATJ]!0$V(-2!"99-/.ZM
MQ\L9KUM$V8X*>36\0`Q?3D2;XG'0Q,!TFP;K#]0CJ.4J79\P\BR=GPW^$S/O
M=2=ZAK-$\LU@3JQ0#^-L]D]6)%G=/,&>_C#S)L4'N"UR,)KEJE>I;X/Z8#0S
M'"Z!N?>X"H\+@]!-Z?P9%@0OUW4@[!,!--5@/'R932P=:1]D_0>M.+M8M[].
MK7X2-T3JAUJW1GH(20-`T`+P7=-2HV"!HD\=O,3$QQHJ\!)7SS@5A)%607DH
M6GV>:3:KG#5EYSZK.P&0^C@U>^Y3S#LWL_F-:J&^TB=Y%497D#_(+(OU,E?/
MI8;%SE+JLZ;N5OP`("-5<)5/1Q8@<3'RNJXUPW@Z$`3@,(ZB3W&45*!1EW=X
ML?910[#60J4B08/6Y!J*2`.G".<(26Y#0?=7Z&C/*_:?&_NU7H!\L1=@[/TK
MGZ<A+^&>-PUN26@0U^Z(V[?B9Z9YA`UKZ"!V)Q=BER&CW#=UG:SJ4A&!IOXB
MF_K0J0Z^D<XI!B+/A@=*,\=Z?T!FZ&NL9)*_FQA+D'/J@58^*)BLZ"`8GY_D
MXY&E&@7K(T7GWK*&%D+#98,PL+WPQ$OUV07MH+31^[XKJE7Z.('_ESAFNBRA
M;6AZ:6(37\R_DX0_U<,7\8&9^$6UH![WT]_I<8^TEW_@MV`;"S_/\!//S&+[
MO^;VYM.;;#E+[);S=(NLE?!,^8[JSG!V-NL'8.H[%5\?E&?]I&;>5V7(DKD,
M01Q^I1#+W-MW!XI]1SC"Q-=Z_U<W(:<R?!`\*FYM9F;L]3OD@^Z1RD8++'0<
MCBK?;J].33*[HK6=/AL`/(890<R0:>]-JPD$XUW;3KC_)\DG&A&D'[K^*/PW
M+SK2U$F^[I$`.FUBWQ1M<Y]:-/2F__[TW1I(X=NCTH$?."Z=1N9T3VM/A5,#
M>X[WE-Z01X>3Y$3Z<:>&@[L+*[-Q"0$GGH_SR9W-V9,V\W,=W4GVA2-9._"J
MEL^648.P7HM#^*XGG,RFIT%LS[>01W/_5ODL)-$)@W[C@*5FQL=6#8/*NB^G
M(\W42]/302ZHU"D.W=51Y.AXA$3(C>47.QRC_J?<&/HP(&TBE@9ZCCI2IA:L
MT@3QW3EB;\8@_$LU#"`T-1V);_6T7UG91>B]A/GM@3V.Y9:L3_M&C0D*COKA
MG:.CVDL@,CBV:HJ-W`YSLQ<4FH,NX\USG^0J),+VAKW<:2&,<PW4=)9ZK.G\
MH2WQ'FTSD^;'8!62LCYU(8[&8S:J/J9&VJ7G7$3#F424Z\!>4I'FGE!?RW%[
MYF_,4+J/O9P7!*\L"&##Q05^Y"\_P0N3;&F!GX=IO+@@BZ#SI04I?25H:4$2
M9LM[B*D'L+0@NO:*,%S6`T`R67Z"'RRKVO>"*%I:D`>QM_1Y=N7S-(@6#9$$
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MW?DQG6)97)%XV1594F\YI=_YF9=?6Y&GR_L(8+9E60+@X/).`_#:9>\)0B]+
MEU=$($'+*X#)5]Z2X"G+*U+_BFU#+XF6WQ+Z]-7UQ140=SD>0>?B99V&4>!=
MV4<<7`FH$`7'E9VFT968"[/HFK1Y["WO(_+H2X^+*_QXF9W>10$0:'E%F%SQ
MY"A*KNTC3K(KSTB2?-DN49H&5]Z2T3=@%U?DV14/BCVJ(Q=7^-0>6EP1I/DR
M.L1A%B[O-(ZR*YX<Q]F5_`>E7T&Z.,VO1$.<Y5<\*$'^7]YI`J1;CH;$S^/7
M?1W)_OM?;F]N;_X?%>X220T*96YD<W1R96%M#65N9&]B:@TT.2`P(&]B:CP\
M+T-O;G1E;G1S(#4P(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T
M871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W
M.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q
M.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@
M,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=
M/CX^/@UE;F1O8FH--3`@,"!O8FH\/"],96YG=&@@,S8X-"]&:6QT97(O1FQA
M=&5$96-O9&4^/G-T<F5A;0T*>)R]6UN3V[85?M^9_0]XZ'3<CJ3B0O#2/,6)
MTW;:F;3QSB0/?J$H2*)-D3(OJZQ_?<\!`9#:2)"'$1./8ZX(`>?RX9SO'&#?
M_O+X\/GQ@:["1!**?_13O))!_[_L\/C`]!M&>$A8J#_A)!*K).$QB2DE21*1
M6CT^_$Q*/5442)Q'QC'^0^K=X\/^\6'[5YP)_XP^H*L@$##_*A!2P#\BX?S\
M?1)(?)^("-_'<2@N3\C),F141"1FE,01A5E1INW7C?EL7W+WDK-!J;=/CP]_
M^R%=9V`!09[@"]I6>E)K'<8)S!V3IP.*S22+R%/V^+`$W2@^GQX?WFSS,BVS
M/"U(5I6;O,VKDE0UK--T1=N0:DNJHZI3_+Q9D>]4W:9Y29HV;=5!E3`"OH8?
MJ0V!S]M]WI!OR[*#^7Y2QZIN"<SW0U4?0)*_D*>/CP_O0/#_W44]&26#?@D'
MI2@C3U]`J>7=EXK%V)24Q8$UI=#/:,I_OW]+/E!)\S(KNDU>[DAFS`56;/>*
M;*NBJ$[XXM[R:4_#EXRG`_C9BI?@,XI7Y\TGLDVSMJH;$).AYYHV;[L6):M/
M:;VYNUA1.,@UKX=83,],$`4#V$-J/%14U2<T_P#?%?EOH=)&P6);59.VTHYJ
M5*8W`HS(VP*@?6]I@V@D;:@%??.!<W'_=<*Q56@4Q@X8')_1*C_TSB?_,=9Y
M[ZQS;W%"GEQ2.[C[.D(.Z[RYN_=""`0CJW((VL:H$A_1INGQJ-(:K0DP.J8[
M140?!2`^SK+Y$>*]CV4<.A]3?$9Y_JB8S*08A)EYQ\OH3&\1.6SS.(J'F`S!
MC>0'5#PM6U+DA[SM\QG:`;9[,UO\"T"Z/\@:`8W'UH#XYU)`J)^OQ;^I@H37
M4B63@R#3]]ZUZ0'L26PF_\"#:0!.O)LI"2.[LREP.YM%)#ZC%7^"1-J0?Z@2
M>%&!*>/'KB9ONP9(4-.H:4$S\DLD:`^A<!6&J/T7+1+D></B?H:<M:^Z8D/6
MBCSGZ@0Y*VU("BDLK8N7NXL4RT&FWP]K[TK)6'L1`^.WV@MNTCK`&0)L5AV.
M:?FRNC?B>,2<"/?/)>#=.`EM#!OAC3N\(<RG_"5/>VV5-5#\GM<#F0>HOBN_
MO!R40^R]->(0>ZU*@<OQ_.[+Q&/+,3'P/1$'9ELT,&610WVC2'?L@SU1OP)*
M&F,._"!+C^DZ+Z#T48TUT7>,O/OU"$60'OC^I8%P";MIT\\P>4MYU(G"P*DS
M;Z9`#C@83D!]VSM)[Z+%+`"'0LW6H'P(J)0;@&_4LRJJ(R8D"*@`UJY6UA-O
M\^I]EBMP8>,0"P)\[G(8T^[3EIP4!KULG]90VZ@Z_W*'V.<K!>&-56CFHA.B
M^V`Z3J7C=4$2\4NA3V<BK..[K+7P'AMP#M^&W-'@P;6Q\:SS&-#>IEM_A+K*
MUEBUSJ)9U[35`9AR\4+2ME6EKIOQ_=!V0$U`NWG<&02##C,SM"`<6XNB9ZT[
M17C!G0LR=!+0(J-M@B8IU8FT*MN755'M\IF\&T@K+^.NR@DB:?R+(?%85XBW
M9J&%3($"'=;H37CU2F(S$D,JOOWIS]^?!=]^`MV5J,TP^!)L[+)4A4;!)H=7
M^;IS4^`7#FD)1M-KS&$![OIGX0C@Z$QM`9!J5U>G=K_`H`,"`J(;VPP;MWR0
M-9(?^O;+1-;M)XE1PBQ-@@0X(HF1="1QGSZ#BPA4H2#&2X\B*(DJY*T+;=%#
M^D+*JB5IML_!>]@+/*2Y;O&A_[90.VE_3>=95ZMJ2B+9,_LE4B'A$CH/V2L-
MP/M9UAVZ`NH8A-DVSW(-,:B[Z^K7_`"?`P;_)((%I3'\I1!=R/<J`VRJ&LF1
M8`O"*94K\E9E:0<U(.01F%05&'9@4DP^B%#P6/[<DP.TSPP0B\10;\2C3=;K
MK/G*!@1:5^U>2]6DA1$&`N<GU2*Z]&;`8)!GD$*;[JCK?`@GVRTX]F3L!G-!
M@L1<@`#-:NQ\;4B!N[0Y!X.>L%0[B,#/2)&:/=D"D*>7BS[].;5;C"=R8'&V
MK_KS7L%6JGL']:@\0^+"A8(&DK\E#B-=CG5>F=X>H*#-#T!S3GE1`'".D'$P
MSI(BK2'R'M.Z79BV`$$<D-'^SG4:6M@%YK`$%=82R=!A#O#80EOB%7,'+8QI
MKC(ER+OINE"H_$X7K*V.L"UR)0,D,$VE)QEP90R@@6'51>R48,T5>:K(!N;1
ML)K!"&$\D/IA.X@D-F%,(WD#.'Y&HE<<JJ;%AL,'"KG*R-IKLJVKPP4J<:$$
M6A&(+)NJ#WQE"\'DB(;"*%+CT<BU^2S'FL,*H>/,7(IA4X0F+%ST=E-5)7:Q
M(65B<(O0MQ@BZYX9OM+:Q7J@SQ8DX&/5:I0@O>CCBX:(*C]6+UK9_`"[#VW?
M;\)9E)>6)L%$PTF+M`4_R+7+P9L8$9R[<#?DV1[@C7T0ZSMD(IMG53>8#T!T
MQ+T.`W.5OP%\P<H_8_D;<#DR$\5#2FNF2-B^B`E=Y%BU>)0!2#:$;93&R?L!
MW*_#R!RN%991LC@9DIUDX:N*(87ZKBOM"=K:)&F4T$B.<&U4AK7BMM,E8P9D
M*UU79F^FNUJ9,\I1L!\:`7::"W62$P*6F,,&+'8U4S@<4R6QH3D07K98*9E.
MQ#\QPCU9IJ_U3C>;6LNWQXVJ-HW5X@AE\"'-%%#DS+A[G5?(#"#);3JDSZH/
M=QC/^VJLT79I\EV9`X_"'GEZJ#JT&[S<=O.0GI`.IY7)P*L9-3C0U`N65N5>
M]V\J7=EBS3\J>5;D6P"*.:S6^<AJA3L<OV)"-3`DF[]Z,%CV,U8;`T1I3)I"
M%%6U[OG,TA*1<3"$]^"WX1VK(/6Y4RC5PO4YM.CH[[-\?N:Y37^&[Y(6@N42
M:5J1=\^J1$YSTJGO"K,ZJ7&6F,,0KMG.HF38"SPQAK")J0'LZJ/T>O#=F:Q(
M6E+RN0,&IVIP)0Q,^T.O==KDS;1RQ5]Q2=N8CE94RL157#(0KE[IL]$VS?5)
M05^K:F1:5MDGK9,>AODI[]G<VE*3&<HLO>%,/TX,70B&SRCVCZ/UR;$`,H&4
M41V.R"6:<S2B&EA;P2Y,C_E&D^9%7ZO@9H(]I&/3P"UA0S855O0K\J\6^>DF
MWP)X80./#.1*ZGF"#QZ+V^`CAA/Q1!B>C0XP.:7IH"8$,_390Q\9OLI!"L7/
M]4[M(]86@S>PTYYP%#H'_7T&-W+FMHZN$.S686)PXTC.:HLW'&RW1HO:J/HY
MQX1GM-QVA5$"QCO9S_#8XR$OK<-AO'JNBF<,L;NB6L-^ZUFC;=+.PB*`W+H:
M08QJ!&FRA_.!%K<$X1:P!M;$ME@>=8W`))D^N3O+BY="+FZ#O.R4,0_28&V<
MX1+5,'5M[E2U=54TL^00%@O7G!M=[7*GO8/"C3[`:"S[@_*_J\UV1`#K#D/_
M4ZUC+*ATJNI/VZJ&S`M/Q>:4;Y0V3UHTU45[@-8=WB[2O?MN!+0Y-`_=_@V'
M[!FX&RVOMZ01%3RAT\+F(R03>QC4DX):]:TD&`G,8S%T5A:CT+4S1[[:6IM#
M7F([LN^0C+I$8$`P[A$3N%X8^,NN_W@.2P2N3$PD'YU5FPH`98=`J[,\,FI,
MY,-F1Z'&MAI\J&^NC+VH^X"`:PVG#C*6-9WNVM8VT:W[YEQ?<=EZR\1,>Z=P
M#C,(/IAA"(6!C%V7=F@"+%[MV>'BH^TC65QOR',^*A.NYV4,23*1E$0))4*+
M/\BI;X7"@$`&7`_@5P:((`F\`V`*_PPL`%KM&T#QGHAG`$NPL^T;$`?4/R#"
M"M@W(!2Q]`Z0MY8(A-\.`(?$/P/G?E,SQJ/(.X!R"+^>`<F-]S&>DWO>1UQZ
MWX><>ZTH6>PU`=`]KWR"4>_\D'/\;J8>_3[W(@CP`2+FPGZ'4'#]!!N_VG,?
MCC63[;*$T>O0\GL6B=TB2[;BW$02\IOP!96<7@.*^HN+>"*7_JH[X.6C?H@^
MS.F3>`/%*,3;T5';V;D:?+:K4TCN?2$!E*3.J@,05QW4L2[$%%042F>AT:F<
M[O"=T4%'A+Z9H..UZS.1Y$[)WUZ?0:!!J3<5!88&WD;!Y$5BM\A-%.@U)J*`
M\N&4D8TJ,C;*XV>L9'38TY-X[<'^.!U[^>8$R*+CDD=OR7O-HT'`G,"7/8I'
M>=,\*D+QM1Z=NDCL%KGM45QCFD=%Z$[.*1M=(K3%V=DU)"06K[C7<&2!'1P\
MU3Q"1='VUY4R)"3FV`X[1<!#,12<<G-""*/QJH7J23U."CBI=?'NSK,N(N*&
MOE?WN#:J]"""B\F(X.'7(F+J(K%;Y#8B<(V)B!AN$HQ_.2&V5WF<RTV%<490
M=>UBRKAOI@AVS760YIUD%UW'D49,<QV/DZ]TW>1%8K?(3=?I-::YCB=#LSH8
MM1L"EZ2SNLN'@WBLHO$'%WWQXPDB7;V2&G,GTV6G05DXU6GF4.DKG#9UD=@M
M<MMIN,9$I\FAQ3[ZE8C(_DI$UM6U*K,7?1-MW`_21;W2YPL3)+KN,^9$NNBS
MI*\>+\[KZ4,C/4ELKNEO3[SA\G5U&GNY^C*1WEI@"66AMQI:"KQBXQL0X/&\
M;X"D0!*]`Y+(OT1$J5^+F#+_$@D-_79BE"8W+,5NU%5+QIF_\EL"[4N\]>T2
MZGQ_B;QD$G_%SSLBI,)O4!;1\-:(Q-\N`.10ZM>%4^IO6BPYH\(/'LZI]-;S
M2RX8\^O"`R9OK"*YOWNRY*&OZM4CDI#Y5Q$T#/T6$PP"LG^$OJ[I'2%8=$..
M@-_83T*RZ(:D87!CRXDHN*5M'$0WY$CP9H@_^DCN]PLX/[HQ!SC7+VD@PEMR
M!*&_<[4,9!CZ_1*$H;]WM0RBR-\;6@+KO(&@((G\#3`(V'AQT3N"1:$_.H!7
M_%VFI13Q#23+(&9^FTH9WXAT,HQO[`89)3<0)./D1I:5"?SG'1'2A%_'.J3R
M=[\\/CP^_!_%-F<X#0IE;F1S=')E86T-96YD;V)J#34Q(#`@;V)J/#PO0V]N
M=&5N=',@-3(@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@
M,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO
M4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P
M(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^
M/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^
M#65N9&]B:@TU,B`P(&]B:CP\+TQE;F=T:"`S-CDW+T9I;'1E<B]&;&%T941E
M8V]D93X^<W1R96%M#0IXG+U;67/CQA%^5Y7^`QY2J4V*I#$'+N?)CM=5>4KB
M597]D!<0&)+CQ<'%(:W\Z],]%T")'"I<(;4EBR8&,]/=7W]]S.C'W^[OOMS?
MA9LXBX(0_ZE/Z2;B^C]%?7]'U!,2T#@@L?J&!BS>9!E-@S2$)R'C02?N[WX-
M&C57PB.<*$I3_!5T^_N[P_W=[J\X%?Z;?1%N.&>PP(:SB,$OEE%Z^CSC$3[/
M6(+/TS1FYR>DP3H.0QX&*8&?)(19<4^[MXWY8A\R]Y"22:@?'^[OOOLYWQ99
M0%CP`"\H9:E)K7H(14VDP4.-VZ:P3O!0W-^M0;8(/S_=WWWX1?:?^^#3411R
M)XM@:(-_CEWPL?GCN1;!CV,O&]'W?PD>?K^_^PA+_OOM&TNN;"PD:F-9LH&9
M8)-_J)V1B$5Z9[B/.N\^BR'H#WDG@GW7/@V'H!1'T91]T#9!T?9#]1PTXBDX
M=FTY%D,@FT%_DFW3!WE3VCGRHA#'(6\*<9,T\65I(GAA$H=N6)@D2IP/FUN7
MBB\K+DOU0A_^0WGXWJ+@_#%7\R>;)%)P40O9G_=>$/S2+@BV3\B$4,:8QL%\
M>?P)'@XBV(W#")#H1[!J#UC8!>UKV`9/LJH,7@`](D>P`&QP:+Z5E1R>$?!%
MVPRR&=NQA\>(F$'6`CZ6XE%4[5%]96$E%-B64#M/G!;B;-(",);2@L%W'PR'
M',!<EAT**![;ZE$V>POR3GP992=JT0P:_.@W^3!T.3C$HU#2COW0UJ+K-\&O
M0CWO0%B<PVCF[R3X^/6(TX,+!9^>^T'4:BY\V`X'T2TB/[QMY>=TDC^*G?S'
M3HHA[\!FHC@T;=7NI>A1)/'U:/?W$@&6%BKX7VW(&KX"3>!@(!08`JK;RT;Q
MR7!H>V'?`07]8Q<\`=9R6>$RRV,`'VH=9&3"0$0-!C00F_8Q5\:T^USA)HMV
MK$JWU78[Y+(!@0$I`(E\0"N#QS36R+_\^2>8ZE'TPX05/46%*CCA79P/7BG:
M^B@&.;0=KGB0Q6$)':19/+'!#`<LT3JHY?XP!%L1E'('`6NLAJ#MT*I@2KFM
MU&X[L0?I-\$/S3,(:3Q]%>Q@X`2=(J_P30UHX(8>XL4*W[9N;[AE-U:&%D[M
M[QQR"24DF0W:A*=."3$W0-"6ZH3:C$$RAL8.#6V%>I)@R#*O\[T>LS4^L410
M2J/LVX.2;WXVF]\%@O?6/&:/9J'_3_2+B5L0\,Y0`]K4+)L%OY_'#NVY`@`"
M0X'?Y_V`+G_(@02`^P3P(J0UY4JA]$F3>B4_8PPSKYAPJ;G2C%\!TJO\N;=C
M#.Z1#T[@CID4!M@E<`ZIM77V<,(YH\EIT-L$/P.JQ=>\/E:P;T2SV($[#[V.
MW_@U(/^E%+#I/#@`8<"3KAWWA^,(G*8#&CK#WL:[MMOGC>QKK=(A_RPPMVQZ
M68HNWX(:J[;9HP66T$$861VD631+T)GU=;!VW78Z?*D-J@C6H.C`@_4(1*R>
M3XP(.4*C$0(9`"0WA3P",Y2*`@N4>U2*0WH_@G0]<*$(MGGQV1"]RH=$>:),
MJ_`%5)"DJ5-!-&6`4(=-<:\7XC-8$YFW:*LJW[:=B8)Y-S2B4]E,G4,QT*KP
MD)M8\%F((XP!GGR2PT%!I,N/LC1<N0L*T!4PI-1Q40>^'DET%@I.^+Y=)/])
M$F)U0(ES!9:RR14P&@F3`*K,MA9BT!+-TSZ0";_3DAPK%!VVG!<'"=*\KH8V
MP2=(!^U;.T@4(<`'^6XGP/.GS')ZP2;;2R@AXJY836<)$'X^28)E4U1C*;Y?
M8`\1LYQ$*76$S-/(Q%ZL/I!$&[0%*!;R)?R4]WU;2/0R#;2QF?('EX6>4"QF
MY'*09A;E?+O+VCZ!H([_2PA/'!EE&(*L)]IPU$/LT'424$=]DE8`N4"NU8`.
M*F204JJX@:X+I020DB[2(/CDJC2_+0OQ]Q1XDMJ6`KC3U%)(DGAJ*>AR4"C5
M*I97Q1$HOAD1_!`F.ZO@5S+>G#I=3`#"@'/K^"%VDJSC1R&=]ORRJBG&K@,,
M@1F@=E,(NB@))KTY<`4H7P[]["'XMBUP#'U@5:FL!A8\&1<4.3`H5LL+0(Y3
M5_[',_*G$9G('Q.:L;&4;HH;B<T>R-(QZ$GT**AS('!AIO]T-A0`:6">K[/A
M'D(>8+;MU,BM4T*)(VO(`()'`:5F/V[[`:=%5$/<&.#W$DH($T<Z*+A10F*5
M,"_5,.R/$N"I`H$US1+09(FKR6>6`3/-&W0O<:*J+8FZ59:#$LR@%75M\M"\
MZS#H:GE,7)9=J6(YPEE5:@<!III8<G5B4EO5FI%+V`3;OT9ZDDV9>4J,^#-^
MAPRT%AU2G_PCM_DRHDPVY=@/':)':!^>-1=TVNTHT8;@%\Z^LNY[=KY>9X20
M#RZG!^8J<I6OVYC`;&<&RY%2%&"3E>LY880L,!BZG8&EP*!".>-4CFSA':T2
M&)L/)G.98PH^&42I;.TLRT&I#Q'8!!KE_DOH@4Q%>38KRC/;G<$4W`27(1B/
MK:G61`>BURJ6HW8@(VLFM]5&!^R_]X894(?=<48W7/6GL2>]?O^5HIEN",MF
M5,&YQ4@'LKZPV<,!:S+580,%B0["V=@C`3^U%^RL3`NEWB+F#5TMRK`7:POQ
MR+B[:AKO.Z%82Y-6VYB\&5MF%^(O.((TM5O3/L$K6DJ,7I@>J?(4"TQ92W27
M;=Y+4,V9H+]"-'4"W6B%3B$6*<5H&DUER)2-I-:0G3HN`J%=L8F.B=I8V::!
MZ+KQJ(]?9+,ZP?_VV=#Z*=UKXI,OHPFX\Q&+\"FB*+XL=#S1J?%B?4@:NYJ4
M)!,<4IN6Z0PQ+X'>>M5HJ8]H?-QAE8\-;`K4\5UK$@W+W[,"9M:7.=/>.((&
ML&JOSN-J%?RKK79Y\)!WQ:&M4<]+Z"!R-6E"9V<2MB[_M/EA8UO!A[P',A>-
M$1'M!]7Z6&^!_E\*#X`&ZU&D)$1..PXGN%%S@=BJQ"M5$]OY'80,['[(4NCF
MMDM8H_=O!Z(&V'0VE<P:5)FIRHMQ*PNHPP=T=1!S)SK<IH[GCN-54)SJPTX4
MK4HNW0#7FJCSW]O.A07A4LY&8*J!9Q\ZX9&]/O101S2Z#V34LDA92$GB:I3I
M8`)P8("@_;I&2C_9F0.%;=&5ND6)S8LMHA];ZRX!`CG!+0`6\2;XZ3DO0;,:
M"35PXZ`S\Q+(%'SAF#\K.*`V"M&I>J`3=?NHTHLE-!#:5#B,77QC-#&-":P=
MCFY'+^R#;<@CF.>KK,'^(/&?"&.K,`PA;9D`?!XZ$ECOT#Z)1_1YEU1IBY]4
M+-@*6J@K0U*7",?95)RPT$3&D^[33C4SP!^"9Y%W^@Q-%2J[L2F1%9Z$S?RP
MI'O,984V4Y68-$//4AZH8G:N,56#V*<=NM%P;R/$0CY`8I<&1[,^+37QH&Y+
MT34V_4>4GP#@.+72K6TA8/:JB.V=P&.N'&);R7VN[;QZ>5CM##V;\=6IKSD.
M6D(+W"5Z?'9,32PA8G8+^8`^2=1'$%M32C=BKSJV>)JFNHNB5$U;'4FW*@LL
ME-#?W[SS2T=('+":1!>.J%2TQ_/W)(.:5TT\S:"N]&`HC%BF!M`+`S@'W_`-
M8##".X`R*"5\`X@2PS,@Q):Y9P#)>.@?D'+BW0-)6$J]`^)K2T3,KP?":>:?
M@5&_J@FE"?<.(#0-O0/"*P,RFGA-D0)@?,\32KUJC)%T/<\CPKS[XR"![SDC
MH1]KH5\^$B:7W_^B151B`F+.N"IX\4662?!5[:L4$N[8'L/&R4M6^)9%4K?(
MFFRHO6$1O&*>E.LUP"W.+N*A2_5J,E414P\IM@UI$__,!84OP/_JPZN>02?Q
MD\J%H&C2(=_>QYA?!?G;#=N_Q)D`,;?_#Z_T@AA%B-QFX-ATZJ\;^.9%4K?(
M50.K-6XS<)RZ%FDV'=]S3HR!=9'7%#K),YD]GN7H#$'VZHS-9[YKF[MD/KP_
M9W=WWGPLO=E\YLSB#>:[=9'4+7+=?+C&C>;C-K6E(9L=.+)L,M\@:W558/?J
M1L1)47NC=U[;_&7O#-WNSYLW)#>;-^1O->^MBZ1ND>OFQ35N-&]H<W;&3`/C
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M>H2$;[3>K6ND;HVKQL,E0#UGU_#;CA!W'J;.P`K\F'+3[MJ-70/6P:Y=+PIT
M--WXO-B].]_-Q@NINI,GA]E-_C/=LI/>E_'M=Y4WLP=?C+L>9\K)R<4SW!!V
M&(%-_O>U+UYO3B.[^'DBT8V`LPCWW(?B81A$]@S+W&6F\<O&%_?V2=99Y.TR
MK&GH;_:L6<B]?88U#[FW4;'F6>)?(@Z!AGT#DM#?:UFGV-/WJB',_$N0D+`K
M(PA)O4VK-:'@:/X1+`R]K;,U=@C]HI`H9'Y]$@AKUT9D_A;>FJ2AOU6Y)AG^
M.>(U;/FQ0TD8)?X1E!"_+)21Z,HJ'";QCXC"*[:E:>SOJZYI%L=^C;&0)GYO
M9,#9?ITR2CQ].S6"T2ON!/SH[PVN6<2O>!PDE=>D32!-\(]((^JW/LLBYK<+
MN$OBGX.#._AWRFE\91^<Q?YN\)KS.+["DY"M7%DE3NB5.9+D"H)XFOC[WDC'
MW#\B"O$/&+TC@![\.XUH>@7)D;J(YQW!TRM,%T7I%6\`I5]!4)1DZ96=`M/Y
MO2'*,GH9ZQ"H/_YV?W=_]U^5>E8(#0IE;F1S=')E86T-96YD;V)J#34S(#`@
M;V)J/#PO0V]N=&5N=',@-30@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@
M4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@
M-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A
M8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y
M(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM
M86=E25T^/CX^#65N9&]B:@TU-"`P(&]B:CP\+TQE;F=T:"`S-C8S+T9I;'1E
M<B]&;&%T941E8V]D93X^<W1R96%M#0IXG,5;6W/;-A9^]XS_`]Z:W;&U),#K
M[%/3)KM]Z+1;)],^](6B(`DM12H$*<?Y]?L=`+S8D:%N:G8GDU@600#G]IWO
M'""O?[F^^G!]%:R2/&8!_3&?LE4<V7_*P_55:)Z$C"<L3,PWG*7)*L]YQK(@
M8'D>L59>7_W,:C-5&L4T3YQE](.UN^NK_?75]N\T$_V9?1&LHDA@_E4D8H$?
M(N?\\?,\BNEY+E)ZGF6).#\A9[=Q'@0)R\*`96F`66E/VS\VYH-]F.7Y^)"'
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M*@PG'6'R;=-BCE+2`JI;?9F,J5?&+$V,C!`L2",^"!GFY.XDY$]RUU?&LS4$
M>F"5.JB.-2U3AV,!TY/@Q=K:`")H">OM9"T[5185O%/6.P5G:*$F9W'-5&T,
MNNU)-5\HEC]P,Y$[T_$L'$T7"_I,4GW[4&Q4R3:P1-4<89'ZT\-!3COLR=G8
M&I'(ZJ9^Z0T*GH\[S#GP)(!'?<*V;E]\)2%FN@BS8-1%%&?.C9^QUD&5;=.T
MNZ)6^J!O"&$1U_=D7_SL]HV&S^Z+CNV+DV1]O9'MKJD1I@T4N4`T9DB%3HP0
M&77$I-")L9$$K8@<VJF3"4&V45O(1OZ[H@?T]\?!RMBR.D'4;=L<V+^^_T$;
M9-7]^C>)\(4WMZ/S(P3IU2U0K2VJ&Z8[1#Z"NH'>#'(C5J7:U6S7G&1;&X1?
M0@G(JH,2Q`1):6YU4$#N4DEM1`7HPD3#5ZS8'!1,V4F#F_(C/M('1+*-0U8<
MCQ5415@TDQO/*[E3VOU*$%`W'8.W-/>TBHLD*,L&CS3:.!3M[[*CYPIZ7D`1
M:98Y101Q-"DBB%R`'Y^W,="G8)TZ2/@[X!7X2T(:!V:=+/>UBX6&DOCA(-M2
MF=^W$LF,M$/I6AE$7"TA61P-P"""-+7`,+CNE_Y=`&*'?1(WRL,15D+A.,)W
M4//&ZNEF<*BF?6!%.?C5$99!%"&E=&IGW:ML^FJ#T;JO.C(4>)6LM=0WL&-5
M/&AZS=`C2C]RHRQEZ)K)$[_2`XH/Z+Y4+*9B)(=)-I%#P>/1!7=M<3![IG0W
M.9/Z-%)%*RH%XN"Q)G8-8WK[[=<SFF?"4VI+A8J#G.L4:%1OBG:CISCL*%UO
M"*+;IM_M%U$`'U@BYWDZ*B`?V/$`PD-2,?QW2!U6G,VC#3N#T;=NUR!2UH6`
ML@>)-S=-U>P&A/M6PCLV!L5JDY^&J>`$#LV,G@F1EI`_&/EA&DT1("(G/PP$
MFU12:[(T`2'PQV2.'@ZM.@.FZT<)IX*NNOV#,7TK3TK>:[/[OMX6I\8217JV
MD<!QX+DC9FI+;M':RD`76PDR!I0JD8F,^]GG2^C`>+[501SS"05REY6-#^^+
M>@?/)0TX?YXY+QGN".9</DR>_Z9OX0:H)-[7!CY<!+UY?P.VH6?IR7R&DETI
M,@_YFWF%,>4D&KF$'I*!9`51-L:""+FCT43H!S<?4Q')>[]7Y=[8C<*EI4Q#
M7YOJ`.#0M0H2G`S5JC$%4CJT]_YNK@.KM[=0DOQ8'(X5>$EQ:"@J#%+.JZL;
MZ!#*4`?$TQ8EVB*JB$>BQE,^<13Z[,("W,-5RVYSE)5??"MBVLNR+#M$L327
M.IP<(*7/)/5)G4R6DEOBHR6*)6D(V`V;L^KFHRH-PA&M=",(/.`63VL4($A=
M5OUFGCNL:RU0L22Y^(MTF2"3C"O%JR3,W$J$G4MXJQ@9M4BF)!8,E>+C,FB"
MJ#FC.4^Q.\N_J3:P!+M]4DKOE>&<(V^9E=%S+KVVLQGOL1BVB!["D5"G8G1?
M+JP63%'GDMC36OG_SJ?]'0Y3YY(SI2LH,#/.1!V.)'"R?5W!8)1)"65IOXYB
M&!N!8I));9>/FEI4Z#G9R2Q&,58CEIK=XZ5[)*+FQ6L#<&Y3ZKA2/AO[<E&4
M.U&^+^JQO_;43)1BG%MMR&9;$`BD!-GJ%;MSYB4!!O:LY<XUY"3;(QO;[DY[
MDF,-N(7_$HTQD*8H+V%(KQ?A&3%/O?6>Z2<-$I$,)6B7-)N72(G-P^IQ@ERK
MYJ5WR<%YAFTNBY$\CV<*X7$ZDL\X2!WQDD08&MN;L#Q@`9&C(/^+1$9=.1,Y
M-(UYY_VFJ44B;WM9Z<=]94>8X/V$,EIM7+/5X6AS/#9MU]>$NA372SAN.+;2
M4SXK$APO=-"Q8O]N[L%=6RJ5M2Q:<,*U)(`A<(0XB%DZ,'"=TZ+71]MOW]J^
M.B)S;+`BHF_8^]7=BKENU;PG1>Y0-FW-=BT6;*$8K1L`LM'7`N(;:'+BYV/7
M+B(/MND56*)[U&H%P<<<8P=0/8]9-\P29V51]S'8D2P.`@@`IAH:X+1$BHGB
M9$@Q(DO'#)-ECOM]<Z[R_P:<KZ\:C0+YC8O5`5C7<DR.BW3'49X-V!&**9#2
M)!LSXMZ4W^6TQP%/]-ZU:`P_(=VC1B/WO*..J/X*)1@5Y9*.+2"H.E"$X7&C
M*L-86P@F'8^0[>Z!CK]Z<RY$KNFFI<=4^B^22J)@9.I!,O9MQ"#\1E(VZV[.
M]VO.:,3%Y",U$-D!&,E[4Y6?L:MQ\8*=BE9)>R9&BAF+N:^G^@VN;FO[!50A
MLGCLX&1BZN`$KE2C8GLM94V)?4.MNH)51?D[;5>K76U:ZXC;H9%'%IQAS;:W
MS1D2=40U&C-OS"EJ^M5X1P]UNHM<0WIG=,P42DOH(!F);Q:,`"TB[A+I4)MM
M71-BOGGH`5FUA<?`EZDKQ=[V+5F+RO?!;I\I$<+2.5K7$1%1*.[JAQM;`FY0
M"ANL/_;K"BYF^B)$1<%A,(T]<EU"!W$X%D'!5++GL8L)!0/I;DP@L-!)&=,B
MH/$EF/.DG\_#AEY!-"/]FE^AAL^CR)X1#]VAQ['T(YP'F1OK()<M(;T8674L
M9IULEZ*&JLYU+&P#JK0)Q=C5&FL\#\>7-3RBT^?Q@MS"@*NB+MBA4+7IVE(?
MD"8#8ABV!FT29.@>,>,6`$Z8P_$E5!"F$R;.NQ?10%-VTA1T\[`_$^ID:KK.
MT*!LGCL'!#S8+K\[('3%!IV:[1ISUEJTB*#6#+V$O$LH(!AI&MWC&0])H_01
MG7;HK(U=QKL8NB.SR%-1]44W>('\V+F2R#(5-]9*2R5^W^J>,B@HS)R'#JUO
M?90E:9J5Q5%U!>69(0AOEM"`20".J<73,3&/G0N43545ZZ:EGH>>RHI[]:6<
M*O=O)QH:RSP24ZF;"W?4^9/2OVMV-R@)"OT!1>]KU=Q1*4K<^#4=XB.1+$#X
M>)"/MR9R/BK+*LY<#+))GZYS/'5H::KS;T+VYB-5)R;MW3WH3AY&")73$QLG
M;7&4/1VE`'D[E`5Z$5H8)A,MG$I*U%?B"2TD`=Y8QCTHV<#B='Y#[J&;BDC[
MIJ<F=O%9_]*,H;=`RC?/ZX22IIUV":</IZ[MS,F"(?=;]!T;KLTS'F;$(+1^
M0$T)6Q\K2>GK+(S]">,O(?_4_8SY7`'Y>(;I_.V[[?/BDYL;X-XT!L\,,+K#
M+8A5VF.^X<3*5@TO%JD>`6-4F8.$-DA?_<HY?_EE\KDB\UE)%0F7/PCC9>N:
MO^3YE?K0*T,'5??%K<+GKD:F<3#NZ-5COR'T2O,,8_*`"3/M]+ZY0XH!29P*
M,X`_,R".>>P=$$69?P81">X=8&#?-R",TM0[("#M>P:$>11[]Q!F$53L&Y!>
M6B(1?CV`<7+_#.9"@6^`$$'F'<#IVIMO0'AI0"`"KRU`F;S/,QY[]9C2D9GG
M>1(FW@W&=`+G>1Z%D=?0(O3+Q\/0[RA!^KP)/@PZA".0RYP)Y3!X'EU2\ZXE
M0WPEW$T3`%F2/H6-/[5,-BUS&U(_P`(7^RSM9)%;)<S.+^.!2OMN-N:<$2A=
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M49YZD?LVSC/_$BF2GW=`%B3^)?(P\`\(H0=O_KL-8>?PP@BZ=^<=(0+NEP0U
M4.Y79QA3:>`?D8<7]I'DZ059TCR]L-,\"/RNPX.`>YG7+4?6ON"?/.075A&A
MGX3>\BBX8%N>QA?BB&>)\&N,Y]S/@"B4<K].11A&%\(10.;W9`$FZ=\I>/^%
M@!-Q=$%:D41^/G<KTBCW6U]D@(8+V(*-^,$EB"]X<H1PN#`'3_B%.40B_':)
MHB2YL$J<Y!?F2-(+'H1R*[HP`J7JA1%Y*OSH$`=8QC\B3"]X<LS3S*_36*07
MD"Z.L@O1$*-$]WL0E!Y?V&F:)_YHB+,L?][7D8;?_')]=7WU7^,VJ9X-"F5N
M9'-T<F5A;0UE;F1O8FH--34@,"!O8FH\/"]#;VYT96YT<R`U-B`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
M97AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#34V(#`@;V)J
M/#PO3&5N9W1H(#,Y-C8O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<
MM5M+D^.V$;Y/U?P''#>ID0R`X.NXZT?%IR2UF[(/OD`4)-&F2"U(SD3^]>G&
MBY1&(FU'+#]6.X1`].OKK[LQGWY^?OKZ_$3721X3BO^83]DZ%O9_Q?'YB9DG
MC/"$L,3\A!.6KO.<9R2C\(3&$='J^>DG4IN]4A'C1G&6X1]$[Y^?#L]/N[_C
M5OC/Z`=T+40$+UB+"#:AZRCG_/)Y+F)\GD<I/L^R)+J](2>K.*.,DXQ1DJ44
M=L4S[?[8FJ_^(0T/.1N$^O3E^>F;'^2F,"KX`E\PRC*;>O7`MHQ&,?D""OKP
M"Q?TWG]_(U]^?7[Z'K;\]Y]Z<73GQ8(.+\[Y.J)I2K[\[@[Q\)=%P\OHFF4<
M%A;/3RNT('Y^NR,\^6>OR:>R^5R4JBY42S[U;5FKMB7'ONW(1A'U*JM>=FI+
M9$L.\K6L]Z0[*-+*HR*Z;']K\4%W:%I%ROJ@M*H[^$"4U-7YT6+&*;M0JJ"4
M6:6N'O^J>*Q2GF>)5VD2<:O1MI-[139ETZGB4#=5LS^3HCF>9%V"*C>JD#UH
MY=$G,Q[-,F]KSF)_L"C%SW@RM)`\G:JRD%W9U*39D08L_2TCW__WI,&^^,//
MY[931](UQJ!J>`"KX?.CSQVE8CCXLL:+TNQ"1S0+\1!ES*JHJ,H:U%,166])
M^,O77M9=V:']0`N@%RU/JN_*`C0"9B[KEI0M:;NRJM#+M^I55<WI"$Z_)C\M
M9&M4DY4CC[,0UW&26D&.\DSJQ@2KW%0*[=GV!01SN^NKZ@Q!JTU$HY'O.8`L
M#B6(XN*XV?RJBJY\5>V:_-!KU,(+>5/DQIO`:U!_N/<"LN>9\*(+E@?1:>0@
MK9`GN2FKL;WNB@CVV_:%P@`]*EV48.S7INJ/$Y:6'9Q8MDUMI"V:M@.%?*S:
MYD(;H#<=5+*$$M#0%H1X-B@AIPZ%KNV-"%2I3HV=TP/`KJ_W(/BAW!]`9-WT
M^\.I[TAKM`2RU=L7E*<FI57FS=0``>#-[_U&UF>KQ689P,MCZG5`HP#$(G%P
M)PLC=-D>4-CVGK->J,EIQ_O,YT(K56-V&URF5=K$A$*]%0BDQE?VJ@;EEFW1
M@.5!;FV6C+6]A`;0YVTHI'3P@D@X.(-SU>H-P>P;.%!Y!"=^A:3M?)EL=;\'
MY_T<-'#M'4X-_P`G)U^&=+:STH%53[T^@75;\H;8I]77OM1``\I]7>X`.F&7
MI36`',_Z`,L''$SPLW$"P*&R!M#J\`0O\+FH^JWA*_`S^//%P0#8M.Q:HG9X
M[N)L$P#(_?`L!!39'WKA?!?'(_6PF(F@'IX(JQX0UX(ZQO":?&G(%FC=B_&,
M$6L!BA=\&4F?T8U'S/)W^%%30_3()2R<Y;D3@8HARGF.GPW?.DIPO;H_;@!Q
M72`^_AAQ.,>R1F,\'TG,HH0'CI)G+K=O9&N#&%(7N"P$LK$4\&[(;8ZX=4TG
MQUHQ!CTVE2KZ"@PJ7V59&02$;^/ZH]2_J>Y4R4*MR8_X,P!TK?92;PUP2@CK
M@P*F#V9>PL@9=R)'/`U`%J?X&47>JI.JMX@A_0FY*&0M9-$&HDJ]??B)LC@<
M:6%[0_(>A&=9.@1IS!V*@VF[,VS;0OE4'""U["$J?Y<V]6"^!58#`-VWWIA_
M",6-F3%8M*Q>C$:!MBEM\OHB)DY"V12-LG7NZZ:#Q.I(H01`L120"&#4ZN1E
M`G?')$5P62=_@W554^_!N3U0@W=K1S]\WL<OUNB]!PD(I<M]64O,\K`7<ED%
MKHW?1O<&?E^4)\`^^WKC_O#O$GH0H0(9X5D4\*PJ?U-P1A!$JZ-TTA<0\I!C
MNP.ZP0G.CL^;.V7ZPQ-),IS:NN>'7SCGCW]-$E[SX>&:CY)\K/H4*9+/AIXN
M%0VX0=TC.QB'$"3)1@/+_ZM'NM>%B@5]@,`3/:Z,9T.+ZR_MGTZ[,K-%:)ZN
M$YYE!B)7B&(^4WT[(@GS/0='*]^77!;]@69CIJL@;S7:HM]Z":VE.?L_M3;A
MA@DE:1KJ5QH%R@K>G_\5I6W.=W'@OMXLE#2H;(+9I<2B_L>=3_18(2V`?&F<
M!C*:IT/XN>CS!=FN-(CNS]OHD-=V?==K8*=WB]`;Y=U51?=>@;>=;A'Y!0T]
MFR'+,V=VS^=&W14T[";(UFP5EEB5:6O40+8U%N4]E%N=5O((DNH2J[N=;HZ7
M]O8)S["%#38M:GP5K+5^`*\I^K9KP.U:U[]!)2VB`QXJUMBZP(=@YX=WAI,T
MO&]9%I>RD6"<)4.CW3<67;7Y!UJ):_*15%+O@?)`UG'A;UJW@:-L,49D;=I5
M6KT!1Q^'NNVWW`32)0Q*0X69#L6*$)0%M]Z;B#,C`M-<LL7(.,/:*AT\;Z@J
M@0*UH[Z$[51\1+"R#FZG#!`.TN@5OOMV4`;0[L)A(1<)ZR3+0QN*CEJQ-`O]
M2(0M%.<PQ-D+`H]_!.<^HNE:$*;=R0*#@71*'VW7RC173`U>HXKJ3C<5P3X3
MN,CC.Q0Q3X),"X]3(CK2'DOYP,DRD7A.=@/(;GO0$K9-^=!KCD>]9N%/=Y6K
M1^@-AMI5):)NT?35EF"!K@!^NS>L<J!:PS-?8B^XA#PV=IAV)+:'#N6MS]&V
M-K&[F59CKW'69%M[:JN6ZK@G<1@BBI0-)4OJ,S>VD`*HW8N_O\R?)[A4$L8Y
MG(HAJ28N]#Z76,Q"!&T;PPN*7N,H$DO`IFW]_&,,IBV<'@]=*X0>J<]C#O&N
M[P7;=+`??M5X9.C)&$,A&X$=^VH1-I4,$Z`D&;7V4C<&,2AYCS:^^`;U(+%%
M7SLDP,Z]/&%7%"1SE3<V>0\E0!B*M5&^V;L==X.=^+;5CK-B4`Z@E('V!500
MATD03?*A418Q]@X[<!RAM:SWR@P#IJUZ84L@QAVV`K`[8CB3:Q"@P!=;&I0&
MQ:`^=N5_<24BN&TQX#/8`;OC2R@B3(,8'544WA7D#JT@W:FPR=-L#:LHC\KP
M?I#F')@_1(AZPY:NQH'/$#PC6^)0X4JYD.25F[.@T[6R4H-*P$WZPC6.\>D2
M*@C#(!J':(BHN"37XPKALH/]\.H>T`GSVY+U=\P<N4W62<1"^2VHFX#]I"QK
MJ,ICV5F+7A.(*PQ`U\;@'Y=?1F<0+$VG?-?)D#IY?'Q+!(02>;1H^2W2,#&B
MH\EIZB>G2RK-`<I'.QBULU=#`"_+7?SN`B$BXF&N,`R#HMP/SC$N`!P`OXXH
M8@E4>E.5>]<RD`,$KLD7`W_O3[W1IG&+&0&P#_*J::CB5@$@;,W9&[)C.A!O
M2(MVLJQL"C*EJ?O2$DH0?"A`A[3)\OQFSAB8S<6<V!8L`*D(H?#WHZQKI:]*
M]_?J41625]3S*/\$;$*"B+5,TX?1_!(*X(',Y4,;/L[BV9P)!G,>W?8X)BW1
MFA<$XFKX\()ZZ;&>,6T;.V/";3`[N+)V1!M,*@J7!O`)-CBZ1<I604,K.$J'
MNU)9ZM30%,`5[UT9\)9#"X5;7H;]ZBLF<1'W"X!9E'H2R'DZ&JKXVO-?@9]>
M]0.LQPTCW<W9A>2-CE!S[<K25+/F/I`9N)!*U?ON8,.B!\JM.QQ<:+7O*]/8
M6<*"43Q<`\J&;B+-DY#R"S/4_M%[TZTVWRCX+/NQM%?9J6>CYU1A&,Z5>URZ
M`)9R8<ZTA!ZB<!,HB0,)CGEZ=1-,0T53NILKQQ+86=?4RIQ+-V=9=5`3R;-C
MLH;GHT;LJ-G,7,W]SJ$C([>O4#2IT8QQ%,FATV,``=GT$H+S</U'C&J_7(29
M\65[X+J@62(>>1;:FPD;39A\DQ?R)OGANX^V.'*N9B#O1GB"2^UPI%EVIG.U
M\4-ZM?7]\/_4AJ%\[B#-@J-_LNO?IQ[\^@Y,#I&*S'TI@_`DM`)Y-KJWP'P9
M,KY[JO&*+,)F`4RK4'5[>3?5P%!GM?7B!\!&*R#,ML1;*E:)?;U5>H\]:T"Z
MUCBXO]@SW/61=7ETESH//>2DX6KG$FH0@69E8F`8PJ>63@,R8(ULH@QM@_-L
M3)5G<E92VXHQW*7J-VTG+88C_P+A,9N"N;^3G02&AE#KN_ZFQ>A;S1:EVT*=
MNM(ATZO49WQ48BEWTJISW&X)+40#STJ&2&`N,3GA;2M+5?+\8@DW.L;)##:Z
M<?[PL6LN+<@MZ`#._4**`[(3,Q\:+3XUX$;VEIIWFA#[VU[[R^I#'>Q7+:$&
M%@_MS0&D.+\#4F.9]ZHNL(/T6D+0PC'MG8A^`VK"L#<W^RY#R@MR*Z(P#]B[
MYT;?)I=I9>[TXB3UT94<#ON\\(^?Y@/4LC2T_H8+T#'WO9]/[J+]56(JZ]>F
M<EGPZBX\ZO."S:$]7+-KE`?-LA%:&]<"RZCVQ?91W%>6N/6=A);?Q44AAZ\C
M2C9&#>=`P/#V6+W6Q^O8ZKM#HVV1(_&N[_PR%'&OY>T8;>U-G"7D%X'RY6PD
MO@/6MFK>JO.-?B26Z/48#UK2FTK+'!1*3H0;\`*DR2,'6).?#I@U;]P/.N*%
M(U>CW2"$IH&PA`)X.M"+T00]<DX_NL'E<,)FOPM7=W4:TA"<-V"]9>9F-VQ]
M?K&WI^SDR627X166U-:J--]^PR7Z?1]D"2TP.A0]P\3(WQ7$&V)GJ#,'I+Q2
MP)A;S*O`^`TN>4]`[.TYVQ,>^*Z[F.A:[XO<^AZN/`\3U\S_2M>-9C]:QER<
M<T+7\U+[.N@N.QW4,%21O>M?+"6Y:]V!N)0/5V>X&3S?%-T8[]V0SO/GBQ-B
MLLYR(&EI#G6U.=IP!O/[B[`@Q4X[+N!W%B1XGV-J02S2Z1V$X,GD@DA$T>0"
MCD.ZJ04,?X]S:@$58O(,+!=@PZD%V<PK6!I-ZX$E$9_>(8ZF50U24CZY((IH
M-KF`SRU@$9VT!:-8$4XLR'D\J<@,"<W$\Y3%DR=,X(13SV,635H:[#QY_HC1
M:6^EZ;0-:'K__%_M*X19`/GN3\U'!(4P]I68[?!]X-F[D(^G3K<"^TVJ;\4I
M$],+<C']BBB?T``N$'D^_8J$3MMPE=)D^A49F_;S50[1-J,H-HV,L"+/)EUY
MQ3B=AKX5.#.=,9C`7\^=7I%/`\L*;R?.R)+DZ<Q),SJ-D"N64SZ)7RN\3C0M
M"V<SX;WBG$T#T`HP;L:VD-3RF;>D232M,9YQ,0D$$"C8NIV,%,JFP7(5,383
M3)!4Q/1)HRB:B;=(B!EIHUB(F7,D$-;3*])X&GI741:+F3WR>,:3!8UGSB%8
MPF?VX(F8MHLPMYLG5XB4SNP1IS,>))(TGEF1IFQF18:_&3`-QVDV?=*8IC.>
M'(.;3NLTYMD,TL5@_IESB'S&@^(XCV=."D@W'0UQFN7W?1VR[/<_/S\]/_T/
MQW.`W@T*96YD<W1R96%M#65N9&]B:@TU-R`P(&]B:CP\+T-O;G1E;G1S(#4X
M(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O365D:6%"
M;WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E<V]U<F-E
M<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2+T9A8F,W
M(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO4')O8U-E
M=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE;F1O8FH-
M-3@@,"!O8FH\/"],96YG=&@@,S8R,"]&:6QT97(O1FQA=&5$96-O9&4^/G-T
M<F5A;0T*>)R]6TN3V\81OF_5_H<YI9P4R0`S@]=1LJ4XAU0JTJ;L0RX@."1A
MXT'AP17UZ]/=\P"XX@X=6TBIY%T1P\'TU]U??]V`W_[\^/#I\2'8Q%G$`OQ#
MOZ6;2.K_%/7C0TA70L9C%L;T"6<\VF093UD:P)5`1JQ3CP\_L8;V2N#?\"-*
M4_S!NL/CP_'Q8?\7W`K_S#X(-E(*N,%&BDC`#Y%Q?GT]DQ%>ST2"U],T%K<W
MY&P=P=DSEH8!2Y,`=L4S[7_;FD_VHG07>3@9]?;I\>&O[_-M`1`(]@1?(+!H
M4PM/R`$)D;*G&H\=I@#74_'XL"83(_;T_/CPW;^;<E`[]G'(!]6SMF.JZM7S
M475JP_XY=JQHJRK?MET^M%W/ZOS"FG9@6\7R;:78T,*"9C<6`RNJLBF+O&*P
MSU`V!]RKW0YYV;#AJ%BC"M7W>7=A^>G4M>>\ZMF^:VNZ^/Z'-[0<?N_8G]G3
M+X\/[\"^?WT[%.!+&@7.P]"AD!H0.G48*[003C<.Q[8KAQ+0V..9``,X+YK8
M;]@3'':^^*":`E>V>URLRD/##NU9=4VMF@'@&ON!@:6M,5K1=FAE?E+C4!9N
M:T`4-R`T%@$@D!:`#,+:`!"EH0;`':/(&W1NWU8[1IYK>V7\4K1C,W1@[>8_
M7`:_^Y3QZZ?,4GW([_`&"Z"0Q0GMGVR2B""@&]F_W_J&0#GVAI!\@CO41293
M#?O\]@3JN[-J6+X?`.ZR.9M$ZB&LRCWD5C.PH:PA]9H=4Y]/JMF5P]BI?D5A
M=3M330K.@];D'X4W>+:<!S@=H-SCYY<E`C&+@@F1=(9(8C.Q4.59W3KO"@Y5
M]M/QT4+(LKRL6%76)1!8V3:0BIIO2@"GR)':QMZD\O.Q+([L65&0UWGWJX+D
MM+9OV/NQPS@',)OBZ@!+P""$A2%.N>,C$1@8G)%@L/:@VJW@L/K48)0Y-85"
MB4R3-^,^+S`<.I8#D?3C]A<%"S1#0QR-L%NGSJ5Z7M&W=F5?(%5=D+Q.>*4=
M^^K"QN;7IGUN\`[`\'7/GLOAN`@&2`4:`YYE4R@(PTG.-5@:KNQ#ST/8C]7`
M*+1[H*7BROOFFZL7N(#9TP>86O!;697#904;%=6XP\_0WEV7/P->[7Z^VQ(@
MI&BY!D'&4V$*XTR#X$JD]OR&_;UAA>HHIQTAKV[6)*H[O2+X;/DY`5!`X$N0
M=YID?Y"\$S]2,:?]LP3B!<GT"T$51K$IXC^JO()(+3#Z.ZRF-04*<8,MXWN@
MB2UYG!'YY0/ZF-@32G5;JZ[?+(&-Y(L6MI1'_]_"9F\(<@*EM@W;.'FEKJ&2
M_#YD/[:@AYY4<6S:JCU<D-VV"G-NI\ZJ:D]`;,!7>=^7_7#M%737=8$SNM)\
M$_46J;`14_VFQ%HMDK^!D]<!-">6Q!+#81.KG(YY5^<%'0F8Y5I2NIC<WZCD
MQ.`U@%"4>55^4:]M-0.1*+N=8;Z`Y4EF)74895,(\,`PU\S-F(8[A7H%O7;*
MN\'RM/H\H./`1%V<04+7V['K%?G3"!0POQ\T%Z,:=?8^EU5%G<@9-`"U(\26
MDP!G1TT)2UB?2,?;V>3W#'^GXK6KH1V"PD2J9-Y5K)"$SZ!,[.G*IL?JU%-Y
MTE*[[0YY4W[1B@9#I.QVWSR+1>*LR/A&!D%(G/K=^IO?289SO'@P"9X@,M&"
M07&!T+@0$!WJMZ)3>0^I`YJD..95I9H#)1*5,`R'6NTH`99P;Y2X?C%+W'%)
MLESU2^BS7G5G758_SI3ZV)@Z#7:ISQ`*L)B2>:`><A[G/6C7D4QJU'-E%2_D
M\7%6TB8:PWMBF"C;K37M(AA()]5Q;N*D268P`)H>NQRU,M71?*<^C1C6`T8K
MTPXEA0F*Y%:NHBQI+DY<`3*JH2LCP50C="ASR.&L0G+K0=;N`=_2D`9$"#$B
MP$"8P5(\P1)@<"O8><CE%!#"]2U0=QJD-:1=W;N1;[5`57D'[(:.L^;.ZM8B
M<BP)Q*)R+$YC)\>$D#,Y9GK;-SMP/=`UV(FC$%.N]Z6J=D97?ST$P4*1Z^]A
M&NSWV,&,5/R_JHN_6Z>]9E0<L%AFSLOAQ%*)%-JF[\>N`VLJZ!>@C<2LQ!8;
MB`E"G&J;\2KRU$T#[40)&ZR\(`&_8ML1PZ0?5(Y[#%@FJ>9;8Y6NY[MN/"P1
MVK'@SNALFA"FW&@8$!\GJ$:*LE)]AE:Q[V];UP$#0-P#%-L+KJA=!8=6K:S1
MDM/8G6BDM#>CAUD>K-SHD+I:Z&UH7ZJ?/5(C0?`'NA<?"*$5M&&63FHFRDQ]
M^@D[,'#[L7V&`W<KXW03UF`0M)3E68\-;:AK*7K#Y=#%[3&`;H6U!>05":MO
MM@``46:%+(\G.1=1:E]5/#UV(3M`J?3C%JI7,X`TA9-7^:6?I0$1(/K2C3-V
MH[(E<";33/=*CIZOAA\X--ZP%URRA/EI.`TC9I.Z,+7\?FJ[02<Y--BVP[C,
MQMY0>RH-3X69C"4,)[HS._NB`W<V9N+28B+LOMK@%6Y<,3WE`,PA6%2%:;($
M#K'3:9F8/RZ(+0Z?QK)3>KQMLGNNR6FRY.(`_>R\B<T-J=OA<M("[HH6IQZ'
M]7FEEJ#WB+MQ;))-BD:&IHB;+O6=YC@,QX\7H+.:'7-L5%5#!`4^P_../67_
M::Q.NK"#Q]PD%;Z[<BT-(=;30PX'!FR(8=2!KL59UB'O=K!OODQLAT[(A7(:
MM)'&1;/[?*]62$9_^_#FHY:71W<^,VRLRYY&T;`49!TIT/8S"#'XQRX?<LUR
MD!:J^7*I%60LZ\K^5RB/C0*?5U@RC`@FL8B!<1-ITHD+8"`SI]^DF,FW.;G=
M'AOH:3N990Y_S,_J)A(E*&(<O/5]6Y2$'!5NK(1+A+.,XDF@BYE`3US-0J)0
MYK'33@%Y0%>JB=:,-L');0W68.5&*6\F$.";(S7=U(CV-<X:*^Q'(-B1V*#0
M';"<XUIRM/5JIV71V.#SB0(A6,*9P@U-(SEK)O%W&]"_T3?M:RF/7S;386NH
MG=(``/L2ZY1^#$-Z"-4))@SQVK9LO[7521`XLY?MUI-`S@#F,G%$F=#O"/`\
M3Q"%)7S,N2O(TWPEM4_.["-)5S.`5$?@G1^M/GO9(+_L5AM0[E>9`%%@F]3]
MB*R,_:GI:7$$`2JXPD<OFB!!_905*P<<82YA?3#-5X,IM6.KQOJQ0&6D#SH[
MFNE*T$!\P`-B`Y_,PW4U0,H"$<"'T&"!8$/Q"H'<8_:[L:->!RH4BQ?*]"L2
MZ#7S42$D:;.`X2)U,C29.K`HXM)&7MNUX^%(55.WU4IGHCZPYK/Y235&QM]J
M]SN[A\Q_ZLB]7B"CJ7O((O-HX@-09,_>G$X5*#WSW@2*C7=45MC;$8HKL@C:
M@9^_+=N/..3`09>]N,",0(APT1F!"+68!"P"I!6#"X@OHR8_*".62"U^^-,/
MT`OO#LI.`G3_C\F)BE!3:XNDK>/5(J,6F07P9"86PYD23B>Q.#V>T(-^-04E
MCC&'^?,+?>9;'C^U.`2G#@I;?-UO7[[^[CPJ%D@]'@>.<]+)8",F[(DW['T%
M/AMSYS;TS]QUFD_[%UCHF67Y8K9M=05F:W[UHH/2SF_M4YZ:"K+IF)>P7CJ!
MR(/9&T(OVM\-^S"?YLT;76O_WN"C;+=;'//FH.<"T_@3P`%+"GP>`#X^&#?/
M`H`>%?3TDH>>>MNWDA8JN)P[-8EOO+D)2"3MHRPH)\.(;H-(U<;BZURGML*!
M;*]?%YMRTK@67R92G7FW8)?7-"G;7FCT._?W3M&\GWJJJMS#MVRH8VS-WW8Q
MPZ5EQB#T^,J\F#&->4.#`;4P=D`UI:W+5-`&!6B&&F31#"[X>#8$<*.>4K]O
M9Y\&[=NQV9DG/@MP<9APR\5A(%V`A](^@?F^;?;@R:&?A/'U8,JF:E?3Q:TE
MA`6X-Q23_)F]%1';:=R;AI4U#F0P<O3S1$V1],!-X9/EYMQ69XI">CU1YQ`^
M(-!1ZV;R\.&ARVL(7SWBPPDE=`JL/>'^8^-&>C2Y-AV@AF*)]_1"]S@YB6;O
M!:7"SF*UDVQC:4:I7P_'V3]`H+6DA%'R'3IE9C9>Y]K9(WX1^KK#<:"AKWZD
M`3*X4LAL-)@[J6ZX0)_?+/)^5!C,QG'Q-([CR2T<7C.G4]35O^C=S!MQ9CP[
M?8_&CQ-0F.*-@BX79#-0%\1;7NB7$CJEAY7]L3SI`SA>6.(-`S>02V8/GK@5
MQ%=VVYG35^:3?OKFF<IE;(\'/:D(4#%]N24G40L&`4]9D@5,T$VFW>BE:6#>
M-.8!+>"O+$BBA'L7Q)'P[Q#))/,ND#*-O0L$=B*^!1PE@V]!*#/_&0)H\WP+
MPNS.+<)4^G$($Y'X=XB%'^HP$M#;^!9(`<3M6R#N+0"LO;X(<0OO@D`$7B0S
M'GMA2/%=<<_U)$R]^\=AZG5U%/HME&'D_;X(N=<)/!1^B(,D??7Z)WT$'09A
M\K\)#HGC*ML_F5?2>/85)WC16V?^`%D#NMX@7?/,C\]:9-)_"YGY/;R.@]!_
MBR3P)\H:N->;K.LL#+U1NJ;_[<4+5)`E?C/",(O\6$(=3N^L$&E\YQPR\[/G
M&@*>WSEIG$6)?T62)=ZT6H=9(.Y$3H#%S+L"Z,?O-^@C[WB61Y&X<Y<X\G/]
MFB=W2&;-TT#Z,>49!(@_48([5+,6$&3^DPHN[F2;$.*.M4**[,XY(BG]WA>Q
MC/Q^@>J8W=DCO:,#@%JB.^>00>2OPFO@_]3O%\GC\,Y=P-P[>\CX3@3)*/9K
MEK6,8W^I6LLD3OWL(-.$WSEIEMR)Y"A(A!_3B!HK[PJ>W,F&"-SOCZ!(9G[I
ML8Z`Z?S9$,6I?#W6H8*^^_GQX?'AOZ6WHOD-"F5N9'-T<F5A;0UE;F1O8FH-
M-3D@,"!O8FH\/"]#;VYT96YT<R`V,"`P(%(O5'EP92]086=E+U!A<F5N="`Q
M-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X
M6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P
M(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O
M1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G
M94,O26UA9V5)73X^/CX-96YD;V)J#38P(#`@;V)J/#PO3&5N9W1H(#,U-C0O
M1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<O5O)<N0V$KTK0O^`TX1G
M0E7##5R.7GJ6RVS6A'V8"XH$JVASJ09)R>JOG\S$0I9:0GG<Q8D.V[((@L#+
MEYDO$^AO?KR_^WA_%^S3@K,`_]!/^9XG^E]E=W\7TI.012D+4_I-Q+)T7Q11
MSO(@8$61,"7O[WY@/4V5)1SGX7F._V'J>']WNK^K_X`SX9_5+X)]DL0P_SZ)
M>0S_B8LHNGQ>)!R?%W&&S_,\C=^>,&([SHL0EAT&+,\"F!775/^Z,1_MP\`]
MC,)E4]\\WM_]\4_B4`(",7N$%P@KFM2B$T8L#.*</0(^V3[C[+&\O_OJ/U$2
MV']^SQY_NK_[`'/]\R9?!)C=%X-]R+.,OKD#-*.@8(_/K[Z/_[!OI9I$T[.A
M9L.L6#FTK3@,2DR#&N'_YK9BHAT'=I#ET$GX37>64T-/X:WI)%D]3[.2>_;W
M=UZOY)-LA[-]M3^RLQJJN9S&!_A)ENU<23:/[-9PD`'@)0U'D`)O#!QQB#\C
M'+4:.B;[22I<5]-/PVH+S="/[+F93KC-1JWW_L!JT;0,A@\'@F]J.MF^W-RB
M\,3MH8CV<8`V_63L>/NOI6O$PA!\RR)69*E&3,GCW*)Y7Y@X@R&?@!T/#`#L
MFEY,TD`ECDK*#H`U`()YP=2=0*:T+VQ0VU@;7C=KSXJ%_`G$)6UM8S-@Y`!+
M'>>Z;LH&5@F?&H']I1SQ,9+:D!:WP$1?H>T[J<I&M,TG8@8ZC.7QGGW=O^`O
MX,WQXEWK`R>A.O(O\\H6VR_RS.X^"1:N%X'A^GI+LJX'!0N_]3)2B/X\L"Y7
M+$:(T]@0Z`<)E&A;)H$74ET`*QVB:)"YI6!!+FJ@.ZM&3@*H!S\?E>A&5C40
M029-J>FDAOEX8FU3RG[$=]$_[5?.HF\DF`J^?Q)/<A,+Q+'VU&R?AU%,G@I[
MC](\UGMOFZZ99,7D+V>(.+(O)0;1VZ]D60J0(4*O,%9`BN!".M'/M2C!'1$F
M)'@GU,^7T9G5A"D8!=DK2CE/32E:&GUHP('*4S^TP_$%]E#-XZ0(WK^"9Z@*
M(,>W9_*G2Q-O@3L$+KW9*`I=S$KRV/B]=DNW+\N9!_8,7"3_["5814<&])$'
MI).-[(95PSQ1C"#`E!+]40>X!\*H%&=Q:-IF>L%I-)B$U"B!ZY<+V&^!05X4
M+O;%A<,@C@OG=M7`^F'2[-<K<JL&TSW0<@&13KS0N(-DXM#*%2R$"OK3<P,O
M.WPD+/;CW(Q`[16-:/.BA9"Z_@H0I,:/"+4)$_(\<K2/EN"36P><>[NE<2XA
MW(_UW$+P^&U!"!Y+H<J3C:::3QC;RJ&'UV;Z4-.7\%X[C*/\`LNG[P7</'&;
M_NKVL\-;J9G\2Q3'>_.CQ1(]?Y%`I6'$S3_FW_2A['UJ8&5B/@1\"*(\M=R`
MB)%H;AP@;["G1CZ/#-*[G$XNVHT#4H,UXS@#G=$_*)!#>)-6-[MH"!RG=Y0$
M#DEZ1E[PFU.M#[OH2VV3^></5O.[BN'6;DM58_1_K)/2T'T0XD11.*V4I/%2
M)6$Y8X*$=NI*GB48%D+>62@P_AE%(`Q:Q7T;)U>I9BR')ZDPN[@\HMBW(?O+
M,$[LT>70/?LSCNLQI0#5-@B-6<Y=@DCXDB"XH;^8I].@*$AKT?I`*=QPWT9^
M=I[5>1@Q76@?P/!O_.`H>PC])>X>48-Y!@J8I^9@!IX5:(ZF=%[S%@X?5HZW
M!0RI*Y`S'BTP9)&&P>I%T&8*RC^H!.?IG;4^$!&:$NHA!4GD%1*C3AH]U3P$
MY9)E5BCB-M](.+@*23,\;(("=U5>'*Y0"`T*IO"O@)(C%FRBKD$RF>+.JAOP
MC?,D`*C;IS5<8AQ^>7#S01#J8K%(]VF,^4"+=:B=C&K\:ZTY.U-BJ`:P*,HB
MO6U+=H'R0?;'!A0D>OG2VEA7>Q64OE1$ZGY(V<+P+6JO-',EX*K^Y077.WH\
MR34);70SSG@&20^R!=EI^?A6W(.H9R!9"&!JWU>!X#ULMB!TF@:N!$@7^9L7
M)KJ!"FOG"CVK4O,1.T^MP/*<W`]_7*GS;UO10&DYG<15,Y..G?M1U-;%^W'N
MSKI!@)`"(()56"PHVUK88O>)J_9XL11`D=F\[)\:-5!N(?72]'4[4_5I+3E-
MS317*%`Q[5W;M*T0CJC_/R>#*0J>A&J&>735H6@W"65IE+J]ITLJCT)3ZKZJ
M7L$J[Q>O?Y-',35/#A<E,5^!+<%T:U"ZH6KJ!B`9U%'TS=B-EW%<.[J.Y@C'
M$2::Y"9-KS1P=5^1+I&<VTK_Z&0%,ZT[T[RRV=I5,5JUXI+7[O#`%M=!F$K<
M1RL.LL7?M.*9LOPRM4EI&H%2S-H!9`D(C(X:&^#`"ZOHHF#I6R;<2CH3@M%)
M5Y'Y]K(<XA#/;E`R>:(\YXN2B[.5A$F7,#_.AY\P8[^*QF\0]R10=Y02:(]]
MD`L'0%D+)OLP0]4KR:Y6'LT]N0R4O*#63C2)`'T[8IC0OK.%C9?#C21<)&P0
M)];&!W"S/4,`C'9Y<R.:G*T4U/.QSKER#]SII$2%G0U->CH+@"=-=\92_S6N
MHITN0B2U.480R"`--T'"=>FCA>M%:'H]EWM?HMA0EO-R;O/OGGJ1WT^P>S#D
MKXP'!KS#0K$5A-70`5XTR0668A,,7+<_"O-5#9>[?O=ET'DG`EP$ZRVJ]"1/
M-A6R29JYQD:2+HT-YQ94R=(Y!_A^^?J`"Y-Y>4*%8IW9N`>5=U3@:IFHY0OH
M?^I>3\VXB81-8BOD0FIIVC@>AZZ/24=(5'ZC64>IGAH\N0&7%*R?NP,0$7YV
M/-:A[I/-3BLDP$^:$0\J=<9:'UT*%/H0`#H<YN)>TX\HE&BF3;JX>.#GQ(PS
M91+FBX('0ILMC$9_HA1#.\GNW`XOTC2@T*[4ZG4G(&!/?29%RO9Y965S:/<D
M(%XMW8P9#[;:Z>3:%F]!MP$(<>$479JLSK!30P&,5$J'73QFI/W#<H&4X-O=
MBA#]ZLQYW:`#38-<`;%>0WRD)-G@&3#$+@ALT[.4O8'$S65.,R@Q?/YD"Q"R
MPNF99/&#-#75J>BU7=$@8*YG;!?@<1>&>&I$=\WQ-&'?6;Y:\:\PZN?^,#;'
M?GVJ:S#'_A9]`F?:`H74]>F"?#G&RF+7I^CKIC)E*Y0U8'_R<[`P".\1"["Q
MH8X_4KZ\O.OP)-J9C@/63?V?^^&YE=51GX.86P\ZD;;ZZ7(D!+AVM^]]9/#$
M[OOV+?TDX"Q.;M`W]EDMXBXC\=P)M2@,3%'R*)4:%`4PTQ,1G3AJ%M6B="=2
MY)4U4IMN$>#C?_WN.X9RYDEW*HFI5&6`I="[L<;#BN_VX1F24Y0O`I0O3AD4
MQBF_IH6-IJ\P+;ND0#R>D#R"NBH0DGJ35)O^)^P0GN5P;K7(-FB<3R\C[6<-
M"9ZT+=<2H)2UF^Y0@8$;T)P;N&*4A4N/84E-D;U<883V)XGU8#TKBDXZ\H"'
MNF62L2`&?7-1A+OS^45>"C:>94EQ"1SS*"E,6P\^@@.>3;<"%+W5,D:RZKR_
M!0;<2<Y@=6R0!28]KXBY[,,U4:%V@`&R,ATUS$I.Q9@V,6Y`_H)].-SM.*,,
MIW+B>_S1\$)/K<MRB2'8YFP`O@(A?K(!;@L$XM4EDR4W!Y&I/<$6X]#WLGVP
MJ\7,_#F1C0:1=%2*IP+FHM62QE\Y^J#TP;J]MR`O1#Q\#0NUN;3=#2!3A[ZP
MT2E"%#F5&J]JCR`TW8:W_/(!3:7FLUVBOF[7=7,/XQ;^5F(2N$^A[Q>P<:BG
M9VHS8G&-:@.1(5-?[!A_"W7\H"IS'XG8L\7>`Z=1BR1?%#HWP?V"I95L(8W:
MP`WFPI)16_,D+\U97Y9EA(4MX5Z=LP%IJ*^NKQYJJO3K"QSVR1:WS/)%G:XN
M6D2VW>@Z`-\9'`09[O!BV`P:$W=O<P/Z,2F8B]N6.J7IJQ6M1J"&)/))J`I;
MJBM.+=VY\H35BB7]BH%;@)"ZKF.8K'09C^W](K?`=4U94I\`B@YW'\0*:^3S
MH@&4/,^3;A^8XMTXRO2"[7DI>HB<VLT-SPU,KZZLTK7,3?;/7;<QY,F2"++"
MZ=)Q[NPUF'(8I_;%>"4(:4QJV%,A>6,B`K5EWJ$Y_OHPCPTIAE6Z&SZ30[:7
MX>X>*/`'O(BR!08Q=T<N\2H9VDI=T*'1RH&Q;]"/KZ]"H%X$81BSK`A83*M8
M/D=WNB'D%&G*:4#TSH`\#3/O@(QG_AE2'B7>`1Q[$+X!"0>O\`V(>>0?`/K"
MOX:0![EW0'#E$Q"R_3B$>1+Z9\@2/]10M`>!=P!/@M0[(+DV(,8;KKX!$:9E
MWP"8PHMD&,2!%X<BXMXUYJB,/<^S*/;:.HW\6^1XK]/S'*SDM4(<9M[U1WB#
MU0M0]O[^/FJ(]`1`E_^I@D3Z%+;0,O>!XN!UT,B]N]_EB9>DNS#/O?#LHKSP
MXK.+B]AKX%U2^"VP2X/0/P`*"Z^S[O+`'W)V.5Y]]`V@O[7C!2HH@BM0AD5\
M9424^\FT`QF=^7<2)KF'<#2"%^A7OA%IX8_ANS##:_3>$440^[\2!4'N-QM4
MCU<,&R5)<>4KD(_\B$5IZ$\G,*(H_)A&.604_X@BN.))<8`=3.^(,+KF;%%\
M9;=Q'/,KZTBN9(U=S+$]YAV1XM\_\X[(DBM,CG-^;1W%E32^@W4F?KLD(<_\
M7TFB-+@R!VS7SZ`D2?F5$1QHZ!^1XOT5[X@LS:^L-$^O,#DITMR/*0^R*Y&.
MTYU![PAT&/\(,+]_I1PBG=\;.,\]$@ORXX<?[^_N[_X+>$*Y]@T*96YD<W1R
M96%M#65N9&]B:@TV,2`P(&]B:CP\+T-O;G1E;G1S(#8R(#`@4B]4>7!E+U!A
M9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W
M.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&
M86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B
M8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O
M26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE;F1O8FH--C(@,"!O8FH\/"],
M96YG=&@@,S4S-"]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU6DUS
MX\81O:M*_P&GU"9%*1A\X^AU=BLYI%QQ5+4^^#($AN1X08#&AV3MK\_K'F``
M2M30L87:VEU*&`+3K[M?O^[!QY]N;WZ]O?'ODSSV?/K#G[+[.#+_%,?;&\%7
MA!<DGDCX-X$GPOP^SX/,RWS?RT/AM>KVYHM7\[W2**8;Q5E&_WGM_O;F<'NS
M^QO=BOXL?N'?1Q&^C?_".,1_81X$Y]?S**;K>9C2]2Q+PLLW#+R[.,H#W\L$
M_J;^N*?=[UOSZW11V(O!PJB/#[<W?_\LMT4*R[T'?('!XIM.\`B@XH>9]P"`
M[OQ[X2?X7)C/41AX#T^W-Q^^**]HAJKTNF&W4ZU75%(?.V_7-D>O&5IOZ)37
M[+R#_";;LAFZC=?*4C>RZ/4CKK3>5C=5L]>%K+RC[%6K9=7=_]5[^.7VYA,V
M^9_?;PI[TV&*,*9\^#F(_#_Z@+>P2O"/[PM^@'_OYWDX014FL4'J!Z#QXU_^
MX9W:IE!=ISI/UX]-!13Z`X%8]VU35:I\!=F,RP9?*:JAU/7>*P[J2*B]0%36
MY65(/7K^>YL-7/,L&JT._,!:'27Q:'9S4JWL=5-W'K;1D/GE4*B%>4^RZ]7X
M^QX;I9"2==WTGJKT4=<P@2%J=?>5@)%%H4M5]S"/4).\!`^@:"IU5QQDNS=`
MR/H9]G1#U<NZ!W:_#.WS*A@DZ8B!2&8(@@D"3@98`+\N_/%9E4"FVGA=3Q;2
M?JN&?%;)IXY_;-5^J$;L]LVC:FO&`?&QP8WJ80>?#ZVB.S2MW./#`5^K*#KH
MZ\#BU'2X(3![]?0U4(A]&_^I#?\X?4$46P6NV/ZBBM[K&Z]HV<6P6LNMKG3_
M3&Z<6(0\*H\PC9*%C5>/\#Q'0>WI(X(&X47?&&HY](>FU=\4`5<IR5FTH6OJ
M-^``H.AKNB[UHRX'@(#';U;!(0QM-,3!(AP2@\2%Q+[W_E5[LBPU.7MCS$?(
MTHIGH$4^9S#&$":$SB*_/\A^C/27W-M.,>-MG_%1MZ5WDFVO`:F-BS5`("XV
M(`@4X"D:,C\T("PXC6*5MCM'`%FM?BN4,A?ZAG)=@C.)'KYOCB<LK<$A3[H_
MC"9<3!JZ#\(-_E=U!W8TSRJ&MN4@:KW=0`DT?WD%(+(\GX#P4?AM6M!G`N+E
M?A'44K=L-QRJ9%L<-EZ)L*^:TQ';YH@>R9)<KW8(C+[C7S?`HGW2Y&M0ICZJ
M][8G]A-K4![<1USROL&*NW=_$GW-0A<$<T&-Q4BK2(%N.$YL5S1=7SUS]=BB
M;BBNJ\@*`G+R^!KNS0+K7A',[A7!J_)74.`^$Y'):J[,Y.43R+`ST2Q/".Y"
M;JO+(?V'E9%#N&10MZ,)D<W4R,]&"\Z8B=&$3)%;5!Q4'1.S3TW[=9F,_?/)
MT,L%JB/[X;E:F?#E;YW?E>WT'AK^]=>Z>8(HHN*VAO>";#(]#:RZA;C-C.U$
MG6R<[CPX$IEV!">1!XNB:<O?0T),[>>5B]<-FAD(&E!UO=Y+@^_3HDH>5%5R
M=.`NF@*"*@!)FC6`$,(",;-4%":1`6(L/(5$(2FI;@.-CH+:D!%^`FUOG^=2
M2[6U:<\JL<'H8O7[/+1$71N4\9*:"-Q.4ISHMAB.T$?`N6-P*-KDOE7T@#5P
M2//(UNYT$1`BG7`HU;'6N^<+F2#WV'/76\7"=8W,LI6-BJZ$C"7.:@8.A@6S
M>RSAS:J9X[M),9>7,F<-"-))S`8BRV=!3Y_'G.C4RW1=H6%+X_1/]FNYV\YH
MDJLP<Y9I83[RW@_LNH\#O(5VS?L1W4?G/5!)08GY+(L_7%Q=-@?^G[39W<^G
MOI&F>7H/-^=<NZF=3]/,JO3C@!@F>:EKJ&04K(8;^UH]S2%)H=VKXE!SHZE6
M*4M)8A5D[L_^B<-103Z`4Y&.V"V7455_>SZ.68<&V.[NV2[BY$/DHC]$IBG3
M*H"S6GG22W.H!\.B>C_J12)O?%%2NNY5K:PNHZH@UTC!)+*:,1)S"O(PAC4C
M[1B>430_(#+9:=0*T^*/DK8;"IHR@"6@-4H%`0PRJIFU)I4-!CV"L9AI):L3
MU6L>(H##]<PQHT"A]><@R?*1F?G>^Y$A7`.),+`2,)Q;ZW0*@O,-+<D4CF7R
M-0K%]$;$H(3`FW&,L@L<F)ZW75.I7JT1V7$>SZIC46SCD7F^0XVW6V01B\HW
MVH:?VV;8&\WTO?#^"=GK/<S!SOXVOJ3T\`YZ?T"D++U[E.U7[J3^36+"-($H
M.'M9ZV^C5%W!DW%JI19U$9/1(K!JGG<(Z#GH!MOQC]ME]8.H/LS0'"2L@1@@
M'0%I<M*]D=.`AO4"3=O(P^8.=&M(B=W.N'TG"UN2J7V0)UNC-VOU@G$B9J4]
M4YJ?CZ5ULH4:5O`5J4N*V"VE*&U_E)4-E!CZA+9YY/YY'@71FK/8MI;?>]^Q
M8L7'ZGF2\28D)A$/Q<EM!])\BK4U((CLN#`.DKFGFZ:D9]E()EA[C@UH#6)2
M(YR?#AJ!\,1*&9T=:48>%+SY9</CC9FLOI9N4[:OYOC`#@CS>):543P2>MW4
MBPQ%R[!;,#(-P8Q#.B0`14:S,'6<!G7]>V\[S(3=][J]?IC%"X0"KGYC7$3!
M*+P51,@XX:Z0(C3W0N-$P7I&Z$8WF_FZ"?/M*.#PDVG%D2-K>%A8-9F&"TZ/
MXFG,8X9S3#VZ1MW49GYM.NO%;)3\.W0(<N@4=)LO1H-H/_@637MN.+?A2GY5
MM5<.G,2MFD9$X!"BPNV`-MI@M`(`46ZGGNGLP"B(1FZKFHY'`J4F+;8=*.\V
MWEB!3#X?4:MZP^J2;'Y$]5:>\?PD7BY@MT:)CN))?/KI/,N>@O'A15FBC7UB
M_6G[A??>4[#85,0;0H\0!.__F&AANXCGT2TR<9P%=`M:I=,'A->1_%A(3CIX
M[5QO&"+6!<5VW8T,]\-KR*8Q7;7*A`.-W615&$;6I7F4+?6'&L=P.Q9*I#8J
M.DTZJY8;5"&J/K2N)+5(ATLF'*QR9O72J3U)4?X\5BQEM1FA\G1HD`+41.PA
MZDX;[]!4J]2?*`CLT4PRGTSZH^TL)G[3-)`!^*G_LP_:&BWJ#M0TC5KL1*T/
M'Z6]ZKO,\E.%QOC>^T0`V>.%I=(X2"IB6YKI])K;RTGTV,Q>9=(7^0O-G2XT
M=_YB3LLG<K)2+P34K"M)D=>LR!M>PO'>Z7VM=VA"`,ZY>@/S+N9;KP$AXD;4
M=)0`9EJT@O5A9L6W/\=^DB=S[%>*8E7"EJ6*VAC)+3GGD<2*5Y2Z!26C>SY"
M-160I"VWHH,YB[+*9#/QNE&71L#-=;RGLP[S6`(8MNMUC$^MZD[$W'D$R:L>
MT@B*2?T"E:-JN=8LN[':JN?+D,U6O=&C08M7'1*_:XYJU3.X,+;#S'"><(79
M-.$ZSTNX!'M6+0\:Z63V;,)GZ*Y2TKQ\@&^B71S9<NRJ5ZZ`,6359-&*%3`.
MXR5P2;88/4U]&N*`JD)O14`_O]<P\>%N'9D5AI-.]I/%>9,0LT]MT`XMB&6=
MX5SH^]-[0=-K01^^J*IZ[T>A,Y@>M6X/DN7V033X7IR!9/ZH^N@HJC:S@:WJ
MYY*ERLV+B>.<'F9V.L\VSHAB-Q[.=_*HSEM5-`&/FFH-B+=9Y[V=(+-Z/4ZB
M>1XSU82/NOEOP56LFQ4:RGMMFBZV:QA/,BZSW/>0"*"XJ<:U:L>C#>C_B4(N
M8$*ON9S=<0W3Y\ERDB]ZM6FPO+"!9.I%)/A=IITLIFG1.'?CJ3FW7W2-M'$/
MS3M7?"J0YOV,LWG;5&19;+X(IC4`L//E0,P"/YU.>&SXLCA]0EJS2"UD2:^<
MC0><TPB\ACO[87S!"U?,BTKF/&L/T+0:9Y@D(T%)W>#P/G!3-4^A%F\XK`'`
M/%:.TIG@\W0ZM>>JW,J3@F7%XB0/V^J5KNTQP[OW7Z%O-[<NX05H@F88SMY-
MX9,A?DG'R#MSEK^H+)IU`I(3;E4(^H;?1(26?]3L/!I'T1$^"YOS2"<J6'&\
MR/$\R?S%H5Y\4>M-86FG:I=F2Y>H[0OU;X@,?3(O)X[OF5QD"F8&8@-Z>;.E
MT_#RC`Y60$'D5N[GBU,3RW#(9CK.F\L4"S\V85(T_/ID=W:B@AA8O%EJZQ4?
M0OT)E?'6<2B]4IN^]<HN*:'`3U(OS2%&^,;S'?@]:BSP$W1WM""XO"#($R&<
M"[(X<=\AC47F7)#$0>Q<$,?H0UP+HCAP+T!PN_<0Q'[@7""N/<*/W#B(/!+.
M.X@L<D,MTC"/G`L2D*%S07QM013F3E\(B&OW`I"F$TDA0M^-@P]GN!;D:&E<
MU[,@<#H[%6X;$^(&Q_48.+NN1R)U[A^=2.H.I=2-H)^^O;]?1T<GO`(/^K_>
M?Z#P$/8$SNB>#Z%XR2LB<AIPEV6)\SJ_K>!:$.21$^*[,$_=CXA]X5Z0H#ET
M+DA]=Z3?I5GFS/B[+`_=5N2YFQ+NA)]'5U:(+'#O0@19YC9$A%GFWJA`E7+F
MQ)V(\]`=%&@D\BNV9+Z;IBEP<K?71)Y?\2L(RIW?=Z@GD1NQ(!9NCKH+$M]W
M8QJD?GQE'YE_)9&"W(_=.P797LFU4(17K`U1/]W[",/(=WL_C*Y4M[L0H%^Y
M1Q)=B604IVO[R&AZY::6.'+[)?+CU/V42-#!@7,%9(\[@J(P2:ZLB)+@RHJ8
M3HJ=*Y(DN[+3-+T2R5&6N"OJ'=K&*TP'OUW)!LC(*Q$4!YF[,M]!!F;N;(#O
M_;=C'>7OTT^W-[<W_P,<>(#W#0IE;F1S=')E86T-96YD;V)J#38S(#`@;V)J
M/#PO0V]N=&5N=',@-C0@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2
M;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R
M(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V
M(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y
M-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E
M25T^/CX^#65N9&]B:@TV-"`P(&]B:CP\+TQE;F=T:"`S.#DW+T9I;'1E<B]&
M;&%T941E8V]D93X^<W1R96%M#0IXG+U;2Y/;N!&^3]7\!YQ23DJ:\/TXQFMO
M*E79;!([Y3WD`E&0A#5%RB!I>?SKT]UX46,-M/&:+J]W9`H$T%^_OFY@7OYR
M?_?A_BYZ*.J<1?B'/E4/>:;_UQSO[V+Z)F9)P>*"GB0L+1_J.JE8%<$W49HR
M)>[OWK&.YBJS'"?*JPI_,+6_OSO<W^W^A%/AG]F#Z"'+4EC@(4OS%'ZD=9)<
M?E]G.7Y?IR5^7U5%>GW"A*WSM*YJ5L41J\H(9L4][7[;F`_VR])]F<1>J)=O
M[^_^_"/?-"6+4_867B"P:%(+3YP`$GG%W@)`=?&09#CR\_W=.GJ(LR)F;\_W
M=R_>"7;DCZP38LOX=BM'V7>\90T_R1%^RHZ-!\%VTS@I\<#^R-[^>G_W&A;_
MUV_?8G%CB_`2;K%\*'/VMH$]_3?)(OOW6Z\(EN!6C!ZBLBAI3<`DS:)"8S)?
M'_^RGR=E('#`*/%ADDH<13<.["S;EFT$&Z;-,/)NE+Q=L1-7HVRFEJOVD<D=
M.PO[$AODOI,[V<#0:Z"//=N*CZ+M3Z";;MKQ!I:6W1X'\$:.C\OH(<H,*@"0
M1Z7(#"J[7K$>@'C=?7X\"O9R&F0GAF&%LC7]\=0*%(/U.[(8(P#B@X_PQ1]B
M]OK32<$[..[-XS"*([.SOI3]FT:*KA&#FYJ-_#W\L^V[O8!1RN(W+"%_7956
M_+PLK/A9#-&'Q-\KP4>!>QA@O[C-\<`[U.J!;YGX=!+-*+8KH^FF!ROH)C'7
M)<)R%0,8`^_S;LLD&--)]=NI(2Q1WQO9@GW@<OW,&L0B$)21LX!T9@&YL0#0
M\E&H!JR;?>S;Z0B;TMI6_"0F,';<^RAD-U@83I,:$(0O#4*0%0VD_T:T[=3V
M`TP@$-2^#<'($<0EI(=X;Z2OX\P90`ZYA*1_TR@A.G1#K;856J3</6^]9L,#
M[+B;CALTX2_00DT/#^PO[7CHI_T!9=Z(5L*;:%ZC-J^/&%EV$"\D@M?PX<#`
M.):`("TL!*E#("5@$($#FBAH8C?!3Q2[/X$P:*D@(SPZ"C'JYYM6[LT7XT&1
M9*]$(PB$-%ZQ)(J*%0VEQ(-&<"4.4EC=BI/`Y3JT_D>&YM\K,+`EQ(]K*WX"
M6=W)'R5:?MDU[;1%"Z"<*#O>D3,,4].@PDV<^R)`G@\"U4Y?_K-O)>@/#5N!
M*'.75NS8;X7JY&>A\=1!8:"H<)D(X!.&A442`8EK_"#/O1^4F4:!XX:8'&PT
M)I/8/-(NG5AG.1[8-),=#)ECYM-0[2:B%OUFY))<ZL0?=2K=J?YXW9V::1A[
MB#\#`_.#&1<0O:IR)SI0,2^ZC7]MRS<]FCRX)(>,H//_BNP!O'F/@9U4-S3@
M&]8@GKR'<;[39HW^_.\_O,)W?X7\`<%?*'"&(X`*B-*[3FI\;S;3,A&@*BJ#
M`+JH0Z"(319$4M,)9406NQWL&L5$U^0-V,,@M=NCZ*3XC=&?3I@4T9!P'B&U
M7[++%4FH/:L%FU@A*H-H)I*5_*$#;!IA4\@)\C%\6@*%/+:LN:R3C%CSBZ;E
M\C@\++%<G'U?!FP71`*,,<\$NC0IGR'`?S.&[,BOY4#HTY#O?79"EF+3P%6N
M',@'8!H4\BGCP42*RT',$P,F'B)""RBAK$N?^V;!WX8]3T6NL]M1-`=@+OU>
M"NNKQ(GU"YXZR<_<\F2;_XGM@`>M$-BI'2G"8QQ\.N\#*L(4(DM`4$7.^0L?
M_@I;*Y(^R+6U(K8]ZYMF4A0,'LFM&SZ!RK:RU5X+JD(9Q"<YD%3#`0SFT+<0
MOT$86WOV(Q9/?-.&M(ZS"74T480OA$#A.&!6^=P7588!<,A>I]'N=!J0`E)P
M>C2;.\/FAAZL0Q$]-,$.I)NZ2_EF+O,E\R$]P[L[+MNKKQ`D.F`BODL@D3DJ
MF,RX8)4:=WA"<I`/>!'WHD-B>+'E%EUF,&:_`RFIL'G\TNO!H$:4FPH#/@@"
M<BN'$R0#>!W^V0E\=.R5R[">B'Y]CZ)X!HRRKAT:+[[Y[`AU8B;_ZF@?;@*5
MD::UH#\HZYQ?)W%2NQX0:8"XN"]&+SSWR-5[09^(WO!6##X-?'52#*!25/7O
M1"5LX$69?-^D:Q?$!),G/L$4SW6=WATDN).M`!7DRVYL'XUVA-;/-;5`<*#V
MP;"Z5HY<JGI>8!NU0RRGE@1O#E2'+H%][GAVX:'(DM+P#TV:.RBR3RV$D2T(
MUTU().`?%$+VJC]#@8';#3>0^EG%T3X:N)[OQ%BSOUA\"0!22[/C.'$T.[5<
M`_;VM-OPP'Z8E"(+6.E6(HAS4A(DDO`)"<6$85(A(3=V@&29\$%Y_]-)%.;-
M2!@:(#1/F==L&)PU)EC8TCQ\3\1M"1A<(S9.R\JGV\@$)MP>1/Y1R<V$5;\3
M1H)Z5,=-UM3"`(OR]?E9F[:">DGW%X3<=]2?E5L)D"&7>C4#ZR1Z(&M$*RCL
M@>[[1V&8'#X]<0D?%@'!]UV);-JBLS9=%]@?5Z#K=AJ(1DK2#A$BK1]#OMX+
MTJ"NJ:1B?,`V,[JY4$H"?"3T#T;;8GNIW9F,&TBZY&KH:<AB13=HSDI[6`""
MW/5>DRBM9L0S]8W'WR?VJ[D5G2!I'5!(2\`UVYX&6X%VF-H$A$FT!3>((JQ0
M'V6S3`<Z]^W7+//MUSHS41&"&<BIMOID`:7"<XD>&9;M#WB[==U2[#9@(:)K
ME8N4`9"`EO<04/BL_PBL'MB4[+>RX1@S1;<'&P&6WGUKF<LX=D+7"?I]K$OM
M];=?*9_!&^4:W1<6KD6TZ=K):9PXM\Z+Q->36.MQZA^!0U(.'RXZ0S8R4[\3
M,S*8]C"BG6IK'Z@#TZMQ$0)&C>\%"5@>%]^7@-D%P;\JW_7(,CPBO4K`?M))
MDO(H:`"8Q$&K"'(S'^A`#J/C2-7;ZO(YZ(G(Q83'528[7_;R=)'4,@%J[H^R
M077K0A#6PJK1GA8N@'U6VTYWDL:^SJVM<4Z#.7'I(0M0H34[]M(UO<D>V/9W
M`<58HSL9:RQEF1,J#R0$X6YOV^D(9:^[A[:J\TLL`4'EZ'@2E;,"UY3Z\S#)
M=SM-E>R&+^/H44#TW$(\?DL^2:.(8SV:A@[ZZZS*Q\/";J!VCG_N"V&PH^GB
M/,0P@"5`*"P13\`GG!U4]B3<[I1MA.[LG#7WTN=`QN#%,]23&CR\'7I"XH"F
M?#%("?00L`_JBY-AP:.6-^(B"NK!2PB?.1*>IO-\:X1_NC_=AO`TPK:S`9<'
M]D8>)1WUVZ/+"W"`K4L.I8D^QK)V,TL!%^']J2G8HV>,*KH'N`0:J>/B4>+[
MGT5JFG_(#$0CM^(+S?/M1P&$9*">O=TYZ5UO_R#W>!!P+6`8B9#'T%@E"*2=
M6V"KA^@Y]9G!J`/2$A"XMO@%#<U3DR"V$KD6^C/6(3I&ZLZ3<$TM-`"4\>Q[
MFT\/<%T7>YA.)XB7@%5KCH8Q>A`D"^1S,.Q%\WE:EM\WG]L%,8+7WF(K6SA=
M.\4`M<RZ6_,Z61_+S<QZUEH!=O:1+F&0?3<<,]0.3+HCIYT4[QI[O`69P-,R
M;;8^!Y#AZD7[1;JV:>%*B-H[,5BP26K&%144!]TD\-[!T*],1?W$X83QWHWM
M.-F\=\V//3NP1N^%MM'+R0W/S#Z60"!S'?R\]B0OKFL;U(WH/TX*SR=7#!]<
MB]D#)B`2NKLF\VKNXK/CBR.'!,FE97Q$@'3S&WW<3^0V\LW[U57N4/C*?G6X
MGYQ&A>LGQZ6SLJ2H#'O\>Z\O0[R'`AW"X]!W'4C?]%.[90>`G:"QY\+?'H`L
MREE2_=Z>>L#,P,F2PET5*1-/G%++'=[I7A+:.;!?3V;ZSMP5`%.3)^Q=T2&H
MNSMRY!T4VU2KZVL$F#'PJJ!FH=I76X/OF6*-:TD<8;%19^,!NX,+>%>26](<
ME5'E#X[M'2EY/&$G$3=IVL?S(])^@Y<<D$L]8;Y`"M4D71M;"7LMY,/$6Y!>
M7"#A36KL[84)>RJ*ERG.O7KOKF0N`4+JNM>5K^RS++/=*@6B-/H>)P42W8$F
M.NPKHFU_E1R(3W3CX:.8F\*%Q+J3K<>)"U=B0)Z[ZY?)EH`A=O0YBCU?M(=*
ME@ANGE[ZX2,U-4+*?MX+'!*^BB1C,Z;DKIJ"[>W8&__>S[I+MLBUL21RUXGK
MNI@Q9W-GYJ^MZ#KV#[$]@_3PWT]<P<[UE8=9`X%()19<BDXQG-B#[4]VTU&H
M7G>!(2';>P:\X5N!_0-B-:/.[X.@160WP.23OI*#R6J)B\.5ZU]GJ3_,B3(C
M?@N5D0[YYLB76@O`?GLZ.I^=J.,).B1F+EMT9:R(M*G,[.1Z'#A3:CE12J7^
M&.%%ET]UE3&[-;44]8H+U\/./.^PM,.T8RV'<CUE/.1&4GAQRV.!?!6GCACF
MLZL=AA9B_86Q`]OFGNQ:]JJ[4$_Z%UCPT04NH$D-J0-J]@FK8W]H`L[)3Z<6
M8J'A1N::G!;=0(*=>G,E:*&K#''L*&&:^:1%%[ZIKWYQPT;W<)Y#X6FPZ<1Y
M'I/\"90/8?Y>VY-;0U<1W2QSI]-U/GVSCV#131YWQO]EQB%`0*Z9[](]/XW%
MG'[@T=S\LKL<9F)I\H?T0.H3/'V"ZV\^F<"]'"LLH?RMK][B0$J;U'4%0R*F
M?W'(OTZ_TP,#H)J(:$#RS(`HSY+0@*3.H^`,295!X`@-*+.\"`XH,A`R-"#/
M\O"`+"O">X#*(@T.2&XM$6<W<(C2+#A#7*=AJ.,J3?+@@#)-X^"`XM8`**F#
MNH!<&(4'I$D91#).\.)5:$",/=O0@`BV&1I0@U6'OJ_BL)`E7B$*?%]$=5`/
M.3+'P/=`(JJPTT5A8\2;!$&`RN?G_Z"WJ%40E_]?F8PVGML2T;3#TN1IV,F"
MZ*SK,HC.&HAG4/QU&MU8(8NJ\(`<B4-H0!&'G75=U'E0A^OJAA+755T%W7T=
M1U%\:T15AW<1QW4X;JW!UL/>M(Z)4P1'Y%$X*JSC(BINR%*"V89'5#!+>$0=
MW=!KDN1%>)4D!=V'1V1)'/2_=9)'X2"X3HHXN;&/,L[#1IQ4>`(?'%&G-WP-
M7.F&M&F<A;/..DVR,JS]%`AJ6"]IEH=C\CK-\QN6G!;YK7V4>"LI.*(JXK!>
MTAI_=30<?8HR/$<6ES<L*$O*<`Y:9RE>)0V.R,HX'!VRO,QO[!1$"5MR5I9%
M&-.L*F]$N@Q"87@?>53=L*`<^%-XISE$NK`WY&E5/F_KD-Q>_W)_=W_W/^"Z
M>Y8-"F5N9'-T<F5A;0UE;F1O8FH--C4@,"!O8FH\/"]#;VYT96YT<R`V-B`P
M(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X
M6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\
M/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q
M.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;
M+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#38V
M(#`@;V)J/#PO3&5N9W1H(#,X,30O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E
M86T-"GB<O5M+D^.V$;Y/U?P'')W42"'!]S%^E5WEV$YV7.M#+A@*DI"E2"T?
MTLJ_/MV-!RF-!"7KX=;6[&A%$$`WNK_^NAO[]>^/#Q\?'X)E6B0LP#_T*5\F
ML?ZKW#T^A/0D9#QE84K?<);$RZ+@.<L#>!+`UZU\?'C/:IHKBQ.<*,ES_,7:
MS>/#]O%A_5><"O],O@B6<1S!`LLX2B+X%16<GS\OX@2?%U&&S_,\C:Y/R-DB
MX462LCP,6)X%,"ON:?V_C?EH'\;N(0]'H;Y^?GSXV_?BI0051.P97B!ET:16
M/2$'340)>P8%9<L,/I2/#U_]F\>!_?D+>_[/X\-W,-<_WV1%4+-;L>#+*,@R
M]OR'6?1S%TMO+9:/BYU)Q=Y:K#0>5PJ685SDI,H%&$D8@H1'V,![R5[D1M2L
M;YBJRU:*3C)1K]BPW[1B)5DSM$R493/4O:HWK.O%>LV.JM^R?BO95K7X;;.F
M<=]LE5RS[U4MZE*)BOVR7JM2MD_LO3C5DOVC:5J:&\:BP-^J5I8]?`>OO[7L
M9$1A;F0/TIA;V2,.=DNRCQO]E]PW+<GWD^H$^U:RGP3[M5%U+T$K).E:M5W/
M/@ZB[27MF`=!LD0Q?@')5T:4CN3K9*U(+!*_@YU_'&``S"-Z=I1L)V!F^+EX
MS8V?11E!:`TA#YT=@..2*E3=#2TH`\Z^9Y4\R*IC9;/;BU:\5!*-H]\V8!D@
M=Z=VJA(M_/Y#KMA^>*E4J<?62G9+!A:U%0<)3]IR"]8$ZAC*[2CJ6PN7%.$H
M76S!@O.W7R<9U_GJS<\H*?*S0XKRS%ELGAMOG5K)FZ-%^F7TF*:SZC%-S_08
MA*/C6RU62KRH2O4GYLQ^R="+9_"[(H_=B?+";:6(8KT7N5X#\G3H8>`?[:!Z
M)E8KU:NF!EP:\0$`N%H!5#.UV\L5.)5:$RR)'2(S^N7HPF5SD*W8P-B.'90\
MPFB8'M^%(6@]2M;]DGT_M#`#H#-,!:`D`*"&VKK['*I(,ZN*+)Q`$$^T*O9M
M<U`0<2#J`,SVDD!%UIU`93`,'6<[="`ZRG0+3U^KYDG#\(G538^:L9.*OF]%
MV>-JK:39YU!$$C@HSIQYIO09%?%!GM@>]MW4M:R6L^P@BJZ3G5L_<^P!&=*7
MI'AV05![6D23$)AKM5_*S'ZU9\`@D-4;V9'%K%37#ON>"$\#QT3F"7'O!TV%
MT/#`AE2-_ZCE<3Q)8$U5Q20:+<S8=+VV4CTGF*6>LI4=_"JE?CB#WO.BL&I(
M1E84![&Q/G`!V".ZW+IM=C#]0=:#?/.-@`7:G8`5QH38:(6+MU\IF\C,H]3%
MU20(#!/<R)H.$H[,`#+`(TK?JYUF/_";,$-470-GN$%X+>'<AZH7M<9OT74*
M*.*`>$-'^3)TJI:=`:.)J3QO)7"I.<XVYTY.9+GF;(O4T+SICCO9`DL3N-N5
M!)Q=(8#"``)`@-`GVO81Q,8H(4$K\''5$&(2P8-7=\CLZ)VF8@BM.%9APM"K
M`P0QM.(.U0;OV<?3AR9OF$,3J<M[TCAQFN"IC;N[?=6<)!)6C/Q3Q:!#8DB`
MZ`%,H8?H2>D.A`3S$L3A$VM0*PP(,@JB==4U.QU42#UF2DJ/6C-<K`ZJ:]H3
MA+(6$64G<4&:?@X=Q#;_X3P<<[\\,CQ([PF=G0Z#LA/</NQ\#:2>HB#%8(C%
M-N.#PVV`\6^T*:/9#Z#"'^N#QHP.WX%`#OC5P92`E11QM<IZ,GN-AYU&0S2F
M6N)HT:KJ-(L6(L>ITVCT?<<&7V2)YX9V"!N'W?6GSX^YMY)^W$<8CCG_9\V?
M>>7,"LTTBW29)`F!Z0(QWH:W'VO+>N'00-)>ECKBP(=MW53-!HU`\\RM:'<Z
M\Q]?,98P"Q_)DNS+<@&[('+1N!BY0)+=X`(($I#'HJ5JR]68B5"/&,":^E)?
MS0OQQ[WHR<EUJ#>4U5%<<PY$<#46:J?$RD-5P9,!L@!KEFR-0#(/7F:QY:0\
MC)V7Q%EJ(N29D:`LL*G54/:=K8_\5BN$RG<]B&4B'DE"E:.6*@,_KDTH0*^W
M*@"GGQKC5<&?C/$IHO8&G^=0`H^<$H*)$BPS,DG"'B,D9!:OO0?%EJ`8_<AN
M6F&P7!T@N`!KH.C/*G&DZ$<A`T.KVM2CJJR.K&)0#_!]+R!RM&JSU7P#M3Z'
M$H()3>83FFPX1"=@R_(36C4&]WXBS2L[>#)F7Y_&"I&.CK(F:2DT=""\@E0-
M%(2B@I9W9%;6.2""ZLAS10_S9&AI/G+D"8\*;.501[)7YV:9G1,"1$)3+<70
M40A\(A>6GP00"6!3`C17?D#-M4-ES&<G^VVSZFC@2JX!8U#^ZWB@=;!\ZV"5
M`5VT&OC\`HTG%*9I\2=#X9WC2_B7#2=V0;27;"QMA,6-:((UT@;B;+]M)99I
MN@',X[?EN^59N.`QG7M;"U,.,@^?L%)?#6089274SG"WTE'L;T+VW:<]I)(=
M1I9WIZZ7.YKR`#2K@0Q%8_,<JA_[#440.TTDW*A"='N)4<.@!6ST!\B$V;-%
MT9.&#*.8*](SL=\#.37\\[A5D('(3WO]DE4"9F>"HC/J2=JEWI4P*R7F6B6S
M<)G4=1W"G(^L.XZXZ[A0$DDPF(1L;US\MGA'Q%M4&Y7JM+4\:19",^ESMT=[
M5\.,"(BN,<Y4ZDO'.G:6371@NTZW;%0'1Z.)?=,IDU.LV8MJ^E$"%TRFKD`,
M_OS5)ZH9ZNR^`J8QU"4`)S$PLHY#4QUF":+)6/9-1B\(X]CFX1@`/K%*;L"P
M<2]KH;']XR`[4R5X+_493\J34Z9T)1A2P6:HQ0`AI*7V#,0=G7FI=F635>"J
MU<D2"!/(R77FT,-8\YV4W)+8H,&E'.=DJC7U6IT]'D2E5IIAU1`<2TE*L7AI
MRL-RO4;&<$!::=DVO(X\A;J9G00(Z+5R$5UJ*HVCSVEV/8<*DI%9!Z,O9,84
MK``D*9KQ2X/%AFO,TE%N4U.1".I[K3^!F=D/S5$>L*(O/ZFNM]7(]=`/K;R*
M+X9*EUOP#EEOY"P%QR1RK)JG8W"D"HUM:ME2/,#!4/6(4"8H&O7H*HT3:QHE
MD5R>B4C*,=G7I,0_M@G@K%_:1JRT1V%]L]<!T7C0'#H8:\_1)+T*\!W=^Z"4
MPL+8V=&#6=*V5MB6;?84]75F@9HP-N':.3NJTQEQ4/Q)>0\$-Y.X+B[Z366B
M[#Q0&(^UU[$7Y\S_4M*5Q&P`?!DX]6H"Z=C#F@S%DI,+8F?B.EO&V0#A$34P
MTQZG@J!A\FAK+_C>&JOR\T3#>*S*<AY-TLKHO/$UF%*@39=>Y8Z?3_5]NXN_
M\%4;NR!>2<E'BZ",^RI;_AG+!1`(387D:L`X8;-35FJC,"H@E%LJX"HL2_;W
MLFQ:Y`H5TDQ*HL]R3[P#8O@&+F09U73!.0Z`CX0Q')--8$NO781Z$"U&MV&/
M[&T2U*:U)%LHPDJN0L]7AF9,15$81G="J\;>VNC%!UGCC$.+=:R=%!T@:W=)
M/N900SC6:=,Q3O*B<%YR?>LZYW8[M9#_JIU\13]GI&`LT_NTU$GY82:<B`I'
M&BFAM)67$2:NDK_)#I$G(5BVIF;0G%D`'JC80`HT:3NX/@C6V*I*O#2M<`WT
M25=DR7Y&:@'JJ8"Q/\TB?N:X8CQ>E8B#Y+)E<[G5YG7_!F@"UFA55U9T;>FV
MRFR;Z]IM`+`IS!;70W51I=1V,X<.4D<6@TG;B@IQ5'RS_/56^+L1[8>7#I6C
M*`O"VV@0%PTZ7K6CQG`0A?F(<XRC`EUN*'W2E?"9_"!VA#&)'!*D/,_'K.&"
MSL_03XE,'12;*$'JSB+,D]`V5*[5Y,#+3'?LLI=BV\%O7W4`H^&IJU@6(\=.
M(L.Q=8]SMY,MW7>TG0QM*]VTBU%+93H0:T212[9])>ND0L,DOWP"-P)I6RG*
MK<Y!4"NEK#O;9)S!9OA8@<NBR>4.V^L\2EMWUC5G`D="P!9R\)9R`6_2!1F(
M]C*:9JTJK,'H*H*^'ZI3$$Q"*_5!Z@P;ASU=S;Q<NC>'+L8:7%A,;A$&X7C;
M@9P:/T!N(38Z((S74T^@FFY+W5T`4O6'Z?_2'=\K%3OS_:MRCGMR67@S76*=
MS<ZA`5>#`_[HK"$)+,6$Y3O:B!$:3\UF1)KIZ*T9_+17`/"<!WT+]KHJJ,=E
MVMQ7#OU6=CO751\^EN'2R8T[GN3.*=PY=[I*2O7D:;)U(LIY)"BKI;Y*:))K
M8=U:YZ?X^@@$?Z*)[H&Y,'44*0XFC9G8X-SS6:$+#5ET'5ZMLK9-12(B$M?;
M2I.$`H^\&>`(33G-<,"SR-N_6L_H9HXKW''FC)JGHU%?%)(N\`AI')ZIUL#$
M>L^0SJ`]`?1HO;I.IL.8JDMJ@3LB,;G"1M?7.M/$WHE:Z)LMLR@AFO2I1Y*8
MV7H"]0&(N908E=W=.[QL[[II('XGJP,B/+(9<&&,48UU7=-3P4X=51K/B\N3
M/,'7E7-3SZ&$,'(`GT^N>47IY&+/94G(&NE;]_/`*XOH1CN/R!S^[Z"L"%A$
M\XX3T'\[@@$\Y1$-X#<&A$F6>`<$6&+T#`#Q<NX=D,=YX1V0)3SS#DCCW#\@
M20+_'N(X3;T#HGM+\/B.'D+,L7P#@LBOZK"(('CX!N010+1O0'9O0!HEWK,(
MX;3]`V+D[KX!8'->/80<T,4[@!S/-R`("^]Q%Z%?RCQ,O>]G(?<>1!I&7@F2
M(`]]S\%MO0)&>&'8:VNA=_XPR&[O_Z,1D0:$V?^7N\5!P#);;C<ES2BZQ"6_
M=A=%'GB?\R#T3P"@Y!\0!X77!A?)'0TNDH)[G761%IE?BJR(O4:XR(O,/Z#`
M-HYO0!@4W"\&)"G<O\V0%XG7F!=A5&1>Z%N$`+]^4<(TR.ZL`D[G/[,P*^Z<
M*@?X\J_"@9_[-<:C.^BS@$`<WS'@)"CN[",%&/2/R(+BSD[S*/+"U((7T1UI
MHR#R0^DB"N/8?_H11%?_N401\"?_B#BY8\E1DMS;1YID=^;(\.Z`=T0.V.X?
M4:2Q?PY(GNY84!RFQ9T1/$WNC(C2W(\.<"K\SDZ3[(XEQVD6^76*Z8'?]X%9
MW?&&N,CO6!`X5.#?:1(6H=\;$F"BMVT=(M=WOS\^/#[\%]"_:54-"F5N9'-T
M<F5A;0UE;F1O8FH--C<@,"!O8FH\/"]#;VYT96YT<R`V."`P(%(O5'EP92]0
M86=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@
M-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO
M1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A
M8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT
M+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#38X(#`@;V)J/#PO
M3&5N9W1H(#,Y.34O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<O5M+
MD^.V$;Y/U?P''GQP4M*$!-]'V[$KKE2>WI1]\`4B(0D>BM`"Y,S*OS[=#8#D
MO*!D/71MS8Y$@B#ZZ]?7#<S7/]W>?+R]B>^*.H]B_$>?JKL\L_\UI]N;A.XD
M$2NBI*`K+&+575VS*JIBN!-G+-+B]N;'J*>YRBS'B?*JPE^1/MS>'&]O]G_$
MJ?#?XD)\EV4IO.`N2_,4?J4U8T_OUUF.]^NTQ/M55:2O3\BB;9[461Q5"?R4
M,<R*:]K_;V,^^IOI=),ELU!??[B]^=-W?-<`!&GT`1X@L&A2#T_"`(FTBCZ<
M<-E)G,#'YO9F"T(5*8L^/-[>?'GB][(_1$W'Y<E$_,!E;X9H--&)7Z*=B/BN
M$]&@(K4;X%8D^U_&OAGD@XB4CM1P%#H2'T<YT#@M.BGVT>-1-L>H46/71F*_
M%S2^@^DZU=Q':M0PJ^SD<,&)]Z.F65H!8]1Y$_TA^O#+[<VW(-^_W@\%>,BA
MD('6'`I97#D4&G4Z"=U(WLE?0>:^C8SHNNBL53LV@]G0)2N0%F;L!@`B@F5'
M_)'K-E+[R(P[,_!^@"FBEI_X02S1O(N^WT?<HHRC9;_7`+LXB7Y8@BX-3-0T
MPIC]V*T$19QY*.ITAB)GN87B47C5:U2L%BUJZ0R7)K$`"V<.JB<[."DMHDXV
MHC=P?Z_5"<"1`,R9ZT$*$/]'.VNOAE>,"H`TB^<Y0`(OYT;U-'`%%.JJ]""D
MU01"6M>EMP<S;"*YI[5T':@/5PE?P$A[N`,@.?/NX7<_D/UV_&+0+IS51$NC
MXH-4/3H&R`,/\V$0I_.`&#B[A]?`+#TGUSJ)X:A:@]!Z$[Q;!88R]C"P,IM@
M*/$SPO!GL4>5H,7R_A)U_-&`J^.R]EQVHUXJ$0?`N&>ZM"B=->&&%D[&L40&
MHP]_@.E(UY.XGRMM\8:T19%,XG[YV5B^.7L<U;F;_&>6Q>^M*YP?G=4%\H+-
MNDIJJZOO;!S=4%@:^"?5JY-L,.08(_>RL18(&L+X^TT2'<'$09,'WDMSBAZY
M`4L$"SS)'CQ^-"XIP+,-1#1P\/-1=>I@OUGSO(O^AGY_4BT8[BKFB7A;D?,I
M4"7X!`K\IHS>>V3?XB5A/?=UL25$>0IU?@X0'J#@42LA<6DTVH/H1QOTS%DT
M/IIAJ&_D>9K^40Y'@GX%'*JZ]CB4Q>2F&?(/0@)62#@8"-@0D&P"XWN,2K@B
M\0G6/0A,8*=S)[P=4/KJ(2+SY16`B*83%.0\/CLQX&QG920.MCEALA=Z<(9I
M#00P41,"C-7)A$`%?(X0<)I9"/&7I9[OHA]`(G\7I#`2@XU_BA3HGB/[L%'K
M%;N8;N!H2/F_`+`X+=H!F(J6A^,`JWA$A-:`H<@]#'DZQ8`\R1(+P^YB*9DU
MT1VRL0=0Y(X;6`_J&'Q`//!N?*)R8&UP$98/4G:6S``LWH[PF5::9@085&^L
MH>/%!KX!$\)``5%[+^@^[\S&XHGY`+C,<14<LHG4+MA<"N4`P?!4&X]>9[('
MT65KR=RC(,HRR(/#XL%YBS1FI+P&"6RT7N"`Q(_F."4T2%E$Z^!J*UNB-N[R
M!A\WX#*=6!>&U+/:.(MKCP.K8Y<2EN(ADQ#OO88ZG=90,Z#3,7S^%5Z\??<7
ME0MA$Y;G<_[+\Q?"VF)FP=*>D5E!A$WV\!$XN89P\-[KS>+B=T(FP\=F:*IR
MJO&R8C(#)&/$L[3FKNK8$*77Z@*\DR*G1I3V2C<6(S,`)UW#9A-;?L`"X[BN
M%D;[2BDVA2GCPC?5CEA.2EM6K,#CRCI;E<>593DG\V)25A8[.X;`W2J*)E`"
M0M%\4KT<E(U-YW$'RJ1PW"D#_)LRGJW",;E#LL-+9Z$YQ65I0SX0H=$,&M0M
M#E"NXAUX1,*<HCGV$ZUSE0C5I"MHOBRF8J.,DY=16^S!^@:SC*DN5XF`\+;>
MF(4'D2$Q]=ASP(++L;*@K.[%E!86')BRV!HX9.E<=,V!K(X=#K#<2_0@5<>1
MLUG]#:+K0*214T\"]#M<YOZ+S7.6KU&X6W)3V][A9WQ,2[S$"9K-DRZ-[)MN
M;)<)\0X8U".`I#>4PM;`@4WLOIKI_12UN-,@R2!>-%^6_1:LUIWZH'K6Q@6-
M$^^Y;['`/3(`4C[@9]!&('^[J@D;&+9R4N/0N&"#<L^K6`.!>.;U;,'KT])7
M./?$1$!W`Q'-T2M[V4P!3%3W(%KO[7O^@*:A7QT#E@XYKQ/]83A>$`BIB/$-
M\B3>/YR"C$55_\9P6@8Q+$I;&=0%DJ"<LNP6VWS)'$]=/POHG`7`-V@ZZ?J0
MJS17J,4**ROOG)<3!/[GW7E`/KT0"$<:8Y;Y]3=FL;?4"NS;O^N)3.^.(A2[
M_D64->9TF?IH.:OWB,4+JA18M[3>ZQ6-Z<2WE]$!EK<H"DKTJ%;,5?QHJ+$)
M<5'IL]*>B&Q\FPL=;<XHPJS2JRV2?)(]6]0YA:MZ&SX:2GF_C)KR`8BQ5R,6
M;1C4'B4(,?;&=^?;4;MBC20?A$&2L,$X.>XAT-%M_*KO!=$'F-'P#N+"!TJR
M6II["+,:*ZFC[8VX+OC*S"&O?;D7%Q-Q2)FO>D$=S5&<,+2#?@Y:-I`C1@V!
M'L/^^<CUB3=B'&SLG_JI/_IF[(E#@N6+QNT4%T`^(!H<2N%-)(<IH%IBUE#)
MB(9P5EAO8B;R3_XF<AI"HIJ9/JL62=,B\7WO%CZW9<VXWTLLYX=9&+MTR(W4
MWNXAR37B;&VDL6V3A0$M\H_?J)CE?8F8VTAZVO==`XEBVL;(Y@Y^%E<N=Y+S
M'N5.VL[.JU6%MP5OOY`>=A=L4BOM.AQ=QW?H_4I/O!3M?\HD&`V<^Y$ST@1D
M$M/.$7Z;X5D#B<P7%"R=NP!9Y;L`;J/B4R,<G1S4@+YAC%BASXX+8N6J*3]/
MXJF$+(J).B95FGLW<%LIV(^""`CLQVY:`,N3!R@01@W1J[E$^VY$4CU08\OB
MQ%MDD+A;R6GGTI(NHIV?#U9`&-J._#U9@G\A!=-RCJ:IBR'+UU-2?XHF)@2#
M$8.VO9P78'7Q29Z@N@#<JN+G&-Z#L;=.Z*/+E[T8W.,0EQCN0^(8^)!O$.&S
MWR>^B_X!H^_%A0J?^=4V,9DU?"C+IUHD*Q=[#:X4T;8"_7;$V@L"YG]ZJJ#^
MHB!)_E5ATL3;_Q3JC-+]6[A2%>3^YBA[3G)^W[>26]'D:XCB3@I2D.&HU7@X
M/AL$5>^@Y6[$2+0*`.E4BM3+Q,(<U:`"BNKHQZ/"[&=[W%B%29!+$P6R520Q
M!Y#R*R-Y/X^X;%R%IM&KJ`O7OKMYE\DDR<IM-["2&3.6SIZ4Q[7;/85\`(F@
M@R+5=<W/_((4R:#T(^&%W`M3AT'X6MK&Z:GL7T/%;&+25?&".L@I+%(+B1H+
MPQ%M_>Z'NZC%3$@YL'?IM*>\[SQ[A_N%PEB1>-2/IQU2(SSG@$5Z(VQW`FW\
M^:$"?%R!MQQ<%'ZZCC5@B"=27<U[*!F>Z;'$X2W1OX*81\VS[C))(SZ=E;'"
M-$=LK2X%N&#2I:L14`CAC,!%.MHY?RL6(&VUMK(&`FDUT>FXFCNP9>[L=J$.
MVD?"_4--&T+M+%JGC%E$<M#U%RQ)-^B!=%;&CR/*Z(91)O@B*39EE;\_/2[B
M*,V3UUN,;HM\F>X#>CKR!^%+FS,WMGV$Y-]=VX\#GGWHQ8&[DTT+KK`XVG2&
M4L3V)J&>\B,=AUY#K^E$B:MD$<,SMTV\H+MSH`&1.H6%T>QU8.J=49NE1;]@
M3L\00W`(-:PF+(-R)[_\MN,>WM<W5#.X3>15($BFYGK.9@-(LCF+.2Y'H<LV
MRM$:N$$SAWO&8O+4]3%I+[J)KB5O7H/E[%K3SF0VWF8H='"L$P`->Z1F#?EC
MWV-G+)FKHBIW'C`'ZL4>V$M:K#0=:X,H/VB.%H,%T=G39']1"]NBQMTBW$F'
M.O/E7#"V-[:+:FSOQ?>F6\Q[J^R+LBJ=$G,U6T'M"J)]IQYM9',;+4?1'H2E
M)V3$O7+K'RA]4[ZF,4\#@#MJ@P)V4TTYVSEDOD'8?(\="I!?=;(EP9>T"0F5
M6:6]S(J)U+*ZG)UAVAXFO]\I=6_-%8@96*FGHK8G8KWAN597"=Z,U:]V^E*7
MF#_@YOQIBAZ`:3OZK4N7M#42Z!W7@*O&<PCT79S@RD$A![&VO(_`]+72TIP@
MD8.#VW,.]BSK@U78.(""A#_G,&C548Q;0TO)1,N2?'%`-_?,^WE!^I0QN,:&
M/:L!\."I4A]S%ZEH[O&)C379L])4%--!UV7+(J)COJ\47N_>*RBANO3B?^:9
MO'"G("GSJ5.0S0<<&4M=0OC:Q4,KL![/RU;`O1#GZ<BB:Q'YXF8"BV#O&SRN
MZN\1B5O%11)WF!OE28J9NJ6>X?R=V\8G[?[T[VZM\'J_A'7+JR1CTYN>AJ^T
MKFI_<KW%76(#!(V\G4[90![?0WF!"8[KX?AQY/?XY0B!2S:\Q\]G]0B.;ODK
M^(+H!/K0V+OC@\:?;:6;-DX,>&"7-_=PZ80NA7E\C;/9TREUQK)BD;T],5_P
ME><1:R<NRIW66@:LR:YMH35-\"3]$7'#K6\07+03II00(/A<*`M2[<?;5KK=
M8[%60$RF`^HL9Q,*>>*[>[CD!F+\9=G;WKWFR(N.-Q9HR,.!BPR"G%IY&[`;
M_2B,:AJ,FGAXLI\J'!CG#[X_(@%H"&&,#PZW-0[)S!W=N4";3SMBHTTCQ7B=
M:A.M(I)C3ZW:/RB@8ZWVG!O'0YT.L*=!'2ED#J$R*FNHIFC=\P+IKUNPS"C2
MF@:P-P:PO$Z"`Y(\"\\09W45&L#J'*K)T`!PFC0XH,SC\(`B3\)KR+.*!0=D
MUUZ19F$<(%'5X1F2-`PUBU/(>X$!8*E5'!Q071M0IF50%TF1YN$!><J"2$(Z
MJ((X)"E+PXMD+`Z_(F%Q4-U)G(3%K),R.$&59$%-E$D>%*&(ZS)T'SPB*&$6
MY\'UI0D+SL^PL1D$*"#_1[L$"R`4Z?\7DP.B$>6^L'6[)&GV(G`5H=5MZSI\
M'SPE/""-JZ"K;;.X#AK(-L.3N:$!>9T'(=X6^%<@H0%E780'5%4XY`!.X<BZ
MA?HQ#J\RP:`2'@$!/&ALVR2+D[`DX"YA@]XF19*$5984]16ELOA*&MBR)"_"
MB#$&%6UX1!JS,*8L"[D7C<B3^(J)%W$XA&U9>242;R$07Y.V3LMKGI2%0\TV
M3?!O<(,C6%9>F2.]PA&V:99?6T>>AU/7%M`HPGJ![!@.W-NT*MB5.>KBB@5E
M<1%.T]LL*;(K(UA1A(-#EI;A++G-LO**)6<Y9+KPB**\$N9`]U>\`=CR%0L"
MBEF%5YK'=9@T`-&OV-NV#GGIVY]N;VYO_@O`@P,3#0IE;F1S=')E86T-96YD
M;V)J#38Y(#`@;V)J/#PO0V]N=&5N=',@-S`@,"!2+U1Y<&4O4&%G92]087)E
M;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O
M<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q
M.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@
M,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O
M26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TW,"`P(&]B:CP\+TQE;F=T:"`S
M,S`X+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IXG+U;6V_C-A9^#Y#_
MP,?91>P5;Q*U?=H6+="'W<5V`K0/?:$EVE9'ECR2'#?[Z_<<4J*<1*8"3;P8
M9.)8-,_E.U<>^OO?[N^^WM]%ZSB5),)_]I5:2^'^RP[W=]0^H83%A,;V'4:X
M6J<I4T1%\"3BC#3F_NY74MF]$B%Q(ZD4_B+-[OYN?W^W_2MNA?\NWHC60G`@
ML!9<<OC%4\9>/D^%Q.<I3_"Y4C&?WI"1E8Q4"BS1B*@D@EV1I^W[UGP='BK_
MD-%1J.\?[^_^]I/>9`FAG#S"!ZRR[*:#>BA#32CR"`I:1>LHY2EYS.QK*F-*
M'L_W=Y]^-40WAN3F:*K<5!VI*]*:)]/HDGPQSR0[M5U],$V[_@MY_./^[D<@
M_)_WLQ?/L!=1RUZR3J3E[=/O3$3#ST=3!"OP%$$'-(X'??`$Z9]?T<<?\G-%
M6!3)!]+M#2CJC/]UYWI4##S0'=%95I^JSN1D6S=$'X]-_6=QT)TIGX'H[Q'0
M-CK;DWI+*M.15I>F7?>;BQ>;5X&];X!!JL2@$)8*KY`TXDXA*,ZN,2!)@]Q4
M@S0O!7F\4,Z^,>9"A,(ID)SW=0M/&YT;8#(SQ9/>E(9L=*FKS+3$?#W!7CD!
M>N;/S)@<7LN!5%=W8)#CQ]J'F^@B3@9=<'#*7A<BHHG316..C6G!2XIJ]QKC
M&%E]((G[I:N<]._`)XXFZXHG6/8PRM*#VEX(9=5(RKIM<=GFU!:5@=?;ICZ`
M6QK4C"99?=@4E>X*<%3<##YQ"TW(J-=$%'/N7/.'^G#4U?-'4X/X.5`30PQ@
M[,.I)!<RL6@$-P%I+;@M:8M=56R+3$,8'.T78"ISHG.(B2TBK;=;@),4`-T`
MD07Y5'86M_H(P1/A::T5;`&L*BL`\:RN\@(?K,EG\)!_U9TA'#^!K\#5ZYL`
MB>@YDQ88^KQ[]_'_!^"S+HM<8WCYR?/ZN8,W#@;MLZBR\H3.:,K6G*V?@TMW
M^Z(E_Z@J\%GRBSG63;<X0<0![JGC_M/B=)`&M:/2N-<.IZ-V9#QHYY>B_=*"
M?*55#R#T[U-#P`\.X'R?NSK[LHBG<,Y6,O4I._8\,1[U0>BSR4X-V)&QUO9]
M`<:3[:NZK'?/&!S`1?$1)O5ZVYF*/-7`?8'1Y<-]"CX%U5%O7E*,3D55SRP&
M-`SY&#"/39$YIC<33#^3%A5J\\7.5+8``?:MULV?X%.%@30!+[L&#--M1K;E
M*>M.SMM<]'S29?\W$CK@OC?P*@7YK`\E(N7>;JA(G=A3`B(JYZ+;UZ<.0T%;
MM!W66Y!$<A#")5(;,8QN*M"7PQ#EU74#"M1-`=%G7^SVD#-;3)05[O.$Z:BN
M0%M>=-`D[*.;'$+:"6J.&R@@46I4@"^C1(JO40&Z[1%"]+P\()Q_U\EK(Z6#
MKGUC*;C^`L^#?H;BJ",;`V*!B!!Z\S7$('C7[#0F6))!@;+KXQ/8R&E3%ME'
M2Y\`R(/X-TQ8";0?HY93T2?A]B9H)D-1S!CU38)00C@TP?LR<[PL.<!J;55S
MU9W1VEWFS&W1!`LA=%H7[VV@`=":O#2NVL&GDTET3?Z-Q3'9-+7.P0::+U!U
MWD('TM?!*AXCF12#18,Q%E4.AM<\DZW.NKIQ)IF;#,ICM-[7L6Z0*W,)PPK_
M,"'W+:3AOI(5(Z"42@\HU/4'++S7Y)].IY>Q%`I8"%:F+/'W$(V/4"=T4!V5
M+DI![*D/13:6-7VTP4_JYL'6M6UK;:8!S4'_8-H.'=X6LI##&@CHS^Z-6VB`
M11Y/.:I`(+:VKWDI;MG6"]"T'9S.G?P/;TS<.8"-5YL_L&B$N'<N\I=Y"Z,5
M]@CP\C:*B(8*,$J3L>%5?7\'+`W6["H]$/@!*MO.QMJR.!2N]+$]*C2W95F?
M8<G?%[,:*/=B]:WE7F!_`3D[%O%M"<B$?3N!`)C,%ZPT1E*#8R=]$_-SG_ET
MVSTX4]S798YMS%X_#15A4;5=T9T0UW8L)K-20T@"4T"714_?N6)";['UQP*L
MSFW(Z@O*HGL>$FT?E;V;Z*&F^_"D"&%M4,$M<Z^@%YJ^;>YE23H@FL32(\KB
M/E2/"$&P0=5>H`K-I2T:K\+8GHJ.Z)U&Q,D)XMS9D+,-2N#K&*Q.&ZP5.VSY
M2LA+)=F:OO#"6`8)0N]L&_CA&H:@-$A^2R"A:1H5S.58JR=<\*'OUUWGBF@K
M^"TPCIFOKS@?CQXX'\Z56E`WEKSG(6/D4,XV]CC1GOZX<@A2$<+B3X8@=KO,
M8;LD],31;Y>UX^'6E#$YM*;0+OLBB291W_=@>SSR.M1SJ-6I,.%2I4^2-VU4
MZ=BP,"G&$C?F(^=?3QI4WD"7]58&&SZ'M&URWV)`H+7R8:]6%E_P@`B@R*&_
MJ8<UVU-W:LS0X[Q(_4[V3)_@P5@\W.*DW5?XU%:TOD\?"L*A+?,B7IZ&H48:
M+(U*L+LU^5P?S-`(#+7#>5]`[?=:GK=Z?$&B/UKZ^%HB!E@'D3^]W!V4P>-(
M00^71H3;;<?/VPD.+(`JD=H%[,H"CJ>BH05,IN$=`(<HN""2(@DM8*D$]$(+
ME!3A!8F,@SQ`$F(BN$#.D1`BK`<&<3B\`Q-A53,JP`Y""R+!6&@!3><6**BP
M@@L2GH87Q#P.:I)*,)G@`L&2,),<E!U<`)$O"#>E;$;,B+'@#BGTSJ'GBJ9!
M&1+*T]#S.$J#(DH:!?D#2PGNSRD/FQ(-RT^C1%U]_M6)$(,_H,5,1#0(=M=+
M&?RH.Z)@:Z[BH6B*D]?!\UN(*$]D12%3]KTR>1.@E7`TH`B8)!+(1O:C\7AZ
MZ).Q9!$;SEJJ^E1E_0#"3AK/Q!\QV2.(`I8\#0>]C5W0GZ2V9/,,M2Z^V[?K
M1P/M#B2I[Y:(<2W%2$6]')_>;&QM52`&?`G0+'DOT$N)*$]D'FBD`1J:)#(#
M-!MJ;XC28]65RGX\X,YKVU=]Y,LS_-H=_TV?,4Y#.L/PU09>,L_Q6TB_86/[
MT?3ZP<"W;*W&K:>L4*ID:;B1:?1.*UQ,1'DBLU9H:2P+-S(=AU2)/P(3O&]:
M<O-DROHX3#NA>#^8MBLRXHY\H2-PXW:(.KL:NK(*5_;GH9FMC!NS.Y7.8B<-
M<H[WJS$&==LS/XTN)O2%Z$K^7G27$E&>R#RZ2&,ANE*.![WC`8IDD\GD6FZP
M_>C%_%]G7T]%6_3'PVV'Q]20>:#A:[K*-.V^.,+[?]1@'P1'<-#AV6TS?2PZ
M.^P_'(K.TIPVB1F!KYE$8K4J`R8!NEIJ$C1^KTDL):(\D7F30!H+38+Z9A]=
MR-<7;-KAC]I.8M$H;*Z!0@+Z8=/IYIDTQ6Z/[;_!,XK!=N"%77D%VAG&KZ:?
M"\XGH15)O!1:T1^"S4.[F(CR1&:AM32602N4/\A@%]Y.:7^.XVY/X16R8]'X
M6U+H[!C)R]+@T4-I(39--^`[B>,<E]=PY#'U;$[CB$W.0AP%>R^.2XDH3V0>
M1Z2Q$$<A_'G<6!@F_<"YU&<\ND;OA!!L#]PV-M..9]G?+>#G&F*@0<_0-&(1
M6XQ8?U7D'8@M):(\D7G$D,9"Q*+Q<F1_?^Z3FPI](!U*E2>4LK6PUW7_"Y16
M'TF$L0MIQ##>Z>J/I,'Y_T$0Z!9&05B4^(`HHV0<]0-$;R;.DZ>STV%PAKFK
M83`9M3SI5#R62YV*Q^J=3K68B/)$9IW*TECF5#P9;RFHL36):1\(W>R`-/6S
M+NUXSXZ#7MP9>R#%%EJ5YP<;(NT0X76Q^MWD8.L=G%\M58#M@?5I;$%A2['E
M]+W8+B6B/)%Y;)'&0FS'J[>7=R/9X)GN!MS$K9*Q$KV8Z_9')."S57].\G9.
M]@Y^KR+*F6=X$E'*%A<ME+^W:%E,1'DBLXA:&LL0I=S?$>/\XOL!PQVQET4G
M?E5`-W8J5H%+XLDDWO^$/\M2;VI8"'WG0S\YN[C<V)C*G-T7(1IS+'5F\LG`
M/"?(U5.%./&23$*=+BYVTO?6.DM)J('$+,SIXD(G]0F5C]\0DE$Z7)C:XWVN
M#"^W];?9G`?G19OA\=`S,=MMW0#:I7'7Q[J:'/"B1E=7_>4*'\\G@9UA_:H+
MIY[W*X=%=C0QN6U@[@^E"P[0G4KZ;VEQ^7JF*H)SDU4:GMNL6!0>_*QX)(-3
MP!587'!VM1(I#<Z>5E*%1Y6K.&7A!8F*PCS8;PL&]:3B,),TPN\L!%?0E`8G
MB2L('$E8$/RNR`P5&85':;`BG<&4IK;%#IJ%9&&%,4K9]9&;6Y&JL$X9C\)C
MOQ4347A\NV(R"H^I5RQF*C@\7+&$STFK.)_A(^7A6P'@25S-^!J=F<FO.!,S
MA@Q\SO$A[$%9:(64+(P+U*]RADHBPR-I#!PS%L33F(=70/^=SJR@.&\+KF`X
M3@RN@(XD;,E"Q$E8IT+&,U$.MYCA(TEF+$@H)68XA4@7]@9H8=5U6X>L\^-O
M]W?W=_\#QV<[T@T*96YD<W1R96%M#65N9&]B:@TW,2`P(&]B:CP\+T-O;G1E
M;G1S(#<R(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O
M365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E
M<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2
M+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO
M4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE
M;F1O8FH--S(@,"!O8FH\/"],96YG=&@@,S<U,2]&:6QT97(O1FQA=&5$96-O
M9&4^/G-T<F5A;0T*>)R]7%MSVS86?O>,_P.?=KH[MI:XD>#VJ6G3V7W8Z>PF
M,^W#OD`D9+&A2(47.\JOWW,`$)1M"709J9-)[!%!')S;=VY0WOUV>_/Y]B9>
M)9F(8OQC?I,KP>T_^>[VAI@G)*))1!+S"8U8O,HR*B,9PY.8QU&K;V]^C6JS
M5\H%;B2DQ!]1^W![L[V]V?P-M\(_1Q_$*\X9$%AQ)AC\8!FESY]G7.#SC*7X
M7,J$G=Z01O<\DTD221)',HUA5SS3YFUK/H\/A7](R<34NX^W-W__6:US(X*/
M\((1EMET%`^/!8B"R>@C2.B[_U$>_S7Z^/OMS7MX]S\7HY#!JU<ED";BVPFP
M,P0(C5)N)92N4B"4.T+CWTL3!$L<"<:K6()%(LG[>$4$OO/T@CS^C7Z(*M4^
MZ&C?M'W9U%&SB9JAC?27O:X[W46JU7"(2O7EHZX.T:;\HHN[J*SS:BC*^F%:
MN&G::*/RLBK[4G=WD?X\E/N=KOM(U46TUVW7U+6N5M$/>=ZT^&YU@(TV4:<J
M>+W0>576.KJ&$L#RK4Q(!GZ',@'Q@"M:D<"YBR:JFSYZ:)NG2`'/=5_FY5[U
MNHB*04=]@VR6K1HEU.I.JS;?1GE3]ZW*^RZ"71Z:1]W6AF6_X*&%S3K#IZJ!
MWXTJJZ$U6S;K7I5U5.NGY]LT_5:W5Y$#X:,<4@`>E`-9@0<X.8#R^J:%LS[I
M:*<.1B)K':EU98X+2@.N]DUM50?4BR'7QE@:T"[(YL@:5M'/$Z,JWY;Z43\3
M:P4?5!W*TJH_;X8*[`I9UV!)^NX:`DBR='*.T3<80+<50%<^U.6FS.&<P-]6
MM;L7W`'_0]5;4U?17H''Y`.X#WA%EZL*C;QLBM7BHY]#*@;@,9[]NXOOCH))
MT^OA+#SP^U]<JTD<)4GLM$KCC(UJY2)S=OV3]6`P+0"YKBO7"%$'-+U-->3]
M8+RZ`T@SVF[!,.L!@0]0:S1GXQ-K71DS[K>JCSX/H'W=7IH=P;GG)Z,K'L<`
M75^!B?O+4Y)'DC-@B.&I;RY.2&1_%DN0+1T9`Z&C+0C\%4W!:0W09@?>6W:H
M=Q?P7GOY-0`(Q6P1.$E2;ZHT3>SY,-@B["J()4T!)ED`&AV'Y<W0(ZC"60&#
M=JK.]2KZY>3IP9R[9J='0^T\I.^T[HTSH''GO;-^!.*^R3_!LO:3QIBMJD-W
M)2E`;CTZ+)NDD,K42:%&UA]UA^%H%?VKMBZ7JP["`DK!GG3?EA!_GC!PP._-
M&@+584PC%F)P&CRWD)FU8LCF:"R-%6-RE9','OS7DX%S!U'>1'H\^@\[B!$0
M8:(/AH?W7_*MJB']JLK.J.\*^"@$'8V.L,2'O93;0Z/Y@#_LP,BL7+>0`:VU
MKLV9(%0WM3&7<R?O(!?4T;^!;YK>132.Q<HDEA\QE$=E!^*`G*H;6K16JTD`
MTZ>RJHZ%=`4S$TR,T3Z;HCT?@ST8?K<YA%B[])D@//E#\;$:H/3B9.#)Q#L1
ME'L7BZE3>F=2SA("7>%-K^O!\51;8+3;EI"[VB0??$Z!<3S8O!0>[LJZW`T[
M:RW;IBK@TXN;K:!_AJ@2>'4D<X7<1&3'1DB(F`(2_HZ*P"JIA[K`P>XUW(#X
MBC`6W@^H&+/>7.W+7E7E5Q,)[@!*+V[X!"KM\1C730$(NIAGF,3>])EPEM^K
M+VC8&!I=71IU6XR[M@XQ0<4"V+]LR'V&C246JA<OV_F?)1[.C\4#YN`MDC'F
M+-*A_J9M=B%P-"FQ#;X`XY"-Y/#2E8`\]O4[(1.2IS293OQ:52YL_?+QQ^C=
M4%4:,"YZUP"^88UM4B-;:'\>&IL$0694E,/N#C0,6;]I;C0V:"M7,F`P'[.G
M#I(G+!:!&W#A5F/9;]*H*PB`2U^X)WQ"<YJX"J??-IT^8J2#S$WO.FO&'W15
M&5Y>"L@K;P?U=E24FPU6LYBZY&J`_;J=`K&A@+!PQZ:.R1+163KW<E5^PJ80
M[+%NAH>M;?5T$!*N(H4D]6ECXO,8GB3)E#;VD&5T*K<Y;3XR6.A*'304YI"3
M`&.NT>&>VX09\^6J>0)V#0+8\L]TQL!8`!)585)JU/RZ+,Q3U7T:%V-#P`FF
M>88:UQ"#&"L<PM/)?[/4^:]1[@K1J]\"7&W5'FO8.Y]T;174L`_`$19"7NN'
M2.7`28>6@DRZJ.#B4H>FWZJR0]"$I451HHCA>:WQ+=4>QC=6EVX?H'Y'GA?&
MZ'!:SXDMRC*Q(I0QG];')/5IO6L0VI()A;&'?+<H'\L"D,);AJW.EO=_`DD\
M2WW-E%*/@8*QZ8Q&L;5^1!M68*-0+VV/SNBPS/H^VJ_C:>K*(5.H_]"+(Z<-
M=CBUR=Y'KL&YKF'O3&0ON[>FO9,XSN'0IN4*CO?ZS,8G3?<5Y7)G/<#B^[A&
MJ[8&KF'5IJRA1BG!JG/L<AHH14'9.+$>P#G`UFUC"%8T.T#_$4O49@.6@=(;
MKE(S,TY]7^-("BEWI2=45=T`.7M?8F+36:"RT0[ETFI[3"Q/X>@=B`E;795^
M!/4;L'CR1O[,M(\+;GP9T+1"(3RJ:C#:'Z.%@NW`#NKH.JC'J"]HDI2]#H&V
M7V`,P>BXJ2$N-7D.AS>M]V)L`>HO/2XR=>C+7@)`)0BJ!%<`ODT78F/;AN:I
M0W;[0M'HSKJ/?\=TKVO;PO;U;7V5C(C%/L7-X/41#9*46&E,JICD<I66"$UM
M:H9X2::3$)9F4W<!$>;2M`$41MH72)D#A,#`GC&99!.3C(PUQ2>-LQ]`E@WV
MB[$=]5AV)@E!IRDTQMI]@Y:'\*)RDS*V%DL`CEITJ1?6>/%`*N"X(RM7:<13
MYM/4.$ZG^0ISW=<?=6OZ8$?2&;,E>&(F+[UQ,ZS/VGW3NHIT?:C4DY753Y#)
M/6&U!C_N$.>>(+O%G[G;6T%FXW+Q)Q<2G\I^ZV::.A]PCME=9;I$2>HA:G(%
M3JES!9^.`ES"SX,Y$[`Z[-:(2#M5JP=S=-LT_*2C$D%]C7T9-!L`M!>9NIU#
M09H',(_3J(.=MAGCLC/%ID)Y#MV8^AZ)_AH2B,?4-&93IY%*EHP@;1I*+H.H
M(-^&@/F/9P=!<$L12=(,DAYS@HF4N0.!&4$*I\`%],P"*`I$<`%+:'@'*E(:
M7$`$0%QH09R`/006T$RDX0529,$ST%2`ND(+DCD20H3E0#E67:$%(.N@J"EL
M(8,+"!<\N"">64`R[&N$%DA.PPM2E@4E21(PNN`"P>+P(<V4)[2`41E4-P%1
MAKD@5(1W`*<.ZB(#$J'GDJ0D]!P\-\AC`DR&G@L:!_?G)`F>'[PR[#$$L"TH
MH/3\_I_=$DB_4S29$_`(NY_%Q]2\:ZLXNF(R&=O:2?H2BK^)C)S(W),5I:[-
M&[T"?,D=%;")DV0"8&_?E=-\96JT)@D=NU(:RQ&LB3!T8T8,OYL2"F)2#OBO
MUACCL2XQ]TMV.]UB^55^M==*(%@5`UZ*L>.(IQ?MFK8YJ`K;4M\O8NULOX&+
MB;?7>9+1#;R\V`1(]F836$I&3F3>8`)(9:D)4-^9Y<G4F<T21_%!U[K%A-=,
M=(NAZ]O#U#GU1;0OM_WH";-F6U*[;MJ1L5R2"<'IQ$5@T/1M-)*)QFN#^K:M
MLV,EQ#SS>2?-,E>=_/<O/]F++"#C`=SG^R4G..LM@H28PYB">=(R9\DD?:.O
M+"8B/9%93S$TECE*YAOXE)&I-)"$3%"IBF;O6T[8C-WW9F+N2B3G/E@^ZOKK
M8>=:U+8WY9$2JHH<EC4[+"[=F^_-\NB=ZU^=4O\<:V>U#Z%RY.VT\JE`O4!A
M^,>5S\5;E;^4B/1$YI6/-$!")XG,*)_[NE`FQ%V[9)*Q-^O^1Q+]L^GZZ*/.
MMW53-0^'._SL_1?3.,#W/IB)CWD='GS(H0C&IN;X.9C%NFQZ_[I9>&$NV326
M$$=C">'&$GN\3ZER#05X;CJLN[VJ<::TUGA0.V>P(T17&K\KFP]YJ6L<L`2-
M=^;09^]_'YWZI/'*E"PU7IF1-QKO8B+2$YDU7D-CF5IEYF^LB6R\.TW,9=31
M>$OL,R#\H"$ZW:%Z=5^:W`Z,&.\XOP*P";6:]OGL#=[07]RM%+\(;TR_1K,+
M<IMFU+,;3@664TB.!)J-=RY?]V*^46?3K,ATA)&&CPJG/&B.UMF;O<#!2.RT
M!\&."V._9.E;/6@I$>F)S'L0TE@6^R7S\RLNLPD89?:'74A/@.^QO#27Y^W2
M\KC;>2I`?(_`OX"]<P:0QA-_)PT@E?%B"'7-Q'D#6$Q$>B*S!F!H+'3'V-^_
M9"[^QZLT&>>71=FU@XW^[H[H3M4#SA6'UDYC]RHW%]9;>P5X^F+%NG675(X&
M\F=>=K=4"G^'Q178OT.)I4_F`M_`<2K]L(X1ISO\;DV_?374>`.A\]];$)[2
MZ3H=BOBE97KRUOB]F(CT1.9K=*2QL$1/?/R69+HZQ(B[#N>^ZU-VW8`!66]T
MBU;B;@@AEK3EPQ;";P<))5B@F:+B;:/F]>VXDX7ES-'/#JOPJY;N[*>52\EB
MY5+^5N4N)2(]D7GE4K)8N?XB/2%T"BW).'$:)V`JRBL%<6!3@FK?C;<"?AIO
M!9S4V\RISNF-9L(?ZW1*L#PC>'-"L#P?>&LZL#P;&).!HUO9XQ4.'_Z?VK+O
M=6UN:N`\$#XZOFQM+]7W>'=UAPN+DSG=LHC.LFP\XTGU<3L%.;EM8(K.P9W%
MB$3NF[`L>37Y"S;W[\U4.;2`QC0X/KBGD@6'5?=,RN"`X)Y+$9S!W`LIPPN2
M-`V?(94LS(64+'S(3";!,0Y($O8(KR`9"_,!B"-GJ'#\>D]X13:C4B(YGZ&2
M8=<S;!9Q>+H'*S(1%BF%3<+GH"P.#[?NJ;FF$EPA:'A8>D\!W&?V2%D\<PZ)
M__U`<$4V,^Z\9S$H-[R"\!D[9I3/G(,Q+F?VX#P+ZX7-S;CO62+"`^9[EHH9
M"X*8%,^LR$027L%CD86A@4-*%#XII\F,)7.6\+!,.4]F0(Z+=,8;>)+.6!!/
M97@8"U@K:=@;>)8&!KX05-[_=GMS>_-_S,#$``T*96YD<W1R96%M#65N9&]B
M:@TW,R`P(&]B:CP\+T-O;G1E;G1S(#<T(#`@4B]4>7!E+U!A9V4O4&%R96YT
M(#$W-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!"
M;WA;,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS
M(#`@4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@
M4B]&86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM
M86=E0R]);6%G94E=/CX^/@UE;F1O8FH--S0@,"!O8FH\/"],96YG=&@@,SDP
M-R]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]6TMOX\@1OAOP?^!A
M#Y-`5L@FFP_L:1;9!7((%L%.L#GD0E$MB[L4J>7#'N?7YZOJ;I*2I9;CF(/!
M>&RSQ>[ZZO555<\/_[J_^^/^SE_'F?1\^L/?I6L9Z2_%X?XNX">!)V(OB/DW
MPA-RG64B]5(?3_Q(>JVZO_O5J_E="7[&/S)-Z1^O?;R_V]_?[?Y,KZ(_LU_X
MZR@*L<$Z"F6(?\),B-/G623I>18F]#Q-X_#R"X7W$*4ISI@&OI<F/MY*9]J]
M;<T?]F$P/A3!)-0/7^[O_O)3OBD8@B_X`(/%+[7P1+X$%$'J?0%"G_XM(O]/
MWI??[N]^Q&?_\6$[9&FPW`:!\++H`]X?.M[O1_Q^?RU\_/BEN+][@/;C,/&^
M/)MMK_WUONQ5I[QCVSR57=G4G7?(7[QMV17-T.:/RBM4V^=E[?4O1]5YS<[K
MV[SN\J+GQ67]U%1/9?WHY;6'7PYYY36M=VQZ5?<E?BCV>8VWX`5%4_=M4ZTO
M[YA77>,M@$V:)@8;/\Y"BTT8T/>$354>RMZ#K%[7-\7O^Z;:JK;[^(,DXTDB
M/@24(L2';P/GL]M\^G@TPV@&IPB3Q,(I?3_3<.:;LBK[%Z]OO/Q(*E:G]M+O
M\QY?U(LV,Z4.M'3#!H)?ERV^[WK\U*L6WW0PJ^W<&L^,SWO>E\6>U;>$[22^
M$3;P)V%#F1B_FEN,=R@?]S`D"-$^E[#O5A6JA/@Y+%T=RN'@[>`86L9NG[?D
M3$^*?T-_X1]#V\)I`$S[N^KQJ;)0ZW=)E;BE"D.6"J+X0HY2^:GQB%^5M\]Q
M<..O%3GW7-+U$E`G6<R'2M:)M/XQ!:F/WA"YU&X(W091/**0I/)RS/1^AHTU
MNQV4TG8KF"3TVS>M-E#HJB[*(\+=B4GTS:,B>[!0:I?X6A[R7E4OGD2^_S?E
M>015LN!FZ+L>KR/`B^9P:&K]NC7OO6N&&F_E_9900)*-<3*:K$+$D<:CV)=J
MYZFOJAAZ,FL#Q<K[.\S5^_&05[N\W:Q@RFTS/.YA]GT[P),AF_91F'G9:6NG
M!TJQ)!M5*[RHS-N7%3^DUQ'>G]?C2[TO](&5USS#YT\A7`*(6%C#2"EOFV0:
MQ;$&0LBWZ>RGH27=:ZE^0M@J*(I969[W#6+$)'V)<("8P(N[8S-T&IZMZ@I5
M;_.ZY]1[AC4#L@0$9`#:%F0ZY4SAIR;(G^A`^&\!A$0N*^7M(&J]U6[3JBHG
M8]*RM>N9:,"'\:B;_I+7K9ADC%ZW!`8BM680AY,9"/DZ]+,BS@R3V-!V6U*>
MPOG>:#*?`0L.V@U5SV8#(SC=I]SIW(D$.`878%56%:70)5`(`HN"2*<,F!'+
MU.D>*D4"1UQH>QR^*Q_K$MJ"P<)V'UM%@0)Y>E<-JBZ4SG@$PB&OD<X/E._(
M$O+=+B]-,.4U@+&G$-JJ/X:R/4M!AEKD%1"IBVI@*,ES%D`@SBRW#K(H&^U`
M)B8NJDHQ&R$Y3Y."/20]F>-2-.VQ:6$F)V1F[?UM,AG2/H(ET@:\'ZOL!K`S
M@+(OCX8]5?C*CJ">&$G+MI?`(4G&L)C(65@T,6$B^'3004.@.1&4JPIF?2?<
MQOJ#)D,KCV2`W^/+*`=).7+#<V:(C^=5=49-_MZTB@QHM9@]Q)83BD".O"%*
M$FEQF)WO+5JD")=7S_D+K:2`ME7PZ%Z3VMG;-%,\>3V3S;,0`=CQI8"1D5=4
M.JLNDBCC*+1(B*FRBA);68&R5UNOR"F7#1U'"3H\B="<\GC(EE.LH'#0&;KP
M#!3X!9P!1E8-,#L@U"Y!C&,_'HEQ/`H4I,G(BRDCE6!AFUYM22!2496WCV28
M)W:X`-PRSKXM0[8;`HTDG!AR**\QY,]LE']%W7/80,]AL`(W\.6*=-D\$V(N
M?L<!XP)7XE3Z"/-XI)!IT:]5IR/`2=;]+ES'2YBZE",G!"D<H4@#`\4!&9B<
MF\-^4;0#A+6>>N&42;CR?7_E:4(/QHPTV:ECSDD!*P]EUS4MAP:E$P/,OC9Y
MAF.#IM$S%P*1.%:JYWUADOTBL4^&<H2!>G*V9K)]II^1_$CST'IT@\TC+B`J
M5A4._%VP$D(2(CIDGBFY54AO'84.5`LO7$Z?`$0"JZ\F8>QLF.RZ(:]UCED"
MB&`DAXD_`A&%@6T,F/I^=T+PV#R>\[8E.K_2/RF<O0<A-MX!"QE:ZI]L284&
MCE8=\K(FCG,"#$51`[%WW9N6D-X?2:&<XF04Q";PGSDP>&U5V62?=YWJ=:ES
M:-K^$21PRQ0&EO"H@VJ'$M-40INVQ&^]JD$,T!&D<9L5G&7'J0.N!_>R]'0!
M$*)T[+F&4TB(,IO]'E':L3]W`Y4O)?&S(N_VWJYJGDGB*:<U&VZP[@:JB^#F
M4"[*83KW$?R`.<2)XIDC;0>UFI*D)DE;M<NY=M#*Q^?H4YXAS4N`$(_=0"E'
M/Y!!;/Q`'XZ[26S(3`<A%]Q4%155P/"-$O90`1]-&5G[Y`$3T^&>X<PJC)AJ
MR^+-*FVF"C4B+#<:SF%33R`.B`F+M$\BZ4]EPD2/&15"XF+D8L'HK!3)=S`7
M,E>L)$2TTE;>9NA)S9I,;1730R#8JEU9<X1[+:AMP70E\E+>&NA@)$W;-L^(
M(QVJ\.:P"`RAY81!%$]5LVT<;/+Z]VXT?@Z.JBUH3%!1#"0"_[E^&?&@ZK&%
M1SR;QZ1A!`,$>FZI=5A7UCHM<-]D5B&>T7!G7VD)'(*QNRC]R1Q\WQ(&0_Q'
MU^CR`^AEWY?]``7GFV:@$/[BH2RNR.ZI<D#X!$=@!SHHI8<6FU(W$I`E\Q<N
MIYM-53[FFA7DW8TLS`7:N]GJM9%7`M5;!-XYAG`S]=`T*XFI)_'$U&-Y0M75
MUR-B#&>-:2#5EMWOG>FR$'+L"F1CNM5@BA!V3<K.*.`'"N/:W?@%"N5[K[LW
M7/!VALC]8AA:Y$?6ZI:0W?0G2?;05*"??H%*<SC_1^^'E&[WRP39+WSZ/]CO
MX<,W2DX$\Z.)98O4S)9^_EJADOU<,*4&QQ3OGT1<'=8FP7B.]P_0'*/@,!*+
MCH)#(;]ME6@WI(@?3538C\65*M'ZIG8L<J.QT4&MTM&GP&>:ENNCAOH\($VS
MGB%G0')#CYIEW#7DEVS5D3(%5J!>+#O*`5OO."`D%MP4&6KM\V5[6(@7AGXZ
MD>-DAH>A1-37[$B`U16YN?UY(=JL*)J;&,4I[T*X^;_"@$,N*;)1L`^(`ZZ=
M0"`F"'V^PF#B0)3)JW'@5]TK!+TC%0/`H4;P!T#+L#V1C150$$TG3!)C]-R9
M91,NJ2PGD[4MZI,LHP<@]*3YGRR!V),B$LTE`$IIXA*;Z:Z&Y@_<)``')!=;
MI`P6R=@;3[+9J,RR'-.4L&U/F+OU>FYQPP_TQ1&:!!W4MM0=TEE7D$OYPY''
M'>;B``W&L."I[&EDQJ,/)E&&(#5'U1KRTY6:'E,I"(I<+^+N0HYM\41,XX%0
MFO'`D:X!<$#*GT#E+,/7/4XF<GEGZYI\"]O(BQ<+%L-7$LEG`^<;,MJJM;T4
M5$]/0R9Z5'?*7IF`\70&^27DCFR]XTOM`)^F\/S1^X'MV?T6O#R3AC.I@EC,
MAGY&F1VYDZ(X;,=TA"XL#JYXL`[>O2#M',RU@*;0E>=MJQ\C^SSOL06\3"V_
M)10IPBF4!;-0%MI*94RZ%%UXB-7;7N?_EG!UZCL1E\.@;=K8>:_MVA#8D/Y;
M@."/Y5J635X<!Z9N/0G:'4HO*!RG@:IF29ACL9YX;:CML_G->&H'%QY#6ED_
MD07H"HU"`7`;D`6H*9`/_;YI.;+I0K@;$"5T/#0=@'Q+?KW0U8<@S48N%\C9
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MZ%`A&"<K(I!3\6COFVYQ,"(:FB[RX*B_+'K3J9G&9JLI7-<T9!JG2Y:0\(^G
MG[O&S*<9Q1*7;L>Y2C3Q$2DLH7YF/L_5P"CR5`!I"LU35MNYV^II"*14V[,@
M1>4Z#DL$T_="/NET)/Z?$-1N2Q#6:8&XLD`FOG0NB.+8_88PYANPUQ>(.,B<
M"X(8YN):X,>!<X'(XM!Y!I'*+'8N2&YM$4LW#D)*W_V&2+JA%B&LS[E`1%GD
M7!#<6N!'J5,701;%[@5I%#J1#)(P<^(0Q&'D/&0@81'.!5$HG.H.N.WJ6B!$
MYGY#(*13%X%/EXL="S(1!*[G<%VGD`FQ'<?S6$3.]TNZ\.IX'@5N!,)`^FY;
M"VX`E%Q__H=9$L*ER&0NQ%F$X.LE-7]65SUB'1HJ"/X1)^<Q_?_:)IVV>0C6
M0IB"RGN5.1#V]2[`Y.(VKLJ=/SOU78-I'N\')F]0CORAR9'YZ8[2>%%S;T9D
MZFM1H:1YF@^IB7$\Y711I51V.*V[:O7`W'=^Y?/[]PATC?K*N42OYQ#D&Q2,
MWZ=WKG#?I/9W;Y*.F]Q4.N_Q7IU/=,F?]=JE[;47PV'0-\R]IX9)#NKM\__J
MI7N#O9XQJ.WWI.AWG/.:*L-L=M#+JI2,LO#?H4HSJGJ#*M^[23IN<EN54D-T
M<1.W*K-X;*AG,TU&XT62L9M`'1`F?=`972*F&K5N0(KSU[>P+VF;^Q7-R2^I
M3W=LNKQZU7MX@U#7]!XCMUBI/KV:L%/VT+GCHCTY!J61[WN1[3F;HC5,7M%:
M)]%ZH/_PZGH>))F39SV(-'*FM@?P:B=]0)D0N1?()'2?(::9@VM!0@]="])4
M.`D(<(K<0`9^FKG%",`'W9L$(G/3O8<`WGUC14*=-.>*E/[/MW-%YDLGG\**
M+'`C*OS,S>D>!%[B9$T/():Q^Z0BNL','@0*QAOOB/''O2()`[?V11JZ2YX'
MD87NFN<A],,;9AP&T8USA%PJ.U>$D73K!15%>F,72<3*N2*6-RPH3*2;LR-P
M2'%C12:E.S)$OG07<0\1JGZW)4<B]MV8HHJ[%>-0^=\XATQN6!!28'+CI$GB
M+GH1:Q-'@P$9X\=_W=_=W_T7I0^0E`T*96YD<W1R96%M#65N9&]B:@TW-2`P
M(&]B:CP\+T-O;G1E;G1S(#<V(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P
M(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P
M(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&
M86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C
M.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R])
M;6%G94E=/CX^/@UE;F1O8FH--S8@,"!O8FH\/"],96YG=&@@-#$X-"]&:6QT
M97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]/&MSV[BUWSWC_X#9Z;2Y=V05
M`/$@^\V.E:VW<9S:VCYF^H62((N[%*F05+R^O_Z>`Q(DY0?D9LE,)K8H@L!Y
MO^F+?YV>?#D]H5,524+QG_T43J6H?RRWIR?,WF&$*\*4_883J:91Q$,24KA#
MF2"%.3WY)\GL7EI(W$B&(?XBQ?WIR>;T9/V_N!7^ZWU!IT($<,!4!#*`7T'$
M^>']2$B\'P4:[X>A"E[>D),SH77(2,@H"36%71&F]=O6?'$W=7N3LPZIB_GI
MR9\_Q(ME2%A`YO"`)9;=U)&'<:!$$)+Y%L%F$:Q;GIZ\NYK/KO^'S'\Y/9G!
M)G]W3][^B$\^X+$_P2<^E?BT@%_PN)#=97IZ<C<(?$+UX9,6NC,ZU?`)P'A'
M^%$HA3J`4HX!I>Q!"=!1$3E`>2B"&M0IN9S=O;^]^CR_NOE$;CZ0S[<WGV>W
M\W]/R5$<Y"$.7/!O1<)JP\M(\#ZMWQT"-<#V5M+8[]W]-0XHU&C*G!QST/*&
M`X'&S\B!^<:0]_EV%V>/0Q_/`MF=+VH=^@_G?/ASHCZ>EEL-FC10-9HE6>;%
M+B_BRI"-B5=?]G%1F:(D<6%(FB_A^Q6)*\($)5=95<3+/"ZK."6?\R2#9RZ+
MY*N9D+M]`A>"B@GY:;^#S\6$?$CS(EG%$Y)D)-[MBORW9`O;I8]$3C08U<'1
MY20*A4,VTJ+%5L*F-;:(GB%K8RJ2KTFYBY>&Y,LE@`QH[K.5*4A,4A.7ACPD
MU08NMGE6;0#FPF2(MB44//J'T.)0;8`VYK==4IB2Y!FY-$NS7<`N`9L03JF>
M$A2D>L<D6Z;[%2RLX*MF/]AJ##HHW3*=]<P+?D8ZQ*M54B5Y!@#4-%B8^R3+
MDNP>F76^*Y(4H5=DG2-!JKP!-9Q(0+I/14"_1R-''"8G\/AT!*L0B1HS4!A!
MQZ!<0.W^$0<ET7#6_S5GN?]#GPGKW9G`+16V7BL(\/B')\>_]?]51J[C1V2B
MG%AY:VP9V>V+Y0:D$;0ZLQ+_U:3Y#B[9%&",E\#875PLC>5W&F<K\A\J*>XP
M-.:2=N16K14,AC\F;(]!=RMU?=8=6*G!S^+A"RB)P8\)1%]0A;7Q5E`I1)*#
MGR;Z(LI5U!H4*67C1D"JRGV<56`JP!X4!LR%`3<!YL#)&_@9ZSZJVK".H;IX
M$RFB07=D31$`DBF@E@7RPQ_?D[_FZ0K,7#DA'S^^MZ(]/"2B!65$L6;`$7<,
M(JE8?99#</#S=/0"6H.+-@,#V#)R=-%F42<V:!N8T*VSC'03":YL#/33'AQ<
MX]7%:#81O?5W$)Z`RY[P4$'##FW:H`T.8VN*90*J_!'=P&>GR.=P<1>G\.&^
M,&8+<<S@%B?DWT/6,'M_2=90$FB3B%FQ&\-,R"CJL8!SD$1G53EMPK32&/(I
MKR!BC`BR`(P<V-=\7XQA/L-(.6/2!<XU'&"ZRSQ-:D58)UF<6;&P!A[Y7R*5
MZDC7A1D0.&YA\>5CO$J6Y!8=PJQV")T%OLJ6TPFXBR91:#,1"$PMN@^;/$T'
MS[Z4EBVN!Q;F;/B3HAY5(<%3+8LCW3C._"$#,I7[19FLDKAXQ/A[#.8"*`US
MT7PY_BJG[+U8,0>Z)\L-22H"ZD[BLDSN$<8FB'S9)L3/;(+]"I_!.*N6#?PT
M<;N7-BTD.P@Q<?<E[+S/DNIQ%.P5=]CKJ`VPA>2\QO[7#-@`F)(?SA>8X/Z`
MX+GD%\!$-.:X!$+BI^GM>*Y`B1;P,5V!IGWZ*%V[@G>([]!G"5"UYR@-;M<%
MU>TQF,<I*KL88CHXHP33?0J*KIHDF)3/JDE6J_)%%2=98TW3NCSR%3ZLBWS[
MDKBA6HZA&$*Z&"#LF86`BL[P5\5^B=K\I(8CZ(3V:@%Y7ED=;JQ#OEXG6%9(
MP'N!MA>F-)!4;JQ1:%).:R06^\1Z@\%+!0J>XG*\4@'N3UVEF6K>T4ZR`Y:_
MV5[FBS2YC]'9-TX36&XIF@$A^S0#J7!VU>92:*`><FN'N`U7'H'6);`D3?,'
M+.F,(#@Z:JNGD6YC9B%<R0(!7*9YB<=CV#`EE_L"+P#<$L$=/F]0+5#C>G46
MT1[Z5-$V'0Z8"]R0`V1GBB1?31P[`6_0GTVR2&P4A8I>#%Z`$*"YWX<,F#/T
MI4!V5D\I)P5%G)5K4S2<;V062P1@!G/XPA*IA'"OOJ@V8&90CA,KQR#88(`R
ML[01X5AE`ZW;FK$6JM-CT00',2E144'K:D9.:@AK$"TN)`9KER:V^%DT=^O;
M%F9$O#7P[39_*LE%'A<K^TU2`)(Y*"T^')-M_`O$%A`+P;VDPDAI978&?H#V
MK]Q:/,"&:[C_AP)C\G(YBI?0LJTF:QWTZI--CC0O]F555QFOX^)7<CXELVV<
MKN-B0>P]-'=_QDHRL!UP0,QLX3PIZZH06"H#BE*C!KX%E@+*S=6$+!Z?[]OL
MB-9D'6\3>&AK"^_EE%S9C3-P2&/00KA"&/CVSO#9JJ(S?".UC<*@/7W$IE&H
M>SARQ5F7EKHZ&@IDA7P$K03YVV-K`Z04(Y;U/EN5^&7CL&I[#[(/>EX]6ADI
M#.2&YJ`F7<L!9$#&6HIR#Y%"OL/],?^`+.$7;#:1KW#FOK!*-@9G>5M,T[SC
M;"`:?UZ;J+@`3;NO/38J_Q)<]"Y-REK-7W'3-OT!P)=@*Q8&1!.SJCVJ+.1#
MF_P!GBHFM4H@.9YA^^SH$BQ+FHY"!>KR51ITC>E`Z(;WV"PKVK`#\-M!;+<L
MD@5FB,G6K(MX:[X]QO:$<RI4HX9S2KD4F4:ZZY3*L-'LJS78>1N*0[#5A%@N
M6G>ACK7];>=%UR:Z\?\8]F<N2@;.KUZ3%JLE65LG(>4F3E/;136_0?0((F#;
M<B,P7TG>D2#JD2!PKA!,<IY]-8\HNN32H-7>Q8\6]!]N^_?:2/=S`8G`#\1`
MGI`Z;P4Q;XR4;)!N(]6_])S_']B4$C#L*5J9UJW63A=/0X]@*O*/.-W#]LU.
M8]`DD&V,0SNS((,F/`#NV-[ONF_1_E1:-@/D994O?YV@%5N9-69\X.8,X+ZU
MV5_</KAJ6J=U:[A'2!`9S*2LJ#F1J,LI!_0>`W/63OJHH$UP!&=-S>B0Q<ZX
M[>+$UDQ`9N&K<C-!YA4&3)G-9_%KQ/$M9'/BXMQ$F9,T!RV+RS;6<!(PI@!T
M@R+6%S1*$0GY=@%`#^>$W@:Y0)-6(_J2;JD%\0X\O$BRNA2*@PIO.0-SRA'P
ME^U,!03YK%,`Y8K#ELE6P%NY;GQ#F:=UJALOX.,>)'P%,2H(0X/6H3SWHX%]
M@?,1$-6!HS2EM:T88L0I'(%D^6I*:P1?-:%C$*(;J@AY+^%W541$%,/9)-L;
M&P.9WW80P;Z:QP.;GXZ+J#'J(/)WCTSX1P)EUQN6HBTB22J:D`''`\EAW;+>
MYX4!0<E5;_*NOAIR\$Z^--[QUIFZ%CC%A@=.=82TG<BP:\D%K)&PC[,?SS_B
M*.#[V>SRZM./=].C@*L#JG+*OQ%R_U2.9'2D43W87$1M8"ZB+D&/(O6\MMHD
M?C'.L&"669<:L&198!$N-??P$]*1)80NUO*,H`]"MHVT_WY"5DC>&Y"MKX:<
MC^T!Q]M.B.)N0E:\01?LC&P+I]6%@>%4'1&M+D0]7:"-+MS]?'%]=7?7C,=>
MG\_GL]L[,K\AY^0?-_,9?GDW>__S[=7\W^2O-Q\OX>X;M:7'`OJ-N/FU101J
M1&UA;1HCPTY;:-AHRR=4CQVDK,MXD9K!_4W403#\5+"@D@11]#N]F?8TPR#6
M"<*F<Q1,(QF)=B)`!DTB^/G\=DZNACY:@`ZZHW4$"1@F7>B=ONTDOXD*VKX/
MT[2MZ"GMIAZLRY9OL`769D%8W+,%]=60MJ"#E@K=1J`\<E.]U^>W?YO-R8>;
M6_+^YOH:+,+L[S^CWI]_NB2WLX_G\]DEN9O?O/];;0B<M7BC/6C1D_Q;\?..
M#'8(/ALZ/1Z7\"<0BN$AA!`RZ%I=(JCE!5^C<27R<YN:7-L.'Q=U)-O4^L@#
M_N!\HAF?1)`S=*E,4Q<YR&'R?556$$AWQ10<F<8KKL5$@\MOGM^8U*896'S*
M'^I"RU@=`MYU>X)^6<1U20\;HTRK&ID-9#<X20^H8D9?K(8OBW'P)`ZZ45Z3
M@(B^37X[9]+Y$K*`;!\K^R7DN!D._30Y:T%V^T6*7<PBQI%W*P:%V>4%=K\L
MIX"-+C\:L6HNX8[#8L2RN62Z3RRMHBY3#EVIZ%#6=T62%P[[:U/<0QZ(9?#]
M=FL'3_)1)H%XX+)81D6OS"F:JL[-LLHQ(^51/>HX)>>E'>DM]VG3Y+%E:!3K
M37)?M_33_,%*0E\$,#U_L6XQQC2TPVI,#@=ACW@TC+IY"4WUBQQ&$I@8C.)Z
MGZ:D>;4&3$3=&1ZKBLMY^SH!5ZUSYUHUSMT.L+I$Z6N<I#80[)=@!G_'@=(6
MJA$YQ`&O'O*RF[<+F*M6/>'0`]82T4)9=4,AO9F_)Q?`+E.!=ZD[M'>/966V
MUA_!W8L+6X1&YMG^1\W+IVH#]XI\?S^./Z+=Q'+8U:29BH+>-)^R@$`0=Y=@
MY<E^IR?/WP@9G`M*MQ".R6S-VF.P&=N59@5_11VQ`[,P)K,<QYBB8?GY%GB(
MY>L[NVSFNBSU^V"VD/FX7>0IN;SZ:/6D'*70S,(V-=>=Z`H[-HK8?-GG55PW
M10NS3M%U8A^V&/[-@J"%9>11&C"G[B0[=-U-W[L785<F3G%,!%L,91WB08R(
M#04P7&0;%[\./A`)L>[W03_H,3W24RW;9).Y.:K];C(.DE)_+R05ZTDVI[(+
MC$*7P*WLL&-AM34I2Q3QB8TKMF"TT$U!X(@CA#A5O*QLVP0GBV([&%0.'U;K
M'F/&>?M8M./80K0N6E#)NY)F-[]7H8,FI:ELSZ.9*'H:>]7]D)=R*N>IGL8?
M97NG[F;C@-'JL"4QAI4+VAZS[+J*`7/]5/1/%B_K1>.R2QH6C\Y!7UR\V?WV
M76'=BGJ^XVOV?PSL69/IRVG(,>1N]!T2]QI]V^?M^^J_'(*!Q9N(4QQVA+3<
MGM\=9/]<!"S0.@KM`O[*`J4E]2Z0FOIW$`HLB&]!H)3P+N!`0.\"II1_`57:
M"P./%$0%O@7AD2,@:/;3@2LI_3M(Z2<U%Q+\K6]!((/(NX`?6\`P1?(M@(#6
MNX!%(O12DH5">.G`=!!Z@60*/85O@02Q]2X0@1]-"&P"_PX\H%Y>,!90/Q:4
M2^5;$''FQ3+DS`NBYJ%W?P7"X+LON9\$@D7RB%;ZI15HZ">0?EVAOM0HUAL`
M'?Z[`CHDF?KP;[^\"\*GQM-OE,Z.V,4S^_Z0;P''<6+?@B"D_@5"17X8)(XI
M^Q;8OT[DQ1(<A'=!>,2!G$6A]&/!:!CYSV`@:5Z3<<8XSEEX5ZA`'CE%"^JG
M%@NI7R5A1:C\!&51Q/QP<(I_N<*[@D7,#RD_IGQG7/`CV')YQ,"<<<65G_E<
MPS__BC!@1_:(@B-2C'^CQK\'!(W1D3VX\-OK,W`9P9%3!&BD?X641R0H4$!V
M_PI]Q,."X<`I"^^*2`H_I)!A')%D?&7-3U/!Y1$3)\"3'X%#J",2)*3F1R`%
M,^?7!J&5)V(`?S#[U^G)Z<G_`]T1F6<-"F5N9'-T<F5A;0UE;F1O8FH--S<@
M,"!O8FH\/"]#;VYT96YT<R`W."`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@
M,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@
M,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O
M1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B
M8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O
M26UA9V5)73X^/CX-96YD;V)J#3<X(#`@;V)J/#PO3&5N9W1H(#0P-C8O1FEL
M=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<M5Q=;^2XE7TWX/^@AP#9#5P5
M?DM\G9D.-HO-9@;3P.0A+^HJV5:V7/*HY/$XOW[OI4A]4BQ1MC'H:?4511Z>
M>WD/J1+YW3]N;WZ]O2%[I65"\#]SE>VE:/]W>+J]H>8.39A*J#(6EC"I]EJS
M+,D(23(JDKJXO?DE.9NZ4B&Q(IEE^%=2/]S>/-[>W/\)J\+_!@:R%X)#`WO!
M)8>_N&9L?%\+B?<U3_%^EBGNKY`E.Z%2E0(:0)02J!4QW:\K\ZN[*;N;C/:=
M^N[K[<V?_Y)_.Q@*OL(#ABQ3J:.',G@J2[X"/__Q3R;(?R9?_W5[\P6>_&E]
M_3JA/%"_HJ9^LF=:0%.'VYL=V:?F^A6:_:'\K3P6YV/R8W4J#V_))@A7NBCH
M.[NHPEUDPM2?[E-I.F@:<G\^ND$(5-<@<$J%=IP*K-1P.FP>_R2_/):G(FD>
MB[I(<OASKJ#-2U.7AZ:LSI>D.N/-Y#E_>RK.35+=)T?KELM=\L-;?BP/R6-^
M@>>:Y%@<3E#',:EJ>*`\)OGY+3GDE\?^&:SO\@B%+EB5??XSB">IY8%J*3L>
M!%XC#X?JZ0FA--7A_Y*R[>,IOS1)\UHE]^7ED)^2MR*OH9,Y1.`K,`"8@8'3
M&W3W-\-3>6[``"QA5X"@\OPP[[&K_+["YXO\&[!]_]*\U,4^^0KV[ZNG9WCH
MHRE(=<^!<)''V,<WHP94:\';IBZ?X=)4$^?23&8#E]IT<7BI:PS1YS9;E)>D
MP5AN<O``>/(,[@%OEO?HHSN\=U^>\_/!!']2_`Y>N%A?EDWR[>52GHO+I752
MZS#O($A>R],)(O\9?6T'"WCZY=28"/\,'D`Z+`]]UA0DLS14ST6=F[%[9WM8
M0BP?JO.Q1.L=A.=SV8`)NER@T?3L!+TWD5YA*DCN\T-3U<#@8]Y@\!^+X@F`
MGHK?<NB_&1'8[6^0,QK3Y4L%<7V$<0.$6Q;1_%V5U\?/XD$JRP/A:=H&W@]E
M71CD^\]0BY2K]ZO%8OVJKW\;^+#:IE0[9<BH"QM%<<ABV'SY]:5LWDPZ*LX7
M$T#)CQ`5R5_/D+J>6L,G<*JT_E0%5FE;OV9[3C!,_OU9_I-=6Y_3%]W5#R-?
MBK0?^L**NTE5U>E4O:(4-49KGNL*,]4%=*CW8UT\P+@TA7#L-GGS<G%#]I,$
M27#1X?]$01(\&]!$E&*.)BY2J_T72'WEI<'N%VW4'X91;W-AD_Q0'(JG;Y`-
M.;U+&"'RXY-**@=1\RG#2WY`2`;J%X)_7LB#O`G2X@<'$J*[O,4)A%,X;X'J
M@\_$=I\%4'&<1MJI"*PCW4#D>(V@$,`?(8:.U3,"VG\"\9S+SW.L(A#STA>5
MZ'+"&#&S,6YJ[1\W2UB`EF5VNL86"J2I$L$"*F7A&J1*:;``]#\+%N`I*FZ@
M`(.U=;``53J,@2B(DT`!IJ\TP3(5YH'!)"A<@Y)AJIE$*0D5@#43#Q;@UPHP
M*8*^8%2R<`$B=)!)JH4,\D`S08(@:<K3<!.*9T%W4\G#W82YE@S7P#D-^H(R
MSL*]H"PEP0(P>(/=U(P',6:<!!M(8=B$[BL6YD`RR/B!^X*FP?HYY>%P)CHX
MHB@)Y8WNW1LG<$5@Y?MDGX++D[VD%"_;$NVU?;WW:U^`91IG=+%9'YX=+$%F
MTG:U]G19UB"G=[5K`=,E2"PX6=Z9:91=)?STDM<-S(B^G(_%<2P,/354=-1T
M-'6$@'=/71D])J<K`2`!3A0YENXE4>P?$,B-@^>@3B#9,E-XK@2%3!'K/"X-
MOR+@O>OU!]S'9=;7#Q,D*;HU'K%3)9S")C_G)U@,_%B7AV+!?Y*PCJ".K`DI
MMLR$H*X$H(SEIWUVR,^"_Q2,?P>O@SJ!9,M,X'4EMOA/\NR:_Z[7'_"?%&J%
M_\0*_ZFL'W\=61-2;)D)05V)-)J>]M%%]XT3IX;6V[R)5R=[E;DD82]'21-M
M&W.FUDM+E''.LJ@<P`Z,<MG!7H[S%1HWIBL-2G0MVCG,>QPPBW&,IBTP!6;O
MPX0%)A1Q>40@,.H6793:Q?I_E0^/"^0)DG48+=PQL+;`%*.]OR%7F$?UTB\W
MXU1O@3F,8S1M@0DP=W\#>0+F'@Y8IO<RPU<.^,+I?ZK70+9U&"W<,;"VP!2C
MO;\QT:XA3V;<`7,8QVC:`FJ>8S>2)YF.C3RI58?1PAT#:PM,,=K[&\@SCZX@
M#].A`V8QCM&T!:;`[/T-Y,&T.C;R4`,L1@=W#*PMH.8:@<9M$A'@KOTQ''\:
MY^8O!<M2\S@$E)+#Y'_?B8*S^\@*OQ;6J?LQB70OE=S;F[_E]>$1%A+K\)E,
M#D#Z:+KOQ6%DCQ,'"S""*9/UH<5T`J0W1_)DGK0X1N_/_[`2$&LI2,4$T<`>
M"RE=@*3V<BU-J!X^A\WL<8(4[S"C-'.'#<R1[)@GW^$P0:7784-[+"2U`(GM
M4[D2%2J6QV%S>YP(QCO,J-O<83/S>CTA;!L.[?73T![I)WR/V"=%GE+[4_[Y
MS_E*3"B-'B_-[7%JNX$=E%&/EZ;F]3BTVH)#$>[UTM`>Z26ER/N\9$1XSLW,
M'*?JB]STLPW47%CB>F7<V3?(N'2?D!&6=9_YL#2S/_7]]\NY`#D-K46%\DNW
MV+8TP4?ETB1GLN`4RJO5K7F+5MN&`ZE_@("UG?2*L[5O$6<?!KXG<@D&2J?/
M!S-[G!JO\(%1R[D/!N8M\AOC`Z.K'A\,[5OTUH>![=F2#XP:>GPPM\<)[`H?
M&`&<^V!FCE/450UK+_5#^Q8)[1+2<G(>@$"!\Q`_M\=IYIK^HZ9YB)^:XT1R
M1<-&_3S$#^U;5#&*>*-:\][/S'$RN-C[X.*6I7Y5=/8-JLA9]]$$OE>VLDBU
MM&^2?RZ>&_MIR]I%$^H:2_U2.;+'225??`4:7.5"BS[E;,U;E-/BV+S*Q99]
M0FKM6X34!XGMLYA5KL]A,WN<KL8[S*CBW&$#\Q:9?8?#C+IZ'#:T;U%='R2Z
MS]*(5:['87-[G`C'.\Q(Z-QA,W.<)F_!H;U^&MJW2+1%LGV5Z_'2W!ZGV!O8
M0;WU>&EJCA/P>!Q&MSU>&MJWZ/E[O&34>,[-S!PG[XO<C%:YF>9&M[D8Z_G$
M'J7G]K,&U/.,RU[/4[=3:OJEJOE$_Y]$DK\?F@IO,(T['D;E/!^/O`-CIK,N
M^^$G/*U<$2(`!0VLO[%)J'?$UL#.%D(G.*D@2Y_IC]??V$0Z:;DS;YE%##E8
MM?XV38D)A-Z^9=K@Q<#WC`?6WUX?]/8M\P0'X]KZV^.#WKQE8A#E`U1\GP\&
M]BTS`2\&.OV!8KS^]OE@8-\B_6M\@-+L\4%OCE98PN)\@&KN\\'`'J_R"QC2
M/5]Z!X(J[//!P+Y%V%?Y`#?1>7S0F:/[;YZ,\`%JM<\'`WNTALL%#'*OEWR`
M*NLAHC=OD>UE#_3E&8BJ`N5H/TK"JY.]XGC5WN:SCY+0QAA/9/3G^P"-!S9F
MK*A[B?=,)?C-N-V=0!COMDQ(QOO="<GW>5,\5/7;`B-",,>((V=,1%M@PHF[
MST@:#9P)G2C1(=>Z^P!.F&M$_K\O9O92W2>7XO!2ETU9F%V>WXJDO%Q>BN-\
ML\=[$/'4?%=A=\WA%X`6D>P^B'UYKLY)\7M1'\I+@<"JE^;2P.P+=Q>UNS\N
M\ZG6NU!E@(ID#A53_1[05-GYX&M>U_FY:7=TUN7#8W-9^E"%*>=GY_*Q<]L"
M$S^[^S03T?@%S-%[/W-B=V[^4B#,R4?%[VQ*$M(U!3E($/S6`W/0[F-;$8,.
M$?RG<PAS+]SRWXHZ?RCZ2'G&#SAG<?$^7M4P6C/>[_%TP;H4GEVX?"PMHSC5
M/2U2N"]:KX9G1KHTY")U')-M@4EXNOLT5=&P%:=#;[*T.T2!*\H#::@NGO(2
M-YG/6'P?'#WP*A5IOP5.XW4;7'EY:@\6J&JW5QWS(>YN7_T>6JK4",YTW3JQ
MQZP)9=9M.994]LESO'7/M_GR&;>M0CK_-C_UXYV0TGZ@ZK3?3JCM%EKKT+?D
ML3H=B_IB%M$4U[#FBL]6LXN48HXW0,ED.C.\`9$1O<J4F>?7/7H'W;F#:%GY
MLE&T+.+`'B\Y!C=BP4E&_.#^P/>*K7QS`XV:]F&LC">!@QNQP%1&1\"H[K>V
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MH3$7;0$_+>T]V3\L)URT!5;1XI[",3NBQ7,C;@+@H\4S`1@/[I82Q\Z8A[:`
MGY+VGNP?EA,>V@*K*'%/X4`=4>*Y$3?U8.^<>K2C%P^ZXBI:Q5F6B*S__AJ7
MB>T9.&YBNW0:'9Z^`4VF4D2W*?HV(6$P>TP5A^64>P?U/2P\RTLS/`7NK^>F
MJ,]F8I.?[N"?ASW^ED63I2,^8.'Z6!X>AZ?6)#DL>YX*<^K:H3J?"W.*7?):
M-FVQOQ7U`ZS</KBKRAW(16A_+`]GN-1HSYH[`ZBGO"G,"6']3W)W"R>4K("S
MI!@,(L3AF1\H@U$$P<CCXQBCB"E_%+%K4<2HZ4OT3RE]F[@'G7;S3TZIG7]^
M^?UP>L'3C6AVIYAP1PO:8\OP2,/7O#X"[_CCIPFS#\3'H<$!*:'72^]I9,@"
MY7KPNH_;%P!_.55U><R3XNGY5+T50,#+&:;B)N(_U!^L@V+R%^N#W;S',S]%
M7QG,&_`LOMV'P>;P>&.=PWIQ6ZSSE/ECG5^)=6QR8ZSS[M4$';PM$=2]_.YB
M7<D[T`[W^@Y#^_FE/CSFER(9'6OY@"_UVM@_5^<^.)[KLJK1BO'A2ZX;^K7L
M(]YUS.LCEK8'FD1OM04&6.I6I_9PU<F\RYQ_$SS]9I>&SW39@>8'CSO9,;P9
M*L"OG/&S@W$</)%D)]/PD2P[:"%XILLN3;,P#5DFPKW0619N@A+-@Z??["!I
MDRLE)!=76H&I=9@LJK0.'@`#+LW"1]#L:*;)%1P:9H_AN"":A)$R<T)OL`1,
M%Z_4(5CX6*,=D_@C1+"$8C+L%QBCY$H=&;\2Q$SS*S@XX5FX#DYY^!BH'4@R
MN](*%^%#N7:0\*]$$)?XXT9XT(OP,4@[G@H=S@L\P]<&P1):7HED0:0(<RJH
MO)+A0&*OC`;!U94($B*E5Y#*E(5'@U`J<,X8I/LO_[B]N;WY?WAX#BP-"F5N
M9'-T<F5A;0UE;F1O8FH--SD@,"!O8FH\/"]#;VYT96YT<R`X,"`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
M97AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3@P(#`@;V)J
M/#PO3&5N9W1H(#0S,3@O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<
MO5Q9<]O&EGY7E?Y#/\UXIB1-KU@>95O.Z$YBWXF4RIVJO$!@D\0U"-``(47^
M]7-.+VA09IJW;$*51131[.ZS?V>AWO[C_.S+^1F]2G)%*/YC7F572MK_E9OS
M,V:>,,(3PA+S#B=<7>4YSTA&X0F5BG3Z_.QWTIB]4O@=?J@LPQ^D6YV?K<_/
MEO^)6^$_DS?HE90"#KB20@GX(7+.]Y_G4N'S7*3X/,L2<7A#3BZERF&3C%&2
MI11VQ3LM_[4U7_Q#.3[D+!#U]O[\[+\^%`]E1I@@]_`!PRRSJ6</X\`)H<C]
M!J_-8'=R7YZ?70)M'%\_G9^]N;V_^84D5_]![O]Y?G8#F_ZOW^G7GW"G)[S&
MW^`5OU*X&X,?L)W*PJ_U^=G=OWY?([+#]U5YN.^;/[BD>[<Z`4-`4E.&,,H,
M0][\<OWQ^J>;7VX^WA_E0R+V^,!4^KV,B`E.9>&BTM[Q#\[Y<2E-Y8+72]@<
MUTLFB@7:1/-1L8`?5J_NR/O;NW>_W=W=?OI(KC^^A_^N?_Z_N]L[\ND#^7#[
M\?KCN]OKG\F[3Q_?W][[-;_>W/WV\[U9\NGO-[]>XX.[XT0G^[J9TA]1SK\B
M.J43[<SYE:`ID/KU1S0U8@KIU';?D._:/HUZACS/O/S`$*P`W_RD&]T5]:FI
MP>/2[`?M.H^3DS!OU@EX>6O6NEOI[ON8=X0:R7Z0FHBF)93D7#IJ*/H"9UP\
M39UUW:\U>==NMD7S3)Z*GK3=JFBJKWIQ089F`33O8$%3;&#5N[^3W]NN7CQ5
M"WU!;IORZH+`)PKR7M?%4]%I4K;=MNV*7=4V!/Z]T]N=WCS`)EQ<$$XIOR*?
M&O*IW+7FS=R\*2^^FZ\Q*=+42Y%FJ:=;.*J?\*Z;;:UW>F$H=`)NEZ0=.M+H
MI_J9E)TN\'G1+,C3NJWAK?:I@3?ZX:&O%E71/5\8KER77X:JKPS9[X`%R!?R
MH6Z[:E%,>7)!GJK=VNQ7-;MVLF@&!F0Y]0P0<O2J(D^E9<%45LNVV^@.Z/O<
M`(4HU/?/Q:(J0<@[W35F45%[F3^MJW)ME`4YUP_=8_58-:M]Z2^G;$6*'W2)
M6H3LW6/F'*0#G/(6G.0!J:`U(^E!?E?D=PW;+U'/6[AQ!31U1=,7I:'"D6BI
MN"(?X-KM$Y(:WKWP"C/1"E*NBV8%M%6[WMH.;'Z(H^0/JNAO=]?P@\UB!9E*
MQM`JDM'ZF=,!E*>YPZF/%OEX=#*"#G'J4P"*^U.`OM2=9!E]ZK,R,9X%(5M2
M!'P8LB]/?E"Z)[4T=V0Y5W%Z)9$'1"5/?HR@A_F'JG]ZS1?IGF:HT0D(CJ]1
M]Y==NXFZ.71:NQ`=3V\BP4;^"IB?PD:HV&-%&D*!XBYS<TX*/;KW7'_AL"QO
MB.'="SPPA_<"-^+N+=R]K<N:`8=E+)\5AV64^YC$P6_YF)3GRLK@NJYM(-)-
MJ7OD_\D9"H;F;S&C4\:\+1!+>2ZG;OGBY,?EV0&J3NZ_.)4OCKE,KKB3'9F#
MCQR>^!/S]"K-,'Y_-=CUY$SDXI!JG)Z)(GUM)LIDHHP`?FTF\&;H3\_#A+\*
M#Y.7^CX[#].I03.JG"<&W'MZ)KZ.-8N)-7]G222Z^Y1A7(W99^I+6JU-JT]^
ML'P5#R_DOH>7KO;I@-+)E4+25_%.<B*VTRN%9'0_+$YJ,;G+2S>Z:,@\Z8M,
M\Q!-9LU?9":FVD]#_IVYK-,7/;9=U;J\.V33B+H=5,#TNQ]*@$-]6#<#S$PS
M7\?G!BG;ZRJ!K_&^#T-?-7`)+&K,(QW&U'B+>:7#`.8&>FG&52B-2;XG'^#_
M$J`_6=GJCEXN=;G;%]?ID;@0V7B_[S?"",Y/DQ_M"L5Q?BHSKTP\5%Q&W;]M
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M]';HT-:!6Y.".99BW!K4;_B$L?<91)OD8Y\$_;_O$KA0L"G`5\'A"PV7+8N:
MF*Y%IQ]!V!IN&/H>SFA]*^GA>2ZAIN'.,PLU3:;<24,31<KT1:34?Y9Z"\%Q
M7>Q(TY)5VRZ>*G1E'6F!+2B^7=&LJ@?PUT7?:W!YZ^(1C$#K!FY5MAU8QO='
MTYA\L[$-Q$6H_:7"U?ZN2SP<%+%^OI@+W7`Q7F-F=,/3*<%CXO4"V1CS6FB]
ML=[H01O5G=BD4>S.]@/WM%J7Q=#;Y;9G1OI=6WY>M_5"=S.ZLA0^]CHL1#<6
M6$C3-.!WQ?-]-MH&WCQN*1'!FP8@D7BUW13_A#OLGKV$JKX?7*NV'78]&!OJ
M]`0-E>UF`V[*B.NE6"W.G>*PJBGK86$[?8A8W#[N%/#%YLP&7!_XQ+(&T`%+
MYV"#3,;`2T-0R2GS@=?<!#*IQV('/Q'H;,!76T_4EN70=0@C&_O&`A;9``2@
MJ.T.Q)]I][/JB08[>`20V8S`'UE0-*6!G9:9L[GZ5*F1`3,KO<K'DPXUW681
M+??-#<;221;FF]1+5R1J](Z`YNH=HG<7._;UUW?D@QI/I-B[Q,UJP<O1"XN0
MFZJ^,.X/MZM@)8@4HWQ9;*M=45=?#5B?)SPQ/G*=TE`3D1Z!W$/TU,`+;7.#
M9=6`]J'550UZ8#MM8,W56R;H+3MY:H=]#'_9>9412T/^)(S:+,`RG.4R7/F?
MN[<&%4(B5;6+_E`I!<W7>H&Y@I)*LU=BB<KXA"64!GOA*E7[00E">S47Q4FF
M7HGB),NG2I#34)?B+\IHZV)A<>1,Y3&5CV.N2HYH(#&O\1XAE&"2L'N>I3UK
MQ#SCT)]2OFS#,C:ZH<2\]F-R;WW&.@=]XD>'&N-E*<5]R8"S0)],/'V_`_Z%
M2%"0AZK=Z7+=M'6[>B:E0TB3JA%JV0(2P+K=(M*X()`C#DL(-@-^'O"7+TIM
M.]BI:@!8Z.;K\P81QA:2),@E;9W`)D9PWNFC.1_IG3O?((K*,7^>]/6Y;_5L
MVEJ70ZW[,%!2MG5=/)A).4@!ZZK4C<&/;O@0^`;NW,;[4125[F>)OZ8P^1IC
MR$R-9\VS?Q[V/SFCP(!DXBL!7,G1@!1+TM&`3$;O3,/D1>\8^>^VWY'[8%`8
MM!]:5_4%22^&TDZ&POOZSRTD&;W]-=C/J#>+JB_;1XTP$,VL[,#I.[U9:7!,
ML^B'\JD@YY2'<K;+/_`B>#9Y++JJ:':]&:A\P0B#2`,+'$K9MI7/4YZL\VG:
M)]_O60XX(#KT?M82.'DS<H?</?<[O8$3(.V9E']GH5^,HZ0J]$HD<Z#C6PF#
MF0-:7SGO-K7?"Z3<BMPY2@V`UOE&SY5BU57@+L"9XK!5U2R&?@><A=?E6F],
M"2[X3O]8]Y,YUCF8P'P6RD0`(B+W8Z1^='93=)\A6W%3LS>&LA`U[5.XJ6]Z
M'!*J':=]^=$U;&D@3H$%-#C.*1?.W5J_NJY6ZWF(QSD]/T!OT<\;$.*RVIV^
M0SR>-7.'5DV(8NFDO&(&Q6UYI5M56-QQ+LJW4T`*=06\-U*"K*O3!;:IMN`"
M=GN3W[UV\NZ)*80^:++"<?K:Y+!5O[-9YN@*#QHXGCF'1+/0G0Y82`G%?)-*
M'W#=L\!:D?!989^08VN;I:$;F8Y3AXM%92<[L?Q[F/`P"'M(1L;7%W7?@B=#
MZUR`U[9%U16"Q18B7@GOM,V+B(=Z,H=L^8CC>1;*W9DO)Z#?++9ZV%6E#[!D
MT0VKWD3F]0!@%ISI)]#N50N^UA9A1M<V?O=A\J4!Y^W>5NU=6=GAS1<N[\*D
MXL@2@-.V>%SK8C%3R5"PL04KTU`!9]ZT@>K':F%KVP%QD+ZMA[$ENUT7W:8H
M#9NPP.D*0]8+',H03`BZM?50U"07T<L6^-$8SX`AL?%?NIF)=#-KZJ;4)KT.
MY8O&D[3%@^V#.@T<<)P!'=$G[RO!$W_3F3M8+)WPA)IQ:L<3(5SV7M95,\**
M\9<O0X&Y?&5KYR,217-`:P%<TZ,0;>P%KC:[P0H>5V"I77=8I#MY9I=EK\0Z
MU*9T1/PB"3$R2QSJZ4M,=/<]V@'W,G.RRR&2^YO.K$U43'C"1/@.N,@S_B+;
M-8#45!0P-#RUW6<#Y0-R<\9W-V8QSO9\V3LD._,$"IZ,;4+)@G2IMPN;4?G0
MM]6=J3:[QH=)>3;MHEJ"M?AOT)%J@[Y5>_>">;SNO`WA+LZI6%CE:B,FH.`/
MW82O),+O[5`O7$C%B#H'!^3D6W*3RD6:C:@>+O0`D2R.T-S#;R0)GV^72_/M
M/VQ_ZU5GODT9\E;C.R81:/R8D3^ZF:G#GH,#?.RNC=\O<3G5/'"/TV16N,>R
M/,3^,*Y`\VS23`G9U&8`++,='NJJQ%9JIS%8`T+OAZ[#@2R??1>U^PH00+WE
MH.M)+F>3?>OW"](,YMN^H.[/NL`!H*IYU`;KXZ26L1:0Y*__]GX.:4(F\^TD
M2S!H4#/P.0C/OBUBF@8Q9.-#79A.Z)_/=='8E\%YF_Q[7.0HQKJ'MFWH8KNM
MG3N`S_4(]>#=$3#ZS*DTEOTP2[6"J3#9.4&_BCKWK'%.J[)"-M8'`*TU5053
M;0D%7KU;%P#PIM$-7F)EYHI\&#KDQX5%P4YEUA7VF=]W5^2G6C<-^:@73Q;_
M][K##*$G[]:57A(#DG>H"N23G1J;A1%BG,*D?%+NYEFH6Z%/,NX+>V2-$18B
M?="3+4BP>JAJ"X`>3,5!/Q;U@#UV,^+F@M@6U,1J`H8S1+K/]IO=DYP!C&1=
M@1,W7SG'\9+![-?I35$U-CNRO=DYV#!6_9F:V(0,>:[^$^*U1R](1(]H76.]
M"G7!:K[/Y$__718Y7G'FGFJ239G!^33BNS%O(]D-YK[;`L(VP)BB\UGQ=JBW
MYOD6T)UGR,GYH01])7XH(2?\X&.:J!1SN1+JJ[>0]H7"HSDT?M9@#K4-/95$
M3J:(O>*^C$=CX1$N6[?M9Y>%C%T6]%X@T@9'M$S&C@4H1%5^7`"HU,5CV^W_
M\2)3^:3`J32G1!@JPG7-'VC"ZF""`[FP@/_%@@S;Y+$%J1+Q'1*9J>@"A=,2
ML042-2NV0,@\OH`K&K\#DTD>74"/'`%Y79P//!-9?(=4Q%G-$Y&PZ`(011I=
M((\M$%C2BRW@0L870&85Y21$M#3*!Y9S%KTDMKBC1["4Y5%QLX3%R62*)?$=
M)!-16<!C$:>"TTQ&%S`$?[$%%/^Z6V1!SECTA(QF41I2&F="0KF(/9=Y'MU?
MY"JNSS@W$E6$N.-@-&)07^P5[0:@<-]Z^<B?C8+81J2O)=CD\\V+E,CXI=CM
M+G,9I>Z2Y6E\`<_B6GPI<A;U*)<RCYO:I3HBHLLDCUOS94;C$>8RIVG\"$;Q
MKWS$5^3YD1400XZ<HHY$NDOP&EE<HOB7!>/\9!F-VP1(W7S)+29V"NE1?`43
M(FJYE^#'CU`+H2#N92^YE#(N>ZY@27Q%<B2N7O)4'5%BGJEC]\A5$M]#4!7W
MA9<"Q!\_10`Q1_80R1$-$H!#CJQ0B3JR(DFR(WXA3?F1FV;I$4T6><J/.!>:
M'O%PDJ5'K$'R[(@&25#3^$TE>+FX-4B514(M./.;?YR?G9_]/T(^K[4-"F5N
M9'-T<F5A;0UE;F1O8FH-.#$@,"!O8FH\/"]#;VYT96YT<R`X,B`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
M97AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3@R(#`@;V)J
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M$5`41RS/(G@JTK3__ZWY;-[,"_<FCSU3[Q]O;_[[YW)7@00$>X0/D*SHH58Z
M*?R(1,X>3TAV'`&AC]7MS3TPE68I>WR^O7GWV+.ZG!1[5NQ8/BE6JZ%Y4C4K
MVU,_3O#YZ+<(A-?O63\/;"Q;-;+]T)_8=%3L0_?U<E+L_3PVG1I'=BJ'3VIZ
M8/_H&(^BY(X^\[[I?ZT:U57P2;?RH#HUP+ZU>20\_[_8X^^W-Q^`KW^MPGW,
M@7KXD.8^RC/NN)>6^[YK+^Q/<1+=1:`U95>SKC<4-<2#?&`?02@]O#[!^U-3
M-6<4UPE^#$W9OI1(?T:VFKZS$GN5^['O@7WX0$F;I`_L5_^83>002:L%>9Q9
M.4B92B.'[U%:#HK-\-(PE2"0G:K*>51WK#SUW8'UP#%RT72'49]UN6O:9KJP
M":2HJAD^7/5M6^YZ(Y3R,"AU4MTTLN=F.K)ZF`^@<D^J[<_X\A;,%WEF>4^E
MLP#)9:YYK_K3N>P:A22U+5!S5J`'\QG/\)HE.-N]JB:F&L.X8G^-V8<OYP%$
MA>S]>ADG=6*]>^_7"OCM0#[V+7A*6=>XGI9T2M6D_*`*$ZA</8_3<'GX,3$4
MRV)((BN&3*1>#,*8PDM;_KFOYG'MXP"/5.";VB03\.;6).,TTW08WT'&B`9X
M1X*:U)>IT6:I9<3PV(9F!`^2<7)1^('\REN]9*E3D[;7.Z!Z/,-1@JMK0=R/
MX0[:B=VQYV-3'5DS;J&3>9':PQ!>)T61&"%4QW(H*W0Q7X'!W86U_3,[#_V^
MF9"^0].-Q&_33:H;%0E#30W:&!AG5?4SFM@>%+&$];_W`VJPD0J8Y8"FYJ1!
M+HZ<O_H"*DXN``(`.PQE/9=H$54+`MQ$#A"G;73*OPU.C3;!\8ANR%K)]?E`
MW`(U@-<:\.3E-`W-;@;_#';V6Y1$#?R(Z1E@HT]-/X^L+:M/^*RR5I]G=.6@
M"K``O1Y\"/PZ/!0UKD6OA`N;[DF-$WDGH`>\G5613022<J<86>P5PTIDI]"9
MG(!XU`HZ3G/T_0!JC3I!?'O&R_.Y;2H7D_!8%08O=NZ',%"I/:@+*`V\<FP.
MZ-^THM$S6_A5OX)\]V?\[-R!OJ$MC3.(K-S&3L"8C;,HA'<6`,Q(&GA.Y[D]
MLS^S<PFJ2[2"+S^!UN[!M1J"0<,!YCRC\M0*(]!K6.:%_>M@4/40\KN9],F:
M`2F!8OMYPO@6Q@S$"%L(@>=."+&W$AGG`8@)3&-M$O"3A@1]!.]^XYROSF@4
M<LIC[N":S&2L.1U9?>G*4U.!UH&9`T@=>U18/`\X/C11T&;P!Q5:"85EPB"D
M\?4K%J,/,W`JI!AS56&X@/<,-,&GH6IM<;BQ1:AQ$K`<BT2SK`E#`CI%(:">
MJ\E8^@MX`C$"3$`[.UJ&UET!BA\??N,R0E1.W@N4NE.5CA7@/M&W@N-O(4C`
M+B-P/(#YF$>`&RQK'4D:B+?]$ZY!<6\@BJSP(-4C`YF@2T11(/SJAU,)X0F/
M67UIQDF?LQ8*R01I"P$E+`P%AW[J68');N"O()$+>."I,]7$66KH./'(!@54
MJ;4)23(9$`*.PB'^5`B#^$E0+_1$AU@UNC?&'T2B;YQSY@`Y!Y%9?Y8G1DH?
ME<8U-4I(?5%#!3"/U<T(N1=YX/[)H.\7L0U5_RJ:O^;7!]66B/OP?9W`F"!!
M4`(V4_;-_=YLLX4,4H_&`>PZ-!X9L_\K)247%ZR]YEP>?I2<]/N@/).:G'?H
M*#8`_1D7SK1E[O-/BW?_V2E[/N!U';(C4+I3A[DC5>A^[R^0.P.D#UPT*$@U
MDQ\@WSUA5>%PT:ISME[2%1D,M+F"TMXY;''0D4/Z.8\]Y[&QPR,XHAWDB!96
M$)Q!LC6@\2DA605&,DQYR,E?K]0L0HC+$IT#H9'H!$K+<U`8$"GW+COW+`V`
M4OH(R"SF-H':0!9I'J#]`,WE017B1<ZV/A6I(Z/@#R)"7_1U(\6/>1'P'.59
MZGF.#*0)LK!_(@K_@FDI>30==;$\1*>\4Y<>T2UF0N>I.6'PJVA)D)+`0]`_
M[I$;E.;4GQ$.8?Z'$:>>*<93?OU<DHO<XI@SE\,47N,3BV@PFSL#8M7FB92B
MWH/']\'(,_!"R976#F>PY..O*B<?C^#LT7?L5-LH].17`<UX]1+]1J7.N!N`
MG:>RG3=Q\VEB\Q<>Y;[HDA8&T0S]N1\I;?<G:7DA<$:97FG=&APX9"$-U9JP
MDG2&!Y0F7X4,1$V^]ACFJ51J`Y;+"E-C<`&XY9-!C93+E(#T2)`H\RWDX*K0
MI'M.)VRXFS"_G%@%C(-['QR7JY,BA:,%S%]&:(9H_O?K[Y0%7,<BDD&5)[;8
M_I,:=(T5ZU%@\LT.E!<UX7R\C(!L`(>W)7ILA&=@NG<8)DX(#)ING!`)8_YM
M(/MQ[NH!DUY(25$+:BR]PO/A<:=^4#IGP,VV.&!7:(^S-*@NIJ9N45;F;&N=
M2I<M.B)23`S)F,"JZM@1RSJ23:H\F2HQ:#^6F\>90)#)WU174?5A#USVS_BT
M%A:M#Z5SQ]NV"I/D5U+DO/!2Y,9?`!(\L0G[#N/+Q.:!_515_5"#(%IP'5L<
ML>\A9+FOH\O(I&?/Z%H@)]_UD)E3;E,-<S-IK1M'=4+=+NE<D?@1T$??N080
MKO*YK@%U3VK$0$!YW;5Z0&ZG=8/2_A$A^U4A:`/^$]]'***@AQ)EMEAI*M.^
MBDI<80VIQ-"CD>:IGVPYX51"U(/_X6]D4PM"YR?@"X[-&3_SU+>4=(_S#BU^
MPJ;3^HX1M<\RN+6>IX$H>22$3Y-M!GCHB6.G&,'AJ^&)JCN;9*9)%KG>A"^T
M"7O"?_/PB8*SR4+V<PO^RZ@[5<[_KX&S_P5\>E.;&H3N[_V9_8]3\=6K#UPZ
M^K<]0<ESMQ/()Q*9BVV\2(RK,D!^O",#?BF1]=TT_X.83P#$>S6)>1[4[&QI
MY1?MB7Y!3Z2C;OI->-M">Q.79&>9=]"B,%;E$D"J?T!L/?8G/)T`+&-23,BQ
M5F,U-&?=M/4EL[*N&X.97S+T\NFF=_/3V`#R1.?5U$TYF&:;?8ZI.&TB#9&Z
M6G+AI9'')ER]%G;@O$8LCH*'K:A-AO7$H9\/1XII6$TZ-D/-/L_E,-FS+<.X
M^^R&!70FISOARLEHG-O)-QU&+XEM-"(VF6[V@!:"%G&/VA$;`#I#.&D!+];K
M.WF_]Z;FF'HF,<-.?3E19D;M*8,&#-QB(>V!>2>>TG%]T^?Q>>EWJRS76M-T
M^Z&$R`\P;":83:7$YW[XA(^KRC,UBG:]3L*V..;()=RI]\62%X5%)E3KH2;"
M?-IA.5&#1Y=O:4QIL19(`S**R5?8:3#FV_68M(-Z-X>NV8,GZ#36&V$1@!JP
M'6JA$E)](<4-9"#SQ-79BB##M$[9]C-\Q_OJS(%/'.FQU0@SHU$B9#5)-&9E
MU">U0GE9BU@NX.F7>NQ1(8(S']Y"$*E+.I.@U!IGXDH0HRDX?)]@,R?07JPK
M1_=>#MCKA<5AC^7<G!45YD&2.Z6+LE2>A9/_4_P0L9W.2'\<LWVW=)T*Q_"[
MU:691@Q'`8TTI?2FE66^5T%%:K1VT'A*258_U*P(Z4A-4>V=S?O7WH_SD&]P
ME%E0N#(NQ3??KK7'>@A"%UHT)>;G()N9RG5V\,\U&,F5X`QBN?[Y95DH."&"
MK-6F&M:LYY$4=P2@LP4ZS_+P#*69^7DW]6MOA-.O=J/U+0+]2^S*`$GAP&\B
MI,%5NJ=V:/M=V3(_6[<Z):)PI&`2$IMVZ[OWK<*2Z/I&F+O]-JX<YE="#N<U
M16PRT5UOZX'OF]55B"?R#V*5)WG`:I1%?D27V[+2H/94(2$G\[?5>^5"1G\0
MLT+**XT51F&;[E.S?N%2H.]SHN6)QT1)5)BJ>U@\''6_M39YBZII[G+UO""5
M(56\<``EC>P\KL'8U:5JUP=(*<^O/%@P<I/*S(<$C=I)[:Z1[P8>51294PKI
MZPD\LF,C.D1"5EZN?A["[8['$3LER>AW.@XLJZ_.=AYN'(N@-Q87;JQ-T2QC
MOP?0S%)V`KQ^)`P!<M%_W%%>!_2I`><=UR]["YX&=`KIVIFY'4F;CE@>0.-9
M?>_\:N_4S-X1IEJ]I`>G'>Q52!USWG5P".`&V@TZ\3*/0MU+_4!`&MDPIR<C
M*`O;H%6=)/&5[0GC(_%&P`G+]^OG$YG;,$\>\@)AX%<"A+%M"5/W;GVW)SRK
MVIVL/]J?9*%)\Q"V6&QHVGDF;_FD+D%&O(5CS2,7_T1ASM8F*.LG&^%^(DB:
M<ML_\(-KYW*<V-A\,7YL=5P%28`EYFK*Y8=GQQ929+K`8(S8'/J[QPUJNN`@
M[%9HK3P+!H2YB1D_Z=GOGW'V>W6%2CP!1?I04-7MJQO177\_R*Z\;&.JYMD8
MF:1^>LP5WK'UA!,A7ZB4U5Y8YN[%I.&UF-4]>9*$A,K($9K2[_YV47"Q;'UG
MG@5$1#*H!(L\>3%K92[WA9>,KB\$K9[^9W%H)R;.?-RD6L0)M5@_Y&M6X92=
M[UPR]7G&22``O,U4MJM3DR:.G(W39CAQNQ-%<^X\,'?%SZ%LJ`Q>5C0`U?A[
MGM@+6!W!@3OT9R'B`.(D#N)T_;.NDVW1!T-($V@#C:.Y9GMB$VP[,=TI5(IR
MN.A"+H[&[N>NMB/_`[PR^A&SU4-)(0-:(YF\,A9]78'?PG0BVTSBN7>X@!Z*
M%]5SVQ)Q+X"@:'#-E\5-@7T,;@6O'NE%E@0TQUQXMY<)"RE-9^+#/``A9<?^
MM\,3Q-QJ=2\<A>2(++9US@UT.^%^+S3XX'H[E\*8%UU<&^W]'DP2UT=`(F`Y
M2GSG74AS`+I/;!K"[N;X8>B?P?_;.X4;*#,ON+.FV"D&+V)#UT'UAZ$\'ZF+
MO\W=L1CV\F2`(PY@,;?S$B2==E3/1S4$MSLZ]65BTW.OIU3QVMY%E8-NWM'-
M+]]BWRF7)>[QWO+ZRI;&`1^F`>.G(597JEB&8LNXBQP)=V*S'930YU`#%B'.
M^@T,3]$F?06>^:N>1?!5#87)'>W]5&Q&AM=VUF\L)(Z6J]SI;OV=\H!KGJ?.
M-I+,@C5WN1;;9H?+'1LGUX+=#>I90;!>/:8($=`5T[">:T#(\%KB2,,.);;2
M1\"1RMS,,Z-P]OY=,#3D!VSPAOO!=DSK9D!#WD*K$M<-+Q+?K>*Y!S]Z[EK?
MHJ1N(/B?4:G-+CKF>4@5E4SLY;PBLU1=(:WU.[QI&M#`N3!I^Q;9(0?U\7M)
MO)9N^"TB.PA_A:I65^<T#IG-_#!8P@N3%]AK=A0\,(^>J"R%TE]_U/9:+:EV
M83LS:>QO9X[JU?OV&PQ11(R;FPI;W?_C_)OQ!7(G%M<_]C@B#CJ/4P)FW$0!
MH"Z?W"5M]<K%?GQ'H]IK#''G+@\>FX$F<DU/"4Q];G&*VE0B@]&E+9R/GY@7
M'G^)@@L[1'$U*$Y_3LVH'"9TLS@X3`%_V]Z<S\]^.@]-R^([\S5"?P<1]@/B
M.3.,2$(8^[9^Y9G-1&.-5CCV>L46WS_DYKTC8MY>@K,])@AJ^SW@F!HO\VKV
M@OM+&CXW$TJ@O[XCIR\MT5HW4DH#?>YZH[_]N:A%](T?:/4#.Y<#A2TMT2VD
MX<>'HP#I)!;I/!(,!I:ZGAWF<@#M5*#2Q_X9"^=W_J*6YNN:WT"EVPNVQPQS
M4W/"NY[E2>G/X\5_]W56UV5A'/+@48:7V2,FB#W/!WW%&2R(TBRF!?SU!:)(
MX:27%N1)OOR$+!'1XH(T@<"UM"!)`,8L+:!;B4L+X!'+-'"<,%Q:$+^U1227
MY<`+R1>?P'.Y+&J>P7$M+D@E??_"]Q<D;RV@>S!+"X3(EQ=PD2Q*DH,3799#
MQ--%(N,"ZZ%+"W+\GHRE!1E?9C-.>;S\A"3.%L\BEC@`M+1`X+WBI04<;U<O
M+0"_LTQD%">+6Q1XCWKA_3Q>ED(6I?G2^VDD%I\OBV+Q?;ICN6A3RYZ#Q\L6
M%4?9]^G_;);H%7'V2H#(%KHI$?QTWY%F.@4R?NFAB\7SN2_$(O_W-%:VM`!@
M^Z($[@5^H>+2`EDL.YU["'B+]GR?%LN>\3Z/EM7POK!A[+L+"KF\(!8R7]XC
MAB"R+"JP>;&H[K`":QZ+*[)(OD%''F6+9G\?%Y%<IA1<Z+)GN.<T1KNX@N.D
MV^(*@7V)Q152O*'@$)'D&\](Y1LJ#''Q+3KR9-D1W/,B6795]Y#DI,N[0%Q;
M=F?W@J=O:)`0J7QCA4RC-U8DZ;);O!=INAR][D66OJ')(D_S-UQ+D47+A@]@
MXPUKD''VA@9)/-SE%>#CEJU!2OR>I>^M`$_]X=^W-[<W_P$D1QYC#0IE;F1S
M=')E86T-96YD;V)J#3@S(#`@;V)J/#PO0V]N=&5N=',@.#0@,"!2+U1Y<&4O
M4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R
M(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\
M+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&
M86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X
M="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TX-"`P(&]B:CP\
M+TQE;F=T:"`T-C@W+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IXG+U<
M68_<.))^+Z#^`S$8['@7F34D=3_:TS9V%CL[NVTW>A[ZA:ED9JJM(ZVCTN5?
MOQ'!0RR[2F48J89AUY&4Q`A&?/'%(;_YU^W-I]L;?I<6">/XA[[+[Y+8_%,V
MMS>"/A%,IDRD]!O)8GY7%#)G.8=/>,19KV]O?F4MW2N+$[Q1DN?XA?7'VYO3
M[<WA/_!6^"?X!;^+XP@><!='201?HD+*QY\7<8*?%U&&G^=Y&CU]0\FV,5Q=
ML%QPEF<<[HI[.GS?FD_N0^$_E&(6ZLV'VYN_OE.[LF`B8A_@`E(6W=2I1TC4
M1,X^-+AM&<-&/Y2W-UM0@<2++K<WK]Y4W?NRTFVI!_9F&JI6#P-[UY73P/Z=
M??C]]N8M/.C_OG\[="(+VQ%F.Z]^DS'_T0<\)V^*)\^%E5=(7CAYHSR*C;R_
MGJI:LXMF.UU7^EZS\:1&UDT]^YM@;S^?>Y"_ZEKV_F$8=<-.:F!EK]6H]^R(
M7UEW/G?].+75^,`.74^7OFV_/#3:ZV\3WE^Q9BI/YF+=_[!2%\ZXR&-WQ%PZ
MB>&P"R-QN&']N1K&@8T=V\/>ZN[\O.0HVWC2[-QW^ZD<\9/NP$[5\012W*MZ
MHH]&7;4@[X`B@JI.4Z-:O*Q79SV-5>G7W+%?-6@3%+*&!M+,'7J>)5X%<6Y5
ML-.Z=1)7[9&I=@_/.%0M_H`::+I:EU.M0.2NJZV"5,TNU7@B+31=KUG9->=:
M?V;5,$S@+E5[W]7W8!A5^X2FQE,W/*6B-<1/N!-?%"*P^=R(?ZP?RFYXJ!7N
M;>/V!!(>>[6G7Y)&\&S9>>K14&I4%FSDTU3UNM'M"#9]JE`"U`,LJ4I0#]K(
MLT<>Z..._1,`AAVFNGY810%1Y)T^BV8%%-(HP!Z]WC_R3&OZ_]D-(_N@RU/;
MU=WQ@94@3M6.J)Q1/^\?9!KVT_<`$9J,R7[8=A>FZJ%C4[L'=['/-WI<0W[$
M7"-_@'F)M7XP9@-A@$5T!-?>01'['13R+B8(_@(/WE[]07DH:AZ@72*ML/[D
M]FQ?#65WK_L'LFX]G^!@#HF0_U+5-3OI^DS>K=J*'!NNA0O!?ZMV/PUCC[^]
MMC!)EOU!:DMR\<A$^`R169(8O8&D93WMT8;/)]4WJB1G!B.^NN`9T+8_1O`,
M:.`LN(R2U!,@P5,K.&*]M915G#,O"J?Y+)DMEC83@!,9Z:['`X`=-:K_J$?6
MZ@O]OFH`3#'4.&PEBS:LP\+LP`Y]UX"+7RJ$G%ZU1XUQZ*?_><T&P"DD>'@5
MX=9.CTA&X-*S[D>T;G"&EMC.&AK(I=4`SQ-O>U'L;(_"\[D#Y]PA-R-@Q8!B
M'16XP_L*XP<&V4&!R*4&IZV!:VT`?3?&AW6K\&H%W_[\;S\QN/#\.$23;BGZ
MDTZLVF9E/XH-:V@A36:0GE$Z2ZT=$!Q9'K%3NZK&.`P'",2A1%).4NZTHV!X
MEK@:A2T?2A!]K!KM5PTG('VZOUN#Q>=QLBJ)SV7N/6;.6>*8VW#^3XBZQ\[R
M#PS!3R8Q%=&XG09<-Z93:V7P#5R)?`24&T:%KIZ0K-!ECS'0^&8%KN=9PAH&
M(ESJP@,2(VVBYL/3'?L[</D*#/V!3)9.O.Q`^'8TE*4USD!0`G(_25]`1BL[
MZ$-?/>(`NCIQ5HYM>)E7G!"1Y[\QCS.K.E"%/T;_PZ=)M6-%X$=T_=N<98U#
MSHK88^$<AZ.(6RQ$D][W$YR<'D8XP8V!^GLXW,D<.:X`8VAT7X(17'N+$AS.
M[7'=DY.0M,W:D%$:^Y/+4YNM#W!0WR963YP4*LG$#'#3J]M8$O]!.DF2/+00
M.:-?)"SXV535X``[*PC?E+D2%H!+:XQI04UC#1O.7+K-BSSS.TREM>&GDB7`
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MK\[^KBX]7!;L)I)!J=:E\D-U;*L#8`&X,_#_7JOAZD0%Z^#!/H1X(@BA)2*8
M7OW9R2,=A$E!4E@=E.H,B%DCEB%WW5Q[#U$TRX^.G!4SCEEG0(RY^F,AHLZB
M\VR._9%T:C?55D0"A:C0-55Y=9>`W"LX@2(OOJT=LT$#,K>ES1Q^Q_@*23.`
M60-;VSVPU["Y$NQC1.0=#/)>O9`!7&G>:!Q[WRWB:"YCK`%1B4O=A8SF0RI2
MRT:L<DQ$Q[0:L-T2CQ/65;O^"$G+T*`/_4/UY0D78!#X\<3T69L"503;C=*@
M$IY:6_9X9HW+4\IJ<(>+/.KZM(Z'6RNB=,9>X5"&FB,[?9Q:/$M(4"$[.3R`
M\0-9.&IVK_I*FXI`VV%Q?HW3CGR)(IZU5PCOD#;I`#XU#?HPU12N+5.C\`W$
M[[[JI@%7M.I>534Q,Q!H&JX/(GFXXR)P7NN[KFDQG+JIM@T\V)D";CH8@NSJ
M+./UDX9<A+O+<^^S">>6(3%5EKK6OM'@:E(AD5WCF(7O"<MB)JY98;>E#X!N
M(R555P<R'CR=YT4Z9\"%*\@>`$N![E]=<%Z$SRZ"F),*%^LL9R>,`#54!.>V
M1/!,OPAI;:,^VO@PIZ.F/&MHKVLGF$KCL`FJ[6N<[]P#GWEYS%U#^*L\:P/Y
MQ^<16#A\=YYJ4X@^0X;=8X95-<@^M$NW#EVWIU8N9AVV[UFC^0ZC.AHUM?K8
MC94:3:.5*?`ZZB"2(A0A;Z]/NAVJ=>JLB6^'BS0(Z)$#6M6VG2'UMII@V(5V
M8$$9I:T1VG8P[MP!LNL?ES7"B/F94'"#]ZJP-M-#]GONVGUH$D9]C1[5KJNQ
M<J'&TT4]4,:G5E&#[XG++/-@GLA,N,B-X=C4S&%G@.?7]SCP-K>-=>LF0H8"
M\RR;<25V!=0#Q,]V7Y/#-FJ\8Q].>G`G3(<.@:V[L)\>U!X.Z%$,WN\K4TD(
M*F]?]5^HO&P\/[S4!,@USM<W_7DZYW*1<(,]%YH_:+H]I5"VFH!M$]@F[=`@
M'7KFX#SY<:481?FZLSW\6#J^T$](.4LBOFH_(1'S>$`A9U[C:J[$"L]Z[+M:
M3PT<:(6UDQ8<A/T9+E=LI\"E:W+P7E.7C%I6-"A@\M(]C0R`YD9J-57=8=*U
M;<GM.DLZS],.79_P%4``X+=2.!GSLS[4P#Q-O;Y:Q5KBPK=_LY`H.28RH+F:
M^83_!2G(?+%Z=*(>86<$9+BY]U3`L\CY2XN&\GJ_IT8"?/M?JIU4_\`BL4&:
MG]*JU_M[!3G"GKUM=0\1T_0O1L!_A[DE\3/5=%-+';E5$#'.YH1S=IC(A44I
M?^-QXD_4^<1/&FNLKJ9H)/C+X!)R4XT'G\*>"PD'FB!D)7RQVD/<`'`9_%`5
MJ"9C[_0>J%\-:MX?-8EM6(&FZAAKP%M1NVMH(IW3I&)N0A2NZH#;='*@87?4
MB(;@=>KV0TAX-+:-._`,"*GL]PFLGRP>0F#+/NJ^11_XC2?<G#)VY##WFL";
M0)WF?O`QV,IN&LW`#%U_`9;!RE-UAK!)]QK&U=KS<>PXNN1!>SY)I,-1G/H;
MQEY=-FRX5&-Y.O80^H.6@VNO@WW4U;'ML#T]U=T`O@Y(T,!B8PRS9PUPWLKT
M,*G__%$;S__V2L`>=#ZK:-#&,%Z=DT."Y[2P=IAFL>WM4M68^S`M<S%GF0#%
M%:*#X5EAUGE?*3<B`.XY5)_9`QCI</TN-\`^8>.*48GR:IL'Y?E<^I.V:_F/
M1RYF'.,9\W*#>LZ`$+YHHD\WU?P;FY!L<"35C)<,^DC`!KHT'FJYSQSAUO"X
M*/,$/8J",H/EYX9/H5OYH0\X8SA\R/#Y7^"LWU6UPFUW$\'PL:)D!,=>8-''
MMKNTIO%O!S<!E."6-=(@YNX]V,&*D\_2#-H#?6_5."$J#Z91M4I5+4K\O&HD
MTJ"J9E6P@PCT<8^"8-4'Y80L"MM\9FM?6\%%`36#,\69GL'@]4'WJ"+REF$Z
M@H_X4`NA:J==DHW=)D!6TV_!F0!C;7?6$B#0T<CP2HEJ%,\<-I5!"=B6`G!P
M^0!'U]&HALNGT1&`J<[XBT$6BV-(/,@@-CAH>\$A(?CJ"FCMU.S,T,=W.$G`
MB$UV:"G*&DJ0GIV*9.8E66*)_+E66`4,NR%(5'&'8"9U]<7->?CP`J=&H07C
MD9I:"*2P(K`7!RG?PB@F]AB%71^YFR?2=DB'B<5V%Z/&-73A&W-2"CD7S%(W
MRS[U+)CP-*>CGY_T7'%@!WFCV^ZZ41,+V[-B1![-G;O$306`@4S40K;9!1P1
MEF=#S\!$EXA',.9&?5=;VG*!MP,,6650/ROD'Z2Q#+(=]Z17:]BIS.?693#%
M@S>U4\BLZW'$#*&X@A/!4W&#GJ9\[R;N(6:Y0N/XJ&9H8M7W4H`[]O>#FP:P
M$X-H``1CZZ24,O-)A)!S+363KHK<[K6Z[_I'<Y668!@P74`V!!H[>_W@X(Q&
MUH"'`S#E'.0VZ=$1JS8M!?1'>D++=FM&NV`-+21SB7\>/8N=(3Q'V"P1\>^.
M_/(>4P1(-."L</"K(7PS-`;BSW0\X0\$<DR=X>K/M`2,!^6$(^[W+B<'#;4#
M1DY3],%"!*1O>N]CVAI:\&^9"1DDE+D;A?GE_>:K@P[*3XRD(K*F0*RI04DB
M2L8I[%-:;22@1I-E,`U"F>_GV9PR`'S2%Y$;Y'(FDWV<F:ZA""E\``N*SX6K
MLWQ+L:PO[$#.0S5B0WF8SN>:ZLH.#C!'U-I,!QM%V+-^(JC/%!<0YJ^`(S0!
M:^:>=VX<"$L:+:Y90P7<T_ML)K>Q%*G'QF_'O]SNJW'0]>&'BXQ+;P;.[XBE
MX3MB;JCX#>79G=D<X*\^=J[4;U@F#EI7OG(UA.-V9&E`DJ?K.U<<IW[K1096
MA46L+R9G%I'T*L5B6S@">/5V9AP'*G03"*]6R(]P!G)^$D_,@"'("#Y^_29M
M$AI&,!25<E=(?P1;5S?,.`LV(&7B`RFHP8TO=_C.IBLX(E5#4US!<X5O*4B>
M!J6PU)N9M_ZP@VGVU^O:Q2S=GK#>:UH+U^^LRZ((MTKJ<R^]IE9GEM$"&?(1
M`4?GK^Z=<(';"E#:B.-D[)>5:D8QL*Q`[ME2A*-<KS';A=QGJL?-,_ADJLR@
M'(@:`[X2-*PQWY4%>@GZ_*]<U6$-X_7O@,K45I7\JU77AXWP<3*R$-5='Z"R
M-'@2X--<)$EC-SCT'5T[TWW>357MHIFM&"(!/?0*:#;$8IQY->^%U%TU/C/O
ML'GBE=@UCG-^7S%+YQF5*+=89`?+*3P__1+N'7NO-?O3?T-67.UQQ@?7_LW.
M4_ZL;='^3YB:=!<[G("%A,G(9+-BXT*@IU(-)_0M6^O'Q&ZR#U_CC=["(_$\
M&AO3F+EYIQ^'AF@NV;646LB-&(!"`YY^,@T'?%7;<.6VPZ&GJ5>FHFK?#G!S
M/L2B@?"HGN![I+YXM\-I.,-TW#ME/J]<H>!>>*&_RMBQ:0!)-KX8P5E$=YTO
MI_]Q`Q:(%-`&%\AG%O"4RZ4%49&DBW>(\H07BPNR!*1;6I":%TF>7Y`D8GD!
MO>>\M""*BVAQ@7SI$2)^00\\YHMWD$6\K&J9@RX7%V38&UE:D+ZT((GRQ;.0
M<90N+XAP-'II@01!%Q<(&2]ODN/T^<("44BQ>-PB%\MB0@:6+]\A%<GB60@P
MZD4I1"QXOK@@XNFRF!+KNTL+A(B6'\$%7Y0"\N_%)^3XKN#"YQD7B_=/BFSQ
M<_#*9:<J7H`.\8)+89JTJ*#L>05^,B*8&XCL"=S.%D@IY\Q/$]BW6&+Y#8`O
M'M\V7S[>+1CQHJMM9;X,>]NHD(L*VL9%O'@"VY0O'\$V>\&&MA`9%XU@FQ?9
M\@(A$[[\#!&]$&.VX*_)HB]L@;@OX])6I#Q]81\9+Q8]`LZ4IR_LM(C$(O1L
M)8]>D!80-EW>AP247CYY&<5R^5QD'"]'DRTD]B^9</H"?=C*#(LPRVZ0+./`
M5A;)<L38`EJ+Y7M$0+:6+0@[N"^LB-)E)K.-XC191H4H28L7=IIF+UARE&7+
M;&8;Y9E<=ORHR%[PAICG+UA0+/)L>:<Q8-RR-T!RM!"E`(C?_NOVYO;F_P&A
M*VP5#0IE;F1S=')E86T-96YD;V)J#3@U(#`@;V)J/#PO0V]N=&5N=',@.#8@
M,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O
M>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S
M/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@
M,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T
M6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TX
M-B`P(&]B:CP\+TQE;F=T:"`V-S4X+T9I;'1E<B]&;&%T941E8V]D93X^<W1R
M96%M#0IXG+5=WX_C-I)^'Z#_!SWD(7=P^OA;4AZSFUTL<)?<W0YP>T!>/-WJ
M;M^Y[8[=/9/)7[_\411%JTB3S`P&F-&42V9]Q=)7591$__"/FW>_WKPCMVJ4
M'3%_[-%P*X7[Z^[YYAVUG]".J8XJ*V$='<3M.+*A&PCIAD%UI^GFW?]T!_M=
MO9#FB^0PF'^ZT^/-NZ>;=P__:K[*_%D(R*T07`]P*[CD^A\^,A9_/@II/A]Y
M;S[70W'\"UGWG6##.'8#U1;U1'^KL>FA3.=7_^$P?\AH`/7#^YMW__:7[8>[
MH:.\>Z]/L,ZR7^K=0[57"!^Z]\_&;"H%Z][?W;S[CMQ*-NKC3S?OOOWOZ?RV
M?SUWQX?NYY?IM'W='0_G[E^Z]_]W\^Y'/<9_?1E+.`^FC.Q6$$*[][_K\;_[
M\D/U2]2,]C-JH7I`W?WOM#UU/Q[NI_ONS]/=]/QA.G6<;CI&B.S^='Q^V9[T
M1Z_'G*)H,MV&+&ZZ5"*8_FW;)&2^WH8#A6__A0G2.D#*]4K_92<6/,]ZZWE]
MJ0RT=XY__S1U#\?]_OAI=WCL7K<?]E-WGG3\/1Q/KT_=+T22[?/Q[:`ENT/W
M^G1\.V\/]V<MI_I_DYN:P^<O;;G@(I@NK-7:0XQ]^7&&I8O(8*;#ND@)#K&I
MKT5W(6H'[0[:+\_VHC0>LB[XK"/RW$V)V-7>:@Z<#(^,@W#7+KVE/8=KUUP#
MWW_I*.7C/-B7OP1TA([J#WWYF'63X`JFEE,F/>\,]MC,[4_3:_?W[7YJ9-C\
MQ2VH^JK7-M=I"N*6L]&#8Z-.RA;<7Q8!FHK/3?=IZAZG@PEP_?E!^^-L_:'S
MS_;EY73\;:?#?=I_[KZA<C,,?$-T.M^>N[L%)V?.^@JASP=F86NLA)I+%W!+
M`ISV#56;7E!KZ<-U'XA-M^WNI[O3M#U/!L$W@QS,R;?=WP[@)/,5/^R.?[_;
M38<[C?.'M_/N,)W/"]=I_Q`[I.9)ZXR-O?8/Q\-D1%_#$4K.CF#!#1#:!MEM
M]],\-0^GX[/%\>/A]\_/4X#@H=]W'SZOYEPC`E]\C0!F<RTT"CY7!5(QGYQV
MUKS]SODPQ-EI>MA/=SHI?3CJ+&50W1T/FJ'?-(KG[>E1*[^<-+BWT^3RUM2]
M3K^][O;FO_=OY]?39SL[V\='H[;[.&G]W9VA>.T$$]O3Z^[UJ'G]T]/N[JE[
MVK8S1&X&Z9R<;0$(#NA],6@FQL36MM,6'[5Q]\=/AT_;TWU`=SS,EFL;/TW[
MO?DW\H@.Q+W)W(]/?JZ-MO[X;CJ\N@K3A/U73.>ZWI^Q?L5LKOIAZ5*JY**^
M]LG<!9!FK450?)7)9:/P]#SRF9ZYE#"Y.D[_7P>T*;%Z]@L1KE88B#TL+RX<
M@^EP>-$7A`[D_6=3G-UV[\-T=COW%=N/QY,M\S3XT_9PWMFIW[V:Z^GCI$.E
M^V`H\&OXHN_]E<[(/"M\(#`M,SGI0E0#A$O87[*392P[:4^[QZ>@L#7!W)W?
M]!6Z/<]JWG<O;_L7ZZ*7K2[@-EI^O'=7_4$3W+Y[F+13@0YVGJ^_TI7.--V!
M`U0_7^BL!_P?IL>W@\&WO7O:Z;GH'D_'3YK9''>9M/1J8#N$D<V[PWQ%!WJ<
M3PN:AM>87,56,K2^A@\,QSL?$#H[@2O=MELG'#]J`P*(DM1MKQZMQWJ+3+-8
M.%]_V_GMK-7,1^Z:B$"9"DV08>CZ4:<BBR:8;5<.M`)3`[$*+*%`E>X3<@I$
MCMEOX*/4[)!3&*10685>Z@(]IZ"DR"M(*?,V",EX5H%?&X*)*WZ@ING+*1"1
M=[4F7"JS"H/089M3Z*\I*%/4YQ3T9.85=$N2]23CVE59!<;ZO)'47&DY!:(G
M(Z=`1Y:'20=&\]_0TR$[%U31,8N"2LJ'K(+0>36KP,F8-U*CS`]!*<^C(#3O
MAY'HS)?Y?#"TE?F\-UR<^5R.*L]/8YX[!,U?4YP,6?L9)7D/DC[]^:_.18)H
MEN0ZZ*H[[%'(=(=MR,!\MXWGNJ]VI^:^F_7VNYE&IE/9^LO[=":4G,]?/O:W
M4IKCWVTNI#V![LWDM<L%MTLC>NJ,4-7XW)DI?&$UW/I!9]EGB&71[>%H,$?N
M8WOX%,VHEK7.*.77K3+.=U9Y`V=CE#VT"BJVRW]N:;XA'.B8,"SH:\::#0,;
M8VN<PJ5A\/F@JD-)M\K:,-_PN+K:-/XRX3G)YOGTML96.84+`_WG#1>2/14,
MS'E.43$;QN8I75CC%"X-@\]U55I]$4J)>DXD/*="S'E;8ZL4%G/^<UI_+=A3
M"SQG+V4P+,3<PAJG<&D8?&XJ7U'G.26&;IP7;H@IH*WS_G:`%;1+FOI#8['%
M+!$);;1EQS_#LM6*&<.D]6R^'KV;8H<XA0O?^,\;:34]9^[6I+E1R>T_2O3N
M=%T&Z&)IP9@/GDEGN:SNMDRO!@LA0LPMM["T[Y>^;:-49J3A0&--((&'F59C
M>16M#B.I=9?A2SLBN;!D)2^WQ)R:M*3LN].WF.C\W2.[Y:8@M'=KOBF$R]W0
MO;J`NY*7F]0KW"2WQ+\"?WVD)/^3L66*3=K`@FTMK\I$+98P".^+:W,M+[>$
MY<*^[+N3:8V-B6"K@*S;+BS@UO)RL_H^$7#V3LW*`=='2J=-TC+-)MMBT[R6
M5R7P%DL\TUQ:LI*76W*-W0J^.YFAD^Q6`5D0-]W]!>25O-RL,3:+08]E*X=!
M#BL/7!\JG?2;B,74"F;$BXML(:Y,^>[,<?U$3Z9`LAE8^?[.'.WA:.[OX'#U
M,!5HV>*DORA:8GE5T=+[)6+><^&+%L4XW-+^T_'\:E9Y'X_'^W-W/N[O,STB
M(/,@9T!SCPB'*VQ>#:UU(GE=K=-?+^=MKE5S"^GM#L8ZA83=H(961I&\KC(J
ML-NF5[";![N#L4XA83>HH24.R"MC20QDMCO..&PSR#[3'P,*#R@VW2G@*+P:
M6K2T18T]M<3[)F&JN7WV=@=CG4+";E!#2YQ(7E?B%-AM<R38#1!B8YU"PFY0
M0^N4MJB1`TU'#>>9M0%`X0'%IJL,UW@UM/)H\[X]M<3[)NFI>>G`VQV,=0H)
MNSVG8'5*H]V%7&,S'=@-$&)CG4+";E!#BPV05T:-6;1%HX:)+K,R`1`\FMAN
MIX!#\&I8Z:!:URTRCL\N"0CNJP=]!-6#_MPG6W<X/ZJ=60'1AV@Q$<NKB@G)
M_,I13^=B@C,*Q<1?3\?SN7LY'1]VKQ5+#PZQ!S\#E7.B=H?7,/NST")#M"^H
MR&0I&A<9``,0Q;8[A3(8<!9:<XCVU9@"&#8[`@P>8`3;G4(9##@++4%`7EV"
MJ!E&1`M\0YBJ6'YP$#W:&)=3*(+HST+KD[:`LZ>6S)1)R0"#S=?-PG:G4`8#
MSD++%=&^(E,`PR96@`&(8MN=0AD,.`NM7MH"3@Y]*N!&,E0L/SB('FV,2Y4S
MG#\++6W:9LJ>6C)3)IL#C,!P"]N=0AD,SV18I=,(HY#A;&(&&(`HMMTIE,&`
ML]#"!^25`6=?!).I59:!%:Z$L)G&/=X8F5,H`NG/PDHC)ZZM[6AT316MJIC2
M0Y=^Z/V<6%YS9WQ@J1O0%PL7>@BTIHCD=35%R=`FI,T06!T0R>OJ@)*AN1L"
MS=V1O.Z^1<'0-@$B#E_+ZW)JR=`,YA3+@Y&\+@^6#&UR%.+PM;QNW;Y@:)L`
M$-1K>5U.*1G:1S*6!QJ'+HQPR]'&L1AW1_*Z9>N"H2T!ZB$P1EV*ZYK-Y,#9
M%I$D;I)[>4.+2.?'LGEX+Y4/_KW4G^<W_Z;?7J;#>3I_7]$;DT1W1]J[.]IV
MNYPD&C32WJ`U6,+=B"A/D_;[R_666(Y%9F<MKZ/M!DL8Q`/&XJ2]FVFPQ)`W
M,CMK>1VIUUMB"1GQR5I>Q_$-EOAK!*/\1DO:KAW+]"11O9/V&Y?UEEC^)GB)
MO137)82D'5%9W0\*S0"SO#X#]./\OABA-+R#:(YA/X9I>S(O&!WNN_OIX[0_
MOCQ/A]=,!6ZLP7@_EE?QOK?R6@5NAT"(/I97$7W1T-P-@3&[ES>LGOFAH\4,
ML1G&,5..8]Y?RZMXO<0%AG7M$`B1Q_(J(B\:VKPG@7A_*6]82D*]SS>*I?I>
M0[*8"];R*MXN<8'R,8X0=>O0A;%O&-AZ&6%F+Z]>5R&X]^F&]4.F4#?C(;P<
MB:MX.>V`7*'>JQZG:=5\+Z?OYWLY*NQUP*E_K]=MXF`XVKU6JTOV\D+=V(42
M=B2O(VRPM[)0MR-B_!W)Z_B[P1+N1D3I'.0M=`Z6Q/=(-P,9RZMV;*K6\CIV
MKW>096;5XV0?R>O(OL$2P_'(5"WE+=R/315=/3F3+>$Q!ZWE=:F@WD'*7SU8
M9FBTI.VJL@G!3`F6*$!>G2A&?*I&6;KX3IT;L*RQ%-=EC:1SXFI>#'B:$,W/
M#_;2/S](%COB^+?L_VHW:]F[/0#NGW>'W=GN?_%QRE7SVAHT.43RNN0@RUYR
MLT-@V2"2UV6#DJ&Y&P*E?Y"WT#\,'06JW/!D/6G)&?'^6E[']P4NL&PL!IS@
M(WD=P9<,;9@;\?Y2WL+HF/?YID\^"VGY%G'!6EY'X04N4#[&,<YN'+HP]BT9
M&R]C)`WREFH>\S[=2)5ZW]#2J!X/X^6EN(Z7DP[(E\?:=^X9+W/DGO$R>\[!
MHT]P6/",E]'$GO&ZD%<1_KS!&Y5A]8;0>0>T:?=XZ.[>3J?I</>YFWZ[>]H>
M'B>[;\CC=G>P&QGNC^?SQNP<4E&H.Y]X]WA7Z*2S]PICZ5-@1A7-,)&\+L-P
M4?04F(<!B&+;G4(9##@+S5:1O"Y;%<"PE`XP>(`1;'<*93#@+#3S@;PV\XT!
MAKGZ.1G",Q*TL)RVN<-A]'!C8$ZA"*,_"\VJ(*_-+^;4@#'SD,1BVDPZ`TAL
MOH@6.)Q"&20X"\W6D;PN6Q=$GTUI``,0Q;8[A3(8<!::^=NB3YK-:!;1%]IN
M*BKZ)P?08XU1J7*R\V>A)47;/-E32^;)Y&^`$<AN8;M3*(/A20TK3QIA%)*=
MS>(``Q#%MCN%,AAP%EKJ@+SA@;!EN$4/A#%."WM2-C.ZQQLC<PI%(/U96!WE
MQ`T/A)5Q7=SKDD2OV[Y5BKE_5_)`F!D"+2](>P-;,K0):9)H8$E[`ULR-'=#
MH&F<-#:P9!XZ+N+YAE"6ZV`1]Z_E=1UL@0]L`B.)#I:T=[`E0YM\A;A_*6_I
M8#'WCQLA4G<#;6Y`7+"6UZ6;`A<H'^18BF@<NC#X+7V31`=+VCM8S/M<=["I
MM^(L41*\@R7-'6S2`;F^4PTC2KX7\AKR56,R6>=:/3,BQL6QO(J+6RS1H61'
M1*@YEE=1<XLEW(V(,74LKWHDK,$2PZO8[*SE553=8@F#>$"8.Y97,7>+)9JP
ML=E9RZL>"6NPQ/`NYI.UO(K*6RSQUPC"[*V6M%T[AM#M+"!$'\NK'@EKL,0P
MLQD1H?I(7$7U:3OB\E:I`58GE=NJPASUS"_)P2&V?X7Y"%N.O)#7+$>JL,^U
MV?/<KT?2'EXY_7?SQJG=[/HX_[A/IGX&;![F#(GXE3HX1'>P,)^AN2:2U^6:
M/K5G9+RLZ.T&"+&Q5B%E-ZBAF2F2UV6F`KLM6X/=/-@=C+4**;M!#<UC(*_N
M.-ALMRFZZ*A"+SUNQD%E*G\`XC'%UEN%!!"OAJ9!D#>L#BZ`%*\.>@QL#OZ%
MX58AA0'4T`0:R>L2:$$0V:0"=@.$V%BKD+(;U-!TVQ9$<N#I()(;*9+/\@7V
M\9ABZU6&?;P:FJU!7MN"V%/K@L@F0L`0F&AAN%5(8?",@^7YMB!2A4QDLQ_8
M#1!B8ZU"RFY00ZL"D-?ZWCP^F`HBH1OPU':S9IT.@'A,L?56(0'$JV%%A1,W
MK-P5AE"NEQ2)7E*T]Y*RK9<4B5Y2M/>2#9:8H!:)7E*T]Y(-EG`W(IJ#17LO
M66^)S7C([*SE=;UD@R4,X@%+A:*]EVRPQ"0Q9';6\KI>LMX2FTH0GZSE=;UD
M@R7^&L%R3*,E;=>.S0XBT4N*]EZRWA++T@+O)45S+YFT(VX(.<&YW<L;&D(>
M?J.-D/!(HACA$96?[0_[[`YWQV?W5`J\:&J2TO>YMI<GNKM(7L?^O.`7`4Q\
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M<=%2WK*8],<F3ODK"\L2;1.GVJXXFQS,!&%)`^0-CW$E)XY27E'):P.PE.+$
M+0LX1=,65?4F#+%\,LOK\XD<P\^9LCF?<+.<!?GDH\XF9IL`J.PSA;PQ`\L@
ML;PJ@WCSKA7R=@@D9<3RJI11-#1W0V`YPLNK<T1`?;$%;VZO`,SW:WE535_B
M`$/1=@B$]6-Y%>L7#:WI'//]4E[+%H3AOE>Y![,P_&MY575?@E_Y\$9XNW7H
MPK`WA&Q=C!"UES>\_XFZG@ZY0M\FYC4K1^*J0C\-/U?HRY[CQ.SE#<3<S[\H
M+]5,S,H>&V+^C]WA>-J]?M:T#!5_>:EOS$*).I+7$3686UGJVQ$QWH[D=;S=
M8`EW(Z(T#O+:BE'/NK?$Q+,0R]N5Y84^-E5+>4.AOS"KM="WHV.4'\GK*+]^
MVBS3(].VE%<7^D,T;4WO.%D&1SRTE#?4^7]PWI2_K+!\T39OJNURLVG"S`^6
M/D!>6U`3&<W;XN<NRDM\,S:63);BNF22],U%X2P9//AECO9PI/Q34G"(/?AE
M/L(>_+J05R4>-?]*I5(T[$^CD&7^]:NF%V6Y`^8QSGCFGP*"0_2I+_,9FJ5D
M\_:_YK?A2Y[Z\G8#A-A8IY"P&]30G":;]PXNL=M2.]C-@]W!6*>0L!O4T`P(
M\NH,&.R.&YE<+^$`>"RQU4X!!^#5T%S9%C#NU`+'FW0#=K,YT!?&.H6$W:"&
M9E/9O/=QB=TVIX#=`"$VUBDD[`8U-/>V!8SMOK"`H<F-'0+%>#"QV2I#,5X-
MS=)MGG>G%GC>)#JP.U#,PEBGD+#;4PF6QQOM+J08F]/`;H`0&^L4$G:#&IKU
M05Z=]6D4,7&UEGN6"U!X0+'I3@%'X=6P.L&)&Y8"%QA:*CN;V3CU)83;Q,(>
MR3GE\J(?'8"3T(J"-V]-+87?FIH,)@:AHN#FV%04[X^OVWUWS#P^4-%0.C]X
ME\SPY]\%@L.2W2R,*EJ`\/8VF2>KY;@``1B`*+;=*93!@+/0>H2W]]@%,&SZ
M!!@\P`BV.X4R&'`66I[PID[/W(OS,%9W!H0J;='9?.EYO#$RIU`$TI^%EC"\
MO=WG16UC7,X`)#9?10L<3J$,$IR%5C>\?:V@(/QL+@88@"BVW2F4P8"ST&*G
M+?S,"F4R_"0KW$=2!<;S>&-DJISQ_%EH/<3;5RTJP\^6`P`IL-\"AU,H@^19
M#BN5VL)/%;*?3>L``Q#%MCN%,AAP%EHY\?;U$HZLEZC"S51LC>3P>:@Q**=0
MA,^?A=54O'GM)3E)\0(*3=Q2I>VW5.E\2Y7TX9:J648*;\Y]F!Z.I\F7.Z_;
MWZ;DVW.F;*").ZNT_<XJ+;RS2A-W5FG[G=62H;D;`LWXM.W.JC['#VU?_O`Q
M;[L%LA')6^\VC2)3L)2W9.9@3-$3`#;UT<3-5MI^L[5@.FRF0Z9C*6]XH2N:
MCN6[.&I#^MP3E9@;EO*61%4Y&\I?!%AR:9L-57AQ6.*GB?NOM/'^*XEF8_$C
M!7Q(N<#R+,7OP-+F.[!)!V2;-5//NP;8'.WA:&Z`X;"@`3::6`-\(:_*"&1N
M@,7\*C4;X4WJ_SP=/^[.N^.ATRDAG1&R/1Z@]XZ80<]M+QR6M+U&%4LVL;PJ
MV8BQK.WU,`!1;+M3*&Y[K;E(XHKE58FK!(8A=@^#!QC!=J=0W/8:52P)>GGU
MJCR=8305?B9C`#X/-0;E%(H[7BS:UO*J1?NB:=*)R\-@\T6SL-TI%'>YUEPD
M+\?RJKQ<`L,D+@\#$,6V.X7B+A>+MJ6\84D?C39:\5X9X/-08U"JG-O\65C=
MT#A-[M2":=*)V<,(W+:PW2D4-[4HC)6\JNXH@6'2LX<!B&+;G4)Q4VNC"JEA
MO+RAJ46C358TM8#/0XU!.87BIM:H(K51)*ZJC=*3%/>+8MY)1LP[R8BPDXQ(
M[R0C>KP?%NT[R8AY)QDVR-Z7/Y*;8U/__#2]VGVK,TVH"+O'B+![C$=D%!*(
MO!I:S_3-S;.'=+6>";O'B+![C`B[QXC,[C'"[1+#Z&4!`[O'U+:_]E2YOCJ^
MR54R81L9$;:1$6$;F20`4--)(P80Y"W]^Q+`9?\NDW?\;#8-^\B(L(\,Q(U5
M2(205T.+E+ZY^?<A5+,L+\(^,B+L(R/"/C*IV?!J>MQH-A;R:@SVU(IPLKDR
M;"@CPH8R(FPHDP0`:I?AM)"WK#^(U%X@:D.2SQVK0$@>TVS]?",_%4U>#2U"
M^N;%B]IHLEDV;"@CPH8R(FPHDYH,KW8930MY-89:<K+9,.PL(\+.,B+L+),$
M`&IZD!A`D+>LGZ``Q$;PW),((NPJ(\*N,A`^5B$125X-*S#ZUL67=&)S90#3
ML=6/B>339[B;Z$1&_*NKTA8!WXJ+#5<-P3+[]<Q^>_@:BYQUWPU*9#^GIA;+
M*;#!_(A!1H&/5&45Q-CG;52$YH?HB0FQG,(H\@J4FGG*:C#)KKC*_N)@7F,<
M\MZDDO`K=BBB9%ZC)_S:I+*!YC5&?@4M(YSG[6"4#_F99XR/^7EA7/`KWR'$
ME1!F4ERS0TEZY3MZR?+SHBMQ>664T?UR:N92L;]?F=6@BE_18'*\HL$5&_(:
M0JDKEDIU)9*Y,IM<9C5Z=86<^-!?N1KXV%^)($$&D;=4:([+7PVZT!_2L:Z)
M]L=_W+R[>?=/C5DHT0T*96YD<W1R96%M#65N9&]B:@TX-R`P(&]B:CP\+T-O
M;G1E;G1S(#@X(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E
M(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=
M+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@
M,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2
M/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^
M/@UE;F1O8FH-.#@@,"!O8FH\/"],96YG=&@@-3DW-2]&:6QT97(O1FQA=&5$
M96-O9&4^/G-T<F5A;0T*>)R]75MOY#:R?C?@_Z"'()@3V+TB15'2OFUNN\$!
M<G*R`^P^Y$7NIFV=],4C=8_C_/I3Q:NDIMBBQKT(,M,I%<6ZD?55B5*^_??M
MS:?;FW3%JSQ)\1_YJUSE3/VQWMW>$'F%))0GA$L*30A;514MDS*%*VG.DU;<
MWOPKV<M[%2S'&^5EB7\E[=/MS?/MS>,W>"O\IT=(5XQE,,&*97D&?V45I</K
M%<OQ>I45>+TL>>:_(4WN&4U)EI0D3<HBA;NB3(_S>#Z9BZF]2(E3ZMN/MS=_
M^;%^6(,)LN0C#)#&DC<UYN%HB:Q,/NY0;))6\'-]>W,/2N7X^_7VYL/'0_+Z
M7!^3C7AJA4@.IS;9BV/2U5O1)8_M89<<GT5R%'\<&Z3LZO9WN/S:;+?)^K`_
M-OL37#W`\/6VV8NDV4O^Q]/QU`K%MA$O8K])]H=C<MAOW^`/8($9U:W^*_GX
M?[<W/X`V__LN.A>4.:69U/?#;Y32]Y^G'!BWY,P8E\O?:-PNV;SMZUVS[NZ2
M]Q:`0,CC(#4_9=PZ-T\+JN9_.!V3>ML=E,U%`EX4^R/ZZ_6Y63\G+VVS;O9/
M\+?H.G38NA7U46R2AS<9">O#[D4<F^.A[:RW016X&U[M3NLUC$.?;\1GL3V\
MX+WVXA7N=]B<UL<NJ<'QR%H_--OF^(8S7\4.*;-^R#)C!\98H>RP/;R*5@JB
M)6M`A?6A.W:KWRA+DW^)Y$%L&U!"*2:#7P8O&.:T$\E3>W@]/H/5Q'ZHX(-`
MG;7Z8#BY8O`>WY'D'S!!\E&LG_>'[>'I31D#W-!>PP9561@35"2W)LBI#L6C
MD:/!=7UHI1IJ"7;);VF>BM73*GDY;5^2KY.7^D6T=\!VV$BIZWVSJ[?)HQ`;
M8"6@]1,N]$-2KY^EU6"%BV-;2[LZ-8>AT.+N<)3_B1$&+%<*AZI(K2D*;DW!
M4Z),(?YHNB.Z;2BI-L8*H^&Y!J5V]49(GOY&MZM_%Q#Y#]VQ!B(8I=E_%MUQ
M!^NJ4TJ!9<!ZW6&_%]O>%,V^`?YC`]Q)U^S7XBJJ0\K2JN,&953'3"95__GP
M6>P>0!J*2P;4$7^\F#4JH_Y.F\&81[O/1#BJF8A'B!^]N$'9>O.YWLMMI!_W
M1U_<]X-P=17],VXVQ#2KG.O-A@RN[3NS.[V\@"I2<)WBDO6I.QYVX,"[9-.T
M8BU-@9OG7N!N5[=ON"G`"/@OO(?AMS=#=7_]^GLPS?[P62T)&3<0_/"OR:#=
M,RZ(:YB`5#;AN[TPXV8OE!FZ@1@43^C-%;CK%9P+R_U5+E#,U3(P1+MN.@%&
MZ-;-BTSN$#RM-$7]`H2UTNWP.+2'#R[@_J(R#DR\!LWK]5&TS9\JT\#N?!5#
MI-08@G`;"UE1Z5B`T'YL)`R!S<Q$,ZC?"9OW0#^YW[5B*U<NZJ<B^;EYPK_T
M/7#L%NX#%*WQ0<;""=<\IA*P[`:,W3R^K9*?#[!7/@LP#X086LOLPK@KU]>P
M1%GF-CT6;E4P@P'W)[DG@"<5_!OMVD^PN;?U%J";QW5[5%HES/7;>JN3"\`(
MV``[;3A<0(?D<]TVAQ-<ASL<<'D!?GA.:F3Z=(*5MDF>,,#V&)6PKU[##MS"
M-4ZL&8A."RTDM<XD,3``KG;1RXV^;)B(_9]O.R$QT`^G%B"`C!?DLEJ9+?38
M0KH`BQ[=%O/>.N:54_**V#>ON)WFP[L[*J\J>_>J6.4T`U7^E+XB6`I*9T$0
M(:+$Q05ANSMMC\U[RP$PWLE!5RQ%_`!R?+A_]YFJM!>;X#"[;>=5H3/W#M+6
M<[(YJ?@$K:^"(LO<%!0DI[TE0BL#I.5Z]^)%C/P[&?JPW:WKO=S<6@';@8"2
MX?$18=8A>3HUFQK13]VI.D0`(RC3/$K^3@SW'PG"#;J$_??YT`F'U)9:@$\6
M=;DUP?L'-MJ7F$(EK5QN9MK''[%R/FPA'\HMLWX`.`(&W`JT!&:*[R`OU?NW
M]Q:,9L1*=L5M@V9YSP`08*Y,(14U%;/K/D!^:?8;V"L!<F%200N\B1IJ4<`H
ML+%^#X!,)JX,X@X$RV7P262+`2J!#B0<('88FW]]]W`!ATHTL9,&8^F[WY^[
M^U\C&G->.*C(76\(?Z,SOOE)F1_+G!]DHDL,12S.79/*%L0*M%S;@*MR5GRA
MJZJP-3-3=E*>NV9,56E\\1V619"L_@XXHDO^>=ANKJ(E2;\\(`,-15:9"C-E
MW&UA::D7\(^]A3JU3N]D[P5M\21MT:$M7B$A0%W1'OX`='44@#:_(O2NS(N[
M-$UEBBC35?5;RG(<:'>).TPDB-=KQ%K7:2BP0E65H&A*<[M0J"VK/7)GF96[
MX*O"(_?C94LQS*>P"6);#O(>C!_-1!G.LDH^8D5G^9J]-?`UK)%7KKWB,$)>
M:&C6\RFZ%)LA:X3T3V)@`.EPU!];;%LI+.C:82F*X-H4";ILW*^WIXWXZ\`<
MNM>,#9@],,NZ7+2?/7:ZAA48M9F<LM[>J6NJKTC.5`34FXVL)$$KK&^>1;W1
M!>/#H55=2(]G`7+A<%5!J<B6M>)!5:&UA$G*2F^F7?L/0&?)?^,?&AZ_W26G
M??W0'=H'L7RW"5F!VLHR=5W'C.>ZQK8*]]0P0N\.&ZCVFC]KUXV5:T(UGO='
MK#0!ZNU/..#4RA9:\LMA*]M)Y_:JN#;W'KNP`NKSHS/N-51/;3%)*A<`)>7^
M/8$0Z4]9Y+N(@$)P_;OTZDYWYE5_X16V,P0O`DILU6CI<)4+;+X!'$2=H!@'
M,"Y+3\38S1,8\=2V8K^&E0"SJI8&!LT5M,\J6RA4O+<'5*:6QC5=JV:AE%>M
M5;,MN34K^ZNBE:TQC]<1""LO;L3^L&OV,HITM=UAF2'OL*O?U(..#LS0/#9`
M/X+5&T@+6'E?R0:%Q;(LI]8(D/V5$;`H1?<KK6';0N_(MDD/RP^?F+U_28-R
MYE^*4</`)\L,C$QS9H,AE[_1#G\'3W7)+ZI5=@5(DJ4&>,%][$H$-U0QD.1)
M2JD;>AXP`OF<<IO32;4BE['(U;,0+3.+3$AAX1AE>O\%J:NTM%+3;)4M1B*M
MP,>$V,7$9P/XQ'<*E90E-;!$))2NN)S3#H"(OX8I.+<[4ME[`&::G`/_XIXQ
M(/1`2H-$T*5M0)>->E"@]J[=`^X_NNEMU-GT((WL#KK-76U<9N$;+(,MU8WH
MUFUSI:1,F05HC%F`EE6,V"<`/X/(_[0BGU<FZ.WN!1]^?`:/KI*?CFB6*[8@
M,H#81NXKMB"R,NV;IV3,!8JI>CNH2L!Y\E"#?.AENU%R#75BNTWL(T1W"1>1
MZ>2#A96O58Q=P\>9?;A1$:>$_-U[N.'"6N7*!X$YL06XL9'/.=^]Q4/+OFBI
MZV1F.=7%DGG2_BKD4MC5OZ,A>XD;C?K4ZI,%B`;-`T=\VB8/*,#VHQY(/0X?
MQ+Q_"]BI<^T6\-"GN?,I,V!:/:ER3Q3>_?%!T1/B*@TG2DRYD/4R=5Z:%@E`
MH]Y)D@=Q/(K6]8)/G7G(/#C,@#O8N^\3@.*=L"J;H'3O/@_+>O,`C.P=7NDU
M%[9OJ/G9IH,+8G!RX=T?Q0#"[?F,,(5R/_0>8;[[0H`L-9C2':LB!M7H)PMF
M1]L#T,+C2_65#E60RE9ZA3M3P<PA*WF8K;]-R6<6^G#4XPF?FVZQ!`9GF;UW
M"GMT_X%J0.IPK08AWI\3LU]F:5&H_?(JE4=NYP+$FQ/K&DZYQGR_`EZM6\1<
M>X2T[@C+->S*R%4;KX3:1T<I+7I53E3CM>U;9'"HYX\7//J@,,ZO7W^/QT%:
M,4;V[*ZL*EM.9.FJ])035SGA9TM,XHYTT<(\#@[675`$<4I<$41T03+H1BZI
M@4*MV:L<:#$VX+V&4Y92TW&\HT6I"B\\?U0C>L=#EZ_2.GL\VR#A`^PQ\B&9
M[AINZ_7O4OZ-^'22[8KZI<$3&/98#T#%YO@\/O,)=Y,)N5_PZ)%Z!GFDZ`J&
M*,PC"-#7UC>%_(V&D(?W>D?TQMZ0W=L*4EL!%LWD[&X:>80;&+*<<\E`)QCD
MCA-B(/C8(,208O<TP``56T:##"4KTB!#P;(P`P><$63(65H%&=BE*;(L;(<,
M(&?X#B0+FQK`9$I"#+2"5!1D*"\Q%+C.0@R<EF&&'`O/$`.C)&@'FI$\+"3%
M@QHA!D*RH+MI2L)J0K69!N]`RK0(^H(4B`I"##RE+,@`BS>H)LFP`Q1D2//P
M%!3WI1`#2<-VJ"J>A:Z751:<H,"B*'"=ERRXJO(RO'?DZ84UA2>/@DNJ"ENP
MXN'K:1&8W[X?DU'0`BJAG3(*_-KJ7P7^4I?E3_WZS2=[.8/51*KX$QV<3N"X
MGE09-U(9`:TPN?PI&?*A7.8Z@:*JB)-+#N53P-WQ,V+-960<2J,8QH+IZ[!/
M$Y]@1:"`!61:\'18*"/4G!(0MWHE(',.[4FE&$8"FNNEWZ'%M.'D2#YU)*(G
M%[>&,R(.A5$,8[GT=4;C!</E/RG8O'M/.87A)J_OK2MV!+Q3JA<VF(T5AOHJ
MAK'JW`9SM.I\GD_RW,5*88.Y)XUB&`NFKP.^BPUF5E7>8&93`E960"/K4"K%
M,!+07&<3VU/`<GEOM7F#9L:])WL]N%_/#AH.`-ZH7CG5G;Z*8:RZO@Y"Q.[,
M<NB,H(&\:`0S,@ZE40PCP<SU$EMR<7;CF$<+]P0T5;7YAY]T:?B7L8^^:"[2
M"]#4O-_Q`8\[?J^?1^%11[2/?+%M(G_AI@@.P`RI17BTF5/3EV1..O6<>93/
MX=ZP;0QF[M$7Y<9L9M*&*<K1S)8<J[(<.4=GQN0,?#SS&7U^W[B"H-,GD"J^
MJC)\V>M/'0F>YZM?,A4KK);X*I4^\O5A<+9VP7R3V2$M9UF5Z6`=&=618]W)
M9H:P3,QP<SJ>V=&CIT9SS9F:E=[5TZ/'3SW3W-R_<'OTZ*GY3(,7:H7R8C3U
M&7W^@PVLDR/6SQ=,Q8HR?OW,F&\R46;5+*OF+)-3C(SJR-$9&D?.F3C7ZV0\
MLZ-'3UW,G!H[#T0^4QA.[>CQ4Q?SIJY2_]2.O@@2S9A:`@YTZ6CI]NBQ4_.9
M!N?:L"-7.W+\Q"%SZZ]QX+<Y,OD7OO5J`$^:]H&-`SR&/@$[0GWH-#_?03ZJ
M=U^_F2>8!"_XQ1(V%.R<'H>'M&01)I)H!F8L1X(X<J2!\%B@M5#_8>!7,P7"
MI`@S\[%$/7JL2-@W](E$R!W+V3RYF`Z:D5AGY#C@$>\PB3=@0CH6I$>/M`^3
MSO;8IZ`S94(TX0GG/CU6)CG4'I$PZ?.\-IV4B?N76)\>*Q.?L-/,T);I'4.X
M&(G4HT>*A._]^$,[N\OHS)"2*1SF'XEU1H[#!/&A+:$`AO!8D!X]UCX\]]NG
MG"L39AX,EVPD4X\>*U-1?%EH2P3@DZE'CY6IRKXHM"6HP%@9K;8^/5(DSH:K
M3;YQ8,`ZN2LYGRF:]M0HJ'KD6,&*089SQP//(/V@]<*Q\^-!(I8>CT3P777=
M%**I.QQ2I/JC'W]3GRSX48C--U-="JHD\"&1(3T*B1C)+G5F<`H/]!B0HSHS
MLR8&*($S^""&H<="C-+I/-R'[]*LN-#/\!CAC!P%*^88`?$"SN##$88>G;,G
MC%`$&AN^X.O3%^`&MRRF-]=AB\,KQ!D]JL4QRP>%"G4?(##T:$"0308B"04B
MYFR<TP,"!N0H$##'")C=9<!YLKZA1V=8XC<"#W0(I*\]6=[0%V3YN$#$].T5
MXHP>U2N8XP-,T]++GO1MZ+%9$I"7UP<TU#7P1.`9.:IK,*U]J&O`.?7G:D-?
MD*OM5Q?2,B_<.;Y<Y^I?U#=5?L%OJD1T$5`B;^X>T.-R-Y_Z8D*PBX`S^E)Y
MGQR7RA?(@1E<;KZ>S*[IT9D]MY*,-M225\G\YH''/F?DN"P?;Q^9W#GU)WU-
M7]`\\-LGHGG@B^(^?0D(<%\Y6=8\\,IT1H_#!`L\5J@EY(4(FKX$(O@C.N55
M1+F."1Z[*1[$T"?'(89X$TF@@,'K`Q":O@1`^$PTL^:4R1_CQ(<G-'T)GOB2
MF)98P"?3&3T.7L0[3*(*C!`?VM#T6+213^Q"99I&"*;=XT,@BR*:]YP6PE^X
MFT/P>R&'H2^`',R^P92[[U2SU'P6]7_P?2KUJ</<?'.K$?+)9+!=`!)Y(<>`
M'@<YV-0AQU&[`*;P88P^.0YCS)D8P8,L9CR@0M.7M`M8Z=N"LR*[U"XX-\(9
M.0Y(S#""1`CXVJ(/.6CZDG:!SPA5J%W@";X^?0E2<,MD;KO`)\09/0X:S/%!
MH4+=BP4T?0D6F`C$++_4+L`VOR?Y]\EQR7^&$616QX#S97M-7Y+M?48H0^T"
M]+4OO6OZDO0>%8@R^?J$.*/'Y?,9/I")&KWL2^":OJ1=X/-!-N4$KHWM2]:+
M(I#W7!!3<V+^@EU0O:N`O[;Z%S.O!^B?]G\E$F@\`*<7!1CZ`A1`S8<OTDI_
MQ>[#M\VA6S=BOQ81];W2T:@[5$TQS-+2C/)"B`$]#D)H-4.GA&7&UFIHC:SL
M5/Z4#'26&GI4F5`RAB-T<<N#3H)IR\^(C3>CSU!RQ3!/"3V*C[5P]&AH4Q&K
MQC"CY!XD[K1"'*&T8FX9]511#+.T,J-&2CGR(I`TQS6()K026I^AY(IAGA)Z
M%!UKX>CQ8"?MNZ;W79.S#YO,F"5TM-0:*YFR%+=!;(PV-(]BF&<I/0H/D9,Q
M+*3+&TAT1K'M%"KL#FET&VJA&.8II$>=*>3HBR#FC`B6*$RK4=@=LB>[8IBG
MAAX%L'2HAJ-'HZ2,)M[-Q?LJU9?,D\]>*5\PB[3EU+>/9]QX&DOSRTM0`F;E
M:N/UH7\5PRQ7FU$C3SORHFI@3KPB9M-*Y';'[4FN&.8IH4?1L1:.OJBR\,7K
MI#Z5<XI6;:B$8IBGCQY%LI$^CKZH2HG:%V5)H!6JG(.<%HIAGD)ZU)E"CKZH
MXID19]S%F=%H*#N?'V=F5#':WGOT1>W/>-"%+\49K5RT]511#/.TTJ-&B\>1
M%Y5CDZX9]$[S4O5(L\+,/.Q8YNH81V;+C6%)@-^OU24!_M0E`0[2P%K_-"88
M#BZI'5Q2-SAS@[/>X&$_$Z^5/;$_]<E+3E[C_^KRTAF^025A=-=F&"HL&29T
M5]>H'5S2D<),.\:KNV;C8^4=?<DA;Z_V)+\KRRQ0=F@3&&L,]98,4R:0UZ@=
M7-*1WHK!;P+#-K*`(R\I4HP!+A4I1F6M_5!/R3"ELKQ&[>"2CO14#!,J:S8Z
MUMG1XY\^IQ->3T/O_!O]M2F&2DN&*?VYC7ICBJ'2BF%"?\V&6U$Q*E2&]+AB
M:_*D];Q[AXH@8]OY19`Q+7>KR=E3,DR9MN#6M-RM)F=/Q3!A6LUV9EI'7W+:
M/VH[1<QJM"]L*NFI+!DFM%?7J!U<TI'*BF%">\V&[PT6HTI+TY>\6.!?6/RN
M8%/'G(V0?3F&8%T;"#&U-I#\J0V$#%,&DM>H'5Q2-SAS@_T&,FQT9*`>/=I`
M^52^F=QY$&P:_;4IADI+ABG]*YMLC"F&2BN&"?TU&[Z&6(Q*`4U?4@K$[0Z(
M;XWZE7._TUDR3*BOKE$[N*0CG17#A/J:[4Q]1U_RPD34[L!=\!M##%7F@>#G
M+OB-(88J\T#P&[9BM#?VZ/'U1C[0GK+<O9M1YF6@WC`V<`N@I[ADF+)!:<$V
M=PN@I[ABF+"!9ANM?T=>\A)(SP*!ET#4`QS]V:_H;]/@:ZKF$+'^-`T;OK$H
MOP`7^N;6?17^\MH]34GPHV/W^*6](`-+R^!GR>YS$O[NV3TG9?##8??%A6^W
MW9,T#W\[[9X0G@6_?G9/*&7![Y_=DRRMPM8DC.07Y,A)^$MV]X03=D'2(JN"
M7Z*[!X->TK9BX6\30F3D:=CSE.1IV"^4RO?W0AQ9'OHJ''(P?DF.G-,+]^#X
MD>D@1\'#']:\IV41_N3D/:V*"Q$$J2*_P`'9]`('Q<]8!#DR_#!JD(,5%R(9
MW1*V:<;+-+SP08P+JR$KJPL1E%55^`N8L/]417@U,%)6T[$.V^@/_[Z]N;WY
M?Q!S)/@-"F5N9'-T<F5A;0UE;F1O8FH-.#D@,"!O8FH\/"]#;VYT96YT<R`Y
M,"`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA
M0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C
M97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C
M-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3
M971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J
M#3DP(#`@;V)J/#PO3&5N9W1H(#,X,30O1FEL=&5R+T9L871E1&5C;V1E/CYS
M=')E86T-"GB<S5M9D^.V$7Z?JOD/>'`E3DI2"(!GY6G7CF/G\+63X\$O$`5)
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M[E^W-W\`Z7YX/1W`2U8'M"JS20=):G40-O8XW_L*I10MD7M0QD"&CHS-H$YB
MD,TC\6HC6C12>^7LU4!.HC^HUGX%[XA&=P3'#I*(W4X-JFM%0[:C5JW4FG3G
M,\P^MO!`Z@VY@S>T5GK`Q1?1!0IM=<&SRNN"5T7I='%4^E(+#V;C8"`:ONUA
M[^_E(SG)TQ9,`R7$\WU7*QBK]JHF;W;W2G?](WG;B7[W>WS]J'IX77CS`16U
MXB#[%;PZ:+638![MT`MXTH@M&!ZJ3D\S+J"&JBR<%I("G-EK@1=6";`?#8<M
MV@$,]>&HZB.L@-^`&&@4TSG*C^`Q8`;H+^@#Z!7H-*K;H>V+,\C\T1O-9QG-
M5PG`$XZ>1$4_T^/YW%@+@%FVHA%M+7$&G'0)!12)5T!)@TOP-+U$A6=D*')F
M9``S$</0J^TXB&TCT1*\@1C@\%!AU0=6,+8[V0]=]YX\*`"-X=A+Z?%!P3.$
M'H0,L,`>O$GTPZ.9:0GI$?T<*):YD?YS7+`%D]Z\]GHYA",(4M[I:#DY76:U
M_4U+OI+;?A3@-19605T*(4$,QG$.LNU.X`E:?AAE6R-`>U\RNGP#`VK0XT#>
MJLYX3NT.Q(R71L=?4'+L`%BZ_B!:I4_6U.#;!11<0OQU`J=!7IBTL@(_)X?0
M``.G<R.-R$<IC`/I^BAW8R,-&/]5]&!*J*$-^8<$)4%0\;:G=@8N'H,1MAU@
M&$YYDGVM1`.V.VJY'QO4IH7L%1G/W2(P6Y8L''C^#,HZ20%#C(<9R7MY!"A1
M]R!3VW:#\$\1`8P!2&,7B#BU"4?;9Z07@"O]09)[T2L)#@3O7U/$<!3#(CK(
M,Z^#HIR,(*6.>9CC`ZGO53=JW%0K[H5JO$AC@%Y][,9F1PX81&&<BX]HTF*K
M&@528IRM:]G`P0_6V#VEF',1&\AM9/9<18'>03]+P6R9>O:55#D+=I!5#F=A
M2\JX*T"_QT+PR*_13^\F5H+QXB3>.W\9I.<7LOWY\01OXO,=6$X/B`W\X[W$
MN`48WHR&S)V/HC^)6HZ#JH&/K(")?1Q4@RSL/#9GRU[$&2/R$CK@GGT!`0VA
MAE6I0S\`HQ/XZU[*G66%^Z[;;<A/+$T6@.*B\OPGH6D>=E/D$Q9_*6O#;AP6
MHVE\`?XI6J!]6H\`3S2GJPPFTZ!8>W#H7N"N>NCJ]VB.=]]^1WX8A;%.>/P7
MM9?DIR1+X*3`#<&*W[?=`S`);49^.T(@-?Z^$`4N"L]W:%GQX(N\<K[X%:B<
M_"BU-`C[3:L'-8R#A!U3W/6K[PC<PF_)A=^?&..OO@QDBWZ9JMAPQF&QGV$Q
MT/FKKU4FSXB4OOXR^202V_`<Z*81"8]J`?>M\KGM%,6400*0>ZZ(_!UY?&]C
M%M@X.#*XPX%T!F2!T;4';1QID/U)M1>Q[8NN._M7WP#(2PO6+0PU=!N\Z<UX
M&`$1*5L$H(H\"<&:3R#M,1I0@$.L'1ZD;.=@``@+P42/6Q!=`75;D2\?Q0Y8
MVK=_,6Z,C@U[KYUXDG0VG?P(L&S"_%9`($->@Y->I%P0G\T4%LL1PD%77ZO#
M<1'Q4T^&:58$\5-:N63H[MAWX^%X'@=(\^!X6MS/NT<]R),F$%(:];.I&(SM
M`6#<LTN7`!\Q0QZ4WD-VY]E.TQB^OP6B9U/@_4QS%COGT4L0R`TA23R+1\,-
MEE`!RT,V5*93-E0Z$\#XVGMTU+*_5S7`?H\)"]KH]M$?]B2'.]99\H0N,=J2
MR&>\*#")LA3<!@TDP/>BP?"RM?485U41JG>&8)_C!$OH(`F4/<N*B;-GA2\,
M!,M_[=5+'E9/`W2R5U^EF,M(Z43+"^YHN;Z,X^X$=L9Y(<8WG0:#W)`W6-#9
MJ>'9[-@DQ[9:8-RB[T[$%%7`BEOMW,#X/1JX+2@$VUHH_.=52$>R2>Z4EH[T
M7+!D5]'P!ES7]M!1&,3YKE$[DY9J2%$,5EOFZC%<AUK((\A$T$=V$Z7B$*1L
M`K<`M\NS+`3&!*.6"8Q+\$@>UD)3*@*CXF7B5/IF^%3H%2E6&>,OT4:3$('.
M6DR`P1!@D*F0#6*JR7X*/J:L`B`Y/\,E3"C4D6F6T\F$'#J(YP,W&-&?QL94
M-=*5K56(BP+/$.J=%S2[-0DLY(67KC&7,1284"TP*63,S4+0F+OZ,7#(/"TJ
M8U=KI$/()XWTER!`-R4YJ:8Q`>]>NLI@_MH[8_!:V!H#J$ZH-?GUZZ^4AI4@
M1B;!WEGN60*8,1RNJWRZ2X1W\CPX#TB,!^0VX$W&@D$/<E$+$A@_G[A,CJ80
MOESB:$,Y/$FS2:S*7X^@X6[(WXR//:%IDQA/<T38Q8?1U+RQCF$8DEP%/C0W
M_Z.M>IW4,-C16(W`BK@``X*\>#RA2=,-!7K5-*\M?X$XYA2PK`$5>3&ME$$2
MBG_C2H,Z+<+HLE#@I[R<(A[D_*[P`@<$;`J/\>W=C_ZV00.<@`D38\S65C])
M;?`,\=['`[&+XQIL/%G!?S-TGUG%KR^IQ<I3/3$@7"2+J""4^"DDHE.$8DX%
M#J&L87[&LL0P%PQ*0A]]V1[L\RS4SA9*Y4=9C_/4[5EOV)"WG:GORXFO#H'F
MNOAFIP=7@8,`W`;+7Z@"EX52/YU(+6<N2E]NT!^I<\)=<-E/M(.A^44"]PR;
M6EVG4TO(SL.U0S+=>_(2*Y&&[OY_,3C8<>KN#5Z'P56QTE!8RR0YH3Y=E(E+
M!MZ%F]V_AC3\OQ4YCXA<V&TL0U03DN8LQ.V23@7/)/>EO^MGO9I=<T\U"6?;
MVEW$7'(@MBJ3"GUF16`!6FR*GR#"FOL(2&3-="MS[2%<G%S"FE++T=<8W:=;
M3L8":WW"VU9E5DQ[AK!K]OP+O`'(;2_/B`*M48UH2>0*M<J8S_YM(F@'PM]+
M*($%XIXDT]UCSAW#>>D2%RLV77]QCS"7"O`,#A%OF:Q9/(@#_(7%XFE\+^M^
M5(,!PKV4&FN4SZ@CK4H#KKM1^D#@;]@740@-W2!TU@V2I`X5T415ZSL[Y.G<
M=(\R!'I;D?H[Q`GR/9RWN7A[]5VRDH=M+LSL@2?-%)(G4P&0.1PDW_L[HN_M
M'=&L_>%IXP9B0=/@YVR0::_!FR>GTN`I$&WNC6*7.&8>+GHN$];2X1Y>M;W1
M"FQZ*N$ZCT16/N_WF'JD#%>'?!5I$PA^[_JB3,X["-4:4Z\[;2/J4TC,TB=V
MKB=+UPMA()^J]Q4+]UV0ZV136<\>"\!<+0WIO=@64AUATI7`DT!?V!NC!!9R
MX00'RR%,+QBHZ[)GS%X!N&X&<][8$02J@T@"B8Y6V)_P+:3)_LHM740-4XT_
M9\7L$L-IH<-H9K:+77`V.DV1SK5WO72C_-]3H0@OX&FR'"_`^1G_GU$MOQ86
M#-*09>?A^O&/LC4Q!_7\9H>9KQYZ8RV+:#;ABS(N5N93I61B7'G._Q/&=9CI
M1%SJ)$J\LA5G-)`8SC=9C'@M8%@LKP+K8B'U9IQ5P=>>;)FOBAGO8A#P/MGR
MZY,PO,%/9S1L"4UD@7I7TY4*STKVI,LNTDOWOZ-A%2_FX6D)??"I9EY.^BC*
MV1538'XFV&"+X)R!&1/XV^;=YO*"\(NCDGORE6I%BQU.Y#MLJS%4!51BR-S%
M)%_CU?2?.[S*N1[MEM`##92\I/-@Y//RI0,LVM<@]A<5*M^5*6?3+R%[$LAF
MD4]=83QWW00M.+76V`F)K<7NYASY)#F/VT;5Q-5/3*NTN5>3V,CG13;]-=@R
M:;J/S=6R`ONW+K3'X-Z-YFCW"*3P^7#L3JZ<$UI0K=U(41\7NE"@9:@Z5U/W
M<>8[*LR>D(0V1I0=(#_8^:CT$2DH;-;T3N_WLK?NW<A[X6I-_:"T<=^C!-(.
M[^SD_)`WY)O`9;%?71HN:[NOGJ.LI6M87D('^=22E$W$-'7T'*02KB:.-;/1
M0/H*-'(0<[-W-3OBAX?0^.+%$C9MF*M8"S,X[HEIS=.8$Y!Z)/:+=4G2S!-3
M1OGLMPF>GV.-#ELA#3#A;PE<0+`;,OD7A@VK*11U'AI^`8>X;'?&]#A/.+;)
M)80;8:9=FU^W8%4E9\P,8"\,X%F11@>PC,=GH&E)HP.2M"QC`WB50;83&U"F
M97Q`D271/?`\S;/H@.S:$FD:UP/GO(C/P'A<U1R,JH@.2#CPTL@`5ET;4`*C
MB0XH.(\/R'D2U200J3RJ!Y:"]T0'<*SUQ`8P6D6/FU%Z1<R$YM$98`$6/0M@
M`SPJ!2V2,HD.`.>-B@EPD\8WF5(:7\)DB[$!++FB!YK0*C:@PI_G1)Z7"+F1
MY_`HZE9Y&0>//(D[589Y312=LJ@*><*BS\&6H^O3I'AY_Q^LBNP`8)>?!J3B
MY8"4XF\G?:YNH]'G:?8T1!11Z==5%C7!-:WBZEUS'X%>&I`F17R)C++H":\S
ML+$K0L0=:4T3S..B(TR6$QW!KGCC&KRMNK*/E+(H:*S!YZLK.\TYCY\I+?@U
M:4LLY\3/'>MML1'X$]7XL3":5E?F@&`1WRFDH=?VD6(G;'1$EL7CR1HB%KVR
M2I&G5^8H\RL6Q"KLP(D[4QYG`&M.\SA/67-6L/A.@:A<L62>%G&RLP:F$L?-
M-<^+*][`B_**!?&RBO.Z-:^J>'P"_"G3EVT=0/(/_[R]N;WY-Y4FHM,-"F5N
M9'-T<F5A;0UE;F1O8FH-.3$@,"!O8FH\/"]#;VYT96YT<R`Y,B`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
M97AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3DR(#`@;V)J
M/#PO3&5N9W1H(#,Q,3@O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<
MO5M+<^,V$KZ[RO\!AQRR6Y(63X(XSF2=W=F=/';C5'+(A:(@B0E%>DC*C_GU
MVPT0I&39D#,VMZ9F1A9!`/WUZ^L&_/[7RXM/EQ=TD1A%*/YQG]*%DOZ??'=Y
MP=P31GA"6.*^X40D"V-X2E(*3ZB0I+&7%[^0RLVEI<*)5)KB?Z397%YL+R_6
M?\6I\,_!%W0AI8`%%E(H`?\)P_GQ<R,5/C="X_,T3<33$W(R%\8HV!*C)-44
M9L4]K5\VYE-X*(>'G(U"O;^^O/C;M]DR-X0)<@TO.+#<I`$>QA&)E%SO<-M<
M,46N\\N+.5TH]_GN\N+K;^O&%IN*?+-O&EOE#^3J/M]FU<:2?V1%U9+?J*(?
MZ[:U+7QB,_*][<A?R/7OEQ=7L(/_O'R?3E61?3*_SZ]_XY).L(`Q?O[40>!6
M"7_?>C5X,ZQVM,YKUGI.Q8D<UJ(+JH0)&A8,'@4-DVYKR8/-&F*KE5V1O]O<
M[I:V(0(TRBE5,S?BFWIWDU4/I*ARM(85J4#9Z]Y`\F`@-AC(QAE(O2;9S4U3
MWQ>[K+/E`_F*Z1D%)\Q:DN.$.%%7?['11(S;I"Q(GN#'7G*![Z#D+Y2C=.;]
MA""<22?)^CR"<@:[OVEL:ZNNJ#8D(RN;-S9K+<X[A>RH7B<[4X('V26#T.1D
M?RP*[!-$69#K;0%Z\8+#)Q0+=KTO.R<_:;?%N@,#<`]@AINZZ8JZPH=M5@)*
M79-5;9;CERVJU=[?`")%MV_LHV?;K".@?`"BJG=%!1M930*$U`&(-!V!D(8%
M(P"Q3I2?U_N;$C9T5W1;)VM7[%!O("?^U-JN*^T.E!F^.91M0=Z1,FL`P0-X
MZGU#EONVJ&S;.F3[%\(B80M30"!H@$!J-MH"AE2$(-^W7;VS34NR:D5N05\U
M?`9@3F`9=-6+F>=ULP)<RH<969?[O-O[1T^^/#A4`[IN9V`^8'Y-`>;7V#)S
M;@$&@V!.@0$^[,T@,:,9Z!Z#JWU3STB>560#;MG!I@J(37GG]I/MZKU7]8E0
MFR$+ED,6)'?H-'F]J8K/UD&Q=_9_8YNB7K6/Q6T?6\\OX!0UJ>INYA0R`1JI
M24+6%P,6/1+;[-;"XKV(';DI,^?*,PAMFVQCX[K=VM7&B78HT03Y.M7)*_E`
MG!BER@2$.!OL11FT'43I!U!<0SY4D,*L4_\5!KK6.OU/(:\PK^<_,7F!Q>+\
MAB\$U1`R/T^%K1K6`E\T^M`7>VP_5)V%I-.1'M,IX*1\4CAUJMS\>J'5VS'*
MYQ:$ZB4L"$!2K@:GYD)S#^ICIDE>QON*H`OK=4'N@+<](@^:L:<8W:-1RJ2G
M;&D*Z).![XXP&-;;U@OI684D=^!GCPDL$P=D:1B(R*SV]B"O]>EL&-'S)D@G
M0`L^9X$:3`&"&JBO&E.^X#WI6=K*KHN\R$K06'4+J1^WLH;$!WGJ::J;H,@S
MU/'*MGE3+`'&I2WKNP7Y,0-QLA+&U>LU4B.7`!";\-X!!.TA]RVJT<"F0$$$
M$@P^(0=C2!/=&T-OTZ?R&N[%O=L6^=8G;.OX;`;JGW&NG%20HD'=V4.V+&U0
M]G=9\P=YMR!7NZQ<9\V27#=`KSS=10L!BI';$KDE"#^D372**0!@>H@*B=)C
M5)!]"202/4O!83Z`$;2=([0_5T7G"-SW]:UW$G20Q11)+3%ZNBB<4)*D`_%-
M:#HD&LYU2#1H_I5U-&7D^M]9X.Z-XUY0\0!I\R[AK6!U1&U\8?R^*5:@Q(\U
MQ(T=^E#1`5>&P6Z.QR/NL@9F`(SOP/"GT'J2B,'L)1O-7O4]G5V]*M:%M\`C
M)>-VG8MG?=$W0RI[5Y3E`9\]]A20)UM!?0=@0##Y2BC:^_MIYNBV3;W?>(@K
M>W>,U&P2(&0RF#\=FEM<J3X9_"NK]EGS0'P2T%#0E&U]@LKLBYT^[N]/^-X4
M&'`S%#YC0I22]C[@W3W8Z4$V@#26H^%7!P^Z`H5&!'RJZ\5_)':8[%LP\[QH
M\SK`@?8^&!^\NR[NGUQU$AQ8()U4CY%0"*PC7$.D`^N%G[%*(^T62,P8_=$5
MO`(S$DV=3V02I7R3",1=#JG?BQ_UD`D@4$8%""@=.X'NLXL+1Z$+1#GQCPER
M@-)JTD).J71HA.$^O-")^^QSP.!]?34WA9#B#;K7D42G.!L#G4['2"?UGVGR
M#@99>"2>X/I<FA=P_<0\UQB=PJSIP/(.-"R8Z-/=*\E^2CW9__`(G/`.TN!-
M454X54_PU_6^`2[Q"9P'WL%)778]B)@3P"!3/00X>4#Y9<_YL<D-DN76KEJR
M;NI=W\,M;M';;\HL#PW--5`>$`;U6]H^\($&`8U'>=''1Q?6W?MN9+N%$/?V
M-BX&`0U?2$J9;U',WWXE?0BE,$/.%"HT3$&I.Q`U!`[LA';'_C2%?G4@LU3*
M=-0O[P.9=^',<;5=5CA['/3M=.1W[+6TJRO[`!2L^0///O;5JOWRZ![;M!#_
MM[926,NQ_;'3;T(<^+&I;PN?K>NA=7>=W0.7F2#DR[[A/%7(%T,+EVDVUC9`
M:+RTOU@2.KDW1X+_O/AI$6)8YZ3/T#[\Z.%(K`8:Y)O4_?$7DA^PK=##[N,G
MC$2VYU980>#;PY#;K/3'`%,8E-!F<,WQ3(_#K#V-*\OZ#BDWB.5Z\]W!&9;K
M2V3W/8=#OWU97G3HK`[.B4;X#L`]S1V)IWY3P)`,;-8<]'=4VMMZ)#<S^N)#
MRP7Y8=^0=VT!*;+=+]MB52`=]+;A;>*?-6#Z;_C''5MD6#\Y0^KMIS\+F@(!
MJ09O%V-=PP/C^;$N70$/?Z]!S.\M-NSQJ_89J5SMZSH\I06+!U#N.[#PF3NY
M@]F*=GLX?`,VU+C,V=1H2^.!)EB%JPT]&2@:\*`<JH4I,.#CT;Y6(_,)SO`[
MT/EV581SI>O#7J1C`(Z6@,QHYF.=,S8PW2`D#L?A`(K:!B``$[K+&@@&^ZXH
M75&S?'!HG6"[VCM&X9:;`@<6NIV,TX$!2AJ:ODXU$!<L>@3JR@+'`51NO0L[
M-?9;=$/1)R8I=KAADQ8[7(^G_EJ,Q8[NVWUX.P=OZTPBFY*3)CPN1E+&^-C5
M8OP+[[&\]1X%%'EADS(<^G#^YLM(?H0%9:>5?.N<UKGJ$S4<9`#%E&]P'R6*
M\:V37#:!UW(^$%HS=B.4Z67X*IG1],_DJN/3&(B^1QB<G,R$D2Y!C?&M[\7X
MEE@XJ%CYVRV3\'I.QYL)7(\-NM"DQKT7;;YO<1O9$BHPEVJ7MBPL!C!WL-!W
M:?,:2UI?9CHJ-V#@Q?2M5P#153#A6L*`RM+FV=Y7P1C&\>2_@D5+6*?L6^`M
MO`TUWP0XL'0@M"(=3X5I.+/R^H"=U#>N3G79?6P]^WQ<]E_OH/YI.U0I0'1P
M!ZE/TPZL)6(!1+'%#(7FGX,S[&K7_$*@\#5W/V?3U'=0SO?X756?'U[1)8HA
MD(QW#L9.%3V0_WU1_Y07UM';]_UE(ON*RNVY<`[AELG^PL&739[&)16!OO)D
MO(VC6+A=\;'XM`?JT#E61K[);HH.5/M?VX)9@NQOGKT@+8<M?:&\9ZZOLE=-
M'D_Z0U?7T4$/I:9]QA^PRZ!(@?#V#FD/^,SCHM<W&+@AVD!MZ?8P+N;N+<,`
ME<#V<`!_9H!$IA$;()2(S\!E2J,#&#9G8@.HXBHV0`#:\0&IHM$]""T3&1V0
MG%M"R3@.0@H=GT&(.-2""Y5$!S`L(F,#Z)D!W`@5U05/L1T1&Z`%C2+)$YY$
M<>"*L_@F)4OC2T"]%%4WY^R,F(PE\1DHXU%=0``242E82K6)#M#X.PVQ`0F5
MT4TRQ6A\"4EU7`I!XSA`=<;2Z`!JTN@2$"JCSU-#HWZETWCTT#3N50GE40$4
ME5$,74T:=\KH^AR;J%$`]?/[^^2WZ!=@^HE$HR-WS"`F#D=I_9TVF9SDD*@-
MSDT\J,TYC8?%N3AC@G/)>!3@N30F/B!5(KZ$46E41W/\996HE<P9HS+J[W-P
M%1/?!H,J.(XV.*PYLU,EXD%ASA)Q3EH-&34^(I4RKG=F9-QOP#*D.6,[3/'X
M3CE79_8!.3/N_W,N53Q"S;E*V)E5DB0>Q>9<)V<LB*>).3/")"H^`L)U/!K.
M!=/QQ#477)^Q9"0J<4R%Q.N*T1%*G_$&D:1G+$C`PS,[30V/>X,P:23"00B\
M^O7RXO+B?[,FDB`-"F5N9'-T<F5A;0UE;F1O8FH-.3,@,"!O8FH\/"]#;VYT
M96YT<R`Y-"`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P
M+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]2
M97-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@
M4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^
M+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-
M96YD;V)J#3DT(#`@;V)J/#PO3&5N9W1H(#,Y-3,O1FEL=&5R+T9L871E1&5C
M;V1E/CYS=')E86T-"GB<O5M+<]RX$;ZK2O\!!U>R27$F(!Y\)"=[O:[:K6PV
MB95*#GN!2(P&NQQ2"W)&EG]]N@$2I!Z&'&=HNV3/B""!;G1__74W^.8_EQ>_
M75[0;59*0O&O^U1LI?#_5(?+B]1=20G+2)JYWS`BTVU9LH(4%*[0M"167U[\
MF[3N6;F0^"!9%/@?L3>7%_O+B]T?\5'X=_$+NA6"PP1;P26'_WC)V,/KI9!X
MO>0Y7B^*C#__0$8VO"@9K#NEI,@I/!77M/N\,;]-%]-PD:6S4&^N+B_^]$Y=
M5Z`"3J[@!J<L]]!)/2D#3?""7(&"\FTNR55U>?'-STS0Z></Y.J7RXOOX%G_
M.,N,H.8P8\FVG.8YN?KX:%+\(>>>.:/SS'2;<M@4E':#&U@*<G4'BWAOVDH3
M_.=V,%V;D&&OR;?=X5:U]V2O>K(SK8*K->ENM54XIB>WUAR4-<T]N3/#'KYV
ME=8UC+7=P3V@5XWN2;=S7^!R?:R&\;*!#]^U'^\/FKPY]J;5?9^<77*WRW#3
M)+DH@^0%?D;)]8=!VU8UY+JSMKLS[0TL9/X\K[8?NNK7?=?4VO9$M?4LW:W5
M.VTM*`=_776'0]<2_=O1#/>DU]71FL'H?ONETF6Q?:5>NF_6,%E07UF(K^LC
MTX1T2W.1A^WB1>:WZXFW?-^2OW4G?;C6EC!*10)63%15=;9&@_6F^?YXW5?6
M.-LFKV^LU@?=#GX;%?F[-2<U:/+3#K81-IW\J`^=A6O'`_F92HK6^U,U=#C%
M-`9^GY(:[JK#I374G^63-H0L@C9HF7MM>(&7OMJ#@9(\R5B9,"I`.R?=#R@L
M^5<+5IS`$E1C/J*4-[;K^]EKP9#5+7S[`$X]:'#J5TPF@LJ$4KHEK]O'SP)#
M;WO3#^[.KM6KR"_IY+Q!>L&][/U>63V!RRC^[_O)_9RWNOW%I>W,29][>0Q,
M<EH?`+IPKHB`OCG[3"5=:@*>%71!Y>@7]UI94JFF4=<-&+VR8+\#&3IR>[05
M`+AV>O@LG0WDE=S"=`#TXPUK["SGDSPRG>5)I1=GUUFB3]K>D^&N>V+%0:@:
M#-.Y.MAS<Y\0GA2I2#+*)@WT#U00D?I.@YRF[X_@T'B+LH.IS*U[!`#*&AI`
M8/<:@#_!MW/!O`J>0YTM++^%@&)!%2COTO/'Q>=IF@!F_<\*>&;;X<X5Y"[*
M,B`\GP,R%X67^['JG1XF9(8EWS8:41>N_'`$E/(0"`SE3C<-_L]$GN3\+`I`
M^%A#`P4+.R]G,I87(QD3)0!O]F42<-#D+`$R&0A_>'^C*A?TB+K12\T^L;"S
MTY0R"Q)_<_:GHSHSMBH'*H"6?%4.-$T('I+FP4-87A:?X$"OV\H`\B-:=FY7
M?]3V!C85[??Q!CM^](@Q*6!,=6V0'0$1YEF>%%GQ%'4=1CJ"`=/\J.ROY/66
M?'=0S4[9ZU4<A86LA=&9#!8TGR#2=L>;O1?Y\7JN[+$?4%C]`3RGO0$6`$$%
MAU9(#$%?C@T^"89M!U3P5MV[0#KI\_F'.VZIR+5J'-6$1ZVAA-13?)"<LC+`
M!6.3%EZE"6,C3?L>+*'6/O(OQ#H[(Z$BK$M,/L'8^:<IPC0@,><R$(6R3$<:
M.,6$Q68NS!^_CJD8!DBW3P.@:J\JG\36&C.#:TS>KL$KP!F>94_I5JZQN7DY
MISLLFX,A'WG0`?P:!7-HWK_`W$8&`"8/U+S53D!OH]Z&7;#D&",HF1YL]:EK
M3AA:/\ONUU!!'G*<$KY.*I!LW&#O:IB']5H#<L$J<UQ?=[0N!>D:X_,P7Z(P
M@&#]`+]P&9Y+T^Z`%1RZVNR,)W>0J1\K'TGU!VTKTV-UPL"O7++_2B`+@'&/
M@BEPS0"2$_E:0Q\9#3E?/NN#%J,^(#O#BL*]RSZ]19B>O+&F!HC[:P=8CO)B
M6:.MO;P_J/:(P2%-T`!RD`,R7UA7?VR&Y''2QP5'*,%$\1:&@!+1.%!6TU;6
M:14TO%/&DI-JCB&;6$,3@L^:",[!RGS,><*>3@ZK/!@HZ^7&93U=:&?-C<$X
M-]UE#@==&R_^M88@X4W#/[WR40+-KP;>:0^FA8=CQ<HKY0WPJE_/+7O.:!!^
MW=0R9V*A9H#P$<W?5_L.JUMK["J;\YYBKFEDQ<AN.E^E08=$)<,VZ"99:'S7
M-8VKS<%V]\>#&]W_F5C3GWT?.,O#<M?=!\[3A6(`M.98D)933FPU.B$8(=`R
M8D?OY]LR_9D*F9#:G##VU^3>:.!H<(WZ"_K#+00#,%N`>C#G!L$#KDIWV=?`
M5LEP<QHR/9DM!,KE5'H=UP6PHDR+6]J8G9.JV&8$2QJ]A]EY`+K@Y,FC`WN,
MAW@&WDO4H8/T\:,'@*`LG*EUR=-,&%M]1QY@Z99<K8-C6<E"D%]$.,Y'`@<K
M=/!;?PY:[54-<NJ6[(X0A5Z0MS[:R6U<@<B'A+>Z\NR?^X@@UDCZBB#V*DE?
MEJ^;]&7R*R=]TX18ZI3Y7.R4^:>2/BQ?0W8/^VB^$NN7(BQS3=8OBX4V&"^"
MRTB:_<^L/T[V73K80:)K^RGH0-1SG'D-HYJ[<-FBZ,G2L1<%OHN(.&WCE+JS
MTKLI+J_%RECC0;NJK.?[H]>/>2BD";ZV\RA;==1YTLX[BURYK[KEQ>=)]AJ*
MF)MRM!`+#C`JXC-Y/=8C=N8#;N<SI:])U!K0%)\T%C`^EQE/9O6`!ZZA"SJG
M@'E(<+F@(\L=E_'82C%1O=:MAJ6A:A:7=QJC&N9PP-0=3WK(\*44R/"_,&2N
MH`%9A`PP+P-/D.[SDXSG_+$*5S#VV;X\FI1Q"4/WAL^-K"(=&>^WJM^3=T!J
M5Q&-TW5%2^?LH0RR@5&/PKW#E/HG?V@`;/$U(/')]</7$%:4?#U6`'FY2T/'
M(#T+*R0;>Y(`'U;O&L]J3?MY-8H$<`EHW<EEV$=WCJ#I^EZ/9P\6!RY&.J=5
MM9_0J5'@J]@C&]FRQRX<M8*C"AD(O4CGQ@5E8\L*)&[U0"JTYV,_JB!LO9JW
M_FFO.4^*U-4P'6R_DDF9YNXK/`*@V:<IOEH]1DES@AL]9W>5":S2/;>`-?0@
M`J''%#$4)L24P3XC,A9EY@,S&)/&*/]X\;CW0>JGBA()<$*/WWL#=N">BRTS
M+$K!^%T/S[B^)^8`MYVP.-+97]>R!Q8:%1"[@QZP>>##N+HU6"TZJ%;=.&,_
M^R$87`65JZ8"O/C$J:VSHZD,<[GZ?B!&(J=B@::^,?,035<`.R[3.7V?25HZ
MD;1W8SLEDEG*Q$'@$Y\T08)''O+8V$7A,>%A8>_AJ#6VG(L9Z.;&$YY!'%LN
M-'4+V[VL`X$89?K9SY_Z-!<>ZZQN'$]=-![&`V8(*4"`$`0QK[EUOH38AUUJ
M^&E7:=7S-`_YBIRMD=-1#:%RBNUEB$^HC49!%A:$=4@VP8""H#;TGEG6!CEJ
M_Q>R[^[PH$>R``EB<+NQ\'QTH(;W]:[^UQ\!\2QJP(XGN*IP'F*UK(W34)#/
MRMD/Q-2@0`N_L=W=L/?1:#J0<5`U;,[B`,Z.O"JR-($?_-S@9D['R\Y>3\QY
M6'<64G5^_FG*,`WV)\?"Q3?OS7#V\U:\+)\129R]%`/19)H&$3_#Z.(0'U+.
M\Q]1Q1-/LX&E,E^X&1M!?P[TW?6@7`-BF96%OB96@RE-\'%SOW#L$*[@%ZP(
M[9ER4=Z5H3/KFI(/:@HE0MNW2T+\+A#B]X$0(V9\#Y])BCH/3G7`5AT,_"LZ
MSM\GK\(O[U6CYV.=H*7&W#@@?7NO:E.M=)")92$90*H6Y*=R*F+`DG%?:@"X
MIKOU:_.T'1W$`18>PP'VCEIBKJCA>/RBR>%R?^"$^-GGOV^GHB[`)-Q[;LDD
MET&T=9L>DI<+)=*,SJ?!4EHNSC5"\#-=G4S;:=RIU;VY-BZE0DIDSPXWN>1?
M20UH2J(,II3-?".3HQ9<$1//F$\6X>P'F1#$&5\#!AWU6`MU7X:]\CU+XVSJ
MF1,!RAU?1W/T2DW\<#_>/9BHW<XT+KI#6/=7S=AK&8\4.!IS`I<,C_G]*BU#
MQL.!.5Z&:O"(CF\Z95VWZRV0@FKHP'MPL0KB[R^='7M=QJ%*K9%YH!O6TUB/
MZF,J]J@HFL3._@#N_*FS;@.P1XZ5YKT*U,6"_^IZE3<:6!J2+E8N3X>-MN)%
MPUP0&P/3MP1SPB>BC$(@DNS4`1/3@^.N_18`&&5INV'-CH(HBR#/BAT%P-:%
MVB"N9G.=:BK=]*[TV3H/`7,X8D*.9]OOL-/6UHZ4CT#NH7>-EU7*T!]PYZ.G
M\I(<ZRM3'N`,T\Y'%>8CP/Y0?NT/RSJV[-OI/:90BOS2@9#D!&)B@1AVWL.%
M:RV.W!M]OW+-%=-[+_]$^/KR0FQ,`\7\MDX9#D6+*>'P"4\%X'3M<AX\`8`^
MJY,YCW!NB-IX6=C>U\"["E*($(W=JTJA3S28@]Y9==`/N?U*^Y]-:2<D_W-_
M2(9WE;`UK,*!'%6?5#M`TN1?9*E-O_@-[)0+$LO=<_FE.4VE)V.Q2@09.#:,
M/'Z?W?/PM;=1JC4='#2T4!Z?N^PRS<K)P7=';PD0URI/'/_YN[>D=6^_N#>W
ML$2QQK:*D$878C9J,9UX`6N#'++2O>]9@6VIIN\>N/)HNHU[5PVWT.$1^O;!
M?/0@X++KAX<'G`&H8:2*YK!"\P1?0F/_;_/D!?6E]*O5WZ:Y,*#.")R)@B_J
M;V/.$NEF8%6RH!DG>4D)=ZN8IW.OPL*`#)O<.(!]8H#,:!X=`"/B3^`2M!$;
MP/"896Q`*H&#Q@90?'TG,H"7DD?7@*]B%M$!^4M39"*N!RX%C3]!B+BJ.>=P
M,3:`\3*+#DA?&D`QXD4&L)+G\0$%YU%-LAP98VQ`AMPH-@#L)3Z%P#.$L0$\
M?4%,EI;Q)Z1I%MT+1M,L*@6L(.71`>"\43'3G.;11:99*N)32,2:V`"PV?@4
MG$H6'<`HBT]!RR(ZH"QYU+&*,@X?`,11M\II%I4@HT54B9+*Z'619G&WQC?O
MXJ86US#-/VTFOWD1_(`T?R86Y;$R)&S,5%\;3Z")_'&0B6/SIBRCTF^`94;%
MVW!:1O=_`Y@6'Y!C[A4;4"!WBPJ1RJ@;;%)*:=19-^!I<3O;@*O$\7V#WA9?
M*#@\C<+.)I7\!6'3C,>Q;9/F(FZS&R29\4T!@,WBSP#+*.(K90A@\1$,"WS1
M$5S&$6S#A"Q>F$5F<1_=L"Q[P8)8GF4OC"BR>%C;,/"$*!:!,^&)V.@(""MQ
M2^8LBT?P#0>2$/=Z+O(7O(&#TE_P^ZR(!\@-SXLB[@V\*"(1$`#NN_]<7EQ>
M_!?TAR.<#0IE;F1S=')E86T-96YD;V)J#3DU(#`@;V)J/#PO0V]N=&5N=',@
M.38@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I
M84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R
M8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B
M8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C
M4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B
M:@TY-B`P(&]B:CP\+TQE;F=T:"`S.#4Q+T9I;'1E<B]&;&%T941E8V]D93X^
M<W1R96%M#0IXG+5;VY+;QA%]WZK]AWE0Q4H*9#`78`:5)UFRJIQ28B=2RG[P
M"P@.EY!`@,)E5^NO3_=<`)#+';IDH61+*V(`3I\^W7VZ!_K^U]N;S[<W\3K-
M$A+C+_.36B?"_E8<;F^HN4()2PE-S2>,4+'.,J:(BN%*G*2DU;<WOY#:/$N*
M!!^4*(5_D/;N]F9_>[/[&SX*?\T^B-="</B"M>`)AS]XQMCI]4PD>#WC$J\K
ME?++#V1DQ646P^9I3)2,X:FXI]T?6_/97539>)'1R:CO/]S>_/UMOBD``DX^
MP`T&+/-0#P\%5&*NR(<#;AM`8>1#<7NS`J/2E)(/#[<W+]\V+>GWFCSJO"6Z
MWNHM>:,+?=CHEG`:$1;'242:H26U[DF1=WLR=+"HK,FNK/.Z*.L[DA=]>5_V
MI>[(0]Z1_'ALFR_E(>]U]4A>9"J*XS@B._BJLNL&N$F3HNGZ#LRI8-&6](W9
MQ$]%W^`7_Y5\^'A[\P.8^)]O!P3<9(&(J5`>""9E9H$`0P4YMN4];(@TNYUN
MP;(U>3/@G]<@$M$$#]A^7^*BS>,?AHB)2,D,85J3#_NR6P8!,-`AP&DV(I`A
M0Q"!_-`,=0\N0A@.>5O"SK:#1N<8PUHPNKP'PW9M<R#]0S/"=:QRP$/7X%'@
MA4&RU=U0]6@Y?(+8@+V%UML.L'UBO8QXQM%Z\K`OB[U!:`$$,B6G6,BF6%#"
M`G#,V[[,*]@2^+^#/8,'<_*"1@G0%W=WS!_12L-D9$2KM_IP[,NF1JN:H>_Z
MO-ZBT=T^!P3LIRUY#V2"O[T"UM?W&KYD4P%HK0:2P2-(US?%)P)WG@&S!`0R
MGJ)@I$#J``!38VH=@2:VVAL,=M1-#R;`!SEL?OVU6TL#6TOLUE[^QD3\5<_/
MPJ9S[DS''ZSE:8H_H^FO]WE]IPU_7R/9?VZZ$AW[]40,F4KYGS0UX.44[LI2
M[V61C;F.4^:,_443_>6(I(14O#7AN=5%J_/.(F#"'?EH?M"?!PCSRH3WT^!5
M$4^IH8P-_81`\!;-`8+))O:\ABOVX7C["ZHBY>Y8@.`*\[DU764CPWD2.]-]
M?G*)#:,8@K(;7!AO;;HW=L!FS>6GN0]CVCRER(]EGU>DS<ON+,M/.12^IAN.
MQZ;MS8T-`)_WIZO7WYQE,I,C%B^7X+!*LD7#50GFPU6`>O,!RV/FA(LMK0#^
MZP9RKO$>4O9="72%OT/J[I]*F6]..8PV>*RCG$SD2#FNW$Y_\FS![9E-8,!5
M30?1%D'%TS7&RZ:L@5X/9;]WES!J!E,?^GW;#'?[)];PR)59J\<@T/*B&`Z#
MU51;O2N+TN3N!>),*JLKP=(XBZFWFDJ1.C5QFB:X@(A75N&\,GGD@LPTA7#?
M5%O==M^9O`-NO""7:!(QR:RJS,?4=2$Y91'-I$DUS?TRNE)*.N+`Y<A31EEB
M<7@B%5'AZ6G3E^06IAW/D0M6T3A*``+$<H'`E@E=M#A)/LI0D4X=2:SH6)SV
M.4@A``)3ZP7S6423V)><YVL5?@CQT;=E@?%@KC]]&C=`8M$ZY^02;*&3`IV*
M4RK9V(,D:X+Y8JXE2V@Y-F!!K;N+S8.(&!7/&6$#R^`#9:[L$(ES-6<4/LC2
M'."<A^`R$,1>@=*4C>X73+D^['1G*$/?Z;X':V#7KR$;0D;+M_?80W;6+@R6
M[]MR>Z?)N\:*C6HPP/GN$K)B.Y@<"<\!0HPJ=HEJ`))R5-A\UF=F8J0W*"/,
M^(>R=[WO(?\$G];U`'P_E'5Y&`Z^U^C(`.YOSY1#9:5:?G?7ZCLG)LYHG2IL
M6PR`P(%T$5^FPNK,3(+:0A+_;HN`[R?.^[R4SX2BC,[W;%.ZNZS"E[/H0L/T
M@B566`(G(+ONP-UK@H!776-07P(#EHT%@&8CH9E(7`'X&D__W%0E9"L(V;X%
ME0BWU<,.?K#J-`>O:]^7G?N=JAE*Z3F(2P!`V9C/)\+S&*60:2HYC>=NO^0W
M&L];"&6<ML_OG>>TB5L3OPVYATK9#-T$0F=%$V;)(TYG`)9^7[9;8MIYB!+,
M;B`1!\#QOW]YLP0$29:,.6W20H+%C@*SM@!'!>#@C=[GU0YR?:VA.2CVDSG1
MJ;F`R#\'@,@.F4IG;#XST308>8>YW>3"U]A[U8]XI\<*DI[.V\+6R27LEVJD
M@)+39$DY"FSUO:Z:HZ$L^/VC+OK.S@-G5?X%72N(B:I")8^52+?WI<GR1KNA
M:2S]UIOG*AEWG[&UB-%]D,5>KK[]-V5SG+)TY`F7U$F?`\3[GF!CWFQQTHC!
M_EX?>U?.X\C%M)V2[:'<;S1T#_I+;\>20(0EO)N.DU.<=?M="]_?G.N-=$W^
M9S(9NNS-S/6O)HZ?$!4)"KK-S0N&OJS*W_54W.=4W]OAPI10W;1UHO@2``BO
M6"F=[)>I4RRXSSG#;2R:*3=(410>T(F>)[PU]`>.[+8A,/)L:PH\\-]-&*$_
M\&'@=`W\P*'M@?]G,\89FM\M,CE-F!PI@+V#IP"?U;C&B<=H9C78&7LSHU&E
M1UBH;4V`S4\CWV->;LEP;)#1NAC\7/59&JW)ST.+YPF];YJ6,)V.>I5GX]!8
M8"%S['^6X$\=-<>)/$"6MZ-ST[[KKFB;!P/2`R`&H6U.2Z;3D7D<`%I`=YP8
M;*<#B@6L%YE7LW0L[4+0S+O=ZA-4,S9K1>AUZ]&^/.">]>-HSA;!,>;`7V8=
MC@V`BT"2\G!L4.K:HQ5=YY4IHX8EYZ`L8;],1_OYU*W@":`?)^(N8.M^2EX#
M$!"]!Q/_P[4\N-&/C4MS<--.ER#Q["`#$N,SO#FGS)J\ZA>Q/<FF:C4)N^2Y
MO`]]IHP2QH-\=ZPU&K`]88')>6.V:[&B847P$)8SR3>6AC&/&'HL@<$XA:12
MI;,(</X_3F<DF,%PJE[[X]$!6=_T^RG)H<4NC9LE)[IL7D+<<R+B^`4=K$WO
MB!-6"N@/MJ:W!?1Z)X.7&?0)-DXW9]J6B\2=&KJF%$]*=G_@+'F1GILK=9&I
M&9\FL%`?#[HU`^-W"#>4CF*/`SC\R_N\TK.DTVRJ$MIJS#.N?8![,9[G/G*5
MJ;)<Q+2'?G(Z!E4Z^NZA(;_%2<S@-[J$=[BD8W6:,C17U'D'73%*A*)JS"D%
M[@@V]Z_<M!42]_8/LF\>P+@6*&>.@.OFI)OXYFHX3<>]VT'8R]\88]_\:V0\
M@X@E4W^:^+.PSHR%:B,V4'WB2!:#Z0$CN-X:_SNWVRP$.@XHWS]&=LH`I-<G
M<G8)+R>C`,VR*0OY=SC*;E2/YNP9^\GF:&,2QX7D8P,V$JQ1IKJTI,&M0SIJ
M\=#3L!E[2)-DS."AWU_D^ONRU[98S[2[1KEG9U`+B1#.O?K$P<]H?A)[`8[S
MP#['XUN32,MN]@EL';=]8HX9#);W?M9>MB@S<,X"''CSF&_+XEM;(9#OSHP%
M^2Z0[Q-:0LWX3E-/^-W@5,8.2JV!#.<BM7D[8YRD0VUJ($7Z*2N67YS%+.%>
M-BKLZ:T,P;S,F%/;\;;J=5L;#YKP1*X?H&6TI;+#-S=,"S*G+>I2$[XH2Q<I
M0DR-4IG&LS:1J=FY!G!.0XPU5C*<S[`ZS,!F&H*>::TW/H&"MO?H)]V>[3.P
MJ6RQL,$?A^Y4;FQ1(Y8;JS<6<!Y+TVF</QYI""[="/C?#6`/Z]!-4(5/M,MN
M/,*=J9BY/C(.`X75M/U7NBQ\QLR85[A,RG%NE5*O[MX.5ID"HF]MS/PTJ9T%
MCMY8_&?/U,,4-?-IIV;CJ8YPW\\!13>Z*C5F1E0T9X<.]EC:='/8^97UH/V<
M>4U^K$F^M>?P]GU!DT5L4@'G8RTU'_OD,W^L?^IFD?)!93+U<#,-+]SPHALV
MV(/@JU]F\'P"`8@ZLS43NMV`@5EBZ/HW/^:FS:0P!NY!:P>AE9/F@C_+]QK9
MH$<V.38-4'W,B7^]2#M'D_%-4"FG5I9G+L]VH($[<M]4PP%?2+%UT`S<-,"S
M05V`C1NI!R/H(29VE?YB7V6#]KN&?+4OC]W8LN#Q-JXZ.[NPA[(7VQX<?>,7
MP3*KNY=`0=`IY,=V)L$YL-,2'X>N)]U1^\-7L*;IO#WP7PTM3=?E+29?%$U[
M1Q;@]`8GVZ8JN1?_-@,(;CRVA9[=#<``#M`EKC$<VJG.3J773D#M('`)"-BH
M)M,IZPDFW40+.&Q5'AY3YC5&96U.&(86AQK1U"J<1(A'PK_9X$_<AWY7-0].
MB=KW55P5`U21&`V>-.-9P`3EP;,(J_6NS0_+)(9X/(V?=0:""A<1L/4*W\J9
MCJ,>=6_[`:RT<`FA(`>CMZW#44CI'?0$_932=DTQN/"^H*MK_0"T_QT$@6V@
M30-28Y>Q'<R;PTN\!3J^!)K%LW:9.@(4NJH&[!4+HL'%=5-%P(#6&&O=-CO0
M.D`7B4::6HY8_6A?(89B87+#"4<ZK3^-90*RY_1^M&^8O40S3C?`XQ?@^W6+
M4$".FBV1?`H%YI/!M%/;"[KL?1P@315(6O\*]&@)<+EHJBK?-*WM,6RS`;D?
MLV-$X#Y=FS;<C+NJR@D,_P)&KXL](-[<F=/""ZW:(B\+*H_$V;N"9@0<@Q27
MP!ENGCK=;OZY@YF1@MK#!>R9!6G*TN"")%'A)XB$\^`":)'CX`*&AV^A!28'
MA!;$21+<`\\P@D(+U)6O`-4<QH&GT!<%%R0B##47`D1F:`$')((+V+4%4&.#
MON`QSX(+6,:3()+0:]$@#DRR-+A)EC(>_HJ$B:"[F6!A,QEG-/P$1F70%XQ2
M%;8BIIR%%E`(WJ"95,59<)-40F,77)!2%K2")C2,`Q6QI,$%R)C@`IIEX05Q
ME@0C*\O"^2.CX;A2^/YBX+JD<1#%-);!ZPE5X10*&(6#D@?W!ZUGF"=Q('U^
M=E]A%D`.?%I\9&!F%4-E\4,$^P+M2Z'.JQ`+HK,"=(,46[%8!O%;L4R$%Z1"
MA;]")F$7K!3EP6A>J4P%6;S"?\,5W@2E5V)I15D<IOH*<DHX::RHX%=LA6HJ
MKNPCQ=8SN$+R+.P3JO"`+K@BPYEHF!GBRCX83=B59[`K^F3%>!).HRLFDG`F
M7K$DO4(@EJ;BR@J9QE=6J)0'4R6$2BK#.^5Q>H7)G*8JC"EG:1:L\2L.>NG*
M/H2\PB`.RO/*3E.5AJ.!2YD]SW7(7S_\>GMS>_-_%RI`P0T*96YD<W1R96%M
M#65N9&]B:@TY-R`P(&]B:CP\+T-O;G1E;G1S(#DX(#`@4B]4>7!E+U!A9V4O
M4&%R96YT(#$W-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=
M+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C
M,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@
M,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA
M9V5"+TEM86=E0R]);6%G94E=/CX^/@UE;F1O8FH-.3@@,"!O8FH\/"],96YG
M=&@@,SDY-"]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]6TESX\85
MOJM*_Z$/.4Q2(H->`>0V7J;B)!4G-5-E'WP!P:8(&P1D+)+E7Y_W>@4U4BNE
M(>RILDBB@>ZW?V_!5S]>7_UZ?95M52E)AO_,IV(KA?U??;J^HN8*)4P1JLPO
MC#"Y+4M6D"*#*YF09-#75S^0SCPKA^_P1Q8%_B'#[?75\?KJ\!=\%/Y;_)!M
MA>"PP59PR>$/+QD[OUX*B==+GN/UHE#\^0<RLN&J$"4I:$:*/(.GXID._]^:
M7_U%'BXR&HGZZM/UU5\_5+L:6,#))[C!,,L\U+.',N`$+\BG$QZ;<CCHI_KZ
M:H-$J9Q\>KB^>O=^OV^FIN^JEASF;M]TMS>D.9"QGV^/TPTY58^DZR>RTZ2Z
MKYJVVK7P:2)5V]Z0?GC^>M^120^GD1RJ^WXP/TT]F<<M^3`/TU$/-Z3J'DD5
MM]:_SLWT2`Y-5W4UG('\F7SZ^?KJ6R#ROY=C!=SD6,&0*XX5A72L0%J`CGW3
MSE-S;\X\3GW]R[%O]WH8\=![LM>[*9[3\"H0;MG5=/=]"[</>IR&IC:/JOM[
M#;=,P(+OYP'X`GL,9H>A:D:X7MTU$_#AX:@[TFF]UWOSK%78D`G/!E0\QP:1
M9\JRX5@-)]+#*7?SV'1Z!,+[.SU4$\H%B)K;:32L<%R`8]=]9T6Y??.)U<LG
M+@M[X'<_,9&]Z?E%DB/&%N#YI=@R*D!'?H>]OC\<+KT5*^-6;"NRS&VUN?1&
MG(>-LBW+<V6$_.ZKJ@5YZ;>)*+%=P1;;97G.['8?CUI/%]^,4KG8C=+2[?9^
M&*KN5I\T&-G%=;",#'VWBH:+_`LU/&'S*B,ESQS#N)#,F[PL\3.:_`_@]7KC
MQX\5>"MTSOT;]3_E?(H\G.0"!I#:J:0+FAFG(?")`C\CS3MG#:-1T^H"ZO.R
M.99+NCF8B*7[\MX2Q!NV>J.FIGUE`:;@N"H`C#FNYN8S<O7K`>)`#2'A?5WW
M<S>].98GCR'/SL'S(-V2NUC^G[YMZD;;0/7M.#6G:M(7=PP*[^*KFFXA/:&T
MC'2JK+1T?CIJ<C?HNPKC,^"N_H#!>`3J]T#P,D:/$_Q@]!O.`'`+(CE`,H0@
MI^H73;3GD>'8S_/^UJZ=CHCV#@==3_`94<U=/^"3JQ/*=\0=5T`I!5=>OIF4
M@6Z)GY'N:ASU!,BD;:I=TX+.:?@R:$!9LR-!_W:GNU$[V#;HUO!CWXQUVX\(
MOBRK4$.!4&(?:-8NG@EPK8/?`-%>FD991B+7=8:R5$MVPG\A`'#AS.6V1T/=
M56,#_'H`;;BOVAD89G#@&N*E9<"@9<2@DCDW$K1Q2R`VP;GL2:*2@JK7\S"@
MY)KNT`\GH_XWY-@`9!^,!T(%&!J-/AZE"G?<5T/3@\[WF(.@Q.?3'=[FM1R4
M8J?;!K1HCW:Q0VVO1DA0,(-9@PL9"US(HW&+PBDYY&-P3K2ZNAGJ^00F#-2`
MA*PA6B0.:OQP;.HC02Z8*T:,^!4M&^4:K;G:];.UXQHBWB->1$EK\YCG32#R
M!O'!"ES(D5S'!4HC%UR<!A%`1@;9XATX.93W8>A/3H20I0XU*LG[>II!Y)XG
MF#KM&W!:@UV-!$?=F4>0[^X1O9_EL%WJO$#0">!?R&N<'EKE6(4)*J3I:I&4
ML=P9!%)PZ-NV?T"9P;EJ.*[U^59BM0^\50R\=SX(6N^'.HU6=.I!F&-SVS4'
MN`.H7N@'.LYS1C6=8=^3(+.27\AE2-&55,%/"9^;OAK;_K;*J3C]'+Q]2;Q_
M,1608:]5\`1XW8O3\F*V^P?RC:W,-[8"WUZ$\)%O;T3P95J9J0B5`1H1O/F,
M)O8!O`/X!O*]K?F@?UDAXU7EE]9TTK!9Y:%$8+"R]Z=2A8S7I+I+-]A'BM$/
MCE4+/A#`(?YJ'>'!\<9XV,'@PX]F%421!E&#B39AU0Q8Y*2'T?MD7`!1!2+9
MT/]F?&R[2HE/*9_Z4J[$HN9;6.)+^A,6R)'(0IF/SJ-/_62BJ(/10#'+,KL0
M/@A$V..=-B7-]M&6,M^/#>#C<=Z-S;ZIAD<"T*/M:\^QO_<0A_[98Z44G_+@
MV#X]]"Z$KT&^X%'V(LK>(XIP6),T])U>'A@21SRH18QG5S#5^K?&0^,*$'U(
M*VU\Q8CK(FS3`0<!ASX2BZ,--!UTK9M[6T#'0.ZPW!H,8![M4Q&3)U[ZY.FN
M'\<&S]&<[JIF<(E>3V[[?O_0M"WY*9.9!946.8R>L*?2AH742K8%&5^:%"&S
M0,NZ.1+6+Q9<4R5?I)R6::TQ<(>1P9S;/28("_\!MHS\K">++ANP]Z&K7(-C
M#2EG/H?BBEG<_`XM%YL,*WAL691?Z+'3<4GF/AF2JA"NA(SMETOO!6[`[W4!
MI4IME"^(XED66DZ%^?Q@2O((L;_N3UBKL.#ZXJ)3,AQCE>*UE&S54"ZYSP^Y
M5"$G4)EZ$LH;R-V`F0^FE.MRF=[G]UC=OG@-!V0:3K>N?^(0QR(?&"M8+'DZ
M-NC37=L_:FTS_U$/]TWM2F$-(I:NP\`-"O;03$?2[Z:JZ3!DF8:F3_*J<8);
M[P'QM.115X/->U=P7I*&?#<K0M+/%TU(TT&M>W"OOX-4ESC-5?;.HBZ>'A7`
ME/0!S<!W6.':RDTW3L-\LJ[QN\YAF7,8]J>BS&\R$.A#-9J-!^S!^K*AVV$-
M1F0AXZ5%Q&IYZ<#*J=\;NGWB'=3;J?LSLD6)WKBB$*"QG48>59#U3X:5TW'`
MYKXAR`@?.#`/R*>]J?@=R#^J;D8H!Z$=6)4#T$.&PJ-LS7<5S"**T)5FT<IY
MF?F"[[FT>$[/I.74I!IMW-5C5!.GVXC!(3QWCZZ`$NL(H7I@8'!,`M".\$XT
M!*([U(=O`,.==NO`5A%[J(I%U,8<`[B5AMR2]U:4027,D`*IET'$TXY5O7/&
MY5'+JW;LE\SS<'^A]/;1WHLZE8/?UR!?AJ0EC],9P@RM^-+/W$ZH^[8`V@_-
M;=.9Z8-QBF709S2^OW=EU)B^>`=)L$;<(YHW6,.3>+#%/]P0'Q6\Z1X,!;X;
M-JW!`^XSEXRR8`3,(%-;"\4365$]D6O)C%Q-4^-S1;A!RWC0;;M=(4#S,@!G
M4[\+N38-`=K7%/=&#`=(.FS=V;KJ?D1YU.B$&E-V-$X=%G[55F_$?ZE86M)P
MY)6C=BD7S&%2!>;(3#GF?*R//580K(U=/*_)Y1]$J\C+,T50L9\AJ>LRW0V-
M&>Z"F*;M^)CSS75E?95U-[=#-')LUJTT#P8Q-O0=8H>1RWA6CR2\&[2']5'2
M'/-FV6O<GS4:]F=Z[EW0N=\A)L2DXO'6U!U6,80<@)=GPLKS&,!M%7I=2M'/
M&QS>#HQN8.=A7+0TGG;JSK/N17?Z>=Y['U,!>-J#8HTSQ`D,@-WBAOL>T61K
MQA`AB0?!K-?FP#$-Y^?+/((=D8<VQ^D$VF;4[N8)85B'&+UB6HH6]1J(?@!Z
M@6<.L9XJ"!'SR72ZA\IVR7`VTQ8B[=WK)$>*\4#GNMJE6+[@*,V+@!ZDY,63
M[`@K5L9F[S"8GH"A:\B7^>R&41:Q3.Z';G$*`9$T&6R/.P[AMH\F5!_LG*P9
M5YA'TZ_4;?]@>O/8BG43'`:+!03W`@3LGL%O,5E<@WKJ4YJL4$OM=JYUIP&W
MF=S3(DX5:L-X9F/)8./PU=0B9P0'S:EIJ]#_1_).&FP:<=O71QS<&GTH69BQ
ML]^E,=FB@&'MXEDK\("5(9U1<>).4#]Q9UW,>8MU%2=/!0^'6=G)BWQ)MER,
M*S'UK)>OL9;\3`'UB<>S7MQ.\;@4X%S5;0+0137Y+.U?1<2AQ<1X'$&3WL9C
M?FX@[PPQ7:]2F&7R2X='TX59>*JOOU'KR][]ZZW%_E2U-`L[K5R6%0N2J(A`
M50DONW^96O][6^N_N,C@9/X`JQ1D&<M6+<BR+/37`+_%4@W+0[XWZ/M&/QCW
MNT9C"&O:_A0K.S55+NDM8HE.2$X_[PS=@,'7[8SOT9!#\UOL&(4IJJ-N;7O1
MN'Z$8<BE6':Z,;\M.W/X4@C69(GM[F#.L,9[(45(WLH(663I!DWK&&;/AM'@
MASV6)[6E\&RTS)8+`U9%1BQ?&$+@@J5F\^9,-490LWLD'Y<UN0]AT.=+IXI?
M88$*'35\$<NUH$!6"),O;D@J[+?Z+`[L$_:26U'BS/+OMK:4Y:Z^]N]^"R%<
MO+&XFPHA5"XXRYA8`&+AX/E"KK[J^EVP`%3X;YKQKA]!`T`=UH@^6!1:B&/%
M\(-%H<B.%>//B_$/P-CB`%Q%=.H<&J:3'S^\_XCZ@/G2EGQW<$ES9YV0&8XT
M'N$9A[`*VJ(RU`_*Q<!_&&D`:*BQ'./3!@\?C2[ABXUC&,$Q4`QK3D=R@*0*
MI\CU."Y@&GCDR5PAG0:*1NR%X`"$Z9FYUE+3N7MMSN)3,<2G<>9T#3[$+J"*
MP4@R9TCSJ,_]K>G_@189L6'VOS>6Y-[6^\[5M^:3ORO-*C/=8YE5=2EG[WL(
M/BJNP8G00LS,9).#(:;7C:SPFA#S8SARC*L`3,;1ETGT;Q/^]/E@-%RIM=Z/
M3^K6=O8ISLT^Z1,&G0!Q'.8VUFQ6>9^3!M=*;1WSW1J8"_R$WVKE2G*VI&G1
M"BJ+YT9Q3$8/PK`#ZX_6#*L6Y7VFRTLE[HQ8QU!&>Z+$XYD)C0:VV2*C!2<^
M>?=UQ#5>#0A#FB*+[VMDLHCCX"!C\];&J<*69U?Y%QU`Q0?`558QSPBY(0L4
MM^]/Z"-K^RJO&UD$4^GZ$_P8)]_M=+F[[XQ2V[T&`>5E1K@A,=)B7H7'MF[.
M,[.`O;`@5P5++E!*I)\@<30IM4#@*S"I!5QQD5S`9)E>8*9,4PLR"4`KL0!@
M07H+7L@T'WB./?34`B72K.920&*56B!$3I,+^&L+&,@SN0`P1WI!)FB2DPSP
M09(/K.`L>4B6PS.2"Q0KD^)FDJ7)9(*I]!,XXTE9,$#2:2H@0!;)!1D6!Q,+
M:$E%\I"T8#2Y!<VQMY9:H&B:#U12EB<7B*Q,;\'Q#<+4`F!$TK)H5J8=",2K
MM&65E">)**A,\C''-D+BN@)]2EV7F-TG_5>1/!^G,FT0-.U`:9:_?/Y?G8\U
M"VC^3*S,4V@A(\(78AW\$>73.,63I]_0C"458$.+,KU`BK26;I1(.Z5-GN5)
M0]CDY2M4%&5:B$!F1I.6`"O*=`S94,9XTNUL*&>OD$H%2WN%#:@;3RKLAD+(
M?D5F.4\K/4A5T%=.6HI7SL$RS*>3*ZC(TW)A3&:O[,)EVH%LF)"OZ`][#2=M
MF))I?[]AN4P8LEE1*/K*24OUBB+S#/Q9>@55:8>WX9`>I\_!`2:D-0C`3!H'
M;+C$5U:3*U2>B./@G;[]\?KJ^NI_H&W0L@T*96YD<W1R96%M#65N9&]B:@TY
M.2`P(&]B:CP\+T-O;G1E;G1S(#$P,"`P(%(O5'EP92]086=E+U!A<F5N="`Q
M-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X
M6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P
M(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O
M1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G
M94,O26UA9V5)73X^/CX-96YD;V)J#3$P,"`P(&]B:CP\+TQE;F=T:"`S.34T
M+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IXG+U;37/<.)*]*T+_`8>)
M6,]&E98`"7X<W3/=&[Y,[T9[QG/H"\5"5;'-(LO\D%S^]?L2``'*+D$=MKCA
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MWOR,%?_OJ]@E9>H-*\1=$D6<O?\":[:O_J@T6F(H9,)G#&4B+89-_0`<RF%0
MX[#!3P+M5'Y4;#^-4Z_TG6$@1`;VV@O4/L:7[/HX=HA=7Y+29UI?MV?C4<$;
MAXZ\K#Z?535BQ54Y'-F^Z1X'^(U^[?L+#2A/W41KQ?>ZJ5_%A0A`O^YU71CG
MZ1(B+H2#*"ZRY)H+@=8`[Y75V/4#J[JI(70F7)L&$^]E0]%^PF[HZ[)9QOPJ
M#@9!S`&8ZL6_J8YE?U##W7<_+WW^>45N'O?F=Y%$WS5_$;2G2+/9G#Q)W7XJ
M,FZ<\?-#V4Q@)-`'0O!_NA&X$LK_W76[Q[IIV+L?ASMD?I+]H/D!=X)/BCBR
MYD<BSEPLZL]D_KN6E575]3OB8?98CT?VVR]O?V/_Z.X83\3F^VP.N$0DR6)1
M(I.%\TF>VPWBL">F^!4;I&?OVK%L#_4]LL1;O7%>/?83*=S"L)HHB5RT`"UA
M5O9[)".-#[#!9[XA^GU4X-UEBK*IC1)4V;;3ZGNVH)N&<-+"Y=TDCNRJ>_50
MJT=FJ?DPH_MXK*LCJP>BHJZJ2Z)I'0%$Q&^'&LL?IONAWM5E?[EC[X\8.JIA
M9'7[T#7$830=,15FQO6:*$ISUDZ!JTYUJ_2(^=8.+%?WC#:<_LH*2.1%.B.1
MY[%#(BELN%^S3$<9K;/JX*6^'@P5C,=RO+YT&*B'SRG,&417>W7N>BUPIK8>
M"36*CA+_#35DR[ZN2@0!$)].9V*=5;)TGA4S#$7A84BY#0CX;`<O8L%PZ2(V
MR;L;0(.P@++PQOODO6&[>J@H9;->>QMF]PK*HS4P:K<CX#4FR!B_J0<(OL;G
M-T"/=-(>E$U\:UB?"A<$D=\.B;!!L`!_86S5M=VIKA`%[:XVGNEZ@#2,Y7W=
MU..%`,.V5G`C]A#,:K7*VI"$@;L[S5-`M#W`[E\1:'Y+V-A8Q%"-AU0:6QUG
M]2J\D*,2L4!P+AWY9R(V0*C/E5([NX__7#B_U<D"OS>7#72Z)Y-%%!FYP!Z!
M*HGU'D^X8^_V3[C@"B3VRAHX"%^7Q%Z/)<E,CTL;B1`;2&AR3'L-&;BK;"^S
MWCZI<L!/;3@5+,/&*/(+*I=OZI8>LB\`V>L+K`SR8K;^S:OG<D";%5[KYD[K
MIF).Y>]:L*IB[\O/ZON9+J"?LHROJI\RF3@N\?(Q23++)1]LR3H'.E+?7O7:
MY>5GJ_%QLS$U+\*@5>.B"&ZZ83#Q1=3R6/:[@3ZP?R(0,<=OHZ://38ID2A-
M>9[Z<S=0F"$+(W2ZOJ9?5M@U69SY,L9OFUQ*8_I.G6%U;;0SD3]X$-OHB[ZP
M,5>JRE1W&*CJAY+D6]D@CY#:?$J<L/<$WOR@_$;QRMQ]AV%#$1`=U2F_1^"W
M]5@C$Y%35911K.N%M)7#MX1)ZH+\>RT&-`/L)IA`HYX909:8@MBFA8$!4\6:
M^J-J+H:1;'-$LXNN#'=?MT_6P")R"C,O7!F1."B0+6O$*.DD0XNP2WN[-ON?
M@F%N">@H;B",Z9=A)!EQ0`Q3>C7-"ST(2+2*YNMZ_<N58-@8"8.@H(W@E#C`
M60&!-'?*4G(O*CA/YMW@)6]I%J-+>?A)`[&HY)\+`&N-11"_47X>9O50F]AR
M1&,;)]A%N#9,C>83'6)S,;O2ODC365Q&J?"J0EA:N+9K#12(!4`P&`!L8%B;
M08AUMS-B;$;23$(JXE3ND!O?:B3^#B8YW8,P8A1?(HKDQL0]`#F?^^ZS5A?8
M*VL8+F==&<F4+PRW<NHOG&_22&P0(&37H2=RO^+HC:V\=+3NIP:K[?9[W&'W
ME^NTMTKG)8W%JJDSY;/ZC#+IXR3.GV;.YQ*BRX=P^E/7_D6D=PD[04(12,^G
M2QMBRZQI-R>IKWNP3KL26<@B=ULD6T1*+F?A?:[-%A>1B'21N&R$$EO>JU;M
M:_R^[[O3%9"4@:DV%$E(S:+3R$I<!S!-?=+(X$F5ZL>2?M9]-9U0U2"ND'!_
M?EBK52QS+PU][4$%.D%@M@`MV30[]4I+4W=94K"9$(!<-7_F69IC&FM-K91#
MH,T[T/!%E9IEFFF'3'$_C;H(I^PY@S)V1)X`8R)YMD[BE*G3CSJ#S&DCMS!T
MCZWJAV-]GJMB6*M3OL[UTFH<%)M8Z7CLE7KM-8K,+W+=WKC(TB4<D71PI/HS
MP:&=9I+!ZW->G'A3O[,8"C.J3-;M94OA>ME2^+;I?/3RUN5;XL2_=]/]B.RB
M2_;I1_9XR.)HW?9U4C@-'F=^^T213R(GD)HFMG*I.`B!W8R`*T/HJN]J61[Q
MZDE3+3$/Q(?M^5A57TW#B%S2:Y6NC]M<:;\":239K+:!JJN\9)38]MVYO.C6
MDVDS6>NT`5>MACHG@`8VM38)C)0H#.^>RK8\F/;%"4;J=NX?T^Y@^H&=E>2V
M/]HT"NK20[-:"R^1L]H6PN7/)$\*V\&SIE'EHUJ&.I0:MZ9L&'R3"4IK8=Y<
MI`R@TG;2&A(FV,;DQJ:*N?8H#_2)<K'S_7\,,Z0;=BZ'53IV2>P:MQGWAL>I
MC7=42^U05B9-ZEZ]B\P-@[K>U>,CBO`CZA!3.`QGE.A[:FOZ<<=ZH+9!185T
MK]J=.9&U97BK#^7I`;88-T<'/LZ>%/-K0"!FE2UX[+=\ELFY6S>H'LGZW#5U
M=;')@HRACN1]29UMJ,)J@NBF)G4]?*1#5F^GR;-:9-3M#JCTET7/UVJQ%WB$
MBI(U3(^<8A;^_0F1)W/C^JD,EBB!HBBBAN0W51'*I68\=M.!R@QL]J9&D6SZ
M_=XX_#),>T1'K2BH:]N2!?NU%9V!.EB^I<$5*^TX]^*Y*'S=8*NLJ9W?*0`&
MNE:L.^HA;!9$;K+!\N60N82>>7VF\9E*H01WQE;8[1`:OFWDDN@TA_3S@?PZ
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M)7D9JM<-!PR[GP:3-+4(I`*RHYJKZD[W<RO*MM3^1L?$[>75W_[*,F><L0NB
M6HA7?PRJ<H^AX/Z47,:SJAZ>G%7[V#*\5^Y0C@XK]=CB1:,Y77C7;O;]'KYE
MU!:Q[0!*V2O4-2*/5ZWD1#KKVUADKI^>B\R]EF/.=B[L7ZX;N`+:(DGGPC^.
MZ-E??K"4>Q92Z9ZUSOR%G__5@4(=*H33Y3SSW:R<%U_Y*TB4(IX)]IN\;8\`
MKDDY5!L]9NCKYF*R\F"ZA$CU]7#$=^E`>5C4+VL$"G>O5"S>2DWXK$:,D";9
MH=HO4%0#\Z^8*.9OHT@YJI,N/?3YX`%E"#3;1.U:F/A18X`;I$Q'`\RHIX`@
M,_5:U:'R`C6;T6QRIT4EO6AR4&;`&B]&%NYE"EEX".9W*4X*<GMWQWZYYA6D
MX/+1"49C(BK3B8K/21>NM&K]-LH]=69'(ROQ/S+9M$I+W3#6=<V.^MG#5-H*
M'0K%"#U3$:YA>^9>2A:1]#59Y/VOSJBP=!?!V84LH4]M4)O/"GQQN(&-0:=;
M&WO*!=OAXU=_J0\I;5[\NMW-Y`E,3UX\DG/;_]0]:%*`]W?E"<&Z6Q[B:P^;
M,^*=/0RNE^TJ4IQK^#;EKMSR+;:89^DLJ.C44HM'?=!]M>FTI@]%6KA%KMVA
MCA=P")'X4"_F-T`#/KS\6*=M#=\FKG@J>+HXMK>^=6]C/5(;S5#U;(L])&/(
M43OWBN0G(AV4R<IP&!(3U1)T#J,Y*C"#304M=9>HLP`"4TO=K;M-:T#@>N8\
ME_[-A<2'MVMP^96OW6/Z0"VFH5OTKHD.'^IA/M!<`PCN1?_B#S?RB#^-A64\
M#T<DIX^45;55L&""_)[A8.?C9="Y?,EBB&1<JNA,#5]#'J!>Q)-Y_/RP%DCM
MOFGCKO&.M&NIBWC14<ZMX/YSC>-%Y]0TFQ:O85U8HU!TV@"PH>$/+4UT:-?K
M8V]%[Y4V1BKXI&@#;Y7N8K9X-7KQDG@^-U*^>@E\34KGJ-:S]/^!T7F:>[L%
MC_VIF9#9GR!TNOKJQY!I/*_IJUJ%#M0X5>19$3'S1X7^Z_KO_01#)LJD'B">
M&9!GH+S0@"S-PS.D:9P$!\@414!H0))F17``0`@/$/079:$!2-1Y<$#TPB/B
M0H9QB',IPC-D,@QUG$K$2&B`I%P<&I"\-"!&R`0'B*0(#^#TQX6A`5'"@SB(
M(DZ#BQ0YO?83&I#%2=#=(HW#9@H).X(#$I$'?2%BD8>M0.J(@P.P><-F1KP(
M+I(7(@T^@N<B#EK!,Q'&`?LF$\$!DB?A1R0\"@^((QG<65Q$80+A7(1W%H^`
M1&A`(:(@D#G/@O<SD0<7D)*,"-R7"*<P?Q7A3<?##"KH6"@(4/;\_)\LM^@!
M/+N2O[)038WD-+?#3(7T1D9?)S(1#(`M_6E*Z'X2A]V[E4F8F[=I%$YBVS0/
M;]8M<GQX#7F1!??!MBC"*6C+.0]SSA8;X05#H6K"^W7+@54P6+<<F2[L$`Y-
M\,(<69R^L-(\?FD=Q0NI9@OF"&^L+?@O#3\%E7WQPARQ?"%Z1"+#&6LKI(Q>
M&)'*<$+9BDR&R7HK<OE"&,.S82K9@JZ+(-EM8RCV\#IBD;X007&<)>&5QI"F
MX=T0R[1X/M;!/#__^_;F]N;_`'5QZ=T-"F5N9'-T<F5A;0UE;F1O8FH-,3`Q
M(#`@;V)J/#PO0V]N=&5N=',@,3`R(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W
M-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;
M,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@
M4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&
M86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E
M0R]);6%G94E=/CX^/@UE;F1O8FH-,3`R(#`@;V)J/#PO3&5N9W1H(#,P,3$O
M1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<O1O;<J-&]EU5^H=^V*J=
MW9*T]!5XU'@\$Z42>=96*GG("X:618)``\@>Y^OWG`8:9#NMK")-N49"</KT
MN=^:>?_+>/1E//)F*I3$PS]S%<RD:#[B[7A$S1-*F")4F3N,,,^;A2$+2.!Y
M)/`]4NKQZ&>2&UR^D(A(!@%^D?)A/-J,1^M_(RK\&]SP9D)PV&`FN.3PQ4/&
M#I^'0N+SD/OX/`@4?QLA(U,N?(`-J*$(L")-Z[\&\Z5[*.Q#1GNFWJ_&H_]\
MC.YC$`$G*UA@A&60=N*AC%"/!V2U1;(]Y2FRBL>C*3#%8*/5TWCT3E=UNHUJ
MG9!J4Z;Y[]&#ADTJ73[JBA1K$NUV9?'5@&3/Y!\J5!,/!!S5Y(..]?9>EX33
M"4I?SLAJ`RM)A[(B<923>TVB]5K'N,7],XE(OC>K`/<ZBNNBK"8DS>-LGZ3Y
M`_D76?TV'ET#<_\]GPA@42,"JJCL1""8:"3PH'-=1AG1<9$7VS0F\)VD=5KD
M%8GRA!3U!LAM:6UY05(3O<7'ZP)XV9?`PZ/.`>1Y1A8Y@35$XPWSK)=(DL)Z
MP%866P(8][`O2'N?U2`%7',1_CUA38!:"Z"M`4195CQ%>:P-)_IKK"N@I8*;
M9Z=%#H@)V4QX'M#P!]`P/?]6:L@W%>#*G=XI9PWGV^(1]8A*3*(M&'YBE9B"
MJK;1LS'>Y+=]A<:+<'&QSQ*"JBQ3$-PS2;<[4*-1,IA-561I8IQIG>8@4X`A
M50TWMH"UFIVL7?4G;/I^V+/Y[C3TH=-X0N6W,N2"6N.186<]MVCD>TUNP7L>
M<N,UY]:E\DC(?*M)Q:PFO9`?4I%6@-H0\@?HX&FC<Z*C,M>)"4WDJ@!MY<__
M1*AF0=F337:@O!@5'Y6`*0=];G=9:CSC*:TWQCTA%CZFE0D-:57MC<60N_E[
MLBQ.UZY+_+#RK=`EV]A%/3$A;^@`R?IH3?!N8((=L(E`P$ZR!_.MH@SXK@L2
M@ZD76XTQ.4FKNDSO]TW4`]O'K)!E\*P3<YET0F[Q5)<008!*-B)@E/I6!+YH
MO;C>0"Y*"I(7->#^LD]!>^M]:8(VIK$TQD2&\1D\,<LB(QY(1'5O$$;CU2;=
M[70R:3C"Y=K<SPNR!QLHZRC-:S2/:E^6Q3XWZ:J3%\3R6.]J8RR7D(&O.C,(
M6&AE`(5*&\/;//2T2>,-&"ZH"7+4?9JE]7.CK:@J\N@>`E8$9EN^<(C&K!/@
M#9$TQE#J>E^"F=]'%6@91!:1#5@$A,88+"K*H^RY2DV%T$(V&+M,A[M>0A`R
MM(+@O3%PO$9!['=M^`4^8M`3)N"&/LRVZ2/*`X5UX,M(:Q_E8S1LT&T&B?QN
M8^*]3=2-2#!':LP".>0,=*NS1SRA+*?",/GN5\;8V;>1WD"@C'M6H%*)-KY7
M?>TR>2&U2Z@7G;I1KV2TC_.LI093\DL?;S2':C":'>AO0G+=Q39<F>@8'4'/
MSIV&D7+64`Z*$MY)^(.A9.@K_)[L:KBPUQ,77FOXB]7UC\2?D8^+Y7QYM9C_
M0.Y6<[AWO5S='9#38+S]A-B?D+3OX8K-H,/R*'QB*\7ZG]EX='<6%ACCE@<H
M_<#6_*;T>R6OMPB$U8<4RA,I="B103/947AB*>4V$3_XN\@=GN.KKLVCH==7
M2)*W&0)C<P0M%H:XHX5JF^ZS-I06->36IAO\\!PET"$M<BB`<Y-*HVP"/^-9
MU^NM,37"Q4.:YY@A;>FTR!/]%6N,2W`O;8='41"M=RB\1NZOAAR_51<!V=@&
M(<&?H[(FB\4"V:TAY9%YGF/TO]6[`IY@H8@]\L=SLR$4MWQ<MCD24-,/=NI]
MD9X],@HH7+JM+N-4G)XS[K[&3VT/Z7NVAU3FVL;=X$7MWV!Z(\;ZU&LBF*+V
MU]\(L2_2>4\MD.CQP/8+4#C+UA&^FR\_7=^1Q9+,EQ_(A\7=_-/M=9,FR,^+
MU7=D?G5U\]-R-<<;-\ONYV+YR2SHTPLLO?KAYNZGV^NCK*L#UGT:G)]WGX:6
M^5#-`@']OS'IU\GO)76P](`\DUM.(<\=HI1O6U@:M$7=LLCUB6VCVVJ5Z-I&
M6&WC(?-I,+3:^8Q<W2Q7MS<_W!GE?KZ]N;K^`!H]+C1CS8JK-A_+P/X\FTH9
M5*8='\<KAI<$PNH#"HW#G4*A0ZM<$>4US6GH@Z2[@/VK)[T(/NC94YWD=D>P
M(V\PSY5XC:J=5UV%;,:MM_M,`[[H[$DWH#WSEQWE01P;,*V\OO]EO!N#2.C1
M$V@&L-"XT]#YI:95O_X:;Z(<LO4<9W1K0D,N)M`"-[D=NE4<[S:7.UVF!=9&
MC[H5W>OD?YD1K?*(#`;]?5^]<<:Z^J7IT^.H+%-LQ_?8[!#]&&7[9J#1LU_M
M=SCU,"T:UG'][`H*FS1.=\V"ENT6\]D-->26J0MVL#+TA[+CUA^$ZD:#U:!/
M'QXT7$J3JNNG/<6;>N'=A61,*;7;75#&6#L,N`JXL$&'=_Y7D:M-JM?@;^![
M=?JHR<UZG<;8G8,%-L_ZLKM]-K%>V!RI/.I<5]8U$UVE#XT%%V#0W\)H?1Y\
M"X'BY+(7:"A:*SG_O`S-4=J!BBU>><C#1FU)6L59@?-`[`GKLLB:UF]7%K%.
MX'8UPV1+WIL9X'Y7X%PTJ@=QIXF()R@?-T17U$F#\E+NR.4W=<=VNTN[H^4*
M-F5]NTM9YX['-4N><,!M7:]-BJ_/=,_=LTG(:1W]YY^$0`8086![(,G\5A-0
MDMU?IB03=D<\G>IGTM1C=O0"DC;BS@O2%"05'M#4!T=2:3-3R3J%$:Q$!N.9
MTI0@F+K2!')9NDZ;TR<`SU&'X)PVU0\*@V$Q>`$'$T$W>?'\T#:<G(5MPPE%
M1_101KL-014D1@7%^K`PPQJUND21RJ!EZ`B\;)'*8)=N)]-\B[[W5K9&10^D
M,CF[T4/>^C9L<DA=`XTKP0:U@+1\FHA>Q.8`)B$0;KJ":PUA"4SYRQY*43!N
M*+_A^:N8TZS?1!"5!B?MES!>U;\8X?=C0^JW;7+WWLH$SP_Q+'!PCI:EO^,+
M,74QI+%9,#G5LT\+MNY1@+!'YTSUHU%)U<$HX/U?Z_B%F</C_$K87^>;7TE+
M++H0ZU_98$RTQQPS<K/Z[OJ6+)8?;VY_G*\6-\O9\?F3')+.Z*FTNP<\//3>
M'O"<I%3?,;X5=B_W7.0,>_$`&.-MFP_%:H`>\X?Q&,':*O+S_':%`_,+S/59
MV/5V!^/,,*#]J4::KXMRVR0[""Y9>_H+Z:Z;Y$_(HM;;BH030CWX!V$&<)M@
M+/#L%YK"H@07-*<#F*Q3\X)`J==PC2?ZX.3X@D^BP6=34RU]+HNOS_WY@7T)
MK!T77$(4OFW!1/\6%PBH%<6/6IOB`)+K75W$OV^*+,%W-0Y;)F0%#VE2%),M
M%P83$Y2*3<ZP:)M655=:@%@H\T@2/7^C6A$;LH[O%[4B2`0J22CW?'`%;M#V
MZ\UKF`#@!2PP`.QM`!'Z@><$")`$%X"O`M\)H%0HG`#2Y\P)(%3H!N"^YZ:!
M*9\Z`>BQ+:![<LJ!AS)P8@#W=8N:^Q(/P!P`"IMF%X`\!B"D<NH":ACA!F"2
M.B7)H0-PR\$3U$DD@^[<N04+>.A4-_.YFTVFN')CD!CS70""<S<7G`7*"0`Y
MW<TFQ:3O`O`X=6Y!0Q"5$R!@;CE0GS'I!%`T=&\AJ70#0)_H]"S*/7<`H8RY
M/8M2QMU<0*WEE&2([T8XG@=<."GP6>!D0;'`2:`$MW,'.'<(A8K>;8R4._%3
MS_]S'7UI4326!%__7S'G>>@+;6IO2IQWDK[,=<QM)%,.';<3`)*$4P13@465
M"T`&;BN:JB!PT^"'U.ENTR!P!XTI]:@[,$TI/:+K*674G;*GE#-WMIM2P833
MXJ94LN`(#G4D?DVISX_1$7!U!$?(?;=6F">.&!=T3.YH/X5@?L1Z&!?NM#9E
M0KB]?,JD<$>Z*5/2G5VGS)='S!ABD3O:35EXI$R8<D\>\070_1$+X@S_WY/;
MZ7WJ]@8N%/]S6X?0<OW+>#0>_0_4B0DY#0IE;F1S=')E86T-96YD;V)J#3$P
M,R`P(&]B:CP\+T-O;G1E;G1S(#$P-"`P(%(O5'EP92]086=E+U!A<F5N="`Q
M-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X
M6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P
M(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O
M1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G
M94,O26UA9V5)73X^/CX-96YD;V)J#3$P-"`P(&]B:CP\+TQE;F=T:"`R.3,T
M+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IXG+5;27/;R!6^LXK_H0^I
MQ),2Z=[1?91D.6.7MY&4V(>Y0!1((28)&:!L:WY]WL-*FN`#!#'E11#1?$M_
M;V_@[,MX]&T\XE/K#>/X)[]R4Z.+_V:K\4CD=P23E@F;?R*9$%/OI6..PQUN
M/$NC\>@S6^>T`FV0D'$.?[!T,1[=C4?S?R(I_+/U`9]JK8#!5"NCX(?R4N[>
M]]K@?:\"O.^<5>T$)9LHY9Q@3G#F`@Y44:9YOS7?JIM!?5.*1JFSZ_'HY>OP
M9N:84.P:OI!O5DZTVAX!N\*58]<K%%MZT.=Z-AY-..PC7O\8CUZ\N;YX#Q1^
M8]?_'8\N@.@?%:7+?R&E'RC&6[B24X/4-/P`<G;KU^5X='44>6$CM^3E*K"U
MO/DURCME%U]^?W/VYOJ*=<ILU8[,0O&A0N=V=F"3E6ZD?K$K%`!@E."6!9XS
ME=-M".3&`@N$]2Y?(`\LX-9P:H'VEI,4M#,F(!<$QFIR@;5<D@N,L?0";0):
M!F6T(!?(+A;"=.P#UX:DH,"UR:U63BM%+@BT\N0"V[7`:$5BH;06]`*P9W(G
ME52:W@<A'2TDEY9D(;VT)-S225I-&4A%4["2DUA((SFIA02+L>0")02MIA2"
M%E((1[/@PI!:""_H?1".0X*D%@3<TBS`N>D%V@>D9PGEZ0`BE*`]2TA(VN0"
M(22YDX)S3R[PP(*Z[X0A=0B$(26TH`,9R$5'#.6:E%]Q3M(77M,@<0+$;\46
MP0X"$;#I_1P8'$[<$+@%"H<IT*NI=T#F^B](AZ=_<B/^E)KCOYW4"/PLS_D%
M6CZ9H>4[##7F6&0XP;+!N+*T6=]&/]DF81<_[^*;>),]50`JZVO?2/"BK13!
MU4XQ#YEW5>PM7"W+*X]7^=W\ZFX'`_@,RI%#$A'%'OI@OB-VZJ%Z*B!H5;[Y
M.D392L92VAW)BMN_"%G>MIH_64K\:BDEG\(F^JK"4QZO$;97439+X_M-G*Q9
M,F>ODMG#*EKOHX<>B[%5X-^G@0=;!9CGT+499C=E"@1I"A#D5/&@!$%.Q:],
M8">0"6[B4^7'3:3D[T&:PJ=4`%P)"M,*'BN#`I[311I%"`B"\SY*%U'*PO4M
M^[0,<[PNHR1=A.OXKS!'\#;<1+<LS/#6572_B58W\`7I3B#S<<UN'O,OAZMD
MO6"O'L/;>,;>K#=1NLZ_'B[9D97C=7L!Y4&EG?2B-#Z(5_S?5WG8.@%!9E.&
MG\Q??GT9MHI7+"J6'[Z_1>3\_!/[G*3+VQ_Q;=1\.]\%O'<Z^_809W&^=\=5
MW7E110<GO:[BI=`EL.=)>E](R@2*U.85"K,@@S3Y5'_#!HOT-YHRX6_.Z#9_
MDVV;!TQP\YXJ/WZ5DK\':0J72H%@:AUF%%3@ZGX9;X[(!W+_]DYI7C&:'),)
M%,L5$TS$:&1E^."!+*SLXWS.FA!21(?]N'#2(S#T<-4C`X4IM5!-N'J4(JVK
M1BG_O\#PD&V2%3M/P_F&?0IG7\-%O%YLD9`''#;`SD!`5_ITAQ4!Z;`=E"F'
MY7S?8=54M*&%7!"MIRJ`:%$*]"!-&4*I`1A"()H4*459>)Z";=]BU@/H+J-L
MDQOY>91NXGD\@U\P%P)T$&^3-*SKG,-&4GC)A^1[X22BS)TD\%`$#P,^<)P&
MGJ9,`!]`%]H"?%ND1B8#<2?E[T&:P+U2`''G36S30A*XGSTNPQ_9,Q'>\PW<
M3BF&0JP5#3%-F8(86O0]B'5K\8M,AD),R=^#-`5QI4`PA7#OZR(I\&65]#I)
M5PCF>;*"U,2N-LGLZXYO4UYIG1X*&;<D9!V4"<BL\VV0M7DE,AD*&25_#]($
M9)4"V/MK9^J\S(79A>QO9@JU[0YPGQ[2V5V81>QSF*8A%"0D>E`I#T//6D^C
M1U.FT#.R#3W5ML7`9"!ZI/P]2%/HE0H`>$XW,57A]0YX"CZDP<M8G&4/$$<W
M"7:CLZ+$/%W@\(`&5O"AP"IZC-!!F0)6M(P1]%2W[3XP&0HL)7\/TA2PHAXC
M&*F:1D"J76#/TOAV$;%W2;BN@3RB)%*;]KT\LL92NQT^EIN2#V%X)E`##<]X
M0QI>!V7"\$S@V@S/M.P5,AEH>*3\/4@3AE<I@/,KL56D[9I=$4(^%F/&-+I/
MHPSB!'15+%Q`>[K`5)[&B[L-1I/[*M)8<\*A^,_N0EB_5P:04`L_<'1BC*.A
MIBE34&NQ#[7@K>4:<ADX.R$5Z$&:PKK4`&3F.,<JP<ZKN&*FE=Q'98^%5?F[
M>!:M`<=?)Q"G#PMHL6%/\L);L9MH\R.*UL<</#Q'2UE/S(79&LDV!QVM@X=<
MX^L/']F'ATT:UWOP.DGR]B0*P:AA<;:)-P\=A:O6;N"@W7!-6F\'9<)ZM0O:
MK;?5?I'/P%D[J4(/T@2RE0X0J[BL[5<&U3CZ.DI7\;K;?E]%L[)S]+D%FQ,6
MS>?1;!-_CYJV4JKBYJ_F?62=`E[7XT(V];C1\J"YML_(]CVM7O<AVMQ%Z1+V
MY(2=3?\#-RIC_^,A7,:;1PS.[^)Y8=9S"/JP^I%]72<_6N?JS]'75%,!H41S
MGN4J#,.LOQ/F;HL2!P<<$6>JP]((/KA".6('9<H114O3#X[8UD(BEX%IA%2@
M!VD*PE(#K%65V1KHJ>I(\GNT3.[+?F+7]=X^@%TI7IUG/3-Q'`KEQ]57>5\/
MLM36`%.5"04M]"Q.CLA40`JKN':>/PQGXK95@Y#:!!\NJX@ZNUO',T`#O"^!
MN@[JN%?Q]S@KQ["GZ5>\RD/'U2R.UKC@W;OSP^GQ&5:MC:T%?M$VXU-%2!K@
M[OGPBG)WFC+A[LJVC!S`W=MF#LAEH+N3"O0@39F_K6<.S3&.M_4YZ`J2Q2P&
M$WF7'VQ7Q3_^<A4N][-O$0+$<T/`D974IDG#09V7)$2U,JC1$2?/4G\_9[\G
MRUMHB[(3V@OR!_+\P")12;J;[:!,&2MOZ6;!6-OF*,AE8(E(*M"#-(5C_<2"
MX$VH#I2MBJGO4;9)TNP?[!+;U6S/.M_G)8;4I7D6)ZI0/>&-K^QTRBY6X7(>
MIC?L.H4FZ"2_]SH-U[,XFR75AX=+Q6?H)GW=OAE1]^JZJIR.ECW1EA,L&(O.
M_0Y,.DK!HJ$T"[?.;,(L>UC!]<WCL?4,FD-QWI3YCI<AYS):Q-FF<P`MA1F8
M#:2AN[`.RH2#2=7>A;7-BY#+P&Q`*M"#-`5.<ZS/K6AZ,%D60Q>K^V7RV%K[
MG=ZG\;(\K1-UX-_S*[2M8V2#YR@IJR-K(:7?&I3X/LF@\)3&.WK:J[!BJ+UR
M^A"Z@S+U0HQK.81&>VV=&B"?H19+J="#-`%FI0,>>&UUG-R5.>%UG&9@K!C9
M<F/%1V`/&W&1'X3-K=@^W8I/VDSU.=K9^@A6B*TC6&/KYVQ*1_&'[$X./685
MFCYF[:!,V9UL.68%N[/M=B<'G[22*O0@32$CZ][*JL;NA/*=D;(PLK)-;@90
ME^%F'65W.9J7X6.>K,_OP-+2D+"WV@#TH><4AQ[4"DYW331A\JG@`^BW/J<X
M^*"6E+^;,OE4<'U,NS6"KI^U)Z!_&ZX?PK1ND!KP/X>/:ZA"DR3M@[4]-!$K
M^M@!CU301[<T7>I4I>6P,8=ZKT%^CO2*;CA4V3<.>%*#/A'N($R=8FR=!P=;
MY\'!T.!QNHQ^@N%`58_V<15";9\'D+-D?1OVLJE#\6,R.'[0J$R&._8APBBM
MU(9\SVVB#"??+)KHCO?<)MI;\MVGB>6"EB'``SIJ@>."%M)+^C6VB8#NBB8A
MA*+?UYL(J2SY%M5$*"B;Z15:BPX:1M/O>DV$U5UR!)I^WVTBG*%?@)P(;Q3-
M17)C:1H2:CW:>*2T])MQ$PF)I&.%MO3;>Q-IK.Z0U-H.*Y:!I=\(G4AG`_(M
MP8GT08<K8%Z@+4@))VE)E72:]@8P4^(57`@=%U_&H_'H?Y<B!H(-"F5N9'-T
M<F5A;0UE;F1O8FH-,3`U(#`@;V)J/#PO0V]N=&5N=',@,3`V(#`@4B]4>7!E
M+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q
M,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\
M/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O
M1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E
M>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE;F1O8FH-,3`V(#`@;V)J
M/#PO3&5N9W1H(#(V,C8O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<
MU5Q+<]O($;ZSBO]A#CDX*9&>]^,HQ_9F-Q6O8RG9/>P%(B$*,0G0(&5'^?7;
M,P0!2`8;X!AR;4JV18O#[NG^^NN9[AGHU:_3R:?IA,ZU4X3ZK_#*SI4\_+/8
M3"<LO,,(UX3I\!-..)L[QRVQ%-ZATI$RG4Y^(7F09:3R@I2U_ALI5]/)W71R
M^Q<ORG^U?D#G4@I0,)=""?@F'.>/WW=2^?>=,/Y]:[7H%LC)3'`+G[:,$FLH
M2/5SNATXAA,EF5;$.$I$^&EP1_A84`0#N%$F#.`G!C!#'3J`:HU*D$Z#B[$!
M5G.!#C!:,W2`UAP?H+3`YR`UH(X-$'TJN.KQ`U,,ET`5[FKAI./H`"N=10>8
MO@%:.A0+H:3!!T@I44\*(2GJ!\&%Q"?)!,=54,%1N+GCN)G`*(=+,%RC6,#;
M&K6"*\X4.D`"]]`!@AE\DIQ+7`6#+W0`9;@?F&.04K$!EG%4!1AI\0&:"I19
M3%$\@3#)<68QP31N!6<6]21C3.$#*-?H'!QGJ!&6,W2*AEDT6B`+H[13C*(&
M2*I[2$=1E,"\T^]_JGRDO!V0IIJU]]7U=/+R;7*S@)5:D.O;]B>/J_CAHX9<
MPSKN^%Q0`Z__-YV\8+!6S^6?R?5_II,W(.B?09,5!TT:$M6YJ@Z?/:BB<PHD
M)]>+Z60&RSSSK[^`UC>;[;IXV*3YGERNRC0-KY;)/EV2?R3EX@Y<=0',`G??
MI/LO:9J3O_L15]NR2/8DR9?D]4.RS!;DQWR?EGFRSXH\65_`?Q=S\ANL$A+^
M84^M"D[P&>6T_S3F/W$PZL5O7-((V2@VD*Z[L5&=V(`F#)M39H3/8F8,$8X"
M7]D!P'/84E;`<^-?#P*>Z0"\KH'_89WF.7F7+K]D^1#DW0GDG><V@_U>!/"4
MHL#WB$9P=^"S+MC-_"L38*37XX$YUX8`#&;#`-D(Z$<CZ)SYO=.1[,Z_]IC_
MM<AOLR4`G25KP.FV*#<!-@_:9__C(M^1R]TN6^4A'#S([XI\Q$G"MK#M:DEA
M>Q5</1M5B6VY@OHM_=$5?D-8N6*S3?=I1^P_0/8/D<_JR`="?"0C0Z5U/3_1
MRLNBSLO)^C8I;TX2+5#L7U>7GF0MTMV^_/@R09AY&)[LX,_N?@,&WSR0#^DJ
MV^W+!)S@1?!3O/5K9A1OG=0X;7')&&VY.T%;WH47Z(FD+6K"`-%8*%0V?`?6
M1DXRL+;Q=`]KHY78EBNH]@2N7*$DBV#M!_CAR$A!Q%73<ZZ9GB]##].[`]^7
MR1^(LU:)2,Y:QU'.]DA&.&N-.L%9T0&7UQ/)6=2$`:*12#C:\/R<C9VDYVS+
MTSAGXY78EBN@-C:U*[25$9P-Q<7(4"E[A,KOI^N<PJJ-<$\I\_TY:VPH+`T[
MG[/"HISMD8QQEK,3G.VJ6+T>C]:Y)GBT,!,&B,8"H;+A^3D;.\G`V<;3.&?C
ME=B6*Z@RJK60<9RS5^EVGVYNTI+()\0=&2HJF_FY>GY<55!]R!9W2;DDK^[+
M=9:ODDUZ0=[?S5_/OP>-QS75V+I!`\RJZW3K7P=3!R8-;B,7>J/Q9DJ/9"1I
M&-7=2C&=K12O)W*A1TT8(!J#1]'OE30B)^F31LO3/4DC6HEMN8(JU=K]QNS-
M+]?I?\$5D$A&ADN(9K'GK<6^2FR>0E?)[B[Q-"*OBGR9E'^@I5\;&<MB)E`6
M]TA&6*R=[F2Q[>R,>3VQ+,9,&"`:"8NC#3YT_=)R[+94.?9'B,1-GMUFBP#D
M5R%\>;^ZW^T)<UU]H<LY^;9FS<BFFKJ;P'FS=!K_VMOZ/''+:63<:N7PN,4E
M8W$K^8FX[6H->3V1<8N:,$`T!J;D=3K336UEI/ZVP+W:I]L[^/[3G/R2E'EZ
M5@X<V42N&A.;>%7:-1G[&3.N"HDGYA1*4X5&;H]D)'+]Q9WNR.UJD"@K8D^@
M4!,&B$9@/=H`&;?.M\<4U!>U/R7Y?5(^$,:>'#TB!TX^?NNJ((5-6!Y@%Z=@
M!P;%P:XT7F/W2,9@5]TUMNVLL;V>2-A1$P:(QF!7=6&I6\T@Q@>NM(>C1^[.
M!+Z`DG1/KNZ2;586Z+%SN+84![Q@./"X9`QX)D\`WU4G>3VQP&,F#!"-`<^:
MBETVQ0&58N!*M2VS->'Z/.#_EI20)SX4NS1?)>4AT]L3R$N#WM=`D)=.HLCW
M2$:0EZ;[(HCK`,=KB<0=-6"`:`3WHP5^^9:R=6(C^[:;AQW)FT_WV?Z!A.(Q
MWQUBX_TZR0_+.03($H+#0WW^TBY9;$M$*KPETB,9`UQVMT1<9S'E]41N2E$3
M!HC&()=-'\`UD'-3U=A7^\27U4OBFR&DN"6OLS)=[(L2MIW%XB/Y>1M0_B$`
MV.2!^]`.B(F7D<WCU?4$/==&RP#1S+=_*O-\=*)["V%9;**A>!'?(QF).V&[
MBWC760QY/;&I!C-A@&@$F*,-X4I'JXAG5:JY2A<%)(I+GS1"1.V+J'`*`!]6
M)<A!$+_U?I17JQ.*OI21Z`N-WY+HD8RA+[MO2;C.@L+KB40?-6&`:`Q]65\-
M4*:UP3A>Z'GKD\WA4EN:'G/,T^RROTNC0^+1BH1M,;F+;88(CC=#>B1C$<"Z
MFR&NL[;P>B+7'=2$`:*Q"*ALF/FCDNI4Z,7[M`P]]WR1CJB-0;"U7(;WU*.5
MJ,8FOWUJVM7FV*[^=[H+QV[M=7/TF!X7I7#9%*D`CPQ:^>4?OD.2?G2Q%+LY
MRIF+/!GG!F_6]$A&F,55=[.&=48_<[$'XZ@%`T1CD-4W)*CQ]7M]L%.=<5W=
MWQ3E,LO#DOB^+#;9;E?`>OBNV*>M0Y[JIC@CFV29^GWZ2&<J(QLKFZ/OUL50
M=CS&>MQ//`3K!=DF#\G-.O71ZOD&[@#FP=;`_^>K4X#KTC==(98/0[-5Y@V'
M`C=?9%MXE6R*>Z`O?/Q/1M$+H_5)'GZ#G?Q8D#,MZ[ZJ])GMP,.SZRDF;2S[
M*%Y`]TC&KNO;[@*:=9537DTL^S`+!HC&;NHW%P#^3]CW+<::^CB=.M8ZG1*Q
M['L+<;O(=HOB'-II+2^LL(_.#$8V5-7WSYUH'9:+RM`SKH.92-8Q@5>3N&",
M=*R[F&1=M:0QL9Q#Y]\O&0.'-<?!SK2N%XGCG9O/Q?ISEJ^>DJQJ3(NQ2?8H
M[$<UU355DVU6.\X>[\:>;X$3%Y32\+>':_$F6CX2TWCL76F-7Y7&Y6+=PNZ+
MTJRK:N?1UZ2QV?<+QCIIJF%9<\F0'QMI5^GBOO1E2>>-H8II%_51`!*)8UV[
MB#>5USMH+9I#;";.N'31ZBQ\':`0##,F\<?^9UQ*]*G6F0C/K&(#'$6?H)Y)
MAS]8.U/.HD^2S[3#?XG#S/J]%C;`\1XSH916^"08$_A#UC/&!?Z(\PR6)]4C
M0PK;,U,E^^:A)?Y`^8P9J7!,F)6F1XM3K">VJ.J)'<X4_EL&9IPK_/'Z&1?^
M`!F/<>5Z9JIT3Q!S[5=]=(31^.\[F'&K>YC`G>F)($CJ&I^I8,;B9!#<T-.Q
M#IGCS:_3R73R.[2=AND-"F5N9'-T<F5A;0UE;F1O8FH-,3`W(#`@;V)J/#PO
M0V]N=&5N=',@,3`X(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T
M871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W
M.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q
M.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@
M,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=
M/CX^/@UE;F1O8FH-,3`X(#`@;V)J/#PO3&5N9W1H(#,R.3<O1FEL=&5R+T9L
M871E1&5C;V1E/CYS=')E86T-"GB<O5Q9<]M&$GY7E?[#/&:W1&;NH_PD*W8V
MMQ,IQT->(`@TL28!&00M:W_]]@QQ60(;U(A*R6511+./Z?[Z&`SQ^J_3DX^G
M)W2NG2+4_X17=J[D[K]T?7K"PA5&N"9,AW<X87;N'+?$4KA"%2=5=GKR)RD"
M+R.59Z2L];](]?[T9'EZLOBW9^5_!F_0N90"!,RE4`)^"<?YE]>=5/ZZ$\9?
MMU:+<8:<S`0S0&09)=90X.IU6AQ&\[&]J+N+G/5&O;XZ/?GZ;7*=AB6X@@^$
MQ0I,V^41&E:(D2M8GZ_(O\C5?T]/WL#'?CT*<P9++L3+,7?ZY7@K]W*\(5I&
M>'NABC-)C*-$!*;]IT/8`(&P5`<"OH>`&V51`F88SH%JK3`"Z;3A*($UL#08
M@=$&)]#:XCHH+1U*(*=$"(VO@^1*XQR8PI=:4B491B"<D@8EL%,$1DG4%T(K
MCA,H:=&5%%(J=!V$$`Y7D@N-BV!@!TI`!6XF=T*B'+@5#/4%-X!JE$!S+5$"
M`"]J)I><XTH*[G`1W"=KC(#QB76@G`J,@#E($"B!90(G,-2BR&*:X@F$*8XC
MBTG.<"L@YM"59)Q3G`"LQ'6@$!$8@>,:U=%RCH:+X7@6U4RA%BA&\11)%>HF
ML'__]8_-&O@U8@04>7)C0)795<&_N:0/B^P!O`7&6]+`V_&YH`;D_`_D,#IG
M\J$@*W:"-'SBJ5:$SV)6',)\GQGALXT9H+CP6J2G)S/?;0)ZKNY`YG?%S3;-
MUEE1DZ2X(>?PZB8OWI/S]U6V>_LFJ3.XL'V_W=0`[3/`/X1]LBZ!JEYFY*>D
M^D#.Y^3-.EDMDNJ:7%5`>1:NO:V2(LTW:;E[\U$C]&SKN&BLHY#<&^.X:VSS
M!GUSG]SD*?FNJ+.J2.J\+)(5^9LJ^OOE.?QB9W`IG8=W%E]_^#H9_<".R),'
M0NY?C82;\X66^7]/CV0JT$B>8(T$LK-Z/([5B#.\&.^+IYH0?(&9<`!OQ,^M
M#:`UI9V?H2.0.T=?E$5=)6D-L5AL%_!B6XW%\"]I75YG%=3I,PADY\AU5M]E
M64'>E1"YY"JITF6YSHLS<GE.]@;/D4W3KHW@'IU<N)UA\8%Z1I(-@!30#(9?
MW^^`[==BTRS&3\D]L0',--CZ-KNNMDEU#XYL(0[O'ME8M9M:P$9*H65L`2NA
MKPKVKK(:K&E5[%5BC4H8^JP3D77$"8Z";X(S!CZFQL&G1Q;6BXFL(:@%![#&
M?-:8`"X32G4A2OU0WA20;%WDBSP-,1BBYLTFK<J[1_B[S&[K;!T0:+\H(W_D
M=;8B?P#EMLHV9[N2<E6N;S_D!?SY6_8^WP#`FQIU7/NLLZU]7'80Y,:_]O;]
MDP7$^FZ*P43VY!"VQN(AC'-&0M@V6SN/0MB,^0'$>#\\U0+_4<R"`UAC+FY,
M\"'<>]@V#GY;5FM2+LCE]AK"-K\-4=R'[J(JUR0O/F6;NH3,E!?DMLH_03R3
MVU72=$[E8I&%BI-"S$(.@U@'NBRI5O?DY_)3$_-3"<SX_8JH]L%*AGI_@C/F
M?2['O6]'7.3%1'8/J`4'L,:\WY@`WK>T3V"R[8#W=@DL=`FVR5'?9D7V*0$<
M^T@(Y/\I5[Y5WI`?\S4DL!LHN>1N6:[`Z>5=`9PV$%'Y3>XK&,17DQ>.;!PU
M7?M@^@9"R"X['R=M01+VBU*3UW-RN<Z2NLGTOR7WL#HWY&*9+^&_+2S4#W>P
M7*'].*ZI?HQL46S[9M_:MML?-#NM2]M.XGOH"T,C808=S_?;5=L"<1R8?D,U
M"IC&4!R8.&<$F$:)<6"ZL54',9'`1"TX@#7FT-8$XSM>O3/AQS+]<$0Q8?^B
M7RI)*=O)F1U3".N-@>@TK@>B;('X^^TP*D-1R9)TZ1/#_B$ZA.G#2Z_&)NM7
M.[(C.TCH/KGTF5.H9NQJ.[2@YG=_7)!OJW)[^PJ20EUD&Y\/X$*5P!MYNDRJ
M&_)Z6ZT@8P)2X;WM8KLAW\+;15:](C_XC'IY6Y4)V'(%8QCDC]=)OLKN7^UK
M^IYC&7/=(")8/X@PVPPBYZOL,XB%,O`:TEM2H?E!2Q&9'[1S:'Z8X(SD!VWY
M:'[@8R#V8B+S`VK!`:P1)[4F>!^Y?O#0;GSP>%C'(8!\5[=OYHCMZX]LH^ZF
M*\GZG0W((2/U>UB.]Y?K@<H7%^_(GV6UNKG+;[+AIP&YY'*YK3-?U^_)NPJ:
MU")=PBJ%;8_D4PZE?7YL6Z7M0!?R8@.ZL/^Y`]TJWX`GO0%J']9H[(BD.3XB
M37#&L,;&1R3^R`"_"C1Z1$(M.(`UYAO6C4B*B3X.F=@_!3?A=ED#W)HQB'R3
M5QGTSQ6Y@-J0%9L=--^5JSR]#WX5>_RJ_.V]*+\JAP\_$YP1ORHS-OS(^9A;
MO91(MZ(&',`:<6MK@8<<UWV=XX*U.Z<WF??;FWJ9IYO@(4;WN4CP6!<IB;L(
MYXRY2)C'+AK%G9<1ZR!,_0-88PX2W?QFI1G,;TU*O&Q'R#S;M+WB8#LL^(OM
M\9=T*M9?#+^O-L$9\Q<=N:O&Q<BB>AFQ_L+4/X`UYB_:W4[CIJ_7IMU,N"B+
M39,*?7]RZT=2^'/GLJR"MN3=]AJ2(3E/TW);U'[3Z&U>K2<\J6RD)Z7%!]`)
MSH@GI1X90`4;38Y>2J0O40,.8(WXLK4@])>#?4'7;`Q>9%7=MY?@T8MEGD&J
M_)REVSK_E)%?%G`5>J;;;;79>CC6)?2;J2?WV@K*6\A>PMR6P$QT1`,@7(8^
MP"?;>"&J%Z+!T=P%(3,?_W[CW*_3+Y]A2H.`#E'?;::,!_,S@D'S/N@>'ZD+
MIZU8+$HD?O=U@C.&$CYR]Q50PL<6!J3$H@0SX`#6&$IXMPD@!]MNKMUVVX.2
MMWGA-RA@ICH.2B(-D!"D`Q],H"12B*(#1Q\+)9'!H)GK=!E%B=`F\C:II!I%
MR01G!"7"NA&4\-%:XJ5$WB5%#3B`-8*2U@+?9_L0:VN)M$^L)57V<9M7NVUL
M9LGO\\OYQ;S%"ZB@:(@;?W/_IKSU^QQ[<.7`V`971S;5M-LRW!]T]Z9^A2`W
M5A(3O!,UB=QX(;H7HN=,"=LC5^T!;G<;=R]X8V.4*].I,PY>%O8#I7XR>(7$
M1[`)SAAX^<@(!N`=*W%>2B1XA<*/.$RQQB):=)MPX8L,;8FC.'@?E[A_"KS/
M,)79)X$W4E(`;R-J&KS10G0OY(C@C8S1`-Y&G5'P<J-AG"'LJ2T,)=SV&XQ2
M-G?*@A'>!A\P8Z#0-(@TDC]9INYE^L7D@TF7=P='T[*Z+:NPUP[Q7F4+F&^+
M--O=W/*AZ_<`D^+^B'IQYSK%Y"YZ_P;MCBA!4-%)"('4[X8R;IM=F0T)AT8>
MG8%XCER(C(&;$<0\1XCB0^.H;S*[7?CVEL,/9V21K[XXKB7:(X%W>;W<M>K0
MMU1Y[7>EPH&OS^DR*=X'EZ_SS0;2V#Q"[WW0,K)WRCBT_&QH81&?#BTIQZ'%
MIZ#EOQ,C^9-EZE[F`%IBKKFQQT!6I%K^+FBKUP2R8B5PT4D8(DO,K6EO,V#`
MBA4+,3=P\@2P8H78H5<IHZU7A1+J`:RZ`V%R!ZHO3NI.`NS(D=CT;CX9N&9N
M^6H"PQ/2]O>@MA,WBF%F561Y9(Z.8UA,8-B+C"R/S-&7*X^Q>OGRV"J&@SA6
M@B^/K828\A@MUT=&[V8<Q=%"%!\:1[GLJJ-B#U#<G2C;H5@]J32.H7A*Z;VU
M4?1*C^,*EBX25X,S9E_@2D[A"N3%XJH[1_42N(K4*^"J46P"5Y$2`JX:"5&X
MBI7K(^.@\W'/$>)QU1L'L6,[X[I]Y`Y9Y[=5OB(L`E81*N]%%>W791Q5C,6B
MBNEQ5*DI5/EO'T>BBND71%6D7@%5C6(3J(J4$%#5+K>!Y6Y.F?K`T^)+5+%C
M+KD_(CGP\P2LHH78@6,I=X-OY\BFZ_SU\C7Y%0I5G?GO(OR6@8]KLBBKX-(B
M+S*R+HMZN2&[]O/QR#=>JR8TWHLJZ/]:C4=1960DJ(P;QY2>P!0(C(24<2^'
MJ$BM/*`:M7`\1?(7X6O_T34J5JI/X>XP*,6*4'Q@&-KW]=])/%+?-Z$RUO:9
M?<^7"4_UB$22Y.-(,A-(`H&12)+\Y9`4J95'4J,6CJ1(_AY)DD<C*5:JGP0.
MN:/V#!&*#PRC2O<G!IBU#[#T398V1[./!:8)K;']1;GO@4HSH=!GE<R8<.A3
M/F:<XL]+F7&KT.?&S(3#GSPSDTZ@#^J8*7\W"R,P3*%/?9E9-F&FX_C#0F;^
M<2?HXTAFC$T\(&?&N,`?:0+N$`)7E$$?.,%#"3O!0TLZ$18051-2K,0?Q3-C
M3DV%3CBOC5(P:28HN#_!@E*(B<=0S;A4$S',E9(3.-%*HX^3F7&C)X#`K9Z(
M(.X,_I2FF:!&X%@03*O]L0YYX\U?IR>G)_\'2X`LB@T*96YD<W1R96%M#65N
M9&]B:@TQ,#D@,"!O8FH\/"]#;VYT96YT<R`Q,3`@,"!2+U1Y<&4O4&%G92]0
M87)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO
M0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q
M,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q
M.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G
M94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ,3`@,"!O8FH\/"],96YG
M=&@@,3,R-"]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU6-^/VS8,
M?@^0_T&/MZ'V)%(_'W?#'5`,>Q@:8'WHB\_U-1XNSIV30]O]]:-D)[E;$ZKU
M$@2(#8OB1U+Z*%+7[^>SI_E,EC88(>,OO?G2Z.&O7LUG*HTH`58HF[Z`L`'+
M$,`++Z5`YT3?S&=_B2[I<MI$1<;[^!#]I_EL.9_=_QQ5Q=^+#[+4&@F@U&B0
M'A@`7H\';>)X0!?'O;=X7"&(`J4#);R2PCM)6J--]]\G\[0;5/M!4`>GKA?S
MV2^WU5V=0K"@"2E82>DN/`J$DNC$@@)T)7X2B[_GLQN:]^?YM%.L+Z8]4&`O
MIYSVSO]3CB>4HQ5!AJ1<E@IIRR[J^`H0E%A\)LB;JEZ*5=55GYI5TVU%O>ZV
M?55OQ;JG]]5CTVVJ;;ONQ.-#U<6/5=]7W2C<-T_/;=]\%-NUN&O$??M`[]5&
MD&3S9=G>M=LXLEVV&Q)]7/=;\?C<;YZK+GU_NVU6T70:?6@W6YK:=I>(@`^0
M(D"DU,0GL?AG/BMD*=&&(0:CK1O:0Z5YD_Y+E9YV_X3QB>-3C\]!/@S_HW08
MI<,H'4I-(?D87T&5Y]Y`1NN]B^??GEI2PG.C]@^@Y44`S*4!\-(`ZL(`+EP:
MX)*+3"QTYN@6I;@9"Y;&`QV52>MA>CK#2$![XY,`G!#`:!<G`,[R&I13CA6@
MDU%S`CHX"ZP`T8@7<`Y9&[1U4K$")@>A+1\'C5;Q&L#RH=;*!&0%I`F!$\"0
M$_`FL&N!SCA>P!K-1A*-D6P<D(X2WDC4P$.`!G:Y46'&38F!U0`!+;L6X.,A
MR`DX5)85L.!8-X&XQQNI4?,02)%@!:B<X2$4&,,*2``60@7E>0&OD&46)1@^
M@2B+/+.4`<MZH31X-I(*P?`"@(ZW0:'BO:"V@362VB)VOWC@TZ@#R;I@E67U
M&R7Y#`C,.CZ-/IJ8SFE)?ZP6U3).'7J@`"6E$)N*T:L/TDA/?RJ>O<?.7RL'
M4*?AAU'M"U1J`H@LJ0F@"ACC:9$JX+==O>ZI0*]B%7[WE0#NF[[I:JKI^_6*
M*OA&_$;-0-5]/:=E0&E^;]K0FE#U`7!.#,J1!XPB^A]%Z_'=N\'_C;A=]ROA
MSXH<=\B+Y=:2#N^TW,5980R\<I!.5[-S$!2EO>3@[V_&[NS7Q[Y]H+S_AG(>
M57V?V^TR+>^[IG[NVVW;;%*K<O.E7L8V+R[[JMULJ`,LO^DMOL?L4Q5A++?V
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MQV.9@3]Y"T[S=OA'8^G&WNBH8L=5`S2/LN>0-(9]=67@OW=0F8N5(M.B%L'P
M\Y67;%=4@#=L(UZ@]VR/6VC/]W:%I=Z,%7`JXZ57AK<A`-]<%708\?=+A:)>
M/:,#,FUNH1!S=FC$C`Z#_`5/$3-O!L5IF='A=6[G$"UX"9"9FZ8"E#9L6U\`
M:,];"FAR6UCKP,<4C.%O#PJP)L,#<)D;2J*2Y>])"@B6O\TI4%IY>JM3SKAY
M/Y_-9_\"!QX,D@T*96YD<W1R96%M#65N9&]B:@TQ,3$@,"!O8FH\/"]#;VYT
M96YT<R`Q,3(@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@
M,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO
M4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P
M(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^
M/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^
M#65N9&]B:@TQ,3(@,"!O8FH\/"],96YG=&@@,C8V-B]&:6QT97(O1FQA=&5$
M96-O9&4^/G-T<F5A;0T*>)S=6]USV\81?^<,_X=[=#LD?=\?>;,=.4TZL5U)
MK=.9O$`@***E``4$K=!_?7</P(&6S:/L`LRTHZ&$`Y:WG[^]O3WHY2_3R6_3
M"5UHIPC%'W]E%THVO]*[Z83Y)XQP39CV=SCA8N$<M\12>$*E(54VG;PGA9_+
M2(43*6OQ#ZENIY/U=++Z,TZ%/P<WZ$)*`0P64B@!?X3C_-/G3BI\[H3!Y]9J
M\>4).9D+*B3(S2BQAL*L*-/J:32_=0]%>,A9K]3+Z^GD^>OD)@43"'(-7_#&
M\I-VYA':@BF$)==@(:<6S"E#KC].)\^N?OSAS8OKOU]>7/V)7/]K.KF`V?XV
M"$_&@25EGB5%CIQ<I_!X81B#NP_`_,>")&E:5LND2#/RD-=K<I6E=5X6.&U9
M$:9^I8HNX1<CY8K4ZXQ<_)ZND^(V(R_2>N;O5-EMOJVKI*A)FNRVV1+NYENX
M?5]6-:E+<I.1;7Y;P`.8.*^W<&.=;%;D9N^_ORN66=40S,@(5G!6!B-(X8TP
MQ]C":[0"R%!ENP($7>XV>Y+LZG59Y1^SY>);A=''A($X[J1Y-KBJ`O#F`&Z-
MKI1)WNG*-5ZCKK]R2;_T(=_ODV6>DA^+.JN*!$,@V<Q@F'ZS$8Z)*94^%--(
MY\5\AI%V&4()0VZ$6+"V8>S,PBC'/0;!0,R8UD#?)W7V'?DYJ=(UX6Y&.*5Z
M\##@(@CB/3(\`Q,8V-:Z!\X>G)T>6Q]]5GTX'5D?3L^KCQQ;'WE>?>Q`^AQ+
M%-SV^D!R4*I+I!HO,4V\W']'GF^?#Y_#N3K,44H[T^>H=M6&Y/1O\F)!+NY@
M$4VJFT]D:*:\_`&G?$!Y?II.8-(%3BO@-\PKF0G#S71R-8A/)+/CQICD??;^
M]K7S>,8D5A](?^HSN.-5+P"#$DT-AZ)C'"&R3G`<@RM3?PA;SOX8MJ9G:\_&
MU2<1'9*(L+)/(EKUA6`TD0P"6=:C:HS*WBK:*,D7@IIV1_44^/X_?1J[_L^I
M/<+2:?J`,`O&8<_:1;W2N@G[5^L\6\$>-DMW=?XA(V]7JSS-JF^2Q41D@:V^
M<:*112P,#SL-*EM)WKU]?W%)WKXF+ZZOWUZ^N?CG"/@PL-5J:A@NF0L[7X?7
M*,-%`KN<>]A\P[[\85UNFWUZ4N^JC"3W]UE2X5Y]4SX0W"+#=CTMBVV=U[LZ
MVY*D6")1F1>PHW^<2OS3]\F^R,C/95GY88;<FB["W8Q@BR"IZ[(JLOUV:-V-
M=4%Y2`[2]T$P.<S'L+)PGA%Z%]LZF.+S8O"EI&<TKD9<!T:X7MB^8\)-NWBL
M$NS]>'_ZIA%V<>[+AZQ"]VYW-TV,Y&4Q(RMP_CJ_\P&0%][K17*7S<C])DDS
M?WM;9\ERAD^38M^$U69#TN0^2?,ZS[8S["%A8'[R'"8IEO"!X(/'8[@50=OT
M*!2&4F,$097NVD9]DPOP\[JL[@@;OE[B+D@R<B0+<:`SHZ+76>,BCCK_]>KE
MS'L`3+[*-YGW_-;[TP<".B;[?9W?8)?/]]6`L//8LDQWC</`U9!)BK;5Z.GP
MZ[,^FJX@05?>^_[K8[B7JK"_XS+$.,5KGQN[/N>K\NXNWVY]--]B:RHO;HEO
M%VZ3?#E>#N.8PUHA1T8\K%0=IW&3&'SY3#I!/7C@8DZ-#2XV_""--=%YBV$Y
M^VR5(JL=Q&V3V3Q=TQJN]QC_RR:R8?E<(?3]]_P$'[)J/T;$:FL[=3AV\#MU
MNFY^T`9DAD79(\U+N*ON86V'P1;6<7*7WZYK;.ZGY6ZS1#4`CDT1,.O6^2JI
M\]4>`QTG`*RN\NK.#V'N>IW4D.51W;%B7RL7U!TW3K06@=.XL:^-.)=.L!7J
M@T5P%PX"M&3FB[%/?(TV3M@:%E#H#E#8GKYT4/-U@I<#AGG5EQ$9WNM'`-.[
M9$\VR0."<X_QB[&,!T_M6=.RA*H3@OA#7M6[S(=TN5H,W[%1A[HQS?I"27%W
M](#M2V=HH/<8AE?=N1<7)K0PI>VJN+9V62=8Y&=%=T;7%/SMV=RJW,`(D=]D
MB"V6.NWQ77L@>'#\UQ9Y>+<OW_S=9IDGRP3<F1?+/(6+X<_7M'-!ZU$:#IJ=
M\?@H(H=2ICM*MGXM^-CTI(<VJ*"!U2B-=OAF-S\F7ZY#S<FY:`LQWV?_^IZW
M7"B8NVUY,ZG#<+"6-Y.FM\[@T28M43)T,[[^(&`@$;@(WI&V]PYEK7?>57F1
MYO?)YO.FRHR\6B=0-R1%ERI>EDFUQ,'W>07%?UD-7CB@R#0T/?"UBY#V\-J7
M29".WE79-E_"PC<"-J76Y\)FQVHL;';S>VSVIV"<2W6`S1\V65&0BP5YDRT?
M'M5-1Z$I->^@R<)P0&CV?A@%FE*Z#IK20`G90I.K=AUX9)-11!"\KUI=*#Z8
MH^8Q-*_2'&(]!U3VV.SA^@^XT2/"+]<=/D>`AW#\7/#H6(T%CVY^R"ZLWU]J
M;>P!.OHFZ-.`(:QM@>%/;9OA5P/CN`-T[X''IR;#'ZJZW@=C0,"7M<TF1^O0
MP['^&AUPT(`>@[OJMEA4]KG1J<?H>YT74/[G<(70>@'[@5W31/IO#A].@(S9
MLX&L934:R%CH>BAN.C,KRLT!R*[J['X-6YB?%H"WJLB>BC4F6ZPI%H;#+4*J
M=\0XX=^_W6EM.-Y16K2[S\^L,H80O'V?$9<AX=H3[A'7#R[EN4*[8S56:`=5
MADK$1WF9P`LK.1EBA?NW+S%6$$67>;K&`OUEAD7[:0CA:T0@;0NA@^%PRY6P
MPUOI>-'(>I>/`A4>MKJ,LM"48]*V!4/$`0-)P.A9P<H,/1=8.U9C@;6;'Y,M
M[<^+!#UL4UR6-UE5DZMU<I]7Y=,6(:9UAR`1A@,BJ!=]?`1!H@E^&`-!^`)]
MF\4<#4<@0M*V(Q*Q_T`""'U6`+FS]1+<N*T$%YHR^#)WAYYPL(S@^4M257N`
MT#8K;I.J?AIZ7-=&$+8;#5?`02$UA%F.+S@BS#\&6DQXBT-2W1\!T?8%AD?V
M'D,"S9^(%NQIP[9-@,RPI?!\^@G]/W-ATYL+Y0GX$0+)K(D20(4?GX%3)Z,$
M#%;N*`'%J(D02$==G,`R%I5!&CS-CA'H4RP4C=M!"F?C,W`7-[5D#A:"&`%U
M1L<(A#M%8)V)^D(8I^($VK&H)6&+;Z)V$-+RN)`@1)P%QW(B1L#,"35A38_.
MP)V145]P:V14"VZT$U$"`&]43:[P8"Y&(`V/LP!OQ;7@^H0=F!8\2D`UC;)@
M3NDX@54LBBQF5#R!0/T71Q93^-]\,0*)+S7$"(06<0+8%\9E8("<*`'5+BJD
MTRH:+U;'TZA1-JJ"5B(ZOY(VG@'U"3_&<O!O;8;S!.S@'Z"?\NZPA!"475^S
M73.5>+Q:BJCYYRJ.A#F3/&J>.8?$%B40BD61,)<RGCI!QGCJG&O(.E$"8VQ<
M!FM/V,G9>$DQ9]3:^!2,P8H>I^#NA!A0,Z@3<TAGX@YAFL8SRQRV9O'\-X>M
M[:G`<=3&*3BE\@0%@"<*WCF^X!:7E`MV,H+!,W$*A1O6*(5F)V#`S8FB=,XM
MMR<D=8+&D2`H%\<C'3+"Q2_3R73R'_]GOHP-"F5N9'-T<F5A;0UE;F1O8FH-
M,3$S(#`@;V)J/#PO0V]N=&5N=',@,3$T(#`@4B]4>7!E+U!A9V4O4&%R96YT
M(#$W-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!"
M;WA;,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS
M(#`@4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@
M4B]&86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM
M86=E0R]);6%G94E=/CX^/@UE;F1O8FH-,3$T(#`@;V)J/#PO3&5N9W1H(#$Y
M,S(O1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<M5IM;]LV$/YNP/^!
M'[-A\LCC^[ZE>1DR=$G7&%@'](OK*(DWQVYM%T'WZW>D9,EJK)/,>`B2R!9U
M]]SQ[KD3R3<?AH,OPP$?&:\9#S_QRHVT*OY,GX8#$>\(!H8)$[\!IHP>>0^.
M.<Z9X9JM\N'@3[:(LJS209!V+OQCJX?AX'$XN/\QB`H_.U_PD5(2%8R4U!+_
M20_0O.^5#O>]M.&^<T;N%P@L`P_>,B<X<Y:CU(#IOM^8+]N;KKH)HC;JS7@X
M^/ER\FD:73#&!Z*SHM"M>Q1Z07"IV1@]=/(1%/^!C?\>#B[PV3_Z:[#M&B3Z
MQMM"@4?_"\O&_P8?"2,E&S^CVO-OD[O9E%TM-OEJ,=G,EHO)_"?\.!T=&PQP
MP7QIK;<XVS@Q!1KNI2O07%V?7WQ@XQMV=G-]>_/VZOQT?''.+J^N3Z_/KD[?
MLMLQ?O'[Q?7X-@D=,1D"F#:J92K"36L\9Q9_911<2XA1%9X&!W$`M`S0(!4Y
M0`E/2Y!""7(`".7(`4(X0P[@0I$#E!>&Q*"<`$T.L%TJ#*?]H#27M`3%:5<K
MR3$7J`'`09(#1-<`S@4Y%])Y3P^PWI">E,8#Z0>IG25!2N44K4(Z34ZW!-=A
MIG!`2^#6D7.!_.M)*S#M%2<'V%"DJ`'&<A(D:&MI%<I*V@II:3\`@O#D`&$4
MK8(;3@X0'EF*'.`T32#"6CJSA#&.M$)H*TA/(CLX>@`F!HT!K*2M$%;2(+GE
M9,!X0_,H=AVD#58[4K[1DBX%AIY(Z"!A-+#=0U\*$ZQ@)K1P_N!*ZJQIJ:3U
M<(OT&53@,(.S%2[GVTL9+HL!\?*QPK6]C]Y#`M^+2[;@,@:;`[0Z`,,."(OU
M>(H0WTT>\N^;B6""AF3KM6UOZ:(!&J(!!XHN'B5D!]W88$78!SHG/(H<6OI&
M!C>A<S+LKZ/+0F_V/O^\7&W8\AZ[P[O\<XY_%AOV/G^8K;%WS._8NZ^?YMA*
MGDZGRZ^+S6SQP"YGJZ>]#D"4O690-!U@:Y3>C+!TF=A!GER^B#'!WO\:'GP.
MG>%OJ-7""'5*BW]#Q%E7?<3XNGT],E\C@U&H_06RK`<RWT#FX+C(G-Q%AL6V
M>`<X@6YD3C:1I?FL-9Q=[;,3MB^6\='4%,122Z<@/IV:@I3L0.WXNDC!IE*0
MJVT*AJLB`Q7&5DS`L^5BO9S/[B8;3+;+V6*RF,XF<W:[P2^>,!?7O[SPHHEU
MT":;RH$VU1:F`C]XAJPC1$?8-L(^5'1\%&.>A&UX*DE:4[S`VE%XK9Z6.K:_
M1]05VO)25R!D;,++<-`B<,MSJ;D1$V\F<XR)G-T^YOEF7T:E@@'.*S0$O;U6
MB:J5F!$VDCXJ09NQF5&%S>P\G^9/G_(5OE?\%'#I!`2MRR6\=OI+1HJ1A9(3
M"]>.:8<7+FM@MW`5'QLDG(S,]YG9]L)5(W-P7&28Q#O(ZL(E>Q:N'61I/J,*
M5WN8A/A3R9VS56V=\Q8SRDYD<U)VT`TJF1;!'TB+B;H"+9:ZD!;P972'%DT+
M+=8%,C2O-Y_S55SG7.^=ND1<@*&T!=;-D,E*5*4$3>:N='9@2!_J:63(O_+)
M:LU">W[WDBW99'$7+E2*\:T+V6']IL35PILH.94WMUY-XDTP#=Z,'YL<D(K,
M]YEO@C<K9`Z.BRSP9HVLYDW5ES=K9&D^(WFS-4Q"_'&=S)N"=_`FU\F\2<D.
M:S7E0HE4!_.F\?(PWDS5A;RYU176/E3%FTHJV8LWSQXGBX=\S68+O+&<_O.X
MG-_EJ_41,4HI*I!JZPV`HVJHW;`W`M,%NTIP8&:O:P=S90L'7WSY.MM\8Q^Y
MYN?Y_6PZV^"E."8,!75(=5:A="7F_W&B0FZH@Y0'BMWZ,-R*/MQ;W(Z(0>.+
M1N5!,S(N[`D6+R$@PN9E`-$HID<FA'+EM+E4@_5Z'Z<%/<AIW6I>5M4=&P^O
MJL;SW:I:?&Q4B&1DOD_\ME?5&IF#XR+#JKJ#K)X;W;.J[B!+\QE55>ET3%_)
M-ETKV29])9N4'72GKV2;<E6Q?U5-U!6J:KUJ'C;?JC4["?VJZF3]R"[GR^>]
M;R.IN,#("EAW'4A68BLEW[^-&-`'O8TDP*)>1DSKLG*,O/3=!_.:W0?3W'TP
M+U?2DY'Y/M--T&9S]^&(R%PC$&O:-'UIL[G[<#@RDC:IW0>3OOM@NG8?3/KN
M`RD[;`Q[GTR;]>Z#%=5ZLP)1KC=?+S?8_V^6K',C8I_-`5AJUI7`TK*.BT;6
MQ8^-"$I&YFMD25E7(7-P7&0AZVID==;9OEE7(TOS&9EU);*]6:=%<2Y#';ZC
MI%7;\;U"M"J/Y^W%;(EW.^]B40FRT1T"K-\7@:]3$LZ";I5T5NQT);Y2$MK/
MV!J)[T\Z*OK(6"8=>8PI$TJ21T\R4*9#@Z(/OV2JXZ14IBW0$HR5-`9K'7G&
M*'/6D6>,,N_HDU*9X(X^Q),)X3I0"/"B0X;T]%$@G#"O.[1H3Q]7RH3E0!X]
MRX3C]`$Y'.$]/0);1?K`8P:"TV<F,P#>$<"`A$G[%`G&D\>[,M"B*PN,Z`@@
ML$`?]\W`@:83`</#M0<Z)OS%A^%@./@/C)1<[PT*96YD<W1R96%M#65N9&]B
M:@TQ,34@,"!O8FH\/"]#;VYT96YT<R`Q,38@,"!2+U1Y<&4O4&%G92]087)E
M;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O
M<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q
M.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@
M,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O
M26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ,38@,"!O8FH\/"],96YG=&@@
M,C$Q.2]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU64N3V\81OK.*
M_V&.2HIDYOTX6K95I4/*CKTI^Z#+$!@ND8``!8"[6?_Z=`\>Y$K+H:,0M2IQ
MEVC.='_]]=<]P_>_+Q>?EPNZT4X1BC_Q-[M1LO\O.RP7+#YAA&O"='R'$\[T
MQCENB:646#!LPG+Q&ZGB6D8J7$A9BR^D>5PN]LO%[J^X%/Y<O$$W4@K88".%
M$O`B'.>OGSNI\+D3!I];J\7;"W*RYE8[3BP#CPR%5=&GW9^S^3P^M--#SLY!
MO7]8+O[VP6^S",$#?"""%1<=X9%4$4:9(@^`T+M/7-*_D(=_+1<_PF?_\>=W
M,-=WX$P29_H-UG3#!./D(8/-?@G'NKG[;DI/NSFU,1+2^?`'IH0Y*\G#,VS<
MD7I'/E9Y.`;XK^K(+^&Q:+O0A)S\?-J614:^R[+Z5'5%]4@^%,V!?).;`+NX
MXB9@X)B-7H)GBKD("<`CX^_HY<,^D/>U;W+T]H>B"5E7-RWQ54Y^W?LF[.LR
M#_#&'*Y1-KA&+>6C:T+@[^C:#R\^!Y`^5H!9Y;NBKGRY@C^SS;V=T?`I+0=G
M.(4R0F?X1C(V)/.W0/;^*1!_RHL.$M@!;!ZR=SCZZ@7SE]556Y=%[O'IUI>^
MR@)I]R%$&EP/)2+=GK9MD1>^*4)+/E%%<?GO^\7A3T9\BZO,D`,KS9D>?=C`
M#F?-D(*0A<,V-$2P%>&4JE7T%]UK0AEC?15XV\'+`<@>_:V/H8G!MBMX4F?_
M'LAT[SBDU5,@LJ_Z3YSSNV_CZ+3-N[LG0SIQF0VMIUH58S;"YU/1O42"Y&%7
M9$77DP,RDOEV3W9E_=R27=V0X+,]9@`3U3W7Y"5XJ.&BFH5"@HY.,VAZZ#7;
M&#N((#@`+"CJG*`*YN0K1FT(2%`;R*ZHH&8*7UZ2"`1H(%M[!!H5VZ)$!(;(
MA@JY=TP*%'P,:D8ZX0AP@9U09L!.:2EZ]%IR\)5_C&!LR$^GYDL@BI9T]2Q)
MQ8>]'$I[;AO.#FTC_.<(KF"?@"HO*JAQ`O^ZZYG<^A:RCV801531]IME_%I7
M%O;L^/T+%)J$,7I$Y9PN(829F@2H87[*4`K/<6+=8:]H\M@4GHMN'^D+Z%0Y
M=-YVY/,P%0RT)C\]@586C_MN:-!8]_^L8OOY%8%ML?JQ?.KV<K$9V&"4F[J$
M-$.7X`K[-\;=H##%2O4=>8:"A^X750DJ']3HT'=+Q`+96F\[#X@TP;?0!K<E
M/&K;4Q.Q\=OZ!$OL`WRBB1^[*@N[)@0$[@#O-OC\4+23R686%"0?4;"&#RAH
MS>V4_6<8[DA5=Z!UCU"V.88[8H"01`CF%2\ASH[.*%Y"Z$L\F-,C'M284;R*
M?MPIL2JZIBY)#8R^R&B#HSE.O[VV]?`455:>\F&P*/)A@D#4IN7FR"U78V6S
M84R&RI9RD+M;`>"`YE'CBK[_Y@$*MXH/8E#'ILY"?@+)[(L$">R/\.X1J-L%
M5`CD1%8TV>F`I9P%F)FV4`O()EPQ-M)3<\1:GV<4--1^"<$:1W/]6O)C4%^J
M/@F['9P<BJ=085>8F^)L<G96BJL+3)A2YXF,:_4-'/\N]@#XM7Q9H4R./;2J
MX0"`\UH/*1C.,J=IQZ;F9=QPPE&*#:'T1/5E6X\EV(*'_E`@C5>89T^@YW0]
MRU<D/$%QQD/.Z3A60=3Y`QYI^Q-D7K196;>1]P/%W]+S%7:`@5IH,T?P1DZ3
MM1VU&W(Z'._\^2`.%0G^'4MP^80C2SR?83'#P.WA%`\0%-AS<#;+`]F^7,QH
M_>DH//GRY"=`D!"^+-^*G"`!X#5*W(9`!]F&L@A/\T"@S)1_3/K`93L2(`K3
MQ=0"ZH0IAK1?M.JSQ*'ER-B[#W+P@='=608YS<]S-QWEWC`VW#Q\K"[#6UT?
M1)JP"TW3-WJ872!Q0T;)SA<-UCG.?I#\:4K!`1Z4LNT7?75X/N\`*E^,76\.
M)M!QN&<7PSTW3MRZ>/GZM@(XD[@D>!4?A'XJN[$[%,W%_<#X`7@S<9*=`0IE
MQXF>4<FF.R@EA]'VU>'Y]F$VYAN"QHD/SV=QUG\ULY-':)&H!R]X)@A'?/*F
M^MR]J+014[C?7E175Z=$R?]W\42B))V.('C;/2;*FH&SWP=H0;OBJ[M5D.R[
MWS>!.\*-LR]E?!)3KKD:#P/0*7_VY8&\1P:OR(>R;J`.YG!EO(<V``U>/O_1
MWX"K80[_NV^@A+B)#-6O'(@%P!W,.8X2$7<^;Q&_0@`#;:V)!OR*@;+")0VD
M<>D5A`'JI`RX42)IP`Q,-RD#:E320#JCDSY(H!I-&IA;6VB=QD$J+=,K2)V&
M6@K->=*`XWDU9<!N&5#-D[D0#OM+RL`JDT02&"V2.`@M3=))$'"5WD("V$D#
M(6^$R0'+I`%#D4@94.&247`GI$H:6$&387+@;-))KE$^4@8*@$@:2)'&@0L.
MJI0RX%REMV"<I0THT\G*8HZE!819D:XL9KA+1L$T3M4I`\5MVD`*E_8!2)F.
M@@.ODP9,L"1A&.5I(75<)(.PS"4W,-"^4\\U3V>2WU!A.-ZE(:()Y?@\D*7G
M,W[Y]S_-0+%D$]]QQV+HO6/F[2^<KUY&@%)PT5]&6+MA'$_PT.C??;CC)O@M
M_;B)XQM)\8(7-UG?=1,W;4(W_>CTCG\YEG">Y/':IEFP9E8EI16F+I[DV5I2
MDW9!,99>0;-T)UT;F%K24;(TF=>.\_0*4,\J[26+7$I:<$%OK"$$OY$/*>2-
M792P-];0,CW<K)F1XH:%O=&4U\Q)GE3`-:=2ISWE3)ID3UP#O],ZMP8I3[>+
M-9?J1A5PG,W3%EJ+&YX:K=*%`&TMH:E0SS_^OEPL%_\%0H"-40T*96YD<W1R
M96%M#65N9&]B:@TQ,3<@,"!O8FH\/"]#;VYT96YT<R`Q,3@@,"!2+U1Y<&4O
M4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R
M(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\
M+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&
M86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X
M="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ,3@@,"!O8FH\
M/"],96YG=&@@-3<R-2]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU
M74N3(S=ROG=$_X<ZZ#!VE-IXHTH^2=Z50Q%K>]>:".]A+Q2;HZ'-)D=LMJ39
M7V\D7D6P$B``CV-B-%`R4?FH+Q-OU'=_?7SXY?&!/*E9#@3^V-+T)(7[S_;E
M\8':7^C`U$"5I3!3>)IG-@T3,;\0PWC>/3[\UW"TS])"PH/D-,$_P_GGQX>/
MCP\?_A$>!7^N".1)"&X$/`DNN?F'SXREO\]"PN\SU_#[-"F./Y`-7S,]<:,2
M)<.DB7DJZ/2ACN>7\".+/S*Z&/7=^\>'?_I^\]-6@PO>FPK66?:AP3W<:$X)
ME\-[XZ&OR1.E;'B_?7QX]X?/F^=_&-[_]^/#'\UC_O)EA,EI$3;+)\JI'M[_
M'1Q&9V&*OQG!^^WPP_&R.Q\WE_WIN#F,YG^W3U]<%<J'>8YFDUEK:W<H@B;_
M<CJ^G@[[Y\UE]SQ\MSELCMO=\./'W>[RQ;41;)CEH@V=HS:V"-K\8;?=O?RT
M.QO5QX$1(KN4F`=C.*Z$>?/:J6`039P"1ADIO0(_[G;#9KL]O7S:'#_OCS\/
MQ]-E]YJ^&?,,.5,Q#WHF`[?R%T$6^H9!:T$M`\LP*#7S(H-4LOP$H4R(EQBX
M,A:6&)@R^:#$0!4I,Q#%BCJ(64ZBR##=$2&T+/M!*".DR"!%V=5""*V*#%Q,
MK,C`[C%0H8OO0A`ABPQ\-D**#"9]%OU@\C0O*LD5)V41DM/BZS8Q7C;3:#"5
MG\"8*+X+3IDL6V'2R5QB8#.513/99'!?9-",E44H.A>M8)*6_<`$-:UAB<&\
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M<=:*W(3Y_$M;1OD`9F,X"O)`[P"YGD.*8N8I(45I*`/(_W/W>CGOMS#`!9AG
M=+/`@[>"83FAMV'9*U=RB\6:$8&!]YK<E-YJ!%LP@@0,I)[>"E+3CPFB$Y!R
M,2HYY10!`*T]L"*W(3+K@6(6EA(':*!W`-2,)AQ`B7DQ'I_<#',L/+_=;D]O
M)N6:QVYW)O_^=-B-PW%W&4X?ALWA</K-3LE\.)V'M^/V=#CLMI>]X;'3%+:>
MX?M*<C)J7AG_%I?&'!3J";T-ZM[,UK1M)&+(OR:W(;]=#PMX$(@%@J<W9^LY
M:I($`ALG-8]4Z89DO7;1BMP6&ED7I<G:@!>-A4#OB`5!0[+6QD.V*__#\5?3
MYSB=/Y=2,U<X7A-Z&UZ]*G=3LQ&!`?2:W`;0"L$6>2`!0Z2G]R#2BTX0*4=!
M^2C+V7GMA!6Y#8)9)Y3S%I7#BP.A*1U\:8:2^]D6XQI%(<\;SBL,+]A.Z4W8
M9B)BF]#8VV90ADS_Y_/NTV;_/.Q^_[0[ONY>;<_[=/FX.P_;9!C5D#R=.X)G
MHA>T+5H&7>.04`L-L83>%F*,Y5YRY+>(]F9XBU+='4.=&;X6%J[7Y+9PK3$"
M$.V,"/:DFCN&*B-"+33T/;TU]&%ES9N1A/Y$3+>,U8X;)A&-]/:FECF&.B-]
M+2RG=+TI6S/[IM+&1,_")Q$H'7QI"N'CBZN%3,^%98T;>LL,RP0S6GY!ZGI%
MBO@9EO>GR^902A!I:^5M"V9&DU2(*E]<61?8L!20TMM2`,GF^20%!+V]":FR
MCB&CMV=#8CXAM\5\C=9VJ4.$F/=:7ZGJ&'"M`QL6Y('>,S]`D/:=T9%I.DYR
MSC7P=G)8A,`.EBSJ.X:,)9X-B>0^_]M(SON_T*9KC8_=;NC5FD#5J7U0`P&C
M\>%52F\*I!Y-P/\:'5XEY*;0Z-##@EKCPZN4W@"2+H]85*X]LB(W@36O1]IV
M2'PT%>GM;8=6833E]I;XJ2\1]IE\O_]]]^S;##NI4&H492;WR^[<']2[-\("
M$1A&96_ZKA%LP2<S&5AVC[""Z'2&=M2<C3/+)F!`T=H)*W(;++-.*.90KG&4
M!GH'2@4+XZ)Y&18)/RKZX7C9'']V4UH9H)93+<>'+2F]#;<BV^,OIEJ.CCP2
M<AN,V_6PZ.7XX"'0.P8/09,4U6(:J98-F7?MH!6Y#>)9!Z69ETXXIFEWKUTS
M'G;XJ5EZA_SKZ?3\V_YP*&59(Q)%:T)O0ZM7Y6Z6-2(P>%Z3V^!9(=CB#B1@
M>/3T'CP&]U_C42@]3HR6<NS:!2MR&P"S+BCF+#5K/P"%DA^`FBYO&*VY8L4L
M%G"BXU%2V&QQ!]DD;K:(/0KEUXO_PTY6M4Y2>6N#X8=0G,,HSQ=K)JF`%8N?
ME-X6/T14C5"#&=ZB5'?'4&>&KX7$8D)NB\4:(PQ@O1'!GE1SQU!E1*B%Q76@
M]\2U-R-M9TS?B4VU#:`9J@8CO;VI98ZASDA?"TD9?6_*IHSLFTI;"J7#)!64
M#KX4)ZE\$9ND@I^PYB[2VY."FN(DU23B&KOB0EQ/4MV=G/(V!?.B*7%RRA?1
MR2GXS>C(Z&WH>SII#WTUU<U/![V]":FRCN%:[]O*2][02]YP[\\QX*\RL&&)
MPI$[-K6$-UG:U))F#!VGN+SM5P8[AHSM]K<EW6A]8[!CP&T/;&A^T7W]!L9Q
MZQD?M>0C4:(P/Q;<X#V2JN\8,I9X-BR)Z-Y^1["C;6RG,GL;;N@M\V.J8]$?
M`B^S_4#U;S_HT03B`=]^H+JW'W3H84&=V7Z0TIOFQWHT`6SANPWZ/&)KUNTV
M4)G=!JJTVZ"\<5CY168X;P3G"GR[Q9CT[=:?]IN?]H?]9>]78U\OI^W_?#P=
MGG?GU=[B_XLJ2D1=7.MI?,'8%Y4P10GOAB_Y8$WC@^$XVP3=%\B:L%OT\KE9
M5`$KC.B<#3<]@<QF$-6_&415;@91^&80U;T9I$:PS0.9S2`IO2T_U(B&^,7W
M?O39;&NV[_T`6%%\9C+2.[JU?L'8GHXD<\@/5,XTW=Y^6/+$-PVM7&9'14IO
MPVE^,T*QE<,W1:BNI79;LUT/B];,OH:4WH;B#DT`@_CF@SZ/V)H5FP_LT5%\
M<"8[=Q"8(%3+#@*U-'**KG:8?MI\ANVEA<P*6F"(3>EMB"5UTY,@`H&H)_>,
M=,C=D4Z:8JTH!)R!WK$:A.K`1D7H**0LY%S$&RMR&SRSKZ&4<Z6><;3J[EUR
M<!+-KP;!$>BP'`0G"0-:SV^[99=<?;H%I5#PZNZYP:!L8[H%B1B6=>_T7H<>
M%KD:GZ$+]`Y$!TUNUC<%(>/,&_8T(RY:D9L`GG=1FG_-8`1%=*!W(%K)B&BV
MG+*BC*6(WL.5#[O72\C#P^64'W#<Y&6C'0KMA-X&;:_UW;P,9Z$1+%^3V[!<
M(=B"%"1@X/7TCNGE(/IF&=,DY.+2/.*"%;D-JUD7%).QH#AT1=]B#T!7A,4>
M.H-.80,)E.U]&!]/Y\M@8/OB;L)`NQ#EI&R40Y&;T-N0*W+'7<M)65`4R*+G
MV*VKV:R'Q2\(Q'#MZ3VX]IJDW0RE1SDW=(D1!ZW(;3#/.BA-R8SAN&9]QY8!
MURP>6U9J6E(RE`'7_WX-YML\#">J7M]^>MT_[S?%0RF@((IMUGWB.2A^-RLS
MAH*9]9Q9=C7O"[8H!0D8>CV]![U>=)J5-1WG296R\MH%*W(;7+,N*&<X0OU"
MG73K]K84#V/X8L5B/G!BB_DW])8)#DGCT4.R;!!D,FP0!$MS?^%.JM.+B8[-
M[\V)'P#EW!(\%+W!PPJ8+]:L^@,K&F@)O2W02/:0>>2WN/9F>(M2W1U#G1F^
M%A:TU^2VH*TQ`I#MC`CVI)H[ABHC0BTT`9"^4^U"1#/24VEBI$15MEZ3B#9Z
M<U/#'$.=C;X6EEJZ7I2K>?]T/*!23,3G$B@=?"FNE/LBMN@//V')XX;>DCS$
M%`[6$[CN+"0/!>7UR92K*=)"N^4-#+9&NUB(+%]$=P#`;U@:2.E-:4!,V9R?
MI(&@MS<A5=8Q9/3V;$C<)^2FN*_2VL#.:QT,2%5U#+C6@0T+]$#OF#P(>J?;
M]D;3"1@UX875]V"(MRG5WC%D#/%L2#3WN=_5[+G?12A\^'9#;UE]%ZI])`2@
M5_B8+*6WQ5&')@!DA8[)$G);9+3K83&M\#%92F]:E^C1!+"U]LB*W`;6K!YI
M^R'P05BD=[0?(@S"*/<SO>_^=#K^C"P9]THQO=0@Q>040>#8&.24K[^D#+'(
M4*;OS%S>@G5"-ODI/CM#DETDK).?C_/%R.*R.`A`PUKT-X^B;C@*(K`X%MTM
M7(5@&Z`BTT@E]+;`K1$-@;6V>45NB]2LX&*SPO!KPR*]??9$L'!M&&-L.9),
MPV[/XNS)..R/V\/;,]R>N[F=^6YHHQ@^Y$OI;6!F7?>*@40,VZQWU-:AAX4T
MPP=>@=[3'V/(P(N;_A@=#2`;&JVUBU;DME#(NBAMM`A^FUBD=V"?S'%+B&)Q
M2IQ.6EZ?@:@8[0#B"'ZA6$IO`S&INU`,1&"H);T7BM4(MG`D^(5B@=XQ01A$
MIQ.$1(UJ*JVA(RY8D=M0F75!,95Q\]<-ZJ%T\*5X$,87*R8(@1,;X]_06_IH
M?`YG,PEGRP;)B:F*"<)_VQ]/9]@$&/)[?5+U/@GNB:Z(E[_X8LWL(+!B49;2
MFZ*,S]FML\FT0###6Y3J[ACJS/"UD(A-R$T16V6$@;4W(MB3:NX8JHP(M;#H
M#_2.Z`]FW$0_'Z>95C91DXA&>GM3RQQ#G9&^%I)8^MZ4K9E]4VE[PA4+F42Q
MD$F4BN&C\-,SG@M-':J\5[>4.G2\?$"1N)%'4,*OIP</^("O5Z[24>[=`5^O
M#%,ERE!/,Y4\#OA$^%+%[8"O0WQVO&>ZV4%^?KP'\>W0$(`101`/*/DB.I<*
MOZ%)4W5W3;C*-H]ITO1Z>Q-291U#1F_/AF5)U=NOJ=(:8M1I'0Q(574,N-:!
M#4V+JJ]39/KN0>^;OOLDV,AD:2XU&.)M2K5W#!E#/!N6^KK<[VKV]:E$6'2%
MDL^$(BZZ^F)-GTK@BZXW]*;$*$D<0LBE4T5GG9R6S&6/<B=!Q%55;[@K+GT/
M4;VJ"JQH"A#=0VPNZE95@QG>HE1WQU"]J@JL6$80O>/S*B,`NB*NJGHCKC1W
M#-6KJE9;+$&([L%],".]\&\4$QEGV;"P&LST%J>V.8;JA57D7:W(;>DC^Z[2
M[D]FB]$-O67MA=?LU(&0R&P2XOV;A*I$`Y#Q34*\>Y-0C6"+VLPFH93>-"M;
M)1H`@>\*ZK/9U>R9E>4$GY6-](YFA8196:J5_X+=C^7SBKW2ID5:^;ABMP`5
M!:"G%;N?.U^[B2G7^/JSBMBBS#U!^020M:#<YF9V,J7TMFR0WP14;#;QS4@)
MN2TYM.MA<T)F/U%*;\L5'9I`I..[?OH\XFI6-4YLPF>Q6>?6':Y,U646VT[Q
M^7D]2J9X%_6'W?F\\T>>Q^&K)P*#Z4^;\_#KYO"V^Z;0I(%B&(A3>A.(@\+W
MFC00@:`V(3>AMD8PP-%*0&":TIM@6B7:P`BQ>45NPF5><*E)8PJ_/2+26_NH
M9&`Z;$]EDL:!DK9E>W+F[?+Q=-[_'6#Z<7/>O6)M1:]\JFA4X.Y<4K\0>64E
MA3NSPT09IWY%:9"CB3WX^\_#\73<#?O75U@UM=?#OUU>+Z:P1V?1[FF5`P'7
M<]2JI?4">6C@J^Z9]JA&6^L%$K$\H'HGRSOTL.&O\/GN0&^-"35G,+D"9864
M8@YH?/VVSMKI*W*?$G<:2('?#!+I'0VD7&X&D6R9HIG"9Y%?7D['Z[;QJFD<
M2TVCP*^F2.EM$2+KKJ:P'TY%0D+T7DU1(]BB4.!74Z3TMJ:Q1C0`:&WSBMR&
MR*S@8M/(\*LI(KVC:>3L"S2-G?)MT\A99=/8+41>64F)CE:*^,D4^'+JTCCB
M[>*7-!SFL?_?#>=JNA:R3,Z9)X[&]I%.4X>X'*P%6_S<U-@S_/:2E-Z6RGC7
M[24@$<MLK/?VD@X];$)C^.TE@=YQ]`7%@8-!0[N\]L^*W)8%L_Y)VV6"WV42
MZ1WM,@UWF5#!XID3,X3U9TZ^?7[>7_:GX^8PP+>4L##I%$Z-%4'Z_=#O%<+X
ME8D$/ET=AN9:^G7S_7'8;C[M+YM#A^#L?)6I$P07-Q&#`#3J2?<-,%'NO0X,
M06^`2<AM85XAV,8OP2]^"?3FQ1=^C:2KDR[SJ.D\SJ2T:PWQPHK<%LQ9+Y2Z
M-'3";WZ)]/;8IG.X^872>":;IT>REX]@#A_.IY=A]_ONO-V_[NR9;.B-#Z=/
M$/\-U\*`QABB4WH3HH,EC>T82$0`GI";`-ZA!^#:"D3P'NC-F[1$U`3P3I7;
M,//N;T02H=@H24-CACCIBMR\74A?J[8D=:-:[J)X`+G&+XF)]`[PZW!)#)F6
M_CSGL3^_W;Z]O!TV\)GBY]V'_79?^E@+*()B.J&W85K7W0<#(C`0Z][[8&H$
M6W1J_#Z80&^%AGE0$&U1*Q9H$"[,B$.;;*T+F1KQQ!6Y!ZF+.@6DEI.=F/V^
M&"BY?3&P@<UO%/'%BGTQP(GMB[FAMRQ@4KD<*UG&>EI=;XJY<P%KM_0K\>45
MS7X)*DI`ES3['SQ?>TY>KVCVR,GV$&76@'*CYA`7P!>!%G?U^&+-CB1@1=-:
M0F]+:S)[##/RVRSBS?`6I;I;ADHS?"TL1<K>4ZU51D`"<48$>U+-+4.=$:$6
MFFYEWS5%;'D7Z4YN.3+-1DH:OD(:[/0FI\99ADH[?2TLBW>]+%?S_H%;BTR3
M!'VJ9BJD:A[O1/!%;#,W_(1V3WA?]\16E4O?7%QUSG-;%FNNR^[6QQ[<D#79
MNEO"'"7@V;KWP?.U+]-LW2$F>U4V4SG];WIK#F0!;P%;;(H9CF4^/N'9*/+%
MC4`G'>F8UWUL)^CM34B5=0S7>M]67G(Y6W(YCS=@Y&(KL&')F_?TZEQ-Y-+!
MTA<WO.W!#:G!CB%CN_UM:0+8?&.P9<C8'MC0G,_[NMCVK"YB?=47-X(;O$=2
M]2U#SA+/AF5UWGME8XRVMED4@B\,W=!;]IU"5[9CPSQ(1+M6";TMECLT@7@@
MZ&Q^0F[K';7K84%-\-G\E-ZT;-FC"6!K[9$5N0VL63T<_#A\9)HT?PN"S]/`
MW0AAFIXHT[,+Y^^_G`A!9!!Q_WQ7KX@YB"!/OH&^.2\#6POLLYE]]/(,FVC8
M\#4EY`[#K'F1@3/3?)88!%/E)TBFRSHH;OH?)0;-X8.U!8:)Z_(39D'*2E(B
M[BA!J9!WGL'@#ILB!Q?S'2D"3N(4.:144YE#27V'P[1J=S@FJ?0=Y"A2UI01
MN&:ZR$$5+?O4="`Y+7-P^+!7D4/H._AAQF%W-%43*<<!T[H0C"9:__C7QX?'
MA_\%)^0MLPT*96YD<W1R96%M#65N9&]B:@TQ,3D@,"!O8FH\/"]#;VYT96YT
M<R`Q,C`@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-
M961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S
M;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O
M1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0
M<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N
M9&]B:@TQ,C`@,"!O8FH\/"],96YG=&@@-S`V.2]&:6QT97(O1FQA=&5$96-O
M9&4^/G-T<F5A;0T*>)RM74N/)+>1OC?0_Z$./F@7J5Z^R?11*]DPL.M]>`![
M`5]:/34SO>ZI&G6U9&E__?+-9%:0Q:`%8=SIR&`QOB#Y,3+(9'[SE_N['^[O
MR(-:Y8&X__R5>9`B_,_3Y_L[ZN_0`U,'JKR$'01[6%=F#H;8.\1>O![O[_Y\
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M31YD0OVGX_'P^/1T_OSE\?3+\^GCX71^.U[J!K`_H@@C_*!7<N#>@%*3[^+L
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M[;>EN,'#7*[]IE[[W,&LD_H`.^SU0X!H"5#8R(2NZ*!A=3=;08.P4:W[;1L5
M8'\Z%.W\MB0T_+;U/M5P%-8*1J0=GNG';30HS1JB,!N/V($7`Y+_.3Z^'KX[
MO;=!V+?'I^/G[X^OEN'V9B@7T%DS#!IA*-E"6`)QYPEC_WT.O<U>O80KRU(O
M\7:X_+1M4R>;;%.SZIM6.?='JY*!V1CB+KU"N"QVI?NV96P3H#N$65ON*OK2
ML&18LK&VQBOL#4OW#9WH3-H6E3&TE3ZP_8H1(EN><P^-T4"3&W1CE5>X,C#>
MGQA*H:B\Z3G7(9-AT<;:&J]P95B\/^$YQ2CH.='PG')/H\'`9&MME5?8&YCN
MSXW0MN/B,+-/EK/#S`;P7>ITOSU)G=W?]IW=_K9K,FQ?<D6[OVW8K-V^:/>W
M75>;M-L5[?VV;VOWVW.]I/G3,0WCDC+<_U$V;O/%+5@;J6[ZSH?<IY(<&D^J
M^XQM9!I.S#XZI8=LL;IK-ZG]\?AVN#R^'"]C1OJN)+>L\Z'T3CG%1J%HDXU:
MEOB.YR+[VI"-&.FL4#)F8IA+2<0,U&]&#0HNL"V_LZC(L28Q`YM$Y6(,6U:U
M#MIF&-ALUW+<X)QH-C?N@&8K8JR/?,GY9E.$@<VVE2--4HPUFDTM6I#%"#UH
MFV,2N9FI/A1JDM,36+/1RL3JB(,'SHEA6>&B6HZ:W_CMFCT;\&U`N"$8/A\H
M\MMQM2<`EWVJ:R[BJ;EQ`+-G".Z[VJ[F+$=7K<U8U8:![M[(IXAAI&HW<`%W
M9_'4E#Y0L1_9@+LW<ORX&L/LQQ]W([>N.8NG!G2SXOXT3M;T"&FOXB.D;>_T
MU!8N\U)2)VJQFIOHI#!%+4=%+=2DE0'-18I:?*(NKHA<WMSRQ\?S^?WE<#F_
MO$<$#0%W<D&&2_-C8;B\A3R5`D.A^1R':68`-H^T)#=?0E3;[A7&8*124!RU
M%>-8;P2$806$*2!*6SB%41"A%!A[1?E,[)520M4DSA8CU:+(X"3N:2GB-'FP
M;<!YA4&<L108Q\WUN5#T=G-Y=HPP(J+:=J\P"".6@H+`N3[G2PZ`<'090"0\
MM>5>80Q$*@4&CG-]S@>.K3['[;]UD-]]WB/BC)!K<%YA$&<L!06ATWG.=F/5
MH:#.>4Z=\YRZY#EUE>>LXE>=TIV[66DGQ\Q*.J9!R0/1-,]*W*U0^5GI]Z_G
MR^7PY?7\X?FM$V/JDB75)4NJ2Y945QFKG4-6^.%;SZ4"0]';J4!'I+HD475)
MHF:[3=/NI`9,,948-<4,66U8L=H4JXNW#>M8'=2@.27)L7.*7V@$'@SY0IA:
MN&*=6#D!,7DL;*R7<8L#""2J09/&9+<)10<RR*0T0(10&ZM(IP&B&C!+3'8;
M7W(L[QVM3@!J4[U"P^JD!DT+D]U&,=/J-BO1RRIUZW'#LGP"$C'5UGN%%I"H
M!O"^GLZ>=]S?><+0=4Z]</E\KEWC$[2>*ZM,]H9^YS/S$Y9X_K,U0H2Z%>,(
M=<:.@!RDR$J.2ES,6&(8V#;7<AS'35CB2`9HF[T8QUIX.SS?`&US+4=E.68L
M<>-^NY*R(9+I!9:V'744V%A1T?,K*CJOJ!#-:(D"6=PU&K=DGCX>OOOYR_%T
M.5Y^VPMP&XLI>GXQ10\D>/V`AU=/*C&.088J#MBJ;KF+51H+%9,N"47'\I&0
M2_9BW,`=J-B/R+9+?&^'%P'T]")`VZ[N/,PI/)J2'#F:W$;-F)@G#XS0/)J$
MVX'I1]-_'R_'Q]>G3X?'T_O#^^-/QY?S%[?[&3%E<SA'5\MQ(ZRYFM"?LCF8
M9JO$N`$W8T=`#D[9?"Y3YIYJ.)"U$(M9S6*T0LSA0&-=RW%C?\));N0"C;47
MXZ@`;X=G!J"QMO*99PFHL?BB&%WLP$-,ZAS,"E5B'"L-K-(YNJ$,IB$ZE]IQ
M-$1S:D>Q-4_JU%W[EQ'<%@G/09\?7_]V=--[;U+W.U4!RJGD.,JA8UOP7!40
MQVS%.(X9JCA@`TDERF=()59=]5.V&&*6E;>>>?V0!_Q_+<>QR(@;W"@'_+\7
MXVACH&+/!X#_M_(9GH#\3_WJAZ:])4Y7)T0,6S&.&)I.Z(4K:N4@3V0YGB?4
MFA8F2:$)IB-+_/YXLK'_B^>)Q_>?GT_/ES?W+/#3<3Q<<<9!W%'+4=R1C$:&
M*ZY&@$HJ,8I*INP(R"%F2?()9DF65#U;+MS.@(PA]E1!C74M1Q'-C),L34"-
MM1>C>&?"#D<W4&-MY1,T!#867[2EH57)\7#%F0"P4B5&L5+;156XXM[+`VDH
MR2=HR#&.IR&ZLK*K4["XJ_-WY]?C\\?3X>G'U]?CZ>F7P_'GIT^/IX_'PU^)
M)!\?GT\7>T$/+^?+Y7A9#J=C:\'*\X=K.(B2*CF.DB*`6^&,?Z<1X*"M&,=!
M0Q4';"#I1#F6=(3,5;M^3%,_=NWAM@6:YML!AH$-L)5CC?%%LS&"$)J-H9W8
M!FJ,O1C',0.-X<D#:(RM'$LJ7%>-46)+RA>A6R[P0]Z]\`QPR%:,XY"F"_I1
M@N1Q7=Q=O<0KG1:3X^7`YBVG"2V3[^28!*E2+*=TI"XIG?1B][OSFXV1SCE-
M>HQI4D1D$M`G1V30,BU*Q\N1+5Q.%22W2HXC-T6&%M0CC(2HMCTH#,%(I2"B
MW(IQ1#D"PK`"PA00I2V\PB"(4`HDW2B?V,*58-3/,'PAE"U,(K9P)9PF#[D-
MN*`PAC.6`OE\KL_YH@/-Y2DSPHB(:MN#PAB,6`J:#^;ZG"LY`L*19@"1\-26
M!X4A$*D4.+?,]3G5ZG/K(H19Y#JZ]=^(##,BKK$%A3&8L10T<6W%N(FKV59U
M\,L;P6\MQRS=*WX[:O`TS!MA*Y\/6P>J]N3)X;"53X>M0Q4';""#5G+4:OQ0
MU8:![KZ6XTAMI&K'&X"[]V(<$0U4[$D"</>U'+7`/E2U&W\<CD3Y="3:K+@?
M/]$<B=(<B=(2B=+A2)0V(E$Z'XFR%(GZPW%2)$IUW+#Y;VZ_YH?7\^<4C>[/
M4>J'7+1$H>6]"45+%$K'HU#:B$+I?!3*!J-06J)0RG>V!X7Q*)3"42B=CD)'
M0!A60)@"HK2%5QB/0FDC"J5S42@G&89_]!>F//JORVKD8M;!-);G)EH"4<IW
M^(+">"`*=+NM?":Q4*!V$@N[H)26H)3R'8Z@,!Z4`EUP+\;-!0-=T/,G+4$I
MY3O+@\)X4`ITP:T<'92*=A>4BQ1D4<-)7A=WTA*84K[#%Q3&`U,*!Z9!C`7J
M2@YUP"I(E2L<I.[DF"!5KF-!JJL"(OY:CB+^D:H=M[HJ`+*NQ"BR'JLX8(,(
MMI:C@M2AJ@T#W7TM1P6I0U5;'H'<O1>CB&FD8D<:D+NOY:@@=:AJ.W!<%<#@
MKL2H(+5=<2^TE%K"XSO)\:&E-(%E;#Q)""E+P6)-VT#?/AU?#\^GI_/GL.H2
MTYR.B7X['EX[$T%^T-.!83(=N1SL:H3H0L_&=E-V!.0@>U1R''M,6&(8V#;7
M<AR93%CBJ`!HF[T8QRUX.SRE`&US+<=1S80ECB@T&%948ASS-.VH0PFI8*I)
M\@FJ4>F87"+<>6>1:59W_?=H4.^?/\7X>'E+"RV]:$0JF&TJ.8YMHO4WHQ%;
M!40O6S&.7H8J#MA`/HER]./>FJOVL;;B)=;6E"RRNW4-:H&M?.*);&/-\%(O
MU!I[,8Y0!EK#,P70&ELY>JF7MUM#KGI9B>K%+[96B$6">.+A9*PMNK$,US#!
M\.DTF10I3;:-9.1ZFUX.?SC]9)G%;<B/H0XBLN$:YII*CN.:"`0;V=@:(>K9
MBG'4,V-'0`XR492C]YSP;$F]S4&L"S.80`=HJFLY+M"9<)&C$:"I]F(<+^'M
M\'0$--56CJ6&5E.I=2$4L27?U0\1UE:,"WNV_O%#OA/[4`-34Y)/4!/CB9HX
M*[&/80.QS^'?GT_GU^>W7RPUA0BH%_E8&T$VJN0X-HJVWXQ\W(G6`/ULQ3CZ
M&:HX8`/Y)LJQ?"-+U7ZN=0%JFFO%HEEOBQOD_ZU\)NXIMHS'/4!;[,4X?AEH
M"T\<0%MLY>BX9ZW;8K??<#7-,P/<H+>50BP2Q#-ASU!3=,,%L>JXSNBNPCJC
MZ^QQV2U>#JPS.DUHG7$G1[$44249M(J2#"(C-!4R1;L440RGKK?F=B.9Z*3D
MKY=TF<\'BY<C2Y).%6+$6HYC1-)\>3SK.P**,!*BVO:@,`0CE0+8M1+CV'4$
MA&$%A"D@2EMXA4$0H13$U$F.9FJ98>Q>[I$<L129()H\*#>X@L(8Q%@*F@`F
MNYN?``9:RG%L@A$1U;8'A3$8L10P@4QVMU6.@;"T%4$D/+7E06$(1"H%34:3
MW<U'MV!W4XN28C"Z-2)CC'!K8$%A#&,L!<QQE1@7*3<;JHXTW1P3)S)[%28R
M84@F:P,?QQ.UH)EK)\?,7,*DPRRH%CF^%DRH:J^VGZ'ZZ<,T?7XN*!,BG0\+
MBY?@R6;N'CC?Z.D(7)A6\+6;;X+="4)M;%"`[4YJT`2C9\/W(:L-*U:;8G7Q
MME=H61W4P!E%S\7^-MY,=E_EV802BQ#-K.<J,Q23!\7&_J#0@!+5P)E#3S\Z
M;*`,;V))&"*<VO"@T,`0U:!I8ZX3N9(#G<CS7;`Z`:A-#0JPU4D-G"?F.I%+
MUC8[D63KPICIG'26H$14M?U!H0$EJD'3@9Y]Y!GL0IT'%2'A3.].CMF5(A0Z
MV^5Y5,*IVEJ.HV:\)9X;)9BJK<0XLIVQ(R`'Z;.2HQ:A9RPQ#&R;:SDJ;IZQ
MQ%$.T#9[,8[#\'9X]@':YEJ.6H2>L<1Q@`2SL948%6.V[:@#10XG8K-\(E`4
M*1%+_2=JXP$ITEWGK=3?'S^<7X]IT\O;X\^[E_IV`1]O!'Q\/N`38RE75P5$
M(WPZ9ANJ.&`#>8//A5U,Y*K#QDZZ2?.114BR<-$\5=8PL!&V\IG@2>#SKE"#
M[,4X[AAH$$\*0(-LY1,[;>L&V>RT50M1ZV)4,XAQ(YS#<0B?CD.&6J,;AU#X
M]-6='!6'L*G35UV-(&/0Z93DA"5^O%,XJTAGLXI3=@3D()_0Z=-79RPQ#&R;
M:SDN#IFPQ`U]H&WV8AR7X.WP%`*TS;4<%X=,6.(X@,*Y+CJ;ZVK;44_Q?$W'
M][NKF.LB^?C^>`GFN@A\?/].C@IA2#[C390UFC6^"_:?K^>?GB_/Y]/!QC`C
M(8P;M1%?@IIAY:/\XR6<\++W0#:KY#@V(V-'^4>[$X3:6,\?#;N3&L1]9/;<
MV"&K#2M6FV)U\;8CC*;500UD2C)WE+]8L]WUC@W125,X-DDH3!X4&],]W;10
M1#609>?Z3"@Z=HY_LCM"J(WUO-:R.ZI!G#S79WS)L7/\H]4)0&VJI[*&U4D-
M9/"Y/J-:?69=-.U]XS:!B'AJRWUFJP4BJD'D3V;/#NZXOA>\<9T6\-U5F`NX
MR0OX\7)@`=]I0E/#3HZ9&KC)IQ";<F2-Y.G(&O>55'=6UGB`&-$FX`FDSBOQ
M\7)D)=ZI0A-%+4=-%-R,K<1'&`E1;7M0J&#4A0W)A4V>$F-#!X7A3Y0Y55TW
M^95XG+Q]2>`0W-_T9A^=U_.S*TJ+>H6&*]R]Y`I37)'Q!X7A#YUYS&+OB[T<
ME4/8.F.?0Y!4+%(CXN_D*)-'^@:@5QC$&DN5-$29[VHY*CVQP3J\MI,@170)
MA\X[!%IM[^_%MO?(R<X)06'XJVG0,-B+Q[WA2R*&@9^`=-YG$%VQP1\4&JYP
M]X(KDE=J_$%A^-MKT#"XEJ,R-_4PJ#,W>EUL[QG?JY#\%%U6X_,*@U!C*;-#
MNA>CDD)C8Z!Z(.,2SBGOY)@L$%>W<W1^LI)PHKB6X^:_@:K]+"'!1'$E1CWK
MC%4<L$&/*[4<E=@9JMHPT-W7<M0SQE#5CHT`=^_%J,>$D8H]:0#NOI:C<C5#
M5;NQ*,&,;R5&Q>?MBOM1)I<I/N<RQ><\?R`W7H[$YQS.%V?Y1'PN1%I]HBIO
M4^)*J1*?.YYV,?IF]^SA\<N7E^>GQ^]?CH>W\^'3^>7]\?7B/AQL[WX^GPZ7
MM_/3WQ!!?7!1\E;V3`F,^=!I1ZF4A<SHGM2BG$R06G/-8Q>7!Q@)46U[4-!P
M).OOE=01-Z5P>2(8ZRBI%,2N03P3U`M@EV$WJ$^N,,45I46]0L,5_E[)1W&S
MPQ\4AG?X>LP0W_.Y';XNFMDXXQ\/ZJ.C3*:'#<"@,+S5UZF"$TR4SP3U!>MX
M4!\A17091PEJ&VT?[I5L&#<[)P2%X3W#T#`HXIF@'C,,_)017)&\4N,/"@U7
M^'LEQ<;-#G]0&-YY#`V#K1P=U!O8&6+AJUXT0QQZE'P4W55C"PK#FX^=*C3G
M\]D%F03RQL803N'3"79R5!#/;K_8[2<G"A\M4,MQ\]U`U7Y6H.#1`I48%\0/
M51RP@:1>R7%!_$C5AH'NOI;C@OB1JAW[`.[>BW%!_$#%GB0`=U_+<4'\2-5N
M_%'PH(!*C!O0S8I[H3=;X2VC63X1>I-\.(!R[P*G+V.YZU[H_>7XFJ/L3X^O
M1\291\Y:B"IJ.8XJR-1V4U<CP!R5&,<<,W8$Y!"1U'(<D4Q88AC8-M=R'*],
M6&)9`6J;O1A',W@['+M`;7,MQ['.A"5V=+L:`1*JQ#@2:MI1S^W,X@RI`W?U
M$J_R?@C6V'<?M4#"TM,[59G)1P8P&_XYPOKJF\?+\U/KY`(_H@."!"8;GE\&
MBI?@1@YW#WJ43_*)1WEFFCV@>AJ/=B<(M;%!0<'/K_Z>+H5U*6Q*X?9K3PQ^
M[2F*)Y[=V>;-CZ%G]XS=%.RES;Q"`[N_ITMAO0,<%-HO3['&RU-L[KT7]V64
M+7KF/N.4'M;)@^CM)DE.,'GL;8P/"NTWIUCCS:DDGW@09Q-O3B4,$4XV/+^.
MU&K(<$^7PGJ'.BBT7[N".G$13SQYHSJQ)^>`/;FA!AP4&MC]/5T*ZQW@H-!^
M>0OJQ%LY]E%;-M"[8+&SMR4Y(/JB-CPHM-_:8O!;6Y48->.Q]FMSW8@U?XZ)
MY<\QL?(Y)C;\.2;6^!P3F_\<$TOOC'S[_/+CV_$](OHMGUEBY3-+K'QFB8U_
M9HDU/K/$YC^SQ`8_L\3*9Y98^<P2*Y]9VL'8%5:E<(D&9)DRQMHVE0+VL%1B
MW)2I@".CNE-F^5@3*Q]K8N5C34U7^'NJ%%8[_$%AT!6A%+2'I9;C9M"-,_HS
M:/^QHGSGB97O/"647F$,92P%[5ZIY;CYM:`<GU_+-Y]8^>83*]]\:K5ZN*=*
M8;5S0E`8\T<L!>Q>F1P`KB1F`'A^+U^.8N7+4:Q\.:KI"G]/E<)JAS\H#+DB
ME8)VKTP.`"5I;P!PQ%>G6/GJ%"M?G4HHO<(8RE@*V+A2B5$;5\:Z?_V(&5]3
MXF(WI=9RU)0JTHF\G)C\^56YIIS8GX_/'S_9J?;P^-/Q]?'C,63`PO?CCS_\
M^/S3XXL[,3-*?[Q8S>=3_7CZC]O(\I*Y^Y64M],T'NOY]/CR].-+^`+CZ?BV
M/:D\I_)<#@](WNV>?L,+/I5[-W+6:.7NS,YOYQW\_.=?Z:EJ+N*9]!P;>*_%
M3U/A%9Y2\^ZY"G#)1CZ3)!NRS#$BX)(LGLF*C53LB:OM$C]P_;M&E5U%/!6I
MS[U"Z`XE#)&ZNXJ1.LFG[[!J(WTW4B<$SER1Z<-X&)%PYFH\9(_P$M*7=)DW
M:L3+D9#=J4)IK22?26L-'@`7821$M>U!P<!QJK^WEL)YOSTK+S<--G(J!66Y
MIM]U8H/O.F4/F.*!TI!>H>$!?V\MA=<=;,\FHQX(I<!<U^1[4\QD']2'$K.%
M<OM/(F+UY"231_,&G">O09RQ%)@+FW^S:J2M'74F&!'12[K,*:Q66X=[:RF\
M[H![8A[T02P%I<.FW](:\H`GT1Q91P]L8`>%A@?\O;447G>P_50QYH%4"DR*
M3;[QQ1C<VZE8N-&+Y'P\,$].BOZJP?G`?!!G+`4ESJ9?"FNW=!TM4ITR9>[J
M)5[E3%F\A):*W"UHPLUR_(1+32<U5H>:T>X$(9N;<V'Q$EP@HN&#,-<S:91/
MS*34-/<'U).ASLFO:/?&V*#03GY17:;ALA1&RWI)J[F2&C!U5F+4U$E'UL0,
M*Y!-@5R:RBNTDUP9LBF0,\Z@T((<U*"Y,LDGYLH$>F2NK)\$DAM,'FH;\X-"
M`TE4@V;#6HZ:#4>:SW.XSMFJ9+>_S-FJ5O.%>V4JU6J'-"@T0$<U8/J;[+&N
MY`AD3UTY*Q4A;W`&A796*D).Z&N<00&&G-2@^6ZRQ[KY#NRQ5"V<B868UAGP
M?H+3.?.4W%#,#PH-)%$-F-$J,6I&:S=>F'?L%*Q7^ZR')&\W[33W=H5?EJO_
M9=#YNNU\]VJX"L]7QCQ0IM?@^]_]>E6X5[\5L-/ZZU^SBC5501Y";NVKW;OQ
M[F1G_]O,_W3Y#=\KV.'KE:[=^\R]1-)3X(ST?T$PUC=!,DV["HJY;Z)U%+3;
M`MA3,%STC5SY#1LHX6O_)R@5]D]7@PEQHQ8N](W?$)**OH9T;S1T-90P-S2T
MM+VNJV%L-7V-52K3[UM$REN]3SIV[6DP1Z1=#:YN=!]FG7[#4NF.?.YJ**7;
MW=P.Q>_^<G]W?_?_RA3,I@T*96YD<W1R96%M#65N9&]B:@TQ,C$@,"!O8FH\
M/"]#;VYT96YT<R`Q,C(@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2
M;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R
M(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V
M(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y
M-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E
M25T^/CX^#65N9&]B:@TQ,C(@,"!O8FH\/"],96YG=&@@.#@Q-2]&:6QT97(O
M1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU74V3X[B1O7=$_P<>?)AU:&J)3P+'
M^7*$(S9L[[HCU@=?U"KUC-954H^J>L;C7[_X!D@F(2!57D?;VE>@,O,E2+U,
M@N"W?WO_[N?W[\8'J<4PVO^X3^I!</]?A^?W[XC["QFH'(AT"!W(2!ZTIFI0
MXSAHJ8?K\?V[_QW.[KLF+NP7":7L_PS7']^_^^G]NT^_MU]E_U,`XP/GS!AX
MX$PP\S],4SK_N^;"_EVSR?Y=*<G@+Z3#UU1,0@Z*C(.:1O.MUJ=/;6-^CG_D
MZ8^4Y*"^_?#^W7_^8?_Q,%D*/I@#'%GN2R,]C#I:Q/#!,*2G!TWD-'SXU_MW
M7WW_V_[Q=!C^8_CP?^_?_6"^ZK_?QJ!A)!L4#X2:>*S!\8%H0]J'7XWM/YY?
MC]?S_O5T.>^?=L,?SX<'E!]RVP\^BD%K[\97?Z=\?.M`R60,3"%.^<!''^97
MWUW.+Y>GT^/^K0U23I+!KPV;G*CAP\$1ZSY:8E^/C\-?7_>OQ^?C^?5EN'P:
MOOMI?_[Q^#*<SN8/E\,_?KH\/1ZO+V_MG*!3<DXXMPSIE+ZY&4:3F:_>?.X*
M)G-*A3FMJ8Y35_+),_S#SU].K[\-?Q_%^/WQT^EP>C4?R5O/7LG4O7'>.C?$
MO>=&Q0`Q%QT]W?G]>B"L\OUJ=-]OKL[CY":<.2>$"%GZZ_$X[`^'R_/G_?FW
MT_G'X7QY/;[,+S+F2Z2[.DUZ')AS(%MREW$Z"*TH<P/HQ@`UF335!DP3JW^#
ME(I6!PBI='4`G\S95QO`I*H/H"8'U0%$2ED=,-XPP;6L\\"5H:HZ8!)UJKD4
M0E4'&"IY=0"_-8`)4<T%IX+5!Q!#577`R&65!Z8YJ3K)%%-5$^8W6E?3S22K
MAVETD:Q_`V>TF@MF_J\>!:6*5`>8D[<>YDAYU4FJ&:F:H(I.U2CH1.L\F#_3
ML3I`$%4W8;)='\#(6#VSC`?U"P@EM'YFT9&R:A1$FSBJ`Q2E]0'F,EGU@4@Z
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MBHF(&(31O5VSPA[JB&J9%;5_O3Y5B)WL)8VDWTS"+;-!(!';#?^UU`8?+J_`
M3_8]YDTBXH0U>;7SU^6UUGF^QYPI:Z,YOMUT;LCQYOS1^0Q<]V'O<9U-^8P;
M'[B.DR?TE]_4%$TGFYD'HVW5>Z[J/>Q)\]I95^FCNR,WS[IPO\S>/6/N?VQO
MW1UN_#3*NB@-/Z62,>)3WSEJ#Q4DW3*A1,>?/6*[2^YT^';_M#\?CL/^=?C>
M_/`_?SQ>3<6V&^@XLC;'7=W)W32:.;[&V^M1>VCPO(-"5US9ZF3AR!)N]\,>
MB?%#.8.F8E@XDO'.5+)1)$]FEUM"=UR..S7*-M]L:Q/@:`6WE[SVR'Z.F)Q`
M/S+<RY`]$F+H=XT.30),6HEWNL3-7[:31MK\<N7VFJ@5W%&%2TS"7&4&^)'A
M7G8$ORMA7%(P827>ZY+:.,NFG1#3CHZZS3576JZY6L$=%2?#Y,R5+H`?&>XD
MR!UY1\X$UV#.2KS7I6E^WI,@^MP//!7C;AP;V7+EUYJM`NYTS1V97<N]E97@
MJ/BD8)\4VB=U5P8EDV`&2[S7):[G&>29II%,NY'+':6JS3]7+:T)*^!.[]R1
M]R71R5?`IPSW^D0VKE.-29PH`Y-8XKTN<;I(HLI)U+N)2G,);<VA!G]J"KC7
M.<T;<Y@7IEGQ;&H%4(]''*''33GBZT.BM(ARG+-8G7Y_^N7T>#P_OM@%'-<O
MQ\?A<AX^7X^?CM>K^7]>;"FYX;`3S72"=?@,[]/AP>/USTYAVNID8P(2WB7<
M)[R;#"MG`53:`>_5D4(DTY6&>/;!">!U\"NX3U$W!.\4+V!X"7?<O9K:#%M)
M#+!>XKW*B],^UIV*70>_@OMD<4/P3K8"AI=PQYVKMI/,Z5J`]1+OU4Y4]['N
M=.@Z^!7<)VP;@G?"$S"\A-L-VR.;#&N0]1+OU3M$]K'N=.0Z^!7<<;N@[?+J
MQ")D6*$-JS;#3(*LEW@OZ\5OV:I.8*9.D(IO>.,DX)J&`L9H2F@&5/2(TWR`
M$TNXO;M+1%,NG"@$<E'BO?$+@LZ%!B^_!8S1ADVYJ+9N1P5+Q8@CI")A02I2
M6^/&&Y9.Z__J[TY=C_8^HEWHOI"(P^GEY8OKZQXN+Z\O;6$XM6?\!07D#.\3
MD&1K85&]D6LL0GJRA/OT),8/Y0R"\C+@&'E)V*V+?[U_NZ9F!?>IS7YJG%8$
M_%C"?>(3X8?5G$"*2ARC1>](D5.2:VI6<)\T[:?&"4O`CR7<IU01?D@*IJC$
M,<+UCA0YV;FF9@7WZ=A^:IP*!?Q8PGVR%N.'!E-4XAB5>T>*G$9=4[."^T1O
M/S5.LD)^*+0?"N4'DV"*2KPW1=-8IHB1M(;#-E[E3HK&6\!.SZXY*F",0(8F
M3V?3%?!I"??IY?Z\.9D,Y*W$N^7S]$9YT^`O1`%CQ'13WF:-UFGB3B4S/E?/
M"[Q'/;OEC'XACIY4;K22L.[AF^?+]?7TKWT4T(]1/]O'YH[G%_^'Y:J0.WRR
M3^M,.BEZOPCE<H:60-UA1;#2RC2FR`4=PU.RY\OY^/SYZ?+;\1B*A0NP'''>
M5[;NF!-CEI\"IQO3I%863&KK$<EY7]F:4`O+"<;4`9&?6WUE:\&<G`O+"<<(
M_VBZN:\,!)]AC-)O"=XJ<<AP@C'2OLFP?0X+8+W`,5J^BW6KM8'@,XP1[RW!
M6W$-&4XP1JTW&9849+W`NUG7O&0]WY]D1.VX$I7N,D!!AC&JO(4"JYHAPPG&
MR/`VPQKDOL`QNKMKQEM=#`2?88S0;@G>"F'0L$(;5FV&F019+_!^P<KZ6+<*
M%P@^P_V+O=LNLE;&0H83C-'%388I`UDO\'XA+##7F4F#E]H,=U.@:Y?:6M_8
M!F]UGBBWO5GC7<I7QB4&U.U$$Y2OL@^?N.UG8FO8J-Z#?Q#2R\#]^7'X=7^]
M[NWF*:?SL`?E+](Q>VIQ$=<^<,628^ZS=>SS]?3+_O4X?'[:']P6+KOA?'RU
M;A[_:27YT6WI\L8^406LHB%F^E#9VB2V8M9X8)^[G6U>E'&V\<A-51]SCFF;
MN[)RX4B"47(Y,-39-G=G-5DZDO!N]6RW*H!R17:<TMVH&U=F.@V\IBC#*%'=
M3Y&3Q(`?"49I;(0?5EH#J2KP_E7/NI*J]A8Z0$^&42J\GQZGH0$_$HP2Y0@_
M)`735."8M<Y@FOA.$K'38^-B/:>QUQ1E&"7:^RERDAOP(\$H#8_Q0X.I*G"4
MI,^I0K72`6HRC%+X_=0X?0[YH=!^*)0?3((I*G"4_K\C14Z]KZG),*H<Z*?&
MB7G`CP2CJ@.$'Y2!*2KP_A7*&W+/7O"F'6.MKFGP-R'#J.IADZ)9HUQ.%"P7
M%GA7N4#(O[%<P#IFSD2I^;^G7+C'IVD"R@6ZF^BT$X1M),[*>6L4JA`"CJD0
MI-ZZ&37OH%L30$G@84Q)$%FXU4&W%J`:(."8&@!,P+235._HN+5FS&IT@(0,
M8T1_"PE6E$.&$XQ1^4V&C7R'V"]PC*S?9K_230<(R#!&Q[<08'4V9#C!&.'>
M9%A2D/D"[V9^VF#>%+YR&G=DG"H-=8"%#&.T>0L+5CM#AA.,$>-MAC5(?X%C
MU'=!?UM#'0@^PQBYW1*\E<.@884VK-H,,PFR7N`80=W%NA6\0/`9QBCHEN"M
MPH4,)Q@CF9L,4P:R7N#]&GFL7&JFW<3DEC,:O.!F&*.*MUFH]=3M]M'0:I(%
MWB.2I8S[+8_"MM>]%F5\"FLJ?OCGX?CR,AR,''8;+O^R?_KB%/-?C]>3$:+?
M#'])"[0A18KTS)Y>/*T2'^V2EZ"2A?WL]@/T*SQ^.5Z-=R\_;2PWP5/#"P\(
M(<D#Z3Y;#TS,QV>WPF38NPT%A[9,.HG+%+CN)."8=2<2MZ^(M0@L0_$P2D1S
MU')T:Q!:E1)PS*J4Z`EV.3I`3891TKJ?&B>,`3\2C%+:"#^LP`925."8)2SW
MI,A)YC4U&49I\'YJG((&_$@P2I(C_)`43%&!HQ1Z3E%QRV/<*<YWDG5L'`)P
ME&&48._GR,EMP(\$H_0[Q@\-YJK`47+^CM/)B?$U-1E&J?M^:IPVA_Q0:#\4
MR@\FP105.$K[WY$BI]S7U&0850KT4^.$/.!'@E&5`<(/RL`4%3BJ4'B+*YZ3
M^0!'&ONKX([<Y&C>31_A9><+O*M0H''9.>$Z]ZSUC5[ZI\MU2(NR(7U^AT=C
M7`YNW];BEYU_O)R_O!QK"[ZM05!XC^@%WY*T+?BV)B"E/6(7?$<&;K:K1WC!
M=\"[I;69"M'T_!11.TFKO>HU`QE&">H&!IS@!0PG&*6@6PQ;:0Q07^#=>HSQ
M#>JKC>IU]!E&B>2&Z)V(!0PG&*6*6PQ+"M)>X-U/98XC3+LD.ZVWJ'<2=<U`
MAE&:MX$!ITD!PPE&B=PFPQJDOL!1JG;L7/4-!)]AE(QM"-[)3,BP0AM6;8:9
M!%DO<)10[6'="<EU\!E&*=.&X)UR!`PG&"5%6PQ3!K)>X-VL2[)QF:&[D:@M
M1S1XH<TP2FAN,E!K4(MI!'7G`N]1>4*G1=^4T/S0'[FUBN/U,IS.OQQ?7NT*
M"DAZ8IVB?!"32$[%S=`_[L__6.Z#7FT!6_N0$@TX1HD*A=J1Q%H$A*F',<(T
M\M/9`K8&(9T:<(Q.C9[,'Z*@JS45U3XPP$^&,;(5P8\5G9`?"<:H6(P?YA`H
M3P6.$;4;>6IO!`/<9!BC<1'<6(4*^9%@C.3%^"$IF*,"[U;`9)KEB(W%+JBM
M>;+Z%>`GP]U>N2/%6J:T[Z9@I2WD4X(Q6AF1,RN1H9P5.$8Z@^QT-(0!:C*,
M4=((:JP.!OU0:#\4R@\FP105.$9GWY,BJY(!:C*,D=T(:JQHAOQ(,$:%8_R@
M#$Q1@??O_#'>ER(-_BAD&"//MZF9]8'MF\]!/3['N_2X4+$/+$5N!+O/]4ZP
M?0?:&7K7VYT.\;3,6PN_2N.KP\4H_^O+Z7*N=(*M35!_>QREOWE+0W9T)B#!
MS;#O<HDDW.H$6PN@PF:XE[?0;'JNW.2T4W*K8G42>$U!AE&:NH$"IWD!PPE&
MB>@6PU8=`]P7>+=JMC]B,/=;O#M9NPX_PRB=W!"^T[&`X02CA'&+84E!W@L<
M\W@AR#O946KO#](-7YQ879.084P[N(4$IT@!PPE&2=PFPQIDO\!1FC:SW]8.
M!H+/,$K$-@3O1"9D6*$-JS;#3(*L%SA*IO:P[F3D.O@,HW1I0_!.-P*&$XP2
MHBV&*0-9+W#,<WV;5QJQ>OW/O",,D:"QEUMWY"8)M8ZPO5I"S_4M\"[!1]/C
M<U052Q'B^VZ+UU9_O%ROEU_MNF6W6_1P.A^^N*7*3HP".O0>MT:_"L"^BY&1
MY!<EZ86$U]/CC\?AOR[[K;WQL-:M`!S32X`Y#2HX/,/XQG%RG5[[R\3$TLN.
MJ:+S]Y!N_1N>+X^G3Z<#L!%AM5]N?88>-`PXYD%#,4I,O]R]36W]W*&',?(]
M<MK9+W<['0"/(08<LV0Z91>Y9!J@)L,868^@QHIRR(\$8U0^Q@\C[J$4%3AF
MR?0]*;*"':`FPY@*`$&-U>^0'PG&%`08/R0%4U3@F"T"BQ05=1FG.Z4[-A\!
M",HPIEA`$&1_]2$_$HRI'5!^:#!1!8XI)>XYEVPA`%"384QE@:#&U@6@'PKM
MAT+YP228H@+'U!WWI,A6#0`U&<:4(0AJ;!$!^9%@3%6"\8,R,$4%CMFI\/[+
MG2TP(((T]O=@TK7?@UF3G!N34)-\@7=IY"D^.3@2F7:J9E2''3Z^/9[="]I-
MB9);U<.GX_[UR_7HBY-MD7R_=T*F2H7*L'SE\FFK*$$:,E5(-&0?X51I!Y;)
M??XUM>E?3Q^?CL/C\>.B4IEWZZT;4+<^X)AN/9=;&Q'.N_76!-"M]S!*[HNM
MLF/>K;<6H&Y]P%'Z/IANWJ@;"#[#*$'?$+P3W(#A!*,4?(MA*\T!U@L<)=E[
M6'>2>AU\AE$:O2%XIZ$!PPE&B?(6PY*"K!<X2H5GUO//DA!\QU1M7Q&`@@RC
M9'<#!4X6`X83C-+9388UR'V!HX1USXQWPG<=?(912KHA>*=T(<,*;5BU&682
M9+W`45JYAW6G9=?!9Q@ECAN"=^(5,)Q@E!IN,4P9R'J!H^1O_W7&R5.``HV]
MU$ZZ=JFM=NC)!,O?.=XE,%E\,H^(XA4U]IH<-A4Y7@^G%[=&!'YCR_"C[5P?
M'X>/OX'B]P[?*$WBE\OPMIK/U]/Y</J\?]K2P$A[DB1[AHLQFG-;E_QT>7H\
M7CO:WV2"!;#'40*8(=K.H[,(Z6&"?2%ZY*BW_4TF6!X3]/O1HR?H]O>:F@RC
MU'(_-4[K`GXD&"6>$7Y8S0RDJ,!16OJ.%#DEO*8FPRAIW4^-$\:`'PE&*6V$
M'Y*"*2IPE/#.*2HVVB)T)\;6=J^5S6N",HS2X?T$.14-^)%@E"S'^*'!1!5X
M]]KY:9HE:O:JZJYD.;6])BG#W04$'>'3O'U9OQ/BD$\*F3AW9'_BG*`'$E?@
M**%_QT70R?0U-1E&Z?Y^:IQJ!_Q(,*H,0/A!&9BB`L>L&;\K11K\?<@PJCS8
MI&;>:65:#L].]MI/3UX`CZ/]Y$2C__B3<>KWRT[Z.);OA,^EQ!SODNMC>M)2
MB?2N^,E]MJ7$GXZOP]/EY66S=6SD90@HQO84/RKWT0U08$AQF*%U]AK1-=XG
MN\?-IS33>*MCH]\AA+FS?L"&WV'8XNVG*[A/I#=X;15K\EIEKY.K?L"6UW[8
M\GVR)8Z1]./-_9;FC><00(QE[K4?``<0ARUH7\%]!4`+[4911Z]#`'-7_8`-
MK\.PI==+N*]<:/#::N?H=0A@[JH?L.%U&+:<+"6.*2YZ)HL5W2&`&,O<:S\`
M#B`.6]"^@OM*D1;:)4U>BW1%+%SU`S:\#L.67B_AOL*EP6NKWZ/7,OTR%:[Z
M`1M>AV'+R5+BO>J9ZK[)8H5_""#&,O?:#X`#B,,6M*_@OG*HA7:>+N@Q@+FK
M?L"&UV'8TNLEW%<\-7AMZX?DM<Y>)U?]@"VO-3A92AQS0Z1GLMAB(P008YE[
M[0?``<1A"]I7<-_=E!;:F<Q>J^QU<M4/V/):P5XKM->JR6M;O42O6;J*%Z[Z
M`1M>AV'+R5+BO9-EKED8X<63]G(W3GHGU-8S1K8$"L'$N.81^`%P,''8(@4%
MW%VI3O"\7]?Q.1TT7>AC,'.W_8"-",*P901+N*^D;)E$.DF!&,#<53]@P^LP
M;#F)2KS[T1&*GT1J3`HAQC6/P`_8"$:#"J&`NVMIWCJ)*G>YV.3OX,R<*O'^
MTI2I=">)T/S`!Z'I@8_]DWL2>O\Z?'\\')\_'J\#([N!CJV;S[A"<YK@`G2&
M=Q6@T?/.^S[6(E123MC[/B@_E#,(%HD3[K[/*)(GBX[U3K-QI\S?V^\``22M
MX*X"$$&2J]T`/Y9P5TF'\<,68T"R2KRW2#-_V4Y6X_7`%5EK?E9P5^V%X,>5
M38`?2[BKFL+X(2F8IQ+OS=.DX3QQM>,CW4T]>P8!'*W@KM('P9&K6@`_EG!7
M,8/R0X.Y*G'$G:`R5[,[068.]-T)`D@J8,2=H,(U[)T@T">%3)P[LC]QKB0`
M$E?BO>SP^4E&."ENX;$=UVQ'^-3FGY/Y:YX*&*'^[\R=$^Z`3TNX2\\C<N>4
M.)"[$N]6Z./&#QG?<:EW(Y&-OFGP1V0%=]TKVN9H=L.'<0:N'5O@7:I:QAL^
MHR[6CME79/JGNY\OU]?3O_QS$9=/PV-\^]3A\FQ?CKKYP`36)WMZ\KCG$0TK
MN"Y;CW!CK0A66IE&E7<Z'<.KN,Z7,[Q8KG8OS[@#+1H+.&;1&&MZ>&%T)H!5
M8AY&50O\]IN$71G`&;@L+."8>TC1=/-3$T#P&495`0W!.Y4.&$XP2O:W&+9Z
M'F"]P#$W8[I8=Q)\'7R&49J^(7BGN0'#"4:)^!;#DH*L%SAFG_N"]>)5N'(G
MIZVW0#M%O68@PRB)WL"`D]"`X02C-'F380U27^"8>P1=$]Y)XW7P&<:T^5N"
M=_H7,JS0AE6;829!U@L<LY:JBW4G:M?!9QBS>*HE>*=<`<,)1DGA%L.4@:P7
M.&:?^_[+C-.E``,:>Z'U1VXQ4.TFCQK6O7.\2_>RM(TE2=J/-+Q=Z6`4X)>G
M5[O)$:1'D1[94XK$?99HW.GSJY?C]9?3X=BQR[UU`%2@'D<I4,SC`J.S"`E2
M!Z,$*=EZ?KC>OC8&07WJ<<PN]]&3>2$Y[01E;7XYB;GF)\,HS=K/CU.<@!\)
M1DE8A!]6N0)Y*G#,+O<;>>KH6J^YR3!*X?9SX_0IX$>"48(7X8>D8(X*'*5_
MH1QI8LZEQIMV3KVN^<DP2@[W\^/$+.!'@E'J&..'!O-4X"BQG/.$VKH'H";#
M*.W<3XU3OI`?"NV'0OG!))BB`D<IZ]LINM=(<75?R9^&+]X6Q^/6%]<;Z.MD
M9AA5&O0GTPE[P(\$HRH%A!^4@9.JP%&%P];UN?FF@@9_OS*,JB,V^9DUS.DD
MP,)A@?<4#E3'G3\)Y;EA[C[?+!Y>C]?GTWFS9XYUR^[FK\;4QP]-\_V/U^/1
MOHVKTK"V%J%R(>"8<L%JZY:&M34!U`<>QM0'D8);#6MK`2H(`H[9E#^:GF\;
M+,U9(C>;N$:Q`Q1D&%,"M%!@)3ID.,$8S=]DV,YN@/L"QVS*O\']UFH[J\*!
M\#.,D?4MX5O9#1E.,$;'-QF6%.2]P#%/'8.\4S7M.!&5SC5`088Q4KV%`BNE
M(<,)QFCS-L,:Y+[`,6*\X+ZM<PT$GV&,^FX)WJICT+!"&U9MAID$62]PC+YN
M8/U>(\65%-37-[ZXIJ\WOGC>:P?2E6&,H&Y)EQ6\D.$$8Q1TDV'*P'E2X)@-
MBC:OC&*J;5`$4:"Q/PZ3KOTXU)KM5$APZ7;"^Y=N4YF;[5SDEUAQT:"9G_;G
MQ^'SE^OAI_W+L;T1;MV%UG'/\3YE*[M?R>!TJ2C>`5$(78%]^Q3*#^4,0NNX
M(X[1O1)Z(=(X[ECK$D:G6M<$K>`^&=Q/D!.Q@!]+N$\5(_QP)>`Z426.$<D;
MB6IOA0/DK.`^S=Q/CE.\@!]+N$]"(_R0%$Q2B6,4-90DY:K(UK>K6CV\)F@%
M]PGL?H*</`;\6,)]>AOCAP835>(8^9T3A>J%`]2LX#XUWD^-T]*0'PKMAT+Y
MP228HA+':/4[4N1TZYJ:%=PGA/NI<3(6\&,)]^EBA!^4@2DJ<8Q,WKK<J=;+
MG1.Y`$%+N$\U;Q*T:)TR$?;ML9^>PB<=][L)'Z%]>^R?H'U[%GB7PN9I\4BQ
M;X]@RWU[:OU8'T\,+84QQ9UPPD=PVQ[[-U!M,_13DY1O+CM)XYU\#7Z'$.;.
M^@$;?H=AD#9GV&<L6[QV$C5ZK;+7R54_8,MK/PQ4\@R]$V?TNWG;GA!`C&7N
MM1\`!Q"'08H?1;L[LH5V*Z&#UR&`N:M^P(;781A4'^"\MD<V>.VD<O`Z!#!W
MU0_8\#H,`ZL)W&2Q*\6[)HO3V#Z`&,O<:S\`#B`.@RH/%.WNR!;:)4U>BW1%
M+%SU`S:\#L.@.@7GM6B['CJY'KR6Z8>I<-4/V/`Z#`.K&MQDL=OV=$T6I_-]
M`#&6N==^`!Q`'`95/RC:W9$MM/-T08\!S%WU`S:\#L.@6@GGM3VRP6M7.$2O
M=?8ZN>H';'FMP<E2XIC*JF>RN(K#!Q!CF7OM!\`!Q&%0'8:BW1W90CN3V6N5
MO4ZN^@%;7BO8:X7V6C5Y[4J8X#5+5_'"53]@P^LP#*SQD).%SZXL\V=QR;@3
MA._$5+WCX*.)@<U#\`/@:.(PJ#QDV"=WP8E_8]^>&`%)LJ!PVP_8B"`,@PI+
MU"QR1[;,(IVT0`Q@[JH?L.%U&`:6H;A9-#%YQRRR^_+$:'32"$4(?L!&-!K4
M"`6,V+BG<195[YN8:C*4M>9?*&M)VL8U?`SA5.\CD8W[2`1_'XD2]!9`HI$"
M6\-Y"B(;*7*>BDO_\18)\2@;</F:O1(?$84QW;RM-R^,0Q@AHKGO?L`LC,7!
MN:HFN:HF,A_<-!'B45"13=`WP.AF#VM>9$<&5&8@A>T'P`SXO^4*G8A%V'Y`
M(P/^*+!@)[A;;Z-(',QO,M,=I^..J,;W0+HBU),4^9H'YP<TQ1F/@NIZ5*;=
MD2V9ML5L""+$DSSGJ5C>RK3[6VX*$+$(VP]H8R`<!?4(/-R;9WLDE.??U9H%
M@8K`RCQ^/P"FPO\M=QJ(6,3O![11$8X"&P^X26^WHJI,^HX[B)Z@R-4\,#^@
M*<9X%-2;0$UX=V3#A'<%>0A"I-\H_Y&G@G\KR^YON;%!Q")L/Z"-@7`4U.=`
M37AW9,^$=Q5ZH$(FR5+$[P?`5/B_Y6X)$8OX_8`V*L)18/,$.>$G#9/!]6XB
M>J=;-8UK"'B2(E_SX/R`ICCC45"/!37IW9$-D]XU%D(0(9[D.4^-BZU,\_1[
M[H\0B[#]@#8&PE%0OP8UZ=V1/9/>=1HB%3I3D>+W`V`J_-]RUX>(1?Q^0",5
M&IST)8[8'*TDXY[-T9($CH3-H_,#F@*-1T'-(E3.W9$4N$5=*?E=MR0&I')`
M2='Z`1MI9^G'W1\A%A3X`8UL*)@-A69#]9T!KF,2J&#I9[R(WP^`J?!_RZTL
M(A;Q^P%M5(2CP,X6[@QPG:WR#"A[$HSOQG$RE__67>9(TL:1LWF`?D!3K/$H
MJ.^%2KL[LO,D<,V>$!!)"M=_Y*F9M)5YFG[P_1%B08$?T,9&.`KJH>'8(!M%
MW>9)H).6C:S,X_<#-JC0/%$16)G'[P>T41&.`AMSN)/`;M<'DD'$CDYT1\;&
M"M>UX`)).FGE(C@_H"U.#<K=%=RWW&13^_AV&1'"O=^JMU-DW^1$Y%:G*'PW
M4>Z[P>Q,E;K4OHR)^CW"E7H@U"A5EYT_O*$1%P"]^1:'>XWH9&1\"`].+AY?
M,M]N'Y^U.7!?GK_%=73I\#4A3%4'4*)(=0`CFE8'<&KW_JD,$-3,TMH`277]
M&R9&ZTXJ=L,'S:;Z-Y"1*7Z#2EOG5T=0SF]\!^-*UD=PKF^,$/;USM41DBM1
M'S&9I-1'*&$N=-416K`ZIW2T<KL^^X2N^T&IO#%[*)O&NJ=F_I$;9X&0?'N6
MFU/MA[^]?_?^W?\#W:W(]0T*96YD<W1R96%M#65N9&]B:@TQ,C,@,"!O8FH\
M/"]#;VYT96YT<R`Q,C0@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2
M;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R
M(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V
M(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y
M-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E
M25T^/CX^#65N9&]B:@TQ,C0@,"!O8FH\/"],96YG=&@@.#(U-"]&:6QT97(O
M1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU7=^/Y+:1?E]@_X=^\(/O(.^)OT0I
M;\X/`P'NDEQBX')`7GIG>KR=F^D>=\^LO?GKCT61DC@LLEGEQ(:]O9](L:I(
M?2R5BN2O__K^W8_OW_4?ALGL>OC7_QH_&#W_[^[I_3OAKXB=''9B\(C<"?%A
MFN2X&WMWI3?3[G)X_^Y_=B=_+ZL-W,B,(_RQN_SP_MVG]^\>_AUN!?]N@/Z#
MULHU\$$KH]P?:I(RO3YI`]<G9>'Z.`X*OZ'<?2.U'>UN%/UNM+V[*\CTT%;F
MQWC1+A>E6)7Z]??OW_W'=_N/=]X$W[L*WEC^IM$\NC?.%,KLOG<6^OIO4O?_
MMOO^[^_?_<[5_>_V%FRY!>5L(WHQMS`-'P8MU.[[?X"5A-+NYT^NX=]^V=\?
M[W:_/_W36W=V6ULW'_2HQ]CZV`]SZR^'RVG_<CR?]H^=D^'N`TN*&U:>IG^A
MD:5U#=B@I?U@X`:SEOTT3;.6OSF?KN?'X_W^Y7"_^\N+^^/I<'JY[LX/N]_L
MKY]VWSV>?[K^2S0W)<V%W`U2NJ?13OU.^3NOM_!/BBO0VTGZ`A(O8":K=;4`
MR%TM8`?WN-8*#(X7J@7,,`W5`GHP]0)JL'49Y.`>TUH!<:N)?JC;04].S&J!
MT=1-K:V1MEI@,$I5"YA;!;21U;YPI-S7"[@17;6D%EK5[="KL2JDFI2I-N'J
M#]7N=C-'74TU*%6_@Y%3M2\<^_9U+90T?;6`>WCK:@HIZD+V<JPV(2?76]4"
MHZS;05HQ3M4"@S#U)HP0]0*ZM]4G2ZJ^3B!2ROJ3Y>PXU;7H76?4"HA)3/4"
MH^JK,@@K=54+,4A=%5(8*:H#1FA1)U*AA*YK(?NIWH3H=;6SG+]0[\WA%A.#
M$UGEV3I[:"&K5E1]G;]D7WED?@PZAB=[TAR'L3:CB]Z6M9];G]P3:P9WNXG6
MN*\ZE-TH8^=[NQM0;SU7K=W;]2G<6SJOT;$!ZIZIPLT'J9:;.R?4C-/L`G_C
MO-!^L+-_]K^'_67WN].]\\Y^>[@[/'T\7!Q_OA7#N@X#,4:RAG/-DH;K^X:W
MA)M!G^:N<K\>YU_NO\=P>?[Y*>E3[R?Q^M39\Z948/Y9JBC@(DSO?T*!^><J
M5[SN6G?D2!\0HF2NM?S@GN4H6)`QE<87R`0+UQU5T0>3<%7G![#_X/Z\<P(Z
M)]H4+#>X>2,(&&5-I?(%W@H8KS,>I;EJB2'6\GY`!L&"C*DTOD`F6+C.L)QS
MJ5#+Z8+EQGYY$J*LJ52^P%L!XW7F$UHTW/R8C<Z7\8\947>HZFX/MW:LX]X$
M)J\^,-`XB9F!_OA\N+CWX-,/N_W=R_'S\>5XR%X(X;$`&9@4&V4H4BS<&[J6
M>F^H6KLW#$JFW+YJ]=YN2#+E]E5K]X8Q`??FC:;RK4-4"F)4RO\Q.)_!5Y?P
MGK^E\H=E[$4<&WM#?>S9^-C)T3G;8>@99<+D]X?#R^[Q?+VVR>A'DMV2T\,Z
M."V+M.:J1=(J2@+CSFX>]H=U),\PT59SS1#)D1^<JV>]J_#U5XT".??9MVS?
M2+3!B2(-TB0B.1]]%NEOSHD4?6>$[HQM-)A_F)"NV^)4^7S513[=]ZM\HE$J
M>`SS;MS`5)E\37XWVMZBW;C%B2)9+=]TX[AVX]#U=NK,*!O%`V[)[;6!J<+Y
MFBU]N$[/0"M&X$P5<093F2$RE38J,I6>3`A5?WO_]]?KRQPZ?3F[V]^=3W?'
MQ\/N%"@,4/A]!T'5UZMSYX^GW1F96G]5<<!!`93=#/OM)BIVR\N&)C`Z,YR7
MCKEF0\-`3]`"1EL)WCZUVJFI:4\?B+ESG.8QM#0-+)&;.X-I[D1#PYY&$'/G
M.,'=Z-N:AB<]USF#:7Y.L>&JGZ,DSAX1)[*'>[D>E0WLT8]61_90"G[[#UV'
M9\<81_^U:;<_W>_V3^?+R_$?,W!^V#T<?W:,L;]>#R\49TA)G"X2G$87JO12
M7G>&7(L8>VQA&GLPY`#2@`8Q,@DX=3[7>I$DF<^-<L[/I`G.#])5.4ZC&KJ)
M/%'D797!-.:AR^$)!^FJ+4YU)8S!NTI/0V?,0/!P<@-E,(VFB@9*O1JG&\I+
M$6?PDA@#+XE1+Z_^6NGP<?C;-S1T/+WL3S\</SJ_!ECJ_/+I<,%8Z8W7XD1`
M:2C!:304!+_IM;@F,-[9PC3>:6D8"`5:P(@FX%2B,?W2=#)ZA[$3:JCY,(CQ
M<YQ&+`TV\`]^;OP,IC%)0\.>(A#C;W$J=0P"-_[4.^/+FD>36R"#:511M$#-
MHX&:&',L.)TY+.2/S,P!EHW,(7N+,\?=^>K>C"Z'1Y]GXMZ%GL[WQX?CW5+@
M='XY7'?/^R][8!=7X/IROON_3^?'^\.EW>,!C3"J27$2U41-B1Z/[ZV<>1*8
MQ#P<.?Q'4XT24<09'D^4)'D6E!49$U4]'JRK<IQ$3`P3#?[S>=95&4SB*88<
M\!!A7;7%&1X/VE7"F*X7JMWC00R4P20:*QLH\7BL-3AO19S!6V,?><L,:QRG
M'T(<Y[^.I_/E^/(%7)W#Y7!]J?@U(`9*-@E.(YL@WBV_!IK`V&4+T]BEI6&@
M#6@!HY.`D_V:M4M2K[RSLOCI$AYUQ/8Y3F./!A/XISNW?0;3Z**A8<\#B.VW
M.,.M06TOAFX:;<6M02R0P30^*%J@ZM:XP8/20\09].!L$L*\"O*``STL.<%_
MNIP_'Z_@LCR<+[O[\^O'EX?7Q]W^[N[\>J*$9D!&E#L2G,8=07:JH^):Q*AD
M"].HA"$',`@TB#%+P#F.2I`D'=VZ[R;9^$7#\P+253E.HQJZB3Q1Y%V5P33F
MH<OA"0?IJBW.<52PKM)*=5HU?JSS/)(;*(-IQ%0T4.JH*(LS4<093*3E\L$)
MOGK%#TY]R,KX"[P>[8[7ZZM[GP(RNCN?KJ^/_F/2]7#Y?+P[U&(R(!G*/PE.
MXY\@\4W?Q36!$<X6IA%.2\/`)-`"QC`!9\1D8M-I6$!TIOAYTC_^B/%SG,8H
M#3;P3WQN_`RF44A#PYX;$./G..F[4E/3\!#G.F<PC16*#5?=%3'B)!%Q!DE(
M%4D"LOHC2=C)QL4]3\^'TW4.LAQ^AM^'G?MY.F=+JGZ!('ZI3I`D^4K_S3^U
M$;U55PUZ]<Z&\!GM\/3\>/YR.,RQH]WY&?3.<M4:A"BN&X,U!4&(KW<$;\^U
MA[)M@M/8-HI!]/9<BQCY;F$:^3+D`,Z%!C$N#CB'B]<AN'*Q';K!-H8Z/(\B
M/97C-&JF6\@3:]Y3&4QC:KH<GJ"1GMKB'&</ZRDEQDZ/AN#LY0;*8!JM%PV4
M.'M@2XS'%YS!X[T.Q*8FN_"X4S;P^']"`A&D!L"GMMW]\?I\ONX?*^X=R((1
M3HK3"*<O)8VF[IW_4),S3`+3&*:E84<=<W)=3BD1YX2F0M/)0)6=UF/%N\-L
MG^,T"FDP`=P>L7T&TSBCH6$@`\SV6YQ*$F-B^XU'D;D4#:U4G_FHX*[B0")F
MS6!>JR0'<ACQ!.P%IQ//,,8$;&&'-0%`#G%U^*?]Z8?#]4VNHO_@[S,`'H_[
MC\=')&^QZ@Z!P"@[)3B)G:(B1'<(6L3(:N0LU)AKTN4`CAKQW.P4)R4Y,B3Q
M+(7T38Z3V(LC";!6WC<93"(SAAR>79"^R7'2FRM'$B"<W"(93.*ALARIQS/@
M^=0+3IU:G06&-9]ZY9VX*<6W(9[N;GMW.'Z&E(":LS/@6=$I3J.3H2TK&IK`
M^&/@9D4W-0S$,.!9T1%GO#_%IM/\(MM-DZIY.XCQ<YS&%PTV\,]S;OP,IA%$
M0\/^R4>,O\49KT2H\=V<W(VF9'W_`.<FR&`:(Q1-4/5,-)XRO>`,@M`Q95I:
M.3/$U[\_?3Z<7LZ7+P170^,IT"E.XP;-2H&&%C&JT-P4:(X<P!`:3X&..+6K
ME%DD20=O)Z5[H[>-;_3^P4<Z*\=I7$(WDF>"O+,RF$8M=#D\HR"=M<49B[VV
MG94L]I)=/_7=*`F)08B9-C!CL==&N-;%7K"+`LH]DI<6#=PCQX5[UF]O1L9O
M;W^Z')[WQ_L84;]NDJ'O7B\7QU&WDZ)!/)28)#LI.HI]TVF1:%)T`M.8J*5A
MH!B))T5'G..T2"0O5XK.R-H'.,SX.4XCF@8;>"+(C9_!-&9I:-A3!F+\+4YV
M6D1B?#&HE4J,-EU?3$OW#WINA@W,88Y5%LY27[^E')XEO>`,(NECEK1:H[HR
M;*M06CQ1]V=Z/,$YQ6FTT;,2G*%%C$5Z;H(S1PX@CQY/<(XXAU1Z)&M6VTXI
MPHHNK*=RG,8Q=`MYALA[*H-IE$.7PS,-TE-;G)&_B/:4M)T>"5E#B'TRF/82
M5;1/XKF8$4]O7G`ZX9@IIC>K02_YBX/0PYO`2EAH47%00`J,:5*<Q#11NEL.
M"C2!4$L"DZBEJ6''&;X%A$LB3LY!7'LDFR/5H#KW\E3Q4K`>V.*,#3$VTC3Y
MU_Z;9MX;&4RBCY;>`%[`>F.+,\(LV][8,+OHA*VMXT),D,$DABB;H.:AF`%/
M>%YP!F'8)>%YF);U$$9,:B&,"V08QE>==D\%A$+Y(\%I_&%9&<[0(D8G`S?#
MF2,'L,B`9SA'G.&I1$FRF*ULW>(&2`'IJ1PG>2H,"\WI$VB",Z^G?$VZ')YA
MD)[:XASFP7I*C\Y5L8U.Y;Q:$TUPYAG(URP:*'55-)[@O.`,YC%+@O,@Y<H\
M4J;,$Q=B%=:&UF(L(!U*00E.HR#3EN0,36"<H[E)SDT-`YEH/,DYXAR2,4B2
ML]*.9*K>"V+\'*>Q2H,-_%.?&S^#:332T+#G!\3X6YSQAH,:WPR=*.8@^<<Z
MMT`&TWBB:(&JPR+QE.<%9]"&BCG`POVS;*4S"!&WTGDX7"Z.-RZ'SX?3ZX'@
ML$@\23?%:6RA6$FZT")&'I*;I,N1`SA#XDFZ$2>_#@V+)/YU*`YG>!VRINM[
M0IX*UEM;G/-RM,K&W2T0Z;D,IC$/O><\X2`]M\4Y1+3IN374,G524_R7W#X9
M3..EHGU2_Z7'<W87G$%$(N;LBFDP2PJ+AM]^@=:G\^5EYWR7IW1OBYJ_TN-9
MNRE.8R#1EK4+36"4TW.S=IL:!B[I\:S=B#.6?<:FTY'JWHK<6W?-84&LG^,T
MAZ7!"/XISZV?P33::&C8\P%B_2W.R-O=6/]6WNZ-5JK/O6C(VT7,FL&\5DE>
MD)[PO-T%IY./GI:\W5Z-BQ=DX/=//E/F[OSD7I7V/Q>(I^H)@6`8#Z4XB8=T
M\9RKJB<$+2*TE,`D6N+(X=C(-XBP5,09;U51DC0@(#HYV78O".NI'"=Q%L-"
MP#A(3V4PB<(8<@"G8#VUQ<F>C\5[2G5V(&3*(.;)8!(5E<V3.#[:XJF["TZT
MAZ\ZIPCZ`P.D60\,L&;[97NS-*#B\H`<*-4D.(UJ;%ON+C2!<8OEYNXV-0RD
M8?'<W8ASR,0BZ:.V[\;B9PW_J"/&SW$:>S38P#_=N?$SF$87#0U['D",O\49
M;T:H\97I1E%+W44LD,$T1BA:H#[9N^'S-'."Z<.A/MKH>(Y.^+F<85IQ<TR2
M)[-2C>'ES_BJ,7]&"K/$B-TK5H@1?W]^V3_N]NO>ZP3/8E8[6F#15L9S>L+/
M6XK'6BB)&7:2L3;%?-&EO.>,H$;0*)5]+M"F1JB%$:+A9BBW*.%)(R@1]$DE
MGPNT*1%JH>1JV.G-48TWJT`=ZW3:C@07:58S:ISJ-A=H4C/60JF;-^3FJK=[
MRS-E4"-HE,H^%VA3(]3"I@'6D)MK-B@!9#DK$?5))9\+-"D1:Z%3"F_(P=="
M=,B)`09=H],)AU!%)8.^J69S@38E0RULNF+UU%RSX7@W8$(YQ?G)_0KSDY,O
M,O;\,SM#.Y1")R3%RPSW59?,<#A?=-EP18GUP**;)WS4?-)9V:CWHJ-8F'W^
MF:D;BZ'3$/_L0UT\&?#--!3D#BJDPOH");E#,6S>89UG.->\+;5GO"!U4"`5
MU1<H21V*H1.-XGGQKEJ4.UN:89TO:;I^*CKSP'RS,E&O5`-?H*!,+(9.)P%G
M?$W9*%/[FI).+4&'H$XJN"]0TB$4P^82UC"::]X>1I[)9JFC`JFHOD!!ZE@,
MG3QXPPA6^!2'D>DF,73C.!6&D9\2@C)!KU0#7Z"D3"B&31(SS,CJ;QQ$M;<2
M40B^BDKPM7YBH@Z',4(`)*Y-A`"(M2)&7S\?KC72K[]-).=K;FB<=^[F7)47
M?15X])5UC.5<DQ=]%87HJV#OCL"0Q),:TC<Y3G.[&9(`.>5]D\$TMJ/+X7D*
MZ9L<)^V.P)$$N"*W2`;3/-2B'(F;J28\Q+K@=#=33>ON"&+=Z&X28:.[/[U>
M[C[M8>7A^6'W?`$G\^6+7X5X^/'U^`RAD(I'#8)A!)/B)(*)`M^*N4(3"*,D
M,(E1FAIV97P+"(5$G)'9'YO.,ONU4)T<:UM$83VPQ1GNUD::YLQ^I#<RF,0A
M+;T!Y(#UQA9GK$4L]H;H1:=LR>6!YQPQPP9F>"UM?5%U`I2-45GX]1A^+5'9
M\+,A*@LEL9?@-SB)G>P2E1W'=7FT&H/[\V?G_%R.=W#0BW\7/I]V]X?G\_7X
MTNYZ!/VC*1:UE_!L^-D2GH6B*-]9=GA6V;;P;%0C:)3*/A=H#L]"48P[+3<\
MVZ*$IQ:[A&>C$JOD<X'F\*R7%N-ARSR`;UC4R%(*E>X&0XC/!CVCRJER<X'F
M^"PVYK8XA^%MR]X(Z0MU5"EHE^HQ%VB.U2+C+X-ILT7#^/-T:I=8;5!B(_E<
MH#E6BXV_+<Y(>$+[!4]XNM%*S1E=C-6X[3"\JD?#!1NFUIH+-,=_D=[/8)Y"
M-^*_<!AAF`EUC/\JL\1_PT\L_@N7T*G/L.._RBSQ7S4,FQVHAT+\]W@K%/#&
M/]9+_#=H.^NXQ'_#3S3^JPJG0RO^Z="J?()N.L_I)?X;Y5Z%]05*<H=BV,3&
M/EJZ16K/J'J)_T:I5U%]@9+4H1@ZDQG^&X4IO5%HVTVZ>,PC<*E>HK]!E8W\
MOD!!E5@,G:P,_W7$-+G`Z62EE^AOU&$5W!<HZ1"*8;,3^\#LED'D>4POT=\@
M]4947Z`@=2R&3D>\0>1?A$J#J/XBY*<#O<1^HRJK_+Y`2950#)L@#/LMJFT(
MU=Y]%![[77!Z[%>I-?:KQF7!M!0B;-7]W?&T/]UQ8[\@&4KA"4ZC<,6*_4*+
M&"DK;NR7(P?0J<)CORE.BOTR)/&4AO1-CI-BOQQ)@)KROLE@&M?1Y?`LA?1-
MCI-BOQQ)@"MRBV0PS3LMRI&ZF*(0^Q7\V*]88K^]7G/>C);+$71WA\/]=?=P
M.3_MKOO'PWR^[M/3^30OC.YV)^>&PG'=U^NK(Z/#?/INS<<6!<]1\#U'T1@1
M%KCS)]C.7TO#0""BX+\)GO]FS=+TC3?!AE:JI!$5+"U]F0L57#I>CR;MWDCM
M17HT@VGLU-"PIQVD1[<X^5-ZO^W19'\I-<EN5+5#IQ`K9#"-D8I6J+E`<L)W
MYEUP.D'YDZ8B0>D-0<6/4_LO\`$J)Z#=YOCOY\OQL_N]>W[<WQVR[U55'PE$
MQ\@JQ4ED%54B^DC0(L)="4SB+HX<CDQ\@PB519P15(V29$'5R79V(&R#A_76
M%F>\6VYDXZ[31GHN@TD<Q>@YH":LY[8X(QR)6@</1]YHI<9&B[Z-X<BY#AI"
MY!D]$:+NI$F+[Q"\X`P.M#$.**9^/;]`]Q/FI,%S`UL&1UZ$L9HN"B=L:@-2
MH_1GV1L'1VUN^6K0!,9WEKMQ<%/#0&06WS@XX@Q?+3;=X*O=:*7F,RT*UGPU
MK$=SG-?N#5\-Z=$,IO%@0\.>>I`>W>*,P->F1]\&OE0W%/<J\D22FV$#,V)7
MZ.@BQ:ZDP7<CEOS55')=327MZKA9J^-W^Y6BPG;FY9TKZBZ:P7<I3G$:1QG6
M+L70(D99AKM+,4<.X!"#[U(<<0Z#F:F9P>JM5)DDZMLXT<]U\*V/F=V?B$&+
ME"'=G\$T?J/+X6D-Z?XMSJ&[M?M3NG,.23?JB>"7Y4;:P!SVPT9F)1?-/]]*
MA,^\<DXP][],_`0:?F*?>>$2RI2*MXTR5-5Q&^5^7)?Y*!67^<177#AW_7*X
M/SSYDX:!-O_L_G9X\B[=7PZ7HR//;^%D]L^'R\L1P.=+W)_,NWLU9VLV2+1-
M:H>Y`&Z26`PE8,7>O#G:Y-:GX"AW4&$15L7OJ[*P8BL6<_\7;^E:L3U,5?)'
MUO*>7X+408%4U+E`0>I0S#W%J=@KSB)WU>Z>UENILJJZY9X"Y<VFB59:[&'B
M%]K20(S%T*F`-Q!]U8:!Z+DUR!U46(15\1MMJ4MCL3<#<859$T?#0/3<.4L=
M%4A%G0O@4L=B;P?B!N<L)MH,Q'0QD>A,WV=[]J4?E*,R0:]%`Q,_*)>&3BR&
M34LSS)F6=,OFYU6G7!2BJ8(?314QFBI&NT82?(YMDE$$-@]913Y^\'PY?S[>
MN[]__+)[^$4?G4%Z=+(0_("JX`54!1Y0%>R`*D,.H%11"*@*?D!5_+,"JDAO
M;7%.0%7\\H!JWG,93.-+>L]YID-Z;HLSO@%M>V[]!J0[][AVR@P$/SNW40;3
MXI]%&R4.,FSFC['6@M-92TQ+'J16Z_HDM7(6#.W[P]WEL+\>/%\=3_-?("O2
M$QHL5_(_8,W2Y_UCMG]+ZM*"M!A+I3B)I:(6M^*>T`1"2PE,HJ6FAJ=A;@'A
MH8@SUIC'IK/Y?.S4T'=N4JY$*K$^V.(,[MG(T[QN">F/#":134M_`(M@_;'%
M&>RR[8]UIX^Q&P?1]<5%9/#T(U;(8!*=E*U0\XF$Q0.5@K_`2*P+C/R!D/%H
M`!UR['Y3HH_=_F7W\?##\70"7\B]CG\Y["_MCA"(C%*,98<MHRI$1PA:Q!C'
M<L.6'#F`:"P>MHPX]8&7TR)).IWVG1%]-QA"/A[66SE.>K5D6,G31]Y;&4SC
M([H<GH:0WMKB9'H:\-X2W:"GS@RRW?=!3)3!-+(JFNB-VV!B7%&8&%<49HDK
MAI]87!$NH<1FV'%%,<2XHAPGLZZ<G$P#L1W@D%F$TM[X*F8)&P:%YY\J1N)$
M8<%,+":&-X&L#=XS"+`<,%_*>T8Q2]@PRKT*.Q?8ROVVLEXKZ[6R62L78J6A
M&,:UAA-G\#4'Y)"QKRK!QZA[,$.J\%P`UWV^IM?*^HW"<X&"[J$8RN^&=^`=
M\#NFO9"=T/!9HK@J'EC/+(%&L:[!B9KX`N5`(UQ#9P/##C1&36X%&J/<085%
MV"706.J^^9I>*^LWFLX%"DJ'8MC$PQJZOB9EZ'H:-DNX4JP+=:+NOD!!=W]-
MKY7U&X7G`H7P8"B&3G:\H>M]<4S[@FN2!CJC&8)%4O'G`N5`)]*+&4R;&\L#
MM^;(*SRX^09OEL17I8??[-PBZH<G.&T:8D@"5*[0@&0"T_QPAAS`QPH/2*8X
M:14,0Q)/BDC?Y#B-9QF2`%?E?9/!-*^;+H<G'*1O<IRT"H8C"3SWN44RF$8D
M=#G@J1>%>*.HQ!OKR^Z$"%&2X8-[[1@\,\.6:WX)GC]MY_7Y^=$GDN\?9^_Y
MX?'\T^YX>CA?GO;P=?Y7!/X1A5"CX(<:!3FVXNE"X)%'P8X\,N0`GA&%0&2"
MT_B'+HDG"Z1O<IS&/PQ)@"[ROLE@&O_0Y?`\@_1-CM/XAR$)T$5ND0RF\4]1
MCO2]=8J;)4UQKZ1IV2IITJCC-9?!:&IBQRVG&+84@UTVAS!]3`KW;_?/^^.]
MSQM:SC6MO,Q/RR9(T[('TK1L@31)_+UN+H2]QP>8\1I?#@TG+^+3LMW1U*=B
M^JL2?17PE]12<8E43,O;;*$/0R&$("=.ZIJOB(2[:J_NT[(UTM2G:OJKN,+^
MDEHJJE1-?[6@\%P(8^*)%Y#5&E593F,GA:Z\K$_+7DE3GTKMK^+RAT(8?T_L
MH.UT.\`$=#@M.R%-RT9(T[(/4J&G_"6U5%2I?OYJ0=.Y$#(_L(:FKT@8FD">
MT[)KTM2G:OJK!87ADEHJJE1-?Q57.!3")B+>T(1M\/&AJ3IE2B>KP+OVM.QZ
M-/6IU/YJ0?ZY$#)]3=P0=7E@UIS/P8:YS/V8YS*[A''M=ON-F@M>./6)?^B3
MC8O2^V%8SYL3PXA/;>OI<^V^[JQX,$&B,%QM4SW4P9QW_H%2Y7-UDBDLR#]K
M$J0>EEV%YE_HW+?N$;AN$6B7,'"CXG,=9"JTG/U7?$5DZ7-M*@SZSY9(M/97
M<?WATKJ]X+J[H%WBOXWZSW6PF9%_JA9ZKE/?64%X2YBM$NR3J`17VY0+=;!I
MDW]25\.H!O(.\L^:!*F'99NC0J_"I77GP77C0;M$B!L5G^L@LRAK5/N*A%$-
M)#[K'RR1:.VO%O1WE]9-"]<]"^T2&F[3/]3!)E7^<668!<S43:)QR0A,HL$J
MLWT2E>!JHW)S'63&91^!UG`&'.S?CQ]*G\*4,+>Y?0:UWX5_1">F!"9-3"WM
MPJ[[Z&GRFG^8?%/NFL;/CD]@4L"HH5V_GWYNY0PF$65+N[!_/GKR.\O*\\'O
M31EIB)4SF!3Z:6D7]L9'SW%G:3L?X]ZTD!\_Q%U6SG"_L9N;7C9S&X1<3S(=
M@UO[A_-I3E5=LNI_57F^)7YZNV0?WJ[:SFZ7Z-'MDGMR>TNK?G.1PIXC[&W9
M&LY*][M_%/83X3[?+>WZ'3[P'4.XFQJU'=".6#F#:1NL-;3KM];`M^K@;E[$
M.3>]<')/[>">&^E7\=#T?MJ\Q$[Q)?:[_?&R^[Q_?/4[JGT\G`X/Q[LC?$_R
M"SBOL,3SX;!_>;T<&A=#FWEW9"02.[+SJ<B6])]]T,T<9Y23X80<B/U5HS3P
MU0C?TE'PSE*W9B//K<62]3:J7XD,>1U\X;`@_EE!O*."\)."6)T_9Q>Q.]]_
MEL+WC.1U/@0),7F,T9T:+>'3%;I_)/OHH/+)07+WC7!OC4#%TM]WO8$/2,)U
M6!%4*R"E5-4""O;WJ!70L$%)K8!1LGZ'09FZD%;=D&'4??T.$QS`5#54KW6]
M#2&TO7$/:=R@JY9PFMXHH?5XHX0Q;KQ42PS&W)#4&BOJ)48SU$TJ)C/V];'5
M#[(NAQ3#C<$C)1R(6BWA!D?](9!ZL.5![IZDW_WU_;OW[_X?LJ5YF@T*96YD
M<W1R96%M#65N9&]B:@TQ,C4@,"!O8FH\/"]#;VYT96YT<R`Q,C8@,"!2+U1Y
M<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@
M-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N
M=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@
M4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O
M5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ,C8@,"!O
M8FH\/"],96YG=&@@,C(Q,"]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*
M>)RM6DN/VS80OAOP?]"AA[2(77+XOK9([D47:`^].(XW<>NUNUZG0?OK2XE#
M2N)2(UH(@G8)S3><F8^/&=+\Z??UZGF]8EOM5,/:?UW+;I4,_]L_K5>\D_`&
M=,-U]P4::V'K'-C&,B^RMKD>UJO?FG/7EY&J[4CYS_Y/<_VT7GU>KQY_:+MJ
M_PT^L*V4PAO82J&$_R,<P%CNI&KE3IA6;JT6Y0ZAV8`PK4><-=8PWVOKTV,=
MYCD*>1("[X/ZZ6&]^O'][L.^H^#!*W1D=9U&>C@T3MGFP?/SY@^0[/OFX<_U
MZIW7_*6^?]=P0?0O>=>_YXF9YF&_7FW85BG?_.J-_GHX-+O]_O+T]^[\[_'\
MJ3E?;H>7[2(_9N($/A&G%VH!RC7&L49T'?<]=`/F`=SZ(6T!,`%@E@D*H)S1
M9`_*&A\<!3"&&Q*@C5(D0!E.`Z01M`]".TD"8,X$US,\,,W('J33--72*JM)
M@%$.2(">`R@_7"1`^M$@`7[S()F4(!W-`Y>2=I)Y"`403@(YW,(*.DR_PSFZ
M!RT4.1:>!DU&(:1@C@0(T'28`(9VD@M!FV""D5&``YH'L"`M"3#`:1.:&QJ@
MN"!7%DA.;R`@!+VR`$#147`P))/`_+2F`-SY*4,";)M(*(#?PT@GN09#3ABN
M@-Y(N>2.CD)P19L`SLC!XASHT30S.['6DJ1),WKW4&V)1&X_]/XE^,R2X6+:
M/ZR:VAI*='_:8%JA,IX:IE7S%%AJFZ?8=&T3$5W[\TQO44UI7R6X6%A-&_>,
M1./)D=ZDZ=H!8VK,)SV_\B'5=3T3RNG>7K2=V4#,R%[>@1UT8`<=N$$'57PE
M/3ND*YG35O3^1M\S'Q%3]A>%=M"!S7U$3)V_4<]GL8KQU7Y11_]3+)E)Q%29
M3WI^?$M\&;^1)7O1=F^CXP@Q9;Y0:`<=V-Q)Q-0Y'/7*XVO\CA/]3;YG/B)F
MPM\@M(,.;.XC8JK\37IUXVM9OWFD6#*3B*DS'_6&=/5'M["\_2X;]RK?C'N5
MU/W&$=JO3H<1-]Z<GC.!*9^$B!,99RH>R9CRV1K/9#ZKNG`H>[\[7IM_=J<O
MA^;RV'S=7:^[\ZUYNGP\/A[WN]OQ<O8V3[O;X6-SNS0?KL>/GP[-Z;([CX]5
M/0_=KA%X2)STT<M^1PKM5TPDX&B??,X$[+XS8=!5;.)4F&^BZ'X,)7,9,;(X
MZU$XV,;E8!O'F1`PY9F0@'8\$8;?[YP'014G@H-V]/V1_#_/Q'<3-(3-#&F(
ME&2A(Z9,`PH'V4&J/'3$3-`0@:/5_IP)[B3"GYE'1$CFZ[*.B,TFOX:HL3,U
MW4)D:.=-,[%4P@8<2$Z$9[P@ILQ1`HY2SG-1L-!W8JF$_1C=CZ'T+LM^KY^8
M(R@<9$2I\I@1,Q%_!&9+9?C]WAG2J=ZS5$)>"#0D2K+0$3-!0Q`.$JU4>>B(
M*=.0@/E2&0GN)**]72H3(22\M<Y.3.J04I&.2$T6`6(FHHG`;%!??Z^>TD%U
M>DK3);NW%G,Z=RFG@^BS6FA7G3\\M)SBHV!)B@>+*;YE("3X]B+V=7K?7YZ>
M?$)_N5WV?S7'EY<O/JL_7J[-:7?^V/S]Y;K_O'LY5'+3Y93`3>*I9X3W.2^T
MZXY''EM.^RA8E/;!5*9]C"9&ED40,.-HL@Y@4#?`H&[`R1(P59,EZ16K@/!]
M416`<^6.*@!9B0QE3`3,!"LH')01`#D3B*EC)>J5BP(4W+OEMR5ED1>K^5O_
M7]V"")DCD)6(R^(+F+I8DUXYN8\$=R9WF/H5*,_-&$V,K(^`]PEJ8NA1.*@.
M`'(*$%-'1]0KYOI%"P)5[U@0(9$$5A)#&1,!,\5*$`Z*!8"<"<14L9+TRJE_
MV8(P5H]XH:KD&CMT6HZ3L:E;9J%VP"&(PY&Q%C"5#$:]8KDQ_+XPKM<_08Z.
MNL[O7*&\:%NQNF"LSZ6A7;XQ\+)R.1$%2\H)IF(Y8=HF%A30MMN2XN>)(N+R
M^'BXMC_K[B\OMQ?B>@!#CM&?8C/=5F*S>#70RDHE0OR^J$)@LJI"B(YC#&-O
M`\`6EWV0N5YY4%S@4'<);&*H$[!8#(3OBXH!'.GJ8B`2@%R,HPZ`,@%!YGIE
MEP<=,M,4`1%8SOLH6'09T%,P?QE`VZ%S+MHA+P.0WLATQDI(5Q,,)6"Y6A@)
M%GH^4RU$YS&.4VRF.]^IN1%DKE=V>;0AR4Q%'H'%PF#1XD#5.Q9'N^4C`9&+
M<=0!,$%`)W.]LLN##AEE@H`$+-<`RQ9'./Z7*.#,O`7AB.-_)`(YR?P/R7DJ
ME@@L9N/A]SNS\?0DI@ZDSHB8G(W`Y.R,22G+5/WRATJE1)V^WY^GG85XL6_2
M6RL!AD[2+X?;[71X.IQO[7W`Z;C[<#P=;_\V[07`[7!].I[#G;\7[CY=#QVR
M_D(`^8K4)9K2#3@V:RX#6F@QT>/W!8G>V?E;S2X]81@8T=CW`%#%E1QD?9%@
M^B+!F%ZY[O=BU"KD?/R\(.7'25.?\9$*9&4<?P"4J0BROEPP.HL_`.JH0*U2
M]H_?%QSZBV2`-6^5,?5G?F0HDC6.+`"J@HQ:I00^_GY7_HY!SJ9O#`,C2KZG
MJ^BI@0ZR/O<;G04>`'4<H%8AE2^;\YWF/7.^2UJ!BLC*./X`F*"BD_55@-%9
M_`%01474*B7UA7.^/=</R)@[UL]8H?)MFG1W'.HCZS@`8[8"H(XXU"I4$*//
MRP(J/9SVR=CB"[$B669Z2(0O"1V>/JW==@_JNB%Y_PV-2%_\1"/C<?^F1EPR
MPK;AVN"-SM]>6_KAY(8K\CG@AG/Z]><&@'Z1O!'`R<=\&PF:[D&!HYW48L8'
M(R3=@YUY1[MQPM(F.)/T"U-/I:2?=VXX2#V#$!)F$%(J\F6B'W+I9CS5BI.O
M%S?<*/HMZX9;!>0+RPUW2M-^`-,S<P>X-K2G`'IF"8#0Q$-NOXS>_;Y>K5?_
M`P9>R+4-"F5N9'-T<F5A;0UE;F1O8FH-,3(W(#`@;V)J/#PO0V]N=&5N=',@
M,3(X(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E(#`O365D
M:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=+U)E<V]U
M<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@,"!2+T9A
M8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2/CXO4')O
M8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^/@UE;F1O
M8FH-,3(X(#`@;V)J/#PO3&5N9W1H(#,T.3@O1FEL=&5R+T9L871E1&5C;V1E
M/CYS=')E86T-"GB<O5M;D]NV%7[?F?T/>.A,W`Y7)4#P]N@X<9VT==QXT^0A
M+Q0%26PH4N9EU_*O[W<`@N3&6FRZ%CL>>RT1),[U.]\YX'[]R_75A^LK?Q6E
M(?/IC_Y?L@JE^2<_7%]Q?84S$3$>Z6\$$_$J347"$A]7?!FP1EU?_<PJ_:Q8
MAO2@,$GH!VMVUU?[ZZOM7^A1]&?VA;^2,L`&*QF$`7X$J1`/KZ<RI.MI$-/U
M)(F"\P\4[$8$H?19PO$W]O%4DFG[Q]9\L!>#\:+@DU)?WUY?_?5UMLYC,L$M
M;M#&T@^UY@D@.??#D-W"0BGLPZ.8W7ZZOGKQS2G;%#G[,[O]S_75MWC4ORZS
M(2PR;1BNN(`^M"&9T1?L]AY[?U=UJJFRKJBKK/38=U6^NK@@(H*!?3YI[D?1
M((B?!+$1Y&W=J99U-7M55VU=%INL4QOVNJBR*B^RDKWO\,5!55U[<3M)P=+8
M2'<#D7@*D7(MG?XO2?>-RM5AK1H6<(\)WP^?*T3PB!`<,@3)9*%`:`M!'I[P
MU`C!5^R'9I=5Q2?M+Y95&_;#437ZT_/,DK@E\KF6")9(PU0;Y<7?5(4=RV?M
M%CWNA#`:=WOQO`!T/!RJ),F7/MQAIR22@YTXCX2V$QP7Q+3G_93@YW+M5S_T
MN[U"U!^.675B=</,:EQ`J*VS%EE05.S[_EC@;H^]+NL&R>&Q^Z+;LWIT/RVB
M!_U4%90X.EU:5F_9RX-JBAPWO*FK'?L[_4.!LX099&S-$/J)-8/D8C##(2NJ
MDO9^M4=:>^Q=K3_1WUM(_E9!_H:^:CU6M"QC&W6G2E)1K]D4;=<4Z[Z#C:!7
M>U0$#-V)J>K3Z0!E:5&C2@T<QZ;>]'G7LBU6MUFI"%K(/IWZV!6E\G"AWGB+
MF`%W&S,(/PA',Q#FD160OP?@V58I;-]V69/O/7;LRZ.6_YA9=6NR!KRZZ4EM
MU:ZTD6R<%*19WE-T``FV?96;L"+%.U4?BAQ@NF_J?K?7:L-X>7VGFI-GK4I8
MNE@DT$43"8$_)40:2!L)5;_-\JYO"H0CG%E!MG)T&MQ?Y66_H8MSYVK=BJHE
M'9KB#KIOF_J@]=L!EG2XYS!0J3ZRLKC3S]:`V1Y:G6G38_<]9&@IR6#'OM(Y
MMH`AXC2RAHB%'&,AB(>4(-%5UG3[KUJV+NH-E&K:HCNMV$\MB5D@@J'U$0&`
M2#FQ(Z(;$0V=5;ZOZK+>(3)TC),!)B]K<^FOU,=CH]H6P>$-R$*Q,\0`;9%M
M-L40.TL8($ZM`60\&<!/AYH&I4F)/)N\KSVE5KN5-W/X$`;XJBY/1W7LBLT0
M%"VRJ62'NE1Y7RKKTH8A-]CZ1!94Y5:OI&^SX['$;B-DEEFS4ZQ5.TTM*(#(
M)4L8@@J#J:5Q,*5$)`=#9#N@=%\B):@V4)'=G;PQ_>F[?*\.VE`Z%?99<\AR
MU7?ZJSE,+%`]8VF$?_&KD/X2QA'A")DI'Z/$9LD<^!#/BH($<(YL[AM6UFU+
MJ8^PU[ZK`/!PZ!VQ%'9"<B%,X.H.R%!U1=4;ECDD@$ZP![E$QE6`Y759M`8Z
M@2@HH9J$+J&ZG]@$22>HE&$0&-W+;%VCQ->-%<[4A49]Z(M&<X-MD\'U/:&I
MKG*P4%E#7ZQKU0/E5N``]V09CRYB=9Y5;`V3U3!1B\BK<MRPS_2]UN)`)K5%
MZL!0FG(L8(,HY2-*1I/[HS@Q-FC4+FLV0P6'3H>L`Q<B>9#YD+_M\QP8M^W+
M9T:_FP9'H1RC,XXF%\5#19^3<@3)&_"4NCDMD(91(!=-PXB/!,Z?JA4P*K#-
M(GN)4E12!\2]>9`0MAX0C>>8+GM_7+%/K%[50/2,6!]E5EXWQ]IP5T\C,SWM
MV.-+.!@PC/*<[8J!K.9UW:!L8S6^6`B@(]_2-G1<4R+2>$$K/Z4#`4D#]L(^
MHS$37(^\!37&\%Q/:]+I5$.$6+Y^R)K?5&<5'3DN]7>Z&)$Y;&6\/+;'N,$J
MODC?%2;^HB$;1L'8N`L^QJP0233&[/=P$Y$G1*UT1>U;M3']!_MZ]6_3FEU:
MX@"I9$4V2`+#B.#RVZ1SR_!94>7@7@^ZTK?_N/3NTH_.*"DOOLW,_:D`3/FA
MF:>9UOGBVXEI.S+CK+7C23B0./9-W^6/@-NL[_(T.Z5(F](?V?ZFV"U27T,Y
M=B%^D$[M6!A9?J4;Q6/?L?=YHU1%\E#XO[E]K_GT^U/;*?10P*6R^$17T7'N
M@')C>[4([0Q%]"7(Y*[JH3]V)BF??"GYX,M_@H$34WJ'3C/K%'M7@F[KIAF>
M`H`<@-#ONSK_S<SA-"O[<9@^W()*M5G^_+F<PRY2^J/LBT"V3+[TX0ZKRUB,
M,Z(X'JTNA!SA^H>\J]?#$.0M:+V>NWZ.W8HXAB;`5%.)M7]$!TC6M^2?ZK0Z
M4")6JNX?SH>ZF8=TJ.=UB0ZR0P->GKRE.(8,QSZ'3Y`<AF*(N7G<Z,3+J%5O
M<U`"R+P&?-PODF@:S+ZH2J=NO?G8Y$2)F0P.^;6$E8-D'%O+,<0"/QE"[-OM
MUCAZC#21>D\'&'NY`S1:`!BDIY`",&BN]J.JY]-Y.]DU*[4W=?_TZM4[]G/=
ME)O[8J/,%)AH\1)VF,;2P=16!4DT,-ICCR8WQV.1(KH$Y49SPU2I,[[?(RN>
MW<D\)IK`K58V%&[I^^9<ZL7-Y7>2<RN@?9NL$`_A4-]7A!G]NBTV148#4O+0
MRQS]=:L'8PB(!AW,2YI(-ZKMR\Z.B6R).'_#/9+W0"L6&;$&\V&[G`W;!W:G
M8TW[L1HFWZ^L=_6E>:2OE>VKVKZY,X/3&85Y.'G.]UE%.E%\5-E!CQS.MGV4
M`#^]?ZDC?PD##&/V!Q&T!&<'<-J]%J3L8M*(1H3#3L:PE]XK\L];[^+YA]2S
M&U&#IJ?AI-9PB'5Q3T&1SUUU\<:#`T9F]ENZ\>`\GH4&/DT,/N'<TJ9\A?1C
M7=]4WKD2\X?3=JQ(-%HG>HL2L*%AVX!Y%@8:E2LZ@O$6.CD)9D=(8J:QQ3?U
MT6BDVRLK5+O/&CHD,#\U43]C"CHZQS_JXEUWZH]B+YM702K'G2BQ0F$*VPL8
MX_+=?/I_TDKBRN1VA/SH]B2P0PNXC0[%BP4:3AE/[END]Q'QV(:'-%*U)5O&
MGQ]S(+WJ9D.-RL@SJ!F@3T7;]GI23X?@N@&U$X9*=0QMJ3DJS-I6=8_F`!7*
M^WV1[]D]'01416G`*\L-"2RHWS@MPTM%.)T)BLD.OAS'_7EV++JL'*@T\0]Z
M'P"B]94FJO@$52IS]J7I3=8-W$P/)^A4F,@:G:8JW#A2,P]=8JZ.G;FCJMFN
MKC?Z&(%>*AA.W#O@2K$NE36AMM`2=I!C+QS-CGZ$?5_"Q@#IWQO?<]]+_-B+
MH@3.OK<XIY714E)L#$'C`F_<!6F[ILZ&CA>?MM3^XEY$F>&#==^U,(4^+M='
MI^4B!V!B//OC<3A%P\#.CZHIZ@T=@JN6&K*-G9O;0#T9LCI[9VP[OC/6CN^,
M@;Z/Q]S4WZ\18C2".Y,:7[4ZC^:^1W8L-A(0X_F?GXJI/0G#X04][D5AX/$@
MF16UW$R?M(<]ZM^,<2R)SW8[.C'K('BOAR<$%.;FO2IU7O\^.,Y!1'$X*'1$
M'87'$5YH*-,6L`"?3O_2>';ZQY/I'0G;:>TSM.UKI2I7^)X+W(O%T1(&B*?7
MQY)HHCKV")A>@BSM5.I_D_>\F<R#^FX/%OX)=PYP.U231\)!GUXMDP,\''M9
MGD[GCDD26R`D9,^JCEG.1P`/]#YF.BC_A.0!*Z%/=UG9*V)X#T^PYQFSR`2-
M!_&BYUQ<^!,=3F8C_-2>3M++$`U\;@-E4K[>;HN<$MV<,**L='73:@RD/F"O
M'ELQ5`TSQ""@&09<"!F"&WI-Z?;!3L@NMMQ<C_MC2Y!.A4*/D34U7)?%;GBS
M!T%A7O?8:8N8NCA&@<%"```E4[/19,K,2R`3G=WJ!)KS!F#J,/P#@S@<R_JD
ME$V7H][20SQ6XZ5%7C*UHV,@PS@ZYA8D'@BC_7B?-4U&&&!.T"N0H4[3FHU:
MT_$SO31B0$(7N:QLS6L@!V(<#Q0PKQZ`IL;4X6C))Q'U:_98(.AHB1:(1Q;X
M*8#>L2!,4^E\0I@D:>)<@&NA<T&4@GB[%H2I[UX@4^Z6`;`EG`O$4UOPY`D[
M^''J?(),8[>I91*CYK@6Q''B.Q=$3RU`7CI]@7@*W0N"6#@M*464N.W`H\`M
MI$_$V[$@2"/?Z>X@"=UJ!G$8NY\0A=+I"W#!T*D%4C.-G0L"&;K5%#)T"\EI
MQ.!:X,O4J85(I=L.(I%!Y%P0HT5T+HAHUN]:$`;<F5E"!FX`$8%T9Y804KJU
MX$@=YP(?@>]:P-,P=,I`^.'4`H0S=0K)(QDY`X8C9IVIQV60N+4(Z/=N7`N$
M2)S.XERZO1D_@<1`#Z>9(N%&CS"(G5:4@1N_`O%$R@3"[4;?D5$?!I#5"WA\
MAFXX?ALI0)V59DB3)"LN:.1,([_7O^<US]]"(M&&+=Q3Q2_9(K5;@"F9`6G\
M>V+C#H&;U.WB&^&[<?$FH-\B="V0?NQ^0LC=F'03\2=DB+F[TMXD/')B\TW*
MW17FAOM(5_<*2.E,IQO*^"=6H%`]L0*DP`D*-QPT_`E)(VSC7A&C(+I7H'MW
M`N0->AAW0;RA2N".'123Q"VI$*&;X:`O@<D>78$D^?:7ZZOKJ_\")`9%7`T*
M96YD<W1R96%M#65N9&]B:@TQ,CD@,"!O8FH\/"]#;VYT96YT<R`Q,S`@,"!2
M+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP
M(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO
M1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T
M(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]0
M1$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ,S`@
M,"!O8FH\/"],96YG=&@@,S0R,"]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A
M;0T*>)R]6UMSVS86?O>,_P,>,K/9'5E+7`GL6Y*VL^ELMMV)=]J'OE`49'%+
MD0I(V7%^_9X#$*1D*W":F)U,:UD$`9S;=[YS`+_^]?+BP^5%ME1&D@S_^4]Z
M*47X7[F[O*#^"25,$:K\-XQ(LS2&::(S>))12IR]O/B%-'ZN7$B<2&J-/XB[
MN;S87EYL_H93X;^C+[*E$!P66`HN.?S@AK'3YT9(?&YXCL^U5OS\A(Q<,29,
M3C3-B,XS'O:T^;(Q'^)#/3YD1T*]OKZ\^/L/Q:H$%7!R#2]X9?E)HWHH`TUP
M3:YWN&TJ>4ZNR\N+*Y`MP\]WEQ<O7W5D7[B>M!O2;RVY=D73%65?M4VW($6S
M)M5N9]=5T=OZGNQ=U3K2MW[H.^MNK%N0-V]^)K^TKE[?56N[(&^;<DG65;=O
M.[O&::N^(VT#;[=[ZXJ^:FY(=UAU%4SJ[DDQK5^0]_NZZO]*KO]W>?$]R/>?
M9]%"KOFD!L-`]HR2ZT\@^]7S+Y5/2X&:,\F"RE^VFPUY[M6\>>&E8-XL-S2:
MEPLZ6/?&6;NS34]6MK^SMCEGK84WT=VVK=%(=PV8;3+0PMOZ3;O;%\V]=XB"
M;%JWLX[L[&X%/P;/6;6%\_9>5\Z6?>LZ_`67FT7N3$2YF1%1;ND_H^`/'?)K
M]Z`^OP>CPQ9>_L9$-H.,1N6#B`RW,02N4F/<%C!E=ZC'V`T!Z6V$O\X23+B5
MN+%Y8XFQ[$@%X.A\].X\&]P;HVIT\>"I'FE6AZYJ;-=%R`$PBTIJ[!T,\!Z\
M)M_=%^NJ!`_IK6O\N**.,1&<',;.Y,)&9E$VGHV1*ZC49ST8P-C9(.$CF8;H
MG,?+>?:-7F[2:L"'P<N%,@$L?W;5+22<KQ,GL9R4Q\MQQ8?EZJ(,(#F#_K3A
MLZ*$SM68`.#7&")<\.!&;QOR[_8V(#4#U`2P;TA1EJU;%TUIR5W5;\E[@/O2
M57OTJBF@N@'NHSE^VFRLP_3]SNY:X`GKPX[\ELD,7?`G0'Q<(HZ![RE9PUOK
M\5%8'0?/H09IHAI,/M(<KC(3U!`36-?6:Y(O%#,+!BGD;7-KN][;_K\-9,$%
M+%S4U2>4\L:U@"![UY;6KGVLO6!R(3*Y`,*V)*^:AV^3$F*RZGH_MFTLZ;88
MLZ=!^I=N%O$%&UG>$<D;.%[9[G9@V*YOR]^]37%SF^K6/OM.`+SB5N;-#E2=
M"!VAPR-H$/K>%HZ415T7JQK<O'#@L3URU_W!E=NBLRD3G6JL)R_D$N`:@'=X
M`9(#L;<6^&M_UQ[[P1RV97),%&**<*,'0;WCCE*MP3-]=(,+U\#>^$)3L5`9
MBRKH3G20$/O.@J!5UQT@AO$58.E56>W]%(`AYZ+^ZS-02OYLK&"HTA,),#R&
M=E,>G`/MUP_8ZK#YG-(%P-0?5L`9NW].#Q$99Q#?T_J`;'*D@=QK8HCM?6T1
M9V$O/QZ`KR#.8EFUMHCI*WBRLG5[M\#O[FQ=XT\F\D7.GT4EB"?"`#"J;!;Q
M<S$BFQHIH&#@T%[^KY&`0WZ<)%A`Z0(Y$-\?B4!Q8V=Q\P11R.6\Y43.\Y$H
MR".B(-5(%$;W.0VCR<4*[`!X+M!&CT<"`'KO#@.Z%N3:NAUYO[6V'PC`*WBI
M)G3AI_;$8.@*#(9!#]H["Q,Z&&T_'*H>$K6%H*[ZRD).GD,;;&+?0D\9<R@?
M<4NNJ+"#<88&B&5.=E5=`UM:DFO0U*,]!_#T2D*U(9-Z=BF$,$=BL$Q-B5\+
M$8UZPE`6@>[9HMR2PQ%C04-B#H1<YD/"BSF'UK/(OC.EIWJ.Y2I!5,84_1X\
M#K;V&@AI=);W.'*!0>U=L_3C7M"`3RAAL$_TY`,:]`5=RFB^F/E'\VY<NX-O
MJF[R\!GTH'0D[91-33FNY9#2(8Y`.F#A!/@+:0]]UX,V?.=L-,^@C5>3-I;D
MG\!NK1OKPL\I+'@G.$75UR&Y.UM:X(.DP5RZ.]107\)OZ^H6ZL\&U%+,PFR4
MBJ2=YG3R7LZB&D`&%]"&Z-\R(;U9BZ:!PN-N:P-R^$Q7U@5*M[I_`/VO8U/J
MN]B46I!M`:*5UO4%P'O`'0N5D$?[NH)(7OOJ.G0__>#;UD>(JVZV_2ST7<F1
MR2HZH1'C@R+0"D`ZBCKT7MMNI*S;4XN?3WI`"=&-PI"D-SUVE>+0M[O"+UYC
M*@!`<0CJ<VB!CT1731E*,#FD^JK!_-(@VH(FP`F&[N,DQ0E^'/;PL:S;+J*;
MC_/3]`6:V?0PRPUX.HRR\'79QP;W*/H@=G<$&*.^YM`#U5/7:RIE^8#IC]$/
M-MP7WL!T(1A;9,9\3BG'I![\'01KK._VA\S@'6323?<Y'@"AMUY7H6$VBPHR
M.B'#Q/IXS&N/:,@IHQB$/^8E09!F$T()=GVNFS%1YF+5WMI3&G2#/-.&WFID
MFFZN3"FUF#*$G#*$RD=H!!!XV+XXX?-%"5B&!'URCU@)3<[QA[C^+.6=%&./
M5XC)U%DL<([S=Q4J/<CA;)&S?"%S'CP<FR[.UIYN#L9^2-K'OG@\MX+)ZH.'
M0?P63SP`6%"5SMX`)PH]UC^E>R/YR.*HF8!/F0'X!G--87NFV_^X1KGV+A)T
M@PPJR#O04>07AS)*>!3,^Z):/[>(V(6+,L[;%E+P)*Z$YV\9F]1I<AWS""F+
M?04Q\?R%G((`C1MX.4>9*.F\_7AAQ@8Y.&-47NX_H_)^`F=S)\?$<T@I\GF[
MYD*JZ(T\PW[QIV]9*T]U1*>UU%)+IOQ:5UZ]0]7S!AOQ=3WBS=MF;5>`9/X$
M:P[E<C6O<NG8BY>2'[6LXM%E4T+UA8?_)S<)/)0]A#%_7/'@`..4?7"5+S0D
MB\>Y$*F.[_?#,N\*]SMYM23?[XIZ4[@5K.O:P\UVKO,(D45&G^FCIJT0`Z0_
MVL^U.W0]"FL_`K-H;D*/&7=7/G"/TW34M$"#]L6][W)'?9Z?'%LUG;6@3G@E
M]XT83_I\Z=Q@2W,6+@=E;?#_?`FA9D;_Y]C71EVLBMH?1?G2?<&87&19-DN/
MC2LYJ^?[5M*?!"OC6FHI?3<TJ!7X\E`TOFO7U0;JMN@WKUVU!K?Z5POQ\\MP
M'#*'CIF>5\=T+`U$?M2YT^P++C3A-^>.@HY;0E]$CM,EU+O"]U$YMIIGZ8K[
M>R[Q^LO8.6':#.5!E,79V[;VI>TWX@1PQIWWI]@O`O88^NSVHW5EU=FA_^8;
M:"\$U@TP[D&K?98"@N5C8UOH"6II//U\->:*>#ZT"I%08R1`@8\]VWO?J_9R
MVH^];=9!SA^+YH")*C2O<U\2QVLWD(CV>]=^K';A<MP++C@B%YXA[V$(UIE#
M<0'HZOS!`B#LIJC<+&I0V=A;S?21&@;6>UO4A[%M--HR!D/A_7OONVB#=_B-
MGKS5NNJFPIP;WSJ^&[BRD+#LT>P#\J`WK6UOW:["FV6'+BKE=5V4OS__#3PU
M:F+F$VA0N8A<F7I4BD5Z1.#WY;:M$4K"Q0H,$!0>U&/KQ9$F-FU=MW>^1@58
MV?G1W3^(J[IGUP_/IVW/JQ^>JR,%98*)R2?I$)H;9S$XP#F`NHVM7KXT%+N]
MB[$!3>XK6_L^;A8>V(][P%QP)X`W<+,:`QB>2O_8$\DYS,W&JS9JNI''&8MG
M1M.V(-J+JD&+UM4F]*^7BN"5A"$)30,P,F*`#7$U4+.ZAJ`BQ:YU??4IQ.6H
M*URI\2>=$XUM[-TIG(7#CSDTD8T,_^324;Q4##OTJ+C^$A#9%GA";1NR.6"+
M.2WO^N!BU/@+'@&IO[-E*!!X`&H^0V%O]"CV+(4]U696WD1S]J=QTW$MA8$_
M<5/?V3['3=^$<X4*R0G2CEG:;'0Z7_`'D;&I'.'Z5=VUQ_?1S]/'H[,`SWBZ
M0/O`2_='9P?CI3<3CKV/2BQ_:%66+O#'P;^'&@AOROOW1THVAQZ.SA?,U%O.
MU0!D@05Z]A>[BS^`&H#DE2TY>GB.)V+-O:D^8I?QS$6+$V&PS2^$R4@._W$O
MQ;1=_Y<4>"2$O!X'L,\,8!D7R0&9,<D9I#&")@=H`Z56:D!N@'6D!B@CT@.D
M4>D]"`/5<FH`?VH)*`[2>J":IV?(=%K5PFA([*D!6C.>')`_-4!IFK2%0&,D
M!XA<)34I@"(E]2"8RM.;I$JDE\B43)J;&Y46DVO%TC/D4B=MP94T22FXE")+
M#H#@38K)N<S2FV0R3R_A_V8I-2"3:3U`H9R;Y``-'I$<D.,]VM0`Q54RLICD
M:0!A0J8CB\$$:2D8G@ND!E"ATP,R:9)[H$;RI!14`P@E!^0R2SH,Q$T:2*D4
M/"D%%=AM3`T`DIHT%F4B;4W]!!+G.D^J*6=I]%#8/D\B_5/X]43(<)5V1IJ.
M*)HEY/L01`Q&A&3PAX@C!^36H;FG]9*RH5?\\H>''.CKEQ#@@,,2Z>KW6Y8P
M<8EL&=C52_V(^"1-=(5_6I9Z3HU.VO"*/\&*KB`%);W\"K)]>@9%:7H&J`R3
MCGJE(9S3:J#I8+ZB&6-I35)_P2XY@E'SQ`C.THS@B@(G>&*GP+^2875%%<O3
M"H6JRB31[PHH'']B'X8_X3HL$VD^?`6Y1"8A"BH4KC\/<A`"W_]Z>7%Y\7^R
M?^-]#0IE;F1S=')E86T-96YD;V)J#3$S,2`P(&]B:CP\+T-O;G1E;G1S(#$S
M,B`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA
M0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C
M97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C
M-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3
M971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J
M#3$S,B`P(&]B:CP\+TQE;F=T:"`S-#0R+T9I;'1E<B]&;&%T941E8V]D93X^
M<W1R96%M#0IXG+5:VW+<-A)]5Y7^`0^IBG=KI"4NO#TZ%]<F#YNL[=K-@U\P
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M]9#`0P$)GJD)"9D794#B=.K:#_8($.I[]DV:JDT"+MWI'N^JVH[0L`W[I1K:
MK>D("L4(/4OW][6I!@S0'IK=6$U(-"V!>M+W>EN3A:P?VNKW0UOO8#Q-2%#I
MJFJ/)]W<KV8\%CL9S_/9^(Q^D_'8C+ZM+3%@Q[:ZUDUE6'\P9F#[MG-KO#>Z
M8YX4/YC*'`D$Z3FAKME/`[NS=8T-9OK8=H/]Z,ECFP%\Z@<PZF2:'@@<NG:\
M.;@I&W/'CK3U=KAW[+M^KNW9$[;G4B[&OW@VM$]-#VC+(DS^3JCD6?/GT:TK
ML]S-C^WB22FGK>.%4'[K?FJJSF@@"RZ].6B`S5Z;WG2WV`#:NQ__&`G>7[&G
MJ]BO\B^T/T[=4B83<S,YFZ]$*B;SV1MS&CP?B8L;MKUG=Z`4(A@%F=XTP\;1
M[7OO8]_V[+M6=SORSA\L?'MHX8GDR@]<T\4#`A&XV3.,G;^.PZ'M',>;T;T9
M<_4>_#4PH)N>`TDALYD#)0\<P-L10(Z(.,X$-L)-O=>>[_Z^:X^(XC(1FQ)1
M#]Z9;G@J-DHAJ*]`W0)/3\M.RB7D3LS]I\5JD1F0#%Z[;-(3C+^<3.?RR/.A
MC-"U2+-5Z5K(<J*K1#*?3(:$<2:_76C(#IKB?S5VR!>L;OL>Y'%;U"X([!`;
MD1)H)VN-*-H;Y$S@1<&XW["[@ZT.F.C6A'SL<Q3V&AEE/(ZUB^<[EW)=KGZ4
MY*1:@ZX%B8N0;,22;'*5>1".2!24';7;[\?))+UFYRCI8>CL=J0D"A3@@@$=
MH-(%T@SMAI(.KK080KS'7:#3F!L,!#9#A[PU)]L!XL8B%YOFX_UQ'8<MDG1"
MH#P+6FG./0*]"SH;XB#RHF[Z(!8LN<"\^QN&Q`G98/O#$4',J0ED3+W?V]J2
M5MMX`1*"TXX``2_`"+J\`U7J]N2>[)%[=P`%>1KOZ5QP:)G>W;H\3V]=`82\
MF*5GF?(%A*"W^LH:>KM3H.VT7&<A.$H*JG\0MIV_()YCZ\=)6\!YV,[VL)\`
M(Y'Z)`1.?^PLZ4S'!,^TKZXWE)KM?K[<B(&:SBHV/]/S4F2?!IBMJ2T0(,?1
M`T$)B3V)M'[<4U`@9"I]LM#=A.A^)#X](*$#\DA"T%T'&V_"C4G)3<*0(,V0
M?1T5P6<7V3#_&BC(6<YF:;:(@B+(V5[7,/NVK4<X^,-X0BR:W8JR^UD&AXK_
M8$FFGW0W-!`!!WM:-#HY&8TZHA[:ZVKPH9G@>8ITFU5LYWFP791S<$W3/"15
MTY!I6!@"OO/Q]V._!`!O3-M/YN"_!O&W[^$[&S>^.A!GG,7M]CWBE"4&A=BT
M'7O;8#0[04_XZ`,T](UA6X1>-P18M&.'*=W=2O>'54!(9E689')),2&^C@CP
M]J.O1CNJ*SZAP&'6'LB#1/NG<_"=A6D(294QNW"7RN.N@<]LVZYK[WRZ67[[
M02N%U:R02VXY"ZMIB`#G(M9OD?<&;.$)A:IQ<L/MC5>,QBM$I"2JPRSYR\L=
M`B4%U-I!TV.3*9J`*F87'NZT)3>?8L!I!.DJI!8J]6^!.-O;!LG%([,&"EDV
MH:#R?.EK),54T-:UQHYX`="9VF\F.?2&8:FH1<D=L.#>U,Y?2$.;;M#D(:8Z
M-&W=WEC"K0NR0G>=;FX,.?:G&&&&#;,H`@@..#XAAM+?U<.WVM:N^M>K!,-,
MS9)3\248)B)H3E!\0U;\Z9):LK8[@K+Z%FB%'L59VKUFK\:.["<N08XM9@?B
MS!L]L61GZ]'+KH?-CDT(C]MU4)"3Z$S*!07I$"$4YF6Z;9H!\#ME&^0*+Z*A
M-EW,@WO<(I:ZO7Z%P;X_Y7D_I\R[`VK,X!4T#RK`XSEX7]O.3*:SH;Z>0ATC
MQ-=_37F&IRP6/'.N)OFV)`/:UD65K[&W?)+30I!\)+N#^%^E<$WS2;DFB9SK
M5I'*D&/%-7LS'H^D-Q$UWMB;QC4_H75>5E4[-@Z'7]N:!%:_0A&;IL47%K%E
MW'XUB4S)D]G^-$N"_;]"^53V%++*]W/O$''AJUN+[#XM9Y7^72J^=/(8D$O;
M-1=+:*:3@UFM/^C]/NC#AI"%.`.].OC$0T5//>[,W#8>&]\V.:^4=%#Q1_V^
M=;W5]J[!?/VX[>W.ZLXG>10"_1EU5S!?%?EL?JX6\\L00UQS.%B/(AUUL*Z6
MHB.TH7O?W]@:A%H4-$>`$MH<U3GQW+'$SJ`6M%M_^U\M9$BQ83_<ZQVT":D^
MW;!"7*?O$I4Z3)S"7WK4]OD=TA@*^:Q5BW+1:TD`P2GM<<`6>X4>VHC4K&F6
M6M_5<!M&L:5F/X^-83)Q[1*Q<4<4@0JAY[OT_T*2/AJH?D!J*CWVYE$W=$%B
M#>O36:XNIRY*I/*,`H3]SNZ<.J%-'5"FPV1]1F!/\'.<;MOA(5S.(R:\7*?C
MYQ'BWF/TP#TJ@.)4\")FPFR=A7I;1;8K.0O6/%MH(+,IGX[5(6RR#N9`+E(@
MV%`II^N^#6[\9;"\I38`.&(\)E`^0-]U2*8Z=Z8<\6H-)/BL5[.E@E62A^+M
MKU%YJCP>^0(%#G<(]R"2SI'OGKU+TL15=.1===V&,TM(.T06C^K$R7=TC*SW
M@WO_.MH=*GU2-KP(BLX=A*V1ZF0AOKSW_72B7N9_WN+CFD1FDP:4JIC+WK0L
M`FN^ITX#[;[[0<<>MRA[D1Q7V#4IBEF/YHLOYWGY:1..>&C]@5+OVR%F61LQ
M<*;;UUZH1"T\K;04*`@30/41R[OZZF]Z@`G/BC.I,YU\;(UV_;*=.;6]:R5V
M9\$G=%G@?S>6PG$X%;93".L,?6/0#`?W7$U5AZN]UMA</HO?1/D.ZXO3V%4'
MZFNNXI>BY*O*>9%/*E0X*1U<)U'!=5Z'JM=XYUD!4R%G(9@E9RJ`RT]6X%P$
M>_Z-5)L,=8[SG]YK7-^,.IAZ1V>\[=BQ&].X\["][>D8L3,GZL4V@V_[(*.A
M"IM30FAQW4\<=/GE!)4(486'_Z/KT5!?!ZMXJS^LP2TAO!0LL^LBH2*`W!')
M=HN,ZUIO*^P^G_N%XNP8)J6/F!SV+Z<BXK6I#`+3MC9K?(&B9OF3I>E9Q_[1
M(KIY$=2A7KZ\\0<8MF.-&7!54WN7!MVZ36N]=*',B9NWIL$UZ[_;08'SD?SV
M/";3P3YBL@N_[9TO,H@+NW;<#ONQ7N43'#&KGE0L1X)<B0>JQR\$[N#.:.>>
MM.]V4/QTK66OW#QM[J?F?#7V0WND3$-]*G/2]P&RY=`&JM@+PJ6TA']Y$?RH
MB/QV%>W'^=*E6S*G1!H/;=O9!O<9FCL71':TU,B%8EU@\*?<%DNUW70XZJV=
M4)E`V)S+_+,-#]W*SOABX`F&T&ZL\47'?#Z\'.))]VD'H;#$I+&A1C:=PCB/
M^!,OF8_;^I.IJ):?><!@`&:9/\NC.+@<>[!I8CH"^'`"QOXTUIT7!>UM/F"X
M[^QVOYMU3O+F3ENY5$4RR_C\79K?N]Y1-ZQCN0IZ5+5MZ-O":AB?M&IJ?;MS
M3+I>#>>GF[C[P#1J.:8IY%)>)DPZFY;%NX\\J>M.7V/1`/'$`$E=AM@`5"SQ
M&9(R%;$!:5FF971`4:+"B@W(RS0^`"5:?`UI"=K&!JC/O4*6<1Q24:CX#*B=
MHE"G28%,$QF@RD*JZ(#B<P/R0D3W0F5%$A^0YGD42:5R&<5!R:R(+U+0<7EL
M`,^RZ':K)(N;*4LZ.8@-*"C:QP;DI!%C`^"</#H`SALU4T+]Q!<ITR+^"DCI
MN!4\_0P.B<+-R`!1JC3Z"K@%CP_(J=,<&Y#)>``1:1KW+*'2)&Z%I`Y[;(!0
M97P`:H;X&A+$F-@`7H(0T0%%RJ.$X;F*!U*>*16U`G0HXZ]04D4WBTL5W\WR
M,Y&X*(HH3(B14;_+E8RBF,EX_$IEW&64S..AA<<]2B1Q^WB2/_W^/T)H<0-X
M_O^=&4I$M'!(5137W#6%J+1[]5@Q/?\5"CX07A%OYGS)*THVG_SY&NU%^5@8
MB:@;7)5Y_+Y(1)3#5S*)Q_8KE<2]X"KE27R&C/,HSZ]R'O?$JP+Q(`Z#B,>3
M*YX(\9D1*`T^,T(('@V,5YS25'R$$GG4J:]0KF9Q/'DFXHY[Q7/ZZ#LZHI"?
M80XO/Q-^P"T5#S"H5F1$S8+@/_YV>7%Y\3]CQVH[#0IE;F1S=')E86T-96YD
M;V)J#3$S,R`P(&]B:CP\+T-O;G1E;G1S(#$S-"`P(%(O5'EP92]086=E+U!A
M<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#
M<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P
M(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y
M-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E
M0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$S-"`P(&]B:CP\+TQE;F=T
M:"`S-S@T+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IXG+U;7W/CMA%_
M]XR_`QYNIM>.Y`(@0`)YNZ2]MM-,DB;.)`]YH4A(8DN1"DG9Y_OTW04(DK(E
M^,^)F;NQ97(!["X6N[_=A;[^]?KJ]^LK>A-K22C^LY_4C13N1[:[OF+V#2,\
M)BRV3SB)XQNMN2**PAM*!6G,]=4OI+)S)4+B1%(I_$6:S?75]OIJ_1><"O]-
M'M`;(2)8X$9$,H)?D>;\^+T6$M_K*,'W2L71Z0DY67(*LQ#%*%$)A5F1I_7+
M:'[W+_GPDK-1J*]OKZ_^^C%=9:""B-S"`*LL.ZE7#^.@B4B1VQVRS077Y#:[
MOEK2&PEKDMO[ZZOWC6D/94>*BN0F:TS:FIQD:;LEZ[*^;TE:Y?#.OUBE.9"M
M.F(^[4W5FAMRNS5D7Y=%]D#6=0,O.]/LBJJH-F2?MAW)#X:T7=H=6E*T,!YG
MJ2O2P;"LKKHFS;I#6@+MP\Y4'?DSN?WO]=7?0;;_7$X#,,AI@'&4VFD@4D(Y
M#2#'+:G7Q*39EF2'MJMWIEF0^VT!?Z>-(1M3F28MRP=2F8Y$=$%B2D!:34F>
M/K0WY/LJ0WG*TF1=`>*9-2BC`WD?K*3?U+M]6CTX9<+C"64*<X/N<!7S:9O"
MXB9?S*,&.!).#52I40UXN)P:@%&_?:GE#3<TVZ;-!G>S7J_)H?*<KTH#'&2F
MN$OAH]W;79J#/;R5\_@\YUHYQM__Q@5]T_PZJ!D=)^,)2:QBWO^KN@-SK)N'
M&79"1]3;8Z28WPA!:>PV8E@;3TA;M)TUSB:]!Q7#]A1IZ8[E&HY9NX7SM*GK
MO%W@,2T/.>Y54>5@2$A)3/493E9+#GCP"G?PQM<+V%^S*S(@Q!G335-DX`T.
M8.RP6/,_T\&\UFK;.6Q2XTNG"94,)BF$2IPFT'$`VVEGV09_9!I415:#8P';
M=!R":"@S4J1W<$PWQA'L3+>M\QOR\4A-O9;,"7WNTNJP1G_4X'PX!PC?'E;`
M1=45]OC#CSGTH'3L+9!*/N@A5KV/!IE'9P0"')H&Y-D?FO8`K)&NQITS!CUH
M2^Z+;HM;;,!#Y^A31[E,`[[JAZ:^*UHXWRW9@L+(RIC*'EZ<!^8]9.B*,M.V
MJ.-ZU=8E>`68T5OE'`I(M/=-DLK!-U'J?5-M/2]$H;+XC!Z'W*7EP=S,X&V4
M=*R\O[B<$#.4X(.<H\%'-.DW^D-'_@9>=;<"0X_8@G#0P&)0?6%:[Q(PBJZM
MS:_!(]?W8+%?S:",1+`O44;8[R;<!R26`)#S5L]Y[P<_%I]`S`]M"UYH#MGZ
M>'CYC8;)8S7$%,;E>**YG,J66MGLJ89@6C>Y<W;6?:%'@C,,SPOG!-$_[P!5
M%)_AK]'G@2-/B\VVN[000B2#%)IC>`)3^`RL+R^^$J#I45\T48,M1#(63E]E
M49G>HY,:O#R*7C3$M%VQL^J!^+8^E*0L[DSKH5N35A`,UDV]FV6+DR&,"ZW'
M,(Z?'9X"EXP^M0/_^F!2]+W?(HS>UB4$U-T>_'#OLM$`QKWU\A$`5JV+>$[:
MJ8SHFQT-S$@LA+TA/^\!M;4IN$=XVYBN:.P"BQYN]U8UAR[D$,BC6`W;I_60
M9)3.B+/LL#NXSX-Q6Q@\6G?_``%Q65@L"L1V$YT6(&'9(P2%T`73U8?*8Q04
MTF4S>#8V*:`=4$-9MQ:>]G'?@B!'-0NDB:,AE',^0IJ$CZ&\W@-*02%AQWXT
M^[1H//XH*K"5U.82"+M'2\XA_M7=D(A948^MP04#YU`65GMNBAPM<%P1*`8`
M<?'HF<A1_EDBAM0>)G`9Q6,N&PW(&:#:QB8G,X4-`"2>B;?'C4!0DLE<Z`,G
MCSWZX)-3*E2LGJBOCTP>+._A$%;.>W0FVU9U66\`#6>_'P!)VO-JX?($I:X,
M'L(_,F#%$*"\A/,&K!BM8-`EXV)(XB(+F,X%+-+=F_+.7)H=/'9_C.")C*>"
MR]Z(WF-TF\5@A1PSY7@25AX5;E"WSD3!I7X'V5">6ZN$+-;9I8\_&(U'VL?V
M#.GE)+W"EUFZ+SK,.5S<0#B.,05^"U?Z`E"^*7`=FX\@+W.H@;L2'LANBSA.
M#=SZ"M1#\>3<`A_OI&"+2"J,?1!H6Q`8A,`L"EY.X_!1V,6!D8X6#%+/U,YS
M(A]Y$JS[:B"YAR'O)%\P8'@./3`VZ('1`7)QH?M#AP4K6\3K;<*B+H)I</Y4
M#BN&V\D/)X4I(-E?@4KW@-0^69A9NG)>F^Z,"Z0X/O83)?:#'S:#_$*+0?Z(
MJE%^[L0_YO2=$`M*:<^E0BAA;/VG12-_;#$]VUD-H@&LP%J']]VS%/5$\D79
M5Q@G".FSB8A+YYS?_Z.N<Q3RTK+$T;#<+(A`1%\Z>4A1?"Q%RC%-I:JWJ-L:
MS;\W^_U8.(+S]1/6YFS-'O[X6"!LQ7KC!P?),=@#196G3=Z2WZBD/WW\\!/\
M9N"?(6'B;ZQQ!_8=JX:C/#R18[-#J3Z-]$9@3^KW(%1#GF#&R]=]M!P8TS%@
M+RSK?;:<,9[TI4ZO(@*Z035=6CN)G##!L>24.)"PN#Q(4)-]B!(V9$'*?D9I
MK3W-8<_4YZ&<RC'[BI/>GGTCID!(`."U<9B@P#IIL7ZPS9G&[-'Q@0$?J@(!
MQ=>^:97B_[1\:`O7+LKJJMX5F<VTT@Q+R6U79`Y6;.O[H]:/2\&P4X)M(43#
MD-S/TNBQ2*G7P:2H'FLU]GD\5UN(8KEIBXW+LI&WC:DW3;H'(`^I<S;)&I^J
MYBLKX<_P$<9:?^".NLL"^MRAG:KA3ZTMJ!=YD38/&)E^J$O0%AK\/+J(?<+(
MXC@92XRJ3Q@1PGUGT`\@&[`?_ZQ!N'_C#Y^1XPORS18<'.`$\!P;[T(*5$M;
M]^4Y6W5'2<<9CK5U`Y[&%BR:W&;XPX")6YU#`W*H..LXFA36DJ$>X=W.XLA@
M$<M-SPC8+\"KG3L$%?9LBQW6+FP(:,Q=8>[Q4'CU(#P&#8%)8-GBKH:\)_=E
M"WMX^LI=BW/[MJ.9RR]$T9!(\+'!$BG9V\$:!!DA_+'!?FB+M'JTF4.]*4,R
M./<..D^FZ3.-+&V:!QQU-/ECRT`S?*+-><R!^=L`5(@A0$;V\W@;P&4[53TQ
M]I$[5U>:!11RK>8#A5SY:P!6"8@)OX5C>G$80H>5+I",AQ82$Y&8&-U;I/WA
M_K:XFZ^#PD9!9\&F7`SM(<$FR3^;^&[OK/R)P2!5OG530^Q`MN+YF;?$PA(U
ME5Q%8M(6'VI+=T/S:-KV7T^;2MTV[6PE;FM*5\SP5P!026-%>&&O>4S.-Z:)
M!BM6YLX62>I92CN<^Q2-Z0E2D[(W7?`RU<;8'#LKFNRPPRY\9A_D!<`2XP0\
M\K&0L1Y</C+4PB&$/]C2^<JUV/""`$#]!9E&M]6#CX$"HO0:(`H6,2NG@+GD
M9T.FPL:X+!*EIO*?$'^HYCP*U^BE?5!U@184U=ID#/LG!VS_3RYV+6QWR760
MW;OZT+DK7Y7!YC\"-&P=K#ILI,QQ(4D/6/WH8AH?[B/5ME+1LXMEF:ROX?5W
MUGQ3R&.*<=?]12N[@XA50!7[VI6J[1;;,LYAYT>%=85*[[65SJ.*)#X-3Y(1
MLI^Q\J&SUGN#)S:!5K^IBL\&+7IRS&U?K$<IYI,M[Y\`+'@1Q.2]G0SHQB&6
M.10A![QN>X<^=V&/\C?7+6\?RV/:20/06D>Z`E.H*TL!9FR%MB^F3;@^[P=E
M@)=PEN+N5_2-^1*46ZP+JV7O7JU77<_C&]AP2X0).O86-.W]O^WP/KX4Y9JC
M3ZRDF8)2:\2N(@["M@9A^B\-I&\7;^GS48J9+P_@%6`Q]K78Q).P7E]Y?5]9
MB8.JZ'<;D3GN]`IB1:]A;S-S;#4?$A,Q"8,V;[7IV=BYM1VEM/6745T5/L>[
MMMA1L_WPX5;N$:?8E8XE^)5$4Q)9%D=>[(UE;.!#\+,$_`R!@/PQ2!!1&9Z!
M4QH%"1@%/88(*!4J1"`UI6$"17F0!QEKE80)GEM"Z+`>9*1T>`:NPJJ6#._+
MA0BH4C)$(/1S!$JIX%X`4HG#!+'B04T*B6`G1""2*,QDE-#P$APKCB$"%C\C
M)L5+F`$"2+9$<"\B!6<O2)#$E`<)8D3%(0(IXS"3(H["2T1XJR%$P.4S>F!2
ML"`!E32X!-<B#A,HP8,GBR<B[$!X+,,GBTLI@U)PL-J@)GDD19@`F`CSP,#%
M!`DH7G4($$!&%0<-ABD9=J20[^J@%"S&^X$A`AGIX&9!O`OO)J//N&*M15!/
M.@J[#X4)=>!](L(.+(["9T:**.Q;V'-'*BP?9SRX/J/)^4WNO[>$WV**[*\8
M]M."$]QW!?Y=@AW9@>Z[2-/GR:MQCAH:,X#0ALZU')H2QY?TC^#+64Z%-0^%
MZQYQ^O3YBXM:.-2S^O3K)F<YD?;`*A(?,S)Y_$J-X4C/QU&W[MU+&8KMRLD3
MCL;GKV4I$J=9$@L`L0LF7ZHKY0PI><39X\<OWC,<>7[/QF_:H0$#;#IIV/[Y
MZPT[Z;^<I),;S?!B4M_85;QO.?\X_9[)&=:LQ2;ZM"4?/7^5)2=GOS@U+FUM
M%)8X9;K3QR_?#ASYHH5CN\))$^V?O\%$A_V8FBA;<*46@JISO"AG`Z=L<OKX
M539Y7@EACP;H8.>L$CZ5[A-`[;)_[3YN7^#%@?*DL1\_?]57)F+Y)M?H1/+2
M>4FDPH^.0+U$*#\*#("SQ\>D?T[?<$SBLQLUT%NK=&)XB8YY=P1'8CP:K,?!
M>ACL=M,2O&QC_:A3Y]4]?D.H\?L:"C6C-(J/JHA'50SR.X(SJK#O]#A8/Y+?
M$KQ4%6[420_2/W^+!SFE#+D0+%I(J5X:Y/2@(S6<Y(ELEN"%8O:C3CFGZ>/7
M.:>S)]DYB1Z9GM1?<EY_B/F5Z^$JA;>;7$!\__%R2V!%M%\B7%G\DB6D7P(P
MJFL5,_JXII8$LY>E#N>)2T[#6=XRHCP\`[`9G@$.0C#!6,8TG.4M$Q8NERT5
MBX,YUE*S)$S`*`NG:4O&(-L,4W`>+BTN6<19,%E:,L'#Q8,EDYP'L^8EBWGR
M#!])Q(/9_Q*2PG!Q;\ETI(.)*=@6B'N6`LSW[[]>7UU?_1^7T*\9#0IE;F1S
M=')E86T-96YD;V)J#3$S-2`P(&]B:CP\+T-O;G1E;G1S(#$S-B`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
M97AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$S-B`P(&]B
M:CP\+TQE;F=T:"`T-#`P+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IX
MG,U<66_DN+5^-^#_H(<&[N2B[(BKR/LV*Q`@2"9)7R0/>9&K9%N96CREJO8X
MOS[G4"2U%$5+;!<0--`6J"/J.PN_<[B4OOO'[<VOMS?YO=0BR_&?N5+W@K?_
MK7>W-\3<(1F5&9&FA6:4WVM-5:9RN)-SF1VKVYN_9WO35\$%=B24PC_9\>GV
MYOGVYO%_L2O\UVO([SEG\()[S@2#/TQ3.KRON<#[FA5X7RG)PAW2[(YH[$N1
M/%-%#E>(Z7&>S*_N)O4W*>F4^N[S[<WO?RH?UF`"EGV&!XRQ3*?./(2")9C*
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M&Q.`-711V('Z\G(\_%;O@!RW;]DGPE8YY"U4X1,A>+V"%S8OU?H$7+)]6YE;
M:"309'M&`P#C-H"],7=VY?&7ZH3Z6B,:1D9-R_6ZU;4UQKXY;.L-O'63`5.?
MJEUE2?@:%L";-O4(:4SPS>$%N.A4`XX/9YVB>^-51HS2["L9+<XYJI"><XCJ
M.`>O,63^6C40_^MGX_`?(`5O#R_HOBMX3C'M/8=:.RA4!*!L.BAVM!VKK8FP
MTR%[.)R>LQ<(9;R+TH_GTQG"&*)_<U[;@0]%Q/&IE>_B(WM]KO8]'O@K%AUG
MD]`JDU\?H?RXANY0[EGN*CK=.7<%TW%*][HQR?9I7_^[Y;`^T>PJS,M8Z1P>
MMO635?$,5'8T<LYDY=.Q,H/R_AJZ%4HXW6A!/"\7>#W#KP,6?7NID#?`D?\"
MELHV2VG:5I,-^'&[/;PV__?10U9JY16^2I:3U/$;D;R+%(+7,ZSY4&*N.[\<
M]MZ8>*.S\G^?20O&O-97,2GS=5>N>!>@7%Q.5GIC[1,1N<F?D/,FA^?1\@?2
MAC/IE$570#XU]%$W@WR[KTXVY]KD>@T+2%\Z*:RB'/U@#6$*A_?S.492+\]F
M?SJ\;Y77<L!>H]`+V>D:NHO<S=58CI42SM4PL#^\5N`P:I@MT*Z5SYDO?PA5
MO"-;93WYASUXLLH^E[]5'SY]`-IC7UT+172COE8AG/AQRG/*+P<J1JR9ZN/(
MJUNE3ZAT=FY<D&WK\J'>UB=,E*?G`Z3[_[>I$89@V[2"N'VL##'"TYF=Z6(\
MNX?KJBTG-M6I.N[J/28JP[&'JXU6*K1/`=X*-+>SQ$W]"(BK_;J"F?CIM:I:
M'(_UOMROZW+;&[*H!ZJ%@$T]'M9O96U6[<OUR5H"QGG+2!6\#3+Q@."@N:6R
M:QF`4S_+D=V"A)!R;()NCK>VM2%RS[&I[K-OAZ[]4F[/AKNR$M,8KB<A$U=@
M+:B=FF<DX\<5JK8K]^63,>#_@-%>ZCT\!#=,+;8['#&N?L'YU>FYW)L%$;,.
M!;UFUZD=*?7U5<Y5K[ZRUBBSE\/1:`8>[I6'@#X4W*\U(/7K..46J3FQ+HQ3
M%5%^D9!VH]E5A7^"M/?/7.1_/#0-_"699:Z?88#^#4KWZAHK78)X1(QWD)@E
MF._*IEZ;A(S(M@Z9I1=(?EF#R+)GR&L/./`P:YXQ\#K2>:WJIV=H^FCX3&N/
M_[K+CCQG?4N1O'.>$M9[):[^/579_FQ2-P2>L4S3UIN['01C<SJL?\D.YQ,N
MWF[0/+W\#[:L#ZEA]XZ3&??L27O\*0J7(8$SCO47LUY\FO1V^?*RK==FA1-8
MI:_3\V$+6018$W+0\0S.AYFH'6:MSAOH?`/%34NT*%6YX3D6K9OF;*CH&H8@
MON@K.M[@3-HY9[=&!F78V?`GLGQ5`K&W_G%S[+90;2F_.<-_Z_/N#%-+F#%?
M:(0U7\_I]]E/[Y?&?'6M3$+RO./.KO27W,9Q]1ODD,81Y]]`:XCA;[.?O5)^
M:P'S1Y6YG8MZ9Z96(%'M7DXF0>""N+GYB:Q$WDX=UF4#MBSKUK*=-*:2<K-I
M,Q9&($8?VO@JRRZ^J.J-Y%RY($`&0P411C#V;;R/A[;)E5B&'3<F@E_K4UL0
M_+BKCD_8XQ\@N,&<`YUPAEL((;-"YQDSRG2HS4X7"$@"\8H"=$)`H%]C`E"*
MQWM@>5Y$!6A.>%2`Y()&!8"AHP)"YS2*011:D[C`>Z\0.FX'P0%$5(#IN*D%
M51!A,0&H`W14(']'@&NEHK[@2LFX0*%8U))<%CIJ!RX*%@<)E4W\%:P@47=S
M*M]1DT@5[R&7(NH+IJ6(:L&4S&54H!`RJB:30D9!0AG/XJ_@,H]KP43<#HP*
M+J("4-_$7Y%#51@3H,#*T9$%L_,X@<!L-SZRJ!0BJ@45HHA:DG+!XP),RC@&
M*O.X%D3F<9"Y**(!0[2($RE17$>U@/)&Q%\AF8XZBP"$N`!YAXI)KGG44"1G
M<0+14%W'[BL>I[""QT>-Y"P*$'@Z3BXDKB`C+#YB<A5W<UY$7.#/MG",1U9D
MNU9IN-I:]0E>F=OMI3TZ\ZN_S31&V^(MNH++B26]'BKB43F`#@QX?>L$]!"7
MNP^U'<V7KC6BGF("6"?/%?'`2`>L0],*C('9^\#DD+,N@161V2-&`7=3,-%N
MT.+R]Y3E-/4`+=8AJE9@#-#>AY2[U*/F40LP9CD\8^"`:1]I/32MP!B8O9]@
M.4%(T')\PG)""@?081VB:@5&`-U]N=APYLE)P]EA1E3R,'-;0*&N3;A#WS!2
M%OL;'XWV3=J^EUO$/!GM&H:UZ3HA3(OBG;XQCM$DB4,@VK>FJ2;1[WD2,W&:
M24PY%.O;1&@2;//D9-?V/":>SF3FC^1%^SBD5:W[$?_H1H)O#['`.QOJN5_!
MHK([Z%1([5:P3M5Q7V[[>V[S\.)80&#=,'KTPVO8OFQXY9-T.HF$M&^4(R!=
M\T*[F;%H<0RV^C[-!`1#U;R9C!#UVI="PE08@D171+,55(0SH2G2>F<,[:)]
M&0,D>$W3H->ZYJ4FTO3KO`9L$O1:KWTA)).&0Y#(2A;%BI*9MD)*"=CJHGD9
M1TWZ;%@A2ZBE=W:U3=D*64+];8M2>WEQN-Q*]7BKX[-A^Z(C+<HO1.-1=%/7
M?'_8;LN'@SU.$*FJK29.*:]`[NI8>WFABQ,+<MV@?1'7236CZ$;.L+A)A[L#
M:P2F<%NQ$#/VFQ=5*;-0(YU8U%:!(50C,(7:B@7IT[8GT*?#/:+/(A>KHI@J
MC`T=646L3D/T1F!*$2L6)-M!^R*RG>4`)"V+6_N1VP-K!*9P6[$0-:>%C7GR
M?=2&T!QJU:'V4(W`)&H5#IM>>P)_!\.&K#3G*\I)9#YE%7$Z#=$;@0E%G%B(
M[9/,WSXY:?YHA0=ULB5_N++D+[3G3M&?$D9K6S%1VP[;E\SRI$PK%5N5G'9>
M$[^:82_?4\H]A2LN9)P4;'O"2HR4DU.'85*P:I!.C0Y[*S!08_1PEU%$EU&L
M8XW`+,>ZIT()1J26WLZOL2)NF&FL*:Q5AOJW`A.F,/>Z-"742/]68)XI[%/!
MK"62B_Z@,?A*:;521;&@U+8VLN8:ZM8*S%/3/A7,:2)Y`A$9R\.<9M70GI#:
MR\(GBBE7FWM=0A1JI'@K,,\&]JE0?DR+>DV71;UA=&<*U9G"Z]\*A$W1WNNR
MK%`C_5N!F:90X:COM:<DW9`QV$I2LN*"S)PT88IM;>3,-=2M%9BEIGLJE))%
MZ@1L.N:',P]1N!R,5UNWG^\RE[T<;%%@6V)6%6H&*N)1.8`>C$^C]G*X18&-
MB8E1J!F)$:C$`2,=L`Y-*S`&9N\G;E$(Y8Z8SMNB<``MUB&J5F`,T-Y/)%<'
M\+W2VP'3/M)Z:%J!,3![/W&+(F2YV!:%!>BP#E&U`B.`[G[:")TVG!UF0B8/
M,QGY^;$)=R%3UQ7B?9.V;W19PNP_WC<&&^).C--HWYHFX];OV-OX&OM.BY+)
MKF,3(L&*X(3(MR]?'!/^K#OAW:<4F':_#/RY.C:'_;[:9O;7?//G@8@JM/HU
M;%\6I7R2E6+3#7QC8+IAFQ.F&PY'ZDJ_>7.@Z'?M"45_$!)9Y05?,;5@I=]X
M)U"H#]N7C=$$KVD:]%K7G%`N?Y77H#@->JW7OK1H18>'(!5,KM3LDA79Y-)2
M%\W+Z&G28X/%>C'<;N_XR+4G\)'__2EEI/=I%V+YZ(_MJOWA^&9.MS=G/"M<
M3:[@(V<,]NU[-)2^GR\FMVI']6Y_,[C'.\F[_;->C&$UV.'N\8MM7SIX>.>8
MT>\8^4KG4RN:9NP/C@CTZ"3]Z,`L(V@:M/ZX>5D],.O%*FS]7OMBGI!AZQ=J
M19B:JGUQ&%]:X*)Y&2\DG5'@$V<4>/H9!>'/*%`NNE_9:&%_E/;G\ZFI-U76
M5,<O]7K$#]&JA4^<3^#IYQ,<V(55"P^?3^!)N[>&/1)P`&GPB6,)//U8@D,R
M8U\M6JSPB6,)//U80HJ1-`TZ:]R\C&Q2<*BPLWKM"0MK06>%=[.B54K`1!?-
MR]AHQFD$\_.,/$P_KGTY_?#>-T<(ZXY($?N5C!]_/=<O_C?0F^KE6*UK<]8@
M4JCPB=,"//VT`)_<P1L6*CR\X<^3-_QGO1@Y9&+/GB?NV?/.-X-PE046*C)2
MJ/")37>>OND^RPB:!JT_;E[$'?->K,+6[[4G3&C"UN?RG@H6J50")KAH7L0-
MTR:(9W]XM%TWY^TJO_EQ%G-+U?9RQMXU2H;.,8W:%Y&.5'ZIIO=9`NU^4/M3
MN?9?5,!?@SY7Y<;PSP&_=+F@[FAMX,SA52=N7=Q>SMGL1M$@IPW:EW&:G/H]
M1"=O*,2J03HU.NQ&8*8:]JD0/_:;E_'C'"600JP25I\A<B,P4PG[5)!K;7L*
MUUHUAG4<4RM-YBXY:>J5M/H.-3,",Y6T3P5I?-"^C,;G^`I9TZJA/7GTL!N!
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M6WN>:"_]`9Y)[YE[74KK?@[IE5;32ENQ4`Y+BUQ-ET6NH5*GN^IT]PJW`F'=
MVWM=)F1ZI+`1F-1=A2.WUYZP#!/4/GR^:7@"PEK!&62(W@A,*.+$0NF-)T_,
M)N/6)J'V5^9+CX8PC46UZ5DI_!*L;@WTT\>]`K]?PWWY$?D"UM>\0KA7^/,M
M9.1;_+Y$[(?L=SK^N8([BE]?C@FP//[9ACN`&?V6P!U^4R4J(`F)]U"0^'<^
M[A2)?]?A#J8@<0&2D_C7)^X(?G<A+D&A^(Q+,!K_I,D=X91&/VUP1P3^$#,J
M(1F-1P4I6/$.4H7?Q8Y*:!;YA@P$YX__N+VYO?D/5>'W30T*96YD<W1R96%M
M#65N9&]B:@TQ,S<@,"!O8FH\/"]#;VYT96YT<R`Q,S@@,"!2+U1Y<&4O4&%G
M92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y
M,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A
M8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C
M."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="])
M;6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ,S@@,"!O8FH\/"],
M96YG=&@@-S(Q-R]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]/5V/
M&SER[P;\'_HA#TZ@G?"[V?MVM^<%%@@NEZR!NP#W(FMZ=I3(TJRD\9[SZ\-O
M-M5%BN3:P<+K=G51K"]659-%\H]_>_OFU[=OT(.8^(#T?^9)/G!F_[?[]/8-
M-F_P0,2`A8&0@9&':2)RD$B]0>KA/+]]\]?A:'YK9%S_$)=2_S6<?WG[YOGM
MFZ=_T3^E_UL`T`-C5'7PP"BGZB\Z$9*^GQC7[R<ZZO=2"@K_(!F^PY)*13Q&
M@QR1^E5-TU,=SJ_^Y1A>$AR9^N.'MV_^]<?MQYT2`1T^J`9&6.9'O7@P49*@
M<OB@!/0=>D!42>7#SCP3/)+APV]OW[S[L+W\S_#CZ;R;A[\CCM[_].%']3<>
M/IQ>]KOA3_\\?/COMV_>J][^X^O0I%08B)K(`T-(]?6_BI#OOGY7<M&5XEDJ
MA9JN&/E^Z.IM*O0VBMB;ZHPKLW#"YD@_&V$_S\/[IZ=Y=QU.Q^&J_O7#]K![
M/6RO>_7OT]/P?GL^[H^_7(:7^3S\_+P]S\/3Z6PP_W-^G#^]6,3S\-/Q\74W
M/PX_G(Z?Y_/%-?_+>7Z:SV<%__EZVOW/UY;H.)%$>12-HY7H0Y\\[QFO:F3%
MB:9I\N*D3#]K<?[H1/-EWIZ'^?BH^/[3O)L_?53"HW@S$(38QHKY].EE>_PR
M/&\OP^M%X6G@_NEK$TU''*G^MM:MFRX$A(4>LU9`C.E>M8!VQCJNBM]/\_7Y
MI-@^#3MG<;.1P>/^\'K=?YZ'V9GET[`[??JDS.FB+6C87RZOVX^'^=OH%S$_
M7&A0+\?,$O_R>E9]'Z^&Z&CF3_/V^GJ>+V9@*)R7TT7]0]%M6%&L[H^*@]F,
MH(L>0?VV*?*T3]*2_N[OA*%O()M)C$&S.,B&$>73@B=Y.AT.I]^4NQBN1D5J
M\!^4#B]&L;O4L7S<7I0[WQX?@YB.\]5X_,/I<C$>_U9NP?,HR/[TJ'R2DOI\
M5&T[O6=!HH+RP/*[;Z(O-OY^?15^GPGQ3>V!L<G;`V?1'A";('MX.5V5HO;;
MP^%+'.&7>?=ZWE_W:K3\-BOU'D]7K?/#ZZ,9-)#5+&U%V\G".+;&S+[8GU*C
M=/^UF1;C%+C^MJY42+J0+Y(ZJ#GY"C):^08I^D'Q+71,B7>'*@?U-*CA[[('
M-?Q>U/C65/P_#$E-$";?=-!@^6T'#19AT$@M6Q\>.0Z#1ANO_J."S'5[T#9/
M$=JH/SKD7-584M)5@RB$06/\*H=0R<99F?VP_>4\SY_F$*545G8=M%*VY]VS
M];?SY_EP>C$X6ZT].P35`/LX/V\/3[K/;V10F)-@U)C$_$E]-QG^?5:TC+2:
ME.WYO%6<&Y(?]Y?=Z^5B7<2?E5]1/[S1-/_VO%<<DHEL1C5@-*=><D:@A\MI
MF/_AO,O3^?3IGG_Y%ORKJ.+T3TG,'R?F@JB+>$D47(<_G5U>,NDE-XS;/#,.
MS\.7A^'G5R4=9RVW297^]=>C^MGC_+A1?ECE-I>K?OP6,L`R)!+C(I%8.)7K
M>;_36G#47I^WU^&W_>&@#%2;]&6O;%V]/KU>+U?%K@XPIZ/Z7K0,N+%@[,8/
MAH?A#X;KE;@VP[CAA/JNGK?*EWV<YZ/_+2W-;Y)IACR9$!8,820NU=0*6;#W
MH`S].-O0Y@A3MK#D7TEH]:7QD!"N>A52(*(^FM!`#<61-#-1H!!&/#&#0#((
M`C-11.`8E7^!(?756T*@2*`B`D&3+")@Q,L("(U%&OB$Z%A$D'>ZX",JRX%S
M/>I+"&PJBYK32?F0$H(:4[R(@.\AH(D6=:&^?'$90>KLI80P2EJ4`Q.C+!+)
M^,C+7;!1%-7-Z'B'33+2\B^HR%[4!4,C*G)!)\%)$4$-WB*;=!2X2"050I:[
MX((5N:!,E.5`*9]P$8$HPR\B8&65103$QN+((FK<%+5)I"B/+#(*5.2""$&*
MDM1<EA'8B,HT4,'+7!`]PU)"4!_J18,AB)<=*9XX*W*!)9N*7>"1L:*RL.!E
M;6)ZQQ5C/$U%06%,RPY$A0M:E*3Z5B^2(%EYV(Q,WHEHY5&E1D39/>'QSI@B
M13T33,HZ0&.^_:]61$1'"Z%LJGTFA!1F0KC*%O5O8];\T[:I+/PVM70K*U:&
M"OSXF,_A.!>!\(D_<#G9J7R5Q6$DW#?Z?^EIX/>W>?HM&2,6A@S5V]3&H6V9
MDUY<U-&2D"H^?;+6JIX.5FF(ZB<C*/OXG.A4P;1.6\DR37-R7U!%B:?*$QB(
MP>91Z\<^1KK\^UZ#0#EQ17SM-CUA-,AK08U&6!/FWBM?TVQ,*EY-2+@O`FX^
M!][IKY.,Y(1R5XY`3VM*E498$>C?*\FU:M0VS<V-1'QMD)XP1V-*C;'8%6'N
M?8?DA$HF(,FQC.1&]:GG"/2TIE1IA!6!_GWG",T*S@XSJ9QWI^N4I4E_,ZC4
M;W>.%"EYV77JW]8J:[8E6J;;F+2EN\=.R[^MK;*/[O&>O(U!Z4#<927YGW9+
M^GJ!GYJ_!!MM<T60\AP+%_T4;,K#H?%4GIJ0PL]1$<G#Q/-HGG50^[.?>J\C
MTIB2HB9J\RE:9P)OLTZ1L\X\)=3*9;PA)((;A65;\O7B\S_5$C39GN4M11'>
M2A*?$I(P<VL4>DH1HPW';,/'2H&9T02H;@EOI,\VY>LU%#W564F5'L)K-2[`
MK329EOUJ%%2":ES"6TD2[$:-,JI1;-`X;;@D=>09Y[*6UP+<2)QM6:/#&'?-
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M._Q^^,-N=WZ==?G-Y_WC?'PT*\`O-YZP(<>SDS1K%Y7`VUQ4=FJCG.,MYU(6
M'JMKBL6V[*!CLAU"#LS!>QR8GW&J<&#E7HJ.A(!U3^4\$5#_&MY'1KW8C3=:
MJW\%;G-O/71(4/U+>*OZ1[I4/\6"QI20<K01DC4DA&LA+<`]"2%DF86$T(QO
MA>>F).V,BWGB?A;0/:[*V!W6PCE&IYG"FYPF1J&>;5'?:)Y_<\JO^:/=ZNS+
M26[=J:G:T94*N]/E>LE%)^-SK&R\F()(J)^*E,F$[:U@*>R+$WB;+\Y.Z$9\
MXW8<W30H=4&L1<C0[=`@S[T$MWGN"JJ-J_%43Y'J0*I%R%%MT4`_[^`]?AY!
M^Q%@/U_NI>A@O72RB:KV?E8T7DJI/"P"+!J/!D:%/D-,B"ZIE`;GXEE(B;4(
M&;H=&A1#N@S1MKQ/M7&CGFH9J0ZD6H0<U1(TQ"6\.>(DADBQSZ_-7)+8"$Y+
ML^R6$\]42KY%@#GQ:%!XLN">\`0-J/HY)[V&*^$\/<#;0\XH0TD](7A1!(;C
M3"M4$+]]>3GL=Z;Z\WH:GD^'Q_F\KNG3U8*VR'X'3&+TDJTWE$2ZD5X&-9,8
MH8JR_HM!DP!%J13>%*4\98U?#+I'(.XDX*:XTT7'9#L$(HF'=TP&>TJ^RF0P
MI+$EO&,R>$%?[V0PH+T5N,E9=VA/NUE(>TMX\_2&3+07IC?8AD[C9B2H\O-,
M^S]`1BMPTV1'7D9)HJX+[T"OZ>$=7E.$^N%I43]LGN.D;_OL1II":P)!YR2Z
M4VA/^+T95U.L"'@CT9L%UW4\V1X@]R.Z$UG?=44B>Z>74DX8&"S-N$(:7</[
M^KTSXPIH=`5N\U!5'4M0HTMX<T8X+C4:71(T_Y!F=(`(5N`V!Y0503&+8PSV
M1Q[>X8_B1K@1Q3T]TF_4JIDT&))9@](L03FC4ER`3BN!MSDMQUUK1J6K/@$?
MM@2W^;`>.B;;(>32'+S'I8%;`&&75NZEZ%H\OPUSL)#ZU_`^,MKF8`'UK\!M
M#J^'#@FJ?PEO5;^D2_4O5IS67\/E=&PMGQ6XS1MFY9.F8X3#[H]TSYOJG1-^
M2^,4]ZE*OVF^ROW]=+S.>M^73M(NKQ]/Y\?]<:MW@+GS`O;Z6_=XNLZ7X67[
M9;W]_R9W4]R`;C"!M[E!Q^7=W$UU`?F]);C-[U5U/-D>($?GX#V.SG5=X^C*
MO10]C&>PF+L!&EW#^_J]E[NM-;H"M[FRJHXEJ-$EO,=W18TN?!??2$)*J=M:
M`BMPF[/*2J"<W2#FEHOTT\$]2;\VXA[#J4B%)%!A0JM'-_`F+ZA?NDHD*N)4
MGA3+)?>62J1%#5(\9P>:R.LDFDX)U4)8W_UN^^GT>KS6)IV4>+5X#05M"+_X
MXQ[O*<:W`CUW`F_SW!A7+5QY-F@PKP7M%J&.#=<*B@)+<%L4J&#".#7/Q!29
M")1;A$HF;"LPHCAX3T3!T$%$<$0I]U+T[%Y8M:FS=LI6<%Z&J;0L0I7@?"LP
M6/49<<+2G44OSX;C**7=(M2QX5I!@:_+B$W+"B9,>/!,R,A$H-PB5#(A02->
MPEN-F,NE$:]FU%W96>6'`*&>5\]VRJ!%J.+5MX+BM`5W+)J!P_5.38=.,VR0
MUD\']S3ZL.`>H9H._0J*RC?PEJ@L)G_<"*;+,XK\<6UA*T/]BIH_(&1Y;DCA
M>\")PTLF2('[`.,>P3(._0Z*ABF\*1J**9MZ)='0TTV#'A?$6H0EW;>-16PL
M8N,Q-H:MP*.-J1&LP$T[-+P1E$K[DR`:>)\B[X%ABP#S;M^)V%C<,&P1<KQ;
MM.B58LA-X4WK?TON:];_TH\?)PHOE90%BP!SX]'BJF",@RF\:;5PP4UIM3")
MB9X'QTX@G/O(DE6G>2=B8W'#M47(","AW9CR"MRT2Z7)E+4'#[S+R'M@V"+`
MO-MW(C86-PQ;A!SO$C3E-;QI0TQJRNF&&$$WH\A9LHZC3A)>*"D'%@%FQJ/=
M*'(%;HJLE79<^(;5`H%F\F[@+9M)A6B?8M<A1<"+#BF\+4IU4$(M[\!G5P)N
M^NSJHF.R'0)?3BF\:<-L!R7&7P*Z6<.;/D5Z**$8TLT*W/0UT46'!'6SAC=M
M"NZ@Q/B`M416X*9IM3P=:9[-X#6``._(L[E?`R!(Q%-_N7"%;'^=][\\ZZQY
M^WD^;W^90UKMSBYTA_DIZ,NK/N(P?Q0L,`'62S=#2\*1G.*T'9W<M)T[>>_[
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M*SI]O&[W1S,G^?IR.BYO'%BN&$(942>AE+%`J;Z>Q6X=?A?7)$MI$!IA5YC`
MVUPASAWV?9,&H1'T?4MPF^^KZGBR/4#.#O7-<:`I=%VQ0G:GEZ+7\@R6:BX@
MC:[A??W>R[36&EV!V]QC5<<2U.@2WE'"O]#HPA]N!%9_Z%A*O=9"6(';W%]6
M",4DA]MI0'T,I9T%Q.9\9+^6X1XKRBXT)K3`<P-O\:O&@6KAL@=N+N&Q)S"B
MD33LVE5^%W"BO53Q,5"E+UT*SIXC=[]5O8]?5L)]10JID$L26?CN%7[C65W1
M73$A=5;C#<@;BY1^.<@]UE2%:%0HMJ3PIMC")UJU#L;C4A:/2UF!C:F:#=<*
MB%,)N"E.U3"AW2Z/:U(\KDDYRBU")1.V%13S4GC3IW^!C5(.[;CR#*:L6(0J
MKGPK*-9U6IAI6J,<&MRKYRBEW2+4L>%:`7&SS\),RPHF=&CA<:F(QZ4B1[E%
MJ&1"@A:VA'?L6?%LI'M6"-M,F%=^CQ#JF?3\IIQ9A"HF?2L@N/=IRK3,:BK-
MT_47M8OFPM=G<!'J,]PC5)^A7T&?10'>$;Y'EY'\R555%+)\1[CG(=`;*BG<
M(UA)H=_I8U#Q;01Q<-010<:ZND)/-PT27Q!K$?*5%%S$\"-B^!%C;)ROI-#O
MH'@C>K^+@KKNQ1L1"B@"RX%/BY`OH`@L3Y'EP*=%R!=0&-Z@Z"3Z"BCT+M41
MR-]STT_I9XR3@Q=)2K]%R%=/Z'=@2!+=GU]5^J/!1W@6`K&A8B*K/_,NQC,A
M;CBU"/F*"<!D5^"V`%;!LG&?(A1*!)8#GQ8A7R@16):1Y<"G1<@72D`FNX1W
M3,&!)HO%1D<\)'GV4#P=PD0HDW!R6-!O$?)E$H#V5N"VH);77ND[,[/'\P;>
M4AK!.W8?ZAB1V8_)^_=C]E!"+>]0+.C>C]E%QV0[A!PTZRZ-Z*#$.,/,9LE.
MW=BF7:41@&Y6X#:GU[=9$M+-&MZTS-A!B1GW\/;(/HG8EE6E$3RS/9+W;X_D
M87LD$BS>>&B>2V?\Z%O_EE42WY<FWWEFPR/OW_#(*S<\<GC#(^_>\%C7\61[
M@#P)Z:Y!J.G:C//,;L1.<9NFE;L1`7&OP&V^HG(W(B3N-;S-.51T;08OO/^P
MCV?3LF__H9[!=9_.ZLE].J,XMUFW4\,U`MT,ZJYFX/AW5C-0XOGSK`:VPF8X
M]U@U98L8_,'MX#T?W+ANZX)G@P8]+6BW"`Q,Y>T['AO'J86X"[!2R[X5Y!J[
M]N.8EAA86B_M9`BBF*(H`O\6`1:%?<=C8W[#OT6HWDO(,WL)/;Q5&%,J#*)<
M0:@&UX</-"1?5D1>6BEK%J%ZXQ_/;/SS\(X-#[QJ"];-%[ACR7$7^`A;Z;):
M-^]X;,QOA&`1JG<0`@-@`>[8_]`T`(RG]Z*0412!?XL`B\*^X[$QO^'?(E3O
M0X0&P!+>*HR)P\)0J67E'@+S,6_%XR65LF41JG<?`LI>@=NB=':[:)K\,NE/
MD=9/!_<43I%FF0UV#@M:D+Z!M\1AYO?75<QH.\(]#X'>,$GL'L$9;?T.2OE3
M>%.`9;+NB&=/-PT27Q!K$2@XJ.P[%ANSV)C'QIEI?(<&[`U,P$T1U:NK.J(&
MWJ?(>V#8(L"\VW<L-F8W#%N$'.\6#=H;F,*;0NB2^W((33]"G!"\/%+B+0+,
MAT>#=@6F\*8@N>"C.DAZ'AP[@?`P]YM5I'G'8F-VP[5%R`C`H0&[`ON,V+1L
M,6+M60/O,O(>&+8(,._V'8N-V0W#%B''NP2->`UO"(.X9,3Y\BH5VIP0O#Q2
MXBT"S(='`S8$]NG0M*PRX30$T+#5GH:M]C1NM:?)AL9?P^O.JR;I5%>-2>..
M=QIWO-.XXYTF<OTUOH_?BTUA*T]8:K@T;FFG,<;2:+AKPMS[WON!J5?J[[@?
M.#5:&G>QTCA<:33:%0_^?5\.1K/'!=R8HD#>%`7RIBC"84#N,37%_HVJM&*C
MF]&=I<H3&(@)DP+N\<841?=MTS1_)FF2"'C":)#7@AJ+<$N8>]]YN3`5_L3V
MNLN%'8&>UI0JBW!#H'_?.?_I";P[B!UACL:4&HMP2YA[WWFY,"2YTN7"CD!/
M:TJ512#`"!6]YW#G!>>&&4/='I^5+@#6YJY^NW>D9.]*\\:N?KOS<N$BW<;8
M+-U==EK\;6UJ?72/]^1M=,U0KY5D?[HT3TT)?&-G@+=_'U/B[[\DB-&X$48_
MZXCXT_%R/;]^FH_7BSZ)Y^7UO'O>7N;D')[O*Z>TM9DI2J&OY!3>9KFD^98_
M8\\$O$8S`3>MDW71,=D.@9G8%-XVWMHI,4,)T,T:WC8Z.RC18W:MFQ6X:5&M
MBPX)ZF8-;_,I[908?[&6R`K<YH"R="0S<A3!E^P$>(?'0>$R3(*GN!N#N@7X
MG^V-O^9\S<MP>KU>KMOCHSZ$0#D??0[[53NBZ_.LXISZ,'O_Z^O^^D5OU7N9
MCQ?@_*_?1[#^0(L4(T+'>*OQZ/<*;H^F9.`RS\.?3]=YP-A4#I3R<P1?M9/"
MV_P@NG\!B/%3"+Q;)P&W.;ZJCB?;`^3I4-]E.F(*7=_LY>+36+ILUG@F0`%K
M>)NSJY"#<49K!:S`;=ZMJF,)*F`)[RCD!Q4P<K1!")7N^@5DL`*W^;.L#$H)
M%9'P;3@!WN[>B/2WX9"1A2O0!9O<%>C_KCS7V5]K[IQ<??Y$,JL,I'^5@>17
M&4KYD^X1<",)N,F-=-$QV0X!K^+AK5Y%LD!)8M2"KVVZF$Y!JEK#FSQ,AXBT
M?P!4M0(W.9PN.B2HJB6\U?^H9K]?5=IY``):@9N\45Y`279%,F?&!7B'^Q'^
M\ANB(Z#/KD;A;G_XZ_9\WNJ/N65BE20OT[W<A63.ER/]Y\N1R@E$`A\H1[H/
ME*OK>+(]0%Y&=-U;HG,7WW5JNIN)D\TXBE+N`BE@#6_S+!5R,",?/C6N3P&V
M94W'$E3`$MYQ$$"?`LSPAD^*ZY.";=E<EJW'>N;@.-)_<!R)!\<1Q,-TT(C<
MN2@_+(]?-M=BZ5WHRP^SQ8[YIWE[?3W/EX;Y(9(YO(WT']Y&V@^X,IX!/LN-
M=)_EUD7'9#N$/$__T6X=E!@?D3GIK5,WIFD')=IIP`>_]>G&M.RA0X*Z6<.;
MYH<Z*#$.!#X6KD\BIF7-R8-Z=!%_!XQ^.KBG<`>,>X2*O?0KJ-CK!M[DO:B_
M/H70,7HO.3KO]7/535:E_(.$JU4<N_8Q[`1VCV"%&,D<3D?Z#Z<C^5/&`KYQ
M%B04>7FZ([$6(4.W0X,\8?=1=C54&^]`0GE6H#J0:A%R5%LTT&]V'GPW1FFG
ME_^.="-I:>W6L>$Y2FFW"#`;'@UTNOU'Y%6)GX:A[5E(B;4(&;H=&N2BNP_4
MJZ':."X2RJ$"U8%4BY"C6H)&LX1WS)!U&(U>E79L>(Y2VBT"S(9'@Z)!]T%]
M!>$7LSGD*X'UDPL.*%0"N\>*#3H:$\QT47^FB\,UB9.(5Y$PX0ZJ^G"Z;@_A
M6*B;BT=4[+CL'V=]!)]*>_?`>D,O982/@;3TS+FOV8G`"_X1=><*FJM4]I]G
M:/WD7E<YZZ&(A:YJ[W\R,0*%6FQG._8QU(FYQYJ]3QH5VOODX1WE$@1E/]C2
MP(M":;9G(])N$?*EV23>@$;BIB\2]_Y4#B#?"@KBJ/MSIF+WEXDV*!1H!PD$
MMBU"OD";Q.O32-POYMBV")42L*W`A`#UU6OK*1P,%/I.&R2GC<J?&[YG4*C?
M=C):\&81JMCTK<"$`?5_I=6HF@9W[SD*M(<2[JRJS;N8;<2;TDC<YU,K`]<*
M2CZZC-VTK)"`B9,H%'('"02V+4*^D)O$:]9(W!OFV+8(E1*0H+$OX3W399"Q
MRPUAYNS,^CU.3D9>7"EO%J&*3=\*2G2Z%&U:9A5MPR"?AG%"S86+=&*#GH%7
MORSE`R:C/1GSW8]?KPN&L._B;M[0W07W783J2WQS4:VNLC`_3LQOQQ\Q62H9
MOIM&4GQ/]-)-"8$B16`)@2%6[H*CL?P+RIYY$6'$I(P@];$^13%@Y8Q+"!AA
M7J828RRF,@;!HBQ,3+%R!T4,1L@=.C@911E#4'*'TI&J85W$D&3$60QE>N__
M]O;-VS?_!_N8FBT-"F5N9'-T<F5A;0UE;F1O8FH-,3,Y(#`@;V)J/#PO0V]N
M=&5N=',@,30P(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E
M(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=
M+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@
M,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2
M/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^
M/@UE;F1O8FH-,30P(#`@;V)J/#PO3&5N9W1H(#0Q.38O1FEL=&5R+T9L871E
M1&5C;V1E/CYS=')E86T-"GB<S5Q+C]M(DKX74/\A#P.,=U'2,I\DMT^VQUYX
M@.WQVC68.?2%1:5*[*9(F:3*7?WK-R*?5+4J[:T6!PL#EBPFF?&.+R*2?O//
MZZLOUU?96I629/C'?"O64MB_ZOWU%357*&&*4&5^8404Z[)D!2DRN)(Q1@9]
M??4/TIEGY4+B@V11X`<9[J^O=M=7VW_'1^&?V0_96@@.&ZP%EQP^>(G/FE\O
MA<3K)<_Q>E$H?OZ!C*QHSF5."IJ1(L_@J4C3]OO6?/$71;C(:&3JS>WUU7^\
MK^[JDE!.;N$&(RSS4"\>RD`2O""W>R2;"TK);7U]M<K6LL3O7Z^O7GW2#[H[
M:O))U_U]UTQ-W_T;N?WY^NH=;/`_WT^&T<1S9!21CE?D\H^'I],_^O2D##/J
M9)B5(LB0*U%:&=[N-'G;[P]5]P@/-W+\38_PU8AV)$U'JKKNATW5U9I\;:8=
M^3Q5VRUY#;\>NZGI[LF;8]MJ^$9^RF3V^?4;^*#DQQXV%S<79THR/N>*HH8<
M5X*!U3]G&<C)^Z8#-IJJ11XFO=?=-%Z<P%SED<`R7Y<,?KC]#:ARXEE"SV4A
MO$`R7L[47%B!@"I0*VN"^\,_R*B!]6T_@#ZW_7$@=]78U*0>FDD/346F7361
M_7&<R)TF>XT?L%B3S^_>`FWWS3@-%0JOKKIH-MYJU@2L:M3Q:=6@_Y,<]#`>
M89<'3?1#L]%H3_UV$6&@P*TPRHP%ZQ"ELWF@N1J`_GMC`99-_2OP]`/9Z!8(
M'![)KMJ0J8</('>J?M$=.;054CR`Z(:'I@;?F*^YTQHET6WTH#<_@/PTK`.W
M&/X\DL,`RW$E_GIW?-3PC%U_;#<HW&WSJ][@8Y<0A,R\(#@/;L)+Y02QT:"?
M/3C%7:M_(%6W(74/--=3<]>TS?2(^D&:0<.Z><!5,\('78T]WOI(JG$\`MM@
M754+<NEZ$*K6)C9@7'%/J=""4.+@C<#RW#I`[EL]F$<L(0;.@SU`,O7V()6P
M8K!4(QDU1,*A&5$A6W(_].,L$L(:5&7_T(S`@'$>L)H#2`N9`1OJ]Z#804_'
MH1MO2+-%WM<0@M!>M%L_3LV^PAO<.B/TIH,MIAZLK@81-).E90E!8"(R@F"<
MAV0@2L6L((`\T&<S[H#`NT>C-)<;##\=F,$X5@/\J^Z[^@@*ZR90O\D*SDY"
MN`4!SL,!J?:8+D;[NQ,)LGFR9X6B/Q[@]@6X+]#_K1D4/)^9@;3<`T\CQ*6A
M\O17Y*$:&FW]8%O5H")4;%>WQPW:MM?FZ`B'NW8017IP=T@Q3L,OM^@$:"CR
M<CG,4*`Y6"N1N,[!+LI=+GGM-`DQHM4F`GKK-W!A--Z$^6$$D1E7&71KC!Z6
MCKOF<+"!80.1L]NT\(\;6'%`JX!H'/Q-5P.&"70;M*W[OM\X_]O`SWC[0EY2
M8(RP_(L9N$"`;OBW!J#1;\$E)LOP&CQEM.9]ED5#[/S.&I;C:N!H<ZSASK%O
M-^LE;(59=E[]Q$1V\>>K^/R7Z2)=`Q29+P%800.ND9RZ#/8>4DISWY&W)AC5
MC^06[:ZM_D@MD"`GSP/NE%(%TZ`%C6AZ&T#F&$&F2X$NFO[99`-#^'B\@Z#3
M8)P99TAB<FP86P&W^3M$5?AN8.M(-I"EJ^$\.'__^C-@[S7@Y!=B[[1"<BG^
M_R@DSV?TT%Q%K,=\2EN3UZ/!NNB,;5,98(.R_CZ-H-?.=`&@^!'BTJ4943/!
MEFPM3/6`%</J\CNIN0H5C_$]ERZ^`8@%8%/O$""3`0WNQD@O1.8E'(L'R*Y$
M="R6%QZR;PS8ZL:S2@&_&2I/+814_5`U)NINC@-^H*:A_FAZ`)AO]3!5SG-,
M'INAV^W0[V?9S$)"@XA=RJG=S4N(@&41G$5++J6++8'>0_5HB(6P``K9](Y0
M_S/F%NM\QLR!=4R@4/.@$+;'SN1DB$[S12>^8#$I9J29)_B:SL.XA7)OG@6H
M7I31#CA^-T+8_`S:L5!BT%O4S"(>2;D(M"SKD0BK(M<LFQ4HJF3/>>2:_`C(
M8XJQE5C)V&QCO;5JH2:?W7@/ANOB(!0VSH\")*G@WZ;^@>*LFQ:JS%41"A!*
M([0JF%.OC\&USQY/B,<.BB4>NQDW"+\0D-ORLJZM_:+#(Y;OVV9C`L1I'NX/
M#N(O`\V54LO!(=.VLQW1@H4"3G'F8L3GJ:]_(7\[&(OXV()U7)Q#4)NG8I'J
M`W.A#X-8H'L3\<7ZO&$90B(6"29B(?^7)HIE,E"U;"Q@63GCG\I"SB)@;OFW
MI2::.B1#Z_H'5#0Y8N]IWI;]"*FO;@Y8C;WIJV$#=M%TN![@(=8"3%X>(2I.
M9QQPRD(,5\PGLAF)J#=KLQ_&\6C#^@)N(TL9LDINW>;5N_VA[1^U?K&'/-O_
MS<)^P'86!Q<L%TZ')HZ]_OB&,&EZY1B3`;>_(1^Z20\`7R:K6,3QXJ4]](1(
M6%G,9,)Y1(&*^<'`$RUYU'0[K^N;[J%O'W")5>+;N55>'+KF49'85N=8&O[F
M)>ML"P7[_L./(#6;(&*S9H%0)?,BF%46&TI"N&SFVQX5Y)Y-S,S-B9(=N':-
M#=/A0('O*[)IQAJ2W7&(".W$[1T>)KZ+BZTS$P,,T*N:@3Q4[5'/>Y9+"$&%
M`=,,MK*".^P"E)N:E#*^AC+6Q"AC^3=D;+!L16KUKWJHFU';5OE30'IIJB%W
M!K)MAGGU$V/L\MNHF71H*6(V4]))9R3:Q2&;NP"=6-?27XZ`T5$(^VKX!;">
M'2(XP1@]MP;IN-L6*4FD",5U.<O%>>X,'$E!B&6[Y54'8*SKSQMI,\8YT3)=
M?IGY$I*S6#K(W)<.GT_DBS[WU4R!P"N;D'P0-Q[;J?*^:LNG[O*]"PY%N*=X
M65#!H:Z/LF%,Q:Y-YKLVW@A'+`-.]+>=#[Q"]]7-L@(.&[3'8G!Q`=V*,HMN
M5,PB;1'JAMB#]^'OXG2`M#PAH#*>Y7ZN^P<:J\\S?<+U#$9PQ9U%V_#N0L+O
ME>0:YW'F9'*""R<G]UJGP!N<2]R0K[NFWND','[PW#V.?B&;-6;:M]<5)"73
M:UA"U3F/V"GJFG$?,I]K>D*",2[[[L/M>U*JBV-S+@)M"U<!O)CO%.V,%@M`
M0:G"9E[*/CKP\X#]W9<CSH8_=`_:-QQN\;@`1H$(X_]F(N<M-IX"U#:WOZ[A
M?M.5PZ+MA7DKC?>%#&V&,LXYI?`,O>V[GUTCS!F0;DV[\+_,D`F+$N=--Q=7
MKN0S\JCDL=?)G('/0.OW(4@[8/5KSV9<TC\X8&C;H(MX+B]#<V?6P%0>"9Y$
M*=.Q=)%JB:F7H`OV*$06:G2F`M3@1>YZ%!\#AF\Z\VDL;=#W4(6C6G%JZ%M9
MI@`$C?=[;73[W#70&V;F/3QHW)F$.^),?IZ&\3Q*3,.^)_($8"X@#EZ$\GK6
MNL^<,#SB.EN;[/6TZ\UI"XSAF$@QC#>FAX_C8#P4H-O^ZYJ\!W8.Q^'0C[8^
M.%<GW9Q+>&<R'2*^102A0D&8E[-C::6?8D`BG8P[0H#T?AH\T]%V\8A#12!L
MP6J'T2)L<WFG8W!#E"ZC+)3;N?ENX!`J'KS+#WHN'55X)A;D$,V'SZ;+<;CL
M.Y\?.O(77>O]'=@+RS)IK=VV]L"\_])`N,<C*K\;YQPPT*+1V2ZY;F=G7+S0
M_#&+H\GJL/B`INK.P;0MZ8_3"&61/??B(\H2,J"QY"RB"ZF,AL,7>(+LX6F]
M7`%R1=!K)GC_73VBA"BZF3]7$L./PR_8'K\Q8P],KEB48A9U(2:<6?/B@D=[
M47V%>U[:ITPSS\I0IN7Q%*=DW)5I+F&2:HF*M%!A_V7Q+50U,T997LX:"X[1
MNAIW$/@[O6VF)\7FQ2.+X(&<)<,CW!JYIB*+#I[Y]!!SM85YF"3:!L]G3CBY
MG8[#,QW`N;=_-><S3=_B*W;4XNG<9<;6K(ACZU+$XH&Y4W5V+'-^`&?!-S@H
MGJ)T>AY/G2Z@AX.K[*N-KU:WL_/<LQ+E,X8I"`9^ZA&.>B\TTV0J%JR0ZJT)
M1<HNW@;G84?84)6Q+T#+W]=K41@X2T!LA=CRDWXPAUPA1KH^^6>$E!?O/`D1
M:%VXQR6*F51HED=0+GVS\HWI#WVL'HTMH!@N387@>:!"A5#"+[Z-B"90*@!#
M.?6#$,!"?A+L6B*?+O[^1<;/,"DNOTTYMQVN,&"ZERCHY?O'DI9SM^**1[<2
M3T6*U8/>;O&</.`0CYRVS3!.\/>(AW_Q3(I]B6*)B"-"_\",A7T>\0V$.WUO
M3GIL)T`\`3)2`(P6-IK>=]/B$65LQ6A+Z-G,4HUC#V$,([&)U:>@ZT[/6PSN
M',9IL%^"?5;&=E4\Q5[X^7+,+S=X6":<?ZJP_]1/70_9--:,GNRE9DTB$KSD
MK`E,(LH%,D&$SKGO>HVGIV+.G5.U&'A60"=`QQ*:C6<_SL+"I];X/%PP%FVA
MT/SUG*>VNI#2998%7A94NH2"=":R+(O=EY)QK_1GP9>!5`T@3G,U5(1+O(4X
M/P\1"QO&U;G0:NK57XT%MH_D3W3-R1ZB%9"W)J^Q%+7X[][.[O85%$1X_@U?
M"#`1[Z]5=ZR&1T)-O%,VU-WIIZVQY\<(GR[>D,P+&82PS%ND^04.^:<T*$/O
M18C9B$`ZE/^/7=.>UB'3XP%?@P$-FNGJ>.J:6$O;&3<L,!TP\Q8BILW1%N58
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M/!]/DB>>%RX5ST@.O'+SV'B_^1\M\,PY3E9Q`7MF04YSD5R@<)Z96B"S@B87
MB`Q,+;7`')5-+6!9D5Y`:9:F`;"03"V0Y3>VD$66EH-499Y^`L2_I*BE*&6>
M7,!!W\D%[%L+`(@E=2&SDB<7B++,DI*$&*.2<A!Y09-$"H60,;5`YF52W4+D
M:38%SU7Z"9#HD[K`#)+F(E-%EEJ`RDRRR0OT_M2"/*?I+93*DUQPJ=)R@-J:
MELD%7!;I+9@4Z0549DG/XIE(!Q"P^K1GL4*Q)!<LAS"67*`@""47R)RG:4"S
M3B[@*D\3R91(&@RC*AU(62;S)!<0'EAR"UJ(/*DLFJNT-JGX1BBF'/]7H-0"
M)M(!A%*(M<D%F4P'L5*D_::`I)>ZGK.T6RF69E&R[!O11R85#3Z55`*C6?)^
M@!S/T_?%Y7VS`##U[P%-GFC6E?ARH<$S18$]^]*VMM\_14XOWT)DU&^1GKS\
MD2VDWR);VVGF*\J?PK.TCE9EVI-6M$RGP14X2C+DK$26#A@K,..DG:U45J87
MY%D:LZR*;P"K54G3(6<%V"Z=!U>4?@.DKBBCZ0"_HAR;5,D5@HFDUZZHY&D<
MNJ**I_,IE`LXE7]N!1C6NW]>7UU?_2]JK=ZW#0IE;F1S=')E86T-96YD;V)J
M#3$T,2`P(&]B:CP\+T-O;G1E;G1S(#$T,B`P(%(O5'EP92]086=E+U!A<F5N
M="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P
M0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y
M,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P
M(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B])
M;6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$T,B`P(&]B:CP\+TQE;F=T:"`V
M-C(R+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IXG+U=W8_<.')_'V#^
M!ST$B!/,3D12%$6_>7?MX(#@D)Q]N`NP+^UNC:?//=VSW3WV.G]]BM^BNL0A
MZ?%AX;5<*HKU0?ZJ6&1+/__]^NKWZZOVMI>\:=5_^FJXY9WYW_KA^HKH.Z2A
M?4-Z3:%-1V^EI$,SM'"GA8OC>'WUMV:OGR4ZKA[$AT']U1P_75_=7U_=_;MZ
ME/IO0FAONXY!![<=XPS^8I+2^+[LN+HOF5#WAZ%G^`-I\Q/I&0/A2=L,HH6G
M*IGN\GA^=S>IOTE)4.KG#]=7__%N]7$-)F#-!VB@C:4?ZLQ#*%B"#<V'!R4V
MH6"4#^OKJY]`*:&NOUY?O?IP/S:_'!X>5_MO_]9\^,?UU5MX\/^\2/>#"-UW
MNN=7OU%*7[H;2:9:MHQU3DLZJ&NEY:EY/!Z:N\/Q8=5L]_KO\_:P;[:G9G4"
M^FYW^'IZ72M9OR`9G5K@5?/2CP?W=J+_OH>+Q+.YM#;EQGGDI3T'FG5<Z$[`
M6X1(ZCQ'6&O'YYOFY]UJ_?FEN^:#[UK2VZYM2?/A_Z"[GUZZHY[ZCF!`\IXX
M%7FKKI6*[]?WA]UX:@Z/:DR^N)$[^D]2E73]5%="A=.UZ]6UTO7QN%UO]Y^:
MA\-FW#5?8?(]G<9-<SXTF_'+N#L\-F<`I+O5]MA\6>V>E%7N-,D8Y]1\.J[V
MYW%S^]*3B0-4..$K9Y-,(G$'8<18AK&A]Z-@4-?*,K\<Q\WVW/QE>WKQP0Z]
MLX$'OWB`!/A@IO=WV_UJO]ZN=@"/I_/QZ6'<GT_-U_OM^KYY/)SA7W!O]ZTY
M/7W\Q[@^:Y?8L*&<MS[LU\!S7!DG@<_61ITCJ`./7.^>-F.S7IWNF]5^8R[&
MWY^VX&/=D2*NUNO#D_K'CU"_#U&PESX*#L*J?QS7(PCS<3<VO[6\/8UC\V?0
MNF'P+W+;3((D*/-E/(&46_@S_K$>3R>CSG8/@WH_?FL>5L?/X[FY>]IO3J;I
M)1T4>#R.)]`=5(>FYQ'^=5;/@$!DC/;7V_>W/\04D+Q84_0LS%`ZV%#YGX<O
MXW&O_-\</NZVGXQ+(QO\Z\E:P8R2U7%L]@<E_>D)O-X<CLVGIY6>I_"OC]_T
M8-'JA&??:.*[<3,>8<S].CX>3C!:_J2>`.-P_"&*JV3`3(&6L@##U(Z!7P['
MQX,9P4H%Y>L#"`G*!(NL/HW[];=*OZ3Q@4J'G*V0'A\8E18?_GH:U;QZ>SIO
M(7D93R^>34#>[&3X(;D*%=_[\)3U^M:-ZLY.<$C->Q&27)AOCROGWKOFS@/>
MZ0SF-",9YA\@F4H/M^=OS=?M^=ZADHI9$+N@Q:,*U3`,U,`%0(3[XR,$)-56
MC_/]5OWKO7JHFN8`<C"U8?+O8>SH,01P^2,,T#%G@$$2:P#!!SNX'U:?QV9T
M8\?@[>GT]&"CZOE^!8/[[LY!^^K!0#'8['"<:`?6.1UVV\U*T3`3WC9OUN<G
M(('23SMX`EAOMVDV6WCVL;D['A[@.8?3#YG@E/;.!*RW"PZO\HLG##WW'?Z0
M?`'<Z."J(P&G);%C^B_:-6I<*E0^CO?C_K3],C;_=3A58T-*'$Z].&*2Q$H'
MGE,9=B"#6EMM1A@CHQIJ9O3<K_:?1C66U+2`&0;S<-5\?#H!$S0851B$20:C
M8_-T5)JMFL?QN#UL[,"!T'!:K<V(52/8P#/DC2Z%^!%Z,Y\XM1,W]-S"\GI[
M7#\]P`2`J'6ZT1G!XUFM-.TX-_-`*:-UF,9-B(R'KX`C1O;-%O*N[<<G.R$/
M]IX)O#99\.BUOC2WA9H?8P0RN%5:*QCWZVLN[2H-5'G_[LU[2)INX4'MS<M/
M"!AH3@HU!#D+,X*S](SXTQ[,-;ZT6:AD4XE(&P:'4,FVDNA&30*5&GGG6!Q5
M446G4DK:9T'5S1^7@MZOU%-_B*-;GQSRUE>+NHYR%T9@BBKAE/B0U2KAU"1>
MPQQXVFD%S*2\'*"SI`DZ$VT/H")DVS`M:)!(U]%HTTO:=9J!+C`,!-*C%(,@
M//V$GK0LR<`)6#/%T)%N2#(PTJ898$F6E@$>()(,[3-=<-FF[<"%E.DG]#)M
M:LZED$F&3L*\2#&PYQBH')*^X#`<T@RMI$E+@HQ#T@[=,+"DD##[VW07,&J3
M[NZX2*O901_I)S#1)7W14<'36A#`CR0#3-ZDFDSV?5)(M?I.=L$$C+DD0]^G
M[<`XS,XD0]>WZ2[@$6D&RFER9C'"TP#"VCX]LV`)R)-:4%CH)"U)1=^E&7K!
MTS)PT2:U@*RP30L)WDH.&,BFTT!*"9=I+0#DDET0V<FDL\C0I[VIPF*ZBZ[M
MDH8BK$L#"*%\2%J20"Z>EJ'MTA,'4J:DC`--SRM!TSKVE*9#`1%ID"7BF3E%
MGQDIZ<$*R5JBO=^<4Q-7PH!Y,$:#JYV]&M25N:TO[=[?[_XVQ!$8;<4U$I#;
M+.-?_08FCA.F(!9D"U8L)Z&7IM>7FJ&/!7/W(?9,-T>S:N-$;:F2=D&RT$"T
MG9?,"AF+8QCFDMG[!(8]$X6K<*+6!C8-OQ0MY^DBL4O4<>42DQ-+?LL'2/K5
MYHG:HFI==>E_Q]6Q>;O?0/+[Z[@>'SY"_LO(@O,@(74F<M:*[6(89B9R]Y6V
MA:-*-?4Z)(>5&B"PM+>C':[L:!?<CR]S&8]VH%6.=I7-90UV(Y43T`O#_.@R
ME[/!#D0UV-ORP:XRV>?&>M_V7C`K8RR-89@+9N\#OI+2P<B58&[!:?=D:=OR
M!<OUU/O3R1I+91AF`KK[I"OVJ&FZ-!5G*&$%H]ZE$VD,PUPP>W_HBBVG\@K,
M<EUJCAH!G:RQ5(:!(7-46:YNCB8L9\Z8J!,G3/_50Y:CFZM(3J>S[\[/2D=?
MP--$#4#Z+5S"*`E[9=1N5_]Y/.M-,K6H5]MC:GOO\#`VJ\?'W7:M]]#.A^;^
ML-NHTI8I5CT<]LWI?%A_OE&U#%]55F6RCZO3=MVL5[NU*B#,-\`7==?3E*MT
M*M;]DEXV\]T6<+X7])2&'ON9((%<Z`/3TN_8LU9MG*@=^W_)%4CJGJ'93*)`
M+Q5)S:")2*2SAPC40"#M#2?=#:P0\N33.*%<U,7R3>F%\IFFR"$'-4`SI:)F
MX,R,-B&7RD3;[W*C.C.!N7%*+Q6)][A(W0V3XD;03`]JO%*>(K%HE_0R"%R<
M?`&;%4"!,"CF.7H%YH53<CR<CFCMEOB;S>9U\U[!USRY_(Y>1>@U?2SG>_KH
MIYH-D_T+YK:1`'X!B,>'Q]WAVSCJNNVX/YF-AO7A9*!^NS\?MWN%T_I03O,P
MGN\/FXNYE2?LT@A@DGMI9SMJLR25,1SV(WH9[+.EX#O+1*$+#.>GY/R.=<N<
MCJ7N`<5S2R_%<_`//OHNAE]&+\F$\#F/&B:&1P-6GXAF&%8CM%(-@?PI.;]C
MFC>4-(0C'IW22Z%=]KD>S>@EB=+/>=0P,3PZL/H$>=&PZ201(,DN:>&/7=*2
MWJ\BR72IG4RUU7'5@&LA[,3THK!#PW9;)R=QQ^ZJ_SINGM;GU\T[?Q[20J])
MINVAR&;\0V'V6)"N&ILX\WA3A'*-N7S.*JX5BL81O0R-R?/+;PU+5@VK42R[
M8<A3P[;"D'U*+D/V#"4T4#DE9%#"2VX8,I4PK=`H8>FE40)R(:>&R?J'2=9_
MPZ6\(:PK2*^-JD[K6#_#D*6J:X6&#$NO64`$55,+B.`]A:-6)>IGTD0/PY"G
MDFV%A:(IN2P490Q!C:Q."1&4\)(;ADPE!#H$I_12O_0D'H(]FPS!CMV`*)EK
M%E6S,8HZG6/M#$.6HJX5&N$LO315;[O,`1@GP\,@;7A35R:\J2JUQ71[>?';
M),N%+:,\O3R>#=+_#&>8G&'M.WM8ZK_]CW#VX]G5C:):4F81"5EVU(K-!)G(
M3;K6E[QZ?6T727&-:G%Y`L!O/>*<XQWAZ\/V\L(GCDT5K<DLFCIZ13%[D(LE
MK2B:.KFM"K&PFB&2>]98^E"L+GUC%AKC`]&Q(;'7DBNJ9\Z?J;)+%(2][C+H
M[A76#`NZFWL^@GO=O<*&84EWPX:%;$>O*-1-M8\+=?2&$'8C%@O?*FA84SBK
MQ"IHA@5M'!L6E1V](BI/M,F.RDX'ZJ>@$9RXV+;H3GW/AW3KSHG6AF'!`)8-
MB>&67%%!+!K**HAXW470W2NL&19T-_=\)N!U]PH;AB7=!3J4I_2*8B6J?7=#
M.01^EMJ^L59P!HFEUPP+BC@V++3']*+%JU.D;'=G$"T>HF-ZR9[K('C-*EKU
MB*WR8GI97*J01&$[](@%BRFY:*%6)8?4':+`'=$+:E95OM$(J7R`@6Y$+ZJ>
MU4A"S6C`T&]*+EK!5,DA4-]<T@LF<)4D>MXK'V!0$M'+H&11DCB]AVP:Q0Y'
MKTCON?^!#9\<=V];$7:&]6\1*K>"-]O=D[I>V@R>I<J<X)`4T<L@R2KXW#:`
MZ@+#($.N25AMQXDH/TL;U8E0#'TLO29MG,B0L[\[R_R4U3$0LO2:S"\(E+4<
MUH"A]$<0R)!K\J\2SVB,03PSI1=G073FF4D-KK]I>\CG^R7':+A0#L`0R-(K
MZA1YCDDF-@P_MN+I%>#$_+&5TBW<VEY%Z/79+=SJ/OJI9O^D+=SGA$UMX3II
M9]M#Z>R2X0=Y8GH9E+.J@SRJ1PS9I^2R[+)&#JD[1/&=U9W?`6?B0Q7=[WVF
MEV3F6.A^TP8_#!33Z\0H3&`9>@`H(I<EL#5R"-3]4WK%YG"F^S-Z22:GA>XW
M;?"31#&]3HQGSCL/Q)UW5E>V>D[\>6=[B5;/"4=W@V?TH@A&VQ#!7G8W>):^
M$G^>VJIM+OUY:GN)5Z@)?OHFII=A]>+Y_5F1F?CCUD[N(*QA2!29"5YD)K5'
M=W*DUE#DI)9!:B^J84B4A\E">9C4E8?56_3(@&>3^([N++\F_D"Y56:B@6%(
M5(?)0G68U%>'245UF/BSYTZ'(+AA2!1X"5[@);7GA7*&D88T)[4(4GM1#4.B
M-(L,HRF]8E<V&D;/[<K.BK/$GZVWJDSD-PR)XBQ9*,Y:>LUZ)F\0I3)8,0PV
MD*@K$TB$]$=K[&7&*2/%B:V,/+T\K@C_9B%"V22NN/5#O"M;4L!!E@ZU<C(:
M"3IY0U/OW]"$U(=R%QGJ!_;&1<Y;WC.M"R3V,N?0DV+%MFD=O6*;5K_T*2,(
M.C6L1K'LW/[N<FF;5D@?0478D!9AUS)SH+I62$"UY(HBF'-_]JZM-X4,IO#Z
M:X8%4YA[/BR+L,=M]3<,F:8PK;`H[>@5U;BI,7(V<9/+&FLH9[-80<V0IZMK
MA05Q1Z\(XA-=LX.X4XGZV6ST:%UD7/2]ON<S`"')S`B&(<\>MA62$$3DHH1`
M9)S74%'+6T`$"WBU-<."!<P]GTV(L"UNU38,F180Z.B?TBLJGO'HCRJ>M!4W
M?5=PZ,O:R9DLUD\SY*GJ6F')AZ-7)!]Y@S]:>XI>XCE"3"_9%A:BRUHPJRZP
MU5],+PM\.5VK\`!=8/%F2BY:P.5U+'4/*+I']**=WIRN-3(JLV)@&]&+*F-9
M75/C40S7IN0R7,OJ6*#FOJ07;=[F=*WGHC(K-KTC>E$E:KGKY"J`XP<_/+UB
M%<#=B^P(:7DXF]GRL'F+G<A\-&_STEG__>HX1MNVKPM62!P_01+3RY"#5YT@
M43UB0,)K3Y!4R2%UARBN\.H3)!62:$S@^`F2F%X&,Q624#,:,-29DLM0IT8.
M@?KFDEX&0N62:`#A^`F2F%Z&28N2S((]*&R+&G!EBQK,%XSM)58=5[=0_&+5
MAT\$<X=/6O<ABU<_ZW/9J9S!:."4<8)3?[S97J*5;G4/7>1;>LTBGRV.@7B=
M;N6V*L3"&@:)YO;Z'FM]8Q:J&RPL<A<<Y]@P<&2U1UN<W_)7]4YW&73W"AL&
M7'=]S^DN@^Y>8<.PI+MA0P&9U1VJ4:_QFFA/U5LTW4*FO>V&5/9EC.#L$0NO
M&1;T<&PHG+/JLS@3/?*7Z%8'ZB>?N?2'DA<=J>X91QI5VYG6AF'!`)8-BR*L
M]A10T2#6$.MT%T%WK[!AP'77]YSN(NCN%38,2[H+=!!/Z:7:#PM3&'+'U#NN
MK`&<+6+!-<."#HX-C7D1O2SFL<7R:C)KA;%O0V#;NQ!(6A])2%;)V#;"]HMG
M]**(2&PP^=76Q0M28*.6T]!ITX9Z<COD*.9:H8E]1"\+DV3I+7BS2&?5L!K%
MLAN&`9UEYIX,C4-"0$+4R'.N:]7'OKT@ET5-Z]O\J.E,(8,IO/Z&`3>%N2=#
M8SG37S/DFL*T"C@S":(1O2R(3HR1#J+IM84QD;-6K)IFR-/2M0JA=!)B(WI9
MB`U:YH=8JQ+U\]A<AG+PDM?U/1D:RYD1-$.F/6RKF=,OR&41MV0":(!WIA#!
M%%Y_PX";PMR3H;&<Z:\9<DTAT`EP2<\WAGJK]O($8**@$FY,Y*P5JZ89\K1T
MK4+%>Q*B(WI9)3QK`D3KS'X0Z#IS1B^IA/>29BV.51=8V(OI16$OJVL(#JH+
M9(T6D8L*6'D=2]T#MD"*Z445JYRN%3IJLR)KFIA>5*+*ZIH:CR*KB8A<5)/*
MZUB@YKZD%Q6A<KI6<U&;%<G`8WI1!K[<=2IO[OL!G^&.7IXW]\)]*JD=PA=1
MV;!X&F9>`B^H>BLQ493HJY-C)WYAU5OUB('&E%P&&C5R2-TABB$1O0Q#RB71
M\U_Y`(.4B%X&*1624#,:,(29DLL0ID8.@?KFDEX&..62:+!0/L#P)Z*7X<^B
M)+/`WG&[Y%=7.WOE7^1A+[&JM[J%8I6C5V`5[\JKWE8#IXP7W!>2[25:]5;W
ML*JWHU=4O7N>MYQW<EL58F$-@T!3>'-O"(V'T%B&Q@NE?LN&@:,A5ZS?G=^R
MU^]>=QET]PH;!EQW<V\(C8>9PH9A27?#A@*RI5<LV*?:S]8K//6Z<FL$9X]8
M>,.`Z^'84#BW](HE^42/["6YTX'ZR6<N?1%XT9'ZWA`:#S.M#<."`2P;%D4,
MN6(-7C2(-<0ZW470W2ML&'#=S;TA-!YF"AN&)=T%.HBG](JJ-ZH])(J+:3,L
M7ZT!G"UBP0T#KH-C0V->5WWZQ.E06/56'\&Q(9"ZCY[TU)^9MI<956_%B56]
M9_2BB,A8;=7;JN4T]-KXRK&]S*EZ*U8TL8_H96&2+7VD8Q;IJ/_"BE,CR&X8
M>G26F7LB-`X)`0U1(\^YKA52]8[(95'3^C8_:CI3R&`*K[]AP$UA[HG06,ST
M-PR9IC"ML*IW3"\+HA-CI(-H>FUA3.2L%:MF&+*T=*VPJG=,+PNQ0<O\$&M5
MHGX>FTM?]5WTNKXG0F,Q,X)AR+.';854O2-R6<0MF0`:X)TI1#"%U]\PX*8P
M]T1H+&;Z&X9,4PAT`ES2BZK>B0G`,K=]=,BE_FM+UD03U0Q#EI:N%5;UCNE%
M5>^\"1"O,UN.KS/;ZD\Q]8M?]YJM#J$+-.Q%]+*PE].U"@[0!;9&FY++"EA9
M'4O=`[I`BNAE%:N,KC4Z*K-B:YJ(7E:BRNF:&H]BJXDIN:PFE=6Q0,U]22\K
M0F5TK>>B,BN6@4?TL@Q\^;-YB;R9#STZPSV]/&_F_GOR1(9W\W:=M._F_=NX
M_72O\NG5E_&X^C0V=^$U`ZH`;M\N\.FXVBLN^X5V]5EJ\XUVY+>@ST@KEGX*
MRF7#I7LSOOU<%_::FN>LL?B:&C"[,T?):VI4?QCXQ?0B\'-Z%A;S58\(%EIR
M1>;MY*C]WI3J&<-(1R_.?SDN$KEEF3_]4EBG'8/`9TPO@L\*ARGPTW:X1%-+
MKL@4O\=A"DTQATWI%063!8?QW!,*@);:,0@`Q_0B`%YV6)13\1X_2>#I%8@K
MJ,4P*EN#N*_>G$Y/#QI)3Z\3:9;J%46:B%Z&-"+O<('J`H.6OO9P05['4O>`
M0DA??;@@IVL]J7O\<$%,+\.)G*ZI\2@&#'WMX8*\C@5J[DMZ49J5T[6>DCU^
MN""FE\WRQ:Z3:5:''R[P](I)S_WA`OTY!WNZH"/V)4Y*/O>G>6-3K>/V]+FY
M.XYCLX7DZCB>SLUQ=<[]H(^:W!U^S""FE^'%\J9=,C/IT&,&$;D,/FKDD.8=
M"AB:=)4%.>XEB5]&?ML6'#G0_L"`IJLNH(4!1X3Y=,6KW]JNH$"H+8(@4%=[
M^*#"8QIX$(]-Z349">8QEIU":F#I\(,(CEY1\<GQ6)R;4/Q<@:=7P!3SYPI$
M>-<<HUT*IKX<U$MW=MOS-U@<KL^'8RJ#H?B+`F)Z&2*QO!<%Z-H,`D&T]D4!
M>1U+W0.*.;1N)QTR5]=U-()O>3*9H?@^>$PO2V8R#*!G/D5WH"-R&91D=2Q0
MRT_IQ=@A2RVO)S;%-W!C>EE>LVB`9%Y#\-<'>'H%8!#W^H"6</\28MIS@0#&
MVS\>Q[6N$FV_;#?C?M-\VXZ[34$^0_"7!<3T,O0@52\+X`1]64!$+@.3&CFD
M?5,*@BV5ORIH@T7B`PX%R0S!WQK@Z#7)C!]EM<D,0=\?$)'+$*C<71IX$'=-
MZ:6V@4G[/>[24$+P%PDX>DTFD^&N*)/I)/Y>`$\O!Z;.OC</T*A5N&V1B:@W
M2R:0:;>]&^V+T9MOX^IX>N8[>YWY`-L%(L7T(D3J%M_X%^<SJ@L$@B)R$03E
M=2QU#QCF.'K%&LIU'0UB/E]#Q0F--C&",S&]**')L8":_5K32SB)R$5PDM>Q
M0$T_I5<LADI-KR:X-C&"&3&]**-9MH#-4<P;'%$-1>+]H5(=E--/'H9;0H4T
M"KY[N2[4YR![Y$`H]KF'ZBZXZR+L?,W>QPP/-R\ZI/K9X2'Z1"%M?I(]2]XG
M4KV8+\'`6II^0M?V/,G`6Y%FZ%N69A!MWR49!M*FA92$R+0=6D+2EB2$J.,K
M*0Y*Q#/69I3V:8Y.C=8D!Z"N2'/TE))%#A@V;_]^?75]]?\0=#FL#0IE;F1S
M=')E86T-96YD;V)J#3$T,R`P(&]B:CP\+T-O;G1E;G1S(#$T-"`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
M97AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$T-"`P(&]B
M:CP\+TQE;F=T:"`T-38R+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IX
MG+T\VV[<R)7O`O0/]1`@WH6DK3O)?;,G-C`!DIFUO9D\Y(5B4VIFV62;9$M6
MOG[/J7M+FM)$TQ0&&-'-8M6YW\D/?S\_^W9^1J]TI0C%_\Q5>:6D_5^S.S]C
MY@XC7!.FS2^<J.*JJGA)2@IW*!-D:L_/?B&#V:N0"C=298E_R'1[?K8]/[OY
M3]P*_TM^H%=2"CC@2@HEX(^H.#^^7TF%]RM1X/VRU.+Y#3FY9$K0@I2,DK*@
ML"O"=//;UGQS-WD5;G(6D?KP]?SLOS[5UTU%`->O\(`AEMG4DX=QH(0HR=<=
M@LTEJ\C7YOSL$G"K\/K^_.S=I[J;R-_J_M"2\89\ZH9Z:+JZ)S\.\S(==NVP
MS/]!OO[S_.PC'/@_OQTLPYGGP>*`;H#K'3GU]@9KYG;_!Y?TY`?HY(!7@Y]E
M&F6.::PJ56":Q&MDVM=M2WX8=_MZ>""'N9W)73UUXV$FNW;9CIN9U,.&U/-\
MV.V7;AQFLHRDG9=N5R\M6>#A&^3ZG>=Z6S=;TO3P`/[K)LA`%V3@BOP)EL(N
M\#`\.6_':3DUX@4H;\"\XE?27/\+T+T\^5'BB,A4E](369EK)/+23CLRU,MA
M:M=@<H7G.!X7D<>::GL\LG#7UC,<CQRX,'QKZFEZZ(;;R+NFGK>&W>:B_7;H
MX!9J[06IFV8\P!6`UK3P\W7?)C_NZP?\Q3P[C$N;_++?3^-W*RQ14*Y6(8(N
M/!&$"#P0I9!/!/V/()Q`@NE9^02)!RX!&F3N;H?NIFMJ$-I7`9RWIY6@#F"!
M/L8+C<)K!/@SD'I8R'M+9>34S],XP'73_BY;F@&IK(0!">"@%2T]3$Q5W,+T
MXT#^4C^`V:7JXM3GERR<CSRL`@_!AS)[O!'<Z%@2TGQ90/CJ">S5AQ'^D']0
M13^]__(!_K*32YM010*J9"AY`.J[#LQDNSG]<1BT))31/$JW=HP!_!<C%L>N
M]UD*(6V^`'&0-J>&51=5@+52$!Q`8(.&UTB1<CZ'_'6\(DS)B]>1*J-6:/@C
MJ43A/-Z[A`XK:')9:!\8%541-!DW-?C^L*V'V]:ZTH_3-$Y@B":PI,:AGAP>
MP-D#=`+7ESVI.D*=\H@Z=7)9PY;[OFZ";+[_^0/Y:=\-@+H1`TX-65!7211B
MO"-.+9M*T@1>2L'@.'AY595.-+URH'RB@EP1C/N^;KLY`<_A-!MLUK##J@IV
MN-!5!+-TAO"8@J?7(R"'AP'42$>AULP+=:)23KY/30B>4`+YQ0(4@DDG7Q=&
M>@S#C,R<GA2"5BDMF&(QOE/,N^H]1+%(BJ=4@=`",B"(`+M=8IB#+)V<:EKI
M%%ZTB`[>@FJ64JUQ`*)374.(D4?69>G@RKE/%B>,+VT\.I,;,(D(11VIAS\A
MD%,@+1B/VL&,-$W6[J<.J+IW$6AK+&P3+>RS*@R1:=^U)IVI^Y[<C3UL5D\/
MJU""*V\D$^D),MQ$07D.*0O^CP!R/X\IW/XY1\H-N7X``ASOD02,N#\2^3`<
MYH,+>4$:,8NKE]6$@(::@1`LU@R\%3F&<#,".AAZ`^K]8=.2>=\V&(*39:J'
MN4-V(E)WW1P9^\NV!:2?X&HVF%_8`5.A<6Z37]8@0E&%]+"B(=(7BKG\#'+@
M0P_L@QQI[/OQOMU8S+P?(B"Y[<T-BO-=:S4C\KA)@HM$Z$TRCIH`F7R],1IS
MT\T-\/VAK>''Z_:V&P;<H+X!XT3^!-G&[AHNF+HP\?TJ25I1^$R5EF4D!'6!
M(2+]L9Y`P"<KZ$UM&`;X[R&%[I8%I/QU^(]-<Y@F?.`E2GQI]XLCQ9J44(4/
MT00M"ANB_9X2TZ^>I<)9H(2L$K$^4(FG-:"@@I#U=F!_;)G'&8AZ,YHJ$!(7
M_SVT]V1V>06Y[\".;NL[M,).7,EH38[;_.0!'02@'C>;+0(%.3_Y,4"G2$)6
MTECA8<+9L1ED;YC'OMO41D:#H]^/UNB\,C!Y08@D#8QET;IJGR]/[7SH%Z,+
M(RA0[31CLA6>&S`U\]4J,@>@41%*8DK%P,WG@*:2,#5;6TNPB3WF`"Z'-A'3
M?FH7:P`PMI/%R4L.@M(`Z&D4,1M(BH0JO(K9D@\$WA^'/S^,P\;(#B;R\]PN
MY'.[N)B)_'3==[?UZS/(7`2))B.R3\3BE."\2O*D3S_^%;ABLR2T(9NQ.5CO
MB^9X#8'794C?>%(&$:53P^Y8;+`6<IQ8,KE"BL#!D4?(N%`!,EDJS]LW9*``
M+QOA8:6.ID$IX5.`^VT'ZG=?SU[GP#'^^3"TJ)&.H:E&HH8^TDJ,G3<;,#*K
M1$U:^R2&*1I2/\F$H^@&@J%I;H_CW1J\?V-R&G!9QAEMVKNV!^N'#FK9`A2W
MZ*QL_X$LW<ZE%GU77W=]MSQ@B7N\'6RDB&K8PQ,]&2.[L!TR@G%?_)ZXTQ0Y
MNP8M5,BE5!5;;[1RZFAR(W#$MQU6W?MQN#TY$!"C>2C6[:@P2+A3?+E.>&_1
M[8'UIBO5FJS&2G+"3XP%T4"-DZG_VE86<AD>6'J7`$XM^NQ@84=,(FX.ID<#
M(C,L5H9V]0,Z3/R#41'$Z,ARETJMP6GA<T6&G>90`M>NC0$@+]/8^P@,X`29
MO3)UAVF#N#O)/E;5"X*9T;348"`A2;P>#\N_2R^;?B<$L^1?6>Y9&3*G*E@Q
MH7W"$+62)$D4&(%Q,@;-$2-I?GG"17V_Q_QQ/MQ`DMC9U!&T?F<W;;]W\P)Y
MIO5T-@-O^GJ"C!*,C'D2@UW#!')O`#!&9PU2Q$8NBY5+6^(V$>CS&``%)L`>
M.';=/^0ZMU@Y>,S12-Y`@J-4=!A)7V/.!*HR.'G<V,9ODF"M0`P5.IY4JF`/
M!?4-5P`CF]J"'YY&+`T8--)4$X#O7+4N[0Y&@J:YZ`6Y/IAH!TV#+\-<$4QA
M'QXE2]TZ=`A-3PA88\.LHM)'V4<.&YDW@+><ZEN$\^M+*=VF,PW=-\[J-`UX
MK9G5@46-Y&-53%)DY9.4WY#5)2G6&OQ5-`"H0\%$2NW:%6^=U9GFM&M,*!TH
MQKDL0EKGU0U!`&V33Y,[7Z['%8P+XWJF]JZ;X1X^@4YHA4*^CO!CSB!ME/[N
MRQ9"@9,?5LEPV+I=.%&5"5J<Q_D367AS^*%&TOY</Z!5/[582/!&$0"J91R^
MD$H_::MQ\=GRUT9MH97F[YI@9#[L,;;'`NX*4BPKUQ[5X#)D:%!SY;N`V-;C
M*]3]5!G.1L\5)RP$Y<6OUD6^?/PA:,Y2W]RD3:8/A[X'?VTK)`S2)$/H]Q_P
M.B5S^WV/>1K.=W7M_>RM/6X]FSUM7F0"R'4"6UG$=(['A!2WBJE[;8JW$,0M
M]RW$5D%B;'77!K`&Z.G0NYHO`'[HK0VT;2U3R]^XOI9![H\>ZV,D,?0)3G]^
MM17(SJ'1@/?*8VA<)A2&*RM:[ZZ-YJ_!3ATR-"Z241WE,M*]-3:09DU8GX]]
MOOT!@LH&'"L&#Q!%GU[+N!(!O$M3P`IZQEGI!V9P`,;ZG\\^=)M-*W`529!4
M!YC6E00)CT7F<*:3L+!P1L9*A6.1'>G<[?OQH6U!AVSK#)7D%EAG0QM_&_1I
M;/YO%7F2*J8WL5Y<5-)'.D[%`=CKUA=I_F7+5B:;"<'9''KKQ")JXU5(=F+&
M`QO%OD\HXMQTT[R$^-]TH`=LE8(SZB`A?B:=6(,2O'Q:D%ZG#R7C::`G26](
M4/K,?+#)%7S\9A0GIH)_KH%2TX/KF>G3PRJT3H#E*O8/E>DE>F"-T)Y>J<J4
M+VNJ+T]YPF122V:%LZV;XW':8P5%ZT6<MMA8JMMU?3T=C;AV1NG7$%[&`H<J
M%3E4.7$"U?4UB`TYS+;XY,`].3@H,>PMAL!901/,&9,\J<\P/^G0-8CN;MRT
M/:C2/P]SZ&;C[/W0?0-6-L`^"(+`W@"5FME6W?;U!/\X'#/QBOQHBC;HNK"F
M=X\)._`5]L?JE+=6*T5S9CS7B6@RUX$OG1ALC182%%3C4&P]"2PINOUVF&W8
MU8RS&[<^-N=8BMIAA(O(P4.NBM=^;]HYA*['\F^J?`%S0XOQSJ&?K%R#$H6O
M(5"5U.6HY[L#;IPZ<#=8-K6,VNW:#;80^@=P1"`$;8)"XTIN7^_'=&RE[H&A
M0XWFUE*MML,B87S*A5:F'`F1U7\?4>7D$2?<\;BO'-NR(J$R+UPA&&>'?`GO
MY$>6](V00PG2H<C#DEZK]MV.1`1\97Y:E;4XV.N!6AE["#DB^K0LDIYNP?T0
M0UJK?4(,6\;T(8H90C%Q2A*E6#^S)L6T9F]$,:U50K&W408(1]X&.7R9*M&&
MLK2MOU0#UM`_&=ZMH(4CIY>M-8ZCH3,O8X@D*A\BO4^'W:X?@AQ?I$5WW_5V
MUG^5G%6(*@"[+M^1`Y$LG!6QY:L+_6+.ZA3<5NU.7[.C`;8UVQ&E3$E`92"!
M8@7S[0A(32<(`<')VWC&^8-E.XV'V^T:TLK+4+83*L`D2E_9#=FP<-.2F'-<
MD'HF\Z'97I#;=F@G"%0>TAAO&)\&@D:.']497!J3M+?[AXLGDXA>0=;`O@@E
M&R&P7&N&PZBBG]=X>0KLK#]P14D3$2V,.)*D/PR$SFG,[&0,)R!L'S!],1("
MV7V]>DM0@'*\!67*,B&-B*_2ED5H"/I^W\GS?J&3L[F.TVV*^9?\CL<X-^W>
MM;D=\7N<=)I7*V;KA`DKQSC'?%`L,L)</^,.UM!]%2J2,HE+*Q^7FA0WJ3^:
MT:$+S-*VQAAW2S(2#1;OC32%!<!7U125T(=62<%#!U7!!!P+ZD_;YH^:U>1_
M]YC>/F/2@ZF]0`JNP601!XQD'"21LO+C5HF;:K_C=6O9>E2$-@X/<779_EK<
M51'B-;D+SCTE3#)Y):L0BSSOJTUAXN:`#O^N-16NVIBD)W'"ZUZISWQ+HX#'
M^._^%$A.5N($EM0Q0J6N^/S3\'32R`8K]I5T)$*'KZ?@.RG'<F*_DW#GIFPA
MM&][9^9Q(=+1SX3;%[@<9<V;<7:-D;W#8B9W7OV6\PN?$HE?F5`ZOD7"?/$]
MR$,WX(<+,%E_)!E8^<*$91IW_C,"#`-Y;$UCK_`P;%S)[J,M:O[<UX-5+;#R
M&QQ9^F7;]>T1Z9:'/40B*&^F1[Z**V!Q3JC4R4=4"G'4G+(3H\@<6[@$F$P1
M\F8\3'86SB+C@H@P&.89G#+^XA'QD$R'J=G6\]%7->`(=L7)#BR2'8*LL8WI
MI&L-2H2!)*J%%8)W*QD[D#%_VHJV#CB;X,3*H-?<3-#[*;#=#JF+'+E`ZMJA
MBF,^:$HO**7&`&[;WN3N*_H"J>E;T$=JF1)(QG<)A"C*X`N^M\W!J/R(4ZCM
M9%M/&V_OL-O:@!(?U;W7$$\1YI!*&5\7%WX\#>"<FF[&;]/8NJ'[`=\`->\-
M.,VI35\3;-6Q$II1!FN__L"N*HI:^0=U5=FA)?-5G7Z<W=N[3;MR-(`O2'B$
M5]40D="5,QELOY+%LRI"UJG3,1;&MGBIBO!=$>[3UF?<+[[>`JPJ'H4;^((:
MTR4E!3#1?M\M'FD^O89OL&$.@@OX\PMTQ;G,+BAQW"2WH&""91=H!A%-;H'"
M8EEN@60BO\!\TB"W@#-\(2RS@+UT!*5Y.JB*\NP.JJ1Y4JN"TB*[0.-'EG(+
MU$L+(./-\@+$N\PO,%/&N06T8EDZR`H_$9A;4)8B>P0.A6;9+7691U.JDN5W
MD$61Y84$SY''@A>"9A>`\N;1I+K*`@EYO,X>(<J"9[$019&G@]!HH7,+(([.
M'R%5E5\@E,IJEN`J;T`$*_*:)2A^TRFS`(PZS5*2E[K(+RAP4CFW0&,/*K=`
M%3P/I,1/?^86")TWI)QKGL>"J2)_!%4\RRQ6Z3PWF7[!%$.DIK.$8E+F#0B8
M<IJE).,J;\0`Q+SB,*I4%LA*Y!6KY'DD"Q"'O$>C>6^#GZ_*6A^5?5ZP%Z25
MY<]GM/CUY[]9%*V^L.*9**K(OY;@IH3+$B(GO,82[J?'X=KKCY"4D=\T\OQ[
MCE`DS#J[+[PQ]3C`TUDIO:QTUN1<LBIO,"X%S1OO2TEE?H%Z(6:YU#0?6%T6
M-&]R+DN:=X.7U0NAV26C+&_>+QEC,@\%XZS*:L0E$SP?A5XRR?/>%/(+;&;]
MV@H0BH]_/S\[/_M_&&$9J0T*96YD<W1R96%M#65N9&]B:@TQ-#4@,"!O8FH\
M/"]#;VYT96YT<R`Q-#8@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2
M;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R
M(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V
M(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y
M-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E
M25T^/CX^#65N9&]B:@TQ-#8@,"!O8FH\/"],96YG=&@@-#@S-"]&:6QT97(O
M1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]7%MSI$:6?E>$_@,/'3&]&Z7:O)!`
M^JW;TXZ=68=W9MPS.QOA%T0A%;,4E(&2NOWK]YR\<*F"%-!5#H=;*$G(<_W.
M)1-]_.?]W:_W=V0;2.$1_$]=15OAZW^2P_T=57>HQP*/!FJ$>3[=2LDB+R)P
MAS#I5>G]W?]XA7I7Z`M\D8@B_.%5S_=W^_N[IW_'5^%_O0&R]7T."VQ]+CC\
MX)*QX7WI"[PO>8CWHRC@XR]DW@/UF02Z*?&BD,!;D::G>7-^M3>C]B:C'5,?
M/]_?_<</\6,"(N#>9WA`"4N]U(J',I`$C[S/!R2;A2'U/B?W=P]D*QA>O][?
MO?^\3[WCJ3J6=>J53UX#O\9)DN9I%3?ISGM)ZR8KGKW7N/::TCM6Y4NV@RE>
M41;_YGW^U_W=)R#DKU<AEW/1T2O9UB<$B/P-B'RX_E)R(!H62BL:/\1K%$T2
MUWOO,2W2IZQ!YE$VWY>'8UQ\O38]ONRIRE>DO/^%,7;]=8(^WS0`V[9\"QQ&
MOFLO/1SS\FN:UEY<[)#U-,\.60$6X3V=FE.5>@G((2WJN,G*PKLVE<INX2&K
MG*"E,8J$IC']@LNG?9UXK^4IWWDE#%6O&=RKTJ1\+K+?4B\KO*RIO;H!#@YI
M`9=@ZN41;1SHK[W7K-G#]/J8)E;3]=`/RJ.>>3H"O\I)=GH(WW03_HEOE13Y
M?BL`/^):`#__\.%GF,C_MO70A=%-#XK2,059:<5U72:9FJ98GN:SV<>-$>@^
M?DG!#=*B$^@.)8I2N`'G,@H-XR3@7+O"C;P.@-NN=D.?"\(^3R%KE<FY+ZW'
M39JF,K@,_%'=C:W)M>KW,G#2(^#R%Z7__*OWCFZY=\CR'*9NO0]Y;I3J/5<Q
MOO\0`X##K^C:\5.35MZ?X^(45U]OHLV0*,Z!7<(";EEGC(>:=;KQ&"$!V",0
M^JB,L3P5RI#+"LT,!ZI=7"2IMMG.\->2&SC(%9I<,`2?W$(<:-'&$$38&H(?
M!%H:?RJ\/Z9)>G@$K8!8_(WR,N#X(^BY/H%4%/L_E5N/"K[Q/GU)]G'QG"JK
M^:DL#F61-JC*#W6=@JZO'C_"H.7AMA':CTB[$AH/[VS'9UI88,%>#%ZQ0\]`
M`7SXRT?OOX]9@<:.(H(D\!<BB+88P>&:(EIFUY<+JA;M2@,V96VBQ4/?X+5U
M<$URK8@%`@?!%96=?DE2[:_H`$5/IVE?V34\D\<59F2[4])D+PK=4>?HUU5Z
MS.,$9D+FHKPF]IXAD:GBO/?^&P@ADM)&;<J[J!4*`W3(TH"-/G^&?A5Z=B7<
M:G3L@5!V2"N(6[E7GQX!*0$+`-A&90-/U*,/>)E.;FUXQ-SN%@*(F+4"(5K^
M:<M_7K[6-L\&8\@:8+M*58!.$/3`'`PC=0:A]BE+`+-SE`VH$#*44]ZTCQN6
MMYXU<(P%Z=-3JLWAW'R4>/O23Y)356%R?PLY!,("G<K9+-#9_`V`_2FK$]`0
MA+JL!']X3)^SHD!R3%`Z%2DPI<*#T$F.3?14[H7"0E?N'*MC_<\G$!GM/]I/
MUUIQ[;)=9V7Q3<3@MZEVV,OBF&]0H:=D#/(QI)](XZD"&R[J,L]V*BO3BC]+
M#38@P0),&\T<RK=,LU=ITU:&=FV&!*"]Y0C0GY,PU.B_.A2[1$=IESF0-E:R
M@'2Q\J?R96:L!&-81:.<II%!4F>)Q(PF:B.4H+XE\04,LP3G^[ZLF_H[C%@?
MVH@%OO[A;Q\5@3Z_NO4)G_7((Y'?>2&\3-/7BXZT%QW;9-1+(,2`?::UDFWS
M]:A1^P;J#J6M=QBAG:<$W!;C*$`=&^J]JDL>4UO7@(/$6/7A[0+L_Y@U<:[*
M%(#-S.K@@KDXK\LS#I.L2DX''3$@]RYV\-+7?9:`0V5?L#QZ2:M]&N\\1<Y*
MFWI#$*&M%2AV*:S.I&W8U">@!L/!8U%6!_#]^(`)L])+MLL!]^,DRS&P&.D`
M3E1I]KQO-@!TQ2Y'B-72Q$SA-:X18;!VJ`!)-A<UH@$<>,B\&&4%0BWS%UT'
MWD(&`;$R\+LTV2=A8*.']2M(?T!3-9(W8A8*#5MKT)%`M;!J55NI0#HT"8S%
M@PAJHM37-*[>B%&WL0:?MVT`R;M>C?7@.&^`[>>]!_3E&9#4!CK@"S1WR)K&
M<F[#9[+'9A\FGO",B:;*^M'N=W&EM(H<*0/!A`H+_VJ'_@09]^Y?I[I1TE+R
MT;9E+.I&V,#:U%IT?3I&32YQ5OX&T880LC%^FZ&Q)OEIIXT5R40JGTO,.2#"
MMJT,K#.5?+1_]*)O9Q[#TAS9QR?1-B"9PQ5NP3S1*;446\D0&7]3[%-J*XNV
M8.0VXUE=O(9.2H*0M1$Y()TQ`C9I2O@6;`R0LVBLB&X@CX#;S)*2T._%M*!K
M:!M+_P.4`E6Z@QJHRNK_JY56,]#_L0)CJ3(P%E#HJ4C*/$?XLS%#=R"4U:?9
M2_R(F%J5!R\!NR^AL*BMR33IER:#N^@FJNT(-W8PJ0*('+K<+>1`NRYNT)4:
MG)DX`78*!GJH38*=)586Z4N<GXQ^,&8`IRUG?^CEE""MG4XJD3_3^8>@D4-J
MJ>,C.L"N/#TV3Z>\$YO"BU]/686X<^T>34C#EO/W5W\[B%7(;WVY0V<BLOD8
M[>TX\"B*VI161Q(TIM1[Q7^:U[)G>2H!&O;(AO!'R2\$4KTT!NS#^AI*OCK.
MT1[UR_W^NXLW7GT+$01M7[MK$'`I3%O[N4K1%74F9W@9LO&Y)YI]E:9#MU1A
MZU4'N`H;G3TG?HQS;;=@G?`NE1Y@-R1%Y!9VJ::$=*'WV&VR/.%W61Y:G,UP
MJ('2*CU"T8<=`DPVAAH.D-2-%^H?Z)QFQ.Q@0.J2?]UTO(P`FD:GO*P5!#R>
M((&"+$K#7`DY#9H5ME$>L2]ERN8;]?L%)[]CO]^N=MM^?\<3(SUL%H%H^_V]
MPK\SX$1EL/$.JHP:51VK5%1!=)=W7+WOS25I*;X)[/F2MUW!J*OM(GH9LE74
M.24#AM&O_[,$/_@O^&<#I4I6Y&CUW^_!.C?>7TKU&_Z/+_HI18##(82T2B7'
M*$#`,\A4"]41S'99W`5I!)?X-OUR9#X,VI9_!_D^\;L2/,_B1U-9815NG:UM
M=RDGO4CS-&"KWI7E#1MZ:9'TVJ%0"I4U-CS51NX>\3"/#;SW'\&B#HN?&`6%
M$;[^[B;"$":9#;8DXJQ-9B.?CN;R+`PW'F3SUZ?%)QTQ-]W(H+[?K11N!1&1
M99LQ&_:4+>->[/^>XF+CO>,TW-R";1:*WXEMS&_L2JAAW.,SQD^E-,;?N;7W
M1TS"*V6F[]`G^$:2`&6@/.+Z^UCT=Y*#WY,X0D`/_P2W8OATJLIA^+Y^YBRB
MSN)ODCG[7-YT[]1G[=:*J@!L&\#N)/>CB-[L:A#4/#`K`,)C6=E$1AT%P63R
MO*S3&7"%B5&B3T.<FAJ/.R%P_KW(<$AM-T#@^+E[`52!:55@Q=2^Z1;LDZ[N
M[;87`V;ZHW$#9>?CR>PAM>B.B1]&NHVW2Z&TTRW19F]8[&5V25F!B'`3LGR"
MO,0<!L,\NN5JH_-)>,<[ZF_`EC8L(-IC\?=0;"+&!UV1FPB"1U';AJ"RS:Y8
MR$Q/3+=B+N,E4JHW"J[@:>Y6"1=MX]VG[1$K)JDAT=]Z/ZB&LMZGO[8W`KY:
M"FZ2T'%JBS@BNA-DG%@-?&@NQ;\Q+723:9E>##J9V9A5:0>4.]]=6QKH.='4
MN0[=7H0$-80LF*L7=V]0YSEA`F614!/8Q`2"*.28$$BT5->$"/,$UX20@D9=
M$P`4I7."H+Y[@D\#-PT<!.&<P-Y:@I(WY$`(=[Y!2.(6-<0Y1IP30%N!<T+P
MU@2!-NB:H!(*UP0F`Z<D!97,+0<2A4XB?8E;M:X)422<ZO;#R,VF'T3,_0:!
M-UT3_%"ZN>"X`^*:`,[K9I.&Q$TD"4/G$ER&OI,+'H5N.?`0).6<$`3"O80`
MUW%.4-T%UP0NW`#"6>CV+$X#Z>:"A-0I2;1Z]X0HE$X:H"#TG5RP(/2=1#+P
M?Z?!,#!KI^LQCHTJUP2&'QJX)E#!G<IB)'!KDX9O0#$-2.04%!6^&T"HCZ?#
M71/`*-TT,.%V'$I%Z":2<+=G2>;F,F*ADX*047?`PEU&)TX'SN=]ZC973MWK
M,R+?$%`XK8+N-VPW8;/A8%R`>[FY$GBE;ZM+\Q7+K^UMCI\F]+ZFF5D-LF`R
MXVH_?@'A6*HL@4-B](0SNNQ]P$,6+LT$X=$@FB"L)RXP*DL8[0CKJ-$3S@DS
M]X,0T'A9R>`S[)CH+0'I;XFT_8A/[;G^\ZSX6U:C8:L?K*+"L,WA:<C,7M3?
MZQ2W]7[,GM(I]4G62LD(;"@:/>%<2N8^I8O-2CTZ:5?=?"%D2YALS;U'C9YP
M3IBY#P*E8W;E$*A0=D6L^@3!LY^HO@_J;,Z$_#!@&S(MQ4/:](0S,NW]8+'X
MU)/3XM-?LN%W;5S]"/Q0/XX1S^_CP%.+#W9\P@\=)23CMB=&:7=RC@?V^Y8?
MXT=5L!_BXO04)\U)G53%?>4C'L681[KR=Z`1H&)`^N7X,@B9['1-4T+UBL$9
M(>?#\^F@Z^B`VD@M2,\(Z8TO5";V_2PE@U.A_`*ROF$17_07<31LOVF1"4[H
M13]SQBJ3FH-G6LUY,]6&R(<&>ZZVB_%E8+K"@"0;->1N>*G0)1L7^KNY!$7C
M%MT;7TB2H'2<)+8A)-P0&LXC30'NI:PNAI<A^*3.NLBB2XQQR+;C*R";M3OU
MZA2'[?H%9AOCAU-59(W=;'S*ON!U/94\((Y2,0[-@_%ET,QFIIU4C&(Q71-8
MU9-S%D;0P!7&P->,+X:L3B\SP'?M(E%_D;?`=^4B8H*3<,4BDYH2'2=GV-M3
M$R(C%>-@2]=GKG,L1+)1TSP?GK^P9#,7CL9-LS>^%$5136,*A?)CP_UH*BM&
MC+L4P<7P,M"<%($K[:4R&,70=GP%AI+V!"#I(%08!/TQC>MTKPXE'_#`I?XB
M>'ZN2]7G_9>`.AQ?!JB&X(6Y+JXX@J^#X67XNH(.1O2"(W!KQQ<C8=A2,K!I
M,3^/4\H8@9;A^#)H62$<R4:5=#Z\#&G6T!&-*ZDWO@9XQI1$`[Z)0CH_>1L1
MT,7P,AR:%-`@>:-`\2CPV/'EP$/;#U-5DUZ=?OP1\C1'>H:KC:+)8'P1FE@J
MWDK/<(DQ^.@/+X*/60LC+N`*8WAAQI?B!1-]R?M"'X)Z_Z="'<?(FLG>&@("
MRGD,*`;CBX!BEA@D&Y7_^?`B9)BW<#0N_][X"BBP2P^@0'*Q8;YPY"`C(K@8
M7N3[TR)PYB"0L8Y"@1U?`05!]V<5`J+/I+[_1[K/DCQ=DFP`!:/P,!A?!@^&
MLJ7)!JPXAA;]X65HL8(.M#1<<`P\S/B*VLY2,DR@QRJBU8M$_47>J.W6+B(F
M.!$K%G'5=JWB%O35E+V.P>Q@?!G,KK`?R4;M^'QX&>JNH2,:M^/>^!H0'M,^
M]:.-3Q8TTT8$=#&\#),G!33,Q[@<!^'A^)+]43SN]69`1$A4?ZEN!&4'X\M0
M=L[25"\Q!JO]X66P.F=A-!9<80Q'!^/SE\9\:<[2Z+DHUC$P&(PO`X,Y2TLV
M*N[SX67>/VOA:%S<O?$5W7.[]+`EN0E"NHDB5^=G1`@7P\L\?%(([N2&1N:P
M!%[EYC@+L^<3S&7[)T$=^1MC_3RM@X[A^*+\C;7?#E(F>D?!A>TBU35^]'<Z
MG/2W/CO\F!#_IH/]F#<^X&GXW]3`@C1+R\2*IQ4%L8<CS.5;4K%/C<+:8'P9
MK#&Q*GFD&#P8/4<YNCIY9,N#+L*$D2X*P$@7+XUT<<),Z9JG1@%T,+X,0%=(
M5[*6*\/@D!4U8297YJE1;!Z,+\/F::[:^0H*#1NRQ8,>[6K"3#;,4V,XWQ]>
MAO,SF%!0:)F(.B9:RM6$N4Q$XQ;6&U\:,TAG81@SJ*\_DE.?1]*-Y-%&"CDS
M40R$9=5R/>1/39C'JGUJ+"3IX:6,JB?%9;F%G[DYTD`I3#B2PD0C*2T"ZZN+
M/S^MYXREK7)]UDKFI8Z:7$.X)3.T<4)?71!L)N&Y/GH6%LPP61$5R-L9OJ$8
MH@`_BP)R[78P)3/VW`"`C*"`,R,HO`HM3DX)2D_"<R3T#.%EN!K@R;S6H*%8
MTSZ@4]V=H%A/HN<4M\.KP'N2XB%X&XJE=9Z.3G6W3_'9@RWHRQ;SC=OAW7&W
M,Y-&$%Z/KC@>8[W.=3QF@/26XZCEV/*I[HYSK&ZU$4)&0S[5W2F.U:2Q<"#7
M5Q!C/---R-E&,CE500"R:]Z-%`:$J[OC+)A)(S`O5Q<>DU"I05CH<]M+CYIR
MZ7NF:1%%YL_(H&A^N-X2/J'>K([@MRPA[!)DJTN8]S0X_S#/_2W9@W1_4_/`
MB/O;@0=.^!L3\$MUUP1!F/-+D(>`!&XB0]<!?IP0$?<7!@^21,Y/9AXHH=Q-
M!(4DR?F9PP.4J]Q-)ZPAG-^3/%"?1M,?8X#*/_WS_N[^[O\!5]^SK`T*96YD
M<W1R96%M#65N9&]B:@TQ-#<@,"!O8FH\/"]#;VYT96YT<R`Q-#@@,"!2+U1Y
M<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@
M-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N
M=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@
M4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O
M5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ-#@@,"!O
M8FH\/"],96YG=&@@-#0T,R]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*
M>)R]7$MSXSB2OCO"_P&'.M1NT&J\'W/K5QTV:KIW=[PQ<^@++=$VMV7)34GE
M]OSZ2;SX$@F3M#Q1#]/)!)"92"0^``G^\(_KJS^NK_!*&H&P_>.>]$IP_]_Z
MZ?J*N#<$48F(=!2*F%D90S72&-Y@1E!57%_]'>U<78H+6Y'0VOY`U</UU>/U
MU?U_VJKLGQ8!KSB'TO"#"08_F*&T^]YP8=\;INQ[K24;KI"B&\*H!.$)1EI%
MF>ZG\?P17XKZ)6TI]</M]=5W7_*[-9B`H5LHX(SE*HWF(=1:0J-;,-`-7D%Y
M@V[7\!XL83BZ?;F^^OQ3\5P5ZS(_EOL=RG<;E#_MJV/Y3T\H_GPN=H<"[>_1
M??EG`6\/A^)X0/?["AT?"_1:Y-4!%;L-O/JI6!=/=T6%&,D0Q5BXZN"!H_*`
M\N?G:O]G^90?B^TK^B28R##TE&7YQ(VROV3H/]#M_U]?_0RJ_<_E#`"%H@&P
MY,X`X`/<,&^`JC@\%^MC^0WDRJRB+X_E^K$OKVZ)*Z1[!J7*W7I[LKJ7.[3>
M'XZV^,-^OSF@PWZ[\>;LUL,%;NG-R5!-'V(%Z`5K!;RBSB!K9Q`N[+.UPJ'8
M;LO=@Q=Y\U3NRL.QRJU5G&*'#'7M!&+:_L_7Z_W3<[Y[M677^QVH76Y`U0TZ
M'.''4[$#9P&C[)^+RGG48;54.SFBG5"Z4>_S8N.-50_&,SI4_AOE^.+URZ;^
M9<*K9,\;J:+[$R)D['G">`@`8H6^7Z^K$_39SWZT'RYO0U[+L;R'4DHR'+P;
M*\VBCHSJ,,:_/YY'I\PZKU,[!+F#<V#P>R"!RUKWOM]OM_L7\.V_?$#/*$&=
MT$;!Q`6_W_[3]XSFRDLM5^AOCQ",T6U1/:%?]D<0\;_SU_QN6WR`#141M0VI
MJFW(.$G9T%KI1Q\"T&-^%NZH5)DPV-KSX%0Y6E5V3I5GKXJ-+%L7,HY[=)?O
M?D?K_`#Q=_,MWZV![;[:/Z'UZ7#</T'+7XLC5.%BR@?80!H=NT1Q0^HN45)[
M(_Q8%9ORB'[#8G$@&&L>,$5LWH]2"#>47;P5U2A)5PPKY93\_/77'R_=E&X4
MXK5"].*MB+H5B\S\X/^\.(2--6.&>H=?O)5N[TC`4*YWP-_(ZO(.CU7;XYEJ
M'%YRZ1W^%L;W!_@&$>+?X1Q$F)9W8-V:&P2@>H]\T$M1%0A@[7'K\==_Y;M3
M7KTZ+/2EN*O<+Q!P(.)!2+YM13Q`;:<*0@):/^;50^'"4C\"9@807BO$0<0$
M0/T1P4N3H"AA0M>*:A%B5QU1K5XOY7;KQ8?_(:(6`%XCV,^/",":U^:N.+X4
MQ0[)WS#W@%ZNJ'"_`*0#PN[TM`S2I2='R7D-6["F-6SA)&BC5NCK?O=PZ:9A
MR1>;AA'(,?9CXO/-Q1M2;1TQY_642[$(L,7-^U_+_*[<EL?R`W`9C/(HQ(?@
M,HE5[9(FA.;%O99HBN.ZJ0OT6JHA7C?D>HW6GDD9U.IZS4&<;=-K$5:>@4H[
MT,X@U5\NOH)A4M9"?\CZ",J_?WV46KPVR)0*4QM<JS!,?MVAO^:OB!IG0=8%
MI?N[8U[N[,X%^L16&#U!X+,[&U7Q;;_]9GO!HE&/,G/T4.U/SPZM'O?KWQ]A
M$0]@,PNK<\OLJGXLBWM8+!7KDUL@_WI_7ZZ+*D,OC_L/6=W4$Y@TM?J,V&>K
M/KC7L2KO3G9^@>F&^*V*S"_E&XWV('J%?GK--^7ZTD)"7Z`&MWS@^*.`PVIS
M$$%J<P@J@SF^;/=5N<D[/?BNGAGS?$Y-E*4WK.QJBBF(#0J6/LS5VA1W>X3P
MBC+"'0,=82`4!FZ*`0,"33%(0V"(I!@TT3C)H"C,MRD&252:`?HH+0,G,!6F
M&-A;35#RAAT(END:`-@E30U+6&Z2#!J#(Z48U%L,`/:3?2$$9FD&9DS2DH(:
MD;0#]!5."XFU2C;!C<78*0:MTVIRI46Z!O#:9%]PH6E2"\!:BB89F-T!23%0
MQ=)"PL!*-X&53&K!C$K;@6E%2))!295N0DJ69A#VF"#%`+9.]B8#(9(CBU$(
M,4D&HGC2D@PKDF2@1M.D##![J:065"F5%))*B/=)!J'2@91R*=-:,`BU208J
M9+*S*)'IWB3ZC5!,P..2AB)2I`,($3`A)!FX2`<Q6-NF!PY,FS@M)&'ID65/
M#Y,U&&J2(FC*DYVM*']CPC)OQ.FTOW*2;I\1FO9WNS.4-%!B1O[#FPA+B-0&
M0:B>?=Q"R/AR@FOBZ@:>N56[HLFZC9=;JOEUFS?DADCJZYY=M2LY6G4X?[:G
MT<S]D%SYXN"&@,I;?7`?^Z:FJ]E+$6UH/$;4O`'?C`?P'4^27O*'L-%T5^R*
M^_)XF":U[2,K7M.]]W6W=^FSNCV*/<-^MD=MB[(G2$.>:3U7,LC1V7K_-%4@
M[5ONFZ9%GRF2@#`P*)(@,L-&3A/,.NB`I<[(LSQ^O,>:W`GKCP#L!UT\TA>X
MN-U6""Z.5>/B6'5=O#XU='N[;F]@C[X5N\V^\I[O%MR'$=F=5X*0@X[>H<]S
M]"!\RFS.$:&)(<]NDV<%OVD-:]_"D`<'^A(/#DWW/%ADRK`129R'G9O@C#S/
M94=-D`S2$#H'/3C2%WBPB+D>1-<.#&N:L#_2RN.9$91!G$%?[=#G^:H82ZM(
M!V5H<<AUV^1YKKM$#NT;'/+D0%_BR8*?>S*@U4QK/2,6GQOHC#S/L4<-U(W%
M#`][<J0O\&06=WXI)JVL)1)R$OZW.!1Y9;.U(-YNBF_%=O]L<XY201>D&73D
M#GV>(P<IWPRZT,20Y[;)\SQW4L/:MS#DJH&^Q%5#TSU7)9DP)!5TSTUP1I[G
MFZ,F2(<SF,V?O'?"T]8_0?=OPVO_6&=\)L(W<`XZ?:0O<'JK<'1ZUG)ZU@4@
MQ_S/)HMF1OSTJD<K=#5V#-.4CZ4&!U.'/F\P!>T'.K3F=[X;U#!U%_I'XQ]U
M?'Q3C5!*(DKZ`Q,OGE+(Z)12\SOOC4KH1HE:<L\P40E?"@9S3XN:OFB0DZ'Y
M",,@EV;B?&0SF[V24=^HF?<RQS#-X6*IH?C1)L^+'Z/NUITVE.8A8-BG;7C2
M<?B$Q[,4\,`U%"%Z]#D[),I,0_E!Z"A_+:N,PR4\GHD=V4C?GUIT/']LJ_%E
M>&=L1[E-;>V6L)ZA+7>_L&H*JZ:P;@H/]U5D&YBB`WG!BC]V56K%WPD)M>ZZ
MT;U6V#,,Z^[?J::PZBGL&<9T]VQ#*"'2YP80=SHQH#W).,:986H,)T!("%:(
M!NE*[QF&%8EL`T&B0YX5),;'VQ_A[(XAH>:;R!6-I]E4D#II2V@1$.XO[519
MN\/0/M8^SQ41FCEIH,G9BKJB.K&%::2K6\^?V'W11-T2G,/6/7_GU9=,5&V-
MS+GOG_FA5MB=S5&+6)-!W4NMG:S;F@SJ7FKM5-W.9O8(8IFU1ZM.`64.X\CV
M@1;=:;!'GS5V6-R,QIC70)G*F!CS=9_OZJ'S4AYAF>@2&VTVC/;YC"['\?SB
M$HRSO^;5[^C[%?KY*=_>Y]4=NJU.A^/9@'N'!O8664L%"?+4>S4FY)+91/,?
MJG+S4""KC<T#SM"A6)]LTND%97&'2G&M38CA=9J142$2W;VB?+N-%\!"+EO(
MLJKO`^VK\J'<Y5OT7)6[=?D,3Y>5DC?)4(0TR7<Z)/-:EVS_L[?93CN7>O>)
MN;0HEQJU+0X']$D3?ZD+7`1M]B^[K"6U2YX*"ZTZ079S.D_<?9<#Z%H?E^?:
M7,RBB@8GCLG(WC75>1;X.^U9)PUC3II;'Y3V#G1J&UA+4F8RPTGGTEICNKM\
M:_.,5^B7XJ+CQ>5^-!FS1.MFR,?DK[/^!W%/NW"EL8BG4>L2Q%SO=]]@#K6Y
M@/=%?H01Y70CX!1@_9Z=QQ<E$,>M0B!U)[*UZ(+.GQJX47-CK(WZMD75$Z0F
MSP9PMJ0<6`%./+"2V)M`\:Y$+?I<D20UPR+1C&&3R:G+4CN-#=BJ(2^9%Z-@
M;VR3<O#*%AAI)L(N?0Y(X?SM?4#G5=!$@U5:CMJASW/4*4U;1X(F5*_E/GD6
MP)G2L/,TVP+OMGQ.G]'1TW1V#G&N\QEYGH>--IQ"7DQ0'V]UU^%Z]%EQF-:S
ML&$U;&$VA<F%X?_;18SBH^RQM!#,)5JWEC(C$,MBGA[)KH(L]AF:3I:JP>T1
M<:.'S0"->KAGJT</-+I+,-G0%>UWFI,T5]19ZTJ!NX+HKA0,0ZL6N%$"9TK*
M#/G;URX?'F-R?J7^?9(RPVNX@)O+5`Z*#<Z_$Q#5&<+YL9F9H?C:S\MLQ=@@
M^%G<_TRWU:&M*U,BVGT0_6B986"^L&%5O"F#19-8P[@,"X$)4*L'=2XLGVAN
MO=#F#D;\?,!9OT\`6DQD4O.SRV,3Y!R+D93+6M"QO8#%=0O<U#T#'-KV+#C4
MO3DWT`6?/^>R^=E,=L:T+:J>(#5YR10\;NHD)G0-\JX@+?IL3&C'L5#GF%!!
M^".3!8-2`P9JR$OFZW$#=1"A%64($?;H<Q`A8V,[8EU$:)L80H1=^CSOG-*T
M]1[&AA!AASS/'2<T[/S,MC"`"+OT68AP4M/6(<YU/B//\[#1AI-!R>8?^],L
M^[0-3WYSW;W64P[D0J&A7;T>?=9,0^MKS)+)9DM,LCG8\DL%$V-Y6.\#@CQ]
MEW_7NLU-=0;V!J>Q8-.BJX&98JD.7.*V$DK7TZ5TSRX)JRO>&+9]CQGK#_Y@
MFW)??\Y#Z69GL6^D&F:/XM[I>WSO$-W>)HQ82#6B4_WV'I^4/-/,G,/@&3CT
MDJX`TWO4QB(G(43K_F:`=D.X]\(&5;C9-J.\V3;3P:1]F#V(>Y7,*#;)+U6]
M4TS!ZM58L[@`X,7>7%RD@/`$*$IQ1C1>3<=2(8#&6%K'37]*ZQCDI)R&4,HB
M1-6;@P-=L/ES,-6C&P4UOYWRHAI!HZ[LGF&:&J&4ZFE1DY?,YU2,7GIHE(`Y
M,"@1]>E*[ADF*1%+66RJ>M@@T)=@TZA&!YM*\#B;:3P1G&I>:QD4[JKF&:9I
M&4KUNJHA+X$AXUW5A9MVO1AP!R41=U!1CQ__.)1%8U\-8>0>?0Y&IN&C86\!
MU2!TE+^6E=7CQ3^>YR($-G"/3A9-FSXSB\87'3U_[0[N('=0H2NL9V"#F23^
M71,9:!,9?`=YAN&^BFP#T#Z0%QQ#Q*Z:E$7C'-+K'LW05=@SC.CNWC4!A?*>
MPIYA6/?(-K2ZB/0%)QZ#VK-,,I*!-&/+#1L2@A6"0;K2>X8110+;P%JE0YX7
M)$;'6W*%@>GPP._29PU\//]PS8X[3`?7REWZO*&\0!(['#`='%]XZ4[.`CF<
M3V,Z[.L=^JR5]!))K&^=6^2,/,]91^7HQG?"8R*Y??(S&A'U+!$>AV8T^\HZ
ML"!=Q^[19WTHQ\3/8-(&Y7/#`\K_V^EN7VU@Z6:71KM^8IE=VCV5.UC='5^[
M'T^Q'S5#A]/=H=R4L$#*FF5!#G^'%@%+=;!G,HT2;H445LYQL?12E`^/5OX<
M@'S^,+AP?X\%PQTN]W$GUB08L'C`42^)5SB5092!?<,7DY^K`JQL;Z5<6E8A
MZQ4^;<YB%!];)]L/4QTRM-[FAT-Y7[I;8,A]P&YW[!VM=.?SX.31WZ-O<Q-Q
M07@<1$#V7;.,:<)FH#,Y/VP2-6%E@.O!&57H"NL9S"@"(@+7A>$Q%A8UFA@;
MVY%-=8=V0UZ"@&)G3T9`0?=HAJ["GF%$=_O.ZQ[-T%78,PSK'MD@^G>4;]&7
MK*$&M0<OR(R6"?P3;1#,T97=,8RI$=AZ7=B0ETPI48GQ+&+W385!^R0^)&C/
M,*4?#UJO"%7&F^?+Y9K@F,0FTI_W>D\3(C:!5S[L0P?WOZK%DY^EN#$F^?&1
M&Y?;F60P,LW`3/H3*C<"IS\,="/?^)+4C<(\^7&.&XW37W&Z,02G92"8B.07
M<6X(L5M]20Y*T]](NB&,)+[U`AWZ\S^NKZZO_@6HG$19#0IE;F1S=')E86T-
M96YD;V)J#3$T.2`P(&]B:CP\+T-O;G1E;G1S(#$U,"`P(%(O5'EP92]086=E
M+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR
M72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B
M8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X
M(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM
M86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$U,"`P(&]B:CP\+TQE
M;F=T:"`S,SDY+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IXG+U;6V_;
M.!9^#Y#_P(<`VUTX7EXE\K$STP*SV-F91;.8>>B++-.Q9BS)E>2DZ:_?<TA1
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M+*DK\H^L.F3-$^$+PBF5"S?>?NYLM89==#7Y*[G[_?KJ'8CX[\LI`EY"18#T
ME&L>-,$%%UX385?,[4KA1M_;5>._$WZK2_)VOV_JST69=18$NC%4H,9(O2'=
MUH(*ZMS:=4LV35VZ;W[.NWH%.L.WR<^;C75Z?035D$/KI=UG3_"^GR"8`"><
M10NP"^\.C`LUN$,J>G<XMF%V+*S686M9GC<'.S'RIFZ\`NJF*T!SO3Y63;&^
MMV179Q69>MKJR3V^;^K#'L?6\%M#?GC*UD5^:;'AC5%NPY>24O"$+R#L[>67
M2L:ET-%2DS@=OWF_@S!89W/8U.@TF#3A23"I%+@--&G;U?D?VWJWMDV[)'?;
MWAQ%"Q;9[<"T3;8KOGBC9*2U^:$INJ?1M$7E@KRWZ/=UN<^JI[^T)&M;V\&,
M<X@$R-N#E@:0'4`K[4,5A?@I:_X@;Y?D79GM-EFS(G?-`8$*W'9.;^(J&;8W
MKS/QA$X4P7#AH`@3PC6XU=3&"V=7FW?%`T3MPF--MFMK"+>LPNA[S!K\U#KP
M.33Y-FL!C?;X*ULJ4A:['<9PN\W``69"(B.24;)!,"T3+]BQJ^5U6>*&4$JD
M(GRZL^!_#>[N1BX5=<3D=DQZ*/H`4`O;?TM^:2S`;@."`P0]@(90.`"ZW"Z`
M=?:%0V0@'_($K#>![C7$!L[OU$8^4D7QVSETP<S`T28=E"'1M5`9WWD4_2>&
M[:_>=K`;MB0_5N1?]8,M`\$LW+[M9]OD16N]C"%PGYD$'*&%S:X/N2>B&P$Q
MYB((7P#4]TC@](!#9Z9H`T#=JT&J,>IIDCQ'T"D"$QBT0D\'@[IL!/?]DVWN
M;0-,#1`%>V@/NVYQRF1""I_H-'8/0VS5.1^`MX'^&EO"%T"!FZQHR$.V.PQ*
M+.MUL2G&$`(0G$,36JN@B42,FN`R#4D;1$;C#8';.M]H2+J&C19E:=>%%W]E
M@:[M1*`\0Q5B1@=`OP*T*)'&O_@%!B*`6+%5B^\!;=][95?V<724.321A/25
MR0$F)*2R7A'HFI[3P&A94:$5#]6X_4DZ<L,@L^(I1^(#0$"`A`&9=Q((@3"N
MJCM`#<C)LM7.HOQ3;$6?0[$A__'@A`N"$[;UKL"]K&?1@6+!&U@ZI/`\-5X'
MJVR751#G[=9:YY`@Q`\V]Z@@^FSV+'%E?9Z)T7[#C/N,,1XW_?K0A$#Q8.GQ
MX&BY.30@Y!`/R4B#W/3QX/)UE,2#(&QY'_@/0?)$B+HZ`T3[.=\=UD&T7@?9
M429K*PN!4D!(35AD8]'W@4><ZHXT/(<:6#IDEHD<'(%BC*`:P(YR-"I4E>Z7
MD)J_:+"H]F80(]4TQ+2A8U`KUB>L/\9PW5/<*9&WP4S^05=@[)Y%<A=/&_'Q
M>P!+X,Z\[K]WR=,<.DB&#->HD?*5ZCUZ4WQ&=.IBG-SZW4U9^80BCTCPF,/R
M(^\^3XRR%SQ^#EW(D`I2E0R%N6"Z3W_Z(`/Y@)0Q1D_(7"DYP%=C\[I9N\KT
MN/1&#7XCO8UD,X<2N!F(CDV8+E#^Z_S&E5IH@(5Y^2VPS1PJ8$/^1^G8H$E8
M3_9_CN"@7AJQT*=[%R*X`2]GT`'V.@/$LW2LYC67`]7]/S`Z44/;4,II+JX#
M1C]/JB_C[SE#WIA)"I*RKR*K.427(=WRO<'>`D8,D3C5/<+!L:"N<7;:'^L[
MGW$58?$Z?0K!^`B!Z2I:R/>Q%8/Q.I3E,Y6C"1^RK71L*`E7DZ$"7J[+X5O2
M%272!_QRQBH.II#/OMYED\BV^[[;FX]<TAG4HL8^&QX0#`C=HU,DL3A-*M#.
M9?8[6/4(>X\[;-Z/D/;PG;:GXZ%.'8WP"WA#L;:57^O[;6%G:=BHE`[(1$?Y
M>6+Z\OS=9YL?,"RPS0W6;A9#VO)8;'Q<Y-MBMVZL(Z)3A5T*U2(NHA2=UT7$
MT*X31H\NPM(X:K:'%60M4*\CPSZ;MI9%5;LDY-1C,GP9[%]@VO<,QC*Z$$.9
M1Q?)&<;.H08V)G18I89RK<_G_EP)LG@>4%'T8TE3ZABDP"0&JSF?!)Z].%'L
M#*)+,[3R8*91=/Q\VHQ_.969P?5EZC?VYNLF3^-2)SYS,^E2,>,;XK=X'F'Z
MK$5C&?X`ZL?.&IKE+4#$#MM1%Q<5BHFPG:^4]15%RF^=/*9(K@8`&:M"D^KQ
MW"/00_U8M43SI7+'L@X)L*M7W`.D0$E8[("%\ZTMH=+SAWFV^O)46K(ZM$5E
MV_XH*,R69X#)%831`Z`/9`#CM(@4KO(B]:%K.Y@)*6C6LP%)AZ:?&I-/R4(M
MU$-F0+U#!=*2PH5VZ]`M6Z\+K'=@TR`/[K<I[K?=B<Q;1$L0>^]*H^E92'?4
M4#R:PL\?-(*'#]1EL;-DX<*$5)319#PE25(9_`'0KM\_6G`U-O\=^-WP'A-#
M4]MOWV;YEK"I@6,*&Y<H,7DY6J/&4M!-$.)Y%C6DXXGJV##B2O.0D8-`X(TW
MA@9Y27XH#[O,I2/`$I`X+1!NUY!"57:-8ODB_PQ\^_[2Z=O/4:OR%>9`4(["
M[Y&Q9DK,A0H9**=B4AL&E#W?=9<U]U`SHZ=#6@&,C_:#]"OKNLPK8@:$%"*=
M-<L2//0/.4L'CE54]RCY#MT[(-=CW1\'.\0*S#O781X'_`[;ZT_^/W(N+KX,
MY-^C%JC28Y)%=7\L,&2,(?.Y]"8$T\_(*B^^#+P:ECDZ<,<CT(L;4!QIEM/)
MH5,:&@"]:TT8R#')?6-]]NZ::A:O3#3>]Q[Q,+:#(K#=X(GU8P4NN"WV?;.M
M:&;!"CHVF)-)@SEEI_W$XW["".2>5L<F*H,D[C_NNVZ+9_"NSN].^11X""7W
MA%$_N-MB3V$-#+O^O!4`E#V;9<R@"ZZ'NP9B<IQJ5,\?YXF-\ZTSC:#EAKM+
M'\#"[K9%SX:^@[.!6/-OK4!XX)LV;XH5WJWK\P2<==0]ME:A=F]\,QX5Z.`9
MK],M9JI0H&#OE2'4>*4D24*W?4B")G:;J]>DS&0[C*=#R2QT.-J+:]\G="<7
M'B!A664^.^DS.3S^<%+4^U[7S_A[*(M!1V5===M92F.N^."*<CC"DTF:AOMW
MD)`,!Y&#8/[H80:NYH+/RM6<C06-X).*)B2P+Z9AE2T<;T\1INI-=,9M$#H/
MT[S4%4B;9P/10],WW%M[29N)3@=Q9ZD\67\V\/6VBE?Q+!VO"D\NG?1=7[,D
M'R;-BTNO;_2POAR2"7YQ*>DHY@R=$"A.PNQ&@<<C!_M6"#6A!_CNTP$]%ZGP
M!W>^ZNYR7=Q=P!EG%!2T*,?KU'H\P6:)[/WEQ[8]X$FA0]KO_4&!<Z`Y(J._
MVST7BK')K>G^2(B!>74R7%@8;HJ/-60`K;:XKQPD^131=<#\U?D*\`N;8H!J
MC=WUO(0I`=`54L"F:,J^WU!7OE]+`.]*=_$OE.R8)CB^VF$7I]W.<O%D./E@
MD^LWAB7C=31;M3Z)\7?Y?7N[L46Y.C2M$_I8*P6X!VB%^8)]S#/Z(Z5+.XDT
M+$AQ$@[N`D*J!$D-)<+-.K[N_J`#!@@!:2H.X"\,X'@7*3:`<16?@4*Q$1N0
M&,Y8=(#FTD0'I)S&!R2HX=@`Q:#(C@V0KRTA6%P/"4P0GX'1N*H32C6-#5"&
M0N3&!NC7!J141VVA$IK$!RC*HYI4PNBH'A3'*]2Q`0SDC`X`4HJ:6QH=%U-J
MK>,SI%I%;2$3K:)22#"&B`Z`X(V**46:Q#?)M8@OP?"/RF(#:!K7`R2\DD<'
MZ)1%EP`ATO@`B-YH9`F5Q`%$R#0>64*D*BX%3].H)@5+97R`2R8B`[C1-"H%
MUYI&-PE[3*(.PY,T#J1<)28J!9>)C"\AE(D:B_,T;DUF7H%BIC%%BPT`THN&
M'G"]CFJ2J20.8DPF\<!A`@@A.H"+>&0QJ*/C,U`AHGLP>),Z\ESS]%7N?X71
MXE3`XNM+IN)A"XEHU)58G)(9@->+SS_U(.P&0`GSI\H$823I;UQHC?T=XSNW
M[T^SNZ]?`O]&1CW3'#[[:ZQO64*%)>C2MX/?,'V:0\9#Z1;P/_J<&1$?P$T2
MA9Q;2>.P=ZLHB_K)+<1JU%%N(4>-8O.MIFE\#X;%4>V641;Q1C>",1/7-52#
M_.6(!W.]^^WZZOKJOZQ,$<L-"F5N9'-T<F5A;0UE;F1O8FH-,34Q(#`@;V)J
M/#PO0V]N=&5N=',@,34R(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O
M4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q
M,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C
M-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q
M.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G
M94E=/CX^/@UE;F1O8FH-,34R(#`@;V)J/#PO3&5N9W1H(#0W,#`O1FEL=&5R
M+T9L871E1&5C;V1E/CYS=')E86T-"GB<Q5Q9D]LVMG[OJOX/*)=KQC.EUF#E
M<O/DQ'&-IYS<3-QU[SS,"T5!W4PH4N;2;>77WW-`+%0OL&]&=,IENUN$`)SM
M.PL.^.V_+B\^7E[0=9(K0O&/^2E;*SG]4^XO+YAYP@A/"$O,)YPD=)WG/",9
MA2>44=+IRXO_)8V9*Y4*)U)9AO^1[N;RXO;R8O=7G`K_S#Z@:RD%++"60@GX
M3^2<GS[/I<+GN4CQ>98EXND).;EBC.6<9+";+*4P*^YI]V5C/KJ'F7_(62#J
MV^O+B[^]+38EL$"0:_B"89:9U+&'<>"$R,CU'K?-!##ANKR\N*)KF@,GKN\O
M+U[U0UO^2HJ>E.W^H)N^&*JV(;NV([WN[JI2]V1HR4;#RLU6=WJ[(O>W57E+
M[N$7<E?4H]Z28B`O1;ZBP/I-T<,',,5PJ\FNJ#JR+[I?]3`-)>W.//@.%BN:
MXU_(]2^7%]\#*?\\"\&H*9YB:8A]]6_.^?G7R>><Y4P*QUDET\1R%EFZ!TY,
M+(8?SKT-(U_XDI,OGW;!UC11=A/([&TQ&,;?=$4SK,GKAA3;;85R+FJ8P(BM
MORTZ$#6,.MFT$7+5]^,DTQ^*(^%J13BEBE0P3UFVW;9H2DWNJ^'6B+:XZ;3>
M:USI&GZU\X""+4(]E99ZFE)FJ$=K!_$8ZF?JR=.5^J/54R0R;'E!]11)-F<-
M%T$]&6+`T]KYA*J@`$^&W8(<FW8`/-`-[.FFZ@?$A"5DFV>I4^Q4<+-_ON8Y
M3Z?]CXA&9L\?=#EVH,Z@OJ_+@13-%F1ZM-L$8G9FAPAH;0VZL.E!-^W>NPGM
MGIT+OE2`EA\.=546FUH3_4GO#Q-"=NV>]",`X1*TI]31GB2I4VN>RHGVD\UW
M^N-8=<;B^KG)E;H;JAWL&R2J[ZJM;LJJN9FVW`<R-[KH>E+`-#!C50[`JEK?
M`-:O_\TEO9X;M+%BD/>^:HIALJ+7X\W8#P83EF`#.&!D`SHL1KWSXLHI`>+0
M1+-S/RA]9^L%8E=3UN,6-@MHU>NZ!A:L")"G.\`^'%QL@1S+S3L4,#I!X`MZ
M0-2((_"'H.O;DC>ZU/L-:(I@$P2N?S?1R;..17JJ7YU]=F2I^$\GC\D+5Y[4
ME@GFQ"52"SGOK`,!SJWF,.L<C*!T)9[W18>QZT>`)8Q'4%]!@*"SJ-[PI`1D
M0JQJ0)!@N,8;O?W3=^3O8/,@\WY%WK__;@F:,_0U0'/.UY*B"_H-09TJ>O:U
M$K]6XEV'./<J/%!DP&>2XBO'QG,OE[(GB))G7R5]5DSL[#J12;^8P2V9>MS*
M4QMT;PU^_F.LCPY+)$&=0:,XNT394SP^O^*P=*8Y5-(LD$TMV6#O>]V5%5CN
M>\3>GYS=OH9?/A3@7U\[7W/N[<E4?@U-DQF=JYI(T&LY53N_CY0YG3,]ST4`
M73`MPW1P?/H3L+FYT<:I%5.\<Z?K]@!*R"!O@#@>7.6AZ$I=(^S6*)PEL!*^
M;9$E3X25PD)J+Q*_W():+P-1:.QJLO57'ZI!GSWGY$\0='8%ALS!K?)(?W]_
MN/,L,&<SG:`9]U`IA`OQKF=Q0J<QW02E184Q2HJ979:P%?[]8W,[!0KM:%DP
MM5.0#@26<>[+#D;W/I_8E77;@R,_ORC1O!/E1)G,1,F%1:+7H>I0MOW08W`^
M=B8YVY&7J5@)\)U%W;<G43ON_D2`1O`&R2`2'&`R__1E+M2*2YL2.*V!H7N,
MWH_%MBK)SQ@W?C_%C4OP0/IR&^,S-!96.B$>?=>4ZQ70\+9NNVI;`$NZ0VMS
M.J3P_K:M(3YH[QO8?#]N^FI;%=T163*+HEM;C:L&DYL7?5_=--9"GG6WA7.W
M2S!`^'J44IX!DN+/1@E\-HF[,#DW@.5Z@50G8VRY5"?-776%B3P)9/(LP!82
MYJJE56_J9>0`VHOR01L=FVHXDE\;$#$68%^\WA1E6[S`L75;FA#1ZO\U#@$%
M_\=X@#F[E5>:I;RGRIDG<4'WJ?)TSLDDG8+&5TCO^?UG]@1)YW>@0OIEOH('
M3:2<<9!+Z=-NE;J\>PZ&"!+M9BBJ9IFJ79JFWIT+7[$1,K'XMZL0_HO#H6L!
MMJ<JVA,:CL`&R7P_=*,IZ4W?^%3MP2H`%*4M6G\<L<:S:]O!&)0%NW:WJTI-
M-E4[:#"]3O<:0MM;`S@V\#4`M`3Y"?49D$6_5YNQ,IC_NS$NMAX7OOZ=9X'=
M7)R(_C-N(&!RNZFK&^!Q[]RED0-\'TO\<]Y97XP09XHM"%3WK<$C;M+JHZDK
M[L"'M?=8=UP"I9`!U)><TL0S0/+$XK"-=TS\LR9OQF[:"T`L;/?\)9K$;^BD
MT'!U]I52.B.=)C3WLF?4'GZ8RN5!=U6[73EQ`MU@1[?5ID+O8JRO.WNF@F'<
MUV&#R+*Y!KBD$C4@G(!U1=/O=-<Y+30ZBS5$@,,6/C!,ZB'JFGX9(%4V>EP9
M/0;%!B!J=&D",U-7+)90Y"3S:7PJ9,B#A*WY]VBH8'63(%?3#J<M&EI(`:A7
M5R;,[^S3Z7$XF7.HZZ?Y<T^^;8O.!.!O*DBOAA:,%K]<0.[T"\08$*#`L\H$
MZUM]P$(X6/_6C9W*&K`!G/\M<+JL^K)=A#^ISQ/3-`36>`8_(5TW]L-45OX!
MLC[R>DV^WQ?UKN@VQ#Q#N/N;J7\<"="`E(&H!S0)4S8&I,+#[8DT#+P[)-G^
M!LGE\?&\=D9$DUVQK^!+>W-`T*_).S,QGD$MP0NE0HR=SF+L-!SZ+I3F9L*O
MOF"6FZ4S&GG"0U##O3V`=`:4(R:X+1G!GZ&68ABQ&YNMZ5JP#FO">]!]L//A
M:'2DTY`5Z@>'$";BJ+:Z\^=DK3GKP[0*C/Z7%E8D=[#FV!DC6T*RH5LC#2FT
M%-*FT!-$%5V'Y3SCB-'X2^S=J*M^,O-GW+1)BF'C)6#%1H-J8K(XHLE"DG+;
MWL.WNM5D$LB.1]0^6KH'9*GK1;@0>AI4&KC`*;=<*,NQ\V$'T'>`&*_LJ@TF
MOM5>[[IBKT^+`"!=C74"R*^M&RBV=T4S%#<0ZYC`L.IGGP#?C)N8\[+3]71&
M.,%=!?@`<^,I\2*='<FLM<'F*Q-HGST)HWZM)0M7<D81RU0>E%OESJ1WXZ1M
M4P"/8GDV>%_BB$U`H.(VN6#6*VCJE\G5.I/8WH#QT<]_>G/VM81\@J2S9[U"
M!B5:_HA-R'2F3%PDP3_0Q"I3H_5VLNRRZ$T2V$+>H_N5^0S@P!0:YXAO`:Z&
M]+,QAFY\"+J`??6;7BJ!4:'-)<D#UBEE_1R`],,*MD$F@.DIC:D0ZA8HGV&E
MV93/L`]D"<*53Y7SD+VHW-+];@<1K:D$0%IIDTE7+'!)G8ER?3DTG8)1F^FX
M3B67O6Z?\XLF'FA\HP!V']3UBCPZ-EM$^,*G[WG(7H5Q>E.C#RCHG3Z:#KLW
M&N/30W$T6W_Q\_R9S^E_Z@`Y7Q#]<80XW\;ED-T7R$E+M,_)_VN6YKQD:TH@
MA*TQGO()Q)1>X&H_3"<I_X-Z^,+-M`1'0@M)3F?F(*SK#[TAL]CMSZ=G'BN,
MU[9ZAS4N".CUU+*$?8#^B^XX!'\^83*H#+H>HVI.):9(XH3?"U`N9VT7@H>@
MA]E*QJF(71AW*"I3)0:=-4"W0N%U&MRH*:?AQTCCE[#-J8L+F0`>ZQ:L#)N^
M;%;E-&!!!9#AC%B$8J;(?=_BEU`"N.B4WJ3SP!-O$7---]R"S`Z^O,&F-J/\
MNR_CUD)GY-(?HG'&5"AG,$O_)&2CX%ZO;13<M_44-!4;^''$\!6R<5`&2Y;7
MYR6VS5WB0KGRYR$\2WWKE^^>>[;_BR5LI9)G^[]`=M<__C?Y)\C1EB7>5SMM
MD,H<\77U[#`%1_XX#EWES]/>MNTR`F,^64G"B9]DK@3[LXM@WS7]4`T@%D35
M13K$6.IWLV#XBI2Y9?(4SW>3*=8#GI]]+9D_0=+9PU>F5"!I^;8=EJBYVO!9
MO2_+0]N."T[]E8RYPT;[<;VXUKXGD\(JQ_11*.O#7],$#2E]ZWIV&3>-9P*\
MR'"/[=P+`;KPIU-/-WA8$%B9\DTXY_:!W(_OC?F"<GWS,"HQ#KGK+?D+J)\$
M]KC]+Y@;2XATQ.P0+PT'RGFX38*'64U;MS='4D,$T&#%JS&]L!@$G#U?AX5%
M_D1&=_8BOLKH7$GR4-$4N:MHCH<5AN/UV$->MB+W;5=O[\$V/"=L"7`)_9V=
M:"8S_4U\L152,70W,_E8A[RK=&UJZV_'Y@:BC[]??R#]L1_TOO_FI$2_@.J*
M)/%;7_*J24IG'&(I"S&[Y+.K)@V>P``+Q@,8:[!LBUH;W4"X;M(RO+905.XP
M!HNV7:4';'PIVSO=%%AW7$+*X>`V4R'L%,H57@V^K&QG$B:?!>FJFUNSYUW5
M]<-TTP2+@4U[]N8%KL(6E[5&C-X",SA-9DF8/\1_I,XD-)1".(W6L!W]@=MP
M"W[H[*@!T/!U.*(2-E</(4.U@B?JT5GK@S/O[T$K2E,V?@/YB#7[NT7*8JC&
M4GR5N$QD?JDE_6(@"-/!N6-(O%L,UY/`!X`(,!<(96-_B15K.`%WGCC5Q?!#
M[V#8T-NNAT.M!_W4D4HQ!_0/Q@(6.@0`#?.MGLQ'!<K\;*J#9%?<M1C:`4R:
M^UV;HJ_L@=7YPU;J-[1D?H&>RRZ#3=4\7%OF7%F#^ZG3Z%&`\`\C7L_3W=F!
M$,W^$;5G3STX@&J0,N59(#;-++'?+'+:`?//5\[2T*[EKVS=A5@;ZUYU[9.-
M):)MEOL-+8HJ8D8WRZB<E1F9@Q7CW`T2=+K4B-^VGWHZ$EZ1KCT6-5ZA7&&4
M`M%+;ZI)-Q"\P$_5CIBD9@E,H+Y3)&/!%TGNB\9%7?WFVGL*/,D&`.QW8SUK
MDJM^.TD;@T?_QF1;J&]W(='"MP+TNZ)T7\&R(O:#;`:];6#NT%&"X#H5:DYC
MI:$KMHN$YSSW?2$J#7DT3FJX<2B.YN;NSM1%'WH%]U(#%[7`UD^<A&^;F5H/
M2;%OQ\D'O(2H%YL0I^(P9N*.E]>SK#RDX`#*\,UJD?-RGOK&>S4+7IG(0C_(
M%*/B@98Y/(>]GM82]N.`!=+[KAH&W<R\JJ7J4'3FOO#CLP']Z5!U)]I4N^,&
MECW9!W@:$STQY1(\4KZS0H;J.F4BW,ASVW^*H(EWYHD.+!E,&X3-09]4HDD]
MGE4),,KZ:+OVC9K"%*8O;;'Z.I>^[I2)4*Z4KL/$RGDZ)L7&*,0S"P)[,(!N
M4[F;Y]A-5O6N069Z543S?!7JX?L@[,L9/G]K9PDN<-^*\`=T4+G5E^V@FM'(
M9GXB=:CPA1>%7I,2`')*SD^[L%^FB6G#!E@=:]-78T]H\5@:NRZMPS!W'\*%
MGI.6CB5D2WTY0@6Z)7/1U#R8M]?]/=2;3BH0.A*#Y=>VKJ:[NN;"T-3U!'SP
MVKWT>P(B9++PC@@N9P5DE?T_CES2E8)HZ(LNW+^9L2U@F&V(!9EW6^,CCJ?O
M#O(.=@D.*)\;2LI#;NC:Q!Z<9YY$``_;B4"O?P&?U#]VYT_3C3D6Q.Y+W")T
M9"U=U4AG#*2S.@_/,]N#`:H`TK5E#1`D6L4'?1BL=E.CW<F:O%OFU4;"YR8T
M*#A/G(+/M5NN'AV(&"!#/Z,_#9-=HE]^8)K):9?@H2[*S[^(`EM#^K)K[]V;
ML!9J@S2H;1B`+PZ:[I(\B`GP!H1*<T72'')SLT*8RKR-#`9(D:5F`']F@!`B
MCP[@/(_/`!"41`=0#KH6&9#DW%PY>WY`QE5\0,J3Z!Z2A`L:':`^MP1DJ%$^
M)(+)^`R<Q5F=,,9Y=`!EYB+;LP-4_KD!&9[@Q@:DC,8')#2-<E(I?)%=;(#`
M=V'$!O!<Q9=@N8J*6]$\3J;,<QZ=0699'I6%3+,\2H5,,JFB`Q2^KC`V0&8T
MODF!A9O8`)[).!6`4O$E:(HW>IX?`,)4T25@CRP^(,7W7,4&)$D<0(3*XI8E
M)-Z3C`T0&8MR4IB*7&P`PY=QQ`;03$:I0-\;W23/T)_$!J1I'$AYDHHH%5PE
M>7P)F8BHL#B(,SZ`?@:*60[9:71`IN(`PM*41SF);U:+[T$E<<-A$E@9'2!D
MW+(`B#]#)A-I?`]4\*BX<\&BHLAX&OT^<#'NN'E\?<#I.`JS+"H%P>(^F3,>
MER*-Z,G'B<2)0<"GQQ%:&CD#`SBQS8I9!DE8FD^A^MN'H>#O7T)"^!_>QA+)
M!OZ3)91;@JZG$X!7+'\89"916[OZC)^\8GE<2:YXGD2E>"6P$28V0.9QR+E2
M>1R\KU(:QZ2KC,:-]2K'E"7*!\I4%)0@9XCI*PCC^W]=7EQ>_!^O>O]##0IE
M;F1S=')E86T-96YD;V)J#3$U,R`P(&]B:CP\+T-O;G1E;G1S(#$U-"`P(%(O
M5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@
M,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&
M;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@
M,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$
M1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$U-"`P
M(&]B:CP\+TQE;F=T:"`T.#$T+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M
M#0IXG+U<6W/DMI5^5Y7^`QZF:B>I5B\!`KSD;;R>;%P59R;K23D/?J'8E$2G
MFVR3;,G*K]]S<"4I-IKD3*=<LBC@@/S.!YP;",YW_[R]^>WV)MA&J2`!_B>O
MDJW@ZG_YX?:&RAY*6$1H)%L8H338IBE+2!($)(T"TA2W-S^32MXKY@)O))($
M?Y'F\?;FZ?;FX8]X*_ROUQ!L.0_A`5L>BA!^A2ECP_Z4"^Q/PQC[DR0*IV_(
MR!T-:,)(0@.2Q`'<%3$]S)/YS73&MI-1I]1W7VYO_OO/V7T.%(3D"PR09,F;
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M"#CYW)3/^*2KD`#WUR2P-#0DA&G`%`F?]UDN22`_%H>Z@3DZ';;D"P!\R,IF
MI$#1/`-'+:"H=D4#^I<M=E1D5SZ7._C[_M5IJ@F%L8H:('57=$5S**LSI%Y!
M_S2)M?H!C:A1GT5XC>JK9:X4?H/GJ=CO<+J*-F_J%[0*Z/N^`+Y0+J0;G#Z!
M)+"4;>(XWJ[5(/)H$"D-WO_">+#J_K&?(1'(^]\A16DL*7K_<];`4NC::^@3
M!E^ISX49QTZUX`-PWV;!1Z'05M]-3"$L>VF*&Q)M4H%S&9E%`%.>UX=#79&V
MJ_-_D:?LN0"7!HL>>L$@8-4_U(UT"%F%#@1-H^_PP$DH,K?D`[A&;4NF\1J+
M/DDCL^@C[FR>XC52@,;Y<-KO7\EST7:@`*HO]2I^/Y9-UI6@[0X\$EAZ5CVB
M#@]-?2"?\JY&VE@J:4O1I'_,7O7?--R2'RK@XJ!N`/$B+YK*A(__J0_'K'K]
MUNI&8.!&7ZX6[R^,L6_^F)3V:*6<N7@:&U_2FDDE$"7!(4(@+:\SOW%JYE>(
MV,YO@-=R?EM8DOM]_=+^Z0H&',7:(5U#M2@*C&K(MM9,Q%P;+QB0M9Q'_%5(
M#RW#Z`N$)/P#%MZOIRJ7B_"E[)Y,=)<QMGYX*#"E:3>PV//BV$GKI4FX24/N
M[MT4&/MM<I2C:>_W:F&#!9=@Y/?07Q6M]!#78();/Q:FW%*1I)H*&4%KT.B8
MO6;W^\)`_3%K_D4^;,G'0[9_R)I[\J4YM=TU(E/$PJM&IBB(;&0*(^O*&<6\
M%BF`M)_\7X&)IB3@)YA8<%D?P-54ST73E=CXN2E@PC%7^0G=]Q5H$$ETU8`F
M(FOMB3,)GNAX]JE2/EA(GPP![7AJ,!1UN"`R'Q?D\ZG)G[(6<M%A)JQ=-6EK
MR'_8!MPI_O0"8E6\0/#(3MU3W93_U@'D&JH+9E3GPMD`W%;IOBO:\K&2AKIP
M'9!?`A&@KE;8"D`/1>Y:*$\:J'5.E7$&987QLFY:Z3.RX[&I?R\AVA5`QCL:
M;()`_FRO0@7F+Y(*%@A7S$2QMH6_P%P53:O3B]96&X>LK#KX`?@0C?$*7"%J
M6E2Y*D;VY6^G<J=<FTH$=N2Y[C!NXY\UW*XA3?GX!&Y1NE.X[;'(.^L;8;74
M;6E<(S9=0W]JBUG*7,R+3630:_:_6O)=G4$ABYEZV0!,F"Y(O$"UW4YBA!E-
MDF0#/[T%_785J&@RG>)!?%4%3[5KUT_V.9<207UNM%T?8ST.BZ?)51T63VS=
MS8+41:Y`>ZP?W&1LR)-;M^<F`?Q2V>U5,(89+4I(5+.JPGT(.PU8@>/*:U2,
M)^\PY7?5N#3WY!?P(FC=6_*WNC=4/D3M4QRS\BJ.C$?<.C+:R]B8=F0G4'$O
M%8""=%^J*A0QE\H;O=3D%7H@:9&-JC4C?^V9[L=GZ;]Q;18/:.]&5M]"[>"T
MI\/!9C%9I:J5EZ;L.BAH/I_N]V5./ND4:>)FS_9>UR")QW:_)K#AGM-4N[A<
MNO,6P8-/JX=E&:KCJJN)I:1[U'HC8,ZHD--G)Q=.9;:S9,9HAFH_(==)E@/E
MC=OJN`8/H<N!T69,$HRVU'-U6_*/8UU-3RSY.UA'^5`"3N^DE@^8&`,9F"M`
MQ-<D%;B69'`HN^+0]E?B4U.?'I\<>1M)NS.F:_#A*OK>-B9-M.?/\KPY&5^A
MS+CX'</7J6R?<&_G>PM.TS6Q.@Z00KG*7KH!K"2R]@F7B@Q[$Z/4PM@8YW,%
MW4-7<P8\<;L9R3CJU4><?*S`>\[UM&J!G%64O-0GR`@A[ZOQ5GF&6PC**CME
MDM=@P!:[+(AL_LN%V<4>>@'0'OY7?',<4'(8("G;\@`ST'_#T^^^^9.X4QD+
M'Z&3G?>0@7SS9XGX/Z551'L32:/>1(:AWI6":2/W65N"/;6G^U]UAIGM?H7R
M56Y0.\=E]M"7%3?2.$P2?(V5&IEJ!4)6+T4W6^UYV>2G`VX+YH5+?+)]6\N<
M&Q525JP2'1EG!O68;,8R1Z:CTCE)I]W;:_2FM/?%8UG)#;DK$<!5C9+&VS2"
M.^%:DMXJUI%+%JI!$%VE0@H#6R&(F+HX81[^@TG?\[KM=#2_+V29`Q&DP`+O
M=#1%S01[_3I)OA;9Z&0!7P+!;$$ZJ@=_@FJIQ$+#KL'/\E7(<7]J9;@T(>L*
M++#4)M]Q$+J77H'9^X62[E3)`&>#]D86>CU"`'3SJ!)N@'HZG%3]B]:7EQVI
MP>C`ST;?O'C@H5/@N@Z)0W70HRIQ)25@T-NH$%8@[*M7G5!"JAA?5#:5_/;Z
M1S3]#^F/>W=._\!E%BD3;[67B6+?$UUCX<:V1$JY*Y&$T"42NLBJ[N1VPUY:
MJR>)P:3MQP+6<#/,=^7+RB(#HS5UP*2CS&6>4_Q>-'D)UIO![3ORZ:B2*N69
MS6N-:S`A;!V4].)(;.)(+QP<C8-!KW(^;QN\?K_"C@(+O_8=Y05&6&!W%*BK
MB!+&[1ZH?3?%Y3YH.-S)1/_FJK_64R9"GJ#>;%=F^]1N&\%U*_,0N-G/68E.
M$&3<"_3KO`>0GEL[=)KVTB9=`OQ4Y">HWTL5];]_S79@!S^@%E6F@&_@SWQK
M=SS?JF%V/,MJ=\K?I!QX[J.L3@74@A#G'B#U@-^J/=^?=F@>YN7*T7)QC:,,
MB2V%1"]_I+%V6"H8-QE8K-P.VA=9VY%W;!N00[G?8]C&M*FGG8I[3O%C4\N=
M3=Q@<GN]-M>TC!358_8H7S55Q6/=E9+GUKUKNJ*7I/9E`,6C2-8WF+<!1Y7>
M2N]4NYE!NQS"@7O%$6[)Q6E`0HG#/5`>9@(!$::Q%&!G!'C(4Z]`&`;^.S`F
M(J\`95'H%0A"B)(>@2AED5\`HK\7`^2R0)]/(+KT",'\/$2<"O\=0NJG.F(4
MLB>?`,4JUB<07!`0*0V]<R$2>(97(`X2+Y,B"KB7!\'3Q`\RQ!.`/@&61M[I
M%C2]H&:0AMX[\!3/5_D$DC3P:H$6+;P"$3H1GP!,AA\D3Q+_(\)$^+5@R04>
MH/CB7H$@CKR/``?$_`()GD?P"<21WX&$4>*WK%`D@5>+D"?,RV08QJE?@*6!
M'P--A%^+(!%>D"Q-F'?!L"3Q.U(6XUE:GT`4!_Y'B(A[)XOQV#^;C%YPQ2P`
MZ_4)T%3X'0A-XM#+),7`Z16((K_A0`*3^$%R[K<L<,07U&20'GL%X!;>Z:8!
M5L(>@90EWAN`4?@C-_,#B##U]?MIOP>D_J`<TO#"4KJP4(+8T^_.>8-W24#3
M@R(%KO;Z2N"5ZI:7^ACY;[8;ZRK(^9>68PD_=\2RATI85`:@!1/*2V$O'2[3
M#Z&'!<MPJ:'I&6!.GL.D&V#"`7-HE,`8F.X'PP'[7';4*(0!B3TKK\K+]W@L
M]`QUG'*#T(`=PE("(X2FG]+%4ZJ&GGMI[^2%FU.#<8A&3,VIZ8>"8C%U'(N9
M">KX&>I$)`Q"X2:W!TL)C!":_F@Q<VKD.>:&-AJ#-2L;Q2MEHS'X4&T6^G)@
MH]BVTD;CY-R6R=!&-2H#T(()C%7HRZ&-8B/8*+B0Y38:T(L++63<`A,.F$,C
M!=X`T_TPQ4L)4T/%1<9"T%@#,QB':*3`&)CI7V&::N@Y8$.O9H!IC$,T4N`-
M,-T?)1#L%CHUCML,O?>(^OS<^Y\+/,HU\?+AJQX6P;IAYN5/F.*[>=RW_H!'
MZ![?[I)^U;.$91STPA@M]?JH=VL]3EM/@)F+(>M28#P!IG^ETYZU,C")TL"H
M7;(]-%+@#3#='RUW/FKH95OB*;/`-,8A&BGP!ICN7\.8''J9,>'<HL$X1".F
MW*+I!\:6+CDHYQ?:TE<\3&"P7V)+7_4LML:6,$CK"1#._?=8EP+C"3#]ZZ+X
MG!4K(Y\0)HH+8:(XC#>!4UT.HSBTK8WB^ES?Q2BN4!F`%DQLXZ:Z'$5Q:%R9
M:<?1N;/YHRBN@0D'S*%1`F-@NC]:GBTR8"O6AR0N?VXVBNH*J,$\1*<$XHFH
MC@RNC.H:Z,6HKH%IC$,T2F`,3/=#\%M<J@@'+-@R9AR1/%_@BWP*I,$[1*8$
MXHG(MXX].70.>^CO-3!JI[6'1@F,@>E^C'Q+JQ7<`%NQ_J2'U4`UYB$Z)3`&
MJOO71L(9#`KG6@S&(1HQY5I,_PH&!0T6KS\9#!1(X=Q,#YD2B">B!8)<%RW.
MDZ>^VL=O^$/Y"W<DY7!\6Q7U`\&##1"F?8HM__NZF)LS%HQ3=Z8YI?I=_B?W
M9MX>(W7'M.H'>>Q[G@+2[0-2F**!`F_;ET42?K8>/(M$J">*$9!Q\[+R;P4.
MC#?PP&C,2*]]<0A+>W,:RL.+:`#VL^%YR&2`P3FA0V1OVY?%K.4<R6"$>\TC
M(*YY:8C"D98AO27T;B88KHPM&M/2:U\*)QY,&&4:$0<,\T#)<#8Q5V_;ET7(
MY7,E0Q_2,`(R;EY6"J[`@7%T8IKZ[0M=)0\=(RG;A@%^9(Q5#]T(]57=3&@8
M.:<FZTW[LF"\@J2434Z6:UY*4<JF*9II7/C9U^2L]=H70A)X7F`*$OZ#'_-0
M"1T41C2]:5X6_L].UZA8I+98I+98I*Y8I/UBT0W54KV4P*4*P_9%J0*S!R!I
MHH[VO/]?]8F[K[*DKK*DKK*DKK*D\:021FPR71BT+TL7V.6T5<9?Z@I/*D9@
ME<`9W%IL*KGH-R]++F:@E@%6H]8*#*$J@3.HM=AD*J+;%[^VBBSNX6'AMZ>%
M+SSE4EIAV"&^`IVZ`IV*$1]*8)H:(S:9"]'U]?N<*>7,XM8J#,$J@3.XM=A4
MYM1OGH\:1\Y`+;,'C9I;U]6#J@3.H-9BDRF6;E^Z$%,Q=R%>>LJEG.G20I0)
M#75['52,^%`"T]08L<E$;]U"'(#V32EF3M1MA5`Q`JL$SN#68E-I(5U30<N1
M<U!C9J11:P6&4)7`&=1:;#*)]"\1;Q+I%J)+1\2&3U1GHPT>ZC9XJ!BA5P)G
M%-%BDRGGRF6#0^=,`*9NU.W_4#$"JP3.X-9B4PGJNF63LEFHA4M;C`)#J,*3
MMABQR2QVW;*16>SDLH%KWZ86=9M:5(R`*X%I'8S85,Z[BGGA3V%\.T813)I*
M@?%JKZ\BDTCJ2_L/8)[?/$/)J<TSV[XB(P[LYIG\G%!MG@D\07]V\TQ_G[5@
MVTQ8$@P?5G=N\E)]>8D&,PI?VM!13FW:U[S,"<Z=YQKFU$8-X=1PV)7`0(W1
M8.$&"S<X<H-G+04S:B(_'S0OR\]G'DHQ#&@RAFHK@6D&5)]P@\5(;24PCP$]
M:BK7-^UKMAV#K]]VA`Q34V38&JJF!&9I:49-I>W#]F5I^YR9YLRJH36RV+G)
MA<_.M.P3;K`8*:X$YG&@1TV4`+IYS>9IX-\\'=0!A@9N_7=/=R4P38/J$VZP
M&.FN!.;1H$=-U12F?<VV;?!5V[;4N@-#U%`K)3!+03-JJC)8N=9E93!CK6,Z
M;-2@UF35)3?I]ME)EGW"#18CQ97`/`[TJ(DJ8]"\K,J8PT!"+0.:C*':2N`,
M`[)/N,%BI+82F,>`'C55L?B6^:6*)9C80%WHV#'U-AQINH:Z*8%Y:NI14_7,
MVL6.]<R<J88DWJB16H^F+KDI$LY.M>P3;K`8*:X$YG&@1TW41KIYS>;]U$2?
M<^["I:6&E:'^XFU:.AHLW&`QTE^(V:F]&355<*U<];+@FB)COG?'\DK3(URZ
MVU-+"<S2T(R:*,?6>3;AS5A5643UMS7+-]N@C`A5J9<D6[A-JKC[\S=\"`?P
MYB'^?X?BJQXB[$-ZWPZ,OU*FU/L1SEU*O1_YW%'\!\Y]`I<^![T+4^']#NJ.
MI['WN[B[*/!_>G<7!['W4Z>[A#(_R!2_?/'R$`31>2:!ZX__O+VYO?E_",58
MO0T*96YD<W1R96%M#65N9&]B:@TQ-34@,"!O8FH\/"]#;VYT96YT<R`Q-38@
M,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O
M>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S
M/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@
M,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T
M6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ
M-38@,"!O8FH\/"],96YG=&@@-3`U-R]&:6QT97(O1FQA=&5$96-O9&4^/G-T
M<F5A;0T*>)R]7=USXS:2?W>5_P<\3-7-;<DZ`B0(XN9IDDRJ=K?N-G<[>]F'
MO-`2;7./$C449<?YZ[<;GZ1$PB1C;4U-1@*;1'_^NAL`E>_^?GOS[?8F6J>2
MDPC_J$_9FB?Z/YO=[0U55RAA*:&I&F$DH6LI64:R"*Y$3)*FN+WYF>S5LT3"
M\4$\R_`?TCS>WCS=WCS\`1^%?SH#T3I)8IA@G<0\AG]BR5C_NDPX7I>QP.M9
MEL;##V3D#NYE)*,1R40$#T66'B:1?#/7J+O&J)?HNZ^W-__Q8WZ_`?EC\A7H
ME:;4(ZUNX$X:Q1GYND.>*3R*?-W<WMR!8#Q.R->7VYN/ARK?%+MBWZ[)UZ>"
M?%_OC_"%Y/LM^3DOGXN&O.1'<CS=_Z/8M*2MR:9HVKS<DTV]WY9M"?3DY:G<
M/)%ROZE.VV)+6GA.4VR*\M"2^U?U]?MZ=\CWKZ1^((>FWA3%]D@>FGJG+A[S
MJL`K_TZ^_N/VY@L(]C_O)CV*K*2/,II9Z>.$"2W]7XNF+([D._)34SP430/<
M`R-Y2ZHB/[;D`UM'9%=6%8A)3OLM:*,MFIW2Q['-]VV95]4K.99`DS>H'93G
MJ:Z`\@@/<H\_N,>#,I5^RL>G]KB""^5S616/0(4JUW3%?@/?KZ&.*+'.D`GN
MG"')C#,`RQT!B)?@LU?0N)_4IVI+GO)GM/[Q5+4@+?A)OMD4!]#5ID!G<,\K
M]\_%L:WU+)MZMP,-P_?-_Y.'NKF"[#(35G0EKA$=XD.+O@4[;(L]^"4PW)S0
MC6NRS=OBDS)YN<_1UXG1$#A_6^Y/Y?Y1D^<57G'/^(0.4C?;SEV7BB1_5>+"
M-`->J*]=00TBLFJ(I5=#9-7P2\0CM"D&JU7$_:D%YS_DY7:<4R<Z/("BV5%+
MQ3.Z"`84J<IOIW*KM+$"XN.QKDY:->`X)2`):/)TL.HU</&)%%7I5'\%90"Z
M:V4P)KPRA/#A4.\5-+4O-3D6>0O>NN]R^&^@BSIO%&K\4`+HH4=_4E&1X[WO
MS#.F&\NT9&@V@+??@-.[=Y](N(E`)6A3HQTJI59.6^X*R`W/)80^FA@"XIV9
M2,`._Q)I$Y%U?`'PP>?)6`J+#\9A-7+WL,P'@T.U]5)W34=X%,SS^/&]'XZQ
M$)MG_\*2Z`JAAG,;W!'2)6*)60C5^\<]^;&X!R!M7@F#-+4Z3T3X=4#A]0/F
M2P76QZ*J?.K.HE\BJ/C,G?6IQ7RM8.;XE$-^&L%DD\)->*^N`#H9!I!Q-%^2
M))$%'<0.P,__RANHJ;PJ;`6%EZ>I!K"WT#X)0N7O+4F2\:XH//+XF6#1A:+\
M;[$M=@<5-9\?FT*5F<`MV*A;('2ENX*Z,V9Y9)EWO,S&-6@(&%.)O*KFNLO*
M%+VN#L`"#PQDLJ6O*>"A38&I#XN;G&SRXQ,YY*\[DQ\_T#5W=69YC527I5SC
MJ%C+5#"%HZB'5!@X_],),AVZV[LC%]Z9\&N"2\9LCQ/QE#D;L\C(]OU3OL<*
MVSC;0*R@6?#2:Y%#3(')8.P':&%V]Y#=8KI"S7!E6E01`8_`0OZAKJKZY?B?
MU]!8E/T^C8F@QCBS96"44-<(,$D-'%.Z-H7=7U3\'M_?:$EF$VX4)YX#8;#C
M"P#[IH7&`I!0I01ZAH/;^M":9O.'UWQ;;L@?$?!TL9A7*_BZ6:L;R1>H/=M7
M=6NQ/^IJ\J<JWQ.L=O$!A@#'5/VJ6SW=UM)5'+&5!.RX@@Y2EQ5Y[(L.RE.M
M!(\]O0[I!<`$(;1HGHWO0D%]PA9K#5*#?X-FE.?J]`&ERDM3MFVAFG9LVU9O
MUK#*U]5L-M%<0?I$.B?T!68<&>'SPZ&IGQ6B(LPVD-8+&\+YJ7VJF_(WN+H_
M*5&!^1%MF;Z];V:]^N!M"RF2KRAGJR01:_(94@%DKJI^+0IHTB'47["XN((*
M8I>=*//K$P*'E0Z.9*=,>3QKC<:-]N?BE7S>/I='&%"L;XN'<H^Y"E$+&JK'
M\KXJ4.!#WK3EICQ`DVOUVM'0FOQM2''7*(D4!)D^+'$Y.LG2S+0:G;C?`1J@
MMR/+&W!E1`AMYUHCE5+"OMY_@Z:\?"B+[=EE%/P$M15ZT[#'K(C)!I=SOK_L
ML;2YBV$^L"UHFH00`,#Y!-"D+T(1\J#9`QLCJ_=%=[T.*-JFW"CAM3^4QTU5
M'WWQU3,ZX$>^U0M[JJB^4.T55)!1WWKY@EB:)0G-PF,#'>9Q=1''N4K!+H%;
M($2-_50T,+Q37_^V+UME>[C%1C::N1,M:_(E!Z6>WP7B'!!K]ZU>N;N"_*E;
ME6-QIT1-C`^HCE.;<E.@OZ/8N_J$.(X+L5A,8@XX7YGH^[1"`KV4A6LZKUB&
M`@'FA6(2N-AD>04%),*MTB8N"&+.3#7RO>43DS/DLQR=URS$/.?5R?%_;CL5
M&N#_^7U5'I_@ID.'X+'.JZ,"Q5W17J/JC9FX9M4;4U?#2;]B$7/I6^H_Y7O;
M47/P`&B1<=4>G`<J7-V,U1<!A<O]+O4VQ:Y^QNX&J50($ER1:]VR)HVB511%
M%B%6#E*;@?![?QTPZ8I($;LZ-H:V1NM`PR*:G>`B([1CN%2+7S=Y!4K(&U7R
MG[,+G\L:T!0D.>@JM'KMYE*[!F[#QP66A@C\HK"R^+5H-N4QOR\KU.]5]CB8
M<#5DZM$C2:@IHXQE/I&G^J5X+IJ59[$\0J)43E#\BGLR8$W=`2V.AA"?L5_W
M2'VFBTR._\O>-UR4KXS+(JL#4-2'*^^NJC3<;(JJ:)R'XH(<>K#-$">U1(=.
M43>61K7^G9[_"M(S5^CQ-/:5?F;$=SEIM*IY`2U@M8]UJVV)5#&CD]-PF:N<
M5H4[.NW/3R56?AW-M:^'<J/VL%2D7"5$(UO<4;4(8?U3Q#W_U.M":!I28.D&
M+-6XJ_10GW2,ZN(E-TM'V@7`@:UYNV9?!4H^Y2N_ECLH>F$*NF9NW<676M?)
M<LK6&JO26+O`1V.'=YX,',Q.ICMKR$",O?<DHBL1V-;U\&EFV]?SLOK!]-1]
M(Z0FAV`J?BJJ[=FF\7LO7*;1OT`["=1T'?4DJ4_0L<BL>B`_;$XJV.N'AW)3
MF!9N:X$.:IUB`^%+RMVNV)9:75?P3.%WR;$4LXPF)HNZ-%85.O.9@0*WKS<^
M9G*U9G/1<36X^J:!ZP-=RPCC\0-?0^JVB]G8CV`0J\>=H?M[NVTJG;S7#(ZX
MHU5&$P?Y/!&#T4&NLL-)N6XM9+IF&1=VV9<RVUP-Y%PL`,%.@J_?OR2F<7+-
MDIA2VT@P(5S$<687%=%W(1,<H/MU/FOS!KBMS26H`959:UR_AYRSK_?OO<$*
MU:KE]KH[N5!V==3"_.9;(NS:O^H@[XL]%+?MV0[8>\.B]$:Z(OC*M",S39G;
M$TAX[,'7+O!I&*K=80/`JE-[:O"41V?!^"K'<1R+O+/E;/-#\2O.WB_8]"&;
M&O>37A"`(5'4C_OR-[6"AST6U+"MVFA3J%P?3$ET)"]E^]07`E@00D!-)@"3
M8\6^YU.=8P."-`;80`(V0L#C2`8)$I:&GQ#CRE>(`#PD#A)0!ODU1!`Q%B1(
M)8N#/*09@&.00+PU14K#>@`?H.$G)#2LZA1,P8($+))9D("^11#ANER`@$OH
MQ(,$690$-<D%@F&(@,LDR"0'F`E/$4L6-#=GV1MBTDR&GQ!E:=`6B<3U[1!!
MEE$>)(#H#8J9I!#>00*..[,A@B2C82EB$=9#P@34("$""I$3)(@@^$($L4SC
M8&3%8(J@-0%RPY$5I[@B'R+@(@MJ$HII'B8`+L,\L(R&I:`9#3,9@9PA`B9%
M&$@99+J@%$RD:7@*N!XT%N,B;$W(!F$H9I3RH*)8Q,,`0F4J@YJ$=C<,8A04
M&71:FJ9)D$F0(1Q95)U.#Q%`!Q?F@3$9-#=N2@9M02.6!)\`)5*0QXR&.1`T
M#=Z?4AY&>AK.RDDD@_?'4=A3&)ZO#RI(!*Z[EP"2"-P-RH.=*;H$J4Q]1O&3
MNJP_FE<,OKG+,9;4G5<=)G9BPBP;7W9B':ZHX\HR:)D!J*HL@>SS9:]#7<S$
M/+[4K>;`UB5CGAXJ`,<8]8QY;C3!.6/F.H6<!WWHK#,SB4K%;I\R3OQ*ICM"
M-7;$^W++_'=Q@@XO$GN:*TU3=YJ+0JVM6?GOFOR4-^3_<'-LQ+@<"W^M0ZO.
MON(TP9D.[?5TML^I.\58^W\6"C&UH1!3&PK0,5OOTQ_[H0!C2T,AB::%@N;*
M,NB8B9WSZ8]GH0"#2T,A&8M13Y^`]UG&J&?,<Z,)SADSU],ED0"`QLUIP@3\
M#SMJXW_J$)/R/W<H9]#U%\[,8&;W.A-+]4J&.2(Q9K?,J\=HJJ\337"N'G,=
M[#;7G_2M8X?WSB#,,)9YQCPWFN"<,7,=ZGXZY%`![?&(.<;`;CQ"&^**TV=U
ME""$$II-RW&?-TT0#Z`$&GD92HRK3[]JAR_>Q>J?-!'Z=K4(T`6`!P<,=GPD
M``,+-,*L(:D54^H6SJBT1]2^RRNU7YRW%Z=%8S*-<Q7GJE#H<WXY/@\ZZ-C9
M@W%.J)Z1GS%R/CR=#[J0#ZDF3,\UTAF?:4M\FU/XU5;H@_12^$>V@FX"_TZU
MEI##UKH8GP<8"[24C7!R,3Z=DRS$R;1GCR_)QL,6^#!17#GB%'*Q4W#L9(=8
MHG0EA<"CH1.]0H$6,M'G[6)X'@J.6L*CLUJYC`=ASXW/A[W4'4F,F7`'\E)L
M:!7J?=YLFL(>G7`'[C;U\?R(3[^H0XZ&4*X_/@OE+*=O56XXQ0"L]89GP=JT
MB:6:80C'[/A<'(-^ST[=WS6ZV#::,$L(D9R`HQ85<MBB%^/+Y@TI-AN9^F)\
M%O1-FEJ.V%0NMBEG:=>F'1A*5RF/Q^HR;B:\A)S>\"S(&==`J/!*H:D;1"`[
MO@"!A#TKQ@3/_#XNSSP"X;D^]X+5]%H+N1I$H=[X/!0RW,ZLM7#&(5#J#L\#
MI25\2#7A($:9\24893B9@E'A68)88>6=4;P-FO]B?!D;\XJW04XNQN<AV`).
MY(@#R,4.@.^6=1S``UK,HU6:)=-K*L7``,!UA^<!W*B"^C45Y\.(9L<7(%KJ
M7[@SAX&ZK\>>1\;OF`P]TDP6/ECR.^;(8C^'6#.)[P'K)2"6V!^6(>Z-TLOW
M(R=,/;I>ER1N[O'B!%$9)A@$^M[X/*!/IRT4XA1#R-X=GH?LDR:6:H9!*.^-
MST`W/FUJ(8?5?3$^#UBG3)V-3'TQ/@])ITPM1Q1^,3X#HZ8I7&$9T@Z`8W=X
M'CB.3ARL_N)T&"OM^`*L3-S!R8RY53<N>6)_5N"Y:([Z)W=.^UQUH_@V6Z`3
M#9>$P.H@4O3&YR&%$6%N20@S#@%'=W@><"SA0ZH)!W'$C"\I"0TG4TK"\"Q!
MR+#RSBD)A\Q_,;Z,C9DEX1`G%^/S@&P!)W+$`>1B!U`]KG<`7Q(*OHIB.:,B
MQ/D'0*\[/`_T1O73KPA!XD&4L^,+4,Z_$91T?HLMLR]$=5$.,.ZT.U7JD++_
M49%0\0,,#4):;WP>I+&Q??FSX@>F&,*P[O`\#)LTL50S#(*6&5\"6F;J*:`5
MGB6(%E;`X%K;D$4OQI?-^U9]-33UQ?@\6)HRM1RQJ5QL4QZ)KDUC];[Y;^9G
M[]@*[+A*118JNG#>`?S1PW.YX7+8P_`UY^GE"Y>I.2R!G_1AB32*[/D$\]']
M=&F@E`/*#IAYD.N/SP(Y]_)?)/RO+W'U61V9P;U[THPTPL%:R8AM-5#9CYD]
M_V`^OB6XO6L(+OOC\^`R&OL]-4^/N&'%H%X,VA%#3A;#W#4`O;WA>=`[10C1
M$4)Z(1SGFF"B$)IT",;M^%P89\*),1#R9OMW>HUF115>5"^?)I@FJKEK"-/M
M^.R,);NBAO#$6T]ZD3(ODI=#$TP3*1L1Z6)\7JZ8X(0(I58,Z<7PO&N":6+(
M$2>4BYV0@R7Z3N@M$U'U]BO^G5@'I]S*:L7N"Z@))LEJ[QK(:69X24Z;Y(/]
M@I5#"6R2F.`FB7$A':R+[CG$7FF.EX:RUMGXG*S%LV3QN9]DM(BC3DHKL!/.
M'5\U'R_DM&2#24HLKNGYA+.V"GL-W]3S33M\RW&^#=E05A)+&X))7(L.U])S
M[5C5!&-<ZVN#:4@L[B8LWQ.ZB3=F"57U3CNCCIAYU0BO&J\/33"B&D,VF+86
M.F*7Z9!)I><[\WQ[9C7!"-_9"-^=\;DFE3V3CAYIZB<I(X#T`GBN-<&(`'+$
M)^5BG^1\ND^^/4MHE>5-GU0I2ZO&:JFO#TTPK!I+-I3$NL/+6)ZQ<(:(RIG-
M8_#)Y#'NVQ/]<4(SAI1#*TYN?$%:2^GBM,;G=&9:!U8=3O3$)0[]<5)GQM5N
M.*/G2<^,1PN2WO@^1S_I&3&H%X-VQ)#G8IS=[#,F]QF3^^9HFB?8NX82*%^Z
M*V`=X<T$:C4@O0:<V)I@1`.BHP'I->#$U@03-:!)!Y,Q7[P?874P)1F'9PGF
MM73F?D3FM2Z\UKVV-,$TQ9F[!E-U;WR92&^E:B-&YL7(O//(@/-([SR9=QXO
MN":8IH-L1`>=\25I/QW8RPBF?:,,Z97A-:`)AI6AK_F:@?,S#6B":<J0(Y$D
M%T>2*B$F1M+;LP3S\<Q(4@6#UKHU0%];FF"2XNQ=0P4&7[KS-!Y')M'K]T;G
MON:#_U>75/??609Y7NBC.1]_?+\IDHC:*=X\8;1X"FZGB-9Z<^PC.UL_P)]0
M"+UZ>R?#K_;>05D3?,'ZCDD9?/OY#C01?!O^CD?AM^'O4AI^/_I.T#3,9$:S
MX*OJ=Y)&XZ\@@R*__/WVYO;FGSTCEO$-"F5N9'-T<F5A;0UE;F1O8FH-,34W
M(#`@;V)J/#PO0V]N=&5N=',@,34X(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W
M-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;
M,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@
M4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&
M86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E
M0R]);6%G94E=/CX^/@UE;F1O8FH-,34X(#`@;V)J/#PO3&5N9W1H(#<Y,34O
M1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<M5U;C]PX=GXWX/^@AP'6
M"7HJXE54WCRSXV`7R>YFQL%N@'V1J]7NRE97]92JW-/[Z\,[18EDD>QN#,:6
MCPZ+YSOG\%QTH7[XV_MWO[Y_UVYH3YI6_">/V(9@]<?VX?T[(,^`!M(&4$F!
M#0*;OH>L82T_TZ*^.8WOW_VU.<C?ZC`1/T08$W\UIZ_OW]V_?W?WK^*GQ'\S
M0KO!&/$)-A@1Q/]"/83^^1X3<;Y'G3C/&$7A'X3-]PSTJ&&@;5C7\A\5(MUE
ML?RJSS%[#@*'Z(?/[]_]VZ?ARY;C1\UGSB\U)7_2Z`9`H0;6?'X0,D.NJL_;
M]^^^Y[A8WS>?G]Z_^W`:I\=Q>V[.Q^9\/TYC,VRWXWX\#>?QMCD^GG?'P]1<
M'H\'<;H9;A6I.=XUGW:'X;#=#?OFXW9[O!S.N\/7YI?S<+@=3K=3\\.1_R7^
M?1X?QL,Y8\2?CIOF7YK/__?^W4\<VW^_F@+X(*&`OMMTW'<^_U-J`'2=4@"`
MJ/E[2]J?QV^[B6.&;8OYO\%-\\O]<!I?6R#<S22"&]RV0(KTX?O7GHD[J)V)
MXVT[:WU$Q+$`_\,@(/]E>)8F$FIX92D@;IT42H`/?X<0O?HT=*96NH&@`];2
M4!P+M+]\^O@+=PGT\RO/CEH:`HE?>QK/F^$&T98HWQ'^^NIK!\'9=%R/+1"1
M1'D0)(`M=-KLIF:\N^.Q9/=M;.Z.)QDP[G:GZ<S_G+9\U3^/@Z`.Y^;+^'7'
MX\IP=QY/S>_'[?CPA1\`<B.6'_^3AX3F:;??OTD\:+$)B+CM#"(BXZ2*B+]>
M=J=1";H]/CR.AVF006_\31SS*#A-1Q[&1(1\VIWOF^E\W/[#!LLO(Y=I>_QZ
MV/V3,^Q4X)Q,')Q$(#P^B@`KN&\:?G`_2K4<^`]SQ1W/A^-Y;&ZYSO;'Z<(E
M>7TE]*PS<0&VR,:%3AP+'6BI?^3HA\/S*\_?4SL_MHL%OC9(7@(XE'PQ$IO[
M>H@5RHF;]S`=][M;:<L[FYZ<M3;-9ZZ'<3KO'A3/Y2PLDN46\7PJ7>L-K-JU
MQJJ48HL74(WWZ7C9WS;W`U^?7\;Q$'#3MS$XCQ96MK>S."1DIH$6$NO7L$?0
M6#RV$%6-LWMXW,NS@ZERO/@V/#Z>CK])5]@_-]^!#6H>>)3BK)OF(X]6NCAZ
M`\L*,`H7A39F\82@BYBOIT$@>AANQX8+(,*GBJU_'`Z7X?3<`!E9J0JJ7Z17
MB@),>#2/U-SZ@G"ZY?X_*N>UN#>5:&@"#5)HN!?@URXXQ,^+N<TR@'89V#+@
M8S-='AZ$5KA]!Y&O=N=G/LM^D`4IKX2U.B^'VU&EL9]X2N`\?]D/2KF:@8^G
MY*;EH<:N[&-S.!Y&[D;'YW&<FL?33F3"X_)7?C>Y6OKU-2"K>YVU.ZK\Y</=
M<;\_/DW_7CM?PJ"LZU]LT-C/,]P0]J;^0JCQEY8P&S91RW38_$5ZBPZ3?+D\
MJ.`@E\FL?3(N<+R<)]'3"%_B8=Y6-TBM02(#B4CTRARO;PV$5('SX0T\"P&;
M4MO6K2T*=$/Q^\M)X.8G.5JC$;E:N/:XDLI6QM,H<JT(2OL]'R]6WFE\W`];
M_H\OS_-%]W@Y;>]Y,]-,HFF3*U/\[ALHH&VM`J#+L13K?EIGT-^)VN+A@6-0
MQ>'=Z?@@)?IT$C7&M#TVGT^72?5<TSCRYI?7?)TJY#]>SO?'TTXDH6\V5`NU
M[G=GD:]$!:*K5%U+3)?M_;P`/9]&67`,XOSQ\O7^#30!F<E)$/6NCD9`+QN.
M]EE9<.D'W'2S8J.Z<4DL`4C?-&*(=M.T$-VLA>CU*O@HDRFWV/[YQK?-($UW
MM^<QPU5=PY<CM_-Y^++G]A1.SLO2[>5T$CVYJ23-,E"Q1ZV$W31=9,;FWNY[
MP//"U]Y`!;`W*@#`]H6XP[J#D-[-&[GF,#XU#^,@&AEYD4'4VKP&G50)RBMK
M#GLWW2MM/-WO.`R^GD6!?3E'"FV;JH\'7H;)$'*<G)N9$'%CYKU]"_S\?UUD
M,.("(2:ZTI0K3W1QO"7FAMR*DOO\)"#+MGC8G7BU=OK'>&Z^#?O+:`)69*DL
MHX:POZ"/OXTG3A]%--WJ'YFI@H>2>:WS!LUT3VR'U=EZF[90>X'TRC,7?A)U
ME@#VAE4(Z$ADT?.3':]1<-/U;8/D#[M?D!=L.4.'&)4,,,)`$6))!@+[]"]@
MT8:F&!#D_I-BX,NN33(`2-(,+:1)&6@OEG:*@5V9@G8@K0=*`4[_`@%I55,,
MN(.D&&1OE&*`UQ@`@$E;T!:T20;2MS2I2<):E-0#H7V7%)*0'J>GP#U)FIO(
M>QLI!MC#]"\`UB=M05K6)U'@GF&<9."+-PD3=ZQ-"HDIZ])3\-(_B0)CEM8#
M1AT/7RD&V)'T%*`#:8:6TN3*0CU-!Q#$6'IEH:[KDR@092"I240ZEF;`K$_+
M@!A.HX`,IX4$K$TZ#&J[=""%?8>2*""C+#D%Y`DC:2Q(N[0U(;H2BB$$+*DH
M"$@Z@,"V@TE-\E">#F*`T?3"`1WMDD("BM,K"Q"4A@GXVDO+@!!,FAM`!)*V
MX-F@2_\";P>30O(XF_P!!OIT[@==.B^#=%HF`*1C:)MV%=32M"N!-GF>GTZL
M>GL[''$I&2+-@U(*/]KKHUX<J=/R4-]L_]6>YHN:^VOYU2N,8W6CDXH'`RV5
M$=`*T\E#R=#Y<IGS@/!P42:7'$I`1##'+V[$&<&TC+XTBF$IF#X/>*3F?Q5)
MQHM8+EGB@M_5'^_B/066]C"ME;IG\T%<-8O8A2!HX!M-^)@5PP*^.<\36:F_
MR*%:P)1=.OX+1C!D_7@FC6)8"J;/U]B%\CHN:9>K/YZP"Q5=6<`N.&(7D54T
M?*,)'[-B6,`WY\N7L1P9-8L?73J>3!YT4PAU=.EX[[<WI^DJN@A:973I^M@B
M]J.+ELH(:(7!9CWK0S^Z""*/+ER]Y=&EC;7+CA\[=1D9?6FPD]&/+H+("$_^
M97Z&1+?">O/`#N&5@WS"X<_J@D9$?Q@A(R9V^IO)IA@68IKS%5%`#8VM-3\Z
M&\&TC+XTBF$IF#[/]4="ET%2\9.W@PPB>_>'$'W#]:_C[NO].7`I["63$;Z&
M6VJ,A7JF'J_Z\/';>!J^KB^_OV0NY!R#X^K%<RGZ1@V&^L;>3^9JV%_$U;!$
MQM`F,=;Q[:`8\#IC5/J*&GK=5RA?*T8P9&/33!K%L!1,GZ]8:X2@BK5&$3!B
M&HE]V13#0DQSOD)_:NAU_8D48`33,OK2*(:E8/I\A4M2W!6NM9=,Q@<4K;67
MS(70ZZPUV5LJDQCK^'90#'A=!<A+"%550,)5U'.ZXJE=)/\2!I3#Y<7=>8*_
MLXG?T"/%6.+:>$?=@[?\9^T=$J#O%/[9W2>^40_$'>0]C3OYG%R>Y+($X&=X
M">!)OJ87E09&]`(=RIS/SRQ4N"+GRR%'ELLA+D:("=E"D!F]M";I\,R8J(?*
MF!\8D,]^Y,F%C46P+]>:7E:$E&M()N&UI6;DTIY-CF1^;_!=IC#B1D#`7'-Z
MJ3B]9RX`M41X`V">4#)C!VRUII<5`>6VDME];:L5.5\.!.ODZ(-FFM,+(R3I
MG$;$P\SBZI-,:(2T^<M*%@<!4ZWI9?5&N8IDOEV;:D8N5)`:&5!0YM*BB`5M
M-J>7BM23L$AX`[L\J62*7JMI12[+^5%SN5I$WG_%X21OZ(7J$)?WL2V3`%-E
MTH?_4/?N4U<@,`ZG;(]>EK)QK.Q97&;`.)BC<4V]I49F3"R2KY@AE)0UO28I
M6^6[I-RS]H:Q/G:AP"@YE(5Q_:6`#!W(++E6_HJ</[$<F3&Q2*4!Y<_I-2G6
M*=^F6+2!--9VBP08T/R:7I93,Q0@<]Y:\RMR61+-FK@/:GY.K\F:>FHO`O.E
M=$/:F"0RIP6TOZ:7I<D,)<@TMM;^BIP_L1R9,S$+:G].K\E_0>UO"(OUP"(_
MK?&OR&4)+XH_V>3R=1K,?X9>D?]0:Z\?8?$&U3]GUP9N"YI8+D(P(WKTLHRH
M12MM8L6]Z$""G)/+$F2%'"(OB@E#^5+3BV^L`6<L[[W3U8NGUV:YE@P-WJ:@
M,Q9F#N5DCUXG1F%GO#;_BER6HBOD$)DY8/XYO?1:+VASS7]MEFL9N=#\<DS`
M_&MZG1B%S?;:_"MR69U0(T<?-/^<7EHV,,_\")C$)5X_Z`HN8\FL'[#6G%Z:
M5,70D&N*ER$*>N^UY5;DLAJCW'*RM`A8;DZO*3EFEK,E!]PP5-!RK[6S(I=5
M(%'M+%K=%IN;[2TV-]M;9N]OJ\/5OAF::U:5N&K%IQ=5*\"^1JG?9?_PZ7BZ
M&W>)=EUD<(7!P+&B4WLSO*5!%(8M6-EX]++*!EQ_+D@F<2VWAN`+JQ@B<FNV
M4!TT)Y?501E28^<Q!H`O*G:*7TNMV8)5DZ877V5HK=SBE4!H=G?@81,@=`-)
MLMU72+#SFYGXBB&,Q+`%2R)-+Z[_G-]<B;+.&J(2T!@T'%]PQ1#!H-E"Q525
M#\F1&3XDL[^66@/P154,$:DU6[#TJO,A>;'$^5#\?L3BBH6"8-#X<BN&,`3#
M%BRH/'I9096C>F27KX'@"ZL8(G)KME#Y5>4P<F2&U+(`,5+W3FHKJF*(2=T'
M'69.+R[6Z'RI(O$VC2W6DE=YD(WY!I,OO6((`S%LP<HN$7.N57:%,4>62AH#
MLAE@)KABB&#0;*$ZL,J%Y,@,%Y(5D9&:.:FMJ(HA)C4+NM"<7E,USEQH=J,F
MFK'DLQ@*@X'C"ZX8PA@,6ZC&K-*\'!G7?.I:$F5`EYSB:*^/[`/;^M!NY1:_
M7B8X0]?+++W\H1#:V]?',9MM22..5P^%C(?;PL=!>)FET1M%6-#(U'_Z\!I^
M,TH\NPX6M:NAM^6U*\UXDDL4;`:&1N3+KA@\&(O!V`W&;C!Q@[-\P(P*U,$>
MN:@.-BYPK0XV&M#*\&%C9].5!M0Y[`;C!6R<OPK,J%!-;>BE-37%LV6`Q(2R
M'@(WE,(;BOK\BW5:1=CY^@R:8LA":4:%ZFV?7G0),LO2O+`T,#0B*SLRA6O4
MTO(<=H/Q`KABR-.!'A6HUS6YXK$@9^?P8T%>T6[4H#7B8U<,836H<]@-Q@OL
MBB%/#7I4J`&H='C1`,P<?G:WE&9>WQ*5K-:.492/2C%D`32C0NU!I:_+H1F^
M+FIB`P/9[*P.D:FYHT9&-JJI$7@!7#'DZ4"/"K0:=7%=CLS0@*B(K09ZIP$+
M6S&$-:#.83<8+V`KADP-]$$WG],K;DT;'7@U9]%SDJ+BUAHRRO*1*88LD&94
MJ*6I='4Y-,?0R,8S@\C*CDQO$#4TLO%,C<`+X(HA3P=Z5*`E2H3U*X^E!<T<
M"^VBDK>J8$X5%K]B"*M"G<-N,%[@5PR9JF!!GY_3*_JLH#+R'S857956C]&4
M#TLQ9"$THP)=6%U<DR.C[NY?Z*:$F;:+,--V4?LFFSX,7>D7IX)]EJ%7]%G4
M[%/6MFX/0$@H]%Y?$%LNQ?LL_X*XQF>@6EBM[2_48?`N@#@7[*0TO::3TMO6
M7>VDM-P:@B^L9/#D7@RFK@VCK@W39I4,8;,:ME#K-">7M4[:JE=;)PU9H_=Q
M8F>U<.M$7=]%P0(G3GBR80OV2II>TRM95Y[W2KRHO&GCSSF*VELI`3M_G0DO
M&2(X#%NP&_+H9=U0CO%$E:WEUA"LL*TMZF/&D^=<*T7!`JEBB(#6;*'V1Y%K
MVA]KNISV1^/6*O#!2H8(;G7.]4X4+,`JA@ANS1;L=^J<5O8[SFGG_4[TZ5`$
M#7ZC"E]NR1"!8-B"'4V=OZJAU_U5ELM:;F03GQ*VM=5YS&[(!ALU`BR0*H8(
M:,T6:F&JXJL:>1VRK(`-Y-Y!MC@E0P2R.N?Z'PH6.!5##'(?=-4YO:9GT:#]
M^DV$U^BE<ED#*QT8=?BR2X8(#,,6[$KJW%4-S;`=LF'&0+#"MK:PCMD.V3"C
M1H`%4L40`:W90FU(/+Q>:T-"EDNV(08[<]@M8,D0P:[.N1Z&@@5@Q1##SH)^
M.Z?7]!U!O^7'B?L[6@%&%[[@DB&"P;"%.HNJ<*-&1ETV>5?"[@Y$[>Y`U.T.
M1+W=@9+W=_P]@US?8>@5?0<V'Y<`[ML2B.AMVO]L=H']-NSVHO>0NZ_K;PK(
M+3^]9D1N#@SR'X.3);+;I(BZ38JHVZ2(>INN7%%T%VY:-+VF:<&QC7D7?8?;
MTHBZ+8T,#,G0!5>J.N<Z'N0Z'NTBDB'+1<RH4`\S)Y?U,-'=IA9MB-:`5H8/
M&SN;AGL8Y!H@Q!:P<?XB,:."+8VFU[0T=I6XE@;=$$1O`,,%MW^4BK#S]1DT
MQ9"%THP*-CP>O:SAB5OZ&JJN@6C9A:#:)]`I+G\$6=2_6KNB$4#N;I+;52PS
MDIA1W%>\2#*CEY?GPH>BFW`E+_N[S<*HVRR,NLW",E&945P2#]6,7M5T9&PM
M)NM=M[48=5N+61CQZ*#.N8X%N8Y%+1;%D+5NS*A0#U(5'^7(C/@HZUVC@=YI
MP,)6#&$-J'.N@4%L`5LQ9&J@#\;'.;VT):$N<OBEW0UBZ(;!S*>^98&L=&34
MY6-3#%DPS:A@RU(7(.70\@!I4"T"I"/7/.%5$2!E^:JUBVPH48=V>[_,4&)&
M+0/DC%Y>7<.:`"D[`+=K'W6[]E&W:U\F*C.J\T$Y<E7'$,6D*G<B-A:&Y>T4
M3R<MLDL.X_D#EZ+^%M.%IA0?IQ%3@O)USMR<O%D@;H\EW)H]EC[:-L%]VN#V
MHC]^`M@-A7CVO1/O>R/BTQ#++Z[L#O+CEN+O_6Z\R#'#=-]\.1XNT^HS3QG0
MHFNJZRVVQ6M@KJ.$B,J,ISHY<:0Z.0)E!RI/PWDS^JL]#6%YO)%#8^WF3"H>
M"K141D`KC+PT(!E@Z\MESN/BGDB-O'XC!SMM&1%]8;`3<2:7/B^>("ZMTR'C
MN0@2\W8OH]!^4%/N'#GO9V=/+28V(=#R8Z?7F=`XI%=L]5I>]U(K?;*6HL#*
MY?0Z$T8RK.0R>N4KM?CJ.*:>7I'XC([Y)FV_N%`PNTT9NW).B0%@L/A22X8E
M`'.^HDBE($NQPK'%-Y35\A9'>WV$S(K2A][R%C2YO$O?;V4-UA\Z%EOQM:W=
M<`WB7H?3GX?#5_F-E*R]Z\3:T0`,%E]NQ8#6D4`0>?"$Y9$`=QDO=K7,RJ5%
M](51#$NY]'G*&H0+`P$17T?0#DLV8L=XE1W_=)'?-5LFCI=,)8=:,P*(U*W[
M#]<##-)>]N`TY.L".>>;[52KSY>O`S4RNDN4,U=GS87<0I@)HQB6<NGSE(K]
M&\NNKP"^WO5&D?+[?UB_L_;S^##LY!:#JQ?^7S`;%%_GL'N(7M^6\D7(Q(<^
M5`'8TTW'J.Z,?CP>SJ=A>[X,ZP\&OP@;<8Z/-TR40B92RTO7(JC\Y^YNE-=I
M_[#^D..+YNZL>XD/ES.D2]+_'8?3M+HD/%L'S*V#SJT#YV2*8>EO7?4ZZ/+6
M`7;YP(CH"X-#&<&<)^*!^T(-,N>9>;NSOF@RZEPS:QF\9"[GEB+5,?TFL\UJ
MKSE7CZUUQ3ZF1H>IQ(E=XL0N<<[,BT.)$]O$65/JY7@@X1V)D<LESIDPBF$I
ME\EFJ#B;B;VX2Q+GBZ;R$R<@U'.*5`'9=D8M1D.^+A3#0BWF?$4!*4=FF(L"
M)U?GY++"*(:57%VMK\NA10'C)9,!4!8P7C176Q8P7C177QPP1(=B+*V-[IM7
M,2PMK<_7M3`)#TS<,,;`N_A@;QA;>OD-8PQ"SS"`3=^NS/*"B;`WT6SWG]><
M@X;!--]!CJ9BHNB%0#=1[B9#LKD24_JF6Y'+NC50_/B";'#`ZC&*%3E?#CFR
M0HY.3LA7PD(01R\T/Z1]V/Z(%KS^(=NJM:%6Y+(^K5Q!2/OG\M;_DESP\`.L
MDZ.7$Y)^O8.,H9?N@T.ZL*'P<A/#N%1=V$I+<ED74:$=ILQ!%W(X<JEN6"PB
MYPJD-;!\7F)&+PVKO)\/BL3C>.:>RS@<_5;DLI*[W%Q8A[F%N5;D?#GJHA_&
M"CA9/NP]HQ<G/QRQ$@.K78+BMY-%;;PVU(I<5FR7*T@6@&M#S<BE-[7;2,S)
M7%<$H."ZFM-+19KYSG)=T4RI*`B::TDNJTRCYO+>F4(]"I:BEEY>BO(F)+2S
M+7>A0/%6.P^/'+-YTI5H[1S<LD$L#=JP4"%Z;9[H?4YLYTG>YA2_'Z@\/7)1
MY6EGO7(G4\P0*#4]<E&IF3=Q)V<(U9:&7E%;!BW:4;3:,6)V+53L%+C6_8I<
M5$SFJ`!IIPI4CW6Z1[/E>>T]3#%#J%PT](IR,1(9^MB>UZ*<"RE^22ZJ#[/P
M,Z7A0$'HD?,G9IF*9QI:H/`S](K"+Z)X%%,\#D>;%;FHTLO!CW58"91V=8K'
MF=%&U&S2LP.UG*%7U'+A:`.Z&Q2--J+6"NA^12XJWG)4((JK@.Y7Y(*)N[R)
M`0HZ_9Q>4965.KVHFD**7Y*+RK`X_N1%)M29;\N*H[T^HN;1`7V8\6Z*X)S5
M)*Z^\^E%]1V+;`@7K.\JYQ$@66#+OV!]5SF'\)$0EH9P35;,DZKO]#S9%QJ%
M;,H'C#M8TV/SH(8^O.8%9E2H=)R3RTK'[OK^:[)2TR`T'E]RQ9`'0H\*E:%=
MS><OU,B,3>1$K69`=`Z$E5PQ9()0HX(EK:;7E+1=X%,B!.&"RZ4ZT#PXO#XR
MQ9`%THP*5<M5[J9&9EA*%*<:A`N<,\D50QX(/2I4>5>YFQJ9`:)C#D3O0%C)
M%4,F"#4J6,5K>DT5'W(WL.DSW[B2I;!&V#E?<[`40Q["+NQK2W)9@Y!C)N;,
MQ)RO.<D50QX(/2K4;,S)9<U&!@CL"@V#QY<<NWQS'816>:AQT?2:QB7D:WC3
M96Z*A%T:Q2Z-SF#A_#2*PVET12[KB7+,A*V9L$NC,\D50QX(/2K47U7Y&LY,
MH[(),2"<)9SDBB$3A!H5[-4TO:97"_I:3U8[92>O=VN0!J^/3#%D@32C0FU@
ME;NID1F6`LB!Z!P(*[EBR`31A=QM12YK*7-`B-9+@P#.$DYRQ9`'0H\*MJ=U
MH8W,5LTRM&6^ER<>9C$(-5@?EF+(0ZA'A3K?.E^3(Z]_6T]V$K@WK2[N3:M+
M[-/]^C"TWYLX%;QW0>KO71#[S)'>;>CS\3SLI]3%<26_@6+%ML_3Z\,5`L.V
M>/-W1JYX"4CN$9'3EVFI-0!?5,G@2;T83%Q31UQ3IXTF&<)&,VRA+HY4WTP@
M&8_/BQ["0.X<9(M3,D0@JW.N!21P@5,QQ"`KMF#/1RIO8SC0?A$>W/IZ<3]!
M:<$HQ)<>N;6WWI9.LX7Z.E)]%R3'=J)=T5*[**%$M1O31VTGS[FFD,`%3L40
M@:S90EU@E;NB68BYV@4:R+V#;'%*AACDCCG(O8-L<2J&&&3%%NP92?V=GY"[
MHN4=\L4-&*V`SGFJ$UPRQ#!T84]=DLNZPARS,6<VYCR5.4]E";,Q9S;F/-7A
M5`P1R)HMU$,J<L433$&CQ?;%PBZ5&S7X@+'+BNN]9N0YUXD2N`",$Y6`80NV
MGJ3^GEG896GLC1GL:@'L:H&9X-CER,"VD33DLBMR67.9X;*R9])2NUH`NUI`
M,L3,AJW9L*L%9C@50P2R9@NUHJ3Z5E\&9-D(&<C.4`ZG9(A`5N=<'TO@`J=B
MB$%6;,'&E=3=9"013[VVM:OLI)06C$)\Z25#!(AA"S6G5>ZJ1F;8#B`G=>>D
MMG6<9(C9#EC;J1%P@5,QQ"!W(7>=D2N>92N*L+*ITMB!LY@#+!EBV.4YUQ`3
MN`"L&"+8-5NP`ZZ+L`1':MC4[JZBH]4*T+KP!9<,,0R:+=3CUKFL'!ES6=6)
M,M+TD9<V01M7CMAF@:A7;[EJF/E8)*3=Z\T!6F@G^1YL(&3J1=1F?1>7U^E,
M[$^/P[.D.FH^%-B6NNV!VJ0-;EJ$](NO_W.X'4_-P-7/4:A-1A[&P[D9OI[&
M41X][<[WS7!HCG=WNRWG/=XUY_NQ^?'X\#@<GF_$9B3B3I?=W.1\;!XOI^W]
M,(VS;4UF0WXWO3I&;+[+"#IFMPS`&&`%\D>UI\HO<D^5I]'LTCC>;IH_')K_
M&IX%"'#33)?MO<4A^;;#83ON]^,MU\`M%^QQ/^B-6PR;_B5!$A@_\7]N=]/V
MV'P^72:NQ_.K@X5V;TJ"[+?'`#2;3@@IIN%A;$;S8MBC>&OKIOER.3=?QOWQ
M20K*_S\TV\OI)&Q\-^Q.S<-P^L=X;KX-^\NX:3[?C[XJ[B[[_7/S;9S.6AOR
M5SC<:=@*-HYDNNS%R=WZ'>J78F[M=P",@>&&$J(W,/D.0>V#<O^<QY'+)$4:
M?Q/''/O3_8Z;]FD0V^=L]Y=;):5`\/MQ.\KW.!&0O@SX+QRFXWYW.P@LTYG_
M)=<!_^WCXWB2/SQ)QWEED/;;0BT!UJZ\9>T52"LH%Q+>2-G-DC26%C;937KO
M(&4\::G'8:?,Y;N$@/0=ULN7+]N0_VHMW1U/#YQ=Q-D:V-%WP/K>P/X0?%&.
M<9:V?'-*+@I1&Q<QQI>&N!0JDMNGUYL"M\!,<?U5O-HIB)G"[CP/%]^:%8\U
MRA]7VY2X'Y'9%S;?]SRQI\Z#GK(D`^S%=TP3#+@57]=,,)"6X20#!2@M9`?X
M2D\QL+:+JX'KZ:>_O7_W_MW_`S!3?^\-"F5N9'-T<F5A;0UE;F1O8FH-,34Y
M(#`@;V)J/#PO0V]N=&5N=',@,38P(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W
M-B`P(%(O4F]T871E(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;
M,"`P(#8Q,B`W.3)=+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@
M4B]&86)C-B`Q.#,@,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&
M86)C.2`Q.34@,"!2/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E
M0R]);6%G94E=/CX^/@UE;F1O8FH-,38P(#`@;V)J/#PO3&5N9W1H(#,U.#,O
M1FEL=&5R+T9L871E1&5C;V1E/CYS=')E86T-"GB<Y5M;C]NX%7X?8/X#'P)T
M6WA<WG1A^[3I;H`NL$V+#-I]V!=9IL?JRM)$EYEX?WW/(2E*OG&2B=P"701)
M9BR*Y+E_Y^*W/]W>?+R]H<M8183B'_-3NHRD_2??W=XP\X01'A,6FT\XB>12
M*9Z2E,(3"A\W^O;F7Z0R>R4RPHVB-,7_2/-P>[.]O=G\`;?"/Y,/Z%)*`0<L
MI8@$_"<4YX?/E8SPN1()/D_36)S?D).[A.&U&25I0F%3O-+FLY9\=,^D?\;9
M2-';^]N;/[[+5KFA_Q[6&TZ9+0?>2!H1A4^!.]_\S"7]/;G_]^W-]_#J/[YD
M?W%A?T:!UTJ9_>F2QK@PO[VY`XYQGI#[9SCVKQ7Y6_VD=RO=$$ZI7)!NJTGV
MT&B]TU5'GK.69/#36J])5Q/]J8.?S9IU#W^S3I-Z8WY_PR.ZH"#:QZ:H\N(Q
M*\ECMC>;P(L_])4F@B[PD(ADE=GM&O2FW-'+J!KIC96CM]$?^Z(!"LN2]-5C
M5JQ)EN=-#^055:<;W9KKKC0QSXJ*;'I8FL&G6_RGV.DE^=93!K2_D99LY-0N
M6VM\'?GQKLF`#6U>D_NF;[L%>006XX-K4!U'@Y1%.E)-F;14`V&[=A"4$2?>
M_L_D#8O,W3=U,R7IE"/;INX?MN0[G5M5$<Q(4AI)@N3-+L"LO*[:8JV;K"OJ
MRFQ[+8IE.E!,%3<4?^,)6U[E1,:\)2G/8D&E-R2CXZC?(2/*2*N!2VNC2J\W
MJ4U3[T:CN@*YB9(#N4QZ>GD2.4,R=@S7]RK!^:%QPXT;G;7:4.(UJ4'RS.7C
MGRFX?#2*K*KZ';Z2''ZT('JST7E7/&D@M=P3JW31DMQ?1ZF2)'$T<PHNW]$L
M8X@BAN91#$CCB94\PW^DJCOK.E;[`YDNAG?J9EU4#^5^<<Y+@#;H!G[';;N6
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M&X!#E=4EK4URT)==5@&R,6!H_52T==.:/*'5S1,`AW9)X"`+DP`Y:*M^']Y]
M^P%8O(1[B@5I^WP[NQ(!`^2`_ICD(\)7W'F*@3;`*K`W7A#A/$#QK&C(4U;V
M@/'Z=C"LMR6@HYDO">C;WU+QI:2H];_"U>YF/TA-V$&QON)!X>!'/N3;ND34
M9MB"KB]'VG?U6I>CTQB]#4#8?F=9^"<`MBU"1WULBN!ZQ))%QLZN4"``(0L+
M^^[04TCO'CF3SE.()4`-<WY1.3U'795+4/W)QQ`DUL43I+KP;%_H<HU7I[@`
MLI9/CY"U@'(\U25XU++H]O@T,H^MYE?CHK+8&+HWF.;L=0;V\#.-*#)OEWTJ
M=N!ZP'``,N==#X$%'34\9_/GN,`<?&@M0"6C"XBERP/0V'75VBB1UR@T#13:
ML`@7AF1O,)("DA>]*2V)A<U<T*J-MT!U0&=0E\7:O+Z!T`.!$\AK._@`XP[8
M6>NT!_1E9F\:Q\(3>Y0``!L2E0H!_U(BS+;C^Z9Z"`M2R2.S@%]8D`A()4,+
M8B'".T0\E<$%X*-8<($0X+E""SA/PPL85C=""RB/T]""6+UP1)SR,!_BA"7A
M'6(69G4,R1@-+I`LCH,+Q$L+.(N#LH@9D^$%U-9<+BZ(%%:=0@M2K*B'%L0J
M#1\1*144=P30*DA%)%0<WH$K$91%Q)0(4T'35(062##>()DR367PDI`:L/`1
M<9H&J9!1&N:#A'R6!Q<(?!A:`%@@O(`E-&A9$A0J*$VATK!E"1!%D`J1I%&0
MDP+M/[@@4B)\!Q!GF`J!+8'0`HZUY-`"EH8=J:#@[T,+N$IX\`B>QDE06#Q)
MP]+D\@57S`7G049Q'H<="&=)'.0DITG8B3$5APV'08H>O"2D)F'+@BPF3":+
M)`O?08+2!1=`Z`[*`I(4&MZ!\;#2,LK#=U!<!#=(L0H0#.TOQ&46A6,%"^L*
M\#CX7"#>#NH:"YH]H\GE^WVT+`(.0?K/F/IR'$Q%.B19:-PVR<*T^W_Y]P0$
M(V1`*K%._^5DPLN>3LR&T'\,V1`X"XOX,SSXC>M"Y5F[]84MD\:0-\(]@SQ_
MUNL)</M3,01RW:\[1[+Q',A[XIB/I0_?,\[KOFE-;T=CT2=K,(/QF6O6'3>S
M%L"K,N]M;H2<`JYEJQ+2HVILF%U!G)QY<<80+P9Q@FQ=<LM,<2_+MR;37$P*
MEMC)9M2U&]UM5WI3-_JDZRML2GSXKF]5!MZ]`L74%JU4M%20TZ&"W&$7"Y#N
MT*642*6>]VCP_^/1UU-.!D'`GX-F&7F9RM2)=.!W9HIN6(RM40GWY+%NAFHN
M)M^KK#3UM*PS3TWW&218^T[=4,MV%=*V[<UZ]SJJOJM\Z_79/N17"U.EON"$
M$7@<8G"4UDWQ4%2H;K;BA)60)?FN;X:2&ZHTL1<\H[*FH3YH>)MO];HO]?JT
M9+_`6G#9KTW-RA6TYZ<U\1W7=-)IEK'3V\&W+/Q8B17+>-M!GD6+`P4]MDWK
MJMP/;><++=NV+H=BS="I79QO9A>GS8FOISKR]:64C_4E&;G^^D`(T("*/+GD
M[UITKFV-XL_:5G>MY4>C=SIK^T8/HROY28G*C.YHJ_!.F8<FN_T=.6B8,S^]
M(O;U-*I&>NE!11GVQ;*XK9-58,/K=8&?`ZD'U&#%L&KU26?!)-X&ZW!P%:>7
M!+A[\9;P4N*"!D"=U'9.`.G$R9RG0&#RQ]PQ\&-.R\E9ED>.Y>?/>6F4@7L5
MXY&=A*)+E2C'<><MF%+JL'_QT&25#=;>O=2F3#LT+^#7Q[[)MSC1XD+=:&.3
MG4!3IQ:WL*7P^>FD7K6D4RT<=!RB@M=P+,O#'5>Z>]:Z@C"]A(N;H2V!/R%B
M,60LR%H_HN\$,^H?X?;/6VT:.&!\759@?;]>][GA3*F?=-G:<9>LPZ=ZO23O
MQ];/[-3&J?*]J63$-0)_-D%PD,S$FLWUX#)/Z,UJ6X%&0&:F3H[C`U]@V'2K
M3$_4=`RS*=D/-5BD<<?:S+$4OO>!'\Y/<^)''F(;(<!R)'6F8SNKX[00:AE(
MJ:Y<&/1C.4!R-TS:P(V1&V@!MN_;3.D=C0'=3JF=.?2@%,US4\`VH`7]JLBO
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M=^0NMGHW=CPGB2YW,BM9F7%)"%[`V,Z`X/EI'B$[%@VLX<9>F^$R>6\\"PIH
MK<OB2=O,Y.P@I&T!.Q&/HT;&V4+L+?+M&1\&W*H?;%@VJ&):@<BN0+&'ZS2-
M',&13\>&?OWIJ(Q-6B:S/\[U;HK&S@2904]\]WCR:CH:]5ES2O/3["$[E<DX
M'J`25PL*#$:=`O//N<RE%C5/8G^9TQE5TUSAB,8A8_QBR"]Y_)F0_[6'(.(?
M3GD9\>,IR*2SQ[PT),E][8XQ:Y9RR6.A_-22"Z/T,"AH8SLFX06@3[KG>LZ;
M"7"0P\U>+A"]^A3%)O2#PD:.?I8PEU+;FLBHM).I1N-!P&M^T!66@?Z)8>;O
MX$YPJ`7BS(\&5*']S7GE1*7_!<88Q?#?UV!<^>0;../\U]NB[G2^K>JR?MB3
M#_NVTSO`E@92(-63438?E=P773XG\3/1G3$[\^-6%A5``*PT]:OR`HS^&HJ%
M_\H&$S3V$"1FASC:(0HWE`.YG/O23W5\OQ%XSP-&9Z?7?UW#3J59"<=LF%`[
M#WY?<XN+3EI0?XNS3AJ\*OI/")]?[*2%2Q1>=M*O/02=]'#*RTX:3T$>G3WF
M)4G)`3M1Y:L5G`F7X9U@(X0SF^(3R.PXB</OVP$(F18N+%I"R('?O5EI0`U6
MLR'1V]GQLM,D<7.01US`R%]%\EB(BEVMDRTE&Z9IIYC&Z.>2?#O];E!5GRW^
M$7!#0**NQHS5C.!YH%FTPW87T?;LE(ZE*,4]9)(TX@=5SEG1_9>B[;EIYF-!
MBC./C1/I/,_\X/[+T?;L)/MZ%(V$+]X+YH#Q%<!]"&N_BKR+WP>CPI-WUHTG
M=M@":#W=-PGA,_R>F=DV34%3\#LGB'7>S7>$A&#GCG@!3GW%$=%P!.BXC41<
M'`_-AD>#[E1XA.J.*1D<^+@##!<^0:)5A!9$5`5G6N[B%X9:[A(J+X\.`1N^
M_^GVYO;F/T>?S/D-"F5N9'-T<F5A;0UE;F1O8FH-,38Q(#`@;V)J/#PO0V]N
M=&5N=',@,38R(#`@4B]4>7!E+U!A9V4O4&%R96YT(#$W-B`P(%(O4F]T871E
M(#`O365D:6%";WA;,"`P(#8Q,B`W.3)=+T-R;W!";WA;,"`P(#8Q,B`W.3)=
M+U)E<V]U<F-E<SP\+T9O;G0\/"]&86)C,3`@,3DS(#`@4B]&86)C-B`Q.#,@
M,"!2+T9A8F,W(#$X-"`P(%(O1F%B8S@@,3DT(#`@4B]&86)C.2`Q.34@,"!2
M/CXO4')O8U-E=%LO4$1&+U1E>'0O26UA9V5"+TEM86=E0R]);6%G94E=/CX^
M/@UE;F1O8FH-,38R(#`@;V)J/#PO3&5N9W1H(#0W,#8O1FEL=&5R+T9L871E
M1&5C;V1E/CYS=')E86T-"GB<S5U;C]M&EGYOH/\#'PR,=R%KZD[6OL6)LS`6
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M5N;V('FXV@F>%9[)STW&"*&+;/]0H08>R^8Y`T:KKEIG=;-O0159%251>DED
M3_7^(?NI['[)OEMFGW;E=E-V=T?W^5.?_5=7]?7:7(@:?:BK3?;I]VIUV->_
M5=E_;C;UJNJ6V0QLY]JS7:!R+=]<J-SR_17(C+RLP/3`SH#EMLF^>^SJ;08B
ML8)!PD$<N[HI]W8!,+UZR#@Q*\0BNSOL@;ZF>H*?-VV'$BO7ZWI?MTVYS?9/
M;?9<E5V?W56K\M!765.!Z*IN#JX5"UPS.>!:6*X?RV[_G-V7(/NGKM[OJR9K
MVCWH(%,D6Y?/?0:\`P>@]B,F^3+[[/F&?RJKYH$ME."R<+0&"?Q,),%?)^9.
M@D(]>\IP!@[#^-1/*>10B`HQP@F1XC$*\<>ZZP$2D%UD?F(*5)Z/\"FF?DK!
MPU,T6PJP=`.`[T%[=&K5*4T&0@70#Y:IS#$*%2RN^AWL<3V'5T!(=]&'$J9"
M]!&Y<PLT5W3QK-UD/W41S:8F19!`BPBJ99,_182G@`G+`?K1W)EP/X3TNV<`
MM<I@U"+;=.WNV/?5"S3('2BV"',&[0[[=E<"CE@8!-![[-K?ZAX`T`#B#"J%
MJRV#3.;!G"3)G3GUA]6JJM:0/@3>C(;[[-!LJQ[XMQ#L`!&"46\@K35G2X^*
M8`]-VTQ,OF"1_B/?^S#Y@]1`4%3JW`M*<.9,WRL,&,Z,8/8/H%!]&@U0-M7O
MCW578E1#N<P`\:A72KWAZD@N%SH/GMH812XSC.`G4)SMRE]`D4WK]+@"7NY1
ML^V<;BU`?Y[N^=Q:$#F0#D!)R*+!GMB(6X?H;$45@[7QS36(Q><J37,`"YA>
MF4H+[Z1<A4`JM,_![DI(AOIR6W;/:%'O."$+`B69`1<@^;&TG,!OD<R[MCGT
M)LG`RTT^=M^66ULRM'?_J%9[Z\TMY%N6ZW5V>(1E@'-XUX]MV:W-ZI]FR3PQ
M@#LEL3QDW+S0OJJP1F@"+6J@*@%9-W6_`N8,3L&YQ[;S?E8.?UM`2K[:'@RN
M8=9IO+:&JJDR<`S)=F6`VLC"N,#=H:\;].M=#>Z]!S#L%RAS_&L&WA7QO/-<
M!-XU%-,V_^S:3;TO[^IM#;`+C*[*'IC?MD]6B=94?1EBE&<T:?-F5UKL,'&M
M\/1]5X)Y#%T[:Q]1<+W'K!ZR4IM8@$/T,X&6$MQSG<OHEH*Y8!1I-@0;XJQV
M^JI!@*U\1=1[9`TB:(R%!U9L#,.SJ[:Q)4;_9B-.%*6*S5J4*A**4LU#0L:E
M5*XJW2RR]:%#,S>1)Z+:8P4A:7U<KH;JK#^RA3\-X7#A)&["V\98'IH4'*SK
M?F"0`!)=5?;6]^8!"%GXTI12$F-<7LACA`#ZUU4)1?8I6<C[IJRWAZXZM1<#
M`A#13\4V=3`""(]L`&:SV%F@+K,(`6>!#-3'F?509P,R43'W;3M'$2#S4(`$
MD2N?`Z%DCVVJ?RBW6Q\JCTDWC0\?C08A#+T2+[H#!0#*]4#BJ@*G7J/VCNY0
M!C]?@P3,L1.'SYC+.20@9<RM8EU;$"<&ZUI(34B9335PALXY8,>4@_/!CJ0A
M&29Y]#RE56B&A1Z'3+3$QK*LWMH%=GM`3JC^@.IPPO2Y>ELWU0V"=X.)BH7V
MKL)+%VAMN]:$\H=JAZX\@P1(R*^EB@&::H<]"!V6VO[?C,W^!S+YTS+[`L25
MX,I@G+NJVSYG_X/U46CO+4!PS6%3KO8&M1>F(Q3Y:0=-O],+/S7_!%%F'WVB
M,E]F)@H16J'YH+'C,K._E'L@X,'DEG\IGTV"]CV$BW57)OGN?JFP3STUP9SI
M0/&L92+G?"B:?-`P\/$X^UBW7U8UMDC[E[K]8K.8;R89E:MO(QE5D(%D:)&'
MY$Z98R^:?;5Z:-IM>_\\A]6J4$\0&EU6^CC[Y;G?5SO(`M%IK)O:?NRV;X_4
M9/H;QK<1H<XYY$E&,75_%7)BS]!\M;)$UXEBR[6(Q:?W=@C!$/!*8Y_]X0Z8
MKR&(+[(?GLMUO<H^(][;0#=+;2RDKY0(#5#$E.O/(03]]<MW"$$+(&6UA,B1
M_;AMNWI=0O#HH#ZTN0(NG)HXB(:>NOD:[8P<R2!W3[+2G_I9@H1GS8H73(CP
M(-SJ-'MOR)93W=2/*^B(IJ;>*F!%/I0>5T3&K8+)PS33^=`NT),]XH4VEVEG
M#?+O%4!5U?2A-3D`0I],N#B>U7WVCNK89GI'<[)@DLS1#!$\M`68CC$UUX4O
M._I'VZW:/@_1>X9=!T_*O+L.D6%&8U4OE*^S^E-U3.Y^_!MPRD0^5&T>2W@A
MJ$PU8GO7O:OB]HCIM^^S77W_L,<:H]YOJY#^VPTQ"-Y]]1N$*DB^8FTY@[E2
M%=H2<4M%N(BT:;?;]LDW9-K5ZM!UF`[:%N74U.0DD#-?"**81M+8B&(QN1)^
M>^1[LX.`3.(T2M=N%U-;$]2A+UF='L-Y>,K[R2&[&,J1QK)2,%]8E]C*VD!]
MMUZ@+-WFV["^QA81F/6@S@@5(3:]S=H5@KW#]U"8E;-L&7.M_S\Y@R=G7F<8
M,BU9;(](=L89)O<%,<+I]+X0Y3F#+_"A&*6,P8%Y3$DZ@.V&O&+\-D]89G^%
MZ-!E=^W^80X7*%A,7_@@?>$G_5V@T>ROE4==3%=&AB;8U()6*E`X8ZQ'WPMR
M8)S&K*:@:B36NSW&$Z6::82^;[O)Z]RHIED+&\FBM+&P<6;]OIYZ-D)R]8TX
M$D>:S5G`.R5RAW>UZ?GV^^'6T=0=)D$#&?.!.[`T8)9H&K=`!*4^IG79][@G
M-G6&DY,Q%J=&=4S#_5,F1_6<#HV%\#A#)DSGPJ!Z=P*`,R"RDB$^D\'NND<B
M@-R'>@R.XD[$TT.]>L`J>/(TA4D=")RQ;01/B&(8SI)SH;3?;F_Z?7<PE77V
M]3@D#6:Z_P8QN#WLYS%ZF=,1:4QM]!**!_^4R8U>8IX412U5G"<VQZ=Y/>YA
M0:X"=KJ#[/`!QXM\ECR#*XBPDS<8+>+:-U#'\O*7M5P&JYYJLV6[:G%0Q!;@
M=K3Q9=6-EQK>ML^0E?7[<KOU9;V=A]ZU!]M`IW^F##?NK4.:H;499,##-%@Q
M&*_B7@9G6V0(];1P:EI.3QC3<3,ICW4$]T-\G^-\?&*3=6-V3DWD3>RW^JU5
M4P?^4CV[M3@WY`9(<"_7SA75#3P3)_+=J.\,G(?9+Y*3:):,.)4,&#F8W!WG
M!=#.QM^Q`"QOUCT.`/U0K:K='5S`J1_!M6,(8?*V;:9.L25D#9ZA>7,Q20>2
M8RRF)Q+O:B1GQA'<L.KX$._FT#5U_U#-->7%PFP;A+K!R+'?.O\6H\.4\4#'
MK"JA+!\P3&7<^134I\=_:'1X,,C["0<@[>D=IB;5MKZO[[9FP@^TCH6E'?HT
MDY)V1'(#)><\$Q(L#/,Q.N`Z]R.,@OQ,A/30?A9C[7"JJXLM^8];$(\;2UVW
MC[@KBZ"U*P'N2HRAP^HQW"@.#SK)V?G5>>"+A2X>DS''Y86K$7ZHNVJU;[L7
M8XHSO?.#32E/TXRMKV+(.2%Q_H&9ER?<".>(2J8>Q("@_)+=J9-&'/WW3YG]
MU1_,4096I75(!V0N6*P\^X-S[<FGRJ!""Q1,GB.#S]`X!JD'R4YH(AAT&WV!
M$C-#6YT@V"%0K%8^@9RS=<8+$:B>KW7&`3"C;!@1<5O`S&/8UED8<(U3N`LW
M[SK$ER=7JX6AW<G?4%.!V/F`!JXX,I>8YP@FY$D;9IE]GNLE&QI&80ES?83W
M<QF;BH^;S]:4&O!$5?!"(?C8FS'1\?;'0=>T;&?K]6%AYLF<S\BXTD,%?]M>
MGV!C+$X=P02++$X.Z6@R`V/*XZ"H,,.S*#^3UIE-&?\2AMW&Q[E\6X6\0"]\
MC^<`Q=X]),W=+!-E-(QWTSS.XPONQ[N[:EM!4FJ:'IAE#WH=;E!]\IY'L@,Q
MQX@[?B`CO+H=^U6<\M,1=Q6[5$@*4'=G4O#'%M\5PB[!J"ALU5$^/G;M[S44
MWA6(Y9W4'`>*3E(7_+0#*83.<BB)N&$ETFP^_X$?9Q""F@7LS(*":YY<D'.9
MOH/BA"072`XI4FJ!X!"=4@LX)^D%C+,T#:!VD5Q`7GF$TBPM!U7@D'MJ04[3
MHE8*ZY'4`HFE1&J!>&T!IWE2%XI!+9Y<0"E+2E(14B3E(#7A22)E`352<D%.
M:%+=4NHTFU+H(GT'KD52%Y)IF>8",C&=7`!R2K()-*HDD:+0+/D(D1<ZR850
M15H.0A8`>:D%`M_O22W@N4HO8#E+>I8P,W"I!:1(>Q;7^(V6U(*B4$E)<@3*
MY`*E99H&6>@D%QS4F2:2%RII,!Q`+NEZX/U%F@N2B^0CF%8ZJ2Q6%&EM,OD*
M%#-(\I*"PI>]DZ['6)XG)<D@`4O30%3:<2C4XDDB*5A<TK,HA+WT'93YOD)B
M@>1Y4MT4GI#4!>6<I>_`6-IH(1J\0@/!>=;$`LUX4A4%>R7V@R#3`>N5:$-9
M\G>!]5[2IWC2[QG12?HH2=EJ^#R;@)!(\6,I.W<5'&[=(03#K5]AC]T'X'Z-
M"[A&4JYK;=EKS[TQ.:"-1MH"G8$B4IAC&H\C=6$%4'CN$VOG&V\B15Z\`+*!
M2!X=D#<@R:TY)<^OH("K-!^G[VRA!Q=0XCZ^IN524AJ^`4?\Y]'^%W<;/IDA
M[.$6W!E!X[ZXYR1P=4*]6W/"25@!ZM;7R=E>>O8C<L<FJ@ON+!2/MNXH]];@
M#H_,$\^A=5Y+%UZJV47&Z:CR!`9BI#<#=WALF'@2[7+,:UZQ2_SHXVMF*0H:
M"*.1L$B-77!*F/M=Y=<;)`"5UG[/S5:O[W'W^ISD="30T7I,E5UP2J#['21W
MK4;-I8[`UQS:$Z8C89$:N^"4,/>[*JZ6'+KNF.1$PD\=@9[68ZKL`OG21PV!
M;W+1A.#LAT'Q,Z'<_(7C>N9R\"`EALZW"4[ISU\I*7.I]M^]A,1=!\QC_F7?
M?W<M*O,]@_6N;NI^CYNW)[WALV0;!U-B8&&;Z+-'YZ_S64?W%0(TSH@Y^0DA
M\?35,2/2$0SMW87$0`#%IZI3L0S.7TN.X`-RN'M1X;W,%U*I"ZDJZ+BR7IR_
M#B;>H"Q-1Y453U\K'4W?KBPH]8Q2Z"DU\?S5(#6T':[=FXWOH=Q:*$DOH\L@
M"3[_F*P7IZ^#IK/*BI")P`%)UB@6^?-OP"+_7JE<%I1%+*+<?Y-A^$6K=?5;
MM6T?7WQT\R3%$7(<>L3;@AY>*L]A]TD>@^7]"-8,3U_^8'KA@Q$_X`FCN.+.
MOP57PDNX`5>H7D`U=(Z,@HZ+_L7YZX#D$@EH.BKZT].7/UA?^N#"BG@,)=SY
M:U&"T3'1<[XH^-ET!GU8R%%0$&_.5\[RGP[\4*V[`@..7('!0KGI#L,'TA.9
M#[YR,H8VQ^>O*D?XV:P_F4%8ECQW@1,1Z@%[^!I3_JI82P_`R9U_2RW#7\_(
M#18X-FAD(])N%QRQ<7*QC!?'LLPIUBRX2+'^JC&4M*??DI&%0>CQ(']<TCDQ
M.(D<\VX7G!%#$<7@)'+,NUUPF1C<5:.8[<Z_!;.#(`)PY&JA<GY%!N;$4T3Q
M1+;L@LLX=%>-AH.C\]>%@_,N'!6%Z.O8T)$-';5L%IS1LOE-QHOE">-VP64R
M<%>-Q:6W&;NFEQN[`7$OAB**(?!N%XR+P?XFX\7RA'>[X$(QV*M&HZ0[_Y9<
M.AI[R*4Y+1:BD!?FTECD6P%Y61TS9A=<Q*._:BP$#T]?%X+/&KMO`IC&]+7"
MX]HT9LVMBP*_4FL3[_<_3O<,_":R?T9Z4/V//$.&9\2NSTF2A/_OD51[_P,*
M.?4[U>E-_P^<I#=Y/PB2WO3_(&EZ0N.#(HGM,.#RT]]O;VYO_@^1<J39#0IE
M;F1S=')E86T-96YD;V)J#3$V,R`P(&]B:CP\+T-O;G1E;G1S(#$V-"`P(%(O
M5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@
M,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&
M;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@
M,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$
M1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$V-"`P
M(&]B:CP\+TQE;F=T:"`S.34V+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M
M#0IXG+5;66_DQG9^%Z#_4`\&,@E:G5I)5MX\UW.!&R2Q8T^0&\`O;':UFG8W
MV>8BC?SK<TXM7%K=-6K=(0QKJ.)A\2S?68OZ^/?[NS_N[^@ZT8I0_,]>96LE
MW8_B>'_'[!U&>$)88E<X47RM-<](1N$.91EIS/W=_Y+*[I5*A1NI+,-_2/-X
M?[>_O]O]"VZ%_TT6Z%I*`2]82Z$$_",TY_/[6BJ\KT6*][,L$9<WY.1!,9F2
MC%&2I10V199V;R+YP]\3PSW.1HD^?KZ_^]>_YILB)4R0ST!O-66W#+IA'-0@
M,O(9M*.3=:JRA'S^\_[N@:Z9A%=^?KZ_^_#I>#K4+\:0CZ8RN[(C/QWRZI_)
MY]_N[S[!._[[S8Q80T0888Z1#[]R2=^Y?U10RNS^=$TS9*2P<@K)G9B?]X;\
MI3Z>\NJ%[/.6Y$12]BM5]'?XP<@61*_,EA1UU37EIN_*NB(GT`0I*_*\+XL]
MR0\'8KRRX/G&$',H'\O-P9"N)J>\Z<JB/.6=69.?PB]5UY)C_@*4INB0#-YC
M&M*?\#JCOU(`9;TCWUX=.I->&TPR%K0A:5!'`:HP59M;.1T[.7#ZI3SV1Y(?
MZ[[J@-?.-$>KEKRJ>I#_A9SZINU!+'S@;Q7<K_(#^=D\F:HWY!?3/)6%`68?
M^X/=NEV3J>*M&F"[JK8;G)KZJ=R:)<1/T@`&J;,!#)PF3OQ=W8"T7;$OJ\=@
MU&9F_)8@30?,OYB\:8FIML#X#Z8PQPV0"K8BG%(%FMGBA5R_5XJ(SVB9_F,N
M$X\-6E"[_0.ZC!!!2RQ)?&CXS[SJ=WG1]0VJZ?O'QIBC`4@O("FC2P:'3(O@
M#7QP!I&I]'5L,`AJL'19H4M4)`]2KWP8*%M2Y%5A#H<<7;\'7`!R3-/E$"F*
MLBGZ8]LA08NR8(1!$%U1I8T]\-R/15<CK)C6>N7W7$`-:1+4D*1#B)0"(R?J
MP<<Y1+XI'ROPD,"T<XYM7T`\LUX"J^B^N((1!&)84(%?'?TG:#;O2(G+>5$>
MRJXT9['!!X/6/A,X6$`'2@<=I(D:=""I<#J8R?Q<=B[N=Z;85V4!L0[]W?Y6
M'^K'%[`=L'JTL6X%O[1=XS326D*0J3!;V`I^?<I+AQC`U4PM0%=!6&G;O'D9
ME#;J=K6$$C`-6"5PE:9!"8JFWB%.>?$[XM0)VW9X#2:>,&9M]XT9XUQ,.&-Z
M,([2/FM=<R-XSQ]]V7CPG/(7NP@<'P&K>TA;Q3YO'N'V)F_!MP&P10XREMT+
MZ=O\T8#+'0#3NQ)_6D`OH'.N@F1*CL!CB$>7D=NN79%MV9[J%H#F?V_R9\Q4
MIBG#FK4*N,=Q`[G8!$FQ5NE`WFVY`YQ:&2SU&M(T^?<>=`!9"I+6#'JHOZVK
M7N`WN.C@)8O4(QG-AERCU``YIJ7WN_P$R(+R`T0%7K]C4*(?R\,!Y2BKJ]+A
MO6!C]#[P59NA4(CON%HQG:[@X;XE__&WCS_^3#`<\[6T=1?$HU?I'./QBM1/
ML)23%LN:;ZR*-,D&76C@Q%:M4))_>/C6+TI'I2/D$E<%?<!J9@'[IGJHOG4V
MIM@$NC$740#`]18KXQ=G(*R?MZ:JH;[,.YMOR:>^J0&O/YLCY!'T;[AGZ]%3
M>,@EQD@^Q1A<'/HM+I8VD[<=&AH?&8R]@/2I#$V6ED.+E2I?;0[%H@,AA!B(
M.*B`'+/DX5`_M_^V0/F8*KED496P4$V`;$.-+1,^J:JNQ6LHHC;&9IBBP%X#
M`("9S_9EK>\BALIK3;X'J@:->GA9^5YD!`4JLC$[WUK8+;"[J2L?&3%0+!/4
ME`ZU!.=RK*<TH@$U\%C7VY:T]<'"&S$8>+?>,+:6)H<?(6V!;K:]6:*?4*E>
M$A`J&7)WRM*QO!2OJ^QC#FU?;M.V<=;!TM#7%O.Z$[*3^7+RU52H-X?T#2H$
M9#@R=]^0??FXAY6G^M`?C4T%YDOIBAA7;#TO@04YI'?*]1@`E<="*(OG12_4
MTABN;(<]`AZE&J(5-I>N$$4`G:LFM-#X^'9;HG(`7XJ2HM^4!3EB"V]5L(-6
M'K9>JKI1?$@U>E+=J,2+/Q@,+9"W;5V4-NPWIL!L^S):="+J;W6#*[[R!(H2
MZY/S8AG\Q0*D1<E`)1L3M+(EFY=76D,#P",+J("-`Z@)`F2H<$8F<?ZT,::R
M<>I@;-@"M3Q#O8/<[WJ<M-00)')O3\`#P"!9DQ]>\BV8%3>`9X]EU[GZ;0O%
M+W9D/H2@8D(_UIAC_60;#ZR13\/];ADM2"W'0B"=%`+)N1;`K.=%GQ`K2NF:
M_+*O>PB:TUK55_A3E$^#@&T:>S3PRG4M")B^:5#:H6&=][,0B^MN"0VD8?;$
M)],&F4K?9=<;:Q?'<65+E1'2$Y=&@@KJ<YQ*>NC#W7U=@?$P6M:;0_GH_/FL
MI7Q#F62M;P&W@`(2.HP9L)WS"N!AK%099/L)39[O=G8P.C+_3Y"_-S@@L+HX
M&M--4P,*ZY'@D[^S->3_&L!1PA:%'S-`75D5V#1!.U6Z1AJJ0>CS;#@<O,MM
M4>3M?@E-R&'NI-18(K',AX0=EGZV0VM[G+Q4!%N.;MZE/5M?V.=/=G1PJ*'_
MN>P&;EH!H-Z'6>8<]`@!/WUYF:>AC3F4\.9%X@$?JD29C8E!XS6JH.QL-`.>
M6RSCVKIOBMFXI-QY+UBA^&U_.M4-U/38OHXZF,`#B=OUMR^>)$V6',:*3(<6
M(N'H->&<)@RFQN(9U/`7-XR#7JF%?LY"!X?3X%.UB_#?@S*>[)0-IQT?S3X_
M[$(B]5;_]BH2R:+UI5#\<F!-+A_QS$:YV,PW.+\;IMC.7TJ(E2<<[J-B]V6S
M=2<Y.$JJP\P3<3FJ>3M1<SY3\V:FY@44((8:D].QPLB8#ZQ>^#7Y]*4PIPY[
MH:UIBZ;<8"D$3#^O2`5]D>>P-5-M8!MECT5"TVU[%#MA,5\P/=FP6;GS$)=D
M\9%'4Z%><<9FI^+69WW9M8`&6#8.\B<3[)!;AYAI0^'V"5DBSPW6216>.D%?
MN41CQ?6B9YL\"Y7E_##/3T5_]`,^0>V80<[3Q_Q`8QXDAI#B]#5Q`)M]H4Z'
MOFFV&Z#A*0=@].UUIUA``8D<#R[&N3!+]=!<_6;PS,%.[I!?GGQK+L#)`AN+
M#NXPM(WR4JJ&"HHGH6ZP(\\P13"NAOP%/-X/,QT.$EM8S/I(APQWJNLJQRT6
M$\\8++]T[H@3['X^%H6=_F<H*1>PKDP'ZX[HYN&H^B)BYQ@OVU`56O[[#FJ<
M/R>=P!37KWHG7V^O(E'>^H&-)0M(+T*U3).Q<Q9ABO:4'WKL#[M7S=*:JS`B
M=]4<9*L6!/$G&/XD"8*\'ZBU?C8*%X+2%?Q/VGW>N`G)O`)'_<`6;5<7OZ_(
MR`*\E"ZA`B8&%8PM(]>^1/1"KH9*?86S?8JM(K+N1FB(X5->;DE_JC%CF:(/
M)Y-N^'L!1&ORT^1SAJMD#FM!9PM\NJ*'8UE%)^%=>PB,5IK:A3Q#6,>#D<)-
MSS'1U\^S04+9MKW#^+D3H,/G#7[9L75]0>?P8UN&<4*Y0J,[_7;ET;:D+TMU
MC2P=AJD,/U[Q6K#?\J`60)ZZ[]`-,=PYQ%].9M`%UJUI75,'M5U^L`6:!<:Y
M(GPC;MLNU#"41R"Z/=-%=Q\[Z1\637!L&)W2;.R2A-3ZK/A?@5U?:A_6@,V=
M*7&<88<I$`BO0.4<)6OR_87#KQ5)5XJ+:YM8O"T@^C@X328-(M=^<NAQ&NK-
M"09LB!N"6X/I"Q-`L!DDA7&BB@=_K3'DOVK(=]I^=A&2PQ!+'%X:$Z9H+BWB
M9U).=SB7(QMHKY<Y36#C"#5+QS"@0@/HO\[`,4<8&MOQWI6DY3E?#4</1>'B
M.VH.4T5]*+=V!@OZ[,QP;#J9C$R_@#K_`&H!^?W\%*HK8;]$^'-R='96M>.)
M,D0)2E)-B;"O&O>TGV#BZ:<4W!+PRP2I%A!H8@09?CX8(TBY9E&"!%N#&($2
M(HD2@"?$"81@<1XX3U64@'WM%93']9!HED5W2-!:48(4*OLH0<)2$2507R.0
M$&"B!(+).`%G+*K)A-$TK@=*>91)E6D=?87*L/.($20Z+J92.HWO(+6(VD()
M_&PC1L`S3:,$`(>XF#13428A-?+H*V2695$I9)K%]2`3/,>)$:A4QU\A4Q4G
M$"F+>I;D23R`2);%/4O23$2E$#I+HIH462;B!*F641Y$`L:($J@LBS,I,Q4%
MC!!9/)!"1Y7%I8#X$7\%!4#$""#6QZW)DZ^$8JXXCRJ*RR0>0+A(DZ@F(1O$
M@QB',!D%+:<IBS+)M(Q[%GA_7$R62A;E@24BB9J;*9%$;<&D8/$=!(^#EG'^
M%1X8%_$=*.=16V@6S\S0'7TMM<=S(F/Q0`YJC$<?'G=\".-Q*,7!"OGTN@+_
M\/4/)3@*!;S<_-F6GZ?C1XD)'WH/GE+?=OV?+WRQ9)ZU2^?5KV32,J(!^[=-
MC]V3ZOKX6*(%86N5W;ZW?32V=\;<WK=O;9^\MK7_DRC\`REA_TEDZAY'2#)G
M+_?&W6#'L/X.._HOT6:=`\XMW\:4-0&\7<]Y>K5\FTW9M>/"ZWR@N>"%R1D?
MX_*-JG%/7M#-=V]E2-LW*W[.T;A^*TORBKD$RU8R>:O%$'W(P!E?Y\NWP?FJ
MQ<8_UK.]#K^(WV']=OPF.KV(W_0*%X@O?-T%P,Z6;P)L8"(F/@(*WW`!H;/E
MFR+4VUZL[1LN(3&LOP.)%Q4OJ%YEJ;K&"2#%OO$U]&;+-T'ON@JB00N:9G(,
M[3,Y^"N%5^ZVO1S^:/5Z3$;*"79'3,_7;\)T1B]B.GM[+/3B!4D'J82]M`3B
M+0*&IRZYRW3Y-G=)KQWYCO06G5X(+\^<<T?P-B'\4Y=<;[I\F^N]10C$9Q!"
MCT(,G#N"-PKAGKKHQG[]/6Z<9J^QQBA;B8R_-:$D@Y!>WKEDCN!M0OJG+D6(
MZ?)M$>*JI<[2@LQ"2(`K'Q)`K<%YW.6KOU/W5!?SVGS]EL\B$O7&E.*8#OP/
MO-+!7=SE*[8#F2:<G7NV6Z;O\&QUM7*;>[;GV@LP9]42S+@^>UB-84&-8<%;
MRA)<ME0@NQ0'W/([BL1@J%B1.`\(078]RCX(;`FNR6[OC=%$L3.!'<$UV1W9
MQ?"AWE\%7)(^Y7J5<G&U"D@&'7AUS'FW!-?$\&27`H1Z=PEQU==">6K[Z(OZ
MB7R9*#2T,NYCE"Q;,XZ'M*B>OWZ[5TB<9[_EPYI_Y!4JO(*N79__@:OS$Z7X
M%/1!QT<9#YS&AST/4%A&IV(/DM'H-.1!47%]'`-"?/K[_=W]W?\#@+];RPT*
M96YD<W1R96%M#65N9&]B:@TQ-C4@,"!O8FH\/"]#;VYT96YT<R`Q-C8@,"!2
M+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP
M(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO
M1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T
M(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]0
M1$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ-C8@
M,"!O8FH\/"],96YG=&@@,SDR."]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A
M;0T*>)RU7%MSX[85?O>,_P,>=J9I1ZOBQ@OZEFR2)FDF35NWS4->*`J2V%"D
MEJ3L=7Y]S\&%%&4*EK36["1+@R!PKM^Y`-ZO?KF_^WA_1^>QB@C%/^8IG4?2
M_B_?WM\Q\X81'A,6FQ%.>#17BJ<DI?"&RH@T^O[NOZ0R:R7P,_P5I2G^19KU
M_=WF_F[U)UP*_QP,T+F4`C:82Q$)^$LHSL?OE8SPO1()OD_36$POR,E[R;@B
M*:,D32@LBB2MSIKRT;UC_3O.!HZ^>KB_^_.WV2)/"!/D`>8;29DEO6P8!S%$
M*7G8(LV4@A`?\ON[]W3.(WQ^NK_[XL>B*]995]35C'PHLV+;DJQ:DB_;5K?M
M5E==^T?R\+_[NV]@OW^<3911RC11DD9`E;!4??$KE_3*#8)<PT>6:X::<EQ+
M&CNNOZ](M]&DWA45<$[J%=EF5;;6R/`,7S6:9/!?59/?JOJI(CM=+8MJ34J]
MSDJR:^I<:QQH87+6D:=Z7R[))GN$SV"I3C<%3-.KE<X[4MO-/M3;758]_Z$E
MJZ+*JAQG[.JVL+*_A1"H=$+@H&\OA,@\HQ`:W>[+KD7NZYUNC!'`3PW)LW9#
M5F7]U,ZOI2ND?97*SU-^V.15G'C=JX@;MK_X46=@SS<0LA+4;\8!>9R,18+/
M*..'0?%OO'F:])M+R^2OG/,WWD2Q$8>B!Q"1QI;!EN1ULZO!>C39Z&SY<9\U
M8/ZM<9^RSF%\28J*_+#?%3`^(]^6=5,LLQD.9COPI$\%.DSY3*)9`L#=X@J:
MK+3NT#+;79:#H^8Y?`\K[:NE;L#'2E0H>2JZ#?QP`[7B2XN:B9`]TT(XM6[K
MJML`R0W@!;BQX1Z('?/S+C4,&8#0GW8%^!MBP=<ZU]L%<"'8C'!*DSE!*[$<
M;3+$7Z+;/"N-0Y*\S/:MGN%HO3,C70W+=0!(!E;L=RMPV[<70ZIB+X94\%X,
MTEMW]U239YTU[<P$C:+*R_U2MX8N)QJ4RG)I0`Y^LMI<Z'5150BG8`-?[IJB
M1#G$AHD,V'/?I;/HR!Y`D`"O7O9.Z.]8-(//K11O((-$>1DP-'H70).46QDX
M[[9Z:-$TLP5997E1%MWSM.4[LSUA1.^8X?O8;'[85YH(:DPFMLSZK;.RK8?]
MQ8Q%]!:"B+D7!$^&3"))7$SUBJKK;BP#-(V,M!V`Q!J4OR_*I=/]7QNMJW91
M-_6,_%0W()4/65.7$![/$)**(O*T*?)-R+GB^0T$P2./B"GD?SZYB(0:,/_+
MM@"';?>+ME@66=.;1V'B[:H`+]@U>EL8E8%\VBY;@:?D>;W=UDL7BBW8@:-H
M'Z!-!H+^GC5-5ME\I;V%\\>0+1_P>9`Z2NI31S!JR!:1#J1KU=1;@H``\`3@
M=`L#I&F?S]B(9[#G!AI.DCY]C`;<DPQ3R:.H#NG<*5UG(QCXK@8A_:WVD@++
M+BK``W@)GI'_MJE+5#:8-H+GL-B<_!-TC"8.GJ*=272;HCTT@1L(.XELD@9\
M0R75AT!(,:25P1-&JG&\X]&,`G*A/;_CPCRC:2)#1E,$8A;$\&,?C<P7\"!G
M0&:[@YRY>(0%WSSY1+:$RSUO(3*6])&"]Y&"I2JQ$OOZ.5L6.?E)@PI+9/FK
M^7_FWE@<*.`P@J<-E&$,/)*^1('/SH!$LTD.)KNX1;S$E,=)(9:]%`23L:\Z
M*OT$5H"645?6,J"\:HIZB8E#4^_7FXD<Z8U-08"N/*57VT+`SN+T,]<.2#B.
M^^0TCH::@[OP\^V^VT,<!G@IMONMBQ<85XK.AHOEWN:+#IT*%X+TQWVQ,VCB
M3-*%G[H"6\EU"699O@A$+>9D$PZ-]?,MZBUC4@Z6$BST,`RLZA*+U;_<0H\\
MOF6C0HI>E4R*(:>*78(]@?U96;Y4PF4P:U-LF'*$((+%!P`><0LHAY!\BSZ%
M9(-*:3P((7)I!B"=Q;3CZHH-Q$:6<(B*K@8Q-6=>MZ:&7->(+2U$6)N+'D4M
M<1"VF)I<:0V@U0#TXIRWEX!0OL3@8-1#0IDXR,R6Z,QMASI_U(:M]E@OA6TR
MF0P2\Q(TCAR22,BFEZ8&APRS<_GBJ.'SULB*_+B2Z3KP"W=WA*M"#`"POJO%
MDM3E9C\W=8=BL6T]^`GJ2]UA6O:@\TU5E_4:$.\&3$M^2Z00?3(.*5C/MDP1
M-5ZFI.T^SW7;HADO-?8N$4?`1'998_J16(9D"YN;0KY>+[K,O.V,?:"5;V'`
M#&9+"`R8<>Q&@JVQ20I+@@^5,+JW75&P*EC1H]$-I#"4`)(E?4O3I%L'Q3A(
MH#M0MF$(J%ON\Z[UGO+OJD"W^!>ZA9UA6<KK?=6!R;1S\OWJ1FQPU=<7:3K4
M%Q$3XY["L@;2*JBGO1(`KYP:C`HGQ3_#8+_370$%=PMZ?,8\S\1NT/2NR4"%
MD%KBYR]DI$%&]I5?`O'F!OPG?6>:ID-[/DXC#WB/&5C?6KO66/9D0*NMMR9S
MT<6Z&O0$4C(R\H+9';A\4ZPWR&AMJZH,OC>MLPZSD^Y@Z1<6,7->`%JX`?_1
MT*(^T'_,7&UE,1QY,T<*NC+,Z@9A''@OH%0`^2"GH-:M,6GOG0#[P$O13(G!
M6GX[(4,CYU8/*[KR(,?>XY(L;A+X`2?[[F(Z-%DCY3IK""/Z4[;=E=C^!%7E
MOZ&JFGWIS'6KNPU&=IRXU"MW1#.-258$MR@I.:>W!'Y.?8K(4]I+*1)4O@!^
M@DT$4T1I\.*VW8/JQC!WB/#=$SR^]:F$B%5/L>)S22FX]^]`YONWWB@1!Z)A
M0J5#FT:FWH#VC9<#6D539:X/[>0P<TF>29;LX:=IN^;UH[8A[`,CWWS:0:K5
M8MR[P2%=ZCOLC"<]$@KE&TT>H9_)KS2B&6@84]IF#>C0;BVQ8-_@`$"Z@0#P
M<3T0C'IN=&D30-T\`O);=X%B#L]L:@0'</RLR3<0-TI(,W,03X?'E]9*L'#4
MC3VLM!$4U@5:V"V$$:N^[3:D=D/;#>D1Y.</#^3G_:($2FT".^J%XP$*S'\9
MW:<,`$N!?AVR*J`FLJNYU_YXUH2(15'O-EFSS7*][XR8;B"!R/?863(<)TKA
M>^S("-#1#6;1AXI#6QX?-Q\Q8XIS5]!`/K&'VKZQF9Z1TF-=FAH#8?>3.^_&
M-ZO,(NK'O6Z=W&_`O^A;SO%!8.3J9>.5/!50"8]2FR$QF@A^INNZK[(]Q(RF
M^!W/$B'@+9ZQF=HL369<F(99^>SS!9<J&"\[7G64.]U`$*Q/=!D=2L+$A494
MH0$I$YS)8P95GLW@*O#N7!N9>+#'4S68;V\CF'*QS^ZQ!P"8UT!^"?B0-[H[
M<B?TFFII,BCT%9O;^X4-!6AO"TB=;W*#H4^3%3^HBWTK<3*'[?/\#$];("_`
M=,:4_*`[('Q.OJN?]",>R.E/4%0C_<:^;=ML"AA<#IUOP&%TM=9+EQL^F[S3
M7J/`Y.H&1QY]GAPQ-I0[#@U<:'/J&"D.W+[G[C#HHTY'G!HAV?JO[5E:X`D$
M-J0+F`%*7S1UMK0^!I*[_KSA5!:%'<UTLC%OCMO2*"6)HH#]N.KPN;EK!1.8
MC*B9P$],H)+RT(1$B3BX0I(*JH(3$@'<A2;$(I+!"9%@X0D26[RA"?!>!"?P
MU[:`0CHL!\II<(58\;"HXY1!E1>:D#!`^]"$^+4)$695H0F2Q>$)@HF@)&-.
M55@.C,HPD9`9![>(%&5!=4>)"K,9Q2H-KQ#A&7IH@E1QD(M(*)H&)W"\&QF:
M`+H*$TF5"&XAE:)!+F2:AN4@DU0FP0E@M>$M(KP&$9H@$Q'T+,CQP@`"25#8
MLR0X5I@+FB9!24(1)<,34A4':1#P+L@%U(<T2*2(\$Y%:(),PT`J@(@P%QRP
M-CB!X=%@:`)-P]KDR2M0S&,N@X+B41P&$`Y6&Y0DAQ(Y3`-/PH[#62+"1%(9
M]BRF9)A-EDH1I`%(2(/J9K%(@[I@D1#A%:0(&RT3_!4:.*@K.(%Q&=0%WE@.
M;J%8&EP`DJ"@N21,A.,12\)(S^0KZ$/#/D5?L5:JPA*D(>SJ;]-+D&($"<;6
M$@U/I7M2^&1?FT=W5_]C_QIS1(BXE[;_(G7J-O,!55QXJCR!/3&)>303DC%=
M_KT".+F,+/PRIJ?:DL-\F;*>+D?BF!@[X9@N]QZR<G"LBP[P)$?"E#_!8RQQ
M=Y?_WI]H'Y<6G[,;X)_I)D_>!C^E*TBJO$R<>,:"L!..9>+>1Q>;D/E2G3H[
M=+]<@K]J(LQ?,60JYG/,[^)#HUWUQNS'3UA-H-Z,W,4WQ>>")HEMW>*=H?.(
M,A8+NZLQ32^&+S)D3],%PC$V`QO&1W0,PQ>*QGPY)9MWYQ*DS,X1/Z9H&+^4
M)'E"72(V%Z?/)`RM#PDXHNMX^#)S/JFQP<U,=9%,VZ\?O\)^7?_TV'Z34\Z.
M]B6328,]'+[,8*-3WGP4$6"'*0L]'#Y_8_SRK(V5V6'2$MWX-98X*?A8S&B4
MG@1:9G><,#UY-9*>%$$027DZ;8E^_`I+%&+2$M,+D!1VGS+,P^'+#-/1="F2
MPH93=GHX?)F=7D.',AM.FJT;O]ALTVDM)6R6QLD%^(G[3QCQX?!E1GQ2/F/\
MI&K::OWX%5;+Y*35*A("4'@]9:>'PY?9*3LSI88=I@SS</@RPSQK8V5VF+1$
M-WZ-)4Y)?L(2C_`3-YPPO</ARTSOI`2"4"73U)5<^%2ZOASW58Y[[']]^C02
MX\P#V^UM^FC\HONEJK^6SP]^;<F=H7#*[-5/\TN_V:K3S?G(Z-CV$NBYI;Z,
M<H^O,>Z_FO"BT?!%7B15]'H!"$;KF7#\C"DW$\YDPGTUX9&CX8L\\BPF4C8P
MH08F>LK-A'.9L%]->;<?OR(]\FR,<35B,\G/3M3CGDG'[Y@S,^%,)MU7$\@Q
M&KX(.4YK:APM9.R[,_CDH"+NNS/N\<6_I.!F3<6[?OP*;.@O(D*-FPY7S_W]
M^P?SNZCC7Z789<\O_UV$<6!R/'IV>];Z7H][?,&EGZ8(9\=`8(?I%4"0G$RW
MQD`0]YT@3_5`JIUP2/7QQP.*Q`.*.,6:"=.*]=.F8,,.7U&K>[V&:O4Q?GC>
MU<![S["=<()W\VX`GS@]8MA..,6[G3:)-O%UN80XP3V;41[/$L8#?2\O!2>0
M,?5VP@E&W+0I1(FOS44\&Y,7*\V)F&D(3THHT!44"EW"K)RF>.U.60%]^W9;
M2,K\%N%+D)^S1>2WH'.;UD"]?7QW(GP`])Y1'CPZ><]I^##NO:#AL_CW((K3
MYSM`Y#>_W-_=W_T?L>U@-PT*96YD<W1R96%M#65N9&]B:@TQ-C<@,"!O8FH\
M/"]#;VYT96YT<R`Q-C@@,"!2+U1Y<&4O4&%G92]087)E;G0@,3<V(#`@4B]2
M;W1A=&4@,"]-961I84)O>%LP(#`@-C$R(#<Y,ETO0W)O<$)O>%LP(#`@-C$R
M(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V
M(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&86)C."`Q.30@,"!2+T9A8F,Y(#$Y
M-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X="]);6%G94(O26UA9V5#+TEM86=E
M25T^/CX^#65N9&]B:@TQ-C@@,"!O8FH\/"],96YG=&@@-#`X.2]&:6QT97(O
M1FQA=&5$96-O9&4^/G-T<F5A;0T*>)R]7-N2VS82?9^J^0=4'G:]6V,M`?#Z
MF'CM2E+.9==3M7G("T1"$F**E'F9\?CKMQLWDIH9S*8L;J7*EB4(1!^<[C[=
M@/+=;]=7GZZOHDU:)"3"__2K?)/$YH_R>'U%]2>4L)305+_#",TV1<%RDD?P
M291PTLGKJ_^01L^5Q0E.E.0Y_D6Z_?75X?IJ]W><"O^;O1%MXIC#`S8QATFB
M#2\86WY>Q`E^7O`,/\_SE#\](2.O>93#LFE$\BR"27%)N_]IR"?[6>8_8W2R
MZ+O;ZZM_O!/;4MM_"^,U4GI*ATT<)8A#0FX!GE>_LSCZ&[G]X_KJ+7SW7W_F
M`?R9!U#`/.*YGC_:4`XSW9;75Z\!N0B^<P]/;8>#['JRZ]HC.76B'%2IFCV!
M=\F;]G@2S<-?>S+(\M"T=;M7LB=M9T97\D[6[0E'ES!2#OCJU+756`[]AKP;
M.YSZV';RAMBG',4#44TE3Q+^:(;ZP4U">G54M>C(&@#`EPP`C,?,`9#`1P:`
MCHAZD%TC!G4G'YE:R5[M&R*Z=FRJ,UA.8@`K9+7XTN;2-L1)/C>"<O`UMXLL
MRHP5/\`2JTH-JFT6:)<'4=>RV4NT135WHE85K/K,D#50CV*WX"*E?L$IA`>]
M8(-=?Z/7-3@LS:)W0M5D:)%,=ZI:+);<J^%`\(7EG-XT4=V)9A#[KT#_.1\%
M6XH\7M-#BS1S2*51.FTM^BTB=3NSOI,U\G(\M0T9.@'8]++LY(!0`0EQ^\G.
M(EJVS4ZAFRE1`V(5CCEU2@ZB0R^$84>!7]B0^1,.`MQ=?)0-SCQV:G@@1RGZ
ML8/'PI:L8'X2.?/S>&)VG#NB&,L,20(6]'):*)*H:0=/(`#JTXBT/X/I+,K-
M`-6^K_UH\=`5S.?<.S;WT8D766',?W:C>BD_]M9+7@*(;!\(1JH.0[1JX$MS
M<N`>BWTGY5%[H/8P>3S5[8.4X*!E6]=BVW9B:"&H()%60`']S_I`,I&`4VI0
M@.7V8SV`DX.'_PPY`W-++7M8WK,KA0V<?4USHA]479-*]67=]N=!\!GL;K3)
M\Q"$,UT>@KPH'`19/KD!M3Q`.F^!R=M:XJ8#U1O8S-U80Q*=,V!!X@UY+B\\
MDX7';8]H`2G@7?`9!0D#ACS+JQ5@R)G+UDGD<4A8DOMTK;.M^C3*R4GO%6SG
M7BBPMBR!%@A1P+G7R!)YRM;,$CHVVC"99+,PR:8LH1JQ5=J=V]V"L8"&"X%G
M=)EO[$+ZE.U85Y`-,+L"8S!V8!JIP/4`:@7SP@R8A18H;\=>-=HM5T"`>2&;
MIA,"6>&$W$F"YV.$@Q0`7F]BU0Y`:4I<.P0#XPBK['Z4?]WN9T';L\+(/S"8
M1I.*IS&45]KX]V#9WL:K7W3:^K5K2RDKP$.[R>U!=17Y573`CC>U4,<>2?(#
M)`70A^4P`D#P#8`0/O^AV6&FT/G@\E!E&5W34;+$"\^<%9.C..%YNR`LJ,BC
M[#0_^M&$#M43'QO!I4"9=IKIC50:6&70T=6.%:WGZJI3^\/0&R]$V'$*A1FJ
M@9W8=E*4!_PZNN8*`'"O)_-L)JCP-0)0JU(V/<JY@Q@680*UGY8)4-)HE:"E
M0"?W`FR`?^K\,@\2UFY;\?UBTHN.&3M5R\JD3F6"Q&X<0)M!(25)K3YB'((9
M<=B-A7$-*)C7EG-M%5LDQ.D$8&BO02;<&7VTEXW)+/@"2EVQ-[KH$5R81R'Q
M'-"0$92%^B(-8LN8^(:2[]M^(+<.N8<;9#Z""1^]_7R"<-6ODTRSR(O+C$^E
M!4^MK/KPT`_R>$/L6CY`<I0H*XCY`)?9=GZ'`1-\I]>?]?A20X([ZLIW(T>?
M&>UD!K#+PS1",EDFJQEBEP<DS5/?"\@F0(K",F+:(Y!.>EFP/DO/!5M,BD%N
MJ[X?9;4(!<MZM3^8TFFTBK/$Z#MO&CS<++^A,V\#L7L-`%*O,F,VE>7,E1NP
MSG8[:"%%;*`PW1Y<X13,'M;(H6E<K)D84LZ\Z?ED.J5>0<U"M79NT?>0#Q\[
M/F0(4W783IGJGM91IEO1CL"=$?[NU!=;QRU4^?#HN78'5H"`)I[^,_;GR:(G
M<QZQ@=&:LX^`..\,VLRH4\OD./VR;C7"4C7EV,WK#7B_M^Y3*129ZT3$I/`B
M,LLF$<D+JZ,@%AU%(XSV,<ZLJXT25@CBJ&^;1M8(4"5W(!%T/3WTLMY!!0U[
MU@\ZJ;<N=)16:7605Z%J*NUX'RU\DT'-A=C)"3&K(U:`(??M1#KU1"$DVG:B
M,\94C&?-W(FJ'W7SU]CHOG*>(6=%J^6U:OX8FU(W[KS]6&L.>IQN<>W(_4&5
M!TN6%>Q/O4AD4Q[@1603H]SMI%XAR)1MW98?SVCOZBR4,`8:E]QN9I(2!0%2
M"/A1^[QH1)$Q;,HB.+VX1YT%W)F[126.V-=<`X/8Z\0DGUR!%G3)@9GE.BD*
M&PU@H6I6*#Q)`(B45E;OQOKF*6YTN/,H.%$ZP%O.7@3)\J5M-%%60(![>9BR
M65.=6020[L3+99L&9\%Z&=A<T_$QX4TL\!.A9H*U"@@F>B!&/M!@._U!7>OT
MH$,M,*H9EJBM``*=&I!I/+E"7KC6&S)5-O`WE@;`\UH\Z!QA&;T@O&D+@?."
M70K,&4#\G0:M?UR3:7[:<I20%RL=!Z<ZXI\86HTN1)-K<=]#<-#G3D+5F)(N
MCT)<^`8D*^8HI(]TT3R^^STU*(&4QRU;[)BFS1PB7?G=@25Z\R>S+R^HXBQ=
M4U#%B=>243(ED;2PS+%)PQ!X$)_;ICVJ$J,'U#L[*Z6?4/_D@.*_[?:B4?V1
MW`ODAX*"6W<E*PGT.:H&0@8VF_9V/DS0X*^G@Q8C^E^&6QOR4[L.96(V.4XQ
M4::(7?2H@.?/&^ZXKT!&E.9,[I&\@DKH#`QL8.NPZ68#'``@`:H)<E:'[(.Z
M=30!M#_)TL>I%1!@R:2HV72T[)S&N0"FLE*AYK%5M"__8*D:FAZR`(08DR[%
M#N.,+I5@@EK.:2(_@TEXY"H:B+5+!E$SG<1ZU@.E*YFM''#*%1"(G)R$I#'E
MT)Q:'75J>ZWR3?RSQ'66+S=I9L;W\RW?D`]@D_L4)NP5Q@WWK8DTEBHF$CU!
MD;6T%"_\^7H\G5\F3DIMC;V@:?[`IC/88>MIUR2[1U?>/GBM.<^I6Q2#=]@Y
MVXH>A@&2*)_EG:C'Q>:#:I1X!DS`VMJ(*(#',0I/?$;=9+''6RN@D,6>"7S&
M!%M:M:,_C;+7)':FZR-JNX?Z3&\$S;N$Y]YMISV\-_+Q7FIEXGJ^!'M7&@?=
MC4"V05H:Y5([.##1/58`()GDY.R&0N1:*_W!ITC(?:Z]XA=7J<H>V>K/T80>
MO+:6$S!S>U$OR$M?M."YMZ)@L'2D\!=8^NM+/RA>P#4=<_&<NQZM-]645\N=
MG/GXI)YUY];T;<4:^QL[L1S;\Z=790?1Z-+84/^D=?<@F5E$HRB;](M+7T;<
M:;G6=<*6.3>Z2NG:!Y"Q]HH0[`/6]F87^@$D[F-%C`')AG$,8'C/ZDX-7W-=
MZ#G=E\!7G66O5A"5W/;45Q*5?-:RCOG4H'&G%_/L4+6P`1@TS#'XL6W48&]U
MG,8M;)\[ZM>70@!ZTVLH]=?UYODC0V42"VBQL1_P!$<?>DS]O:G/A=+2EC+'
M=4XMF&]2TZD4B5/.?6^B[?39_N,(:A.C#&!@&U,>`["\Q*Y6N<:!/A[AS\S!
M6YO^/(I;@>#$8!!E:_1*UT_8K"N>3Y!39B&?U1Q.;SV0.]760M_^6TCVISMY
MOM%ETOI3'?]))>,%+!UV3J:MC&^)TG2+35]L!0@27\UD^>S4T"E9W[:MQVHN
M/3:@5N_Q0LZ-3M1FF<O+!^*C+Y"GAM=+K=]0(W8%Z_ETNV)V!R^V%/6=W[-.
M*)K9CD-I(_L<`'V%#E3MV36,^=T+J_!F?2.`IZWOI#\SG5BU$W=(H6ZERT>,
M^K9X$A>S@T*VN'WDUX>7YP3!BZ7#X0$;XZK5HGM01[E&)X,6JUZOH/ETO8).
MMU4IY[:5\6\)M'L+A`5/_'7LR@-4([`[S8`WIE<P-UWUB@2-??>;TUG='B7^
M,O%/0#,&;RP#U<F:CL&*C,UTGDMA)J!^AV<^H(1JY$*-3OM[E$3#Y9L/>)O#
M66'<%:!B_-)/22/_%``H<KKW@QHN7GODT1,&Q1=_2NJ?LE#7L$WTXGM4\!G3
M&)NR2A(5KC\R=OV(9;LN6CKT,FF\S%$-Q8GV,E.XO_O+FS5NJS-;]66;C.--
MPR_&_[/4]O*^;VM]D^J&O'__1I/ZPHLH4K^(]?A,H\E4?8O.1#IOW:4?E]`G
MC+HTIREXI=^_M3E-@1#N81@1:.SK1E9D]HIJI57ACR.4))S>8!B-UXJ#K'@*
MXDOS!DR;\2:*IX8%*Z+<]WK=1;KW&/A]EOP6_O%!U/#"73&_=(V1Q/\'FB68
M"YZ@&;+`_99*,VZ%X)!D=(Y_.I4HW+8J>BG)SZ`L28%K6/90\;8V\/&?#Z*"
M:G"%X$FG-DHRG8.D&7^LG:8X^D-3;J!D(._JME.5@##?G?#F/HIGW>$\M%C3
MF^XP%@NJ4N;V^5R;M+8>4H.^O(CM[GTSE61/,W*-'W'X\G&NI]S-(O'(!?PU
M,9029KOPE2OO5&_.+4Z@H=`<[">-#5XX^-@`(MC-_^;;K2A;\0V.K=M2AQQ;
M-=SB$!!@/XXGF!,*,X?Q2D$(+QJF:Z>NW#T#$Y?]@<0KM/3BJN6Q,1>/)8E[
M!D02GJ+L=@GKXK\>3),9<#.USW/*'G?4T(G,.;<T5^=KTX2X@Q?^&N`9OXCY
M.5$_='@90`__K([ZIP:7;FVFF3/FK+.)-_!Y`7$X*R)B?E<\?5W_Y!=_/Q`7
MB1[`GAD`:C4+#HCP%[N!`5G!(1F%!N1X]S8T(.-%$1R0\B0\(,&CJ-"`F/,\
M.("_]`C&7\"!LC@\0\3"4*<%/",X(,<KC*$!V4L#4L:#>Y$FC(8'Q/A3K=``
M3GD0AY3A87EH`.34\".B*`UN=U)$83.3/.+A&;(H"NY%@HL(#@#/X\$!'(5D
M:``HW?`B:9&''Q'A+TT#`^*B".,0YWG!@@.R/`T_`E@;'I!D6="S($*%`TC,
MB[!GQ:#9PU90\+W@@"@O7AB`YVF!`3PODJ`5/"N2X")Y6M`@8:",#P=2'N=Q
MT`H.BP@_@N'_LR(T0/\`)S"`Y2^$8I9AA1<:D*;A`,*2G`>1A$`<#F*,9V''
M82S+PXND2=BS6!2'S:0%-LA"`W+@=7!`AK>50@-2V._@@(2'24MC_L(:.(_"
M,S"6!_>"4A9.S32"*4(#P&V"?,EI%OP\8_2%A)4'73^A<7!],0W3E4.)%>9:
M.'C1*,#V3WK(:S,!J*@_I4Y1&R:!"Y<ZYNB9:?;G3B@@I!-N3BCS'&^L%Z9@
M>'>Y1T"QZAX1OG;Q-8](W".BC>D%OV+9N8P/.^EKX'>0/J\AE`3Y^9H5V?.1
M!-;P]K?KJ^NK_P+9A13T#0IE;F1S=')E86T-96YD;V)J#3$V.2`P(&]B:CP\
M+T-O;G1E;G1S(#$W,"`P(%(O5'EP92]086=E+U!A<F5N="`Q-S8@,"!2+U)O
M=&%T92`P+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@
M-SDR72]297-O=7)C97,\/"]&;VYT/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@
M,3@S(#`@4B]&86)C-R`Q.#0@,"!2+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU
M(#`@4CX^+U!R;V-3971;+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)
M73X^/CX-96YD;V)J#3$W,"`P(&]B:CP\+TQE;F=T:"`V.3`R+T9I;'1E<B]&
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M'XGT0Q@<>'TK3G&B<:*<]3AE))4X?7JNHK\,D/P-??_Q`BB4726`^*G<5]'W
M3VU5"2R:AWW]5)ZK+GK_4N[J;71N)*1'0'(,6O,8G>':/]7G*OI2GY_K8W3^
MTD0_QWE,X(\D>@&P.XC)?M]\`7!%Z]<'@+-,^9_0HO<_(_@;_=_NFPZU[\"G
M^^C]I96FU!U:^]KF%$5O#R?WF8C-[V#$N]=61..1XW$1\Z&#X&]T'.&/3E5;
M-[N-CB5X?6J;Y_H!@K:+'MOF`'I?V;84[/I_`2&%$7$4?0YCF8Y^D1<2A'-;
M'KO'JFUU`HITA90NCR]1`P(!4=<<U5_.S^51I'`M4AAR>ML<C]7V7$,3S/*H
MO$4.%[3OPVG6AS+%W^A%AUT4^IN,XD8:*"T4KD0E#'3[&C(\:EIU5!X6)J/?
MY0D"_UF,B>HR?^JB'YJRW0E)W8*/#717/+F,#N4O35N?7_!8?>X`AUUUJN`/
MZ/<[W185;-``O/Y?`>AMW6V;6\"3QST\-!W@H7J(:R_=>2/,^'O9_AI]?Q]]
M.)3[Q[)]B,0Q'.?^#,A@T,$%=`P"?<;N`.$]MS!$5=!)I&?[%P01/%9_VT0/
M+\OKJBOB./)8'FHXZ5`='B"5[J./XL)'F(IN`$6:ZGS/<]KG>XR_1;[+T?X$
MGKZR<I;VRF6&PH1&R&LKH2,/20&G*P]STO<%",T9@P@=$G+O`K,89FCSY1@]
M7HZ[#H5JFI+#/.0]=/'SBTB0MGIL@"B,8%))T-6[2@P2W04(0G/"ZW=1"?]&
MOS2@,?H,.B^MZ&`W""M2"#6)D2&L:99(I^7@5+;0R9[D-(W]?@OS\FE?=[*'
MK\S-]]$G=#O:PC#Q4$%:@E/=!7MKM8F>FR]P5KN1W0'16#B[4-W!H++?WP`$
MQKGNYFDV3&@959%OMMM+VU,-<.\$A&[;U@\PE9WK0_78E@=P]_4Y'*/\EA2.
M%43[S0>W<Z[<_O@(P_L9YR9@5XI3X<2-"&AR(X;\(XQ2+Q&)8RI'9C7G`]$3
M@Y$F<;NU3!$=Y!C]6R.X<!=US^5^O\$YL/H*=!'"#V2NO<D$R&"-HR$82%R:
M4S6LP4C<'#]7+YBUT?L*!^M3^2(L_\-_C8_US/;'%IC_'Z(*%@9[/4<!QRT1
M2.5SSTR_&\WX?TSNXPC&\SV.+_UD*J=:U(83076._KO<7^#RZDHW`(2PGM?$
MPX"0IT2-@L^PWNFT?C64_:D300;#NW.S_76#P]>N>JR/8G*KP/4#_D:Q.G$G
M*(/\/<$8$@973B+1=$*(D22:P'T#QQ.]G$D*=%;3^431^6F`]:AV*NL=)BHD
M+(BZYPV&KJU@##NB>RA&%UU0T\FBIX>NB?8-=#$`31,,'?_;A9_RGM:*.4#U
M!Y[E[N''B4UGO*"U`$G?'<9I+L`"C@,G/]3'4LRL<&4G';B`O('[E/;9GR=#
M]A?*?1EBD=U]4JLYH6OV<EE;/L#/"Z3W#E@II(+R:IK,8PYP:5L8$('(P?Q8
M=6)816)1[D$%HO*YZL3XMSIZW@"'HB>^C)"!^!(U"J"?2&#KXZ42Q*?Z>@+.
MNKIDAR"_K[:"IT8IS!`P5Q0WJ'G0+/[F^7+U\L5P^2#$J1UQ(MDGITBP,[%P
M?8=DFZK42]+[Z*?J2<#YOCR7T<<C),5!])K7=A5T:GO"?+5G5\$TZ20YR0:F
MG2O2^1]`F\$OY,328>@,;:5G%.Q^R#^;HSB"H^P1%U=5>VIK&)^KXU/Y)#H1
MC-`7Z$[0IU[;B8PF(R]$Y;0?*A5S*&'I_KD^U]`_RH?F<HZ^/-=`\+OJ5+8X
M^8$ON'"%4;$>`HGCP0WP+C2_35@QS.D94[6*\G-9[\N'?=4O3BM8L%]*+-6T
MU=-E7[8P.CU(VK-]KJO'J.E#M*M@]8VF'\I?D>*T,/8WEQ.BCX=PS$.V+]8-
M0'NVZ#L,[PU,IPC-44Z?_<AW`^]S,DQI9!0G17/!$X$_C%GWT3_.];[^7=5L
M()F`Y4-BU>5F,C4CLZVQ)E$_UC@#0!JVU:EISP+$/FD?@"[LHD;.#T]5\]26
M)T@""/E!3.9B8H>)OFH_PR@N\^,V"9!JEDL@5_L$X)K;B&5HAXM;6;<1\1KY
M*Z.MPB4]E:MAF)_V^Y=;+'V*)+_ETB?G`\T=D5PV*5WWL3X_MU5E"O%WT3_N
M?[K7O0%0W$3?=S52GEXB,/OW"A>S^Q++!,,A207$%9;7!GRW^\L.0;]!1N2L
M9[N,9<.0P%5EJ[L\=-!WR_8%N^>/#9H^+EV)J@6.Q9>O6/^#9K(GGRM(\G[=
M,P-'^HO5@\M1C!VG9E]O:T5O!(D:C_="`"MKR8";[A9\-R]&1?P!AY2J3-CU
M"WU-\RZ'`[J+/+5^.L(``"N!L\FI*=%3#:2KHNOH.&.-511\ZD?E,O[]"Y9.
M!(QUNX-E1HLSB2J7W`"&K.>]>3I4LY-<\;T:5(-B1575\!6=<"749W$TQ'J8
MN3%=2DT%L=X#X^SE$>;&2XO%'=P.@X$'$+Z<&[$^KHZ_OQRPPM+L+MLSJ(5?
MYZK&GG6J3N=ZIT:A&V"0:LY+8C8:%!@?E\(>ZM?>NP&JK57?=-<"TGMP,<F&
M9(^9HBP'6,)L+YA]6)+\K#=JGJHCIIY8VT#?WP-5:%JQ+HD@TZMCIR,'PY?H
M`&T#F5&=L9O@]N>QV3=/+WT?'Z\+\)I#1N#)<*$;A#;I2[M)/CA.F>+6$%0P
M4<S,.O&$::+&>US=OI69/QGPIYDOJ.@P=DP]G22_6B2^ONL9'PJ\P_"6J)S>
M/E<'X38:,^MZ>A`_5U^!%,FU[>FR/\D?)?B+>Q47=$`/`H9I;C84[+MF/!Z,
M>OP-7*>:]A*6#,N,--'$[]H8<ZL>3]*B-^ZF71ZHTPB%A,>C84VO*VV=7J"`
MVQI(V@7I/7ZN.EP68+5C_V+K'-&P`+J'M>HMXMN7KV'%/!1K$EVL(7&<;X!^
M`XN'+&T.(F$E+_G)D)XBXH;&:_U;S>@(&!:G<9OS:PW+.,0EB7^.LSRJ2MS2
M>8R.U2TF[:RO7<."?52QU).V(!(">T`BDYM0DE<<F][+3NW`3)R95.^4+\H-
M>='7Y_M@]BWY/DQRP\TJ0YF_&!'^T?TBDH<+IE?_7G6S.N0X82:KNM%"_KL;
M+(GPM@,S1&(C@^=%1'D<R9NXABN(^ZN@09IG3#0@*PU('L?6!@F0(6N#.(NI
MK0'E&0R^M@8LRXFU`<T2>X,B(W8;\I0GU@;9-15I:L>!DC2V7R%)[5!#?K#4
MUJ#@!'BIK0&[UH`29HU%49#"WB`GJ17)(DNX%8<B35*[D21)["K@N#7<11S;
MW<PY\E];`X;E/5L#&N=6+W(PHK`V`)9F=1-RMK`;F<:I707,`78O8F['(>.X
M"V1KP'AB50&$F]H;8-9:&^3,/H!D>6SO65G*<[L7A%,KDI#4V94&<6&W(<;Y
MV-(@Y4!=K`THI]:$20MN'TAA".-6+]*,Y785*=[V:6M`N#V:A%\9BF$0S*Q`
M$4KM`P@I&+,B27)F'\1(QNP=AZ1@I;4!Z+#V+%R4VJ\08U7&T@!2DEG#G3#H
M?-8&-$OM5R@R>](F>7K%A@PHB+5!BGO.M@8PX=A5)+#4LS:(B3UA."'6XXP4
MUN,4UUS6&2VVC_2)/5]Q]+%VNL0^>I'$GNY);,N3_AY\K""D,,H=U&@31WOU
M*\-?\K#XJ>[P_ZT_G`)'A,/>[+=8NQ=J9!7T$F65-K`WAHB?H@&9VJ6/P\Q"
M8C^[Y*EKM'QH3^$*VC!EX]0:V6!NF#H.`PST3[\M99CGX%RJ]Y2S`BN\:D^Y
MH&KC[W_Q3NT/QQTL^^;;\_D*Q+@OK#S13DW-EPUFGNCC_I&79]+KH<=(0-=2
M"0F_5$+"1*IS0/Z<)B3(0A,R6;O98):0TBIM8&],VJ>`_#E+2!!"0J8L("')
M&EQ#>QS+M6'*QJDULL'<,'4<N$?N>8M#FM-(;+]B/N;W":P59<U+[!'-%\O?
MH@C&WU05$S#9$ZKN&A[N*GA5;0A37UO(U,;!6W6GQDI:9+"H4>CK0$PAEPUF
MZ.OC_MDJS[P^3"&)T'8I$Z?&R`9SN]3Q`/BR-.ZS`N&36T]O9<EM'J9OT9,P
MWZ3X%FV$A"0%ZT<P'8<IXK+!''QU/"`I&'%*"EB]#G;QP:[>&-E@81</AH\G
M?5*\PSO0U"T+;\?;"XMP?8N^PCLYPK5AD<T_.7*8`E40=#RFR,L&LR#HX_[)
M(<^\GAP%3%"]772PJS=&-EC817OX3+S&8EB!\&666O&W7MM6A[YV;5O8"]8#
M*OB8GO\^[.N#NOFU6PE^D>4:9(WW%%G98`:R/NX??'FF(ZM5=BD3I\;(!G.[
MU/&0`,':Q!K\;[VV+?C7KFT)?E&D/:!BA$GDHP9O/S7G<K\6=L&D);P:Z2FF
MLL$,7GT\D&JOAUT^M(V/<*?B?[BB$*=CG8:,6?2C9M>]?"46E@T;POHG$X<[
MM'#M+18N,!.(QX>[[]QL1%J,Q@"CGMBXE'LQ;6VD!UKX5]0X`VLA=K=#G.EO
M!]!D5%C,$5G(/5AF'&()DE,#(@NQ%]L-L0,(G\F.N=C=#G%F@!W,&)FEW-T2
MRH(L8<2(R%SL13F#[.!F.WBP'4%]%XFB,3(+N3O/RHL02Y">&1!9B+WX7I`=
MU&P'#;:#!ME!,V-DEG(/$A0TBB!W,B"R$'N1L1`[@*V8[)B+W>T09_K;D1-C
M9)9R#YX2-(H@O3$@LA![\:5U.P8>)[:A4C-!TO(`@E3T:\AD>*R!%)FZ^^?#
M5WE[_G"GCZ5RBG88N=%$[L>-5LOBT_(HJC"1(2GVQ$6>R?2==0"MK'J__>.:
M!4AW0)61!BFYKPTXI)MLX)N"TTV>T+4"$/*6)1H+L1\1<@B#("H&Q8/8$P)Y
MID<8!+<QA&$L][4AS<PV%)N$Y9LL)VNV,&)$8R[V8STN86#<K)B'AH%QSS`@
MD3&%823WM"'/R=B&T;VNBYM=';18Z8N&.%KQ3C9:X+L0AVFU!%:0&I-B&AA8
M>:9'8`4/,@1V+/>TH4ACU\`Z:+&RGVN!E8T6^"[$85HM@16<R*!X$/N"*L[T
M"*R@48;`CN6^-A3$;$.2;Q@C&U[PM8)54IC@6(C]&-;Z]KJUV@,\Z*!NX"%J
M+YADA=Y^53_[UQ-::EM9,:9H`W6;RKVH6]X_?*=?*_7VX^B1,(]*DO12.]P[
ME^G=7/7SFI_Z+",'G,C].&"V=L_&T%XP+>6&\FAJNVS@YH8ZR\0GQV*_XIJ#
M$X)I*2>4/U/+90,W)]191DJJY+Z4M,A[-R9=FK%T$^>91X%,.JG]G7HF&S@Y
MJ<\R<=V@2,DS'2*%C%(YH?R96BX;N#FASC+QYC`GQ)D.3C`R.,$&)WK+90-'
M)Y@QW<9R7]Y)LW&Z63G?=2U66JW!BAQ3F/4S@\9PBI9LX`:<.LNT3@B+_M@A
M6_21)VLG^.!$;[ELX.@$-SO!@YUP&_8%=U9.*'^FELL&;DZHLXS+EK`4%LL6
MQQ2^KL6Z@/!,8<'])7`:PRE:LH$3</HLTXHH*/H3AVS1I]G@!!V<Z"V7#1R=
MH&8G:+`3U,D)L4I03M!^/AQ9+ANX.:'.,B[0`E.83R?]!%]3BRF,;Y;SFOC%
MJD0ZJGV>>B<;.#FJSS*MU:38>QW*S#T57YVW%KF\GS^U;U,O9`,WA]19IC5@
M4/K),Z^GGU@<*2?R?BX;62X;N#FASC(N(\/2C\8K<5F.H`Y:K"M$SQ$4;YM0
MP&D,IVC)!D[`Z;-,2]Z@Z$\<NK*I0%8V%4CXID+_]D<B7L"C'IE/$O5(M;A?
M97@.V+:C0%9V%$CXC@)QW%$@YAT%$E*"D&<Z*,;5&5G92""!&PEQKWI:B(DW
M.8/_:+)BC%@,+5%8B/U65PXHB`6,0?%<[+<B<E+,C/"/Y2$;"";XG380#"#,
MQ7X+`Q<0&#<KYL&*W7J=H,`F]$?R$`).W/<-[%JL?)6X[!LL85V(P[1>VS<P
M*:;!BJF;8IH9XSF6A[#146^ZRD9GY?TE#"-Q"&4TY=:",LY*_08CYF(_FN<0
M"T&.#+$8RT,J_,:)Q:G"OT1A(?:C.ZLH6.OR<69F/W'P(X8D7F7=UL)YO%(X
MC\,+YP&6(%&)S;7O.+CV'6`'$IYXI7P]D?O=6.IOB2`M2T068C\6%&`'<AB#
M'7.Q'RD*L8,9([.4^]U8&F`)(T9$YF(_AA1B!S?;P8/M".J[@L&8(K.0^]U8
MZF^)H"9+1!9B/ZX38@<UVT&#[:!!=M#,&)FEW._&4G]+!&E9(K(0^]WD$&`'
M\A:#'7.Q'Q$*L",GQL@LY7XWEOI;(CC,$I&%V(\4K=HQJ0'AVR),+*B7^]>`
M$MZ_^Y\GPR<@<-*1WS\$POZWIA-?X8H^'K?-07VN8WC1KZ4NA(:9R-)4[D66
MM,'7ZD+BS1I+=C01>[$C)\5`>U"#B0YIN7==:`B26$IE;%A*\4U2T`W/5HL3
M2$J70(S$OF42/),;WE]K64QA+IF,F(N]&)%+-)#JF*(QEOOZGZ63:`R+J2S9
ML**P%(E,$,S%7A3("0+&S8IYL&*W+HADQHC]2.Y;5(C9>D](-G%*-VG,+&4=
M`Q`CL?==F;%W3T!:8C2"!D9#G.D0#20PIFB,Y;YEA3@W]P1*-Y`DENJ.`8&%
MV(O7N""`O,.D>"[V(C).BG-BA'XL]Z[H9+8I@;-\P_CJ*WV2P@3$2.R[]8=G
M.G4$6X$'OVEKI#9%\(V7">UOO,1RE:8V5'^R^*-XO;'^^@(0&_<B$%IEY#43
MN1^O4=9Z%H%0HXGFC,5^-"?`#F0WH-#(>I0\X!Y&;<ED="$\V60Q=5QI(UM9
M`K00>]6$`@`2A,5@QUSLQX!"[&#&0(WEOH2HR,R!HC-2:BT/F<"9B_VX40`X
MC)OMX,%V!/5JP9!,01K)?;D*3!#FWN11*#)@LQ![%8H"L!%\QV0'#;:#!ME!
M,V.,QG)O/I5,8I3H&.&DGI$-FW$J:^G(@-%('+"!-K(L9((79,E@TUSLQ[[\
MXR9(ER%N8[DO.I2N]*V,;PCSJ"H9`%J(O:I*ZP!-JTH9-5,O+0^@7L-7V/*X
M&+X]$Q>:>IVK%LB7^)+DL:OD]^`M*R?!D,`>(^F:R/U(E[+S:C$)5)A8UECL
MQ[)<%"-]`@U&6J7DWK0JZ54O]N7S)-E0GMI*24L81N*04M)@BWLIR6#$7.Q'
MI!QB(1B2(19CN7<I*9_&8CS@%_FFB%=#P8@1A4'L_>@P\0\%XV8C>&@HF%M_
M%#S(%(J1W)<?P0FKW2*AQ29.U^_:B4TPC,0A=27/6`@68S*"!L9"G.D0"\%W
M#+$8RT/J2J-8]/.I@0/-ZDI+!!9BO[J2`P*"B!@4S\5^S,9%<4Z,T(_EWE0F
M7>\&%.]#3=?>9B'HQA*&D3BDJN34#:Q5)<+,U$;+`ZA-JK\NAZ#T5:4X5I_5
M>U^=VFI;RP_\BJ_H'9KV7/^^_'2SO<)$F)GL3.1^9$=9[EMAPL\Z&+C/6.S'
M?0+L0,H#"HU42,E#*DS*DMEM<=D&YF*/"M,2H(78K\+D#Y#@,08[YF(_8A1B
M!S,&:BSWYDG<'*@BV?#$-4Z,&/&9B_V*3`'X,&ZV@P?;$=2Q!5DRQ6DD]R4N
M)#''*67%ID@+Q\I*$9L`6HC]*DW^``D&9+*#!MM!@^R@F3%08WG`NUQ&@;KV
M+I<K6JP$2OOK^*R6.&<)^D(<9H3?74\F.^9B/U(78$=.C,$?RT/*5<;1-"8;
MFOJ4JY8`+<1^Y:I5@*;EJIB;.9V6!W"Z).LY73KL%,:IVBG\2WFJ\5$X4:W:
MU?@Y:^M=3S$W<[>)W(^[*0NO%JI`A8FLC<5^9,U%,;(PT&!D9TH>PLZ4ZFE5
M-<$'LFPOU3-`L!#[T3$'"`1=,BB>B_WXEY-B9L1^+`^YQ\F$?5+P39ZM+<$%
M(S)`,!?[42P7"!@W*^;!BMTZG"!+)NQ'<F\215?RGF[RU6<0!<=9(K`0^Y$F
M!P0$J3$IIL&*J9MBFAFA'\M#:-$`_55:9-=B923:0=LK[@RP+L1A6J]5LPR*
MYV(_XN.B."?&>([E(4S'U)6R)-T0MG:CH&`B2P@68C]JLPJ!K7J%GW<V$!TM
M]N<Y7']"/!Z]0YB3\=/^9==5YRXJSU>^$6<M7O'8R'\F8B_ZP]>^U&&M7($^
M`Q<:2[VH4(`10(!`G8D7*7'`2P*4&=/9`6OCQ2:FCJMLI#5+=.92+Y;DCPY2
M'(,1,ZD78PHQ@IE"-!('O$C`%*)TD\7%AA>IHUV,F,"92;VX5``XC!N-X*%&
MA/1D9%.F"`WB`(YEBA!--[1@;D8A05HB,Y=Z\2U_9)`LF8R@H4;0$"-H9@K/
M2.P;'E:,PS.YN9EL"IB\:>;8B9#V+`$:I`$W0@V6A=X'93!H)O5B5_X10TYE
MB-A('/"&`>.L!*'*TTU<.+YY#)G2$IVYU(MXK:(S*2G1Q$BTIF*?=PO@)W>O
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M`G%Q(JX]7`1?A0E'WW&>6H\G',Q::P`:/OSS[LW=F_\#3PC[T`T*96YD<W1R
M96%M#65N9&]B:@TQ-S$@,"!O8FH\/"]#;VYT96YT<R`Q-S(@,"!2+U1Y<&4O
M4&%G92]087)E;G0@,3<V(#`@4B]2;W1A=&4@,"]-961I84)O>%LP(#`@-C$R
M(#<Y,ETO0W)O<$)O>%LP(#`@-C$R(#<Y,ETO4F5S;W5R8V5S/#PO1F]N=#P\
M+T9A8F,Q,"`Q.3,@,"!2+T9A8F,V(#$X,R`P(%(O1F%B8S<@,3@T(#`@4B]&
M86)C."`Q.30@,"!2+T9A8F,Y(#$Y-2`P(%(^/B]0<F]C4V5T6R]01$8O5&5X
M="]);6%G94(O26UA9V5#+TEM86=E25T^/CX^#65N9&]B:@TQ-S(@,"!O8FH\
M/"],96YG=&@@-S(X-R]&:6QT97(O1FQA=&5$96-O9&4^/G-T<F5A;0T*>)RU
M75NOY+AQ?A]@_H,>`F02:$_$FTCZ+;;7L.'`3K"SB`/XI>=,G]DVSNF>[>ZS
M]OK7AU>)E$H4BS.+A<^T2Z3JJRJR^+%T^_5?WK[Y\>V;X6'4HAOL?^Z7>A#<
M_WE\>?N&N".DHV-'1B>AG:`/6E/5J<$<&8CJKL>W;_ZW.[MS22[LB812]I_N
M^NGMFQ_>OGGZ=WLJ^U\B&!XX9T;!`V>"F7^8IC0_KKFPQS63]KA2(X-/2+MO
MM#2`R-`I.9AS6D1/-2U^](?&Z1`ELSF_?O_VS7_\[O#AT1G_WC1W;G(GC(XA
MU/B`B>Z]<<V[OU(^_%OW_F]OWWQKNOX/XO1L^_1R\&<?'HRKWS^^??.-=1PU
MPK];E8,8#N8/Z?YPOA^OQ]N]._[C\_%\.QI%SX?[Z?RINU^Z^P_'[O/K]?&'
M@SGPX6?W_[]_^.ZANWP^7GVKV_'3R_%\[RY/W<OA_/IT>+R_7NV!XX^OI\_N
MT.G6'9Z?+X^'^_%C/.N?CN;O]?EP_GA+3O9UO<!5-YH!%;P@Y>C\\"X@?FC4
M5@CI.*HOBJ@L1G0TT;)GU_)!23,JW__3!94HXF-*^(.)YN/EY=B]/_SC>/OZ
MYC'R"P[8D?`8*J+&.&29U-R;]Z=+]_EZ^>ET.UW.W=/EVGU_/MD!]=W=C*M;
M=_*6WZWEG1FOW8?C\6Q`/%X^G4__-.UL%SOR?CX>KK?N>/YH9+\]/AY?/ARO
M'2-]1P<S9<R`M#]X9\Y@6__F\O+Y</[9G=&H>+U>3;>O;KO0,MA.R3!/5\F8
MMWV>(<^7V\T8:&%:2&;B'CX\GVX_&%2'[NGU^;G[Z?#\:MH:)]E)]_?#^?'X
MT+V?3?G7:<)=SM:F[K\O=AKVW>\OYOQ_M'_LV=\O)NGA>NQNKQ_^=GR\_P+V
MJR'&GM$I]MS&P=EODD867X/:(#,YZ6\FU]P^GAZ=,=[,:9#<7,BS?H]&>KJY
M9&6#^W2Q'C)N_=77SP5B'+YTLA3.SF@X^]>/!1M8C(7@=(Z%_6UC87V<3ST[
M7(RKCZ=/9^/AE\^7LTFO-^MD.UJ[I^OEQ7K>C-]7.X23T??A:/OE,;(#[7`+
ML;GM3=M??5W72CT[H-6WI35_I+]4V`B?UGMJ5WD?-BJDGL/V^7IZ.5Q_[CZ>
MGI[,HF\R@XG`_>\V4=ZS!#$'Q#0X'Y].=Q?85QOTPWVF`2;[W%_O%W-*$]&C
MC3CC?QVX3Z.VU=$H,I/S)W^NJQLN>42_OB/HM.13K:,C!B&]'W83_\DG?L-Y
MSI^.(=-`234>,N3I<[#1#.S3Y:/M;YQDY*_/]S#\TZ7D?+F[=>GZT<Z&PR_@
M`4*F;#K.JXGE@=8#'X\F^'89`Z+L,J8!?3[>N^6B\[4)$QO&">IB0A@CU#@,
MVLS'H6/NM'-_1^)-`SX.Q#6@&PV8,!N$4@,J2/D,Q.@H-ACX*$L-I!9F;)4:
M&#/*#21710QRY)P7&X@]%9R7_6!XB"B?@;*RJR5A;"PV&!BGI0:CWFN@&"O&
M8I2,E!N,5!4].0K*BWX8.=%ED(R,9164R&*X1T)VS!P(+YY!:#(48R$4(44K
MA-E<ZF(#"Z+80`RT#)(/JJR"#:)L!1UV_#!HK4H-N-9C4057FI8;2*6*,XN/
MJIQ`3`(JSRPNAJ%L!1]HT9/<+),[#<R8*S8@=GDM-3`K;!$DTP,M#ABFAG(B
M9:/F12N8T$-9!5>B&"S&=#F:;-A)Q50S77045;*<0*C4K.A).JIR$J-"E2<.
MY4J50;*Q/+,,`=TQDPA5QF!&?3'<1`M6C`51)IS%!I*7!ZW)U#L83)(JGX$S
M78R%717+*BACY3,8DEL<,&2@JMA`,UH\KLR@+:_]8F=%*P]8LZ:6<P<MIR]&
M=L8[V1DH@RS@FTK!C&C3U,3[)?0R/Y_#3\.>GF,+_SO4FG^<&S#3WC3`5XGM
M4;".D&!C;,(VX9P0&1K]/+71.;JIA5FNS8*,X^_>WJTB]MQ!FE-,\"+4!:30
M9@DOMF#*_)"XDJF9?!8?CT53/IJ!%HNFHZT&V]W0_YE=:/<MN"GD&^XV;'>R
M9[)M84-HL[!G:H$?"[YKL*8X&,R9-5=AG-I??IAJ0>.8"#^S06IEC6-4"UDU
M1`.J"'`",\3!$'[FP],*C=E,X4>GEEONFMMS0PHBL(`Q1^,:K("%XY)T`EG)
M9\9;VG!;-RK%`U&VR&E&Y3M745ENL;]$D5FDM?0%)SODB?6&O0#RY\WK+5^D
MS;HIUJ`&KGSIY=UW_FK+QK"P&\_@_1B(W.6NP=+[\3A^M/J>^RF+*SKA"A!S
M,*[!"E<XWN`^SH9I5%CW,>^]_[R=#N=5F+Y$#U'80?$EVBAM&11JRF`Q#KG'
M78.5\\/QAD&A:-6@L"7]"9>><4U@7(,U+MWL/DVF06%KF&KPA=UWZ8695;B^
M1-^('ASMVLS&M6%P"+-?#D&(\<@][QHL@Q"/XP>'[[D_.$:S0$VXY(QK`N,:
MK'')R7T0O2D`&ZW[--V^R/2EYY9?<.Y2V$<U.=2QLKC^??M\>CF=_96AC>"/
M7$0G1W_GGG4-EDZ.Q_'!]SWK&&[$%2#F8%R#%:YPO"5`9L]2#/Z7GKL4_+US
M%X(_CFQRJ,LPX>:4=^\O]\/S5M@MF0[NC9[.?>H:+-T;C[=Q[4+8_2U%]@8C
MYOZQ^PK7W2PC9J^:L.BGB5U'^48L"E=S-(OW10QDNIQ%QW!9SZP$W7>'Y^/M
M5W48'2VF;K^785S+<4R;;3+M3226:])D*_0T4U#:LD-R/1MP6)IL%(Y+CZSD
M")8YM"!QY'3MD948QW8;<%C"!^!8BNMQV)XM.!08F;6\'HG-;0U(%`4]LA3C
M*&<+#@WCT,TXFN:N(XI09%;R>IXEQA8DCIZM/;(2X_A>"PX)XY#-.&03#LG!
MR*SE"!+4E$4<=UI[9"7&D;$&'):M`#B6XGH<MF<##D'!R*SE")[2E$4<O5E[
M9"7&\:5-'#./LW#)`!.D*&\@2&3:0Y+YAC4ZQAO6OOW'_7@]'YZ[Q]?;_?)R
MO&[13$=DR`!SHTR.XT:;)?)%>90,(!GR8J1??,^PRZ(/QK6^]OWN7[806+IC
M5($T*,BQ&,0`8R!#+QCI3<K?J@!9XK)VQTJ,8T(5<7!,!5`\BY$^\#T1<7#D
M!HA#*L=B8!S&,/9TT#W59+,01T%O+,4XVE,3!J5AQ;HU#$HCPV"9#!2&1([$
M(`1-,9A-`O$8OOEF557;UU+D+]'%W89UOM'*ORMQF]9"8!VK@13+QL#ZGHC`
M.B($!#:5(S&,;*@-;(66(OW9"ZQOM/+O2MRFM1!81XH`Q;,8ZU37$Q%8QZ.`
MP*9R+(:1PAC(V$L^](K+K8H5&2%WK,0XBK5]K;U4[E$F]_F+P?:7OQBL-(O7
M7\//Z>FY[>*6;9EPM(F[+>08[J9T\GQ6N.;EGDB[`1<!BJ6D8&4T>#*.Q,NY
MX>>>G;$71`)S.8H$*KUU&\?<WE*M:$:P*,?N&E2:$7H!A#(3HZIK-498IA6-
M"/;DR%V#2B-"+XB31CF6DXYB,B.;TE(/_:#'ROJ'877!R&AO;IEK4&=D[`5P
MW;9(^9X5D3*,,AH1[,F1NP:51H1>`&]N-,+UK#!"T=D(-1LQ(7<-:HU0X'!+
MY5C>*7DZW(J<;U]+B59/SNHJA[":5H;HP]Q;KD&EXT(O8)_0&/W4H%+T39O)
M"#T;,2%W#6J-T+`1NMF(NK1ON7,T(MB3(W<-*HT(O:!M2^,0MMN6VB&\KZ6T
M@<`.8<O]@^.B#W-ON09UCHN]@!U16_0S@TK1EWPV0LY&3,A=@UHC)&R$;#9"
M5AEA=PG1"#FMAPERUZ#2B-`+VJ"U#F&=+_K$*'9#V+X&`;7PVUU),#3:G%OG
M&M09&GL!>[4@1N]#%3Q3[8L>MB(GIO4SVI9;X1I4&A1Z`7O`MN'G>^X//[LY
MBD:(:2U+D+L&E4:$7M`VLG'XR6$C+NL,6J&EM$/$9E![WT1P7/1A[BW7H,YQ
ML1>PY6V+?F90^:J"DO!5A4G>L#.5\:H"'<GT/+4@)+Q!Q=VPXIZ3O=G;+PJ7
M%"P(<#>9R7&[25EW2<&J@':`LJ4$X7M6*.;N<6!XUR:;KR1$U7DAAO2,DMY,
MF\*5!,`+*S%N=U7A!;>!`10OQ;@=495B!;H_E3=<0`#=7W,!`7+"4HS;&-0X
M06E8L6Y67#?K'`6&O)_(6PBXK+YNL*.ER%=EQ74#P*TK<9O6G>L&H&+9K%C6
M*98<C&<J;V&CR6S:9:-Y>1]P0R)NH8S0V%I1QKS4#X%8BG$TKR(6CAP!L4CE
M#15^>&&IJ?`#7EB)<71GTPO%NKP@,/L1S8\=VD>$6RXUB(W">2;'49T&)):H
M"+CV+9IKWPTX+.$1&^7K3(ZZL[0!B2,M:X^LQ#@6U(##<A@`QU*,(T4M.!08
MF;4<=6=I"Q)%08\LQ3B&U()#PSAT,XZFN>L8#!29E1QU9VD#$D=-UAY9B7%<
MIP6'A''(9ARR"8?D8&36<M2=I0U('&E9>V0E1MWDT(+#\A8`QU*,(T(-.`0%
M([.6H^XL;4#B.,S:(RLQCA1MXLAK0(S"+"C*&VI`++Z6<]#V167AE:1VT9G>
MHOM?E]LMO$C7O4W-O>YM?L5AJ2[$*$R6,CF.++&Z)_&M"H@=I6(<.ZI1;&D/
MHS`="G)T76@.DMM*<35OI7@_:M%+K4JEH;4C$C&V3.)Z2M1FRA$8`,12C&-$
M%=%P5`>(1BK'VL]9%HUY,\7'GG)1*A(!+EB*<12HQ@5*PXIUL^*Z*>C(#.3[
M1(XM*I@.V4Q(BPIZ)#T?6:FHLW9#(D;?DSF@YX$C)1`(V1@+WW,_%HZ^`+%(
MY=BBPD#R6,1Y8&-!=3_2K3?+."*R]D(B;JGO($/A6`@`8BG&T9J*4#B^`H0B
ME:/K.[S;7"!$+_C0CYMX'/E8.R(18R\$NIXUT2B6>PB#B0YIOPV3S._,I6Q^
M]SH-[Q__P_FGX^WN7^;O:`ZB)&3T@BPGD^-8#MEZS7ZY)&1?8@B0GE2,(ST-
M."S7,0I!#A3D+7<T!B2+:V.T5YI6[KLM=UD[:"7&58CP#G+T!<"Q%./X4`L.
M!08JE6/IT<CA0%&J*D$I"CIG*<8QI0;G*`WCT,TXFF:UXTM0D!(YEKMP!0=I
M09_*9:.U;U9B7-D([QO'?R`<LAF';,(A.1BC5-["KY(89?R*\Y[(RJ3GV-':
M1XFXA6[-R%H6>$>6`$Q+,8Y]X>/F2!<0MU2.]8YB&W-+]P.I](_C4&O_K,2X
M$M.F?[(2D_T6#<2\)CF>>4D=W_E&Q#`F7SX9(_-:?)YI^G)3H;)D\4"<*Y>C
M.%?$N5=9LBH`DI6)422K2K%['3$'6564HUD5F52O]M-"JIZJK2O#W+UF>N6&
M1-Q05TJP5->5(!!+,8I'U<3"$B0H%JD<75<2>2S2?#^R7JK-Y\@5!;TPB]'/
M$5-\*)2&0>C64*BZ^6AI$!B*1(Z^%VG(0L'YF$R+0H$)<$`B;B@P8:,@W'OV
M`1"R,0J^YWX4+-&!HI#*T00HGQ#30@J0G[RX!'A@)49=-JOQP.CF[UKQ4HRB
M-%6*!05=G\JQKI>LVUX7M.SUL)6,+-$`W)"(&\I)==.@5$Z24L"D)LH;2,WT
M.3=[1]M43K*OR7:DYK?'S]?CXRE\4.G\L3N\7*[WTS^=H+ZT9!&"-">3XVB.
MVOIJ6[&T9#5"K"<5XUA/`PY+=HQ"D`0%>4-I*2+)2TN2]&)`E)8`!ZW$J-)2
M@X,<@P%P+,4X2M2"0X&!2N5HAJ3A0''6#R.OQ*4HZ)^E&%5=:O&/TC`.W8RC
M:6([F@3%*9%CB0LE<)R8I#VAE1/*T9^U@U9B5(FIP4&.`4$X9#,.V81#<C!0
MJ;SAE2Y)H/9>Z;*CI4B@%/@ESV+-"G#Z2MP&`G?S$X1C*<:1N@8<@H+!3^5H
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MUFY=B=NT[A7(`,5+,8Y+U2@6%(QG*F\A3^"J-)">R:W<Z,C-V@4K,8XM;;J@
M6!!C$B9/4=Y`GCB-Y"EY0[&FZ:L$#K?;\7ZSGU<O?X>N7!(S&$%:E<EQM(IO
M?0JD7!*S7RD&6%8JQK&L!AR67!F%(.D*\H8W$40D^0Z>],.H^G&HO9?'TJ:U
MCU9B'`_#^\BQ*`#'4HRC92TX%!BK5-[PV@(X5OT@>:\61*U<&`-<M!3C>%N#
MBY2&<>AF'$W3V_$J*%2)O*4P!H9*#;V0B'NO``>MQ#A"AG>0HU,0#MF,0S;A
MD!P,5"K'!LI^MSD)5'9#->F5^9]0E0N6HT=K-R7BAMNO$G"MMU]!F)9B'!7#
MA\XQ,"!TJ;SA70?P'*.]I+3GM/(E:(Y:K7VT$N.XVJ:///L2;.R8INASVZY\
MBP:&!=>>VW[?H6'%+9^;A'.;,8#^>K'I$$^NQ8.P+UF.'R\>1EGZ>#$:1G&[
MS688Z:#I5[LSH9V6$9_=;,]-/^:E*V&0OO@!05AXF;5]]NDY'I:K+QM;6>O(
MH5N#,BTO3:@BP`F,\"^CG7[FG["U0C/LL-_==EWIYLYF:L\5F8"1&=B,QC=8
M`@O'QXWT6QJR)DT(&B_]AT^5FOW+YH-_FDX``]8<E6^P!!B.&YJ)YSMD`EA\
M)Z<=D`&8GD9:@L8W6`(+Q[<\5WQZ;_9<_FC`]E?(Q2@BR(@W1^8;+$#&XXVS
M=-MYA0TUM[?'SA-PVE!/<OR&FNOYJ[@\/)K][C>OU^OQ?*_\$J*=1A;!G/CG
M'5@N1\U,OGE?4F'KXS6NMF`+,6(+UH:#$J=P7'ID):]'8@9R"Q+E-<YS_&F:
M^[D<-?=;D&@_3L?E5F<AKL>A:1L.Y14N/;*2(R:T:$%B\P#@D948E5BV<637
M-;F])PW*)%'>D$GBA5[Q0%3\%/'W#]\]%$B(50>FC4R.2QL5%W;=M(9N8)K$
M:(XY*YX6[,TO(MDL8"^H0]DAR+'Z)9O]OW,M9T?+WLR'[[)(+Y'Y\X,91S:S
MC:JP:C^`H13CQ=BZEZ:I6VL^=J6\*BBY!#EZWT"J0[NOI9@Z]D+K&JW]NQ*W
M:<4Q(3'"^2O*&_+7?%^&U/X!HG>_NUR/IT^5=]*Z["-&.*%E<EQ"PU][<>D(
MND-@(<;QH`8<-M?8JU]0I@MR;*;C+(D4DR'7CKQ'//SKM8,9*I/C,E2#?[0?
ML5#"$BT%`->S!8?R"J&T%>38M,5F)%GJU+TDE65-EQ[6[EF)<?FFXFJNS09,
MP@F&-==`^&9A;D&*["5&*(=D<EP.J5%-O`HH:31>OZI4;+.!K<1"62*3XW9+
M-:J55P&F@DR.2P4UJK4?3-#<3\6XN5^E6'D-T&3/Y+@-4(5J-__6-J_$N`F-
MOR9@)R-1\/R.\@8"85_R$DHI2ON[$][]]OATO%Z/'S&U%`,!G/^9'#?_`S0L
MA["7C(%TD(IQZ:`!A\T"1B&8'3(Y+CLT(%%>(Y@L,CDN630@T7Z@0KDC%>-R
M1PL.Y15"J223XU()'HE+!&N/K,2XS+*)(Z,*3&LPE4SRAE0R<'0MQ:J#TD8N
MQZ6-8?]3]'9:6Q5`GLC$N#Q1H]@D`*L!2@Q1CMWOVS)*=/U^&65'2W'21P-+
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MT=$(-1LQ(7<-:HWPO<`U+L@;UKC:0;ROI;3:8`>QO7$B."[Z,/>6:U#GN-@+
M6CZ;HI\9M%.28V97$M9+(>)Z*:9OE8>?P81\<R`V-@>Y'%-'9&,E*_>@(_X)
MJYS6$2%!V+&9O:6*+!>](&^XU8J-F]NZ?-$+N,F,>P;K&Z2XEYWG%5/,*V:(
ME6L`QRHV@Y9(+VZX)AQ#M7%->+%.!KN#"W)C?8,-N]5L=W!!;JQOL&%W:`:N
MJF)[@[-SC6:VO'2-9K'I"`Y0LP-FX+[!A@VA&;C`B>;-TO9$6RQP`;>>TH/_
M*:=E8BMP[MB\.@JUL-0WV#`Z-(.60R]NN-H=32Y<[5ZLB]%V-=L^&>P;P+;[
M8_.B*M3"8-]@RW;?#%Q%1=M.D6U8O[Y@E=\Z&#P0G9$C]PU@(V(S:$43K1O"
MJL5A8!V=5C0ZK6@TKF@L_LQN_Z5NR<)/)=NU:LFB$54$.($)2Q:-/]/;?_UQ
MW;`DF9XU2Y+A"!'7[*X$C&^PQ!6.FPT&_NY?;H#1?.$HWOW+)X`!:X[*-U@"
M#,=U0VH4$[XB;39+1\05(.9@?(,EKG!\Q"<P>SMN!(:Y^3>`C'AS9+[!`F0\
M+IH>A"HXKU!JH>ZY#;)BDI,<7VJA/-Y(00F;/LO$1Q8^R_3]^70_?NR^NQ_N
MBW>0%`HFS"'2RWK)0HR;IIO/-!0J'MXS*SHWB=%T+O473.>VP6BG=5RNU8D<
M"X>.:?A&&6[==E^IZ1E1O635U[4$&+)9C,5F>\Z/NK0\/>:R``/NC)G$:'+#
M4TR;Y&9S^SD,7O.")J=R;+H:5`9I\4F509*>2U&[T_8PQ`+=+,:"LSVK8IAM
M=ZE[1`A(4E'>D*1H7`JI5"(F*4'M;YND?G\Y?^K^:/Z4V`Z18$8B3>N?[5GU
M/).W&TI!I.V&&EJI6#L-8+HAVTMK<4LGDT!,6SI%>KGYFE:7!@#'+\4XXE%C
MOYWK!+BU9B%&%`IYE6*7#,CZ3J94CGZ>>W9\OBW1O69;;RAVLY=(,!V09MJR
MZ8$B&R!Z##L-^ROL-(9A(O=#5?DO=$IRR)Q;<CDJMPQBNM9$YG>Q41+>Q?;G
M^P_':_>$N_I$H\G1^N?X4\6=0_BY?_7)]P)25R;&I:ZA8L]#]&3$'+@$N6]0
M9T3H!:3!3(Q+@S5&*#$;H6<C)N2^0:41OA>44J.\A<$%,Y8,CO1F"%H65\^6
MHJ7!Z-P\WZ#.TM`+R-I!W,(&@YT[;'#>.@[#9%"P+;?"-Z@S*/0"5H-,C%L-
M*L:?&"<CHCTY<M^@RHC8"UI9HKR%?LYQ6;Z`8M"J9[2:?DY3+5J=V^<;U)D:
M>@%K5Q"W4-FJ`9A16?MQ#(C*+N28,AA1-7>`,Z<"ROFRE:Y6*0ZV07E:;KY$
M9&?''!7O/Q1G$ZF$.6N4H_7K1#]5BB4)=NBY&'K&MQB4RW=`&&9Q0QJ,:*H_
M>&)SE`2);!`W[((3$/L/M+G\(F%&&^4->2?%D.6=L1]&W:MQZS*1RP(2)+9!
MW)`<ZL+B9_]HOQB#OR3&[./GO@:NU`.A4GLMO_MZ*OA`HHK\+H"OJ4)$%7-A
M>O$B0MJY;\J8E.O./9_$7?R@W3=JY)O'S0F^_<O;-V_?_#]U)136#0IE;F1S
M=')E86T-96YD;V)J#3$W,R`P(&]B:CP\+T-O;G1E;G1S(#$W-"`P(%(O5'EP
M92]086=E+U!A<F5N="`Q-S8@,"!2+U)O=&%T92`P+TUE9&EA0F]X6S`@,"`V
M,3(@-SDR72]#<F]P0F]X6S`@,"`V,3(@-SDR72]297-O=7)C97,\/"]&;VYT
M/#PO1F%B8S$P(#$Y,R`P(%(O1F%B8S8@,3@S(#`@4B]&86)C-R`Q.#0@,"!2
M+T9A8F,X(#$Y-"`P(%(O1F%B8SD@,3DU(#`@4CX^+U!R;V-3971;+U!$1B]4
M97AT+TEM86=E0B]);6%G94,O26UA9V5)73X^/CX-96YD;V)J#3$W-"`P(&]B
M:CP\+TQE;F=T:"`U,3@V+T9I;'1E<B]&;&%T941E8V]D93X^<W1R96%M#0IX
MG+5=2W/;2)*^*T+_`0?'AG>#S:T7"L#>NFWWA@\[,]OVS,ZA+Q`)29BF0#5!
MVJW^]9M93X`LE%`P'0Y;4"*!RN=7F84"_-,_;V]^O[TA:UGE&<$_ZJA<YT+_
MLWFZO:'J#,V8S*A4%)91(==5Q<JL)"2KF,@.S>W-_V6=NE<A<KQ17I;X(SL\
MW-X\WM[<_P?>"O\,"&0M!(<!UH+G''[PBK'Q^4KD>+[B!9XO2\G#-V29(%E)
MX6]!X(XHS_WKYW_'$[D[P:A7Y*?/MS?_^7-]MP&U>?89F)6!U,VL22A8@O`R
M^_R$HM(2-/Z\N;WY`?7!XZ^W-V\_/S99WSYT[7V[J;MCMMD_/>^[ICOVV?X^
M.\+9=T"INY=_SS[_Z_;F`PS[O]\L&!.5ETPHH=[^RAB[ZAC@L8'VI(#(,=IS
MAL>H?9]US3';-O?-X=!LLV/]1U;W?0/*U]TVV[7U7;MKCVW3@UVZONV/P&3,
M<K_?[?9?V^XAJX_9^V;3/-TUAXS35<8(R?]KB2IR0I6"#E1YFUWSUA`B16YN
M_"L3Y)H>P'L+:J-/<.:BCS`3?9]^_O$3J%;!C7\_M0>P<YU]J7>G^MCNNZQ&
M"]?=ILF.>^#8GO`(3!_RUZ%YWA_0/>W]*KNK>W14I[B_-NW#X]&ZK?G2;ANX
MY2IKCUG;9T_[0P.._JW9O<#YNLNZ_7&1A6-6``0R5LA)X:Q`T2MH!1CWF/7[
MIR9#'5#S_0&5MS*']/W:PGF4]:X!>>I=^V>S76<_WA\A"%6L;IN#MB+<!.\U
M5OYN?WR$T7H([B^-"O:N>:CQE]75M4>5=0Y*ZE.0<:W\4]W5#\T3($[V6/>@
M*VCPU':H+9JESNY/('TH*$"Q-Y2N)&$K"BA</]1MUX-3CY=9#8'5(G73]'U]
M>`$CXM476;O.$`ZOK+^LB-(?M"94.@AF'!,"+;"!L'MHLK8+:GD/L8"^>VGJ
M0Y\UW18TNA!<>1`.!*KY1JQ84:UHF2/U#5OEDJT@!E<@>O_<;-#+NY?UM=4$
MO+5J<B*]FK32:OX8@,G5<(8!_V^S^OGYL/^C?:J/F)%OF%P)5JX(S./@L+^O
M/ZV5;_?/*KH!?'?['L"Y/AQ>P%!?Z\,6H>`)(@%.KK*OC^WF4>=*\\<S``RD
MRT/;X4FT][5-P*5#.U9>HATCC$".(LB!)TX[!4J;YG`$<;/]UZXY](_M<Z;C
MH1_;YJE^P53O3W?_`@\B(`)6U5UWJG<`7T_MT22[QKS3$>:M/UW^8TI,V>[:
M-D!W*QN`MMS90+I@'[GJ^73H3UAV@#Z?,#)!7EXR"WP?.P"##C3\I?G2=">T
MQK8!"V;]\;1]P8L<7&A\N[^'FYC*!3)!6Q*@'B"P>UDI@-&8V5S?^82Y0DO#
MW-L3)"LX][>F6Y1LD3D[+]DW%`,1+7*96RU([J8JGN.Q2F*X(TPO&P@O%UW?
MJ4@$_'+B?*<:D9;54&/`29^TDMD2L>TV.#?K:003[VE_POIX4^\VIUV-10=,
M5*HF;'#6W4%XUL?3<0\3#61:@Y@,@:<+QOXU0+]NY5AZEUZ]<,Q%_FV%X^2]
MI;_WM87F)5UZXR*:.5SJ(J\JUKR`,?Y4<42E,$4>A>KBT^FNAT(7:YT/7[#'
MNG+V<E:X.9CX8&:"FQGH8Y?]3WV`*1$F7WDV^;98*_WWKNFZ[,,Z^TNSA>9F
ME?WM<?U^C5%_UZ@L^)7DI(5_Z/=*>R$+I\=W2GL!_AF:*B]]N4+1C3KOWSVV
MS7WV:=."I[`]SOYZ#_\VAY4V@K8"S,(?_F@V)U5'_P-.9W^#N1W+;-=R7-O)
ME#C`8G1095`MN'4H%G]:4.^O"]E^:O=*02B,L[M3#Q-I_ST;?\&(D_][.1>:
MK8&):"G<+"9+Y]NOCX#&5X[;RHU;,?`'T2#P]H?KABX?:$=*7V+QPBB'A>06
M"T7P=`O-SBI[_U)O(7Q--873-LQ1&!I___0CAL8*3FW6V?O#^MJQRBH>*B>D
M-.LO&F5T@?Y8?VE4AX+=JUIW>5%S)3:OO4]"#.M?_NT]<)JI%_L9O48SCEO%
MV=0`=J8"=B9!7CRIAJUW_5XWT6;DW=4SEA6N+V!TX#!J6F#4LC]BJ?``"KHT
MW$+1N]L_/YETW>P/SWM53SS7AR,T"ZK#\=>!G5K5,:)JV#\=6G#S!N*\OL/K
M6FW>!O%?.UM;_YK*2@A/J^UWRF]9%`.#LK)PC98DA-O\-IT1+@1E?;W#GK^]
M>J_#<M_K%'Y=1THSY;_AA&#KNE(N>52%8+-K'U2,P90*KH`>+KO;=Z=>1RK6
MA.CKTS.>9_FO!.H@^!V;&0CM+J277NPZ/>_]O9YWV!QN]\\J050XM!UVF?#K
MM6T@7-O#N5_>J9AI&.Y>7$XV7:][!O@%&M9CT[A9:`_=H%J1@2)D`X7S12ZK
M%#D9"PVC5_5TJI]K=G`I+O?L!_>LL=E^MZLAG3Y^_'AUY9GM'?RRGFUTMT85
MC6$9MJEF.4*O1/2V:8!2K+!^[8_[S6\P-4$;<=7:D.=>V.^4ESR7;HCKMJ4<
MTLS>62VB:5N_?6H:7,98-FE-M0@"G/%M:D2:#T:F.B8XB;<LLJ*""DG=V-]!
M/4H"AAP75Y"!33"('"K;&`/$0?P.3`">QABH@+8\QD!RJ$DB#$4ERCA#*:JH
M#$4A)(LRR->&R$7<#H7`!WHQ!L[CIBX8ST64@7))H@SD%099\3SJ"UER'F<H
M.(E:4DHFHW:0T(+$A12TC`_!:1EUMV3T%34IS>-W()1%?9%7E$>UR$N<X&,,
MX*VHFKG$!W@QAIR2^!``37$M.(G;(6<$T"G&0*HR.H2H*A%G*,LJFEF`+W$`
M$06)9Y:0A$6U$#D144L*@7-(C(%3'I<!"KZX%N#,N)"$B&C`\(K$@907E8QJ
MP25N5X@QY*6,.HN#O^,,]!4HYD30J*%85<8!A)55'K4D@W-1&9@LXXD#=3R)
M"RED/+,8EZ^HR22)RP`@%W4WU`XBZ@M:Y21Z!UJ*>-#20L1EH%*P^!UR0:.^
MH(+'IV;H(O+X'1B/!PP%+(\S$"ZB#!6G\3**%?'Z@\4C%B;5J!5S]@I^L7C`
M0U9&(X61*BH?8-=TM/^N350)M5(+.)K:-"&DV*:)#]HF;CK&=Z?#`9<\IC?C
M7#PB$46E)*H@"1++?75E-?T<`R8T=6LH!Y/OK2Z-W!OJ>6W(Y%OK*Z=N;3:B
MX;8TKGY(B"=U.5@?($`Y3H]X[QQJZ8D.Y3*K2KL>R63EEK<*=:R>&6XVAQ,T
MYM#W-EW?G"W#3`JK7`-256-9+\AIOC:R)AA-N1&!\TP.3PZ9+/*P2%WI;*9W
MI;U],U.8*E>C2GDFS8">*$Y.AR[D%71&2B*8%5>,%O/D4@&)(306ZX*<%N&3
MSO(;)S%T`6V#(6WI"T):4K?`*-T#A)S;AT,?.WQ\IQ[P-GUS^-+T$^*IF`,Y
M0D$\)*<%L9$N9A<59#@-!:)V2$Y#LSD#8R3"",$(-?0E$>H\,HA005;0/$X(
MHB((0R`0DD-R6DA.6B`*NC"W!2/4TA=$J%MW)7X%G-N=1G\]/C:'K#TV3_T*
M-_TD("Z(%`K6(3DM6(V@J8@+`X9B=TA.B]T%<F#(PH#!4#;TU%#F9.`Z;L"_
M6/$B3P!:#)M`5`_):5$]:9LS)(.[/.G(A:.=/F($C]1I?7BQ^=UP#2+=9\"8
MGE1'#I>$J=_LX+:VHS)3?[/WS?.AV9A-3%A?UD^X]U;OF8MAJC:!M8;5G);J
M4#&402-8ME!R#<EIR<7X5%`[?A6M1FJCP%A4S3`AM6$+I>*0G):*,Z1686FD
M-@J,1=4,$U(;MF#B&OJ2.8CQBSD(^M455.*3<Y"SO55H++IF"&MAV4*I/B2G
MI?JT[2,36%F%)[`S>LJSD(JDXS%$/(X82*$1.2V%%L@!,8P#!I)B1$Y+B@5R
MX,M057A^LO0E8>YVLOHPEU!J%44U?XY2D7$9N"-R6N!.VF<TT>!^@&"DCNDI
MD5J64RDS1G<<(A2:Q5)TGS4P!ET1!.@1.2D69PV,05:$,79,G^_FO)@UM`JD
M(@B,(W)2?$T/'`7&O`J'FZ6GUS6EM&\+,7R.H=+O+_N+;3K?,`B4G7:0^$ZU
M;QFC&BA"\<FVVTMNMX9LTA?Z9@@TY6-&2B?1VX0E*!POE-5#<EI66R$2)QP8
M,)3D0W):DB^0`W,;!@SF_(B>EO/IDJB,Q4@(0,"0G`8!DW*<`3TO31N$1[H-
M*J&%,LV`.0RU07@JU`:=T5,6`DIA7Z^CO*I<EN%C6+/%\N*5'\PR3+K-H=FV
MQ_';4[%I1JMM+>"T);:?,(?!U@?/A=)H2$Y+H\FW#\:MCY7:*#`653%,26W8
M0DDW)*<EW0RI52@:J8T"8U$5PY34ABV8HH:>NEY=>6O[-0M*5I6D*UZP2.]C
MU+`:C657#!-J6+90?@_):?D];?SH#``&,^D.1R;=&74)H`_=)P$BQ0*CX>P?
MTY.*!>9VPN+>+[M0C5LH].O]^V.-[PD'RX>%PP)*VF%?+Q^6CE$.5*.R,F_4
MF9)AP4"3]3V1;J3990$FL@X*&Q\V%B`L+<+HP]?"PEX5PD:ZN,1@DQ/J&!N-
M$D:?L>2:89X2YJH05-+%]<D,)516&R6,/F/)-<,\)<Q50>0T]"7(Z5[^?P4Y
M([6.\Y35=ZR99IBEI+TJA*MT<=TTZ:EQ#5!4=OD8CPR0$K=\;`Z#=1,)+Q^?
MT9.0D[B]VX2Z1WPLI^81WS\NW\6/U$9&-:OESAZZ@L,<!FLC/!?(_Q$Y+?_)
MO&5A*[518"RJ9IA>%L9S@80?D=,2?H;4&&Y6:J/`6%3-,+TLC.="&6[IR1F>
M.[GQ87')S>YZDA/_;8I(A624L7J--=`,TZO#>"Z0R8:<NO2'F6Q4&<WK^(K8
M_&JI*+A-<CC:F2,W0YK#&=42<H:65AP]/>>+TK^CG[O/`0G<1NUZI<#'5N97
M!49Y:P>G<^YR2Q_.J0H*M<F%T7-4T&22C@I%.?GL>HP*1@FCSUARS3!2XNQB
M#RF%AY2B\!?/"@![50AA-'G!KAOO__"NFS',&#,8BXQUUPQA,^AS'J,*>::[
M9IAG!G-5$+**94O\>>$,$:G?H^6(L8TUTU@GS3!+/7M5",2*I4\*K'*Q<H1#
M*YB[OBYW?5VNFSEU>M37_>Y.HPH+GB+DMLF(2943*Y45T`JCRSO-4(WELN?S
M9%30:LY81R'4R65$'`NC&<[E,N=SFARC'-R8N\+9)"M^,&BJ!&/.<%;6L52:
MX4Q`>YXNJ+*(%S!JN<)9SLHXED8SG`O&%EL.OU<8LIR8+%ZE$[#PEO-2:89S
M`<UYFB^H3Z.6BQ0$^%K8(/E<0>#HZ05![DHW6I+*%P3$+)[^?/%!%_45F'DB
M8W:A;/E8X@MR6KI.%\F3<D`>BLM*\8(\7PY,["5R"#U@<2Z(IR?CA!SXD''S
M>355?G,!G=W,THU0)0$][\(&]-0\1(!PDI7<E)NJF,:WNF<*QH*NNR#/SSZV
MR'7X48V0ZX;TQ.P3PDL"90BGT/W8=B/)=X7Q47[>07MZJFB%]]T/ZM.A$=^-
MUBFPS`Y"E*6G0Y0H+9B#7=QW:C@AYB,#GX[J$U.#;U2M]&?>[MWGJ+"3N6NZ
MYKX]1LHAE#$$54-R$E19R5^K>'"$$#852]:CU)6S!A9ZA!`8&7HJ&$$E[+U%
M\9F>!Z.UY%,S,-'M61!\#'T!^%A)XJW\N(0*>.*"G`0U<SRA,"3@B2$]&5OD
M4'^N7NC_<X8K"F/R$)88^@(LF>>*:.DC21A7+'T!KOCOWC'IGQL7TCXWWN.7
MZ4Z;H_I:B=I*GE#V@%PA+!F2T[!$)C^Z4T@@+QXA7I#3H&6)'$(/&$(:0T]%
MFE(,_,=,:;%F,Q\H*'B`D8.(,Z(G]4,+;*,PXM)'%^0TT%DB1]A'0WIJXJNW
MCW*'0>H+09CX:UDF5#;HCA`:C>A)S=>T><:EC*!AR+'T!9`CW!-=ZC^Y!T6[
M*67>Q3Z$'*M<0*00V@S):6@CYJW5X`@A>!F2T^!EUL!"CQ#"$T-/KES(P#GV
M.:7`C02QH@4&"T+(B)X&(3/T5RE^:?@+<AIFS!HX;/@A/;E0$6[H$4@(^$7&
MJA2T<0@71O0T7)@T07RJ!^OI552A7_]11\(N7)K#&<][U(<;/;!XP!G3DP"'
MV5?-:57ZY1U1FAKG%_,Y/+4C;OBY/;TS;F[!@XFKK6`-XI1G=J'4'+YF!WM5
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M^3.DT6QJ+<-<DNG#TLY)DQ''7)+I*ZHS6ZHI:,JL+)ADGKQH[IV39`7U*@NO
MLD^R(I)D!?4J"Z^R3[)B.LDLVWF2#>C)<YCT&1#?8/\M@Q2#<+WXSNV,&T^W
MDF+JQN-=!]9?A4]>;V=514R9W+#1_,SDGOXMUH#*W+Q)<9ED>FJGYINHR?5_
M!1D@]?^V5Y9KRO#!(CKVYRL.@C!C!WGU]8SE@^1N$+?+A%]\TIA&/H$+'!_^
M>7MS>_/_$>/#80T*96YD<W1R96%M#65N9&]B:@TQ-S4@,"!O8FH\/"]4>7!E
M+T]U=&QI;F5S/CX-96YD;V)J#3$W-B`P(&]B:CP\+T-O=6YT(#@X+TMI9'-;
M,3@R(#`@4B`Q(#`@4B`S(#`@4B`U(#`@4B`W(#`@4B`Y(#`@4B`Q,2`P(%(@
M,3,@,"!2(#$U(#`@4B`Q-R`P(%(@,3D@,"!2(#(Q(#`@4B`R,R`P(%(@,C4@
M,"!2(#(W(#`@4B`R.2`P(%(@,S$@,"!2(#,S(#`@4B`S-2`P(%(@,S<@,"!2
M(#,Y(#`@4B`T,2`P(%(@-#,@,"!2(#0U(#`@4B`T-R`P(%(@-#D@,"!2(#4Q
M(#`@4B`U,R`P(%(@-34@,"!2(#4W(#`@4B`U.2`P(%(@-C$@,"!2(#8S(#`@
M4B`V-2`P(%(@-C<@,"!2(#8Y(#`@4B`W,2`P(%(@-S,@,"!2(#<U(#`@4B`W
M-R`P(%(@-SD@,"!2(#@Q(#`@4B`X,R`P(%(@.#4@,"!2(#@W(#`@4B`X.2`P
M(%(@.3$@,"!2(#DS(#`@4B`Y-2`P(%(@.3<@,"!2(#DY(#`@4B`Q,#$@,"!2
M(#$P,R`P(%(@,3`U(#`@4B`Q,#<@,"!2(#$P.2`P(%(@,3$Q(#`@4B`Q,3,@
M,"!2(#$Q-2`P(%(@,3$W(#`@4B`Q,3D@,"!2(#$R,2`P(%(@,3(S(#`@4B`Q
M,C4@,"!2(#$R-R`P(%(@,3(Y(#`@4B`Q,S$@,"!2(#$S,R`P(%(@,3,U(#`@
M4B`Q,S<@,"!2(#$S.2`P(%(@,30Q(#`@4B`Q-#,@,"!2(#$T-2`P(%(@,30W
M(#`@4B`Q-#D@,"!2(#$U,2`P(%(@,34S(#`@4B`Q-34@,"!2(#$U-R`P(%(@
M,34Y(#`@4B`Q-C$@,"!2(#$V,R`P(%(@,38U(#`@4B`Q-C<@,"!2(#$V.2`P
M(%(@,3<Q(#`@4B`Q-S,@,"!272]4>7!E+U!A9V5S/CX-96YD;V)J#3$W-R`P
M(&]B:CP\+TQE;F=T:"`S,#DS+U1Y<&4O365T861A=&$O4W5B='EP92]834P^
M/G-T<F5A;0T*/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M9FEL=&5R<R!E<V,](D-2
M3$8B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z
M>&UP=&L])UA-4"!T;V]L:VET(#(N.2XQ+3$S+"!F<F%M97=O<FL@,2XV)SX-
M"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B
M92YC;VTO:5@O,2XP+R<^#0H\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG
M=75I9#HX,60P.30Y8RUE9&,V+31F.#`M834Q,"UD.61D-C`T-F5B864G('AM
M;&YS.G!D9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R<^/"]R9&8Z
M1&5S8W)I<'1I;VX^#0H\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I
M9#HX,60P.30Y8RUE9&,V+31F.#`M834Q,"UD.61D-C`T-F5B864G('AM;&YS
M.GAA<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R<@>&%P.DUO9&EF
M>41A=&4])S(P,#8M,#,M,CE4,34Z,S0Z,C,M,#4Z,#`G('AA<#I#<F5A=&5$
M871E/2<R,#`V+3`S+3(Y5#$U.C,T.C(S+3`U.C`P)R!X87`Z365T861A=&%$
M871E/2<R,#`V+3`S+3(Y5#$U.C,T.C(S+3`U.C`P)SX\+W)D9CI$97-C<FEP
M=&EO;CX-"CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C@Q9#`Y
M-#EC+65D8S8M-&8X,"UA-3$P+60Y9&0V,#0V96)A92<@>&UL;G,Z>&%P34T]
M)VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G('AA<$U-.D1O8W5M
M96YT240])W5U:60Z,#(W8V)A,C0M9C8T9BTT9#EF+6$Y.30M9C0Y9C1D96$S
M93@U)R\^#0H\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HX,60P
M.30Y8RUE9&,V+31F.#`M834Q,"UD.61D-C`T-F5B864G('AM;&YS.F1C/2=H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R<@9&,Z9F]R;6%T/2=A
M<'!L:6-A=&EO;B]P9&8G+SX-"CPO<F1F.E)$1CX-"CPO>#IX;7!M971A/@T*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^#0IE
M;F1S=')E86T-96YD;V)J#3$W."`P(&]B:CP\+TUO9$1A=&4H1#HR,#`V,#,R
M.3$U,S0R,RTP-2<P,"<I+T-R96%T:6]N1&%T92A$.C(P,#8P,S(Y,34S-#(S
M+3`U)S`P)RD^/@UE;F1O8FH->')E9@T*,"`Q-SD-"C`P,#`P,#`P,#`@-C4U
M,S4@9@T*,#`P,#`R-SDV,R`P,#`P,"!N#0HP,#`P,#(X,C`X(#`P,#`P(&X-
M"C`P,#`P,S`P,S(@,#`P,#`@;@T*,#`P,#`S,#(W-R`P,#`P,"!N#0HP,#`P
M,#,T-#DV(#`P,#`P(&X-"C`P,#`P,S0W-#$@,#`P,#`@;@T*,#`P,#`S.34V
M,2`P,#`P,"!N#0HP,#`P,#,Y.#`V(#`P,#`P(&X-"C`P,#`P-#,W-C`@,#`P
M,#`@;@T*,#`P,#`T-#`P-B`P,#`P,"!N#0HP,#`P,#0X-3<Y(#`P,#`P(&X-
M"C`P,#`P-#@X,C8@,#`P,#`@;@T*,#`P,#`U,CDU-B`P,#`P,"!N#0HP,#`P
M,#4S,C`S(#`P,#`P(&X-"C`P,#`P-3<T,#(@,#`P,#`@;@T*,#`P,#`U-S8T
M.2`P,#`P,"!N#0HP,#`P,#8Q-S,W(#`P,#`P(&X-"C`P,#`P-C$Y.#0@,#`P
M,#`@;@T*,#`P,#`V-C0T.2`P,#`P,"!N#0HP,#`P,#8V-CDV(#`P,#`P(&X-
M"C`P,#`P-S$Q,S8@,#`P,#`@;@T*,#`P,#`W,3,X,R`P,#`P,"!N#0HP,#`P
M,#<V.3DQ(#`P,#`P(&X-"C`P,#`P-S<R,S@@,#`P,#`@;@T*,#`P,#`X,38X
M-"`P,#`P,"!N#0HP,#`P,#@Q.3,Q(#`P,#`P(&X-"C`P,#`P.#8Q-34@,#`P
M,#`@;@T*,#`P,#`X-C0P,B`P,#`P,"!N#0HP,#`P,#DP,S`X(#`P,#`P(&X-
M"C`P,#`P.3`U-34@,#`P,#`@;@T*,#`P,#`Y-#4W-"`P,#`P,"!N#0HP,#`P
M,#DT.#(Q(#`P,#`P(&X-"C`P,#`P.3@X.#@@,#`P,#`@;@T*,#`P,#`Y.3$S
M-2`P,#`P,"!N#0HP,#`P,3`S,C4Q(#`P,#`P(&X-"C`P,#`Q,#,T.3@@,#`P
M,#`@;@T*,#`P,#$P-S0P."`P,#`P,"!N#0HP,#`P,3`W-C4U(#`P,#`P(&X-
M"C`P,#`Q,3(U-#0@,#`P,#`@;@T*,#`P,#$Q,C<Y,2`P,#`P,"!N#0HP,#`P
M,3$V.3DY(#`P,#`P(&X-"C`P,#`Q,3<R-#8@,#`P,#`@;@T*,#`P,#$R,38W
M,2`P,#`P,"!N#0HP,#`P,3(Q.3$X(#`P,#`P(&X-"C`P,#`Q,C4X-S$@,#`P
M,#`@;@T*,#`P,#$R-C$Q."`P,#`P,"!N#0HP,#`P,3(Y.38V(#`P,#`P(&X-
M"C`P,#`Q,S`R,3,@,#`P,#`@;@T*,#`P,#$S-#0Y-2`P,#`P,"!N#0HP,#`P
M,3,T-S0R(#`P,#`P(&X-"C`P,#`Q,S@T.38@,#`P,#`@;@T*,#`P,#$S.#<T
M,R`P,#`P,"!N#0HP,#`P,30R-3$P(#`P,#`P(&X-"C`P,#`Q-#(W-3<@,#`P
M,#`@;@T*,#`P,#$T-C0Y,"`P,#`P,"!N#0HP,#`P,30V-S,W(#`P,#`P(&X-
M"C`P,#`Q-3`W-S,@,#`P,#`@;@T*,#`P,#$U,3`R,"`P,#`P,"!N#0HP,#`P
M,34T-S$P(#`P,#`P(&X-"C`P,#`Q-30Y-3<@,#`P,#`@;@T*,#`P,#$U.#4Y
M,2`P,#`P,"!N#0HP,#`P,34X.#,X(#`P,#`P(&X-"C`P,#`Q-C(T-#(@,#`P
M,#`@;@T*,#`P,#$V,C8X.2`P,#`P,"!N#0HP,#`P,38V-C4V(#`P,#`P(&X-
M"C`P,#`Q-C8Y,#,@,#`P,#`@;@T*,#`P,#$W,#<X-R`P,#`P,"!N#0HP,#`P
M,3<Q,#,T(#`P,#`P(&X-"C`P,#`Q-S4P.3D@,#`P,#`@;@T*,#`P,#$W-3,T
M-B`P,#`P,"!N#0HP,#`P,3<X-S(T(#`P,#`P(&X-"C`P,#`Q-S@Y-S$@,#`P
M,#`@;@T*,#`P,#$X,C<Y,B`P,#`P,"!N#0HP,#`P,3@S,#,Y(#`P,#`P(&X-
M"C`P,#`Q.#<P,38@,#`P,#`@;@T*,#`P,#$X-S(V,R`P,#`P,"!N#0HP,#`P
M,3DQ-3$W(#`P,#`P(&X-"C`P,#`Q.3$W-C0@,#`P,#`@;@T*,#`P,#$Y-3DP
M,"`P,#`P,"!N#0HP,#`P,3DV,30W(#`P,#`P(&X-"C`P,#`R,#`U,S4@,#`P
M,#`@;@T*,#`P,#(P,#<X,B`P,#`P,"!N#0HP,#`P,C`U-S4S(#`P,#`P(&X-
M"C`P,#`R,#8P,#`@,#`P,#`@;@T*,#`P,#(Q,#<U-R`P,#`P,"!N#0HP,#`P
M,C$Q,#`T(#`P,#`P(&X-"C`P,#`R,3<X,S(@,#`P,#`@;@T*,#`P,#(Q.#`W
M.2`P,#`P,"!N#0HP,#`P,C(T,3(T(#`P,#`P(&X-"C`P,#`R,C0S-S$@,#`P
M,#`@;@T*,#`P,#(R.#(U-2`P,#`P,"!N#0HP,#`P,C(X-3`R(#`P,#`P(&X-
M"C`P,#`R,S$V.3`@,#`P,#`@;@T*,#`P,#(S,3DS-R`P,#`P,"!N#0HP,#`P
M,C,U.38P(#`P,#`P(&X-"C`P,#`R,S8R,#<@,#`P,#`@;@T*,#`P,#(T,#$R
M."`P,#`P,"!N#0HP,#`P,C0P,S<U(#`P,#`P(&X-"C`P,#`R-#0T,SD@,#`P
M,#`@;@T*,#`P,#(T-#8X-R`P,#`P,"!N#0HP,#`P,C0X-S$R(#`P,#`P(&X-
M"C`P,#`R-#@Y-C$@,#`P,#`@;@T*,#`P,#(U,C`T,R`P,#`P,"!N#0HP,#`P
M,C4R,CDR(#`P,#`P(&X-"C`P,#`R-34R.3<@,#`P,#`@;@T*,#`P,#(U-34T
M-B`P,#`P,"!N#0HP,#`P,C4X,C0S(#`P,#`P(&X-"C`P,#`R-3@T.3(@,#`P
M,#`@;@T*,#`P,#(V,3@V,"`P,#`P,"!N#0HP,#`P,C8R,3`Y(#`P,#`P(&X-
M"C`P,#`R-C,U,#0@,#`P,#`@;@T*,#`P,#(V,S<U,R`P,#`P,"!N#0HP,#`P
M,C8V-#DP(#`P,#`P(&X-"C`P,#`R-C8W,SD@,#`P,#`@;@T*,#`P,#(V.#<T
M,B`P,#`P,"!N#0HP,#`P,C8X.3DQ(#`P,#`P(&X-"C`P,#`R-S$Q.#$@,#`P
M,#`@;@T*,#`P,#(W,30S,"`P,#`P,"!N#0HP,#`P,C<W,C(V(#`P,#`P(&X-
M"C`P,#`R-S<T-S4@,#`P,#`@;@T*,#`P,#(X-#8Q-2`P,#`P,"!N#0HP,#`P
M,C@T.#8T(#`P,#`P(&X-"C`P,#`R.3,W-3`@,#`P,#`@;@T*,#`P,#(Y,SDY
M.2`P,#`P,"!N#0HP,#`P,S`R,S(T(#`P,#`P(&X-"C`P,#`S,#(U-S,@,#`P
M,#`@;@T*,#`P,#,P-#@U-"`P,#`P,"!N#0HP,#`P,S`U,3`S(#`P,#`P(&X-
M"C`P,#`S,#@V-S(@,#`P,#`@;@T*,#`P,#,P.#DR,2`P,#`P,"!N#0HP,#`P
M,S$R-#$R(#`P,#`P(&X-"C`P,#`S,3(V-C$@,#`P,#`@;@T*,#`P,#,Q-C$W
M-"`P,#`P,"!N#0HP,#`P,S$V-#(S(#`P,#`P(&X-"C`P,#`S,C`R-S@@,#`P
M,#`@;@T*,#`P,#,R,#4R-R`P,#`P,"!N#0HP,#`P,S(T.3DX(#`P,#`P(&X-
M"C`P,#`S,C4R-#<@,#`P,#`@;@T*,#`P,#,S,C4S-2`P,#`P,"!N#0HP,#`P
M,S,R-S@T(#`P,#`P(&X-"C`P,#`S,S<P-3$@,#`P,#`@;@T*,#`P,#,S-S,P
M,"`P,#`P,"!N#0HP,#`P,S0S.3DS(#`P,#`P(&X-"C`P,#`S-#0R-#(@,#`P
M,#`@;@T*,#`P,#,T.#@W-2`P,#`P,"!N#0HP,#`P,S0Y,3(T(#`P,#`P(&X-
M"C`P,#`S-30P,CD@,#`P,#`@;@T*,#`P,#,U-#(W."`P,#`P,"!N#0HP,#`P
M,S4X-SDR(#`P,#`P(&X-"C`P,#`S-3DP-#$@,#`P,#`@;@T*,#`P,#,V,C4Q
M,2`P,#`P,"!N#0HP,#`P,S8R-S8P(#`P,#`P(&X-"C`P,#`S-C<U,S$@,#`P
M,#`@;@T*,#`P,#,V-S<X,"`P,#`P,"!N#0HP,#`P,S<R-C8U(#`P,#`P(&X-
M"C`P,#`S-S(Y,30@,#`P,#`@;@T*,#`P,#,W.#`T,B`P,#`P,"!N#0HP,#`P
M,S<X,CDQ(#`P,#`P(&X-"C`P,#`S.#8R-S<@,#`P,#`@;@T*,#`P,#,X-C4R
M-B`P,#`P,"!N#0HP,#`P,SDP,3@P(#`P,#`P(&X-"C`P,#`S.3`T,CD@,#`P
M,#`@;@T*,#`P,#,Y-3(P-B`P,#`P,"!N#0HP,#`P,SDU-#4U(#`P,#`P(&X-
M"C`P,#`S.3DT.#(@,#`P,#`@;@T*,#`P,#,Y.3<S,2`P,#`P,"!N#0HP,#`P
M-#`S-S,P(#`P,#`P(&X-"C`P,#`T,#,Y-SD@,#`P,#`@;@T*,#`P,#0P.#$S
M.2`P,#`P,"!N#0HP,#`P-#`X,S@X(#`P,#`P(&X-"C`P,#`T,34S-C$@,#`P
M,#`@;@T*,#`P,#0Q-38Q,"`P,#`P,"!N#0HP,#`P-#(R.38X(#`P,#`P(&X-
M"C`P,#`T,C,R,3<@,#`P,#`@;@T*,#`P,#0R.#0W-"`P,#`P,"!N#0HP,#`P
M-#(X-3`Y(#`P,#`P(&X-"C`P,#`T,CDR,#4@,#`P,#`@;@T*,#`P,#0S,C,W
M-B`P,#`P,"!N#0IT<F%I;&5R#0H\/"]3:7IE(#$W.3X^#0IS=&%R='AR968-
- -"C$Q-@T*)25%3T8-"C\_
`
end
</PDF>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
